PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
33737223-9	2021	Further tests found that these extracts inhibit the phosphorylation of Glycogen synthase kinase 3 beta (pGSK3beta) in HS27 cell line, which may explain the activation of apoptosis in melanin-producing cells.	Melanins	183-190	glycogen synthase kinase 3 beta	Homo sapiens	71-102
33895139-0	2021	The small molecule DIPQUO promotes osteogenic differentiation via inhibition of glycogen synthase kinase 3 beta signaling.	SCHEMBL22497334	19-25	glycogen synthase kinase 3 beta	Homo sapiens	80-111
34002210-2	2021	In the present study, we identified ANXA1 as an interaction partner of glycogen synthase kinase 3 beta (GSK3beta), a multi-functional serine/threonine kinase tightly associated with cell fate determination and cancer, and assessed the functional significance of GSK3beta-ANXA1 interaction in the metastasis of non-small cell lung cancer (NSCLC).	Serine	134-140	glycogen synthase kinase 3 beta	Homo sapiens	71-102
33703980-10	2021	The mesenchymal transition of cells could be induced by treating cells with an inhibitor of glycogen synthase kinase-3beta, an enzyme that inhibits beta-catenin; this morphological transition could be reversed by antagonizing AR suggesting that AR functions downstream of beta-catenin.Conclusions: These results suggest that MDA-MB-453 cells undergo partial EMT induced by DHT, beta-catenin is critical for this phenotypic change, and AR probably reciprocally mediates the mesenchymal transition of these cells upon activation of GSK-3 beta.	Dihydrotestosterone	373-376	glycogen synthase kinase 3 beta	Homo sapiens	92-122
33920768-11	2021	Comparative analysis including analyzed compounds and reference molecule 3a, which is also an oxindole derivative with a confirmed inhibitory potential towards GSK3B protein, clearly indicates that the proposed compounds exhibit an analogous binding mechanism, and the obtained binding enthalpy values indicate a slightly higher binding potential than the reference molecule.	2-oxindole	94-102	glycogen synthase kinase 3 beta	Homo sapiens	160-165
33735117-7	2021	In addition, vinpocetine plus sorafenib activates glycogen synthase kinase 3beta (GSK-3beta) and subsequently inhibits cytoprotective autophagy induced by vinpocetine in HCC cells.	vinpocetine	13-24	glycogen synthase kinase 3 beta	Homo sapiens	50-80
33735117-7	2021	In addition, vinpocetine plus sorafenib activates glycogen synthase kinase 3beta (GSK-3beta) and subsequently inhibits cytoprotective autophagy induced by vinpocetine in HCC cells.	Sorafenib	30-39	glycogen synthase kinase 3 beta	Homo sapiens	50-80
33924188-8	2021	Moreover, salicin treatment significantly elevated the levels of phosphorylation of Akt and glycogen synthase kinase-3beta (GSK3beta), which is a major downstream target of PI3K, in the ischemic CA1.	salicin	10-17	glycogen synthase kinase 3 beta	Homo sapiens	92-122
33864716-1	2022	INTRODUCTION: A key mechanism of lithium is the inhibition of glycogen synthase kinase-3beta (GSK3beta) and activation of mammalian target of rapamycin (mTOR), two contributors to insulin signaling.	Lithium	33-40	glycogen synthase kinase 3 beta	Homo sapiens	62-92
33492962-0	2021	Novel 18F-Labeled Isonicotinamide-Based Radioligands for Positron Emission Tomography Imaging of Glycogen Synthase Kinase-3beta.	isonicotinamide	18-33	glycogen synthase kinase 3 beta	Homo sapiens	97-127
33707778-4	2021	Cellular volume regulation in healthy chondrocytes was associated with changes in anabolic gene expression, in the secretion of multiple pro-inflammatory cytokines, and in the modulation of intracellular calcium regulated by the ion-channel protein transient receptor potential cation channel subfamily V member 4 (TRPV4), which controls the phosphorylation of glycogen synthase kinase 3beta (GSK3beta), an enzyme with pleiotropic effects in osteoarthritis.	Calcium	204-211	glycogen synthase kinase 3 beta	Homo sapiens	361-391
33135264-8	2021	Sunitinib-induced decrease in KRT6A expression was suppressed by the inhibition of glycogen synthase kinase-3beta by enhancing ERK1/2 and p38 MAPK phosphorylation.	Sunitinib	0-9	glycogen synthase kinase 3 beta	Homo sapiens	83-113
33682722-5	2021	The accumulation of mutant CUG repeats is linked to increased activity of glycogen synthase kinase 3 beta (GSK3beta), a highly conserved and ubiquitous serine/threonine kinase with functions in pathways regulating inflammation, metabolism, oncogenesis, neurogenesis and myogenesis.	Serine	152-158	glycogen synthase kinase 3 beta	Homo sapiens	74-105
33492962-1	2021	Glycogen synthase kinase-3beta (GSK-3beta), a cytoplasmic serine/threonine protein kinase, is involved in several human pathologies including Alzheimer"s disease, bipolar disorder, diabetes, and cancer.	Serine	58-64	glycogen synthase kinase 3 beta	Homo sapiens	0-30
33521925-8	2021	We show that DFX unfolds its cytotoxic effect by a rapid induction of reactive oxygen species (ROS) that leads to oxidative stress and severe DNA damage and by triggering CD1 proteolysis in a mechanism that requires its phosphorylation on T286 by glycogen synthase kinase-3beta (GSK3beta).	Deferasirox	13-16	glycogen synthase kinase 3 beta	Homo sapiens	247-277
33557839-2	2021	Lithium Chloride Promotes Apoptosis in Human Leukemia NB4 Cells by Inhibiting Glycogen Synthase Kinase-3 Beta.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	78-109
33627622-6	2021	We further reveal that compromised phosphorylation of MYC proto-oncogene protein (c-Myc) at threonine 58 (T58) (producing an unstable form of c-Myc) caused by reduced nuclear glycogen synthase kinase-3 beta (GSK3beta) levels contributes to the promotion of miR-106b-93-25 cluster expression upon H2O2 induction.	Threonine	92-101	glycogen synthase kinase 3 beta	Homo sapiens	175-206
33440320-6	2021	The series of twenty-one newly prepared 1,2,4-thiadiazol-3(2H)-ones were explored as potential inhibitors of cysteine-dependent enzymes - human cathepsin K (CatK) and glycogen synthase kinase 3beta (GSK-3beta).	1,2,4-thiadiazol-3(2h)-ones	40-67	glycogen synthase kinase 3 beta	Homo sapiens	167-197
33440320-6	2021	The series of twenty-one newly prepared 1,2,4-thiadiazol-3(2H)-ones were explored as potential inhibitors of cysteine-dependent enzymes - human cathepsin K (CatK) and glycogen synthase kinase 3beta (GSK-3beta).	Cysteine	109-117	glycogen synthase kinase 3 beta	Homo sapiens	167-197
33502043-0	2022	Icaritin and icariin reduce p-Tau levels in a cell model of Alzheimer"s disease by downregulating glycogen synthase kinase 3beta.	icaritin	0-8	glycogen synthase kinase 3 beta	Homo sapiens	98-128
33444905-4	2021	Lithium is known to inhibit glycogen synthase kinase-3beta (GSK3 beta).	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	28-58
33502043-0	2022	Icaritin and icariin reduce p-Tau levels in a cell model of Alzheimer"s disease by downregulating glycogen synthase kinase 3beta.	icariin	13-20	glycogen synthase kinase 3 beta	Homo sapiens	98-128
32776713-5	2021	Moreover, honokiol attenuated the expression of alpha smooth muscle actin (alpha-SMA), transforming growth factor beta 1 (TGF-beta1), phospho-Smad3, phospho-AKT, cyclin D1, c-Myc, Wnt3a, beta-catenin, and activated phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) in HSCs.	honokiol	10-18	glycogen synthase kinase 3 beta	Homo sapiens	234-265
32991030-0	2021	MiR-155-5p regulates mesenchymal stem cell osteogenesis and proliferation via targeting GSK3B in steroid-associated osteonecrosis.	Steroids	97-104	glycogen synthase kinase 3 beta	Homo sapiens	88-93
32991030-2	2021	This study investigated whether the reduced miR-155-5p in steroid-associated osteonecrosis of the femoral head (ONFH) attenuates osteogenic differentiation and cell proliferation by targeting GSK3B.	Steroids	58-65	glycogen synthase kinase 3 beta	Homo sapiens	192-197
32991030-9	2021	These findings suggest that reduced miR-155-5p in steroid-associated ONFH attenuates osteogenic differentiation and cell proliferation by increased levels of GSK3B and inhibition of Wnt signaling.	Steroids	50-57	glycogen synthase kinase 3 beta	Homo sapiens	158-163
33431651-8	2021	We further show that CSE is depleted in 3xTg-AD mice as well as in human AD brains, and that H2S prevents hyperphosphorylation of Tau by sulfhydrating its kinase, glycogen synthase kinase 3beta (GSK3beta).	Deuterium	93-96	glycogen synthase kinase 3 beta	Homo sapiens	163-193
33473107-3	2021	Under starvation, Glycogen synthase kinase 3 beta-mediated phosphorylation of ENDOG at Thr-128 and Ser-288 enhances its interaction with 14-3-3gamma, which leads to the release of Tuberin (TSC2) and Phosphatidylinositol 3-kinase catalytic subunit type 3 (Vps34) from 14-3-3gamma, followed by mTOR pathway suppression and autophagy initiation.	Threonine	87-90	glycogen synthase kinase 3 beta	Homo sapiens	18-49
33473107-3	2021	Under starvation, Glycogen synthase kinase 3 beta-mediated phosphorylation of ENDOG at Thr-128 and Ser-288 enhances its interaction with 14-3-3gamma, which leads to the release of Tuberin (TSC2) and Phosphatidylinositol 3-kinase catalytic subunit type 3 (Vps34) from 14-3-3gamma, followed by mTOR pathway suppression and autophagy initiation.	Serine	99-102	glycogen synthase kinase 3 beta	Homo sapiens	18-49
33137853-7	2021	Besides, expressions of glycogen synthase kinase-3beta (GSK-3beta) and Wnt/beta-catenin were evaluated; these expressions were also significantly increased in bacoside-A treated cells when compared with control cells.	bacoside-	159-168	glycogen synthase kinase 3 beta	Homo sapiens	24-54
33332393-7	2020	Citric acid also impacted the upstream regulators of MITF, glycogen synthase kinase 3beta (GSK3beta), and beta-catenin.	Citric Acid	0-11	glycogen synthase kinase 3 beta	Homo sapiens	59-89
33087512-1	2021	Glycogen synthase kinase-3B (GSK-3B), a serine/threonine kinase, has been implicated in the pathogenesis of many cancers, with involvement in cell cycle regulation, apoptosis, and immune response.	Serine	40-46	glycogen synthase kinase 3 beta	Homo sapiens	0-27
33087512-1	2021	Glycogen synthase kinase-3B (GSK-3B), a serine/threonine kinase, has been implicated in the pathogenesis of many cancers, with involvement in cell cycle regulation, apoptosis, and immune response.	Serine	40-46	glycogen synthase kinase 3 beta	Homo sapiens	29-35
33132196-7	2020	Moreover, rALR reduced glycochenodeoxycholate (GCDC)-induced-apoptosis by decreased expression of pro-apoptotic Bax and enhanced expression of anti-apoptotic Mcl-1, which is regulated by phosphatidylinositol-3-kinase (PI3K)/Akt activation and glycogen synthase kinase-3beta (GSK3beta) phosphorylation.	Glycochenodeoxycholic Acid	23-45	glycogen synthase kinase 3 beta	Homo sapiens	243-273
33132196-0	2020	Augmenter of Liver Regeneration (ALR) regulates bile acid synthesis and attenuates bile acid-induced apoptosis via glycogen synthase kinase-3beta (GSK-3beta) inhibition.	Bile Acids and Salts	83-92	glycogen synthase kinase 3 beta	Homo sapiens	115-145
33488754-13	2020	CASP8, GSK3B, PRKCA, and VEGFR2 were identified as the correlative biotargets of DDI-CPI and PPI, and their binding sites were found to be indirubin, G-Rh2, and G-Rf.	ddi-cpi	81-88	glycogen synthase kinase 3 beta	Homo sapiens	7-12
33488754-14	2020	Conclusion: Taken together, our results revealed that YSQHP likely exerts its antitumor effects by binding to CASP8, GSK3B, PRKCA, and VEGFR2 and by regulating the apoptosis, p53, and PI3K/AKT pathways.	ysqhp	54-59	glycogen synthase kinase 3 beta	Homo sapiens	117-122
33365328-10	2020	Besides, the compound termed streptozotocin may be a key candidate drug targeting on GSK3B for molecular targeted therapy in GI cancer.	Streptozocin	29-43	glycogen synthase kinase 3 beta	Homo sapiens	85-90
33343576-3	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a multifunctional serine/threonine (ser/thr) protein kinase that can participate in B cell growth, metabolic activity, and proliferation.	Serine	64-70	glycogen synthase kinase 3 beta	Homo sapiens	0-30
33415011-9	2020	The levels of several proteins, including GSK3b, Nrf2, LKB1/pS334, and SMYD3, were significantly associated with sensitivity to trametinib plus navitoclax.	trametinib	128-138	glycogen synthase kinase 3 beta	Homo sapiens	42-47
32986894-0	2020	Glycogen synthase kinase-3beta participates in acquired resistance to gemcitabine in pancreatic cancer.	gemcitabine	70-81	glycogen synthase kinase 3 beta	Homo sapiens	0-30
33132196-7	2020	Moreover, rALR reduced glycochenodeoxycholate (GCDC)-induced-apoptosis by decreased expression of pro-apoptotic Bax and enhanced expression of anti-apoptotic Mcl-1, which is regulated by phosphatidylinositol-3-kinase (PI3K)/Akt activation and glycogen synthase kinase-3beta (GSK3beta) phosphorylation.	Glycochenodeoxycholic Acid	47-51	glycogen synthase kinase 3 beta	Homo sapiens	243-273
33125126-1	2020	Glycogen synthase kinase 3beta (GSK 3beta), a multifunctional serine and threonine kinase, plays a critical role in a variety of cellular activities, including signaling transduction, protein and glycogen metabolism, cell proliferation, cell differentiation, and apoptosis.	Serine	62-68	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32623920-5	2020	In this study, we demonstrated that curcumin regulated TFEB export signaling via inhibition of glycogen synthase kinase-3beta (GSK-3beta); GSK-3beta was inactivated by curcumin, leading to reduced phosphorylation of TFEB.	Curcumin	36-44	glycogen synthase kinase 3 beta	Homo sapiens	95-125
33125126-1	2020	Glycogen synthase kinase 3beta (GSK 3beta), a multifunctional serine and threonine kinase, plays a critical role in a variety of cellular activities, including signaling transduction, protein and glycogen metabolism, cell proliferation, cell differentiation, and apoptosis.	Glycogen	196-204	glycogen synthase kinase 3 beta	Homo sapiens	0-30
33299813-8	2020	Resveratrol also increases AMPK and inhibits GSK-3beta (glycogen synthase kinase 3 beta) activity in astrocytes, which release energy, makes ATP available to neurons and reduces reactive oxygen species (ROS).	Resveratrol	0-11	glycogen synthase kinase 3 beta	Homo sapiens	56-87
33299813-8	2020	Resveratrol also increases AMPK and inhibits GSK-3beta (glycogen synthase kinase 3 beta) activity in astrocytes, which release energy, makes ATP available to neurons and reduces reactive oxygen species (ROS).	Adenosine Triphosphate	141-144	glycogen synthase kinase 3 beta	Homo sapiens	56-87
33299813-8	2020	Resveratrol also increases AMPK and inhibits GSK-3beta (glycogen synthase kinase 3 beta) activity in astrocytes, which release energy, makes ATP available to neurons and reduces reactive oxygen species (ROS).	Reactive Oxygen Species	178-201	glycogen synthase kinase 3 beta	Homo sapiens	56-87
33299813-8	2020	Resveratrol also increases AMPK and inhibits GSK-3beta (glycogen synthase kinase 3 beta) activity in astrocytes, which release energy, makes ATP available to neurons and reduces reactive oxygen species (ROS).	Reactive Oxygen Species	203-206	glycogen synthase kinase 3 beta	Homo sapiens	56-87
33099479-10	2020	The up-stream regulator of MYC, Glycogen synthase kinase 3 beta (GSK3beta) was found to be responsible for MYC destabilization mediated by gigantol.	gigantol	139-147	glycogen synthase kinase 3 beta	Homo sapiens	32-63
32816241-5	2020	The upregulated activity of glycogen synthase kinase-3 beta (GSK-3beta) by Abeta1-42 treatment was blocked by DMF pretreatment.	Dimethyl Fumarate	110-113	glycogen synthase kinase 3 beta	Homo sapiens	28-59
32768677-2	2020	Inhibitors of GSK3B were reported to restore sodium current and improve heart function in various arrhythmogenic cardiomyopathy models, but mechanisms underlying this effect remain unclear.	Sodium	45-51	glycogen synthase kinase 3 beta	Homo sapiens	14-19
32768677-7	2020	Inhibition of GSK3B led to the restoration of both Wnt/beta-catenin signaling activity and sodium current density in patient-specific cardiomyocytes while GSK3B activation led to the reduction of sodium current density.	Sodium	91-97	glycogen synthase kinase 3 beta	Homo sapiens	14-19
32768677-7	2020	Inhibition of GSK3B led to the restoration of both Wnt/beta-catenin signaling activity and sodium current density in patient-specific cardiomyocytes while GSK3B activation led to the reduction of sodium current density.	Sodium	196-202	glycogen synthase kinase 3 beta	Homo sapiens	155-160
32768677-8	2020	Moreover, we found that upon inhibition GSK3B sodium current was restored through Wnt/beta-catenin-independent mechanism.	Sodium	46-52	glycogen synthase kinase 3 beta	Homo sapiens	40-45
32768677-9	2020	CONCLUSION: We propose that alterations in GSK3B-Wnt/beta-catenin signaling pathways lead to regulation of sodium current implying its role in molecular pathogenesis of arrhythmogenic cardiomyopathy.	Sodium	107-113	glycogen synthase kinase 3 beta	Homo sapiens	43-48
32592921-0	2020	Hypothesis validation of rosiglitazone a potential inhibitor against glycogen synthase kinase-3beta, for the management of multifaceted pathophysiology of the diabetic wound: An insilico study.	Rosiglitazone	25-38	glycogen synthase kinase 3 beta	Homo sapiens	69-99
33295884-6	2020	Phosphorylation of insulin signalling targets Akt substrate 160 kDa (AS160) and glycogen synthase kinase 3beta (GSK3beta) was upregulated with lactone-, but not with acid-form simvastatin.	Lactones	143-150	glycogen synthase kinase 3 beta	Homo sapiens	80-110
33295884-6	2020	Phosphorylation of insulin signalling targets Akt substrate 160 kDa (AS160) and glycogen synthase kinase 3beta (GSK3beta) was upregulated with lactone-, but not with acid-form simvastatin.	Simvastatin	176-187	glycogen synthase kinase 3 beta	Homo sapiens	80-110
32829895-2	2020	Tideglusib, a selective FDA approved glycogen synthase kinase-3beta (GSK-3beta) inhibitor, has been shown to promote dentine formation, but its effect on bone has not been examined.	tideglusib	0-10	glycogen synthase kinase 3 beta	Homo sapiens	37-67
32464315-11	2020	Similar to CUR, hexahydrocurcumin (HHC) and octahydrocurcumin (OHC) improved insulin sensitivity by strengthening the PI3K-AKT-GSK3B signal and suppressing the phosphorylation of ERK/JNK in HG-induced insulin-resistant HepG2 cells.	hexahydrocurcumin	16-33	glycogen synthase kinase 3 beta	Homo sapiens	127-132
33110983-5	2020	The first AD target that we have addressed with this method is the serine-threonine kinase glycogen synthase kinase 3 beta (GSK3beta), which is a proline-directed serine-threonine kinase that phosphorylates the microtubule-stabilizing protein tau.	Serine	67-73	glycogen synthase kinase 3 beta	Homo sapiens	91-122
33110983-5	2020	The first AD target that we have addressed with this method is the serine-threonine kinase glycogen synthase kinase 3 beta (GSK3beta), which is a proline-directed serine-threonine kinase that phosphorylates the microtubule-stabilizing protein tau.	Proline	146-153	glycogen synthase kinase 3 beta	Homo sapiens	91-122
33110983-5	2020	The first AD target that we have addressed with this method is the serine-threonine kinase glycogen synthase kinase 3 beta (GSK3beta), which is a proline-directed serine-threonine kinase that phosphorylates the microtubule-stabilizing protein tau.	Serine	163-169	glycogen synthase kinase 3 beta	Homo sapiens	91-122
33425704-0	2020	In silico docking and comparative ADMET profile of different glycogen synthase kinase 3 beta inhibitors as the potential leads for the development of anti-Alzheimer drug therapy.	admet	34-39	glycogen synthase kinase 3 beta	Homo sapiens	61-92
33052244-3	2020	As a serine/threonine (Ser/Thr)-protein kinase, glycogen synthase kinase-3beta (GSK-3beta) is a vital signaling mediator that participates in a variety of biological events and can inhibit extracellular matrix (ECM) accumulation and the epithelial-mesenchymal transition (EMT) process, thereby exerting its protective role against the fibrosis of various organs/tissues, including the heart, lung, liver, and kidney.	Serine	5-11	glycogen synthase kinase 3 beta	Homo sapiens	48-78
33052244-3	2020	As a serine/threonine (Ser/Thr)-protein kinase, glycogen synthase kinase-3beta (GSK-3beta) is a vital signaling mediator that participates in a variety of biological events and can inhibit extracellular matrix (ECM) accumulation and the epithelial-mesenchymal transition (EMT) process, thereby exerting its protective role against the fibrosis of various organs/tissues, including the heart, lung, liver, and kidney.	Threonine	12-21	glycogen synthase kinase 3 beta	Homo sapiens	48-78
33052244-3	2020	As a serine/threonine (Ser/Thr)-protein kinase, glycogen synthase kinase-3beta (GSK-3beta) is a vital signaling mediator that participates in a variety of biological events and can inhibit extracellular matrix (ECM) accumulation and the epithelial-mesenchymal transition (EMT) process, thereby exerting its protective role against the fibrosis of various organs/tissues, including the heart, lung, liver, and kidney.	Serine	23-26	glycogen synthase kinase 3 beta	Homo sapiens	48-78
33052244-3	2020	As a serine/threonine (Ser/Thr)-protein kinase, glycogen synthase kinase-3beta (GSK-3beta) is a vital signaling mediator that participates in a variety of biological events and can inhibit extracellular matrix (ECM) accumulation and the epithelial-mesenchymal transition (EMT) process, thereby exerting its protective role against the fibrosis of various organs/tissues, including the heart, lung, liver, and kidney.	Threonine	27-30	glycogen synthase kinase 3 beta	Homo sapiens	48-78
33061441-12	2020	Furthermore, the glycogen synthase kinase-3 beta (GSK-3beta) inhibitor IM-12 abrogates the effect of TP53INP2 silencing.	IM-12	71-76	glycogen synthase kinase 3 beta	Homo sapiens	17-48
32464315-11	2020	Similar to CUR, hexahydrocurcumin (HHC) and octahydrocurcumin (OHC) improved insulin sensitivity by strengthening the PI3K-AKT-GSK3B signal and suppressing the phosphorylation of ERK/JNK in HG-induced insulin-resistant HepG2 cells.	Octahydrocurcumin	44-61	glycogen synthase kinase 3 beta	Homo sapiens	127-132
32464315-11	2020	Similar to CUR, hexahydrocurcumin (HHC) and octahydrocurcumin (OHC) improved insulin sensitivity by strengthening the PI3K-AKT-GSK3B signal and suppressing the phosphorylation of ERK/JNK in HG-induced insulin-resistant HepG2 cells.	ohc	63-66	glycogen synthase kinase 3 beta	Homo sapiens	127-132
32902711-2	2020	Hence, the aim of the present study was to investigate the regulatory role of miR-133a-3p on the regulation of vascular endothelial injury-induced IA through phosphoserine aminotransferase 1 (PSAT1)/glycogen synthase kinase 3beta (GSK3beta)/beta-catenin signaling pathway.	mir-133a	78-86	glycogen synthase kinase 3 beta	Homo sapiens	199-229
33015048-8	2020	Proteomic analyses of selective GSK3b inhibition in calcifying human aortic valve interstitial cells (HAVICs) revealed enrichment of proteins involved organophosphate metabolism, while reducing the activation of pathogenic biomolecular processes.	Organophosphates	151-166	glycogen synthase kinase 3 beta	Homo sapiens	32-37
32470749-1	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Serine	48-54	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32450268-1	2020	Glycogen synthase kinase 3beta (GSK-3beta) is an enzyme with a variety of cellular functions in addition to the regulation of glycogen metabolism.	Glycogen	126-134	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32947427-3	2020	Lithium"s ability to inhibit glycogen synthase kinase 3beta, an enzyme that participates in the phosphorylation of tau, a microtubule-associated protein, stimulated interest in its possible therapeutic role in Alzheimer disease and other neurodegenerative disorders.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	29-59
32470749-33	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Serine	109-115	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32574796-7	2020	miR-455-5p inhibition promoted axonal growth and regeneration and downregulated activation of the glycogen synthase kinase-3beta (GSK3beta)/Tau protein pathway in murine sensory neurons.	mir-455-5p	0-10	glycogen synthase kinase 3 beta	Homo sapiens	98-128
32888132-4	2020	Lithium chloride is a glycogen synthase kinase 3beta (GSK-3beta) inhibitor and exert its effects through modulation of nitric oxide pathway.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	22-52
32470749-1	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Serine	109-115	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-33	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Threonine	55-64	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-41	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Serine	48-54	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-1	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Threonine	55-64	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-41	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Serine	109-115	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-41	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Threonine	55-64	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-49	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Serine	48-54	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-49	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Serine	109-115	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-49	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Threonine	55-64	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-9	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Serine	48-54	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-9	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Serine	109-115	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-9	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Threonine	55-64	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-17	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Serine	48-54	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-17	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Serine	109-115	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-17	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Threonine	55-64	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-25	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Serine	48-54	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-25	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Serine	109-115	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-25	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Threonine	55-64	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32470749-33	2020	Glycogen synthase kinase 3beta (GSK-3beta) is a serine/threonine protein kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules.	Serine	48-54	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32567157-3	2020	At present, we explored the underlying mechanisms involved in the protective effects of ATX via the phosphoinositide 3-kinase (PI3K)/Akt/glycogen synthase kinase 3 beta (GSK3beta)/nuclear factor erythroid 2-related factor 2 (Nrf2) signalling pathway in SH-SY5Y cells.	astaxanthine	88-91	glycogen synthase kinase 3 beta	Homo sapiens	137-168
33397556-0	2020	Nanoparticle Shaped Titanium Promotes Osteogenic Differentiation of Bone Mesenchymal Stem Cells Through Integrin/Integrin Linked Kinase/Glycogen Synthase Kinase-3beta Axis.	Titanium	20-28	glycogen synthase kinase 3 beta	Homo sapiens	136-166
32635299-6	2020	Additionally, it is well established that many flavonoids exhibit anti-apoptosis and anti-inflammatory effects through cellular signaling pathways, such as those involving (ERK), glycogen synthase kinase-3beta (GSK-3beta), and (Akt), resulting in neuroprotection.	Flavonoids	47-57	glycogen synthase kinase 3 beta	Homo sapiens	179-209
32674468-5	2020	In this scenario, glycogen synthase kinase-3beta seems to play a significant function since melatonin decreased its phosphorylation and preincubation with specific inhibitors of this protein kinase (lithium or BIO) reduced the expression and activity of tyrosinase.	Melatonin	92-101	glycogen synthase kinase 3 beta	Homo sapiens	18-48
32674468-5	2020	In this scenario, glycogen synthase kinase-3beta seems to play a significant function since melatonin decreased its phosphorylation and preincubation with specific inhibitors of this protein kinase (lithium or BIO) reduced the expression and activity of tyrosinase.	Lithium	199-206	glycogen synthase kinase 3 beta	Homo sapiens	18-48
32545801-7	2020	Additionally, 1,25(OH)2D3 restored the decreasing GDNF and the inhibited phosphorylation of the phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt)/glycogen synthase kinase-3beta (GSK-3beta) protein expressions.	Calcitriol	14-25	glycogen synthase kinase 3 beta	Homo sapiens	156-186
31828721-6	2020	Zn also increases phosphatidylinositol 3-kinase (PI3K)/Akt and glycogen synthase kinase-3beta (GSK-3beta) phosphorylation and preserves protein kinase C isoforms.	Zinc	0-2	glycogen synthase kinase 3 beta	Homo sapiens	63-93
31828721-6	2020	Zn also increases phosphatidylinositol 3-kinase (PI3K)/Akt and glycogen synthase kinase-3beta (GSK-3beta) phosphorylation and preserves protein kinase C isoforms.	Zinc	0-2	glycogen synthase kinase 3 beta	Homo sapiens	95-104
32307979-3	2020	We found that in normal cells, the levels of wnt3a, beta-catenin, glycogen synthase kinase-3beta phosphorylated at serine 9 (p-GSK-3beta(Ser9)), cyclinD1, proto-oncogene c-myc and vascular endothelial growth factor (VEGF) in arsenic intervention group were higher than those in control group, and the level of glycogen synthase kinase-3beta (GSK-3beta) was lower than that in control group (P<0.05, respectively).	Serine	115-121	glycogen synthase kinase 3 beta	Homo sapiens	66-96
32307979-3	2020	We found that in normal cells, the levels of wnt3a, beta-catenin, glycogen synthase kinase-3beta phosphorylated at serine 9 (p-GSK-3beta(Ser9)), cyclinD1, proto-oncogene c-myc and vascular endothelial growth factor (VEGF) in arsenic intervention group were higher than those in control group, and the level of glycogen synthase kinase-3beta (GSK-3beta) was lower than that in control group (P<0.05, respectively).	Serine	115-121	glycogen synthase kinase 3 beta	Homo sapiens	310-340
32521784-0	2020	Glycogen Synthase Kinase-3beta Facilitates Cytokine Production in 12-O-Tetradecanoylphorbol-13-Acetate/Ionomycin-Activated Human CD4+ T Lymphocytes.	Tetradecanoylphorbol Acetate	66-102	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32521784-0	2020	Glycogen Synthase Kinase-3beta Facilitates Cytokine Production in 12-O-Tetradecanoylphorbol-13-Acetate/Ionomycin-Activated Human CD4+ T Lymphocytes.	Ionomycin	103-112	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32446205-4	2020	Glycogenolytic dysfunction in astrocytes is responsible for glycogen accumulation, caused by inactivation of the protein kinase A (PKA)-glycogen phosphorylase kinase (PhK)-glycogen phosphorylase (GP) cascade accompanied by the activation of glycogen synthase kinase-3beta (GSK3beta).	Glycogen	60-68	glycogen synthase kinase 3 beta	Homo sapiens	241-271
32364678-7	2020	In addition, acidosis related the activations of glycogen synthase kinase-3beta and nuclear factor-kappaB signals, ER stress and Golgi stress, and the abnormal autophagy-lysosome signals were completely reversed by melatonin.	Melatonin	215-224	glycogen synthase kinase 3 beta	Homo sapiens	49-79
31718329-11	2020	In addition, CpG(B)-MLAA-34 siRNA upregulated Gsk3beta protein expression, resulting in retraining of the JAK2/STAT3 and Wnt/beta-catenin signalling pathways.	CpCp	13-24	glycogen synthase kinase 3 beta	Homo sapiens	46-54
32546976-0	2020	Network Pharmacology and Experimental Evidence Reveal Dioscin Suppresses Proliferation, Invasion, and EMT via AKT/GSK3b/mTOR Signaling in Lung Adenocarcinoma.	dioscin	54-61	glycogen synthase kinase 3 beta	Homo sapiens	114-119
31978503-1	2020	Glycogen synthase kinase-3beta (GSK-3beta) is an evolutionarily conserved serine/threonine kinase, functioning in numerous cellular processes including cell proliferation, DNA repair, cell cycle, signaling and metabolic pathways.	cholecystokinin C-terminal flanking peptide	74-80	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32366893-11	2020	In vitro lithium also enhanced BCL2 and GSK3B expression in these cells.	Lithium	9-16	glycogen synthase kinase 3 beta	Homo sapiens	40-45
31978503-1	2020	Glycogen synthase kinase-3beta (GSK-3beta) is an evolutionarily conserved serine/threonine kinase, functioning in numerous cellular processes including cell proliferation, DNA repair, cell cycle, signaling and metabolic pathways.	glycyl-threonine	81-90	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32425837-11	2020	Research in this area has been investigating potential beneficial compounds, including the D-amino acids D-aspartate and D-serine, that act as NMDA receptor agonists, modulating the glutamatergic signaling; the antioxidant N-acetylcysteine, a precursor in the synthesis of glutathione, protecting against the redox imbalance; as well as lithium, an inhibitor of glycogen synthase kinase 3beta (GSK3beta) signaling, contributing to oligodendrocyte survival and functioning.	d-amino acids	91-104	glycogen synthase kinase 3 beta	Homo sapiens	362-392
32306228-10	2020	Proteins of the network were mainly classified as transcription factors and kinases, which also highlighted the crucial role of glycogen synthase kinase 3beta (GSK3beta) in lithium responsiveness.	Lithium	173-180	glycogen synthase kinase 3 beta	Homo sapiens	128-158
31935492-7	2020	Our results propose GSK3beta as new target for neuroprotection, therefore, we verified that the two GSK3beta inhibitors N-(3-Chloro-4-methylphenyl)-5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine (TC-G 24) and LiCl are neuroprotective agents in OGD and also can be used as PostC agents.	N-(5-chloro-2-methylphenyl)-7-nitrobenzo(c)(1,2,5)oxadiazol-4-amine	120-189	glycogen synthase kinase 3 beta	Homo sapiens	20-28
31935492-7	2020	Our results propose GSK3beta as new target for neuroprotection, therefore, we verified that the two GSK3beta inhibitors N-(3-Chloro-4-methylphenyl)-5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine (TC-G 24) and LiCl are neuroprotective agents in OGD and also can be used as PostC agents.	N-(5-chloro-2-methylphenyl)-7-nitrobenzo(c)(1,2,5)oxadiazol-4-amine	120-189	glycogen synthase kinase 3 beta	Homo sapiens	100-108
31935492-7	2020	Our results propose GSK3beta as new target for neuroprotection, therefore, we verified that the two GSK3beta inhibitors N-(3-Chloro-4-methylphenyl)-5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine (TC-G 24) and LiCl are neuroprotective agents in OGD and also can be used as PostC agents.	Lithium Chloride	204-208	glycogen synthase kinase 3 beta	Homo sapiens	20-28
31935492-7	2020	Our results propose GSK3beta as new target for neuroprotection, therefore, we verified that the two GSK3beta inhibitors N-(3-Chloro-4-methylphenyl)-5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine (TC-G 24) and LiCl are neuroprotective agents in OGD and also can be used as PostC agents.	Lithium Chloride	204-208	glycogen synthase kinase 3 beta	Homo sapiens	100-108
32425837-11	2020	Research in this area has been investigating potential beneficial compounds, including the D-amino acids D-aspartate and D-serine, that act as NMDA receptor agonists, modulating the glutamatergic signaling; the antioxidant N-acetylcysteine, a precursor in the synthesis of glutathione, protecting against the redox imbalance; as well as lithium, an inhibitor of glycogen synthase kinase 3beta (GSK3beta) signaling, contributing to oligodendrocyte survival and functioning.	D-Aspartic Acid	105-116	glycogen synthase kinase 3 beta	Homo sapiens	362-392
32425837-11	2020	Research in this area has been investigating potential beneficial compounds, including the D-amino acids D-aspartate and D-serine, that act as NMDA receptor agonists, modulating the glutamatergic signaling; the antioxidant N-acetylcysteine, a precursor in the synthesis of glutathione, protecting against the redox imbalance; as well as lithium, an inhibitor of glycogen synthase kinase 3beta (GSK3beta) signaling, contributing to oligodendrocyte survival and functioning.	Serine	123-129	glycogen synthase kinase 3 beta	Homo sapiens	362-392
32395524-8	2020	Dezocine has diverse effects on aerobic glycolysis and adjusts the serine/threonine kinase 1 (Akt1)-glycogen synthase kinase-3beta (GSK-3beta) pathway.	dezocine	0-8	glycogen synthase kinase 3 beta	Homo sapiens	100-130
32294900-3	2020	Aplykurodin A inhibited beta-catenin responsive transcription, which was stimulated by a Wnt3a-conditioned medium or a glycogen synthase kinase 3beta inhibitor by accelerating intracellular beta-catenin degradation.	Aplykurodin A	0-13	glycogen synthase kinase 3 beta	Homo sapiens	119-149
32395524-8	2020	Dezocine has diverse effects on aerobic glycolysis and adjusts the serine/threonine kinase 1 (Akt1)-glycogen synthase kinase-3beta (GSK-3beta) pathway.	Serine	67-73	glycogen synthase kinase 3 beta	Homo sapiens	100-130
31917290-9	2020	In addition, DEX suppressed the expression of taurine, TXNIP, NLRP3, ASC and cleaved caspase-1 and activated the expression of p-AMPK and p-GSK3beta.	Dexmedetomidine	13-16	glycogen synthase kinase 3 beta	Homo sapiens	140-148
31917290-10	2020	However, those above changes could be reversed by Compound C. In conclusion, this study indicated that DEX could reduce the inflammation and apoptosis of DOX-induced myocardial cells through activating the AMPK-GSK3beta signaling pathway.	Dexmedetomidine	103-106	glycogen synthase kinase 3 beta	Homo sapiens	211-219
31917290-10	2020	However, those above changes could be reversed by Compound C. In conclusion, this study indicated that DEX could reduce the inflammation and apoptosis of DOX-induced myocardial cells through activating the AMPK-GSK3beta signaling pathway.	Doxorubicin	154-157	glycogen synthase kinase 3 beta	Homo sapiens	211-219
32188010-1	2020	Glycogen synthase kinase 3beta (GSK3beta), originally described as a negative regulator of glycogen synthesis, is a molecular hub linking numerous signaling pathways in a cell.	Glycogen	91-99	glycogen synthase kinase 3 beta	Homo sapiens	0-30
32373984-10	2020	In addition, cell assay demonstrated that mocetinostat inhibited fibroblast activation and accelerated apoptosis by inhibiting Akt/GSK3b pathway.	mocetinostat	42-54	glycogen synthase kinase 3 beta	Homo sapiens	131-136
32140390-6	2020	Subsequently, we demonstrated that CPX markedly enhanced the AKT (protein kinase B, PKB/AKT) and GSK3beta (glycogen synthase kinase 3beta) phosphorylation in OGD-exposed SH-SY5Y cells, and regulated the cell cycle progression and nitric oxide (NO) release in lipopolysaccharide (LPS)-induced BV-2 cells, which may contribute to its ameliorative effects against ischemia-associated neuronal death and microglial inflammation.	Ciclopirox	35-38	glycogen synthase kinase 3 beta	Homo sapiens	107-137
31898972-6	2020	Mechanistically, exosomal miR-8485 targeted GSK3B to repress GSK-3beta expression and targeted DACT1 to induce p-GSK-3beta (Ser9), activating Wnt/beta-catenin pathways.	seryl-seryl-seryl-arginine	124-128	glycogen synthase kinase 3 beta	Homo sapiens	113-122
31899196-4	2020	Treatment with 200 muM glutamate showed increased GluA1 phosphorylation at serine 831 and activation of CaMKIIalpha by phosphorylation at threonine 286 like LTP, whereas 100 muM glutamate treatment showed decrease in GluA1 phosphorylation level at both pGluA1(S831) and pGluA1(S845), and activation of GSK3beta by de-phosphorylating pGSK3beta at serine 9 like LTD.	Glutamic Acid	23-32	glycogen synthase kinase 3 beta	Homo sapiens	302-310
31743802-7	2020	MSC increased the phosphorylation of Akt and glycogen synthase kinase 3beta, which led to the stabilization and nuclear accumulation of beta-catenin, a transcriptional coactivator involved in EMT.	selenomethylselenocysteine	0-3	glycogen synthase kinase 3 beta	Homo sapiens	45-75
30963817-0	2020	Binding and stability of indirubin-3-monoxime in the GSK3beta enzyme: a molecular dynamics simulation and binding free energy study.	indirubin-3'-monoxime	25-45	glycogen synthase kinase 3 beta	Homo sapiens	53-61
30963817-5	2020	The recent experimental report outlines that the indirubin derivatives inhibit GSK3beta, however, the detailed binding mechanism of indrubin-GSK3beta is not yet known.	indrubin	132-140	glycogen synthase kinase 3 beta	Homo sapiens	79-87
30963817-5	2020	The recent experimental report outlines that the indirubin derivatives inhibit GSK3beta, however, the detailed binding mechanism of indrubin-GSK3beta is not yet known.	indrubin	132-140	glycogen synthase kinase 3 beta	Homo sapiens	141-149
30963817-6	2020	To understand the exact binding mechanism of indirubin derivatives in the active site of GSK3beta, the molecular conformation, intermolecular interactions, charge density distribution, electrostatic properties and the stability were determined.	indirubin	45-54	glycogen synthase kinase 3 beta	Homo sapiens	89-97
30963817-10	2020	We have performed the CD analysis of intermolecular interaction between indirubin-3-monoxime and the active site amino acids of GSK3beta.	indirubin-3'-monoxime	72-92	glycogen synthase kinase 3 beta	Homo sapiens	128-136
30963817-11	2020	Further, the stability of the molecule has been confirmed from the MD simulation and the binding free energy of the indirubin-3-monoxime-GSK3beta complex has been determined using MM/PBSA method to validate the binding affinity of indirubin-3-monoxime.	indirubin-3'-monoxime	116-136	glycogen synthase kinase 3 beta	Homo sapiens	137-145
30963817-11	2020	Further, the stability of the molecule has been confirmed from the MD simulation and the binding free energy of the indirubin-3-monoxime-GSK3beta complex has been determined using MM/PBSA method to validate the binding affinity of indirubin-3-monoxime.	poly(tetramethylene succinate-co-tetramethylene adipate)	183-187	glycogen synthase kinase 3 beta	Homo sapiens	137-145
30963817-11	2020	Further, the stability of the molecule has been confirmed from the MD simulation and the binding free energy of the indirubin-3-monoxime-GSK3beta complex has been determined using MM/PBSA method to validate the binding affinity of indirubin-3-monoxime.	indirubin-3'-monoxime	231-251	glycogen synthase kinase 3 beta	Homo sapiens	137-145
31867745-0	2020	Inhibition of Calcineurin and Glycogen Synthase Kinase-3beta by Ricinoleic Acid Derived from Castor Oil.	Ricinoleic Acids	64-79	glycogen synthase kinase 3 beta	Homo sapiens	30-60
31867745-10	2020	RA inhibited GSK-3beta at Ki = 1.43 muM in a peptide substrate-competitive manner.	Ricinoleic Acids	0-2	glycogen synthase kinase 3 beta	Homo sapiens	13-22
31867745-11	2020	The inhibition of GSK-3beta by this molecule was further assessed in mammalian cells by measuring the inhibition of glucose production in H4IIE rat hepatoma cells.	Glucose	116-123	glycogen synthase kinase 3 beta	Homo sapiens	18-27
31769621-2	2020	Glycogen synthase kinase (GSK) 3beta and brain-derived neurotrophic factor (BDNF) play a role in the therapeutic action of lithium.	Lithium	123-130	glycogen synthase kinase 3 beta	Homo sapiens	0-36
31881375-9	2020	Moreover, baicalin treatment inhibited the glycogen synthase kinase-3beta (GSK-3beta) by suppressing its phosphorylation at Y216, and upregulated the downstream mediator of the cell cycle arrest - cyclin dependent kinase inhibitor p27Kip1.	baicalin	10-18	glycogen synthase kinase 3 beta	Homo sapiens	43-73
31991293-0	2020	Wogonin inhibits cell cycle progression by activating the glycogen synthase kinase-3 beta in hepatocellular carcinoma.	wogonin	0-7	glycogen synthase kinase 3 beta	Homo sapiens	58-89
32075767-5	2020	Importantly, this latter event is linked to glycogen-synthase-kinase-3beta (GSK-3beta) hyper-activation, leading, in turn, to impaired recruitment of hexokinase 1 (HK1) to mitochondria, destabilization of mitochondrial-pyruvate-carrier (MPC) complexes, and decreased MPC2 protein levels.	Pyruvates	219-227	glycogen synthase kinase 3 beta	Homo sapiens	44-74
32158616-5	2020	Glycogen synthase kinase 3beta (GSK3beta) promoted doxorubicin-mediated apoptosis, but this effect was abolished by overexpression of SIRT1 and AROS.	Doxorubicin	51-62	glycogen synthase kinase 3 beta	Homo sapiens	0-30
31832810-0	2020	6-Gingerol induces cell-cycle G1-phase arrest through AKT-GSK 3beta-cyclin D1 pathway in renal-cell carcinoma.	gingerol	0-10	glycogen synthase kinase 3 beta	Homo sapiens	58-67
31832810-7	2020	Western-blotting results showed that 6-gingerol reduces phosphorylation of protein kinase B (AKT) Ser 473, cyclin-dependent kinases (CDK4), and cyclin D1 and, meanwhile, increases glycogen synthase kinase (GSK 3beta) protein amount.	gingerol	37-47	glycogen synthase kinase 3 beta	Homo sapiens	206-215
31832810-9	2020	CONCLUSION: The above results indicate that 6-gingerol can induce cell-cycle arrest and cell-growth inhibition through the AKT-GSK 3beta-cyclin D1 signaling pathway in vitro and in vivo, suggesting that 6-gingerol should be useful for renal-cell carcinoma treatment.	gingerol	44-54	glycogen synthase kinase 3 beta	Homo sapiens	127-136
31877369-0	2020	Sonchus oleraceus Linn extract enhanced glucose homeostasis through the AMPK/Akt/ GSK-3beta signaling pathway in diabetic liver and HepG2 cell culture.	Glucose	40-47	glycogen synthase kinase 3 beta	Homo sapiens	82-91
31877369-5	2020	Positive effects were observed on glucose homeostasis due to the down-regulation of AMPK/Akt/GSK-3beta pathway, as indicated by the suppressions of adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK), protein kinase (Akt) phosphorylation, glycogen synthase kinase 3 beta (GSK-3beta), and the hepatic insulin resistance.	Glucose	34-41	glycogen synthase kinase 3 beta	Homo sapiens	93-102
31877369-5	2020	Positive effects were observed on glucose homeostasis due to the down-regulation of AMPK/Akt/GSK-3beta pathway, as indicated by the suppressions of adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK), protein kinase (Akt) phosphorylation, glycogen synthase kinase 3 beta (GSK-3beta), and the hepatic insulin resistance.	Glucose	34-41	glycogen synthase kinase 3 beta	Homo sapiens	252-283
31877369-5	2020	Positive effects were observed on glucose homeostasis due to the down-regulation of AMPK/Akt/GSK-3beta pathway, as indicated by the suppressions of adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK), protein kinase (Akt) phosphorylation, glycogen synthase kinase 3 beta (GSK-3beta), and the hepatic insulin resistance.	Glucose	34-41	glycogen synthase kinase 3 beta	Homo sapiens	285-294
31877369-5	2020	Positive effects were observed on glucose homeostasis due to the down-regulation of AMPK/Akt/GSK-3beta pathway, as indicated by the suppressions of adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK), protein kinase (Akt) phosphorylation, glycogen synthase kinase 3 beta (GSK-3beta), and the hepatic insulin resistance.	Adenosine Monophosphate	148-174	glycogen synthase kinase 3 beta	Homo sapiens	93-102
31877369-5	2020	Positive effects were observed on glucose homeostasis due to the down-regulation of AMPK/Akt/GSK-3beta pathway, as indicated by the suppressions of adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK), protein kinase (Akt) phosphorylation, glycogen synthase kinase 3 beta (GSK-3beta), and the hepatic insulin resistance.	Adenosine Monophosphate	84-87	glycogen synthase kinase 3 beta	Homo sapiens	93-102
31877369-5	2020	Positive effects were observed on glucose homeostasis due to the down-regulation of AMPK/Akt/GSK-3beta pathway, as indicated by the suppressions of adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK), protein kinase (Akt) phosphorylation, glycogen synthase kinase 3 beta (GSK-3beta), and the hepatic insulin resistance.	Adenosine Monophosphate	84-87	glycogen synthase kinase 3 beta	Homo sapiens	252-283
31877369-5	2020	Positive effects were observed on glucose homeostasis due to the down-regulation of AMPK/Akt/GSK-3beta pathway, as indicated by the suppressions of adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK), protein kinase (Akt) phosphorylation, glycogen synthase kinase 3 beta (GSK-3beta), and the hepatic insulin resistance.	Adenosine Monophosphate	84-87	glycogen synthase kinase 3 beta	Homo sapiens	285-294
31881375-9	2020	Moreover, baicalin treatment inhibited the glycogen synthase kinase-3beta (GSK-3beta) by suppressing its phosphorylation at Y216, and upregulated the downstream mediator of the cell cycle arrest - cyclin dependent kinase inhibitor p27Kip1.	y216	124-128	glycogen synthase kinase 3 beta	Homo sapiens	43-73
31894292-0	2020	Clinically relevant GSK-3beta inhibitor 9-ING-41 is active as a single agent and in combination with other antitumor therapies in human renal cancer.	3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione	40-48	glycogen synthase kinase 3 beta	Homo sapiens	20-29
31894292-3	2020	The present study aimed to investigate the antitumor effects of 9-ING-41, which is a maleimide-based ATP-competitive small molecule GSK-3beta inhibitor active in patients with advanced cancer.	3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione	64-72	glycogen synthase kinase 3 beta	Homo sapiens	132-141
31780563-8	2020	Using a panel of kinase inhibitors targeting signaling pathways of the osmotic shock inducer sorbitol, we could largely rule out the stress-activated and extracellular signal-regulated protein kinase modules and glycogen synthase kinase 3beta.	Sorbitol	93-101	glycogen synthase kinase 3 beta	Homo sapiens	212-242
31894292-3	2020	The present study aimed to investigate the antitumor effects of 9-ING-41, which is a maleimide-based ATP-competitive small molecule GSK-3beta inhibitor active in patients with advanced cancer.	Maleimides	85-94	glycogen synthase kinase 3 beta	Homo sapiens	132-141
31894292-3	2020	The present study aimed to investigate the antitumor effects of 9-ING-41, which is a maleimide-based ATP-competitive small molecule GSK-3beta inhibitor active in patients with advanced cancer.	Adenosine Triphosphate	101-104	glycogen synthase kinase 3 beta	Homo sapiens	132-141
31930698-0	2020	Inflammation has synergistic effect with nicotine in periodontitis by up-regulating the expression of alpha7 nAChR via phosphorylated GSK-3beta.	Nicotine	41-49	glycogen synthase kinase 3 beta	Homo sapiens	134-143
31894281-8	2020	Immunofluorescence and western blot analysis revealed that AnxA2 promoted CCL18-induced EMT via the PI3K/Akt/GSK3beta/Snail signaling pathway, and LY294002 inhibited the phosphorylation of AnxA2 in vitro.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	147-155	glycogen synthase kinase 3 beta	Homo sapiens	109-117
32082480-4	2020	In the present study, we determined whether farrerol can interact with glycogen synthase kinase 3beta- (GSK-3beta-) nuclear factor erythroid 2-related factor 2- (Nrf2-) antioxidant response element (ARE) signaling, which is critical in defense against oxidative stress.	farrerol	44-52	glycogen synthase kinase 3 beta	Homo sapiens	71-101
31910234-8	2020	The phosphorylation of rpS6 S235/S236, a downstream effector of Akt, was strongly reduced in shCK2beta HK-2 cells, while the phosphorylation of two Akt direct targets, PRAS40 T246 and GSK3beta S9, was increased.	compound 235	28-32	glycogen synthase kinase 3 beta	Homo sapiens	184-192
31941827-0	2020	beta-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3beta/tau cascade.	Norepinephrine	23-37	glycogen synthase kinase 3 beta	Homo sapiens	75-83
31941827-3	2020	Our results show that Abeta oligomers bind to an allosteric site on alpha2A adrenergic receptor (alpha2AAR) to redirect norepinephrine-elicited signaling to glycogen synthase kinase 3beta (GSK3beta) activation and tau hyperphosphorylation.	Norepinephrine	120-134	glycogen synthase kinase 3 beta	Homo sapiens	157-187
31941827-3	2020	Our results show that Abeta oligomers bind to an allosteric site on alpha2A adrenergic receptor (alpha2AAR) to redirect norepinephrine-elicited signaling to glycogen synthase kinase 3beta (GSK3beta) activation and tau hyperphosphorylation.	Norepinephrine	120-134	glycogen synthase kinase 3 beta	Homo sapiens	189-197
31941827-4	2020	This norepinephrine-dependent mechanism sensitizes pathological GSK3beta/tau activation in response to nanomolar accumulations of extracellular Abeta, which is 50- to 100-fold lower than the amount required to activate GSK3beta by Abeta alone.	Norepinephrine	5-19	glycogen synthase kinase 3 beta	Homo sapiens	64-72
31941827-4	2020	This norepinephrine-dependent mechanism sensitizes pathological GSK3beta/tau activation in response to nanomolar accumulations of extracellular Abeta, which is 50- to 100-fold lower than the amount required to activate GSK3beta by Abeta alone.	Norepinephrine	5-19	glycogen synthase kinase 3 beta	Homo sapiens	219-227
31723002-0	2020	Bi-directional regulation between NDRG1 and GSK3beta controls tumor growth and is targeted by differentiation inducing factor-1 in glioblastoma.	Bismuth	0-2	glycogen synthase kinase 3 beta	Homo sapiens	44-52
31723002-6	2020	Conversely, GSK3beta phosphorylated serine and threonine sites in the C-terminal domain of NDRG1, and limited the protein stability of NDRG1.	cholecystokinin C-terminal flanking peptide	36-42	glycogen synthase kinase 3 beta	Homo sapiens	12-20
31723002-6	2020	Conversely, GSK3beta phosphorylated serine and threonine sites in the C-terminal domain of NDRG1, and limited the protein stability of NDRG1.	glycyl-threonine	47-56	glycogen synthase kinase 3 beta	Homo sapiens	12-20
31723002-6	2020	Conversely, GSK3beta phosphorylated serine and threonine sites in the C-terminal domain of NDRG1, and limited the protein stability of NDRG1.	Carbon	0-1	glycogen synthase kinase 3 beta	Homo sapiens	12-20
31913260-5	2020	In addition, we found that SGK196 N-glycosylation performs the regulatory function through the PI3K/AKT/GSK3beta signaling pathway.	Nitrogen	34-35	glycogen synthase kinase 3 beta	Homo sapiens	104-112
31910234-10	2020	In CX-4945-treated cells, the changes in rpS6 pS235/S236 and GSK3beta pS9 mirrored those induced by CK2beta knock-down (reduction and slight increase, respectively); on the contrary, the effect on PRAS40 pT246 phosphorylation was sharply different, being strongly reduced by CK2 inhibition; this suggests that this Akt target might be dependent on Akt pS473 status in HK-2 cells.	silmitasertib	3-10	glycogen synthase kinase 3 beta	Homo sapiens	61-69
31910234-13	2020	However, we found that the PI3K inhibitor LY294002 reduced GSK3beta pS9, and concomitantly decreased Snail1 levels (a GSK3beta target and Epithelial-to-Mesenchymal transition marker).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	42-50	glycogen synthase kinase 3 beta	Homo sapiens	59-67
31910234-13	2020	However, we found that the PI3K inhibitor LY294002 reduced GSK3beta pS9, and concomitantly decreased Snail1 levels (a GSK3beta target and Epithelial-to-Mesenchymal transition marker).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	42-50	glycogen synthase kinase 3 beta	Homo sapiens	118-126
31910234-14	2020	The effects of LY294002 were observed also in CK2beta-downregulated cells, suggesting that reducing GSK3beta pS9 could be a strategy to control Snail1 levels in any situation where CK2beta is defective, as possibly occurring in cancer cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	15-23	glycogen synthase kinase 3 beta	Homo sapiens	100-108
31284868-0	2020	Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3beta (GSK3beta) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.	Pyrazines	100-108	glycogen synthase kinase 3 beta	Homo sapiens	53-83
31746077-4	2020	We demonstrated that the ROS generated by lactate-fueled oxidative phosphorylation (OXPHOS) in mitochondria activated AKT, and thereby inhibited GSK-3beta/beta-TrCP-mediated ubiquitination and degradation of DNA methyltransferase 1 (DNMT1).	Lactic Acid	42-49	glycogen synthase kinase 3 beta	Homo sapiens	145-154
31284868-0	2020	Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3beta (GSK3beta) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.	Adenosine Triphosphate	109-112	glycogen synthase kinase 3 beta	Homo sapiens	53-83
31669347-0	2020	Flavonoid GL-V9 induces apoptosis and inhibits glycolysis of breast cancer via disrupting GSK-3beta-modulated mitochondrial binding of HKII.	Flavonoids	0-9	glycogen synthase kinase 3 beta	Homo sapiens	90-99
30182841-5	2020	Recent evidence suggested that lithium also possesses some anticancer properties due its inhibition of glycogen synthase kinase 3 beta (GSK3beta) which is included in regulation of a lot of important cellular processes such as: glycogen metabolism, inflammation, immunomodulation, apoptosis, tissue injury, regeneration etc.	Lithium	31-38	glycogen synthase kinase 3 beta	Homo sapiens	103-134
30182841-5	2020	Recent evidence suggested that lithium also possesses some anticancer properties due its inhibition of glycogen synthase kinase 3 beta (GSK3beta) which is included in regulation of a lot of important cellular processes such as: glycogen metabolism, inflammation, immunomodulation, apoptosis, tissue injury, regeneration etc.	Lithium	31-38	glycogen synthase kinase 3 beta	Homo sapiens	136-144
30182841-5	2020	Recent evidence suggested that lithium also possesses some anticancer properties due its inhibition of glycogen synthase kinase 3 beta (GSK3beta) which is included in regulation of a lot of important cellular processes such as: glycogen metabolism, inflammation, immunomodulation, apoptosis, tissue injury, regeneration etc.	Glycogen	103-111	glycogen synthase kinase 3 beta	Homo sapiens	136-144
32116245-9	2020	Expression of TBLR1, DKK1, GSK3B and beta-catenin was significantly decreased after koenimbin treatment in HT-19 cell line.	koenimbin	84-93	glycogen synthase kinase 3 beta	Homo sapiens	27-32
32116245-10	2020	Moreover, expression of DKK1 and GSK3B was significantly decreased after koenimbin treatment in SW-40 cell line.	koenimbin	73-82	glycogen synthase kinase 3 beta	Homo sapiens	33-38
31607135-1	2020	Glycogen synthase kinase beta (GSK3beta) is considered as a promising target for lung cancer treatment and its inhibitor lithium chloride (LiCl) is widely regarded as having potent anti-proliferative and apoptosis-modulating activities.	Lithium Chloride	121-137	glycogen synthase kinase 3 beta	Homo sapiens	31-39
31607135-1	2020	Glycogen synthase kinase beta (GSK3beta) is considered as a promising target for lung cancer treatment and its inhibitor lithium chloride (LiCl) is widely regarded as having potent anti-proliferative and apoptosis-modulating activities.	Lithium Chloride	139-143	glycogen synthase kinase 3 beta	Homo sapiens	31-39
31607135-5	2020	Overexpression of PCNA protein decreases GSK3beta Ser9 phosphorylation, whereas knockdown of PCNA using small interfering RNA (siRNA) increased Ser9 phosphorylated GSK3beta, which was attenuated by phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 after UVC irradiation, indicating the involvement of the PI3K-AKT pathway.	seryl-seryl-seryl-arginine	144-147	glycogen synthase kinase 3 beta	Homo sapiens	164-172
31607135-5	2020	Overexpression of PCNA protein decreases GSK3beta Ser9 phosphorylation, whereas knockdown of PCNA using small interfering RNA (siRNA) increased Ser9 phosphorylated GSK3beta, which was attenuated by phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 after UVC irradiation, indicating the involvement of the PI3K-AKT pathway.	Phosphatidylinositols	198-218	glycogen synthase kinase 3 beta	Homo sapiens	164-172
31607135-5	2020	Overexpression of PCNA protein decreases GSK3beta Ser9 phosphorylation, whereas knockdown of PCNA using small interfering RNA (siRNA) increased Ser9 phosphorylated GSK3beta, which was attenuated by phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 after UVC irradiation, indicating the involvement of the PI3K-AKT pathway.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	245-253	glycogen synthase kinase 3 beta	Homo sapiens	164-172
31929796-9	2019	In cisplatin-responsive cell lines, phosphorylation of AKT1 and GSK3B was decreased but could not be influenced in cisplatin-resistant NCI-H2452 cells.	Cisplatin	3-12	glycogen synthase kinase 3 beta	Homo sapiens	64-69
31938062-0	2020	The Roles of GSK-3beta in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma.	Retinoids	40-48	glycogen synthase kinase 3 beta	Homo sapiens	13-22
31938062-0	2020	The Roles of GSK-3beta in Regulation of Retinoid Signaling and Sorafenib Treatment Response in Hepatocellular Carcinoma.	sorafenib	63-72	glycogen synthase kinase 3 beta	Homo sapiens	13-22
31938062-7	2020	Since sorafenib is currently used to treat HCC, the involvement of GSK-3beta in sorafenib treatment response was determined.	sorafenib	80-89	glycogen synthase kinase 3 beta	Homo sapiens	67-76
31938062-13	2020	Overexpression of functional GSK-3beta impairs retinoid response and represses sorafenib anti-HCC effect.	Retinoids	47-55	glycogen synthase kinase 3 beta	Homo sapiens	29-38
31938062-13	2020	Overexpression of functional GSK-3beta impairs retinoid response and represses sorafenib anti-HCC effect.	sorafenib	79-88	glycogen synthase kinase 3 beta	Homo sapiens	29-38
31938062-14	2020	Inactivation of GSK-3beta by tideglusib can potentiate 9-cis-RA enhancement of sorafenib sensitivity (tumor inhibition from 48.3% to 93.4%).	retinol acetate	55-63	glycogen synthase kinase 3 beta	Homo sapiens	16-25
31938062-14	2020	Inactivation of GSK-3beta by tideglusib can potentiate 9-cis-RA enhancement of sorafenib sensitivity (tumor inhibition from 48.3% to 93.4%).	sorafenib	79-88	glycogen synthase kinase 3 beta	Homo sapiens	16-25
31938062-16	2020	Conclusions: Our findings demonstrate that GSK-3beta is a disruptor of retinoid signalling and a new resistant factor of sorafenib in HCC.	Retinoids	71-79	glycogen synthase kinase 3 beta	Homo sapiens	43-52
31938062-16	2020	Conclusions: Our findings demonstrate that GSK-3beta is a disruptor of retinoid signalling and a new resistant factor of sorafenib in HCC.	sorafenib	121-130	glycogen synthase kinase 3 beta	Homo sapiens	43-52
31882719-1	2019	Glycogen synthase kinase-3 beta (GSK-3beta), a serine/threonine kinase, has been identified as a potential therapeutic target in human bladder cancer.	Serine	47-53	glycogen synthase kinase 3 beta	Homo sapiens	0-31
31803883-6	2019	While experiments showed an ATP-competitive inhibition on GSK3beta, structure-activity relationships allowed us to identify 2-(3-pyridyl)-8-(thiomorpholino)oxazolo[5,4-f]quinoxaline as the most potent inhibitor with an IC50 value of about 5 nM on GSK3alpha.	Adenosine Triphosphate	28-31	glycogen synthase kinase 3 beta	Homo sapiens	58-66
31803883-6	2019	While experiments showed an ATP-competitive inhibition on GSK3beta, structure-activity relationships allowed us to identify 2-(3-pyridyl)-8-(thiomorpholino)oxazolo[5,4-f]quinoxaline as the most potent inhibitor with an IC50 value of about 5 nM on GSK3alpha.	benzoquinoxaline	124-181	glycogen synthase kinase 3 beta	Homo sapiens	58-66
31752244-8	2019	In addition, carbamazepine reduced beta-catenin expression by lowering the levels of phospho-low density lipoprotein receptor-related protein 6 (p-LRP6) and phospho-glycogen synthase kinase 3beta (p-GSK3beta) in Wnt/beta-catenin signaling.	Carbamazepine	13-26	glycogen synthase kinase 3 beta	Homo sapiens	199-207
31563592-0	2019	Famotidine has a neuroprotective effect on MK-801 induced toxicity via the Akt/GSK-3beta/beta-catenin signaling pathway in the SH-SY5Y cell line.	Famotidine	0-10	glycogen synthase kinase 3 beta	Homo sapiens	79-88
31563592-0	2019	Famotidine has a neuroprotective effect on MK-801 induced toxicity via the Akt/GSK-3beta/beta-catenin signaling pathway in the SH-SY5Y cell line.	Dizocilpine Maleate	43-49	glycogen synthase kinase 3 beta	Homo sapiens	79-88
31563592-3	2019	In the present study MK-801, a widely used chemical for the in vivo/in vitro modeling of schizophrenia was selected to evoke a detrimental effect on cellular survival via GSK3beta and related proteins.	Dizocilpine Maleate	21-27	glycogen synthase kinase 3 beta	Homo sapiens	171-179
31563592-6	2019	A recent study based on computerized drug modeling software (docking) indicated that famotidine might inhibit the GSK3beta activity due to its chemical structure independent from histaminergic receptors.	Famotidine	85-95	glycogen synthase kinase 3 beta	Homo sapiens	114-122
31706153-8	2019	In conclusion, we found that ADCY9, GSK3B, MAPK14, NCK1, NCOA2, PIK3CA, PIK3CB, PTK2, RHOB act as hub genes in the cisplatin-responsive regulatory network at the pro-apoptotic stages.	Cisplatin	115-124	glycogen synthase kinase 3 beta	Homo sapiens	36-41
31886264-7	2019	Metformin phosphorylates extracellular signal-regulated kinase (ERK), stimulates endothelial and inducible nitric oxide synthases (e/iNOS), inhibits the GSK3beta/Wnt/beta-catenin pathway, and promotes osteogenic differentiation of osteoblasts.	Metformin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	153-161
31920959-7	2019	Furthermore, mTOR and Wnt pathway-systems were confirmed in NFPAs by immunoaffinity Western blot analysis, with significantly decreased expression of PRAS40 and increased phosphorylation levels of p-PRAS40 (Thr246) in mTOR pathway in NFPAs compared to controls, and with the decreased protein expressions of GSK-3beta and GSK-3beta, significantly increased phosphorylation levels of p-GSK3alpha (Ser21) and p-GSK3beta (Ser9), and increased expression level of beta-catenin in Wnt pathway in NFPAs compared to controls.	seryl-seryl-seryl-arginine	396-401	glycogen synthase kinase 3 beta	Homo sapiens	308-317
31920959-7	2019	Furthermore, mTOR and Wnt pathway-systems were confirmed in NFPAs by immunoaffinity Western blot analysis, with significantly decreased expression of PRAS40 and increased phosphorylation levels of p-PRAS40 (Thr246) in mTOR pathway in NFPAs compared to controls, and with the decreased protein expressions of GSK-3beta and GSK-3beta, significantly increased phosphorylation levels of p-GSK3alpha (Ser21) and p-GSK3beta (Ser9), and increased expression level of beta-catenin in Wnt pathway in NFPAs compared to controls.	seryl-seryl-seryl-arginine	396-401	glycogen synthase kinase 3 beta	Homo sapiens	322-331
31920959-7	2019	Furthermore, mTOR and Wnt pathway-systems were confirmed in NFPAs by immunoaffinity Western blot analysis, with significantly decreased expression of PRAS40 and increased phosphorylation levels of p-PRAS40 (Thr246) in mTOR pathway in NFPAs compared to controls, and with the decreased protein expressions of GSK-3beta and GSK-3beta, significantly increased phosphorylation levels of p-GSK3alpha (Ser21) and p-GSK3beta (Ser9), and increased expression level of beta-catenin in Wnt pathway in NFPAs compared to controls.	seryl-seryl-seryl-arginine	396-401	glycogen synthase kinase 3 beta	Homo sapiens	409-417
31920959-7	2019	Furthermore, mTOR and Wnt pathway-systems were confirmed in NFPAs by immunoaffinity Western blot analysis, with significantly decreased expression of PRAS40 and increased phosphorylation levels of p-PRAS40 (Thr246) in mTOR pathway in NFPAs compared to controls, and with the decreased protein expressions of GSK-3beta and GSK-3beta, significantly increased phosphorylation levels of p-GSK3alpha (Ser21) and p-GSK3beta (Ser9), and increased expression level of beta-catenin in Wnt pathway in NFPAs compared to controls.	seryl-seryl-seryl-arginine	419-423	glycogen synthase kinase 3 beta	Homo sapiens	308-317
31920959-7	2019	Furthermore, mTOR and Wnt pathway-systems were confirmed in NFPAs by immunoaffinity Western blot analysis, with significantly decreased expression of PRAS40 and increased phosphorylation levels of p-PRAS40 (Thr246) in mTOR pathway in NFPAs compared to controls, and with the decreased protein expressions of GSK-3beta and GSK-3beta, significantly increased phosphorylation levels of p-GSK3alpha (Ser21) and p-GSK3beta (Ser9), and increased expression level of beta-catenin in Wnt pathway in NFPAs compared to controls.	seryl-seryl-seryl-arginine	419-423	glycogen synthase kinase 3 beta	Homo sapiens	322-331
31920959-7	2019	Furthermore, mTOR and Wnt pathway-systems were confirmed in NFPAs by immunoaffinity Western blot analysis, with significantly decreased expression of PRAS40 and increased phosphorylation levels of p-PRAS40 (Thr246) in mTOR pathway in NFPAs compared to controls, and with the decreased protein expressions of GSK-3beta and GSK-3beta, significantly increased phosphorylation levels of p-GSK3alpha (Ser21) and p-GSK3beta (Ser9), and increased expression level of beta-catenin in Wnt pathway in NFPAs compared to controls.	seryl-seryl-seryl-arginine	419-423	glycogen synthase kinase 3 beta	Homo sapiens	409-417
31815665-5	2019	TARA, an interaction partner of NDEL1, scaffolds DYRK2 and GSK3b to form a tripartite complex and enhances NDEL1 S336/S332 phosphorylation.	TRIM10 protein, human	75-85	glycogen synthase kinase 3 beta	Homo sapiens	59-64
31563592-7	2019	In this study, we aimed to investigate the effects of famotidine on the Akt/GSK-3beta/beta-catenin signaling pathway on SH-SY5Y neuroblastoma cells in the presence of MK-801.	Famotidine	54-64	glycogen synthase kinase 3 beta	Homo sapiens	76-85
31563592-8	2019	We investigated the effects of famotidine, olanzapine (an antipsychotic drug), and SB 415286 (specific GSK-3beta inhibitor), on the basal cellular survival and MK-801 induced neuronal death beside of Akt/GSK-3beta/beta-catenin protein and gene expressions in SH-SY5Y cells.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	83-92	glycogen synthase kinase 3 beta	Homo sapiens	103-112
31563592-10	2019	Our findings suggested that MK-801 administration decreased cell survival probably via the increasing GSK-3beta gene expression and activity in the SH-SY5Y cells.	Dizocilpine Maleate	28-34	glycogen synthase kinase 3 beta	Homo sapiens	102-111
31563592-11	2019	Pre-treatments with famotidine, olanzapine, and SB 415286 prevented MK-801 induced cell death via inhibitory effects on the MK-801 induced GSK-3beta activity.	Famotidine	20-30	glycogen synthase kinase 3 beta	Homo sapiens	139-148
31563592-11	2019	Pre-treatments with famotidine, olanzapine, and SB 415286 prevented MK-801 induced cell death via inhibitory effects on the MK-801 induced GSK-3beta activity.	olanzapine	32-42	glycogen synthase kinase 3 beta	Homo sapiens	139-148
31563592-11	2019	Pre-treatments with famotidine, olanzapine, and SB 415286 prevented MK-801 induced cell death via inhibitory effects on the MK-801 induced GSK-3beta activity.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	48-57	glycogen synthase kinase 3 beta	Homo sapiens	139-148
31563592-11	2019	Pre-treatments with famotidine, olanzapine, and SB 415286 prevented MK-801 induced cell death via inhibitory effects on the MK-801 induced GSK-3beta activity.	Dizocilpine Maleate	124-130	glycogen synthase kinase 3 beta	Homo sapiens	139-148
31563592-12	2019	Overall, the present results suggest that famotidine has a neuroprotective effect against MK-801 via modulation of the Akt/GSK-3beta/beta-catenin signaling pathway, an important mechanism in schizophrenia neurobiology.	Famotidine	42-52	glycogen synthase kinase 3 beta	Homo sapiens	123-132
31563592-12	2019	Overall, the present results suggest that famotidine has a neuroprotective effect against MK-801 via modulation of the Akt/GSK-3beta/beta-catenin signaling pathway, an important mechanism in schizophrenia neurobiology.	Dizocilpine Maleate	90-96	glycogen synthase kinase 3 beta	Homo sapiens	123-132
31292604-5	2019	The specificity of GSK3beta and p38MAPK"s mechanistic role was tested by co-treating cells with their respective inhibitors, CHIR99021 and SB203580.	SB 203580	139-147	glycogen synthase kinase 3 beta	Homo sapiens	19-27
31798454-0	2019	Corrigendum: SCD1 Confers Temozolomide Resistance to Human Glioma Cells Via the Akt/GSK3beta/beta-Catenin Signaling Axis.	temozolomide	26-38	glycogen synthase kinase 3 beta	Homo sapiens	84-92
31819479-11	2019	Conclusion: This study provides evidence for the clinical development of the GSK3beta inhibitor (AR-A014418) as a potential chemotherapeutic adjuvant for the treatment of chordoma.	N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea	97-107	glycogen synthase kinase 3 beta	Homo sapiens	77-85
31699039-9	2019	Further molecular modeling, docking and simulation approaches revealed significant conformational changes in the N-terminus region of normal to mutant CTNNB1 gene critical for binding with Glycogen synthase kinase 3-B (GSK3) and transducin containing protein1 (TrCp1).	Nitrogen	113-114	glycogen synthase kinase 3 beta	Homo sapiens	189-217
31699039-9	2019	Further molecular modeling, docking and simulation approaches revealed significant conformational changes in the N-terminus region of normal to mutant CTNNB1 gene critical for binding with Glycogen synthase kinase 3-B (GSK3) and transducin containing protein1 (TrCp1).	Nitrogen	113-114	glycogen synthase kinase 3 beta	Homo sapiens	219-223
31640277-2	2019	Here, we report that the phosphorylation of Tau Ser409 in SHSY5Y cells was increased by overexpression of GSKIP WT more than by PKA- and GSK3beta-binding defective mutants (V41/L45 and L130, respectively).	seryl-seryl-seryl-arginine	48-51	glycogen synthase kinase 3 beta	Homo sapiens	137-145
31533931-2	2019	Glycogen synthase kinase 3beta (GSK-3beta) is an emerging target in human malignancies including PDAC.Experimental Design: Pancreatic cancer cell lines and patient-derived xenografts were treated with a novel GSK-3 inhibitor 9-ING-41 alone or in combination with chemotherapy.	3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione	225-233	glycogen synthase kinase 3 beta	Homo sapiens	0-30
31519753-10	2019	In contrast, phosphomimetic substitution of the glycogen synthase kinase (GSK3beta) site in the Pro/Ala-rich linker of C0-C2 did not significantly affect the TPA results.	Alanine	100-103	glycogen synthase kinase 3 beta	Homo sapiens	74-82
31574243-0	2019	Omethoate induces pharyngeal cancer cell proliferation and G1/S cell cycle progression by activation of Akt/GSK-3beta/cyclin D1 signaling pathway.	dimethoxon	0-9	glycogen synthase kinase 3 beta	Homo sapiens	108-117
31574243-8	2019	Furthermore, we showed that omethoate was capable of activating the Akt/GSK-3beta signaling pathway.	dimethoxon	28-37	glycogen synthase kinase 3 beta	Homo sapiens	72-81
31574243-10	2019	Collectively, these findings demonstrated for the first time that omethoate could induce the pharyngeal cancer cell proliferation by activation of the Akt/GSK-3beta/cyclin D1 signaling pathway.	dimethoxon	66-75	glycogen synthase kinase 3 beta	Homo sapiens	155-164
31404613-5	2019	Suppression of GSK-3beta activity also reduced glucose consumption, lactate production and adenosine triphosphate (ATP) levels in HCC cells.	Glucose	47-54	glycogen synthase kinase 3 beta	Homo sapiens	15-24
31404613-5	2019	Suppression of GSK-3beta activity also reduced glucose consumption, lactate production and adenosine triphosphate (ATP) levels in HCC cells.	Lactic Acid	68-75	glycogen synthase kinase 3 beta	Homo sapiens	15-24
31404613-5	2019	Suppression of GSK-3beta activity also reduced glucose consumption, lactate production and adenosine triphosphate (ATP) levels in HCC cells.	Adenosine Triphosphate	91-113	glycogen synthase kinase 3 beta	Homo sapiens	15-24
31404613-5	2019	Suppression of GSK-3beta activity also reduced glucose consumption, lactate production and adenosine triphosphate (ATP) levels in HCC cells.	Adenosine Triphosphate	115-118	glycogen synthase kinase 3 beta	Homo sapiens	15-24
31404613-7	2019	Mechanistically, the metabolic change and anti-cancer effect by GSK-3beta inhibition was achieved mainly through activation of adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) signaling, which negatively affected glycolysis and cell proliferation.	adenosine 5"-monophosphate	127-153	glycogen synthase kinase 3 beta	Homo sapiens	64-73
31635074-4	2019	The results demonstrated an improvement of the insulin signalling pathway upon treatment with vitamin D alone, with significant increases in IR, PI3K, GLUT3, GLUT4 expression levels, as well as AKT phosphorylation and glucose uptake, while GSK3beta and TAU expression levels was decreased significantly.	Vitamin D	94-103	glycogen synthase kinase 3 beta	Homo sapiens	240-248
31640277-3	2019	We conducted in vitro assays of various kinase combinations to show that a combination of GSK3beta with PKA but not Ca2+/calmodulin-dependent protein kinase II (CaMK II) might provide a conformational shelter to harbor Tau Ser409.	seryl-seryl-seryl-arginine	223-226	glycogen synthase kinase 3 beta	Homo sapiens	90-98
31635074-5	2019	On the contrary, vitamin E alone, increased p-AKT, reduced the ROS as well as GSK3beta and TAU but had no effect on the insulin signalling expression levels.	Vitamin E	17-26	glycogen synthase kinase 3 beta	Homo sapiens	78-86
31750236-7	2019	Supratherapeutic concentrations of lithium decrease the activity of glycogen synthase kinase-3beta (GSK-3beta), leading to cell cycle arrest in several in vitro cancer models including medullary thyroid cancer (TC), pheochromocytoma/paraganglioma and carcinoid.	Lithium	35-42	glycogen synthase kinase 3 beta	Homo sapiens	68-98
31750236-7	2019	Supratherapeutic concentrations of lithium decrease the activity of glycogen synthase kinase-3beta (GSK-3beta), leading to cell cycle arrest in several in vitro cancer models including medullary thyroid cancer (TC), pheochromocytoma/paraganglioma and carcinoid.	Lithium	35-42	glycogen synthase kinase 3 beta	Homo sapiens	100-109
31680960-10	2019	Our findings indicated that the phosphorylated activation of Akt played a role in the proliferation of HaCat cells upon long-term, low-dose NaAsO2 exposure through the phosphorylative regulation of its downstream cell cycle regulating factors of GSK-3beta/cyclin D1, p21 and p27, which could induce the promotion of cell cycle progression from G1 to S/G2M phase.	Sodium	140-146	glycogen synthase kinase 3 beta	Homo sapiens	246-255
31502580-9	2019	In vivo experiments, recovery of GSK3beta prevented xenograft tumor growth and DDP resistance in the presence of miR-425-5p mimic.	425-5p	117-123	glycogen synthase kinase 3 beta	Homo sapiens	33-41
31680960-0	2019	Akt Regulated Phosphorylation of GSK-3beta/Cyclin D1, p21 and p27 Contributes to Cell Proliferation Through Cell Cycle Progression From G1 to S/G2M Phase in Low-Dose Arsenite Exposed HaCat Cells.	Arsenites	166-174	glycogen synthase kinase 3 beta	Homo sapiens	33-42
31325197-5	2019	Western blot analysis confirmed that delphinidin treatment can significantly decrease the expression of beta-catenin, glycogen synthase kinase-3beta (Gsk3beta), c-Myc, cyclin-D1, and matrix metalloproteinase-7(MMP-7) expression in breast cancer cells, and inhibition of miR-34a significantly reduced the effect of delphinidin on c-Myc, cyclin-D1, and MMP-7.	delphinidin	37-48	glycogen synthase kinase 3 beta	Homo sapiens	118-148
31325197-5	2019	Western blot analysis confirmed that delphinidin treatment can significantly decrease the expression of beta-catenin, glycogen synthase kinase-3beta (Gsk3beta), c-Myc, cyclin-D1, and matrix metalloproteinase-7(MMP-7) expression in breast cancer cells, and inhibition of miR-34a significantly reduced the effect of delphinidin on c-Myc, cyclin-D1, and MMP-7.	delphinidin	37-48	glycogen synthase kinase 3 beta	Homo sapiens	150-158
31325476-0	2019	Phytic acid attenuates upregulation of GSK-3beta and disturbance of synaptic vesicle recycling in MPTP-induced Parkinson"s disease models.	Phytic Acid	0-11	glycogen synthase kinase 3 beta	Homo sapiens	39-48
31325476-6	2019	Furthermore, expression of GSK-3beta was upregulated while that of beta-catenin was downregulated, concentration of cytosolic calcium was increased, and expressions of two dopamine carriers, dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) were decreased.	Dopamine	172-180	glycogen synthase kinase 3 beta	Homo sapiens	27-36
31325476-7	2019	PA treatment attenuated the MPTP-induced upregulation of GSK-3beta, increase in cytosolic calcium concentration, decreases in the levels of DAT, VMAT2, tissue dopamine, and synaptic vesicle recycling.	Phytic Acid	0-2	glycogen synthase kinase 3 beta	Homo sapiens	57-66
31325476-7	2019	PA treatment attenuated the MPTP-induced upregulation of GSK-3beta, increase in cytosolic calcium concentration, decreases in the levels of DAT, VMAT2, tissue dopamine, and synaptic vesicle recycling.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	28-32	glycogen synthase kinase 3 beta	Homo sapiens	57-66
31524268-11	2019	Furthermore, western blot analysis results demonstrated that Cas-II-gly and the MALAT1/miR-17-5p/FZD2 axis could affect the expression of proteins associated with the Wnt signaling pathway, including disheveled segment polarity protein, glycogen synthase kinase-3beta and beta-catenin, and via the MALAT1/miR-17-5p/FZD2/Wnt signaling pathway axis.	casiopeina II-glycine	61-71	glycogen synthase kinase 3 beta	Homo sapiens	237-267
31641423-7	2019	In addition, shRNA targeting SGK1 and SB216763 were added into the culture medium before H2O2 exposure to downregulate SGK1 and GSK3beta, respectively.	SB 216763	38-46	glycogen synthase kinase 3 beta	Homo sapiens	128-136
31641423-12	2019	Moreover, the deleterious effects of SGK1 suppression on cell apoptosis and mitochondrial function, including mitochondrial biogenesis, were related to the phosphorylation of GSK3beta and partially reversed by SB216763 treatment.	SB 216763	210-218	glycogen synthase kinase 3 beta	Homo sapiens	175-183
31641423-13	2019	H2O2 leads to SGK1 overexpression in HK-2 cells, which protects human renal tubule cells from oxidative stress injury by improving mitochondrial function and inactivating GSK3beta.	Water	0-4	glycogen synthase kinase 3 beta	Homo sapiens	171-179
31338947-0	2019	Design, Synthesis and in Vitro Tumor Cytotoxicity Evaluation of 3,5-Diamino-N-substituted Benzamide Derivatives as Novel GSK-3beta Small Molecule Inhibitors.	3,5-diamino-n-substituted benzamide	64-99	glycogen synthase kinase 3 beta	Homo sapiens	121-130
31338947-3	2019	To find out the GSK-3beta small molecule inhibitor with novel, safe, efficient and more uncomplicated synthesis method, we analyzed in-depth reported crystal-binding patterns of GSK-3beta small molecule inhibitor with GSK-3beta protein, and designed and synthesized 17 non-reported 3,5-diamino-N-substituted benzamide compounds.	3,5-diamino-n-substituted benzamide	282-317	glycogen synthase kinase 3 beta	Homo sapiens	16-25
31338947-3	2019	To find out the GSK-3beta small molecule inhibitor with novel, safe, efficient and more uncomplicated synthesis method, we analyzed in-depth reported crystal-binding patterns of GSK-3beta small molecule inhibitor with GSK-3beta protein, and designed and synthesized 17 non-reported 3,5-diamino-N-substituted benzamide compounds.	3,5-diamino-n-substituted benzamide	282-317	glycogen synthase kinase 3 beta	Homo sapiens	178-187
31338947-3	2019	To find out the GSK-3beta small molecule inhibitor with novel, safe, efficient and more uncomplicated synthesis method, we analyzed in-depth reported crystal-binding patterns of GSK-3beta small molecule inhibitor with GSK-3beta protein, and designed and synthesized 17 non-reported 3,5-diamino-N-substituted benzamide compounds.	3,5-diamino-n-substituted benzamide	282-317	glycogen synthase kinase 3 beta	Homo sapiens	178-187
31338947-6	2019	The results have shown that 3,5-diamino-N-[3-(trifluoromethyl)phenyl]benzamide (4d) exhibited significant tumor cytotoxicity against human colon cancer cells (HCT-116) with IC50 of 8.3 mum and showed commendable selectivity to GSK-3beta.	N-[3-(Trifluoromethyl)phenyl]-3,5-diaminobenzamide	28-78	glycogen synthase kinase 3 beta	Homo sapiens	227-236
31410143-11	2019	The current study demonstrated that treatment with gefitinib decreased the protein expression levels of phosphorylated-GSK3beta and beta-catenin, which suggests that gefitinib may be a potential novel therapeutic strategy in CC by suppressing the Wnt/beta-catenin signaling pathway and EMT to inhibit tumor metastasis in CC cells.	Gefitinib	51-60	glycogen synthase kinase 3 beta	Homo sapiens	119-127
31410143-11	2019	The current study demonstrated that treatment with gefitinib decreased the protein expression levels of phosphorylated-GSK3beta and beta-catenin, which suggests that gefitinib may be a potential novel therapeutic strategy in CC by suppressing the Wnt/beta-catenin signaling pathway and EMT to inhibit tumor metastasis in CC cells.	Gefitinib	166-175	glycogen synthase kinase 3 beta	Homo sapiens	119-127
31243899-7	2019	This promotion of fibrosis by FSH occurred through the activation of AKT/GSK-3beta/beta-catenin pathway, which could be attenuated by silencing FSHR by siRNA or by LY294002 or MK2206.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	164-172	glycogen synthase kinase 3 beta	Homo sapiens	73-82
31243899-7	2019	This promotion of fibrosis by FSH occurred through the activation of AKT/GSK-3beta/beta-catenin pathway, which could be attenuated by silencing FSHR by siRNA or by LY294002 or MK2206.	MK 2206	176-182	glycogen synthase kinase 3 beta	Homo sapiens	73-82
31632899-9	2019	To determine whether magnolol disrupts TGF-beta signaling, we examined several mediators of this pathway, and found that magnolol decreased the levels of phosphorylated (i.e., active) ERK, GSK3beta, and Smad.	magnolol	121-129	glycogen synthase kinase 3 beta	Homo sapiens	189-197
31501414-5	2019	Moreover, CCR2-mediated regorafenib tolerance was demonstrated to be associated with AKT/GSK3beta-regulated beta-catenin stabilization.	regorafenib	24-35	glycogen synthase kinase 3 beta	Homo sapiens	89-97
31346036-6	2019	The polyubiquitylation of p53 occurred via Lys-48 linkage and involved phosphorylation on p53 at Ser-33 and Ser-37 by glycogen synthase kinase 3beta (GSK3beta) and DNA-dependent protein kinase (DNA-PK), respectively.	Serine	97-100	glycogen synthase kinase 3 beta	Homo sapiens	118-148
31346036-6	2019	The polyubiquitylation of p53 occurred via Lys-48 linkage and involved phosphorylation on p53 at Ser-33 and Ser-37 by glycogen synthase kinase 3beta (GSK3beta) and DNA-dependent protein kinase (DNA-PK), respectively.	Serine	97-100	glycogen synthase kinase 3 beta	Homo sapiens	150-158
31346036-6	2019	The polyubiquitylation of p53 occurred via Lys-48 linkage and involved phosphorylation on p53 at Ser-33 and Ser-37 by glycogen synthase kinase 3beta (GSK3beta) and DNA-dependent protein kinase (DNA-PK), respectively.	Serine	108-111	glycogen synthase kinase 3 beta	Homo sapiens	118-148
31346036-6	2019	The polyubiquitylation of p53 occurred via Lys-48 linkage and involved phosphorylation on p53 at Ser-33 and Ser-37 by glycogen synthase kinase 3beta (GSK3beta) and DNA-dependent protein kinase (DNA-PK), respectively.	Serine	108-111	glycogen synthase kinase 3 beta	Homo sapiens	150-158
30529756-6	2019	Moreover, minocycline blocked ethanol-induced activation of glycogen synthase kinase 3 beta (GSK3beta), a key regulator of microglial activation.	Minocycline	10-21	glycogen synthase kinase 3 beta	Homo sapiens	60-91
30529756-6	2019	Moreover, minocycline blocked ethanol-induced activation of glycogen synthase kinase 3 beta (GSK3beta), a key regulator of microglial activation.	Ethanol	30-37	glycogen synthase kinase 3 beta	Homo sapiens	60-91
31142701-8	2019	Moreover, QLQX inhibited the apoptosis rate and the pro-apoptosis protein expressions, but improved the Bcl-2 expression as well as the ratios of phospho-AKT/AKT and phospho-GSK3beta/GSK3beta.	qlqx	10-14	glycogen synthase kinase 3 beta	Homo sapiens	174-182
31524255-0	2019	Resveratrol inhibits the invasion and metastasis of colon cancer through reversal of epithelial- mesenchymal transition via the AKT/GSK-3beta/Snail signaling pathway.	Resveratrol	0-11	glycogen synthase kinase 3 beta	Homo sapiens	132-141
31524255-5	2019	The results revealed that resveratrol treatment and AKT1 knockdown significantly inhibited cell migration and invasion in colon cancer, and markedly increased E-cadherin expression and decreased that of N-cadherin, phospho (p)-AKT1, p-GSK-3beta, and Snail in colon cancer both in vitro and in vivo.	Resveratrol	26-37	glycogen synthase kinase 3 beta	Homo sapiens	235-244
31524255-7	2019	In conclusion, resveratrol may suppress the invasion and metastasis of colon cancer through reversal of EMT via the AKT/GSK-3beta/Snail signaling pathway.	Resveratrol	15-26	glycogen synthase kinase 3 beta	Homo sapiens	120-129
31071331-0	2019	Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3beta-regulated suppression of beta-catenin signaling.	shikonin	0-8	glycogen synthase kinase 3 beta	Homo sapiens	122-152
31071331-9	2019	Moreover, shikonin upregulated glycogen synthase kinase 3beta (GSK-3beta) levels, leading to enhanced phosphorylation and decreased levels of beta-catenin.	shikonin	10-18	glycogen synthase kinase 3 beta	Homo sapiens	31-61
31071331-9	2019	Moreover, shikonin upregulated glycogen synthase kinase 3beta (GSK-3beta) levels, leading to enhanced phosphorylation and decreased levels of beta-catenin.	shikonin	10-18	glycogen synthase kinase 3 beta	Homo sapiens	63-72
31071331-11	2019	Histological analysis confirmed that shikonin elevated levels of E-cadherin, phosphorylated beta-catenin, and GSK-3beta, and decreased levels of vimentin and beta-catenin in pulmonary metastatic foci.	shikonin	37-45	glycogen synthase kinase 3 beta	Homo sapiens	110-119
31071331-12	2019	These results indicated that shikonin potently inhibits TNBC metastasis by targeting the EMT via GSK-3beta-regulated suppression of beta-catenin signaling, which highlights the importance of shikonin as a potential candidate for novel anticancer therapeutics against TNBC.	shikonin	29-37	glycogen synthase kinase 3 beta	Homo sapiens	97-106
31261037-0	2019	Berberine coated mannosylated liposomes curtail RANKL stimulated osteoclastogenesis through the modulation of GSK3beta pathway via upregulating miR-23a.	Berberine	0-9	glycogen synthase kinase 3 beta	Homo sapiens	110-118
31261037-5	2019	Treatment with ML-BBR abrogated the increased osteoclast formation in BMM cells via inhibiting phosphorylated glutathione synthase kinase beta (p-GSK3beta) mediated NFATc1 activation.	ml-bbr	15-21	glycogen synthase kinase 3 beta	Homo sapiens	146-154
31261037-9	2019	Comparatively, LY2090314 (GSK3beta inhibitor) treatment inhibited the protein level expression of GSK3beta/p-GSK3beta.	3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione	15-24	glycogen synthase kinase 3 beta	Homo sapiens	26-34
31261037-9	2019	Comparatively, LY2090314 (GSK3beta inhibitor) treatment inhibited the protein level expression of GSK3beta/p-GSK3beta.	3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione	15-24	glycogen synthase kinase 3 beta	Homo sapiens	98-106
31261037-9	2019	Comparatively, LY2090314 (GSK3beta inhibitor) treatment inhibited the protein level expression of GSK3beta/p-GSK3beta.	3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione	15-24	glycogen synthase kinase 3 beta	Homo sapiens	98-106
31261037-10	2019	However, LY2090314 treatment induced a basal level expression of miR-23a owing to the suggestion that ML-BBR has an influential role in upregulating miR-23a level to inhibit GSK-3beta phosphorylation.	3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione	9-18	glycogen synthase kinase 3 beta	Homo sapiens	174-183
31620226-0	2019	Pyridinylimidazoles as GSK3beta Inhibitors: The Impact of Tautomerism on Compound Activity via Water Networks.	pyridinylimidazoles	0-19	glycogen synthase kinase 3 beta	Homo sapiens	23-31
31620226-3	2019	In this study, we aimed to design selective GSK3beta inhibitors based on our pyridinylimidazole scaffold.	CHEMBL96741	77-95	glycogen synthase kinase 3 beta	Homo sapiens	44-52
31620226-5	2019	5-(2-(Cyclopropanecarboxamido)pyridin-4-yl)-4-cyclopropyl-1H-imidazole-2-carboxamide (6g) displayed very good kinase selectivity as well as metabolical stability and inhibited GSK3beta activity in neuronal SH-SY5Y cells.	2-(4-(pyridin-2-yl)phenyl)-1H-benzo(d)imidazole-4-carboxamide	0-84	glycogen synthase kinase 3 beta	Homo sapiens	176-184
31054961-5	2019	Suppression of ERK1/2, GSK3beta and CK2 activities attenuated CsA-induced down-regulation of HSP expression and up-regulation of HSF1 phosphorylation.	Cyclosporine	62-65	glycogen synthase kinase 3 beta	Homo sapiens	23-31
31142701-8	2019	Moreover, QLQX inhibited the apoptosis rate and the pro-apoptosis protein expressions, but improved the Bcl-2 expression as well as the ratios of phospho-AKT/AKT and phospho-GSK3beta/GSK3beta.	qlqx	10-14	glycogen synthase kinase 3 beta	Homo sapiens	183-191
31142701-11	2019	We conclude that QLQX may ameliorate oxidative stress-induced mitochondria-dependent apoptosis in cardiomyocytes through PI3K/AKT/GSK3beta signaling pathway.	qlqx	17-21	glycogen synthase kinase 3 beta	Homo sapiens	130-138
31096153-0	2019	Pyridinylimidazoles as dual glycogen synthase kinase 3beta/p38alpha mitogen-activated protein kinase inhibitors.	pyridinylimidazoles	0-19	glycogen synthase kinase 3 beta	Homo sapiens	28-58
31096153-2	2019	Here we unveil 2,4,5-trisubstituted imidazoles as dual inhibitors of p38alpha mitogen-activated protein kinase and glycogen synthase kinase 3beta (GSK3beta).	2,4,5-trisubstituted imidazoles	15-46	glycogen synthase kinase 3 beta	Homo sapiens	115-145
31096153-2	2019	Here we unveil 2,4,5-trisubstituted imidazoles as dual inhibitors of p38alpha mitogen-activated protein kinase and glycogen synthase kinase 3beta (GSK3beta).	2,4,5-trisubstituted imidazoles	15-46	glycogen synthase kinase 3 beta	Homo sapiens	147-155
31096153-6	2019	One of the best balanced dual inhibitors presented in here is N-(4-(2-ethyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyridin-2-yl)cyclopropanecarboxamide (20c) (p38alpha, IC50 = 16 nM; GSK3beta, IC50 = 35 nM) featuring an excellent metabolic stability and an appreciable isoform selectivity over the closely related GSK3alpha.	n-(4-(2-ethyl-4-(4-fluorophenyl)-1h-imidazol-5-yl)pyridin-2-yl)cyclopropanecarboxamide	62-148	glycogen synthase kinase 3 beta	Homo sapiens	180-188
31055215-6	2019	Moreover, the negative effect of complex 1 was reversed by LiCl, a GSK3beta-specific inhibitor of the PI3K signaling pathway.	Lithium Chloride	59-63	glycogen synthase kinase 3 beta	Homo sapiens	67-75
31324193-13	2019	Expression and phosphorylation of Akt and GSK-3beta were also decreased with an upregulation of Fyn expression after steroid treatment.	Steroids	117-124	glycogen synthase kinase 3 beta	Homo sapiens	42-51
31173209-7	2019	Western blot analysis demonstrated that the protein expression levels of phosphorylated glycogen synthase kinase-3beta (pGsk-3beta) were decreased, and the expression of beta-catenin was decreased in B-CPAP cells overexpressing miR-26b-5p.	pgsk-3beta	120-130	glycogen synthase kinase 3 beta	Homo sapiens	88-118
31358767-9	2019	The LKB1 and pho-GSK3beta may also be potential predictive markers for everolimus.	Everolimus	71-81	glycogen synthase kinase 3 beta	Homo sapiens	17-25
31006103-9	2019	The results of in vivo and in vitro assays indicated that GSK3beta knockdown with lentiviral shRNA (shRNA-GSK3beta) promoted apoptosis and suppressed the migration of cisplatin-resistant MCF-7/MDR cells, while these effects were reversed by activating p-AKT with the PTEN inhibitor bpV(pic).	Cisplatin	167-176	glycogen synthase kinase 3 beta	Homo sapiens	58-66
30866601-6	2019	Additionally, 7,8,4"-THIF significantly restored the expression levels of phosphorylated c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase 1/2 (ERK 1/2), phosphatidylinositol 3-kinases (PI3K)/Akt, and glycogen synthase kinase-3 beta (GSK-3beta) in 6-OHDA-induced SH-SY5Y cells.	7,8,4"-thif	14-25	glycogen synthase kinase 3 beta	Homo sapiens	265-296
30866601-6	2019	Additionally, 7,8,4"-THIF significantly restored the expression levels of phosphorylated c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase 1/2 (ERK 1/2), phosphatidylinositol 3-kinases (PI3K)/Akt, and glycogen synthase kinase-3 beta (GSK-3beta) in 6-OHDA-induced SH-SY5Y cells.	7,8,4"-thif	14-25	glycogen synthase kinase 3 beta	Homo sapiens	298-307
30974114-6	2019	Activation of CXCR6 resulted in increased GSK-3beta, NF-kappaB, ERK1/2 phosphorylation, and survivin expression, which reduce DTX response.	Digitoxigenin	126-129	glycogen synthase kinase 3 beta	Homo sapiens	42-51
31006103-7	2019	RESULTS: An increase in GSK3beta, p-PTEN and p-AKT expression was strongly induced in MCF-7/MDR and cisplatin-resistant MDA-MB-468 cells, and augmented GSK3beta phosphorylation and PTEN inactivation enhanced AKT signaling.	Cisplatin	100-109	glycogen synthase kinase 3 beta	Homo sapiens	24-32
31006103-9	2019	The results of in vivo and in vitro assays indicated that GSK3beta knockdown with lentiviral shRNA (shRNA-GSK3beta) promoted apoptosis and suppressed the migration of cisplatin-resistant MCF-7/MDR cells, while these effects were reversed by activating p-AKT with the PTEN inhibitor bpV(pic).	Cisplatin	167-176	glycogen synthase kinase 3 beta	Homo sapiens	106-114
31006103-9	2019	The results of in vivo and in vitro assays indicated that GSK3beta knockdown with lentiviral shRNA (shRNA-GSK3beta) promoted apoptosis and suppressed the migration of cisplatin-resistant MCF-7/MDR cells, while these effects were reversed by activating p-AKT with the PTEN inhibitor bpV(pic).	bromopyruvate	282-285	glycogen synthase kinase 3 beta	Homo sapiens	58-66
31006103-9	2019	The results of in vivo and in vitro assays indicated that GSK3beta knockdown with lentiviral shRNA (shRNA-GSK3beta) promoted apoptosis and suppressed the migration of cisplatin-resistant MCF-7/MDR cells, while these effects were reversed by activating p-AKT with the PTEN inhibitor bpV(pic).	bromopyruvate	282-285	glycogen synthase kinase 3 beta	Homo sapiens	106-114
31119584-11	2019	We also observed DHT-mediated activation of Akt/GSK-3beta signaling pathway which plays a central role in cancer progression.	Dihydrotestosterone	17-20	glycogen synthase kinase 3 beta	Homo sapiens	48-57
31062382-5	2019	Chromatin immunoprecipitation (ChIP) assay was used to verify the enrichment of EZH2 and histone H3 lysine 27 trimethylation (H3K27me3) in the promoter region of GSK-3beta in CRC cells.	Lysine	100-106	glycogen synthase kinase 3 beta	Homo sapiens	162-171
31218332-0	2019	[Wnt5a modulates vincristine resistance through PI3K/Akt/GSK3beta signaling pathway in human ovarian carcinoma SKOV3/VCR cells].	Vincristine	17-28	glycogen synthase kinase 3 beta	Homo sapiens	57-65
31223033-5	2019	PTS reversed PA-mediated activation of c-Jun N-terminal kinase (JNK), which in turn altered insulin signalling pathway by phosphorylating IRS-1 at Ser 307, leading to inhibition of phosphorylation of Akt and GSK-3beta.	Palmitic Acid	13-15	glycogen synthase kinase 3 beta	Homo sapiens	208-217
30887599-3	2019	Interestingly, epimagnolin suppressed EGF-induced Akt phosphorylation strongly at Ser473 and weakly at Thr308 without alteration of phosphorylation of MAPK/ERK kinases (MEKs), extracellular signal-regulated kinase (ERKs), and RSK1, resulting in abrogation of the phosphorylation of GSK3beta at Ser9 and p70S6K at Thr389.	magnolin	15-26	glycogen synthase kinase 3 beta	Homo sapiens	282-290
30798370-7	2019	Moreover, we also found that (+)SKF-10047 increased the phosphorylation of ERK1/2 (extracellular signal-regulated kinases 1/2) and GSK3beta (glycogen synthase kinase 3beta) (ser 9) in the primary astrocytes.	SK and F 10047	32-41	glycogen synthase kinase 3 beta	Homo sapiens	141-171
30798370-7	2019	Moreover, we also found that (+)SKF-10047 increased the phosphorylation of ERK1/2 (extracellular signal-regulated kinases 1/2) and GSK3beta (glycogen synthase kinase 3beta) (ser 9) in the primary astrocytes.	Serine	174-177	glycogen synthase kinase 3 beta	Homo sapiens	141-171
31104320-3	2019	METHODS: We overexpressed GSK-3beta and observed its effect on reactive oxygen species (ROS) and oxidative stress-induced cell death.	Reactive Oxygen Species	63-86	glycogen synthase kinase 3 beta	Homo sapiens	26-35
31104320-3	2019	METHODS: We overexpressed GSK-3beta and observed its effect on reactive oxygen species (ROS) and oxidative stress-induced cell death.	Reactive Oxygen Species	88-91	glycogen synthase kinase 3 beta	Homo sapiens	26-35
31104320-7	2019	RESULTS: IL-8 promotes prostate cancer cell proliferation and decreases apoptosis, whereas GSK-3beta activates the caspase-3 signaling pathway by increasing ROS and thereby induces oxidative stress-mediated cell death.	Reactive Oxygen Species	157-160	glycogen synthase kinase 3 beta	Homo sapiens	91-100
31104320-10	2019	CONCLUSION: The results of this study highlight the importance of GSK-3beta, which increases the production of ROS and thereby induces oxidative stress in tumor cells, whereas IL-8 and mTOR attenuate oxidative stress to protect prostate cancer cells through inhibition of GSK-3beta.	Reactive Oxygen Species	111-114	glycogen synthase kinase 3 beta	Homo sapiens	66-75
31270046-6	2019	XAV-939, a GSK-3beta/beta-catenin inhibitor, was used for assessing the impact of lincRNAUFC1 overexpression on the invasion and migration of the HCC cells through Transwell and wound-healing assays.	XAV939	0-7	glycogen synthase kinase 3 beta	Homo sapiens	11-20
31242571-0	2019	Design, Synthesis and Biological Evaluation of 7-Chloro-9H-pyrimido[4,5-b]indole-based Glycogen Synthase Kinase-3beta Inhibitors.	7-chloro-9H-pyrimido[4,5-b]indole	47-80	glycogen synthase kinase 3 beta	Homo sapiens	87-117
31218332-9	2019	Meanwhile, LY294002 (PI3K inhibitor) decreased the protein expression levels of MDR1, beta-catenin and Survivin, as well as the phosphorylation levels of Akt and GSK3beta in SKOV3/VCR cells (P &lt; 0.05).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	11-19	glycogen synthase kinase 3 beta	Homo sapiens	162-170
30878387-8	2019	We also found that tanshinone I dose-dependently inhibited IGF-1R activation and its downstream molecules, insulin receptor substrate (IRS)-1, phosphatidylinositol-3-Kinase (PI3K), Akt, glycogen synthase kinase-3 beta (GSK3beta), mammalian target of rapamycin (mTOR), 70S6K, and ribosomal protein S6 (RPS6).	tanshinone	19-29	glycogen synthase kinase 3 beta	Homo sapiens	186-217
30796032-6	2019	MTI-31 also suppressed programmed death ligand 1 (PD-L1) in EGFR- and ALK-driven NSCLC, mediated in part by mTORC2/AKT/GSK3beta-dependent proteasomal degradation.	MTI-31	0-6	glycogen synthase kinase 3 beta	Homo sapiens	119-127
30878387-8	2019	We also found that tanshinone I dose-dependently inhibited IGF-1R activation and its downstream molecules, insulin receptor substrate (IRS)-1, phosphatidylinositol-3-Kinase (PI3K), Akt, glycogen synthase kinase-3 beta (GSK3beta), mammalian target of rapamycin (mTOR), 70S6K, and ribosomal protein S6 (RPS6).	tanshinone	19-29	glycogen synthase kinase 3 beta	Homo sapiens	219-227
31186678-0	2019	BAY 87-2243 sensitizes hepatocellular carcinoma Hep3B cells to histone deacetylase inhibitors treatment via GSK-3beta activation.	1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine	0-11	glycogen synthase kinase 3 beta	Homo sapiens	108-117
30543130-0	2019	Loureirin B Promotes Axon Regeneration by Inhibiting Endoplasmic Reticulum Stress: Induced Mitochondrial Dysfunction and Regulating the Akt/GSK-3beta Pathway after Spinal Cord Injury.	loureirin B	0-11	glycogen synthase kinase 3 beta	Homo sapiens	140-149
31171023-0	2019	Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3beta/beta-catenin signaling pathway.	Cisplatin	42-51	glycogen synthase kinase 3 beta	Homo sapiens	132-140
30890376-0	2019	Silencing GSK3beta instead of DKK1 can inhibit osteogenic differentiation caused by co-exposure to fluoride and arsenic.	Fluorides	99-107	glycogen synthase kinase 3 beta	Homo sapiens	10-18
30890376-0	2019	Silencing GSK3beta instead of DKK1 can inhibit osteogenic differentiation caused by co-exposure to fluoride and arsenic.	Arsenic	112-119	glycogen synthase kinase 3 beta	Homo sapiens	10-18
30890376-13	2019	The results indicate that silencing GSK3beta instead of DKK1 can inhibit osteogenic differentiation caused by co-exposure to fluoride and arsenic.	Fluorides	125-133	glycogen synthase kinase 3 beta	Homo sapiens	36-44
30890376-13	2019	The results indicate that silencing GSK3beta instead of DKK1 can inhibit osteogenic differentiation caused by co-exposure to fluoride and arsenic.	Arsenic	138-145	glycogen synthase kinase 3 beta	Homo sapiens	36-44
31186678-6	2019	Furthermore, glycogen synthase kinase-3beta might be involved in the enhanced cell death induced by BAY 87-2243 plus HDAC inhibitors.	1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine	100-111	glycogen synthase kinase 3 beta	Homo sapiens	13-43
31121982-0	2019	NDRG2 Sensitizes Myeloid Leukemia to Arsenic Trioxide via GSK3beta-NDRG2-PP2A Complex Formation.	Arsenic Trioxide	37-53	glycogen synthase kinase 3 beta	Homo sapiens	58-66
31059055-5	2019	We also found that vorapaxar could reduce the damage of DNA caused by cholesterol stimulation and regulate the cell cycle via the AKT/JNK signaling pathway and its downstream molecules glycogen synthase kinase 3beta (GSK-3beta) and connexin 43, maintaining the integrity of the endothelial barrier and proliferation of endothelial cells, serving a protective role in endothelial cells.	vorapaxar	19-28	glycogen synthase kinase 3 beta	Homo sapiens	185-215
31059055-5	2019	We also found that vorapaxar could reduce the damage of DNA caused by cholesterol stimulation and regulate the cell cycle via the AKT/JNK signaling pathway and its downstream molecules glycogen synthase kinase 3beta (GSK-3beta) and connexin 43, maintaining the integrity of the endothelial barrier and proliferation of endothelial cells, serving a protective role in endothelial cells.	vorapaxar	19-28	glycogen synthase kinase 3 beta	Homo sapiens	217-226
31026007-0	2019	beta-Thujaplicin inhibits basal-like mammary tumor growth by regulating glycogen synthase kinase-3beta/beta-catenin signaling.	beta-thujaplicin	0-16	glycogen synthase kinase 3 beta	Homo sapiens	72-102
30238389-4	2019	The neurons derived from our AD-iPSCs demonstrated aberrant accumulation of intracellular and secreted Abeta42 and Abeta40, reduction of serine 9 phosphorylation in glycogen synthase kinase 3beta (GSK3beta) hyperphosphorylation of threonine 181 and serine 396 in tau protein, impaired neurite outgrowth, downregulation of synaptophysin, and increased caspase 1 activity.	Serine	137-143	glycogen synthase kinase 3 beta	Homo sapiens	165-195
31004883-10	2019	Moreover, abnormal GSK-3beta/beta-catenin signaling in HepG2 cells was remarkably suppressed by PAB treatment.	pseudolaric acid B	96-99	glycogen synthase kinase 3 beta	Homo sapiens	19-28
31004883-12	2019	CONCLUSION: Taken together, our results suggest that PAB exerts anti-cancer activity in HCC cells through inhibition of STAT3, ERK1/2, Akt, and GSK-3beta/beta-catenin carcinogenic signaling pathways, and may be used as a phytomedicine in the treatment of HCC.	pseudolaric acid B	53-56	glycogen synthase kinase 3 beta	Homo sapiens	144-153
31121982-9	2019	Our findings suggest that NDRG2 is a kind of adaptor protein mediating the interaction between GSK3beta and PP2A, inducing GSK3beta activation through dephosphorylation at S9 by PP2A, which increases sensitivity to As2O3 in U937 cells.	Arsenic Trioxide	215-220	glycogen synthase kinase 3 beta	Homo sapiens	95-103
31121982-9	2019	Our findings suggest that NDRG2 is a kind of adaptor protein mediating the interaction between GSK3beta and PP2A, inducing GSK3beta activation through dephosphorylation at S9 by PP2A, which increases sensitivity to As2O3 in U937 cells.	Arsenic Trioxide	215-220	glycogen synthase kinase 3 beta	Homo sapiens	123-131
31121982-5	2019	The higher sensitivity to As2O3 in U937-NDRG2 was associated with Mcl-1 degradation through glycogen synthase kinase 3beta (GSK3beta) activation.	Arsenic Trioxide	26-31	glycogen synthase kinase 3 beta	Homo sapiens	92-122
31121982-5	2019	The higher sensitivity to As2O3 in U937-NDRG2 was associated with Mcl-1 degradation through glycogen synthase kinase 3beta (GSK3beta) activation.	Arsenic Trioxide	26-31	glycogen synthase kinase 3 beta	Homo sapiens	124-132
31121982-6	2019	Inhibitory phosphorylation of GSK3beta was significantly reduced in U937-NDRG2, and the reduction was diminished by okadaic acid, a protein phosphatase inhibitor.	Okadaic Acid	116-128	glycogen synthase kinase 3 beta	Homo sapiens	30-38
31258723-8	2019	Additionally, it was shown that Akt-GSK3beta signaling cascade was involved in tumor arrest induced by nifurtimox.	Nifurtimox	103-113	glycogen synthase kinase 3 beta	Homo sapiens	36-44
31031016-0	2019	Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3beta-MCL-1 Axis.	Metformin	32-41	glycogen synthase kinase 3 beta	Homo sapiens	111-119
31156373-2	2019	SB216763 is a small molecular compound that can enhance the remyelination of peripheral nerves by inhibiting glycogen synthase kinase-3beta (GSK3beta).	SB 216763	0-8	glycogen synthase kinase 3 beta	Homo sapiens	109-139
31156373-2	2019	SB216763 is a small molecular compound that can enhance the remyelination of peripheral nerves by inhibiting glycogen synthase kinase-3beta (GSK3beta).	SB 216763	0-8	glycogen synthase kinase 3 beta	Homo sapiens	141-149
31031016-4	2019	Synergistic anti-neoplastic effects of the metformin/hypoglycemia combination were mediated by glycogen synthase kinase 3beta (GSK3beta) activation downstream of PP2A, leading to a decline in the pro-survival protein MCL-1, and cell death.	Metformin	43-52	glycogen synthase kinase 3 beta	Homo sapiens	95-125
31031016-4	2019	Synergistic anti-neoplastic effects of the metformin/hypoglycemia combination were mediated by glycogen synthase kinase 3beta (GSK3beta) activation downstream of PP2A, leading to a decline in the pro-survival protein MCL-1, and cell death.	Metformin	43-52	glycogen synthase kinase 3 beta	Homo sapiens	127-135
31031016-5	2019	Mechanistically, specific activation of the PP2A-GSK3beta axis was the sum of metformin-induced inhibition of CIP2A, a PP2A suppressor, and of upregulation of the PP2A regulatory subunit B56delta by low glucose, leading to an active PP2A-B56delta complex with high affinity toward GSK3beta.	Metformin	78-87	glycogen synthase kinase 3 beta	Homo sapiens	49-57
31031016-5	2019	Mechanistically, specific activation of the PP2A-GSK3beta axis was the sum of metformin-induced inhibition of CIP2A, a PP2A suppressor, and of upregulation of the PP2A regulatory subunit B56delta by low glucose, leading to an active PP2A-B56delta complex with high affinity toward GSK3beta.	Metformin	78-87	glycogen synthase kinase 3 beta	Homo sapiens	281-289
31031016-5	2019	Mechanistically, specific activation of the PP2A-GSK3beta axis was the sum of metformin-induced inhibition of CIP2A, a PP2A suppressor, and of upregulation of the PP2A regulatory subunit B56delta by low glucose, leading to an active PP2A-B56delta complex with high affinity toward GSK3beta.	Glucose	203-210	glycogen synthase kinase 3 beta	Homo sapiens	49-57
30904158-6	2019	Western blot results confirmed that the active form phospho-GSK3beta Tyr216 expression was increased significantly after bryostatin-1 treatment.	bryostatin 1	121-133	glycogen synthase kinase 3 beta	Homo sapiens	60-68
30771350-6	2019	In addition, our results demonstrated that SB290157 markedly inhibited the activities of glycogen synthase kinase 3beta (GSK3beta), but had no effect on protein phosphatase 2A C subunit (PP2Ac) and cyclin-dependent kinases 5 (CDK5).	SB 290157	43-51	glycogen synthase kinase 3 beta	Homo sapiens	89-119
30771350-6	2019	In addition, our results demonstrated that SB290157 markedly inhibited the activities of glycogen synthase kinase 3beta (GSK3beta), but had no effect on protein phosphatase 2A C subunit (PP2Ac) and cyclin-dependent kinases 5 (CDK5).	SB 290157	43-51	glycogen synthase kinase 3 beta	Homo sapiens	121-129
30667602-1	2019	Lithium ion, commonly used as the carbonate salt in the treatment of bipolar disorders, has been identified as an inhibitor of several kinases, including Glycogen Synthase Kinase-3beta, for almost 20 years.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	154-184
31048708-8	2019	Finally, sevoflurane, knockdown of Rik-203, and miR-101a-3p overexpression all decreased GSK-3beta levels.	Sevoflurane	9-20	glycogen synthase kinase 3 beta	Homo sapiens	89-98
31048708-9	2019	These data suggest that Rik-203 facilitates neural differentiation by inhibiting miR-101a-3p"s ability to reduce GSK-3beta levels and that LncRNAs would serve as the mechanism of the anesthesia neurotoxicity.	mir-101a	81-89	glycogen synthase kinase 3 beta	Homo sapiens	113-122
30806983-7	2019	Interestingly, either specific GSK3beta inhibitors or specific mitogen-activated protein kinase kinase (MEK) inhibitors significantly prevented 25C-NBOMe-induced neurotoxicity in SH-SY5Y cells.	25c	144-147	glycogen synthase kinase 3 beta	Homo sapiens	31-39
30868765-6	2019	Combined with LiCl or MG-132 treatment, SPINK5 can inhibit GSK3beta phosphorylation and promote beta-catenin protein degradation, thus inhibit Wnt/beta-catenin signaling pathway.	Lithium Chloride	14-18	glycogen synthase kinase 3 beta	Homo sapiens	59-67
30868765-6	2019	Combined with LiCl or MG-132 treatment, SPINK5 can inhibit GSK3beta phosphorylation and promote beta-catenin protein degradation, thus inhibit Wnt/beta-catenin signaling pathway.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	22-28	glycogen synthase kinase 3 beta	Homo sapiens	59-67
31143694-9	2019	Cinnamaldehyde (15 and 23 muM) suppressed the Abeta-induced increment of GSK-3beta protein level.	cinnamaldehyde	0-14	glycogen synthase kinase 3 beta	Homo sapiens	73-82
31143694-9	2019	Cinnamaldehyde (15 and 23 muM) suppressed the Abeta-induced increment of GSK-3beta protein level.	UNII-042A8N37WH	46-51	glycogen synthase kinase 3 beta	Homo sapiens	73-82
31143694-11	2019	Moreover, the inhibition of GSK-3beta may contribute to the cinnamaldehyde neuroprotection.	cinnamaldehyde	60-74	glycogen synthase kinase 3 beta	Homo sapiens	28-37
30949773-2	2019	GSK3beta has a unique specificity, with its primed substrates binding to the primed phosphate binding site, which is critical for the catalytic activity of GSK3beta.	Phosphates	84-93	glycogen synthase kinase 3 beta	Homo sapiens	0-8
31114749-0	2019	Clinicohistopathological implications of phosphoserine 9 glycogen synthase kinase-3beta/ beta-catenin in urinary bladder cancer patients.	Phosphoserine	41-54	glycogen synthase kinase 3 beta	Homo sapiens	57-87
31114749-1	2019	BACKGROUND: Aberrant activation of phosphorylated form of glycogen synthase kinase-3beta [pS9GSK-3beta (Serine 9 phosphorylation)] is known to trigger Wnt/beta-catenin signal cascade but its clinicohistopathological implications in bladder carcinogenesis remain unknown.	Serine	104-110	glycogen synthase kinase 3 beta	Homo sapiens	58-88
31114749-1	2019	BACKGROUND: Aberrant activation of phosphorylated form of glycogen synthase kinase-3beta [pS9GSK-3beta (Serine 9 phosphorylation)] is known to trigger Wnt/beta-catenin signal cascade but its clinicohistopathological implications in bladder carcinogenesis remain unknown.	Serine	104-110	glycogen synthase kinase 3 beta	Homo sapiens	93-102
30819803-4	2019	Mechanistically, we observed that the RING domain stabilizes c-Myc by inhibiting its phosphorylation at Thr-58 and that this inhibition is due to activated ERK1/2-mediated phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) at Ser-9.	Serine	237-240	glycogen synthase kinase 3 beta	Homo sapiens	191-221
30896826-0	2019	Songorine suppresses cell growth and metastasis in epithelial ovarian cancer via the Bcl-2/Bax and GSK3beta/beta-catenin signaling pathways.	songorine	0-9	glycogen synthase kinase 3 beta	Homo sapiens	99-107
30896826-9	2019	In particular, GSK3beta inhibitor treatment restored the songorine-induced regulation of the GSK3beta/beta-catenin signaling pathway.	songorine	57-66	glycogen synthase kinase 3 beta	Homo sapiens	15-23
30896826-9	2019	In particular, GSK3beta inhibitor treatment restored the songorine-induced regulation of the GSK3beta/beta-catenin signaling pathway.	songorine	57-66	glycogen synthase kinase 3 beta	Homo sapiens	93-101
30896826-10	2019	Furthermore, in the in vitro and in vivo experiments, songorine consistently downregulated the expression of N-cadherin, vimentin, matrix metalloproteinase (MMP)-2, MMP-9, phosphorylated-GSK3beta, beta-catenin and Bcl-2, and upregulated the expression of E-cadherin, cleaved caspase-3, cleaved caspase-9 and Bax.	songorine	54-63	glycogen synthase kinase 3 beta	Homo sapiens	187-195
30896826-11	2019	In conclusion, songorine exerted its anticancer effect through the GSK3beta/beta-catenin and Bcl-2/Bax signaling pathways.	songorine	15-24	glycogen synthase kinase 3 beta	Homo sapiens	67-75
31005954-3	2019	Investigation revealed that MCC-555 might function as a GSK3beta inhibitor to promote osteoblastogenesis and bone formation.	netoglitazone	28-35	glycogen synthase kinase 3 beta	Homo sapiens	56-64
31024245-0	2019	7-Pyrrolidinethoxy-4"-Methoxyisoflavone Prevents Amyloid beta-Induced Injury by Regulating Histamine H3 Receptor-Mediated cAMP/CREB and AKT/GSK3beta Pathways.	7-pyrrolidinethoxy-4"-methoxyisoflavone	0-39	glycogen synthase kinase 3 beta	Homo sapiens	140-148
31024245-5	2019	In addition, treatment with LC1405 resulted in the up-regulation of acetylcholine (ACh) or histamine release and provided neuroprotection through cellular signaling cascades involving H3R-mediated cAMP/CREB and AKT/GSK3beta pathways.	lc1405	28-34	glycogen synthase kinase 3 beta	Homo sapiens	215-223
31024245-6	2019	Furthermore, the beneficial effects of LC1405 on Abeta-mediated toxicity and H3R-mediated cAMP/CREB and AKT/GSK3beta axes were reversed after pharmacological activation of H3R.	lc1405	39-45	glycogen synthase kinase 3 beta	Homo sapiens	108-116
30965670-0	2019	Regulation of the Nrf2 Pathway by Glycogen Synthase Kinase-3beta in MPP+-Induced Cell Damage.	mangion-purified polysaccharide (Candida albicans)	68-72	glycogen synthase kinase 3 beta	Homo sapiens	34-64
30965670-7	2019	The number of viable cells and mitochondrial membrane potential were increased following GSK-3beta enzyme inhibition against MPP+.	mangion-purified polysaccharide (Candida albicans)	125-129	glycogen synthase kinase 3 beta	Homo sapiens	89-98
30949773-2	2019	GSK3beta has a unique specificity, with its primed substrates binding to the primed phosphate binding site, which is critical for the catalytic activity of GSK3beta.	Phosphates	84-93	glycogen synthase kinase 3 beta	Homo sapiens	156-164
30949773-7	2019	The resulting conformational rearrangement of the A-loop in the L343R mutant disrupted the primed phosphate binding site, thereby abrogating the catalytic activity of GSK3beta.	Phosphates	98-107	glycogen synthase kinase 3 beta	Homo sapiens	167-175
30968232-8	2019	Our data exposed that vildagliptine has lowering effect on GSK3beta and Tau phosphorylation.	vildagliptine	22-35	glycogen synthase kinase 3 beta	Homo sapiens	59-67
30968232-10	2019	These results indicate that vildagliptine exerts a protective effect against Abeta by decreasing apoptosis related proteins, lowering GSK3beta and Tau phosphorylation levels in addition to expression of PSEN1 and PSEN2 mRNA downregulation effect.	vildagliptine	28-41	glycogen synthase kinase 3 beta	Homo sapiens	134-142
30302821-0	2019	Upregulated lncRNA small nucleolar RNA host gene 1 promotes 1-methyl-4-phenylpyridinium ion-induced cytotoxicity and reactive oxygen species production through miR-15b-5p/GSK3beta axis in human dopaminergic SH-SY5Y cells.	1-Methyl-4-phenylpyridinium	60-87	glycogen synthase kinase 3 beta	Homo sapiens	171-179
30690126-5	2019	Also, vernicilignan A increase the cell viability of H2O2 treated cells via the activation of Akt and GSK3beta.	vernicilignan a	6-21	glycogen synthase kinase 3 beta	Homo sapiens	102-110
30690126-5	2019	Also, vernicilignan A increase the cell viability of H2O2 treated cells via the activation of Akt and GSK3beta.	Hydrogen Peroxide	53-57	glycogen synthase kinase 3 beta	Homo sapiens	102-110
30302821-0	2019	Upregulated lncRNA small nucleolar RNA host gene 1 promotes 1-methyl-4-phenylpyridinium ion-induced cytotoxicity and reactive oxygen species production through miR-15b-5p/GSK3beta axis in human dopaminergic SH-SY5Y cells.	Reactive Oxygen Species	117-140	glycogen synthase kinase 3 beta	Homo sapiens	171-179
30320903-8	2019	This study provides biological evidence about purvalanol and roscovitine have apoptotic and antimetastatic effects via MAPK signaling on prostate cancer cell by activation of GSK3beta signaling and inhibition of phosphoinositide-3-kinase/AKT (PI3K/AKT) pathways involved in the EMT process.	purvalanol B	46-56	glycogen synthase kinase 3 beta	Homo sapiens	175-183
30302821-9	2019	The inhibitory effects of SNHG1 knockdown or miR-15b-5p overexpression on MPP+ -induced cytotoxicity and reactive oxygen species (ROS) production were abrogated by upregulation of GSK3beta.	mangion-purified polysaccharide (Candida albicans)	74-78	glycogen synthase kinase 3 beta	Homo sapiens	180-188
30320903-8	2019	This study provides biological evidence about purvalanol and roscovitine have apoptotic and antimetastatic effects via MAPK signaling on prostate cancer cell by activation of GSK3beta signaling and inhibition of phosphoinositide-3-kinase/AKT (PI3K/AKT) pathways involved in the EMT process.	Roscovitine	61-72	glycogen synthase kinase 3 beta	Homo sapiens	175-183
30302821-9	2019	The inhibitory effects of SNHG1 knockdown or miR-15b-5p overexpression on MPP+ -induced cytotoxicity and reactive oxygen species (ROS) production were abrogated by upregulation of GSK3beta.	Reactive Oxygen Species	105-128	glycogen synthase kinase 3 beta	Homo sapiens	180-188
30302821-10	2019	Taken together, these results demonstrate that upregulated lncRNA SNHG1 promotes MPP+ -induced cytotoxicity and ROS production through the miR-15b-5p/GSK3beta axis in human dopaminergic SH-SY5Y cells, suggesting that SNHG1 may act as a potential therapeutic target for PD treatment in the future.	mangion-purified polysaccharide (Candida albicans)	81-85	glycogen synthase kinase 3 beta	Homo sapiens	150-158
30831484-11	2019	Then, we found that the ERK and GSK3beta/beta-catenin signaling pathway were noticeably blocked in CRC cells after treatment with NG.	Nitroglycerin	130-132	glycogen synthase kinase 3 beta	Homo sapiens	32-40
30824926-8	2019	The results proved that inhibited GSK3A (serine phosphorylated) presents a significant strong positive correlation (r = 0.822, P = 0.023) with the percentage of progressive human sperm, whereas inhibited GSK3B is not significantly correlated with sperm motility (r = 0.577, P = 0.175).	Serine	41-47	glycogen synthase kinase 3 beta	Homo sapiens	204-209
30831484-14	2019	Then, the Ser9 phosphorylation of GSK3beta can be reduced / raised by GO 6983 / LiCl, respectively.	Lithium Chloride	80-84	glycogen synthase kinase 3 beta	Homo sapiens	34-42
31008108-7	2019	In addition, phospho-GSK-3beta also was found to be increased following loratadine treatment.	Loratadine	72-82	glycogen synthase kinase 3 beta	Homo sapiens	21-30
31024297-5	2019	Melatonin (5 mg/kg) attenuated ischemia-induced down regulation of NMDA receptor 2 (NR2a), postsynaptic density-95 (PSD95) and increases NR2a/PSD95 complex association, which further activates the pro-survival PI3K/Akt/GSK3beta pathway with mitigated collapsin response mediator protein 2 (CRMP2) phosphorylation.	Melatonin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	219-227
30037362-9	2019	Furthermore, suppression of GSK-3beta function led to a noticeable decrease in ATP generation, and this was associated with stimulation of AMP-activated protein kinase (AMPK) in T47D cells.	Adenosine Triphosphate	79-82	glycogen synthase kinase 3 beta	Homo sapiens	28-37
30912763-6	2019	Additionally, NaHS increased expression of Bcl-2, c-myc, c-fos and c-jun, and the phosphorylation of ERK1/2, PI3K, Akt and GSK-3beta.	sodium bisulfide	14-18	glycogen synthase kinase 3 beta	Homo sapiens	123-132
30912763-9	2019	These results suggest that exogenous H2S restores PC-mediated cardioprotection by up-regulating HB-EGF/EGFR signaling, which activates the ERK1/2-c-myc (and fos and c-jun) and PI3K-Akt- GSK-3beta pathways in the aged cardiomyocytes.	Hydrogen Sulfide	37-40	glycogen synthase kinase 3 beta	Homo sapiens	186-195
30912763-9	2019	These results suggest that exogenous H2S restores PC-mediated cardioprotection by up-regulating HB-EGF/EGFR signaling, which activates the ERK1/2-c-myc (and fos and c-jun) and PI3K-Akt- GSK-3beta pathways in the aged cardiomyocytes.	pc	50-52	glycogen synthase kinase 3 beta	Homo sapiens	186-195
31354196-4	2019	In this study we report the contribution and prognostic significance of GSK3B to two breast cancer subtypes; ductal carcinoma in-situ (DCIS) and invasive ductal carcinoma (IDC) using the Oncomine platform.	oncomine	187-195	glycogen synthase kinase 3 beta	Homo sapiens	72-77
31354196-7	2019	Through computational predictions, BT-000775 is a highly selective GSK3B inhibitor, with superior binding affinity and robust ADME profiles suitable for the patho-physiological presentations.	bt-000775	35-44	glycogen synthase kinase 3 beta	Homo sapiens	67-72
30664149-9	2019	The western blotting revealed that Pris effectively synergized with Cis to induce cell apoptosis by inhibiting the microRNA-23a/Akt/glycogen synthase kinase 3beta signaling pathway and suppressing autophagy.	pristimerin	35-39	glycogen synthase kinase 3 beta	Homo sapiens	132-162
30763586-7	2019	Homoharringtonine (HHT) can potentiate the anti-leukemia effects of ATO on adhered AML cells by suppressing Mcl-1 through glycogen synthase kinase-3beta (GSK3beta).	Homoharringtonine	0-17	glycogen synthase kinase 3 beta	Homo sapiens	122-152
30763586-7	2019	Homoharringtonine (HHT) can potentiate the anti-leukemia effects of ATO on adhered AML cells by suppressing Mcl-1 through glycogen synthase kinase-3beta (GSK3beta).	Homoharringtonine	0-17	glycogen synthase kinase 3 beta	Homo sapiens	154-162
30763586-7	2019	Homoharringtonine (HHT) can potentiate the anti-leukemia effects of ATO on adhered AML cells by suppressing Mcl-1 through glycogen synthase kinase-3beta (GSK3beta).	Homoharringtonine	19-22	glycogen synthase kinase 3 beta	Homo sapiens	122-152
30763586-7	2019	Homoharringtonine (HHT) can potentiate the anti-leukemia effects of ATO on adhered AML cells by suppressing Mcl-1 through glycogen synthase kinase-3beta (GSK3beta).	Homoharringtonine	19-22	glycogen synthase kinase 3 beta	Homo sapiens	154-162
30763586-7	2019	Homoharringtonine (HHT) can potentiate the anti-leukemia effects of ATO on adhered AML cells by suppressing Mcl-1 through glycogen synthase kinase-3beta (GSK3beta).	Arsenic Trioxide	68-71	glycogen synthase kinase 3 beta	Homo sapiens	122-152
30763586-7	2019	Homoharringtonine (HHT) can potentiate the anti-leukemia effects of ATO on adhered AML cells by suppressing Mcl-1 through glycogen synthase kinase-3beta (GSK3beta).	Arsenic Trioxide	68-71	glycogen synthase kinase 3 beta	Homo sapiens	154-162
30664149-0	2019	Pristimerin enhances the effect of cisplatin by inhibiting the miR-23a/Akt/GSK3beta signaling pathway and suppressing autophagy in lung cancer cells.	pristimerin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	75-83
30664149-0	2019	Pristimerin enhances the effect of cisplatin by inhibiting the miR-23a/Akt/GSK3beta signaling pathway and suppressing autophagy in lung cancer cells.	Cisplatin	35-44	glycogen synthase kinase 3 beta	Homo sapiens	75-83
30793366-0	2019	Metformin promotes survivin degradation through AMPK/PKA/GSK-3beta-axis in non-small cell lung cancer.	Metformin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	57-66
30813433-16	2019	EGCG, an abundant catechin in tea, was found to suppress the neurotoxicity induced by Abeta as it activates glycogen synthase kinase-3beta (GSK-3beta), along with inhibiting c-Abl/FE65-the cytoplasmic nonreceptor tyrosine kinase which is involved in the development of the nervous system and in nuclear translocation.	epigallocatechin gallate	0-4	glycogen synthase kinase 3 beta	Homo sapiens	108-138
30813433-16	2019	EGCG, an abundant catechin in tea, was found to suppress the neurotoxicity induced by Abeta as it activates glycogen synthase kinase-3beta (GSK-3beta), along with inhibiting c-Abl/FE65-the cytoplasmic nonreceptor tyrosine kinase which is involved in the development of the nervous system and in nuclear translocation.	epigallocatechin gallate	0-4	glycogen synthase kinase 3 beta	Homo sapiens	140-149
30813433-16	2019	EGCG, an abundant catechin in tea, was found to suppress the neurotoxicity induced by Abeta as it activates glycogen synthase kinase-3beta (GSK-3beta), along with inhibiting c-Abl/FE65-the cytoplasmic nonreceptor tyrosine kinase which is involved in the development of the nervous system and in nuclear translocation.	UNII-042A8N37WH	86-91	glycogen synthase kinase 3 beta	Homo sapiens	108-138
30813433-16	2019	EGCG, an abundant catechin in tea, was found to suppress the neurotoxicity induced by Abeta as it activates glycogen synthase kinase-3beta (GSK-3beta), along with inhibiting c-Abl/FE65-the cytoplasmic nonreceptor tyrosine kinase which is involved in the development of the nervous system and in nuclear translocation.	UNII-042A8N37WH	86-91	glycogen synthase kinase 3 beta	Homo sapiens	140-149
30260001-7	2019	The present results also showed that melatonin and taxol induced GSK3-beta nuclear and Snail cytosolic localization.	Melatonin	37-46	glycogen synthase kinase 3 beta	Homo sapiens	65-74
30260001-7	2019	The present results also showed that melatonin and taxol induced GSK3-beta nuclear and Snail cytosolic localization.	Paclitaxel	51-56	glycogen synthase kinase 3 beta	Homo sapiens	65-74
30793366-7	2019	Moreover, metformin greatly suppressed protein kinase A (PKA) activity and induced its downstream glycogen synthase kinase 3beta (GSK-3beta) activation.	Metformin	10-19	glycogen synthase kinase 3 beta	Homo sapiens	98-128
30863067-13	2019	The activation of protein kinase B (AKT)/glycogen synthase kinase 3 beta (GSK3beta) signaling pathway also blocked by PTX in cultured HKFs and keloid tissues.	Paclitaxel	118-121	glycogen synthase kinase 3 beta	Homo sapiens	41-72
30793366-7	2019	Moreover, metformin greatly suppressed protein kinase A (PKA) activity and induced its downstream glycogen synthase kinase 3beta (GSK-3beta) activation.	Metformin	10-19	glycogen synthase kinase 3 beta	Homo sapiens	130-139
30863067-13	2019	The activation of protein kinase B (AKT)/glycogen synthase kinase 3 beta (GSK3beta) signaling pathway also blocked by PTX in cultured HKFs and keloid tissues.	Paclitaxel	118-121	glycogen synthase kinase 3 beta	Homo sapiens	74-82
30793366-12	2019	These results suggest that metformin kills lung cancer cells through AMPK/PKA/GSK-3beta-axis-mediated survivin degradation, providing novel insights into the anticancer effects of metformin.	Metformin	27-36	glycogen synthase kinase 3 beta	Homo sapiens	78-87
30793366-12	2019	These results suggest that metformin kills lung cancer cells through AMPK/PKA/GSK-3beta-axis-mediated survivin degradation, providing novel insights into the anticancer effects of metformin.	Metformin	180-189	glycogen synthase kinase 3 beta	Homo sapiens	78-87
30863067-15	2019	The inhibition of AKT/GSK3beta signaling pathway contribute to inhibit the generation of fibrogenic cytokines by PTXL on ameliorating fibrosis progress in keloids.	ptxl	113-117	glycogen synthase kinase 3 beta	Homo sapiens	22-30
30447378-0	2019	Dose-dependent effects of isoflurane on TrkB and GSK3beta signaling: Importance of burst suppression pattern.	Isoflurane	26-36	glycogen synthase kinase 3 beta	Homo sapiens	49-57
30447378-1	2019	OBJECTIVES: Deep burst-suppressing isoflurane anesthesia regulates signaling pathways connected with antidepressant responses in the rodent brain: activation of TrkB neurotrophin receptor and inhibition of GSK3beta kinase (glycogen synthase kinase 3beta).	Isoflurane	35-45	glycogen synthase kinase 3 beta	Homo sapiens	206-214
30447378-1	2019	OBJECTIVES: Deep burst-suppressing isoflurane anesthesia regulates signaling pathways connected with antidepressant responses in the rodent brain: activation of TrkB neurotrophin receptor and inhibition of GSK3beta kinase (glycogen synthase kinase 3beta).	Isoflurane	35-45	glycogen synthase kinase 3 beta	Homo sapiens	223-253
30447378-8	2019	CONCLUSIONS: Isoflurane dose-dependently regulates TrkB and GSK3beta signaling and dosing associated with therapeutic outcomes in depressed patients produces most prominent effects.	Isoflurane	13-23	glycogen synthase kinase 3 beta	Homo sapiens	60-68
30899376-8	2019	RESULTS: VICs treated with OST medium for 5 days exhibited higher RUNX2 and GSK-3beta expression levels than did control cells.	METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE	27-30	glycogen synthase kinase 3 beta	Homo sapiens	76-85
30899395-6	2019	BNP treatment considerably induced GSK3beta inhibition, marked by inhibitory phosphorylation at the serine 9 residue, and this significantly correlated with the abrogated TIMP2 induction in TGFbeta1-injured podocytes.	Serine	100-106	glycogen synthase kinase 3 beta	Homo sapiens	35-43
30899376-9	2019	A class I HDAC inhibitor (MS-275 at 1 muM) reduced the RUNX2 mRNA and protein expression levels and alkaline phosphatase activity and downregulated non-canonical Wnt/GSK-3beta signaling, canonical Wnt/beta-catenin signaling, and BMP signaling.	entinostat	26-32	glycogen synthase kinase 3 beta	Homo sapiens	166-175
30567739-6	2019	We also found that upon activation of glycogen synthase kinase 3beta (GSK3beta), phosphorylation of Rbm38 at Ser-195 is increased, enhancing p63alpha expression in an Rbm38-dependent manner.	Serine	109-112	glycogen synthase kinase 3 beta	Homo sapiens	38-68
30616053-4	2019	Lithium was the first GSK-3beta inhibitor to be used for therapeutic outcome and has been effectively used for many years.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	22-31
30567739-6	2019	We also found that upon activation of glycogen synthase kinase 3beta (GSK3beta), phosphorylation of Rbm38 at Ser-195 is increased, enhancing p63alpha expression in an Rbm38-dependent manner.	Serine	109-112	glycogen synthase kinase 3 beta	Homo sapiens	70-78
30809197-10	2019	Knocking down of LRP6 enhanced glucose uptake and insulin sensitivity in PA treated cells, probably through increasing GSK3b activity.	Palmitates	73-75	glycogen synthase kinase 3 beta	Homo sapiens	119-124
30724378-0	2019	Substance P inhibits high urea-induced apoptosis through the AKT/GSK-3beta pathway in human corneal epithelial cells.	Urea	26-30	glycogen synthase kinase 3 beta	Homo sapiens	65-74
29631413-7	2019	Such cells showed increased binding of PPARalpha with p53 that in turn reduced interaction of p53 with glycogen synthase kinase-3beta (GSK3beta), which upregulated inactive phospho-GSK3beta (serine [Ser]9) expression within mitochondrial protein fraction.	Serine	191-197	glycogen synthase kinase 3 beta	Homo sapiens	103-133
29631413-7	2019	Such cells showed increased binding of PPARalpha with p53 that in turn reduced interaction of p53 with glycogen synthase kinase-3beta (GSK3beta), which upregulated inactive phospho-GSK3beta (serine [Ser]9) expression within mitochondrial protein fraction.	Serine	199-202	glycogen synthase kinase 3 beta	Homo sapiens	103-133
30724378-7	2019	The Western blot analysis and qRT-PCR experiments revealed that SP significantly increased the expression of p-AKT and p-GSK-3beta (P &lt; 0.05); additionally, these increases were attenuated after the perifosine inhibition of the AKT signaling pathway (P &lt; 0.05).	perifosine	202-212	glycogen synthase kinase 3 beta	Homo sapiens	121-130
29310523-0	2019	Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3beta.	naphtho(2,1-b)furan	63-75	glycogen synthase kinase 3 beta	Homo sapiens	145-154
30530190-2	2019	Following a multitarget approach, in this paper a series of polycyclic maleimide-based derivatives were designed and synthesized aimed at simultaneously modulate neuronal calcium channels and glycogen synthase kinase 3-beta (GSK-3beta), validated targets to combat Alzheimer" disease.	polycyclic maleimide	60-80	glycogen synthase kinase 3 beta	Homo sapiens	192-223
29310523-3	2019	Till now only two scaffolds (triazinone and curcumin) derivatives have been reported as BACE-1 and GSK-3beta dual inhibitors.	triazinone	29-39	glycogen synthase kinase 3 beta	Homo sapiens	99-108
30678307-6	2019	After THD treatment, Fzd-1 and GSK3beta-S9 phosphorylation (inactivated form) was reduced to promote beta-catenin degradation, which attenuated P62 inhibition.	Thioridazine	6-9	glycogen synthase kinase 3 beta	Homo sapiens	31-39
29310523-3	2019	Till now only two scaffolds (triazinone and curcumin) derivatives have been reported as BACE-1 and GSK-3beta dual inhibitors.	Curcumin	44-52	glycogen synthase kinase 3 beta	Homo sapiens	99-108
29310523-5	2019	In this study, we have explored other naphthofuran derivatives for their potential to inhibit BACE-1 and GSK-3beta through docking, molecular dynamics, binding energy (MM-PBSA).	naphtho(2,1-b)furan	38-50	glycogen synthase kinase 3 beta	Homo sapiens	105-114
29310523-5	2019	In this study, we have explored other naphthofuran derivatives for their potential to inhibit BACE-1 and GSK-3beta through docking, molecular dynamics, binding energy (MM-PBSA).	poly(tetramethylene succinate-co-tetramethylene adipate)	171-175	glycogen synthase kinase 3 beta	Homo sapiens	105-114
29310523-6	2019	These computational methods were performed to estimate the binding affinity of naphthofuran derivatives towards the BACE-1 and GSK-3beta.	naphtho(2,1-b)furan	79-91	glycogen synthase kinase 3 beta	Homo sapiens	127-136
29310523-8	2019	Hydrogen bond occupancy of NS7 and NS9 generated from MD trajectories showed good interaction with the flap residues Gln73, Thr72 of BACE-1 and Arg141, Thr138 residues of GSK-3beta.	Hydrogen	0-8	glycogen synthase kinase 3 beta	Homo sapiens	171-180
29310523-12	2019	The results suggested that naphthofuran derivatives might act as dual inhibitor against BACE-1 and GSK-3beta.	naphtho(2,1-b)furan	27-39	glycogen synthase kinase 3 beta	Homo sapiens	99-108
30604254-9	2019	Finally, coimmunoprecipitation demonstrated that P62 forms a complex with phosphorylated glycogen synthase kinase 3 beta (pGSK3beta).	pgsk3beta	122-131	glycogen synthase kinase 3 beta	Homo sapiens	89-120
30535469-8	2019	Inhibition of glycogen synthase kinase 3beta activity by phosphorylation of its N-terminal serine increases accumulation of cyclin D1, which promotes the cell cycle and improves cell proliferation through the PI3K/Akt signaling pathway.	Serine	91-97	glycogen synthase kinase 3 beta	Homo sapiens	14-44
30445019-0	2019	Resveratrol protects cardiomyocytes against anoxia/reoxygenation via dephosphorylation of VDAC1 by Akt-GSK3 beta pathway.	Resveratrol	0-11	glycogen synthase kinase 3 beta	Homo sapiens	103-112
30445019-10	2019	In addition, Akt and its downstream glycogen synthase kinase 3 beta (GSK3beta) were phosphorylated by the action of resveratrol.	Resveratrol	116-127	glycogen synthase kinase 3 beta	Homo sapiens	36-67
30445019-10	2019	In addition, Akt and its downstream glycogen synthase kinase 3 beta (GSK3beta) were phosphorylated by the action of resveratrol.	Resveratrol	116-127	glycogen synthase kinase 3 beta	Homo sapiens	69-77
30445019-11	2019	Akt inhibitor IV abrogated Akt-GSK3beta phosphorylation and thereby abolished the dephosphorylation activity of resveratrol on VDAC1.	Resveratrol	112-123	glycogen synthase kinase 3 beta	Homo sapiens	31-39
30445019-13	2019	Taken together, our data indicated that A/R injury enhanced VDAC1 phosphorylation in cardiomyocytes, whereas pretreatment with resveratrol dephosphorylated VDAC1 through the Akt-GSK3beta pathway, thereby protecting cardiomyocytes against A/R injury.	Resveratrol	127-138	glycogen synthase kinase 3 beta	Homo sapiens	178-186
30666163-0	2019	Metformin induces apoptotic cytotoxicity depending on AMPK/PKA/GSK-3beta-mediated c-FLIPL degradation in non-small cell lung cancer.	Metformin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	63-72
30666163-12	2019	Conclusion: This study provided evidence that metformin killed NSCLC cells through AMPK/PKA/GSK-3beta axis-mediated c-FLIPL degradation.	Metformin	46-55	glycogen synthase kinase 3 beta	Homo sapiens	92-101
30485790-7	2019	In addition, ginsenoside-Rg1 also decreased the output of glucose by increasing Akt phosphorylation and reducing GSK3beta expression.	Glucose	58-65	glycogen synthase kinase 3 beta	Homo sapiens	113-121
30666163-10	2019	Furthermore, metformin significantly activated Adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK) and its downstream glycogen synthase kinase 3beta (GSK-3beta), block the expression of AMPK, and GSK-3beta with siRNA partially reversed metformin-induced cytotoxicity and restored the expression of c-FLIPL in lung cancer cells.	Metformin	13-22	glycogen synthase kinase 3 beta	Homo sapiens	131-161
30666163-10	2019	Furthermore, metformin significantly activated Adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK) and its downstream glycogen synthase kinase 3beta (GSK-3beta), block the expression of AMPK, and GSK-3beta with siRNA partially reversed metformin-induced cytotoxicity and restored the expression of c-FLIPL in lung cancer cells.	Metformin	13-22	glycogen synthase kinase 3 beta	Homo sapiens	163-172
30666163-10	2019	Furthermore, metformin significantly activated Adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK) and its downstream glycogen synthase kinase 3beta (GSK-3beta), block the expression of AMPK, and GSK-3beta with siRNA partially reversed metformin-induced cytotoxicity and restored the expression of c-FLIPL in lung cancer cells.	Metformin	13-22	glycogen synthase kinase 3 beta	Homo sapiens	209-218
30666163-10	2019	Furthermore, metformin significantly activated Adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK) and its downstream glycogen synthase kinase 3beta (GSK-3beta), block the expression of AMPK, and GSK-3beta with siRNA partially reversed metformin-induced cytotoxicity and restored the expression of c-FLIPL in lung cancer cells.	adenosine 5"-monophosphate	47-73	glycogen synthase kinase 3 beta	Homo sapiens	163-172
30666163-10	2019	Furthermore, metformin significantly activated Adenosine 5"-monophosphate (AMP)-activated protein kinase (AMPK) and its downstream glycogen synthase kinase 3beta (GSK-3beta), block the expression of AMPK, and GSK-3beta with siRNA partially reversed metformin-induced cytotoxicity and restored the expression of c-FLIPL in lung cancer cells.	Adenosine Monophosphate	75-78	glycogen synthase kinase 3 beta	Homo sapiens	209-218
30666159-0	2019	Peptidylarginine deiminase 4 overexpression resensitizes MCF-7/ADR breast cancer cells to adriamycin via GSK3beta/p53 activation.	Doxorubicin	90-100	glycogen synthase kinase 3 beta	Homo sapiens	105-113
30630510-0	2019	Corilagin alleviates acetaminophen-induced hepatotoxicity via enhancing the AMPK/GSK3beta-Nrf2 signaling pathway.	corilagin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	81-94
30630510-0	2019	Corilagin alleviates acetaminophen-induced hepatotoxicity via enhancing the AMPK/GSK3beta-Nrf2 signaling pathway.	Acetaminophen	21-34	glycogen synthase kinase 3 beta	Homo sapiens	81-94
30630510-13	2019	CONCLUSIONS: These findings principally indicated that Cori effectively protects against APAP-induced ALF via the upregulation of the AMPK/GSK3beta-Nrf2 signaling pathway.	Acetaminophen	89-93	glycogen synthase kinase 3 beta	Homo sapiens	139-152
30551472-7	2019	Moreover, Nrf2/ARE pathway was activated after pretreatment with a PKC activator, p38 MAPK inhibitor, or GSK-3beta inhibitor under the condition of HG, and quercetin addition further strengthened this pathway; however, PKC inhibition or GSK-3beta activation pretreatment reversed the effects of quercetin on the protein expression of gamma-GCS in the HG condition.	Quercetin	156-165	glycogen synthase kinase 3 beta	Homo sapiens	105-114
30053574-6	2019	The possible cardioprotective actions of lithium may involve an extensive range of signaling pathways, including the Wnt/glycogen synthase kinase-3beta, phosphatidylinositol-3-kinase/protein kinase B, phosphoinositide/protein kinase C, and mitogen-activated protein kinase/extracellular signal-regulated kinase cascades.	Lithium	41-48	glycogen synthase kinase 3 beta	Homo sapiens	121-151
30670971-0	2018	beta-Sitosterol and Gemcitabine Exhibit Synergistic Anti-pancreatic Cancer Activity by Modulating Apoptosis and Inhibiting Epithelial-Mesenchymal Transition by Deactivating Akt/GSK-3beta Signaling.	gamma-sitosterol	0-15	glycogen synthase kinase 3 beta	Homo sapiens	177-186
30670971-0	2018	beta-Sitosterol and Gemcitabine Exhibit Synergistic Anti-pancreatic Cancer Activity by Modulating Apoptosis and Inhibiting Epithelial-Mesenchymal Transition by Deactivating Akt/GSK-3beta Signaling.	gemcitabine	20-31	glycogen synthase kinase 3 beta	Homo sapiens	177-186
30551472-7	2019	Moreover, Nrf2/ARE pathway was activated after pretreatment with a PKC activator, p38 MAPK inhibitor, or GSK-3beta inhibitor under the condition of HG, and quercetin addition further strengthened this pathway; however, PKC inhibition or GSK-3beta activation pretreatment reversed the effects of quercetin on the protein expression of gamma-GCS in the HG condition.	Quercetin	156-165	glycogen synthase kinase 3 beta	Homo sapiens	237-246
30551472-8	2019	In summary, quercetin exerts the neuroprotection by enhancing Glo-1 functions in central neurons under chronic HG condition, which may be mediated by activation of Nrf2/ARE pathway; furthermore, the increased Nrf2 phosphorylation mediated by PKC activation and/or GSK-3beta inhibition may involve in the activation of Nrf2/ARE pathway.	Quercetin	12-21	glycogen synthase kinase 3 beta	Homo sapiens	264-273
31529929-2	2019	The present work is a follow-up and reveals the importance of GSK3beta-phosphorylated presenilin-1 for responsiveness of pancreatic islets and beta-cells to elevated glucose in terms of cytosolic Ca2+ spiking and insulin secretion.	Glucose	166-173	glycogen synthase kinase 3 beta	Homo sapiens	62-70
30317528-4	2019	Mechanistically, Hh pathway activity increases the levels of the MT-associated DYRK1B kinase, resulting in the inhibition of GSK3beta through phosphorylation of Serine 9 and the subsequent suppression of HDAC6 enzyme activity.	Serine	161-167	glycogen synthase kinase 3 beta	Homo sapiens	125-133
31453785-9	2019	As for inflammation and oxidative stress, IL-1beta was inversely correlated with GSK-3beta activity, while 8-isoPGF2alpha was positively correlated with GSK-3beta activity and GSK-3beta/BDNF ratio.	8-epi-prostaglandin F2alpha	107-121	glycogen synthase kinase 3 beta	Homo sapiens	153-162
31453785-9	2019	As for inflammation and oxidative stress, IL-1beta was inversely correlated with GSK-3beta activity, while 8-isoPGF2alpha was positively correlated with GSK-3beta activity and GSK-3beta/BDNF ratio.	8-epi-prostaglandin F2alpha	107-121	glycogen synthase kinase 3 beta	Homo sapiens	153-162
31875781-6	2019	In addition, it is suggested that exposure to repeated doses of methamphetamine induces hyperactivation of glycogen synthase kinase-3beta in the nucleus accumbens and in dorsal hippocampus, resulting in a long-term alterations in synaptic plasticity underlying behavioral sensitization as well as other behavioral deficits in memory-related behavior.	Methamphetamine	64-79	glycogen synthase kinase 3 beta	Homo sapiens	107-137
31875781-7	2019	Therefore it is clear that glycogen synthase kinase-3beta inhibitors can be considered as a potential candidate for the treatment of methamphetamine abuse and dependence.	Methamphetamine	133-148	glycogen synthase kinase 3 beta	Homo sapiens	27-57
31529929-6	2019	Furthermore, our data revealed that cytosolic Ca2+ spiking upon administration of high D-glucose was delayed in onset time and strongly reduced in amplitude and frequency upon siRNA-mediated knock-down of presenilin-1 or the inhibition of GSK3beta in the pancreatic beta-cells.	Glucose	87-96	glycogen synthase kinase 3 beta	Homo sapiens	239-247
31529929-7	2019	Moreover, glucose-triggered initial insulin secretion disappeared by depletion from presenilin-1 and inhibition of GSK3beta in the pancreatic beta-cells and isolated pancreatic islets, respectively.	Glucose	10-17	glycogen synthase kinase 3 beta	Homo sapiens	115-123
31529929-8	2019	CONCLUSION: These data complement our previous work and demonstrate that the sensitivity of pancreatic islets and beta-cells to glucose illustrated as glucose-triggered cytosolic Ca2+ spiking and initial but not long-lasting insulin secretion crucially depends on a strong ER Ca2+ leak that is due to the phosphorylation of presenilin-1 by GSK3beta, a phenomenon that might be involved in the development of type 2 diabetes.	Glucose	128-135	glycogen synthase kinase 3 beta	Homo sapiens	340-348
31529929-8	2019	CONCLUSION: These data complement our previous work and demonstrate that the sensitivity of pancreatic islets and beta-cells to glucose illustrated as glucose-triggered cytosolic Ca2+ spiking and initial but not long-lasting insulin secretion crucially depends on a strong ER Ca2+ leak that is due to the phosphorylation of presenilin-1 by GSK3beta, a phenomenon that might be involved in the development of type 2 diabetes.	Glucose	151-158	glycogen synthase kinase 3 beta	Homo sapiens	340-348
30022447-6	2019	Activation of the downstream Wnt-pathway by means of heterologous beta-catenin and/or TCF-4 expression, through inhibition of GSK-3beta by LiCl treatment, or by cell stimulation with insulin-like growth factor-1 (IGF-1) resulted in increased EMN expression.	Lithium Chloride	139-143	glycogen synthase kinase 3 beta	Homo sapiens	126-135
30281919-8	2019	EMT course and AKT/GSK-3beta signal pathway both in vitro and in vivo in sunitinib environment was suppressed to varying degrees via NT5E inhibition.	Sunitinib	73-82	glycogen synthase kinase 3 beta	Homo sapiens	19-28
30281919-9	2019	NT5E inhibition could suppress the growth of sunitinib-resistant RCC cells and restrain EMT course and AKT/GSK-3beta signal pathway in sunitinib environment in RCC.	Sunitinib	135-144	glycogen synthase kinase 3 beta	Homo sapiens	107-116
31561361-7	2019	aFGF14-154 increased the phosphorylation of GSK3beta (Ser9) to inhibit its activity, then was followed by a low phosphorylation level of CRMP2 (Thr514), which led to the neurite growth.	seryl-seryl-seryl-arginine	54-58	glycogen synthase kinase 3 beta	Homo sapiens	44-52
31561361-7	2019	aFGF14-154 increased the phosphorylation of GSK3beta (Ser9) to inhibit its activity, then was followed by a low phosphorylation level of CRMP2 (Thr514), which led to the neurite growth.	serratamolide	144-150	glycogen synthase kinase 3 beta	Homo sapiens	44-52
30224543-6	2019	EtOH-treated cells demonstrate reduced giantin and subsequent cytoplasmic GSK3beta; this phenomenon was validated in giantin-depleted cells.	Ethanol	0-4	glycogen synthase kinase 3 beta	Homo sapiens	74-82
30502054-9	2019	Moreover, we found a significant correlation between higher inhibitory GSK3beta phosphorylation at Serine 9 and higher activating GluA1 phosphorylation at Serine 845 in brain samples from epileptic patients.	Serine	99-105	glycogen synthase kinase 3 beta	Homo sapiens	71-79
30502054-9	2019	Moreover, we found a significant correlation between higher inhibitory GSK3beta phosphorylation at Serine 9 and higher activating GluA1 phosphorylation at Serine 845 in brain samples from epileptic patients.	Serine	155-161	glycogen synthase kinase 3 beta	Homo sapiens	71-79
30518934-5	2018	Further study of underlying mechanisms demonstrated that DANCR bound with RXRA and increased its serine 49/78 phosphorylation via GSK3beta, resulting in activating PIK3CA transcription, and subsequently enhanced PI3K/AKT signaling and TNBC tumorigenesis.	Serine	97-103	glycogen synthase kinase 3 beta	Homo sapiens	130-138
30597971-0	2018	Shikonin Attenuates Acetaminophen-Induced Hepatotoxicity by Upregulation of Nrf2 through Akt/GSK3beta Signaling.	shikonin	0-8	glycogen synthase kinase 3 beta	Homo sapiens	93-101
30581378-5	2018	Studies on the mechanisms revealed that MDHB induced the hippocampal NSCs differentiation into cholinergic motor neurons by inhibiting AKT phosphorylation and activating autophosphorylation of GSK3beta at tyrosine 216.	methyl 3,4-dihydroxybenzoate	40-44	glycogen synthase kinase 3 beta	Homo sapiens	193-201
30581378-5	2018	Studies on the mechanisms revealed that MDHB induced the hippocampal NSCs differentiation into cholinergic motor neurons by inhibiting AKT phosphorylation and activating autophosphorylation of GSK3beta at tyrosine 216.	Tyrosine	205-213	glycogen synthase kinase 3 beta	Homo sapiens	193-201
30242906-6	2019	Besides, the CCDC85B-induced upregulation of phosphorylated GSK3beta and active beta-catenin was rescued following the treatment with PI3 K inhibitor, LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	151-159	glycogen synthase kinase 3 beta	Homo sapiens	60-68
30597971-0	2018	Shikonin Attenuates Acetaminophen-Induced Hepatotoxicity by Upregulation of Nrf2 through Akt/GSK3beta Signaling.	Acetaminophen	20-33	glycogen synthase kinase 3 beta	Homo sapiens	93-101
30266538-7	2018	Our results demonstrated that dictamnine reduced HIF-1alpha protein synthesis by downregulating the mTOR/p70S6K/eIF4E and MAPK pathways, and reduced the expression of Slug by inhibiting the GSK-3beta/Slug signaling pathway.	dictamnine	30-40	glycogen synthase kinase 3 beta	Homo sapiens	190-199
30155836-6	2018	Mechanistically, RARalpha knockdown inhibited the activity of Wnt/beta-catenin pathway through reducing the phosphorylation level of GSK3beta at Ser-9 and inducing phosphorylation level at Tyr-216, which resulted in downregulation of its downstream targets such as MMP7, MMP9, and P-gP.	Serine	145-148	glycogen synthase kinase 3 beta	Homo sapiens	133-141
30302523-11	2018	CONCLUSION: FOXC2 enhanced cisplatin resistance of NSCLC cells through activating AKT/GSK3beta/Snail/EMT signaling pathway, which may be a potential novel therapeutic target for overcoming drug resistance in human NSCLCs.	Cisplatin	27-36	glycogen synthase kinase 3 beta	Homo sapiens	86-94
30142593-6	2018	Specifically, the central importance of glycogen synthase kinase-3beta (GSK3beta) is discussed in detail because it modulates multiple systems that have been repeatedly implicated in suicide, and which lithium also exerts effects on.	Lithium	202-209	glycogen synthase kinase 3 beta	Homo sapiens	40-70
30272331-5	2018	The aim of this study was to establish a model with which to study EMT, stemness features and cell plasticity in cancer progression and to examine the effects of incubation with lithium chloride (LiCl), a specific glycogen synthase kinase 3 beta (GSK-3beta) inhibitor, on these cellular processes.	Lithium Chloride	178-194	glycogen synthase kinase 3 beta	Homo sapiens	214-245
30272331-5	2018	The aim of this study was to establish a model with which to study EMT, stemness features and cell plasticity in cancer progression and to examine the effects of incubation with lithium chloride (LiCl), a specific glycogen synthase kinase 3 beta (GSK-3beta) inhibitor, on these cellular processes.	Lithium Chloride	178-194	glycogen synthase kinase 3 beta	Homo sapiens	247-256
30208247-7	2018	We also observed that Dsh-003 blocked PGE2-induced cell migration by down-regulating PGE2-induced beta-catenin expression and by up-regulating E-cadherin and GSK3-beta expression.	Dinoprostone	38-42	glycogen synthase kinase 3 beta	Homo sapiens	158-167
29902094-5	2018	Convallatoxin activated GSK-3beta and suppression of NRF2 by convallatoxin required the Neh6 domain.	convallatoxin	0-13	glycogen synthase kinase 3 beta	Homo sapiens	24-33
30468092-7	2018	In particular, ONOO- and its derivatives could mediate neurovascular unit damages and induce the BBB disruption and HT possibly through interacting with different cellular signalling pathways including matrix metalloproteinase (MMPs), high mobility group Box 1 (HMGB1), toll-like receptor2/4, poly(ADP-ribose) polymerase, Src, ROCK, and GSK-3beta.	onoo	15-19	glycogen synthase kinase 3 beta	Homo sapiens	337-346
30142593-6	2018	Specifically, the central importance of glycogen synthase kinase-3beta (GSK3beta) is discussed in detail because it modulates multiple systems that have been repeatedly implicated in suicide, and which lithium also exerts effects on.	Lithium	202-209	glycogen synthase kinase 3 beta	Homo sapiens	72-80
30627375-4	2018	Results: H2O2 resulted in the increased nuclear and cytoplasmatic expression of beta-catenin, reduced p-GSK3beta expression, up-regulated ROS content, and induced oxidative DNA damage in Eca109 cells.	Hydrogen Peroxide	9-13	glycogen synthase kinase 3 beta	Homo sapiens	104-112
30272294-9	2018	Western blotting revealed that aloe emodin had a significant effect on phosphorylation of pyruvate dehydrogenase kinase 1 and glycogen synthase kinase 3beta (GSK3beta) and AKT was inhibited.	aloe emodin	31-42	glycogen synthase kinase 3 beta	Homo sapiens	126-156
30272294-9	2018	Western blotting revealed that aloe emodin had a significant effect on phosphorylation of pyruvate dehydrogenase kinase 1 and glycogen synthase kinase 3beta (GSK3beta) and AKT was inhibited.	aloe emodin	31-42	glycogen synthase kinase 3 beta	Homo sapiens	158-166
30388099-9	2018	Treatment of A549 and H460 cells with DHC caused suppression of HIF-1alpha, Akt and pAkt, GSK-3beta and pGSK-3beta, as well as ERK, pERK, mTOR, and p-mTOR.	dehydrocostus lactone	38-41	glycogen synthase kinase 3 beta	Homo sapiens	90-99
29298990-7	2018	Similarly, pharmacological inhibition of GSK3beta by SB216763 also facilitated the TRAX-mediated repair of oxidative DNA damage.	SB 216763	53-61	glycogen synthase kinase 3 beta	Homo sapiens	41-49
30188517-0	2018	Glycogen synthase kinase 3 beta regulates ethanol consumption and is a risk factor for alcohol dependence.	Ethanol	42-49	glycogen synthase kinase 3 beta	Homo sapiens	0-31
30188517-4	2018	Here, we investigate Gsk3b in rodent models of ethanol consumption and as a risk factor for human alcohol dependence.	Ethanol	47-54	glycogen synthase kinase 3 beta	Homo sapiens	21-26
30188517-6	2018	Further, Gsk3b overexpression increased anxiety-like behavior following abstinence from ethanol.	Ethanol	88-95	glycogen synthase kinase 3 beta	Homo sapiens	9-14
30188517-7	2018	Protein or mRNA expression studies following Gsk3b over-expression identified synaptojanin 2, brain-derived neurotrophic factor and the neuropeptide Y Y5 receptor as potential downstream factors altering ethanol behaviors.	Ethanol	204-211	glycogen synthase kinase 3 beta	Homo sapiens	45-50
30188517-10	2018	These mutually reinforcing cross-species findings implicate GSK3B in neurobiological mechanisms controlling ethanol consumption, and as both a potential risk factor and therapeutic target for alcohol dependence.	Ethanol	108-115	glycogen synthase kinase 3 beta	Homo sapiens	60-65
30717563-7	2018	The results of Western blot showed that orchinol could significantly down-regulate the protein expression levels of beta-catenin, Wnt3a, DvL2 and cyclinD1, and up-regulate the protein expression level of GSK-3beta(P&lt;0.05, P&lt;0.01, P&lt;0.001).	orchinol	40-48	glycogen synthase kinase 3 beta	Homo sapiens	204-213
30834157-6	2019	Furthermore, NSCs treated with lithium chloride showed significantly enhanced beta-catenin expression and inhibited Gsk-3beta expression in a dose-dependent manner.	Lithium Chloride	31-47	glycogen synthase kinase 3 beta	Homo sapiens	116-125
30486290-0	2018	Nobiletin Enhances Chemosensitivity to Adriamycin through Modulation of the Akt/GSK3beta/beta-Catenin/MYCN/MRP1 Signaling Pathway in A549 Human Non-Small-Cell Lung Cancer Cells.	nobiletin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	80-88
30486290-4	2018	NBT treatment decreased the expression of a neuroblastoma-derived MYC (MYCN) and multidrug resistance-associated protein 1 (MRP1) as well as downregulating Akt, GSK3beta, and beta-catenin.	nobiletin	0-3	glycogen synthase kinase 3 beta	Homo sapiens	161-169
30409167-7	2018	RESULTS: Selenium played a critical role in in vitro expansion of AF-MSCs through activation of the AKT-ERK1/2, Smad2, and Stat3 signaling pathways along with inactivation of GSK3beta.	Selenium	9-17	glycogen synthase kinase 3 beta	Homo sapiens	175-183
30477461-4	2018	The binding interaction of flavonoids (theaflavin, quercetin, rutin, epicatechin 3 gallate and tamarixetin) with GSK 3beta was determined by molecular docking.	Flavonoids	27-37	glycogen synthase kinase 3 beta	Homo sapiens	113-122
30477461-4	2018	The binding interaction of flavonoids (theaflavin, quercetin, rutin, epicatechin 3 gallate and tamarixetin) with GSK 3beta was determined by molecular docking.	theaflavin	39-49	glycogen synthase kinase 3 beta	Homo sapiens	113-122
30477461-4	2018	The binding interaction of flavonoids (theaflavin, quercetin, rutin, epicatechin 3 gallate and tamarixetin) with GSK 3beta was determined by molecular docking.	Quercetin	51-60	glycogen synthase kinase 3 beta	Homo sapiens	113-122
30477461-4	2018	The binding interaction of flavonoids (theaflavin, quercetin, rutin, epicatechin 3 gallate and tamarixetin) with GSK 3beta was determined by molecular docking.	Rutin	62-67	glycogen synthase kinase 3 beta	Homo sapiens	113-122
30477461-4	2018	The binding interaction of flavonoids (theaflavin, quercetin, rutin, epicatechin 3 gallate and tamarixetin) with GSK 3beta was determined by molecular docking.	epicatechin gallate	69-90	glycogen synthase kinase 3 beta	Homo sapiens	113-122
30477461-4	2018	The binding interaction of flavonoids (theaflavin, quercetin, rutin, epicatechin 3 gallate and tamarixetin) with GSK 3beta was determined by molecular docking.	tamarixetin	95-106	glycogen synthase kinase 3 beta	Homo sapiens	113-122
30477461-9	2018	All the flavonoids selected in this study significantly decreased the expression of Wnt and GSK 3beta in KBCHR8-5 cells and subsequently modulates P-gp overexpression in this drug-resistant cell line.	Flavonoids	8-18	glycogen synthase kinase 3 beta	Homo sapiens	92-101
30336983-2	2018	Glycogen synthase kinase 3beta (GSK3beta) has been proved to mediate dexamethasone (Dex)-induced osteoblast apoptosis.	Dexamethasone	69-82	glycogen synthase kinase 3 beta	Homo sapiens	0-30
30336983-2	2018	Glycogen synthase kinase 3beta (GSK3beta) has been proved to mediate dexamethasone (Dex)-induced osteoblast apoptosis.	Dexamethasone	69-82	glycogen synthase kinase 3 beta	Homo sapiens	32-40
30336983-2	2018	Glycogen synthase kinase 3beta (GSK3beta) has been proved to mediate dexamethasone (Dex)-induced osteoblast apoptosis.	Dexamethasone	84-87	glycogen synthase kinase 3 beta	Homo sapiens	0-30
30336983-2	2018	Glycogen synthase kinase 3beta (GSK3beta) has been proved to mediate dexamethasone (Dex)-induced osteoblast apoptosis.	Dexamethasone	84-87	glycogen synthase kinase 3 beta	Homo sapiens	32-40
30336983-3	2018	This study aimed to investigate the underlying mechanism of GSK3beta in Dex-induced osteoblast apoptosis.	Dexamethasone	72-75	glycogen synthase kinase 3 beta	Homo sapiens	60-68
30336983-10	2018	The microarray data also showed that apoptotic pathway, MAPK pathway, TGFbeta pathway and Wnt pathway might be related to the mechanism of GSK3beta in Dex-induced osteoblast apoptosis.	Dexamethasone	151-154	glycogen synthase kinase 3 beta	Homo sapiens	139-147
30336983-11	2018	CONCLUSION: Our findings indicate that GSK3beta-shRNA treatment can alter various genes expression levels and change diverse signaling pathways involved in Dex-induced osteoblast apoptosis.	Dexamethasone	156-159	glycogen synthase kinase 3 beta	Homo sapiens	39-47
30343126-6	2018	Under in vitro conditions, treatment with chitosan-nanocurcumin (CS-NC) caused a substantial increase in the GLUT-4 translocation to the cell surface in L6 skeletal muscle cells and the effect was associated with increased phosphorylation of AKT (Ser-473) and its downstream target GSK-3beta (Ser-9).	chitosan-nanocurcumin	42-63	glycogen synthase kinase 3 beta	Homo sapiens	282-291
30343126-6	2018	Under in vitro conditions, treatment with chitosan-nanocurcumin (CS-NC) caused a substantial increase in the GLUT-4 translocation to the cell surface in L6 skeletal muscle cells and the effect was associated with increased phosphorylation of AKT (Ser-473) and its downstream target GSK-3beta (Ser-9).	cs-nc	65-70	glycogen synthase kinase 3 beta	Homo sapiens	282-291
30388099-14	2018	CONCLUSIONS The putative mechanism behind the metastasis-limiting effects of DHC may involve the suppression of Akt/GSK-3beta and inhibition of MMP-2 and MMP-9 in lung cancer cells.	dehydrocostus lactone	77-80	glycogen synthase kinase 3 beta	Homo sapiens	116-125
30191639-8	2018	Involvement of GSK3beta was also confirmed by treatment with lithium chloride, the inducer of GSK3beta phosphorylation, or MG132, the 26S proteasomal inhibitor, which also stabilized Snail1.	Lithium Chloride	61-77	glycogen synthase kinase 3 beta	Homo sapiens	15-23
30191639-8	2018	Involvement of GSK3beta was also confirmed by treatment with lithium chloride, the inducer of GSK3beta phosphorylation, or MG132, the 26S proteasomal inhibitor, which also stabilized Snail1.	Lithium Chloride	61-77	glycogen synthase kinase 3 beta	Homo sapiens	94-102
30191639-8	2018	Involvement of GSK3beta was also confirmed by treatment with lithium chloride, the inducer of GSK3beta phosphorylation, or MG132, the 26S proteasomal inhibitor, which also stabilized Snail1.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	123-128	glycogen synthase kinase 3 beta	Homo sapiens	15-23
30145470-0	2018	4-Methylcatechol prevents streptozotocin-induced acute kidney injury through modulating NGF/TrkA and ROS-related Akt/GSK3beta/beta-catenin pathways.	4-methylcatechol	0-16	glycogen synthase kinase 3 beta	Homo sapiens	117-125
30021909-6	2018	Inhibitors targeting additional kinases (cabozantinib and sorafenib) similarly caused GSK3beta-independent MCL1 degradation, and in combination with navitoclax drove apoptosis in vitro and in vivo Conclusions: These results show that prostate cancer cells are primed to undergo apoptosis and that cotargeting BCLXL and MCL1, directly or indirectly through agents that increase MCL1 degradation, can induce dramatic apoptotic responses.	cabozantinib	41-53	glycogen synthase kinase 3 beta	Homo sapiens	86-94
30021909-6	2018	Inhibitors targeting additional kinases (cabozantinib and sorafenib) similarly caused GSK3beta-independent MCL1 degradation, and in combination with navitoclax drove apoptosis in vitro and in vivo Conclusions: These results show that prostate cancer cells are primed to undergo apoptosis and that cotargeting BCLXL and MCL1, directly or indirectly through agents that increase MCL1 degradation, can induce dramatic apoptotic responses.	Sorafenib	58-67	glycogen synthase kinase 3 beta	Homo sapiens	86-94
30125702-3	2018	Sequence analysis showed that LvGSK3beta possessed a highly similarity with GSK3beta from other species, which contained a catalytic domain and serine/threonine phosphorylation sites.	Serine	144-150	glycogen synthase kinase 3 beta	Homo sapiens	32-40
30125702-3	2018	Sequence analysis showed that LvGSK3beta possessed a highly similarity with GSK3beta from other species, which contained a catalytic domain and serine/threonine phosphorylation sites.	Threonine	151-160	glycogen synthase kinase 3 beta	Homo sapiens	32-40
30145470-0	2018	4-Methylcatechol prevents streptozotocin-induced acute kidney injury through modulating NGF/TrkA and ROS-related Akt/GSK3beta/beta-catenin pathways.	Streptozocin	26-40	glycogen synthase kinase 3 beta	Homo sapiens	117-125
30145470-0	2018	4-Methylcatechol prevents streptozotocin-induced acute kidney injury through modulating NGF/TrkA and ROS-related Akt/GSK3beta/beta-catenin pathways.	ros	101-104	glycogen synthase kinase 3 beta	Homo sapiens	117-125
30145470-8	2018	Moreover, 4MC pre-treatment increased levels of NGF and its receptor TrkA, p-Akt (Thr308), p-GSK3beta (Ser9) and nuclear beta-catenin.	4-methylcatechol	10-13	glycogen synthase kinase 3 beta	Homo sapiens	93-101
30145470-9	2018	These data suggest that 4MC prevents the development of STZ-induced renal damage by suppressing ROS production and inflammation via Akt/GSK3beta/beta-catenin pathway which may be stimulated by NGF/TrkA signaling.	4-methylcatechol	24-27	glycogen synthase kinase 3 beta	Homo sapiens	136-144
30145470-9	2018	These data suggest that 4MC prevents the development of STZ-induced renal damage by suppressing ROS production and inflammation via Akt/GSK3beta/beta-catenin pathway which may be stimulated by NGF/TrkA signaling.	Streptozocin	56-59	glycogen synthase kinase 3 beta	Homo sapiens	136-144
29980787-0	2018	Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3beta/Snail signaling.	Reactive Oxygen Species	105-108	glycogen synthase kinase 3 beta	Homo sapiens	122-130
29671257-5	2018	GSK3beta-mediated mPTP opening depended on mitoHK-II binding, i.e., it was accelerated by dissociation of mitoHK-II (dicyclohexylcarbodiimide) and attenuated by enhancement of mitoHK-II binding (dextran).	mitohk-ii	43-52	glycogen synthase kinase 3 beta	Homo sapiens	0-8
29671257-5	2018	GSK3beta-mediated mPTP opening depended on mitoHK-II binding, i.e., it was accelerated by dissociation of mitoHK-II (dicyclohexylcarbodiimide) and attenuated by enhancement of mitoHK-II binding (dextran).	Dicyclohexylcarbodiimide	117-141	glycogen synthase kinase 3 beta	Homo sapiens	0-8
29671257-5	2018	GSK3beta-mediated mPTP opening depended on mitoHK-II binding, i.e., it was accelerated by dissociation of mitoHK-II (dicyclohexylcarbodiimide) and attenuated by enhancement of mitoHK-II binding (dextran).	Dextrans	195-202	glycogen synthase kinase 3 beta	Homo sapiens	0-8
29671257-6	2018	However, inactivation of mitoHK-II by glucose-depletion or glucose-6-phosphate inhibited the GSK3beta-mediated mPTP opening.	Glucose	38-45	glycogen synthase kinase 3 beta	Homo sapiens	93-101
29671257-6	2018	However, inactivation of mitoHK-II by glucose-depletion or glucose-6-phosphate inhibited the GSK3beta-mediated mPTP opening.	Glucose-6-Phosphate	59-78	glycogen synthase kinase 3 beta	Homo sapiens	93-101
29980787-6	2018	Additionally, the activation of reactive oxygen species (ROS)-mediated Akt/glycogen synthase kinase 3beta (GSK3beta)/Snail signaling was involved in this process, as determined by RNA sequencing.	Reactive Oxygen Species	32-55	glycogen synthase kinase 3 beta	Homo sapiens	75-105
30226607-5	2018	The results demonstrated that 2HF could inhibit EMT, and cell migration and invasion through the Wnt/beta-catenin signaling pathway by suppressing GSK-3beta phosphorylation, beta-catenin expression and transactivation.	2'-hydroxyflavanone	30-33	glycogen synthase kinase 3 beta	Homo sapiens	147-156
29980787-6	2018	Additionally, the activation of reactive oxygen species (ROS)-mediated Akt/glycogen synthase kinase 3beta (GSK3beta)/Snail signaling was involved in this process, as determined by RNA sequencing.	Reactive Oxygen Species	32-55	glycogen synthase kinase 3 beta	Homo sapiens	107-115
29980787-6	2018	Additionally, the activation of reactive oxygen species (ROS)-mediated Akt/glycogen synthase kinase 3beta (GSK3beta)/Snail signaling was involved in this process, as determined by RNA sequencing.	Reactive Oxygen Species	57-60	glycogen synthase kinase 3 beta	Homo sapiens	75-105
29980787-6	2018	Additionally, the activation of reactive oxygen species (ROS)-mediated Akt/glycogen synthase kinase 3beta (GSK3beta)/Snail signaling was involved in this process, as determined by RNA sequencing.	Reactive Oxygen Species	57-60	glycogen synthase kinase 3 beta	Homo sapiens	107-115
30069933-8	2018	In conclusion, our findings indicated that the inhibitory effect of curcumol on proliferation of NPC cells is related to the inhibition of IGF-1R and its downstream PI3K/Akt/GSK-3beta pathway.	curcumol	68-76	glycogen synthase kinase 3 beta	Homo sapiens	174-183
30405828-0	2018	Dihydroartemisinin triggers c-Myc proteolysis and inhibits protein kinase B/glycogen synthase kinase 3beta pathway in T-cell lymphoma cells.	artenimol	0-18	glycogen synthase kinase 3 beta	Homo sapiens	76-106
30405828-6	2018	DHA treatment resulted in decreased phosphorylation of protein kinase B (Akt) and glycogen synthase 3beta (GSK3beta) in T-cell lymphoma cells.	artenimol	0-3	glycogen synthase kinase 3 beta	Homo sapiens	107-115
30405828-8	2018	Taken together, the results of the present study suggested that DHA may exert its antitumor role by accelerating c-Myc proteolysis and inhibiting the Akt/GSK3beta pathway in T-cell lymphoma cells.	artenimol	64-67	glycogen synthase kinase 3 beta	Homo sapiens	154-162
30459708-10	2018	Robust data displayed that these O-GlcNAc changes could lead to (i) a differential modulation of the carbohydrates metabolism, since the majority of enzymes are known to be O-GlcNAcylated, and to (ii) a differential modulation of the protein synthesis/degradation balance since O-GlcNAcylation regulates some key signaling pathways such as Akt/GSK3beta, Akt/mTOR, Myogenin/Atrogin-1, Myogenin/Mef2D, Mrf4 and PGC-1alpha in the skeletal muscle.	Carbohydrates	101-114	glycogen synthase kinase 3 beta	Homo sapiens	344-352
30213730-8	2018	Further, ATO-induced Akt inactivation promoted GSK3beta-mediated degradation of MCL1.	Arsenic Trioxide	9-12	glycogen synthase kinase 3 beta	Homo sapiens	47-55
30081068-11	2018	We also found that cordycepin inhibited MGMT expression and augmented chemosensitivity to TMZ in glioma cells in vitro and in vivo, accompanied by downregulation of p-GSK-3beta and beta-catenin.	cordycepin	19-29	glycogen synthase kinase 3 beta	Homo sapiens	167-176
30081068-13	2018	Pharmacological inhibition of GSK-3beta with CHIR-99021 or overexpression of beta-catenin reversed cordycepin-induced reduction of cell viability, downregulation of beta-catenin and MGMT, increase of apoptosis and reduction of TMZ resistance.	cordycepin	99-109	glycogen synthase kinase 3 beta	Homo sapiens	30-39
30081068-13	2018	Pharmacological inhibition of GSK-3beta with CHIR-99021 or overexpression of beta-catenin reversed cordycepin-induced reduction of cell viability, downregulation of beta-catenin and MGMT, increase of apoptosis and reduction of TMZ resistance.	Temozolomide	227-230	glycogen synthase kinase 3 beta	Homo sapiens	30-39
30119201-10	2018	The AKT/GSK3beta signalling pathway was also inhibited more significantly in cells treated with the GEM plus TPL combination than in cells treated with either agent alone.	triptolide	109-112	glycogen synthase kinase 3 beta	Homo sapiens	8-16
30197003-0	2018	Crystal structure of GSK3beta in complex with the flavonoid, morin.	Flavonoids	50-59	glycogen synthase kinase 3 beta	Homo sapiens	21-29
30197003-3	2018	Morin, a flavonoid that is abundant in nature, was found as an inhibitor of GSK3beta that can reduce tau pathology in vivo and in vitro.	Flavonoids	9-18	glycogen synthase kinase 3 beta	Homo sapiens	76-84
30197003-5	2018	The structure revealed that morin inhibits GSK3beta by binding to the ATP binding pocket.	Adenosine Triphosphate	70-73	glycogen synthase kinase 3 beta	Homo sapiens	43-51
30119131-5	2018	Furthermore, our data showed that PLB induced reactive oxygen species accumulation, which inhibited the GSK3beta/STAT3 pathway and arrested the G2/M phase.	Reactive Oxygen Species	46-69	glycogen synthase kinase 3 beta	Homo sapiens	104-112
30249058-7	2018	The specific binding did not lead to the membrane translocation to phosphatidylinositol (3,4,5)-trisphosphate (PIP3), but directly activated the phosphorylation of AKT on Ser-473, induced the phosphorylation of the downstream molecules, glycogen synthase kinase 3beta (GSK3beta) and forkhead box O1 (FOXO1), and improved glucose metabolism.	Serine	171-174	glycogen synthase kinase 3 beta	Homo sapiens	237-267
30400057-9	2018	Taken together, the endothelial protective effect of Baicalin under hyperglycemia condition could be partly attributed to its role in downregulating reactive oxygen species (ROS) and inflammation via the Akt/GSK3B/Fyn-mediated Nrf2 activation.	baicalin	53-61	glycogen synthase kinase 3 beta	Homo sapiens	208-213
30400057-9	2018	Taken together, the endothelial protective effect of Baicalin under hyperglycemia condition could be partly attributed to its role in downregulating reactive oxygen species (ROS) and inflammation via the Akt/GSK3B/Fyn-mediated Nrf2 activation.	Reactive Oxygen Species	149-172	glycogen synthase kinase 3 beta	Homo sapiens	208-213
30400057-9	2018	Taken together, the endothelial protective effect of Baicalin under hyperglycemia condition could be partly attributed to its role in downregulating reactive oxygen species (ROS) and inflammation via the Akt/GSK3B/Fyn-mediated Nrf2 activation.	Reactive Oxygen Species	174-177	glycogen synthase kinase 3 beta	Homo sapiens	208-213
30250048-7	2018	Similarly, targeting GSK3beta with knockout or RNAi reduced mitotic arrest in the presence of Taxol.	Paclitaxel	94-99	glycogen synthase kinase 3 beta	Homo sapiens	21-29
30249058-0	2018	Chlorogenic Acid Targeting of the AKT PH Domain Activates AKT/GSK3beta/FOXO1 Signaling and Improves Glucose Metabolism.	Chlorogenic Acid	0-16	glycogen synthase kinase 3 beta	Homo sapiens	62-70
30249058-7	2018	The specific binding did not lead to the membrane translocation to phosphatidylinositol (3,4,5)-trisphosphate (PIP3), but directly activated the phosphorylation of AKT on Ser-473, induced the phosphorylation of the downstream molecules, glycogen synthase kinase 3beta (GSK3beta) and forkhead box O1 (FOXO1), and improved glucose metabolism.	Serine	171-174	glycogen synthase kinase 3 beta	Homo sapiens	269-277
30249058-7	2018	The specific binding did not lead to the membrane translocation to phosphatidylinositol (3,4,5)-trisphosphate (PIP3), but directly activated the phosphorylation of AKT on Ser-473, induced the phosphorylation of the downstream molecules, glycogen synthase kinase 3beta (GSK3beta) and forkhead box O1 (FOXO1), and improved glucose metabolism.	Glucose	321-328	glycogen synthase kinase 3 beta	Homo sapiens	237-267
30249058-7	2018	The specific binding did not lead to the membrane translocation to phosphatidylinositol (3,4,5)-trisphosphate (PIP3), but directly activated the phosphorylation of AKT on Ser-473, induced the phosphorylation of the downstream molecules, glycogen synthase kinase 3beta (GSK3beta) and forkhead box O1 (FOXO1), and improved glucose metabolism.	Glucose	321-328	glycogen synthase kinase 3 beta	Homo sapiens	269-277
29964017-9	2018	Notably, treatment with a GSK-3beta inhibitor significantly abrogated the adverse effects of FGF19 silencing on H/R-induced injury, whereas silencing of Nrf2 partially blocked the FGF19-mediated cardioprotective effect against H/R-induced injury in cardiomyocytes.	r	114-115	glycogen synthase kinase 3 beta	Homo sapiens	26-35
29964017-9	2018	Notably, treatment with a GSK-3beta inhibitor significantly abrogated the adverse effects of FGF19 silencing on H/R-induced injury, whereas silencing of Nrf2 partially blocked the FGF19-mediated cardioprotective effect against H/R-induced injury in cardiomyocytes.	r	229-230	glycogen synthase kinase 3 beta	Homo sapiens	26-35
30119886-5	2018	Valproic acid (VPA) has been shown to influence the neural differentiation of NSCs through multiple signaling pathways involving glycogen synthase kinase3beta (GSK3beta).	Valproic Acid	0-13	glycogen synthase kinase 3 beta	Homo sapiens	129-158
30119886-5	2018	Valproic acid (VPA) has been shown to influence the neural differentiation of NSCs through multiple signaling pathways involving glycogen synthase kinase3beta (GSK3beta).	Valproic Acid	0-13	glycogen synthase kinase 3 beta	Homo sapiens	160-168
30119886-5	2018	Valproic acid (VPA) has been shown to influence the neural differentiation of NSCs through multiple signaling pathways involving glycogen synthase kinase3beta (GSK3beta).	Valproic Acid	15-18	glycogen synthase kinase 3 beta	Homo sapiens	129-158
30119886-5	2018	Valproic acid (VPA) has been shown to influence the neural differentiation of NSCs through multiple signaling pathways involving glycogen synthase kinase3beta (GSK3beta).	Valproic Acid	15-18	glycogen synthase kinase 3 beta	Homo sapiens	160-168
30206967-7	2018	In addition, daphnetin prevented the RANKL-induced activation of NF-kappaB and Akt/GSK-3beta pathways in BMMs.	daphnetin	13-22	glycogen synthase kinase 3 beta	Homo sapiens	83-92
30217003-0	2018	Cryptotanshinone Induces Cell Cycle Arrest and Apoptosis of NSCLC Cells through the PI3K/Akt/GSK-3beta Pathway.	cryptotanshinone	0-16	glycogen synthase kinase 3 beta	Homo sapiens	93-102
30217003-4	2018	NSCLC cells treated with CTT reduced cell growth through PI3K/Akt/GSK3beta pathway inhibition, G0/G1 cell cycle arrest, and the activation of apoptosis.	cryptotanshinone	25-28	glycogen synthase kinase 3 beta	Homo sapiens	66-74
30206967-9	2018	The effect of daphnetin might be mediated by inhibiting ROS signal transduction, as well as preventing the activation of NF-kappaB and Akt/GSK-3beta signaling pathways.	daphnetin	14-23	glycogen synthase kinase 3 beta	Homo sapiens	139-148
30201862-0	2018	Inhibition of Wnt3a/FOXM1/beta-Catenin Axis and Activation of GSK3beta and Caspases are Critically Involved in Apoptotic Effect of Moracin D in Breast Cancers.	Moracin D	131-140	glycogen synthase kinase 3 beta	Homo sapiens	62-70
30201862-5	2018	Of note, Moracin D reduced expression of Forkhead box M1 (FOXM1), beta-catenin, Wnt3a, and upregulated glycogen synthase kinase 3 beta (GSK3beta) on Tyr216 along with disturbed binding of FOXM1 with beta-catenin in MDA-MB-231 cells.	Moracin D	9-18	glycogen synthase kinase 3 beta	Homo sapiens	103-134
29974605-7	2018	Inhibition of GSK-3beta and proteasome blocked the inhibiting effect of GMI on beta-catenin and its target genes.	misonidazole-glutathione conjugate	72-75	glycogen synthase kinase 3 beta	Homo sapiens	14-23
30201862-5	2018	Of note, Moracin D reduced expression of Forkhead box M1 (FOXM1), beta-catenin, Wnt3a, and upregulated glycogen synthase kinase 3 beta (GSK3beta) on Tyr216 along with disturbed binding of FOXM1 with beta-catenin in MDA-MB-231 cells.	Moracin D	9-18	glycogen synthase kinase 3 beta	Homo sapiens	136-144
30201862-6	2018	Conversely, GSK3beta inhibitor SB216763 reversed the apoptotic ability of Moracin D to reduce expression of FOXM1, beta-catenin, pro-caspase3, and pro-PARP in MDA-MB-231 cells.	SB 216763	31-39	glycogen synthase kinase 3 beta	Homo sapiens	12-20
30201862-6	2018	Conversely, GSK3beta inhibitor SB216763 reversed the apoptotic ability of Moracin D to reduce expression of FOXM1, beta-catenin, pro-caspase3, and pro-PARP in MDA-MB-231 cells.	Moracin D	74-83	glycogen synthase kinase 3 beta	Homo sapiens	12-20
30201862-7	2018	Overall, these findings provide novel insight that Moracin D inhibits proliferation and induces apoptosis via suppression of Wnt3a/FOXM1/beta-catenin signaling and activation of caspases and GSK3beta.	Moracin D	51-60	glycogen synthase kinase 3 beta	Homo sapiens	191-199
30012495-9	2018	We confirmed that the treatment of myricetin increased phosphorylated GSK-3beta and beta-catenin which is related to osteogenesis.	myricetin	35-44	glycogen synthase kinase 3 beta	Homo sapiens	70-79
29944884-5	2018	In addition, glycogen synthase kinase 3beta (GSK3beta) remained at the same level and Ser9 phosphorylation of GSK3beta decreased with increasing incubation time and increasing regorafenib concentration in LSCC cells.	regorafenib	176-187	glycogen synthase kinase 3 beta	Homo sapiens	110-118
29944884-6	2018	GSK3beta inhibition enhanced the anti-tumor activity of regorafenib.	regorafenib	56-67	glycogen synthase kinase 3 beta	Homo sapiens	0-8
29944884-7	2018	Thus, GSK3beta activation restricted the anti-cancer effect of regorafenib on LSCC.	regorafenib	63-74	glycogen synthase kinase 3 beta	Homo sapiens	6-14
29944884-9	2018	GSK3beta might be a potential target to increase the anti-tumor effect of regorafenib in LSCC cells.	regorafenib	74-85	glycogen synthase kinase 3 beta	Homo sapiens	0-8
30210588-9	2018	In addition, pretreatment with SAL significantly increased the phosphorylation levels of Akt and GSK-3beta in H2O2-treated ARPE-19 cells.	rhodioloside	31-34	glycogen synthase kinase 3 beta	Homo sapiens	97-106
30210588-10	2018	In conclusion, the present study demonstrated that SAL protected RPE cells against H2O2-induced cell injury through the activation of the Akt/GSK-3beta signaling pathway.	Hydrogen Peroxide	83-87	glycogen synthase kinase 3 beta	Homo sapiens	142-151
30210588-9	2018	In addition, pretreatment with SAL significantly increased the phosphorylation levels of Akt and GSK-3beta in H2O2-treated ARPE-19 cells.	Hydrogen Peroxide	110-114	glycogen synthase kinase 3 beta	Homo sapiens	97-106
29956736-0	2018	Reversal of the Warburg effect with DCA in PDGF-treated human PASMC is potentiated by pyruvate dehydrogenase kinase-1 inhibition mediated through blocking Akt/GSK-3beta signalling.	Dichloroacetic Acid	36-39	glycogen synthase kinase 3 beta	Homo sapiens	159-168
29761559-0	2018	Conditional depletion of GSK3b protects oligodendrocytes from apoptosis and lessens demyelination in the acute cuprizone model.	Cuprizone	111-120	glycogen synthase kinase 3 beta	Homo sapiens	25-30
29761559-4	2018	Here, we sought to investigate whether GSK3b plays a role in cuprizone-induced apoptosis of OL by using a novel inducible conditional knockout (cKO) of GSK3b in mature OL.	Cuprizone	61-70	glycogen synthase kinase 3 beta	Homo sapiens	39-44
29761559-5	2018	While depletion of GSK3b has no effect on survival of uninjured OL, it increases survival of mature OL exposed to cuprizone.	Cuprizone	114-123	glycogen synthase kinase 3 beta	Homo sapiens	19-24
29761559-6	2018	We show that GSK3b-deficient OLs are protected against caspase-dependent, but not against caspase-independent apoptosis.	N-biotin-C-Co4(mu3-O)4(Py)4(H2O)4-beta-alanine	29-32	glycogen synthase kinase 3 beta	Homo sapiens	13-18
29956736-0	2018	Reversal of the Warburg effect with DCA in PDGF-treated human PASMC is potentiated by pyruvate dehydrogenase kinase-1 inhibition mediated through blocking Akt/GSK-3beta signalling.	pasmc	62-67	glycogen synthase kinase 3 beta	Homo sapiens	159-168
29956736-14	2018	In conclusion, inhibition of the Akt/GSK-3beta pathway improved the pro-apoptotic effect of DCA on human PASMCs, which may be attributed to a reversal of the Warburg effect by blocking the mutual interaction between HIF-1alpha and PDK-1, consequently downregulating HK-2.	Dichloroacetic Acid	92-95	glycogen synthase kinase 3 beta	Homo sapiens	37-46
29956736-13	2018	The combined administration of LY294002 with DCA significantly decreased lactate concentration, promoted the depolarisation of the DeltaPsim and repressed HIF-1alpha upregulation and HK-2 activation in PASMCs treated with PDGF, which was attributed to the potentiation of DCA-induced PDK-1 inhibition by LY294002 via blockade of the Akt/GSK-3beta/HIF-1alpha signalling pathway.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	31-39	glycogen synthase kinase 3 beta	Homo sapiens	337-346
29956736-14	2018	In conclusion, inhibition of the Akt/GSK-3beta pathway improved the pro-apoptotic effect of DCA on human PASMCs, which may be attributed to a reversal of the Warburg effect by blocking the mutual interaction between HIF-1alpha and PDK-1, consequently downregulating HK-2.	pasmcs	105-111	glycogen synthase kinase 3 beta	Homo sapiens	37-46
29956736-13	2018	The combined administration of LY294002 with DCA significantly decreased lactate concentration, promoted the depolarisation of the DeltaPsim and repressed HIF-1alpha upregulation and HK-2 activation in PASMCs treated with PDGF, which was attributed to the potentiation of DCA-induced PDK-1 inhibition by LY294002 via blockade of the Akt/GSK-3beta/HIF-1alpha signalling pathway.	Dichloroacetic Acid	45-48	glycogen synthase kinase 3 beta	Homo sapiens	337-346
29636230-0	2018	Anti-apoptotic effect of Suxiao Jiuxin Pills against hypoxia-induced injury through PI3K/Akt/GSK3beta pathway in HL-1 cardiomyocytes.	suxiao jiuxin	25-38	glycogen synthase kinase 3 beta	Homo sapiens	93-101
30607045-2	2018	We propose that the keratinocyte proliferative activity of valproic acid mediated through the inhibition of glycogen synthase kinase-3beta, and subsequent activation of the Wnt/beta-catenin pathway could play a role in the development of PA.	Valproic Acid	59-72	glycogen synthase kinase 3 beta	Homo sapiens	108-138
29636230-10	2018	Furthermore, p-PI3K, p-Akt, and p-GSK3beta expressions were significantly increased after SX treatment, while they were all reduced after administration of LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	156-164	glycogen synthase kinase 3 beta	Homo sapiens	34-42
30017861-4	2018	Our results demonstrate that chronic high insulin exposure increases glutamate-induced excitotoxity, which was blocked by insulin receptor antagonist (S961) and GSK-3beta inhibitor (SB216763).	Glutamic Acid	69-78	glycogen synthase kinase 3 beta	Homo sapiens	161-170
29877972-0	2018	Effects of Glycogen Synthase Kinase-3beta Inhibitor TWS119 on Proliferation and Cytokine Production of TILs From Human Lung Cancer.	TWS 119	52-58	glycogen synthase kinase 3 beta	Homo sapiens	11-41
29877972-2	2018	In this study, we showed that glycogen synthase kinase-3beta inhibitor TWS119 has different effects on CD4 and CD8 T cells in TILs.	TWS 119	71-77	glycogen synthase kinase 3 beta	Homo sapiens	30-60
29959200-6	2018	While producing proapoptotic effects, ATO treatment also has an unwanted effect whereby it causes the accumulation of the phosphorylated (inactive) form of glycogen synthase kinase 3beta (GSK3beta), a kinase necessary for apoptosis.	Arsenic Trioxide	38-41	glycogen synthase kinase 3 beta	Homo sapiens	156-186
29959200-6	2018	While producing proapoptotic effects, ATO treatment also has an unwanted effect whereby it causes the accumulation of the phosphorylated (inactive) form of glycogen synthase kinase 3beta (GSK3beta), a kinase necessary for apoptosis.	Arsenic Trioxide	38-41	glycogen synthase kinase 3 beta	Homo sapiens	188-196
29959200-7	2018	When ATO is combined with Sorafenib, GSK3beta is activated, Mcl-1 is further reduced, and proapoptotic proteins Bak and Bax are activated.	Arsenic Trioxide	5-8	glycogen synthase kinase 3 beta	Homo sapiens	37-45
29959200-7	2018	When ATO is combined with Sorafenib, GSK3beta is activated, Mcl-1 is further reduced, and proapoptotic proteins Bak and Bax are activated.	Sorafenib	26-35	glycogen synthase kinase 3 beta	Homo sapiens	37-45
30127928-0	2018	Anticancer effect of resibufogenin on gastric carcinoma cells through the phosphoinositide 3-kinase/protein kinase B/glycogen synthase kinase 3beta signaling pathway.	bufogenin	21-34	glycogen synthase kinase 3 beta	Homo sapiens	117-147
30127928-1	2018	The aim of the present study was to investigate the anticancer effect of resibufogenin in gastric carcinoma cells through the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/glycogen synthase kinase 3beta (GSK3beta) signaling pathway.	bufogenin	73-86	glycogen synthase kinase 3 beta	Homo sapiens	182-212
30127928-1	2018	The aim of the present study was to investigate the anticancer effect of resibufogenin in gastric carcinoma cells through the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/glycogen synthase kinase 3beta (GSK3beta) signaling pathway.	bufogenin	73-86	glycogen synthase kinase 3 beta	Homo sapiens	214-222
30127928-5	2018	Furthermore, treatment with resibufogenin effectively increased Bax/Bcl-2 expression, and suppressed cyclin D1, cyclin E, PI3K, phosphorylated AKT, phosphorylated GSK3beta and beta-catenin protein expression in MGC-803 cells.	bufogenin	28-41	glycogen synthase kinase 3 beta	Homo sapiens	163-171
30127928-6	2018	These results suggest that the anticancer effect of resibufogenin induces gastric carcinoma cell death through the PI3K/AKT/GSK3beta signaling pathway, offering a novel view of the mechanism by which resibufogenin functions as an agent to treat gastric carcinoma.	bufogenin	52-65	glycogen synthase kinase 3 beta	Homo sapiens	124-132
30233322-0	2018	GSK-3beta Inhibitor Alsterpaullone Attenuates MPP+-Induced Cell Damage in a c-Myc-Dependent Manner in SH-SY5Y Cells.	alsterpaullone	20-34	glycogen synthase kinase 3 beta	Homo sapiens	0-9
30233322-0	2018	GSK-3beta Inhibitor Alsterpaullone Attenuates MPP+-Induced Cell Damage in a c-Myc-Dependent Manner in SH-SY5Y Cells.	mangion-purified polysaccharide (Candida albicans)	46-50	glycogen synthase kinase 3 beta	Homo sapiens	0-9
30233322-3	2018	Inhibition of glycogen synthase kinase 3beta (GSK-3beta) with Alsterpaullone (Als) can activate the down-stream events of Wnt signaling.	alsterpaullone	62-76	glycogen synthase kinase 3 beta	Homo sapiens	14-44
30233322-3	2018	Inhibition of glycogen synthase kinase 3beta (GSK-3beta) with Alsterpaullone (Als) can activate the down-stream events of Wnt signaling.	alsterpaullone	62-76	glycogen synthase kinase 3 beta	Homo sapiens	46-55
30233322-8	2018	These findings indicate that Als, a GSK-3beta inhibitor, attenuated the MPP+-induced mitochondria-dependent apoptotic via up-regulation of the Wnt signaling.	mangion-purified polysaccharide (Candida albicans)	72-76	glycogen synthase kinase 3 beta	Homo sapiens	36-45
30127928-6	2018	These results suggest that the anticancer effect of resibufogenin induces gastric carcinoma cell death through the PI3K/AKT/GSK3beta signaling pathway, offering a novel view of the mechanism by which resibufogenin functions as an agent to treat gastric carcinoma.	bufogenin	200-213	glycogen synthase kinase 3 beta	Homo sapiens	124-132
30165626-0	2018	Role of c-Abl-GSK3beta Signaling in MPP+-Induced Autophagy-Lysosomal Dysfunction.	mangion-purified polysaccharide (Candida albicans)	36-40	glycogen synthase kinase 3 beta	Homo sapiens	14-22
30165626-6	2018	Furthermore, siRNA-mediated knock-down or pharmacological inhibition of GSK3beta mitigated the MPP+-induced neuronal cell death, which was achieved through promoting TFEB nuclear localization and subsequently reversing the function of ALP.	mangion-purified polysaccharide (Candida albicans)	95-99	glycogen synthase kinase 3 beta	Homo sapiens	72-80
30165626-7	2018	Intriguingly, either DPH, c-Abl activator, or MPP+ led to the activation of GSK3beta, which is a negative regulator of TFEB.	Phenytoin	21-24	glycogen synthase kinase 3 beta	Homo sapiens	76-84
30165626-8	2018	In addition, c-Abl directly interacted with GSK3beta and catalyzed its phosphorylation at tyrosine 216, and their interaction was enhanced under MPP+ treatment.	Tyrosine	90-98	glycogen synthase kinase 3 beta	Homo sapiens	44-52
30165626-8	2018	In addition, c-Abl directly interacted with GSK3beta and catalyzed its phosphorylation at tyrosine 216, and their interaction was enhanced under MPP+ treatment.	mangion-purified polysaccharide (Candida albicans)	145-149	glycogen synthase kinase 3 beta	Homo sapiens	44-52
30165626-10	2018	Taken together, these results demonstrate that GSK3beta is a novel c-Abl substrate, and c-Abl-GSk3beta pathway mediates MPP+-induced ALP defects and neuronal cell death, which may represent a potential therapeutic target for PD.	mangion-purified polysaccharide (Candida albicans)	120-124	glycogen synthase kinase 3 beta	Homo sapiens	94-102
30017861-4	2018	Our results demonstrate that chronic high insulin exposure increases glutamate-induced excitotoxity, which was blocked by insulin receptor antagonist (S961) and GSK-3beta inhibitor (SB216763).	SB 216763	182-190	glycogen synthase kinase 3 beta	Homo sapiens	161-170
28871429-6	2018	Interestingly, treatment with lithium chloride, which is a well-known inhibitor of GSK3beta, partially recovered the expression of ATF4 protein, but its effect on the level of total c-Myc protein was negligible.	Lithium Chloride	30-46	glycogen synthase kinase 3 beta	Homo sapiens	83-91
29968232-0	2018	Regulation of Glycogen Content in Astrocytes via Cav-1/PTEN/AKT/GSK-3beta Pathway by Three Anti-bipolar Drugs.	Glycogen	14-22	glycogen synthase kinase 3 beta	Homo sapiens	64-73
29968965-6	2018	Furthermore, IQUB overexpression or knockdown combined with treatment of Licl or MG-132 showed that IQUB activated Akt to promote GSK3beta phosphorylation, which in turn activated Wnt/beta-catenin signaling pathway in breast cancer cells.	Lithium Chloride	73-77	glycogen synthase kinase 3 beta	Homo sapiens	130-138
29968965-6	2018	Furthermore, IQUB overexpression or knockdown combined with treatment of Licl or MG-132 showed that IQUB activated Akt to promote GSK3beta phosphorylation, which in turn activated Wnt/beta-catenin signaling pathway in breast cancer cells.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	81-87	glycogen synthase kinase 3 beta	Homo sapiens	130-138
29749471-0	2018	GSK3beta-mediated Ser156 phosphorylation modulates a BH3-like domain in BCL2L12 during TMZ-induced apoptosis and autophagy in glioma cells.	Temozolomide	87-90	glycogen synthase kinase 3 beta	Homo sapiens	0-8
29947280-7	2018	Furthermore, binding mode analysis revealed that all the compounds bound to the ATP site and most of the hydrogen bonding interactions are conserved as in GSK3beta structures deposited in PDB.	Adenosine Triphosphate	80-83	glycogen synthase kinase 3 beta	Homo sapiens	155-163
29947280-7	2018	Furthermore, binding mode analysis revealed that all the compounds bound to the ATP site and most of the hydrogen bonding interactions are conserved as in GSK3beta structures deposited in PDB.	Hydrogen	105-113	glycogen synthase kinase 3 beta	Homo sapiens	155-163
29968232-1	2018	Here we present the data indicating that chronic treatment with three antibipolar drugs, lithium, carbamazepine and valproic acid regulates Cav-1/PTEN/PI3K/AKT/GSK-3beta signalling pathway and glycogen content in primary cultured astrocytes.	Lithium	89-96	glycogen synthase kinase 3 beta	Homo sapiens	160-169
30008817-12	2018	Semi-quantitative PCR and western blot analysis revealed that the expression levels of p-GSK3beta, beta-catenin, c-Myc and cyclin D1 in cells after ICA treatment were significantly downregulated (p&lt;0.01), while the expression level of caspase-3 was significantly increased (p&lt;0.01).	icariin	148-151	glycogen synthase kinase 3 beta	Homo sapiens	89-97
29968232-1	2018	Here we present the data indicating that chronic treatment with three antibipolar drugs, lithium, carbamazepine and valproic acid regulates Cav-1/PTEN/PI3K/AKT/GSK-3beta signalling pathway and glycogen content in primary cultured astrocytes.	Carbamazepine	98-111	glycogen synthase kinase 3 beta	Homo sapiens	160-169
29968232-1	2018	Here we present the data indicating that chronic treatment with three antibipolar drugs, lithium, carbamazepine and valproic acid regulates Cav-1/PTEN/PI3K/AKT/GSK-3beta signalling pathway and glycogen content in primary cultured astrocytes.	Valproic Acid	116-129	glycogen synthase kinase 3 beta	Homo sapiens	160-169
29968232-4	2018	Our findings indicate that regulation of glycogen content via Cav-1/PTEN/AKT/GSK-3beta pathway by the three anti-bipoar drugs may be responsible for therapeutic effects of these drugs, and Cav-1 is an important signal element that may contribute to pathogenesis of various CNS diseases and regulation of its gene expression may be one of the underlying mechanisms of drug action for antibipolar drugs and antidepressants currently in clinical use.	Glycogen	41-49	glycogen synthase kinase 3 beta	Homo sapiens	77-86
30013652-0	2018	Juglone suppresses epithelial-mesenchymal transition in prostate cancer cells via the protein kinase B/glycogen synthase kinase-3beta/Snail signaling pathway.	juglone	0-7	glycogen synthase kinase 3 beta	Homo sapiens	103-133
29873877-4	2018	The structure shows an unusual U-shaped conformation of PIK-75 within the active site of GSK-3beta that is likely stabilized by an atypical intramolecular Br   NO2 halogen bond.	Halogens	164-171	glycogen synthase kinase 3 beta	Homo sapiens	89-98
30013652-8	2018	Furthermore, juglone prevented inactivation of glycogen synthase kinase-3beta (GSK-3beta), an endogenous inhibitor of Snail in a dose-dependent manner.	juglone	13-20	glycogen synthase kinase 3 beta	Homo sapiens	47-77
30013652-8	2018	Furthermore, juglone prevented inactivation of glycogen synthase kinase-3beta (GSK-3beta), an endogenous inhibitor of Snail in a dose-dependent manner.	juglone	13-20	glycogen synthase kinase 3 beta	Homo sapiens	79-88
30013652-9	2018	Lithium chloride (LiCl), a GSK-3beta inhibitor, prevented juglone-mediated downregulation of Snail expression and upregulation of E-cadherin.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	27-36
30013652-9	2018	Lithium chloride (LiCl), a GSK-3beta inhibitor, prevented juglone-mediated downregulation of Snail expression and upregulation of E-cadherin.	Lithium Chloride	18-22	glycogen synthase kinase 3 beta	Homo sapiens	27-36
30013652-9	2018	Lithium chloride (LiCl), a GSK-3beta inhibitor, prevented juglone-mediated downregulation of Snail expression and upregulation of E-cadherin.	juglone	58-65	glycogen synthase kinase 3 beta	Homo sapiens	27-36
30013652-10	2018	In addition, phosphorylation and subsequent activation of protein kinase B (Akt), which is known to phosphorylate GSK-3beta at serine 9 (Ser9), leading to its inhibition, were significantly decreased by juglone in LNCaP and LNCaP-AI cells.	Serine	127-133	glycogen synthase kinase 3 beta	Homo sapiens	114-123
30013652-11	2018	Inhibition of the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Akt pathway by LY294002 augmented juglone-mediated GSK-3beta activity by inhibiting Ser9 phosphorylation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	87-95	glycogen synthase kinase 3 beta	Homo sapiens	123-132
30013652-11	2018	Inhibition of the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Akt pathway by LY294002 augmented juglone-mediated GSK-3beta activity by inhibiting Ser9 phosphorylation.	juglone	106-113	glycogen synthase kinase 3 beta	Homo sapiens	123-132
30013652-12	2018	These findings indicated that juglone suppresses EMT via the Akt/GSK-3beta/Snail pathway, consequently decreasing the invasiveness of PC cells.	juglone	30-37	glycogen synthase kinase 3 beta	Homo sapiens	65-74
30288222-0	2018	Design, synthesis, and evaluation of 4,5,6,7-tetrahydrobenzo[d]thiazole-based novel dual kinase inhibitors of CK2 and GSK3beta.	4,5,6,7-tetrahydro-1,3-benzothiazole	37-71	glycogen synthase kinase 3 beta	Homo sapiens	118-126
30097126-11	2018	Meanwhile, brucine also decreased the phosphorylation level of LRP5/6 and GSK3beta, and increased the level of p-beta-catenin.	brucine	11-18	glycogen synthase kinase 3 beta	Homo sapiens	74-82
30108501-0	2018	Fisetin Inhibited Growth and Metastasis of Triple-Negative Breast Cancer by Reversing Epithelial-to-Mesenchymal Transition via PTEN/Akt/GSK3beta Signal Pathway.	fisetin	0-7	glycogen synthase kinase 3 beta	Homo sapiens	136-144
30108501-6	2018	Furthermore, fisetin suppressed phosphoinositol 3-kinase (PI3K)-Akt-GSK-3beta signaling pathway but upregulated the expression of PTEN mRNA and protein in a concentration-dependent manner.	fisetin	13-20	glycogen synthase kinase 3 beta	Homo sapiens	68-77
30108501-8	2018	In vivo, using the metastatic breast cancer xenograft model bearing MDA-MB-231 cells, we found that fisetin dramatically inhibited growth of primary breast tumor and reduced lung metastasis, meanwhile, the expression of EMT molecules and PTEN/Akt/GSK-3beta in primary and metastatic tissues changed in the same way as those in vitro experiments.	fisetin	100-107	glycogen synthase kinase 3 beta	Homo sapiens	247-256
30108501-9	2018	In conclusion, all these results indicated that fisetin could effectively suppress proliferation and metastasis of TNBC and reverse EMT process, which might be mediated by PTEN/Akt/GSK-3beta signaling pathway.	fisetin	48-55	glycogen synthase kinase 3 beta	Homo sapiens	181-190
30123351-5	2018	Moreover, phosphor mutants of CAP1 at the S307/S309 regulatory site had compromised rescue effects for both the invasiveness and the proliferation in CAP1-knockdown cells and GSK3beta kinase inhibitor LiCl inhibited cell phosphorylation site S307/S309 by up-regulating the expression of p53, BAK, BAD and cleaved PARP induced ROS production, decreased lung cancer cell viability, adhesion, proliferation, migration and invasion, and induction of apoptosis.	Lithium Chloride	201-205	glycogen synthase kinase 3 beta	Homo sapiens	175-183
29992949-5	2018	Importantly, GSK3beta is inactivated by AKT in response to mTORC2 signaling triggered by glucose limitation.	Glucose	89-96	glycogen synthase kinase 3 beta	Homo sapiens	13-21
29976400-7	2018	Glucose uptake and insulin signaling impaired in HepG2 cells incubated with OA were abated by THC treatment, including phosphorylation of the insulin receptor substrate 1 (IRS-1)/phosphoinositide 3-kinase (PI3K)/Akt and downstream signaling pathways, forkhead box protein O1 (FOXO1) and glycogen synthase kinase 3 beta (GSK3beta), which are involved in gluconeogenesis and glycogen synthesis, respectively.	tetrahydrocurcumin	94-97	glycogen synthase kinase 3 beta	Homo sapiens	287-318
29431119-8	2018	Calcium transfer through MAM sites sustained mitochondrial hyperactivity and was dependent on inactivation of glycogen synthase kinase 3b (GSK3b), a serine/threonine kinase functioning as a metabolic switch.	Calcium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	110-137
29431119-8	2018	Calcium transfer through MAM sites sustained mitochondrial hyperactivity and was dependent on inactivation of glycogen synthase kinase 3b (GSK3b), a serine/threonine kinase functioning as a metabolic switch.	Calcium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	139-144
29345351-0	2018	K313, a novel benzoxazole derivative, exhibits anti-inflammatory properties via inhibiting GSK3beta activity in LPS-induced RAW264.7 macrophages.	palladium chloride	0-4	glycogen synthase kinase 3 beta	Homo sapiens	91-99
29345351-0	2018	K313, a novel benzoxazole derivative, exhibits anti-inflammatory properties via inhibiting GSK3beta activity in LPS-induced RAW264.7 macrophages.	Benzoxazoles	14-25	glycogen synthase kinase 3 beta	Homo sapiens	91-99
29345351-7	2018	Instead, K313 increased phosphorylation of glycogen synthase kinase-3 beta (GSK-3beta) (Ser9) resulting in GSK-3beta deactivation.	palladium chloride	9-13	glycogen synthase kinase 3 beta	Homo sapiens	43-74
29345351-7	2018	Instead, K313 increased phosphorylation of glycogen synthase kinase-3 beta (GSK-3beta) (Ser9) resulting in GSK-3beta deactivation.	palladium chloride	9-13	glycogen synthase kinase 3 beta	Homo sapiens	76-85
29345351-7	2018	Instead, K313 increased phosphorylation of glycogen synthase kinase-3 beta (GSK-3beta) (Ser9) resulting in GSK-3beta deactivation.	palladium chloride	9-13	glycogen synthase kinase 3 beta	Homo sapiens	107-116
29345351-10	2018	K313 can increase GSK-3beta (Ser9) phosphorylation to decrease GSK-3beta activation in LPS-induced RAW264.7 macrophages.	palladium chloride	0-4	glycogen synthase kinase 3 beta	Homo sapiens	18-27
29345351-10	2018	K313 can increase GSK-3beta (Ser9) phosphorylation to decrease GSK-3beta activation in LPS-induced RAW264.7 macrophages.	palladium chloride	0-4	glycogen synthase kinase 3 beta	Homo sapiens	63-72
29976400-7	2018	Glucose uptake and insulin signaling impaired in HepG2 cells incubated with OA were abated by THC treatment, including phosphorylation of the insulin receptor substrate 1 (IRS-1)/phosphoinositide 3-kinase (PI3K)/Akt and downstream signaling pathways, forkhead box protein O1 (FOXO1) and glycogen synthase kinase 3 beta (GSK3beta), which are involved in gluconeogenesis and glycogen synthesis, respectively.	tetrahydrocurcumin	94-97	glycogen synthase kinase 3 beta	Homo sapiens	320-328
29143288-5	2018	GSK3beta also promoted prosurvival signaling and attenuated kainic acid-induced apoptosis.	Kainic Acid	60-71	glycogen synthase kinase 3 beta	Homo sapiens	0-8
30605431-8	2018	A wide range of intracellular responses may be secondary to the inhibition of glycogen synthase kinase-3 beta (GSK3beta) by lithium, while genetic variability at GSK3beta gene was found to be associated with increased impulsivity in bipolar patients.	Lithium	124-131	glycogen synthase kinase 3 beta	Homo sapiens	78-109
30605431-8	2018	A wide range of intracellular responses may be secondary to the inhibition of glycogen synthase kinase-3 beta (GSK3beta) by lithium, while genetic variability at GSK3beta gene was found to be associated with increased impulsivity in bipolar patients.	Lithium	124-131	glycogen synthase kinase 3 beta	Homo sapiens	111-119
30605431-8	2018	A wide range of intracellular responses may be secondary to the inhibition of glycogen synthase kinase-3 beta (GSK3beta) by lithium, while genetic variability at GSK3beta gene was found to be associated with increased impulsivity in bipolar patients.	Lithium	124-131	glycogen synthase kinase 3 beta	Homo sapiens	162-170
29775963-4	2018	We report that IPC causes generation of endogenous lipid electrophiles, including 4-hydroxy-2-nonenal (4-HNE), which release Nrf2 from inhibition by Keap1 (via Keap1-C288) and inhibition by glycogen synthase kinase 3beta (via GSK3beta-C199).	4-hydroxy-2-nonenal	82-101	glycogen synthase kinase 3 beta	Homo sapiens	226-234
29669060-8	2018	AKT inhibitor MK-2206 inhibited DEHP-induced EMT features and signals of AKT phosphorylation and downstream NF-kappaB and GSK3beta.	MK 2206	14-21	glycogen synthase kinase 3 beta	Homo sapiens	122-130
29775963-4	2018	We report that IPC causes generation of endogenous lipid electrophiles, including 4-hydroxy-2-nonenal (4-HNE), which release Nrf2 from inhibition by Keap1 (via Keap1-C288) and inhibition by glycogen synthase kinase 3beta (via GSK3beta-C199).	4-hydroxy-2-nonenal	104-108	glycogen synthase kinase 3 beta	Homo sapiens	226-234
29669060-8	2018	AKT inhibitor MK-2206 inhibited DEHP-induced EMT features and signals of AKT phosphorylation and downstream NF-kappaB and GSK3beta.	Diethylhexyl Phthalate	32-36	glycogen synthase kinase 3 beta	Homo sapiens	122-130
30215834-0	2018	[Evaluation of the Association between Lithium Treatment and GSK3beta Polymorphism in Bipolar Disorder Patients].	Lithium	39-46	glycogen synthase kinase 3 beta	Homo sapiens	61-69
30149419-0	2018	Regular exercise and creatine supplementation prevent chronic mild stress-induced decrease in hippocampal neurogenesis via Wnt/GSK3beta/beta-catenin pathway.	Creatine	21-29	glycogen synthase kinase 3 beta	Homo sapiens	127-135
30215834-2	2018	Studies that examined the mechanistic action of lithium revealed that glycogen synthase kinase 3beta (GSK-3beta) enzymeinhibition was important in regard to treatment responses.	Lithium	48-55	glycogen synthase kinase 3 beta	Homo sapiens	70-100
30215834-2	2018	Studies that examined the mechanistic action of lithium revealed that glycogen synthase kinase 3beta (GSK-3beta) enzymeinhibition was important in regard to treatment responses.	Lithium	48-55	glycogen synthase kinase 3 beta	Homo sapiens	102-111
30215834-3	2018	Based on this background, we aimed to investigate the association between responses to lithium treatment and five different polymorphisms of GSK-3beta.	Lithium	87-94	glycogen synthase kinase 3 beta	Homo sapiens	141-150
30215834-11	2018	CONCLUSION: The specific GSK-3beta polymorphism that associated with lithium-response in our study may help to predict lithium responses and to develop individualized treatment.	Lithium	69-76	glycogen synthase kinase 3 beta	Homo sapiens	25-34
30215834-11	2018	CONCLUSION: The specific GSK-3beta polymorphism that associated with lithium-response in our study may help to predict lithium responses and to develop individualized treatment.	Lithium	119-126	glycogen synthase kinase 3 beta	Homo sapiens	25-34
30149419-6	2018	Therefore, we examined whether regular exercise and/or creatine was closely associated with the activity of the Wnt/GSK3beta/beta-catenin pathway in the hippocampal DG.	Creatine	55-63	glycogen synthase kinase 3 beta	Homo sapiens	116-124
30149419-14	2018	CONCLUSION: Regular exercise combined with creatine supplementation had a greater effect on hippocampal neurogenesis via the Wnt/GSK3beta/beta-catenin pathway activation compared with each treatment in chronic mild stress-induced behavioral depression.	Creatine	43-51	glycogen synthase kinase 3 beta	Homo sapiens	129-137
29625084-6	2018	In HepG2 cells, vitamin C reversed the TNF-alpha-induced reduction of glucose uptake and glycogen synthesis, which were mediated by increasing GLUT2 levels and the activation of the insulin receptor substrate (IRS-1)/AKT/GSK3beta pathway.	Ascorbic Acid	16-25	glycogen synthase kinase 3 beta	Homo sapiens	221-229
29608860-0	2018	Eckmaxol, a Phlorotannin Extracted from Ecklonia maxima, Produces Anti-beta-amyloid Oligomer Neuroprotective Effects Possibly via Directly Acting on Glycogen Synthase Kinase 3beta.	eckmaxol	0-8	glycogen synthase kinase 3 beta	Homo sapiens	149-179
29608860-5	2018	Eckmaxol also significantly reversed the decreased expression of phospho-Ser9-glycogen synthase kinase 3beta and increased expression of phospho-extracellular signal-regulated kinase, which was induced by Abeta oligomer.	eckmaxol	0-8	glycogen synthase kinase 3 beta	Homo sapiens	78-108
29608860-7	2018	Furthermore, eckmaxol showed favorable interaction in the ATP binding site of glycogen synthase kinase 3beta and mitogen activated protein kinase.	eckmaxol	13-21	glycogen synthase kinase 3 beta	Homo sapiens	78-108
29608860-7	2018	Furthermore, eckmaxol showed favorable interaction in the ATP binding site of glycogen synthase kinase 3beta and mitogen activated protein kinase.	Adenosine Triphosphate	58-61	glycogen synthase kinase 3 beta	Homo sapiens	78-108
29608860-8	2018	These results suggested that eckmaxol might produce neuroprotective effects via concurrent inhibition of glycogen synthase kinase 3beta and extracellular signal-regulated kinase pathways, possibly via directly acting on glycogen synthase kinase 3beta and mitogen activated protein kinase.	eckmaxol	29-37	glycogen synthase kinase 3 beta	Homo sapiens	105-135
29608860-8	2018	These results suggested that eckmaxol might produce neuroprotective effects via concurrent inhibition of glycogen synthase kinase 3beta and extracellular signal-regulated kinase pathways, possibly via directly acting on glycogen synthase kinase 3beta and mitogen activated protein kinase.	eckmaxol	29-37	glycogen synthase kinase 3 beta	Homo sapiens	220-250
29781013-0	2018	Design and synthesis of (aza)indolyl maleimide-based covalent inhibitors of glycogen synthase kinase 3beta.	(aza)indolyl maleimide	24-46	glycogen synthase kinase 3 beta	Homo sapiens	76-106
30002689-0	2018	MicroRNA-135b-5p prevents oxygen-glucose deprivation and reoxygenation-induced neuronal injury through regulation of the GSK-3beta/Nrf2/ARE signaling pathway.	Oxygen	26-32	glycogen synthase kinase 3 beta	Homo sapiens	121-130
30002689-0	2018	MicroRNA-135b-5p prevents oxygen-glucose deprivation and reoxygenation-induced neuronal injury through regulation of the GSK-3beta/Nrf2/ARE signaling pathway.	Glucose	33-40	glycogen synthase kinase 3 beta	Homo sapiens	121-130
30002689-13	2018	We observed that miR-135b-5p directly targeted the 3"-untranslated region of glycogen synthase kinase-3beta (GSK-3beta).	mir-135b-5p	17-28	glycogen synthase kinase 3 beta	Homo sapiens	77-107
30002689-13	2018	We observed that miR-135b-5p directly targeted the 3"-untranslated region of glycogen synthase kinase-3beta (GSK-3beta).	mir-135b-5p	17-28	glycogen synthase kinase 3 beta	Homo sapiens	109-118
30002689-16	2018	However, the restoration of GSK-3beta expression significantly reversed the protective effects of miR-135b-5p overexpression.	mir-135b	98-106	glycogen synthase kinase 3 beta	Homo sapiens	28-37
29781013-4	2018	Among these covalent inhibitors, compound 38b with a mild alpha-fluoromethyl amide reactive group emerges as a selective and covalent inhibitor against GSK-3beta, effectively inhibits the phosphorylation of glycogen synthase and tau protein, and increases beta-catenin"s levels in living cells.	alpha-fluoromethyl amide	58-82	glycogen synthase kinase 3 beta	Homo sapiens	152-161
28833099-0	2018	Simvastatin induces G1 arrest by up-regulating GSK3beta and down-regulating CDK4/cyclin D1 and CDK2/cyclin E1 in human primary colorectal cancer cells.	Simvastatin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	47-55
30074204-0	2018	Ezetimibe Protects Endothelial Cells against Oxidative Stress through Akt/GSK-3beta Pathway.	Ezetimibe	0-9	glycogen synthase kinase 3 beta	Homo sapiens	74-83
29231977-0	2018	DIDS inhibits overexpression BAK1-induced mitochondrial apoptosis through GSK3beta/beta-catenin signaling pathway.	4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid	0-4	glycogen synthase kinase 3 beta	Homo sapiens	74-82
28833099-7	2018	SIM suppressed cell growth and induced cell cycle G1 -arrest by suppressing the expression of CDK4/cyclin D1 and CDK2/cyclin E1, but elevating the expression of glycogen synthase kinase 3beta in CPs.	Simvastatin	0-3	glycogen synthase kinase 3 beta	Homo sapiens	161-191
29713826-3	2018	This study aimed to investigate the role of AKT, mTOR, and GSK3beta proteins in the occurrence of CLN metastasis in OSCC patients.	colostrinine	98-101	glycogen synthase kinase 3 beta	Homo sapiens	59-67
29231977-5	2018	Thus, this study aimed to explore whether DIDS could protect BAK1-induced apoptosis through GSK3beta/beta-catenin signaling pathway.	4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid	42-46	glycogen synthase kinase 3 beta	Homo sapiens	92-100
29231977-8	2018	In addition, lithium chloride (LiCl), an activator of Wnt/beta-catenin signaling pathway, markedly attenuated overexpression BAK1-induced mitochondrial apoptosis by restoring the expression levels of Ser9-GSK3beta and beta-catenin.	Lithium Chloride	13-29	glycogen synthase kinase 3 beta	Homo sapiens	200-213
29231977-8	2018	In addition, lithium chloride (LiCl), an activator of Wnt/beta-catenin signaling pathway, markedly attenuated overexpression BAK1-induced mitochondrial apoptosis by restoring the expression levels of Ser9-GSK3beta and beta-catenin.	Lithium Chloride	31-35	glycogen synthase kinase 3 beta	Homo sapiens	200-213
29231977-9	2018	Finally, DIDS absolutely abolished overexpression BAK1-mediated mitochondrial apoptosis through recovering the expression levels of Ser9-GSK3beta and beta-catenin.	4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid	9-13	glycogen synthase kinase 3 beta	Homo sapiens	132-145
29757923-7	2018	The observed beneficial effects of artesunate are associated with activation of the PI3K/Akt/ERK 1/2 (RISK) pathway, activation of endothelial nitric oxide synthase, inhibition of glycogen synthase kinase-3beta, inhibition of nuclear factor kappa B, and activation of the STAT3 (SAFE) pathway.	Artesunate	35-45	glycogen synthase kinase 3 beta	Homo sapiens	180-210
29713826-10	2018	High expression levels of GSK3beta and pGSK3betaSer9 were significantly associated with CLN metastasis, but only GSK3beta remained an independent predictor of CLN metastasis.	colostrinine	88-91	glycogen synthase kinase 3 beta	Homo sapiens	26-34
29713826-10	2018	High expression levels of GSK3beta and pGSK3betaSer9 were significantly associated with CLN metastasis, but only GSK3beta remained an independent predictor of CLN metastasis.	colostrinine	88-91	glycogen synthase kinase 3 beta	Homo sapiens	40-48
29466765-0	2018	Genetic or pharmacological superoxide-hydrogen peroxide imbalances modulate the in vitro effects of lithium on glycogen synthase kinase-3beta.	Superoxides	27-37	glycogen synthase kinase 3 beta	Homo sapiens	111-141
29563102-5	2018	SNO-dependent modulation of the localization of GSK-3beta and its ability to phosphorylate downstream targets was investigated in vitro, and the network of proteins differentially impacted by phospho- or SNO-dependent GSK-3beta regulation and in vivo SNO modification of key signaling kinases during the development of heart failure was also studied.	sno	0-3	glycogen synthase kinase 3 beta	Homo sapiens	48-57
29563102-5	2018	SNO-dependent modulation of the localization of GSK-3beta and its ability to phosphorylate downstream targets was investigated in vitro, and the network of proteins differentially impacted by phospho- or SNO-dependent GSK-3beta regulation and in vivo SNO modification of key signaling kinases during the development of heart failure was also studied.	sno	0-3	glycogen synthase kinase 3 beta	Homo sapiens	218-227
29563102-5	2018	SNO-dependent modulation of the localization of GSK-3beta and its ability to phosphorylate downstream targets was investigated in vitro, and the network of proteins differentially impacted by phospho- or SNO-dependent GSK-3beta regulation and in vivo SNO modification of key signaling kinases during the development of heart failure was also studied.	sno	204-207	glycogen synthase kinase 3 beta	Homo sapiens	48-57
29563102-5	2018	SNO-dependent modulation of the localization of GSK-3beta and its ability to phosphorylate downstream targets was investigated in vitro, and the network of proteins differentially impacted by phospho- or SNO-dependent GSK-3beta regulation and in vivo SNO modification of key signaling kinases during the development of heart failure was also studied.	sno	204-207	glycogen synthase kinase 3 beta	Homo sapiens	218-227
29563102-5	2018	SNO-dependent modulation of the localization of GSK-3beta and its ability to phosphorylate downstream targets was investigated in vitro, and the network of proteins differentially impacted by phospho- or SNO-dependent GSK-3beta regulation and in vivo SNO modification of key signaling kinases during the development of heart failure was also studied.	sno	204-207	glycogen synthase kinase 3 beta	Homo sapiens	48-57
29563102-5	2018	SNO-dependent modulation of the localization of GSK-3beta and its ability to phosphorylate downstream targets was investigated in vitro, and the network of proteins differentially impacted by phospho- or SNO-dependent GSK-3beta regulation and in vivo SNO modification of key signaling kinases during the development of heart failure was also studied.	sno	204-207	glycogen synthase kinase 3 beta	Homo sapiens	218-227
29563102-10	2018	CONCLUSIONS: The results indicate that SNO has a differential effect on the location and activity of GSK-3beta in the cytoplasm versus the nucleus.	sno	39-42	glycogen synthase kinase 3 beta	Homo sapiens	101-110
29563102-11	2018	SNO modification of GSK-3beta occurs in vivo and could contribute to the pathobiology of heart failure and sudden cardiac death.	sno	0-3	glycogen synthase kinase 3 beta	Homo sapiens	20-29
29789524-0	2018	Hirsutine induces mPTP-dependent apoptosis through ROCK1/PTEN/PI3K/GSK3beta pathway in human lung cancer cells.	hirsutine	0-9	glycogen synthase kinase 3 beta	Homo sapiens	67-75
29789524-4	2018	Dephosphorylation of GSK3beta is involved in hirsutine-mediated mitochondrial permeability transition pore (mPTP) opening through ANT1/CypD interaction.	hirsutine	45-54	glycogen synthase kinase 3 beta	Homo sapiens	21-29
29789524-5	2018	Mechanistic study revealed that interruption of ROCK1/PTEN/PI3K/Akt signaling pathway plays a critical role in hirsutine-mediated GSK3beta dephosphorylation and mitochondrial apoptosis.	hirsutine	111-120	glycogen synthase kinase 3 beta	Homo sapiens	130-138
29789524-7	2018	Collectively, these findings suggest a hierarchical model in which induction of apoptosis by hirsutine stems primarily from activation of ROCK1 and PTEN, inactivation of PI3K/Akt, leading in turn to GSK3beta dephosphorylation and mPTP opening, and culminating in caspase-3 activation and apoptosis.	hirsutine	93-102	glycogen synthase kinase 3 beta	Homo sapiens	199-207
29789636-0	2018	Cypripedin diminishes an epithelial-to-mesenchymal transition in non-small cell lung cancer cells through suppression of Akt/GSK-3beta signalling.	cypripedin	0-10	glycogen synthase kinase 3 beta	Homo sapiens	125-134
29466765-0	2018	Genetic or pharmacological superoxide-hydrogen peroxide imbalances modulate the in vitro effects of lithium on glycogen synthase kinase-3beta.	Hydrogen Peroxide	38-55	glycogen synthase kinase 3 beta	Homo sapiens	111-141
29466765-0	2018	Genetic or pharmacological superoxide-hydrogen peroxide imbalances modulate the in vitro effects of lithium on glycogen synthase kinase-3beta.	Lithium	100-107	glycogen synthase kinase 3 beta	Homo sapiens	111-141
29466765-1	2018	INTRODUCTION: Lithium (Li), a mood stabilizer used to treat bipolar disorder (BP) symptoms has important anti-inflammatory effects by downregulation of glycogen synthase kinase-3 beta (GSK-3beta).	Lithium	14-21	glycogen synthase kinase 3 beta	Homo sapiens	152-183
29466765-1	2018	INTRODUCTION: Lithium (Li), a mood stabilizer used to treat bipolar disorder (BP) symptoms has important anti-inflammatory effects by downregulation of glycogen synthase kinase-3 beta (GSK-3beta).	Lithium	14-21	glycogen synthase kinase 3 beta	Homo sapiens	185-194
29784906-0	2018	The anti-cancer activity of an andrographolide analogue functions through a GSK-3beta-independent Wnt/beta-catenin signaling pathway in colorectal cancer cells.	andrographolide	31-46	glycogen synthase kinase 3 beta	Homo sapiens	76-85
29891449-0	2018	[Lithium chloride arrests HK-2 cell cycle in G2 phase through AKT/GSK-3beta signal pathway].	Lithium Chloride	1-17	glycogen synthase kinase 3 beta	Homo sapiens	66-75
29891449-5	2018	The expressions of cyclin B1, CDK1, p-GSK-3beta, and beta-catenin increased and the expression of p-AKT decreased significantly in the cells as LiCl treatment time and concentration increased.	Lithium Chloride	144-148	glycogen synthase kinase 3 beta	Homo sapiens	38-47
29891461-0	2018	[Interaction between glycogen synthase kinase-3beta and endoplasmic reticulum stress is involved in high glucose-induced injury in human umbilical vein endothelial cells].	Glucose	105-112	glycogen synthase kinase 3 beta	Homo sapiens	21-51
29891449-6	2018	CONCLUSION: LiCl may cause HK-2 cell cycle arrest in G2 phase through activation of the AKT/GSK-3beta signaling pathway.	Lithium Chloride	12-16	glycogen synthase kinase 3 beta	Homo sapiens	92-101
29891461-1	2018	OBJECTIVE: To explore the role of the interaction between glycogen synthase kinase-3beta (GSK-3beta) and endoplasmic reticulum stress (ERS) in the high glucose (HG)-induced injury in human umbilical vein endothelial cells (HUVECs).	Glucose	152-159	glycogen synthase kinase 3 beta	Homo sapiens	58-88
29136244-4	2018	Results: An unbiased phosphoproteomic screen quantified phosphorylation changes associated with chronic exposure to the mTOR inhibitor rapamycin, and our analysis implicated a role for glycogen synthase kinase (GSK)3B attenuation in mediating resistance that was confirmed by functional studies.	Sirolimus	135-144	glycogen synthase kinase 3 beta	Homo sapiens	211-217
29891461-1	2018	OBJECTIVE: To explore the role of the interaction between glycogen synthase kinase-3beta (GSK-3beta) and endoplasmic reticulum stress (ERS) in the high glucose (HG)-induced injury in human umbilical vein endothelial cells (HUVECs).	Glucose	152-159	glycogen synthase kinase 3 beta	Homo sapiens	90-99
29891461-6	2018	RESULTS: Treatment of HUVECs with 40 micromol/L glucose for 3-24 h activated GSK-3beta in a time-dependent manner, leading to significantly down-regulated expression of phosphorylated (p)-GSK-3beta (P&lt;0.05).	Glucose	48-55	glycogen synthase kinase 3 beta	Homo sapiens	77-86
29891461-6	2018	RESULTS: Treatment of HUVECs with 40 micromol/L glucose for 3-24 h activated GSK-3beta in a time-dependent manner, leading to significantly down-regulated expression of phosphorylated (p)-GSK-3beta (P&lt;0.05).	Glucose	48-55	glycogen synthase kinase 3 beta	Homo sapiens	188-197
29891461-8	2018	LiCl, an inhibitor of GSK-3beta, attenuated HG-induced ERS and significantly lowered the expression levels of GRP78 and CHOP (P&lt;0.01).	Lithium Chloride	0-4	glycogen synthase kinase 3 beta	Homo sapiens	22-31
29891461-9	2018	4-PBA, an inhibitor of ERS, obviously ameliorated the activation of GSK-3beta by HG as shown by the increase in p-GSK-3beta expression level (P&lt;0.01).	4-phenylbutylamine	0-5	glycogen synthase kinase 3 beta	Homo sapiens	68-77
29891461-9	2018	4-PBA, an inhibitor of ERS, obviously ameliorated the activation of GSK-3beta by HG as shown by the increase in p-GSK-3beta expression level (P&lt;0.01).	4-phenylbutylamine	0-5	glycogen synthase kinase 3 beta	Homo sapiens	114-123
29381861-0	2018	Discovery of Selective, Substrate-Competitive, and Passive Membrane Permeable Glycogen Synthase Kinase-3beta Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling of New C-Glycosylflavones.	c-glycosylflavones	185-203	glycogen synthase kinase 3 beta	Homo sapiens	78-108
28835320-0	2018	Baicalein Inhibits the Proliferation of Cervical Cancer Cells Through the GSK3beta-Dependent Pathway.	baicalein	0-9	glycogen synthase kinase 3 beta	Homo sapiens	74-82
28835320-5	2018	Moreover, when CHIR-99021, a GSK3beta inhibitor, was added to baicalein-treated SiHa cells, the expression of cyclin D1 was recovered, and cell proliferation was promoted.	baicalein	62-71	glycogen synthase kinase 3 beta	Homo sapiens	29-37
28835320-6	2018	In conclusion, these data indicated that baicalein suspended the cell cycle at the G0/G1 phase via the downregulation of cyclin D1 through the AKT-GSK3beta signaling pathway and further inhibited the proliferation of SiHa and HeLa cervical cancer cells.	baicalein	41-50	glycogen synthase kinase 3 beta	Homo sapiens	147-155
29719095-6	2018	miR-135a was found to inhibit GSK-3beta expression, but promote the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and downstream signaling.	mir-135a	0-8	glycogen synthase kinase 3 beta	Homo sapiens	30-39
29719095-7	2018	However, overexpression of GSK-3beta significantly reversed miR-135a-induced neuroprotective effect.	mir-135a	60-68	glycogen synthase kinase 3 beta	Homo sapiens	27-36
29719095-8	2018	Overall, our results suggest that miR-135a protects neurons against OGD/R-induced injury through downregulation of GSK-3beta and upregulation of Nrf2 signaling.	mir-135a	34-42	glycogen synthase kinase 3 beta	Homo sapiens	115-124
29526746-9	2018	Additionally, increment of IRS-1 interaction with GSK3beta, and p85-PI3K were observed in NaAsO2 treated cells.	sodium arsenite	90-96	glycogen synthase kinase 3 beta	Homo sapiens	50-58
29546355-6	2018	Finally, ZINC08383479 and ZINC08441251 were selected as potential GSK3beta inhibitors.	zinc08383479	9-21	glycogen synthase kinase 3 beta	Homo sapiens	66-74
29546355-6	2018	Finally, ZINC08383479 and ZINC08441251 were selected as potential GSK3beta inhibitors.	zinc08441251	26-38	glycogen synthase kinase 3 beta	Homo sapiens	66-74
29546355-9	2018	The result showed that ZINC08383479 and ZINC08441251 had high inhibition activity against GSK3beta.	zinc08383479	23-35	glycogen synthase kinase 3 beta	Homo sapiens	90-98
29546355-9	2018	The result showed that ZINC08383479 and ZINC08441251 had high inhibition activity against GSK3beta.	zinc08441251	40-52	glycogen synthase kinase 3 beta	Homo sapiens	90-98
29471001-8	2018	Furthermore, the active CXCL5-CXCR2 axis enhanced the phosphorylation of Akt at Ser 473 residue and that of glycogen synthase kinase-3 (GSK-3beta) at Ser 9 residue, and accelerated the nuclear accumulation of beta-catenin in PTC cells.	Serine	150-153	glycogen synthase kinase 3 beta	Homo sapiens	136-145
29499407-7	2018	PB also suppressed the phosphorylation of Akt (protein kinase B) and PI3K (phosphoinositide 3-kinase), and increased the phosphorylation of GSK-3beta (glycogen synthase kinase 3beta).	physalin B	0-2	glycogen synthase kinase 3 beta	Homo sapiens	140-149
29499407-7	2018	PB also suppressed the phosphorylation of Akt (protein kinase B) and PI3K (phosphoinositide 3-kinase), and increased the phosphorylation of GSK-3beta (glycogen synthase kinase 3beta).	physalin B	0-2	glycogen synthase kinase 3 beta	Homo sapiens	151-181
28906145-0	2018	Protective effect of rutin against brain injury induced by acrylamide or gamma radiation: role of PI3K/AKT/GSK-3beta/NRF-2 signalling pathway.	Rutin	21-26	glycogen synthase kinase 3 beta	Homo sapiens	107-116
28906145-6	2018	It could be concluded that rutin provides protection effect against acrylamide or gamma-radiation-induced neurotoxicity via activation of the PI3K/AKT/GSK-3beta/NRF-2-pathway by altering the phosphorylation state through its ability to scavenge free radicals generation, modulating gene expression and its anti-inflammatory effects.	Rutin	27-32	glycogen synthase kinase 3 beta	Homo sapiens	151-160
28906145-6	2018	It could be concluded that rutin provides protection effect against acrylamide or gamma-radiation-induced neurotoxicity via activation of the PI3K/AKT/GSK-3beta/NRF-2-pathway by altering the phosphorylation state through its ability to scavenge free radicals generation, modulating gene expression and its anti-inflammatory effects.	Acrylamide	68-78	glycogen synthase kinase 3 beta	Homo sapiens	151-160
29421751-8	2018	When 22Rv1 cells were exposed to 30 pM of 17 TB, which is the effective concentration (EC50) value required to observe proliferative effects on 22Rv1 cells, the expression levels of the phosphorylated forms of Akt and GSK3beta were increased.	Terbium	45-47	glycogen synthase kinase 3 beta	Homo sapiens	218-226
29514056-4	2018	On the other hand, there are many signaling pathways that play important roles in the anti-autophagy effect of H2S, including SR-A, PI3K/SGK1/GSK3beta, PI3K/AKT/mTOR, Nrf2-ROS-AMPK, AMPK/mTOR, and JNK1 signaling pathways.	Hydrogen Sulfide	111-114	glycogen synthase kinase 3 beta	Homo sapiens	142-150
29358311-9	2018	beta-Elemene didn"t affect normal human airway fibroblasts; however, it had a dose-responsive inhibitive effect on the proliferation and expression of Wnt3a, non-active GSK-3beta, beta-catenin, alpha-SMA, TGF-beta, and Col-I of human airway granulation fibroblasts.	beta-elemene	0-12	glycogen synthase kinase 3 beta	Homo sapiens	169-178
29588342-8	2018	The AKT inhibitor LY294002 also suppressed TGFbeta2-induced up-regulation of nuclear Snail and reduced phosphorylation of GSK3beta.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	18-26	glycogen synthase kinase 3 beta	Homo sapiens	122-130
29731706-4	2018	This alteration in tau metabolism is characterized by pathological phosphorylation at residue Thr175 (pThr175 tau) which in vitro is associated with activation of GSK3beta (pTyr216GSK3beta), phosphorylation of Thr231tau, and the formation of cytoplasmic inclusions with increased rates of cell death.	pthr175	102-109	glycogen synthase kinase 3 beta	Homo sapiens	163-171
29731706-4	2018	This alteration in tau metabolism is characterized by pathological phosphorylation at residue Thr175 (pThr175 tau) which in vitro is associated with activation of GSK3beta (pTyr216GSK3beta), phosphorylation of Thr231tau, and the formation of cytoplasmic inclusions with increased rates of cell death.	pthr175	102-109	glycogen synthase kinase 3 beta	Homo sapiens	180-188
29331585-4	2018	In this study, we demonstrated that IR reduced glycogen synthase kinase-3beta (GSK-3beta) activity, via the CTSL-mediated phosphorylation of its serine-9 residue, in U251 cells.	Serine	145-151	glycogen synthase kinase 3 beta	Homo sapiens	79-88
29686616-5	2018	We demonstrated that estradiol treatment of adult PA exposed animals induced an increase in estrogen receptor (ER) alpha and insulin-like growth factor receptor (IGF-1R) protein levels, an activation of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta/beta-catenin signaling pathway and an increase in Bcl-2/Bax ratio in the hippocampus in comparison to PA exposed animals treated with vehicle.	Estradiol	21-30	glycogen synthase kinase 3 beta	Homo sapiens	241-272
29686616-5	2018	We demonstrated that estradiol treatment of adult PA exposed animals induced an increase in estrogen receptor (ER) alpha and insulin-like growth factor receptor (IGF-1R) protein levels, an activation of the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3 beta/beta-catenin signaling pathway and an increase in Bcl-2/Bax ratio in the hippocampus in comparison to PA exposed animals treated with vehicle.	Protactinium	50-52	glycogen synthase kinase 3 beta	Homo sapiens	241-272
29731993-4	2018	Gene silencing of AKT1 or treatment of LY294002 (PI3 kinase inhibitor) increased E-cadherin, whereas decreased phospho-GSK-3beta.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	39-47	glycogen synthase kinase 3 beta	Homo sapiens	119-128
29435803-3	2018	This study aims to investigate whether rifampicin protects rotenone-lesioned SH-SY5Y cells via regulating PI3K/Akt/GSK-3beta/CREB pathway.	Rotenone	59-67	glycogen synthase kinase 3 beta	Homo sapiens	115-124
29893306-9	2018	Hesperidin inhibited insulin-induced phosphorylation and activation of Akt, IkappaBalpha, and GSK-3beta and decreased expression of IKKalpha.	Hesperidin	0-10	glycogen synthase kinase 3 beta	Homo sapiens	94-103
29271701-5	2018	Additionally, TPA-induced phosphorylations of extracellular signal-regulated kinases, 90 kDa ribosomal S6 kinase 2, c-Jun N-terminal kinases, and glycogen synthase kinase 3beta were downregulated in the presence of RGO.	Tetradecanoylphorbol Acetate	14-17	glycogen synthase kinase 3 beta	Homo sapiens	116-176
29435803-0	2018	Rifampicin Prevents SH-SY5Y Cells from Rotenone-Induced Apoptosis via the PI3K/Akt/GSK-3beta/CREB Signaling Pathway.	Rifampin	0-10	glycogen synthase kinase 3 beta	Homo sapiens	83-92
28960426-2	2018	To examine underlying mechanisms of the pathological changes of mandibular cartilage induced by compressive mechanical force, an established animal model was used to examine Wnt signaling activation by glycogen synthase kinase-3 beta (GSK3beta) inhibitor 6-Bromoindirubin-3"-oxime (BIO) injection in vivo.	6-bromoindirubin-3'-oxime	255-280	glycogen synthase kinase 3 beta	Homo sapiens	235-243
28455695-0	2018	PKA-GSK3beta and beta-Catenin Signaling Play a Critical Role in Trans-Resveratrol Mediated Neuronal Differentiation in Human Cord Blood Stem Cells.	Resveratrol	64-81	glycogen synthase kinase 3 beta	Homo sapiens	4-12
29404840-0	2018	Lithium Inhibits GSK3beta Activity via Two Different Signaling Pathways in Neurons After Spinal Cord Injury.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	17-25
29404840-5	2018	Glycogen synthase kinase-3 beta (GSK3beta) is a serine/threonine kinase that plays an important role in the neuroprotective effects of lithium both in vivo and in vitro.	Lithium	135-142	glycogen synthase kinase 3 beta	Homo sapiens	0-31
29404840-5	2018	Glycogen synthase kinase-3 beta (GSK3beta) is a serine/threonine kinase that plays an important role in the neuroprotective effects of lithium both in vivo and in vitro.	Lithium	135-142	glycogen synthase kinase 3 beta	Homo sapiens	33-41
29404840-6	2018	In this study, we discovered that lithium inhibits GSK3beta activity through two different signaling pathways in spinal cord neurons.	Lithium	34-41	glycogen synthase kinase 3 beta	Homo sapiens	51-59
29404840-7	2018	In the acute phase, lithium inhibited GSK3beta activity by stimulating phosphorylation of AKT; in the chronic phase, we first discovered that lithium additionally upregulated the expression of Na+, K+-ATPase alpha1 (NKA alpha1), which had an inhibitory effect on GSK3beta activity by inducing the expression of glucocorticoid inducible kinase 1 (SGK1).	Lithium	20-27	glycogen synthase kinase 3 beta	Homo sapiens	38-46
29435803-0	2018	Rifampicin Prevents SH-SY5Y Cells from Rotenone-Induced Apoptosis via the PI3K/Akt/GSK-3beta/CREB Signaling Pathway.	Rotenone	39-47	glycogen synthase kinase 3 beta	Homo sapiens	83-92
29435803-9	2018	Moreover, pretreatment of SH-SY5Y cells with rifampicin enhanced phosphorylation of Akt and suppressed activity of GSK-3beta.	Rifampin	45-55	glycogen synthase kinase 3 beta	Homo sapiens	115-124
29435803-3	2018	This study aims to investigate whether rifampicin protects rotenone-lesioned SH-SY5Y cells via regulating PI3K/Akt/GSK-3beta/CREB pathway.	Rifampin	39-49	glycogen synthase kinase 3 beta	Homo sapiens	115-124
29404840-7	2018	In the acute phase, lithium inhibited GSK3beta activity by stimulating phosphorylation of AKT; in the chronic phase, we first discovered that lithium additionally upregulated the expression of Na+, K+-ATPase alpha1 (NKA alpha1), which had an inhibitory effect on GSK3beta activity by inducing the expression of glucocorticoid inducible kinase 1 (SGK1).	Lithium	20-27	glycogen synthase kinase 3 beta	Homo sapiens	263-271
29404840-7	2018	In the acute phase, lithium inhibited GSK3beta activity by stimulating phosphorylation of AKT; in the chronic phase, we first discovered that lithium additionally upregulated the expression of Na+, K+-ATPase alpha1 (NKA alpha1), which had an inhibitory effect on GSK3beta activity by inducing the expression of glucocorticoid inducible kinase 1 (SGK1).	Lithium	142-149	glycogen synthase kinase 3 beta	Homo sapiens	38-46
29404840-7	2018	In the acute phase, lithium inhibited GSK3beta activity by stimulating phosphorylation of AKT; in the chronic phase, we first discovered that lithium additionally upregulated the expression of Na+, K+-ATPase alpha1 (NKA alpha1), which had an inhibitory effect on GSK3beta activity by inducing the expression of glucocorticoid inducible kinase 1 (SGK1).	Lithium	142-149	glycogen synthase kinase 3 beta	Homo sapiens	263-271
29435803-10	2018	The addition of LY294002, a PI3K inhibitor, could suppress phosphorylation of Akt and CREB and activate GSK-3beta, resulting in abolishment of neuroprotective effects of rifampicin on cells exposed to rotenone.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	16-24	glycogen synthase kinase 3 beta	Homo sapiens	104-113
29435803-10	2018	The addition of LY294002, a PI3K inhibitor, could suppress phosphorylation of Akt and CREB and activate GSK-3beta, resulting in abolishment of neuroprotective effects of rifampicin on cells exposed to rotenone.	Rifampin	170-180	glycogen synthase kinase 3 beta	Homo sapiens	104-113
29435803-11	2018	Rifampicin provides neuroprotection against dopaminergic degeneration, partially via the PI3K/Akt/GSK-3beta/CREB signaling pathway.	Rifampin	0-10	glycogen synthase kinase 3 beta	Homo sapiens	98-107
29115830-0	2018	Gastrodin and Isorhynchophylline Synergistically Inhibit MPP+-Induced Oxidative Stress in SH-SY5Y Cells by Targeting ERK1/2 and GSK-3beta Pathways: Involvement of Nrf2 Nuclear Translocation.	gastrodin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	128-137
29393481-10	2018	In addition, PGD blocked the PI3K/Akt pathway by inhibiting the phosphorylation of GSK3beta, Akt and the expression of PI3K.	pgd	13-16	glycogen synthase kinase 3 beta	Homo sapiens	83-91
29228318-2	2018	The present study investigated the role of PP2A catalytic subunit (PP2Ac) demethylation and its link with glycogen synthase kinase-3beta (GSK)-3beta in tau hyperphosphorylation induced by MC-LR.	mc-lr	188-193	glycogen synthase kinase 3 beta	Homo sapiens	106-148
29228318-3	2018	The results showed that MC-LR treatment significantly increased demethylation of PP2Ac, with a concomitant increase in GSK-3beta phosphorylation at Ser9 resulting in elevated tau hyperphosphorylation at PP2A-favorable sites in SH-SY5Y cells and rat hippocampus.	mc-lr	24-29	glycogen synthase kinase 3 beta	Homo sapiens	119-128
29228318-5	2018	Moreover, we found that inhibition of PP2A resulted in an increase in phosphorylation of GSK-3beta at Ser9 and a decrease in GSK-3beta activity, which further promoted demethylation of PP2Ac induced by MC-LR.	mc-lr	202-207	glycogen synthase kinase 3 beta	Homo sapiens	89-98
29228318-5	2018	Moreover, we found that inhibition of PP2A resulted in an increase in phosphorylation of GSK-3beta at Ser9 and a decrease in GSK-3beta activity, which further promoted demethylation of PP2Ac induced by MC-LR.	mc-lr	202-207	glycogen synthase kinase 3 beta	Homo sapiens	125-134
29228318-6	2018	These findings suggest a scenario in which MC-LR-mediated demethylation of PP2Ac is associated with GSK-3beta phosphorylation at Ser9 and contributes to dissociation of Balpha from PP2Ac, which would result in Balpha degradation and disruption of PP2A/Balpha-tau interactions, thus promoting tau hyperphosphorylation and paired helical filaments-tau accumulation and, consequently, axonal degeneration and cell death.	mc-lr	43-48	glycogen synthase kinase 3 beta	Homo sapiens	100-109
29593255-8	2018	In vitro experiments also showed that the LSD1 inhibitor SP2509 and the GSK3beta inhibitor LY2090314 acted synergistically to induce cancer cell death.	3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione	91-100	glycogen synthase kinase 3 beta	Homo sapiens	72-80
29115830-0	2018	Gastrodin and Isorhynchophylline Synergistically Inhibit MPP+-Induced Oxidative Stress in SH-SY5Y Cells by Targeting ERK1/2 and GSK-3beta Pathways: Involvement of Nrf2 Nuclear Translocation.	mangion-purified polysaccharide (Candida albicans)	57-61	glycogen synthase kinase 3 beta	Homo sapiens	128-137
29115830-8	2018	Importantly, simultaneous inhibition of GSK-3beta pathway by IRN and activation of ERK1/2 pathway by GAS synergistically induced accumulation of Nrf2 in the nucleus in SH-SY5Y cells challenged with MPP+.	mangion-purified polysaccharide (Candida albicans)	198-202	glycogen synthase kinase 3 beta	Homo sapiens	40-49
29115830-0	2018	Gastrodin and Isorhynchophylline Synergistically Inhibit MPP+-Induced Oxidative Stress in SH-SY5Y Cells by Targeting ERK1/2 and GSK-3beta Pathways: Involvement of Nrf2 Nuclear Translocation.	rhyncophylline	14-32	glycogen synthase kinase 3 beta	Homo sapiens	128-137
29563926-8	2018	Cd exposure significantly increased the phosphorylation of Akt at thr308 and ser473 and that of GSK-3beta at ser9 in a time-dependent manner, while the total protein levels of GSK-3beta and Akt did not change.	Cadmium	0-2	glycogen synthase kinase 3 beta	Homo sapiens	96-105
29563926-0	2018	GSK-3beta-mediated regulation of cadmium-induced cell death and survival.	Cadmium	33-40	glycogen synthase kinase 3 beta	Homo sapiens	0-9
29563926-1	2018	Background: Previous studies indicated that cadmium (Cd) increases PI3-kinase/Akt phosphorylation, resulting in an alteration in GSK-3beta activity.	Cadmium	44-51	glycogen synthase kinase 3 beta	Homo sapiens	129-138
29561817-0	2018	Amaryllidaceae Alkaloids as Potential Glycogen Synthase Kinase-3beta Inhibitors.	Amaryllidaceae Alkaloids	0-24	glycogen synthase kinase 3 beta	Homo sapiens	38-68
29561817-1	2018	Glycogen synthase kinase-3beta (GSK-3beta) is a multifunctional serine/threonine protein kinase that was originally identified as an enzyme involved in the control of glycogen metabolism.	Glycogen	167-175	glycogen synthase kinase 3 beta	Homo sapiens	0-30
29561817-1	2018	Glycogen synthase kinase-3beta (GSK-3beta) is a multifunctional serine/threonine protein kinase that was originally identified as an enzyme involved in the control of glycogen metabolism.	Glycogen	167-175	glycogen synthase kinase 3 beta	Homo sapiens	32-41
29561817-5	2018	In the current study, twenty-eight Amaryllidaceae alkaloids of various structural types were studied for their potency to inhibit GSK-3beta.	Amaryllidaceae Alkaloids	35-59	glycogen synthase kinase 3 beta	Homo sapiens	130-139
29563926-1	2018	Background: Previous studies indicated that cadmium (Cd) increases PI3-kinase/Akt phosphorylation, resulting in an alteration in GSK-3beta activity.	Cadmium	53-55	glycogen synthase kinase 3 beta	Homo sapiens	129-138
29563926-8	2018	Cd exposure significantly increased the phosphorylation of Akt at thr308 and ser473 and that of GSK-3beta at ser9 in a time-dependent manner, while the total protein levels of GSK-3beta and Akt did not change.	Cadmium	0-2	glycogen synthase kinase 3 beta	Homo sapiens	176-185
29563926-3	2018	We examined the role of GSK-3beta in Cd-induced neuronal cell death and the related downstream signaling pathways.	Cadmium	37-39	glycogen synthase kinase 3 beta	Homo sapiens	24-33
29563926-9	2018	Cd-induced apoptosis was higher in GSK-3beta-knockdown cells than in normal cells.	Cadmium	0-2	glycogen synthase kinase 3 beta	Homo sapiens	35-44
29563926-10	2018	Conclusions: Our data suggest that Akt/GSK-3beta signaling activated by Cd is involved in neuronal cell survival.	Cadmium	72-74	glycogen synthase kinase 3 beta	Homo sapiens	39-48
29334667-4	2018	Our results demonstrated that the combination of lithium + nilotinib (L + N) induced K562-cell death and cleaved caspase-3 when compared to lithium or nilotinib alone, accompanied by GSK-3beta phosphorylation and Bcr-Abl oncoprotein levels reduction.	Lithium	49-56	glycogen synthase kinase 3 beta	Homo sapiens	183-192
29334667-4	2018	Our results demonstrated that the combination of lithium + nilotinib (L + N) induced K562-cell death and cleaved caspase-3 when compared to lithium or nilotinib alone, accompanied by GSK-3beta phosphorylation and Bcr-Abl oncoprotein levels reduction.	nilotinib	59-68	glycogen synthase kinase 3 beta	Homo sapiens	183-192
29497056-0	2018	Dioscin inhibits stem-cell-like properties and tumor growth of osteosarcoma through Akt/GSK3/beta-catenin signaling pathway.	dioscin	0-7	glycogen synthase kinase 3 beta	Homo sapiens	88-97
29433844-5	2018	The GSK-3beta activity, measured as serine-9 phosphorylated GSK-3beta (pGSK-3beta) and the GSK-3beta ratio (serine-9-pGSK-3beta /total GSK-3beta), was negatively associated with sustained attention (p = 0.009 and p = 0.042, respectively), but not with other cognitive domains or global cognition.	Serine	36-42	glycogen synthase kinase 3 beta	Homo sapiens	4-13
29363731-8	2018	In conclusion, the results suggested that GRh2 inhibits cervical cancer cell proliferation by targeting the Akt pathway, and prevents cervical cancer cell migration and invasion by suppressing the Akt/GSK3beta regulated EMT process, and therefore, GRh2 may have the potential to be a novel anti-cancer agent for cervical cancer.	grh2	42-46	glycogen synthase kinase 3 beta	Homo sapiens	201-209
29073723-10	2018	For mechanism, we found that high phosphate or BMP9 increases the level of beta-catenin and p-GSK3beta in VSMCs, but no substantial effect on GSK3beta.	Phosphates	34-43	glycogen synthase kinase 3 beta	Homo sapiens	94-102
29136173-9	2018	Addition of LiCl, a GSK3beta inhibitor, significantly increased osteogenic differentiation in FH-pMSCs, suggesting a relationship between the microenvironment and regulation of stem cell behaviour in ONFH.	Lithium Chloride	12-16	glycogen synthase kinase 3 beta	Homo sapiens	20-28
28867214-0	2018	Lithium chloride inhibits StAR and progesterone production through GSK-3beta and ERK1/2 signaling pathways in human granulosa-lutein cells.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	67-76
29490668-14	2018	Expression of p-Akt and p-GSK-3beta was reduced effectively in the presence of the Akt inhibitor Triciribine.	triciribine	97-108	glycogen synthase kinase 3 beta	Homo sapiens	26-35
29636855-0	2018	Fisetin Confers Cardioprotection against Myocardial Ischemia Reperfusion Injury by Suppressing Mitochondrial Oxidative Stress and Mitochondrial Dysfunction and Inhibiting Glycogen Synthase Kinase 3beta Activity.	fisetin	0-7	glycogen synthase kinase 3 beta	Homo sapiens	171-201
29343851-7	2018	The mechanistic study shows that NDRG2 suppresses beta-catenin nuclear translocation and decreases the occupancy of beta-catenin/TCF complex on Skp2 promoter, potentially through dephosphorylating GSK-3beta.	tcf	129-132	glycogen synthase kinase 3 beta	Homo sapiens	197-206
29407771-0	2018	Triptolide induces mitochondria-mediated apoptosis of Burkitt"s lymphoma cell via deacetylation of GSK-3beta by increased SIRT3 expression.	triptolide	0-10	glycogen synthase kinase 3 beta	Homo sapiens	99-108
29445085-1	2018	Glycogen synthase kinase-3beta (GSK-3beta) is a ubiquitously expressed serine/threonine kinase involved in a variety of functions ranging from the control of glycogen metabolism to transcriptional regulation.	Glycogen	158-166	glycogen synthase kinase 3 beta	Homo sapiens	0-30
29445085-1	2018	Glycogen synthase kinase-3beta (GSK-3beta) is a ubiquitously expressed serine/threonine kinase involved in a variety of functions ranging from the control of glycogen metabolism to transcriptional regulation.	Glycogen	158-166	glycogen synthase kinase 3 beta	Homo sapiens	32-41
29531810-9	2018	Prior to phenotypic changes, lithium chloride altered Wnt signalling with elevations in AXIN2, GSK3beta phosphorylation and beta-catenin.	Lithium Chloride	29-45	glycogen synthase kinase 3 beta	Homo sapiens	95-103
28867214-6	2018	Additionally, LiCl induced the phosphorylation of GSK-3beta and ERK1/2 but not AKT or CREB.	Lithium Chloride	14-18	glycogen synthase kinase 3 beta	Homo sapiens	50-59
28867214-7	2018	Knockdown of endogenous GSK-3beta or inhibition of ERK1/2 partially reversed LiCl-induced down-regulation of StAR.	Lithium Chloride	77-81	glycogen synthase kinase 3 beta	Homo sapiens	24-33
28867214-8	2018	Furthermore, by using dual inhibition approaches, the results showed that both GSK-3beta and ERK1/2 signaling mediated the regulatory effect of LiCl on StAR expression.	Lithium Chloride	144-148	glycogen synthase kinase 3 beta	Homo sapiens	79-88
29377106-3	2018	Here, we report that Thr-7 and Thr-8 residues located in the AKT/PKB substrate consensus sequence on GSK3beta are essential for insulin-stimulated Ser-9 phosphorylation in vivo and for GSK3beta inactivation.	Serine	147-150	glycogen synthase kinase 3 beta	Homo sapiens	101-109
29107899-10	2018	Since this was quite contrary to miRNA regulation, we checked for intermediate players beta-catenin and GSK-3beta upon arsenic exposure which affects PMP22 expression.	Arsenic	119-126	glycogen synthase kinase 3 beta	Homo sapiens	104-113
29377106-0	2018	Modulation of GSK3beta autoinhibition by Thr-7 and Thr-8.	Threonine	41-44	glycogen synthase kinase 3 beta	Homo sapiens	14-22
29377106-3	2018	Here, we report that Thr-7 and Thr-8 residues located in the AKT/PKB substrate consensus sequence on GSK3beta are essential for insulin-stimulated Ser-9 phosphorylation in vivo and for GSK3beta inactivation.	Serine	147-150	glycogen synthase kinase 3 beta	Homo sapiens	185-193
29377106-0	2018	Modulation of GSK3beta autoinhibition by Thr-7 and Thr-8.	Threonine	51-54	glycogen synthase kinase 3 beta	Homo sapiens	14-22
29377106-4	2018	Intestinal cell kinase (ICK) phosphorylates GSK3beta Thr-7 in vitro and in vivo.	Threonine	53-56	glycogen synthase kinase 3 beta	Homo sapiens	44-52
29377106-2	2018	Inhibitory Ser-9 phosphorylation of GSK3beta by AKT is an important mechanism for negative regulation of GSK3beta activity upon insulin stimulation.	Serine	11-14	glycogen synthase kinase 3 beta	Homo sapiens	36-44
29377106-5	2018	Thr-8 phosphorylation partially inhibits GSK3beta, but Thr-7 phosphorylation promotes GSK3beta activity and blocks phospho-Ser-9-dependent GSK3beta autoinhibition.	Threonine	0-3	glycogen synthase kinase 3 beta	Homo sapiens	41-49
29377106-2	2018	Inhibitory Ser-9 phosphorylation of GSK3beta by AKT is an important mechanism for negative regulation of GSK3beta activity upon insulin stimulation.	Serine	11-14	glycogen synthase kinase 3 beta	Homo sapiens	105-113
29377106-3	2018	Here, we report that Thr-7 and Thr-8 residues located in the AKT/PKB substrate consensus sequence on GSK3beta are essential for insulin-stimulated Ser-9 phosphorylation in vivo and for GSK3beta inactivation.	Threonine	21-24	glycogen synthase kinase 3 beta	Homo sapiens	101-109
29377106-5	2018	Thr-8 phosphorylation partially inhibits GSK3beta, but Thr-7 phosphorylation promotes GSK3beta activity and blocks phospho-Ser-9-dependent GSK3beta autoinhibition.	Threonine	55-58	glycogen synthase kinase 3 beta	Homo sapiens	86-94
29377106-3	2018	Here, we report that Thr-7 and Thr-8 residues located in the AKT/PKB substrate consensus sequence on GSK3beta are essential for insulin-stimulated Ser-9 phosphorylation in vivo and for GSK3beta inactivation.	Threonine	21-24	glycogen synthase kinase 3 beta	Homo sapiens	185-193
29377106-5	2018	Thr-8 phosphorylation partially inhibits GSK3beta, but Thr-7 phosphorylation promotes GSK3beta activity and blocks phospho-Ser-9-dependent GSK3beta autoinhibition.	Threonine	55-58	glycogen synthase kinase 3 beta	Homo sapiens	86-94
29377106-3	2018	Here, we report that Thr-7 and Thr-8 residues located in the AKT/PKB substrate consensus sequence on GSK3beta are essential for insulin-stimulated Ser-9 phosphorylation in vivo and for GSK3beta inactivation.	Threonine	31-34	glycogen synthase kinase 3 beta	Homo sapiens	101-109
29377106-3	2018	Here, we report that Thr-7 and Thr-8 residues located in the AKT/PKB substrate consensus sequence on GSK3beta are essential for insulin-stimulated Ser-9 phosphorylation in vivo and for GSK3beta inactivation.	Threonine	31-34	glycogen synthase kinase 3 beta	Homo sapiens	185-193
29225110-6	2018	Prenatal nicotine and alcohol exposure induced oxidative stress, did not affect the mitochondrial functions, increased the monoamine oxidase activity, increased caspase expression and decreased ILK, PSD-95 and GLUR1 expression without affecting the GSK-3beta.	Alcohols	22-29	glycogen synthase kinase 3 beta	Homo sapiens	249-258
29449801-0	2018	Lithium Inhibits GSK3beta and Augments GluN2A Receptor Expression in the Prefrontal Cortex.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	17-25
29449801-2	2018	This study examines the effects of lithium on GSK3beta and its interaction with beta-catenin and NMDA receptors within the prefrontal cortex.	Lithium	35-42	glycogen synthase kinase 3 beta	Homo sapiens	46-54
29449801-3	2018	Lithium, a clinically relevant drug commonly prescribed as a mood stabilizer for psychiatric disorders, significantly increased levels of phosphorylated GSK3beta serine 9, an inhibitory phosphorylation site, and decreased beta-catenin ser33/37/thr41 phosphorylation in vitro, indicating GSK3beta inhibition and reduced beta-catenin degradation.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	153-161
29449801-3	2018	Lithium, a clinically relevant drug commonly prescribed as a mood stabilizer for psychiatric disorders, significantly increased levels of phosphorylated GSK3beta serine 9, an inhibitory phosphorylation site, and decreased beta-catenin ser33/37/thr41 phosphorylation in vitro, indicating GSK3beta inhibition and reduced beta-catenin degradation.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	287-295
29449801-3	2018	Lithium, a clinically relevant drug commonly prescribed as a mood stabilizer for psychiatric disorders, significantly increased levels of phosphorylated GSK3beta serine 9, an inhibitory phosphorylation site, and decreased beta-catenin ser33/37/thr41 phosphorylation in vitro, indicating GSK3beta inhibition and reduced beta-catenin degradation.	Serine	162-168	glycogen synthase kinase 3 beta	Homo sapiens	153-161
29449801-5	2018	Similar alterations were also demonstrated in vivo; lithium administration increased GSK3beta serine 9 phosphorylation and GluN2A levels, suggesting a reduced GSK3beta activity and augmented GluN2A expression.	Lithium	52-59	glycogen synthase kinase 3 beta	Homo sapiens	85-93
29449801-5	2018	Similar alterations were also demonstrated in vivo; lithium administration increased GSK3beta serine 9 phosphorylation and GluN2A levels, suggesting a reduced GSK3beta activity and augmented GluN2A expression.	Lithium	52-59	glycogen synthase kinase 3 beta	Homo sapiens	159-167
29449801-5	2018	Similar alterations were also demonstrated in vivo; lithium administration increased GSK3beta serine 9 phosphorylation and GluN2A levels, suggesting a reduced GSK3beta activity and augmented GluN2A expression.	Serine	94-100	glycogen synthase kinase 3 beta	Homo sapiens	85-93
29316328-8	2018	CONCLUSION: Pirfenidone has anti-fibrotic effects in SSc-ILD patients by interfering with both the Hh signalling pathway and the GSK-3beta signalling pathway via the regulation of Sufu expression.	pirfenidone	12-23	glycogen synthase kinase 3 beta	Homo sapiens	129-138
28833404-6	2018	Ascochlorin suppressed the stabilization of the c-Myc protein by inhibiting ERK and P70S6K/4EBP1 phosphorylation, whereas it had no effect on c-Myc degradation mediated by PI3K/Akt/GSK3beta.	ascochlorin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	181-189
29946637-9	2018	Simultaneously, CTS-induced activation of FGF2-GSK-3beta/beta-catenin signaling pathway was also inhibited by si-KLF5 transfection.	castanospermine	16-19	glycogen synthase kinase 3 beta	Homo sapiens	47-56
28190238-6	2018	In addition, GSK-3beta inactivation and downstream beta-catenin stabilization were associated with RA-induced differentiation, which was attenuated by alpha-SYN.	Tretinoin	99-101	glycogen synthase kinase 3 beta	Homo sapiens	13-22
28190238-0	2018	Alpha-Synuclein Suppresses Retinoic Acid-Induced Neuronal Differentiation by Targeting the Glycogen Synthase Kinase-3beta/beta-Catenin Signaling Pathway.	Tretinoin	27-40	glycogen synthase kinase 3 beta	Homo sapiens	91-121
29350680-9	2018	It was concluded that miR-135a accelerates the EMT, invasion and migration of BC cells by activating the Wnt/beta-catenin signaling pathway through the downregulation of GSK3beta expression.	mir-135a	22-30	glycogen synthase kinase 3 beta	Homo sapiens	170-178
28886972-1	2018	The Akt/glycogen synthase kinase-3beta (GSK-3beta)/beta-catenin signaling pathway has been shown to play an important role in hematopoiesis, and hematopoietic cells are sensitive targets for benzene-induced hematotoxicity.	Benzene	191-198	glycogen synthase kinase 3 beta	Homo sapiens	40-49
28886972-2	2018	We therefore hypothesized that dysregulation of the Akt/GSK-3beta/beta-catenin signaling was associated with benzene-induced hematotoxicity.	Benzene	109-116	glycogen synthase kinase 3 beta	Homo sapiens	56-65
28886972-6	2018	As expected, blockage of GSK-3beta activity with a GSK-3beta inhibitor lithium chloride (LiCl) or activation of Akt signaling with an Akt agonist insulin-like growth factor-1 (IGF-1) could inhibit HQ-induced activation of GSK-3beta as well as hematotoxicity.	Lithium Chloride	71-87	glycogen synthase kinase 3 beta	Homo sapiens	25-34
28886972-6	2018	As expected, blockage of GSK-3beta activity with a GSK-3beta inhibitor lithium chloride (LiCl) or activation of Akt signaling with an Akt agonist insulin-like growth factor-1 (IGF-1) could inhibit HQ-induced activation of GSK-3beta as well as hematotoxicity.	Lithium Chloride	71-87	glycogen synthase kinase 3 beta	Homo sapiens	51-60
29299575-0	2018	New organometallic imines of rhenium(i) as potential ligands of GSK-3beta: synthesis, characterization and biological studies.	Imines	19-25	glycogen synthase kinase 3 beta	Homo sapiens	64-73
28886972-6	2018	As expected, blockage of GSK-3beta activity with a GSK-3beta inhibitor lithium chloride (LiCl) or activation of Akt signaling with an Akt agonist insulin-like growth factor-1 (IGF-1) could inhibit HQ-induced activation of GSK-3beta as well as hematotoxicity.	Lithium Chloride	71-87	glycogen synthase kinase 3 beta	Homo sapiens	51-60
28886972-6	2018	As expected, blockage of GSK-3beta activity with a GSK-3beta inhibitor lithium chloride (LiCl) or activation of Akt signaling with an Akt agonist insulin-like growth factor-1 (IGF-1) could inhibit HQ-induced activation of GSK-3beta as well as hematotoxicity.	Lithium Chloride	89-93	glycogen synthase kinase 3 beta	Homo sapiens	25-34
28886972-7	2018	Taken together, our results suggest that HQ-induced hematotoxicity in bone marrow mononuclear cells is associated with dysregulation of Akt/GSK-3beta/beta-catenin signaling due to the dissociation of beta-catenin/LEF-1 complex, and LiCl and IGF-1 may be two potential agents to ameliorate HQ-induced hematotoxicity.	hydroquinone	41-43	glycogen synthase kinase 3 beta	Homo sapiens	140-149
29554905-9	2018	TC-HW decreased cyclin D1 protein level through cyclin D1 degradation via GSK3beta-dependent threonine-286 (T286) phosphorylation of cyclin D1, indicating that cyclin D1 degradation may contribute to TC-HW-mediated decrease of cyclin D1 protein level.	Threonine	93-102	glycogen synthase kinase 3 beta	Homo sapiens	74-82
29554905-9	2018	TC-HW decreased cyclin D1 protein level through cyclin D1 degradation via GSK3beta-dependent threonine-286 (T286) phosphorylation of cyclin D1, indicating that cyclin D1 degradation may contribute to TC-HW-mediated decrease of cyclin D1 protein level.	C.I. Basic Blue 54	108-112	glycogen synthase kinase 3 beta	Homo sapiens	74-82
29554905-9	2018	TC-HW decreased cyclin D1 protein level through cyclin D1 degradation via GSK3beta-dependent threonine-286 (T286) phosphorylation of cyclin D1, indicating that cyclin D1 degradation may contribute to TC-HW-mediated decrease of cyclin D1 protein level.	tc-hw	0-5	glycogen synthase kinase 3 beta	Homo sapiens	74-82
29299575-2	2018	The piperazine-based ligands were designed to be potential inhibitors of GSK-3beta kinase.	Piperazine	4-14	glycogen synthase kinase 3 beta	Homo sapiens	73-82
29358699-5	2018	Blocking GSK3beta by either pharmacologic inhibitors (SB216763 and SB415286) or by RNAi caused a reduced proteolysis of the MALT1 targets CYLD1, BCL10 and RelB as well as diminished IkappaBalpha degradation, NF-kappaB DNA binding and NF-kappaB activity.	SB 216763	54-62	glycogen synthase kinase 3 beta	Homo sapiens	9-17
29358699-5	2018	Blocking GSK3beta by either pharmacologic inhibitors (SB216763 and SB415286) or by RNAi caused a reduced proteolysis of the MALT1 targets CYLD1, BCL10 and RelB as well as diminished IkappaBalpha degradation, NF-kappaB DNA binding and NF-kappaB activity.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	67-75	glycogen synthase kinase 3 beta	Homo sapiens	9-17
29352207-14	2018	In contrast, blocking GSK-3beta activity, a downstream mediator of AKT signaling, rescued the strong apoptotic response triggered by ethanol and TGF-beta.	Ethanol	133-140	glycogen synthase kinase 3 beta	Homo sapiens	22-31
29208522-2	2018	Thus, structure-based virtual screening was performed to identify novel scaffolds of GSK-3beta inhibitors, and we observed that conserved water molecules of GSK-3beta were suitable for virtual screening.	Water	138-143	glycogen synthase kinase 3 beta	Homo sapiens	85-94
29208522-2	2018	Thus, structure-based virtual screening was performed to identify novel scaffolds of GSK-3beta inhibitors, and we observed that conserved water molecules of GSK-3beta were suitable for virtual screening.	Water	138-143	glycogen synthase kinase 3 beta	Homo sapiens	157-166
29226294-3	2018	Thus, the kinases ERK2 and GSK-3beta were immobilized to various superparamagnetic beads with carboxylic, aldehyde, Ni2+, or Co3+ functional groups, with a view to efficiently phosphorylate peptides and proteins in vitro.	Aldehydes	106-114	glycogen synthase kinase 3 beta	Homo sapiens	27-36
29196265-9	2018	High glucose and TMG treatment increased phospho-serine 9 GSK-3beta, an inactive form, and the degradation of FOXM1 protein was suppressed by treatment of GSK-3beta inhibitors in MKN45 cells.	Glucose	5-12	glycogen synthase kinase 3 beta	Homo sapiens	58-67
29226294-3	2018	Thus, the kinases ERK2 and GSK-3beta were immobilized to various superparamagnetic beads with carboxylic, aldehyde, Ni2+, or Co3+ functional groups, with a view to efficiently phosphorylate peptides and proteins in vitro.	Nickel(2+)	116-120	glycogen synthase kinase 3 beta	Homo sapiens	27-36
29226294-3	2018	Thus, the kinases ERK2 and GSK-3beta were immobilized to various superparamagnetic beads with carboxylic, aldehyde, Ni2+, or Co3+ functional groups, with a view to efficiently phosphorylate peptides and proteins in vitro.	cobalt adenosine diphosphate complex	125-129	glycogen synthase kinase 3 beta	Homo sapiens	27-36
28992584-8	2018	Furthermore, the effects of prenatal DEX exposure and swimming exercise on depression were associated with OGT-related mitochondrial motility, including PINK1/Parkin pathway and AKT/GSK3beta pathway.	Dextromethorphan	37-40	glycogen synthase kinase 3 beta	Homo sapiens	182-190
28684297-0	2018	Curcumol induces cell cycle arrest in colon cancer cells via reactive oxygen species and Akt/ GSK3beta/cyclin D1 pathway.	curcumol	0-8	glycogen synthase kinase 3 beta	Homo sapiens	94-102
28684297-13	2018	RT-qPCR and Western blot data showed that curcumol enhanced the expression of GSK3beta, P27, p21 and P16, and decreased the levels of PI3K, phosphorylated Akt (p-Akt), cyclin D1, CDK4, cyclin E and CDK2.	curcumol	42-50	glycogen synthase kinase 3 beta	Homo sapiens	78-86
28684297-16	2018	CONCLUSIONS: Curcumol caused cell cycle arrest at the G0/G1 phase by ROS production and Akt/ GSK3beta/cyclin D1 pathways inactivation, indicating the potential of curcumol in the prevention of colon cancer carcinogenesis.	curcumol	13-21	glycogen synthase kinase 3 beta	Homo sapiens	93-101
28684297-16	2018	CONCLUSIONS: Curcumol caused cell cycle arrest at the G0/G1 phase by ROS production and Akt/ GSK3beta/cyclin D1 pathways inactivation, indicating the potential of curcumol in the prevention of colon cancer carcinogenesis.	curcumol	163-171	glycogen synthase kinase 3 beta	Homo sapiens	93-101
29196265-9	2018	High glucose and TMG treatment increased phospho-serine 9 GSK-3beta, an inactive form, and the degradation of FOXM1 protein was suppressed by treatment of GSK-3beta inhibitors in MKN45 cells.	Glucose	5-12	glycogen synthase kinase 3 beta	Homo sapiens	155-164
29196265-9	2018	High glucose and TMG treatment increased phospho-serine 9 GSK-3beta, an inactive form, and the degradation of FOXM1 protein was suppressed by treatment of GSK-3beta inhibitors in MKN45 cells.	Dihydroxyacetone Phosphate	41-48	glycogen synthase kinase 3 beta	Homo sapiens	58-67
29196265-9	2018	High glucose and TMG treatment increased phospho-serine 9 GSK-3beta, an inactive form, and the degradation of FOXM1 protein was suppressed by treatment of GSK-3beta inhibitors in MKN45 cells.	Serine	49-55	glycogen synthase kinase 3 beta	Homo sapiens	58-67
30235447-0	2018	Pterostilbene Reduces Acetaminophen-Induced Liver Injury by Activating the Nrf2 Antioxidative Defense System via the AMPK/Akt/GSK3beta Pathway.	pterostilbene	0-13	glycogen synthase kinase 3 beta	Homo sapiens	126-134
28877882-7	2018	Results show that FFSS-induced mechanotransduction as well as exogenous PGE2 activate the Akt-GSK3beta-beta-catenin (Ser552) and MAPK/ERK but not the cAMP-PKA signal transduction cascades.	Dinoprostone	72-76	glycogen synthase kinase 3 beta	Homo sapiens	94-102
29128606-6	2018	Further biomedical research indicated that SAAS pretreatment reduced the t-BHP induced increase of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS), malondialdehyde (MDA) and mitochondrial membrane potential (MMP), and the decrease of key antioxidant enzymes through mitochondria antioxidative pathways via JAK2/STAT3 and PI3K/Akt/GSK-3beta signalings.	3,4-dihydroxyphenyllactic acid	43-47	glycogen synthase kinase 3 beta	Homo sapiens	355-364
29128606-6	2018	Further biomedical research indicated that SAAS pretreatment reduced the t-BHP induced increase of lactate dehydrogenase (LDH), intracellular reactive oxygen species (ROS), malondialdehyde (MDA) and mitochondrial membrane potential (MMP), and the decrease of key antioxidant enzymes through mitochondria antioxidative pathways via JAK2/STAT3 and PI3K/Akt/GSK-3beta signalings.	tert-Butylhydroperoxide	73-78	glycogen synthase kinase 3 beta	Homo sapiens	355-364
30016378-9	2018	Moreover, SeMet increased the level of GSK-3beta phosphorylated at serine 9 (S9) and significantly increased the level of beta-catenin phosphorylated at S33 and S37.	Serine	67-73	glycogen synthase kinase 3 beta	Homo sapiens	39-48
29530430-3	2018	MATERIALS AND METHODS: The expression of GSK-3beta was comparably evaluated between children with TC (n = 26) and tonsillar hypertrophy (TH, n = 26).	Technetium	98-100	glycogen synthase kinase 3 beta	Homo sapiens	41-50
29530430-6	2018	RESULTS: We found that while GSK-3beta was highly expressed in both TC and TH groups, no significant difference were detected at mRNA and protein levels between groups.	Technetium	68-70	glycogen synthase kinase 3 beta	Homo sapiens	29-38
29530430-6	2018	RESULTS: We found that while GSK-3beta was highly expressed in both TC and TH groups, no significant difference were detected at mRNA and protein levels between groups.	Thorium	75-77	glycogen synthase kinase 3 beta	Homo sapiens	29-38
29530430-7	2018	The protein level of p-GSK-3beta was significantly lower in the TC group as compared to the TH group.	Technetium	64-66	glycogen synthase kinase 3 beta	Homo sapiens	23-32
29530430-9	2018	The GSK-3beta activation index was positively correlated with the levels of NF-kappaB, T-bet, and IFN-gamma in the TC group.	Technetium	115-117	glycogen synthase kinase 3 beta	Homo sapiens	4-13
29530430-10	2018	CONCLUSIONS: Our findings suggested that GSK-3beta activation index was demonstrated to be a clinically applicable indicator for chronic recurrent inflammation in pediatric TC.	Technetium	173-175	glycogen synthase kinase 3 beta	Homo sapiens	41-50
29863077-10	2018	Moreover, polydatin markedly raised phosphorylated Akt, GSK-3beta, AMPK, ACC, diminished nuclear protein levels of SREBP-1c, and upgraded the protein levels of LDLR.	polydatin	10-19	glycogen synthase kinase 3 beta	Homo sapiens	56-65
30235447-0	2018	Pterostilbene Reduces Acetaminophen-Induced Liver Injury by Activating the Nrf2 Antioxidative Defense System via the AMPK/Akt/GSK3beta Pathway.	Acetaminophen	22-35	glycogen synthase kinase 3 beta	Homo sapiens	126-134
30235447-11	2018	CONCLUSION: Our data suggest that Pts protects against APAP-induced toxicity by activating Nrf2 via the AMPK/Akt/GSK3beta pathway.	Acetaminophen	55-59	glycogen synthase kinase 3 beta	Homo sapiens	113-121
29705809-9	2018	And, we found high glucose-induced reactive oxygen species (ROS) promotes two signaling; JNK which regulates gamma-secretase leading to the cleavage of Notch proteins and PI3K/Akt signaling which enhances GSK-3beta phosphorylation.	Glucose	19-26	glycogen synthase kinase 3 beta	Homo sapiens	205-214
30355923-0	2018	Erinacine Facilitates the Opening of the Mitochondrial Permeability Transition Pore Through the Inhibition of the PI3K/ Akt/GSK-3beta Signaling Pathway in Human Hepatocellular Carcinoma.	erinacine S	0-9	glycogen synthase kinase 3 beta	Homo sapiens	124-133
30355923-2	2018	The following study aims to investigate the role of erinacine in the opening of the mitochondrial permeability transition pore (MPTP) in hepatocellular carcinoma (HCC) through the PI3K/Akt/GSK-3beta signaling pathway and highlights the applicability of erinacine in HCC treatments.	erinacine S	52-61	glycogen synthase kinase 3 beta	Homo sapiens	189-198
29719300-0	2018	Unfractionated Heparin Alleviates Human Lung Endothelial Barrier Dysfunction Induced by High Mobility Group Box 1 Through Regulation of P38-GSK3beta-Snail Signaling Pathway.	Heparin	15-22	glycogen synthase kinase 3 beta	Homo sapiens	140-148
29719300-12	2018	Moreover, HMGB1 activated p38/GSK3beta/Snail signaling pathway and treatment with p38 inhibitor SB203580 abolished its biological effects.	SB 203580	96-104	glycogen synthase kinase 3 beta	Homo sapiens	30-38
30355923-13	2018	In addition, Erinacine was found to decrease the mitochondrial membrane potential, expression of PI3K, Akt, GSK-3beta, CyclinD1, Vimentin, beta-catenin, and Bcl-2, cell proliferation, colony formation ability, migration, invasion, and xenograft tumor size, while E-cadherin, Bax, and caspase-9 expression, and cell apoptosis were elevated in a dose-dependent manner.	erinacine S	13-22	glycogen synthase kinase 3 beta	Homo sapiens	108-117
30355923-16	2018	CONCLUSION: The results from the study demonstrated that erinacine induced MPTP opening, facilitates the release of cyt-C, and inhibited cell proliferation, migration, and invasion, while it promotes apoptosis by inactivating the PI3K/Akt/GSK-3beta signaling pathway, preventing the progression of HCC.	erinacine S	57-66	glycogen synthase kinase 3 beta	Homo sapiens	239-248
29763908-13	2018	Furthermore, treatment of Cx43-knockdown cells with lithium chloride (LiCl), a GSK-3beta inhibitor, reduced osteogenic differentiation and decreased GSK-3beta levels, as well as partially rescued levels of both total and activated beta-catenin.	Lithium Chloride	52-68	glycogen synthase kinase 3 beta	Homo sapiens	79-88
29763908-13	2018	Furthermore, treatment of Cx43-knockdown cells with lithium chloride (LiCl), a GSK-3beta inhibitor, reduced osteogenic differentiation and decreased GSK-3beta levels, as well as partially rescued levels of both total and activated beta-catenin.	Lithium Chloride	52-68	glycogen synthase kinase 3 beta	Homo sapiens	149-158
29763908-13	2018	Furthermore, treatment of Cx43-knockdown cells with lithium chloride (LiCl), a GSK-3beta inhibitor, reduced osteogenic differentiation and decreased GSK-3beta levels, as well as partially rescued levels of both total and activated beta-catenin.	Lithium Chloride	70-74	glycogen synthase kinase 3 beta	Homo sapiens	79-88
29763908-13	2018	Furthermore, treatment of Cx43-knockdown cells with lithium chloride (LiCl), a GSK-3beta inhibitor, reduced osteogenic differentiation and decreased GSK-3beta levels, as well as partially rescued levels of both total and activated beta-catenin.	Lithium Chloride	70-74	glycogen synthase kinase 3 beta	Homo sapiens	149-158
29705809-9	2018	And, we found high glucose-induced reactive oxygen species (ROS) promotes two signaling; JNK which regulates gamma-secretase leading to the cleavage of Notch proteins and PI3K/Akt signaling which enhances GSK-3beta phosphorylation.	Reactive Oxygen Species	35-58	glycogen synthase kinase 3 beta	Homo sapiens	205-214
29705809-9	2018	And, we found high glucose-induced reactive oxygen species (ROS) promotes two signaling; JNK which regulates gamma-secretase leading to the cleavage of Notch proteins and PI3K/Akt signaling which enhances GSK-3beta phosphorylation.	Reactive Oxygen Species	60-63	glycogen synthase kinase 3 beta	Homo sapiens	205-214
29705809-10	2018	High glucose-mediated JNK/Notch pathway regulates the expression of EZH2, and PI3K/Akt/GSK-3beta pathway stimulates Snail stabilization, respectively.	Glucose	5-12	glycogen synthase kinase 3 beta	Homo sapiens	87-96
29843131-8	2018	JNK inhibitor SP600125 partially restored AKT/ GSK-3beta phosphorylation and glycogen synthesis, but did not affect other IH-induced glucose metabolic changes.	pyrazolanthrone	14-22	glycogen synthase kinase 3 beta	Homo sapiens	47-56
29929189-14	2018	CONCLUSIONS: Collectively, these findings indicate that dexmedetomidine may protect NSCs from ketamine-induced injury via the PI3K/Akt/GSK-3beta signaling pathway.	Ketamine	94-102	glycogen synthase kinase 3 beta	Homo sapiens	135-144
29692251-10	2018	RESULTS: Artesunate suppressed the phosphorylation of GSK3beta at S9, and lowered the protein level of beta-catenin and its downstream targets (c-Myc, cyclin D1).	Artesunate	9-19	glycogen synthase kinase 3 beta	Homo sapiens	54-62
29929189-12	2018	Moreover, dexmedetomidine lessened caspase-3 activation and increased p-Akt and p-GSK-3beta levels in NSCs exposed to ketamine.	Dexmedetomidine	10-25	glycogen synthase kinase 3 beta	Homo sapiens	82-91
29929189-12	2018	Moreover, dexmedetomidine lessened caspase-3 activation and increased p-Akt and p-GSK-3beta levels in NSCs exposed to ketamine.	Ketamine	118-126	glycogen synthase kinase 3 beta	Homo sapiens	82-91
29929189-14	2018	CONCLUSIONS: Collectively, these findings indicate that dexmedetomidine may protect NSCs from ketamine-induced injury via the PI3K/Akt/GSK-3beta signaling pathway.	Dexmedetomidine	56-71	glycogen synthase kinase 3 beta	Homo sapiens	135-144
28951519-9	2018	DGT decreased the activity of multiple intracellular kinases that affect the survival of osteosarcoma patients, including GSK3beta.	degalactotigonin	0-3	glycogen synthase kinase 3 beta	Homo sapiens	122-130
29848281-0	2018	In-Silico Screening of Ligand Based Pharmacophore, Database Mining and Molecular Docking on 2, 5-Diaminopyrimidines Azapurines as Potential Inhibitors of Glycogen Synthase Kinase-3beta.	2, 5-diaminopyrimidines	92-115	glycogen synthase kinase 3 beta	Homo sapiens	154-184
29848281-0	2018	In-Silico Screening of Ligand Based Pharmacophore, Database Mining and Molecular Docking on 2, 5-Diaminopyrimidines Azapurines as Potential Inhibitors of Glycogen Synthase Kinase-3beta.	azapurines	116-126	glycogen synthase kinase 3 beta	Homo sapiens	154-184
29848281-4	2018	METHOD: Owing to the potential role of GSK-3beta in nervous disorders, we have attempted to develop the quantitative four featured pharmacophore model comprising two Hydrogen Bond Acceptors (HBA), one Ring Aromatic (RA), and one Hydrophobe (HY), which were further affirmed by costfunction analysis, rm2 matrices, internal and external test set validation and Guner-Henry (GH) scoring analysis.	Hydrogen	166-174	glycogen synthase kinase 3 beta	Homo sapiens	39-48
29104081-5	2018	In this study, we sought to evaluate whether the activation of the wnt/beta-catenin pathway through inhibition of glycogen synthase kinase-3beta (GSK-3beta) using 4,6-disubstituted pyrrolopyrimidine (TWS119) could be an efficient strategy to improve the proliferation, differentiation and cytolytic activity of gammadeltaT cells against colon cancer cells.	4,6-disubstituted pyrrolopyrimidine	163-198	glycogen synthase kinase 3 beta	Homo sapiens	114-144
29299988-0	2018	An Overview of Discovery of Thiazole Containing Heterocycles as Potent GSK-3beta Inhibitors.	Thiazoles	28-36	glycogen synthase kinase 3 beta	Homo sapiens	71-80
29299988-4	2018	The objective of this review is to cover all the aspects of GSK-3beta enzyme including its clinical implications, types of inhibitors with special reference to thiazole as GSK-3beta inhibitor.	Thiazoles	160-168	glycogen synthase kinase 3 beta	Homo sapiens	60-69
29299988-4	2018	The objective of this review is to cover all the aspects of GSK-3beta enzyme including its clinical implications, types of inhibitors with special reference to thiazole as GSK-3beta inhibitor.	Thiazoles	160-168	glycogen synthase kinase 3 beta	Homo sapiens	172-181
30693853-7	2018	Glycogen synthase kinase-3 beta (GSK3beta) phosphorylation was measured in 1 microM baicalin-treated HCEM cells with or without the Wnt signaling pathway inhibitor, DKK-1 using ELISA and western blotting.	baicalin	84-92	glycogen synthase kinase 3 beta	Homo sapiens	0-31
30693853-7	2018	Glycogen synthase kinase-3 beta (GSK3beta) phosphorylation was measured in 1 microM baicalin-treated HCEM cells with or without the Wnt signaling pathway inhibitor, DKK-1 using ELISA and western blotting.	baicalin	84-92	glycogen synthase kinase 3 beta	Homo sapiens	33-41
30693853-9	2018	The ratio of phosphorylated to total GSK3beta increased in the presence of baicalin but was reduced by the addition of DKK-1.	baicalin	75-83	glycogen synthase kinase 3 beta	Homo sapiens	37-45
29283064-6	2018	RESULTS: The gene depletion or pharmacological inhibition of GSK-3beta reproduces some of the behavioral effects of lithium including reduction of depression- and manic-like behaviors in rodents, which attested the intracellular GSK- 3beta inhibition as one of the critical steps in mediating behavioral effect of mood-stabilizers.	Lithium	116-123	glycogen synthase kinase 3 beta	Homo sapiens	61-70
29283064-6	2018	RESULTS: The gene depletion or pharmacological inhibition of GSK-3beta reproduces some of the behavioral effects of lithium including reduction of depression- and manic-like behaviors in rodents, which attested the intracellular GSK- 3beta inhibition as one of the critical steps in mediating behavioral effect of mood-stabilizers.	Lithium	116-123	glycogen synthase kinase 3 beta	Homo sapiens	229-239
29283064-7	2018	Furthermore, converging evidence supported the participation of GSK-3beta in the regulation of various neurobehavioral functions governed by neurotransmitters dopamine and serotonin.	Dopamine	159-167	glycogen synthase kinase 3 beta	Homo sapiens	64-73
29283064-7	2018	Furthermore, converging evidence supported the participation of GSK-3beta in the regulation of various neurobehavioral functions governed by neurotransmitters dopamine and serotonin.	Serotonin	172-181	glycogen synthase kinase 3 beta	Homo sapiens	64-73
29104081-5	2018	In this study, we sought to evaluate whether the activation of the wnt/beta-catenin pathway through inhibition of glycogen synthase kinase-3beta (GSK-3beta) using 4,6-disubstituted pyrrolopyrimidine (TWS119) could be an efficient strategy to improve the proliferation, differentiation and cytolytic activity of gammadeltaT cells against colon cancer cells.	4,6-disubstituted pyrrolopyrimidine	163-198	glycogen synthase kinase 3 beta	Homo sapiens	146-155
29104081-5	2018	In this study, we sought to evaluate whether the activation of the wnt/beta-catenin pathway through inhibition of glycogen synthase kinase-3beta (GSK-3beta) using 4,6-disubstituted pyrrolopyrimidine (TWS119) could be an efficient strategy to improve the proliferation, differentiation and cytolytic activity of gammadeltaT cells against colon cancer cells.	TWS 119	200-206	glycogen synthase kinase 3 beta	Homo sapiens	114-144
29104081-5	2018	In this study, we sought to evaluate whether the activation of the wnt/beta-catenin pathway through inhibition of glycogen synthase kinase-3beta (GSK-3beta) using 4,6-disubstituted pyrrolopyrimidine (TWS119) could be an efficient strategy to improve the proliferation, differentiation and cytolytic activity of gammadeltaT cells against colon cancer cells.	TWS 119	200-206	glycogen synthase kinase 3 beta	Homo sapiens	146-155
29516971-8	2018	MiR-150b elicited these responses by directly targeting GSK3beta.	mir-150b	0-8	glycogen synthase kinase 3 beta	Homo sapiens	56-64
28930531-6	2018	Taken together, our results suggested that ILF attenuated rotenone-induced oxidative stress, mitochondrial dysfunction and apoptosis through the regulation of P13K/AKT/GSK-3 beta signaling pathways.	Rotenone	58-66	glycogen synthase kinase 3 beta	Homo sapiens	168-178
28870693-5	2018	In addition, DMF abrogated TGFbeta/Akt1 mediated inhibitory phosphorylation of glycogen kinase 3beta (GSK3beta) and a subsequent beta-transducin repeat-containing proteins (betaTRCP) mediated proteasomal degradation of TAZ, as well as a corresponding decrease of TAZ/YAP transcriptional targets.	Dimethyl Fumarate	13-16	glycogen synthase kinase 3 beta	Homo sapiens	102-110
28922551-4	2018	These effects of BS-I were mediated by inhibiting the activation of AKT/GSK-3beta/beta-catenin pathway and depended on specificity of lectin BS-I binding to GalNAc.	N-acetylgalactosaminuronic acid	157-163	glycogen synthase kinase 3 beta	Homo sapiens	72-81
28978722-8	2018	Treatment of GAGA6-R cells with protein kinase C (PKC) inhibitor H7 in combination with AZD4547 led to dephosphorylation and activation of GSK3beta with concomitant downregulation of MCL-1 and BCL-XL.	AZD4547	88-95	glycogen synthase kinase 3 beta	Homo sapiens	139-147
28870693-10	2018	Together, our work demonstrates a mechanism of the antifibrotic effect of DMF via inhibition of Akt1/GSK3beta/TAZ/YAP signaling and confirms a critical role of TAZ/YAP in mediating the profibrotic responses in dermal fibroblasts.	Dimethyl Fumarate	74-77	glycogen synthase kinase 3 beta	Homo sapiens	101-109
28978722-10	2018	Furthermore, midostaurin, a multikinase inhibitor with PKC-inhibiting activity, in part reversed resistance of GAGA6-R tumor to AZD4547 in vivo Our results suggest that upon challenge with FGFR inhibitors, FGFR2-amplified tumors that are highly dependent on FGFR2 signaling for survival rapidly develop resistance by switching to a PKC-mediated inhibition of GSK3beta to gain a survival advantage.	midostaurin	13-24	glycogen synthase kinase 3 beta	Homo sapiens	359-367
29262861-9	2017	Protein kinase glycogen synthase kinase-3beta (GSK-3beta) formed a protein complex with HSP90 and PKM2, and directly mediated Thr-328 phosphorylation of PKM2 induced by HSP90.	Threonine	126-129	glycogen synthase kinase 3 beta	Homo sapiens	47-56
29379255-11	2017	However, the activation of glucose storage was effective in the presence of 3beta-taraxerol and aloe emodin though inhibition of GSK3beta activity.	Glucose	27-34	glycogen synthase kinase 3 beta	Homo sapiens	129-137
29257079-0	2017	Sulfuretin Attenuates MPP+-Induced Neurotoxicity through Akt/GSK3beta and ERK Signaling Pathways.	sulfuretin	0-10	glycogen synthase kinase 3 beta	Homo sapiens	61-69
29257079-0	2017	Sulfuretin Attenuates MPP+-Induced Neurotoxicity through Akt/GSK3beta and ERK Signaling Pathways.	mangion-purified polysaccharide (Candida albicans)	22-26	glycogen synthase kinase 3 beta	Homo sapiens	61-69
29257079-9	2017	Moreover, sulfuretin significantly increased the phosphorylation of Akt, GSK3beta, and ERK.	sulfuretin	10-20	glycogen synthase kinase 3 beta	Homo sapiens	73-81
29257079-11	2017	An inhibitor of GSK3beta mimicked sulfuretin-induced protection against MPP+.	sulfuretin	34-44	glycogen synthase kinase 3 beta	Homo sapiens	16-24
29257079-12	2017	Taken together, these results suggest that sulfuretin significantly attenuates MPP+-induced neurotoxicity through Akt/GSK3beta and ERK signaling pathways in SH-SY5Y cells.	sulfuretin	43-53	glycogen synthase kinase 3 beta	Homo sapiens	118-126
29257079-12	2017	Taken together, these results suggest that sulfuretin significantly attenuates MPP+-induced neurotoxicity through Akt/GSK3beta and ERK signaling pathways in SH-SY5Y cells.	mangion-purified polysaccharide (Candida albicans)	79-83	glycogen synthase kinase 3 beta	Homo sapiens	118-126
29079145-0	2017	Nrf2-mediated neuroprotection by MANF against 6-OHDA-induced cell damage via PI3K/AKT/GSK3beta pathway.	Oxidopamine	46-52	glycogen synthase kinase 3 beta	Homo sapiens	86-94
28359686-0	2017	SLM, a novel carbazole-based fluorophore attenuates okadaic acid-induced tau hyperphosphorylation via down-regulating GSK-3beta activity in SH-SY5Y cells.	carbazole	13-22	glycogen synthase kinase 3 beta	Homo sapiens	118-127
28359686-0	2017	SLM, a novel carbazole-based fluorophore attenuates okadaic acid-induced tau hyperphosphorylation via down-regulating GSK-3beta activity in SH-SY5Y cells.	Okadaic Acid	52-64	glycogen synthase kinase 3 beta	Homo sapiens	118-127
29079145-6	2017	PI3K inhibitor (LY49002) abolished effects of MANF on AKT phosphorylation, GSK3beta inactivation, Nrf2 nuclear translocation and subsequently abrogated MANF-mediates cytoprotection.	ly49002	16-23	glycogen synthase kinase 3 beta	Homo sapiens	75-83
29079145-7	2017	Collectively, our findings indicated that MANF-mediated protection against 6-OHDA-induced cytotoxicity by potentiating the Nrf2-related survival mechanism through the PI3K/Akt/GSK3beta pathway.	Oxidopamine	75-81	glycogen synthase kinase 3 beta	Homo sapiens	176-184
29065971-4	2017	The effects of KHG26792 against the Abeta-induced increases in inflammatory cytokine levels and oxidative stress were achieved by increasing the phosphorylation of Akt/ GSK-3beta signaling and by decreasing the Abeta-induced translocation of NF-kappaB.	3-(naphthalen-2-yl(propoxy)methyl)azetidine hydrochloride	15-23	glycogen synthase kinase 3 beta	Homo sapiens	169-178
29089232-5	2017	Acacetin also markedly acted on key molecules in apoptotic cell death pathways and reduced phosphorylation of c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinases (PI3K)/Akt, and glycogen synthase kinase-3beta (GSK-3beta).	acacetin	0-8	glycogen synthase kinase 3 beta	Homo sapiens	233-263
28367588-1	2017	BACKGROUND AND OBJECTIVES: Lithium chloride (LiCl) has been shown to improve the tightness of brain endothelial cell monolayers in vitro by inhibition of the GSK-3beta enzyme, activation of the Wnt/beta-catenin pathway and regulation of tight junction (TJ) protein expression.	Lithium Chloride	27-43	glycogen synthase kinase 3 beta	Homo sapiens	158-167
28367588-1	2017	BACKGROUND AND OBJECTIVES: Lithium chloride (LiCl) has been shown to improve the tightness of brain endothelial cell monolayers in vitro by inhibition of the GSK-3beta enzyme, activation of the Wnt/beta-catenin pathway and regulation of tight junction (TJ) protein expression.	Lithium Chloride	45-49	glycogen synthase kinase 3 beta	Homo sapiens	158-167
28990074-7	2017	In addition, puerarin inhibited the degree of Abeta1-42-induced tau phosphorylation at Ser396, Ser199 and Thr231 in SH-SY5Y cells, and reduced the expression of GSK-3beta by increasing the expression of p-GSK-3beta (Ser9).	puerarin	13-21	glycogen synthase kinase 3 beta	Homo sapiens	161-170
28762556-9	2017	In summary, our findings suggest that NOX5 expression in human UACC-257 melanoma cells could contribute to cell proliferation due, in part, to the generation of high local concentrations of extracellular ROS that modulate multiple pathways that regulate HIF-1alpha and networks that signal through Akt/GSK3beta/p27Kip1 .	Reactive Oxygen Species	204-207	glycogen synthase kinase 3 beta	Homo sapiens	302-310
28990074-9	2017	The results of the present study demonstrated that puerarin may attenuate Abeta1-42-induced tau hyperphosphorylation in SH-SY5Y cells, by inhibiting the expression of GSK-3beta and activating the Wnt/beta-catenin signaling pathway; therefore, puerarin may exert protective effects against Alzheimer"s disease.	puerarin	51-59	glycogen synthase kinase 3 beta	Homo sapiens	167-176
29039491-11	2017	The pathway activity can be modulated by LiCl at the GSK3beta-SUFU-GLI level, suggesting at least partial non-canonical activation.	Lithium Chloride	41-45	glycogen synthase kinase 3 beta	Homo sapiens	53-61
29039496-0	2017	GSK-3beta inhibitor 6-bromo-indirubin-3"-oxime promotes both adhesive activity and drug resistance in colorectal cancer cells.	6-bromoindirubin-3'-oxime	20-46	glycogen synthase kinase 3 beta	Homo sapiens	0-9
28990074-7	2017	In addition, puerarin inhibited the degree of Abeta1-42-induced tau phosphorylation at Ser396, Ser199 and Thr231 in SH-SY5Y cells, and reduced the expression of GSK-3beta by increasing the expression of p-GSK-3beta (Ser9).	puerarin	13-21	glycogen synthase kinase 3 beta	Homo sapiens	205-214
27925497-0	2017	Anti-inflammatory and anticancer effects of flavonol glycosides from Diplotaxis harra through GSK3beta regulation in intestinal cells.	flavonol glycosides	44-63	glycogen synthase kinase 3 beta	Homo sapiens	94-102
29344218-14	2017	ATRA treatment decreased the expression of phosphorylated (p-)beta-catenin, p-GSK-3beta, vimentin, and fibronectin, and increased the expression of NIS and E-cadherin, compared with the control.	Tretinoin	0-4	glycogen synthase kinase 3 beta	Homo sapiens	78-87
27925497-5	2017	Several flavonoids can inhibit GSK3beta and the purpose of this study was to search for the compounds in Diplotaxis harra which are able to modulate GSK3beta.	Flavonoids	8-18	glycogen synthase kinase 3 beta	Homo sapiens	31-39
29441954-0	2017	Synthesis and biological evaluation of novel 4,5-bisindolyl-1,2,4-triazol-3-ones as glycogen synthase kinase-3beta inhibitors and neuroprotective agents.	4,5-bisindolyl-1,2,4-triazol-3-ones	45-80	glycogen synthase kinase 3 beta	Homo sapiens	84-114
27925497-5	2017	Several flavonoids can inhibit GSK3beta and the purpose of this study was to search for the compounds in Diplotaxis harra which are able to modulate GSK3beta.	Flavonoids	8-18	glycogen synthase kinase 3 beta	Homo sapiens	149-157
27925497-9	2017	RESULTS: The methanol extract from D. harra flowers and its flavonoid-enriched fraction inhibit GSK3beta in PAR2-stimulated IEC6 cells.	Methanol	13-21	glycogen synthase kinase 3 beta	Homo sapiens	96-104
27925497-9	2017	RESULTS: The methanol extract from D. harra flowers and its flavonoid-enriched fraction inhibit GSK3beta in PAR2-stimulated IEC6 cells.	Flavonoids	60-69	glycogen synthase kinase 3 beta	Homo sapiens	96-104
27925497-10	2017	GSK3beta inhibition by the flavonoid-enriched D. harra fraction was dependent on PKC activation.	Flavonoids	27-36	glycogen synthase kinase 3 beta	Homo sapiens	0-8
27925497-13	2017	CONCLUSION: This work indicates that flavonoids from D. harra display cytotoxic activity against inflammatory and cancer intestinal cells which could depend on GSK3beta inhibition.	Flavonoids	37-47	glycogen synthase kinase 3 beta	Homo sapiens	160-168
28370561-9	2017	Levels of beta-catenin and RUNX2 protein are enhanced in HOS, G292, and 143B cells after treatment with the GSK3beta inhibitor SB216763.	SB 216763	127-135	glycogen synthase kinase 3 beta	Homo sapiens	108-116
29249966-5	2017	Additionally, lithium enhances interaction between Gli1 and SUFU via suppressing GSK3beta, which phosphorylates SUFU and destabilizes the SUFU-Gli1 inhibitory complex.	Lithium	14-21	glycogen synthase kinase 3 beta	Homo sapiens	81-89
29116196-9	2017	Moreover, THL inhibited TGF-beta1-induced phosphorylation of p38, JNK, ERK, Akt, GSK3beta, Smad 2 and Smad3 without altering the total expression levels of those proteins.	Thalidomide	10-13	glycogen synthase kinase 3 beta	Homo sapiens	81-89
28880013-8	2017	In addition, inhibition of GSK3beta by LiCl prevented osimertinib-induced PD-L1 degradation.	Lithium Chloride	39-43	glycogen synthase kinase 3 beta	Homo sapiens	27-35
28880013-8	2017	In addition, inhibition of GSK3beta by LiCl prevented osimertinib-induced PD-L1 degradation.	osimertinib	54-65	glycogen synthase kinase 3 beta	Homo sapiens	27-35
28803443-0	2017	Solasodine inhibits human colorectal cancer cells through suppression of the AKT/glycogen synthase kinase-3beta/beta-catenin pathway.	solasodine	0-10	glycogen synthase kinase 3 beta	Homo sapiens	81-111
29104639-11	2017	Furthermore, the phosphorylation level of glycogen synthase kinase 3beta (GSK3beta) and the levels of beta-catenin and GSK3beta were significantly increased in the AF group compared with the SR group (P&lt;0.05).	Strontium	191-193	glycogen synthase kinase 3 beta	Homo sapiens	42-72
29104639-11	2017	Furthermore, the phosphorylation level of glycogen synthase kinase 3beta (GSK3beta) and the levels of beta-catenin and GSK3beta were significantly increased in the AF group compared with the SR group (P&lt;0.05).	Strontium	191-193	glycogen synthase kinase 3 beta	Homo sapiens	74-82
29162840-0	2017	Whey Protein Concentrate Renders MDA-MB-231 Cells Sensitive to Rapamycin by Altering Cellular Redox State and Activating GSK3beta/mTOR Signaling.	Sirolimus	63-72	glycogen synthase kinase 3 beta	Homo sapiens	121-129
29383130-0	2017	GSK-3beta inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents.	3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione	21-29	glycogen synthase kinase 3 beta	Homo sapiens	0-9
29383130-2	2017	In this study, we explored the anti-tumor effects of the GSK-3beta inhibitor, 9-ING-41, in lymphoma cell lines as a single agent and in combination with novel agents comprising BCL-2 inhibitor (Venetoclax), CDK-9 inhibitor (BAY-1143572) and p110delta-PI3K inhibitor (Idelalisib).	3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione	78-86	glycogen synthase kinase 3 beta	Homo sapiens	57-66
29030155-12	2017	Besides, high glucose also decreased the protein expression PI-3K, pAKT/AKT, GSK-3beta.	Glucose	14-21	glycogen synthase kinase 3 beta	Homo sapiens	77-86
29098029-7	2017	The results revealed that 5F and cisplatin synergistically induced apoptosis and inhibited cell growth, arrested cell cycles in the G0/G1 phase, downregulated beta-catenin, c-Myc and cyclin D1, and upregulated GSK-3beta.	Cisplatin	33-42	glycogen synthase kinase 3 beta	Homo sapiens	210-219
29049420-5	2017	Here we show that blocking of Notch-1 with N-[(3,5-Difluorophenyl) acetyl]-L-alanyl-2-phenylglycine-1,1-dimethylethyl ester (DAPT) in LPS activated BV-2 microglia not only suppressed Notch intracellular domain (NICD) and Hes-1 protein expression, but also that of GSK-3beta.	n-[(3,5-difluorophenyl) acetyl]-l-alanyl-2-phenylglycine-1,1-dimethylethyl ester	43-123	glycogen synthase kinase 3 beta	Homo sapiens	264-273
29262637-8	2017	While metformin could repress the bFGF-mediated activation in AKT/GSK-3beta signalling, inhibition on interaction between GSK-3beta and Twist1, enhancement of Twist1 stability.	Metformin	6-15	glycogen synthase kinase 3 beta	Homo sapiens	66-75
29262637-8	2017	While metformin could repress the bFGF-mediated activation in AKT/GSK-3beta signalling, inhibition on interaction between GSK-3beta and Twist1, enhancement of Twist1 stability.	Metformin	6-15	glycogen synthase kinase 3 beta	Homo sapiens	122-131
29113182-4	2017	Additionally, western blot analysis, Hoechst 33342 staining and cytometry analysis revealed that PAG not only inhibited the viability of HCT116 cells by suppressing the dishevelled segment polarity protein 2/glycogen synthase kinase 3 beta/beta-catenin pathway, but also induced the apoptosis of HCT116 cells by downregulating nuclear factor-kappaB p65 activity, stimulating p53 expression and promoting the generation of intracellular reactive oxygen species.	pag	97-100	glycogen synthase kinase 3 beta	Homo sapiens	208-239
29163047-2	2017	Recently, we have found that chronic treatment with fluoxetine regulates Caveolin-1 (Cav-1)/PTEN/PI3K/AKT/glycogen synthase kinase 3beta (GSK-3beta) signaling pathway and glycogen content in primary cultures of astrocytes with bi-phasic concentration dependence.	Fluoxetine	52-62	glycogen synthase kinase 3 beta	Homo sapiens	106-136
29163047-2	2017	Recently, we have found that chronic treatment with fluoxetine regulates Caveolin-1 (Cav-1)/PTEN/PI3K/AKT/glycogen synthase kinase 3beta (GSK-3beta) signaling pathway and glycogen content in primary cultures of astrocytes with bi-phasic concentration dependence.	Fluoxetine	52-62	glycogen synthase kinase 3 beta	Homo sapiens	138-147
29163047-3	2017	At low concentrations fluoxetine down-regulates Cav-1 gene expression, decreases membrane content of PTEN, increases PI3K activity and increases phosphorylation of GSK-3beta and increases its activity; at high concentrations fluoxetine acts on PTEN/PI3K/AKT/GSK-3beta in an inverse fashion.	Fluoxetine	22-32	glycogen synthase kinase 3 beta	Homo sapiens	164-173
29163047-3	2017	At low concentrations fluoxetine down-regulates Cav-1 gene expression, decreases membrane content of PTEN, increases PI3K activity and increases phosphorylation of GSK-3beta and increases its activity; at high concentrations fluoxetine acts on PTEN/PI3K/AKT/GSK-3beta in an inverse fashion.	Fluoxetine	22-32	glycogen synthase kinase 3 beta	Homo sapiens	258-267
29163047-3	2017	At low concentrations fluoxetine down-regulates Cav-1 gene expression, decreases membrane content of PTEN, increases PI3K activity and increases phosphorylation of GSK-3beta and increases its activity; at high concentrations fluoxetine acts on PTEN/PI3K/AKT/GSK-3beta in an inverse fashion.	Fluoxetine	225-235	glycogen synthase kinase 3 beta	Homo sapiens	164-173
29163047-3	2017	At low concentrations fluoxetine down-regulates Cav-1 gene expression, decreases membrane content of PTEN, increases PI3K activity and increases phosphorylation of GSK-3beta and increases its activity; at high concentrations fluoxetine acts on PTEN/PI3K/AKT/GSK-3beta in an inverse fashion.	Fluoxetine	225-235	glycogen synthase kinase 3 beta	Homo sapiens	258-267
29049420-5	2017	Here we show that blocking of Notch-1 with N-[(3,5-Difluorophenyl) acetyl]-L-alanyl-2-phenylglycine-1,1-dimethylethyl ester (DAPT) in LPS activated BV-2 microglia not only suppressed Notch intracellular domain (NICD) and Hes-1 protein expression, but also that of GSK-3beta.	dapt	125-129	glycogen synthase kinase 3 beta	Homo sapiens	264-273
29290941-9	2017	Eucalyptol attenuated the induction of Snail1, beta-catenin and integrin-linked kinase 1 (ILK1) in glucose-exposed tubular cells and diabetic kidneys, and the glycogen synthase kinase (GSK)-3beta expression was reversely enhanced.	Eucalyptol	0-10	glycogen synthase kinase 3 beta	Homo sapiens	159-195
29254202-6	2017	Furthermore, we demonstrated that miR-92a upregulates the Wnt/beta-catenin signaling activity via directly targeting KLF4, GSK3beta and DKK3, which are multiple level negative regulators of the Wnt/beta-catenin signaling cascade.	mir-92a	34-41	glycogen synthase kinase 3 beta	Homo sapiens	123-131
28810530-0	2017	Caspase-dependent and caspase-independent induction of apoptosis in breast cancer by fucoidan via the PI3K/AKT/GSK3beta pathway in vivo and in vitro.	fucoidan	85-93	glycogen synthase kinase 3 beta	Homo sapiens	111-119
28981601-6	2017	The results revealed that pyrvinium pamoate treatment repressed the phosphorylation of GSK3beta at S9 which might be mediated by AKT, and decreased the protein levels of beta-catenin and its downstream targets (c-Myc, cyclin D1).	pyrvinium	26-43	glycogen synthase kinase 3 beta	Homo sapiens	87-95
27840100-14	2017	Blockade of GSK-3beta expression by siRNA and inhibition of GSK-3beta activity by lithium chloride significantly reduced tanshinone IIA-induced AQP1 and AQP3 expression (All P&lt;0.05).	Lithium Chloride	82-98	glycogen synthase kinase 3 beta	Homo sapiens	60-69
27840100-14	2017	Blockade of GSK-3beta expression by siRNA and inhibition of GSK-3beta activity by lithium chloride significantly reduced tanshinone IIA-induced AQP1 and AQP3 expression (All P&lt;0.05).	tanshinone	121-135	glycogen synthase kinase 3 beta	Homo sapiens	12-21
27840100-14	2017	Blockade of GSK-3beta expression by siRNA and inhibition of GSK-3beta activity by lithium chloride significantly reduced tanshinone IIA-induced AQP1 and AQP3 expression (All P&lt;0.05).	tanshinone	121-135	glycogen synthase kinase 3 beta	Homo sapiens	60-69
28982598-6	2017	Accordingly, Mlg might exhibit a protective role against t-BHP-triggered cytotoxicity via the activation of the AMPK/GSK3beta- and ERK-Nrf2 signaling pathways.	tert-Butylhydroperoxide	57-62	glycogen synthase kinase 3 beta	Homo sapiens	117-125
28508346-6	2017	Furthermore, testosterone treatment modulated the insulin-dependent signal transduction pathways inducing a rapid and persistent activation of AKT, ERK and mTOR, and a transient inhibition of GSK3beta.	Testosterone	13-25	glycogen synthase kinase 3 beta	Homo sapiens	192-200
28689095-4	2017	In silico hints drove the synthesis of appropriately decorated benzoxazinones and indoles (5a-s, and 6a-c) and biochemical analysis revealed their behavior as allosteric inhibitors of hGSK-3beta.	Benzoxazines	63-77	glycogen synthase kinase 3 beta	Homo sapiens	184-194
28982598-0	2017	Methyleugenol protects against t-BHP-triggered oxidative injury by induction of Nrf2 dependent on AMPK/GSK3beta and ERK activation.	methyleugenol	0-13	glycogen synthase kinase 3 beta	Homo sapiens	103-111
28982598-0	2017	Methyleugenol protects against t-BHP-triggered oxidative injury by induction of Nrf2 dependent on AMPK/GSK3beta and ERK activation.	tert-Butylhydroperoxide	31-36	glycogen synthase kinase 3 beta	Homo sapiens	103-111
28943961-7	2017	Moreover, the stimulation effects of lithium chloride, a GSK3beta inhibitor, on the accumulation of beta-catenin were notably suppressed by ARHGAP10 overexpression.	Lithium Chloride	37-53	glycogen synthase kinase 3 beta	Homo sapiens	57-65
28543447-13	2017	In conclusion, our results showed that Fas signaling can promote stemness in CRC through the modulation of Bmi1 expression via the ERK1/2 MAPK/GSK-3beta/beta-catenin/Zeb1/miR-200c axis, suggesting that Fas signaling-based cancer therapies should be administered cautiously, as the activation of this pathway not only leads to apoptosis but also induces stemness in CRC.	ammonium ferrous sulfate	39-42	glycogen synthase kinase 3 beta	Homo sapiens	143-152
28765953-3	2017	The effects of atorvastatin on the expression of glycogen synthase kinase-3beta (GSK-3beta) and microRNA (miR)-199a-5p were determined using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analyses.	Atorvastatin	15-27	glycogen synthase kinase 3 beta	Homo sapiens	49-79
28765953-3	2017	The effects of atorvastatin on the expression of glycogen synthase kinase-3beta (GSK-3beta) and microRNA (miR)-199a-5p were determined using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analyses.	Atorvastatin	15-27	glycogen synthase kinase 3 beta	Homo sapiens	81-90
28765953-6	2017	In addition, atorvastatin pretreatment significantly increased the expression of GSK-3beta at the mRNA and protein levels, and the expression of miR-199a-5p at the mRNA level (all P&lt;0.05).	Atorvastatin	13-25	glycogen synthase kinase 3 beta	Homo sapiens	81-90
28765953-8	2017	These results suggested that atorvastatin provided cardioprotective effects against I/R injury via increasing the expression of GSK-3beta through the inhibition of miR-199a-5p.	Atorvastatin	29-41	glycogen synthase kinase 3 beta	Homo sapiens	128-137
28704757-5	2017	Low micromolar doses of 10h induced cell apoptosis and cell cycle arrest in G2/M phase, and significantly downregulated the phosphorylation of Akt downstream effectors GSK3beta and S6 in Jeko-1 cells.	10H	24-27	glycogen synthase kinase 3 beta	Homo sapiens	168-176
28689095-4	2017	In silico hints drove the synthesis of appropriately decorated benzoxazinones and indoles (5a-s, and 6a-c) and biochemical analysis revealed their behavior as allosteric inhibitors of hGSK-3beta.	Indoles	82-89	glycogen synthase kinase 3 beta	Homo sapiens	184-194
28935982-5	2017	GSK3beta inhibition significantly enhanced mitochondrial oxidative stress and damage and endochondral ossification based on increased nuclear translocation of Runx-2 and beta-catenin, calcium deposition, cell death and enhanced remodelling of the extracellular matrix as demonstrated by the increased collagenolytic activity of supernatants, despite unmodified (MMP-1) or even reduced (MMP-13) collagenase gene/protein expression.	Calcium	184-191	glycogen synthase kinase 3 beta	Homo sapiens	0-8
28963516-0	2017	Phosphorylation of FE65 at threonine 579 by GSK3beta stimulates amyloid precursor protein processing.	Threonine	27-36	glycogen synthase kinase 3 beta	Homo sapiens	44-52
28963516-4	2017	In the present study, we demonstrate that FE65 is phosphorylated at threonine 579 (T579) by glycogen synthase kinase 3beta (GSK3beta).	Threonine	68-77	glycogen synthase kinase 3 beta	Homo sapiens	92-122
28963516-4	2017	In the present study, we demonstrate that FE65 is phosphorylated at threonine 579 (T579) by glycogen synthase kinase 3beta (GSK3beta).	Threonine	68-77	glycogen synthase kinase 3 beta	Homo sapiens	124-132
28315854-6	2017	We also found that effect of N-glycosylation of EpCAM on cell adhesion was regulated via FAK/Akt/Gsk-3beta/beta-catenin signaling pathway, which further adjusted MMP2/9 expression and activities.	Nitrogen	29-30	glycogen synthase kinase 3 beta	Homo sapiens	97-106
28910976-8	2017	Results also showed that 3,5-diCQA promoted the phosphorylation of Akt at Thr308 and glycogen synthase kinase-3beta at Ser 9.	3,5-dicaffeoylquinic acid	25-34	glycogen synthase kinase 3 beta	Homo sapiens	85-115
28268049-2	2017	In fact GSK-3beta is considered the main kinase which catalyzes the microtubule-associated protein tau hyper-phosphorylation and the neurofibrillary tangles (NFT) in vitro and in vivo, The first classes of GSK-3beta inhibitors were classified as ATP-competitive and, therefore, they lack of an efficient degree of selectivity over other kinases.	Adenosine Triphosphate	246-249	glycogen synthase kinase 3 beta	Homo sapiens	8-17
28268049-3	2017	In light of this consideration, many efforts are devoted to characterize new non ATP-competitive GSK-3beta inhibitors, endowed with high selectivity.	Adenosine Triphosphate	81-84	glycogen synthase kinase 3 beta	Homo sapiens	97-106
28916781-0	2017	6-bromo-indirubin-3"-oxime (6BIO), a Glycogen synthase kinase-3beta inhibitor, activates cytoprotective cellular modules and suppresses cellular senescence-mediated biomolecular damage in human fibroblasts.	6-bromoindirubin-3'-oxime	0-26	glycogen synthase kinase 3 beta	Homo sapiens	37-67
28916781-0	2017	6-bromo-indirubin-3"-oxime (6BIO), a Glycogen synthase kinase-3beta inhibitor, activates cytoprotective cellular modules and suppresses cellular senescence-mediated biomolecular damage in human fibroblasts.	6-bromoindirubin-3'-oxime	28-32	glycogen synthase kinase 3 beta	Homo sapiens	37-67
28916781-2	2017	6-bromoindirubin-3"-oxime (6BIO), a hemi-synthetic derivative of indirubins found in edible mollusks and plants, is a potent inhibitor of Glycogen synthase kinase 3beta (Gsk-3beta).	6-bromoindirubin-3'-oxime	0-25	glycogen synthase kinase 3 beta	Homo sapiens	138-168
28916781-2	2017	6-bromoindirubin-3"-oxime (6BIO), a hemi-synthetic derivative of indirubins found in edible mollusks and plants, is a potent inhibitor of Glycogen synthase kinase 3beta (Gsk-3beta).	6-bromoindirubin-3'-oxime	0-25	glycogen synthase kinase 3 beta	Homo sapiens	170-179
28916781-2	2017	6-bromoindirubin-3"-oxime (6BIO), a hemi-synthetic derivative of indirubins found in edible mollusks and plants, is a potent inhibitor of Glycogen synthase kinase 3beta (Gsk-3beta).	indirubin	65-75	glycogen synthase kinase 3 beta	Homo sapiens	138-168
28916781-2	2017	6-bromoindirubin-3"-oxime (6BIO), a hemi-synthetic derivative of indirubins found in edible mollusks and plants, is a potent inhibitor of Glycogen synthase kinase 3beta (Gsk-3beta).	indirubin	65-75	glycogen synthase kinase 3 beta	Homo sapiens	170-179
29057057-2	2017	Initial optimization of a 3-substituted indazole hit compound targeting the kinase PIM1 focused on improving selectivity over GSK3beta through consideration of differences in the ATP binding pockets.	3-substituted indazole	26-48	glycogen synthase kinase 3 beta	Homo sapiens	126-134
28870200-10	2017	We also observed that DKC-E70-mediated T286 phosphorylation and subsequent cyclin D1 degradation was blocked in presence of the inhibitors of ERK1/2, p38 or GSK3beta.	C.I. Basic Blue 54	39-43	glycogen synthase kinase 3 beta	Homo sapiens	157-165
28910976-8	2017	Results also showed that 3,5-diCQA promoted the phosphorylation of Akt at Thr308 and glycogen synthase kinase-3beta at Ser 9.	Serine	119-122	glycogen synthase kinase 3 beta	Homo sapiens	85-115
27992083-0	2017	Melanocyte-protective effect of afzelin is mediated by the Nrf2-ARE signalling pathway via GSK-3beta inactivation.	afzelin	32-39	glycogen synthase kinase 3 beta	Homo sapiens	91-100
28911173-6	2017	Using dual inhibition approaches, our results show that LiCl initiates the hGL cellular action by inhibiting the activity of glycogen synthase kinase-3beta [GSK-3beta (phosphorylation of GSK-3beta)] and activation of extracellular signal-regulated kinase 1/2 (ERK1/2), but not by affecting protein kinase B or cAMP response element binding protein signaling.	Lithium Chloride	56-60	glycogen synthase kinase 3 beta	Homo sapiens	125-155
28911173-6	2017	Using dual inhibition approaches, our results show that LiCl initiates the hGL cellular action by inhibiting the activity of glycogen synthase kinase-3beta [GSK-3beta (phosphorylation of GSK-3beta)] and activation of extracellular signal-regulated kinase 1/2 (ERK1/2), but not by affecting protein kinase B or cAMP response element binding protein signaling.	Lithium Chloride	56-60	glycogen synthase kinase 3 beta	Homo sapiens	157-166
28911173-6	2017	Using dual inhibition approaches, our results show that LiCl initiates the hGL cellular action by inhibiting the activity of glycogen synthase kinase-3beta [GSK-3beta (phosphorylation of GSK-3beta)] and activation of extracellular signal-regulated kinase 1/2 (ERK1/2), but not by affecting protein kinase B or cAMP response element binding protein signaling.	Lithium Chloride	56-60	glycogen synthase kinase 3 beta	Homo sapiens	187-196
28911173-6	2017	Using dual inhibition approaches, our results show that LiCl initiates the hGL cellular action by inhibiting the activity of glycogen synthase kinase-3beta [GSK-3beta (phosphorylation of GSK-3beta)] and activation of extracellular signal-regulated kinase 1/2 (ERK1/2), but not by affecting protein kinase B or cAMP response element binding protein signaling.	Cyclic AMP	310-314	glycogen synthase kinase 3 beta	Homo sapiens	125-155
28911173-6	2017	Using dual inhibition approaches, our results show that LiCl initiates the hGL cellular action by inhibiting the activity of glycogen synthase kinase-3beta [GSK-3beta (phosphorylation of GSK-3beta)] and activation of extracellular signal-regulated kinase 1/2 (ERK1/2), but not by affecting protein kinase B or cAMP response element binding protein signaling.	Cyclic AMP	310-314	glycogen synthase kinase 3 beta	Homo sapiens	157-166
28911173-8	2017	Furthermore, knockdown of either beta-catenin or GSK-3beta reversed the LiCl-induced upregulation of COX-2 expression.	Lithium Chloride	72-76	glycogen synthase kinase 3 beta	Homo sapiens	49-58
28911173-9	2017	These results indicate that LiCl upregulates the expression of COX-2 and the subsequent production of PGE2 through the canonical GSK-3beta/beta-catenin signaling pathway in hGL cells.	Lithium Chloride	28-32	glycogen synthase kinase 3 beta	Homo sapiens	129-138
28911173-9	2017	These results indicate that LiCl upregulates the expression of COX-2 and the subsequent production of PGE2 through the canonical GSK-3beta/beta-catenin signaling pathway in hGL cells.	Dinoprostone	102-106	glycogen synthase kinase 3 beta	Homo sapiens	129-138
28743492-1	2017	Indirubin 3"-oxime (Indox (1b)) suppresses cancer cell growth (IC50: 15muM towards HepG2 cells) and inhibits cell cycle-related kinases such as cyclin-dependent kinases and glycogen synthase kinase-3beta.	indirubin-3'-monoxime	0-18	glycogen synthase kinase 3 beta	Homo sapiens	173-203
28743492-1	2017	Indirubin 3"-oxime (Indox (1b)) suppresses cancer cell growth (IC50: 15muM towards HepG2 cells) and inhibits cell cycle-related kinases such as cyclin-dependent kinases and glycogen synthase kinase-3beta.	indox	20-25	glycogen synthase kinase 3 beta	Homo sapiens	173-203
27992083-8	2017	In addition, the phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) was induced by afzelin treatment.	afzelin	94-101	glycogen synthase kinase 3 beta	Homo sapiens	36-66
27992083-8	2017	In addition, the phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) was induced by afzelin treatment.	afzelin	94-101	glycogen synthase kinase 3 beta	Homo sapiens	68-77
27992083-11	2017	These data suggest that the cytoprotective effects of afzelin against hydrogen peroxide may be mediated by Nrf2-ARE signalling via GSK-3beta inactivation.	afzelin	54-61	glycogen synthase kinase 3 beta	Homo sapiens	131-140
29863120-10	2018	The results indicate that GSK-3beta activity plays a key role in the antitumor effect of FUT-175 in pancreatic cancer cells, and regulation of GSK-3beta by PP2A inhibition could be a novel therapeutic approach for pancreatic cancer.	fut	89-92	glycogen synthase kinase 3 beta	Homo sapiens	26-35
28686797-1	2017	Asiatic acid (AA) could attenuate ischemia/reperfusion induced myocardial apoptosis through upregulating the Akt/GSK-3beta/HIF-1alpha pathway.	asiatic acid	0-12	glycogen synthase kinase 3 beta	Homo sapiens	113-122
28713974-8	2017	In addition, downregulation of miR-125b combined with the PI3K inhibitor LY294002 enhanced cell growth inhibition, suppression of p-GSK3beta, Wnt and beta-catenin protein expression and promotion of caspase-3 activity in A549 cells.	mir-125b	31-39	glycogen synthase kinase 3 beta	Homo sapiens	132-140
28713974-8	2017	In addition, downregulation of miR-125b combined with the PI3K inhibitor LY294002 enhanced cell growth inhibition, suppression of p-GSK3beta, Wnt and beta-catenin protein expression and promotion of caspase-3 activity in A549 cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	73-81	glycogen synthase kinase 3 beta	Homo sapiens	132-140
28713974-9	2017	These results revealed that the downregulation of miR-125b regulates apoptosis in human NSCLC through the suppression of the PI3K/Akt/GSK3beta and Wnt/beta-catenin signaling pathways.	mir-125b	50-58	glycogen synthase kinase 3 beta	Homo sapiens	134-142
28720477-0	2017	Nanoquinacrine caused apoptosis in oral cancer stem cells by disrupting the interaction between GLI1 and beta catenin through activation of GSK3beta.	nanoquinacrine	0-14	glycogen synthase kinase 3 beta	Homo sapiens	140-148
28720477-5	2017	Here, we have shown that a nano-formulated bioactive small molecule inhibitor Quinacrine (NQC) caused apoptosis in oral cancer stem cells (OCSCs; isolated from different oral cancer cells and oral cancer patient derived primary cells) by down regulating WNT-beta catenin and HH-GLI components through activation of GSK3beta.	Quinacrine	78-88	glycogen synthase kinase 3 beta	Homo sapiens	315-323
28712708-0	2017	Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3beta inhibitors.	2-(3-phenylpiperazin-1-yl)-pyrimidin-4-one	19-62	glycogen synthase kinase 3 beta	Homo sapiens	66-96
28855526-7	2017	Additionally, we confirmed that baicalein enhanced mitobiogenesis through the cAMP-responsive element binding protein (CREB) and glycogen synthase kinase-3beta (GSK-3beta) pathways in rotenone-treated SH-SY5Y cells.	baicalein	32-41	glycogen synthase kinase 3 beta	Homo sapiens	129-159
28855526-7	2017	Additionally, we confirmed that baicalein enhanced mitobiogenesis through the cAMP-responsive element binding protein (CREB) and glycogen synthase kinase-3beta (GSK-3beta) pathways in rotenone-treated SH-SY5Y cells.	Rotenone	184-192	glycogen synthase kinase 3 beta	Homo sapiens	129-159
28676392-0	2017	S1PR2 antagonist protects endothelial cells against high glucose-induced mitochondrial apoptosis through the Akt/GSK-3beta signaling pathway.	Glucose	57-64	glycogen synthase kinase 3 beta	Homo sapiens	113-122
28676392-10	2017	In addition, the expression of p-AKT and p-GSK3beta was reduced when HUVECs were treated with high glucose.	Glucose	99-106	glycogen synthase kinase 3 beta	Homo sapiens	43-51
28676392-12	2017	In conclusion, S1PR2 antagonist protects endothelial cells against high glucose-induced mitochondrial apoptosis through the Akt/GSK-3beta signaling pathway.	Glucose	72-79	glycogen synthase kinase 3 beta	Homo sapiens	128-137
28712708-2	2017	Transformation of the morpholine moiety into a piperazine moiety resulted in potent GSK-3beta inhibitors.	morpholine	22-32	glycogen synthase kinase 3 beta	Homo sapiens	84-93
28712708-2	2017	Transformation of the morpholine moiety into a piperazine moiety resulted in potent GSK-3beta inhibitors.	Piperazine	47-57	glycogen synthase kinase 3 beta	Homo sapiens	84-93
28798343-2	2017	We show that a single isoflurane anesthesia produces antidepressant-like behavioural effects in the learned helplessness paradigm and regulates molecular events implicated in the mechanism of action of rapid-acting antidepressant ketamine: activation of brain-derived neurotrophic factor (BDNF) receptor TrkB, facilitation of mammalian target of rapamycin (mTOR) signaling pathway and inhibition of glycogen synthase kinase 3beta (GSK3beta).	Isoflurane	22-32	glycogen synthase kinase 3 beta	Homo sapiens	399-429
28798343-2	2017	We show that a single isoflurane anesthesia produces antidepressant-like behavioural effects in the learned helplessness paradigm and regulates molecular events implicated in the mechanism of action of rapid-acting antidepressant ketamine: activation of brain-derived neurotrophic factor (BDNF) receptor TrkB, facilitation of mammalian target of rapamycin (mTOR) signaling pathway and inhibition of glycogen synthase kinase 3beta (GSK3beta).	Ketamine	230-238	glycogen synthase kinase 3 beta	Homo sapiens	399-429
28798343-2	2017	We show that a single isoflurane anesthesia produces antidepressant-like behavioural effects in the learned helplessness paradigm and regulates molecular events implicated in the mechanism of action of rapid-acting antidepressant ketamine: activation of brain-derived neurotrophic factor (BDNF) receptor TrkB, facilitation of mammalian target of rapamycin (mTOR) signaling pathway and inhibition of glycogen synthase kinase 3beta (GSK3beta).	Isoflurane	22-32	glycogen synthase kinase 3 beta	Homo sapiens	431-439
28798343-2	2017	We show that a single isoflurane anesthesia produces antidepressant-like behavioural effects in the learned helplessness paradigm and regulates molecular events implicated in the mechanism of action of rapid-acting antidepressant ketamine: activation of brain-derived neurotrophic factor (BDNF) receptor TrkB, facilitation of mammalian target of rapamycin (mTOR) signaling pathway and inhibition of glycogen synthase kinase 3beta (GSK3beta).	Ketamine	230-238	glycogen synthase kinase 3 beta	Homo sapiens	431-439
28790389-8	2017	PPI induced inhibition of osteosarcoma cell viability was abolished upon addition of GSK-3beta specific inhibitor, CHIR99021, while PPI induced inhibition of osteosarcoma cell viability and migration were potentiated by beta-catenin silencing.	polyphyllin I	0-3	glycogen synthase kinase 3 beta	Homo sapiens	85-94
28522298-5	2017	Furthermore, we found that JNK/STAT3 and GSK3beta/beta-catenin was the downstream pathways of beta-CD-induced autophagy and differentiation using the inhibitors.	betadex	94-101	glycogen synthase kinase 3 beta	Homo sapiens	41-49
28606794-6	2017	Activation of TGF-beta receptors and p38 MAPK increased glycogen synthase kinase 3beta (GSK3beta) phosphorylation, whereas a chemical inhibitor of p38 MAPK (SB203580) reduced the phosphorylation of GSK3beta, decreasing active beta-catenin levels in both cytoplasmic and nuclear fractions.	SB 203580	157-165	glycogen synthase kinase 3 beta	Homo sapiens	198-206
28499919-4	2017	Further mechanistic studies revealed that AC023115.3 acts as a competing endogenous RNA for miR-26a and attenuates the inhibitory effect of miR-26a on GSK3beta, a proline-directed serine-threonine kinase that promotes the degradation of Mcl1, leading to an increase in GSK3beta and a decrease in autophagy.	Proline	163-170	glycogen synthase kinase 3 beta	Homo sapiens	151-159
28499919-4	2017	Further mechanistic studies revealed that AC023115.3 acts as a competing endogenous RNA for miR-26a and attenuates the inhibitory effect of miR-26a on GSK3beta, a proline-directed serine-threonine kinase that promotes the degradation of Mcl1, leading to an increase in GSK3beta and a decrease in autophagy.	Proline	163-170	glycogen synthase kinase 3 beta	Homo sapiens	269-277
28726150-0	2017	Inhibition mechanism of CDK-2 and GSK-3beta by a sulfamoylphenyl derivative of indoline-a molecular dynamics study.	indoline-a	79-89	glycogen synthase kinase 3 beta	Homo sapiens	34-43
28499919-5	2017	Additionally, we discovered that AC023115.3 improves chemosensitivity of glioma cells to cisplatin by regulating the miR-26a-GSK3beta-Mcl1 pathway.	Cisplatin	89-98	glycogen synthase kinase 3 beta	Homo sapiens	125-133
28766886-10	2017	The combination of GSK-3beta inhibitor LY-2090314 with etoposide/carboplatin increased killing in approximately 40% of the SCLC lines.	3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione	39-49	glycogen synthase kinase 3 beta	Homo sapiens	19-28
28349361-2	2017	Phosphorylation of serine 9 of GSK-3beta (GSK-3beta activity inhibition) promotes cell survival.	Serine	19-25	glycogen synthase kinase 3 beta	Homo sapiens	31-40
28656239-0	2017	Erythropoietin ameliorates PA-induced insulin resistance through the IRS/AKT/FOXO1 and GSK-3beta signaling pathway, and inhibits the inflammatory response in HepG2 cells.	Palmitic Acid	27-29	glycogen synthase kinase 3 beta	Homo sapiens	87-96
28656239-7	2017	The specific PI3K inhibitors, LY294002 and wortmannin, markedly inhibited the EPO-mediated increases in p-AKT (Ser473), p-FOXO1 (Ser256) and p-GSK-3beta (Ser9) in the PA-induced HepG2 cells (P&lt;0.05).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	30-38	glycogen synthase kinase 3 beta	Homo sapiens	143-152
28656239-7	2017	The specific PI3K inhibitors, LY294002 and wortmannin, markedly inhibited the EPO-mediated increases in p-AKT (Ser473), p-FOXO1 (Ser256) and p-GSK-3beta (Ser9) in the PA-induced HepG2 cells (P&lt;0.05).	Wortmannin	43-53	glycogen synthase kinase 3 beta	Homo sapiens	143-152
28349361-2	2017	Phosphorylation of serine 9 of GSK-3beta (GSK-3beta activity inhibition) promotes cell survival.	Serine	19-25	glycogen synthase kinase 3 beta	Homo sapiens	42-51
28969056-8	2017	The miR-708 inhibitor or 5-aza significantly increased DKK3 expression and decreased p-GSK3beta, cyclin D1 and nuclear and cytoplasmic beta-catenin protein expression, indicating that the Wnt/beta-catenin signaling pathway was inhibited.	Azacitidine	25-30	glycogen synthase kinase 3 beta	Homo sapiens	87-95
28527916-6	2017	Treatment with Cd also inhibited GSK3beta activity and induced T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription, indicating the involvement of beta-catenin signaling.	Cadmium	15-17	glycogen synthase kinase 3 beta	Homo sapiens	33-41
28321536-8	2017	We showed that SA led to an increased level of phospho-GSK-3beta and beta-catenin accumulation in HFDPC.	sinapinic acid	15-17	glycogen synthase kinase 3 beta	Homo sapiens	55-64
28720775-6	2017	Metformin inhibited the activation of Smad2/3 and MAPK, GSK-3beta phosphorylation, nuclear translocalization of beta-catenin and Snail in HPMCs.	Metformin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	56-65
29246013-4	2017	Furthermore, by separating the cytoplasmic and nuclear proteins, we found ethanol inhibited osteogenesis by impairing the accumulation of beta-catenin in both the cytoplasm and nucleus in human bone mesenchymal stem cells (hBMSCs), which resulted from activating glycogen synthase kinase-3beta (GSK-3beta).	Ethanol	74-81	glycogen synthase kinase 3 beta	Homo sapiens	263-293
29246013-4	2017	Furthermore, by separating the cytoplasmic and nuclear proteins, we found ethanol inhibited osteogenesis by impairing the accumulation of beta-catenin in both the cytoplasm and nucleus in human bone mesenchymal stem cells (hBMSCs), which resulted from activating glycogen synthase kinase-3beta (GSK-3beta).	Ethanol	74-81	glycogen synthase kinase 3 beta	Homo sapiens	295-304
28475672-7	2017	Furthermore, our results revealed a novel mechanism in which the synergism between lithium and ESI-09 is not mediated by the inhibitory effect of lithium toward GSK3beta, but by lithium"s ability to suppress cAMP/protein kinase A signaling.	Lithium	83-90	glycogen synthase kinase 3 beta	Homo sapiens	161-169
28475672-7	2017	Furthermore, our results revealed a novel mechanism in which the synergism between lithium and ESI-09 is not mediated by the inhibitory effect of lithium toward GSK3beta, but by lithium"s ability to suppress cAMP/protein kinase A signaling.	3-(5-tert-butylisoxazol-3-yl)-2-((3-chlorophenyl)hydrazono)-3-oxopropionitrile	95-101	glycogen synthase kinase 3 beta	Homo sapiens	161-169
28422767-0	2017	Pseudolaric acid B induces endometrial cancer Ishikawa cell apoptosis and inhibits metastasis through AKT-GSK-3beta and ERK1/2 signaling pathways.	pseudolaric acid B	0-18	glycogen synthase kinase 3 beta	Homo sapiens	106-115
28422767-4	2017	We found that PAB inhibited Ishikawa cell proliferation, and induced cell apoptosis and G2/M phase arrest through a mechanism involving AKT-GSK-3beta and ERK1/2 signaling pathways.	pseudolaric acid B	14-17	glycogen synthase kinase 3 beta	Homo sapiens	140-149
28321536-10	2017	These results suggest that SA could be one of the potential candidate compounds for the treatment of alopecia by inducing hair growth through triggering the expressions of growth factors via activation of Akt and subsequent inactivation of GSK-3beta /beta-catenin pathway.	sinapinic acid	27-29	glycogen synthase kinase 3 beta	Homo sapiens	240-249
28208230-1	2017	AIMS: Glycogen synthase kinase-3 beta (GSK-3beta) is a serine/threonine kinase involved in glycogen metabolism, cell cycle progression, differentiation, embryogenesis, migration, metabolism, survival and cellular senescence.	Glycogen	91-99	glycogen synthase kinase 3 beta	Homo sapiens	6-37
28366661-5	2017	To further examine whether these effects on focal adhesions in triterpenoid-treated cells were GSK3beta-dependent, GSK3beta inhibitors (lithium chloride and SB216763) were used to examine cell adhesion and morphology as well as cell migration.	triterpenoid TP-222	63-75	glycogen synthase kinase 3 beta	Homo sapiens	95-103
28366661-8	2017	Therefore, the triterpenoids may affect cell migration via a mechanism that targets and alters the activity and localization of GSK3beta.	triterpenoids	15-28	glycogen synthase kinase 3 beta	Homo sapiens	128-136
28366661-0	2017	Synthetic triterpenoids inhibit GSK3beta activity and localization and affect focal adhesions and cell migration.	triterpenoids	10-23	glycogen synthase kinase 3 beta	Homo sapiens	32-40
28366661-3	2017	Our current studies reveal that Glycogen Synthase Kinase 3 beta (GSK3beta), a kinase that regulates many cellular processes, including cell adhesion dynamics, is a triterpenoid-binding protein.	triterpenoid TP-222	164-176	glycogen synthase kinase 3 beta	Homo sapiens	32-63
28366661-3	2017	Our current studies reveal that Glycogen Synthase Kinase 3 beta (GSK3beta), a kinase that regulates many cellular processes, including cell adhesion dynamics, is a triterpenoid-binding protein.	triterpenoid TP-222	164-176	glycogen synthase kinase 3 beta	Homo sapiens	65-73
28366661-4	2017	Furthermore, triterpenoids were observed to inhibit GSK3beta activity and increase cellular focal adhesion size.	triterpenoids	13-26	glycogen synthase kinase 3 beta	Homo sapiens	52-60
26996066-4	2017	Moreover, MCP-1 treatment reduced glycogen synthase kinase-3beta (GSK-3beta) activity via the MEK/ERK-mediated phosphorylation of serine-9 in MCF-7 cells.	Serine	130-136	glycogen synthase kinase 3 beta	Homo sapiens	34-64
26996066-4	2017	Moreover, MCP-1 treatment reduced glycogen synthase kinase-3beta (GSK-3beta) activity via the MEK/ERK-mediated phosphorylation of serine-9 in MCF-7 cells.	Serine	130-136	glycogen synthase kinase 3 beta	Homo sapiens	66-75
26996066-5	2017	The inhibition of MEK/ERK by U0126 attenuated the MCP-1-induced phosphorylation of GSK-3beta and decreased the expression of Snail, an EMT-related transcription factor, leading to the inhibition of MCF-7 cell migration and invasion.	U 0126	29-34	glycogen synthase kinase 3 beta	Homo sapiens	83-92
26996066-6	2017	Inactivation of GSK-3beta by LiCl (lithium chloride) treatment notably increased MMP-2 activity, vascular endothelial growth factor expression and EMT of MCF-7 cells.	Lithium Chloride	29-33	glycogen synthase kinase 3 beta	Homo sapiens	16-25
26996066-6	2017	Inactivation of GSK-3beta by LiCl (lithium chloride) treatment notably increased MMP-2 activity, vascular endothelial growth factor expression and EMT of MCF-7 cells.	Lithium Chloride	35-51	glycogen synthase kinase 3 beta	Homo sapiens	16-25
28672902-5	2017	Additionally, DAPI staining revealed that the number of apoptotic cells was higher in the rutin and cisplatin groups compared with the control group, and immunofluorescence showed that the expression of GSK-3beta in the cisplatin and rutin groups was significantly higher compared with that in the control group.	4',6-diamino-2-phenylindole	14-18	glycogen synthase kinase 3 beta	Homo sapiens	203-212
28672902-5	2017	Additionally, DAPI staining revealed that the number of apoptotic cells was higher in the rutin and cisplatin groups compared with the control group, and immunofluorescence showed that the expression of GSK-3beta in the cisplatin and rutin groups was significantly higher compared with that in the control group.	Rutin	90-95	glycogen synthase kinase 3 beta	Homo sapiens	203-212
28672902-5	2017	Additionally, DAPI staining revealed that the number of apoptotic cells was higher in the rutin and cisplatin groups compared with the control group, and immunofluorescence showed that the expression of GSK-3beta in the cisplatin and rutin groups was significantly higher compared with that in the control group.	Cisplatin	100-109	glycogen synthase kinase 3 beta	Homo sapiens	203-212
28672902-5	2017	Additionally, DAPI staining revealed that the number of apoptotic cells was higher in the rutin and cisplatin groups compared with the control group, and immunofluorescence showed that the expression of GSK-3beta in the cisplatin and rutin groups was significantly higher compared with that in the control group.	Cisplatin	220-229	glycogen synthase kinase 3 beta	Homo sapiens	203-212
28672902-5	2017	Additionally, DAPI staining revealed that the number of apoptotic cells was higher in the rutin and cisplatin groups compared with the control group, and immunofluorescence showed that the expression of GSK-3beta in the cisplatin and rutin groups was significantly higher compared with that in the control group.	Rutin	234-239	glycogen synthase kinase 3 beta	Homo sapiens	203-212
28208230-1	2017	AIMS: Glycogen synthase kinase-3 beta (GSK-3beta) is a serine/threonine kinase involved in glycogen metabolism, cell cycle progression, differentiation, embryogenesis, migration, metabolism, survival and cellular senescence.	Glycogen	91-99	glycogen synthase kinase 3 beta	Homo sapiens	39-48
28693280-4	2017	The results indicated that rapamycin alone decreased the phosphorylation of S6 and GSK3beta, as well as the expression of cyclin D1, in NPC cells.	Sirolimus	27-36	glycogen synthase kinase 3 beta	Homo sapiens	83-91
28693280-7	2017	In conclusion, rapamycin improves the anti-tumor effect of IR for treating NPC through inhibiting the Akt/mechanistic target of rapamycin/S6 and Akt/GSK3beta/cyclin D1 signaling pathways.	Sirolimus	15-24	glycogen synthase kinase 3 beta	Homo sapiens	149-157
28575066-7	2017	In the course of this, LiCl induced inhibitory glycogen synthase kinase-3beta (GSK-3beta) serine 9 phosphorylation, whereas glioma associated oncogene family 1 (GLI1) protein expression was particularly reduced by combined ATO and LiCl treatment in RD and RH-30 cell lines, showing high rates of apoptotic cell death.	Lithium Chloride	23-27	glycogen synthase kinase 3 beta	Homo sapiens	47-77
28677426-12	2017	In addition, the inhibition of beta-catenin phosphorylation by glycogen synthase kinase 3 beta inhibitor, LiCl, significantly enhanced the migration and invasion capacities in DKK1-knockdown cell lines.	Lithium Chloride	106-110	glycogen synthase kinase 3 beta	Homo sapiens	63-94
28968964-5	2017	In this study, we tested the irreversible GSK3beta-inhibitor, tideglusib for in vivo efficacy in patient-derived xenograft models of both alveolar rhabdomyosarcoma (aRMS) and eRMS.	tideglusib	62-72	glycogen synthase kinase 3 beta	Homo sapiens	42-50
28659586-8	2017	Taken together, we suggest that PGC-1alpha protects human renal tubule cells from H2O2-mediated apoptotic injury by upregulating Nrf-2 via GSK3beta inactivation mediated by activated p38.	Hydrogen Peroxide	82-86	glycogen synthase kinase 3 beta	Homo sapiens	139-147
28575066-7	2017	In the course of this, LiCl induced inhibitory glycogen synthase kinase-3beta (GSK-3beta) serine 9 phosphorylation, whereas glioma associated oncogene family 1 (GLI1) protein expression was particularly reduced by combined ATO and LiCl treatment in RD and RH-30 cell lines, showing high rates of apoptotic cell death.	Lithium Chloride	23-27	glycogen synthase kinase 3 beta	Homo sapiens	79-88
28575066-7	2017	In the course of this, LiCl induced inhibitory glycogen synthase kinase-3beta (GSK-3beta) serine 9 phosphorylation, whereas glioma associated oncogene family 1 (GLI1) protein expression was particularly reduced by combined ATO and LiCl treatment in RD and RH-30 cell lines, showing high rates of apoptotic cell death.	Serine	90-96	glycogen synthase kinase 3 beta	Homo sapiens	79-88
27863047-6	2017	It was observed that although GSK3beta and CDK2 share the conserved ATP-binding pockets, some different residues have significant contributions to protein selectivity.	Adenosine Triphosphate	68-71	glycogen synthase kinase 3 beta	Homo sapiens	30-38
28431381-8	2017	Furthermore, zeaxanthin increased p-AKT levels while decreased the levels of p-GSK-3beta, Bax and cleaved-caspase-3.	Zeaxanthins	13-23	glycogen synthase kinase 3 beta	Homo sapiens	79-88
28594934-12	2017	Notably, the effects of GW6471 on HNPGL cells were associated with the inhibition of the PI3K/GSK3beta/beta-catenin signaling pathway.	GW 6471	24-30	glycogen synthase kinase 3 beta	Homo sapiens	94-102
28431267-0	2017	miR-19 targeting of GSK3beta mediates sulforaphane suppression of lung cancer stem cells.	mir-19	0-6	glycogen synthase kinase 3 beta	Homo sapiens	20-28
28378189-5	2017	Serine and tyrosine phosphorylation of galectin-3 by c-Abl, CKI, and GSK-3beta could regulate its localization and associated signal transduction.	Serine	0-6	glycogen synthase kinase 3 beta	Homo sapiens	69-78
28378189-5	2017	Serine and tyrosine phosphorylation of galectin-3 by c-Abl, CKI, and GSK-3beta could regulate its localization and associated signal transduction.	Tyrosine	11-19	glycogen synthase kinase 3 beta	Homo sapiens	69-78
28431267-0	2017	miR-19 targeting of GSK3beta mediates sulforaphane suppression of lung cancer stem cells.	sulforaphane	38-50	glycogen synthase kinase 3 beta	Homo sapiens	20-28
28537766-6	2017	RESULTS: Under proliferative conditions, pirfenidone inhibited Tenon"s fibroblasts proliferation and arrested the cell cycle at the G1 phase; decreased the phosphorylation of AKT, GSK3beta, ERK1/2/MAPK, and JNK/MAPK; increased the phosphorylation of p38 MAPK; and inhibited CDK2, CDK6, cyclin D1, cyclin D3, and cyclin E in a dose-dependent manner.	pirfenidone	41-52	glycogen synthase kinase 3 beta	Homo sapiens	180-188
28431267-9	2017	We further revealed that miR-19 activated Wnt/beta-catenin pathway by directly targeting GSK3beta, the key negative modulator of this pathway.	mir-19	25-31	glycogen synthase kinase 3 beta	Homo sapiens	89-97
28537766-10	2017	SB202190 attenuated the pirfenidone-induced reduction of CDK2, CDK6, cyclin D1, cyclin D3, and cyclin E. CONCLUSIONS: Pirfenidone inhibited HTFs proliferation and induced G1 arrest by downregulating CDKs and cyclins involving the AKT/GSK3beta and MAPK signaling pathways.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	0-8	glycogen synthase kinase 3 beta	Homo sapiens	234-242
28584574-10	2017	Furthermore, by studying the mechanism of action of PI3k, Akt, and GSK-3beta, and measuring glycogen content, the study confirmed that the glucose was stored in the liver as glycogen.	Glucose	139-146	glycogen synthase kinase 3 beta	Homo sapiens	67-76
28537766-10	2017	SB202190 attenuated the pirfenidone-induced reduction of CDK2, CDK6, cyclin D1, cyclin D3, and cyclin E. CONCLUSIONS: Pirfenidone inhibited HTFs proliferation and induced G1 arrest by downregulating CDKs and cyclins involving the AKT/GSK3beta and MAPK signaling pathways.	pirfenidone	24-35	glycogen synthase kinase 3 beta	Homo sapiens	234-242
28537766-10	2017	SB202190 attenuated the pirfenidone-induced reduction of CDK2, CDK6, cyclin D1, cyclin D3, and cyclin E. CONCLUSIONS: Pirfenidone inhibited HTFs proliferation and induced G1 arrest by downregulating CDKs and cyclins involving the AKT/GSK3beta and MAPK signaling pathways.	pirfenidone	118-129	glycogen synthase kinase 3 beta	Homo sapiens	234-242
28466863-0	2017	Erratum: Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson"s disease by suppressing glycogen synthase kinase-3 beta activity.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	49-53	glycogen synthase kinase 3 beta	Homo sapiens	106-137
28410220-0	2017	Reprogramming induced by isoliquiritigenin diminishes melanoma cachexia through mTORC2-AKT-GSK3beta signaling.	isoliquiritigenin	25-42	glycogen synthase kinase 3 beta	Homo sapiens	91-99
28484273-0	2017	Role of Akt-independent mTORC1 and GSK3beta signaling in sublethal NMDA-induced injury and the recovery of neuronal electrophysiology and survival.	N-Methylaspartate	67-71	glycogen synthase kinase 3 beta	Homo sapiens	35-43
28466863-0	2017	Erratum: Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson"s disease by suppressing glycogen synthase kinase-3 beta activity.	dihydromyricetin	9-25	glycogen synthase kinase 3 beta	Homo sapiens	106-137
29442024-0	2017	Anti-cancer activity of Bacillus amyloliquefaciens AK-0 through cyclin D1 proteasomal degradation via GSK3beta-dependent phosphorylation of threonine-286.	Threonine	140-149	glycogen synthase kinase 3 beta	Homo sapiens	102-110
29442024-7	2017	Inhibition of GSK3beta by LiCl suppressed cyclin D1 phosphorylation and downregulation by EA-AKO.	Lithium Chloride	26-30	glycogen synthase kinase 3 beta	Homo sapiens	14-22
28656880-9	2017	Functionally, targeting beta-catenin with lipofection-delivered small interfering RNA oligonucleotide inhibited the proliferation and cell cycle arrest in G0/G1 phase and increased apoptosis of fibroblast cells, accompanied by downregulation of Wnt2 and cyclin D1 as well as the phosphorylation level of glycogen synthase kinase 3 beta in the keloid fibrosis.	Oligonucleotides	86-101	glycogen synthase kinase 3 beta	Homo sapiens	304-335
28484273-6	2017	Electrophysiological recordings show that NMDA-induced injury causes a significant decrease in spontaneous excitatory postsynaptic currents at both two and twenty four hours, and this phenotype can be prevented by inhibiting mTORC1 or GSK3beta, but not Akt.	N-Methylaspartate	42-46	glycogen synthase kinase 3 beta	Homo sapiens	235-243
28484273-7	2017	Additionally, inhibition of mTORC1 or GSK3beta promotes neuronal survival following NMDA-induced injury.	N-Methylaspartate	84-88	glycogen synthase kinase 3 beta	Homo sapiens	38-46
28484273-8	2017	Thus, NMDA-induced excitotoxicity involves a mechanism that requires the permissive activity of mTORC1 and GSK3beta, demonstrating the importance of these kinases in the neuronal response to injury.	N-Methylaspartate	6-10	glycogen synthase kinase 3 beta	Homo sapiens	107-115
28320093-0	2017	TMF protects chondrocytes from ER stress-induced apoptosis by down-regulating GSK-3beta.	methoxyluteolin	0-3	glycogen synthase kinase 3 beta	Homo sapiens	78-87
28275987-3	2017	Smenospongidine promoted the degradation of intracellular beta-catenin that accumulated via Wnt3a or 6-bromoindirubin-3"-oxime, an inhibitor of glycogen synthase kinase-3beta.	Smenospongidine	0-15	glycogen synthase kinase 3 beta	Homo sapiens	144-174
28275987-3	2017	Smenospongidine promoted the degradation of intracellular beta-catenin that accumulated via Wnt3a or 6-bromoindirubin-3"-oxime, an inhibitor of glycogen synthase kinase-3beta.	6-bromoindirubin-3'-oxime	101-126	glycogen synthase kinase 3 beta	Homo sapiens	144-174
27871156-9	2017	Inhibition of ERK1/2 and GSK3beta blocked kahweol-mediated ATF3 expression.	kahweol	42-49	glycogen synthase kinase 3 beta	Homo sapiens	25-33
28223128-10	2017	Looking at individual substances, kenpaullone, a GSK-3beta and Cdk inhibitor, had the highest selective index of 3.44.	kenpaullone	34-45	glycogen synthase kinase 3 beta	Homo sapiens	49-58
28320093-2	2017	Previous studies showed that 5,7,3",4"-tetramethoxyflavone (TMF) exhibited chondroprotective activity through inhibiting PGE2-induced ER stress and down regulating the expression of GSK-3beta.	methoxyluteolin	29-58	glycogen synthase kinase 3 beta	Homo sapiens	182-191
28320093-2	2017	Previous studies showed that 5,7,3",4"-tetramethoxyflavone (TMF) exhibited chondroprotective activity through inhibiting PGE2-induced ER stress and down regulating the expression of GSK-3beta.	methoxyluteolin	60-63	glycogen synthase kinase 3 beta	Homo sapiens	182-191
28320093-6	2017	In addition, TMF down regulated the expression of GSK-3beta and inhibited ER stress-induced chondrocytes apoptosis.	methoxyluteolin	13-16	glycogen synthase kinase 3 beta	Homo sapiens	50-59
28320093-7	2017	Collectively, TMF is a potential natural compound with chondroprotective property through inhibition of ER stress-induced apoptosis with down regulation of GSK-3beta.	methoxyluteolin	14-17	glycogen synthase kinase 3 beta	Homo sapiens	156-165
27412761-5	2017	In addition, both GSK3beta and mitogen-activated protein kinase inhibitors significantly prevented H2O2-induced neuronal apoptosis.	Hydrogen Peroxide	99-103	glycogen synthase kinase 3 beta	Homo sapiens	18-26
27412761-7	2017	These results strongly suggest that indirubin-3-oxime prevents H2O2-induced apoptosis via concurrent inhibiting GSK3beta and the ERK pathway in SH-SY5Y cells, providing support for the use of indirubin-3-oxime to treat neurodegenerative disorders caused or exacerbated by oxidative stress.	indirubin-3'-monoxime	36-53	glycogen synthase kinase 3 beta	Homo sapiens	112-120
27412761-0	2017	Indirubin-3-Oxime Prevents H2O2-Induced Neuronal Apoptosis via Concurrently Inhibiting GSK3beta and the ERK Pathway.	indirubin-3'-monoxime	0-17	glycogen synthase kinase 3 beta	Homo sapiens	87-95
28617535-9	2017	Targeting thyroid hormone restoration, inhibition of ACE and GSK3beta via PI3K/AKT signaling pathway using LA, Resveratrol and Quercetin are potential novel therapeutic approaches for developing pharmaceuticals that could make significance in MS treatment.	Resveratrol	111-122	glycogen synthase kinase 3 beta	Homo sapiens	61-69
27412761-0	2017	Indirubin-3-Oxime Prevents H2O2-Induced Neuronal Apoptosis via Concurrently Inhibiting GSK3beta and the ERK Pathway.	Hydrogen Peroxide	27-31	glycogen synthase kinase 3 beta	Homo sapiens	87-95
27412761-3	2017	H2O2 exposure led to the increased activities of glycogen synthase kinase 3beta (GSK3beta) and extracellular signal-regulated kinase (ERK) in SH-SY5Y cells.	Hydrogen Peroxide	0-4	glycogen synthase kinase 3 beta	Homo sapiens	49-79
27412761-3	2017	H2O2 exposure led to the increased activities of glycogen synthase kinase 3beta (GSK3beta) and extracellular signal-regulated kinase (ERK) in SH-SY5Y cells.	Hydrogen Peroxide	0-4	glycogen synthase kinase 3 beta	Homo sapiens	81-89
27412761-4	2017	Indirubin-3-oxime treatment significantly reversed the altered activity of both the PI3-K/Akt/GSK3beta cascade and the ERK pathway induced by H2O2.	indirubin-3'-monoxime	0-17	glycogen synthase kinase 3 beta	Homo sapiens	94-102
28617535-9	2017	Targeting thyroid hormone restoration, inhibition of ACE and GSK3beta via PI3K/AKT signaling pathway using LA, Resveratrol and Quercetin are potential novel therapeutic approaches for developing pharmaceuticals that could make significance in MS treatment.	Quercetin	127-136	glycogen synthase kinase 3 beta	Homo sapiens	61-69
28126496-5	2017	GSK3beta knockdown reduced anxiety-like behavior while increasing depression-like behavior and cocaine self-administration.	Cocaine	95-102	glycogen synthase kinase 3 beta	Homo sapiens	0-8
27575935-6	2017	Y27632, an inhibitor of Rho-associated coiled coil kinase (ROCK) and si-ROCK inhibited both GSK-3beta phosphorylation and beta-catenin accumulation.	Y 27632	0-6	glycogen synthase kinase 3 beta	Homo sapiens	92-101
28226198-9	2017	In the SCN, olanzapine phosphorylated the GSK-3beta, a regulator of clock activity, which melatonin prevented.	Olanzapine	12-22	glycogen synthase kinase 3 beta	Homo sapiens	42-51
28226198-9	2017	In the SCN, olanzapine phosphorylated the GSK-3beta, a regulator of clock activity, which melatonin prevented.	Melatonin	90-99	glycogen synthase kinase 3 beta	Homo sapiens	42-51
28126496-9	2017	These results suggest that silencing of GSK3beta in the NAcSh increases depression- and addiction-related behavior, possibly by decreasing intrinsic excitability of TANs.	nacsh	56-61	glycogen synthase kinase 3 beta	Homo sapiens	40-48
28126496-9	2017	These results suggest that silencing of GSK3beta in the NAcSh increases depression- and addiction-related behavior, possibly by decreasing intrinsic excitability of TANs.	tans	165-169	glycogen synthase kinase 3 beta	Homo sapiens	40-48
28529629-10	2017	Niclosamide caused a dose- and time-dependent reduction of beta-catenin and the key components [e.g., DVLs, phospho-GSK3beta (S9), c-Myc and Cyclin D1] in the canonical Wnt/beta-catenin pathway.	Niclosamide	0-11	glycogen synthase kinase 3 beta	Homo sapiens	116-124
28343940-3	2017	The most potent LCA derivative, LCA hydroxyamide (LCAHA), inhibits USP2a, leading to a significant Akt/GSK3beta-independent destabilization of cyclin D1, but does not change the expression of p27.	Lithocholic Acid	16-19	glycogen synthase kinase 3 beta	Homo sapiens	103-111
28343940-3	2017	The most potent LCA derivative, LCA hydroxyamide (LCAHA), inhibits USP2a, leading to a significant Akt/GSK3beta-independent destabilization of cyclin D1, but does not change the expression of p27.	lca hydroxyamide	32-48	glycogen synthase kinase 3 beta	Homo sapiens	103-111
28343940-3	2017	The most potent LCA derivative, LCA hydroxyamide (LCAHA), inhibits USP2a, leading to a significant Akt/GSK3beta-independent destabilization of cyclin D1, but does not change the expression of p27.	LCAHA	50-55	glycogen synthase kinase 3 beta	Homo sapiens	103-111
28480051-5	2017	Metformin induced glycogen synthase kinase-3beta (GSK3beta)-mediated KLF5 protein phosphorylation and degradation through the inhibition of protein kinase A (PKA) activity in TNBC cells.	Metformin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	18-48
28480051-5	2017	Metformin induced glycogen synthase kinase-3beta (GSK3beta)-mediated KLF5 protein phosphorylation and degradation through the inhibition of protein kinase A (PKA) activity in TNBC cells.	Metformin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	50-58
28480051-8	2017	These findings suggest that metformin suppresses TNBC stem cells partially through the PKA-GSK3beta-KLF5 signaling pathway.	Metformin	28-37	glycogen synthase kinase 3 beta	Homo sapiens	91-99
28339056-0	2017	Nobiletin inhibits invasion via inhibiting AKT/GSK3beta/beta-catenin signaling pathway in Slug-expressing glioma cells.	nobiletin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	47-55
28459216-5	2017	Introduction of LiCl, a glycogen synthase kinase 3beta inhibitor, rescued the Abrus agglutinin-stimulated inhibition of beta-catenin and phosphorylated glycogen synthase kinase 3beta in FaDu cell-derived orospheres confirming importance of Wnt signaling in Abrus agglutinin-mediated inhibition of stemness.	Lithium Chloride	16-20	glycogen synthase kinase 3 beta	Homo sapiens	24-54
28459216-5	2017	Introduction of LiCl, a glycogen synthase kinase 3beta inhibitor, rescued the Abrus agglutinin-stimulated inhibition of beta-catenin and phosphorylated glycogen synthase kinase 3beta in FaDu cell-derived orospheres confirming importance of Wnt signaling in Abrus agglutinin-mediated inhibition of stemness.	Lithium Chloride	16-20	glycogen synthase kinase 3 beta	Homo sapiens	152-182
28233032-0	2017	Bi-phasic regulation of glycogen content in astrocytes via Cav-1/PTEN/PI3K/AKT/GSK-3beta pathway by fluoxetine.	Glycogen	24-32	glycogen synthase kinase 3 beta	Homo sapiens	79-88
28334272-9	2017	ASCL4 silencing also prevented the 17beta-estradiol induced increases in p-Akt and p-GSK3beta, and decrease in E-cadherin expression, important events in epithelial to mesenchymal transition.	Estradiol	35-51	glycogen synthase kinase 3 beta	Homo sapiens	85-93
28106616-0	2017	Lymphocyte Phospho-Ser-9-GSK-3beta/Total GSK-3beta Protein Levels Ratio Is Not Affected by Chronic Lithium or Valproate Treatment in Euthymic Patients With Bipolar Disorder.	Serine	19-22	glycogen synthase kinase 3 beta	Homo sapiens	25-34
28106616-2	2017	We studied whether lymphocyte GSK-3beta activity measured indirectly in lithium- or valproate (VPA)-treated euthymic patients with bipolar disorder is different from controls.	Lithium	72-79	glycogen synthase kinase 3 beta	Homo sapiens	30-39
28106616-2	2017	We studied whether lymphocyte GSK-3beta activity measured indirectly in lithium- or valproate (VPA)-treated euthymic patients with bipolar disorder is different from controls.	Valproic Acid	84-93	glycogen synthase kinase 3 beta	Homo sapiens	30-39
28106616-2	2017	We studied whether lymphocyte GSK-3beta activity measured indirectly in lithium- or valproate (VPA)-treated euthymic patients with bipolar disorder is different from controls.	Valproic Acid	95-98	glycogen synthase kinase 3 beta	Homo sapiens	30-39
28106616-3	2017	METHODS: Lymphocyte total and Ser-9-phospho-GSK-3beta (inactive) levels were measured by Western blotting.	Serine	30-33	glycogen synthase kinase 3 beta	Homo sapiens	44-53
28216152-4	2017	In this study, we investigated whether 1,25-Dihydroxyvitamin-D3 (1,25D3) can improve DCM through a vitamin D receptor (VDR)-dependent mechanism associated with autophagy and the beta-catenin/T-cell factor/lymphoid enhancer factor (TCF4)/glycogen synthase kinase-3beta (GSK-3beta)/mammalian target of rapamycin (mTOR) pathway.	Calcitriol	39-63	glycogen synthase kinase 3 beta	Homo sapiens	237-267
28216152-4	2017	In this study, we investigated whether 1,25-Dihydroxyvitamin-D3 (1,25D3) can improve DCM through a vitamin D receptor (VDR)-dependent mechanism associated with autophagy and the beta-catenin/T-cell factor/lymphoid enhancer factor (TCF4)/glycogen synthase kinase-3beta (GSK-3beta)/mammalian target of rapamycin (mTOR) pathway.	Calcitriol	39-63	glycogen synthase kinase 3 beta	Homo sapiens	269-278
28233032-0	2017	Bi-phasic regulation of glycogen content in astrocytes via Cav-1/PTEN/PI3K/AKT/GSK-3beta pathway by fluoxetine.	Fluoxetine	100-110	glycogen synthase kinase 3 beta	Homo sapiens	79-88
28233032-1	2017	OBJECTIVE: Here, we present the data indicating that chronic treatment with fluoxetine regulates Cav-1/PTEN/PI3K/AKT/GSK-3beta signalling pathway and glycogen content in primary cultures of astrocytes with bi-phasic concentration dependence.	Fluoxetine	76-86	glycogen synthase kinase 3 beta	Homo sapiens	117-126
28233032-2	2017	RESULTS: At lower concentrations, fluoxetine downregulates gene expression of Cav-1, decreases membrane content of PTEN, increases activity of PI3K/AKT, and elevates GSK-3beta phosphorylation thus suppressing its activity.	Fluoxetine	34-44	glycogen synthase kinase 3 beta	Homo sapiens	166-175
28233032-5	2017	CONCLUSIONS: Our findings indicate that bi-phasic regulation of glycogen content via Cav-1/PTEN/PI3K/AKT/GSK-3beta pathway by fluoxetine may be responsible for both therapeutic and side effects of the drug.	Glycogen	64-72	glycogen synthase kinase 3 beta	Homo sapiens	105-114
28233032-5	2017	CONCLUSIONS: Our findings indicate that bi-phasic regulation of glycogen content via Cav-1/PTEN/PI3K/AKT/GSK-3beta pathway by fluoxetine may be responsible for both therapeutic and side effects of the drug.	Fluoxetine	126-136	glycogen synthase kinase 3 beta	Homo sapiens	105-114
28469544-7	2017	Both specific inhibitors of glycogen synthase kinase 3beta (GSK3beta) and mitogen-activated protein kinase kinase (MEK) significantly protected against H2O2-induced neuronal death.	Hydrogen Peroxide	152-156	glycogen synthase kinase 3 beta	Homo sapiens	28-58
28469544-7	2017	Both specific inhibitors of glycogen synthase kinase 3beta (GSK3beta) and mitogen-activated protein kinase kinase (MEK) significantly protected against H2O2-induced neuronal death.	Hydrogen Peroxide	152-156	glycogen synthase kinase 3 beta	Homo sapiens	60-68
27757735-10	2017	Taken together, our data indicate that amsacrine abolishes ERK- and Pin1-mediated stabilization of MCL1 and promotes GSK3beta-mediated degradation of MCL1, leading to activate mitochondria-mediated apoptosis pathway in U937 cells.	Amsacrine	39-48	glycogen synthase kinase 3 beta	Homo sapiens	117-125
28147244-11	2017	Protein microarray analyses showed that treatment with TMZ+GDC-0941+IR induced higher levels of p53 and glycogen synthase kinase 3-beta (GSK3-beta) expression in SHG44GBM cells than those induced by other treatments.	Temozolomide	55-58	glycogen synthase kinase 3 beta	Homo sapiens	104-135
28147244-11	2017	Protein microarray analyses showed that treatment with TMZ+GDC-0941+IR induced higher levels of p53 and glycogen synthase kinase 3-beta (GSK3-beta) expression in SHG44GBM cells than those induced by other treatments.	Temozolomide	55-58	glycogen synthase kinase 3 beta	Homo sapiens	137-146
28147244-11	2017	Protein microarray analyses showed that treatment with TMZ+GDC-0941+IR induced higher levels of p53 and glycogen synthase kinase 3-beta (GSK3-beta) expression in SHG44GBM cells than those induced by other treatments.	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	59-67	glycogen synthase kinase 3 beta	Homo sapiens	104-135
28147244-11	2017	Protein microarray analyses showed that treatment with TMZ+GDC-0941+IR induced higher levels of p53 and glycogen synthase kinase 3-beta (GSK3-beta) expression in SHG44GBM cells than those induced by other treatments.	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	59-67	glycogen synthase kinase 3 beta	Homo sapiens	137-146
28335557-6	2017	ROS inhibitor reversed the glucose deficiency-induced cytotoxicity and restored the reduced phosphorylation of ERK and GSK3beta.	Reactive Oxygen Species	0-3	glycogen synthase kinase 3 beta	Homo sapiens	119-127
28335557-8	2017	However, D-BHB reversed cytotoxicity, ROS production, and the decrease in phosphorylation of ERK and GSK3beta induced by the glucose deficiency.	d-bhb	9-14	glycogen synthase kinase 3 beta	Homo sapiens	101-109
28199981-7	2017	Moreover, a PI3K inhibitor LY294002 inhibited AKT/GSK-3beta/beta-catenin pathway activated by GDF15 and attenuated GDF15-induced proliferation, colony formation and invasion of SCs.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	27-35	glycogen synthase kinase 3 beta	Homo sapiens	50-59
28296937-7	2017	Moreover, we identified the effect of GSK3B rs2199503 on high fasting glucose (P = 0.0002).	Glucose	70-77	glycogen synthase kinase 3 beta	Homo sapiens	38-43
28401001-12	2017	Cordycepin-mediated inhibition of ERK led to a reduction in phospho-GSK3beta (p-GSK3beta) and Slug levels, whereas LiCl, an inhibitor of GSK3beta, upregulated p-GSK3beta and Slug.	cordycepin	0-10	glycogen synthase kinase 3 beta	Homo sapiens	68-76
28401001-12	2017	Cordycepin-mediated inhibition of ERK led to a reduction in phospho-GSK3beta (p-GSK3beta) and Slug levels, whereas LiCl, an inhibitor of GSK3beta, upregulated p-GSK3beta and Slug.	cordycepin	0-10	glycogen synthase kinase 3 beta	Homo sapiens	80-88
28401001-12	2017	Cordycepin-mediated inhibition of ERK led to a reduction in phospho-GSK3beta (p-GSK3beta) and Slug levels, whereas LiCl, an inhibitor of GSK3beta, upregulated p-GSK3beta and Slug.	cordycepin	0-10	glycogen synthase kinase 3 beta	Homo sapiens	80-88
28401001-12	2017	Cordycepin-mediated inhibition of ERK led to a reduction in phospho-GSK3beta (p-GSK3beta) and Slug levels, whereas LiCl, an inhibitor of GSK3beta, upregulated p-GSK3beta and Slug.	cordycepin	0-10	glycogen synthase kinase 3 beta	Homo sapiens	80-88
27580587-9	2017	Notably, CD restores the glycogen synthase kinase-3beta (GSK3beta) activity, required for beta-catenin destruction via the proteasome-mediated system, by inhibiting the phosphorylation of GSK3beta by Akt.	cardamonin	9-11	glycogen synthase kinase 3 beta	Homo sapiens	25-55
27832289-1	2017	Glycogen synthase kinase-3beta (GSK-3beta) is a serine-threonine kinase implicated in multiple processes and signaling pathways.	Serine	48-54	glycogen synthase kinase 3 beta	Homo sapiens	0-30
27580587-9	2017	Notably, CD restores the glycogen synthase kinase-3beta (GSK3beta) activity, required for beta-catenin destruction via the proteasome-mediated system, by inhibiting the phosphorylation of GSK3beta by Akt.	cardamonin	9-11	glycogen synthase kinase 3 beta	Homo sapiens	57-65
27580587-9	2017	Notably, CD restores the glycogen synthase kinase-3beta (GSK3beta) activity, required for beta-catenin destruction via the proteasome-mediated system, by inhibiting the phosphorylation of GSK3beta by Akt.	cardamonin	9-11	glycogen synthase kinase 3 beta	Homo sapiens	188-196
28112375-0	2017	Astragaloside IV inhibits metastasis in hepatoma cells through the suppression of epithelial-mesenchymal transition via the Akt/GSK-3beta/beta-catenin pathway.	astragaloside A	0-16	glycogen synthase kinase 3 beta	Homo sapiens	128-137
28057765-3	2017	GSK-3beta is perhaps best known for glycogen regulation, being inhibited downstream in an insulin-signaling pathway.	Glycogen	36-44	glycogen synthase kinase 3 beta	Homo sapiens	0-9
28122350-8	2017	RARalpha-mediated miR-27a transcriptional inactivation releases the inhibition of miR-27a on GSK-3beta leading to laryngeal cancer differentiation through GSK-3beta-involved Wnt/beta-catenin pathway, suggesting that miR-27a is a usefully therapeutic target at least in ATRA-induced laryngeal cancer differentiation.	Tretinoin	269-273	glycogen synthase kinase 3 beta	Homo sapiens	93-102
28038351-9	2017	Finally, we report that Gsk3-beta is a direct target of miR-29 in MEF-cells.	mir-29	56-62	glycogen synthase kinase 3 beta	Homo sapiens	24-33
28122350-8	2017	RARalpha-mediated miR-27a transcriptional inactivation releases the inhibition of miR-27a on GSK-3beta leading to laryngeal cancer differentiation through GSK-3beta-involved Wnt/beta-catenin pathway, suggesting that miR-27a is a usefully therapeutic target at least in ATRA-induced laryngeal cancer differentiation.	Tretinoin	269-273	glycogen synthase kinase 3 beta	Homo sapiens	155-164
28060747-4	2017	In the motor neuron-like cell line (NSC34) with the human mutant G93A superoxide dismutase 1 gene (mSOD1-G93A), 25-hydroxycholesterol induced motor neuronal death/ apoptosis via glycogen synthase kinase-3beta and liver X receptor pathways; riluzole treatment attenuated these effects.	25-hydroxycholesterol	112-133	glycogen synthase kinase 3 beta	Homo sapiens	178-208
28280366-9	2017	It was also shown that salinomycin could reverse the aberrant activation of the canonical Wnt pathway induced by GSK-3beta inhibitor (SB216763).	salinomycin	23-34	glycogen synthase kinase 3 beta	Homo sapiens	113-122
28280366-9	2017	It was also shown that salinomycin could reverse the aberrant activation of the canonical Wnt pathway induced by GSK-3beta inhibitor (SB216763).	SB 216763	134-142	glycogen synthase kinase 3 beta	Homo sapiens	113-122
28275367-7	2017	Indeed, activation of PPAR-gamma by thiazolidinediones (TZDs) or other agonists may inhibit cell growth and proliferation by lowering circulating insulin and affecting key pathways of the Insulin/IGF axis, such as PI3K/mTOR, MAPK, and GSK3-beta/Wnt/beta-catenin cascades, which regulate cancer cell survival, cell reprogramming, and differentiation.	Thiazolidinediones	36-54	glycogen synthase kinase 3 beta	Homo sapiens	235-244
28275367-7	2017	Indeed, activation of PPAR-gamma by thiazolidinediones (TZDs) or other agonists may inhibit cell growth and proliferation by lowering circulating insulin and affecting key pathways of the Insulin/IGF axis, such as PI3K/mTOR, MAPK, and GSK3-beta/Wnt/beta-catenin cascades, which regulate cancer cell survival, cell reprogramming, and differentiation.	Thiazolidinediones	56-60	glycogen synthase kinase 3 beta	Homo sapiens	235-244
28099142-0	2017	The pentapeptide Gly-Thr-Gly-Lys-Thr confers sensitivity to anti-cancer drugs by inhibition of CAGE binding to GSK3beta and decreasing the expression of cyclinD1.	glycyl-threonine	17-24	glycogen synthase kinase 3 beta	Homo sapiens	111-119
28099142-0	2017	The pentapeptide Gly-Thr-Gly-Lys-Thr confers sensitivity to anti-cancer drugs by inhibition of CAGE binding to GSK3beta and decreasing the expression of cyclinD1.	Gly-Lys-Thr	25-36	glycogen synthase kinase 3 beta	Homo sapiens	111-119
28208696-0	2017	Valproate Attenuates Endoplasmic Reticulum Stress-Induced Apoptosis in SH-SY5Y Cells via the AKT/GSK3beta Signaling Pathway.	Valproic Acid	0-9	glycogen synthase kinase 3 beta	Homo sapiens	97-105
28196122-8	2017	Conversely, stabilization of ELAVL-1/HuR with the proteasome inhibitor MG-132 resulted in induction of GSK3beta at mRNA and protein level and attenuated FITC-albumin clearance.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	71-77	glycogen synthase kinase 3 beta	Homo sapiens	103-111
28451058-4	2017	GSK3B-MCL1 pathway affects ATP production locally in degenerating axons and the exposure of phosphatidylserine (PS), an "eat-me" signal for phagocytes, on degenerating axons, resulting in the failed engulfment of axonal debris in vivo.	Adenosine Triphosphate	27-30	glycogen synthase kinase 3 beta	Homo sapiens	0-5
28451058-4	2017	GSK3B-MCL1 pathway affects ATP production locally in degenerating axons and the exposure of phosphatidylserine (PS), an "eat-me" signal for phagocytes, on degenerating axons, resulting in the failed engulfment of axonal debris in vivo.	Phosphatidylserines	92-110	glycogen synthase kinase 3 beta	Homo sapiens	0-5
28451058-4	2017	GSK3B-MCL1 pathway affects ATP production locally in degenerating axons and the exposure of phosphatidylserine (PS), an "eat-me" signal for phagocytes, on degenerating axons, resulting in the failed engulfment of axonal debris in vivo.	Phosphatidylserines	112-114	glycogen synthase kinase 3 beta	Homo sapiens	0-5
28451058-4	2017	GSK3B-MCL1 pathway affects ATP production locally in degenerating axons and the exposure of phosphatidylserine (PS), an "eat-me" signal for phagocytes, on degenerating axons, resulting in the failed engulfment of axonal debris in vivo.	eat-me	121-127	glycogen synthase kinase 3 beta	Homo sapiens	0-5
28337318-0	2017	Development of [18F]Maleimide-Based Glycogen Synthase Kinase-3beta Ligands for Positron Emission Tomography Imaging.	[18f]maleimide	15-29	glycogen synthase kinase 3 beta	Homo sapiens	36-66
28337318-3	2017	Herein, we report the synthesis and biological evaluation of a series of fluorine-substituted maleimide derivatives that are high-affinity GSK-3beta inhibitors.	fluorine-substituted maleimide	73-103	glycogen synthase kinase 3 beta	Homo sapiens	139-148
28031536-8	2017	Molecular analysis revealed that propranolol treatment of the SK-BR-3 breast cancer line, which showed high sensitivity to beta blockade, led to a reduction in Ki67 protein expression, decreased phosphorylation of the mitogenic signaling regulators p44/42 MAPK, p38 MAPK, JNK, and CREB, increased phosphorylation of the cell survival/apoptosis regulators AKT, p53, and GSK3beta.	Propranolol	33-44	glycogen synthase kinase 3 beta	Homo sapiens	369-377
27890917-0	2017	Sulforaphane suppresses EMT and metastasis in human lung cancer through miR-616-5p-mediated GSK3beta/beta-catenin signaling pathways.	sulforaphane	0-12	glycogen synthase kinase 3 beta	Homo sapiens	92-100
27890917-10	2017	Further studies revealed that miR-616-5p directly targeted GSK3beta and decreased its expression, whereas sulforaphane decreased miR-616-5p levels by histone modification, and followed by inactivation of the GSK3beta/beta-catenin signaling pathway and inhibition of EMT, which was characterized by loss of epithelial markers and acquisition of a mesenchymal phenotype in NSCLC cells.	sulforaphane	106-118	glycogen synthase kinase 3 beta	Homo sapiens	208-216
28061416-0	2017	Purinergic P2X7 receptor mediates acetaldehyde-induced hepatic stellate cells activation via PKC-dependent GSK3beta pathway.	Acetaldehyde	34-46	glycogen synthase kinase 3 beta	Homo sapiens	107-115
28061416-6	2017	Furthermore, PKC activation treated with PMA could obviously up-regulate the expression of alpha-SMA and collagen I and the phosphorylation of GSK3beta, while inhibition of PKC significantly reduced GSK3beta activation.	Tetradecanoylphorbol Acetate	41-44	glycogen synthase kinase 3 beta	Homo sapiens	143-151
28061416-8	2017	Taken together, these results suggested that purinergic P2X7R mediated acetaldehyde-induced activation of HSCs via PKC-dependent GSK3beta pathway, which maybe a novel target for limiting HSCs activation.	Acetaldehyde	71-83	glycogen synthase kinase 3 beta	Homo sapiens	129-137
27128966-7	2017	Cyclin D1 degradation by metformin requires the activation of GSK3beta, as determined based on the treatment with GSK3beta inhibitors.	Metformin	25-34	glycogen synthase kinase 3 beta	Homo sapiens	62-70
27128966-7	2017	Cyclin D1 degradation by metformin requires the activation of GSK3beta, as determined based on the treatment with GSK3beta inhibitors.	Metformin	25-34	glycogen synthase kinase 3 beta	Homo sapiens	114-122
27128966-8	2017	The activation of GSK3beta correlated with the inhibitory phosphorylation by Akt as well as p70S6K through AMPK activation in response to metformin.	Metformin	138-147	glycogen synthase kinase 3 beta	Homo sapiens	18-26
27128966-9	2017	These findings suggested that the anticancer effects of metformin was induced due to cyclin D1 degradation via AMPK/GSK3beta signaling axis that involved the ubiquitin/proteasome pathway specifically in ovarian cancer cells.	Metformin	56-65	glycogen synthase kinase 3 beta	Homo sapiens	116-124
29658259-1	2017	Glycogen synthase kinase 3 (GSK 3alpha and GSK 3beta) are serine/threonine protein kinases acting on numerous substrates and involved in the regulation of various cellular functions such as their proliferation, survival, glycogen metabolism, and autophagy.	Glycogen	221-229	glycogen synthase kinase 3 beta	Homo sapiens	43-52
28153093-4	2017	Mechanistic insights into the process of VPA-induced reprogramming revealed that it was dependent on OCT4 promoter activation, which was achieved independently of the PI3K (phosphatidylinositol 3-kinase)/AKT/mTOR (mammalian target of rapamycin) pathway or GSK3beta inhibition but was concomitant with the presence of acetylated histones H3K9 and H3K56, which promote pluripotency.	Valproic Acid	41-44	glycogen synthase kinase 3 beta	Homo sapiens	256-264
28421199-0	2017	Valproic Acid Protects Primary Dopamine Neurons from MPP+-Induced Neurotoxicity: Involvement of GSK3beta Phosphorylation by Akt and ERK through the Mitochondrial Intrinsic Apoptotic Pathway.	Valproic Acid	0-13	glycogen synthase kinase 3 beta	Homo sapiens	96-104
28123643-7	2017	We also showed that the GSK3beta inhibitor LiCl can partly disable SAHF formation through the HMGA2 overexpression in WI38 cells.	Lithium Chloride	43-47	glycogen synthase kinase 3 beta	Homo sapiens	24-32
27901475-9	2017	Taken together, our results indicated depletion of polyamines by SSAT significantly inhibited cell proliferation, migration and invasion through AKT/GSK3beta/beta-catenin signaling pathway in hepatocellular carcinoma and colorectal cancer cells.	Polyamines	51-61	glycogen synthase kinase 3 beta	Homo sapiens	149-157
27458792-7	2017	The predicted target genes (e.g. Irs2, Pik3r1, Akt2, and Gsk3b) were involved in glucose import and the insulin signaling pathway.	Glucose	81-88	glycogen synthase kinase 3 beta	Homo sapiens	57-62
27816443-3	2017	In keratinocytes, lucidone-induced nuclear translocation of beta-catenin was accompanied by increased transcriptional target genes, including c-Myc and cyclin-D1, through GSK3beta-dependent pathway.	lucidone	18-26	glycogen synthase kinase 3 beta	Homo sapiens	171-179
27889234-14	2017	Molecular docking studies suggest that ICA may possibly exhibit its anticancer effect by inhibiting EGFR in A549, Bcr-Abl in K562 and GSK-3beta kinase in SW480 cell line.	isocyanic acid	39-42	glycogen synthase kinase 3 beta	Homo sapiens	134-143
27893461-7	2017	Dual modulation of MCL-1 stability at different dose ranges of sunitinib was due to differential effects on ERK and GSK3beta activity, and the latter also accounted for dual modulation of mTORC1 activity.	Sunitinib	63-72	glycogen synthase kinase 3 beta	Homo sapiens	116-124
28421199-3	2017	VPA reversed MPP+-induced mitochondrial apoptosis and counteracted MPP+-induced extracellular signal-regulated kinase (ERK) and Akt repression and inhibited glycogen synthase kinase 3beta (GSK3beta) activation through induction of GSK3beta phosphorylation.	Valproic Acid	0-3	glycogen synthase kinase 3 beta	Homo sapiens	157-187
28421199-3	2017	VPA reversed MPP+-induced mitochondrial apoptosis and counteracted MPP+-induced extracellular signal-regulated kinase (ERK) and Akt repression and inhibited glycogen synthase kinase 3beta (GSK3beta) activation through induction of GSK3beta phosphorylation.	Valproic Acid	0-3	glycogen synthase kinase 3 beta	Homo sapiens	189-197
28421199-3	2017	VPA reversed MPP+-induced mitochondrial apoptosis and counteracted MPP+-induced extracellular signal-regulated kinase (ERK) and Akt repression and inhibited glycogen synthase kinase 3beta (GSK3beta) activation through induction of GSK3beta phosphorylation.	Valproic Acid	0-3	glycogen synthase kinase 3 beta	Homo sapiens	231-239
28421199-0	2017	Valproic Acid Protects Primary Dopamine Neurons from MPP+-Induced Neurotoxicity: Involvement of GSK3beta Phosphorylation by Akt and ERK through the Mitochondrial Intrinsic Apoptotic Pathway.	mangion-purified polysaccharide (Candida albicans)	53-57	glycogen synthase kinase 3 beta	Homo sapiens	96-104
28421199-3	2017	VPA reversed MPP+-induced mitochondrial apoptosis and counteracted MPP+-induced extracellular signal-regulated kinase (ERK) and Akt repression and inhibited glycogen synthase kinase 3beta (GSK3beta) activation through induction of GSK3beta phosphorylation.	mangion-purified polysaccharide (Candida albicans)	13-17	glycogen synthase kinase 3 beta	Homo sapiens	189-197
28421199-3	2017	VPA reversed MPP+-induced mitochondrial apoptosis and counteracted MPP+-induced extracellular signal-regulated kinase (ERK) and Akt repression and inhibited glycogen synthase kinase 3beta (GSK3beta) activation through induction of GSK3beta phosphorylation.	mangion-purified polysaccharide (Candida albicans)	13-17	glycogen synthase kinase 3 beta	Homo sapiens	231-239
28980866-6	2017	Therefore, these results indicate that NVP-BEZ235-induced cyclin D1 and cyclin E1 degradation, which happened through activating GSK3beta, and GSK3beta-dependent down-regulation of cyclin D1 and cyclin E1 should be available for anticancer therapeutics.	dactolisib	43-49	glycogen synthase kinase 3 beta	Homo sapiens	129-137
28421199-3	2017	VPA reversed MPP+-induced mitochondrial apoptosis and counteracted MPP+-induced extracellular signal-regulated kinase (ERK) and Akt repression and inhibited glycogen synthase kinase 3beta (GSK3beta) activation through induction of GSK3beta phosphorylation.	mangion-purified polysaccharide (Candida albicans)	67-71	glycogen synthase kinase 3 beta	Homo sapiens	189-197
28421199-3	2017	VPA reversed MPP+-induced mitochondrial apoptosis and counteracted MPP+-induced extracellular signal-regulated kinase (ERK) and Akt repression and inhibited glycogen synthase kinase 3beta (GSK3beta) activation through induction of GSK3beta phosphorylation.	mangion-purified polysaccharide (Candida albicans)	67-71	glycogen synthase kinase 3 beta	Homo sapiens	231-239
28980866-6	2017	Therefore, these results indicate that NVP-BEZ235-induced cyclin D1 and cyclin E1 degradation, which happened through activating GSK3beta, and GSK3beta-dependent down-regulation of cyclin D1 and cyclin E1 should be available for anticancer therapeutics.	dactolisib	43-49	glycogen synthase kinase 3 beta	Homo sapiens	143-151
28980866-4	2017	Additionally we found that GSK3beta was dephosphorylated and activated by NVP-BEZ235 and then triggered cyclin D1 and cyclin E1 degradation through ubiquitination proteasome pathway, based on the evidences that NVP-BEZ235 induced downregulation of cyclin D1 and cyclin E1 were obviously recovered by proteasome inhibitor and the blockade of GSK3beta contributed to remarkable rescue of cyclin D1 and cyclin E1.	dactolisib	78-84	glycogen synthase kinase 3 beta	Homo sapiens	27-35
28484287-0	2017	miR-135b Plays a Neuroprotective Role by Targeting GSK3beta in MPP+-Intoxicated SH-SY5Y Cells.	mangion-purified polysaccharide (Candida albicans)	63-66	glycogen synthase kinase 3 beta	Homo sapiens	51-59
28419994-14	2017	Bufalin did not significantly affect NOXA protein levels, but downregulated the expression of p-GSK-3beta.	bufalin	0-7	glycogen synthase kinase 3 beta	Homo sapiens	96-105
28419994-15	2017	GSK-3 inhibitor and GSK-3beta siRNA resulted in increased levels of Mcl-1 and reversed the bufalin-induced Mcl-1 degradation.	bufalin	91-98	glycogen synthase kinase 3 beta	Homo sapiens	20-29
28419994-17	2017	Proteasomal degradation of Mcl-1 via GSK-3beta activation was involved in bufalin-induced apoptosis.	bufalin	74-81	glycogen synthase kinase 3 beta	Homo sapiens	37-46
29190616-13	2017	CONCLUSION: Our results demonstrated that Apatinib treatment inhibited tumor growth, and Apatinib-induced suppression of Akt/GSK3beta/ANG signaling pathway may play an important role in the inhibition of angiogenesis in ATC, supporting a potential therapeutic approach for using Apatinib in the treatment of ATC.	apatinib	89-97	glycogen synthase kinase 3 beta	Homo sapiens	125-133
28291961-0	2017	Attenuation of Oxidative Stress-Induced Osteoblast Apoptosis by Curcumin is Associated with Preservation of Mitochondrial Functions and Increased Akt-GSK3beta Signaling.	Curcumin	64-72	glycogen synthase kinase 3 beta	Homo sapiens	150-158
28291961-13	2017	Furthermore, curcumin treatment markedly increased levels of phosphorylated protein kinase B (Akt) and phosphorylated glycogen synthase kinase-3beta (GSK3beta).	Curcumin	13-21	glycogen synthase kinase 3 beta	Homo sapiens	118-148
28291961-13	2017	Furthermore, curcumin treatment markedly increased levels of phosphorylated protein kinase B (Akt) and phosphorylated glycogen synthase kinase-3beta (GSK3beta).	Curcumin	13-21	glycogen synthase kinase 3 beta	Homo sapiens	150-158
28291961-14	2017	CONCLUSION: Curcumin administration ameliorates oxidative stress-induced apoptosis in osteoblasts by preserving mitochondrial functions and activation of Akt-GSK3beta signaling.	Curcumin	12-20	glycogen synthase kinase 3 beta	Homo sapiens	158-166
29190615-1	2017	Glycogen synthase kinase-3beta (GSK-3beta), a serine/threonine protein kinase, has been reported to show essential roles in molecular pathophysiology of many diseases.	Serine	46-52	glycogen synthase kinase 3 beta	Homo sapiens	0-30
29190616-0	2017	Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK3beta/ANG Signaling Pathway in Anaplastic Thyroid Cancer.	apatinib	0-8	glycogen synthase kinase 3 beta	Homo sapiens	51-59
29190616-10	2017	Additionally, Apatinib treatment decreased the level of p-Akt and p-GSK3beta.	apatinib	14-22	glycogen synthase kinase 3 beta	Homo sapiens	68-76
29190616-12	2017	Furthermore, the anti-angiogenic ability of Apatinib can be enhanced in the presence of Akt inhibitor, and the inhibition of GSK3beta attenuated the anti-angiogenic ability of Apatinib.	apatinib	176-184	glycogen synthase kinase 3 beta	Homo sapiens	125-133
29190616-13	2017	CONCLUSION: Our results demonstrated that Apatinib treatment inhibited tumor growth, and Apatinib-induced suppression of Akt/GSK3beta/ANG signaling pathway may play an important role in the inhibition of angiogenesis in ATC, supporting a potential therapeutic approach for using Apatinib in the treatment of ATC.	apatinib	89-97	glycogen synthase kinase 3 beta	Homo sapiens	125-133
28484287-3	2017	qRT-PCR and western blot showed that miR-135 was downregulated and glycogen synthase kinase 3beta (GSK3beta) was upregulated at mRNA and protein levels in MPP+-intoxicated SH-SY5Y cells in a dose- and time-dependent manner.	mangion-purified polysaccharide (Candida albicans)	155-159	glycogen synthase kinase 3 beta	Homo sapiens	67-97
28484287-3	2017	qRT-PCR and western blot showed that miR-135 was downregulated and glycogen synthase kinase 3beta (GSK3beta) was upregulated at mRNA and protein levels in MPP+-intoxicated SH-SY5Y cells in a dose- and time-dependent manner.	mangion-purified polysaccharide (Candida albicans)	155-159	glycogen synthase kinase 3 beta	Homo sapiens	99-107
28484287-6	2017	Moreover, sodium nitroprusside (SNP), a GSK3beta activator, dramatically reversed the effects of miR-135b upregulation on cell proliferation, apoptosis, and inflammatory cytokine production in MPP+-intoxicated SH-SY5Y cells.	Nitroprusside	10-30	glycogen synthase kinase 3 beta	Homo sapiens	40-48
28484287-6	2017	Moreover, sodium nitroprusside (SNP), a GSK3beta activator, dramatically reversed the effects of miR-135b upregulation on cell proliferation, apoptosis, and inflammatory cytokine production in MPP+-intoxicated SH-SY5Y cells.	mangion-purified polysaccharide (Candida albicans)	193-197	glycogen synthase kinase 3 beta	Homo sapiens	40-48
28484287-7	2017	Taken together, miR-135b exerts a protective role via promotion of proliferation and suppression of apoptosis and neuroinflammation by targeting GSK3beta in MPP+-intoxicated SH-SY5Y cells, providing a potential therapeutic target for the treatment of PD.	mangion-purified polysaccharide (Candida albicans)	157-161	glycogen synthase kinase 3 beta	Homo sapiens	145-153
26822619-5	2017	Finally, treatment of hBMSCs with the GSK3beta inhibitor LiCl2 increased nuclear beta-catenin levels and significantly attenuated cytotoxicity compared with BPA treatment.	licl2	57-62	glycogen synthase kinase 3 beta	Homo sapiens	38-46
26822619-5	2017	Finally, treatment of hBMSCs with the GSK3beta inhibitor LiCl2 increased nuclear beta-catenin levels and significantly attenuated cytotoxicity compared with BPA treatment.	bisphenol A	157-160	glycogen synthase kinase 3 beta	Homo sapiens	38-46
29075302-7	2017	All these findings indicate that biatractylolide has a neuroprotective effect on glutamate-induced injury in PC12 and SH-SY5Y cells through a mechanism of the PI3K-Akt-GSK3beta-dependent pathways.	biatractylolide	33-48	glycogen synthase kinase 3 beta	Homo sapiens	168-176
29358963-0	2017	Compound Wumei Powder Inhibits the Invasion and Metastasis of Gastric Cancer via Cox-2/PGE2-PI3K/AKT/GSK3beta/beta-Catenin Signaling Pathway.	Dinoprostone	87-91	glycogen synthase kinase 3 beta	Homo sapiens	101-109
29358963-9	2017	The results showed that CWP can suppress relevant cytokines of Cox-2/PGE2-PI3K/AKT/GSK3beta/beta-catenin pathway.	Dinoprostone	69-73	glycogen synthase kinase 3 beta	Homo sapiens	83-91
29358963-10	2017	In conclusion, we suggest that CWP inhibits the invasion and metastasis of SGC-7901 cells via Cox-2/PGE2-PI3K/AKT/GSK3beta/beta-catenin signaling pathway.	Dinoprostone	100-104	glycogen synthase kinase 3 beta	Homo sapiens	114-122
29075302-7	2017	All these findings indicate that biatractylolide has a neuroprotective effect on glutamate-induced injury in PC12 and SH-SY5Y cells through a mechanism of the PI3K-Akt-GSK3beta-dependent pathways.	Glutamic Acid	81-90	glycogen synthase kinase 3 beta	Homo sapiens	168-176
29209632-0	2017	Silymarin Ameliorates Diabetes-Induced Proangiogenic Response in Brain Endothelial Cells through a GSK-3beta Inhibition-Induced Reduction of VEGF Release.	Silymarin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	99-108
29209632-13	2017	In conclusion, silymarin inhibits AGE-induced aberrant angiogenesis in a GSK-3beta-mediated inhibition of VEGF release.	Silymarin	15-24	glycogen synthase kinase 3 beta	Homo sapiens	73-82
27718509-6	2017	We found that a cocaine challenge, after a period of abstinence, induced an increase in the activity of the pathway which is revealed as an increase in the total and nuclear levels of beta-catenin (final effector of the pathway) in the nucleus accumbens (NAcc), together with a decrease in the activity of glycogen synthase kinase 3beta (GSK3beta).	Cocaine	16-23	glycogen synthase kinase 3 beta	Homo sapiens	306-336
27718509-6	2017	We found that a cocaine challenge, after a period of abstinence, induced an increase in the activity of the pathway which is revealed as an increase in the total and nuclear levels of beta-catenin (final effector of the pathway) in the nucleus accumbens (NAcc), together with a decrease in the activity of glycogen synthase kinase 3beta (GSK3beta).	Cocaine	16-23	glycogen synthase kinase 3 beta	Homo sapiens	338-346
28928905-5	2017	Moreover, inhibitors of glycogen synthase kinase 3beta (GSK3beta) and mitogen-activated protein kinase (MEK) synergistically prevented Abeta oligomer-induced neuronal death, suggesting that the PI3K/Akt and ERK pathways might be involved in Abeta oligomer-induced neurotoxicity.	UNII-042A8N37WH	135-140	glycogen synthase kinase 3 beta	Homo sapiens	24-54
26859114-7	2017	Further data demonstrated that Akt/GSK-3beta, other than MAPK signaling pathway was taking a part in the inhibitory potential of Icariside II on NF-kappaB activation.	baohuoside I	129-141	glycogen synthase kinase 3 beta	Homo sapiens	35-44
27908414-3	2017	We used an inducible canonical wnt signaling system that utilizes LiCl (GSK-3beta inhibitor).	Lithium Chloride	66-70	glycogen synthase kinase 3 beta	Homo sapiens	72-81
26952865-4	2017	Furthermore, we demonstrate that alcohol intake also blocks glycogen synthase kinase-3beta (GSK-3beta)-phosphorylation of CRMP-2, which results in elevated binding of CRMP-2 to microtubules and a concomitant increase in microtubule content.	Alcohols	33-40	glycogen synthase kinase 3 beta	Homo sapiens	60-90
26952865-4	2017	Furthermore, we demonstrate that alcohol intake also blocks glycogen synthase kinase-3beta (GSK-3beta)-phosphorylation of CRMP-2, which results in elevated binding of CRMP-2 to microtubules and a concomitant increase in microtubule content.	Alcohols	33-40	glycogen synthase kinase 3 beta	Homo sapiens	92-101
26952865-6	2017	These results suggest that CRMP-2 in the NAc is a convergent point that receives inputs from two signaling pathways, mTORC1 and GSK-3beta, that in turn drives excessive alcohol-drinking behaviors.	Alcohols	169-176	glycogen synthase kinase 3 beta	Homo sapiens	128-137
28928905-5	2017	Moreover, inhibitors of glycogen synthase kinase 3beta (GSK3beta) and mitogen-activated protein kinase (MEK) synergistically prevented Abeta oligomer-induced neuronal death, suggesting that the PI3K/Akt and ERK pathways might be involved in Abeta oligomer-induced neurotoxicity.	UNII-042A8N37WH	135-140	glycogen synthase kinase 3 beta	Homo sapiens	56-64
27835591-7	2016	Treatment with celecoxib also restored GSK3beta function and led to down-regulation of beta-catenin activity through transcriptional and post-translational mechanisms, two effects likely to contribute to Ph+ cell growth suppression by celecoxib.Celecoxib inhibited colony formation of TKI-resistant Ph+ cell lines including those with the T315I BCR-ABL mutation and acted synergistically with imatinib in suppressing colony formation of TKI-sensitive Ph+ cell lines.	Celecoxib	245-254	glycogen synthase kinase 3 beta	Homo sapiens	39-47
27705937-6	2016	Combination treatment significantly decreased VEGF-B expression and inhibited activity of GSK-3beta when compared to the RSV alone treatment.	Resveratrol	121-124	glycogen synthase kinase 3 beta	Homo sapiens	90-99
27977752-0	2016	GSK-3beta/NFAT Signaling Is Involved in Testosterone-Induced Cardiac Myocyte Hypertrophy.	Testosterone	40-52	glycogen synthase kinase 3 beta	Homo sapiens	0-9
27977752-3	2016	However, the role played by calcineurin-NFAT and GSK-3beta signaling in testosterone-induced cardiac hypertrophy has remained unknown.	Testosterone	72-84	glycogen synthase kinase 3 beta	Homo sapiens	49-58
27977752-4	2016	Here, we determined that testosterone stimulates cardiac myocyte hypertrophy through NFAT activation and GSK-3beta inhibition.	Testosterone	25-37	glycogen synthase kinase 3 beta	Homo sapiens	105-114
27977752-7	2016	Conversely, testosterone inhibited GSK-3beta activity as determined by increased GSK-3beta phosphorylation at Ser9 and beta-catenin protein accumulation, and also by reduction in beta-catenin phosphorylation at residues Ser33, Ser37, and Thr41.	Testosterone	12-24	glycogen synthase kinase 3 beta	Homo sapiens	35-44
27977752-7	2016	Conversely, testosterone inhibited GSK-3beta activity as determined by increased GSK-3beta phosphorylation at Ser9 and beta-catenin protein accumulation, and also by reduction in beta-catenin phosphorylation at residues Ser33, Ser37, and Thr41.	Testosterone	12-24	glycogen synthase kinase 3 beta	Homo sapiens	81-90
27977752-8	2016	GSK-3beta inhibition with 1-azakenpaullone or a GSK-3beta-targeting siRNA increased NFAT-Luc activity, whereas overexpression of a constitutively active GSK-3beta mutant (GSK-3betaS9A) inhibited NFAT-Luc activation mediated by testosterone.	kenpaullone	26-42	glycogen synthase kinase 3 beta	Homo sapiens	0-9
27977752-8	2016	GSK-3beta inhibition with 1-azakenpaullone or a GSK-3beta-targeting siRNA increased NFAT-Luc activity, whereas overexpression of a constitutively active GSK-3beta mutant (GSK-3betaS9A) inhibited NFAT-Luc activation mediated by testosterone.	Testosterone	227-239	glycogen synthase kinase 3 beta	Homo sapiens	0-9
27977752-10	2016	Calcineurin-NFAT inhibition abolished and GSK-3beta inhibition promoted the hypertrophy stimulated by testosterone.	Testosterone	102-114	glycogen synthase kinase 3 beta	Homo sapiens	42-51
27977752-11	2016	GSK-3beta activation by GSK-3betaS9A blocked the increase of hypertrophic markers induced by testosterone.	Testosterone	93-105	glycogen synthase kinase 3 beta	Homo sapiens	0-9
27977752-13	2016	Collectively, these results suggest that cardiac myocyte hypertrophy induced by testosterone involves a cooperative mechanism that links androgen signaling with the recruitment of NFAT through calcineurin activation and GSK-3beta inhibition.	Testosterone	80-92	glycogen synthase kinase 3 beta	Homo sapiens	220-229
27835591-7	2016	Treatment with celecoxib also restored GSK3beta function and led to down-regulation of beta-catenin activity through transcriptional and post-translational mechanisms, two effects likely to contribute to Ph+ cell growth suppression by celecoxib.Celecoxib inhibited colony formation of TKI-resistant Ph+ cell lines including those with the T315I BCR-ABL mutation and acted synergistically with imatinib in suppressing colony formation of TKI-sensitive Ph+ cell lines.	Celecoxib	15-24	glycogen synthase kinase 3 beta	Homo sapiens	39-47
27768928-9	2016	The increased protein stabilization of Snail can be attributed to VPA induced phosphorylation of Akt and GSK-3beta.	Valproic Acid	66-69	glycogen synthase kinase 3 beta	Homo sapiens	105-114
27702717-7	2016	CONCLUSIONS: Our results indicate that combining peroral supplementation with Cr and Mg improves IR more effectively than Cr or Mg alone, and this may be attributable to increased induction and repression, respectively, of GLUT4 and GSK3beta expression.	Chromium	78-80	glycogen synthase kinase 3 beta	Homo sapiens	233-241
27702717-7	2016	CONCLUSIONS: Our results indicate that combining peroral supplementation with Cr and Mg improves IR more effectively than Cr or Mg alone, and this may be attributable to increased induction and repression, respectively, of GLUT4 and GSK3beta expression.	Magnesium	85-87	glycogen synthase kinase 3 beta	Homo sapiens	233-241
27929056-4	2016	In this study, we identified NEMO as a GSK-3beta substrate that is phosphorylated at serine 8, 17, 31 and 43 located within its N-terminal domain.	Serine	85-91	glycogen synthase kinase 3 beta	Homo sapiens	39-48
27929056-5	2016	The kinase forms a complex with wild-type NEMO while point mutations of NEMO at the specific serines abrogated GSK-3beta binding and subsequent phosphorylation of NEMO resulting in its destabilization.	Serine	93-100	glycogen synthase kinase 3 beta	Homo sapiens	111-120
27789709-10	2016	MK-2206 also inhibited the phosphor-inactivation of GSK-3beta by CCCP, a result consistent with the ability of Akt to phosphorylate, and thereby suppress GSK-3 activity.	MK 2206	0-7	glycogen synthase kinase 3 beta	Homo sapiens	52-61
27789709-10	2016	MK-2206 also inhibited the phosphor-inactivation of GSK-3beta by CCCP, a result consistent with the ability of Akt to phosphorylate, and thereby suppress GSK-3 activity.	Carbonyl Cyanide m-Chlorophenyl Hydrazone	65-69	glycogen synthase kinase 3 beta	Homo sapiens	52-61
27122541-9	2016	Mechanistically, lithium targets glycogen synthase kinase-3beta, a ubiquitously expressed serine/threonine protein kinase implicated in the processes of tissue injury, repair, and regeneration in multiple organ systems, including the kidney.	Lithium	17-24	glycogen synthase kinase 3 beta	Homo sapiens	33-63
27654922-6	2016	Compared to untreated glioblastoma cells TPEN treatment or expression of ZIP9 results in activation of the tumor suppressor p53 by phosphorylation at serine residue 46 (Ser46) and in inactivation of the migration relevant glycogen synthase kinase 3 beta (GSK-3beta) by phosphorylation at serine residue 9 (Ser9).	N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine	41-45	glycogen synthase kinase 3 beta	Homo sapiens	222-253
27654922-6	2016	Compared to untreated glioblastoma cells TPEN treatment or expression of ZIP9 results in activation of the tumor suppressor p53 by phosphorylation at serine residue 46 (Ser46) and in inactivation of the migration relevant glycogen synthase kinase 3 beta (GSK-3beta) by phosphorylation at serine residue 9 (Ser9).	N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine	41-45	glycogen synthase kinase 3 beta	Homo sapiens	255-264
27815120-5	2016	The binding mode analysis indicates that the activities of the inhibitors appear to be achieved by the establishment of multiple hydrogen bonds and hydrophobic interactions in the ATP-binding site of GSK3beta.	Hydrogen	129-137	glycogen synthase kinase 3 beta	Homo sapiens	200-208
27815120-5	2016	The binding mode analysis indicates that the activities of the inhibitors appear to be achieved by the establishment of multiple hydrogen bonds and hydrophobic interactions in the ATP-binding site of GSK3beta.	Adenosine Triphosphate	180-183	glycogen synthase kinase 3 beta	Homo sapiens	200-208
27768928-10	2016	Collectively, our present study revealed that VPA can promote the EMT of HCC cells via up regulation of Snail through activation of NF-kappaB and Akt/GSK-3beta signals.	Valproic Acid	46-49	glycogen synthase kinase 3 beta	Homo sapiens	150-159
27575008-6	2016	In parallel, GSK-3beta inhibitor increased EdU-positive and Ki67-positive cardiomyocytes, whereas beta-catenin inhibitor decreased EdU-positive and Ki67-positive cardiomyocytes.	5-ethynyl-2'-deoxyuridine	43-46	glycogen synthase kinase 3 beta	Homo sapiens	13-22
27836781-0	2016	Nrf2-mediated liver protection by esculentoside A against acetaminophen toxicity through the AMPK/Akt/GSK3beta pathway.	esculentoside A	34-49	glycogen synthase kinase 3 beta	Homo sapiens	102-110
27575008-6	2016	In parallel, GSK-3beta inhibitor increased EdU-positive and Ki67-positive cardiomyocytes, whereas beta-catenin inhibitor decreased EdU-positive and Ki67-positive cardiomyocytes.	ki67	60-64	glycogen synthase kinase 3 beta	Homo sapiens	13-22
27924507-0	2016	TPPU protects tau from H2O2-induced hyperphosphorylation in HEK293/tau cells by regulating PI3K/AKT/GSK-3beta pathway.	TPPU	0-4	glycogen synthase kinase 3 beta	Homo sapiens	100-109
27924507-0	2016	TPPU protects tau from H2O2-induced hyperphosphorylation in HEK293/tau cells by regulating PI3K/AKT/GSK-3beta pathway.	Hydrogen Peroxide	23-27	glycogen synthase kinase 3 beta	Homo sapiens	100-109
27924507-12	2016	In conclusion, these results suggested that the protective effect of TPPU on H2O2-induced oxidative stress is associated with PI3K/Akt/GSK-3beta pathway.	TPPU	69-73	glycogen synthase kinase 3 beta	Homo sapiens	135-144
27924507-8	2016	H2O2 induced an obvious decreased phosphorylation of GSK-3beta at Ser9, an inactive form of GSK-3beta, while there were no changes of phosphorylation of GSK-3beta at Tyr216.	Hydrogen Peroxide	0-4	glycogen synthase kinase 3 beta	Homo sapiens	53-62
27924507-12	2016	In conclusion, these results suggested that the protective effect of TPPU on H2O2-induced oxidative stress is associated with PI3K/Akt/GSK-3beta pathway.	Hydrogen Peroxide	77-81	glycogen synthase kinase 3 beta	Homo sapiens	135-144
27924507-8	2016	H2O2 induced an obvious decreased phosphorylation of GSK-3beta at Ser9, an inactive form of GSK-3beta, while there were no changes of phosphorylation of GSK-3beta at Tyr216.	Hydrogen Peroxide	0-4	glycogen synthase kinase 3 beta	Homo sapiens	92-101
27924507-8	2016	H2O2 induced an obvious decreased phosphorylation of GSK-3beta at Ser9, an inactive form of GSK-3beta, while there were no changes of phosphorylation of GSK-3beta at Tyr216.	Hydrogen Peroxide	0-4	glycogen synthase kinase 3 beta	Homo sapiens	92-101
27924507-9	2016	TPPU pretreatment maintained GSK-3beta Ser 9 phosphorylation.	TPPU	0-4	glycogen synthase kinase 3 beta	Homo sapiens	29-38
26660108-1	2016	The objective of this study is to elucidate the effect of a new glycogen synthase kinase-3beta (GSK-3beta) inhibitor in RA differentiated SH-SY5Y cells in oxygen and glucose deprivation (OGD) model.	Oxygen	155-161	glycogen synthase kinase 3 beta	Homo sapiens	64-94
26660108-1	2016	The objective of this study is to elucidate the effect of a new glycogen synthase kinase-3beta (GSK-3beta) inhibitor in RA differentiated SH-SY5Y cells in oxygen and glucose deprivation (OGD) model.	Oxygen	155-161	glycogen synthase kinase 3 beta	Homo sapiens	96-105
26660108-8	2016	The standard GSK-3beta inhibitor, AR-A014418 (1 muM), was used for comparison.	N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea	34-44	glycogen synthase kinase 3 beta	Homo sapiens	13-22
26808296-7	2016	Pre-treatment of AGS cells with N-acetylcysteine, a well-known reactive oxygen species (ROS) scavenger, attenuated the H. pylori-induced activation of Erk, its binding to Snail promoter, inactivation of GSK-3beta, and accumulation of Snail.	Acetylcysteine	32-48	glycogen synthase kinase 3 beta	Homo sapiens	203-212
26741501-10	2016	Mechanically, we demonstrated that oroxylin A suppressed activation of ERK instead of AKT pathway and then promoted activation of GSK-3beta to reduce Snail protein content.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	35-45	glycogen synthase kinase 3 beta	Homo sapiens	130-139
26741501-0	2016	Oroxylin A inhibits invasion and migration through suppressing ERK/GSK-3beta signaling in snail-expressing non-small-cell lung cancer cells.	5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one	0-10	glycogen synthase kinase 3 beta	Homo sapiens	67-76
26808296-8	2016	Collectively, these findings suggest that the upregulation of Snail expression induced by H. pylori and transformation to a spindle-like shape as a consequence in gastric cancer cells are attributable to ROS-mediated activation of Erk and the inhibition of GSK-3beta signaling.	Reactive Oxygen Species	204-207	glycogen synthase kinase 3 beta	Homo sapiens	257-266
27800716-11	2016	CONCLUSION: These findings suggest that protective effects of MQA against H2O2-induced apoptosis might be associated with mitochondrial apoptosis, ERK1/2 and AKT/GSK-3beta pathway.	Hydrogen Peroxide	74-78	glycogen synthase kinase 3 beta	Homo sapiens	162-171
27507851-8	2016	Also, the effects of BF on PI3K/AKT/GSK3beta and apoptosis signal cascades were enhanced in APOE knockdown cells.	bufalin	21-23	glycogen synthase kinase 3 beta	Homo sapiens	36-44
28008161-5	2016	Exposure to baicalein led to increased E-cadherin expression, possibly due to the ubiquitination of Snail and Slug, which was mediated by the Cyr61/Akt/glycogen synthase kinase 3beta (GSK3beta) pathway.	baicalein	12-21	glycogen synthase kinase 3 beta	Homo sapiens	152-182
28008161-5	2016	Exposure to baicalein led to increased E-cadherin expression, possibly due to the ubiquitination of Snail and Slug, which was mediated by the Cyr61/Akt/glycogen synthase kinase 3beta (GSK3beta) pathway.	baicalein	12-21	glycogen synthase kinase 3 beta	Homo sapiens	184-192
28008161-6	2016	Further analysis revealed that baicalein inhibited the expression of lysyl oxidase like-2 (LOXL-2), which is a functional collaborator of Snail and Slug, and subsequently attenuated the direct interaction between LOXL-2 and Snail or Slug, thereby enhancing GSK3beta-dependent Snail and Slug degradation.	baicalein	31-40	glycogen synthase kinase 3 beta	Homo sapiens	257-265
27783993-0	2016	WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3beta/beta-catenin signaling pathway.	wm130	0-5	glycogen synthase kinase 3 beta	Homo sapiens	80-88
27608432-8	2016	In conclusion, beta-lactam derivative 19w is a potential anti-breast cancer therapeutic candidate targeting cell survival pathway (AKT/GSK3beta).	beta-Lactams	15-26	glycogen synthase kinase 3 beta	Homo sapiens	135-143
27792996-9	2016	In conclusion, our study demonstrates that miR-101 can reverse TMZ resistance by inhibition of GSK3beta in GBM, thus offer a novel and powerful strategy for GBM therapy.	Temozolomide	63-66	glycogen synthase kinase 3 beta	Homo sapiens	95-103
27783993-9	2016	Further mechanism study revealed that WM130 inhibited AKT/GSK3beta/beta-catenin signaling pathway.	wm130	38-43	glycogen synthase kinase 3 beta	Homo sapiens	58-66
27783993-10	2016	Collectively, our results suggest that WM130 remarkably inhibits hepatic CSCs, and this effect may via the down-regulation of the AKT/GSK3beta/beta-catenin pathway.	wm130	39-44	glycogen synthase kinase 3 beta	Homo sapiens	134-142
27792996-0	2016	MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3beta in glioblastoma.	Temozolomide	22-34	glycogen synthase kinase 3 beta	Homo sapiens	63-71
27792996-6	2016	Instead, over-expression of miR-101 could sensitize resistant GBM cells to TMZ through downregulation of glycogen synthase kinase 3beta (GSK3beta).	mir-101	28-35	glycogen synthase kinase 3 beta	Homo sapiens	105-135
27792996-6	2016	Instead, over-expression of miR-101 could sensitize resistant GBM cells to TMZ through downregulation of glycogen synthase kinase 3beta (GSK3beta).	mir-101	28-35	glycogen synthase kinase 3 beta	Homo sapiens	137-145
27792996-6	2016	Instead, over-expression of miR-101 could sensitize resistant GBM cells to TMZ through downregulation of glycogen synthase kinase 3beta (GSK3beta).	Temozolomide	75-78	glycogen synthase kinase 3 beta	Homo sapiens	105-135
27792996-6	2016	Instead, over-expression of miR-101 could sensitize resistant GBM cells to TMZ through downregulation of glycogen synthase kinase 3beta (GSK3beta).	Temozolomide	75-78	glycogen synthase kinase 3 beta	Homo sapiens	137-145
27792996-9	2016	In conclusion, our study demonstrates that miR-101 can reverse TMZ resistance by inhibition of GSK3beta in GBM, thus offer a novel and powerful strategy for GBM therapy.	mir-101	43-50	glycogen synthase kinase 3 beta	Homo sapiens	95-103
27909397-0	2016	Novel Non-phosphorylated Serine 9/21 GSK3beta/alpha Antibodies: Expanding the Tools for Studying GSK3 Regulation.	Serine	25-31	glycogen synthase kinase 3 beta	Homo sapiens	37-45
27909397-2	2016	A primary mechanism of GSK3 activity regulation is phosphorylation of N-terminal serine (S) residues (S9 in GSK3beta, S21 in GSK3alpha).	Serine	81-87	glycogen synthase kinase 3 beta	Homo sapiens	108-116
27909397-11	2016	The ability to use the same reagent across biochemical, immunohistological and kinase activity assays provides a powerful approach for studying serine-dependent regulation of GSK3beta/alpha.	Serine	144-150	glycogen synthase kinase 3 beta	Homo sapiens	175-183
27638589-2	2016	The toxic substrate that accumulates in this disease, psychosine, induces alterations in membrane lipid rafts with downstream consequences to cellular signaling pathways that include impaired protein kinase C, ERK, and AKT-glycogen synthase kinase-3beta (GSK3beta) activation.	Psychosine	54-64	glycogen synthase kinase 3 beta	Homo sapiens	255-263
27640746-8	2016	In addition, 5GTN enhanced glycogen synthase kinase (GSK-3beta) activity and therefore reduced the expression of active form of beta-catenin protein in MCF-7 and MDA-MB-231 cells.	5-acetyl goniothalamin	13-17	glycogen synthase kinase 3 beta	Homo sapiens	53-62
27523474-0	2016	MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3beta signaling pathway.	Doxorubicin	70-80	glycogen synthase kinase 3 beta	Homo sapiens	98-106
27799526-4	2016	Prodigiosin blocked Wnt/beta-catenin signaling by targeting multiple sites of this pathway, including the low-density lipoprotein-receptor-related protein (LRP) 6, Dishevelled (DVL), and glycogen synthase kinase-3beta (GSK3beta).	Prodigiosin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	187-217
27799526-4	2016	Prodigiosin blocked Wnt/beta-catenin signaling by targeting multiple sites of this pathway, including the low-density lipoprotein-receptor-related protein (LRP) 6, Dishevelled (DVL), and glycogen synthase kinase-3beta (GSK3beta).	Prodigiosin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	219-227
27799526-5	2016	In breast cancer MDA-MB-231 and MDA-MB-468 cells, nanomolar concentrations of prodigiosin decreased phosphorylation of LRP6, DVL2, and GSK3beta and suppressed beta-catenin-stimulated Wnt target gene expression, including expression of cyclin D1.	Prodigiosin	78-89	glycogen synthase kinase 3 beta	Homo sapiens	135-143
27412172-8	2016	We also found that MG treatment markedly decreased the expression and phosphorylation of C/EBPbeta, by phosphorylating, and therefore inactivating, GSK3beta, which is a prerequisite for its DNA binding capacity, and thereby mitotic clonal expansion (MCE).	methyl gallate	19-21	glycogen synthase kinase 3 beta	Homo sapiens	148-156
27669172-0	2016	UNC119 mediates gambogic acid-induced cell-cycle dysregulation through the Gsk3beta/beta-catenin pathway in hepatocellular carcinoma cells.	gambogic acid	16-29	glycogen synthase kinase 3 beta	Homo sapiens	75-83
27669172-8	2016	UNC119 knockdown or over expression experiment further proved that UNC119 mediated the effect of GA on the HCC cell cycle and Gsk3beta/beta-catenin signaling.	gambogic acid	97-99	glycogen synthase kinase 3 beta	Homo sapiens	126-134
27526674-0	2016	HGF alleviates high glucose-induced injury in podocytes by GSK3beta inhibition and autophagy restoration.	Glucose	20-27	glycogen synthase kinase 3 beta	Homo sapiens	59-67
27599658-0	2016	GSK-3beta-mediated fatty acid synthesis enhances epithelial to mesenchymal transition of TLR4-activated colorectal cancer cells through regulation of TAp63.	Fatty Acids	19-29	glycogen synthase kinase 3 beta	Homo sapiens	0-9
27599658-3	2016	We investigated the role of GSK-3beta-mediated intracellular fatty acid synthesis to control EMT in TLR4-activated colorectal cancer cells and the underlying regulatory mechanism.	Fatty Acids	61-71	glycogen synthase kinase 3 beta	Homo sapiens	28-37
27599658-5	2016	In addition, targeted inhibition of GSK-3beta using SB216763 was accompanied by decreased intracellular fatty acid synthesis and blockage of CD74 and CD44 expression, whereas it reversed the level of TAp63.	Fatty Acids	104-114	glycogen synthase kinase 3 beta	Homo sapiens	36-45
27599658-8	2016	These results suggest that TAp63-mediated GSK-3beta activation induced by TLR4 stimulation triggers migration and invasion of colon cancer cells through the regulation of lipid synthesis and GSK-3beta-mediated CD74/CD44 expression could be a target to control fatty acid-related EMT process through the modulation of TAp63 expression.	Fatty Acids	260-270	glycogen synthase kinase 3 beta	Homo sapiens	42-51
27743890-0	2016	Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3beta phosphorylation.	Simvastatin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	125-134
27743890-9	2016	Simvastatin also decreased phosphorylation of insulin receptor (IR), insulin receptor substrate 1 (IRS-1), AKT and glycogen synthase kinase 3beta (GSK-3beta), and downregulated GLUT4.	Simvastatin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	115-145
27743890-9	2016	Simvastatin also decreased phosphorylation of insulin receptor (IR), insulin receptor substrate 1 (IRS-1), AKT and glycogen synthase kinase 3beta (GSK-3beta), and downregulated GLUT4.	Simvastatin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	147-156
29441966-12	2016	In conclusion, CHIR99021 protected LO2 cells against H2O2-induced oxidative injury through reducing GSK-3beta activity and apoptosis, with underlying mechanisms involved in stabilizing mitochondrial membrane potential, attenuating cellular ROS generation, suppressing mitochondria-mediated apoptotic pathway, and activation of GSK-3beta/beta-catenin signaling pathway.	Hydrogen Peroxide	53-57	glycogen synthase kinase 3 beta	Homo sapiens	100-109
29441966-12	2016	In conclusion, CHIR99021 protected LO2 cells against H2O2-induced oxidative injury through reducing GSK-3beta activity and apoptosis, with underlying mechanisms involved in stabilizing mitochondrial membrane potential, attenuating cellular ROS generation, suppressing mitochondria-mediated apoptotic pathway, and activation of GSK-3beta/beta-catenin signaling pathway.	Hydrogen Peroxide	53-57	glycogen synthase kinase 3 beta	Homo sapiens	327-336
27793908-3	2016	AZD5363-sensitized Hs578T breast cancer cells displayed reduced levels of phosphorylated glycogen synthase kinase 3 beta (pGSK3beta).	capivasertib	0-7	glycogen synthase kinase 3 beta	Homo sapiens	89-120
27418236-7	2016	Additionally, it activates adenylate cyclase resulting in cAMP formation which in turn activates protein kinase A leading to inhibition of GSK-3beta by phosphorylation.	Cyclic AMP	58-62	glycogen synthase kinase 3 beta	Homo sapiens	139-148
27418236-9	2016	CONCLUSIONS: Thus, andrographolide probably by binding to adenosine A2a receptor activates Nrf-2 transcription and also inhibits its exclusion from the nucleus by inactivating GSK-3beta, together resulting in activation of HO-1.	andrographolide	19-34	glycogen synthase kinase 3 beta	Homo sapiens	176-185
27338284-4	2016	The decreased expressions of p-beta-catenin(Ser552), p-GSK3beta(S9) and beta-catenin target genes were detected in SGC-7901 cells after treated by EGCG.	epigallocatechin gallate	147-151	glycogen synthase kinase 3 beta	Homo sapiens	55-63
27708248-6	2016	Activation of ATM/AKT/GSK-3beta signaling also increased nuclear accumulation of nuclear factor erythroid 2-related factor 2, leading to increased expression of antioxidants, which mitigated cellular damage from excessive reactive oxygen species production induced by high-dose radiation.	Reactive Oxygen Species	222-245	glycogen synthase kinase 3 beta	Homo sapiens	22-31
26387984-9	2016	Wogonoside (100 microM) decreases the intracellular level of Wnt3a, increases the expression of GSK-3beta, AXIN, and promotes the phosphorylation of beta-catenin for proteasome degradation significantly.	wogonoside	0-10	glycogen synthase kinase 3 beta	Homo sapiens	96-105
27779188-7	2016	Furthermore, simvastatin suppressed BCa cell metastasis by inhibiting EMT and affecting AKT/GSK3beta.	Simvastatin	13-24	glycogen synthase kinase 3 beta	Homo sapiens	92-100
27796348-8	2016	In addition, the exposure of HepG2 cells to high glucose concentrations impaired the insulin-stimulated phosphorylation of Akt2 Ser474 and insulin receptor substrate-1 (IRS-1) Ser612, increased GSK-3beta phosphorylation, and upregulated G6Pase and PEPCK expression.	Glucose	49-56	glycogen synthase kinase 3 beta	Homo sapiens	194-203
27611941-7	2016	The NTS-induced EMT was correlated with the remarkable increase in Wnt1, Wnt3, Wnt5, Axin, and p-GSK3beta expression and was significantly reversed by blocking the NTS signaling via the NTR1 antagonist SR48692 or by inhibiting the activation of the Wnt/beta-catenin pathway via specific inhibitors, such as TSW119 and DKK-1.	SR 48692	202-209	glycogen synthase kinase 3 beta	Homo sapiens	97-105
27801816-0	2016	Marine Fungi as Producers of Benzocoumarins, a New Class of Inhibitors of Glycogen-Synthase-Kinase 3beta.	benzocoumarins	29-43	glycogen synthase kinase 3 beta	Homo sapiens	74-104
27801816-4	2016	Here we report pannorin (1), alternariol (2), and alternariol-9-methylether (3) to be promising inhibitors of the isoform GSK-3beta showing sub-muM IC50 values.	alternariol	29-40	glycogen synthase kinase 3 beta	Homo sapiens	122-131
27801816-4	2016	Here we report pannorin (1), alternariol (2), and alternariol-9-methylether (3) to be promising inhibitors of the isoform GSK-3beta showing sub-muM IC50 values.	alternariol monomethyl ether	50-75	glycogen synthase kinase 3 beta	Homo sapiens	122-131
27801816-5	2016	The in vitro inhibition is in the range of the known highly active GSK-3beta inhibitor TDZD-8.	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	87-93	glycogen synthase kinase 3 beta	Homo sapiens	67-76
27801816-6	2016	Compounds 1-3 have a highly oxygenated benzocoumarin core structure in common, which suggests that this may be a new structural feature for efficient GSK-3beta inhibition.	3-phenyl-5,6-benzocoumarin	39-52	glycogen synthase kinase 3 beta	Homo sapiens	150-159
27454617-0	2016	Synthesis of pyrimidin-4-one-1,2,3-triazole conjugates as glycogen synthase kinase-3beta inhibitors with anti-depressant activity.	pyrimidin-4-one-1,2,3-triazole	13-43	glycogen synthase kinase 3 beta	Homo sapiens	58-88
27602497-6	2016	At a later time, however, TZD alone and TRAIL-TZD combination produced a dramatic reduction of GSK3beta expression, which was abolished by cycloheximide.	tzd	26-29	glycogen synthase kinase 3 beta	Homo sapiens	95-103
27602497-6	2016	At a later time, however, TZD alone and TRAIL-TZD combination produced a dramatic reduction of GSK3beta expression, which was abolished by cycloheximide.	tzd	46-49	glycogen synthase kinase 3 beta	Homo sapiens	95-103
27602497-6	2016	At a later time, however, TZD alone and TRAIL-TZD combination produced a dramatic reduction of GSK3beta expression, which was abolished by cycloheximide.	Cycloheximide	139-152	glycogen synthase kinase 3 beta	Homo sapiens	95-103
27602497-8	2016	Since TZD is a ligand for transcription factor PPARgamma and can activate AMPK, we determined their roles on antagonism of GSK3beta.	tzd	6-9	glycogen synthase kinase 3 beta	Homo sapiens	123-131
27602497-11	2016	These studies suggested a novel PPARgamma-AMPK-independent mechanism of targeting GSK3beta by TZD, elucidation of which might provide newer insights to improve our understanding of TRAIL-resistance.	tzd	94-97	glycogen synthase kinase 3 beta	Homo sapiens	82-90
27713506-3	2016	We provide evidence that PAK1 confers cisplatin resistance by increasing beta-catenin expression through ERK/GSK3beta signaling.	Cisplatin	38-47	glycogen synthase kinase 3 beta	Homo sapiens	109-117
27423119-0	2016	Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3beta inhibitors.	5-benzylidene-2-iminothiazolidin-4-ones	47-86	glycogen synthase kinase 3 beta	Homo sapiens	100-109
27423119-1	2016	In this work, iminothiazolidin-4-one derivatives were explored as selective GSK-3beta inhibitors.	iminothiazolidin-4-one	14-36	glycogen synthase kinase 3 beta	Homo sapiens	76-85
27592552-5	2016	In addition, MG treatment led to phosphorylation of GSK3beta, which is one of beta-catenin-degrading enzymes.	methyl gallate	13-15	glycogen synthase kinase 3 beta	Homo sapiens	52-60
27454617-2	2016	We have synthesized a library of pyrimidin-4-one-1,2,3-triazole conjugates using click-chemistry approach and evaluated them as glycogen synthase kinase-3beta inhibitors.	pyrimidin-4-one-1,2,3-triazole	33-63	glycogen synthase kinase 3 beta	Homo sapiens	128-158
27454617-4	2016	Compound 3n (2-((1-(3,4-dimethylphenyl)-1H-1,2,3-triazol-4-yl)methylthio)-3-methyl-6-phenylpyrimidin-4(3H)-one) exhibited the most potent inhibitory activity against GSK-3beta with IC50 value of 82nM and was also found to exhibit significant antidepressant activity at 50mg/kg, when compared with fluoxetine, a known antidepressant drug.	2-((1-(3,4-dimethylphenyl)-1h-1,2,3-triazol-4-yl)methylthio	13-72	glycogen synthase kinase 3 beta	Homo sapiens	166-175
27454617-4	2016	Compound 3n (2-((1-(3,4-dimethylphenyl)-1H-1,2,3-triazol-4-yl)methylthio)-3-methyl-6-phenylpyrimidin-4(3H)-one) exhibited the most potent inhibitory activity against GSK-3beta with IC50 value of 82nM and was also found to exhibit significant antidepressant activity at 50mg/kg, when compared with fluoxetine, a known antidepressant drug.	6-phenylpyrimidin-4-ol	83-110	glycogen synthase kinase 3 beta	Homo sapiens	166-175
27454617-5	2016	The molecular docking studies were performed to elucidate the binding modes of the compounds with the GSK-3beta target and two crucial interactions namely, hydrogen bond formation with Val 135 and Lys 183 residues in the active site of GSK-3beta were observed.	Hydrogen	156-164	glycogen synthase kinase 3 beta	Homo sapiens	236-245
27454617-5	2016	The molecular docking studies were performed to elucidate the binding modes of the compounds with the GSK-3beta target and two crucial interactions namely, hydrogen bond formation with Val 135 and Lys 183 residues in the active site of GSK-3beta were observed.	Valine	185-188	glycogen synthase kinase 3 beta	Homo sapiens	102-111
27454617-5	2016	The molecular docking studies were performed to elucidate the binding modes of the compounds with the GSK-3beta target and two crucial interactions namely, hydrogen bond formation with Val 135 and Lys 183 residues in the active site of GSK-3beta were observed.	Valine	185-188	glycogen synthase kinase 3 beta	Homo sapiens	236-245
27454617-5	2016	The molecular docking studies were performed to elucidate the binding modes of the compounds with the GSK-3beta target and two crucial interactions namely, hydrogen bond formation with Val 135 and Lys 183 residues in the active site of GSK-3beta were observed.	Lysine	197-200	glycogen synthase kinase 3 beta	Homo sapiens	102-111
26399745-7	2016	ALA suppressed the PERK/eIF2alpha signaling, which may be responsible for multifaceted memory-deteriorating and neurodegenerative mechanisms, including inhibition of Abeta production by suppressing beta-site APP-cleaving enzyme 1 (BACE1) expression, enhancement of cAMP response element binding protein (CREB) function via down-regulating activating transcription factor 4 (ATF4), and suppression of Tau phosphorylation by inhibiting glycogen synthase kinase 3beta (GSK-3beta) pathway.	alpha-Linolenic Acid	0-3	glycogen synthase kinase 3 beta	Homo sapiens	434-464
27454617-5	2016	The molecular docking studies were performed to elucidate the binding modes of the compounds with the GSK-3beta target and two crucial interactions namely, hydrogen bond formation with Val 135 and Lys 183 residues in the active site of GSK-3beta were observed.	Lysine	197-200	glycogen synthase kinase 3 beta	Homo sapiens	236-245
26399745-7	2016	ALA suppressed the PERK/eIF2alpha signaling, which may be responsible for multifaceted memory-deteriorating and neurodegenerative mechanisms, including inhibition of Abeta production by suppressing beta-site APP-cleaving enzyme 1 (BACE1) expression, enhancement of cAMP response element binding protein (CREB) function via down-regulating activating transcription factor 4 (ATF4), and suppression of Tau phosphorylation by inhibiting glycogen synthase kinase 3beta (GSK-3beta) pathway.	alpha-Linolenic Acid	0-3	glycogen synthase kinase 3 beta	Homo sapiens	466-475
27268575-8	2016	The results collectively suggested that once oysters were exposed to air, the synthesis of proinflammatory cytokines CgIL17-1 and CgIL17-5 was induced by the up-regulated glucose concentration in oyster serum, which would be not only a negative feedback to the high glucose concentration through mediating the regulation of GSK3beta, but also an inducer on tissue damage and immunocompetence as well as the adaptability to stresses.	Glucose	171-178	glycogen synthase kinase 3 beta	Homo sapiens	324-332
27567443-5	2016	In addition, Zn deficient cells significantly triggered intracellular ROS level and develop oxidative stress induced DNA damage; it was confirmed by elevated expression of CYP1A, GPX, GSK3beta and TNF-alpha gene.	Zinc	13-15	glycogen synthase kinase 3 beta	Homo sapiens	184-192
27580020-4	2016	Furthermore, phosphorylation of protein kinase B (AKT) and glycogen synthase kinase-3beta (GSK3beta) in model cells was recovered after treated with MAE, leading to an up-regulation of glycogen synthase 2 (GYS2), and this effect was blocked by the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	295-303	glycogen synthase kinase 3 beta	Homo sapiens	59-89
27580020-4	2016	Furthermore, phosphorylation of protein kinase B (AKT) and glycogen synthase kinase-3beta (GSK3beta) in model cells was recovered after treated with MAE, leading to an up-regulation of glycogen synthase 2 (GYS2), and this effect was blocked by the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	295-303	glycogen synthase kinase 3 beta	Homo sapiens	91-99
27534430-9	2016	Presently, we found that incubation of HAECs with excess nutrients (25 mM glucose and 0.4 mM palmitate) increased GSK3beta activity and impaired lysosome acidification.	Glucose	74-81	glycogen synthase kinase 3 beta	Homo sapiens	114-122
27470495-6	2016	The mechanism for the increase in glucose uptake was an increase in adenosine-5"-monophosphate kinase and protein kinase B activity and decreased glycogen synthase kinase 3 beta activity.	Glucose	34-41	glycogen synthase kinase 3 beta	Homo sapiens	146-177
27305963-1	2016	Glycogen synthase kinase-3beta (GSK-3beta) is a serine/threonine kinase which has attracted significant attention during recent years in drug design studies.	Serine	48-54	glycogen synthase kinase 3 beta	Homo sapiens	0-30
27497993-6	2016	It has been found that a GSK3beta inhibitor weakened the damaging effects of PHE and PHA in each of the performed assays.	phenoxyethanol	77-80	glycogen synthase kinase 3 beta	Homo sapiens	25-33
27432879-5	2016	AREG maintained the Treg cell suppressive function via the EGFR/GSK-3beta/Foxp3 axis in vitro and in vivo Furthermore, inhibition of EGFR by the tyrosine kinase inhibitor gefitinib restored the activity of GSK-3beta and attenuated Treg cell function.	Gefitinib	171-180	glycogen synthase kinase 3 beta	Homo sapiens	64-73
27432879-5	2016	AREG maintained the Treg cell suppressive function via the EGFR/GSK-3beta/Foxp3 axis in vitro and in vivo Furthermore, inhibition of EGFR by the tyrosine kinase inhibitor gefitinib restored the activity of GSK-3beta and attenuated Treg cell function.	Gefitinib	171-180	glycogen synthase kinase 3 beta	Homo sapiens	206-215
27349166-4	2016	Additional studies indicated that CA1P induced microtubule depolymerization-mediated AKT inactivation, which resulted in GSK-3beta activation, Wnt/beta-Catenin pathway inhibition, and Mcl-1 down-regulation.	Oxi 4503	34-38	glycogen synthase kinase 3 beta	Homo sapiens	121-130
27349166-5	2016	The induction of HepG2 cell apoptosis by CA1P was prevented by a GSK-3beta-specific inhibitor.	Oxi 4503	41-45	glycogen synthase kinase 3 beta	Homo sapiens	65-74
27534430-9	2016	Presently, we found that incubation of HAECs with excess nutrients (25 mM glucose and 0.4 mM palmitate) increased GSK3beta activity and impaired lysosome acidification.	Palmitates	93-102	glycogen synthase kinase 3 beta	Homo sapiens	114-122
27270654-14	2016	Treatment with FASN inhibitor C75 and COX-2 inhibitor celecoxib individually decreased the number of lipid bodies/cell, downregulated phosphorylation of ERK, GSK3beta, and induced apoptosis by caspase-3/7 and caspase-9 activation.	Celecoxib	54-63	glycogen synthase kinase 3 beta	Homo sapiens	158-166
27484798-6	2016	Its interaction with GSK3beta facilitates control of the destabilizing phosphorylation of beta-catenin at Ser-33/Ser-37/Thr-41.	Serine	106-109	glycogen synthase kinase 3 beta	Homo sapiens	21-29
27423393-6	2016	Additionally, free fatty acids (FFAs) could increase ROS and suppress insulin signaling pathway, which was indicated by reduced phosphorylation of protein kinase B (AKT) and glycogen synthase kinase 3beta (GSK-3beta).	Fatty Acids, Nonesterified	14-30	glycogen synthase kinase 3 beta	Homo sapiens	174-204
27423393-6	2016	Additionally, free fatty acids (FFAs) could increase ROS and suppress insulin signaling pathway, which was indicated by reduced phosphorylation of protein kinase B (AKT) and glycogen synthase kinase 3beta (GSK-3beta).	Fatty Acids, Nonesterified	14-30	glycogen synthase kinase 3 beta	Homo sapiens	206-215
27423393-6	2016	Additionally, free fatty acids (FFAs) could increase ROS and suppress insulin signaling pathway, which was indicated by reduced phosphorylation of protein kinase B (AKT) and glycogen synthase kinase 3beta (GSK-3beta).	Reactive Oxygen Species	53-56	glycogen synthase kinase 3 beta	Homo sapiens	206-215
27484798-6	2016	Its interaction with GSK3beta facilitates control of the destabilizing phosphorylation of beta-catenin at Ser-33/Ser-37/Thr-41.	Serine	113-116	glycogen synthase kinase 3 beta	Homo sapiens	21-29
27484798-6	2016	Its interaction with GSK3beta facilitates control of the destabilizing phosphorylation of beta-catenin at Ser-33/Ser-37/Thr-41.	Threonine	120-123	glycogen synthase kinase 3 beta	Homo sapiens	21-29
27618015-13	2016	However, the abnormal rise of apoptosis at 30 mM of LiCl concentration implies that it might be the reduction of GSK3beta that increased cell apoptosis.	Lithium Chloride	52-56	glycogen synthase kinase 3 beta	Homo sapiens	113-121
27416292-8	2016	Specially, lapatinib activated both the c-Myc/pro-Nrf2 pathway and GSK-3beta signaling to stabilize Nrf2 and maintain a low level of ROS in resistant cells.	Lapatinib	11-20	glycogen synthase kinase 3 beta	Homo sapiens	67-76
27363340-0	2016	miR-199b-5p modulates BMSC osteogenesis via suppressing GSK-3beta/beta-catenin signaling pathway.	mir-199b-5p	0-11	glycogen synthase kinase 3 beta	Homo sapiens	56-65
27363340-3	2016	miR-199b-5p exerts its role in BMSC osteogenesis most probably through the GSK-3beta/beta-catenin signaling pathway.	-199b-5p	3-11	glycogen synthase kinase 3 beta	Homo sapiens	75-84
27320862-5	2016	SNU-368 CD44(+) cells showed EMT through up-regulation of the AKT/GSK-3beta/beta-catenin pathway.	4-(1H-Pyrrol-1-yl)aniline	0-3	glycogen synthase kinase 3 beta	Homo sapiens	66-75
27320862-9	2016	SB431542-treated SNU-368 (CD44/TGF-beta1(-)) cells also showed diminished N-cadherin and AKT/GSK-3beta/beta-catenin pathway activity and further decreased cell motility in a wound healing assay.	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	0-8	glycogen synthase kinase 3 beta	Homo sapiens	93-102
27320862-9	2016	SB431542-treated SNU-368 (CD44/TGF-beta1(-)) cells also showed diminished N-cadherin and AKT/GSK-3beta/beta-catenin pathway activity and further decreased cell motility in a wound healing assay.	4-(1H-Pyrrol-1-yl)aniline	17-20	glycogen synthase kinase 3 beta	Homo sapiens	93-102
27416292-8	2016	Specially, lapatinib activated both the c-Myc/pro-Nrf2 pathway and GSK-3beta signaling to stabilize Nrf2 and maintain a low level of ROS in resistant cells.	ros	133-136	glycogen synthase kinase 3 beta	Homo sapiens	67-76
27581969-9	2016	Moreover, inhibiting SPHK-1 with a sphingosine kinase inhibitor enhanced the suppression of HIF-1alpha, phosphorylation AKT, and glycogen synthase kinase-3beta (GSK-3beta) by pristimerin under hypoxia.	pristimerin	175-186	glycogen synthase kinase 3 beta	Homo sapiens	129-159
27378570-11	2016	These data are the first to demonstrate that GYY4137 protects the heart against lethal reperfusion injury through activation of PI3K/Akt signalling, with partial dependency on NO signalling and inhibition of GSK-3beta during early reperfusion.	GYY 4137	45-52	glycogen synthase kinase 3 beta	Homo sapiens	208-217
27490211-13	2016	Anti-GSK3 beta, pGSK3 beta, Bcl-2, Akt-1, p-Akt1 protein levels were observed with cells exposed to Tideglusib and Lithium chloride.	Lithium Chloride	115-131	glycogen synthase kinase 3 beta	Homo sapiens	5-14
27424123-9	2016	Inhibition of ERK1/2 by PD98059, JNK by SP600125 or GSK3beta by LiCl suppressed cyclin D1 phosphorylation and downregulation by kahweol.	kahweol	128-135	glycogen synthase kinase 3 beta	Homo sapiens	52-60
27378570-10	2016	LY294002 totally abrogated the infarct-limiting effect of GYY4137 and inhibited Akt, eNOS and GSK-3beta phosphorylation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	glycogen synthase kinase 3 beta	Homo sapiens	94-103
27323966-7	2016	We then test protein expression of p-GSK3beta(Ser-9), the downstream protein of PI3K/AKT, which was significantly decreased under the circumstance of GKN2 overexpression.	Serine	46-49	glycogen synthase kinase 3 beta	Homo sapiens	37-45
27581969-9	2016	Moreover, inhibiting SPHK-1 with a sphingosine kinase inhibitor enhanced the suppression of HIF-1alpha, phosphorylation AKT, and glycogen synthase kinase-3beta (GSK-3beta) by pristimerin under hypoxia.	pristimerin	175-186	glycogen synthase kinase 3 beta	Homo sapiens	161-170
27406796-0	2016	Synthesis of benzimidazole based thiadiazole and carbohydrazide conjugates as glycogen synthase kinase-3beta inhibitors with anti-depressant activity.	benzimidazole	13-26	glycogen synthase kinase 3 beta	Homo sapiens	78-108
27409422-11	2016	In addition, 14-3-3zeta and aPKC-iota pretreatment by si-RNA inhibit the phosphorylated GSK-3beta and Snail expression during EMT.	iota	33-37	glycogen synthase kinase 3 beta	Homo sapiens	88-97
27409422-13	2016	Our study demonstrates that 14-3-3zeta and aPKC-iota synergistically facilitate EMT of CCA via GSK-3beta/Snail signalling pathway, and may be potential therapeutic target for CCA.	iota	48-52	glycogen synthase kinase 3 beta	Homo sapiens	95-104
27579985-4	2016	Both, ethyl pyruvate and ethyl lactate were identified as new inhibitors of GSK-3beta.	ethyl pyruvate	6-20	glycogen synthase kinase 3 beta	Homo sapiens	76-85
27579985-4	2016	Both, ethyl pyruvate and ethyl lactate were identified as new inhibitors of GSK-3beta.	ethyl lactate	25-38	glycogen synthase kinase 3 beta	Homo sapiens	76-85
27406796-0	2016	Synthesis of benzimidazole based thiadiazole and carbohydrazide conjugates as glycogen synthase kinase-3beta inhibitors with anti-depressant activity.	Thiadiazoles	33-44	glycogen synthase kinase 3 beta	Homo sapiens	78-108
27406796-0	2016	Synthesis of benzimidazole based thiadiazole and carbohydrazide conjugates as glycogen synthase kinase-3beta inhibitors with anti-depressant activity.	carbohydrazide	49-63	glycogen synthase kinase 3 beta	Homo sapiens	78-108
27406796-1	2016	A series of benzimidazole based thiadiazole and carbohydrazide conjugates have been synthesized and evaluated for inhibition of glycogen synthase kinase-3beta and anti-depressant effect.	benzimidazole	12-25	glycogen synthase kinase 3 beta	Homo sapiens	128-158
27406796-1	2016	A series of benzimidazole based thiadiazole and carbohydrazide conjugates have been synthesized and evaluated for inhibition of glycogen synthase kinase-3beta and anti-depressant effect.	Thiadiazoles	32-43	glycogen synthase kinase 3 beta	Homo sapiens	128-158
27406796-1	2016	A series of benzimidazole based thiadiazole and carbohydrazide conjugates have been synthesized and evaluated for inhibition of glycogen synthase kinase-3beta and anti-depressant effect.	carbohydrazide	48-62	glycogen synthase kinase 3 beta	Homo sapiens	128-158
27406796-2	2016	Compounds 4f, 4j, 5b, 5g and 5i were found to be the most potent inhibitors of GSK-3beta in vitro amongst the twenty-five benzimidazole based thiadiazole and carbohydrazide conjugates synthesized.	benzimidazole	122-135	glycogen synthase kinase 3 beta	Homo sapiens	79-88
27406796-2	2016	Compounds 4f, 4j, 5b, 5g and 5i were found to be the most potent inhibitors of GSK-3beta in vitro amongst the twenty-five benzimidazole based thiadiazole and carbohydrazide conjugates synthesized.	Thiadiazoles	142-153	glycogen synthase kinase 3 beta	Homo sapiens	79-88
27406796-2	2016	Compounds 4f, 4j, 5b, 5g and 5i were found to be the most potent inhibitors of GSK-3beta in vitro amongst the twenty-five benzimidazole based thiadiazole and carbohydrazide conjugates synthesized.	carbohydrazide	158-172	glycogen synthase kinase 3 beta	Homo sapiens	79-88
27406796-4	2016	The molecular docking studies revealed multiple hydrogen bond interactions by the synthesized compounds with various amino acid residues, viz, ASP-133, LYS-183, PRO-136, VAL-135, TYR-134, or LYS-60 at the GSK-3beta receptor site.	Hydrogen	48-56	glycogen synthase kinase 3 beta	Homo sapiens	205-214
27406796-4	2016	The molecular docking studies revealed multiple hydrogen bond interactions by the synthesized compounds with various amino acid residues, viz, ASP-133, LYS-183, PRO-136, VAL-135, TYR-134, or LYS-60 at the GSK-3beta receptor site.	Lysine	191-194	glycogen synthase kinase 3 beta	Homo sapiens	205-214
26346882-3	2016	This study was aimed to assess whether agmatine prevents 6-OHDA-induced SH-SY5Y cell death and if yes, then how it affects Akt/glycogen synthesis kinase-3beta (GSK-3beta) and extracellular signal-regulated kinases (ERK) signals.	Agmatine	39-47	glycogen synthase kinase 3 beta	Homo sapiens	160-169
27233608-6	2016	URM-II-81 also alleviated MGO mediated diminished distal insulin signaling by increasing protein kinase B (PKB) and glycogen synthase kinase 3-beta (GSK-3-beta) phosphorylation.	urm-ii-81	0-9	glycogen synthase kinase 3 beta	Homo sapiens	116-147
27233608-6	2016	URM-II-81 also alleviated MGO mediated diminished distal insulin signaling by increasing protein kinase B (PKB) and glycogen synthase kinase 3-beta (GSK-3-beta) phosphorylation.	urm-ii-81	0-9	glycogen synthase kinase 3 beta	Homo sapiens	149-159
27233608-6	2016	URM-II-81 also alleviated MGO mediated diminished distal insulin signaling by increasing protein kinase B (PKB) and glycogen synthase kinase 3-beta (GSK-3-beta) phosphorylation.	Pyruvaldehyde	26-29	glycogen synthase kinase 3 beta	Homo sapiens	116-147
27233608-6	2016	URM-II-81 also alleviated MGO mediated diminished distal insulin signaling by increasing protein kinase B (PKB) and glycogen synthase kinase 3-beta (GSK-3-beta) phosphorylation.	Pyruvaldehyde	26-29	glycogen synthase kinase 3 beta	Homo sapiens	149-159
27313176-8	2016	PAR2 but not PAR1 triggered GSK3beta activation through serine-9 dephosphorylation in normal and tumor cells.	Serine	56-62	glycogen synthase kinase 3 beta	Homo sapiens	28-36
27470348-10	2016	LiCl, a potent GSK-3beta inhibitor, can obviously reverse EGF induced up regulation of p65 phosphorylation.	Lithium Chloride	0-4	glycogen synthase kinase 3 beta	Homo sapiens	15-24
26346882-7	2016	6-OHDA also decreased the amount of phosphorylated Akt (pAkt)/Akt while increased GSK-3beta activity which was prevented by agmatine.	Oxidopamine	0-6	glycogen synthase kinase 3 beta	Homo sapiens	82-91
26346882-7	2016	6-OHDA also decreased the amount of phosphorylated Akt (pAkt)/Akt while increased GSK-3beta activity which was prevented by agmatine.	Agmatine	124-132	glycogen synthase kinase 3 beta	Homo sapiens	82-91
27525972-7	2016	Moreover, 3MCIC caused GSK3beta degradation by promoting GSK3beta-Ser9 phosphorylation.	3mcic	10-15	glycogen synthase kinase 3 beta	Homo sapiens	23-31
27525972-7	2016	Moreover, 3MCIC caused GSK3beta degradation by promoting GSK3beta-Ser9 phosphorylation.	3mcic	10-15	glycogen synthase kinase 3 beta	Homo sapiens	57-65
27295130-6	2016	In conclusion, zinc might enhance glucose consumption by modulating insulin signaling pathways including Akt-GLUT4, GSK3beta, mTOR and S6K1.	Glucose	34-41	glycogen synthase kinase 3 beta	Homo sapiens	116-124
26346882-10	2016	This study revealed that agmatine is protective in 6-OHDA model of PD and affects Akt/GSK-3beta and ERK pathways.	Agmatine	25-33	glycogen synthase kinase 3 beta	Homo sapiens	86-95
27262235-6	2016	Further, a GRP78 inhibitor, VER155008 inhibited TAM-induced phosphorylation of GSK3beta, a downstream substrate of AKT.	VER 155008	28-37	glycogen synthase kinase 3 beta	Homo sapiens	79-87
27262235-6	2016	Further, a GRP78 inhibitor, VER155008 inhibited TAM-induced phosphorylation of GSK3beta, a downstream substrate of AKT.	Tamoxifen	48-51	glycogen synthase kinase 3 beta	Homo sapiens	79-87
27295130-3	2016	Western blotting and immunofluorescence revealed that zinc exhibited insulin-like glucose transporting effects by activating key markers that are involved in the insulin signaling cascade (including Akt, GLUT4 and GSK3beta), and downregulating members of the insulin signaling feedback cascade such as mammalian target of rapamycin (mTOR) and ribosomal protein S6 kinase (S6K1).	Glucose	82-89	glycogen synthase kinase 3 beta	Homo sapiens	214-222
27343974-2	2016	However, the serine/tyrosine phosphorylation processes implied in Abeta-induced GSK3beta activation and responsible for tau phosphorylation, especially at the GSK3beta specific Ser396/Ser404 (PHF-1) site, are still debated.	Serine	13-19	glycogen synthase kinase 3 beta	Homo sapiens	80-88
26548452-10	2016	Ad-A20 inhibited the effects of nicotine and LPS on the activation of pan-protein kinase C, Akt, GSK-3beta and protein kinase Calpha.	Nicotine	32-40	glycogen synthase kinase 3 beta	Homo sapiens	97-106
28600747-5	2016	NaBu inhibited glycogen synthase kinase-3 beta (GSK-3beta) by increasing the p-GSK-3beta (Ser9) level and promoted nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2), which increased the expression of downstream antioxidant enzymes.	sethoxydim	0-4	glycogen synthase kinase 3 beta	Homo sapiens	48-57
28600747-5	2016	NaBu inhibited glycogen synthase kinase-3 beta (GSK-3beta) by increasing the p-GSK-3beta (Ser9) level and promoted nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2), which increased the expression of downstream antioxidant enzymes.	sethoxydim	0-4	glycogen synthase kinase 3 beta	Homo sapiens	79-88
27343974-2	2016	However, the serine/tyrosine phosphorylation processes implied in Abeta-induced GSK3beta activation and responsible for tau phosphorylation, especially at the GSK3beta specific Ser396/Ser404 (PHF-1) site, are still debated.	Serine	13-19	glycogen synthase kinase 3 beta	Homo sapiens	159-167
27343974-2	2016	However, the serine/tyrosine phosphorylation processes implied in Abeta-induced GSK3beta activation and responsible for tau phosphorylation, especially at the GSK3beta specific Ser396/Ser404 (PHF-1) site, are still debated.	Tyrosine	20-28	glycogen synthase kinase 3 beta	Homo sapiens	80-88
27343974-2	2016	However, the serine/tyrosine phosphorylation processes implied in Abeta-induced GSK3beta activation and responsible for tau phosphorylation, especially at the GSK3beta specific Ser396/Ser404 (PHF-1) site, are still debated.	Tyrosine	20-28	glycogen synthase kinase 3 beta	Homo sapiens	159-167
27477809-8	2016	Furthermore, sodium selenite increased the expression level of SBP1 and decreased the levels of nuclear factor erythroid 2-related factor 2 (Nrf2) and the Wnt pathway components and its downstream targets, including beta-catenin, GSK-3beta, c-myc and cyclinD1 in these cell lines.	Sodium Selenite	13-28	glycogen synthase kinase 3 beta	Homo sapiens	230-239
27346451-6	2016	This study revealed that the GSK3-beta inhibitor SB216763 was able to stimulate the proliferation of CD117-positive hAFS cells without influencing their undifferentiated state.	SB 216763	49-57	glycogen synthase kinase 3 beta	Homo sapiens	29-38
27213824-0	2016	C-Glycosylflavones Alleviate Tau Phosphorylation and Amyloid Neurotoxicity through GSK3beta Inhibition.	c-glycosylflavones	0-18	glycogen synthase kinase 3 beta	Homo sapiens	83-91
27213824-7	2016	As part of our effort screening phytochemicals against a broad panel of kinases targeting AD tauopathy, we found inhibition of GSK3beta by CS extracts.	Cesium	139-141	glycogen synthase kinase 3 beta	Homo sapiens	127-135
27213824-8	2016	Subsequent bioassay-guided fractionation led to the isolation and identification of two 6-C-glycosylflavones, isoorientin (1) and 3"-methoxymaysin (2), with selective inhibition against GSK3beta in vitro.	6-c-glycosylflavones	88-108	glycogen synthase kinase 3 beta	Homo sapiens	186-194
27213824-8	2016	Subsequent bioassay-guided fractionation led to the isolation and identification of two 6-C-glycosylflavones, isoorientin (1) and 3"-methoxymaysin (2), with selective inhibition against GSK3beta in vitro.	homoorientin	110-121	glycogen synthase kinase 3 beta	Homo sapiens	186-194
27213824-8	2016	Subsequent bioassay-guided fractionation led to the isolation and identification of two 6-C-glycosylflavones, isoorientin (1) and 3"-methoxymaysin (2), with selective inhibition against GSK3beta in vitro.	3'-Methoxymaysin	130-146	glycogen synthase kinase 3 beta	Homo sapiens	186-194
27213824-9	2016	Enzyme kinetics and molecular docking studies demonstrated that 1 specifically inhibited GSK3beta via an ATP noncompetitive mechanism, acting as a substrate competitive inhibitor of GSK3beta.	Adenosine Triphosphate	105-108	glycogen synthase kinase 3 beta	Homo sapiens	89-97
27213824-9	2016	Enzyme kinetics and molecular docking studies demonstrated that 1 specifically inhibited GSK3beta via an ATP noncompetitive mechanism, acting as a substrate competitive inhibitor of GSK3beta.	Adenosine Triphosphate	105-108	glycogen synthase kinase 3 beta	Homo sapiens	182-190
27068260-7	2016	The inhibition of proteasome by MG132 and GSK3beta inhibition by SB216763 blocked silymarin-mediated downregulation of beta-catenin.	SB 216763	65-73	glycogen synthase kinase 3 beta	Homo sapiens	42-50
27128528-5	2016	A nonconventional analysis of data from a GSK3beta inhibitor high-throughput screening campaign, which excluded known GSK3 inhibitor chemotypes, led to the discovery of a novel pyrazolo-tetrahydroquinolinone scaffold with unparalleled kinome-wide selectivity for the GSK3 kinases.	pyrazolo-tetrahydroquinolinone	177-207	glycogen synthase kinase 3 beta	Homo sapiens	42-50
27377031-0	2016	Glycogen synthase kinase 3beta suppresses polyglutamine aggregation by inhibiting Vaccinia-related kinase 2 activity.	polyglutamine	42-55	glycogen synthase kinase 3 beta	Homo sapiens	0-30
27068260-7	2016	The inhibition of proteasome by MG132 and GSK3beta inhibition by SB216763 blocked silymarin-mediated downregulation of beta-catenin.	Silymarin	82-91	glycogen synthase kinase 3 beta	Homo sapiens	42-50
27133915-5	2016	The combination of vitamin D &amp; resveratrol completely reversed tunicamycin and Abeta25-35 induced cytotoxicity in SH-SY5Y cells, as well as elevation in ER stress markers (i.e.GRP78, p-eIF2alpha and CHOP), insulin signaling disruption (i.e. elevation in p-IRS-1serine307 and reduction in p-Akt serine473) and tau phosphorylation (i.e. reduction in p-GSK3beta serine9, and elevation in p-Tau serine396 &amp;404).	Vitamin D	19-28	glycogen synthase kinase 3 beta	Homo sapiens	354-362
27133915-5	2016	The combination of vitamin D &amp; resveratrol completely reversed tunicamycin and Abeta25-35 induced cytotoxicity in SH-SY5Y cells, as well as elevation in ER stress markers (i.e.GRP78, p-eIF2alpha and CHOP), insulin signaling disruption (i.e. elevation in p-IRS-1serine307 and reduction in p-Akt serine473) and tau phosphorylation (i.e. reduction in p-GSK3beta serine9, and elevation in p-Tau serine396 &amp;404).	Adenosine Monophosphate	30-33	glycogen synthase kinase 3 beta	Homo sapiens	354-362
27120392-3	2016	Aeroplysinin-1 suppressed the beta-catenin response transcription that was activated by Wnt3a-conditioned medium or 6-bromoindirubin-3"-oxime (an inhibitor of glycogen synthase kinase-3beta) by promoting the proteasomal degradation of intracellular beta-catenin.	6-bromoindirubin-3'-oxime	116-141	glycogen synthase kinase 3 beta	Homo sapiens	159-189
27133915-5	2016	The combination of vitamin D &amp; resveratrol completely reversed tunicamycin and Abeta25-35 induced cytotoxicity in SH-SY5Y cells, as well as elevation in ER stress markers (i.e.GRP78, p-eIF2alpha and CHOP), insulin signaling disruption (i.e. elevation in p-IRS-1serine307 and reduction in p-Akt serine473) and tau phosphorylation (i.e. reduction in p-GSK3beta serine9, and elevation in p-Tau serine396 &amp;404).	Resveratrol	35-46	glycogen synthase kinase 3 beta	Homo sapiens	354-362
27221474-0	2016	Glycogen synthase kinase-3beta antagonizes ROS-induced hepatocellular carcinoma cell death through suppression of the apoptosis signal-regulating kinase 1.	Reactive Oxygen Species	43-46	glycogen synthase kinase 3 beta	Homo sapiens	0-30
27382355-7	2016	Thapsigargin-induced ER stress and co-expression of constitutively active GSK3beta (GSK3beta-S9A) also exhibited significantly increased tau-sorcin interactions.	Thapsigargin	0-12	glycogen synthase kinase 3 beta	Homo sapiens	74-82
27382355-7	2016	Thapsigargin-induced ER stress and co-expression of constitutively active GSK3beta (GSK3beta-S9A) also exhibited significantly increased tau-sorcin interactions.	Thapsigargin	0-12	glycogen synthase kinase 3 beta	Homo sapiens	84-92
27221474-4	2016	In this study, we showed that GSK-3beta inhibits ROS-induced hepatocellular carcinoma cell death by suppressing ASK1.	Reactive Oxygen Species	49-52	glycogen synthase kinase 3 beta	Homo sapiens	30-39
27221474-5	2016	We first found that ectopic expression of GSK-3beta suppressed hydrogen peroxide (H2O2)-induced cell death in HepG2 cells and knockdown of endogenous GSK-3beta expression exhibited opposite effects.	Hydrogen Peroxide	63-80	glycogen synthase kinase 3 beta	Homo sapiens	42-51
27221474-5	2016	We first found that ectopic expression of GSK-3beta suppressed hydrogen peroxide (H2O2)-induced cell death in HepG2 cells and knockdown of endogenous GSK-3beta expression exhibited opposite effects.	Hydrogen Peroxide	82-86	glycogen synthase kinase 3 beta	Homo sapiens	42-51
27221474-6	2016	Moreover, GSK-3beta expression clearly inhibited H2O2-induced phosphorylation of ASK1 in HepG2 cells, in association with a decrease in ASK1 protein level.	Hydrogen Peroxide	49-53	glycogen synthase kinase 3 beta	Homo sapiens	10-19
27221474-8	2016	Our results thus suggest that GSK-3beta is a key factor involved in ASK1 activation and ROS-induced cell death.	Reactive Oxygen Species	88-91	glycogen synthase kinase 3 beta	Homo sapiens	30-39
26994872-0	2016	Protection against MPP(+)-induced neurotoxicity in SH-SY5Y cells by tormentic acid via the activation of PI3-K/Akt/GSK3beta pathway.	euscaphic acid	68-82	glycogen synthase kinase 3 beta	Homo sapiens	115-123
26994872-5	2016	Most importantly, TA markedly reversed the inhibition of protein expression of phosphorylated Akt (Ser 473) and phosphorylated GSK3beta (Ser 9) caused by MPP(+).	Serine	137-140	glycogen synthase kinase 3 beta	Homo sapiens	127-135
26994872-6	2016	LY294002, the specific inhibitor of PI3-K, significantly abrogated the up-regulated phosphorylated Akt and phosphorylated GSK3beta offered by TA, suggesting that the neuroprotection of TA was mainly dependent on the activation of PI3-K/Akt/GSK3beta signaling pathway.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	glycogen synthase kinase 3 beta	Homo sapiens	122-130
26994872-6	2016	LY294002, the specific inhibitor of PI3-K, significantly abrogated the up-regulated phosphorylated Akt and phosphorylated GSK3beta offered by TA, suggesting that the neuroprotection of TA was mainly dependent on the activation of PI3-K/Akt/GSK3beta signaling pathway.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	glycogen synthase kinase 3 beta	Homo sapiens	240-248
27060477-0	2016	GABAB R/GSK-3beta/NF-kappaB signaling pathway regulates the proliferation of colorectal cancer cells.	gabab	0-5	glycogen synthase kinase 3 beta	Homo sapiens	8-17
26095111-10	2016	It was found that WEHDW reversed H2O2-induced activation of MEK/ERK pathway and H2O2-induced inhibition of P13-K/AKT/GSK3beta pathway in LO2 cells.	Hydrogen Peroxide	80-84	glycogen synthase kinase 3 beta	Homo sapiens	117-125
27379018-6	2016	Moreover, they involved signaling through cAMP/protein kinase A (PKA)/cAMP response element-binding protein, phosphoinositide 3-kinase (PI3K)/Akt and its downstream targets glycogen synthase kinase-3beta (GSK-3beta) and mammalian target of rapamycin.	Cyclic AMP	42-46	glycogen synthase kinase 3 beta	Homo sapiens	173-203
27379018-6	2016	Moreover, they involved signaling through cAMP/protein kinase A (PKA)/cAMP response element-binding protein, phosphoinositide 3-kinase (PI3K)/Akt and its downstream targets glycogen synthase kinase-3beta (GSK-3beta) and mammalian target of rapamycin.	Cyclic AMP	42-46	glycogen synthase kinase 3 beta	Homo sapiens	205-214
27325150-1	2016	OBJECTIVES: The enzyme glycogen synthase kinase-3beta (GSK3beta) is involved in the mechanisms of action of lithium and may play a role in relation to affective states in bipolar disorder.	Lithium	108-115	glycogen synthase kinase 3 beta	Homo sapiens	23-53
27325150-1	2016	OBJECTIVES: The enzyme glycogen synthase kinase-3beta (GSK3beta) is involved in the mechanisms of action of lithium and may play a role in relation to affective states in bipolar disorder.	Lithium	108-115	glycogen synthase kinase 3 beta	Homo sapiens	55-63
27060477-4	2016	Inhibition of GABAB R activated GSK-3beta by reducing the phosphorylation level of GSK-3beta.	gabab	14-19	glycogen synthase kinase 3 beta	Homo sapiens	83-92
27060477-8	2016	Overall, activation of GABAB R leaded to inhibition of GSK-3beta activation to repress the NF-kappaB function during colorectal cancer cell proliferation.	gabab	23-28	glycogen synthase kinase 3 beta	Homo sapiens	55-64
27060477-9	2016	This study revealed critical function of GABAB R/GSK-3beta/NF-kappaB signaling pathway on regulating proliferation of colorectal cancer cell, which might provide a potential therapeutic target for clinical colorectal cancer treatment.	gabab	41-46	glycogen synthase kinase 3 beta	Homo sapiens	49-58
27122002-6	2016	These results demonstrated that myricetin suppressed the cell viability of human breast cancer MCF-7 cells through PAK1/MEK/ERK/GSK3beta/beta-catenin/cyclin D1/PCNA/survivin/Bax-caspase-3 signaling.	myricetin	32-41	glycogen synthase kinase 3 beta	Homo sapiens	128-136
27248172-9	2016	Taken together, our study revealed a novel mechanism in microenvironment influence on sorafenib sensitivity in AML with FLT3-ITD mutation that was caused by activating integrin alphavbeta3/PI3K/Akt/GSK3beta/beta-catenin pathway.	Sorafenib	86-95	glycogen synthase kinase 3 beta	Homo sapiens	198-206
27060477-4	2016	Inhibition of GABAB R activated GSK-3beta by reducing the phosphorylation level of GSK-3beta.	gabab	14-19	glycogen synthase kinase 3 beta	Homo sapiens	32-41
26589607-12	2016	CONCLUSION: Icariin protects SH-SY5Y cells from FA-induced injury posssibly through the inhibition of GSK-3beta-mediated Tau phosphorylation.	icariin	12-19	glycogen synthase kinase 3 beta	Homo sapiens	102-111
26685284-6	2016	Experiments with specific inhibitors for TGF-beta, glycogen synthase kinase-3beta (GSK-3beta), and Akt were performed to confirm their involvement in asbestos-induced EMT.	Asbestos	150-158	glycogen synthase kinase 3 beta	Homo sapiens	83-92
26685284-10	2016	CONCLUSIONS: Our findings suggest that chrysotile asbestos induces EMT, a common event in asbestos-related diseases, at least in part by eliciting the TGF-beta-mediated Akt/GSK-3beta/SNAIL-1 pathway.	Asbestos	50-58	glycogen synthase kinase 3 beta	Homo sapiens	173-182
26887582-6	2016	These studies showed that justicidin A inhibited activity of glycogen synthase kinase-3beta (GSK-3beta), which is an important kinase in up-stream signaling pathways; inhibited hyperphosphorylation of tau in AD; and enhanced activity of AMP-activated protein kinase (AMPK), which is the key molecule for both hyperphosphorylation of tau and induction of autophagy.	justicidins	26-38	glycogen synthase kinase 3 beta	Homo sapiens	61-91
26797706-3	2016	Melatonin has been known to act as not only a direct scavenger of free radicals but also an inhibitor of glycogen synthase kinase 3beta (GSK-3beta).	Melatonin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	105-135
26797706-3	2016	Melatonin has been known to act as not only a direct scavenger of free radicals but also an inhibitor of glycogen synthase kinase 3beta (GSK-3beta).	Melatonin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	137-146
26797706-11	2016	In summary, melatonin inhibited the cAMP synthesis through ROS reduction and the phosphorylation of the ERK/GSK-3beta site which is known to be responsible for C/EBPbeta activation for adipogenic differentiation in hMSCs.	Melatonin	12-21	glycogen synthase kinase 3 beta	Homo sapiens	108-117
26797706-11	2016	In summary, melatonin inhibited the cAMP synthesis through ROS reduction and the phosphorylation of the ERK/GSK-3beta site which is known to be responsible for C/EBPbeta activation for adipogenic differentiation in hMSCs.	Cyclic AMP	36-40	glycogen synthase kinase 3 beta	Homo sapiens	108-117
27046645-18	2016	BCL2 and GSK3B, the top CFG scoring validated biomarkers, as well as PIK3C3, have anti-apoptotic and neurotrophic effects, are decreased in expression in suicidality and are known targets of the anti-suicidal mood stabilizer drug lithium, which increases their expression and/or activity.	Lithium	230-237	glycogen synthase kinase 3 beta	Homo sapiens	9-14
27390740-7	2016	Delphinidin also induced the phosphorylation of glycogen synthase kinase 3beta and the expression of adenomatous polyposis coli and Axin proteins.	delphinidin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	48-78
27482230-3	2016	Furthermore, indirubin-3"-monoxime inhibited phosphorylation of glycogen synthase kinase-3beta (GSK-3beta).	indirubin-3'-monoxime	13-34	glycogen synthase kinase 3 beta	Homo sapiens	64-94
26887582-6	2016	These studies showed that justicidin A inhibited activity of glycogen synthase kinase-3beta (GSK-3beta), which is an important kinase in up-stream signaling pathways; inhibited hyperphosphorylation of tau in AD; and enhanced activity of AMP-activated protein kinase (AMPK), which is the key molecule for both hyperphosphorylation of tau and induction of autophagy.	justicidins	26-38	glycogen synthase kinase 3 beta	Homo sapiens	93-102
27482230-3	2016	Furthermore, indirubin-3"-monoxime inhibited phosphorylation of glycogen synthase kinase-3beta (GSK-3beta).	indirubin-3'-monoxime	13-34	glycogen synthase kinase 3 beta	Homo sapiens	96-105
26887582-7	2016	These data provide the first evidence that justicidin A protects SH-SY5Y cells from Abeta25-35-induced neuronal cell death through inhibition of hyperphosphorylation of tau and induction of autophagy via regulation the activity of GSK-3beta and AMPK, and they also provide some insights into the relationship between tau protein hyperphosphorylation and autophagy.	justicidins	43-55	glycogen synthase kinase 3 beta	Homo sapiens	231-240
27109804-8	2016	We found that treatment with PGE2 significantly enhanced nuclear accumulation of beta-catenin and the activation of GSK3beta which could be reversed by meloxicam in HCC cells.	Dinoprostone	29-33	glycogen synthase kinase 3 beta	Homo sapiens	116-124
27482230-4	2016	Our results suggest that indirubin-3"-monoxime reduced Abeta25-35-induced apoptosis by suppressing tau hyperphosphorylation via a GSK-3beta-mediated mechanism.	indirubin-3"	25-37	glycogen synthase kinase 3 beta	Homo sapiens	130-139
27482230-4	2016	Our results suggest that indirubin-3"-monoxime reduced Abeta25-35-induced apoptosis by suppressing tau hyperphosphorylation via a GSK-3beta-mediated mechanism.	monoxime	38-46	glycogen synthase kinase 3 beta	Homo sapiens	130-139
27109804-8	2016	We found that treatment with PGE2 significantly enhanced nuclear accumulation of beta-catenin and the activation of GSK3beta which could be reversed by meloxicam in HCC cells.	Meloxicam	152-161	glycogen synthase kinase 3 beta	Homo sapiens	116-124
27251132-0	2016	Multi-walled carbon nanotubes directly induce epithelial-mesenchymal transition in human bronchial epithelial cells via the TGF-beta-mediated Akt/GSK-3beta/SNAIL-1 signalling pathway.	Carbon	13-19	glycogen synthase kinase 3 beta	Homo sapiens	146-155
27543871-3	2016	Thus far three serines (S33, 37, 45) and one threonine (T41) are considered to be the substrates for GSK-3beta phosphorylation.	Serine	15-22	glycogen synthase kinase 3 beta	Homo sapiens	101-110
27543871-3	2016	Thus far three serines (S33, 37, 45) and one threonine (T41) are considered to be the substrates for GSK-3beta phosphorylation.	Threonine	45-54	glycogen synthase kinase 3 beta	Homo sapiens	101-110
27058759-10	2016	While inhibitor of PI3K/Akt, LY294002, abolishes visfatin induced up regulation of Snail, Vimentin (Vim), beta-catenin, and phosphorylated GSK-3beta.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	29-37	glycogen synthase kinase 3 beta	Homo sapiens	139-148
27243769-7	2016	Meanwhile, Stel B inhibited the expression of PI3K-p110, and the phosphorylation of PDK1, Akt, mTOR, p70S6K as well as GSK-3beta, suggesting the correlation of blocking PI3K/Akt/mTOR pathway with the above antitumor activities.	stellettin B	11-17	glycogen synthase kinase 3 beta	Homo sapiens	119-128
27121204-6	2016	We observed that MLN8237, which is a specific inhibitor of AURKA, decreased the beta-catenin and the phosphorylation of Akt1 and GSK-3beta, as well as blocked the Akt and Wnt signaling pathways.	MLN 8237	17-24	glycogen synthase kinase 3 beta	Homo sapiens	129-138
27035393-3	2016	In this study, we investigated whether sodium hydrogen sulfide (NaHS), an H2S donor, attenuates acute myocardial ischemic injury through glycogen synthase kinase-3beta (GSK-3beta)/beta-catenin signaling.	sodium bisulfide	39-62	glycogen synthase kinase 3 beta	Homo sapiens	137-167
27219337-4	2016	UA treatment (6-9 h) strongly blocked the survival AKT/GSK3beta/beta-catenin signalling pathway, which led to a concomitant reduction of the anti-apoptotic proteins c-Myc and p21, altogether resulting in the activation of intrinsic apoptosis.	ursolic acid	0-2	glycogen synthase kinase 3 beta	Homo sapiens	55-63
27195613-8	2016	Bupivacaine increased the phosphorylation of GSK-3beta(Tyr216) in SKOV-3 but without measurable effect in PC3.	Bupivacaine	0-11	glycogen synthase kinase 3 beta	Homo sapiens	45-54
27034169-4	2016	On the other hand, BIS I, an inhibitor of PKCdelta and GSK3beta, caused YAP accumulation into the nucleus.	bis i	19-24	glycogen synthase kinase 3 beta	Homo sapiens	55-63
27034169-6	2016	Inhibition of GSK3beta by BIS I reduced the expression levels of SMADs protein and reduced YAP contribution to EMT.	bis i	26-31	glycogen synthase kinase 3 beta	Homo sapiens	14-22
27036017-3	2016	TPA dose- and time-dependently increased PKCdelta and STAT3alpha activation and GSK3beta phosphorylation; up-regulated Wnt-1, beta-catenin, and STAT3alpha expression; and increased the nuclear translocation of beta-catenin and STAT3alpha.	Tetradecanoylphorbol Acetate	0-3	glycogen synthase kinase 3 beta	Homo sapiens	80-88
27036017-9	2016	DHA pretreatment attenuated TPA-induced cell migration, PKCdelta and STAT3alpha activation, GSK3beta phosphorylation, and Wnt-1, beta-catenin, STAT3alpha, and fascin-1 expression.	dehydroacetic acid	0-3	glycogen synthase kinase 3 beta	Homo sapiens	92-100
27036017-9	2016	DHA pretreatment attenuated TPA-induced cell migration, PKCdelta and STAT3alpha activation, GSK3beta phosphorylation, and Wnt-1, beta-catenin, STAT3alpha, and fascin-1 expression.	Tetradecanoylphorbol Acetate	28-31	glycogen synthase kinase 3 beta	Homo sapiens	92-100
27036017-10	2016	Our results demonstrated that TPA-induced migration is likely associated with the PKCdelta and Wnt-1 pathways, which lead to STAT3alpha activation, GSK3beta inactivation, and beta-catenin increase and up-regulation of fascin-1 expression.	Tetradecanoylphorbol Acetate	30-33	glycogen synthase kinase 3 beta	Homo sapiens	148-156
26915459-5	2016	Upon viral infection, TRIM9s undergoes Lys-63-linked auto-polyubiquitination and serves as a platform to bridge GSK3beta to TBK1, leading to the activation of IRF3 signaling.	Lysine	39-42	glycogen synthase kinase 3 beta	Homo sapiens	112-120
26942334-2	2016	Indeed, GSK-3beta catalyzes the hyperphosphorylation of tau protein by transferring a phosphate moiety from ATP to the protein substrate serine residue causing the formation of the toxic insoluble neurofibrillary tangles; for this reason it represents a key target for the development of new therapeutic agents for AD treatment.	Phosphates	86-95	glycogen synthase kinase 3 beta	Homo sapiens	8-17
26942334-2	2016	Indeed, GSK-3beta catalyzes the hyperphosphorylation of tau protein by transferring a phosphate moiety from ATP to the protein substrate serine residue causing the formation of the toxic insoluble neurofibrillary tangles; for this reason it represents a key target for the development of new therapeutic agents for AD treatment.	Adenosine Triphosphate	108-111	glycogen synthase kinase 3 beta	Homo sapiens	8-17
26942334-2	2016	Indeed, GSK-3beta catalyzes the hyperphosphorylation of tau protein by transferring a phosphate moiety from ATP to the protein substrate serine residue causing the formation of the toxic insoluble neurofibrillary tangles; for this reason it represents a key target for the development of new therapeutic agents for AD treatment.	Serine	137-143	glycogen synthase kinase 3 beta	Homo sapiens	8-17
26942334-4	2016	The UHPLC-UV (DAD) based method was validated for the very fast determination of ATP as reactant and ADP as product, and applied for the analysis of the enzymatic reaction between a phosphate primed peptide substrate (GSM), resembling tau protein sequence, ATP and GSK-3beta, with/without inhibitors.	Phosphates	182-191	glycogen synthase kinase 3 beta	Homo sapiens	265-274
26942334-9	2016	In agreement with literature data, Tideglusib resulted a GSM competitive inhibitor, whereas SB-415286 was found inhibiting GSK-3beta in an ATP competitive manner.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	92-101	glycogen synthase kinase 3 beta	Homo sapiens	123-132
26815013-0	2016	NDE1 and GSK3beta Associate with TRAK1 and Regulate Axonal Mitochondrial Motility: Identification of Cyclic AMP as a Novel Modulator of Axonal Mitochondrial Trafficking.	Cyclic AMP	101-111	glycogen synthase kinase 3 beta	Homo sapiens	9-17
27063218-10	2016	Meanwhile PG increased the expression of tumor suppressor PTEN, and decreased p-Akt, p-GSK3beta and miR-21 levels.	physcion 8-O-glucopyranoside	10-12	glycogen synthase kinase 3 beta	Homo sapiens	87-95
27063218-11	2016	Pharmacological activation of Akt/GSK3beta signaling or transfection with miR-21 mimic abolished PG-induced survivin reduction and cell apoptosis.	physcion 8-O-glucopyranoside	97-99	glycogen synthase kinase 3 beta	Homo sapiens	34-42
26714831-0	2016	Synthesis of Novel Pyrimidin-4-One Bearing Piperazine Ring-Based Amides as Glycogen Synthase Kinase-3beta Inhibitors with Antidepressant Activity.	4-hydroxypyrimidine	19-34	glycogen synthase kinase 3 beta	Homo sapiens	75-105
26714831-0	2016	Synthesis of Novel Pyrimidin-4-One Bearing Piperazine Ring-Based Amides as Glycogen Synthase Kinase-3beta Inhibitors with Antidepressant Activity.	Piperazine	43-53	glycogen synthase kinase 3 beta	Homo sapiens	75-105
26714831-0	2016	Synthesis of Novel Pyrimidin-4-One Bearing Piperazine Ring-Based Amides as Glycogen Synthase Kinase-3beta Inhibitors with Antidepressant Activity.	Amides	65-71	glycogen synthase kinase 3 beta	Homo sapiens	75-105
26714831-1	2016	Novel pyrimidin-4-one derivatives have been synthesized using EDC coupling and evaluated as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.	4-hydroxypyrimidine	6-21	glycogen synthase kinase 3 beta	Homo sapiens	92-122
26714831-1	2016	Novel pyrimidin-4-one derivatives have been synthesized using EDC coupling and evaluated as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.	4-hydroxypyrimidine	6-21	glycogen synthase kinase 3 beta	Homo sapiens	124-133
26714831-2	2016	Among all the synthesized compounds, compound 5 (3-methyl-6-phenyl-2-(piperazin-1-yl)-3,4-dihydropyrimidin-4-one) exhibited the most potent inhibitory activity against GSK-3beta with IC50 value of 74 nm.	3-methyl-6-phenyl-2-(piperazin-1-yl)-3,4-dihydropyrimidin-4-one	49-112	glycogen synthase kinase 3 beta	Homo sapiens	168-177
26714831-3	2016	The molecular docking studies were performed to elucidate the binding modes of the compounds with the target, and a crucial interaction involving hydrogen bond formation with Val-135 to the active site of GSK-3beta was observed.	Hydrogen	146-154	glycogen synthase kinase 3 beta	Homo sapiens	205-214
26714831-3	2016	The molecular docking studies were performed to elucidate the binding modes of the compounds with the target, and a crucial interaction involving hydrogen bond formation with Val-135 to the active site of GSK-3beta was observed.	Valine	175-178	glycogen synthase kinase 3 beta	Homo sapiens	205-214
27035393-3	2016	In this study, we investigated whether sodium hydrogen sulfide (NaHS), an H2S donor, attenuates acute myocardial ischemic injury through glycogen synthase kinase-3beta (GSK-3beta)/beta-catenin signaling.	sodium bisulfide	39-62	glycogen synthase kinase 3 beta	Homo sapiens	169-178
27035393-3	2016	In this study, we investigated whether sodium hydrogen sulfide (NaHS), an H2S donor, attenuates acute myocardial ischemic injury through glycogen synthase kinase-3beta (GSK-3beta)/beta-catenin signaling.	sodium bisulfide	64-68	glycogen synthase kinase 3 beta	Homo sapiens	137-167
27035393-3	2016	In this study, we investigated whether sodium hydrogen sulfide (NaHS), an H2S donor, attenuates acute myocardial ischemic injury through glycogen synthase kinase-3beta (GSK-3beta)/beta-catenin signaling.	sodium bisulfide	64-68	glycogen synthase kinase 3 beta	Homo sapiens	169-178
26987443-5	2016	In these cells, furanodiene (as opposed to doxorubicin) noticeably affects the phosphorylation of AMPK and AMPK pathway intermediates, ACLY and GSK-3beta, suggesting that furanodiene reduces mitochondrial function and cellular ATP levels by way of AMPK activation.	furanodiene	16-27	glycogen synthase kinase 3 beta	Homo sapiens	144-153
27127602-7	2016	With reperfusion, candesartan increased mature BDNF expression in the contralateral hemisphere (p &lt; 0.05) and activated prosurvival (Akt-GSK3-beta) signaling (p &lt; 0.05).	candesartan	18-29	glycogen synthase kinase 3 beta	Homo sapiens	140-149
25945460-0	2016	LW-213 induces G2/M cell cycle arrest through AKT/GSK3beta/beta-catenin signaling pathway in human breast cancer cells.	CHEMBL4207919	0-6	glycogen synthase kinase 3 beta	Homo sapiens	50-58
26014148-12	2016	Alcohol caused an initial cytosolic accumulation of beta-catenin and its subsequent nuclear translocation by inhibiting GSK3beta activity.	Alcohols	0-7	glycogen synthase kinase 3 beta	Homo sapiens	120-128
26014148-15	2016	Together, these results suggested that alcohol may promote the metastasis of CRC through modulating GSK3beta/beta-catenin/MCP-1 pathway.	Alcohols	39-46	glycogen synthase kinase 3 beta	Homo sapiens	100-108
26987443-5	2016	In these cells, furanodiene (as opposed to doxorubicin) noticeably affects the phosphorylation of AMPK and AMPK pathway intermediates, ACLY and GSK-3beta, suggesting that furanodiene reduces mitochondrial function and cellular ATP levels by way of AMPK activation.	furanodiene	171-182	glycogen synthase kinase 3 beta	Homo sapiens	144-153
26851642-7	2016	In addition, the administration of hr Annexin A1 improved cognitive function after the inhalation of 3.6% sevoflurane for 6 h. Moreover, in cultured endothelial cells, 3.6% sevoflurane for 6 h increased GSK-3beta and decreased beta-catenin levels at 24 h after inhalation.	Sevoflurane	173-184	glycogen synthase kinase 3 beta	Homo sapiens	203-212
26905586-8	2016	PGIA induced cyclin D1 degradation via the proteasome pathway and induced dephosphorylation of GSK3beta, which was required for cyclin D1 turnover.	pgia	0-4	glycogen synthase kinase 3 beta	Homo sapiens	95-103
26995153-2	2016	Glycogen synthase kinase 3 beta (GSK-3beta), a kinase known for its activity on glycogen synthesis, has in the last few years raised growing interest in biological psychiatry.	Glycogen	80-88	glycogen synthase kinase 3 beta	Homo sapiens	0-31
26995153-2	2016	Glycogen synthase kinase 3 beta (GSK-3beta), a kinase known for its activity on glycogen synthesis, has in the last few years raised growing interest in biological psychiatry.	Glycogen	80-88	glycogen synthase kinase 3 beta	Homo sapiens	33-42
26995153-5	2016	After a brief description of the intracellular transduction pathways implicated in both GSK-3beta and mood disorders, we reviewed the results demonstrating GSK-3beta involvement in the effects of lithium and ketamine.	Lithium	196-203	glycogen synthase kinase 3 beta	Homo sapiens	156-165
26995153-5	2016	After a brief description of the intracellular transduction pathways implicated in both GSK-3beta and mood disorders, we reviewed the results demonstrating GSK-3beta involvement in the effects of lithium and ketamine.	Ketamine	208-216	glycogen synthase kinase 3 beta	Homo sapiens	156-165
26995153-6	2016	RESULTS: GSK-3beta can be inhibited through several mechanisms such as serine phosphorylation or binding in a proteic scaffold and others.	Serine	71-77	glycogen synthase kinase 3 beta	Homo sapiens	9-18
26995153-11	2016	CONCLUSION: Our review focuses on mechanisms whereby the GSK-3beta pathway has a part in the antidepressant effect of lithium and ketamine.	Lithium	118-125	glycogen synthase kinase 3 beta	Homo sapiens	57-66
26995153-11	2016	CONCLUSION: Our review focuses on mechanisms whereby the GSK-3beta pathway has a part in the antidepressant effect of lithium and ketamine.	Ketamine	130-138	glycogen synthase kinase 3 beta	Homo sapiens	57-66
26935904-14	2016	Decreased VEGFR-2 caused by ROS was ameliorated by beta-TrCP siRNA, proteasome inhibitor MG132 and GSK-3beta activity inhibitor (lithium chloride and SB216763).	Reactive Oxygen Species	28-31	glycogen synthase kinase 3 beta	Homo sapiens	99-108
27194941-8	2016	ZSTK474 also inhibited phosphorylation of Akt and GSK-3beta, which might be involved in the effect on the above cell cycle-related proteins.	ZSTK474	0-7	glycogen synthase kinase 3 beta	Homo sapiens	50-59
27045586-0	2016	MicroRNA-3646 Contributes to Docetaxel Resistance in Human Breast Cancer Cells by GSK-3beta/beta-Catenin Signaling Pathway.	Docetaxel	29-38	glycogen synthase kinase 3 beta	Homo sapiens	82-91
26935904-14	2016	Decreased VEGFR-2 caused by ROS was ameliorated by beta-TrCP siRNA, proteasome inhibitor MG132 and GSK-3beta activity inhibitor (lithium chloride and SB216763).	Lithium Chloride	129-145	glycogen synthase kinase 3 beta	Homo sapiens	99-108
26935904-15	2016	We suggest that redundant ROS reduces VEGFR-2 through beta-TrCP-mediated VEGFR-2 degradation, which is postulated to be regulated by GSK-3beta.	Reactive Oxygen Species	26-29	glycogen synthase kinase 3 beta	Homo sapiens	133-142
26851642-11	2016	We propose the following cascade for sevoflurane-induced cognitive dysfunction: in microvascular endothelial cells, treatment with 3.6% sevoflurane for 6 h inhibits the Wnt/beta-catenin signalling pathway, increasing GSK-3beta and decreasing beta-catenin, which down-regulates the expression of Annexin A1.	Sevoflurane	136-147	glycogen synthase kinase 3 beta	Homo sapiens	217-226
26851642-9	2016	Our findings indicate that in endothelial cells, treatment with 3.6% sevoflurane for 6 h inhibits the Wnt/beta-catenin signalling pathway, thereby increasing GSK-3beta and decreasing beta-catenin.	Sevoflurane	69-80	glycogen synthase kinase 3 beta	Homo sapiens	158-167
26851642-11	2016	We propose the following cascade for sevoflurane-induced cognitive dysfunction: in microvascular endothelial cells, treatment with 3.6% sevoflurane for 6 h inhibits the Wnt/beta-catenin signalling pathway, increasing GSK-3beta and decreasing beta-catenin, which down-regulates the expression of Annexin A1.	Sevoflurane	37-48	glycogen synthase kinase 3 beta	Homo sapiens	217-226
25846820-5	2016	Here, we investigated the mechanism by which (S)-LCM affects CRMP2 phosphorylation by two key kinases, cyclin-dependent kinase 5 (Cdk5) and glycogen synthase kinase 3beta (GSK-3beta).	Lincomycin	45-52	glycogen synthase kinase 3 beta	Homo sapiens	140-170
25846820-5	2016	Here, we investigated the mechanism by which (S)-LCM affects CRMP2 phosphorylation by two key kinases, cyclin-dependent kinase 5 (Cdk5) and glycogen synthase kinase 3beta (GSK-3beta).	Lincomycin	45-52	glycogen synthase kinase 3 beta	Homo sapiens	172-181
25846820-6	2016	(S)-LCM application to embryonic cortical neurons resulted in reduced levels of Cdk5- and GSK-3beta-phosphorylated CRMP2.	Lincomycin	0-7	glycogen synthase kinase 3 beta	Homo sapiens	90-99
25846820-7	2016	Mechanistically, (S)-LCM increased CRMP2 binding to both Cdk5- and GSK-3beta without affecting binding of CRMP2 to its canonical partner tubulin.	Lincomycin	17-24	glycogen synthase kinase 3 beta	Homo sapiens	67-76
27020460-0	2016	Suppressive effect of exogenous carbon monoxide on endotoxin-stimulated platelet over-activation via the glycoprotein-mediated PI3K-Akt-GSK3beta pathway.	Carbon Monoxide	32-47	glycogen synthase kinase 3 beta	Homo sapiens	136-144
26385055-3	2016	Cocaine SA significantly increased expression of DISC1 in the nucleus accumbens (NAc); while knockdown of DISC1 in NAc significantly increased cocaine SA and decreased phosphorylation of GSK-3beta at Ser9 compared to scrambled shRNA.	Cocaine	0-7	glycogen synthase kinase 3 beta	Homo sapiens	187-196
26526575-0	2016	Effects of the GSK-3beta inhibitor (2Z,3E)-6-bromoindirubin-3"-oxime upon ovarian cancer cells.	(2z,3e)-6-bromoindirubin-3"-oxime	35-68	glycogen synthase kinase 3 beta	Homo sapiens	15-24
26526575-3	2016	We wished to ascertain if the GSK-3beta inhibitor (2Z,3E)-6-bromoindirubin-3"-oxime, known as "BIO," can suppress OC development.	(2z,3e)-6-bromoindirubin-3"-oxime	50-83	glycogen synthase kinase 3 beta	Homo sapiens	30-39
26820690-8	2016	These effects of EMO were weakened when the cells were pretreated with SB216763, an inhibitor of GSK-3beta kinase.	SB 216763	71-79	glycogen synthase kinase 3 beta	Homo sapiens	97-106
27026523-5	2016	Surprisingly, phosphorylation of T308 and S473 of AKT play opposite roles in GSK3beta phosphorylation and inhibition, by which mTORC2 and pAKT-S473 negatively regulate axon regeneration.	t308	33-37	glycogen synthase kinase 3 beta	Homo sapiens	77-85
27010855-7	2016	Owing to the interactive signaling between EP4 and EGFR, GW627368X lowered EGFR phosphorylation in turn reducing Akt, mitogen-activated protein kinase (MAPK) and GSK3beta activity significantly.	N-(2-(4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo(f)isoindol-2-yl)phenyl)acetyl)benzene sulphonamide	57-66	glycogen synthase kinase 3 beta	Homo sapiens	162-170
27007368-0	2016	Isoquercitrin Inhibits Hydrogen Peroxide-Induced Apoptosis of EA.hy926 Cells via the PI3K/Akt/GSK3beta Signaling Pathway.	isoquercitrin	0-13	glycogen synthase kinase 3 beta	Homo sapiens	94-102
27007368-0	2016	Isoquercitrin Inhibits Hydrogen Peroxide-Induced Apoptosis of EA.hy926 Cells via the PI3K/Akt/GSK3beta Signaling Pathway.	Hydrogen Peroxide	23-40	glycogen synthase kinase 3 beta	Homo sapiens	94-102
27007368-7	2016	Additionally, isoquercitrin significantly increased the expression of p-Akt and p-GSK3beta in a dose-dependent manner in EA.hy926 cells.	isoquercitrin	14-27	glycogen synthase kinase 3 beta	Homo sapiens	82-90
27007368-8	2016	LY294002, a PI3K/Akt inhibitor, inhibited isoquercitrin-induced GSK3beta phosphorylation and increase of Mcl-1 expression, which indicated that regulation of isoquercitrin on Mcl-1 expression was likely related to the modulation of Akt activation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	glycogen synthase kinase 3 beta	Homo sapiens	64-72
27007368-8	2016	LY294002, a PI3K/Akt inhibitor, inhibited isoquercitrin-induced GSK3beta phosphorylation and increase of Mcl-1 expression, which indicated that regulation of isoquercitrin on Mcl-1 expression was likely related to the modulation of Akt activation.	isoquercitrin	42-55	glycogen synthase kinase 3 beta	Homo sapiens	64-72
27007368-8	2016	LY294002, a PI3K/Akt inhibitor, inhibited isoquercitrin-induced GSK3beta phosphorylation and increase of Mcl-1 expression, which indicated that regulation of isoquercitrin on Mcl-1 expression was likely related to the modulation of Akt activation.	isoquercitrin	158-171	glycogen synthase kinase 3 beta	Homo sapiens	64-72
27007368-9	2016	These results demonstrated that the anti-apoptotic effect of isoquercitrin on H2O2-induced EA.hy926 cells was likely associated with the regulation of isoquercitrin on Akt/GSK3beta signaling pathway and that isoquercitrin could be used clinically to interfere with the progression of endothelial injury-associated cardiovascular disease.	isoquercitrin	61-74	glycogen synthase kinase 3 beta	Homo sapiens	172-180
27007368-9	2016	These results demonstrated that the anti-apoptotic effect of isoquercitrin on H2O2-induced EA.hy926 cells was likely associated with the regulation of isoquercitrin on Akt/GSK3beta signaling pathway and that isoquercitrin could be used clinically to interfere with the progression of endothelial injury-associated cardiovascular disease.	isoquercitrin	151-164	glycogen synthase kinase 3 beta	Homo sapiens	172-180
27007368-9	2016	These results demonstrated that the anti-apoptotic effect of isoquercitrin on H2O2-induced EA.hy926 cells was likely associated with the regulation of isoquercitrin on Akt/GSK3beta signaling pathway and that isoquercitrin could be used clinically to interfere with the progression of endothelial injury-associated cardiovascular disease.	isoquercitrin	151-164	glycogen synthase kinase 3 beta	Homo sapiens	172-180
26867160-1	2016	BACKGROUND: Lithium accumulates in the colon and inhibits the enzyme GSK-3beta that possesses anti-carcinogenic effects.	Lithium	12-19	glycogen synthase kinase 3 beta	Homo sapiens	69-78
27051274-0	2016	Role of glycogen synthase kinase-3beta inhibitor AZD1080 in ovarian cancer.	2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1H-indole-5-carbonitrile	49-56	glycogen synthase kinase 3 beta	Homo sapiens	8-38
27051274-2	2016	We investigated the role of the GSK-3beta inhibitor AZD1080 in ovarian cancer cell lines.	2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1H-indole-5-carbonitrile	52-59	glycogen synthase kinase 3 beta	Homo sapiens	32-41
27051274-7	2016	AZD1080 also significantly downregulated GSK-3beta, CDK2, CDK1, cyclin D1, MMP9, and Bcl-xL expression at both mRNA and protein levels.	2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1H-indole-5-carbonitrile	0-7	glycogen synthase kinase 3 beta	Homo sapiens	41-50
27051274-8	2016	CONCLUSION: Taken together, our results demonstrate that the GSK-3beta inhibitor AZD1080 suppresses ovarian cancer development and therefore may indicate a new direction for ovarian cancer treatment.	2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1H-indole-5-carbonitrile	81-88	glycogen synthase kinase 3 beta	Homo sapiens	61-70
26631736-7	2016	Lithium chloride inhibition of GSK-3beta increased nuclear beta-catenin content and normalized nuclear PPAR-gamma in Ob-MSCs.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	31-40
26459180-8	2016	Sorafenib blocks ATRA-induced Mcl-1 increase by reversing p90RSK activation and GSK3beta inactivation, maintains the repressed Bcl-2 level, and enhances ATRA induced apoptosis in non-APL AML cell lines and in primary AML cells.	Sorafenib	0-9	glycogen synthase kinase 3 beta	Homo sapiens	80-88
26459180-8	2016	Sorafenib blocks ATRA-induced Mcl-1 increase by reversing p90RSK activation and GSK3beta inactivation, maintains the repressed Bcl-2 level, and enhances ATRA induced apoptosis in non-APL AML cell lines and in primary AML cells.	Tretinoin	17-21	glycogen synthase kinase 3 beta	Homo sapiens	80-88
26809062-0	2016	Lipid emulsion reverses bupivacaine-induced apoptosis of h9c2 cardiomyocytes: PI3K/Akt/GSK-3beta signaling pathway.	Bupivacaine	24-35	glycogen synthase kinase 3 beta	Homo sapiens	87-96
25840567-0	2016	High glucose microenvironments inhibit the proliferation and migration of bone mesenchymal stem cells by activating GSK3beta.	Glucose	5-12	glycogen synthase kinase 3 beta	Homo sapiens	116-124
26767949-0	2016	PHLPP2 down regulation influences nuclear Nrf2 stability via Akt-1/Gsk3beta/Fyn kinase axis in acetaminophen induced oxidative renal toxicity: Protection accorded by morin.	Acetaminophen	95-108	glycogen synthase kinase 3 beta	Homo sapiens	67-75
26767949-4	2016	Enhanced PHLPP2 levels down regulate p-Akt by dephosphorylating it at Ser 473 residue leading to Gsk3beta activation.	Serine	70-73	glycogen synthase kinase 3 beta	Homo sapiens	97-105
26767949-5	2016	APAP subsided Nrf2 nuclear accumulation by activating Gsk3beta which phosphorylates Fyn kinase.	Acetaminophen	0-4	glycogen synthase kinase 3 beta	Homo sapiens	54-62
26767949-10	2016	Morin, as a potent Nrf2 inducer accorded protection against acetaminophen induced renal damages by its molecular intervention with Akt-1/Gsk3beta/Fyn kinase pathway via PHLPP2 de-activation.	Acetaminophen	60-73	glycogen synthase kinase 3 beta	Homo sapiens	137-145
25840567-10	2016	Our data indicate that GSK3beta plays an important role in regulating the proliferation and migration of BMSCs by inhibiting cyclin D1 and CXCR-4 under high glucose conditions.	Glucose	157-164	glycogen synthase kinase 3 beta	Homo sapiens	23-31
25840567-6	2016	In this study we determined the specific role of glycogen synthase kinase-3beta (GSK3beta) in the proliferation and migration of BMSCs in high glucose microenvironments.	Glucose	143-150	glycogen synthase kinase 3 beta	Homo sapiens	49-79
25840567-6	2016	In this study we determined the specific role of glycogen synthase kinase-3beta (GSK3beta) in the proliferation and migration of BMSCs in high glucose microenvironments.	Glucose	143-150	glycogen synthase kinase 3 beta	Homo sapiens	81-89
25840567-8	2016	We showed that high glucose activates GSK3beta but suppresses CXCR-4, beta-catenin, LEF-1, and cyclin D1.	Glucose	20-27	glycogen synthase kinase 3 beta	Homo sapiens	38-46
25840567-9	2016	Inhibition of GSK3beta by LiCl led to increased levels of beta-catenin, LEF-1, cyclin D1, and CXCR-4 expression.	Lithium Chloride	26-30	glycogen synthase kinase 3 beta	Homo sapiens	14-22
26707164-10	2016	We found that the binding between AMPK and beta-catenin occurs in the cytosolic fraction, and therefore concluded that the cancer cell antiproliferative effects of selenium are mediated by a GSK3beta-independent AMPK/beta-catenin pathway, although AMPK-mediated GSK3beta regulation was also observed.	Selenium	164-172	glycogen synthase kinase 3 beta	Homo sapiens	191-199
26607298-5	2016	Furthermore, melatonin completely suppressed the phospho-activation of ERK 1/2, AKT, GSK3beta and NF-kB (p65).	Melatonin	13-22	glycogen synthase kinase 3 beta	Homo sapiens	85-93
25575678-7	2016	When we overexpressed SIL1 in Bip-transfected HEK293/tau cells and thapsigargin-treated HEK293/tau cells, significantly reduced tau hyperphosphorylation and GSK-3beta activation were observed.	Thapsigargin	67-79	glycogen synthase kinase 3 beta	Homo sapiens	157-166
26707164-10	2016	We found that the binding between AMPK and beta-catenin occurs in the cytosolic fraction, and therefore concluded that the cancer cell antiproliferative effects of selenium are mediated by a GSK3beta-independent AMPK/beta-catenin pathway, although AMPK-mediated GSK3beta regulation was also observed.	Selenium	164-172	glycogen synthase kinase 3 beta	Homo sapiens	262-270
26868304-7	2016	We found that protein phosphorylation of Akt and GSK3beta varied over the 24h and 48 h time points, with constitutive phosphorylation of Akt at serine 473 (pAkt) decreasing to its most significant level when treated with Wnt3a+sFRP4 at the 24h time point.	Serine	144-150	glycogen synthase kinase 3 beta	Homo sapiens	49-57
26704305-3	2016	Our results indicated that resveratrol suppressed the hexosamine biosynthetic pathway and interrupted protein glycosylation through GSK3beta activation.	Resveratrol	27-38	glycogen synthase kinase 3 beta	Homo sapiens	132-140
26704305-4	2016	Application of either biochemical intermediates of the hexosamine pathway or small molecular inhibitors of GSK3beta reversed the effects of resveratrol on the disruption of protein glycosylation.	Resveratrol	140-151	glycogen synthase kinase 3 beta	Homo sapiens	107-115
26758421-4	2016	Mechanistic study reveals that Bufalin suppresses the integrin alpha2/FAK/AKT1/ GSK3beta signaling.	bufalin	31-38	glycogen synthase kinase 3 beta	Homo sapiens	80-88
26926171-0	2016	The involvement of cyclin D1 degradation through GSK3beta-mediated threonine-286 phosphorylation-dependent nuclear export in anti-cancer activity of mulberry root bark extracts.	Threonine	67-76	glycogen synthase kinase 3 beta	Homo sapiens	49-57
26747727-9	2016	This event was largely abolished by LY294002 pre-treatment, suggesting that ATRA and Wnt3A at least partially promote osteogenic differentiation via activating the PI3K/AKT/GSK3beta signalling pathway.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	36-44	glycogen synthase kinase 3 beta	Homo sapiens	173-181
26747727-0	2016	All-trans retinoic acid modulates Wnt3A-induced osteogenic differentiation of mesenchymal stem cells via activating the PI3K/AKT/GSK3beta signalling pathway.	Tretinoin	10-23	glycogen synthase kinase 3 beta	Homo sapiens	129-137
26926171-13	2016	Inhibition of GSK3beta by LiCl suppressed cyclin D1 phosphorylation and downregulation by MRB.	Lithium Chloride	26-30	glycogen synthase kinase 3 beta	Homo sapiens	14-22
26926171-15	2016	CONCLUSION: MRB has anti-cancer activity by inducing cyclin D1 proteasomal degradation through cyclin D1 nuclear export via GSK3beta-dependent threonine-286 phosphorylation.	Threonine	143-152	glycogen synthase kinase 3 beta	Homo sapiens	124-132
26915040-6	2016	We report that mutations in both PIK3CA and KRAS are required for the greatest aspirin sensitivity in breast cancer, and that the GSK3beta protein was hyperphosphorylated in aspirin-treated double knockin cells, but not in other clones/treatments.	Aspirin	174-181	glycogen synthase kinase 3 beta	Homo sapiens	130-138
26857144-5	2016	Lithium reduces the expression of transforming growth factor-beta-induced protein (TGFBIp) in colon cancer cells by inhibiting Smad3 phosphorylation via GSK3beta inactivation.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	153-161
26716417-5	2016	Cd potently stimulates the phosphorylations of p38alpha (MAPK14), JNK1/2 (MAPK8/9), and JUN; while the phosphorylations of Akt1, ERK1/2 (MAPK3/1), GSK3beta, and mTOR were suppressed.	Cadmium	0-2	glycogen synthase kinase 3 beta	Homo sapiens	147-155
27144323-7	2016	Next, we treated hESC-NSCs with 6-bromoindirubin-3"-oxime (BIO), a small molecule inhibitor of GSK-3beta.	6-bromoindirubin-3'-oxime	32-57	glycogen synthase kinase 3 beta	Homo sapiens	95-104
26206086-7	2016	We demonstrated that both pharmacological and genetic inhibition of GSK3beta decreased protein interaction of IP3R with the Ca(2+) channeling complex, impaired SR/ER Ca(2+) release and reduced the histamine-stimulated Ca(2+) exchange between SR/ER and mitochondria in cardiomyocytes.	Histamine	197-206	glycogen synthase kinase 3 beta	Homo sapiens	68-76
26655089-0	2016	Obg-like ATPase 1 regulates global protein serine/threonine phosphorylation in cancer cells by suppressing the GSK3beta-inhibitor 2-PP1 positive feedback loop.	Serine	43-49	glycogen synthase kinase 3 beta	Homo sapiens	111-119
26224641-1	2016	Lithium is a well-established non-competitive inhibitor of glycogen synthase kinase-3beta (GSK-3beta), a kinase that is involved in several cellular processes related to cancer progression.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	59-89
26224641-1	2016	Lithium is a well-established non-competitive inhibitor of glycogen synthase kinase-3beta (GSK-3beta), a kinase that is involved in several cellular processes related to cancer progression.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	91-100
26224641-5	2016	We show that the administration of lithium decreased the proliferative potential of CRC cells in a GSK-3beta-independent manner but induced the accumulation of cells in G2/M phase.	Lithium	35-42	glycogen synthase kinase 3 beta	Homo sapiens	99-108
26440826-10	2016	RESULTS: Inhibition of GSK-3beta activity resulted in a significant decline of cellular ATP production, leading to a significant increase of AMP/ATP ratio, a strong trigger of AMP-activated protein kinase (AMPK) activation in prostate cancer PC-3 cells.	Adenosine Triphosphate	88-91	glycogen synthase kinase 3 beta	Homo sapiens	23-32
26440826-10	2016	RESULTS: Inhibition of GSK-3beta activity resulted in a significant decline of cellular ATP production, leading to a significant increase of AMP/ATP ratio, a strong trigger of AMP-activated protein kinase (AMPK) activation in prostate cancer PC-3 cells.	Adenosine Monophosphate	141-144	glycogen synthase kinase 3 beta	Homo sapiens	23-32
26440826-10	2016	RESULTS: Inhibition of GSK-3beta activity resulted in a significant decline of cellular ATP production, leading to a significant increase of AMP/ATP ratio, a strong trigger of AMP-activated protein kinase (AMPK) activation in prostate cancer PC-3 cells.	Adenosine Triphosphate	145-148	glycogen synthase kinase 3 beta	Homo sapiens	23-32
26655089-0	2016	Obg-like ATPase 1 regulates global protein serine/threonine phosphorylation in cancer cells by suppressing the GSK3beta-inhibitor 2-PP1 positive feedback loop.	Threonine	50-59	glycogen synthase kinase 3 beta	Homo sapiens	111-119
26655089-3	2016	It is hypothesized that GSK3beta phosphorylates inhibitor 2 (I-2) of PP1 at Thr-72 and activates the PP1   I-2 complex, which in turn dephosphorylates and stimulates GSK3beta, thus forming a positive feedback loop.	Threonine	76-79	glycogen synthase kinase 3 beta	Homo sapiens	24-32
26242865-7	2016	SH-5 treatment could partly suppress TGF-beta-induced hypertrophy and proliferation of hBSMC, and depress expression of p-GSK3beta and WISP1.	SH-5	0-4	glycogen synthase kinase 3 beta	Homo sapiens	122-130
26129946-1	2016	Glycogen synthase kinase (GSK)-3beta, a serine/threonine kinase with an inhibitory role in glycogen synthesis in hepatocytes and skeletal muscle, is also expressed in cardiac and smooth muscles.	Glycogen	91-99	glycogen synthase kinase 3 beta	Homo sapiens	0-36
25849320-2	2016	We discovered that the suggested psychiatric risk factor FK506 binding protein 51 (FKBP51) increases phosphorylation of GSK3beta at serine 9 (pGSK3beta(S9)).	Serine	132-138	glycogen synthase kinase 3 beta	Homo sapiens	120-128
26696252-0	2016	Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3beta Inhibitors.	Curcumin	19-27	glycogen synthase kinase 3 beta	Homo sapiens	87-96
26696252-5	2016	Notably, for some new compounds the symmetrical diketo and the beta-keto-enol tautomeric forms were purposely isolated and tested in vitro, allowing us to gain insight into the key requirements for BACE-1 and GSK-3beta inhibition.	beta-keto-enol	63-77	glycogen synthase kinase 3 beta	Homo sapiens	209-218
28097141-10	2016	Nevertheless, SB216763, an inhibitor of GSK-3beta, could reverse the effects of emodin except for ILK expression.	SB 216763	14-22	glycogen synthase kinase 3 beta	Homo sapiens	40-49
26727221-0	2016	Glycogen Synthase Kinase-3beta and Caspase-2 Mediate Ceramide- and Etoposide-Induced Apoptosis by Regulating the Lysosomal-Mitochondrial Axis.	Ceramides	53-61	glycogen synthase kinase 3 beta	Homo sapiens	0-30
26727221-0	2016	Glycogen Synthase Kinase-3beta and Caspase-2 Mediate Ceramide- and Etoposide-Induced Apoptosis by Regulating the Lysosomal-Mitochondrial Axis.	Etoposide	67-76	glycogen synthase kinase 3 beta	Homo sapiens	0-30
26727221-8	2016	These results demonstrate the importance of GSK-3beta and caspase-2 in ceramide- and etoposide-induced apoptosis through mechanisms involving Mcl-1 destabilization and the lysosomal-mitochondrial axis.	Ceramides	71-79	glycogen synthase kinase 3 beta	Homo sapiens	44-53
26727221-8	2016	These results demonstrate the importance of GSK-3beta and caspase-2 in ceramide- and etoposide-induced apoptosis through mechanisms involving Mcl-1 destabilization and the lysosomal-mitochondrial axis.	Etoposide	85-94	glycogen synthase kinase 3 beta	Homo sapiens	44-53
26454215-0	2016	Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3beta to suppress mTOR and beta-catenin signaling pathways.	Cyproheptadine	0-14	glycogen synthase kinase 3 beta	Homo sapiens	86-94
26246283-0	2016	Enhancement of paclitaxel-induced breast cancer cell death via the glycogen synthase kinase-3beta-mediated B-cell lymphoma 2 regulation.	Paclitaxel	15-25	glycogen synthase kinase 3 beta	Homo sapiens	67-97
26246283-2	2016	Here, we show that B-cell lymphoma 2 (Bcl-2), an anti-apoptotic protein, is regulated by GSK-3beta and that GSK-3beta-mediated regulation of Bcl-2 is crucial for mitochondrial-dependent cell death in paclitaxel-stimulated cells.	Paclitaxel	200-210	glycogen synthase kinase 3 beta	Homo sapiens	108-117
26246283-3	2016	We demonstrate that MCF7 GSK-3beta siRNA cells are more sensitive to cell death than MCF7 GFP control cells and that in the absence of GSK-3beta, Bcl-2 levels are reduced, a result enhanced by paclitaxel.	Paclitaxel	193-203	glycogen synthase kinase 3 beta	Homo sapiens	25-34
26246283-7	2016	Taken together, our data suggest that GSK-3beta-dependent regulation of Bcl-2 is crucial for mitochondria-dependent cell death in paclitaxel-mediated breast cancer therapy.	Paclitaxel	130-140	glycogen synthase kinase 3 beta	Homo sapiens	38-47
26454215-7	2016	In addition, the suppression of the GSK3beta/TSC2/mTOR pathway and deregulation of the GSK3beta/beta-catenin signaling were observed in cyproheptadine-treated UC cells.	Cyproheptadine	136-150	glycogen synthase kinase 3 beta	Homo sapiens	36-44
26454215-7	2016	In addition, the suppression of the GSK3beta/TSC2/mTOR pathway and deregulation of the GSK3beta/beta-catenin signaling were observed in cyproheptadine-treated UC cells.	Cyproheptadine	136-150	glycogen synthase kinase 3 beta	Homo sapiens	87-95
27802437-5	2016	However, the MAPK inhibitor PD98059 and/or PI3K inhibitor LY294002 were able to antagonize the effects of VPA by abolishing ERK/Akt activations and cancelling GSK3beta suppression, thus it impaired VPA apoptosis-inducing effects on glioma cells.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	28-35	glycogen synthase kinase 3 beta	Homo sapiens	159-167
27537066-3	2016	Effects of atorvastatin on expression of GSK-3beta and miR-199a-5p were determined using RT-PCR and Western blot.	Atorvastatin	11-23	glycogen synthase kinase 3 beta	Homo sapiens	41-50
27537066-6	2016	In addition, the atorvastatin pretreatment significantly increased GSK-3beta expression both in mRNA level and protein level and decreased miR-199a-5p expression in mRNA level (p&lt;0.05).	Atorvastatin	17-29	glycogen synthase kinase 3 beta	Homo sapiens	67-76
27537066-8	2016	CONCLUSION: These results suggested that atorvastatin provides the cardioprotective effects against I/R injury via increasing GSK-3beta through inhibition of miR-199a-5p.	Atorvastatin	41-53	glycogen synthase kinase 3 beta	Homo sapiens	126-135
27802437-5	2016	However, the MAPK inhibitor PD98059 and/or PI3K inhibitor LY294002 were able to antagonize the effects of VPA by abolishing ERK/Akt activations and cancelling GSK3beta suppression, thus it impaired VPA apoptosis-inducing effects on glioma cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	58-66	glycogen synthase kinase 3 beta	Homo sapiens	159-167
27562816-10	2016	Furthermore, it was found that activation of ERK or AKT/GSK-3beta signaling pathways was involved in FOXC2-promoting EMT in CDDP-resistant ovarian cancer cells.	Cisplatin	124-128	glycogen synthase kinase 3 beta	Homo sapiens	56-65
27802437-5	2016	However, the MAPK inhibitor PD98059 and/or PI3K inhibitor LY294002 were able to antagonize the effects of VPA by abolishing ERK/Akt activations and cancelling GSK3beta suppression, thus it impaired VPA apoptosis-inducing effects on glioma cells.	Valproic Acid	106-109	glycogen synthase kinase 3 beta	Homo sapiens	159-167
27802437-6	2016	Furthermore, the GSK3beta inhibitor SB216763 caused a strong suppression of GSK3beta activity, which showed similar effects of VPA on regulation of protein expression and apoptosis.	SB 216763	36-44	glycogen synthase kinase 3 beta	Homo sapiens	17-25
27802437-6	2016	Furthermore, the GSK3beta inhibitor SB216763 caused a strong suppression of GSK3beta activity, which showed similar effects of VPA on regulation of protein expression and apoptosis.	SB 216763	36-44	glycogen synthase kinase 3 beta	Homo sapiens	76-84
27584962-5	2016	In sweat glands, acetylcholine inactivates glycogen synthase kinase 3beta (GSK3beta), a kinase involved in endocytosis and secretion, whereas simultaneous stimulation with histamine activates GSK3beta and inhibits sweat secretion.	Acetylcholine	17-30	glycogen synthase kinase 3 beta	Homo sapiens	43-73
26477526-0	2016	GSK3beta inhibition activates the CDX/HOX pathway and promotes hemogenic endothelial progenitor differentiation from human pluripotent stem cells.	Cefadroxil	34-37	glycogen synthase kinase 3 beta	Homo sapiens	0-8
26477526-0	2016	GSK3beta inhibition activates the CDX/HOX pathway and promotes hemogenic endothelial progenitor differentiation from human pluripotent stem cells.	hydrogen oxalate	38-41	glycogen synthase kinase 3 beta	Homo sapiens	0-8
26521017-5	2016	Moreover, expression of the GSK3beta protein was reduced in MDS-derived MSCs, and was associated with concomitant reduction of phosphorylation at Ser-9.	Serine	146-149	glycogen synthase kinase 3 beta	Homo sapiens	28-36
27584962-5	2016	In sweat glands, acetylcholine inactivates glycogen synthase kinase 3beta (GSK3beta), a kinase involved in endocytosis and secretion, whereas simultaneous stimulation with histamine activates GSK3beta and inhibits sweat secretion.	Acetylcholine	17-30	glycogen synthase kinase 3 beta	Homo sapiens	75-83
27584962-5	2016	In sweat glands, acetylcholine inactivates glycogen synthase kinase 3beta (GSK3beta), a kinase involved in endocytosis and secretion, whereas simultaneous stimulation with histamine activates GSK3beta and inhibits sweat secretion.	Histamine	172-181	glycogen synthase kinase 3 beta	Homo sapiens	192-200
27642355-6	2016	These results demonstrated that the molecular mechanisms of inhibitory activities of biatractylolide on AChE are not only through binding to AChE, but also via reducing AChE expression by inhibiting the activity of GSK3beta.	biatractylolide	85-100	glycogen synthase kinase 3 beta	Homo sapiens	215-223
26787464-2	2016	Compared to healthy cells, PAH PASMCs demonstrate higher levels of proliferation both at baseline and with PDGF-BB that correlate with GSK3beta dependent betaC activation.	pasmcs	31-37	glycogen synthase kinase 3 beta	Homo sapiens	135-143
26521020-6	2016	Violacein increased both mitochondrial and extra mitochondrial apoptotic pathway related gene expressions; it was confirmed by increased CYP1A, GPX, GSK3beta and TNF-alpha gene.	violacein	0-9	glycogen synthase kinase 3 beta	Homo sapiens	149-157
26850078-6	2016	In addition, cells exposed to the MF showed increased intracellular reactive oxidative species (ROS) levels and glycogen synthase kinase-3beta (GSK-3beta) dephosphorylation at 9 serine residue (Ser(9)).	Serine	178-184	glycogen synthase kinase 3 beta	Homo sapiens	144-153
26613980-7	2016	In the context of LPS stimulation, this occurred concomitant with the phosphorylative inactivation of GSK3beta at Ser(9), beta-catenin accumulation and abrogation of NFkappaB p65 phosphorylation.	Serine	114-117	glycogen synthase kinase 3 beta	Homo sapiens	102-110
26648168-5	2016	Our results indicate that: i) bufalin can regulate the expression of associated factors in Wnt/beta-catenin signaling pathway of BEL-7402 cells through suppressing the phosphorylation of GSK-3beta Ser9 site; ii) bufalin can strengthen intercellular E-cadherin/beta-catenin complex to control epithelial-mesenchymal transition; and iii) bufalin can reverse the malignant phenotype and promote the differentiation and maturation by regulating the AFP and ALB expression in BEL-7402 cells.	bufalin	30-37	glycogen synthase kinase 3 beta	Homo sapiens	187-196
26850078-0	2016	Exposure to a 50-Hz magnetic field induced mitochondrial permeability transition through the ROS/GSK-3beta signaling pathway.	ros	93-96	glycogen synthase kinase 3 beta	Homo sapiens	97-106
26850078-6	2016	In addition, cells exposed to the MF showed increased intracellular reactive oxidative species (ROS) levels and glycogen synthase kinase-3beta (GSK-3beta) dephosphorylation at 9 serine residue (Ser(9)).	Serine	178-184	glycogen synthase kinase 3 beta	Homo sapiens	112-142
26850078-6	2016	In addition, cells exposed to the MF showed increased intracellular reactive oxidative species (ROS) levels and glycogen synthase kinase-3beta (GSK-3beta) dephosphorylation at 9 serine residue (Ser(9)).	Serine	194-197	glycogen synthase kinase 3 beta	Homo sapiens	112-142
26850078-6	2016	In addition, cells exposed to the MF showed increased intracellular reactive oxidative species (ROS) levels and glycogen synthase kinase-3beta (GSK-3beta) dephosphorylation at 9 serine residue (Ser(9)).	Serine	194-197	glycogen synthase kinase 3 beta	Homo sapiens	144-153
26850078-7	2016	Moreover, the MF-induced MPT was attenuated by ROS scavenger (N-acetyl-L-cysteine, NAC) or GSK-3beta inhibitor, and NAC pretreatment prevented GSK-3beta dephosphorylation (Ser(9)) caused by MF exposure.	Acetylcysteine	62-81	glycogen synthase kinase 3 beta	Homo sapiens	143-152
26850078-7	2016	Moreover, the MF-induced MPT was attenuated by ROS scavenger (N-acetyl-L-cysteine, NAC) or GSK-3beta inhibitor, and NAC pretreatment prevented GSK-3beta dephosphorylation (Ser(9)) caused by MF exposure.	Serine	172-175	glycogen synthase kinase 3 beta	Homo sapiens	143-152
26850078-8	2016	CONCLUSION: MPT induced by MF exposure was mediated through the ROS/GSK-3beta signaling pathway.	ros	64-67	glycogen synthase kinase 3 beta	Homo sapiens	68-77
26647836-5	2016	Furthermore, the anti-proliferative effects of hesperetin were associated with suppression of the AKT/glycogen synthase kinase (GSK)3beta and p38 signaling pathway, but were not associated with the extracellular signal-regulated kinases 1/2 and c-Jun N-terminal kinases signaling pathways.	hesperetin	47-57	glycogen synthase kinase 3 beta	Homo sapiens	128-137
26890744-7	2016	In addition, we also found that miR-302-mediated Akt signaling further stimulates Nanog expression to suppress Abeta-induced p-Ser307 IRS-1 expression and thus enhances tyrosine phosphorylation and p-Ser 473-Akt/p-Ser 9-GSK3beta formation.	UNII-042A8N37WH	111-116	glycogen synthase kinase 3 beta	Homo sapiens	212-228
26584949-5	2016	PAN reduces Akt phosphorylation levels of GSK3beta, LY294002 can promote podocyte apoptosis induced by PAN.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	52-60	glycogen synthase kinase 3 beta	Homo sapiens	42-50
26647836-6	2016	These results suggested that hesperetin may inhibit PDGFa-BB-induced PASMC proliferation via the AKT/GSK3beta signaling pathway, and that it may possess therapeutic potential for the treatment of pulmonary vascular remodeling diseases.	hesperetin	29-39	glycogen synthase kinase 3 beta	Homo sapiens	101-109
27003416-5	2016	The activity of GSK-3beta (serine-9-phosphorylated GSK-3beta/total GSK-3beta) was lower at baseline compared with follow-up.	Serine	27-33	glycogen synthase kinase 3 beta	Homo sapiens	16-25
26647836-6	2016	These results suggested that hesperetin may inhibit PDGFa-BB-induced PASMC proliferation via the AKT/GSK3beta signaling pathway, and that it may possess therapeutic potential for the treatment of pulmonary vascular remodeling diseases.	boeravinone B	58-60	glycogen synthase kinase 3 beta	Homo sapiens	101-109
27468874-11	2016	We then used GSK3beta specific inhibitor SB-216763 to activate the Wnt/beta-catenin signaling pathway.	SB 216763	41-50	glycogen synthase kinase 3 beta	Homo sapiens	13-21
27003416-5	2016	The activity of GSK-3beta (serine-9-phosphorylated GSK-3beta/total GSK-3beta) was lower at baseline compared with follow-up.	Serine	27-33	glycogen synthase kinase 3 beta	Homo sapiens	51-60
27003416-5	2016	The activity of GSK-3beta (serine-9-phosphorylated GSK-3beta/total GSK-3beta) was lower at baseline compared with follow-up.	Serine	27-33	glycogen synthase kinase 3 beta	Homo sapiens	51-60
26711256-7	2015	We mapped Ser147 of GSK-3beta as the site phosphorylated by PKCzeta, i.e., its mutation into alanine abolished GSK-3beta activity, resulting in beta-catenin stabilization and increased transcriptional activity, whereas phosphomimetic replacement of Ser147 by glutamic acid maintained GSK-3beta basal activity.	Alanine	93-100	glycogen synthase kinase 3 beta	Homo sapiens	20-29
27158593-5	2016	Arsenic exposure alone inhibits the differentiation of stem cells into neurons and skeletal myotubes, and reduces the expression of both beta-catenin and GSK3beta mRNA to ~55% of control levels.	Arsenic	0-7	glycogen synthase kinase 3 beta	Homo sapiens	154-162
26530632-5	2016	Furthermore, western blotting demonstrated that resveratrol decreased the protein expression of phospho-glycogen synthase kinase 3beta (p-GSK3beta), cyclin D1, phospho-phosphatase and tensin homologue (p-PTEN), phospho-phosphatidylinositol 3"-OH kinase (p-PI3K), and phospho-protein kinase B (p-PKB/Akt).	Resveratrol	48-59	glycogen synthase kinase 3 beta	Homo sapiens	138-146
26649051-5	2016	We found that ciprofloxacin exerted its effect through ATP-dependent tyrosine kinase/glycogen synthase kinase3beta dependent mechanism which in turn upregulated beta-catenin.	Ciprofloxacin	14-27	glycogen synthase kinase 3 beta	Homo sapiens	85-114
26711256-7	2015	We mapped Ser147 of GSK-3beta as the site phosphorylated by PKCzeta, i.e., its mutation into alanine abolished GSK-3beta activity, resulting in beta-catenin stabilization and increased transcriptional activity, whereas phosphomimetic replacement of Ser147 by glutamic acid maintained GSK-3beta basal activity.	Alanine	93-100	glycogen synthase kinase 3 beta	Homo sapiens	111-120
26711256-7	2015	We mapped Ser147 of GSK-3beta as the site phosphorylated by PKCzeta, i.e., its mutation into alanine abolished GSK-3beta activity, resulting in beta-catenin stabilization and increased transcriptional activity, whereas phosphomimetic replacement of Ser147 by glutamic acid maintained GSK-3beta basal activity.	Alanine	93-100	glycogen synthase kinase 3 beta	Homo sapiens	111-120
26515726-7	2015	Western blots revealed that EMT-related transcription factors Snail and Twist were reduced and E-cadherin was enhanced in amiodarone treated cells through an EGFR/ERK/GSK3beta-dependent pathway.	Amiodarone	122-132	glycogen synthase kinase 3 beta	Homo sapiens	167-175
26674355-0	2015	The Cytoprotective Effect of Hyperoside against Oxidative Stress Is Mediated by the Nrf2-ARE Signaling Pathway through GSK-3beta Inactivation.	hyperoside	29-39	glycogen synthase kinase 3 beta	Homo sapiens	119-128
26674355-4	2015	Here, we demonstrate that in a normal human hepatocyte cell line, (L02), hyperoside is capable of inducing the phosphorylation of GSK-3beta at Ser9 without affecting the protein levels of GSK-3beta and its phosphorylation at Thr390.	hyperoside	73-83	glycogen synthase kinase 3 beta	Homo sapiens	130-139
26674355-4	2015	Here, we demonstrate that in a normal human hepatocyte cell line, (L02), hyperoside is capable of inducing the phosphorylation of GSK-3beta at Ser9 without affecting the protein levels of GSK-3beta and its phosphorylation at Thr390.	hyperoside	73-83	glycogen synthase kinase 3 beta	Homo sapiens	188-197
26674355-5	2015	Lithium chloride (LiCl) and short interfering RNA (siRNA)-mediated inhibition of GSK-3beta significantly enhanced the ability of hyperoside to protect L02 liver cells from H2O2-induced oxidative damage, leading to increased cell survival shown by the maintenance of cell membrane integrity and elevated levels of glutathione (GSH), one of the endogenous antioxidant biomarkers.	Lithium Chloride	18-22	glycogen synthase kinase 3 beta	Homo sapiens	81-90
26674355-5	2015	Lithium chloride (LiCl) and short interfering RNA (siRNA)-mediated inhibition of GSK-3beta significantly enhanced the ability of hyperoside to protect L02 liver cells from H2O2-induced oxidative damage, leading to increased cell survival shown by the maintenance of cell membrane integrity and elevated levels of glutathione (GSH), one of the endogenous antioxidant biomarkers.	hyperoside	129-139	glycogen synthase kinase 3 beta	Homo sapiens	81-90
26674355-5	2015	Lithium chloride (LiCl) and short interfering RNA (siRNA)-mediated inhibition of GSK-3beta significantly enhanced the ability of hyperoside to protect L02 liver cells from H2O2-induced oxidative damage, leading to increased cell survival shown by the maintenance of cell membrane integrity and elevated levels of glutathione (GSH), one of the endogenous antioxidant biomarkers.	Hydrogen Peroxide	172-176	glycogen synthase kinase 3 beta	Homo sapiens	81-90
26674355-5	2015	Lithium chloride (LiCl) and short interfering RNA (siRNA)-mediated inhibition of GSK-3beta significantly enhanced the ability of hyperoside to protect L02 liver cells from H2O2-induced oxidative damage, leading to increased cell survival shown by the maintenance of cell membrane integrity and elevated levels of glutathione (GSH), one of the endogenous antioxidant biomarkers.	Glutathione	313-324	glycogen synthase kinase 3 beta	Homo sapiens	81-90
26674355-5	2015	Lithium chloride (LiCl) and short interfering RNA (siRNA)-mediated inhibition of GSK-3beta significantly enhanced the ability of hyperoside to protect L02 liver cells from H2O2-induced oxidative damage, leading to increased cell survival shown by the maintenance of cell membrane integrity and elevated levels of glutathione (GSH), one of the endogenous antioxidant biomarkers.	Glutathione	326-329	glycogen synthase kinase 3 beta	Homo sapiens	81-90
26674355-6	2015	Further study showed that LiCl and siRNA-mediated inhibition of GSK-3beta increased hyperoside-induced HO-1 expression, and the effect was dependent upon enhanced Nrf2 nuclear translocation and gene expression.	hyperoside	84-94	glycogen synthase kinase 3 beta	Homo sapiens	64-73
26674355-8	2015	Furthermore, the siRNA-mediated inhibition of Keap1 also enhanced hyperoside-induced Nrf2 nuclear accumulation and HO-1 expression, which was relatively smaller than the effects obtained from GSK-3beta siRNA administration.	hyperoside	66-76	glycogen synthase kinase 3 beta	Homo sapiens	192-201
26674355-10	2015	Collectively, our data provide evidence that hyperoside attenuates H2O2 -induced L02 cell damage by activating the Nrf2-ARE signaling pathway through both an increase in GSK-3beta inhibitory phosphorylation at Ser9 and an inhibition of Keap1 and that hyperoside-mediated GSK-3beta inhibition exhibits more significant effects.	hyperoside	45-55	glycogen synthase kinase 3 beta	Homo sapiens	170-179
26674355-10	2015	Collectively, our data provide evidence that hyperoside attenuates H2O2 -induced L02 cell damage by activating the Nrf2-ARE signaling pathway through both an increase in GSK-3beta inhibitory phosphorylation at Ser9 and an inhibition of Keap1 and that hyperoside-mediated GSK-3beta inhibition exhibits more significant effects.	hyperoside	45-55	glycogen synthase kinase 3 beta	Homo sapiens	271-280
26674355-10	2015	Collectively, our data provide evidence that hyperoside attenuates H2O2 -induced L02 cell damage by activating the Nrf2-ARE signaling pathway through both an increase in GSK-3beta inhibitory phosphorylation at Ser9 and an inhibition of Keap1 and that hyperoside-mediated GSK-3beta inhibition exhibits more significant effects.	Hydrogen Peroxide	67-71	glycogen synthase kinase 3 beta	Homo sapiens	170-179
26674355-10	2015	Collectively, our data provide evidence that hyperoside attenuates H2O2 -induced L02 cell damage by activating the Nrf2-ARE signaling pathway through both an increase in GSK-3beta inhibitory phosphorylation at Ser9 and an inhibition of Keap1 and that hyperoside-mediated GSK-3beta inhibition exhibits more significant effects.	Hydrogen Peroxide	67-71	glycogen synthase kinase 3 beta	Homo sapiens	271-280
26626191-8	2015	Our results demonstrated that glycyrrhizic acid exerted the stem cell suppressing effects through the interruption of ATP-dependent tyrosine kinase/glycogen synthase kinase3beta-dependent mechanism which in turn down-regulated the beta-catenin signalling pathway, coupled with decreased its down-stream epithelial-mesenchymal transition and self-renewal transcription factors, namely, Oct-4, Nanog, Sox2, ZEB1 and Snail.	Glycyrrhizic Acid	30-47	glycogen synthase kinase 3 beta	Homo sapiens	148-177
25920742-0	2015	Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer"s disease patients.	Donepezil	93-102	glycogen synthase kinase 3 beta	Homo sapiens	54-59
26626191-8	2015	Our results demonstrated that glycyrrhizic acid exerted the stem cell suppressing effects through the interruption of ATP-dependent tyrosine kinase/glycogen synthase kinase3beta-dependent mechanism which in turn down-regulated the beta-catenin signalling pathway, coupled with decreased its down-stream epithelial-mesenchymal transition and self-renewal transcription factors, namely, Oct-4, Nanog, Sox2, ZEB1 and Snail.	Adenosine Triphosphate	118-121	glycogen synthase kinase 3 beta	Homo sapiens	148-177
26385428-5	2015	We show that inhibition of GSK3beta with lithium chloride enhances Gli3 processing into its repressor form, consequently downregulating Hh-Gli signaling, reducing cell proliferation and inducing cell death.	Lithium Chloride	41-57	glycogen synthase kinase 3 beta	Homo sapiens	27-35
26385428-6	2015	Analysis of the molecular mechanisms revealed that lithium chloride enhances Gli3-SuFu-GSK3beta complex formation leading to more efficient Gli3 cleavage and Hh-Gli signaling downregulation.	Lithium Chloride	51-67	glycogen synthase kinase 3 beta	Homo sapiens	87-95
26320152-2	2015	Glycogen synthase-3beta (GSK3beta) inactivation plays a key role in mediating signaling processes upon reactive oxygen species (ROS) exposure.	Reactive Oxygen Species	103-126	glycogen synthase kinase 3 beta	Homo sapiens	25-33
26095393-12	2015	We conclude that GSK3beta inhibition by GIN caused an uncoupling of BMP signaling and SOST expression, resulting in an increased BMP4-induced osteoblast differentiation.	2-{[(6-Oxo-1,6-Dihydropyridin-3-Yl)methyl]amino}-N-[4-Propyl-3-(Trifluoromethyl)phenyl]benzamide	40-43	glycogen synthase kinase 3 beta	Homo sapiens	17-25
26618897-7	2015	LiCl mediated GSK3beta inactivation in vitro resulted in increased mitochondrial ROS production, responsible for reduced cell proliferation, S phase transient arrest, and increase in cell senescence, size and granularity.	Reactive Oxygen Species	81-84	glycogen synthase kinase 3 beta	Homo sapiens	14-22
26618897-12	2015	Indeed, GSK3beta inactivation is responsible for ROS production, triggering oxidative stress and DNA damage response.	Reactive Oxygen Species	49-52	glycogen synthase kinase 3 beta	Homo sapiens	8-16
26571119-5	2015	ATRA also inhibited the function of PI3K-AKT and enhanced GSK-3beta-dependent degradation of phosphorylated beta-catenin.	Tretinoin	0-4	glycogen synthase kinase 3 beta	Homo sapiens	58-67
26626025-4	2015	Treatment with GSK3beta inhibitors during the initial phase of differentiation in combination with dual SMAD inhibition was sufficient to induce PAX6 (+) and SOX1 (+) neural progenitors within 1 week, and subsequent treatment with retinoic acid (RA) and purmorphamine, which activates sonic hedgehog (SHH) signaling, resulted in the highly efficient induction of HB9(+) and ISL-1(+) motor neurons within 2 weeks.	Tretinoin	231-244	glycogen synthase kinase 3 beta	Homo sapiens	15-23
26626025-4	2015	Treatment with GSK3beta inhibitors during the initial phase of differentiation in combination with dual SMAD inhibition was sufficient to induce PAX6 (+) and SOX1 (+) neural progenitors within 1 week, and subsequent treatment with retinoic acid (RA) and purmorphamine, which activates sonic hedgehog (SHH) signaling, resulted in the highly efficient induction of HB9(+) and ISL-1(+) motor neurons within 2 weeks.	Tretinoin	246-248	glycogen synthase kinase 3 beta	Homo sapiens	15-23
26626025-4	2015	Treatment with GSK3beta inhibitors during the initial phase of differentiation in combination with dual SMAD inhibition was sufficient to induce PAX6 (+) and SOX1 (+) neural progenitors within 1 week, and subsequent treatment with retinoic acid (RA) and purmorphamine, which activates sonic hedgehog (SHH) signaling, resulted in the highly efficient induction of HB9(+) and ISL-1(+) motor neurons within 2 weeks.	purmorphamine	254-267	glycogen synthase kinase 3 beta	Homo sapiens	15-23
26311646-9	2015	To evaluate this possibility, we treated neurons with 6-bromoindirubin-3"-oxime (BIO), a small molecule GSK-3beta inhibitor.	6-bromoindirubin-3'-oxime	54-79	glycogen synthase kinase 3 beta	Homo sapiens	104-113
26456654-6	2015	In early passage MSCs expressing SIRT1, resveratrol decreased ERK and GSK-3beta phosphorylation, suppressing beta-catenin activity.	Resveratrol	40-51	glycogen synthase kinase 3 beta	Homo sapiens	70-79
26456654-7	2015	In contrast, in late passage MSCs, which did not express SIRT1, resveratrol increased ERK and GSK-3beta phosphorylation, activating beta-catenin.	Resveratrol	64-75	glycogen synthase kinase 3 beta	Homo sapiens	94-103
26320152-2	2015	Glycogen synthase-3beta (GSK3beta) inactivation plays a key role in mediating signaling processes upon reactive oxygen species (ROS) exposure.	Reactive Oxygen Species	128-131	glycogen synthase kinase 3 beta	Homo sapiens	25-33
26320152-9	2015	In conclusion, we demonstrate for the first time that ROS-induced glucocorticoid unresponsiveness in COPD is mediated through GSK3beta, acting as a ROS-sensitive hub.	Reactive Oxygen Species	54-57	glycogen synthase kinase 3 beta	Homo sapiens	126-134
26320152-9	2015	In conclusion, we demonstrate for the first time that ROS-induced glucocorticoid unresponsiveness in COPD is mediated through GSK3beta, acting as a ROS-sensitive hub.	Reactive Oxygen Species	148-151	glycogen synthase kinase 3 beta	Homo sapiens	126-134
26560046-8	2015	Meanwhile, LiCl increased GSK3beta transcript levels and the proliferation of CaSki cells in a HPV16-dependent manner.	Lithium Chloride	11-15	glycogen synthase kinase 3 beta	Homo sapiens	26-34
26449452-8	2015	We found that depletion of TRAF1 markedly reversed PA-induced attenuation of the phosphorylation of Akt and GSK3beta in the cells.	Palmitates	51-53	glycogen synthase kinase 3 beta	Homo sapiens	108-116
26372541-8	2015	In the presence of D2R, cAMP signaling of TAAR1 was reduced while its betaArr2 signaling was enhanced, resulting in reduced GSK3beta activation.	Cyclic AMP	24-28	glycogen synthase kinase 3 beta	Homo sapiens	124-132
26333042-2	2015	In the liver, this effect occurs with a concomitant protection against a decrease in GSK3beta-Ser(9) phosphorylation.	Serine	94-97	glycogen synthase kinase 3 beta	Homo sapiens	85-93
26333042-5	2015	KEY RESULTS: Huh7 cells undergoing combined hypoxia, hypercapnia, and hypothermia reproduced the reduced GSK3beta-Ser(9) phosphorylation shown in vivo during haemorrhagic shock, and this change was blocked by VPA.	Serine	114-117	glycogen synthase kinase 3 beta	Homo sapiens	105-113
26333042-10	2015	CONCLUSION AND IMPLICATIONS: Changes in GSK3beta-Ser(9) phosphorylation in in vivo haemorrhagic shock models can be modelled in vitro, and this has identified a role for PPARgamma activation in the protective role of VPA.	Serine	49-52	glycogen synthase kinase 3 beta	Homo sapiens	40-48
26352871-0	2015	Upregulation of C-C chemokine receptor type 7 expression by membrane-associated prostaglandin E synthase-1/prostaglandin E2 requires glycogen synthase kinase 3beta-mediated signal transduction in colon cancer cells.	Prostaglandins	80-93	glycogen synthase kinase 3 beta	Homo sapiens	133-163
26352871-7	2015	Finally, overexpression of CCR7 was partly mediated through the AKT/glycogen synthase kinase 3beta signaling pathway dependent on the binding of mPGES-1-derived PGE2 to the prostaglandin EP4 receptor.	Dinoprostone	161-165	glycogen synthase kinase 3 beta	Homo sapiens	68-98
26352871-0	2015	Upregulation of C-C chemokine receptor type 7 expression by membrane-associated prostaglandin E synthase-1/prostaglandin E2 requires glycogen synthase kinase 3beta-mediated signal transduction in colon cancer cells.	Dinoprostone	107-123	glycogen synthase kinase 3 beta	Homo sapiens	133-163
26243309-4	2015	Aschantin inhibited epidermal growth factor (EGF)-induced full activation of Akt by phosphorylation at Ser473/Thr308, resulting in inhibition of the mTORC2/Akt and Akt/mTORC1/p70S6K signaling pathways and activation of GSK3beta by abrogation of Akt-mediated GSK3beta phosphorylation at Ser9.	aschantin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	219-227
26496802-3	2015	Here we report aminopyrazine compounds that stimulate robust beta-cell proliferation in adult primary islets, most likely as a result of combined inhibition of DYRK1A and GSK3B.	2-aminopyrazine	15-28	glycogen synthase kinase 3 beta	Homo sapiens	171-176
26301632-5	2015	In addition, we showed that interference of PRDX1 ameliorated palmitate-induced insulin resistance in HepG2 cells, which was indicated by elevated phosphorylation of protein kinase B (AKT) and of glycogen synthase kinase-3 (GSK3beta).	Palmitates	62-71	glycogen synthase kinase 3 beta	Homo sapiens	224-232
26578864-4	2015	The inhibition of GSK-3beta has been the mechanism most studied; however, other modes of action include the regulation of apoptotic proteins and glutamate excitotoxicity as well as down-regulation of calpain.	Glutamic Acid	145-154	glycogen synthase kinase 3 beta	Homo sapiens	18-27
26381174-9	2015	However, suppression of GSK3alphabeta inhibited Cd-induced autophagy and induced apoptosis, which could be reversed by overexpression of GSK3beta.	Cadmium	48-50	glycogen synthase kinase 3 beta	Homo sapiens	137-145
26331790-9	2015	In this paper, we solve both problems by conjugating the hydrophobic GSK3beta inhibitor to a hydrophilic aspartic acid octapeptide using a hydrolyzable bond, thereby generating a bone fracture-targeted water-soluble form of the drug.	aspartic acid octapeptide	105-130	glycogen synthase kinase 3 beta	Homo sapiens	69-77
26331790-9	2015	In this paper, we solve both problems by conjugating the hydrophobic GSK3beta inhibitor to a hydrophilic aspartic acid octapeptide using a hydrolyzable bond, thereby generating a bone fracture-targeted water-soluble form of the drug.	Water	202-207	glycogen synthase kinase 3 beta	Homo sapiens	69-77
26331790-11	2015	For measurement of pharmacokinetics, an 125I was introduced at the location of the bromine in the GSK3beta inhibitor to minimize any structural differences.	Bromine	83-90	glycogen synthase kinase 3 beta	Homo sapiens	98-106
27551464-8	2015	Daily intraperitoneal injection of Z86 at 5 mg/kg resulted in &gt;70% reduction in the tumor weight of HCT116 cell origin that was associated with decreased GSK3beta (Ser9) phosphorylation and increased beta-catenin phosphorylation.	CHEMBL1738945	35-38	glycogen synthase kinase 3 beta	Homo sapiens	157-165
26111662-6	2015	The downregulation of PTPalpha results in the abnormal tyrosine hyperphosphorylation of glycogen synthase kinase-3beta (resulting in activation) and protein phosphatase 2A (resulting in inactivation), the major tau kinase and phosphatase.	Tyrosine	55-63	glycogen synthase kinase 3 beta	Homo sapiens	88-118
25711384-0	2015	Synthesis and Evaluation of 3-(furo[2,3-b]pyridin-3-yl)-4-(1H-indol-3-yl)-maleimides as Novel GSK-3beta Inhibitors and Anti-Ischemic Agents.	3-(furo[2,3-b]pyridin-3-yl)-4-(1h-indol-3-yl)-maleimides	28-84	glycogen synthase kinase 3 beta	Homo sapiens	94-103
25711384-1	2015	A series of novel 3-(furo[2,3-b]pyridin-3-yl)-4-(1H-indol-3-yl)-maleimides were designed, synthesized, and biologically evaluated for their GSK-3beta inhibitory activities.	3-(furo[2,3-b]pyridin-3-yl)-4-(1h-indol-3-yl)-maleimides	18-74	glycogen synthase kinase 3 beta	Homo sapiens	140-149
26243309-4	2015	Aschantin inhibited epidermal growth factor (EGF)-induced full activation of Akt by phosphorylation at Ser473/Thr308, resulting in inhibition of the mTORC2/Akt and Akt/mTORC1/p70S6K signaling pathways and activation of GSK3beta by abrogation of Akt-mediated GSK3beta phosphorylation at Ser9.	aschantin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	258-266
26315788-0	2015	miRNA-99b-3p functions as a potential tumor suppressor by targeting glycogen synthase kinase-3beta in oral squamous cell carcinoma Tca-8113 cells.	Trichloroacetic Acid	131-134	glycogen synthase kinase 3 beta	Homo sapiens	68-98
26236947-8	2015	Moreover, AMPK-induced GSK3beta and SIRT1 activities were found to be responsible for inhibiting c-Myc-mediated upregulation of MTDH, as LiCl (an inhibitor of GSK3beta) and EX-527 (an inhibitor of SIRT1) reversed AICAR-mediated downregulation of c-Myc and MTDH expressions.	Lithium Chloride	137-141	glycogen synthase kinase 3 beta	Homo sapiens	23-31
26236947-8	2015	Moreover, AMPK-induced GSK3beta and SIRT1 activities were found to be responsible for inhibiting c-Myc-mediated upregulation of MTDH, as LiCl (an inhibitor of GSK3beta) and EX-527 (an inhibitor of SIRT1) reversed AICAR-mediated downregulation of c-Myc and MTDH expressions.	Lithium Chloride	137-141	glycogen synthase kinase 3 beta	Homo sapiens	159-167
25393899-10	2015	Furthermore, pretreatment with isoproterenol or resistin-specific siRNA blocked nicotine plus LPS-induced activation of phosphoinositide-3-kinase, glycogen synthase kinase-3 beta, beta-catenin, p38, ERK, JNK and nuclear factor-kappaB.	Isoproterenol	31-44	glycogen synthase kinase 3 beta	Homo sapiens	147-178
26267417-0	2015	Exploring Genetic Variability at PI, GSK3, HPA, and Glutamatergic Pathways in Lithium Response: Association With IMPA2, INPP1, and GSK3B Genes.	Lithium	78-85	glycogen synthase kinase 3 beta	Homo sapiens	131-136
26267417-8	2015	Our study is in line with previous studies reporting association between genetic variability at these genes and lithium response, pointing to an effect of IMPA2, INPP1, and GSK3B genes to lithium response in bipolar disorder patients.	Lithium	112-119	glycogen synthase kinase 3 beta	Homo sapiens	173-178
26267417-8	2015	Our study is in line with previous studies reporting association between genetic variability at these genes and lithium response, pointing to an effect of IMPA2, INPP1, and GSK3B genes to lithium response in bipolar disorder patients.	Lithium	188-195	glycogen synthase kinase 3 beta	Homo sapiens	173-178
25393899-10	2015	Furthermore, pretreatment with isoproterenol or resistin-specific siRNA blocked nicotine plus LPS-induced activation of phosphoinositide-3-kinase, glycogen synthase kinase-3 beta, beta-catenin, p38, ERK, JNK and nuclear factor-kappaB.	Nicotine	80-88	glycogen synthase kinase 3 beta	Homo sapiens	147-178
26284974-0	2015	Idebenone protects against oxidized low density lipoprotein induced mitochondrial dysfunction in vascular endothelial cells via GSK3beta/beta-catenin signalling pathways.	idebenone	0-9	glycogen synthase kinase 3 beta	Homo sapiens	128-136
26441681-7	2015	Enhanced activity of the TAD is probably mediated by lithium-induced inhibitory phosphorylation of glycogen synthase kinase 3beta (GSK-3beta), which is in accordance with previous studies.	Lithium	53-60	glycogen synthase kinase 3 beta	Homo sapiens	99-129
26441681-7	2015	Enhanced activity of the TAD is probably mediated by lithium-induced inhibitory phosphorylation of glycogen synthase kinase 3beta (GSK-3beta), which is in accordance with previous studies.	Lithium	53-60	glycogen synthase kinase 3 beta	Homo sapiens	131-140
26441681-8	2015	When cells were exposed to lithium for a longer period (96 h), cellular NFAT5 activity and subsequently expression of HSP70 significantly decreased under hyperosmotic conditions, due to diminished NFAT5 protein abundance, also resulting from GSK-3beta inhibition.	Lithium	27-34	glycogen synthase kinase 3 beta	Homo sapiens	242-251
26284974-6	2015	Finally, pro-incubation with idebenone inhibited mitochondrial dysfunction induced by oxLDL through the mitochondrial-dependent apoptotic pathway and GSK3beta/beta-catenin signalling pathways.	idebenone	29-38	glycogen synthase kinase 3 beta	Homo sapiens	150-158
26516309-0	2015	Lithium Chloride Promotes Apoptosis in Human Leukemia NB4 Cells by Inhibiting Glycogen Synthase Kinase-3 Beta.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	78-109
26516309-7	2015	Moreover, LiCl significantly increased the level of Ser9-phosphorylated glycogen synthase kinase 3beta(p-GSK-3beta), and decreased the level of Akt1 protein in a dose-dependent manner.	Lithium Chloride	10-14	glycogen synthase kinase 3 beta	Homo sapiens	105-114
25919890-4	2015	Photogenerated reactive oxygen species (ROS) in undifferentiated cells efficiently stimulated cell cycle arrest at G2/M phase, mitochondrial apoptotic pathway activation, the sustained phosphorylation of Akt/GSK-3beta and ERK.	Reactive Oxygen Species	15-38	glycogen synthase kinase 3 beta	Homo sapiens	208-217
26402673-4	2015	Palmitate acid (PA) impaired the insulin signaling, indicated by decreased phosphorylation of both serine/threonine-protein kinase B (Akt) and glycogen synthase kinase 3 beta (GSK3beta) following insulin administration, and upregulated PTP1B O-GlcNAcylation in HepG2 cells.	palmitate acid	0-14	glycogen synthase kinase 3 beta	Homo sapiens	143-174
26402673-4	2015	Palmitate acid (PA) impaired the insulin signaling, indicated by decreased phosphorylation of both serine/threonine-protein kinase B (Akt) and glycogen synthase kinase 3 beta (GSK3beta) following insulin administration, and upregulated PTP1B O-GlcNAcylation in HepG2 cells.	palmitate acid	0-14	glycogen synthase kinase 3 beta	Homo sapiens	176-184
26402673-4	2015	Palmitate acid (PA) impaired the insulin signaling, indicated by decreased phosphorylation of both serine/threonine-protein kinase B (Akt) and glycogen synthase kinase 3 beta (GSK3beta) following insulin administration, and upregulated PTP1B O-GlcNAcylation in HepG2 cells.	Protactinium	16-18	glycogen synthase kinase 3 beta	Homo sapiens	143-174
26402673-4	2015	Palmitate acid (PA) impaired the insulin signaling, indicated by decreased phosphorylation of both serine/threonine-protein kinase B (Akt) and glycogen synthase kinase 3 beta (GSK3beta) following insulin administration, and upregulated PTP1B O-GlcNAcylation in HepG2 cells.	Protactinium	16-18	glycogen synthase kinase 3 beta	Homo sapiens	176-184
26115843-0	2015	Inhibition of GSK3beta by pharmacological modulation of sphingolipid metabolism occurs independently of ganglioside disturbance in a cellular model of Alzheimer"s disease.	Sphingolipids	56-68	glycogen synthase kinase 3 beta	Homo sapiens	14-22
26115843-4	2015	We found that both ceramide analogs D- and L-PDMP (1-phenyl 2-decanoylamino-3-morpholino-1-propanol), which have opposite effects on ganglioside synthesis, selectively inhibited GSK3beta via Ser9 phosphorylation independently of the upstream insulin/Akt pathway.	Ceramides	19-27	glycogen synthase kinase 3 beta	Homo sapiens	178-186
26004524-3	2015	Lupeol-induced cell death is associated with a marked decrease in the protein expression of Brain-Derived Neurotrophic Factor (BDNF) and ser-9-phosphoryltion of Glycogen Synthase Kinase 3 Beta (GSK-3beta), with concomitant suppression of Akt1, phosphatidyl inositol 3-kinase (PI3K), beta-catenin, c-Myc and Cyclin D1 mRNA expression.	Serine	137-140	glycogen synthase kinase 3 beta	Homo sapiens	161-192
26004524-8	2015	These results indicate that lupeol can suppress HCC cell proliferation by inhibiting BDNF secretion and phosphorylation of GSK-3beta(Ser-9), cooperated with blockade of Akt/PI3K and Wnt signaling pathway.	Serine	133-136	glycogen synthase kinase 3 beta	Homo sapiens	123-132
26257010-0	2015	Monte Carlo method based QSAR modeling of maleimide derivatives as glycogen synthase kinase-3beta inhibitors.	maleimide	42-51	glycogen synthase kinase 3 beta	Homo sapiens	67-97
26257010-1	2015	The Monte Carlo method was used for QSAR modeling of maleimide derivatives as glycogen synthase kinase-3beta inhibitors.	maleimide	53-62	glycogen synthase kinase 3 beta	Homo sapiens	78-108
26115843-4	2015	We found that both ceramide analogs D- and L-PDMP (1-phenyl 2-decanoylamino-3-morpholino-1-propanol), which have opposite effects on ganglioside synthesis, selectively inhibited GSK3beta via Ser9 phosphorylation independently of the upstream insulin/Akt pathway.	RV 538	44-49	glycogen synthase kinase 3 beta	Homo sapiens	178-186
26115843-4	2015	We found that both ceramide analogs D- and L-PDMP (1-phenyl 2-decanoylamino-3-morpholino-1-propanol), which have opposite effects on ganglioside synthesis, selectively inhibited GSK3beta via Ser9 phosphorylation independently of the upstream insulin/Akt pathway.	RV 538	51-99	glycogen synthase kinase 3 beta	Homo sapiens	178-186
26115843-4	2015	We found that both ceramide analogs D- and L-PDMP (1-phenyl 2-decanoylamino-3-morpholino-1-propanol), which have opposite effects on ganglioside synthesis, selectively inhibited GSK3beta via Ser9 phosphorylation independently of the upstream insulin/Akt pathway.	Gangliosides	133-144	glycogen synthase kinase 3 beta	Homo sapiens	178-186
26115843-7	2015	Altogether, our findings led us to hypothesize that the PDMP-induced altered ganglioside composition is not the principal mechanism involved in the inhibition of GSK3beta, but seems to implicate, at least in part, their ability to reduce ceramide levels.	RV 538	56-60	glycogen synthase kinase 3 beta	Homo sapiens	162-170
26115843-8	2015	Nevertheless, this study provides new information regarding the possibilities to target GSK3beta through modulation of sphingolipid metabolism.	Sphingolipids	119-131	glycogen synthase kinase 3 beta	Homo sapiens	88-96
25919890-4	2015	Photogenerated reactive oxygen species (ROS) in undifferentiated cells efficiently stimulated cell cycle arrest at G2/M phase, mitochondrial apoptotic pathway activation, the sustained phosphorylation of Akt/GSK-3beta and ERK.	Reactive Oxygen Species	40-43	glycogen synthase kinase 3 beta	Homo sapiens	208-217
25864108-7	2015	Results indicated that treatments of IOMM-Lee and CH157MN meningioma cells with Limonin, Tangeritin, Zerumbone, 6-Gingerol, Ganoderic Acid A, and Ganoderic Acid DM induced apoptosis with enhanced phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) via inhibition of the Wnt5/beta-catenin pathway.	tangeretin	89-99	glycogen synthase kinase 3 beta	Homo sapiens	215-246
26010407-7	2015	Dynein motility is stimulated by (i) pharmacological and genetic inhibition of GSK-3beta, (ii) an insulin-sensitizing agent (rosiglitazone) and (iii) manipulating an insulin response pathway that leads to GSK-3beta inactivation.	Rosiglitazone	125-138	glycogen synthase kinase 3 beta	Homo sapiens	205-214
26392741-2	2015	METHODS: HLE-B3 cells, maintained in a continuous hypoxic environment (1% oxygen), were treated with SB216763, a specific inhibitor of glycogen synthase kinase-3beta (GSK-3beta) catalytic activity.	SB 216763	101-109	glycogen synthase kinase 3 beta	Homo sapiens	135-165
26392741-2	2015	METHODS: HLE-B3 cells, maintained in a continuous hypoxic environment (1% oxygen), were treated with SB216763, a specific inhibitor of glycogen synthase kinase-3beta (GSK-3beta) catalytic activity.	SB 216763	101-109	glycogen synthase kinase 3 beta	Homo sapiens	167-176
25864108-7	2015	Results indicated that treatments of IOMM-Lee and CH157MN meningioma cells with Limonin, Tangeritin, Zerumbone, 6-Gingerol, Ganoderic Acid A, and Ganoderic Acid DM induced apoptosis with enhanced phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) via inhibition of the Wnt5/beta-catenin pathway.	ganoderic acid A	124-140	glycogen synthase kinase 3 beta	Homo sapiens	215-246
25864108-7	2015	Results indicated that treatments of IOMM-Lee and CH157MN meningioma cells with Limonin, Tangeritin, Zerumbone, 6-Gingerol, Ganoderic Acid A, and Ganoderic Acid DM induced apoptosis with enhanced phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) via inhibition of the Wnt5/beta-catenin pathway.	ganoderic acid A	124-140	glycogen synthase kinase 3 beta	Homo sapiens	248-256
25864108-7	2015	Results indicated that treatments of IOMM-Lee and CH157MN meningioma cells with Limonin, Tangeritin, Zerumbone, 6-Gingerol, Ganoderic Acid A, and Ganoderic Acid DM induced apoptosis with enhanced phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) via inhibition of the Wnt5/beta-catenin pathway.	3,7-dioxolanosta-8,24-dien-26-oic acid	146-163	glycogen synthase kinase 3 beta	Homo sapiens	215-246
25864108-7	2015	Results indicated that treatments of IOMM-Lee and CH157MN meningioma cells with Limonin, Tangeritin, Zerumbone, 6-Gingerol, Ganoderic Acid A, and Ganoderic Acid DM induced apoptosis with enhanced phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) via inhibition of the Wnt5/beta-catenin pathway.	tangeretin	89-99	glycogen synthase kinase 3 beta	Homo sapiens	248-256
25864108-7	2015	Results indicated that treatments of IOMM-Lee and CH157MN meningioma cells with Limonin, Tangeritin, Zerumbone, 6-Gingerol, Ganoderic Acid A, and Ganoderic Acid DM induced apoptosis with enhanced phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) via inhibition of the Wnt5/beta-catenin pathway.	zerumbone	101-110	glycogen synthase kinase 3 beta	Homo sapiens	215-246
25864108-7	2015	Results indicated that treatments of IOMM-Lee and CH157MN meningioma cells with Limonin, Tangeritin, Zerumbone, 6-Gingerol, Ganoderic Acid A, and Ganoderic Acid DM induced apoptosis with enhanced phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) via inhibition of the Wnt5/beta-catenin pathway.	zerumbone	101-110	glycogen synthase kinase 3 beta	Homo sapiens	248-256
25864108-7	2015	Results indicated that treatments of IOMM-Lee and CH157MN meningioma cells with Limonin, Tangeritin, Zerumbone, 6-Gingerol, Ganoderic Acid A, and Ganoderic Acid DM induced apoptosis with enhanced phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) via inhibition of the Wnt5/beta-catenin pathway.	3,7-dioxolanosta-8,24-dien-26-oic acid	146-163	glycogen synthase kinase 3 beta	Homo sapiens	248-256
25864108-7	2015	Results indicated that treatments of IOMM-Lee and CH157MN meningioma cells with Limonin, Tangeritin, Zerumbone, 6-Gingerol, Ganoderic Acid A, and Ganoderic Acid DM induced apoptosis with enhanced phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) via inhibition of the Wnt5/beta-catenin pathway.	gingerol	112-122	glycogen synthase kinase 3 beta	Homo sapiens	215-246
25864108-7	2015	Results indicated that treatments of IOMM-Lee and CH157MN meningioma cells with Limonin, Tangeritin, Zerumbone, 6-Gingerol, Ganoderic Acid A, and Ganoderic Acid DM induced apoptosis with enhanced phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) via inhibition of the Wnt5/beta-catenin pathway.	gingerol	112-122	glycogen synthase kinase 3 beta	Homo sapiens	248-256
26108621-5	2015	Candidate kinases CKII and GSK-3b phosphorylate CREB-H in vitro with specificities for different serines.	Serine	97-104	glycogen synthase kinase 3 beta	Homo sapiens	27-33
26983213-10	2015	Tanshinone II A can have a preventive effect in AVC by activating GSK-3beta proteins and regulating signal transduction of Wnt/beta-catenin signal pathway.	tanshinone	0-15	glycogen synthase kinase 3 beta	Homo sapiens	66-75
26827544-8	2015	On the other hand, curcumin could promote the expression of PTEN, GSK3beta and Caspase 3 yet reduce the expression of Akt.	Curcumin	19-27	glycogen synthase kinase 3 beta	Homo sapiens	66-74
26827544-9	2015	CONCLUSION: Curcumin could obviously up-regulate the expression of PTEN, GSK3beta and Caspase 3, surpress PI3K/Akt signaling pathway and hence inhibit the proliferation of Ec109 cells.	Curcumin	12-20	glycogen synthase kinase 3 beta	Homo sapiens	73-95
26310325-7	2015	Consistently, treatment of ERG-expressing cells with nicotine induced elevated calcium influx, GSK3beta (Ser9) phosphorylation and cell proliferation.	Nicotine	53-61	glycogen synthase kinase 3 beta	Homo sapiens	95-103
26301867-10	2015	In H2170 erlotinib resistant cells, upregulation of inactive GSK3beta (p-GSK3beta) was observed, indicating activation of Wnt and mTOR pathways which are otherwise inhibited by its active form.	Erlotinib Hydrochloride	9-18	glycogen synthase kinase 3 beta	Homo sapiens	61-69
26301867-10	2015	In H2170 erlotinib resistant cells, upregulation of inactive GSK3beta (p-GSK3beta) was observed, indicating activation of Wnt and mTOR pathways which are otherwise inhibited by its active form.	Erlotinib Hydrochloride	9-18	glycogen synthase kinase 3 beta	Homo sapiens	73-81
26280348-6	2015	Moreover, the buildup of glycogen was linked to the phosphorylation of GSK-3beta, a canonical modulator of cell survival following radiation exposure and a key regulator of glycogen metabolism.	Glycogen	25-33	glycogen synthase kinase 3 beta	Homo sapiens	71-80
26280348-6	2015	Moreover, the buildup of glycogen was linked to the phosphorylation of GSK-3beta, a canonical modulator of cell survival following radiation exposure and a key regulator of glycogen metabolism.	Glycogen	173-181	glycogen synthase kinase 3 beta	Homo sapiens	71-80
26252009-9	2015	The changes in beta-catenin levels in response to embelin were blocked by lithium chloride, a GSK-3 inhibitor, indicating that embelin may decrease beta-catenin expression via GSK-3beta activation.	embelin	50-57	glycogen synthase kinase 3 beta	Homo sapiens	176-185
26088133-4	2015	Using a combination of molecular and cellular approaches we show that GSK3beta phosphorylation of Thr-1132 on AKAP220 initiates recruitment of this kinase into the enzyme scaffold.	Threonine	98-101	glycogen synthase kinase 3 beta	Homo sapiens	70-78
26088133-6	2015	Interestingly, GSK3beta can be released from the multienzyme complex in response to PKA phosphorylation on serine 9, which suppresses GSK3beta activity.	Serine	107-113	glycogen synthase kinase 3 beta	Homo sapiens	15-23
26088133-6	2015	Interestingly, GSK3beta can be released from the multienzyme complex in response to PKA phosphorylation on serine 9, which suppresses GSK3beta activity.	Serine	107-113	glycogen synthase kinase 3 beta	Homo sapiens	134-142
26088133-10	2015	Occupancy of both R subunit binding sites on AKAP220 could provide a mechanism to amplify local cAMP responses and enable cross-talk between PKA and GSK3beta.	Cyclic AMP	96-100	glycogen synthase kinase 3 beta	Homo sapiens	149-157
26260024-7	2015	TBHQ-induced Akt activation was accompanied by increased phosphorylation of Bad, glycogen synthase kinase-3beta (GSK-3beta) and mammalian target of rapamycin (mTOR).	2-tert-butylhydroquinone	0-4	glycogen synthase kinase 3 beta	Homo sapiens	81-111
26260024-7	2015	TBHQ-induced Akt activation was accompanied by increased phosphorylation of Bad, glycogen synthase kinase-3beta (GSK-3beta) and mammalian target of rapamycin (mTOR).	2-tert-butylhydroquinone	0-4	glycogen synthase kinase 3 beta	Homo sapiens	113-122
26252009-9	2015	The changes in beta-catenin levels in response to embelin were blocked by lithium chloride, a GSK-3 inhibitor, indicating that embelin may decrease beta-catenin expression via GSK-3beta activation.	Lithium Chloride	74-90	glycogen synthase kinase 3 beta	Homo sapiens	176-185
26252009-9	2015	The changes in beta-catenin levels in response to embelin were blocked by lithium chloride, a GSK-3 inhibitor, indicating that embelin may decrease beta-catenin expression via GSK-3beta activation.	embelin	127-134	glycogen synthase kinase 3 beta	Homo sapiens	176-185
26057861-0	2015	Structure-based design of benzo[e]isoindole-1,3-dione derivatives as selective GSK-3beta inhibitors to activate Wnt/beta-catenin pathway.	benzo[e]isoindole-1,3-dione	26-53	glycogen synthase kinase 3 beta	Homo sapiens	79-88
25943886-7	2015	Our in vitro experiments using GSK3beta inhibitors, luciferase reporter assays and oligodendrocytes expressing a mutant, dominant stable beta-catenin indicate that the mechanism of action of indometacin depends on GSK3beta activity and beta-catenin phosphorylation.	Indomethacin	191-202	glycogen synthase kinase 3 beta	Homo sapiens	31-39
25943886-7	2015	Our in vitro experiments using GSK3beta inhibitors, luciferase reporter assays and oligodendrocytes expressing a mutant, dominant stable beta-catenin indicate that the mechanism of action of indometacin depends on GSK3beta activity and beta-catenin phosphorylation.	Indomethacin	191-202	glycogen synthase kinase 3 beta	Homo sapiens	214-222
25273023-9	2015	Genetic knockdown of GSK3beta decreased Cd-induced MRP1 mRNA and protein levels, whereas its overexpression upregulated MRP1 protein expression.	Cadmium	40-42	glycogen synthase kinase 3 beta	Homo sapiens	21-29
25119493-7	2015	Furthermore, signal AKT/GSK-3beta-mediated stabilization of Snail is involved during BPA-induced EMT of colon cancer cells.	bisphenol A	85-88	glycogen synthase kinase 3 beta	Homo sapiens	24-33
25920809-2	2015	We hypothesized that GSKIP and GSK3beta mediate cAMP/PKA/Drp1 axis signaling and modulate mitochondrial morphology by forming a working complex comprising PKA/GSKIP/GSK3beta/Drp1.	Cyclic AMP	48-52	glycogen synthase kinase 3 beta	Homo sapiens	31-39
25920809-2	2015	We hypothesized that GSKIP and GSK3beta mediate cAMP/PKA/Drp1 axis signaling and modulate mitochondrial morphology by forming a working complex comprising PKA/GSKIP/GSK3beta/Drp1.	Cyclic AMP	48-52	glycogen synthase kinase 3 beta	Homo sapiens	165-173
25920809-7	2015	Collectively, our data revealed that both GSKIP and GSK3beta function as anchoring proteins in the cAMP/PKA/Drp1 signaling axis modulating Drp1 phosphorylation.	Cyclic AMP	99-103	glycogen synthase kinase 3 beta	Homo sapiens	52-60
26057861-2	2015	Here, we report a series of benzo[e]isoindole-1,3-dione derivatives as selective GSK-3beta inhibitors by rational-design and synthesis, which show high selectivity against GSK-3beta over Cyclin-dependent kinase 2 (CDK2), and significantly activate the cellular Wnt/beta-catenin pathway.	benzo[e]isoindole-1,3-dione	28-55	glycogen synthase kinase 3 beta	Homo sapiens	81-90
26057861-2	2015	Here, we report a series of benzo[e]isoindole-1,3-dione derivatives as selective GSK-3beta inhibitors by rational-design and synthesis, which show high selectivity against GSK-3beta over Cyclin-dependent kinase 2 (CDK2), and significantly activate the cellular Wnt/beta-catenin pathway.	benzo[e]isoindole-1,3-dione	28-55	glycogen synthase kinase 3 beta	Homo sapiens	172-181
26551701-5	2015	We present data showing that in the absence of Keap1, the electrophile tert-butyl hydroquinone (tBHQ) can stimulate Nrf2 activity and induce the Nrf2-target gene NAD(P)H: quinone oxidoreductase-1 (NQO1), whilst simultaneously causing inhibitory phosphorylation of GSK-3beta at Ser(9).	2-tert-butylhydroquinone	71-94	glycogen synthase kinase 3 beta	Homo sapiens	264-273
26058972-8	2015	These findings reveal that PGE2 upregulated the cholangiocarcinoma cell beta-catenin protein through the EP3-4R/Src/EGFR/PI3K/AKT/GSK-3beta pathway.	Dinoprostone	27-31	glycogen synthase kinase 3 beta	Homo sapiens	130-139
26551701-5	2015	We present data showing that in the absence of Keap1, the electrophile tert-butyl hydroquinone (tBHQ) can stimulate Nrf2 activity and induce the Nrf2-target gene NAD(P)H: quinone oxidoreductase-1 (NQO1), whilst simultaneously causing inhibitory phosphorylation of GSK-3beta at Ser(9).	2-tert-butylhydroquinone	96-100	glycogen synthase kinase 3 beta	Homo sapiens	264-273
26207897-8	2015	GSK3beta activity was only important for spine structural changes after treatment with Latrunculin B.	latrunculin A	87-98	glycogen synthase kinase 3 beta	Homo sapiens	0-8
26229588-6	2015	The addition of NaHS also counteracted the reduction of cell viability caused by H/R and increased the phosphorylation of ERK1/2, PI3K, Akt, GSK-3beta and mitochondrial membrane potential.	sodium bisulfide	16-20	glycogen synthase kinase 3 beta	Homo sapiens	141-150
26229588-9	2015	In conclusion, our results suggest that exogenous H2S restores PC-induced cardioprotection via the inhibition of mPTP opening by the activation of the ERK1/2-GSK-3beta, PI3K-Akt-GSK-3beta and PKC-epsilon-mitoKATP pathways in aging cardiomyocytes.	Hydrogen Sulfide	50-53	glycogen synthase kinase 3 beta	Homo sapiens	158-167
26229588-9	2015	In conclusion, our results suggest that exogenous H2S restores PC-induced cardioprotection via the inhibition of mPTP opening by the activation of the ERK1/2-GSK-3beta, PI3K-Akt-GSK-3beta and PKC-epsilon-mitoKATP pathways in aging cardiomyocytes.	Hydrogen Sulfide	50-53	glycogen synthase kinase 3 beta	Homo sapiens	178-187
26229588-9	2015	In conclusion, our results suggest that exogenous H2S restores PC-induced cardioprotection via the inhibition of mPTP opening by the activation of the ERK1/2-GSK-3beta, PI3K-Akt-GSK-3beta and PKC-epsilon-mitoKATP pathways in aging cardiomyocytes.	pc	63-65	glycogen synthase kinase 3 beta	Homo sapiens	178-187
26229588-9	2015	In conclusion, our results suggest that exogenous H2S restores PC-induced cardioprotection via the inhibition of mPTP opening by the activation of the ERK1/2-GSK-3beta, PI3K-Akt-GSK-3beta and PKC-epsilon-mitoKATP pathways in aging cardiomyocytes.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	113-117	glycogen synthase kinase 3 beta	Homo sapiens	178-187
26257598-6	2015	Recent preclinical studies indicate that ketamine"s antidepressant mechanism involves mammalian target of rapamycin pathway activation and subsequent synaptogenesis in the prefrontal cortex, as well as glycogen synthase kinase-3 beta (GSK-3beta) inactivation.	Ketamine	41-49	glycogen synthase kinase 3 beta	Homo sapiens	202-233
26206949-10	2015	Sorafenib markedly inhibited the HBx-enhanced AR activity through activating the SHP-1 phosphatase, which antagonized the activation of Akt/GSK3beta and c-Src by HBx.	Sorafenib	0-9	glycogen synthase kinase 3 beta	Homo sapiens	140-148
25934514-11	2015	Schisantherin A also protects against 6-OHDA-mediated activation of MAPKs, PI3K/Akt and GSK3beta.	Oxidopamine	38-44	glycogen synthase kinase 3 beta	Homo sapiens	88-96
26257598-6	2015	Recent preclinical studies indicate that ketamine"s antidepressant mechanism involves mammalian target of rapamycin pathway activation and subsequent synaptogenesis in the prefrontal cortex, as well as glycogen synthase kinase-3 beta (GSK-3beta) inactivation.	Ketamine	41-49	glycogen synthase kinase 3 beta	Homo sapiens	235-244
26257598-7	2015	Adjunct GSK-3beta inhibitors, such as lithium, can enhance ketamine"s efficacy by augmenting and prolonging its antidepressant effects.	Lithium	38-45	glycogen synthase kinase 3 beta	Homo sapiens	8-17
26257598-7	2015	Adjunct GSK-3beta inhibitors, such as lithium, can enhance ketamine"s efficacy by augmenting and prolonging its antidepressant effects.	Ketamine	59-67	glycogen synthase kinase 3 beta	Homo sapiens	8-17
26002461-9	2015	In addition, we showed that over-expression of PCBP2 ameliorates palmitate (PA)-induced insulin resistance, which was indicated by elevated phosphorylation of protein kinase B (AKT) and glycogen synthase kinase 3beta (GSK3beta).	Palmitates	65-74	glycogen synthase kinase 3 beta	Homo sapiens	186-216
26002461-9	2015	In addition, we showed that over-expression of PCBP2 ameliorates palmitate (PA)-induced insulin resistance, which was indicated by elevated phosphorylation of protein kinase B (AKT) and glycogen synthase kinase 3beta (GSK3beta).	Palmitates	65-74	glycogen synthase kinase 3 beta	Homo sapiens	218-226
26002461-9	2015	In addition, we showed that over-expression of PCBP2 ameliorates palmitate (PA)-induced insulin resistance, which was indicated by elevated phosphorylation of protein kinase B (AKT) and glycogen synthase kinase 3beta (GSK3beta).	Palmitates	76-78	glycogen synthase kinase 3 beta	Homo sapiens	218-226
26010513-8	2015	However, linagliptin significantly protected against Abeta-induced cytotoxicity, and prevented the activation of glycogen synthase kinase 3beta (GSK3beta) and tau hyperphosphorylation by restoring insulin downstream signaling.	Linagliptin	9-20	glycogen synthase kinase 3 beta	Homo sapiens	113-143
26093674-6	2015	RESULTS: Excitotoxic SCI using intraspinal quisqualic acid (QUIS) resulted in inhibition of GSK-3beta in the superficial spinal cord dorsal horn and adjacent DRG.	Quisqualic Acid	43-58	glycogen synthase kinase 3 beta	Homo sapiens	92-101
26032359-9	2015	Interestingly, CK induced programmed necrosis, but not apoptosis, via the GSK3beta signaling pathway in MCF-7 cells.	ginsenoside M1	15-17	glycogen synthase kinase 3 beta	Homo sapiens	74-82
26032359-11	2015	Our results suggest that CK induces programmed necrosis in MCF-7 breast cancer cells via the GSK3beta signaling pathway.	ginsenoside M1	25-27	glycogen synthase kinase 3 beta	Homo sapiens	93-101
24136474-6	2015	Wogonin-treated cells showed a decrease in the expression of Wnt protein and its co-receptors, as well as a parallel increase in the expression of Axin and GSK-3beta in degradation complex, leading to degradation of beta-catenin.	wogonin	0-7	glycogen synthase kinase 3 beta	Homo sapiens	156-165
26121043-8	2015	The addition of GSK-3beta inhibitor SB216763 inhibited the reduction of cyclin D1 caused by resibufogenin.	SB 216763	36-44	glycogen synthase kinase 3 beta	Homo sapiens	16-25
26111057-0	2015	Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3beta-Snail pathway.	Zidovudine	0-10	glycogen synthase kinase 3 beta	Homo sapiens	131-139
26111057-0	2015	Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3beta-Snail pathway.	gemcitabine	45-56	glycogen synthase kinase 3 beta	Homo sapiens	131-139
26111057-0	2015	Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3beta-Snail pathway.	gemcitabine	94-105	glycogen synthase kinase 3 beta	Homo sapiens	131-139
26111057-6	2015	The chemical biology investigations also revealed that activation of the Akt-GSK3beta-Snail1 pathway in resistant cells is a key signaling event for gemcitabine resistance, and zidovudine resensitized resistant cells to gemcitabine by inhibiting this activated pathway.	gemcitabine	149-160	glycogen synthase kinase 3 beta	Homo sapiens	77-85
26111057-6	2015	The chemical biology investigations also revealed that activation of the Akt-GSK3beta-Snail1 pathway in resistant cells is a key signaling event for gemcitabine resistance, and zidovudine resensitized resistant cells to gemcitabine by inhibiting this activated pathway.	Zidovudine	177-187	glycogen synthase kinase 3 beta	Homo sapiens	77-85
26157370-2	2015	However the use of lithium, a non-specific inhibitor of GSK3beta results in mild cognitive impairment in humans.	Lithium	19-26	glycogen synthase kinase 3 beta	Homo sapiens	56-64
26087957-9	2015	Mcl-1 suppression by MK-2206 was closely associated with decreased GSK3beta phosphorylation at Ser9, an event leads to GSK3beta activation.	MK 2206	21-28	glycogen synthase kinase 3 beta	Homo sapiens	67-75
26087957-9	2015	Mcl-1 suppression by MK-2206 was closely associated with decreased GSK3beta phosphorylation at Ser9, an event leads to GSK3beta activation.	MK 2206	21-28	glycogen synthase kinase 3 beta	Homo sapiens	119-127
26087957-10	2015	Furthermore, the effect of MK-2206 on Mcl-1 downregulation was abolished by GSK3beta inhibitor, lithium chloride and proteasome inhibitor, MG-132, suggesting that MK-2206 acted through a GSK3beta-mediated, proteasome-dependent protein degradation.	MK 2206	27-34	glycogen synthase kinase 3 beta	Homo sapiens	76-84
26087957-10	2015	Furthermore, the effect of MK-2206 on Mcl-1 downregulation was abolished by GSK3beta inhibitor, lithium chloride and proteasome inhibitor, MG-132, suggesting that MK-2206 acted through a GSK3beta-mediated, proteasome-dependent protein degradation.	MK 2206	27-34	glycogen synthase kinase 3 beta	Homo sapiens	187-195
26087957-10	2015	Furthermore, the effect of MK-2206 on Mcl-1 downregulation was abolished by GSK3beta inhibitor, lithium chloride and proteasome inhibitor, MG-132, suggesting that MK-2206 acted through a GSK3beta-mediated, proteasome-dependent protein degradation.	Lithium Chloride	96-112	glycogen synthase kinase 3 beta	Homo sapiens	187-195
26087957-10	2015	Furthermore, the effect of MK-2206 on Mcl-1 downregulation was abolished by GSK3beta inhibitor, lithium chloride and proteasome inhibitor, MG-132, suggesting that MK-2206 acted through a GSK3beta-mediated, proteasome-dependent protein degradation.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	139-145	glycogen synthase kinase 3 beta	Homo sapiens	187-195
26087957-10	2015	Furthermore, the effect of MK-2206 on Mcl-1 downregulation was abolished by GSK3beta inhibitor, lithium chloride and proteasome inhibitor, MG-132, suggesting that MK-2206 acted through a GSK3beta-mediated, proteasome-dependent protein degradation.	MK 2206	163-170	glycogen synthase kinase 3 beta	Homo sapiens	76-84
26087957-10	2015	Furthermore, the effect of MK-2206 on Mcl-1 downregulation was abolished by GSK3beta inhibitor, lithium chloride and proteasome inhibitor, MG-132, suggesting that MK-2206 acted through a GSK3beta-mediated, proteasome-dependent protein degradation.	MK 2206	163-170	glycogen synthase kinase 3 beta	Homo sapiens	187-195
26093674-6	2015	RESULTS: Excitotoxic SCI using intraspinal quisqualic acid (QUIS) resulted in inhibition of GSK-3beta in the superficial spinal cord dorsal horn and adjacent DRG.	Quisqualic Acid	60-64	glycogen synthase kinase 3 beta	Homo sapiens	92-101
26093674-8	2015	Intrathecal administration of a potent PI3-kinase inhibitor (LY294002), a known GSK-3beta activator, significantly decreased GSK-3beta(P) expression levels in the dorsal horn.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	61-69	glycogen synthase kinase 3 beta	Homo sapiens	80-89
26093674-8	2015	Intrathecal administration of a potent PI3-kinase inhibitor (LY294002), a known GSK-3beta activator, significantly decreased GSK-3beta(P) expression levels in the dorsal horn.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	61-69	glycogen synthase kinase 3 beta	Homo sapiens	125-134
26093674-11	2015	CONCLUSIONS: QUIS induced SCI resulted in inhibition of GSK-3beta in primary afferents and enhanced at-level DRG intrinsic growth (neurite elongation and initiation).	Quisqualic Acid	13-17	glycogen synthase kinase 3 beta	Homo sapiens	56-65
26093674-12	2015	Early PI3K mediated activation of GSK-3beta attenuated QUIS-induced DRG neurite outgrowth and prevented the development of at-level dysesthesias.	Quisqualic Acid	55-59	glycogen synthase kinase 3 beta	Homo sapiens	34-43
26061531-3	2015	As for this apoptotic process, an overdose of propofol (2,6-Diisopropylphenol; 25 mug/ml or 140 muM) also causes GSK-3beta-mediated macrophage apoptosis; however, the early deactivation of GSK-3beta with low-dose propofol has been shown.	Propofol	46-54	glycogen synthase kinase 3 beta	Homo sapiens	113-122
26085927-7	2015	RESULTS: Our results showed that 100 muM 6-OHDA treated for 24 h significantly decreased cell viability and mitochondrial transmembrane potential, reduced the level of beta-catenin and p-Akt, increased LDH leakage, ROS production and the ratio of p-GSK3beta (Tyr216) to p-GSK3beta (Ser9).	Oxidopamine	41-47	glycogen synthase kinase 3 beta	Homo sapiens	249-257
26085927-7	2015	RESULTS: Our results showed that 100 muM 6-OHDA treated for 24 h significantly decreased cell viability and mitochondrial transmembrane potential, reduced the level of beta-catenin and p-Akt, increased LDH leakage, ROS production and the ratio of p-GSK3beta (Tyr216) to p-GSK3beta (Ser9).	Oxidopamine	41-47	glycogen synthase kinase 3 beta	Homo sapiens	272-280
26061531-4	2015	Therefore, we hypothesize that low-dose propofol may induce neutrophil survival via GSK-3beta inactivation.	Propofol	40-48	glycogen synthase kinase 3 beta	Homo sapiens	84-93
26061531-3	2015	As for this apoptotic process, an overdose of propofol (2,6-Diisopropylphenol; 25 mug/ml or 140 muM) also causes GSK-3beta-mediated macrophage apoptosis; however, the early deactivation of GSK-3beta with low-dose propofol has been shown.	Propofol	46-54	glycogen synthase kinase 3 beta	Homo sapiens	189-198
26061531-8	2015	We found that propofol initiates PI3-kinase/AKT-mediated GSK-3beta inactivation and Mcl-1 stabilization, rescuing the constitutive apoptosis in primary neutrophils and granulocyte-differentiated acute promyelocytic leukemia HL60 cells.	Propofol	14-22	glycogen synthase kinase 3 beta	Homo sapiens	57-66
26061531-3	2015	As for this apoptotic process, an overdose of propofol (2,6-Diisopropylphenol; 25 mug/ml or 140 muM) also causes GSK-3beta-mediated macrophage apoptosis; however, the early deactivation of GSK-3beta with low-dose propofol has been shown.	Propofol	56-77	glycogen synthase kinase 3 beta	Homo sapiens	113-122
26061531-3	2015	As for this apoptotic process, an overdose of propofol (2,6-Diisopropylphenol; 25 mug/ml or 140 muM) also causes GSK-3beta-mediated macrophage apoptosis; however, the early deactivation of GSK-3beta with low-dose propofol has been shown.	Propofol	56-77	glycogen synthase kinase 3 beta	Homo sapiens	189-198
25588771-13	2015	Overexpression of miR-224-5p restored transrepression of the NF-kappaB reporter by dexamethasone under induced resistance, which may be via targeting GSK-3beta to increase GR protein level.	Dexamethasone	83-96	glycogen synthase kinase 3 beta	Homo sapiens	150-159
25777472-1	2015	We hypothesize that GSK-3beta inhibition is a potential mechanism for lithium-associated medical illness.	Lithium	70-77	glycogen synthase kinase 3 beta	Homo sapiens	20-29
25818165-10	2015	We also found that celastrol inhibited the Akt/GSK3beta and Akt/NFkB survival pathway.	celastrol	19-28	glycogen synthase kinase 3 beta	Homo sapiens	47-55
26166660-9	2015	Apigenin inhibited the phosphorylation of Akt and GSK-3beta in IS-treated HK-2 cells.	Apigenin	0-8	glycogen synthase kinase 3 beta	Homo sapiens	50-59
25687330-3	2015	Interestingly, the same dose of escitalopram could also increase the level of serine-9-phosphorylated GSK-3beta (inactive form) and the phosphorylation level of Akt at Ser473 (active form) with no significant change in the level of total GSK-3beta and Akt.	Citalopram	32-44	glycogen synthase kinase 3 beta	Homo sapiens	102-111
25687330-3	2015	Interestingly, the same dose of escitalopram could also increase the level of serine-9-phosphorylated GSK-3beta (inactive form) and the phosphorylation level of Akt at Ser473 (active form) with no significant change in the level of total GSK-3beta and Akt.	Citalopram	32-44	glycogen synthase kinase 3 beta	Homo sapiens	238-247
25687330-3	2015	Interestingly, the same dose of escitalopram could also increase the level of serine-9-phosphorylated GSK-3beta (inactive form) and the phosphorylation level of Akt at Ser473 (active form) with no significant change in the level of total GSK-3beta and Akt.	Serine	78-84	glycogen synthase kinase 3 beta	Homo sapiens	102-111
25687330-5	2015	Our results suggest that escitalopram can ameliorate forskolin-induced tau hyperphosphorylation, which is not through the typical 5-HT1A pathway, and Akt/GSK-3beta signaling pathway is involved.	Colforsin	53-62	glycogen synthase kinase 3 beta	Homo sapiens	154-163
25869100-4	2015	Capsaicin treatment induced GSK-3beta by inhibiting its phosphorylation and further activated APC and Axin multicomplex, leading to the proteasomal degradation of beta-catenin.	Capsaicin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	28-37
25755051-0	2015	Curcumin induces apoptotic cell death via Oct4 inhibition and GSK-3beta activation in NCCIT cells.	Curcumin	0-8	glycogen synthase kinase 3 beta	Homo sapiens	62-71
26281299-2	2015	Several previous studies reported that glycogen synthase kinase 3beta (GSK3beta), which is widely expressed in the brain including the dopamine projection areas such as the amygdala, nucleus accumbens and hippocampus, may play a role in neuropsychiatric disorders and dopamine- and serotonin-mediated behavior.	Dopamine	135-143	glycogen synthase kinase 3 beta	Homo sapiens	39-69
26281299-2	2015	Several previous studies reported that glycogen synthase kinase 3beta (GSK3beta), which is widely expressed in the brain including the dopamine projection areas such as the amygdala, nucleus accumbens and hippocampus, may play a role in neuropsychiatric disorders and dopamine- and serotonin-mediated behavior.	Dopamine	135-143	glycogen synthase kinase 3 beta	Homo sapiens	71-79
26281299-2	2015	Several previous studies reported that glycogen synthase kinase 3beta (GSK3beta), which is widely expressed in the brain including the dopamine projection areas such as the amygdala, nucleus accumbens and hippocampus, may play a role in neuropsychiatric disorders and dopamine- and serotonin-mediated behavior.	Dopamine	268-276	glycogen synthase kinase 3 beta	Homo sapiens	39-69
26281299-2	2015	Several previous studies reported that glycogen synthase kinase 3beta (GSK3beta), which is widely expressed in the brain including the dopamine projection areas such as the amygdala, nucleus accumbens and hippocampus, may play a role in neuropsychiatric disorders and dopamine- and serotonin-mediated behavior.	Dopamine	268-276	glycogen synthase kinase 3 beta	Homo sapiens	71-79
26281299-2	2015	Several previous studies reported that glycogen synthase kinase 3beta (GSK3beta), which is widely expressed in the brain including the dopamine projection areas such as the amygdala, nucleus accumbens and hippocampus, may play a role in neuropsychiatric disorders and dopamine- and serotonin-mediated behavior.	Serotonin	282-291	glycogen synthase kinase 3 beta	Homo sapiens	39-69
26281299-2	2015	Several previous studies reported that glycogen synthase kinase 3beta (GSK3beta), which is widely expressed in the brain including the dopamine projection areas such as the amygdala, nucleus accumbens and hippocampus, may play a role in neuropsychiatric disorders and dopamine- and serotonin-mediated behavior.	Serotonin	282-291	glycogen synthase kinase 3 beta	Homo sapiens	71-79
26000878-10	2015	Correspondingly, treatment with LY294002, a phosphatidylinositol-3-kinase inhibitor, mimicked PTEN overexpression effect in KYSE-150/RR cells, further suggesting a role for the Akt/GSK-3beta/Snail signaling in effects mediated through PTEN.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	32-40	glycogen synthase kinase 3 beta	Homo sapiens	181-190
25941117-6	2015	The effect of MG132 on MCF7 was reproduced on MCF10A cells in the presence of the glycogen synthase kinase 3beta (GSK-3beta) inhibitor VII.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	14-19	glycogen synthase kinase 3 beta	Homo sapiens	82-112
25974307-0	2015	Marine lipopeptide Iturin A inhibits Akt mediated GSK3beta and FoxO3a signaling and triggers apoptosis in breast cancer.	iturin A	19-27	glycogen synthase kinase 3 beta	Homo sapiens	50-58
25974307-5	2015	Furthermore, Iturin A inhibited EGF induced Akt phosphorylation (Ser473 and Thr308) and its downstream targets GSK3beta and FoxO3a.	iturin A	13-21	glycogen synthase kinase 3 beta	Homo sapiens	111-119
25974307-9	2015	In a xenograft model, Iturin A inhibited tumor growth with reduced expressions of Ki-67, CD-31, P-Akt, P-GSK3beta, P-FoxO3a and P-MAPK.	iturin A	22-30	glycogen synthase kinase 3 beta	Homo sapiens	105-113
25941117-6	2015	The effect of MG132 on MCF7 was reproduced on MCF10A cells in the presence of the glycogen synthase kinase 3beta (GSK-3beta) inhibitor VII.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	14-19	glycogen synthase kinase 3 beta	Homo sapiens	114-123
25864651-8	2015	Amiloride inhibited EGF-stimulated phorsphorylation of AKT, and significantly enhanced erlotinib-induced downregulation of phorsphorylation of EGFR, AKT, PI3K P85 and GSK 3beta in Bxpc-3 and PANC-1 cells.	Amiloride	0-9	glycogen synthase kinase 3 beta	Homo sapiens	167-176
25864651-8	2015	Amiloride inhibited EGF-stimulated phorsphorylation of AKT, and significantly enhanced erlotinib-induced downregulation of phorsphorylation of EGFR, AKT, PI3K P85 and GSK 3beta in Bxpc-3 and PANC-1 cells.	Erlotinib Hydrochloride	87-96	glycogen synthase kinase 3 beta	Homo sapiens	167-176
25248565-2	2015	Resveratrol-induced TTS expression is associated with glycogen synthase kinase-3beta (GSK-3beta) activity.	Resveratrol	0-11	glycogen synthase kinase 3 beta	Homo sapiens	54-84
25248565-2	2015	Resveratrol-induced TTS expression is associated with glycogen synthase kinase-3beta (GSK-3beta) activity.	Resveratrol	0-11	glycogen synthase kinase 3 beta	Homo sapiens	86-95
25248565-3	2015	In addition, we found that resveratrol regulates naive CD8+ T-cell polarization by modulating GSK-3beta activity in IFN-gamma-stimulated BMDCs, and that resveratol induces upregulation of TTS in CD8+ T-cells in the in vivo tumor environment.	Resveratrol	27-38	glycogen synthase kinase 3 beta	Homo sapiens	94-103
25248565-4	2015	Taken together, resveratrol upregulates IFN-gamma-induced TTS expression in a GSK-3beta-dependent manner, and this TTS modulation is crucial for DC-mediated T-cell modulation.	Resveratrol	16-27	glycogen synthase kinase 3 beta	Homo sapiens	78-87
25752456-4	2015	As a constitutively activated kinase, during iTreg differentiation GSK3beta became quickly deactivated (phosphorylated at serine 9), which is dependent on MAPK pathway rather than PI3-kinase/Akt pathway.	Serine	122-128	glycogen synthase kinase 3 beta	Homo sapiens	67-75
25683913-5	2015	In addition to phosphorylating glycogen synthase kinase 3beta (GSK-3beta) at Ser9, LPA resulted in phosphorylation of beta-catenin at Ser552 and Ser675.	lysophosphatidic acid	83-86	glycogen synthase kinase 3 beta	Homo sapiens	31-61
25683913-5	2015	In addition to phosphorylating glycogen synthase kinase 3beta (GSK-3beta) at Ser9, LPA resulted in phosphorylation of beta-catenin at Ser552 and Ser675.	lysophosphatidic acid	83-86	glycogen synthase kinase 3 beta	Homo sapiens	63-72
25349215-5	2015	Cell proliferation levels in bladder cancer cells, renal cell carcinoma, and prostate cancer cells treated with GSK3beta inhibitor (SB216763) were detected by WST-1 reagent.	SB 216763	132-140	glycogen synthase kinase 3 beta	Homo sapiens	112-120
25671776-10	2015	Both the p38 MAPK (p38 mitogen-activated protein kinase) signalling and the redox-sensitive glycogen synthase kinase (GSK)3beta pathways are centrally implicated in aldosterone-induced podocyte death.	Aldosterone	165-176	glycogen synthase kinase 3 beta	Homo sapiens	118-127
25671776-11	2015	Aldosterone-induced GSK3beta over-activity could potentially cause hyperphosphorylation and over-activation of putative GSK3beta substrates, including structural components of the mitochondrial permeability transition (MPT) pore, all of which lead to cell injury and death.	Aldosterone	0-11	glycogen synthase kinase 3 beta	Homo sapiens	20-28
25671776-11	2015	Aldosterone-induced GSK3beta over-activity could potentially cause hyperphosphorylation and over-activation of putative GSK3beta substrates, including structural components of the mitochondrial permeability transition (MPT) pore, all of which lead to cell injury and death.	Aldosterone	0-11	glycogen synthase kinase 3 beta	Homo sapiens	120-128
25752456-5	2015	Our results indicated that inhibition of GSK3beta by specific inhibitors, SB216763 or TDZD-8, promoted the differentiation of iTreg and increased their suppressive activity.	SB 216763	74-82	glycogen synthase kinase 3 beta	Homo sapiens	41-49
25752456-5	2015	Our results indicated that inhibition of GSK3beta by specific inhibitors, SB216763 or TDZD-8, promoted the differentiation of iTreg and increased their suppressive activity.	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	86-92	glycogen synthase kinase 3 beta	Homo sapiens	41-49
25738332-10	2015	Following differentiation with the glycogen synthase kinase 3beta (GSK3beta) inhibitor LiCl, the cells began to express E-cadherin and, at once, Twist1 and Snail expression was strongly downregulated, suggesting a MET-reverting process.	Lithium Chloride	87-91	glycogen synthase kinase 3 beta	Homo sapiens	35-65
25738332-10	2015	Following differentiation with the glycogen synthase kinase 3beta (GSK3beta) inhibitor LiCl, the cells began to express E-cadherin and, at once, Twist1 and Snail expression was strongly downregulated, suggesting a MET-reverting process.	Lithium Chloride	87-91	glycogen synthase kinase 3 beta	Homo sapiens	67-75
25738332-13	2015	Our observation indicates that LiCl, a GSK3beta inhibitor, induces MET in vitro, suggesting that LiCl and GSK3beta could represent, respectively, interesting drug, and target for CRC therapy.	Lithium Chloride	31-35	glycogen synthase kinase 3 beta	Homo sapiens	39-47
25738332-13	2015	Our observation indicates that LiCl, a GSK3beta inhibitor, induces MET in vitro, suggesting that LiCl and GSK3beta could represent, respectively, interesting drug, and target for CRC therapy.	Lithium Chloride	31-35	glycogen synthase kinase 3 beta	Homo sapiens	106-114
25862132-10	2015	Although Tys significantly increased phosphorylation of Akt and GSK3beta, neither PI3 kinase nor GSK3beta inhibition altered Tys-induced TER elevation.	TYS	9-12	glycogen synthase kinase 3 beta	Homo sapiens	64-72
25727910-10	2015	We propose the relevance of estrogen-related receptor gamma (ERRgamma) in regulating dopaminergic neuronal phenotype: ERRgamma is up-regulated by retinoic acid in SH-SY5Y cells, and enhances dopaminergic phenotypes and induces neurite outgrowth; Polo-like kinase 2 (PLK2) and glycogen synthase kinase 3 beta/nuclear factor of activated T cells (GSK3beta/NFAT) signaling are responsible for the ERRgamma effect.	Tretinoin	146-159	glycogen synthase kinase 3 beta	Homo sapiens	345-353
25821218-4	2015	In this study, we found that ER stress-induced inositol-requiring enzyme (IRE)1alpha activation differentially regulates proinflammatory cytokine gene expression via activation of glycogen synthase kinase (GSK)-3beta and X-box binding protein (XBP)-1.	Inositol	47-55	glycogen synthase kinase 3 beta	Homo sapiens	180-216
25812605-0	2015	Tetramethylpyrazine inhibits the proliferation of acute lymphocytic leukemia cell lines via decrease in GSK-3beta.	tetramethylpyrazine	0-19	glycogen synthase kinase 3 beta	Homo sapiens	104-113
25812605-9	2015	Cells treated with TMP exhibited significantly attenuated GSK-3beta, NF-kappaB (p65) and c-myc expression, followed by downregulation of bcl-2, cox-2 and survivin and an upregulation of p27.	tetramethylpyrazine	19-22	glycogen synthase kinase 3 beta	Homo sapiens	58-67
25812605-10	2015	The results showed that TMP induced apoptosis and caused cell cycle arrest in Jurkat and SUP-B15 cells through the downregulation of GSK-3beta, which may have further prevented the induced translocation of NF-kappaB and c-myc from the cytoplasm to the nucleus.	tetramethylpyrazine	24-27	glycogen synthase kinase 3 beta	Homo sapiens	133-142
25667991-7	2015	RESULTS: Our data showed that Abeta1-42 oligomers inhibited insulin-induced serine phosphorylation of Akt at 473 and GSK3beta at serine 9, as well as glycogen storage.	Serine	129-135	glycogen synthase kinase 3 beta	Homo sapiens	117-125
25915038-2	2015	In order to further probe this concept we tested LY2090314, a potent and selective small-molecule inhibitor with activity against GSK3alpha and GSK3beta isoforms.	3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione	49-58	glycogen synthase kinase 3 beta	Homo sapiens	144-152
25667991-8	2015	However, the levels of phosphorylated GSK3beta at tyrosine 216 were significantly increased in the presence of Abeta1-42 oligomers.	Tyrosine	50-58	glycogen synthase kinase 3 beta	Homo sapiens	38-46
25437011-5	2015	Activation of the Wnt pathway by treatment with Wnt3a-conditioned medium or glycogen synthase kinase 3beta inhibitors, such as SB-216763 and 6-bromoindirubin-3"-oxime, delays the progression of cellular senescence as shown by the decrease in the senescence effectors p53 and pRb, lowered senescence-associated beta-galactosidase activity, and increased telomerase activity.	SB 216763	127-136	glycogen synthase kinase 3 beta	Homo sapiens	76-106
26131102-10	2015	STS inhibited GSK-3beta and FKN mRNA induced by high glucose.	Glucose	53-60	glycogen synthase kinase 3 beta	Homo sapiens	14-23
25437011-5	2015	Activation of the Wnt pathway by treatment with Wnt3a-conditioned medium or glycogen synthase kinase 3beta inhibitors, such as SB-216763 and 6-bromoindirubin-3"-oxime, delays the progression of cellular senescence as shown by the decrease in the senescence effectors p53 and pRb, lowered senescence-associated beta-galactosidase activity, and increased telomerase activity.	6-bromoindirubin-3'-oxime	141-166	glycogen synthase kinase 3 beta	Homo sapiens	76-106
25345732-1	2015	RATIONALE: Lithium is the mainstay for the treatment of bipolar disorder (BD) and inhibits glycogen synthase kinase-3beta (GSK-3beta).	Lithium	11-18	glycogen synthase kinase 3 beta	Homo sapiens	91-121
25711986-10	2015	In fact, CE results confirmed the inductory effect of the sulfated sugars heparin and heparan sulfate on tau hyperphosphorylation, probably because of the exposition of new sites phosphorylatable by GSK3beta.	Heparin	74-81	glycogen synthase kinase 3 beta	Homo sapiens	199-207
25711986-10	2015	In fact, CE results confirmed the inductory effect of the sulfated sugars heparin and heparan sulfate on tau hyperphosphorylation, probably because of the exposition of new sites phosphorylatable by GSK3beta.	Heparitin Sulfate	86-101	glycogen synthase kinase 3 beta	Homo sapiens	199-207
25643607-0	2015	Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3beta/beta-catenin signalling.	Paclitaxel	35-45	glycogen synthase kinase 3 beta	Homo sapiens	91-100
25754137-0	2015	Molecular dynamics study of the inhibitory effects of ChEMBL474807 on the enzymes GSK-3beta and CDK-2.	indazole-benzimidazole, 5	54-66	glycogen synthase kinase 3 beta	Homo sapiens	82-91
25691573-8	2015	Together, our results demonstrated a molecular mechanism by which glucose deprivation can induce the GSK3beta-independent protein degradation of beta-catenin, leading to autophagy.	Glucose	66-73	glycogen synthase kinase 3 beta	Homo sapiens	101-109
25747393-0	2015	Antioxidative effects of ethyl 2-(3-(benzo[d]thiazol-2-yl)ureido)acetate against amyloid beta-induced oxidative cell death via NF-kappaB, GSK-3beta and beta-catenin signaling pathways in cultured cortical neurons.	ethyl 2-(3-(benzo[d]thiazol-2-yl)ureido)acetate	25-72	glycogen synthase kinase 3 beta	Homo sapiens	138-147
25796504-4	2015	We found that after treatment with TRAIL, the DNA-PKcs/Akt/GSK-3beta pathway, which is positively correlated with the levels of MDR1 and MRP1, was significantly inhibited and that this tendency can be abolished by Z-DEVD-FMK (a specific caspase 3 inhibitor).	benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone	214-224	glycogen synthase kinase 3 beta	Homo sapiens	59-68
25828701-6	2015	TRAF6 is determined to be a direct E3 ligase for GSK3beta, and TRAF6-mediated GSK3beta ubiquitination is essential for poly I:C-dependent cytokine production by promoting the TLR3 adaptor protein TRIF-assembled signalling complex.	Poly I	119-125	glycogen synthase kinase 3 beta	Homo sapiens	49-57
25828701-6	2015	TRAF6 is determined to be a direct E3 ligase for GSK3beta, and TRAF6-mediated GSK3beta ubiquitination is essential for poly I:C-dependent cytokine production by promoting the TLR3 adaptor protein TRIF-assembled signalling complex.	Poly I	119-125	glycogen synthase kinase 3 beta	Homo sapiens	78-86
25828701-6	2015	TRAF6 is determined to be a direct E3 ligase for GSK3beta, and TRAF6-mediated GSK3beta ubiquitination is essential for poly I:C-dependent cytokine production by promoting the TLR3 adaptor protein TRIF-assembled signalling complex.	Carbon	126-127	glycogen synthase kinase 3 beta	Homo sapiens	49-57
25828701-6	2015	TRAF6 is determined to be a direct E3 ligase for GSK3beta, and TRAF6-mediated GSK3beta ubiquitination is essential for poly I:C-dependent cytokine production by promoting the TLR3 adaptor protein TRIF-assembled signalling complex.	Carbon	126-127	glycogen synthase kinase 3 beta	Homo sapiens	78-86
25345732-1	2015	RATIONALE: Lithium is the mainstay for the treatment of bipolar disorder (BD) and inhibits glycogen synthase kinase-3beta (GSK-3beta).	Lithium	11-18	glycogen synthase kinase 3 beta	Homo sapiens	123-132
25345732-11	2015	In the light of the protective effects of lithium on white matter integrity, our results suggest that the clinical effects of lithium associate with a neurotrophic effect on the whole brain, probably mediated by GSK-3beta inhibition.	Lithium	126-133	glycogen synthase kinase 3 beta	Homo sapiens	212-221
25150591-0	2015	Role of the Akt/GSK-3beta/CRMP-2 pathway in axon degeneration of dopaminergic neurons resulting from MPP+ toxicity.	mangion-purified polysaccharide (Candida albicans)	101-105	glycogen synthase kinase 3 beta	Homo sapiens	16-25
25568334-7	2015	Furthermore, treatment of esophageal cancer cells with the Akt inhibitor wortmannin inhibits NF-kappaB signaling, induces GSK3beta activity, and blocks OSCC cell proliferation in an Axl-dependent manner.	Wortmannin	73-83	glycogen synthase kinase 3 beta	Homo sapiens	122-130
25749514-4	2015	DC120, a 2-pyrimidyl-5-amidothiazole inhibitor of the ATP binding site of AKT, inhibited phosphorylation of FKHRL1 and GSK-3beta.	N-(1-amino-3-(2,4-dichlorophenyl)propan-2-yl)-2-(2-(methylamino)pyrimidin-4-yl)thiazole-5-carboxamide	0-5	glycogen synthase kinase 3 beta	Homo sapiens	119-128
25749514-4	2015	DC120, a 2-pyrimidyl-5-amidothiazole inhibitor of the ATP binding site of AKT, inhibited phosphorylation of FKHRL1 and GSK-3beta.	2-pyrimidyl-5-amidothiazole	9-36	glycogen synthase kinase 3 beta	Homo sapiens	119-128
25749514-4	2015	DC120, a 2-pyrimidyl-5-amidothiazole inhibitor of the ATP binding site of AKT, inhibited phosphorylation of FKHRL1 and GSK-3beta.	Adenosine Triphosphate	54-57	glycogen synthase kinase 3 beta	Homo sapiens	119-128
25686711-6	2015	Analysis of the underlying mechanism showed that 6-S and PTE decreased the expression of the surface antigen CD44 on BCSCs and promoted beta-catenin phosphorylation through the inhibition of hedgehog/Akt/GSK3beta signaling, thus decreasing the protein expression of downstream c-Myc and cyclin D1 and reducing BCSC stemness.	shogaol	49-52	glycogen synthase kinase 3 beta	Homo sapiens	204-212
25686711-6	2015	Analysis of the underlying mechanism showed that 6-S and PTE decreased the expression of the surface antigen CD44 on BCSCs and promoted beta-catenin phosphorylation through the inhibition of hedgehog/Akt/GSK3beta signaling, thus decreasing the protein expression of downstream c-Myc and cyclin D1 and reducing BCSC stemness.	pterostilbene	57-60	glycogen synthase kinase 3 beta	Homo sapiens	204-212
24831601-0	2015	Lower phosphorylated glycogen synthase kinase-3B levels in platelets of patients with schizophrenia: increment by olanzapine treatment.	Olanzapine	114-124	glycogen synthase kinase 3 beta	Homo sapiens	21-48
24831601-5	2015	In drug-free patients, GSK-3B levels were accessed again after 8 weeks on treatment with olanzapine.	Olanzapine	89-99	glycogen synthase kinase 3 beta	Homo sapiens	23-29
24831601-7	2015	After 8 weeks on olanzapine treatment, phosphorylated and total GSK-3B levels were significantly increased (p &lt; 0.01).	Olanzapine	17-27	glycogen synthase kinase 3 beta	Homo sapiens	64-70
24831601-9	2015	Further studies should clarify whether the increment of GSK-3B phosphorylation by olanzapine is related to its antipsychotic effects.	Olanzapine	82-92	glycogen synthase kinase 3 beta	Homo sapiens	56-62
25169655-0	2015	Elevation in 5-FU-induced apoptosis in head and neck cancer stem cells by a combination of CDHP and GSK3beta inhibitors.	Fluorouracil	13-17	glycogen synthase kinase 3 beta	Homo sapiens	100-108
25169655-11	2015	Combination of both CDHP and GSK3beta inhibitors markedly enhanced 5-FU-induced apoptosis of CD44(high) /ESA(low) cells.	Fluorouracil	67-71	glycogen synthase kinase 3 beta	Homo sapiens	29-37
25691093-2	2015	GSK3beta is also an important target for lithium and antidepressants.	Lithium	41-48	glycogen synthase kinase 3 beta	Homo sapiens	0-8
25691093-3	2015	When phosphorylated at serine-9, GSK3beta becomes inactive.	Serine	23-29	glycogen synthase kinase 3 beta	Homo sapiens	33-41
25691093-4	2015	Few studies evaluated serine-9 phosphorylated GSK3beta (phospho-GSK3beta) levels in BD subjects in vivo and no study has assessed it specifically in bipolar depression.	Serine	22-28	glycogen synthase kinase 3 beta	Homo sapiens	46-54
25691093-4	2015	Few studies evaluated serine-9 phosphorylated GSK3beta (phospho-GSK3beta) levels in BD subjects in vivo and no study has assessed it specifically in bipolar depression.	Serine	22-28	glycogen synthase kinase 3 beta	Homo sapiens	64-72
25691093-5	2015	Also, the effect of lithium monotherapy on GSK3beta has never been studied in humans.	Lithium	20-27	glycogen synthase kinase 3 beta	Homo sapiens	43-51
25691093-11	2015	From baseline to endpoint, lithium treatment inactivated GSK3beta by significantly increasing phospho-GSK3beta levels (p = 0.010).	Lithium	27-34	glycogen synthase kinase 3 beta	Homo sapiens	57-65
25691093-11	2015	From baseline to endpoint, lithium treatment inactivated GSK3beta by significantly increasing phospho-GSK3beta levels (p = 0.010).	Lithium	27-34	glycogen synthase kinase 3 beta	Homo sapiens	102-110
25691093-13	2015	CONCLUSION: The present results show that lithium inactivates platelet GSK3beta in BD during mood episodes.	Lithium	42-49	glycogen synthase kinase 3 beta	Homo sapiens	71-79
24760594-6	2015	We found that LiCl mobilizes the alpha-tubulin N-acetyltransferase 1 (alphaTAT1) in the signaling pathway mediating GSK-3beta and adenylate cyclase III.	Lithium Chloride	14-18	glycogen synthase kinase 3 beta	Homo sapiens	116-125
24760594-7	2015	In conclusion, our results suggested that LiCl treatments activate alphaTAT1 by the inhibition of GSK-3beta and promote the alpha-tubulin acetylation, and then elongate the primary cilia.	Lithium Chloride	42-46	glycogen synthase kinase 3 beta	Homo sapiens	98-107
25728276-3	2015	Here we identified S422 as a novel phosphorylation site of Osx and demonstrated that GSK-3beta interacted and co-localized with Osx.	1-(3-trifluoromethylphenyl)-2-(N-(2-hydroxyethyl)amino)propane	19-23	glycogen synthase kinase 3 beta	Homo sapiens	85-94
25680531-5	2015	Overexpression of miR-138 activates glycogen synthase kinase-3beta (GSK-3beta), and increases tau phosphorylation in HEK293/tau cells.	mir-138	18-25	glycogen synthase kinase 3 beta	Homo sapiens	36-66
25662701-0	2015	Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3beta inhibitors and neuroprotective agents.	3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides	39-103	glycogen synthase kinase 3 beta	Homo sapiens	125-134
25662701-1	2015	A series of novel 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides were designed, prepared and evaluated for their GSK-3beta inhibitory activities.	3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides	18-82	glycogen synthase kinase 3 beta	Homo sapiens	131-140
25616162-10	2015	Our results show that GSK3beta inhibitors, including valproate and small molecule inhibitors, significantly reduce HIV-1-mediated neurotoxic outcomes, and also negate interactions with morphine that result in cell death, suggesting that GSK3beta-activation is an important point of convergence and a potential therapeutic target for HIV- and opiate-mediated neurocognitive deficits.	Valproic Acid	53-62	glycogen synthase kinase 3 beta	Homo sapiens	22-30
25616162-10	2015	Our results show that GSK3beta inhibitors, including valproate and small molecule inhibitors, significantly reduce HIV-1-mediated neurotoxic outcomes, and also negate interactions with morphine that result in cell death, suggesting that GSK3beta-activation is an important point of convergence and a potential therapeutic target for HIV- and opiate-mediated neurocognitive deficits.	Valproic Acid	53-62	glycogen synthase kinase 3 beta	Homo sapiens	237-245
25616162-10	2015	Our results show that GSK3beta inhibitors, including valproate and small molecule inhibitors, significantly reduce HIV-1-mediated neurotoxic outcomes, and also negate interactions with morphine that result in cell death, suggesting that GSK3beta-activation is an important point of convergence and a potential therapeutic target for HIV- and opiate-mediated neurocognitive deficits.	Morphine	185-193	glycogen synthase kinase 3 beta	Homo sapiens	22-30
25616162-10	2015	Our results show that GSK3beta inhibitors, including valproate and small molecule inhibitors, significantly reduce HIV-1-mediated neurotoxic outcomes, and also negate interactions with morphine that result in cell death, suggesting that GSK3beta-activation is an important point of convergence and a potential therapeutic target for HIV- and opiate-mediated neurocognitive deficits.	Morphine	185-193	glycogen synthase kinase 3 beta	Homo sapiens	237-245
25616162-10	2015	Our results show that GSK3beta inhibitors, including valproate and small molecule inhibitors, significantly reduce HIV-1-mediated neurotoxic outcomes, and also negate interactions with morphine that result in cell death, suggesting that GSK3beta-activation is an important point of convergence and a potential therapeutic target for HIV- and opiate-mediated neurocognitive deficits.	Opiate Alkaloids	342-348	glycogen synthase kinase 3 beta	Homo sapiens	22-30
25616162-10	2015	Our results show that GSK3beta inhibitors, including valproate and small molecule inhibitors, significantly reduce HIV-1-mediated neurotoxic outcomes, and also negate interactions with morphine that result in cell death, suggesting that GSK3beta-activation is an important point of convergence and a potential therapeutic target for HIV- and opiate-mediated neurocognitive deficits.	Opiate Alkaloids	342-348	glycogen synthase kinase 3 beta	Homo sapiens	237-245
25378227-9	2015	In addition, the phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002 abrogated the enhancing effects of TWIST on mRNA levels of c-Myc and c-Jun, soluble beta-catenin levels, MMP-2 expression, cell invasion and GSK-3beta phosphorylation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	65-73	glycogen synthase kinase 3 beta	Homo sapiens	215-224
26248429-10	2015	The data of FCM showed that curcumin could increase the expression of PTEN, GSK3beta and Caspase 3, decreased the expression of AKT.	Curcumin	28-36	glycogen synthase kinase 3 beta	Homo sapiens	76-98
25591548-6	2015	IL-18 expression upregulated the expression and phosphorylation of glycogen synthase kinase (GSK)-3beta protein in CRL1623 cells, whereas the selective GSK-3beta inhibitor kenpaullone antagonized the effects of IL-18 protein on TSCC cells in vitro.	kenpaullone	172-183	glycogen synthase kinase 3 beta	Homo sapiens	152-161
25614230-5	2015	Furthermore, nickel exposure increased the expression of hypoxia-inducible-factor-1alpha (HIF-1alpha) and induced the activation of the AKT/PKB kinase pathway, as shown by the increase of P(Ser-9)-GSK-3beta, the inactive form of glycogen synthase kinase-3beta (GSK-3beta).	Nickel	13-19	glycogen synthase kinase 3 beta	Homo sapiens	197-206
25614230-5	2015	Furthermore, nickel exposure increased the expression of hypoxia-inducible-factor-1alpha (HIF-1alpha) and induced the activation of the AKT/PKB kinase pathway, as shown by the increase of P(Ser-9)-GSK-3beta, the inactive form of glycogen synthase kinase-3beta (GSK-3beta).	Nickel	13-19	glycogen synthase kinase 3 beta	Homo sapiens	229-259
25614230-5	2015	Furthermore, nickel exposure increased the expression of hypoxia-inducible-factor-1alpha (HIF-1alpha) and induced the activation of the AKT/PKB kinase pathway, as shown by the increase of P(Ser-9)-GSK-3beta, the inactive form of glycogen synthase kinase-3beta (GSK-3beta).	Nickel	13-19	glycogen synthase kinase 3 beta	Homo sapiens	261-270
25376707-7	2015	LPA increased GSK3beta phosphorylation and beta-catenin activation.	lysophosphatidic acid	0-3	glycogen synthase kinase 3 beta	Homo sapiens	14-22
25376707-12	2015	In conclusion, ATX/LPA stimulates the migration of hMSCs through LPAR1/3-dependent E-cadherin reduction and cytoskeletal rearrangement via PKC/GSK3beta/beta-catenin and PKC/Rho GTPase pathways.	lysophosphatidic acid	19-22	glycogen synthase kinase 3 beta	Homo sapiens	143-151
25125499-6	2015	Ursodeoxycholyl lysophosphatidylethanolamide also prevented the decreases of myeloid cell leukemia sequence-1 protein in both experimental systems, and this protection was due to ursodeoxycholyl lysophosphatidylethanolamide"s ability to inhibit ubiquitination-mediated degradation of myeloid cell leukemia sequence-1, and to increase the phosphorylation of GSK-3beta.	ursodeoxycholyl lysophosphatidylethanolamide	0-44	glycogen synthase kinase 3 beta	Homo sapiens	357-366
25142862-6	2015	Moreover, phosphorylation of cyclin D1 at threonine 286 by GSK-3beta was required for PSAT1-induced blockage of cyclin D1 degradation.	Threonine	42-51	glycogen synthase kinase 3 beta	Homo sapiens	59-68
25528666-5	2015	4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione, an inhibitor of GSK3beta, suppressed Sema3A-induced antero- and retrograde axonal transport.	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	0-49	glycogen synthase kinase 3 beta	Homo sapiens	67-75
25528666-8	2015	Overexpression of a partial fragment of frequently rearranged in advanced T-cell lymphomas 1 (FRATtide), which interferes the interaction between GSK3beta and Axis inhibitor-1 (Axin-1), also suppressed Sema3A-induced transport.	frattide	94-102	glycogen synthase kinase 3 beta	Homo sapiens	146-154
25932125-7	2015	In addition, nicorandil increased the protein levels of p-Akt and p-GSK-3beta by PI3K activation.	Nicorandil	13-23	glycogen synthase kinase 3 beta	Homo sapiens	68-77
25125499-6	2015	Ursodeoxycholyl lysophosphatidylethanolamide also prevented the decreases of myeloid cell leukemia sequence-1 protein in both experimental systems, and this protection was due to ursodeoxycholyl lysophosphatidylethanolamide"s ability to inhibit ubiquitination-mediated degradation of myeloid cell leukemia sequence-1, and to increase the phosphorylation of GSK-3beta.	lysophosphatidylethanolamide	16-44	glycogen synthase kinase 3 beta	Homo sapiens	357-366
25632187-0	2015	beta-escin reverses multidrug resistance through inhibition of the GSK3beta/beta-catenin pathway in cholangiocarcinoma.	Escin	0-10	glycogen synthase kinase 3 beta	Homo sapiens	67-75
26040106-0	2015	Beta catenin is degraded by both caspase-3 and proteasomal activity during resveratrol-induced apoptosis in HeLa cells in a GSK3beta-independent manner.	Resveratrol	75-86	glycogen synthase kinase 3 beta	Homo sapiens	124-132
26040106-11	2015	In conclusion, resveratrol induced apoptosis in HeLa cells in an Akt/GSK3beta-independent manner and down-regulated beta-catenin levels during apoptosis through action of caspase-3 and proteasomal degradation, independent of GSK3beta-mediated phosphorylation.	Resveratrol	15-26	glycogen synthase kinase 3 beta	Homo sapiens	69-77
26040106-11	2015	In conclusion, resveratrol induced apoptosis in HeLa cells in an Akt/GSK3beta-independent manner and down-regulated beta-catenin levels during apoptosis through action of caspase-3 and proteasomal degradation, independent of GSK3beta-mediated phosphorylation.	Resveratrol	15-26	glycogen synthase kinase 3 beta	Homo sapiens	225-233
25550525-9	2015	GSK3beta siRNA knockdown in primary myometrial cells was associated with a significant decrease in IL1beta and TNFalpha-induced pro-inflammatory cytokine and prostaglandin release.	Prostaglandins	158-171	glycogen synthase kinase 3 beta	Homo sapiens	0-8
25449432-7	2015	Furthermore, pantoprazole treatment resulted in a profound reduction of both total and phosphorylated forms of Akt and GSK-3beta, which in turn suppressed the adriamycin-induced Wnt/beta-catenin signaling in SGC7901/ADR cells.	Pantoprazole	13-25	glycogen synthase kinase 3 beta	Homo sapiens	119-128
25449432-7	2015	Furthermore, pantoprazole treatment resulted in a profound reduction of both total and phosphorylated forms of Akt and GSK-3beta, which in turn suppressed the adriamycin-induced Wnt/beta-catenin signaling in SGC7901/ADR cells.	Doxorubicin	159-169	glycogen synthase kinase 3 beta	Homo sapiens	119-128
25449432-9	2015	And for the first time, we show that it is possible to suppress the invasiveness of SGC7901/ADR cells by pantoprazole which targets the EMT and Akt/GSK-3beta/beta-catenin signaling.	Pantoprazole	105-117	glycogen synthase kinase 3 beta	Homo sapiens	148-157
25632187-10	2015	Moreover, beta-escin induced GSK3beta phosphorylation at Tyr-216 and dephosphorylation at Ser-9, resulting in phosphorylation and degradation of beta-catenin.	Escin	10-20	glycogen synthase kinase 3 beta	Homo sapiens	29-37
25632187-10	2015	Moreover, beta-escin induced GSK3beta phosphorylation at Tyr-216 and dephosphorylation at Ser-9, resulting in phosphorylation and degradation of beta-catenin.	Tyrosine	57-60	glycogen synthase kinase 3 beta	Homo sapiens	29-37
25632187-11	2015	Interestingly, activation of the GSK3beta/beta-catenin pathway induced by Wnt3a resulted in up-regulation of P-gp, which was effectively abolished by beta-escin, indicating that beta-escin down-regulated P-gp expression in a GSK3beta-dependent manner.	Escin	150-160	glycogen synthase kinase 3 beta	Homo sapiens	33-41
25632187-11	2015	Interestingly, activation of the GSK3beta/beta-catenin pathway induced by Wnt3a resulted in up-regulation of P-gp, which was effectively abolished by beta-escin, indicating that beta-escin down-regulated P-gp expression in a GSK3beta-dependent manner.	Escin	150-160	glycogen synthase kinase 3 beta	Homo sapiens	225-233
25632187-11	2015	Interestingly, activation of the GSK3beta/beta-catenin pathway induced by Wnt3a resulted in up-regulation of P-gp, which was effectively abolished by beta-escin, indicating that beta-escin down-regulated P-gp expression in a GSK3beta-dependent manner.	Escin	178-188	glycogen synthase kinase 3 beta	Homo sapiens	33-41
24854430-9	2015	By using THP-1 cells with GSK-3beta knockdown or cells treated with hyperinsulinemic and high-fatty acid conditions, we found that LPS-induced nuclear factor kappaB (NF-kappaB) activation was inhibited and cyclic adenosine monophosphate response element-binding protein (CREB) activation was enhanced.	Cyclic AMP	206-236	glycogen synthase kinase 3 beta	Homo sapiens	26-35
25544382-0	2015	5-Benzylidene-3,4-dihalo-furan-2-one derivatives inhibit human leukemia cancer cells through suppression of NF-kappaB and GSK-3beta.	5-benzylidene-3,4-dihalo-furan-2-one	0-36	glycogen synthase kinase 3 beta	Homo sapiens	122-131
25120104-11	2015	ITI-007 indirectly modulates glutamatergic neurotransmission by increasing phosphorylation of GluN2B-type N-methyl-D-aspartate (NMDA) receptors and preferentially increases phosphorylation of glycogen synthase kinase 3beta (GSK-3beta) in mesolimbic/mesocortical dopamine systems.	ITI-722	0-7	glycogen synthase kinase 3 beta	Homo sapiens	192-222
25120104-11	2015	ITI-007 indirectly modulates glutamatergic neurotransmission by increasing phosphorylation of GluN2B-type N-methyl-D-aspartate (NMDA) receptors and preferentially increases phosphorylation of glycogen synthase kinase 3beta (GSK-3beta) in mesolimbic/mesocortical dopamine systems.	ITI-722	0-7	glycogen synthase kinase 3 beta	Homo sapiens	224-233
25603341-0	2015	Ophiobolin O isolated from Aspergillus ustus induces G1 arrest of MCF-7 cells through interaction with AKT/GSK3beta/cyclin D1 signaling.	ophiobolin O	0-12	glycogen synthase kinase 3 beta	Homo sapiens	107-115
25603341-3	2015	In this study, we further verified ophiobolin O-induced G1 phase arrest in human breast cancer MCF-7 cells, and found that ophiobolin O reduced the phosphorylation level of AKT and GSK3beta, and induced down-regulation of cyclin D1.	ophiobolin O	123-135	glycogen synthase kinase 3 beta	Homo sapiens	181-189
25603341-4	2015	The inverse docking (INVDOCK) analysis indicated that ophiobolin O could bind to GSK3beta, and GSK3beta knockdown abolished cyclin D1 degradation and G1 phase arrest.	ophiobolin O	54-66	glycogen synthase kinase 3 beta	Homo sapiens	81-89
25603341-5	2015	Pre-treatment with phosphatase inhibitor sodium or thovanadate halted dephosphorylation of AKT and GSK3beta, and blocked ophiobolin O-induced G1 phase arrest.	Sodium	41-47	glycogen synthase kinase 3 beta	Homo sapiens	99-107
25603341-5	2015	Pre-treatment with phosphatase inhibitor sodium or thovanadate halted dephosphorylation of AKT and GSK3beta, and blocked ophiobolin O-induced G1 phase arrest.	thovanadate	51-62	glycogen synthase kinase 3 beta	Homo sapiens	99-107
25603341-6	2015	These data suggest that ophiobolin O may induce G1 arrest in MCF-7 cells through interaction with AKT/GSK3beta/cyclin D1 signaling.	ophiobolin O	24-36	glycogen synthase kinase 3 beta	Homo sapiens	102-110
25445050-6	2015	Furthermore, F015 effectively inhibited the ability of palmitate to reduce insulin-stimulated phosphorylation of IRS-1, AKT and GSK-3beta in L6 myotubes.	f015	13-17	glycogen synthase kinase 3 beta	Homo sapiens	128-137
25632187-11	2015	Interestingly, activation of the GSK3beta/beta-catenin pathway induced by Wnt3a resulted in up-regulation of P-gp, which was effectively abolished by beta-escin, indicating that beta-escin down-regulated P-gp expression in a GSK3beta-dependent manner.	Escin	178-188	glycogen synthase kinase 3 beta	Homo sapiens	225-233
25632187-12	2015	CONCLUSION: beta-escin was a potent reverser of P-gp-dependent multidrug resistance, with said effect likely being achieved via inhibition of the GSK3beta/beta-catenin pathway and thus suggesting a promising strategy of developing combination drugs for CCA.	Escin	12-22	glycogen synthase kinase 3 beta	Homo sapiens	146-154
25472995-6	2015	GSK3beta was found to interact with ST2L on serine residue 446 in response to IL-33 treatment.	Serine	44-50	glycogen synthase kinase 3 beta	Homo sapiens	0-8
25766531-10	2015	Moreover, OA-NO2 restored Akt and Gsk 3beta phosphorylation in a PPAR-gamma-dependent way.	Nitrogen Dioxide	13-16	glycogen synthase kinase 3 beta	Homo sapiens	34-43
25839957-14	2015	We further found the ratio of p-GSK-3 beta (S9) to beta-catenin and protein levels of Axins were significantly lower, whereas downstream Wnt 11 was high in T2R-7 treated with lithium.	Lithium	175-182	glycogen synthase kinase 3 beta	Homo sapiens	32-42
26632346-7	2015	VPA also increases the phosphorylation of Akt/GSK-3beta.	Valproic Acid	0-3	glycogen synthase kinase 3 beta	Homo sapiens	46-55
26632346-8	2015	The inhibitor of PI3K/Akt, LY2994002, significantly attenuates VPA induced phosphorylation of Akt and GSK-3beta and up regulation of Snail and Vim.	ly2994002	27-36	glycogen synthase kinase 3 beta	Homo sapiens	102-111
26632346-8	2015	The inhibitor of PI3K/Akt, LY2994002, significantly attenuates VPA induced phosphorylation of Akt and GSK-3beta and up regulation of Snail and Vim.	Valproic Acid	63-66	glycogen synthase kinase 3 beta	Homo sapiens	102-111
25198120-4	2015	Treatment with 3,2"-DHF resulted in high expression of pluripotency markers (OCT4, SOX2, and NANOG) and significant activation (STAT3 and AKT) or suppression (GSK3beta and ERK) of self-renewal-related kinases.	3,2'-dihydroxyflavone	15-23	glycogen synthase kinase 3 beta	Homo sapiens	159-167
26435723-4	2015	By treatment with PGE2, the chondrocytes apoptosis was significantly increased, the proapoptotic CHOP and JNK were upregulated, the prosurvival GRP78 and XBP1 were downregulated, and GSK-3beta was also upregulated.	Dinoprostone	18-22	glycogen synthase kinase 3 beta	Homo sapiens	183-192
26166610-7	2015	Cotinine stimulates signaling pathways downstream of alpha7nAChR including the protein kinase B (Akt)/glycogen synthase kinase 3beta (GSK3beta) pathway and the extracellular signal-regulated kinases (ERKs).	Cotinine	0-8	glycogen synthase kinase 3 beta	Homo sapiens	102-132
26166610-7	2015	Cotinine stimulates signaling pathways downstream of alpha7nAChR including the protein kinase B (Akt)/glycogen synthase kinase 3beta (GSK3beta) pathway and the extracellular signal-regulated kinases (ERKs).	Cotinine	0-8	glycogen synthase kinase 3 beta	Homo sapiens	134-142
26435723-6	2015	Finally, the inflammatory cytokine PGE2 can activate ERS signaling and promote chondrocytes apoptosis, which might be associated with upregulation of GSK-3beta.	Dinoprostone	35-39	glycogen synthase kinase 3 beta	Homo sapiens	150-159
26435723-7	2015	TMF exhibits a chondroprotective role in inhibiting PGE2-induced ERS and GSK-3beta.	methoxyluteolin	0-3	glycogen synthase kinase 3 beta	Homo sapiens	73-82
26435723-7	2015	TMF exhibits a chondroprotective role in inhibiting PGE2-induced ERS and GSK-3beta.	Dinoprostone	52-56	glycogen synthase kinase 3 beta	Homo sapiens	73-82
25333998-9	2015	Moreover, 5-FU partly recovered Hsp90 client proteins, including Akt, p-Akt, inhibitor of kappaB kinase (IKK)alpha, extracellular signal-regulated kinase (ERK)1/2, and glycogen synthase kinase (GSK)-3beta, which SNX-2112 had downregulated.	Fluorouracil	10-14	glycogen synthase kinase 3 beta	Homo sapiens	168-204
24811996-9	2015	This effect was counteracted by lithium, a selective inhibitor of GSK3beta.	Lithium	32-39	glycogen synthase kinase 3 beta	Homo sapiens	66-74
25333998-9	2015	Moreover, 5-FU partly recovered Hsp90 client proteins, including Akt, p-Akt, inhibitor of kappaB kinase (IKK)alpha, extracellular signal-regulated kinase (ERK)1/2, and glycogen synthase kinase (GSK)-3beta, which SNX-2112 had downregulated.	SNX 2112	212-220	glycogen synthase kinase 3 beta	Homo sapiens	168-204
25874155-0	2015	Corrigendum to "Antitumor Molecular Mechanism of Chlorogenic Acid on Inducting Genes GSK-3beta and APC and Inhibiting Gene beta-Catenin".	Chlorogenic Acid	49-65	glycogen synthase kinase 3 beta	Homo sapiens	85-94
26209183-0	2015	Molecular dynamics simulation studies of GSK-3beta ATP competitive inhibitors: understanding the factors contributing to selectivity.	Adenosine Triphosphate	51-54	glycogen synthase kinase 3 beta	Homo sapiens	41-50
25012937-8	2015	This work has also proven that VPA can inhibit the activity of proteins like GSK3beta and PKCbetaII involved in developmental disorders.	Valproic Acid	31-34	glycogen synthase kinase 3 beta	Homo sapiens	77-85
26209183-2	2015	In order to provide a detailed understanding of the origin of selectivity determinants of ATP competitive inhibitors, molecular dynamics simulations in combination with MM-PBSA binding energy calculations were performed using crystal structures of GSK-3beta and CDK-2 in complex with 12 ATP competitive inhibitors.	Adenosine Triphosphate	90-93	glycogen synthase kinase 3 beta	Homo sapiens	248-257
26209183-2	2015	In order to provide a detailed understanding of the origin of selectivity determinants of ATP competitive inhibitors, molecular dynamics simulations in combination with MM-PBSA binding energy calculations were performed using crystal structures of GSK-3beta and CDK-2 in complex with 12 ATP competitive inhibitors.	Adenosine Triphosphate	287-290	glycogen synthase kinase 3 beta	Homo sapiens	248-257
25333250-10	2015	Following exposure to AMP, the expression levels of Fbw7alpha, Fbw7gamma and GSK3beta were reduced and p-c-Myc (Thr58) expression levels were increased.	ampelopsin	22-25	glycogen synthase kinase 3 beta	Homo sapiens	77-85
25266063-6	2015	Interestingly, PGE2 and forskolin promoted glycogen synthase kinase 3beta inhibition, beta-catenin phosphorylation at the protein kinase A target residue ser675, beta-catenin nuclear translocation and TCF-dependent gene transcription.	Dinoprostone	15-19	glycogen synthase kinase 3 beta	Homo sapiens	43-73
25266063-6	2015	Interestingly, PGE2 and forskolin promoted glycogen synthase kinase 3beta inhibition, beta-catenin phosphorylation at the protein kinase A target residue ser675, beta-catenin nuclear translocation and TCF-dependent gene transcription.	Colforsin	24-33	glycogen synthase kinase 3 beta	Homo sapiens	43-73
25266651-5	2015	Acetylcholine promotes the phosphorylation of glycogen synthesis kinase 3beta (GSK3beta) in the sweat-gland secretory cells and leads to sensible perspiration.	Acetylcholine	0-13	glycogen synthase kinase 3 beta	Homo sapiens	79-87
25266651-6	2015	By suppressing the phosphorylation of GSK3beta, histamine inhibits the movement of sweat from the sweat-gland secretory cells through the sweat ducts, which could presumably be demonstrated by dynamic observations of the sweat glands using two-photon microscopy.	Histamine	48-57	glycogen synthase kinase 3 beta	Homo sapiens	38-46
25872479-4	2015	All of the Akt/MMP2/MMP9 pathway, Akt/Bad pathway, and Akt/Gsk3beta/CDK2 pathway could be inhibited by fangchinoline through inhibition of PI3K.	fangchinoline	103-116	glycogen synthase kinase 3 beta	Homo sapiens	59-67
25344882-6	2015	Blocking GSK3b phosphorylation at Serine 9 attenuated cell proliferation while concomitantly stimulating apoptosis through activation of Caspase-3 in patient-derived GSCs.	Serine	34-40	glycogen synthase kinase 3 beta	Homo sapiens	9-14
25344882-9	2015	Furthermore, knocking down PP2A or blocking its activity by okadaic acid inactivated GSK3b by increasing GSK3b phosphorylation at Serine 9.	Okadaic Acid	60-72	glycogen synthase kinase 3 beta	Homo sapiens	85-90
25344882-9	2015	Furthermore, knocking down PP2A or blocking its activity by okadaic acid inactivated GSK3b by increasing GSK3b phosphorylation at Serine 9.	Okadaic Acid	60-72	glycogen synthase kinase 3 beta	Homo sapiens	105-110
25344882-9	2015	Furthermore, knocking down PP2A or blocking its activity by okadaic acid inactivated GSK3b by increasing GSK3b phosphorylation at Serine 9.	Serine	130-136	glycogen synthase kinase 3 beta	Homo sapiens	85-90
25344882-9	2015	Furthermore, knocking down PP2A or blocking its activity by okadaic acid inactivated GSK3b by increasing GSK3b phosphorylation at Serine 9.	Serine	130-136	glycogen synthase kinase 3 beta	Homo sapiens	105-110
23857500-0	2015	Lidamycin inhibits tumor initiating cells of hepatocellular carcinoma Huh7 through GSK3beta/beta-catenin pathway.	C 1027	0-9	glycogen synthase kinase 3 beta	Homo sapiens	83-91
23857500-11	2015	Lidamycin activated GSK3beta, and degraded the activity of beta-catenin.	C 1027	0-9	glycogen synthase kinase 3 beta	Homo sapiens	20-28
23857500-13	2015	In brief, these results suggest that lidamycin suppressed Huh7 tumor initiating cells via GSK3beta/beta-catenin pathway.	C 1027	37-46	glycogen synthase kinase 3 beta	Homo sapiens	90-98
25575814-6	2015	MIG-7, on the other hand, was induced by growth factors and PGE2 via Akt/GSK-3beta in a phospho-PHBT258 independent manner.	Dinoprostone	60-64	glycogen synthase kinase 3 beta	Homo sapiens	73-82
25622907-6	2015	This resulted in activation of the phosphatidylinositol 3-Kinase Akt pathway (PI3K-Akt), phosphorylation of GSK-3beta at the Ser(9) residue, and subsequent down regulation of E-cadherin cell surface expression resulting in increased tumor cell invasion.	Serine	125-128	glycogen synthase kinase 3 beta	Homo sapiens	108-117
25575814-6	2015	MIG-7, on the other hand, was induced by growth factors and PGE2 via Akt/GSK-3beta in a phospho-PHBT258 independent manner.	phbt258	96-103	glycogen synthase kinase 3 beta	Homo sapiens	73-82
25575058-0	2015	[Activation of Wnt/beta-catenin pathway in NK cells by glycogen synthase kinase-3beta inhibitor TWS119 promotes the expression of CD62L].	TWS 119	96-102	glycogen synthase kinase 3 beta	Homo sapiens	55-85
25575058-1	2015	OBJECTIVE: To investigate the effect of Wnt/beta-catenin pathway activation by glycogen synthase kinase-3beta inhibitor 4,6-disubstituted pyrrolopyrimidine (TWS119) on proliferation and phenotypic characteristics of human nature killer (NK) cells.	4,6-disubstituted pyrrolopyrimidine	120-155	glycogen synthase kinase 3 beta	Homo sapiens	79-109
25575054-3	2015	SB216763, a specific inhibitor of GSK3beta, was given to the cells two hours before H2O2/antimycin A induction.	SB 216763	0-8	glycogen synthase kinase 3 beta	Homo sapiens	34-42
25593505-8	2014	RESULTS: Cultured lens epithelial cells maintained in hypoxia (1% oxygen) and subsequently reintroduced into atmospheric oxygen and treated with the GSK-3beta inhibitor SB216763 illustrated a marked inhibition of phosphorylation of glycogen synthase (downstream substrate of GSK-3beta) and significant increase in nuclear translocation of beta-catenin.	Oxygen	66-72	glycogen synthase kinase 3 beta	Homo sapiens	149-158
25575054-7	2015	RESULTS: Oxidative stress triggered by H2O2/antimycin A promoted GSK3beta activity; inhibition of GSK3beta activity by SB216763 relieved oxidative stress and reduced cell apoptosis induced by oxidative stress.	Hydrogen Peroxide	39-43	glycogen synthase kinase 3 beta	Homo sapiens	65-73
25575054-7	2015	RESULTS: Oxidative stress triggered by H2O2/antimycin A promoted GSK3beta activity; inhibition of GSK3beta activity by SB216763 relieved oxidative stress and reduced cell apoptosis induced by oxidative stress.	Antimycin A	44-55	glycogen synthase kinase 3 beta	Homo sapiens	65-73
25575054-7	2015	RESULTS: Oxidative stress triggered by H2O2/antimycin A promoted GSK3beta activity; inhibition of GSK3beta activity by SB216763 relieved oxidative stress and reduced cell apoptosis induced by oxidative stress.	SB 216763	119-127	glycogen synthase kinase 3 beta	Homo sapiens	98-106
25593505-1	2014	PURPOSE: The inhibition of GSK-3beta blocks mitochondrial membrane permeability transition (mMPT) for HLE-B3 cells in atmospheric oxygen.	Oxygen	130-136	glycogen synthase kinase 3 beta	Homo sapiens	27-36
25593505-8	2014	RESULTS: Cultured lens epithelial cells maintained in hypoxia (1% oxygen) and subsequently reintroduced into atmospheric oxygen and treated with the GSK-3beta inhibitor SB216763 illustrated a marked inhibition of phosphorylation of glycogen synthase (downstream substrate of GSK-3beta) and significant increase in nuclear translocation of beta-catenin.	Oxygen	121-127	glycogen synthase kinase 3 beta	Homo sapiens	149-158
25593505-8	2014	RESULTS: Cultured lens epithelial cells maintained in hypoxia (1% oxygen) and subsequently reintroduced into atmospheric oxygen and treated with the GSK-3beta inhibitor SB216763 illustrated a marked inhibition of phosphorylation of glycogen synthase (downstream substrate of GSK-3beta) and significant increase in nuclear translocation of beta-catenin.	SB 216763	169-177	glycogen synthase kinase 3 beta	Homo sapiens	149-158
25593505-8	2014	RESULTS: Cultured lens epithelial cells maintained in hypoxia (1% oxygen) and subsequently reintroduced into atmospheric oxygen and treated with the GSK-3beta inhibitor SB216763 illustrated a marked inhibition of phosphorylation of glycogen synthase (downstream substrate of GSK-3beta) and significant increase in nuclear translocation of beta-catenin.	SB 216763	169-177	glycogen synthase kinase 3 beta	Homo sapiens	275-284
25522429-5	2014	RESULTS: Our results demonstrated that fluoxetine increased the proliferation of embryonic neural precursor cells (NPCs) by up-regulating the phosphorylation of Ser9 on GSK-3beta and increasing the level of nuclear beta-catenin.	Fluoxetine	39-49	glycogen synthase kinase 3 beta	Homo sapiens	169-178
25541965-8	2014	When compared to women with NGT, omental adipose tissue and skeletal muscle obtained from women with diet-controlled GDM had significantly higher GSK3beta activity as evidenced by a decrease in the expression of GSK3beta phosphorylated at serine 9.	Serine	239-245	glycogen synthase kinase 3 beta	Homo sapiens	146-154
25541965-8	2014	When compared to women with NGT, omental adipose tissue and skeletal muscle obtained from women with diet-controlled GDM had significantly higher GSK3beta activity as evidenced by a decrease in the expression of GSK3beta phosphorylated at serine 9.	Serine	239-245	glycogen synthase kinase 3 beta	Homo sapiens	212-220
25535399-0	2014	Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes.	Paclitaxel	0-10	glycogen synthase kinase 3 beta	Homo sapiens	65-70
25535399-5	2014	RESULTS: A significant relationship between the GSK-3B rs6438552 polymorphism and paclitaxel-induced neurotoxicity was evident.	Paclitaxel	82-92	glycogen synthase kinase 3 beta	Homo sapiens	48-54
25937997-0	2014	Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3beta) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies.	Cladribine	111-133	glycogen synthase kinase 3 beta	Homo sapiens	71-80
25310908-10	2014	Polydatin markedly increased phosphorylated GSK-3beta, decreased the protein levels of G6Pase and SREBP-1c, and increased protein levels of GCK, LDLR, and phosphorylated IRS in livers and HepG2 cells.	polydatin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	44-53
25522429-0	2014	Fluoxetine regulates neurogenesis in vitro through modulation of GSK-3beta/beta-catenin signaling.	Fluoxetine	0-10	glycogen synthase kinase 3 beta	Homo sapiens	65-74
25339176-5	2014	NONOate, an NO donor, also activated GSK3beta, indicating that NO may mediate SNP stimulation of GSK3beta.	pelargonic acid	0-7	glycogen synthase kinase 3 beta	Homo sapiens	37-45
25339176-5	2014	NONOate, an NO donor, also activated GSK3beta, indicating that NO may mediate SNP stimulation of GSK3beta.	pelargonic acid	0-7	glycogen synthase kinase 3 beta	Homo sapiens	97-105
25522429-3	2014	METHODS: The aim of this study was to determine whether GSK-3beta/beta-catenin signaling is involved in the alteration of neurogenesis as a result of treatment with fluoxetine, a selective serotonin reuptake inhibitor.	Fluoxetine	165-175	glycogen synthase kinase 3 beta	Homo sapiens	56-65
25522429-7	2014	The effects of fluoxetine-induced up-regulation of both phosphorylation of Ser9 on GSK-3beta and nuclear beta-catenin were significantly prevented by the 5-hydroxytryptamine-1A (5-HT1A) receptor antagonist WAY-100635.	Fluoxetine	15-25	glycogen synthase kinase 3 beta	Homo sapiens	83-92
25522429-4	2014	The mechanisms involved in fluoxetine"s regulation of GSK-3beta/beta-catenin signaling pathway were also examined.	Fluoxetine	27-37	glycogen synthase kinase 3 beta	Homo sapiens	54-63
25522429-8	2014	CONCLUSIONS: The results demonstrate that fluoxetine may increase neurogenesis via the GSK-3beta/beta-catenin signaling pathway that links postsynaptic 5-HT1A receptor activation.	Fluoxetine	42-52	glycogen synthase kinase 3 beta	Homo sapiens	87-96
25104312-0	2014	Beryllium is an inhibitor of cellular GSK-3beta that is 1,000-fold more potent than lithium.	Beryllium	0-9	glycogen synthase kinase 3 beta	Homo sapiens	38-47
25104312-4	2014	Here we show that BeSO4 inhibits endogenous GSK-3beta in cultured human cells.	beryllium sulfate	18-23	glycogen synthase kinase 3 beta	Homo sapiens	44-53
25104312-5	2014	Exposure to 10 microM Be(2+) produced a decrease in GSK-3beta kinase activity that was comparable to that produced by 10 mM Li(+), indicating that beryllium is about 1,000-fold more potent than the classical inhibitor when treating intact cells.	beryllium(2+)	22-28	glycogen synthase kinase 3 beta	Homo sapiens	52-61
25104312-5	2014	Exposure to 10 microM Be(2+) produced a decrease in GSK-3beta kinase activity that was comparable to that produced by 10 mM Li(+), indicating that beryllium is about 1,000-fold more potent than the classical inhibitor when treating intact cells.	Beryllium	147-156	glycogen synthase kinase 3 beta	Homo sapiens	52-61
25104312-7	2014	Lithium inhibited GSK-3beta kinase activity directly, and it also caused GSK-3beta in cells to become phosphorylated at serine-9 (Ser-9), a post-translational modification that occurs as part of a well-known positive feedback loop that suppresses the kinase activity.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	18-27
25104312-7	2014	Lithium inhibited GSK-3beta kinase activity directly, and it also caused GSK-3beta in cells to become phosphorylated at serine-9 (Ser-9), a post-translational modification that occurs as part of a well-known positive feedback loop that suppresses the kinase activity.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	73-82
25104312-7	2014	Lithium inhibited GSK-3beta kinase activity directly, and it also caused GSK-3beta in cells to become phosphorylated at serine-9 (Ser-9), a post-translational modification that occurs as part of a well-known positive feedback loop that suppresses the kinase activity.	Serine	120-126	glycogen synthase kinase 3 beta	Homo sapiens	73-82
25104312-7	2014	Lithium inhibited GSK-3beta kinase activity directly, and it also caused GSK-3beta in cells to become phosphorylated at serine-9 (Ser-9), a post-translational modification that occurs as part of a well-known positive feedback loop that suppresses the kinase activity.	Serine	130-133	glycogen synthase kinase 3 beta	Homo sapiens	73-82
25104312-9	2014	These results indicate that beryllium, like lithium, can induce perturbations in the GSK-3beta signaling network of treated cells.	Beryllium	28-37	glycogen synthase kinase 3 beta	Homo sapiens	85-94
25104312-9	2014	These results indicate that beryllium, like lithium, can induce perturbations in the GSK-3beta signaling network of treated cells.	Lithium	44-51	glycogen synthase kinase 3 beta	Homo sapiens	85-94
25520943-5	2014	However, it is unclear whether GSK3alpha also plays a role and whether this crosstalk can be manipulated by AZD5363, a novel pan-Akt inhibitor that has been shown to increase glycogen synthase kinase 3 activity through reducing phosphorylation of GSK3alpha and GSK3beta.	capivasertib	108-115	glycogen synthase kinase 3 beta	Homo sapiens	261-269
25265417-0	2014	Lithium stimulates human bone marrow derived mesenchymal stem cell proliferation through GSK-3beta-dependent beta-catenin/Wnt pathway activation.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	89-98
25265417-8	2014	Lithium induced Ser9 phosphorylation, which results in the inhibition of GSK-3beta activity, beta-catenin accumulation and Wnt pathway activation.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	73-82
25265417-9	2014	Utilizing a specific GSK-3beta inhibitor SB216763 or siRNA-mediated inhibition of GSK-3beta produced effects similar to those induced by lithium.	SB 216763	41-49	glycogen synthase kinase 3 beta	Homo sapiens	21-30
25265417-10	2014	In contrast, either quercetin, an inhibitor of the beta-catenin/TCF pathway, or siRNA-mediated knockdown of beta-catenin abolished the proliferative effect of lithium, suggesting that lithium stimulates MSC proliferation via the GSK-3beta-dependent beta-catenin/Wnt pathway.	Lithium	159-166	glycogen synthase kinase 3 beta	Homo sapiens	229-238
25265417-10	2014	In contrast, either quercetin, an inhibitor of the beta-catenin/TCF pathway, or siRNA-mediated knockdown of beta-catenin abolished the proliferative effect of lithium, suggesting that lithium stimulates MSC proliferation via the GSK-3beta-dependent beta-catenin/Wnt pathway.	Lithium	184-191	glycogen synthase kinase 3 beta	Homo sapiens	229-238
25152370-9	2014	CLG interfered with the beta-catenin/[phospho]GSK-3beta complex as well as the E-cadherin/beta-catenin complex in both cell lines cells, but, again, the effect was more robust in MDA-MB-231 cells.	Clorgyline	0-3	glycogen synthase kinase 3 beta	Homo sapiens	46-55
25520943-9	2014	AZD5363 inhibited the synergy between IL-17 and insulin/IGF1 through reducing phosphorylation of GSK3alpha and GSK3beta by inhibiting Akt function.	capivasertib	0-7	glycogen synthase kinase 3 beta	Homo sapiens	111-119
24705818-8	2014	In contrast, activation of the DRD2-signaling pathway, visible in the levels of Akt phosphorylated on Thr308 and GSK3beta on Ser9, is associated with L-DOPA treatment, independently of the presence of dyskinesias.	Levodopa	150-156	glycogen synthase kinase 3 beta	Homo sapiens	113-121
25674233-0	2014	Dihydroartemisinin inhibits cell proliferation via AKT/GSK3beta/cyclinD1 pathway and induces apoptosis in A549 lung cancer cells.	artenimol	0-18	glycogen synthase kinase 3 beta	Homo sapiens	55-63
25674233-5	2014	Here, we demonstrate that DHA inhibited cell proliferation in the A549 lung cancer cell line through suppression of the AKT/Gsk-3beta/cyclin D1 signaling pathway.	artenimol	26-29	glycogen synthase kinase 3 beta	Homo sapiens	124-133
24752588-3	2014	In this study, proteasome inhibitor MG132 was used to treat hippocampal slices to explore the role and mechanism of Akt/glycogen synthase kinase-3beta (GSK-3beta) in proteasome inhibition-induced tau abnormality.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	36-41	glycogen synthase kinase 3 beta	Homo sapiens	152-161
25449069-0	2014	[Regulation of PI3K-Akt-GSK3beta signaling pathway in U251 cells by risperidone].	Risperidone	68-79	glycogen synthase kinase 3 beta	Homo sapiens	24-32
25449069-1	2014	OBJECTIVE: To investigate the effect of risperidone, an antipsychotic drug, on the Akt-GSK3beta pathway and the role of PI3K in dopamine D2 receptor (DRD2) expression and Akt-GSK3beta signal pathway.	Risperidone	40-51	glycogen synthase kinase 3 beta	Homo sapiens	87-95
25449069-1	2014	OBJECTIVE: To investigate the effect of risperidone, an antipsychotic drug, on the Akt-GSK3beta pathway and the role of PI3K in dopamine D2 receptor (DRD2) expression and Akt-GSK3beta signal pathway.	Risperidone	40-51	glycogen synthase kinase 3 beta	Homo sapiens	175-183
25449069-3	2014	Cells without any treatment as control, Western blotting was used for measuring the expression of Akt (Thr308 and Ser473) and GSK3beta (Ser9) protein phosphorylation by risperidone and LY294002 in U251 cell, and real-time PCR was used for detecting the expression of DRD2 mRNA.	Risperidone	169-180	glycogen synthase kinase 3 beta	Homo sapiens	126-134
25449069-4	2014	RESULTS: Risperidone has significantly enhanced the expression of phosphorylated Akt and phosphorylated GSK3beta (P&lt; 0.05), but did not alter the mRNA expression of DRD2.	Risperidone	9-20	glycogen synthase kinase 3 beta	Homo sapiens	104-112
25449069-5	2014	LY294002 could reduce the phosphorylation of Akt and GSK3beta (P&lt; 0.01, P&lt; 0.05), and also decrease the DRD2 mRNA (P&lt;0 .05).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	glycogen synthase kinase 3 beta	Homo sapiens	53-61
25449069-6	2014	CONCLUSION: Risperidone can activate the Akt-GSK3beta signaling pathway in the U251 cells, and PI3K is a common regulatory site in Akt-GSK3beta signaling and D2 receptor gene expression.	Risperidone	12-23	glycogen synthase kinase 3 beta	Homo sapiens	45-53
25428027-8	2014	Pre-treatment of HL-60 cells with an inhibitor of glycogen synthase kinase-3beta (GSK-3beta), which activated canonical Wnt signaling, partly abolished the differentiation of HL-60 cells induced by 6-BT.	6-benzylthioinosine	198-202	glycogen synthase kinase 3 beta	Homo sapiens	50-80
25450696-4	2014	Furthermore, our results indicated that curcumin inhibited OSCC cells (SCC-9 cells) proliferation through up-regulating miR-9 expression, and suppressing Wnt/beta-catenin signaling by increasing the expression levels of the GSK-3beta, phosphorylated GSK-3beta and beta-catenin, and decreasing the cyclin D1 level.	Curcumin	40-48	glycogen synthase kinase 3 beta	Homo sapiens	224-233
25450696-4	2014	Furthermore, our results indicated that curcumin inhibited OSCC cells (SCC-9 cells) proliferation through up-regulating miR-9 expression, and suppressing Wnt/beta-catenin signaling by increasing the expression levels of the GSK-3beta, phosphorylated GSK-3beta and beta-catenin, and decreasing the cyclin D1 level.	Curcumin	40-48	glycogen synthase kinase 3 beta	Homo sapiens	250-259
25428027-8	2014	Pre-treatment of HL-60 cells with an inhibitor of glycogen synthase kinase-3beta (GSK-3beta), which activated canonical Wnt signaling, partly abolished the differentiation of HL-60 cells induced by 6-BT.	6-benzylthioinosine	198-202	glycogen synthase kinase 3 beta	Homo sapiens	82-91
25428397-4	2014	Here we found that 0.35 mg/L Licochalcone A (L-A) had a strong effect in increasing the osteogenic differentiation and mineralization of BMSCs both in vivo and in vitro by up-regulating FasL and further playing a role in regulating the ERK and GSK-3beta-catenin systems.	licochalcone	29-41	glycogen synthase kinase 3 beta	Homo sapiens	244-253
25352148-0	2014	Green tea polyphenol EGCG suppresses Wnt/beta-catenin signaling by promoting GSK-3beta- and PP2A-independent beta-catenin phosphorylation/degradation.	Polyphenols	10-20	glycogen synthase kinase 3 beta	Homo sapiens	77-86
25014275-5	2014	In addition, PGE2 increased the phosphorylation and inactivation of glycogen synthesis kinase-3beta (GSK-3beta), whereas poly(I:C) decreased it.	Dinoprostone	13-17	glycogen synthase kinase 3 beta	Homo sapiens	101-110
25014275-7	2014	These results suggest that prostaglandin modulates the TLR3-mediated cytokine profile in astrocytes via EP2 receptors and regulates the NF-kappaB, ERK1/2 and GSK-3beta signaling pathways.	Prostaglandins	27-40	glycogen synthase kinase 3 beta	Homo sapiens	158-167
25451258-2	2014	GSK3beta activity is inhibited through the phosphorylation of its Ser-9 residue.	Serine	66-69	glycogen synthase kinase 3 beta	Homo sapiens	0-8
25352148-0	2014	Green tea polyphenol EGCG suppresses Wnt/beta-catenin signaling by promoting GSK-3beta- and PP2A-independent beta-catenin phosphorylation/degradation.	epigallocatechin gallate	21-25	glycogen synthase kinase 3 beta	Homo sapiens	77-86
25142972-7	2014	Pro-apoptotic inactivation of NFAT2 also followed reactivation of GSK3beta by direct inhibition of PKB or SOC, whereas GSK3beta blockade prevented Zol-induced NFAT2 inhibition and cell death.	Zoledronic Acid	147-150	glycogen synthase kinase 3 beta	Homo sapiens	119-127
25142972-8	2014	The rescuing effect of GSK3beta blockade was reproduced by recovery of entire SOC/PKB/GSK3beta cascade after reconstitution of rafts by cholesterol replenishment of Zol-treated tumorigenic cells.	Cholesterol	136-147	glycogen synthase kinase 3 beta	Homo sapiens	23-31
25142972-8	2014	The rescuing effect of GSK3beta blockade was reproduced by recovery of entire SOC/PKB/GSK3beta cascade after reconstitution of rafts by cholesterol replenishment of Zol-treated tumorigenic cells.	Zoledronic Acid	165-168	glycogen synthase kinase 3 beta	Homo sapiens	23-31
25142972-8	2014	The rescuing effect of GSK3beta blockade was reproduced by recovery of entire SOC/PKB/GSK3beta cascade after reconstitution of rafts by cholesterol replenishment of Zol-treated tumorigenic cells.	Zoledronic Acid	165-168	glycogen synthase kinase 3 beta	Homo sapiens	86-94
25187650-6	2014	Inhibition of GSK3beta or iNOS suppresses nitric oxide (NO) production, glycolysis, and HDAC4 degradation.	Nitric Oxide	42-54	glycogen synthase kinase 3 beta	Homo sapiens	14-22
25253076-8	2014	Abnormal responses to shear stress in cells expressing either mutant plakoglobin or plakophilin could be reversed by SB216763, a GSK3beta inhibitor.	SB 216763	117-125	glycogen synthase kinase 3 beta	Homo sapiens	129-137
25310895-8	2014	This study first reported the involvement of miR-451/c-Myc/ERK/GSK-3beta signalling axis in the acquisition of EMT phenotype in docetaxel-resistant LAD cells, suggesting that re-expression of miR-451 or targeting c-Myc will be a potential strategy for the treatment of chemoresistant LAD patients.	Docetaxel	128-137	glycogen synthase kinase 3 beta	Homo sapiens	63-72
25187518-6	2014	H2O2 increased the density of nine spots on two-dimensional gel electrophoresis of anti-GSK-3beta-immunoprecipitates by more than 3-fold.	Hydrogen Peroxide	0-4	glycogen synthase kinase 3 beta	Homo sapiens	88-97
25151579-0	2014	Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3beta (GSK-3beta) phosphorylation inhibitors.	Nitrogen	47-48	glycogen synthase kinase 3 beta	Homo sapiens	148-178
25151579-0	2014	Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3beta (GSK-3beta) phosphorylation inhibitors.	Nitrogen	47-48	glycogen synthase kinase 3 beta	Homo sapiens	180-189
25151579-0	2014	Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3beta (GSK-3beta) phosphorylation inhibitors.	alkyl	49-54	glycogen synthase kinase 3 beta	Homo sapiens	148-178
25151579-0	2014	Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3beta (GSK-3beta) phosphorylation inhibitors.	alkyl	49-54	glycogen synthase kinase 3 beta	Homo sapiens	180-189
25151579-0	2014	Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3beta (GSK-3beta) phosphorylation inhibitors.	substituted isoindigo	63-84	glycogen synthase kinase 3 beta	Homo sapiens	148-178
25151579-0	2014	Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3beta (GSK-3beta) phosphorylation inhibitors.	substituted isoindigo	63-84	glycogen synthase kinase 3 beta	Homo sapiens	180-189
25231989-6	2014	We show that expression of a CLASP2 mutant, in which the nine GSK3 target serines are mutated to alanine (CLASP2-9XS/9XA) and are resistant to GSK3beta-dependent phosphorylation, promotes MT capture at clusters and increases AChR cluster size, compared with myotubes that express similar levels of wild type CLASP2 or that are noninfected.	Serine	74-81	glycogen synthase kinase 3 beta	Homo sapiens	143-151
25231989-6	2014	We show that expression of a CLASP2 mutant, in which the nine GSK3 target serines are mutated to alanine (CLASP2-9XS/9XA) and are resistant to GSK3beta-dependent phosphorylation, promotes MT capture at clusters and increases AChR cluster size, compared with myotubes that express similar levels of wild type CLASP2 or that are noninfected.	Alanine	97-104	glycogen synthase kinase 3 beta	Homo sapiens	143-151
25187518-9	2014	The mitochondrial translocation of GSK-3beta was attenuated also when Lys-15, but not Arg-4 or Arg-6, in the N-terminal domain of GSK-3beta was replaced with alanine.	Lysine	70-73	glycogen synthase kinase 3 beta	Homo sapiens	35-44
25187518-9	2014	The mitochondrial translocation of GSK-3beta was attenuated also when Lys-15, but not Arg-4 or Arg-6, in the N-terminal domain of GSK-3beta was replaced with alanine.	Lysine	70-73	glycogen synthase kinase 3 beta	Homo sapiens	130-139
25187518-9	2014	The mitochondrial translocation of GSK-3beta was attenuated also when Lys-15, but not Arg-4 or Arg-6, in the N-terminal domain of GSK-3beta was replaced with alanine.	Arginine	86-89	glycogen synthase kinase 3 beta	Homo sapiens	35-44
25187518-9	2014	The mitochondrial translocation of GSK-3beta was attenuated also when Lys-15, but not Arg-4 or Arg-6, in the N-terminal domain of GSK-3beta was replaced with alanine.	Arginine	95-98	glycogen synthase kinase 3 beta	Homo sapiens	35-44
25187518-9	2014	The mitochondrial translocation of GSK-3beta was attenuated also when Lys-15, but not Arg-4 or Arg-6, in the N-terminal domain of GSK-3beta was replaced with alanine.	Alanine	158-165	glycogen synthase kinase 3 beta	Homo sapiens	35-44
25187518-10	2014	The oxidative stress-induced mitochondrial translocation of GSK-3beta was associated with an increase in cell death, which was suppressed by lithium chloride (LiCl), a GSK-3beta inhibitor.	Lithium Chloride	141-157	glycogen synthase kinase 3 beta	Homo sapiens	60-69
25187518-10	2014	The oxidative stress-induced mitochondrial translocation of GSK-3beta was associated with an increase in cell death, which was suppressed by lithium chloride (LiCl), a GSK-3beta inhibitor.	Lithium Chloride	141-157	glycogen synthase kinase 3 beta	Homo sapiens	168-177
25187518-10	2014	The oxidative stress-induced mitochondrial translocation of GSK-3beta was associated with an increase in cell death, which was suppressed by lithium chloride (LiCl), a GSK-3beta inhibitor.	Lithium Chloride	159-163	glycogen synthase kinase 3 beta	Homo sapiens	60-69
25187518-10	2014	The oxidative stress-induced mitochondrial translocation of GSK-3beta was associated with an increase in cell death, which was suppressed by lithium chloride (LiCl), a GSK-3beta inhibitor.	Lithium Chloride	159-163	glycogen synthase kinase 3 beta	Homo sapiens	168-177
25011606-6	2014	The KHG26377-induced protection of neuronal cells against Abeta toxicity was also mediated by suppressing the expression of glycogen synthase kinase-3beta, increasing the levels of beta-catenin, and reducing the levels of phosphorylated tau.	2-cyclopropylimino-3-methyl-1,3-thiazoline hydrochloride	4-12	glycogen synthase kinase 3 beta	Homo sapiens	124-154
24975844-6	2014	Blocking Glycogen Synthase Kinase (GSK3beta) activity by lithium chloride or Dvl gene overexpression restored beta-catenin expression.	Lithium Chloride	57-73	glycogen synthase kinase 3 beta	Homo sapiens	35-43
25109896-9	2014	Overall, these results provide strong evidence that sodium selenite (selenium) can inhibit cell death and tau phosphorylation induced by TNF-alpha in neuroblastoma cells, through the inhibition GSK-3beta and Akt phosphorylation.	Sodium Selenite	52-67	glycogen synthase kinase 3 beta	Homo sapiens	194-203
24905570-5	2014	Mechanistically, salinomycin activated GSK3beta in cancer cells.	salinomycin	17-28	glycogen synthase kinase 3 beta	Homo sapiens	39-47
24844601-8	2014	We further found that ZSTK474 inhibited the phosphorylation of PI3K downstream signaling Akt and glycogen synthase kinase 3 beta in the dendritic cell.	ZSTK474	22-29	glycogen synthase kinase 3 beta	Homo sapiens	97-128
25109896-8	2014	The phosphorylation of two protein kinases responsible for phosphorylation of tau, glycogen synthase kinase 3beta (GSK-3beta) and Akt, also known as protein kinase B, was markedly decreased in the TNF-alpha+selenite-treated group relative to the TNF-alpha+vehicle-treated group.	Selenious Acid	207-215	glycogen synthase kinase 3 beta	Homo sapiens	83-113
25109896-9	2014	Overall, these results provide strong evidence that sodium selenite (selenium) can inhibit cell death and tau phosphorylation induced by TNF-alpha in neuroblastoma cells, through the inhibition GSK-3beta and Akt phosphorylation.	Selenium	69-77	glycogen synthase kinase 3 beta	Homo sapiens	194-203
25109896-8	2014	The phosphorylation of two protein kinases responsible for phosphorylation of tau, glycogen synthase kinase 3beta (GSK-3beta) and Akt, also known as protein kinase B, was markedly decreased in the TNF-alpha+selenite-treated group relative to the TNF-alpha+vehicle-treated group.	Selenious Acid	207-215	glycogen synthase kinase 3 beta	Homo sapiens	115-124
27486080-4	2014	To identify compounds that are structurally novel and diverse compared to previously reported ATP-competitive GSK-3beta inhibitors, we performed virtual screening by implementing a mixed ligand/structure-based approach, which included pharmacophore modeling, diversity analysis, and ensemble docking.	Adenosine Triphosphate	94-97	glycogen synthase kinase 3 beta	Homo sapiens	110-119
24815187-5	2014	Tcad+-VSMC exhibited elevated constitutive levels of phosphorylated Akt(ser473), GSK3beta(ser9), S6RP(ser235/236) and IRS-1(ser636/639).	tcad+-vsmc	0-10	glycogen synthase kinase 3 beta	Homo sapiens	81-89
25047426-0	2014	Hesperidin induces apoptosis and triggers autophagic markers through inhibition of Aurora-A mediated phosphoinositide-3-kinase/Akt/mammalian target of rapamycin and glycogen synthase kinase-3 beta signalling cascades in experimental colon carcinogenesis.	Hesperidin	0-10	glycogen synthase kinase 3 beta	Homo sapiens	165-196
25047426-13	2014	Furthermore, hesperidin administration restored glycogen synthase kinase-3 beta (GSK-3beta) activity which in turn prevented the accumulation of oncoproteins beta-catenin, c-jun and c-myc.	Hesperidin	13-23	glycogen synthase kinase 3 beta	Homo sapiens	48-79
25047426-13	2014	Furthermore, hesperidin administration restored glycogen synthase kinase-3 beta (GSK-3beta) activity which in turn prevented the accumulation of oncoproteins beta-catenin, c-jun and c-myc.	Hesperidin	13-23	glycogen synthase kinase 3 beta	Homo sapiens	81-90
25047426-14	2014	Taken together, hesperidin supplementation initiated apoptosis via targeted inhibition of constitutively activated Aurora-A mediated PI3K/Akt/GSK-3beta and mTOR pathways coupled with autophagic stimulation against AOM induced colon carcinogenesis.	Hesperidin	16-26	glycogen synthase kinase 3 beta	Homo sapiens	142-151
25070845-3	2014	In this study, we describe a novel mechanism in which calcium/calmodulin-dependent protein kinase IV (CaMKIV), through inhibitory serine phosphorylation of GSK-3beta and inhibition of FBXW7 recruitment, prevents ubiquitin proteosomal degradation of mammalian target of rapamycin (mTOR) and thereby augments autophagy in both the macrophage and the kidney.	Serine	130-136	glycogen synthase kinase 3 beta	Homo sapiens	156-165
25064440-3	2014	The current study was designed to identify and evaluate novel ATP-competitive GSK-3beta inhibitors.	Adenosine Triphosphate	62-65	glycogen synthase kinase 3 beta	Homo sapiens	78-87
25064440-7	2014	A SBDD approach to the GSK-3beta and CDK5 proteins was applied to all primary hits, and 5 selective inhibitors were identified for GSK-3beta.	sbdd	2-6	glycogen synthase kinase 3 beta	Homo sapiens	23-32
25064440-7	2014	A SBDD approach to the GSK-3beta and CDK5 proteins was applied to all primary hits, and 5 selective inhibitors were identified for GSK-3beta.	sbdd	2-6	glycogen synthase kinase 3 beta	Homo sapiens	131-140
25142337-0	2014	Structural basis of valmerins as dual inhibitors of GSK3beta/CDK5.	valmerins	20-29	glycogen synthase kinase 3 beta	Homo sapiens	52-60
25142337-3	2014	Detailed MM-PBSA calculations revealed that the binding free energies of the valmerin-19 to GSK3beta/CDK5 were calculated to be -12.60 +- 2.28 kcal mol(-1) and -11.85 +- 2.54 kcal mol(-1), respectively, indicating that valmerin-19 has the potential to act as a dual inhibitor of GSK3beta/CDK5.	poly(tetramethylene succinate-co-tetramethylene adipate)	12-16	glycogen synthase kinase 3 beta	Homo sapiens	92-100
24894198-6	2014	Mechanistic analysis showed that the antitumor potential of dihydromyricetin may be due to the activation of AMPKalpha and p38(MAPK), as the activating AMPKalpha led to the inactivation of GSK3beta in osteosarcoma cells.	dihydromyricetin	60-76	glycogen synthase kinase 3 beta	Homo sapiens	189-197
24894198-7	2014	Moreover, GSK3beta deletion or GSK3beta inhibition by LiCl treatment resulted in increased p21 expression and reduced Sox2 expression in osteosarcoma cells.	Lithium Chloride	54-58	glycogen synthase kinase 3 beta	Homo sapiens	10-18
24894198-7	2014	Moreover, GSK3beta deletion or GSK3beta inhibition by LiCl treatment resulted in increased p21 expression and reduced Sox2 expression in osteosarcoma cells.	Lithium Chloride	54-58	glycogen synthase kinase 3 beta	Homo sapiens	31-39
24894198-8	2014	Taken together, our results strongly indicate that the antitumor potential of dihydromyricetin is correlated with P38(MAPK) and the AMPKalpha-GSK3beta-Sox2 signaling pathway.	dihydromyricetin	78-94	glycogen synthase kinase 3 beta	Homo sapiens	142-150
25142337-3	2014	Detailed MM-PBSA calculations revealed that the binding free energies of the valmerin-19 to GSK3beta/CDK5 were calculated to be -12.60 +- 2.28 kcal mol(-1) and -11.85 +- 2.54 kcal mol(-1), respectively, indicating that valmerin-19 has the potential to act as a dual inhibitor of GSK3beta/CDK5.	valmerin	77-85	glycogen synthase kinase 3 beta	Homo sapiens	92-100
25142337-3	2014	Detailed MM-PBSA calculations revealed that the binding free energies of the valmerin-19 to GSK3beta/CDK5 were calculated to be -12.60 +- 2.28 kcal mol(-1) and -11.85 +- 2.54 kcal mol(-1), respectively, indicating that valmerin-19 has the potential to act as a dual inhibitor of GSK3beta/CDK5.	valmerin	77-85	glycogen synthase kinase 3 beta	Homo sapiens	279-287
25142337-3	2014	Detailed MM-PBSA calculations revealed that the binding free energies of the valmerin-19 to GSK3beta/CDK5 were calculated to be -12.60 +- 2.28 kcal mol(-1) and -11.85 +- 2.54 kcal mol(-1), respectively, indicating that valmerin-19 has the potential to act as a dual inhibitor of GSK3beta/CDK5.	valmerin	219-227	glycogen synthase kinase 3 beta	Homo sapiens	92-100
25034385-9	2014	Exposure of myotubes to either 17beta-estradiol or testosterone augmented phosphorylation GSK3beta(Ser9) and PKCdelta(Thr505), two negative regulators of glycogen synthesis.	Estradiol	31-47	glycogen synthase kinase 3 beta	Homo sapiens	90-103
25034385-9	2014	Exposure of myotubes to either 17beta-estradiol or testosterone augmented phosphorylation GSK3beta(Ser9) and PKCdelta(Thr505), two negative regulators of glycogen synthesis.	Testosterone	51-63	glycogen synthase kinase 3 beta	Homo sapiens	90-103
25034385-9	2014	Exposure of myotubes to either 17beta-estradiol or testosterone augmented phosphorylation GSK3beta(Ser9) and PKCdelta(Thr505), two negative regulators of glycogen synthesis.	Glycogen	154-162	glycogen synthase kinase 3 beta	Homo sapiens	90-103
24811175-6	2014	Inhibition of Gsk-3beta by Irs-2-dependent PI3K signaling promotes glucose uptake and aerobic glycolysis.	Glucose	67-74	glycogen synthase kinase 3 beta	Homo sapiens	14-23
25017515-5	2014	Since Aurora kinase A is reported to phosphorylate GSK3beta, leading to its inactivation, we hypothesized that one of the targets of OSU-03012 is Aurora kinase A.	osu	133-136	glycogen synthase kinase 3 beta	Homo sapiens	51-59
25170755-6	2014	In addition, the expression of synaptic markers and neurites was induced by Wnt7a and lithium, a glycogen synthase kinase-3beta inhibitor, in the NT-induced hMSCs via the canonical/beta-catenin pathway, but was inhibited by Wnt inhibitors and frizzled-5 (Frz5) blocking antibodies.	Lithium	86-93	glycogen synthase kinase 3 beta	Homo sapiens	97-127
25148525-7	2014	Inhibition of GSK3beta with LiCl (the inhibitor of GSK3beta) increased the expression of Snail and beta-catenin in cultured kidney epithelial cells.	Lithium Chloride	28-32	glycogen synthase kinase 3 beta	Homo sapiens	14-22
25148525-7	2014	Inhibition of GSK3beta with LiCl (the inhibitor of GSK3beta) increased the expression of Snail and beta-catenin in cultured kidney epithelial cells.	Lithium Chloride	28-32	glycogen synthase kinase 3 beta	Homo sapiens	51-59
24858370-13	2014	The present data show that EMD treatment at the beginning of reperfusion-similarly to IPO- limited infarct size and attenuated the postischemic impairment of myocardial function through reactive oxygen species-mediated ERK1/2/Akt/GSK-3beta/eNOS pathways.	Reactive Oxygen Species	186-209	glycogen synthase kinase 3 beta	Homo sapiens	230-239
24944076-4	2014	PTE stimulated Fas signaling, which drives EMT by the ERK1/2 and GSK3beta/beta-catenin pathways, supporting Fas signaling induction involved in EMT regulation.	ammonium ferrous sulfate	15-18	glycogen synthase kinase 3 beta	Homo sapiens	65-73
24983400-5	2014	Ginsenoside Rb1 inhibited lipopolysaccharide/cycloheximide-induced AKT and glycogen synthase kinase-3beta phosphorylation in the D3-transduced macrophages, but not the phosphorylation of PDK-1 and phosphoinositide-3-kinase (PI3K).	Cycloheximide	45-58	glycogen synthase kinase 3 beta	Homo sapiens	75-105
24962437-0	2014	Paliperidone protects SK-N-SH cells against glutamate toxicity via Akt1/GSK3beta signaling pathway.	Paliperidone Palmitate	0-12	glycogen synthase kinase 3 beta	Homo sapiens	72-80
24962437-0	2014	Paliperidone protects SK-N-SH cells against glutamate toxicity via Akt1/GSK3beta signaling pathway.	Glutamic Acid	44-53	glycogen synthase kinase 3 beta	Homo sapiens	72-80
24962437-9	2014	In addition, paliperidone also effectively reversed glutamate-induced decreases of gene expression and phosphorylation of Akt1 and GSK3beta (both p&lt;0.05).	Paliperidone Palmitate	13-25	glycogen synthase kinase 3 beta	Homo sapiens	131-139
24962437-9	2014	In addition, paliperidone also effectively reversed glutamate-induced decreases of gene expression and phosphorylation of Akt1 and GSK3beta (both p&lt;0.05).	Glutamic Acid	52-61	glycogen synthase kinase 3 beta	Homo sapiens	131-139
24962437-10	2014	Our results demonstrated that paliperidone could effectively protect SK-N-SH cells from glutamate-induced damages via Akt1/GSK3beta signaling pathway.	Paliperidone Palmitate	30-42	glycogen synthase kinase 3 beta	Homo sapiens	123-131
24962437-10	2014	Our results demonstrated that paliperidone could effectively protect SK-N-SH cells from glutamate-induced damages via Akt1/GSK3beta signaling pathway.	Glutamic Acid	88-97	glycogen synthase kinase 3 beta	Homo sapiens	123-131
24992082-0	2014	Haplotype analysis of GSK-3beta gene polymorphisms in bipolar disorder lithium responders and nonresponders.	Lithium	71-78	glycogen synthase kinase 3 beta	Homo sapiens	22-31
24992082-1	2014	The GSK-3beta gene, GSK3B, codes for an enzyme that is a target for the action of mood stabilizers, lithium and possibly valproic acid.In this study, the relationship between haplotypes consisting of single nucleotide polymorphisms (SNPs) of GSK3B -50T/C and -1727A/T and the effect of lithium was studied among Japanese bipolar disorder lithium nonresponders and responders.The distributions of the GSK3B haplotypes (-50T/C and -1727A/T) showed a trend for significant difference between the lithium nonresponders and responders (global P=0.07074).	Lithium	100-107	glycogen synthase kinase 3 beta	Homo sapiens	4-13
24992082-1	2014	The GSK-3beta gene, GSK3B, codes for an enzyme that is a target for the action of mood stabilizers, lithium and possibly valproic acid.In this study, the relationship between haplotypes consisting of single nucleotide polymorphisms (SNPs) of GSK3B -50T/C and -1727A/T and the effect of lithium was studied among Japanese bipolar disorder lithium nonresponders and responders.The distributions of the GSK3B haplotypes (-50T/C and -1727A/T) showed a trend for significant difference between the lithium nonresponders and responders (global P=0.07074).	Lithium	100-107	glycogen synthase kinase 3 beta	Homo sapiens	20-25
24992082-1	2014	The GSK-3beta gene, GSK3B, codes for an enzyme that is a target for the action of mood stabilizers, lithium and possibly valproic acid.In this study, the relationship between haplotypes consisting of single nucleotide polymorphisms (SNPs) of GSK3B -50T/C and -1727A/T and the effect of lithium was studied among Japanese bipolar disorder lithium nonresponders and responders.The distributions of the GSK3B haplotypes (-50T/C and -1727A/T) showed a trend for significant difference between the lithium nonresponders and responders (global P=0.07074).	Valproic Acid	121-134	glycogen synthase kinase 3 beta	Homo sapiens	4-13
24992082-1	2014	The GSK-3beta gene, GSK3B, codes for an enzyme that is a target for the action of mood stabilizers, lithium and possibly valproic acid.In this study, the relationship between haplotypes consisting of single nucleotide polymorphisms (SNPs) of GSK3B -50T/C and -1727A/T and the effect of lithium was studied among Japanese bipolar disorder lithium nonresponders and responders.The distributions of the GSK3B haplotypes (-50T/C and -1727A/T) showed a trend for significant difference between the lithium nonresponders and responders (global P=0.07074).	Valproic Acid	121-134	glycogen synthase kinase 3 beta	Homo sapiens	20-25
24992082-1	2014	The GSK-3beta gene, GSK3B, codes for an enzyme that is a target for the action of mood stabilizers, lithium and possibly valproic acid.In this study, the relationship between haplotypes consisting of single nucleotide polymorphisms (SNPs) of GSK3B -50T/C and -1727A/T and the effect of lithium was studied among Japanese bipolar disorder lithium nonresponders and responders.The distributions of the GSK3B haplotypes (-50T/C and -1727A/T) showed a trend for significant difference between the lithium nonresponders and responders (global P=0.07074).	Lithium	286-293	glycogen synthase kinase 3 beta	Homo sapiens	4-13
24992082-1	2014	The GSK-3beta gene, GSK3B, codes for an enzyme that is a target for the action of mood stabilizers, lithium and possibly valproic acid.In this study, the relationship between haplotypes consisting of single nucleotide polymorphisms (SNPs) of GSK3B -50T/C and -1727A/T and the effect of lithium was studied among Japanese bipolar disorder lithium nonresponders and responders.The distributions of the GSK3B haplotypes (-50T/C and -1727A/T) showed a trend for significant difference between the lithium nonresponders and responders (global P=0.07074).	Lithium	286-293	glycogen synthase kinase 3 beta	Homo sapiens	20-25
24992082-1	2014	The GSK-3beta gene, GSK3B, codes for an enzyme that is a target for the action of mood stabilizers, lithium and possibly valproic acid.In this study, the relationship between haplotypes consisting of single nucleotide polymorphisms (SNPs) of GSK3B -50T/C and -1727A/T and the effect of lithium was studied among Japanese bipolar disorder lithium nonresponders and responders.The distributions of the GSK3B haplotypes (-50T/C and -1727A/T) showed a trend for significant difference between the lithium nonresponders and responders (global P=0.07074).	Lithium	286-293	glycogen synthase kinase 3 beta	Homo sapiens	4-13
24992082-1	2014	The GSK-3beta gene, GSK3B, codes for an enzyme that is a target for the action of mood stabilizers, lithium and possibly valproic acid.In this study, the relationship between haplotypes consisting of single nucleotide polymorphisms (SNPs) of GSK3B -50T/C and -1727A/T and the effect of lithium was studied among Japanese bipolar disorder lithium nonresponders and responders.The distributions of the GSK3B haplotypes (-50T/C and -1727A/T) showed a trend for significant difference between the lithium nonresponders and responders (global P=0.07074).	Lithium	286-293	glycogen synthase kinase 3 beta	Homo sapiens	20-25
24992082-1	2014	The GSK-3beta gene, GSK3B, codes for an enzyme that is a target for the action of mood stabilizers, lithium and possibly valproic acid.In this study, the relationship between haplotypes consisting of single nucleotide polymorphisms (SNPs) of GSK3B -50T/C and -1727A/T and the effect of lithium was studied among Japanese bipolar disorder lithium nonresponders and responders.The distributions of the GSK3B haplotypes (-50T/C and -1727A/T) showed a trend for significant difference between the lithium nonresponders and responders (global P=0.07074).	Lithium	286-293	glycogen synthase kinase 3 beta	Homo sapiens	4-13
24992082-1	2014	The GSK-3beta gene, GSK3B, codes for an enzyme that is a target for the action of mood stabilizers, lithium and possibly valproic acid.In this study, the relationship between haplotypes consisting of single nucleotide polymorphisms (SNPs) of GSK3B -50T/C and -1727A/T and the effect of lithium was studied among Japanese bipolar disorder lithium nonresponders and responders.The distributions of the GSK3B haplotypes (-50T/C and -1727A/T) showed a trend for significant difference between the lithium nonresponders and responders (global P=0.07074).	Lithium	286-293	glycogen synthase kinase 3 beta	Homo sapiens	20-25
24756461-3	2014	In order to enhance the understanding of peritoneal fibrosis, the present study investigated the roles of integrin-linked kinase (ILK) and glycogen synthase kinase 3beta (GSK-3beta) in high glucose-induced phenotypic alterations of HPMCs.	Glucose	190-197	glycogen synthase kinase 3 beta	Homo sapiens	171-180
24768148-0	2014	Synthesis and evaluation of [(11)C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3beta (GSK-3beta).	PyrATP-1	28-43	glycogen synthase kinase 3 beta	Homo sapiens	84-114
24768148-0	2014	Synthesis and evaluation of [(11)C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3beta (GSK-3beta).	PyrATP-1	28-43	glycogen synthase kinase 3 beta	Homo sapiens	116-125
24768148-2	2014	The ability to non-invasively quantify GSK-3beta activity in vivo is therefore of critical importance, and this work is focused upon development of inhibitors of GSK-3beta radiolabeled with carbon-11 to examine quantification of the enzyme using positron emission tomography (PET) imaging.	Carbon-11	190-199	glycogen synthase kinase 3 beta	Homo sapiens	162-171
25246272-3	2014	The antioxidant N-acetylcysteine decreased GSK3beta phosphorylation and poly(ADP-ribose) polymerase cleavage induced by 4HPR, As2O3, and PEITC, implicating oxidative stress in these effects.	Acetylcysteine	16-32	glycogen synthase kinase 3 beta	Homo sapiens	43-51
25246272-3	2014	The antioxidant N-acetylcysteine decreased GSK3beta phosphorylation and poly(ADP-ribose) polymerase cleavage induced by 4HPR, As2O3, and PEITC, implicating oxidative stress in these effects.	Fenretinide	120-124	glycogen synthase kinase 3 beta	Homo sapiens	43-51
25246272-3	2014	The antioxidant N-acetylcysteine decreased GSK3beta phosphorylation and poly(ADP-ribose) polymerase cleavage induced by 4HPR, As2O3, and PEITC, implicating oxidative stress in these effects.	Arsenic Trioxide	126-131	glycogen synthase kinase 3 beta	Homo sapiens	43-51
25246272-3	2014	The antioxidant N-acetylcysteine decreased GSK3beta phosphorylation and poly(ADP-ribose) polymerase cleavage induced by 4HPR, As2O3, and PEITC, implicating oxidative stress in these effects.	phenethyl isothiocyanate	137-142	glycogen synthase kinase 3 beta	Homo sapiens	43-51
25246272-4	2014	GSK3beta phosphorylation was associated with up-regulation of antioxidant enzymes, in particular heme oxygenase-1 (HO-1), and transient elevation of intracellular glutathione (GSH) in cells surviving acute stress, before occurrence of irreversible damage and death.	Glutathione	163-174	glycogen synthase kinase 3 beta	Homo sapiens	0-8
25246272-4	2014	GSK3beta phosphorylation was associated with up-regulation of antioxidant enzymes, in particular heme oxygenase-1 (HO-1), and transient elevation of intracellular glutathione (GSH) in cells surviving acute stress, before occurrence of irreversible damage and death.	Glutathione	176-179	glycogen synthase kinase 3 beta	Homo sapiens	0-8
25246272-5	2014	Genetic inactivation of GSK3beta or transfection with the non-phosphorylatable GSK3beta-S9A mutant inhibited HO-1 induction under redox stress, while tumor cells resistant to 4HPR exhibited increased GSK3beta phosphorylation, HO-1 expression, and GSH levels.	Glutathione	247-250	glycogen synthase kinase 3 beta	Homo sapiens	79-87
25246272-5	2014	Genetic inactivation of GSK3beta or transfection with the non-phosphorylatable GSK3beta-S9A mutant inhibited HO-1 induction under redox stress, while tumor cells resistant to 4HPR exhibited increased GSK3beta phosphorylation, HO-1 expression, and GSH levels.	Glutathione	247-250	glycogen synthase kinase 3 beta	Homo sapiens	79-87
24968063-4	2014	Our results indicated that the proliferation of human colorectal adenocarcinoma DLD1 cells was significantly promoted after exposed to low concentrations of p,p"-DDT ranging from 10(-12) to 10(-7) M for 96 h. Exposure to p,p"-DDT from 10(-10) to 10(-8) M led to upregulation of phospho-GSK3beta (Ser9), beta-catenin, c-Myc and cyclin D1 in DLD1 cells.	DDT	157-165	glycogen synthase kinase 3 beta	Homo sapiens	286-294
24968063-4	2014	Our results indicated that the proliferation of human colorectal adenocarcinoma DLD1 cells was significantly promoted after exposed to low concentrations of p,p"-DDT ranging from 10(-12) to 10(-7) M for 96 h. Exposure to p,p"-DDT from 10(-10) to 10(-8) M led to upregulation of phospho-GSK3beta (Ser9), beta-catenin, c-Myc and cyclin D1 in DLD1 cells.	DDT	221-229	glycogen synthase kinase 3 beta	Homo sapiens	286-294
25104922-4	2014	In this study, depolarization (potassium chloride)-driven activity increased the level of active CRMP2 by decreasing its phosphorylation by GSK3beta via a reduction in priming by Cdk5.	Potassium Chloride	31-49	glycogen synthase kinase 3 beta	Homo sapiens	140-148
25076872-4	2014	Tau is phosphorylated at many sites via several protein kinases, and a characteristic is phosphorylation at Ser/Thr residues in Ser/Thr-Pro sequences, which are targeted by proline-directed protein kinases such as ERK, GSK3beta, and Cdk5.	Serine	108-111	glycogen synthase kinase 3 beta	Homo sapiens	219-227
25076872-4	2014	Tau is phosphorylated at many sites via several protein kinases, and a characteristic is phosphorylation at Ser/Thr residues in Ser/Thr-Pro sequences, which are targeted by proline-directed protein kinases such as ERK, GSK3beta, and Cdk5.	Threonine	112-115	glycogen synthase kinase 3 beta	Homo sapiens	219-227
25076872-4	2014	Tau is phosphorylated at many sites via several protein kinases, and a characteristic is phosphorylation at Ser/Thr residues in Ser/Thr-Pro sequences, which are targeted by proline-directed protein kinases such as ERK, GSK3beta, and Cdk5.	Serine	128-131	glycogen synthase kinase 3 beta	Homo sapiens	219-227
25076872-4	2014	Tau is phosphorylated at many sites via several protein kinases, and a characteristic is phosphorylation at Ser/Thr residues in Ser/Thr-Pro sequences, which are targeted by proline-directed protein kinases such as ERK, GSK3beta, and Cdk5.	Threonine	132-135	glycogen synthase kinase 3 beta	Homo sapiens	219-227
25010341-0	2014	Insights into the interactions between maleimide derivates and GSK3beta combining molecular docking and QSAR.	maleimide	39-48	glycogen synthase kinase 3 beta	Homo sapiens	63-71
25010341-3	2014	With this in mind, we studied the binding modes of 77 maleimide derivates inside the PK glycogen synthase kinase 3 beta (GSK3beta) using docking experiments.	maleimide	54-63	glycogen synthase kinase 3 beta	Homo sapiens	121-129
25010341-4	2014	We found that the orientations that these compounds adopt inside GSK3beta binding site prioritize the formation of hydrogen bond (HB) interactions between the maleimide group and the residues at the hinge region (residues Val135 and Asp133), and adopt propeller-like conformations (where the maleimide is the propeller axis and the heterocyclic substituents are two slanted blades).	Hydrogen	115-123	glycogen synthase kinase 3 beta	Homo sapiens	65-73
25010341-4	2014	We found that the orientations that these compounds adopt inside GSK3beta binding site prioritize the formation of hydrogen bond (HB) interactions between the maleimide group and the residues at the hinge region (residues Val135 and Asp133), and adopt propeller-like conformations (where the maleimide is the propeller axis and the heterocyclic substituents are two slanted blades).	maleimide	159-168	glycogen synthase kinase 3 beta	Homo sapiens	65-73
25010341-4	2014	We found that the orientations that these compounds adopt inside GSK3beta binding site prioritize the formation of hydrogen bond (HB) interactions between the maleimide group and the residues at the hinge region (residues Val135 and Asp133), and adopt propeller-like conformations (where the maleimide is the propeller axis and the heterocyclic substituents are two slanted blades).	maleimide	292-301	glycogen synthase kinase 3 beta	Homo sapiens	65-73
24665856-8	2014	In addition, DAC, TSA, and gemcitabine+cisplatin combination caused an increase in GSK3beta mRNA levels, which in turn significantly decreased CCND1 mRNA levels.	Decitabine	13-16	glycogen synthase kinase 3 beta	Homo sapiens	83-91
24665856-8	2014	In addition, DAC, TSA, and gemcitabine+cisplatin combination caused an increase in GSK3beta mRNA levels, which in turn significantly decreased CCND1 mRNA levels.	trichostatin A	18-21	glycogen synthase kinase 3 beta	Homo sapiens	83-91
24665856-8	2014	In addition, DAC, TSA, and gemcitabine+cisplatin combination caused an increase in GSK3beta mRNA levels, which in turn significantly decreased CCND1 mRNA levels.	gemcitabine	27-38	glycogen synthase kinase 3 beta	Homo sapiens	83-91
24665856-8	2014	In addition, DAC, TSA, and gemcitabine+cisplatin combination caused an increase in GSK3beta mRNA levels, which in turn significantly decreased CCND1 mRNA levels.	Cisplatin	39-48	glycogen synthase kinase 3 beta	Homo sapiens	83-91
24801546-4	2014	We also investigated whether sulfuretin specifically acts by inhibiting phosphorylation of mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)/Akt, and glycogen synthase kinase-3beta (GSK-3beta) as well as activation of the nuclear factor-kappa B (NF-kappaB) pathway.	sulfuretin	29-39	glycogen synthase kinase 3 beta	Homo sapiens	178-208
24801546-4	2014	We also investigated whether sulfuretin specifically acts by inhibiting phosphorylation of mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)/Akt, and glycogen synthase kinase-3beta (GSK-3beta) as well as activation of the nuclear factor-kappa B (NF-kappaB) pathway.	sulfuretin	29-39	glycogen synthase kinase 3 beta	Homo sapiens	210-219
24801546-7	2014	Moreover, sulfuretin significantly attenuated 6-OHDA-induced phosphorylation of c-Jun N-terminal kinase (JNK), p38, extracellular signal-regulated kinase 1/2 (ERK 1/2) MAPKs, PI3K/Akt, and GSK-3beta.	sulfuretin	10-20	glycogen synthase kinase 3 beta	Homo sapiens	189-198
24801546-7	2014	Moreover, sulfuretin significantly attenuated 6-OHDA-induced phosphorylation of c-Jun N-terminal kinase (JNK), p38, extracellular signal-regulated kinase 1/2 (ERK 1/2) MAPKs, PI3K/Akt, and GSK-3beta.	Oxidopamine	46-52	glycogen synthase kinase 3 beta	Homo sapiens	189-198
24801546-9	2014	The results of the current study provide the first evidence that sulfuretin protects SH-SY5Y cells against 6-OHDA-induced neuronal cell death, possibly through inhibition of phosphorylation of MAPK, PI3K/Akt, and GSK-3beta, which leads to mitochondrial protection, NF-kappaB modulations and subsequent suppression of apoptosis via ROS-dependent pathways.	sulfuretin	65-75	glycogen synthase kinase 3 beta	Homo sapiens	213-222
24858998-8	2014	Furthermore, curcumin treatment led to activation of GSK-3beta, reduced expression of beta-catenin and its downstream target cyclin D1.	Curcumin	13-21	glycogen synthase kinase 3 beta	Homo sapiens	53-62
24219064-8	2014	INNOVATION: Our findings further extend the concepts of how growth factors and PI3Ks induce neuroprotection and cell growth by adding a new branch to the signaling network downstream of GSK-3beta, which, ultimately, leads to the induction of the cystine/glutamate antiporter system xc(-).	Cystine	246-253	glycogen synthase kinase 3 beta	Homo sapiens	186-195
24884406-0	2014	Binding free-energy calculation is a powerful tool for drug optimization: calculation and measurement of binding free energy for 7-azaindole derivatives to glycogen synthase kinase-3beta.	7-azaindole dimer	129-140	glycogen synthase kinase 3 beta	Homo sapiens	156-186
24884406-2	2014	To examine whether calculation of binding free-energy change (DeltaG) is effective for the lead-optimization process, binding DeltaGs of 7-azaindole derivatives to the ATP binding site of glycogen synthase kinase-3beta (GSK-3beta) were calculated.	7-azaindole dimer	137-148	glycogen synthase kinase 3 beta	Homo sapiens	188-218
24884406-2	2014	To examine whether calculation of binding free-energy change (DeltaG) is effective for the lead-optimization process, binding DeltaGs of 7-azaindole derivatives to the ATP binding site of glycogen synthase kinase-3beta (GSK-3beta) were calculated.	7-azaindole dimer	137-148	glycogen synthase kinase 3 beta	Homo sapiens	220-229
24884406-2	2014	To examine whether calculation of binding free-energy change (DeltaG) is effective for the lead-optimization process, binding DeltaGs of 7-azaindole derivatives to the ATP binding site of glycogen synthase kinase-3beta (GSK-3beta) were calculated.	Adenosine Triphosphate	168-171	glycogen synthase kinase 3 beta	Homo sapiens	188-218
24766396-4	2014	Such a wide range of intracellular responses may be secondary to two key effects, that is, the inhibition of glycogen synthase kinase-3 beta (GSK-3beta) and inositol monophosphatase (IMP) by lithium.	Lithium	191-198	glycogen synthase kinase 3 beta	Homo sapiens	109-140
24548083-8	2014	Stabilized beta-catenin or treatment with the specific glycogen synthase kinase 3 beta (GSK3beta) inhibitor SB-216763 failed to or only partially mimicked these effects, suggesting a GSK3beta- and beta-catenin-independent mechanism.	SB 216763	108-117	glycogen synthase kinase 3 beta	Homo sapiens	55-86
24703913-7	2014	Mechanistically, gallein restored beta-AR membrane density in cardiomyocytes, attenuated Gbetagamma-mediated G-protein-coupled receptor kinase 2-phosphoinositide 3-kinase gamma membrane recruitment, and reduced Akt (protein kinase B) and glycogen synthase kinase 3beta phosphorylation.	gallein	17-24	glycogen synthase kinase 3 beta	Homo sapiens	238-268
24548083-8	2014	Stabilized beta-catenin or treatment with the specific glycogen synthase kinase 3 beta (GSK3beta) inhibitor SB-216763 failed to or only partially mimicked these effects, suggesting a GSK3beta- and beta-catenin-independent mechanism.	SB 216763	108-117	glycogen synthase kinase 3 beta	Homo sapiens	88-96
24802394-4	2014	Meanwhile, XIAP levels were decreased with 72 h of 250 muM H2O2 exposure, while there were also a decrease of JNK2, AKT, pAKT, and GSK3beta levels.	Hydrogen Peroxide	59-63	glycogen synthase kinase 3 beta	Homo sapiens	131-139
25003810-9	2014	In addition, pretreatment with SB431542, LDN193189, or Noggin prevented Snail-induced Smad1 and Akt hyperactivation and reactivated GSK3beta.	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	31-39	glycogen synthase kinase 3 beta	Homo sapiens	132-140
25003810-9	2014	In addition, pretreatment with SB431542, LDN193189, or Noggin prevented Snail-induced Smad1 and Akt hyperactivation and reactivated GSK3beta.	LDN 193189	41-50	glycogen synthase kinase 3 beta	Homo sapiens	132-140
25003810-10	2014	Moreover, LY294002 pretreatment prevented Akt hyperactivation and reactivated GSK3beta without altering Smad1 activation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	10-18	glycogen synthase kinase 3 beta	Homo sapiens	78-86
24802394-7	2014	These results suggest that, after 72 h of 250 muM H2O2 exposure, Akt, JNK, and GSK3beta intracellular kinase signaling pathways converge to regulate PDLC survival involving XIAP.	Hydrogen Peroxide	50-54	glycogen synthase kinase 3 beta	Homo sapiens	79-87
24641162-0	2014	Mitigation of carbon tetrachloride-induced hepatic injury by methylene blue, a repurposed drug, is mediated by dual inhibition of GSK3beta downstream of PKA.	Carbon Tetrachloride	14-34	glycogen synthase kinase 3 beta	Homo sapiens	130-138
24768446-4	2014	In addition, coumestrol inhibited the phosphorylation status of AKT and glycogen synthase kinase-3beta (GSK 3beta) signaling involved in cancer metabolism.	Coumestrol	13-23	glycogen synthase kinase 3 beta	Homo sapiens	72-102
24768446-4	2014	In addition, coumestrol inhibited the phosphorylation status of AKT and glycogen synthase kinase-3beta (GSK 3beta) signaling involved in cancer metabolism.	Coumestrol	13-23	glycogen synthase kinase 3 beta	Homo sapiens	104-113
24444018-7	2014	Furthermore, we observed many notable changes (such as conformation, residues motions, hydrogen bonds, and binding free energy) in the mutated GSK3beta-PKB complexes.	Hydrogen	87-95	glycogen synthase kinase 3 beta	Homo sapiens	143-151
24828835-9	2014	Our study found that osthole decreased the phosphorylation of Akt and GSK3beta and recovered the GSK3beta bioactivity in inhibiting EMT transcription factor Snail and Twist expression.	osthol	21-28	glycogen synthase kinase 3 beta	Homo sapiens	70-78
24828835-9	2014	Our study found that osthole decreased the phosphorylation of Akt and GSK3beta and recovered the GSK3beta bioactivity in inhibiting EMT transcription factor Snail and Twist expression.	osthol	21-28	glycogen synthase kinase 3 beta	Homo sapiens	97-105
24394624-6	2014	We also found perifosine, a novel AKT inhibitor, down-regulated GLI1 protein by dephosphorylation of AKT and GSK3beta dose-dependently and that pre-treatment with PD98059, a MEK/ERK pathway inhibitor, enhanced this down-regulation by 20%-30%.	perifosine	14-24	glycogen synthase kinase 3 beta	Homo sapiens	109-117
24394624-6	2014	We also found perifosine, a novel AKT inhibitor, down-regulated GLI1 protein by dephosphorylation of AKT and GSK3beta dose-dependently and that pre-treatment with PD98059, a MEK/ERK pathway inhibitor, enhanced this down-regulation by 20%-30%.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	163-170	glycogen synthase kinase 3 beta	Homo sapiens	109-117
24986326-3	2014	Mechanism study revealed that LLDT-246 inhibited phosphorylation of AKT, p-GSK3beta and p-mTOR, however, no significant effects were found on the level of p-ERK and p-JNK, along with HSP70, indicating LLDT-246 indirectly affects NF-kappaB and suppresses NF-kappaB signaling largely by interpreting AKT/GSK3beta/mTOR pathway.	LLDT-246	30-38	glycogen synthase kinase 3 beta	Homo sapiens	75-83
24641162-0	2014	Mitigation of carbon tetrachloride-induced hepatic injury by methylene blue, a repurposed drug, is mediated by dual inhibition of GSK3beta downstream of PKA.	Methylene Blue	61-75	glycogen synthase kinase 3 beta	Homo sapiens	130-138
24641162-14	2014	In addition, MB treatment (&lt;=1 h) facilitated PKA-mediated GSK3beta serine phosphorylation independently of AMPK.	Serine	71-77	glycogen synthase kinase 3 beta	Homo sapiens	62-70
24531650-8	2014	RESULTS: In vivo, N-acetylcysteine ameliorated the D-GalN/LPS-induced hepatotoxicity and reduced GSK3beta activity; GSK3beta inhibition increased hepatic superoxide dismutase activity and the glutathione content, decreased malondialdehyde production in the liver tissues; while GSK3beta inhibition suppressed the JNK activation in the liver and decreased cytochrome c release from mitochondria.	Malondialdehyde	223-238	glycogen synthase kinase 3 beta	Homo sapiens	116-124
24064905-5	2014	We consider that HMJ-38 has caused an increase in gammaH2A.X, and DNA damage seemed to mediate through DNA-dependent serine/threonine protein kinase (DNA-PK) binding to Ku70/Ku80 as well as advanced activated p-Akt (Ser473) and stimulated phosphorylated glycogen synthase kinase-3beta (p-GSK-3beta) conditions in HUVECs.	2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone	17-23	glycogen synthase kinase 3 beta	Homo sapiens	254-284
24064905-5	2014	We consider that HMJ-38 has caused an increase in gammaH2A.X, and DNA damage seemed to mediate through DNA-dependent serine/threonine protein kinase (DNA-PK) binding to Ku70/Ku80 as well as advanced activated p-Akt (Ser473) and stimulated phosphorylated glycogen synthase kinase-3beta (p-GSK-3beta) conditions in HUVECs.	2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone	17-23	glycogen synthase kinase 3 beta	Homo sapiens	288-297
24064905-7	2014	Therefore, HMJ-38-provoked DNA damage stress in HUVECs probably led to the activation of gammaH2A.X/DNA-PK/GSK-3beta signaling.	2-(3'-methoxyphenyl)-6-pyrrolidinyl-4-quinazolinone	11-17	glycogen synthase kinase 3 beta	Homo sapiens	107-116
24064905-7	2014	Therefore, HMJ-38-provoked DNA damage stress in HUVECs probably led to the activation of gammaH2A.X/DNA-PK/GSK-3beta signaling.	gammah2a	89-97	glycogen synthase kinase 3 beta	Homo sapiens	107-116
24531650-8	2014	RESULTS: In vivo, N-acetylcysteine ameliorated the D-GalN/LPS-induced hepatotoxicity and reduced GSK3beta activity; GSK3beta inhibition increased hepatic superoxide dismutase activity and the glutathione content, decreased malondialdehyde production in the liver tissues; while GSK3beta inhibition suppressed the JNK activation in the liver and decreased cytochrome c release from mitochondria.	Acetylcysteine	18-34	glycogen synthase kinase 3 beta	Homo sapiens	97-105
24531650-8	2014	RESULTS: In vivo, N-acetylcysteine ameliorated the D-GalN/LPS-induced hepatotoxicity and reduced GSK3beta activity; GSK3beta inhibition increased hepatic superoxide dismutase activity and the glutathione content, decreased malondialdehyde production in the liver tissues; while GSK3beta inhibition suppressed the JNK activation in the liver and decreased cytochrome c release from mitochondria.	Glutathione	192-203	glycogen synthase kinase 3 beta	Homo sapiens	116-124
24531650-8	2014	RESULTS: In vivo, N-acetylcysteine ameliorated the D-GalN/LPS-induced hepatotoxicity and reduced GSK3beta activity; GSK3beta inhibition increased hepatic superoxide dismutase activity and the glutathione content, decreased malondialdehyde production in the liver tissues; while GSK3beta inhibition suppressed the JNK activation in the liver and decreased cytochrome c release from mitochondria.	Glutathione	192-203	glycogen synthase kinase 3 beta	Homo sapiens	116-124
24531650-8	2014	RESULTS: In vivo, N-acetylcysteine ameliorated the D-GalN/LPS-induced hepatotoxicity and reduced GSK3beta activity; GSK3beta inhibition increased hepatic superoxide dismutase activity and the glutathione content, decreased malondialdehyde production in the liver tissues; while GSK3beta inhibition suppressed the JNK activation in the liver and decreased cytochrome c release from mitochondria.	Malondialdehyde	223-238	glycogen synthase kinase 3 beta	Homo sapiens	116-124
24531650-9	2014	In vitro, GSK3beta inhibition lessened hepatocytes apoptosis induced by H2O2 or Antimycin A, as demonstrated by decreased LDH activity, and reduced cleavage of caspase-3 expression.	Hydrogen Peroxide	72-76	glycogen synthase kinase 3 beta	Homo sapiens	10-18
24531650-9	2014	In vitro, GSK3beta inhibition lessened hepatocytes apoptosis induced by H2O2 or Antimycin A, as demonstrated by decreased LDH activity, and reduced cleavage of caspase-3 expression.	Antimycin A	80-91	glycogen synthase kinase 3 beta	Homo sapiens	10-18
24704462-0	2014	Regulation of MDA-MB-231 cell proliferation by GSK-3beta involves epigenetic modifications under high glucose conditions.	Glucose	102-109	glycogen synthase kinase 3 beta	Homo sapiens	47-56
24549719-0	2014	Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3beta.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	122-131
24549719-6	2014	GSK-3beta could be phosphorylated at Ser9 and its activity was inhibited when C6 glioma cells were treated by lithium chloride.	Lithium Chloride	110-126	glycogen synthase kinase 3 beta	Homo sapiens	0-9
24930764-0	2014	ROS-mediated EB1 phosphorylation through Akt/GSK3beta pathway: implication in cancer cell response to microtubule-targeting agents.	Reactive Oxygen Species	0-3	glycogen synthase kinase 3 beta	Homo sapiens	45-53
24930764-7	2014	We then showed that GSK3beta activation was responsible for MTA-triggered EB1 phosphorylation, resulting from ROS-mediated inhibition of upstream Akt.	Reactive Oxygen Species	110-113	glycogen synthase kinase 3 beta	Homo sapiens	20-28
24751519-7	2014	Moreover, the results obtained from the comparison of arsenite-induced GSK3beta activation among transfectants of WT, IKKbeta(-/-) and IKKbeta(-/-) (IKKbeta), and the utilization of GSKbeta shRNA, demonstrated that IKKbeta regulation of p27 protein degradation was mediated by GSK3beta following arsenite exposure.	arsenite	54-62	glycogen synthase kinase 3 beta	Homo sapiens	71-79
24751519-7	2014	Moreover, the results obtained from the comparison of arsenite-induced GSK3beta activation among transfectants of WT, IKKbeta(-/-) and IKKbeta(-/-) (IKKbeta), and the utilization of GSKbeta shRNA, demonstrated that IKKbeta regulation of p27 protein degradation was mediated by GSK3beta following arsenite exposure.	arsenite	54-62	glycogen synthase kinase 3 beta	Homo sapiens	277-285
23280703-5	2014	Knockdown of TWIST in MG-63 cells significantly increased the soluble beta-catenin level, phosphorylation of GSK-3beta at serine 9, the mRNA level of beta-catenin signaling target genes, and cell survival against cisplatin, which was reversed by knocking down beta-catenin or phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002.	Serine	122-128	glycogen synthase kinase 3 beta	Homo sapiens	109-118
24657339-6	2014	The in vivo results further confirmed that morin by downregulating the expressions of GSK-3beta, beta-catenin and cyclin D1 ameliorated DEN-induced liver fibrosis.	Diethylnitrosamine	136-139	glycogen synthase kinase 3 beta	Homo sapiens	86-95
24630930-10	2014	Inhibition of PI3K and mTOR by LY295002 and rapamycin, respectively, decreases the phosphorylation of downstream targets (i.e. GSK3beta and p70S6K) and leads to an increase of catalase expression only in MCF-7 but not in Resox cells.	ly295002	31-39	glycogen synthase kinase 3 beta	Homo sapiens	127-135
24630930-10	2014	Inhibition of PI3K and mTOR by LY295002 and rapamycin, respectively, decreases the phosphorylation of downstream targets (i.e. GSK3beta and p70S6K) and leads to an increase of catalase expression only in MCF-7 but not in Resox cells.	Sirolimus	44-53	glycogen synthase kinase 3 beta	Homo sapiens	127-135
24704462-2	2014	We have recently reported that high glucose induces phosphorylation of histone H3 at Ser 10 as well as de-phosphorylation of GSK-3beta at Ser 9 in MDA-MB-231 cells.	Glucose	36-43	glycogen synthase kinase 3 beta	Homo sapiens	125-134
24704462-2	2014	We have recently reported that high glucose induces phosphorylation of histone H3 at Ser 10 as well as de-phosphorylation of GSK-3beta at Ser 9 in MDA-MB-231 cells.	Serine	138-141	glycogen synthase kinase 3 beta	Homo sapiens	125-134
24786233-14	2014	Furthermore, QSN-10c dose-dependently suppressed the phosphorylation of AKT and GSK3beta in both HUVECs and K562 cells.	qsn-10c	13-20	glycogen synthase kinase 3 beta	Homo sapiens	80-88
23658955-0	2010	Discovery of Potent and Highly Selective Inhibitors of GSK3b The serine/threonine kinase glycogen synthase kinase-3 beta (GSK3b) is a known master regulator for several cellular pathways that include insulin signaling and glycogen synthesis, neurotrophic factor signaling, Wnt signaling, neurotransmitter signaling and microtubule dynamics.	Glycogen	89-97	glycogen synthase kinase 3 beta	Homo sapiens	55-60
23658955-9	2010	Further, ML320 demonstrates excellent cellular activity in inhibiting GSK3b-mediated Tau phosphorylation in SH-SY5Y neuroblastoma cells (IC50 of 1 muM), and in relieving negative regulation by GSK3b on cellular beta-catenin degradation and TCF/LEF promoter activities with EC50 of 5 muM in both assays.	ml320	9-14	glycogen synthase kinase 3 beta	Homo sapiens	70-75
23658955-9	2010	Further, ML320 demonstrates excellent cellular activity in inhibiting GSK3b-mediated Tau phosphorylation in SH-SY5Y neuroblastoma cells (IC50 of 1 muM), and in relieving negative regulation by GSK3b on cellular beta-catenin degradation and TCF/LEF promoter activities with EC50 of 5 muM in both assays.	ml320	9-14	glycogen synthase kinase 3 beta	Homo sapiens	193-198
24686014-1	2014	The docking studies on CDK2 and GSK-3beta inspired us to synthesis a series of indoline-2,3-dione hydrazones 10a-l.	indoline-2,3-dione hydrazones	79-108	glycogen synthase kinase 3 beta	Homo sapiens	32-41
24884462-2	2014	Recent literature suggests that valproate, a diffusely prescribed drug in the treatment of epilepsy and bipolar disorder, can inhibit glycogen synthase kinase-3beta (GSK-3beta) activity and has cytoprotective effects in neuronal cells and HepG2 cells.	Valproic Acid	32-41	glycogen synthase kinase 3 beta	Homo sapiens	134-164
24884462-2	2014	Recent literature suggests that valproate, a diffusely prescribed drug in the treatment of epilepsy and bipolar disorder, can inhibit glycogen synthase kinase-3beta (GSK-3beta) activity and has cytoprotective effects in neuronal cells and HepG2 cells.	Valproic Acid	32-41	glycogen synthase kinase 3 beta	Homo sapiens	166-175
24786233-15	2014	CONCLUSION: QSN-10c is a novel antitumor compound that exerts both antitumor and anti-angiogenic effects via inhibiting the PI3K/AKT/GSK3beta signaling pathway.	qsn-10c	12-19	glycogen synthase kinase 3 beta	Homo sapiens	133-141
24765191-6	2014	BrMC significantly downregulated the expression of cyclin D1, cyclin E and CDK4, followed by the suppression of protein kinase B phosphorylation and downstream effectors, GSK-3beta and beta-catenin.	8-bromo-7-methoxychrysin	0-4	glycogen synthase kinase 3 beta	Homo sapiens	171-180
24561043-5	2014	In addition, NVP-BEZ235 inhibits TGF-beta1-induced phosphorylation of Smad2/3 and Akt/GSK-3beta, reduces the expression of Snail both in transcriptional and post-translational level, and consequently prevents the repression of E-cadherin expression as well as the increase of cell motility caused by TGF-beta1.	dactolisib	17-23	glycogen synthase kinase 3 beta	Homo sapiens	86-95
24759734-7	2014	Treatment with sunitinib decreased MYCN protein levels by inhibition of PI3K/AKT signaling and GSK3beta.	Sunitinib	15-24	glycogen synthase kinase 3 beta	Homo sapiens	95-103
24610780-8	2014	Our results show that the GSK3beta kinase inhibitors LiCl, SB 216763, and SB 415286 prevent copper-responsive APP trafficking.	Lithium Chloride	53-57	glycogen synthase kinase 3 beta	Homo sapiens	26-34
24610780-8	2014	Our results show that the GSK3beta kinase inhibitors LiCl, SB 216763, and SB 415286 prevent copper-responsive APP trafficking.	SB 216763	59-68	glycogen synthase kinase 3 beta	Homo sapiens	26-34
24610780-8	2014	Our results show that the GSK3beta kinase inhibitors LiCl, SB 216763, and SB 415286 prevent copper-responsive APP trafficking.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	74-83	glycogen synthase kinase 3 beta	Homo sapiens	26-34
24610780-8	2014	Our results show that the GSK3beta kinase inhibitors LiCl, SB 216763, and SB 415286 prevent copper-responsive APP trafficking.	Copper	92-98	glycogen synthase kinase 3 beta	Homo sapiens	26-34
24610780-12	2014	We conclude that copper promotes APP trafficking by promoting a GSK3beta-dependent phosphorylation in SH-SY5Y cells.	Copper	17-23	glycogen synthase kinase 3 beta	Homo sapiens	64-72
24412422-6	2014	In addition, PC counteracted the reduction of cell viability caused by H/R, increased the phosphorylation of ERK1/2, PI3K, Akt, GSK-3beta and mitochondrial membrane potential.	pc	13-15	glycogen synthase kinase 3 beta	Homo sapiens	128-137
24276788-4	2014	Glycogen synthesis kinases 3 (GSK3)beta was originally regarded as a kinase regulating glucose metabolism.	Glucose	87-94	glycogen synthase kinase 3 beta	Homo sapiens	30-39
24517125-8	2014	RESULTS: Treatment with GSK-3beta inhibitor, 6-bromoindirubin 3"-oxime (BIO) improved early human cell engraftment in the mice and elevated the numbers of myeloid progenitor cells in cytokine-stimulated culture.	6-bromoindirubin-3'-oxime	45-70	glycogen synthase kinase 3 beta	Homo sapiens	24-33
24677591-1	2014	The glycogen synthase kinase 3B (GSK3B) is an important target protein of several antidepressants, such as lithium, a mood stabilizer.	Lithium	107-114	glycogen synthase kinase 3 beta	Homo sapiens	4-31
24677591-1	2014	The glycogen synthase kinase 3B (GSK3B) is an important target protein of several antidepressants, such as lithium, a mood stabilizer.	Lithium	107-114	glycogen synthase kinase 3 beta	Homo sapiens	33-38
24412473-6	2014	We also found that c-Src-mediated Tyr-phosphorylation of delta-catenin increases its stability via decreasing its affinity to GSK3beta and enhances its ability of inducing nuclear distribution of beta-catenin through interrupting the integrity of the E-cadherin.	Tyrosine	34-37	glycogen synthase kinase 3 beta	Homo sapiens	126-134
23749084-5	2014	Lithium, used for the treatment of bipolar disease, inhibits GSK3beta, a central enzyme of the Wnt/beta-catenin pathway.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	61-69
24534551-6	2014	The results showed that short term stimulation of HIEC cells with R-spondin 1 and Wnt-3a+-SB-216763, a glycogen synthase kinase 3beta (GSK3beta) inhibitor, induced beta-catenin/TCF activity and expression of the WNT target genes, cyclin D2 and LGR5.	SB 216763	88-99	glycogen synthase kinase 3 beta	Homo sapiens	103-133
24590663-11	2014	Additionally, one study suggested a predictive role of the -50T/C single nucleotide polymorphism of the glycogen synthase kinase 3 beta (GSK3B) gene in the probability of response to lithium augmentation.	Lithium	183-190	glycogen synthase kinase 3 beta	Homo sapiens	104-135
24590663-11	2014	Additionally, one study suggested a predictive role of the -50T/C single nucleotide polymorphism of the glycogen synthase kinase 3 beta (GSK3B) gene in the probability of response to lithium augmentation.	Lithium	183-190	glycogen synthase kinase 3 beta	Homo sapiens	137-142
24534551-6	2014	The results showed that short term stimulation of HIEC cells with R-spondin 1 and Wnt-3a+-SB-216763, a glycogen synthase kinase 3beta (GSK3beta) inhibitor, induced beta-catenin/TCF activity and expression of the WNT target genes, cyclin D2 and LGR5.	SB 216763	88-99	glycogen synthase kinase 3 beta	Homo sapiens	135-143
24482137-7	2014	As2O3 decreased the levels of p-Akt (Ser473), p-Akt (Thr308) and p-GSK-3beta (Ser9), suggesting that As2O3 inactivated Akt kinase.	Arsenic Trioxide	101-106	glycogen synthase kinase 3 beta	Homo sapiens	67-76
24482137-7	2014	As2O3 decreased the levels of p-Akt (Ser473), p-Akt (Thr308) and p-GSK-3beta (Ser9), suggesting that As2O3 inactivated Akt kinase.	Arsenic Trioxide	0-5	glycogen synthase kinase 3 beta	Homo sapiens	67-76
24533507-1	2014	Valproic acid (VPA), a widely used anticonvulsant, inhibits glycogen synthase kinase 3beta and activates the Wnt/beta-catenin pathway, which is associated with hair growth cycle and anagen induction.	Valproic Acid	0-13	glycogen synthase kinase 3 beta	Homo sapiens	60-90
24533507-1	2014	Valproic acid (VPA), a widely used anticonvulsant, inhibits glycogen synthase kinase 3beta and activates the Wnt/beta-catenin pathway, which is associated with hair growth cycle and anagen induction.	Valproic Acid	15-18	glycogen synthase kinase 3 beta	Homo sapiens	60-90
24757378-8	2014	The level of activating phosphorylation of the GSK3beta kinase Akt at Thr-308 and Ser-473 were both increased by PPP2R5D knockdown.	Threonine	70-73	glycogen synthase kinase 3 beta	Homo sapiens	47-55
24757378-8	2014	The level of activating phosphorylation of the GSK3beta kinase Akt at Thr-308 and Ser-473 were both increased by PPP2R5D knockdown.	Serine	82-85	glycogen synthase kinase 3 beta	Homo sapiens	47-55
24456747-8	2014	Striatal preproenkephalin/preprodynorphin mRNA levels and phosphorylated ERK1/2 and Akt/GSK3beta levels increased only in L-DOPA-treated MPTP monkeys as compared to controls, saline treated-MPTP and l-DOPA + MPEP treated MPTP monkeys.	Levodopa	122-128	glycogen synthase kinase 3 beta	Homo sapiens	88-96
24456747-8	2014	Striatal preproenkephalin/preprodynorphin mRNA levels and phosphorylated ERK1/2 and Akt/GSK3beta levels increased only in L-DOPA-treated MPTP monkeys as compared to controls, saline treated-MPTP and l-DOPA + MPEP treated MPTP monkeys.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	137-141	glycogen synthase kinase 3 beta	Homo sapiens	88-96
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	0-7	glycogen synthase kinase 3 beta	Homo sapiens	256-286
24944676-0	2014	Twist2 contributes to cisplatin-resistance of ovarian cancer through the AKT/GSK-3beta signaling pathway.	Cisplatin	22-31	glycogen synthase kinase 3 beta	Homo sapiens	77-86
24666969-0	2014	The involvement of AMPK/GSK3-beta signals in the control of metastasis and proliferation in hepato-carcinoma cells treated with anthocyanins extracted from Korea wild berry Meoru.	Anthocyanins	128-140	glycogen synthase kinase 3 beta	Homo sapiens	24-33
24666969-3	2014	It was found that Hep3B hepato-carcinoma cells respond to anthocyanins through GSK3-beta-induced suppression of beta-catenin; however, they cannot dephosphorylate GSK3-beta without AMPK activation.	Anthocyanins	58-70	glycogen synthase kinase 3 beta	Homo sapiens	79-88
24666969-7	2014	RESULTS: Anthocyanins decrease phospho-GSK3-beta and beta-catenin expression in an in vivo tumor xenograft model, increase AMPK activity in this model, and inhibit cell migration and invasion, possibly by inhibiting MMP-2 (in vitro) and the panendothelial marker, CD31 (in vivo).	Anthocyanins	9-21	glycogen synthase kinase 3 beta	Homo sapiens	39-48
24666969-10	2014	CONCLUSION: These observations imply that the AMPK-mediated GSK3-beta/beta-catenin circuit plays crucial roles in inhibiting cancer cell proliferation and metastasis in anthocyanin-treated hepato-carcinoma cells of Meoru origin.	Anthocyanins	169-180	glycogen synthase kinase 3 beta	Homo sapiens	60-69
24646332-5	2014	RESULTS: Leucine is shown to increase the magnitude of insulin-dependent phosphorylation of protein kinase B (AKT) at Ser473 and glycogen synthase kinase (GSK3beta) at Ser21-9.	Leucine	9-16	glycogen synthase kinase 3 beta	Homo sapiens	155-163
24646332-6	2014	Glycogen synthesis follows the same pattern of GSK3beta, with a significant increase at 100 muM leucine plus insulin stimulus.	Glycogen	0-8	glycogen synthase kinase 3 beta	Homo sapiens	47-55
24646332-9	2014	CONCLUSIONS: These experiments demonstrate a complementary effect of leucine on insulin signaling in a human skeletal muscle cell culture, promoting insulin-activated GSK3beta phosphorylation and glycogen synthesis.	Leucine	69-76	glycogen synthase kinase 3 beta	Homo sapiens	167-175
24900862-4	2014	Using the AKT-GSK3beta cocrystal structure and a reactive cysteine near the substrate binding site, we have identified phenylalanine (Phe) as an appropriate scaffold for the covalent inactivator portion of these inhibitors.	Phenylalanine	134-137	glycogen synthase kinase 3 beta	Homo sapiens	14-22
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	0-7	glycogen synthase kinase 3 beta	Homo sapiens	288-296
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	79-86	glycogen synthase kinase 3 beta	Homo sapiens	256-286
24530909-4	2014	Kirenol effectively activated the Wnt/beta-catenin signaling pathway, in which kirenol up-regulated the expression of low density lipoprotein receptor related protein 6 (LRP6), disheveled 2 (DVL2), beta-catenin, and cyclin D1 (CCND1), while it inactivated glycogen synthase kinase 3beta (GSK3beta) by increasing its phosphorylation.	kirenol	79-86	glycogen synthase kinase 3 beta	Homo sapiens	288-296
24900862-4	2014	Using the AKT-GSK3beta cocrystal structure and a reactive cysteine near the substrate binding site, we have identified phenylalanine (Phe) as an appropriate scaffold for the covalent inactivator portion of these inhibitors.	Phenylalanine	119-132	glycogen synthase kinase 3 beta	Homo sapiens	14-22
24571279-7	2014	Medication effects in bipolar disorder, from lithium and other mood stabilizers, might impact myelinating processes, particularly by inhibition of glycogen synthase kinase-3 beta.	Lithium	45-52	glycogen synthase kinase 3 beta	Homo sapiens	147-178
24406248-0	2014	Reactive oxygen species-regulated glycogen synthase kinase-3beta activation contributes to all-trans retinoic acid-induced apoptosis in granulocyte-differentiated HL60 cells.	Reactive Oxygen Species	0-23	glycogen synthase kinase 3 beta	Homo sapiens	34-64
24406248-0	2014	Reactive oxygen species-regulated glycogen synthase kinase-3beta activation contributes to all-trans retinoic acid-induced apoptosis in granulocyte-differentiated HL60 cells.	Tretinoin	101-114	glycogen synthase kinase 3 beta	Homo sapiens	34-64
24406248-5	2014	ATRA treatment caused decreased Mcl-1, caspase-3 activation, and PARP cleavage following the inactivation of phosphatidylinositol 3-kinase/AKT and the activation of GSK-3beta.	Tretinoin	0-4	glycogen synthase kinase 3 beta	Homo sapiens	165-174
24406248-6	2014	Pharmacologically and genetically inhibiting GSK-3beta effectively retarded ATRA-induced Mcl-1 degradation and apoptosis.	Tretinoin	76-80	glycogen synthase kinase 3 beta	Homo sapiens	45-54
24406248-7	2014	Additional differentiation inducers, phorbol 12-myristate 13-acetate and dimethyl sulfoxide, also triggered GSK-3beta-dependent apoptosis.	Tetradecanoylphorbol Acetate	37-68	glycogen synthase kinase 3 beta	Homo sapiens	108-117
24406248-7	2014	Additional differentiation inducers, phorbol 12-myristate 13-acetate and dimethyl sulfoxide, also triggered GSK-3beta-dependent apoptosis.	Dimethyl Sulfoxide	73-91	glycogen synthase kinase 3 beta	Homo sapiens	108-117
24406248-8	2014	Mechanistically, ATRA caused the generation of reactive oxygen species (ROS) through increased expression of NADPH oxidase subunits (p47(phox) and p67(phox)) to facilitate ATRA-induced GSK-3beta activation and cell apoptosis.	Tretinoin	17-21	glycogen synthase kinase 3 beta	Homo sapiens	185-194
24406248-8	2014	Mechanistically, ATRA caused the generation of reactive oxygen species (ROS) through increased expression of NADPH oxidase subunits (p47(phox) and p67(phox)) to facilitate ATRA-induced GSK-3beta activation and cell apoptosis.	Reactive Oxygen Species	47-70	glycogen synthase kinase 3 beta	Homo sapiens	185-194
24406248-8	2014	Mechanistically, ATRA caused the generation of reactive oxygen species (ROS) through increased expression of NADPH oxidase subunits (p47(phox) and p67(phox)) to facilitate ATRA-induced GSK-3beta activation and cell apoptosis.	Reactive Oxygen Species	72-75	glycogen synthase kinase 3 beta	Homo sapiens	185-194
24406248-8	2014	Mechanistically, ATRA caused the generation of reactive oxygen species (ROS) through increased expression of NADPH oxidase subunits (p47(phox) and p67(phox)) to facilitate ATRA-induced GSK-3beta activation and cell apoptosis.	Tretinoin	172-176	glycogen synthase kinase 3 beta	Homo sapiens	185-194
24571487-9	2014	These findings were recapitulated by treatment with the GSK-3beta inhibitor, LiCl.	Lithium Chloride	77-81	glycogen synthase kinase 3 beta	Homo sapiens	56-65
24406248-9	2014	This study indicates that ROS initiate GSK-3beta-dependent apoptosis in granulocyte-differentiated cells after long-term ATRA treatment.	Reactive Oxygen Species	26-29	glycogen synthase kinase 3 beta	Homo sapiens	39-48
24406248-9	2014	This study indicates that ROS initiate GSK-3beta-dependent apoptosis in granulocyte-differentiated cells after long-term ATRA treatment.	Tretinoin	121-125	glycogen synthase kinase 3 beta	Homo sapiens	39-48
24037783-6	2014	The current study revealed that the regulation of glycogen synthase kinase-3beta (GSK-3beta) activity is a crucial factor in the inhibitory action of isoproterenol.	Isoproterenol	150-163	glycogen synthase kinase 3 beta	Homo sapiens	50-80
24037783-6	2014	The current study revealed that the regulation of glycogen synthase kinase-3beta (GSK-3beta) activity is a crucial factor in the inhibitory action of isoproterenol.	Isoproterenol	150-163	glycogen synthase kinase 3 beta	Homo sapiens	82-91
24037783-7	2014	The TNF-alpha-induced JNK1 phosphorylation was significantly blocked by treatment with GSK-3beta inhibitors (either LiCl or TWS119), and stimulation of beta-adrenergic receptors induced the inhibition of GSK-3beta through the phosphorylation of Ser(9) .	Serine	245-248	glycogen synthase kinase 3 beta	Homo sapiens	87-96
24037783-8	2014	Moreover, treatment with isoproterenol markedly suppressed the TNF-alpha-induced increase of CCL2 mRNA expression and CCL2 production through a beta-adrenergic receptor-PKA pathway mediated by GSK-3beta regulation.	Isoproterenol	25-38	glycogen synthase kinase 3 beta	Homo sapiens	193-202
24203573-9	2014	Taken together, our data suggest that (+-)-alpha-lipoic acid exerts synergistic effects with haloperidol on the Akt/GSK-3beta pathway, potentially involved in the therapeutic effects of APs, and antagonism of ERK activation and D2R upregulation, potentially involved in tardive dyskinesia and treatment resistance.	Thioctic Acid	38-60	glycogen synthase kinase 3 beta	Homo sapiens	116-125
24203573-9	2014	Taken together, our data suggest that (+-)-alpha-lipoic acid exerts synergistic effects with haloperidol on the Akt/GSK-3beta pathway, potentially involved in the therapeutic effects of APs, and antagonism of ERK activation and D2R upregulation, potentially involved in tardive dyskinesia and treatment resistance.	Haloperidol	93-104	glycogen synthase kinase 3 beta	Homo sapiens	116-125
24581171-10	2014	Certain changes of expression of AKT/GSK3beta/beta-catenin/E-cadherin signaling pathway-related proteins were in tumor tissues, which were related to the bufalin dose.	bufalin	154-161	glycogen synthase kinase 3 beta	Homo sapiens	37-45
24581171-13	2014	Inhibition of AKT/GSK3beta/beta-catenin/E-cadherin signaling pathways by bufalin may show therapeutic effects in advanced HCC patients.	bufalin	73-80	glycogen synthase kinase 3 beta	Homo sapiens	18-26
24440915-14	2014	Furthermore, EUE blocked 6-OHDA-induced NF-kappaB nuclear translocation, an event downstream from JNK, PI3K/Akt, and GSK-3beta phosphorylation.	Oxidopamine	25-31	glycogen synthase kinase 3 beta	Homo sapiens	117-126
24361488-10	2014	PCB29-pQ treatment has no effect on mitogen-activated protein kinase signaling, however, phospho-AKT was up-regulated and GSK-3beta was down-regulated.	2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	0-8	glycogen synthase kinase 3 beta	Homo sapiens	122-131
24361488-11	2014	Pretreatment with LY294002, a specific inhibitor of phosphatidylinositol 3-kinase (PI3K), suppressed the phosphorylation of AKT and inhibited PCB29-pQ induced Nrf2/HO-1 activation, meanwhile, GSK-3beta expression was increased accordingly.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	18-26	glycogen synthase kinase 3 beta	Homo sapiens	192-201
24361488-11	2014	Pretreatment with LY294002, a specific inhibitor of phosphatidylinositol 3-kinase (PI3K), suppressed the phosphorylation of AKT and inhibited PCB29-pQ induced Nrf2/HO-1 activation, meanwhile, GSK-3beta expression was increased accordingly.	2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	142-150	glycogen synthase kinase 3 beta	Homo sapiens	192-201
24215125-5	2014	Subsequent validation showed that tivantinib displayed higher potency for GSK3alpha than for GSK3beta and that pharmacological inhibition or simultaneous siRNA-mediated loss of GSK3alpha and GSK3beta caused apoptosis.	ARQ 197	34-44	glycogen synthase kinase 3 beta	Homo sapiens	93-101
24425879-4	2014	Here we show that GSK-3beta inactivates the proapoptotic activity of HLXB9 by phosphorylating HLXB9 at Ser-78/Ser-80 (pHLXB9).	Serine	103-106	glycogen synthase kinase 3 beta	Homo sapiens	18-27
24425879-4	2014	Here we show that GSK-3beta inactivates the proapoptotic activity of HLXB9 by phosphorylating HLXB9 at Ser-78/Ser-80 (pHLXB9).	Serine	110-113	glycogen synthase kinase 3 beta	Homo sapiens	18-27
24215125-5	2014	Subsequent validation showed that tivantinib displayed higher potency for GSK3alpha than for GSK3beta and that pharmacological inhibition or simultaneous siRNA-mediated loss of GSK3alpha and GSK3beta caused apoptosis.	ARQ 197	34-44	glycogen synthase kinase 3 beta	Homo sapiens	191-199
24215125-6	2014	In summary, GSK3alpha and GSK3beta are new kinase targets of tivantinib that play an important role in its cellular mechanism-of-action in NSCLC.	ARQ 197	61-71	glycogen synthase kinase 3 beta	Homo sapiens	26-34
24057571-7	2014	CdCl2 exposure also induced phosphorylation of mammalian target of rapamycin (mTOR) at Ser2448, glycogen synthase kinase-3alpha (GSK-3alpha) at Ser21, GSK-3beta at Ser9, and 90 kDa ribosomal S6 kinase 2 (RSK2) at Ser227 in HK-2 cells.	Cadmium Chloride	0-5	glycogen synthase kinase 3 beta	Homo sapiens	151-160
24502201-3	2014	Herein, we evaluated the influence of a novel arylindolylmaleimide (PDA-66), a potential GSK3beta inhibitor, on several ALL cell lines.	arylindolylmaleimide	46-66	glycogen synthase kinase 3 beta	Homo sapiens	89-97
24502201-3	2014	Herein, we evaluated the influence of a novel arylindolylmaleimide (PDA-66), a potential GSK3beta inhibitor, on several ALL cell lines.	PDA-66	68-74	glycogen synthase kinase 3 beta	Homo sapiens	89-97
24396420-3	2014	The present study aimed to observe the effects of fluvoxamine on the expression levels of mammalian target of rapamycin (mTOR), Ca2+/calmodulin-dependent protein kinase 2gamma (Camk2gamma) and glycogen synthase kinase-3beta (GSK-3beta) in fluvoxamine-treated N2a cells and attempted to elucidate whether sigma1 receptors mediate the pharmacological effects of fluvoxamine.	Fluvoxamine	50-61	glycogen synthase kinase 3 beta	Homo sapiens	193-223
23910058-7	2014	Molecularly, LY294002 treatment down-regulated AEG-1 expression, AKT and GSK3beta phosphorylation, and expression of cyclinD1, CDK4, VEGF and Bcl2, but up-regulated Bax and c-Myc expression.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	13-21	glycogen synthase kinase 3 beta	Homo sapiens	73-81
24132507-0	2014	Saturated free fatty acid sodium palmitate-induced lipoapoptosis by targeting glycogen synthase kinase-3beta activation in human liver cells.	saturated free fatty acid sodium palmitate	0-42	glycogen synthase kinase 3 beta	Homo sapiens	78-108
24132507-6	2014	Western blot analysis showed that sodium palmitate activated GSK-3beta protein, which was indicated by dephosphorylation of GSK-3beta at Ser-9.	Palmitic Acid	34-50	glycogen synthase kinase 3 beta	Homo sapiens	61-70
24132507-6	2014	Western blot analysis showed that sodium palmitate activated GSK-3beta protein, which was indicated by dephosphorylation of GSK-3beta at Ser-9.	Palmitic Acid	34-50	glycogen synthase kinase 3 beta	Homo sapiens	124-133
24132507-6	2014	Western blot analysis showed that sodium palmitate activated GSK-3beta protein, which was indicated by dephosphorylation of GSK-3beta at Ser-9.	Serine	137-140	glycogen synthase kinase 3 beta	Homo sapiens	61-70
24132507-6	2014	Western blot analysis showed that sodium palmitate activated GSK-3beta protein, which was indicated by dephosphorylation of GSK-3beta at Ser-9.	Serine	137-140	glycogen synthase kinase 3 beta	Homo sapiens	124-133
24132507-7	2014	However, inhibition of GSK-3beta activity with lithium chloride treatment or knockdown of GSK-3beta expression with shRNA suppressed sodium palmitate-induced lipoapoptosis in L02 and HepG2 cells.	Lithium Chloride	47-63	glycogen synthase kinase 3 beta	Homo sapiens	23-32
24132507-7	2014	However, inhibition of GSK-3beta activity with lithium chloride treatment or knockdown of GSK-3beta expression with shRNA suppressed sodium palmitate-induced lipoapoptosis in L02 and HepG2 cells.	Palmitic Acid	133-149	glycogen synthase kinase 3 beta	Homo sapiens	23-32
24132507-7	2014	However, inhibition of GSK-3beta activity with lithium chloride treatment or knockdown of GSK-3beta expression with shRNA suppressed sodium palmitate-induced lipoapoptosis in L02 and HepG2 cells.	Palmitic Acid	133-149	glycogen synthase kinase 3 beta	Homo sapiens	90-99
24132507-8	2014	On a molecular level, inhibition of GSK-3beta expression or activity suppressed sodium palmitate-induced c-Jun-N-terminal kinase (JNK) phosphorylation and Bax upregulation, whereas GSK-3beta inhibition did not affect endoplasmic reticulum stress-induced activation of unfolded protein response.	Palmitic Acid	80-96	glycogen synthase kinase 3 beta	Homo sapiens	36-45
24132507-9	2014	CONCLUSIONS: The present data demonstrated that saturated fatty acid sodium palmitate-induced lipoapoptosis in human liver L02 and HepG2 cells was regulated by GSK-3beta activation, which led to JNK activation and Bax upregulation.	saturated fatty acid sodium palmitate	48-85	glycogen synthase kinase 3 beta	Homo sapiens	160-169
24396420-3	2014	The present study aimed to observe the effects of fluvoxamine on the expression levels of mammalian target of rapamycin (mTOR), Ca2+/calmodulin-dependent protein kinase 2gamma (Camk2gamma) and glycogen synthase kinase-3beta (GSK-3beta) in fluvoxamine-treated N2a cells and attempted to elucidate whether sigma1 receptors mediate the pharmacological effects of fluvoxamine.	Fluvoxamine	50-61	glycogen synthase kinase 3 beta	Homo sapiens	225-234
24424451-0	2014	Commentary on ""dynamic analysis of histamine-mediated attenuation of acetylcholine-induced sweating via GSK3beta activation"".	Histamine	36-45	glycogen synthase kinase 3 beta	Homo sapiens	105-113
23900020-0	2014	Dynamic analysis of histamine-mediated attenuation of acetylcholine-induced sweating via GSK3beta activation.	Histamine	20-29	glycogen synthase kinase 3 beta	Homo sapiens	89-97
23900020-0	2014	Dynamic analysis of histamine-mediated attenuation of acetylcholine-induced sweating via GSK3beta activation.	Acetylcholine	54-67	glycogen synthase kinase 3 beta	Homo sapiens	89-97
23900020-7	2014	In sweat glands, ACh inactivated glycogen synthase kinase 3beta (GSK3beta), a kinase involved in endocytosis and secretion, whereas simultaneous stimulation with histamine activated GSK3beta.	Acetylcholine	17-20	glycogen synthase kinase 3 beta	Homo sapiens	33-63
23900020-7	2014	In sweat glands, ACh inactivated glycogen synthase kinase 3beta (GSK3beta), a kinase involved in endocytosis and secretion, whereas simultaneous stimulation with histamine activated GSK3beta.	Acetylcholine	17-20	glycogen synthase kinase 3 beta	Homo sapiens	65-73
23900020-7	2014	In sweat glands, ACh inactivated glycogen synthase kinase 3beta (GSK3beta), a kinase involved in endocytosis and secretion, whereas simultaneous stimulation with histamine activated GSK3beta.	Histamine	162-171	glycogen synthase kinase 3 beta	Homo sapiens	182-190
23900020-9	2014	These results indicate that histamine inhibits sweat gland secretions by blocking ACh-induced inactivation of GSK3beta.	Histamine	28-37	glycogen synthase kinase 3 beta	Homo sapiens	110-118
23900020-9	2014	These results indicate that histamine inhibits sweat gland secretions by blocking ACh-induced inactivation of GSK3beta.	Acetylcholine	82-85	glycogen synthase kinase 3 beta	Homo sapiens	110-118
24300824-10	2014	Furthermore, ATRA and BMP9 synergistically repressed glycogen synthase kinase 3beta (GSK3beta) activity and promoted Akt phosphorylation, and inhibited expression of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) that antagonizes phosphatidylinositol-3-kinase (PI3K) function, suggesting that Wnt/beta-catenin signaling was activated at least partly through PI3K/Akt/GSK3beta pathway.	Tretinoin	13-17	glycogen synthase kinase 3 beta	Homo sapiens	53-83
24300824-10	2014	Furthermore, ATRA and BMP9 synergistically repressed glycogen synthase kinase 3beta (GSK3beta) activity and promoted Akt phosphorylation, and inhibited expression of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) that antagonizes phosphatidylinositol-3-kinase (PI3K) function, suggesting that Wnt/beta-catenin signaling was activated at least partly through PI3K/Akt/GSK3beta pathway.	Tretinoin	13-17	glycogen synthase kinase 3 beta	Homo sapiens	85-93
24300824-10	2014	Furthermore, ATRA and BMP9 synergistically repressed glycogen synthase kinase 3beta (GSK3beta) activity and promoted Akt phosphorylation, and inhibited expression of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) that antagonizes phosphatidylinositol-3-kinase (PI3K) function, suggesting that Wnt/beta-catenin signaling was activated at least partly through PI3K/Akt/GSK3beta pathway.	Tretinoin	13-17	glycogen synthase kinase 3 beta	Homo sapiens	385-393
24424451-0	2014	Commentary on ""dynamic analysis of histamine-mediated attenuation of acetylcholine-induced sweating via GSK3beta activation"".	Acetylcholine	70-83	glycogen synthase kinase 3 beta	Homo sapiens	105-113
24081608-0	2014	Docking and quantitative structure-activity relationship of oxadiazole derivates as inhibitors of GSK3beta.	Oxadiazoles	60-70	glycogen synthase kinase 3 beta	Homo sapiens	98-106
24188406-0	2014	Curcumin attenuates amyloid-beta-induced tau hyperphosphorylation in human neuroblastoma SH-SY5Y cells involving PTEN/Akt/GSK-3beta signaling pathway.	Curcumin	0-8	glycogen synthase kinase 3 beta	Homo sapiens	122-131
24188406-5	2014	The results indicated that curcumin inhibits Abeta-induced tau phosphorylation at Thr231 and Ser396, over-expression of HDAC6, and decrease in phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) at Ser9.	Curcumin	27-35	glycogen synthase kinase 3 beta	Homo sapiens	162-192
24188406-5	2014	The results indicated that curcumin inhibits Abeta-induced tau phosphorylation at Thr231 and Ser396, over-expression of HDAC6, and decrease in phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) at Ser9.	Curcumin	27-35	glycogen synthase kinase 3 beta	Homo sapiens	194-203
24188406-6	2014	However, the protective effect of curcumin on dephosphorylation of GSK-3beta induced by Abeta is not directly related to cellular oxidative stress.	Curcumin	34-42	glycogen synthase kinase 3 beta	Homo sapiens	67-76
24188406-11	2014	These results imply that curcumin inhibits Abeta-induced tau hyperphosphorylation involving PTEN/Akt/GSK-3beta pathway.	Curcumin	25-33	glycogen synthase kinase 3 beta	Homo sapiens	101-110
24081608-1	2014	The binding modes of 42 oxadiazole derivates inside glycogen synthase kinase 3 beta (GSK3beta were determined using docking experiments; thus, the preferred active conformations of these inhibitors are proposed.	Oxadiazoles	24-34	glycogen synthase kinase 3 beta	Homo sapiens	52-83
24332167-12	2014	Western blot analysis showed that THSG could inhibit platelet Fc gamma RIIa, Akt(Ser473)and GSK3beta(Ser9) phosphorylation.	2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside	34-38	glycogen synthase kinase 3 beta	Homo sapiens	92-100
24081608-1	2014	The binding modes of 42 oxadiazole derivates inside glycogen synthase kinase 3 beta (GSK3beta were determined using docking experiments; thus, the preferred active conformations of these inhibitors are proposed.	Oxadiazoles	24-34	glycogen synthase kinase 3 beta	Homo sapiens	85-93
24081608-2	2014	We found that these compounds adopt a scorpion-shaped conformation and they accept a hydrogen bond (HB) from the residue Val135 of the GSK3beta ATP-binding site hinge region.	Hydrogen	85-93	glycogen synthase kinase 3 beta	Homo sapiens	135-143
24081608-2	2014	We found that these compounds adopt a scorpion-shaped conformation and they accept a hydrogen bond (HB) from the residue Val135 of the GSK3beta ATP-binding site hinge region.	Adenosine Triphosphate	144-147	glycogen synthase kinase 3 beta	Homo sapiens	135-143
24568493-0	2014	Fangchinoline inhibits cell proliferation via Akt/GSK-3beta/ cyclin D1 signaling and induces apoptosis in MDA-MB-231 breast cancer cells.	fangchinoline	0-13	glycogen synthase kinase 3 beta	Homo sapiens	50-59
24448212-3	2014	Mood stabilizers such as lithium and valproic acid, the first-line treatments for bipolar mania and depression, inhibit glycogen synthase kinase-3 beta (GSK-3beta) and regulate the Wnt pathway.	Lithium	25-32	glycogen synthase kinase 3 beta	Homo sapiens	120-151
24448212-3	2014	Mood stabilizers such as lithium and valproic acid, the first-line treatments for bipolar mania and depression, inhibit glycogen synthase kinase-3 beta (GSK-3beta) and regulate the Wnt pathway.	Lithium	25-32	glycogen synthase kinase 3 beta	Homo sapiens	153-162
24448212-3	2014	Mood stabilizers such as lithium and valproic acid, the first-line treatments for bipolar mania and depression, inhibit glycogen synthase kinase-3 beta (GSK-3beta) and regulate the Wnt pathway.	Valproic Acid	37-50	glycogen synthase kinase 3 beta	Homo sapiens	120-151
24448212-3	2014	Mood stabilizers such as lithium and valproic acid, the first-line treatments for bipolar mania and depression, inhibit glycogen synthase kinase-3 beta (GSK-3beta) and regulate the Wnt pathway.	Valproic Acid	37-50	glycogen synthase kinase 3 beta	Homo sapiens	153-162
25114899-9	2014	In addition, Sal-induced activation of GSK3beta, TSC2, and 4EBP1 was abolished by MK-2206 cotreatment.	salinomycin	13-16	glycogen synthase kinase 3 beta	Homo sapiens	39-47
24134204-3	2014	CCND1 (cyclin D1), a key regulator of the mammalian G1-S-phase transition, is phosphorylated on Thr(286) by GSK3beta (glycogen synthase kinase 3beta) to promote its degradation.	Threonine	96-99	glycogen synthase kinase 3 beta	Homo sapiens	108-116
24134204-3	2014	CCND1 (cyclin D1), a key regulator of the mammalian G1-S-phase transition, is phosphorylated on Thr(286) by GSK3beta (glycogen synthase kinase 3beta) to promote its degradation.	Threonine	96-99	glycogen synthase kinase 3 beta	Homo sapiens	118-148
25114899-9	2014	In addition, Sal-induced activation of GSK3beta, TSC2, and 4EBP1 was abolished by MK-2206 cotreatment.	MK 2206	82-89	glycogen synthase kinase 3 beta	Homo sapiens	39-47
24407515-8	2014	However, resistance to doxorubicin and tamoxifen were alleviated in MCF-7/GSK-3beta(KD) cells upon co-treatment with an MEK inhibitor, indicating regulation of this resistance by the Raf/MEK/ERK pathway.	Doxorubicin	23-34	glycogen synthase kinase 3 beta	Homo sapiens	74-83
24967390-0	2014	Lithium enhances axonal regeneration in peripheral nerve by inhibiting glycogen synthase kinase 3beta activation.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	71-101
24967390-5	2014	Systemic application of a clinical dose of lithium suppressed activated GSK-3beta in the lesioned spinal cord to the normal level and induced extensive axonal regeneration into replanted ventral roots.	Lithium	43-50	glycogen synthase kinase 3 beta	Homo sapiens	72-81
24407515-5	2014	MCF-7/GSK-3beta(KD) cells were more resistant to doxorubicin and tamoxifen compared with either MCF-7/GSK-3beta(WT) or MCF-7/GSK-3beta(A9) cells.	Doxorubicin	49-60	glycogen synthase kinase 3 beta	Homo sapiens	6-15
24407515-5	2014	MCF-7/GSK-3beta(KD) cells were more resistant to doxorubicin and tamoxifen compared with either MCF-7/GSK-3beta(WT) or MCF-7/GSK-3beta(A9) cells.	Tamoxifen	65-74	glycogen synthase kinase 3 beta	Homo sapiens	6-15
24407515-6	2014	In the presence and absence of doxorubicin, the MCF-7/GSK-3beta(KD) cells formed more colonies in soft agar compared with MCF-7/GSK-3beta(WT) or MCF-7/GSK-3beta(A9) cells.	Doxorubicin	31-42	glycogen synthase kinase 3 beta	Homo sapiens	54-63
24407515-6	2014	In the presence and absence of doxorubicin, the MCF-7/GSK-3beta(KD) cells formed more colonies in soft agar compared with MCF-7/GSK-3beta(WT) or MCF-7/GSK-3beta(A9) cells.	Agar	103-107	glycogen synthase kinase 3 beta	Homo sapiens	54-63
24407515-7	2014	In contrast, MCF-7/GSK-3beta(KD) cells displayed an elevated sensitivity to the mTORC1 blocker rapamycin compared with MCF-7/GSK-3beta(WT) or MCF-7/GSK-3beta(A9) cells, while no differences between the 3 cell types were observed upon treatment with a MEK inhibitor by itself.	Sirolimus	95-104	glycogen synthase kinase 3 beta	Homo sapiens	19-28
24407515-8	2014	However, resistance to doxorubicin and tamoxifen were alleviated in MCF-7/GSK-3beta(KD) cells upon co-treatment with an MEK inhibitor, indicating regulation of this resistance by the Raf/MEK/ERK pathway.	Tamoxifen	39-48	glycogen synthase kinase 3 beta	Homo sapiens	74-83
24407515-9	2014	Treatment of MCF-7 and MCF-7/GSK-3beta(WT) cells with doxorubicin eliminated the detection of S9-phosphorylated GSK-3beta, while total GSK-3beta was still detected.	Doxorubicin	54-65	glycogen synthase kinase 3 beta	Homo sapiens	29-38
24407515-9	2014	Treatment of MCF-7 and MCF-7/GSK-3beta(WT) cells with doxorubicin eliminated the detection of S9-phosphorylated GSK-3beta, while total GSK-3beta was still detected.	Doxorubicin	54-65	glycogen synthase kinase 3 beta	Homo sapiens	112-121
24407515-9	2014	Treatment of MCF-7 and MCF-7/GSK-3beta(WT) cells with doxorubicin eliminated the detection of S9-phosphorylated GSK-3beta, while total GSK-3beta was still detected.	Doxorubicin	54-65	glycogen synthase kinase 3 beta	Homo sapiens	112-121
24407515-10	2014	In contrast, S9-phosphorylated GSK-3beta was still detected in MCF-7/GSK-3beta(KD) and MCF-7/GSK-3beta(A9) cells, indicating that one of the effects of doxorubicin on MCF-7 cells was suppression of S9-phosphorylated GSK-3beta, which could result in increased GSK-3beta activity.	Doxorubicin	152-163	glycogen synthase kinase 3 beta	Homo sapiens	31-40
24407515-11	2014	Taken together, these results demonstrate that introduction of GSK-3beta(KD) into MCF-7 breast cancer cells promotes resistance to doxorubicin and tamoxifen, but sensitizes the cells to mTORC1 blockade by rapamycin.	Doxorubicin	131-142	glycogen synthase kinase 3 beta	Homo sapiens	63-72
24407515-11	2014	Taken together, these results demonstrate that introduction of GSK-3beta(KD) into MCF-7 breast cancer cells promotes resistance to doxorubicin and tamoxifen, but sensitizes the cells to mTORC1 blockade by rapamycin.	Tamoxifen	147-156	glycogen synthase kinase 3 beta	Homo sapiens	63-72
24407515-11	2014	Taken together, these results demonstrate that introduction of GSK-3beta(KD) into MCF-7 breast cancer cells promotes resistance to doxorubicin and tamoxifen, but sensitizes the cells to mTORC1 blockade by rapamycin.	Sirolimus	205-214	glycogen synthase kinase 3 beta	Homo sapiens	63-72
23784558-7	2014	Accordingly, pharmacological or genetic perturbation of GSK3beta or beta-catenin dramatically impacted conversion of NSP to SP.	sp	118-120	glycogen synthase kinase 3 beta	Homo sapiens	56-64
25059120-11	2014	Knockdown of Akt2 using siRNAs or the PI3K inhibitor Ly294002 inhibited TGF-beta1-induced phosphorylation of GSK3beta and expression of Snail1.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	53-61	glycogen synthase kinase 3 beta	Homo sapiens	109-117
25301365-6	2014	In line with the reported late down-regulation of the PI-3K/Akt pathway in testosterone-treated colon tumors, GSK-3beta was phosphorylated at Tyr-216 after long term stimulation of the cells with TAC, a finding supporting the role of this kinase to promote apoptosis.	Testosterone	75-87	glycogen synthase kinase 3 beta	Homo sapiens	110-119
25301365-6	2014	In line with the reported late down-regulation of the PI-3K/Akt pathway in testosterone-treated colon tumors, GSK-3beta was phosphorylated at Tyr-216 after long term stimulation of the cells with TAC, a finding supporting the role of this kinase to promote apoptosis.	Tyrosine	142-145	glycogen synthase kinase 3 beta	Homo sapiens	110-119
24448371-13	2014	GSK-3beta/beta-catenin/Mre11 pathway might be the connection between LiCl treatment and the decreased DNA repair in T47D cells.	Lithium Chloride	69-73	glycogen synthase kinase 3 beta	Homo sapiens	0-9
23685991-8	2014	Expression of constitutive active GSK3beta(S9A) represses LiCl-mediated enhancement of IRF3 transactivation activity.	Lithium Chloride	58-62	glycogen synthase kinase 3 beta	Homo sapiens	34-42
24685625-11	2014	CONCLUSION: This study demonstrates that celastrol reduced both LPS-induced cell death and Abeta production in vitro through increasing HSP-70 and Bcl-2 expression and reducing NFkappaB, COX-2, and GSK-3beta expression and oxidative stress.	celastrol	41-50	glycogen synthase kinase 3 beta	Homo sapiens	198-207
24316184-3	2014	Additionally, overexpression of WT-GSK3beta promoted whereas GSK3beta-KD attenuated 2-DG-induced mitochondrial protein expression.	Deoxyglucose	84-88	glycogen synthase kinase 3 beta	Homo sapiens	61-69
24685625-9	2014	Western blot and immunofluorescence analysis showed that exposure to celastrol increased HSP-70 and Bcl-2 expression but decreased NFkappaB activity, phosphorylated glycogen synthase kinase-3beta (GSK-3beta) at tyrosine 216 and cyclooxygenase-2 (COX-2) expression, Abeta accumulation together with a reduction of superoxide and hydrogen peroxide generation.	celastrol	69-78	glycogen synthase kinase 3 beta	Homo sapiens	165-195
24685625-9	2014	Western blot and immunofluorescence analysis showed that exposure to celastrol increased HSP-70 and Bcl-2 expression but decreased NFkappaB activity, phosphorylated glycogen synthase kinase-3beta (GSK-3beta) at tyrosine 216 and cyclooxygenase-2 (COX-2) expression, Abeta accumulation together with a reduction of superoxide and hydrogen peroxide generation.	celastrol	69-78	glycogen synthase kinase 3 beta	Homo sapiens	197-206
24295046-0	2013	Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3beta inhibitors.	1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1h,5h)-diones	48-113	glycogen synthase kinase 3 beta	Homo sapiens	121-151
24390485-3	2014	Sequential posttranslational modifications of the C134W mutant occur where hyperphosphorylation at serine 33 (S33) by GSK3beta induces MDM2-mediated ubiquitination and proteasomal degradation.	Serine	99-105	glycogen synthase kinase 3 beta	Homo sapiens	118-126
25002914-0	2014	Lithium chloride suppresses colorectal cancer cell survival and proliferation through ROS/GSK-3beta/NF-kappaB signaling pathway.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	90-99
25002914-3	2014	We sought to determine the biological function of lithium, one kind of GSK-3beta inhibitors, in the process of reactive oxygen species (ROS) production in colorectal cancer.	Lithium	50-57	glycogen synthase kinase 3 beta	Homo sapiens	71-80
25002914-3	2014	We sought to determine the biological function of lithium, one kind of GSK-3beta inhibitors, in the process of reactive oxygen species (ROS) production in colorectal cancer.	Reactive Oxygen Species	111-134	glycogen synthase kinase 3 beta	Homo sapiens	71-80
25002914-3	2014	We sought to determine the biological function of lithium, one kind of GSK-3beta inhibitors, in the process of reactive oxygen species (ROS) production in colorectal cancer.	Reactive Oxygen Species	136-139	glycogen synthase kinase 3 beta	Homo sapiens	71-80
25002914-8	2014	Taken together, our results demonstrated that therapeutic targeting of ROS/GSK-3beta/NF-kappaB pathways may be an effective way for colorectal cancer intervention, although further preclinical and clinical testing are desirable.	Reactive Oxygen Species	71-74	glycogen synthase kinase 3 beta	Homo sapiens	75-84
24239461-0	2014	Boldine induces cell cycle arrest and apoptosis in T24 human bladder cancer cell line via regulation of ERK, AKT, and GSK-3beta.	boldine	0-7	glycogen synthase kinase 3 beta	Homo sapiens	118-127
24239461-9	2014	Additionally, the efficacy of boldine in apoptosis-induced in T24 cells is correlated with modulation of AKT (inactivation) and glycogen synthase kinase-3beta (GSK-3beta) (activation) proteins.	boldine	30-37	glycogen synthase kinase 3 beta	Homo sapiens	128-158
24239461-9	2014	Additionally, the efficacy of boldine in apoptosis-induced in T24 cells is correlated with modulation of AKT (inactivation) and glycogen synthase kinase-3beta (GSK-3beta) (activation) proteins.	boldine	30-37	glycogen synthase kinase 3 beta	Homo sapiens	160-169
24391739-7	2013	VDAC1 is negatively regulated by the PI3K/Akt pathway via GSK3beta and inhibition of GSK3beta, which is activated when Akt is blocked, ablated the sensitizing effect of NVP-BEZ235 posttreatment.	dactolisib	173-179	glycogen synthase kinase 3 beta	Homo sapiens	85-93
24012496-5	2013	Mechanistically, silibinin could inhibit glycogen synthase kinase-3beta (GSK3beta) phosphorylation, beta-catenin nuclear translocation and transactivation, and ZEB1 gene transcription that subsequently regulated the expression of cytokeratins, vimentin and matrix metalloproteinase-2 (MMP2) to reverse epithelial-mesenchymal transition (EMT).	Silybin	17-26	glycogen synthase kinase 3 beta	Homo sapiens	73-81
24070631-4	2013	In this study, we uncovered that increased activation of glycogen synthase kinase 3beta (GSK3beta) in the spinal dorsal horn was concurrently associated with increased protein expressions of GFAP, IL-1beta and a decreased protein expression of glial glutamate transporter 1 (GLT-1), as well as the development and maintenance of taxol-induced neuropathic pain.	Paclitaxel	329-334	glycogen synthase kinase 3 beta	Homo sapiens	57-87
24070631-4	2013	In this study, we uncovered that increased activation of glycogen synthase kinase 3beta (GSK3beta) in the spinal dorsal horn was concurrently associated with increased protein expressions of GFAP, IL-1beta and a decreased protein expression of glial glutamate transporter 1 (GLT-1), as well as the development and maintenance of taxol-induced neuropathic pain.	Paclitaxel	329-334	glycogen synthase kinase 3 beta	Homo sapiens	89-97
24070631-6	2013	The changes of all these biomarkers were basically prevented when animals received pre-emptive lithium (a GSK3beta inhibitor) treatment, which also prevented the development of taxol-induced neuropathic pain.	Lithium	95-102	glycogen synthase kinase 3 beta	Homo sapiens	106-114
24070631-6	2013	The changes of all these biomarkers were basically prevented when animals received pre-emptive lithium (a GSK3beta inhibitor) treatment, which also prevented the development of taxol-induced neuropathic pain.	Paclitaxel	177-182	glycogen synthase kinase 3 beta	Homo sapiens	106-114
24070631-8	2013	The taxol-induced increased GSK3beta activities and decreased AKT and mTOR activities in the spinal dorsal horn were also reversed by lithium.	Paclitaxel	4-9	glycogen synthase kinase 3 beta	Homo sapiens	28-36
24070631-8	2013	The taxol-induced increased GSK3beta activities and decreased AKT and mTOR activities in the spinal dorsal horn were also reversed by lithium.	Lithium	134-141	glycogen synthase kinase 3 beta	Homo sapiens	28-36
24070631-10	2013	Hence, suppression of spinal GSK3beta activities is a key mechanism used by lithium to reduce taxol-induced neuropathic pain, and targeting spinal GSK3beta is an effective approach to ameliorate GLT-1 expression and suppress the activation of astrocytes and IL-1beta over-production in the spinal dorsal horn.	Lithium	76-83	glycogen synthase kinase 3 beta	Homo sapiens	29-37
23990403-0	2013	The role of glycogen synthase kinase-3beta in glioma cell apoptosis induced by remifentanil.	Remifentanil	79-91	glycogen synthase kinase 3 beta	Homo sapiens	12-42
23990403-5	2013	The purpose of this study was to assess whether remifentanil can induce the apoptosis of C6 cells through GSK-3beta activation.	Remifentanil	48-60	glycogen synthase kinase 3 beta	Homo sapiens	106-115
23990403-8	2013	The effect of GSK-3beta activation was detected using a GSK-3beta activation assay kit and 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8), a potent and selective small molecule inhibitor of GSK-3beta.	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	91-140	glycogen synthase kinase 3 beta	Homo sapiens	14-23
24070631-0	2013	Inhibition of glycogen synthase kinase 3beta activity with lithium prevents and attenuates paclitaxel-induced neuropathic pain.	Lithium	59-66	glycogen synthase kinase 3 beta	Homo sapiens	14-44
24070631-0	2013	Inhibition of glycogen synthase kinase 3beta activity with lithium prevents and attenuates paclitaxel-induced neuropathic pain.	Paclitaxel	91-101	glycogen synthase kinase 3 beta	Homo sapiens	14-44
24326130-14	2013	Amuvatinib at concentrations of 5, 10, or 25 muM readily inhibited HGF-dependent MET, AKT, ERK and GSK-3-beta phosphorylation.	amuvatinib	0-10	glycogen synthase kinase 3 beta	Homo sapiens	99-109
24104352-7	2013	IAA suppressed the phosphorylation of Akt, GSK-3beta, and JNK1/2.	isoangustone A	0-3	glycogen synthase kinase 3 beta	Homo sapiens	43-52
23990403-8	2013	The effect of GSK-3beta activation was detected using a GSK-3beta activation assay kit and 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8), a potent and selective small molecule inhibitor of GSK-3beta.	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	142-148	glycogen synthase kinase 3 beta	Homo sapiens	14-23
23973862-7	2013	Inhibition of GSK3beta by either the selective inhibitor 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8) or forced expression of a kinase-dead mutant obliterated paraquat-induced phosphorylation of cyclophilin F and VDAC, prevented MPT, and improved cellular viability.	Paraquat	173-181	glycogen synthase kinase 3 beta	Homo sapiens	14-22
23990403-11	2013	The measurement of GSK-3beta activation showed that remifentanil increased the cellular level of GSK-3beta.	Remifentanil	52-64	glycogen synthase kinase 3 beta	Homo sapiens	19-28
23990403-11	2013	The measurement of GSK-3beta activation showed that remifentanil increased the cellular level of GSK-3beta.	Remifentanil	52-64	glycogen synthase kinase 3 beta	Homo sapiens	97-106
23990403-13	2013	These results suggest that remifentanil is able to induce C6 cell apoptosis through GSK-3beta activation, which provides a basis for its potential use in the treatment of malignant gliomas.	Remifentanil	27-39	glycogen synthase kinase 3 beta	Homo sapiens	84-93
23880292-5	2013	Acetaldehyde increased phospho-glycogen synthase kinase-3 beta (GSK3B) protein by 31% (P&lt;0.01), whereas phospho-beta-catenin protein decreased by 50% (P &lt;= 0.01).	Acetaldehyde	0-12	glycogen synthase kinase 3 beta	Homo sapiens	64-69
23880292-9	2013	Based on these findings, we conclude that actions of acetaldehyde are mediated by a mechanism that inactivates NXN by releasing DVL, leading to the inactivation of GSK3B, and thereby blocks beta-catenin phosphorylation and degradation.	Acetaldehyde	53-65	glycogen synthase kinase 3 beta	Homo sapiens	164-169
23973862-5	2013	Upon a strong burst of reactive oxygen species elicited by the pro-oxidant herbicide paraquat, the activity of the redox-sensitive GSK3beta was drastically enhanced.	Reactive Oxygen Species	23-46	glycogen synthase kinase 3 beta	Homo sapiens	131-139
23973862-8	2013	Conversely, ectopic expression of a constitutively active GSK3beta amplified the effect of paraquat on cyclophilin F and VDAC phosphorylation and sensitized cells to paraquat-induced MPT and death.	Paraquat	91-99	glycogen synthase kinase 3 beta	Homo sapiens	58-66
23973862-8	2013	Conversely, ectopic expression of a constitutively active GSK3beta amplified the effect of paraquat on cyclophilin F and VDAC phosphorylation and sensitized cells to paraquat-induced MPT and death.	Paraquat	166-174	glycogen synthase kinase 3 beta	Homo sapiens	58-66
23973862-7	2013	Inhibition of GSK3beta by either the selective inhibitor 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8) or forced expression of a kinase-dead mutant obliterated paraquat-induced phosphorylation of cyclophilin F and VDAC, prevented MPT, and improved cellular viability.	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	57-106	glycogen synthase kinase 3 beta	Homo sapiens	14-22
23973862-7	2013	Inhibition of GSK3beta by either the selective inhibitor 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8) or forced expression of a kinase-dead mutant obliterated paraquat-induced phosphorylation of cyclophilin F and VDAC, prevented MPT, and improved cellular viability.	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	108-114	glycogen synthase kinase 3 beta	Homo sapiens	14-22
23973862-11	2013	TDZD-8 blocked GSK3beta activity in the kidney, intercepted cyclophilin F and VDAC phosphorylation, prevented MPT, attenuated tubular cell death, and ameliorated paraquat-induced AKI.	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	0-6	glycogen synthase kinase 3 beta	Homo sapiens	15-23
24064800-4	2013	Furthermore, caudatin treatment resulted in a decrease in beta-catenin and GSK3beta in SMMC-7721 cells, with a concomitant reduction in metastatic capability and expression of Wnt signaling pathway targeted genes including cox-2, mmp-2 and mmp-9.	caudatin	13-21	glycogen synthase kinase 3 beta	Homo sapiens	75-83
23943362-0	2013	Flavonoid apigenin modified gene expression associated with inflammation and cancer and induced apoptosis in human pancreatic cancer cells through inhibition of GSK-3beta/NF-kappaB signaling cascade.	Flavonoids	0-9	glycogen synthase kinase 3 beta	Homo sapiens	161-170
23873283-7	2013	RESULTS: In Hfsmc tadalafil affected the insulin-related intracellular cascade, by increasing MAPK, PKB/Akt, GSK-3beta phosphorylation and c-Myc expression.	Tadalafil	18-27	glycogen synthase kinase 3 beta	Homo sapiens	109-118
24064800-4	2013	Furthermore, caudatin treatment resulted in a decrease in beta-catenin and GSK3beta in SMMC-7721 cells, with a concomitant reduction in metastatic capability and expression of Wnt signaling pathway targeted genes including cox-2, mmp-2 and mmp-9.	smmc	87-91	glycogen synthase kinase 3 beta	Homo sapiens	75-83
24064800-5	2013	Our findings revealed that caudatin inhibits human hepatoma cell growth and metastasis by targeting the GSK3beta/beta-catenin pathway and suppressing VEGF production.	caudatin	27-35	glycogen synthase kinase 3 beta	Homo sapiens	104-112
24252187-8	2013	Hypoperfusion induced a deregulation in glucose metabolism, as brain reperfusion, or the administration of a high dose of glucose, diminished GSK3beta activation, recuperated beta-catenin nuclear abundance, reestablished ABCB1 protein expression, and prevented Abeta vascular early deposition.	Glucose	40-47	glycogen synthase kinase 3 beta	Homo sapiens	142-150
24319338-1	2013	Part B: GSK-3beta and regulation of mitochondrial permeability transition for lens epithelial cells in atmospheric oxygen.	Oxygen	115-121	glycogen synthase kinase 3 beta	Homo sapiens	8-17
24319338-9	2013	RESULTS: Treatment of HLE-B3 cells with SB216763 (12 microM) inactivated GSK-3beta activity as verified by the enzyme"s inability to phosphorylate its substrate, GS.	SB 216763	40-48	glycogen synthase kinase 3 beta	Homo sapiens	73-82
24319338-18	2013	Inhibition of GSK-3beta activity by SB216763 blocks mMPT by preventing the opening of the mitochondrial permeability transition pore.	SB 216763	36-44	glycogen synthase kinase 3 beta	Homo sapiens	14-23
24319338-19	2013	UO126, likewise, inhibits GSK-3beta activity, but unlike SB216763, inhibition of ERK phosphorylation induces the loss of intracellular pBcl-2 levels under conditions where intracellular BAX levels remain constant.	U 0126	0-5	glycogen synthase kinase 3 beta	Homo sapiens	26-35
24534355-7	2013	RESULTS: The 24-week treatment of testosterone decreased the phosphorylation of Akt and GSK3beta in C57BL/6 adipose and liver tissues (43.1% +- 3.2% vs 77.1% +- 6.7%, 14.7% +- 6.7% vs 82.3% +- 2.0% respectively, P &lt; 0.05).	Testosterone	34-46	glycogen synthase kinase 3 beta	Homo sapiens	88-96
24534355-8	2013	Pretreatment with 10(-8)-10(-6) mol/L testosterone within 36 h obviously increased the phosphorylation of Akt and GSK3beta (P &lt; 0.05).	Testosterone	38-50	glycogen synthase kinase 3 beta	Homo sapiens	114-122
24534355-10	2013	Pretreatment with 10(-7) mol/L testosterone for 36 h followed by insulin stimulation and restimulation after 6 h interval obviously decreased the phosphorylation of Akt and GSK3beta (P &lt; 0.05).	Testosterone	31-43	glycogen synthase kinase 3 beta	Homo sapiens	173-181
24140231-8	2013	TBCA also inhibited phosphorylation of PDK1, Akt, and GSK3beta induced by AYPGKF.	(E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid	0-4	glycogen synthase kinase 3 beta	Homo sapiens	54-62
24252187-8	2013	Hypoperfusion induced a deregulation in glucose metabolism, as brain reperfusion, or the administration of a high dose of glucose, diminished GSK3beta activation, recuperated beta-catenin nuclear abundance, reestablished ABCB1 protein expression, and prevented Abeta vascular early deposition.	Glucose	122-129	glycogen synthase kinase 3 beta	Homo sapiens	142-150
24044886-7	2013	Excisanin A inhibited the phosphorylation of phosphoinositide 3-kinase (PI3K), AKT and glycogen synthase kinase 3 beta (GSK3beta) and down-regulated beta-catenin expression and the luciferase activity of the transcription factor LEF-1.	excisanin A	0-11	glycogen synthase kinase 3 beta	Homo sapiens	87-118
24044886-7	2013	Excisanin A inhibited the phosphorylation of phosphoinositide 3-kinase (PI3K), AKT and glycogen synthase kinase 3 beta (GSK3beta) and down-regulated beta-catenin expression and the luciferase activity of the transcription factor LEF-1.	excisanin A	0-11	glycogen synthase kinase 3 beta	Homo sapiens	120-128
23711227-0	2013	Neuroprotective effects of donepezil against Abeta42-induced neuronal toxicity are mediated through not only enhancing PP2A activity but also regulating GSK-3beta and nAChRs activity.	Donepezil	27-36	glycogen synthase kinase 3 beta	Homo sapiens	153-162
23453640-12	2013	Higher frequencies of the C:A haplotype and lower frequencies of the A:C haplotype at the GSK-3beta gene (rs1732170:rs11921360) were also found to be associated to SB in BP.	Antimony	164-166	glycogen synthase kinase 3 beta	Homo sapiens	90-99
23453640-12	2013	Higher frequencies of the C:A haplotype and lower frequencies of the A:C haplotype at the GSK-3beta gene (rs1732170:rs11921360) were also found to be associated to SB in BP.	Benzo(a)pyrene	170-172	glycogen synthase kinase 3 beta	Homo sapiens	90-99
23453640-13	2013	Therefore, our results suggest that genetic variability at IMPA2, INPP1 and GSK3beta genes is associated with the emergence of SB in BP.	Antimony	127-129	glycogen synthase kinase 3 beta	Homo sapiens	76-84
23453640-13	2013	Therefore, our results suggest that genetic variability at IMPA2, INPP1 and GSK3beta genes is associated with the emergence of SB in BP.	Benzo(a)pyrene	133-135	glycogen synthase kinase 3 beta	Homo sapiens	76-84
23892093-6	2013	Furthermore, we showed that overexpression of RUNX3 could inactivate the AKT/GSK3beta/beta-catenin signaling pathway in the docetaxel-resistant cells.	Docetaxel	124-133	glycogen synthase kinase 3 beta	Homo sapiens	77-85
23711227-1	2013	The main purpose of this study was to evaluate whether donepezil, acetylcholinesterase inhibitor, shown to play a protective role through inhibiting glycogen synthesis kinase-3beta (GSK-3beta) activity, could also exert neuroprotective effects by stimulating protein phosphatase 2A (PP2A) activity in the amyloid-beta (Abeta)42-induced neuronal toxicity model of Alzheimer"s disease.	Donepezil	55-64	glycogen synthase kinase 3 beta	Homo sapiens	182-191
23711227-7	2013	This observation led us to assume that additional mechanisms of donepezil, including its inhibitory effect on GSK-3beta activity and/or the activation role of nicotinic acetylcholine receptors (nAChRs), might be involved.	Donepezil	64-73	glycogen synthase kinase 3 beta	Homo sapiens	110-119
23711227-8	2013	Taken together, our results suggest that the neuroprotective effects of donepezil against Abeta42-induced neurotoxicity are mediated through activation of PP2A, but its additional mechanisms including regulation of GSK-3beta and nAChRs activity would partially contribute to its effects.	Donepezil	72-81	glycogen synthase kinase 3 beta	Homo sapiens	215-224
23743186-0	2013	Role of glycogen synthase kinase 3beta in protective effect of propofol against hepatic ischemia-reperfusion injury.	Propofol	63-71	glycogen synthase kinase 3 beta	Homo sapiens	8-38
24033914-0	2013	Insulin and IGF1 enhance IL-17-induced chemokine expression through a GSK3B-dependent mechanism: a new target for melatonin"s anti-inflammatory action.	Melatonin	114-123	glycogen synthase kinase 3 beta	Homo sapiens	70-75
24033914-2	2013	The objective of this study was to test a hypothesis that insulin and IGF1 enhance IL-17-induced expression of inflammatory chemokines/cytokines through a glycogen synthase kinase 3beta (GSK3B)-dependent mechanism, which can be inhibited by melatonin.	Melatonin	241-250	glycogen synthase kinase 3 beta	Homo sapiens	155-185
23743186-9	2013	Importantly, propofol suppressed the mitochondrial GSK-3beta by promoting or preserving its phosphorylation at Ser9, thus restraining the opening of MPTP and preventing the mitochondrial swell and mitochondrial membrane potential collapse.	Propofol	13-21	glycogen synthase kinase 3 beta	Homo sapiens	51-60
24033914-2	2013	The objective of this study was to test a hypothesis that insulin and IGF1 enhance IL-17-induced expression of inflammatory chemokines/cytokines through a glycogen synthase kinase 3beta (GSK3B)-dependent mechanism, which can be inhibited by melatonin.	Melatonin	241-250	glycogen synthase kinase 3 beta	Homo sapiens	187-192
24033914-6	2013	Melatonin inhibited Akt activation, thus decreasing P-GSK3B at serine 9 (i.e., increasing GSK3B activity) and subsequently inhibiting expression of Cxcl1 and Ccl20 that was induced either by IL-17 alone or by a combination of insulin and IL-17.	Melatonin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	54-71
24033914-6	2013	Melatonin inhibited Akt activation, thus decreasing P-GSK3B at serine 9 (i.e., increasing GSK3B activity) and subsequently inhibiting expression of Cxcl1 and Ccl20 that was induced either by IL-17 alone or by a combination of insulin and IL-17.	Melatonin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	54-59
24033914-7	2013	Melatonin"s inhibitory effects were only observed in the Gsk3b(+/+) , but in not Gsk3b(-/-) MEF cells.	Melatonin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	57-62
23743186-10	2013	CONCLUSIONS: Propofol protects liver from I/R injury by sustaining the mitochondrial function, which is possibly involved with the modulation of MPTP and GSK-3beta.	Propofol	13-21	glycogen synthase kinase 3 beta	Homo sapiens	154-163
23871716-0	2013	Inhibition of glycogen synthase kinase-3beta by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes.	Lithium Chloride	48-64	glycogen synthase kinase 3 beta	Homo sapiens	14-44
23325562-2	2013	Thus, in the present study, the roles of AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3 beta (GSK3beta) were examined in ursolic acid induced apoptosis in HepG2 hepatocellular carcinoma cells.	ursolic acid	141-153	glycogen synthase kinase 3 beta	Homo sapiens	81-112
23325562-2	2013	Thus, in the present study, the roles of AMP-activated protein kinase (AMPK) and glycogen synthase kinase 3 beta (GSK3beta) were examined in ursolic acid induced apoptosis in HepG2 hepatocellular carcinoma cells.	ursolic acid	141-153	glycogen synthase kinase 3 beta	Homo sapiens	114-122
23325562-5	2013	Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3beta at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells.	ursolic acid	15-27	glycogen synthase kinase 3 beta	Homo sapiens	130-138
23325562-5	2013	Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3beta at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells.	Serine	156-162	glycogen synthase kinase 3 beta	Homo sapiens	130-138
23325562-6	2013	Conversely, AMPK inhibitor compound C or GSK3beta inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells.	SB 216763	60-68	glycogen synthase kinase 3 beta	Homo sapiens	41-49
25206585-5	2013	The level of active Caspase-3 and the ratio of Bax/Bcl-2 in hippocampal neurons treated with TLR4 antibody or the GSK-3beta inhibitor, LiCl, creased before intervention with lipopolysaccharide, but increased after treatment with the AKT hibitor, LY294002.	Lithium Chloride	135-139	glycogen synthase kinase 3 beta	Homo sapiens	114-123
25206585-5	2013	The level of active Caspase-3 and the ratio of Bax/Bcl-2 in hippocampal neurons treated with TLR4 antibody or the GSK-3beta inhibitor, LiCl, creased before intervention with lipopolysaccharide, but increased after treatment with the AKT hibitor, LY294002.	hibitor	126-133	glycogen synthase kinase 3 beta	Homo sapiens	114-123
24055036-4	2013	Notably, GSK3beta phosphorylation at Ser9 was suppressed in RSK2(-/-) MEFs compared with RSK2(+/+) MEFs by stimulation of EGF and calcium ionophore A23187, a cellular calcium stressor.	Calcium	130-137	glycogen synthase kinase 3 beta	Homo sapiens	9-17
24055036-4	2013	Notably, GSK3beta phosphorylation at Ser9 was suppressed in RSK2(-/-) MEFs compared with RSK2(+/+) MEFs by stimulation of EGF and calcium ionophore A23187, a cellular calcium stressor.	Calcimycin	148-154	glycogen synthase kinase 3 beta	Homo sapiens	9-17
24055036-4	2013	Notably, GSK3beta phosphorylation at Ser9 was suppressed in RSK2(-/-) MEFs compared with RSK2(+/+) MEFs by stimulation of EGF and calcium ionophore A23187, a cellular calcium stressor.	Calcium	167-174	glycogen synthase kinase 3 beta	Homo sapiens	9-17
24013885-9	2013	Furthermore, diclofenac and celecoxib significantly increased phosphorylation of beta-catenin and reduced the phosphorylation of GSK3beta.	Diclofenac	13-23	glycogen synthase kinase 3 beta	Homo sapiens	129-137
24013885-9	2013	Furthermore, diclofenac and celecoxib significantly increased phosphorylation of beta-catenin and reduced the phosphorylation of GSK3beta.	Celecoxib	28-37	glycogen synthase kinase 3 beta	Homo sapiens	129-137
23325562-6	2013	Conversely, AMPK inhibitor compound C or GSK3beta inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells.	ursolic acid	124-136	glycogen synthase kinase 3 beta	Homo sapiens	41-49
23325562-7	2013	Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3beta phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	35-40	glycogen synthase kinase 3 beta	Homo sapiens	69-77
23325562-8	2013	Overall, our findings suggest that ursolic acid induced apoptosis in HepG2 cells via AMPK activation and GSK3beta phosphorylation as a potent chemopreventive agent.	ursolic acid	35-47	glycogen synthase kinase 3 beta	Homo sapiens	105-113
23954465-8	2013	High glucose down-regulated IGF-1 receptor and phosphorylation of Akt and GSK-3beta, the effects of which were attenuated by BBR treatment.	Glucose	5-12	glycogen synthase kinase 3 beta	Homo sapiens	74-83
23954465-8	2013	High glucose down-regulated IGF-1 receptor and phosphorylation of Akt and GSK-3beta, the effects of which were attenuated by BBR treatment.	Berberine	125-128	glycogen synthase kinase 3 beta	Homo sapiens	74-83
24025791-0	2013	RNAi screening identifies GSK3beta as a regulator of DRP1 and the neuroprotection of lithium chloride against elevated pressure involved in downregulation of DRP1.	Lithium Chloride	85-101	glycogen synthase kinase 3 beta	Homo sapiens	26-34
24025791-6	2013	Use of the pharmacological inhibitor of GSK3beta inhibitor, lithium chloride (LiCl), confirmed this result.	Lithium Chloride	60-76	glycogen synthase kinase 3 beta	Homo sapiens	40-48
24025791-6	2013	Use of the pharmacological inhibitor of GSK3beta inhibitor, lithium chloride (LiCl), confirmed this result.	Lithium Chloride	78-82	glycogen synthase kinase 3 beta	Homo sapiens	40-48
23872260-7	2013	Blocking GSK3beta/beta-catenin pathway was required for wogonin-induced proliferation inhibition and terminal differentiation by using canonical activator lithium chloride (LiCl) and inhibitor dickkopf-1 (Dkk1).	Lithium Chloride	155-171	glycogen synthase kinase 3 beta	Homo sapiens	9-17
23872260-7	2013	Blocking GSK3beta/beta-catenin pathway was required for wogonin-induced proliferation inhibition and terminal differentiation by using canonical activator lithium chloride (LiCl) and inhibitor dickkopf-1 (Dkk1).	Lithium Chloride	173-177	glycogen synthase kinase 3 beta	Homo sapiens	9-17
23954827-6	2013	After treatment with lithium chloride (LiCl), the protein expression of phospho GSK-3beta and beta-catenin was increased in each group compared to the corresponding group without LiCl.	Lithium Chloride	21-37	glycogen synthase kinase 3 beta	Homo sapiens	80-89
23954827-6	2013	After treatment with lithium chloride (LiCl), the protein expression of phospho GSK-3beta and beta-catenin was increased in each group compared to the corresponding group without LiCl.	Lithium Chloride	39-43	glycogen synthase kinase 3 beta	Homo sapiens	80-89
23954827-6	2013	After treatment with lithium chloride (LiCl), the protein expression of phospho GSK-3beta and beta-catenin was increased in each group compared to the corresponding group without LiCl.	Lithium Chloride	179-183	glycogen synthase kinase 3 beta	Homo sapiens	80-89
23987666-8	2013	Experimental validation confirmed that 2"-hydroxy-ceramide significantly altered phosphorylation status of Akt and its downstream effector GSK3beta, as well as p38, ERK1/2, and JNK1/2 MAP kinases.	2"-hydroxy-ceramide	39-58	glycogen synthase kinase 3 beta	Homo sapiens	139-147
23871716-0	2013	Inhibition of glycogen synthase kinase-3beta by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes.	Oxidopamine	76-93	glycogen synthase kinase 3 beta	Homo sapiens	14-44
23871716-8	2013	Western blot analysis revealed that 6-OHDA significantly increased dephosphorylation/activation of GSK-3beta as well as the nuclear translocation of nuclear factor-kappaB (NF-kappaB) p65.	Oxidopamine	36-42	glycogen synthase kinase 3 beta	Homo sapiens	99-108
23871716-9	2013	Besides, GSK-3beta inhibitor LiCl and SB415286 inhibited the GSK-3beta/NF-kappaB signaling pathway, leading to the reduction of proinflammatory molecules in 6-OHDA-activated astrocytes.	Lithium Chloride	29-33	glycogen synthase kinase 3 beta	Homo sapiens	9-18
23871716-9	2013	Besides, GSK-3beta inhibitor LiCl and SB415286 inhibited the GSK-3beta/NF-kappaB signaling pathway, leading to the reduction of proinflammatory molecules in 6-OHDA-activated astrocytes.	Lithium Chloride	29-33	glycogen synthase kinase 3 beta	Homo sapiens	61-70
23871716-9	2013	Besides, GSK-3beta inhibitor LiCl and SB415286 inhibited the GSK-3beta/NF-kappaB signaling pathway, leading to the reduction of proinflammatory molecules in 6-OHDA-activated astrocytes.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	38-46	glycogen synthase kinase 3 beta	Homo sapiens	61-70
23871716-9	2013	Besides, GSK-3beta inhibitor LiCl and SB415286 inhibited the GSK-3beta/NF-kappaB signaling pathway, leading to the reduction of proinflammatory molecules in 6-OHDA-activated astrocytes.	Oxidopamine	157-163	glycogen synthase kinase 3 beta	Homo sapiens	9-18
23871716-9	2013	Besides, GSK-3beta inhibitor LiCl and SB415286 inhibited the GSK-3beta/NF-kappaB signaling pathway, leading to the reduction of proinflammatory molecules in 6-OHDA-activated astrocytes.	Oxidopamine	157-163	glycogen synthase kinase 3 beta	Homo sapiens	61-70
23871716-10	2013	These results confirmed that GSK-3beta inhibitor LiCl and SB415286 provide protection against neuroinflammation in 6-OHDA-treated astrocytes.	Lithium Chloride	49-53	glycogen synthase kinase 3 beta	Homo sapiens	29-38
23871716-10	2013	These results confirmed that GSK-3beta inhibitor LiCl and SB415286 provide protection against neuroinflammation in 6-OHDA-treated astrocytes.	Oxidopamine	115-121	glycogen synthase kinase 3 beta	Homo sapiens	29-38
23472710-2	2013	The importance of these cascades is highlighted by lithium"s (the gold standard in BD psychopharmacology) ability to inhibit multiple critical loci in second messenger/signal transduction cascades including protein kinase C (involved in the IP3/PIP2 pathway) and GSK-3beta (canonically identified in the Wnt/Fz/Dvl/GSK-3beta cascade).	Lithium	51-58	glycogen synthase kinase 3 beta	Homo sapiens	315-324
23715499-13	2013	The results of this study suggest that GSK3beta inhibition enhances temozolomide effect by silencing MGMT expression via c-Myc-mediated promoter methylation.	Temozolomide	68-80	glycogen synthase kinase 3 beta	Homo sapiens	39-47
23715499-0	2013	Glycogen synthase kinase 3beta inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.	Temozolomide	81-93	glycogen synthase kinase 3 beta	Homo sapiens	0-30
23715499-2	2013	We have previously demonstrated that GSK3beta inhibition enhances temozolomide effect in glioma cells.	Temozolomide	66-78	glycogen synthase kinase 3 beta	Homo sapiens	37-45
23715499-3	2013	In this report, we investigated the molecular mechanisms of sensitization of glioblastoma cells to temozolomide by GSK3beta inhibition, focusing on O(6)-methylguanine DNA methyltransferase (MGMT) gene silencing.	Temozolomide	99-111	glycogen synthase kinase 3 beta	Homo sapiens	115-123
23715499-11	2013	In glioblastoma cell lines, GSK3beta inhibition decreased cell viability, enhanced temozolomide effect and downregulated MGMT expression with relevant changes in the methylation levels of the MGMT promoter.	Temozolomide	83-95	glycogen synthase kinase 3 beta	Homo sapiens	28-36
23472710-2	2013	The importance of these cascades is highlighted by lithium"s (the gold standard in BD psychopharmacology) ability to inhibit multiple critical loci in second messenger/signal transduction cascades including protein kinase C (involved in the IP3/PIP2 pathway) and GSK-3beta (canonically identified in the Wnt/Fz/Dvl/GSK-3beta cascade).	Lithium	51-58	glycogen synthase kinase 3 beta	Homo sapiens	263-272
23472710-2	2013	The importance of these cascades is highlighted by lithium"s (the gold standard in BD psychopharmacology) ability to inhibit multiple critical loci in second messenger/signal transduction cascades including protein kinase C (involved in the IP3/PIP2 pathway) and GSK-3beta (canonically identified in the Wnt/Fz/Dvl/GSK-3beta cascade).	Inositol 1,4,5-Trisphosphate	241-244	glycogen synthase kinase 3 beta	Homo sapiens	263-272
23472710-2	2013	The importance of these cascades is highlighted by lithium"s (the gold standard in BD psychopharmacology) ability to inhibit multiple critical loci in second messenger/signal transduction cascades including protein kinase C (involved in the IP3/PIP2 pathway) and GSK-3beta (canonically identified in the Wnt/Fz/Dvl/GSK-3beta cascade).	Inositol 1,4,5-Trisphosphate	241-244	glycogen synthase kinase 3 beta	Homo sapiens	315-324
23994329-0	2013	Design, synthesis and evaluation of 7-azaindazolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.	7-azaindazolyl-indolyl-maleimides	36-69	glycogen synthase kinase 3 beta	Homo sapiens	73-103
23912246-7	2013	RESULTS: Perifosine decreased AEG-1 gene expression along with inhibition of Akt/GSK3beta/C-MYC signaling pathway.	perifosine	9-19	glycogen synthase kinase 3 beta	Homo sapiens	81-89
23912246-11	2013	CONCLUSIONS: Perifosine inhibits the growth of gastric cancer cells possibly through inhibition of the Akt/GSK3beta/C-MYC signaling pathway-mediated down-regulation of AEG-1 that subsequently down-regulated cyclin D1.	perifosine	13-23	glycogen synthase kinase 3 beta	Homo sapiens	107-115
23994329-0	2013	Design, synthesis and evaluation of 7-azaindazolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.	7-azaindazolyl-indolyl-maleimides	36-69	glycogen synthase kinase 3 beta	Homo sapiens	105-114
23994329-1	2013	A series of 7-azaindazolyl-indolyl-maleimides were designed, synthesized and evaluated for their GSK-3beta inhibitory activity.	7-azaindazolyl-indolyl-maleimides	12-45	glycogen synthase kinase 3 beta	Homo sapiens	97-106
23994329-3	2013	Among them, compounds 17a, 17b, 17g, 17i, 29a and 30 significantly reduced Abeta-induced Tau hyperphosphorylation, showin;g the inhibition of GSK-3beta at the cell level.	UNII-042A8N37WH	75-80	glycogen synthase kinase 3 beta	Homo sapiens	142-151
24634935-0	2013	Octreotide stimulates somatostatin receptor-induced apoptosis of SW480 colon cancer cells by activation of glycogen synthase kinase-3beta, A Wnt/beta-catenin pathway modulator.	Octreotide	0-10	glycogen synthase kinase 3 beta	Homo sapiens	107-137
24634935-4	2013	METHODOLOGY: Octreotide-induced apoptosis in SW480 colon cancer cells mediated by SSTR2,SSTR5-dependent regulation of the Wnt/beta-catenin pathway components GSK-3beta and beta-catenin was investigated.	Octreotide	13-23	glycogen synthase kinase 3 beta	Homo sapiens	158-167
23266287-8	2013	The inhibition of GSK-3beta phosphorylation and mTOR was achieved with LY294002 and rapamycin, respectively.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	71-79	glycogen synthase kinase 3 beta	Homo sapiens	18-27
23266287-8	2013	The inhibition of GSK-3beta phosphorylation and mTOR was achieved with LY294002 and rapamycin, respectively.	Sirolimus	84-93	glycogen synthase kinase 3 beta	Homo sapiens	18-27
23266287-0	2013	Sevoflurane confers additive cardioprotection to ethanol preconditioning associated with enhanced phosphorylation of glycogen synthase kinase-3beta and inhibition of mitochondrial permeability transition pore opening.	Sevoflurane	0-11	glycogen synthase kinase 3 beta	Homo sapiens	117-147
23266287-13	2013	Phosphorylation of GSK-3beta and Akt, but not mTOR and p70s6K, was increased in the EtOH and SEVO groups.	Ethanol	84-88	glycogen synthase kinase 3 beta	Homo sapiens	19-28
23266287-0	2013	Sevoflurane confers additive cardioprotection to ethanol preconditioning associated with enhanced phosphorylation of glycogen synthase kinase-3beta and inhibition of mitochondrial permeability transition pore opening.	Ethanol	49-56	glycogen synthase kinase 3 beta	Homo sapiens	117-147
23266287-14	2013	Phosphorylation of GSK-3beta, but not mTOR and p70s6K, was further increased in the EtOH + SEVO group.	Ethanol	84-88	glycogen synthase kinase 3 beta	Homo sapiens	19-28
24113128-0	2013	Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.	Sorafenib	27-36	glycogen synthase kinase 3 beta	Homo sapiens	69-74
23917613-7	2013	We found that the total protein levels and transcriptional activity of beta-catenin in OS cells are reduced by DHA treatment, and this may result from the increased catalytic activity of glycogen synthase kinase 3beta (GSK3beta).	artenimol	111-114	glycogen synthase kinase 3 beta	Homo sapiens	187-217
23917613-7	2013	We found that the total protein levels and transcriptional activity of beta-catenin in OS cells are reduced by DHA treatment, and this may result from the increased catalytic activity of glycogen synthase kinase 3beta (GSK3beta).	artenimol	111-114	glycogen synthase kinase 3 beta	Homo sapiens	219-227
23810771-5	2013	Recently, valproic acid was reported to inhibit GSK-3beta in neuronal cells, but its effect on human hair follicles remains unknown.	Valproic Acid	10-23	glycogen synthase kinase 3 beta	Homo sapiens	48-57
23810771-10	2013	Valproic acid treatment of human dermal papilla cells led to increased beta-catenin levels and nuclear accumulation and inhibition of GSK-3beta by phosphorylation.	Valproic Acid	0-13	glycogen synthase kinase 3 beta	Homo sapiens	134-143
24427901-0	2013	[The relationship between glycogen synthase kinase - 3beta -1727A/T x -50T/C genetic polymorphisms and nicotine dependence].	Nicotine	103-111	glycogen synthase kinase 3 beta	Homo sapiens	26-58
24427901-4	2013	However, it was shown that GSK-3beta -50T/C polymorphism was significantly associated with the nicotine dependence.	Nicotine	95-103	glycogen synthase kinase 3 beta	Homo sapiens	27-36
23897984-0	2013	Serine 9 and tyrosine 216 phosphorylation of GSK-3beta differentially regulates autophagy in acquired cadmium resistance.	Tyrosine	13-21	glycogen synthase kinase 3 beta	Homo sapiens	45-54
23897984-0	2013	Serine 9 and tyrosine 216 phosphorylation of GSK-3beta differentially regulates autophagy in acquired cadmium resistance.	Cadmium	102-109	glycogen synthase kinase 3 beta	Homo sapiens	45-54
23897984-8	2013	GSK-3beta knockdown decreased Cd-induced autophagy.	Cadmium	30-32	glycogen synthase kinase 3 beta	Homo sapiens	0-9
23897984-9	2013	Cd exposure to RH460 cells overexpressed with pcDNA-GSK-3beta-HA strongly phosphorylated Ser(9)/Tyr(216) residues and decreased LC3-II.	Cadmium	0-2	glycogen synthase kinase 3 beta	Homo sapiens	52-61
23897984-9	2013	Cd exposure to RH460 cells overexpressed with pcDNA-GSK-3beta-HA strongly phosphorylated Ser(9)/Tyr(216) residues and decreased LC3-II.	Serine	89-92	glycogen synthase kinase 3 beta	Homo sapiens	52-61
23897984-9	2013	Cd exposure to RH460 cells overexpressed with pcDNA-GSK-3beta-HA strongly phosphorylated Ser(9)/Tyr(216) residues and decreased LC3-II.	Tyrosine	96-99	glycogen synthase kinase 3 beta	Homo sapiens	52-61
23897984-10	2013	Constitutively active pcDNA-GSK-3beta(S9A)-HA overexpression phosphorylated Tyr(216) and decreased LC3-II, suggesting that p-Tyr inhibits autophagy.	Tyrosine	76-79	glycogen synthase kinase 3 beta	Homo sapiens	28-37
23897984-10	2013	Constitutively active pcDNA-GSK-3beta(S9A)-HA overexpression phosphorylated Tyr(216) and decreased LC3-II, suggesting that p-Tyr inhibits autophagy.	Tyrosine	125-128	glycogen synthase kinase 3 beta	Homo sapiens	28-37
23897984-14	2013	Taken together, this study shows that acquired Cd resistance is regulated by GSK-3beta phosphorylation state, but not activation state, and intracellular localization of p-Ser GSK-3 regulates Cd-induced autophagy and apoptosis.	Cadmium	47-49	glycogen synthase kinase 3 beta	Homo sapiens	77-86
23085750-7	2013	KLF6 phosphorylation is augmented in the presence of GSK3beta based on in vitro and in vivo (32)P incorporation assays.	Phosphorus-32	92-97	glycogen synthase kinase 3 beta	Homo sapiens	53-61
24086728-9	2013	Cordycepin-reduced beta-catenin stability was restored by the addition of a pharmacological inhibitor of GSK-3beta, indicating that cordycepin-suppressed beta-catenin stability is mediated by the activation of GSK-3beta.	cordycepin	132-142	glycogen synthase kinase 3 beta	Homo sapiens	105-114
24086728-9	2013	Cordycepin-reduced beta-catenin stability was restored by the addition of a pharmacological inhibitor of GSK-3beta, indicating that cordycepin-suppressed beta-catenin stability is mediated by the activation of GSK-3beta.	cordycepin	132-142	glycogen synthase kinase 3 beta	Homo sapiens	210-219
23494401-4	2013	Incubation of cells with the PDF Dianeal  (glucose-based, low pH, high glucose degradation products (GDP)) and Extraneal  (icodextrin-based, low pH, low GDP) caused activation of GSK-3beta compared to the other tested PDF, i.e. Balance , Physioneal  (normal pH, glucose-based, low GDP) and Nutrineal  (moderately acidic, amino acid-based).	Glucose	43-50	glycogen synthase kinase 3 beta	Homo sapiens	179-188
23880761-4	2013	GSK-3beta-mediated phosphorylation of serine 390 in PR-A regulates its subsequent ubiquitination and protein stability.	Serine	38-44	glycogen synthase kinase 3 beta	Homo sapiens	0-9
23880761-6	2013	Consistently, reduction of phosphorylation of serine 390 of PR-A and GSK-3beta activity is observed in the Brca1-deficient mammary gland.	Serine	46-52	glycogen synthase kinase 3 beta	Homo sapiens	69-78
23494401-4	2013	Incubation of cells with the PDF Dianeal  (glucose-based, low pH, high glucose degradation products (GDP)) and Extraneal  (icodextrin-based, low pH, low GDP) caused activation of GSK-3beta compared to the other tested PDF, i.e. Balance , Physioneal  (normal pH, glucose-based, low GDP) and Nutrineal  (moderately acidic, amino acid-based).	Glucose	71-78	glycogen synthase kinase 3 beta	Homo sapiens	179-188
23880101-0	2013	Phospho-GSK-3beta is involved in the high-glucose-mediated lipid deposition in renal tubular cells in diabetes.	Glucose	42-49	glycogen synthase kinase 3 beta	Homo sapiens	8-17
23494401-4	2013	Incubation of cells with the PDF Dianeal  (glucose-based, low pH, high glucose degradation products (GDP)) and Extraneal  (icodextrin-based, low pH, low GDP) caused activation of GSK-3beta compared to the other tested PDF, i.e. Balance , Physioneal  (normal pH, glucose-based, low GDP) and Nutrineal  (moderately acidic, amino acid-based).	Guanosine Diphosphate	101-104	glycogen synthase kinase 3 beta	Homo sapiens	179-188
23494401-4	2013	Incubation of cells with the PDF Dianeal  (glucose-based, low pH, high glucose degradation products (GDP)) and Extraneal  (icodextrin-based, low pH, low GDP) caused activation of GSK-3beta compared to the other tested PDF, i.e. Balance , Physioneal  (normal pH, glucose-based, low GDP) and Nutrineal  (moderately acidic, amino acid-based).	Icodextrin	123-133	glycogen synthase kinase 3 beta	Homo sapiens	179-188
23494401-4	2013	Incubation of cells with the PDF Dianeal  (glucose-based, low pH, high glucose degradation products (GDP)) and Extraneal  (icodextrin-based, low pH, low GDP) caused activation of GSK-3beta compared to the other tested PDF, i.e. Balance , Physioneal  (normal pH, glucose-based, low GDP) and Nutrineal  (moderately acidic, amino acid-based).	Glucose	71-78	glycogen synthase kinase 3 beta	Homo sapiens	179-188
23494401-4	2013	Incubation of cells with the PDF Dianeal  (glucose-based, low pH, high glucose degradation products (GDP)) and Extraneal  (icodextrin-based, low pH, low GDP) caused activation of GSK-3beta compared to the other tested PDF, i.e. Balance , Physioneal  (normal pH, glucose-based, low GDP) and Nutrineal  (moderately acidic, amino acid-based).	Guanosine Diphosphate	153-156	glycogen synthase kinase 3 beta	Homo sapiens	179-188
23494401-5	2013	Inhibition of GSK-3beta with LiCl in Dianeal  and Extraneal -treated cells dose-dependently decreased cell damage and death rate and was paralleled by higher HSF-1 activation and Hsp72 expression.	Lithium Chloride	29-33	glycogen synthase kinase 3 beta	Homo sapiens	14-23
23494401-6	2013	GSK-3beta is activated by low pH GDP containing PDF with and without glucose as osmotic agent, indicating that GSK-3beta is involved in mesothelial cell signalling in response to experimental PD.	Guanosine Diphosphate	33-36	glycogen synthase kinase 3 beta	Homo sapiens	0-9
23494401-6	2013	GSK-3beta is activated by low pH GDP containing PDF with and without glucose as osmotic agent, indicating that GSK-3beta is involved in mesothelial cell signalling in response to experimental PD.	Guanosine Diphosphate	33-36	glycogen synthase kinase 3 beta	Homo sapiens	111-120
23494401-6	2013	GSK-3beta is activated by low pH GDP containing PDF with and without glucose as osmotic agent, indicating that GSK-3beta is involved in mesothelial cell signalling in response to experimental PD.	Glucose	69-76	glycogen synthase kinase 3 beta	Homo sapiens	0-9
23494401-7	2013	Inhibition of GSK-3beta with LiCl ameliorated cell injury and improved HSR upon PDF exposure.	Lithium Chloride	29-33	glycogen synthase kinase 3 beta	Homo sapiens	14-23
23703635-8	2013	The over-expression of RI reduces the phosphorylation of the ILK downstream signaling targets p-Akt and p-GSK3beta in T24 cells.	placental ribonuclease inhibitor	23-25	glycogen synthase kinase 3 beta	Homo sapiens	106-114
23880101-4	2013	However, in high-glucose-treated human renal tubular cells, only the phospho-GSK-3beta content increased without an alteration in the phospho-Bad content, which could be reversed by treatment with a short hairpin RNA vector aimed at Akt.	Glucose	17-24	glycogen synthase kinase 3 beta	Homo sapiens	77-86
23880101-6	2013	Furthermore, the exogenous expression of wild-type GSK-3beta enhanced the level of phospho-GSK-3beta in high-glucose-stimulated renal tubular cells, followed by increased SREBP-1 expression and lipogenesis.	Glucose	109-116	glycogen synthase kinase 3 beta	Homo sapiens	51-60
23880101-6	2013	Furthermore, the exogenous expression of wild-type GSK-3beta enhanced the level of phospho-GSK-3beta in high-glucose-stimulated renal tubular cells, followed by increased SREBP-1 expression and lipogenesis.	Glucose	109-116	glycogen synthase kinase 3 beta	Homo sapiens	91-100
23880101-7	2013	Moreover, exogenous expression of mutant GSK-3beta (via vector S9A) prevented the increase in SREBP-1 expression and cellular lipogenesis by decreasing the phospho-GSK-3beta content and increasing the GSK-3beta activity in high-glucose-treated cells.	Glucose	228-235	glycogen synthase kinase 3 beta	Homo sapiens	41-50
23880101-8	2013	These data suggested that phospho-GSK-3beta is involved in the high-glucose-mediated increase of SREBP-1 expression and triglyceride content in renal tubular cells in diabetes.	Glucose	68-75	glycogen synthase kinase 3 beta	Homo sapiens	34-43
23880101-8	2013	These data suggested that phospho-GSK-3beta is involved in the high-glucose-mediated increase of SREBP-1 expression and triglyceride content in renal tubular cells in diabetes.	Triglycerides	120-132	glycogen synthase kinase 3 beta	Homo sapiens	34-43
23941783-5	2013	Inhibition of GSK3beta by either lithium chloride (LiCl) or specific GSK3beta inhibitor VIII showed cytostatic and cytotoxic effects on multiple endometrial cancer cell lines, with little effect on the immortalized normal endometrial cell line.	Lithium Chloride	33-49	glycogen synthase kinase 3 beta	Homo sapiens	14-22
23707771-0	2013	Reactive oxygen species mediate Cr(VI)-induced carcinogenesis through PI3K/AKT-dependent activation of GSK-3beta/beta-catenin signaling.	Reactive Oxygen Species	0-23	glycogen synthase kinase 3 beta	Homo sapiens	103-112
23707771-0	2013	Reactive oxygen species mediate Cr(VI)-induced carcinogenesis through PI3K/AKT-dependent activation of GSK-3beta/beta-catenin signaling.	chromium hexavalent ion	32-38	glycogen synthase kinase 3 beta	Homo sapiens	103-112
23707771-11	2013	Collectively, our findings suggest that ROS is a key mediator of Cr(VI)-induced carcinogenesis through the activation of PI3K/AKT-dependent GSK-3beta/beta-catenin signaling and the promotion of cell survival mechanisms via the inhibition of apoptosis and autophagy.	Reactive Oxygen Species	40-43	glycogen synthase kinase 3 beta	Homo sapiens	140-149
23707771-11	2013	Collectively, our findings suggest that ROS is a key mediator of Cr(VI)-induced carcinogenesis through the activation of PI3K/AKT-dependent GSK-3beta/beta-catenin signaling and the promotion of cell survival mechanisms via the inhibition of apoptosis and autophagy.	chromium hexavalent ion	65-71	glycogen synthase kinase 3 beta	Homo sapiens	140-149
25438579-2	2013	A regulation of GSK-3 by phosphorylation of serine and tyrosine sites and through Wnt signaling pathway by disruption of axin-beta-catenin complex is described.	Serine	44-50	glycogen synthase kinase 3 beta	Homo sapiens	16-21
25438579-2	2013	A regulation of GSK-3 by phosphorylation of serine and tyrosine sites and through Wnt signaling pathway by disruption of axin-beta-catenin complex is described.	Tyrosine	55-63	glycogen synthase kinase 3 beta	Homo sapiens	16-21
25438579-3	2013	The data on participation of GSK-3b in regulation of NMDA-dependent long-term depression and potentiation, and the possible mechanisms of enzyme"s influence through NMDA receptors and AMPA endocytosis are shown.	N-Methylaspartate	53-57	glycogen synthase kinase 3 beta	Homo sapiens	29-35
23809426-0	2013	Putative role of glycogen as a peripheral biomarker of GSK3beta activity.	Glycogen	17-25	glycogen synthase kinase 3 beta	Homo sapiens	55-63
23809426-5	2013	Although GSK3beta is commonly described as a key enzyme in a plethora of signaling cascades, originally it was identified as playing an important role in the regulation of glycogen synthesis, given its ability to inactivate glycogen synthase (GS) by phosphorylation.	Glycogen	172-180	glycogen synthase kinase 3 beta	Homo sapiens	9-17
23809426-6	2013	Acting as a constitutively active kinase, GSK3beta phosphorylates GS, which results in a decrease of glycogen production.	Glycogen	101-109	glycogen synthase kinase 3 beta	Homo sapiens	42-50
23809426-7	2013	GSK3beta phosphorylation increases glycogen synthesis and storage, while its dephosphorylation decreases glycogen synthesis.	Glycogen	35-43	glycogen synthase kinase 3 beta	Homo sapiens	0-8
23809426-8	2013	Inactivation of GSK3beta leads to dephosphorylation of GS and increase in glycogen synthesis in the adipose tissue, muscle and liver.	Glycogen	74-82	glycogen synthase kinase 3 beta	Homo sapiens	16-24
23809426-9	2013	Glycogen levels are reduced by antidepressant treatment, and this effect seems to be related to an effect of drugs on GSK3beta activity.	Glycogen	0-8	glycogen synthase kinase 3 beta	Homo sapiens	118-126
23809426-11	2013	Recently, analysis of platelets from patients with late-life major depression showed that active forms of GSK3beta expression were upregulated by continuous treatment with sertraline.	Sertraline	172-182	glycogen synthase kinase 3 beta	Homo sapiens	106-114
23809426-12	2013	Here, we hypothesized that the quantification of glycogen in platelets might be used as a peripheral biomarker of GSK3beta activity.	Glycogen	49-57	glycogen synthase kinase 3 beta	Homo sapiens	114-122
23809426-13	2013	Since it has been recently demonstrated that the modulation of GSK3beta activity causes changes in glycogen stores, the glycogen levels in platelets could be used to assay the effects of drugs that have this kinase as a target, or diseases where its activity is affected.	Glycogen	99-107	glycogen synthase kinase 3 beta	Homo sapiens	63-71
23809426-13	2013	Since it has been recently demonstrated that the modulation of GSK3beta activity causes changes in glycogen stores, the glycogen levels in platelets could be used to assay the effects of drugs that have this kinase as a target, or diseases where its activity is affected.	Glycogen	120-128	glycogen synthase kinase 3 beta	Homo sapiens	63-71
23941783-5	2013	Inhibition of GSK3beta by either lithium chloride (LiCl) or specific GSK3beta inhibitor VIII showed cytostatic and cytotoxic effects on multiple endometrial cancer cell lines, with little effect on the immortalized normal endometrial cell line.	Lithium Chloride	51-55	glycogen synthase kinase 3 beta	Homo sapiens	14-22
23919615-6	2013	Furthermore, Akt and GSK3beta phosphorylation levels were markedly enhanced in serum- or LPA-stimulated HIEC but not by EGF.	lysophosphatidic acid	89-92	glycogen synthase kinase 3 beta	Homo sapiens	21-29
23940672-0	2013	Activation of GSK-3beta and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine.	Dopamine	55-63	glycogen synthase kinase 3 beta	Homo sapiens	14-23
23673211-0	2013	Inhibition of cytoplasmic GSK-3beta increases cisplatin resistance through activation of Wnt/beta-catenin signaling in A549/DDP cells.	Cisplatin	46-55	glycogen synthase kinase 3 beta	Homo sapiens	26-35
23673211-5	2013	The regulation of cisplatin resistance, apoptosis, beta-catenin and survivin protein expression by inhibition of cytoplasmic GSK-3beta were determined by MTT assay, flow cytometry analysis, immunofluorescence technique and western blot analysis.	Cisplatin	18-27	glycogen synthase kinase 3 beta	Homo sapiens	125-134
23673211-5	2013	The regulation of cisplatin resistance, apoptosis, beta-catenin and survivin protein expression by inhibition of cytoplasmic GSK-3beta were determined by MTT assay, flow cytometry analysis, immunofluorescence technique and western blot analysis.	monooxyethylene trimethylolpropane tristearate	154-157	glycogen synthase kinase 3 beta	Homo sapiens	125-134
23673211-6	2013	In the present study, cytoplasmic levels of p-GSK-3beta(ser9) were significantly increased in A549/DDP cells as compared with A549 cells (P&lt;0.01), and these levels were further increased by cisplatin treatment in A549/DDP cells (P&lt;0.01).	Cisplatin	193-202	glycogen synthase kinase 3 beta	Homo sapiens	46-55
23673211-7	2013	In contrast, cytoplasmic levels of p-GSK-3beta(ser9) were reduced in A549 cells after treatment with cisplatin (P&lt;0.01).	Cisplatin	101-110	glycogen synthase kinase 3 beta	Homo sapiens	37-46
23673211-8	2013	However, cytoplasmic levels of p-GSK-3beta(tyr216) were significantly decreased in A549/DDP cells as compared with A549 cells (P&lt;0.01), and these levels were further decreased by cisplatin treatment in A549/DDP cells (P&lt;0.01).	Cisplatin	182-191	glycogen synthase kinase 3 beta	Homo sapiens	33-42
23673211-9	2013	Conversely, cytoplasmic levels of p-GSK-3beta(tyr216) were raised in A549 cells after treatment with cisplatin (P&lt;0.01).	Cisplatin	101-110	glycogen synthase kinase 3 beta	Homo sapiens	36-45
23673211-12	2013	Furthermore, phosphorylation of GSK-3beta at serine 9 by LiCl and transient interference of GSK-3beta by siRNA increased beta-catenin and survivin protein expression in A549/DDP cells.	Serine	45-51	glycogen synthase kinase 3 beta	Homo sapiens	32-41
23673211-12	2013	Furthermore, phosphorylation of GSK-3beta at serine 9 by LiCl and transient interference of GSK-3beta by siRNA increased beta-catenin and survivin protein expression in A549/DDP cells.	Lithium Chloride	57-61	glycogen synthase kinase 3 beta	Homo sapiens	32-41
23673211-14	2013	In conclusion, activation of the Wnt/beta-catenin signaling pathway and upregulated survivin expression due to cytoplasmic GSK-3beta inhibition might lead to cisplatin resistance in NSCLC.	Cisplatin	158-167	glycogen synthase kinase 3 beta	Homo sapiens	123-132
23940672-0	2013	Activation of GSK-3beta and caspase-3 occurs in Nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine.	Oxidopamine	145-162	glycogen synthase kinase 3 beta	Homo sapiens	14-23
23940672-2	2013	This work evaluated whether a single striatal injection of 6-OHDA causes progressive apoptosis of dopamine (DA) neurons and activation of glycogen synthase kinase 3beta (GSK-3beta) and caspase-3 in the substantia nigra compacta (SNc).	Oxidopamine	59-65	glycogen synthase kinase 3 beta	Homo sapiens	138-168
23940672-2	2013	This work evaluated whether a single striatal injection of 6-OHDA causes progressive apoptosis of dopamine (DA) neurons and activation of glycogen synthase kinase 3beta (GSK-3beta) and caspase-3 in the substantia nigra compacta (SNc).	Dopamine	63-65	glycogen synthase kinase 3 beta	Homo sapiens	138-168
23940672-2	2013	This work evaluated whether a single striatal injection of 6-OHDA causes progressive apoptosis of dopamine (DA) neurons and activation of glycogen synthase kinase 3beta (GSK-3beta) and caspase-3 in the substantia nigra compacta (SNc).	Dopamine	63-65	glycogen synthase kinase 3 beta	Homo sapiens	170-179
23874688-8	2013	RESULTS: We found that expression of EZH2 correlated with phosphorylated GSK3beta (p-GSK3beta) at Ser 9 (an inactivated form of GSK3beta) in human nasopharyngeal carcinoma (NPC) samples.	Serine	98-101	glycogen synthase kinase 3 beta	Homo sapiens	73-81
24228880-6	2013	We also found that the GSK-3beta inhibitors TDZD-8 and SB415286 partially restored eNOS activity and suppressed the release of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 from ECs.	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	44-50	glycogen synthase kinase 3 beta	Homo sapiens	23-32
24228880-6	2013	We also found that the GSK-3beta inhibitors TDZD-8 and SB415286 partially restored eNOS activity and suppressed the release of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 from ECs.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	55-63	glycogen synthase kinase 3 beta	Homo sapiens	23-32
23505128-1	2013	Glycogen synthase kinase-3 beta (GSK3beta) was initially identified as a key protein in glucose metabolism.	Glucose	88-95	glycogen synthase kinase 3 beta	Homo sapiens	0-31
23505128-1	2013	Glycogen synthase kinase-3 beta (GSK3beta) was initially identified as a key protein in glucose metabolism.	Glucose	88-95	glycogen synthase kinase 3 beta	Homo sapiens	33-41
23582741-0	2013	Glycogen synthase kinase-3 beta regulates Snail and beta-catenin expression during Fas-induced epithelial-mesenchymal transition in gastrointestinal cancer.	ammonium ferrous sulfate	83-86	glycogen synthase kinase 3 beta	Homo sapiens	0-31
23582741-9	2013	Collectively, these data indicate that GSK-3beta regulates Snail and beta-catenin expression during Fas-induced EMT in gastrointestinal cancer.	ammonium ferrous sulfate	100-103	glycogen synthase kinase 3 beta	Homo sapiens	39-48
22512725-0	2013	Famotidine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation.	Famotidine	0-10	glycogen synthase kinase 3 beta	Homo sapiens	20-50
22512725-1	2013	Famotidine was investigated as an inhibitor of glycogen synthase kinase-3beta (GSK-3beta) in an attempt to explain the molecular mechanism of its hypoglycemic side effects.	Famotidine	0-10	glycogen synthase kinase 3 beta	Homo sapiens	47-77
22512725-1	2013	Famotidine was investigated as an inhibitor of glycogen synthase kinase-3beta (GSK-3beta) in an attempt to explain the molecular mechanism of its hypoglycemic side effects.	Famotidine	0-10	glycogen synthase kinase 3 beta	Homo sapiens	79-88
22512725-3	2013	Docking studies showed how famotidine is optimally fit within the binding pocket of GSK-3beta via numerous attractive interactions with some specific amino acids.	Famotidine	27-37	glycogen synthase kinase 3 beta	Homo sapiens	84-93
22512725-4	2013	Experimentally, famotidine could inhibit GSK-3beta (IC50 = 1.44 muM) and increased significantly liver glycogen spares in fasting animal models.	Famotidine	16-26	glycogen synthase kinase 3 beta	Homo sapiens	41-50
23509892-7	2013	Western blotting showed that CoQ10 treatment increased the expression levels of p85alpha PI3K, phosphorylated Akt (Ser473), phosphorylated glycogen synthase kinase-3beta (Ser9), and heat shock transcription factor, which are proteins related to the PI3K pathway in Abeta25-35 oligomers-treated NSCs.	coenzyme Q10	29-34	glycogen synthase kinase 3 beta	Homo sapiens	139-169
23870199-8	2013	In addition, treatment with bufalin significantly decreased the levels of pAKT, pGSK3beta, MMP-9, and MMP-2, while increasing the levels of GSK3beta and E-cadherin and suppressing the nuclear translocation of beta-catenin.	bufalin	28-35	glycogen synthase kinase 3 beta	Homo sapiens	81-89
23870199-9	2013	CONCLUSIONS: Bufalin is a potential anti-HCC therapeutic candidate through its inhibition of the AKT/GSK3beta/beta-catenin/E-cadherin signaling pathway.	bufalin	13-20	glycogen synthase kinase 3 beta	Homo sapiens	101-109
23463670-0	2013	Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3beta-dependent protein degradation.	Sorafenib	0-9	glycogen synthase kinase 3 beta	Homo sapiens	117-125
23463670-9	2013	Furthermore, sorafenib reduced the stability of the Mcl-1 protein by enhancing its ubiquitination and degradation by the proteasome via the AKT/GSK3beta and the ERK pathways.	Sorafenib	13-22	glycogen synthase kinase 3 beta	Homo sapiens	144-152
23624826-9	2013	AICAR also significantly reduced tau hyperphosphorylation by inactivating glycogen synthase kinase-3beta and c-Jun N-terminal kinase in cells incubated with homocysteine.	Homocysteine	157-169	glycogen synthase kinase 3 beta	Homo sapiens	74-104
23829535-6	2013	Furthermore, AMPKalpha knockdown blocked resveratrol-induced phosphorylation of glycogen synthase kinase 3beta (GSK3beta) at Ser9 as well as ARE-dependent transcriptional activation of the ferritin H and HO-1 genes, suggesting that AMPKalpha is an upstream kinase for GSK3beta phosphorylation and activation of the Nrf2-ARE pathway.	Resveratrol	41-52	glycogen synthase kinase 3 beta	Homo sapiens	80-110
23829535-6	2013	Furthermore, AMPKalpha knockdown blocked resveratrol-induced phosphorylation of glycogen synthase kinase 3beta (GSK3beta) at Ser9 as well as ARE-dependent transcriptional activation of the ferritin H and HO-1 genes, suggesting that AMPKalpha is an upstream kinase for GSK3beta phosphorylation and activation of the Nrf2-ARE pathway.	Resveratrol	41-52	glycogen synthase kinase 3 beta	Homo sapiens	112-120
23829535-6	2013	Furthermore, AMPKalpha knockdown blocked resveratrol-induced phosphorylation of glycogen synthase kinase 3beta (GSK3beta) at Ser9 as well as ARE-dependent transcriptional activation of the ferritin H and HO-1 genes, suggesting that AMPKalpha is an upstream kinase for GSK3beta phosphorylation and activation of the Nrf2-ARE pathway.	Resveratrol	41-52	glycogen synthase kinase 3 beta	Homo sapiens	268-276
23829535-7	2013	Consistently, GSK3beta knockdown by siRNA enhanced resveratrol-mediated ferritin H mRNA induction, and the inhibition of AMPKalpha by compound C or siRNA weakened the protective effect of resveratrol against oxidative stress-induced cytotoxicity in CD3+ T cells.	Resveratrol	51-62	glycogen synthase kinase 3 beta	Homo sapiens	14-22
23829535-7	2013	Consistently, GSK3beta knockdown by siRNA enhanced resveratrol-mediated ferritin H mRNA induction, and the inhibition of AMPKalpha by compound C or siRNA weakened the protective effect of resveratrol against oxidative stress-induced cytotoxicity in CD3+ T cells.	Resveratrol	188-199	glycogen synthase kinase 3 beta	Homo sapiens	14-22
23651617-0	2013	Nephroprotective effect of GSK-3beta inhibition by lithium ions and delta-opioid receptor agonist dalargin on gentamicin-induced nephrotoxicity.	Lithium	51-58	glycogen synthase kinase 3 beta	Homo sapiens	27-36
23651617-0	2013	Nephroprotective effect of GSK-3beta inhibition by lithium ions and delta-opioid receptor agonist dalargin on gentamicin-induced nephrotoxicity.	Gentamicins	110-120	glycogen synthase kinase 3 beta	Homo sapiens	27-36
23874688-8	2013	RESULTS: We found that expression of EZH2 correlated with phosphorylated GSK3beta (p-GSK3beta) at Ser 9 (an inactivated form of GSK3beta) in human nasopharyngeal carcinoma (NPC) samples.	Serine	98-101	glycogen synthase kinase 3 beta	Homo sapiens	85-93
23874688-8	2013	RESULTS: We found that expression of EZH2 correlated with phosphorylated GSK3beta (p-GSK3beta) at Ser 9 (an inactivated form of GSK3beta) in human nasopharyngeal carcinoma (NPC) samples.	Serine	98-101	glycogen synthase kinase 3 beta	Homo sapiens	85-93
23376468-5	2013	Inhibition of GSK3beta by either phosphorylation by AKT or lithium chloride resulted in activation of pyruvate dehydrogenase, i.e., a decrease in its phosphorylated form.	Lithium Chloride	59-75	glycogen synthase kinase 3 beta	Homo sapiens	14-22
23729362-8	2013	Cell death of 5-fluorouracil (5FU)-treated p53-null GSK3B-silenced colon carcinoma cells occurred via PARP1-dependent and AIF-mediated but RIP1-independent necroptosis.	Fluorouracil	14-28	glycogen synthase kinase 3 beta	Homo sapiens	52-57
23846217-10	2013	The important role of glycogen synthase kinase-3beta (GSK3beta) in the signal cascades of celastrol was suggested.	celastrol	90-99	glycogen synthase kinase 3 beta	Homo sapiens	22-52
23846217-10	2013	The important role of glycogen synthase kinase-3beta (GSK3beta) in the signal cascades of celastrol was suggested.	celastrol	90-99	glycogen synthase kinase 3 beta	Homo sapiens	54-62
23846217-11	2013	Pretreatment of LiCL, an inhibitor of GSK3beta, could significantly ameliorate apoptosis induced by celastrol.	Lithium Chloride	16-20	glycogen synthase kinase 3 beta	Homo sapiens	38-46
23846217-11	2013	Pretreatment of LiCL, an inhibitor of GSK3beta, could significantly ameliorate apoptosis induced by celastrol.	celastrol	100-109	glycogen synthase kinase 3 beta	Homo sapiens	38-46
24142090-1	2013	OBJECTIVE: It has been postulated that mood stabilizers inhibit glycogen synthase kinase 3-beta (Gsk3beta) activity, mainly through its phosphorylation on serine-9 (Ser9).	Serine	155-161	glycogen synthase kinase 3 beta	Homo sapiens	64-95
24142090-1	2013	OBJECTIVE: It has been postulated that mood stabilizers inhibit glycogen synthase kinase 3-beta (Gsk3beta) activity, mainly through its phosphorylation on serine-9 (Ser9).	Serine	155-161	glycogen synthase kinase 3 beta	Homo sapiens	97-105
24142090-7	2013	In the bipolar disorder group, p-Gsk3beta Ser9/Gsk3beta was positively correlated with serum lithium levels (r = 0.478, p = 0.039).	Lithium	93-100	glycogen synthase kinase 3 beta	Homo sapiens	33-41
24142090-7	2013	In the bipolar disorder group, p-Gsk3beta Ser9/Gsk3beta was positively correlated with serum lithium levels (r = 0.478, p = 0.039).	Lithium	93-100	glycogen synthase kinase 3 beta	Homo sapiens	47-55
23729362-8	2013	Cell death of 5-fluorouracil (5FU)-treated p53-null GSK3B-silenced colon carcinoma cells occurred via PARP1-dependent and AIF-mediated but RIP1-independent necroptosis.	Fluorouracil	30-33	glycogen synthase kinase 3 beta	Homo sapiens	52-57
23646926-0	2013	Cleavage of GSK-3beta by calpain counteracts the inhibitory effect of Ser9 phosphorylation on GSK-3beta activity induced by H2O2.	Hydrogen Peroxide	124-128	glycogen synthase kinase 3 beta	Homo sapiens	12-21
23646926-9	2013	In conclusion, Ca2+-dependent calpain activation leads to GSK-3beta truncation, which counteracts the inhibitory effect of Ser9 phosphorylation, up-regulates GSK-3beta activity, and phosphorylates tau in H2O2-treated HEK293/Tau cells.	Hydrogen Peroxide	204-208	glycogen synthase kinase 3 beta	Homo sapiens	58-67
23646926-0	2013	Cleavage of GSK-3beta by calpain counteracts the inhibitory effect of Ser9 phosphorylation on GSK-3beta activity induced by H2O2.	Hydrogen Peroxide	124-128	glycogen synthase kinase 3 beta	Homo sapiens	94-103
23646926-3	2013	This study evaluated how oxidative stress regulates GSK-3beta activity in human embryonic kidney 293 (HEK293)/Tau cells treated with hydrogen peroxide (H2O2).	Hydrogen Peroxide	133-150	glycogen synthase kinase 3 beta	Homo sapiens	52-61
23646926-3	2013	This study evaluated how oxidative stress regulates GSK-3beta activity in human embryonic kidney 293 (HEK293)/Tau cells treated with hydrogen peroxide (H2O2).	Hydrogen Peroxide	152-156	glycogen synthase kinase 3 beta	Homo sapiens	52-61
23646926-4	2013	Here, we show that H2O2 induced an obvious increase of GSK-3beta activity.	Hydrogen Peroxide	19-23	glycogen synthase kinase 3 beta	Homo sapiens	55-64
23646926-5	2013	Surprisingly, H2O2 dramatically increased phosphorylation of GSK-3beta at Ser9, an inactive form of GSK-3beta,while there were no changes of phosphorylation of GSK-3beta at Tyr216.	Hydrogen Peroxide	14-18	glycogen synthase kinase 3 beta	Homo sapiens	61-70
23646926-5	2013	Surprisingly, H2O2 dramatically increased phosphorylation of GSK-3beta at Ser9, an inactive form of GSK-3beta,while there were no changes of phosphorylation of GSK-3beta at Tyr216.	Hydrogen Peroxide	14-18	glycogen synthase kinase 3 beta	Homo sapiens	100-109
23646926-5	2013	Surprisingly, H2O2 dramatically increased phosphorylation of GSK-3beta at Ser9, an inactive form of GSK-3beta,while there were no changes of phosphorylation of GSK-3beta at Tyr216.	Hydrogen Peroxide	14-18	glycogen synthase kinase 3 beta	Homo sapiens	100-109
23646926-6	2013	Moreover, H2O2 led to a transient [Ca2+](i) elevation, and simultaneously increased the truncation of GSK-3beta into two fragments of 40 kDa and 30 kDa, whereas inhibition of calpain decreased the truncation and recovered the activity of GSK-3beta.	Hydrogen Peroxide	10-14	glycogen synthase kinase 3 beta	Homo sapiens	102-111
23646926-6	2013	Moreover, H2O2 led to a transient [Ca2+](i) elevation, and simultaneously increased the truncation of GSK-3beta into two fragments of 40 kDa and 30 kDa, whereas inhibition of calpain decreased the truncation and recovered the activity of GSK-3beta.	Hydrogen Peroxide	10-14	glycogen synthase kinase 3 beta	Homo sapiens	238-247
23646926-7	2013	Furthermore, tau was hyperphosphorylated at Ser396, Ser404, and Thr231, three most common GSK-3beta targeted sites after 100 muM H2O2 administration in HEK293/Tau cells, whereas inhibition of calpain blocked the tau phosphorylation.	Hydrogen Peroxide	129-133	glycogen synthase kinase 3 beta	Homo sapiens	90-99
23651584-6	2013	These effects, abolished by cell pre-treatment with the A1R antagonist 8-cyclopentyl-1,3-dipropyl-xanthine (DPCPX), involved the activation of the canonical Wnt signaling as, in differentiating DPSCs, CCPA significantly increased dishevelled protein and inhibited glycogen synthase kinase-3beta, both molecules being downstream of Wnt receptor signal pathway.	1,3-dipropyl-8-cyclopentylxanthine	71-106	glycogen synthase kinase 3 beta	Homo sapiens	264-294
23651584-6	2013	These effects, abolished by cell pre-treatment with the A1R antagonist 8-cyclopentyl-1,3-dipropyl-xanthine (DPCPX), involved the activation of the canonical Wnt signaling as, in differentiating DPSCs, CCPA significantly increased dishevelled protein and inhibited glycogen synthase kinase-3beta, both molecules being downstream of Wnt receptor signal pathway.	1,3-dipropyl-8-cyclopentylxanthine	108-113	glycogen synthase kinase 3 beta	Homo sapiens	264-294
23815230-4	2013	Using the scratch wound assay and a modified Boyden chamber, we found that LY294002, a selective phosphatidylinositol 3-kinase inhibitor, and LiCl, a selective GSK3beta inhibitor, abolished LGI3-induced cell migration.	Lithium Chloride	142-146	glycogen synthase kinase 3 beta	Homo sapiens	160-168
23690508-5	2013	Interestingly, we observed increased phosphorylation of GSK-3beta, NF-kappaB, and ERalpha only in MCF-7 cells, highlighting their role as potential targets in prevention of progression of breast cancer under a high-glucose and insulin condition.	Glucose	215-222	glycogen synthase kinase 3 beta	Homo sapiens	56-65
23690508-7	2013	Taken together, we provide the first evidence that high glucose and insulin promotes proliferation of MDA-MB-231 cells by differential alteration of GSK-3beta, NF-kappaB, and ERalpha expression and histone H3 modifications, which may directly or indirectly modulate the expression of genes involved in its proliferation.	Glucose	56-63	glycogen synthase kinase 3 beta	Homo sapiens	149-158
23805073-4	2013	We report here, that indirect activation of canonical Wnt/beta-catenin signaling using Bromoindirubin-30-Oxime (6-BIO), an inhibitor of glycogen synthase kinase-3beta, protects hippocampal neurons from amyloid-beta (Abeta) oligomers with the concomitant blockade of neuronal apoptosis.	bromoindirubin-30-oxime	87-110	glycogen synthase kinase 3 beta	Homo sapiens	136-166
23825920-1	2013	Part A: Monitoring mitochondrial depolarization with JC-1 and artifactual fluorescence by the glycogen synthase kinase-3beta inhibitor, SB216763.	SB 216763	136-144	glycogen synthase kinase 3 beta	Homo sapiens	94-124
23825920-4	2013	Using direct inhibition of GSK-3beta with the GSK-3beta inhibitor SB216763, mitochondria may be prevented from depolarizing (hereafter referred to as mitoprotection).	SB 216763	66-74	glycogen synthase kinase 3 beta	Homo sapiens	27-36
23825920-4	2013	Using direct inhibition of GSK-3beta with the GSK-3beta inhibitor SB216763, mitochondria may be prevented from depolarizing (hereafter referred to as mitoprotection).	SB 216763	66-74	glycogen synthase kinase 3 beta	Homo sapiens	46-55
23825920-12	2013	CONCLUSIONS: Inhibition of GSK-3beta activity by SB216763 blocked mMPT relative to the slow but consistent depolarization observed with the control cells.	SB 216763	49-57	glycogen synthase kinase 3 beta	Homo sapiens	27-36
23825920-13	2013	We conclude that inhibition of GSK-3beta activity by the GSK-3beta inhibitor SB216763 provides positive protection against mitochondrial depolarization.	SB 216763	77-85	glycogen synthase kinase 3 beta	Homo sapiens	31-40
23825920-13	2013	We conclude that inhibition of GSK-3beta activity by the GSK-3beta inhibitor SB216763 provides positive protection against mitochondrial depolarization.	SB 216763	77-85	glycogen synthase kinase 3 beta	Homo sapiens	57-66
23840442-8	2013	Further studies identified p53 as a downstream effector of the GSK-3beta-mediated repression of let-7 biosynthesis.	let-7	96-101	glycogen synthase kinase 3 beta	Homo sapiens	63-72
23805073-4	2013	We report here, that indirect activation of canonical Wnt/beta-catenin signaling using Bromoindirubin-30-Oxime (6-BIO), an inhibitor of glycogen synthase kinase-3beta, protects hippocampal neurons from amyloid-beta (Abeta) oligomers with the concomitant blockade of neuronal apoptosis.	6-bromoindirubin-3'-oxime	112-117	glycogen synthase kinase 3 beta	Homo sapiens	136-166
25505675-0	2013	The association of glycogen synthase kinase-3beta (GSK-3beta) gene polymorphism with kidney function in long-term lithium-treated bipolar patients.	Lithium	114-121	glycogen synthase kinase 3 beta	Homo sapiens	19-49
23506735-7	2013	Furthermore, it was shown that in AbetaO-treated neurons both leptin and ghrelin prevent glycogen synthase kinase 3beta activation.	Ghrelin	73-80	glycogen synthase kinase 3 beta	Homo sapiens	89-119
25505675-13	2013	The results of our study indicate that the GSK-3beta genotype may be connected with lithium-induced impairment of renal concentrating ability in long-term lithium-treated bipolar patients.	Lithium	84-91	glycogen synthase kinase 3 beta	Homo sapiens	43-52
25505675-0	2013	The association of glycogen synthase kinase-3beta (GSK-3beta) gene polymorphism with kidney function in long-term lithium-treated bipolar patients.	Lithium	114-121	glycogen synthase kinase 3 beta	Homo sapiens	51-60
25505675-13	2013	The results of our study indicate that the GSK-3beta genotype may be connected with lithium-induced impairment of renal concentrating ability in long-term lithium-treated bipolar patients.	Lithium	155-162	glycogen synthase kinase 3 beta	Homo sapiens	43-52
25505675-2	2013	This phenomenon may be connected with the effect of lithium on the glycogen synthase kinase-3beta (GSK-3beta) present in the renal tubules.	Lithium	52-59	glycogen synthase kinase 3 beta	Homo sapiens	67-97
25505675-2	2013	This phenomenon may be connected with the effect of lithium on the glycogen synthase kinase-3beta (GSK-3beta) present in the renal tubules.	Lithium	52-59	glycogen synthase kinase 3 beta	Homo sapiens	99-108
23507703-7	2013	In this regard, the HDAC6 silencing or the functional knockdown of hsp90 by 17AAG resulted in the selective downregulation of AR, EGFR, HER2, and Akt expression/activity, while the decreased phosphorylation of GSK-3beta mediated by PXD101 increased the nuclear expression of CRM1, which in turn modified the AR and survivin recycling with increased caspase 3 activity.	tanespimycin	76-81	glycogen synthase kinase 3 beta	Homo sapiens	210-219
23564507-0	2013	Simultaneous inactivation of GSK-3beta suppresses quercetin-induced apoptosis by inhibiting the JNK pathway.	Quercetin	50-59	glycogen synthase kinase 3 beta	Homo sapiens	29-38
23564507-11	2013	Overexpression of a constitutively active GSK-3beta mutant enhanced quercetin-induced JNK activation.	Quercetin	68-77	glycogen synthase kinase 3 beta	Homo sapiens	42-51
23564507-12	2013	In contrast, overexpression of enzymatically inert GSK-3beta inhibited JNK activation, resulting in a suppression of apoptosis by quercetin.	Quercetin	130-139	glycogen synthase kinase 3 beta	Homo sapiens	51-60
23143779-6	2013	MK-2206 significantly abrogated AKT signaling in all 3 cell lines by inhibiting the activation of AKT and its downstream effectors (FKHR, GSK3beta and BAD).	MK 2206	0-7	glycogen synthase kinase 3 beta	Homo sapiens	138-146
23608221-13	2013	Our data also suggest that PI3K/Akt-mediated inactivation of GSK-3beta and activation of mTOR/p70(S6K) contribute to the proliferative effect of ghrelin.	Ghrelin	145-152	glycogen synthase kinase 3 beta	Homo sapiens	61-70
23628417-8	2013	Also, BLU plus paclitaxel decreased phosphorylation of p70 ribosomal S6 kinase, as well as decreasing the phosphorylation of glycogen synthase kinase-3beta, which is one of the representative targets of the mammalian target of rapamycin signaling cascade.	Paclitaxel	15-25	glycogen synthase kinase 3 beta	Homo sapiens	125-155
23524145-10	2013	This down-regulation is closely related to the inhibition effect of Celecoxib on the AKT/GSK-3beta pathway, and was blocked upon addition of GSK-3beta inhibitor LiCl or the proteasome inhibitor MG132.	Celecoxib	68-77	glycogen synthase kinase 3 beta	Homo sapiens	89-98
23524145-10	2013	This down-regulation is closely related to the inhibition effect of Celecoxib on the AKT/GSK-3beta pathway, and was blocked upon addition of GSK-3beta inhibitor LiCl or the proteasome inhibitor MG132.	Celecoxib	68-77	glycogen synthase kinase 3 beta	Homo sapiens	141-150
23524145-10	2013	This down-regulation is closely related to the inhibition effect of Celecoxib on the AKT/GSK-3beta pathway, and was blocked upon addition of GSK-3beta inhibitor LiCl or the proteasome inhibitor MG132.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	194-199	glycogen synthase kinase 3 beta	Homo sapiens	89-98
23516971-9	2013	These results were accompanied by increased activation of GSK-3beta, as indicated by increased p-GSK3(Tyr-216) to p-GSK3(Ser-9) ratio.	Tyrosine	102-105	glycogen synthase kinase 3 beta	Homo sapiens	58-67
23516971-9	2013	These results were accompanied by increased activation of GSK-3beta, as indicated by increased p-GSK3(Tyr-216) to p-GSK3(Ser-9) ratio.	Serine	121-124	glycogen synthase kinase 3 beta	Homo sapiens	58-67
23485810-7	2013	Furthermore, creatine prevented the 6-OHDA-induced dephosphorylation of glycogen synthase kinase-3beta (GSK-3beta) at the serine 9 residue.	Creatine	13-21	glycogen synthase kinase 3 beta	Homo sapiens	72-102
23541574-9	2013	The 1h cyclic stretching protocol acutely increased the phosphorylation of Akt (+4.5-fold; P&lt;0.05) and its downstream targets, FOXO3a (+4.2-fold; P&lt;0.05) and GSK-3beta (+1.8-fold; P&lt;0.05), which returned to baseline by 48 h after cessation of stretch.	Hydrogen	4-6	glycogen synthase kinase 3 beta	Homo sapiens	164-173
23671600-8	2013	These processes were suppressed by using pyrvinium, a recently described small molecule activator of the GSK 3 beta associated degradation complex.	pyrvinium	41-50	glycogen synthase kinase 3 beta	Homo sapiens	105-115
23669633-1	2013	A series of novel 3-benzisoxazolyl-4-indolyl-maleimides were synthesized and evaluated for their GSK-3beta inhibitory activity.	3-benzisoxazolyl-4-indolyl-maleimides	18-55	glycogen synthase kinase 3 beta	Homo sapiens	97-106
23669633-4	2013	Preliminary structure-activity relationships were examined and showed that different substituents on the indole ring and N1-position of the indole ring had varying degrees of influence on the GSK-3beta inhibitory potency.	indole	105-111	glycogen synthase kinase 3 beta	Homo sapiens	192-201
23669633-4	2013	Preliminary structure-activity relationships were examined and showed that different substituents on the indole ring and N1-position of the indole ring had varying degrees of influence on the GSK-3beta inhibitory potency.	indole	140-146	glycogen synthase kinase 3 beta	Homo sapiens	192-201
23485810-7	2013	Furthermore, creatine prevented the 6-OHDA-induced dephosphorylation of glycogen synthase kinase-3beta (GSK-3beta) at the serine 9 residue.	Creatine	13-21	glycogen synthase kinase 3 beta	Homo sapiens	104-113
23485810-7	2013	Furthermore, creatine prevented the 6-OHDA-induced dephosphorylation of glycogen synthase kinase-3beta (GSK-3beta) at the serine 9 residue.	Oxidopamine	36-42	glycogen synthase kinase 3 beta	Homo sapiens	72-102
23485810-7	2013	Furthermore, creatine prevented the 6-OHDA-induced dephosphorylation of glycogen synthase kinase-3beta (GSK-3beta) at the serine 9 residue.	Oxidopamine	36-42	glycogen synthase kinase 3 beta	Homo sapiens	104-113
23485810-7	2013	Furthermore, creatine prevented the 6-OHDA-induced dephosphorylation of glycogen synthase kinase-3beta (GSK-3beta) at the serine 9 residue.	Serine	122-128	glycogen synthase kinase 3 beta	Homo sapiens	72-102
23485810-7	2013	Furthermore, creatine prevented the 6-OHDA-induced dephosphorylation of glycogen synthase kinase-3beta (GSK-3beta) at the serine 9 residue.	Serine	122-128	glycogen synthase kinase 3 beta	Homo sapiens	104-113
23485810-8	2013	In conclusion, the results of this study show that creatine can protect against 6-OHDA-induced toxicity and its protective mechanism is related to a signaling pathway that involves PI3K, PKC, PKA, CaMKII, MEK1/2 and GSK-3beta.	Creatine	51-59	glycogen synthase kinase 3 beta	Homo sapiens	216-225
23485810-8	2013	In conclusion, the results of this study show that creatine can protect against 6-OHDA-induced toxicity and its protective mechanism is related to a signaling pathway that involves PI3K, PKC, PKA, CaMKII, MEK1/2 and GSK-3beta.	Oxidopamine	80-86	glycogen synthase kinase 3 beta	Homo sapiens	216-225
23021822-0	2013	Glycogen synthase kinase 3beta gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium.	Lithium	124-131	glycogen synthase kinase 3 beta	Homo sapiens	0-30
23585245-0	2013	Design, synthesis, and evaluation of 3-aryl-4-pyrrolyl-maleimides as glycogen synthase kinase-3beta inhibitors.	3-aryl-4-pyrrolyl-maleimides	37-65	glycogen synthase kinase 3 beta	Homo sapiens	69-99
23585245-1	2013	A series of 3-aryl-4-pyrrolyl-maleimides were designed, synthesized, and evaluated for their glycogen synthase kinase-3beta (GSK-3beta) inhibitory activity.	3-aryl-4-pyrrolyl-maleimides	12-40	glycogen synthase kinase 3 beta	Homo sapiens	93-123
23585245-1	2013	A series of 3-aryl-4-pyrrolyl-maleimides were designed, synthesized, and evaluated for their glycogen synthase kinase-3beta (GSK-3beta) inhibitory activity.	3-aryl-4-pyrrolyl-maleimides	12-40	glycogen synthase kinase 3 beta	Homo sapiens	125-134
23585245-3	2013	Among them, compounds 11a, 11c, 11h, 11i, and 11j significantly reduced Abeta-induced Tau hyperphosphorylation, showing the inhibition of GSK-3beta at the cellular level.	UNII-042A8N37WH	72-77	glycogen synthase kinase 3 beta	Homo sapiens	138-147
23453973-12	2013	In glucose-depleted cells, angiotensin-(1-7) effects on ERK1/2 and GS were reverted, while relative phospho-GSK3beta (Ser9) content decreased.	Glucose	3-10	glycogen synthase kinase 3 beta	Homo sapiens	108-116
23469846-5	2013	We found that while suppression of Pin1, either by using its inhibitor Juglone or a shRNA plasmid against Pin1, induces tau hyperphosphorylation and GSK-3beta activation both in vivo and in vitro, inhibition of GSK-3beta by SB216763 or LiCl reverses tau hyperphosphorylation.	juglone	71-78	glycogen synthase kinase 3 beta	Homo sapiens	149-158
23584166-4	2013	Here we show that administration of the TRPV1 agonist, capsaicin, induces phosphorylation of mTOR, p70S6K, S6, Erk1/2 and p38 MAPK, but not Akt, AMPK or GSK3beta.	Capsaicin	55-64	glycogen synthase kinase 3 beta	Homo sapiens	153-161
23265488-5	2013	Furthermore, we found that rhubarb suppressed the p-ser(9) GSK-3-beta protein level to inactivate Wnt signalling and reduce beta-catenin protein level.	Serine	52-55	glycogen synthase kinase 3 beta	Homo sapiens	59-69
23021822-1	2013	BACKGROUND: Glycogen Synthase Kinase 3beta (GSK-3beta) is thought to be a key feature in the therapeutic mechanism of mood stabilizers (e.g., lithium).	Lithium	142-149	glycogen synthase kinase 3 beta	Homo sapiens	12-42
23021822-1	2013	BACKGROUND: Glycogen Synthase Kinase 3beta (GSK-3beta) is thought to be a key feature in the therapeutic mechanism of mood stabilizers (e.g., lithium).	Lithium	142-149	glycogen synthase kinase 3 beta	Homo sapiens	44-53
23021822-12	2013	CONCLUSIONS: Despite the several limitations of the study, our results suggested GSK-3beta genetic variants may be associated with the risk of bipolar I disorder, age of disease onset in females, and the therapeutic response to lithium.	Lithium	228-235	glycogen synthase kinase 3 beta	Homo sapiens	81-90
22975849-0	2013	alpha-Lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3beta signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia.	Thioctic Acid	0-17	glycogen synthase kinase 3 beta	Homo sapiens	88-97
23577691-3	2013	Lithium"s action has been variously linked to inositol phosphate metabolism and the WNT/Glycogen Synthase Kinase 3beta (GSK3beta)/beta-Catenin signalling cascade, but, to date, little is known about which of these provides the principal therapeutic benefit for patients and, more specifically, which constituent genes, through presumed sequence variation, determine differences in patient response to treatment.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	120-128
23577691-8	2013	Both MED10 and MSI2 have been previously linked with WNT/GSK3beta/beta-Catenin pathway function suggesting that this is an important mediator of lithium action in this screen.	Lithium	145-152	glycogen synthase kinase 3 beta	Homo sapiens	57-65
22975849-6	2013	GSK-3beta inhibitors reversed haloperidol-induced overexpression of D2R mRNA levels but did not affect haloperidol-induced oxidative stress.	Haloperidol	30-41	glycogen synthase kinase 3 beta	Homo sapiens	0-9
22975849-9	2013	These results suggest (1) that the effect of antipsychotics on the Akt/GSK-3beta pathway in SH-SY5Y cells is reminiscent of their in vivo action, (2) that (+-)-alpha-lipoic acid partially synergizes with antipsychotic drugs (APDs) on the same pathway, and (3) that the Akt/GSK-3beta signaling cascade is not involved in the preventive effect of (+-)-alpha-lipoic acid on antipsychotics-induced D2R upregulation.	Thioctic Acid	155-177	glycogen synthase kinase 3 beta	Homo sapiens	71-80
22975849-9	2013	These results suggest (1) that the effect of antipsychotics on the Akt/GSK-3beta pathway in SH-SY5Y cells is reminiscent of their in vivo action, (2) that (+-)-alpha-lipoic acid partially synergizes with antipsychotic drugs (APDs) on the same pathway, and (3) that the Akt/GSK-3beta signaling cascade is not involved in the preventive effect of (+-)-alpha-lipoic acid on antipsychotics-induced D2R upregulation.	Thioctic Acid	155-177	glycogen synthase kinase 3 beta	Homo sapiens	273-282
22975849-9	2013	These results suggest (1) that the effect of antipsychotics on the Akt/GSK-3beta pathway in SH-SY5Y cells is reminiscent of their in vivo action, (2) that (+-)-alpha-lipoic acid partially synergizes with antipsychotic drugs (APDs) on the same pathway, and (3) that the Akt/GSK-3beta signaling cascade is not involved in the preventive effect of (+-)-alpha-lipoic acid on antipsychotics-induced D2R upregulation.	Thioctic Acid	345-367	glycogen synthase kinase 3 beta	Homo sapiens	71-80
23646150-8	2013	The GSK-3beta activator, sodium nitroprusside dehydrate (SNP), augmented the anti-tumor effects of hUC-MSCs and decreased the expression of beta-catenin.	sodium nitroprusside dehydrate	25-55	glycogen synthase kinase 3 beta	Homo sapiens	4-13
23184735-0	2013	How calcium inhibits the magnesium-dependent kinase gsk3beta: a molecular simulation study.	Calcium	4-11	glycogen synthase kinase 3 beta	Homo sapiens	52-60
23184735-2	2013	GSK3beta catalyzes the transfer of gamma-phosphate of ATP to the unique substrate Ser/Thr residues with the assistance of two natural activating cofactors Mg(2+).	gamma-phosphate	35-50	glycogen synthase kinase 3 beta	Homo sapiens	0-8
23184735-2	2013	GSK3beta catalyzes the transfer of gamma-phosphate of ATP to the unique substrate Ser/Thr residues with the assistance of two natural activating cofactors Mg(2+).	Adenosine Triphosphate	54-57	glycogen synthase kinase 3 beta	Homo sapiens	0-8
23184735-2	2013	GSK3beta catalyzes the transfer of gamma-phosphate of ATP to the unique substrate Ser/Thr residues with the assistance of two natural activating cofactors Mg(2+).	Serine	82-85	glycogen synthase kinase 3 beta	Homo sapiens	0-8
23184735-2	2013	GSK3beta catalyzes the transfer of gamma-phosphate of ATP to the unique substrate Ser/Thr residues with the assistance of two natural activating cofactors Mg(2+).	Threonine	86-89	glycogen synthase kinase 3 beta	Homo sapiens	0-8
23184735-4	2013	Here, the inhibitory mechanism of GSK3beta by the displacement of native Mg(2+) at site 1 by Ca(2+) was investigated by means of 80 ns comparative molecular dynamics (MD) simulations of the GSK3beta   Mg(2+)-2/ATP/Mg(2+) -1 and GSK3beta   Mg(2+)-2/ATP/Ca(2+)-1 systems.	magnesium ion	73-79	glycogen synthase kinase 3 beta	Homo sapiens	34-42
23184735-4	2013	Here, the inhibitory mechanism of GSK3beta by the displacement of native Mg(2+) at site 1 by Ca(2+) was investigated by means of 80 ns comparative molecular dynamics (MD) simulations of the GSK3beta   Mg(2+)-2/ATP/Mg(2+) -1 and GSK3beta   Mg(2+)-2/ATP/Ca(2+)-1 systems.	magnesium ion	73-79	glycogen synthase kinase 3 beta	Homo sapiens	190-198
23184735-4	2013	Here, the inhibitory mechanism of GSK3beta by the displacement of native Mg(2+) at site 1 by Ca(2+) was investigated by means of 80 ns comparative molecular dynamics (MD) simulations of the GSK3beta   Mg(2+)-2/ATP/Mg(2+) -1 and GSK3beta   Mg(2+)-2/ATP/Ca(2+)-1 systems.	magnesium ion	73-79	glycogen synthase kinase 3 beta	Homo sapiens	190-198
23184735-4	2013	Here, the inhibitory mechanism of GSK3beta by the displacement of native Mg(2+) at site 1 by Ca(2+) was investigated by means of 80 ns comparative molecular dynamics (MD) simulations of the GSK3beta   Mg(2+)-2/ATP/Mg(2+) -1 and GSK3beta   Mg(2+)-2/ATP/Ca(2+)-1 systems.	Adenosine Triphosphate	210-213	glycogen synthase kinase 3 beta	Homo sapiens	34-42
23184735-4	2013	Here, the inhibitory mechanism of GSK3beta by the displacement of native Mg(2+) at site 1 by Ca(2+) was investigated by means of 80 ns comparative molecular dynamics (MD) simulations of the GSK3beta   Mg(2+)-2/ATP/Mg(2+) -1 and GSK3beta   Mg(2+)-2/ATP/Ca(2+)-1 systems.	Adenosine Triphosphate	248-251	glycogen synthase kinase 3 beta	Homo sapiens	34-42
23184735-5	2013	MD simulation results revealed that using the AMBER point charge model force field for Mg(2+) was more appropriate in the reproduction of the active site architectural characteristics of GSK3beta than using the magnesium-cationic dummy atom model force field.	Magnesium	211-220	glycogen synthase kinase 3 beta	Homo sapiens	187-195
23085120-6	2013	Furthermore, B12H restored the suppressed activation of the Akt pathway caused by glutamate as evidenced by the decreased expressions of pSer473-Akt and pSer9-GSK3beta.	Glutamic Acid	82-91	glycogen synthase kinase 3 beta	Homo sapiens	159-167
23164673-8	2013	Furthermore, we validated the inhibition of GSK-3beta/NF-kappaB signaling following cinobufagin treatment.	cinobufagin	84-95	glycogen synthase kinase 3 beta	Homo sapiens	44-53
23164673-10	2013	Transduction with constitutively active forms of GSK-3beta could protect against the downregulation of p65 and upregulation of cleaved-PARP that are induced by cinobufagin treatment.	cinobufagin	160-171	glycogen synthase kinase 3 beta	Homo sapiens	49-58
23164673-13	2013	These studies are the first to reveal the involvement of the GSK-3beta/NF-kappaB pathway in cinobufagin-induced apoptosis.	cinobufagin	92-103	glycogen synthase kinase 3 beta	Homo sapiens	61-70
23580348-9	2013	Honokiol enhanced: (i) the levels of casein kinase-1alpha, glycogen synthase kinase-3beta, and (ii) phosphorylation of beta-catenin on critical residues Ser(45), Ser(33/37) and Thr(41).	honokiol	0-8	glycogen synthase kinase 3 beta	Homo sapiens	59-89
23434582-5	2013	In addition, it also abolished the veratridine-induced dephosphorylation of tau and the phosphorylation of glycogen synthase kinase-3beta and extracellular signal-regulated kinase.	Veratridine	35-46	glycogen synthase kinase 3 beta	Homo sapiens	107-137
23378009-8	2013	Collectively, these findings indicated that LiCl sensitized A549 cells to TRAIL-induced apoptosis through caspases-dependent apoptotic pathway via death receptors signaling and G2/M arrest induced by inhibition of JNK activation, but independent of GSK3beta.	Lithium Chloride	44-48	glycogen synthase kinase 3 beta	Homo sapiens	249-257
23490430-10	2013	Citalopram concentration-dependently inhibited the phosphorylation of Akt, GSK3beta, p38 MAPK and Syk induced by ADP, but showed no effect on the decrease of cAMP and VASP phosphorylation.	Citalopram	0-10	glycogen synthase kinase 3 beta	Homo sapiens	75-83
23490430-10	2013	Citalopram concentration-dependently inhibited the phosphorylation of Akt, GSK3beta, p38 MAPK and Syk induced by ADP, but showed no effect on the decrease of cAMP and VASP phosphorylation.	Adenosine Diphosphate	113-116	glycogen synthase kinase 3 beta	Homo sapiens	75-83
23626687-2	2013	Lithium, a clinical mood stabilizer for mental disorders, potently inhibits the activity of glycogen synthase kinase 3beta (GSK3beta) that promotes the ubiquitin-dependent proteasome degradation of GLI1, an important downstream component of hedgehog signaling.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	92-122
23626687-2	2013	Lithium, a clinical mood stabilizer for mental disorders, potently inhibits the activity of glycogen synthase kinase 3beta (GSK3beta) that promotes the ubiquitin-dependent proteasome degradation of GLI1, an important downstream component of hedgehog signaling.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	124-132
23338608-9	2013	The PDGFR-selective inhibitor CP-673,451 regulated cell proliferation through mechanisms involving reduced phosphorylation of GSK-3alpha and GSK-3beta.	cp-673	30-36	glycogen synthase kinase 3 beta	Homo sapiens	141-150
23440295-8	2013	DFMO treatments induced MYCN protein downregulation and phosphorylation of Akt/PKB (Ser473) and GSK3-beta (Ser9), and polyamine supplementation alleviated the DFMO-induced effects.	Eflornithine	0-4	glycogen synthase kinase 3 beta	Homo sapiens	96-105
23440295-8	2013	DFMO treatments induced MYCN protein downregulation and phosphorylation of Akt/PKB (Ser473) and GSK3-beta (Ser9), and polyamine supplementation alleviated the DFMO-induced effects.	Eflornithine	159-163	glycogen synthase kinase 3 beta	Homo sapiens	96-105
23474714-6	2013	Notably, MacroD2 reversed the ARTD10-catalyzed, mono-ADP-ribose-mediated inhibition of glycogen synthase kinase 3beta (GSK3beta) in vitro and in cells, thus underlining the physiological and regulatory importance of mono-ADP-ribosylhydrolase activity.	mono-adp-ribose	48-63	glycogen synthase kinase 3 beta	Homo sapiens	87-117
23474714-6	2013	Notably, MacroD2 reversed the ARTD10-catalyzed, mono-ADP-ribose-mediated inhibition of glycogen synthase kinase 3beta (GSK3beta) in vitro and in cells, thus underlining the physiological and regulatory importance of mono-ADP-ribosylhydrolase activity.	mono-adp-ribose	48-63	glycogen synthase kinase 3 beta	Homo sapiens	119-127
22944069-2	2013	Lithium is also a potent inhibitor of glycogen synthase kinase-3beta (GSK3beta) activity, which is linked to Alzheimer"s disease (AD).	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	38-68
23341496-7	2013	We also found that GW-9508 activates the Akt/GSK-3beta pathway to increase glycogen levels in HepG2 cells.	GW9508	19-26	glycogen synthase kinase 3 beta	Homo sapiens	45-54
23341496-7	2013	We also found that GW-9508 activates the Akt/GSK-3beta pathway to increase glycogen levels in HepG2 cells.	Glycogen	75-83	glycogen synthase kinase 3 beta	Homo sapiens	45-54
23208610-5	2013	CCN2-stimulated phosphorylation of Akt and GSK-3beta was sensitive to inhibition of PI3-kinase (LY294002).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	96-104	glycogen synthase kinase 3 beta	Homo sapiens	43-52
23047001-0	2013	Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3beta (GSK-3beta).	benzothiazepinones	47-65	glycogen synthase kinase 3 beta	Homo sapiens	116-146
23047001-0	2013	Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3beta (GSK-3beta).	benzothiazepinones	47-65	glycogen synthase kinase 3 beta	Homo sapiens	148-157
23047001-0	2013	Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3beta (GSK-3beta).	btzs	67-71	glycogen synthase kinase 3 beta	Homo sapiens	116-146
23047001-0	2013	Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3beta (GSK-3beta).	btzs	67-71	glycogen synthase kinase 3 beta	Homo sapiens	148-157
23047001-0	2013	Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3beta (GSK-3beta).	Adenosine Triphosphate	86-89	glycogen synthase kinase 3 beta	Homo sapiens	116-146
23047001-0	2013	Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3beta (GSK-3beta).	Adenosine Triphosphate	86-89	glycogen synthase kinase 3 beta	Homo sapiens	148-157
23047001-1	2013	Glycogen synthase kinase-3beta (GSK-3beta) plays a key role in type II diabetes and Alzheimer"s diseases, to which non-ATP competitive inhibitors represent an effectively therapeutical approach due to their good specificity.	Adenosine Triphosphate	119-122	glycogen synthase kinase 3 beta	Homo sapiens	0-30
23047001-1	2013	Glycogen synthase kinase-3beta (GSK-3beta) plays a key role in type II diabetes and Alzheimer"s diseases, to which non-ATP competitive inhibitors represent an effectively therapeutical approach due to their good specificity.	Adenosine Triphosphate	119-122	glycogen synthase kinase 3 beta	Homo sapiens	32-41
23047001-2	2013	Herein, a series of small molecules benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of GSK-3beta have been designed and synthesized.	benzothiazepinones	36-54	glycogen synthase kinase 3 beta	Homo sapiens	105-114
23047001-2	2013	Herein, a series of small molecules benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of GSK-3beta have been designed and synthesized.	btzs	56-60	glycogen synthase kinase 3 beta	Homo sapiens	105-114
23047001-2	2013	Herein, a series of small molecules benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of GSK-3beta have been designed and synthesized.	Adenosine Triphosphate	75-78	glycogen synthase kinase 3 beta	Homo sapiens	105-114
23380150-10	2013	Treatment with CP-AU induced phosphorylation of Akt2, Akt3, GSK-3beta, HSP27, mTOR, and all p38 MAPK isoforms (alpha, beta, delta, and gamma), as well as stimulation of AP-1/NF-kappaB transcriptional activity.	cp-au	15-20	glycogen synthase kinase 3 beta	Homo sapiens	60-69
22749643-5	2013	For example, the most potent inhibitor of the present series, the acetamide 26d, is characterized by an IC50 of 2 nM for GSK-3alpha and 17 nM for GSK-3beta.	acetamide	66-75	glycogen synthase kinase 3 beta	Homo sapiens	146-155
22749643-6	2013	In addition, the benzodioxane 8g showed up to 27-fold selectivity for GSK-3alpha over GSK-3beta, with an IC50 of 35 nM for GSK-3alpha.	benzodioxane	17-29	glycogen synthase kinase 3 beta	Homo sapiens	86-95
23354070-3	2013	We describe here the isolation and biochemical characterization of the marine natural sesquiterpene palinurin as a GSK-3beta inhibitor.	Sesquiterpenes	86-99	glycogen synthase kinase 3 beta	Homo sapiens	115-124
23449446-6	2013	In this study, we investigated beta-catenin and NF-kappaB signaling through regulation of glycogen synthase kinase 3beta activity (GSK-3beta, which modulates beta-catenin and NF-kappaB signaling) using a specific inhibitor LiCl and a phosphatidylinositol 3-kinase (PI3K) inhibitor LY 294002.	Lithium Chloride	223-227	glycogen synthase kinase 3 beta	Homo sapiens	90-120
23449446-6	2013	In this study, we investigated beta-catenin and NF-kappaB signaling through regulation of glycogen synthase kinase 3beta activity (GSK-3beta, which modulates beta-catenin and NF-kappaB signaling) using a specific inhibitor LiCl and a phosphatidylinositol 3-kinase (PI3K) inhibitor LY 294002.	Lithium Chloride	223-227	glycogen synthase kinase 3 beta	Homo sapiens	131-140
23449446-6	2013	In this study, we investigated beta-catenin and NF-kappaB signaling through regulation of glycogen synthase kinase 3beta activity (GSK-3beta, which modulates beta-catenin and NF-kappaB signaling) using a specific inhibitor LiCl and a phosphatidylinositol 3-kinase (PI3K) inhibitor LY 294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	281-290	glycogen synthase kinase 3 beta	Homo sapiens	90-120
23449446-6	2013	In this study, we investigated beta-catenin and NF-kappaB signaling through regulation of glycogen synthase kinase 3beta activity (GSK-3beta, which modulates beta-catenin and NF-kappaB signaling) using a specific inhibitor LiCl and a phosphatidylinositol 3-kinase (PI3K) inhibitor LY 294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	281-290	glycogen synthase kinase 3 beta	Homo sapiens	131-140
23277198-0	2013	GSK3beta phosphorylates newly identified site in the proline-alanine-rich region of cardiac myosin-binding protein C and alters cross-bridge cycling kinetics in human: short communication.	Proline	53-60	glycogen synthase kinase 3 beta	Homo sapiens	0-8
23277198-0	2013	GSK3beta phosphorylates newly identified site in the proline-alanine-rich region of cardiac myosin-binding protein C and alters cross-bridge cycling kinetics in human: short communication.	Alanine	61-68	glycogen synthase kinase 3 beta	Homo sapiens	0-8
23277198-12	2013	CONCLUSIONS: GSK3beta phosphorylates cMyBP-C on a novel site, which is positioned in the proline-alanine-rich region and increases kinetics of force development, suggesting a noncanonical role for GSK3beta at the sarcomere level.	Proline	89-96	glycogen synthase kinase 3 beta	Homo sapiens	13-21
23277198-12	2013	CONCLUSIONS: GSK3beta phosphorylates cMyBP-C on a novel site, which is positioned in the proline-alanine-rich region and increases kinetics of force development, suggesting a noncanonical role for GSK3beta at the sarcomere level.	Alanine	97-104	glycogen synthase kinase 3 beta	Homo sapiens	13-21
23123500-6	2013	Analogously, pre-treatment with LiCl, which induced phosphorylation of GSK3beta at Ser9, increased Wnt5a-induced cell migration.	Lithium Chloride	32-36	glycogen synthase kinase 3 beta	Homo sapiens	71-79
23354070-3	2013	We describe here the isolation and biochemical characterization of the marine natural sesquiterpene palinurin as a GSK-3beta inhibitor.	palinurin	100-109	glycogen synthase kinase 3 beta	Homo sapiens	115-124
23354070-4	2013	Experimental studies performed for characterizing the inhibitory mechanism indicate that GSK-3beta inhibition by palinurin cannot be competed out by ATP nor peptide substrate.	palinurin	113-122	glycogen synthase kinase 3 beta	Homo sapiens	89-98
22751450-0	2013	Downregulation of Mcl-1 through GSK-3beta activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.	Arsenic Trioxide	68-84	glycogen synthase kinase 3 beta	Homo sapiens	32-41
23085082-3	2013	The aim of the present study was to investigate whether the phosphorylation level of GSK-3beta at serine 9 is the primary regulatory mechanism of differentiation-induced apoptosis.	Serine	98-104	glycogen synthase kinase 3 beta	Homo sapiens	85-94
23085082-4	2013	Differentiating human neural ReNcell VM progenitor cells were treated with the specific GSK-3beta inhibitor SB216763 (10 muM) and analyzed in respect to the intrinsic apoptosis pathway regulation using microscopy and protein expression analysis.	SB 216763	108-116	glycogen synthase kinase 3 beta	Homo sapiens	88-97
23085082-6	2013	Treatment of differentiating cells with SB216763 induced a significant dephosphorylation of GSK-3beta at serine 9 accompanied by a significant decrease of apoptosis of about 0.7+-0.03% and reduced activation of caspase-3 as well as BAX and PARP cleavage during the first 12h of differentiation compared to untreated, differentiating cells.	SB 216763	40-48	glycogen synthase kinase 3 beta	Homo sapiens	92-101
23085082-6	2013	Treatment of differentiating cells with SB216763 induced a significant dephosphorylation of GSK-3beta at serine 9 accompanied by a significant decrease of apoptosis of about 0.7+-0.03% and reduced activation of caspase-3 as well as BAX and PARP cleavage during the first 12h of differentiation compared to untreated, differentiating cells.	Serine	105-111	glycogen synthase kinase 3 beta	Homo sapiens	92-101
23085082-7	2013	Dephosphorylation of GSK-3beta at serine 9 appears not solely to be responsible for its pro-apoptotic function, because we observed a decrease of intrinsic apoptosis after treatment of the cells with the specific GSK-3beta inhibitor SB216763.	Serine	34-40	glycogen synthase kinase 3 beta	Homo sapiens	21-30
23085082-7	2013	Dephosphorylation of GSK-3beta at serine 9 appears not solely to be responsible for its pro-apoptotic function, because we observed a decrease of intrinsic apoptosis after treatment of the cells with the specific GSK-3beta inhibitor SB216763.	Serine	34-40	glycogen synthase kinase 3 beta	Homo sapiens	213-222
23085082-7	2013	Dephosphorylation of GSK-3beta at serine 9 appears not solely to be responsible for its pro-apoptotic function, because we observed a decrease of intrinsic apoptosis after treatment of the cells with the specific GSK-3beta inhibitor SB216763.	SB 216763	233-241	glycogen synthase kinase 3 beta	Homo sapiens	21-30
23085082-7	2013	Dephosphorylation of GSK-3beta at serine 9 appears not solely to be responsible for its pro-apoptotic function, because we observed a decrease of intrinsic apoptosis after treatment of the cells with the specific GSK-3beta inhibitor SB216763.	SB 216763	233-241	glycogen synthase kinase 3 beta	Homo sapiens	213-222
23207448-9	2013	DEXA inhibited glycogen synthase kinase-3beta (GSK-3beta) phosphorylation and the Snail upregulation induced by TGF-beta1, which were also ameliorated by inhibitors of MAPK.	Dexamethasone	0-4	glycogen synthase kinase 3 beta	Homo sapiens	47-56
23207448-10	2013	In conclusion, this is the first study demonstrating the protective effect of DEXA on the EMT in TGF-beta1-stimulated HPMCs by inhibiting MAPK activation, GSK-3beta phosphorylation and Snail upregulation.	Dexamethasone	78-82	glycogen synthase kinase 3 beta	Homo sapiens	155-164
22751450-5	2013	Both glycogen synthase kinase-3beta (GSK-3beta) inhibitor SB216763 and siRNA blocked ATO-induced Mcl-1 reduction as well as attenuated ATO-induced apoptosis in NB4 cells.	SB 216763	58-66	glycogen synthase kinase 3 beta	Homo sapiens	5-35
22751450-5	2013	Both glycogen synthase kinase-3beta (GSK-3beta) inhibitor SB216763 and siRNA blocked ATO-induced Mcl-1 reduction as well as attenuated ATO-induced apoptosis in NB4 cells.	SB 216763	58-66	glycogen synthase kinase 3 beta	Homo sapiens	37-46
22751450-5	2013	Both glycogen synthase kinase-3beta (GSK-3beta) inhibitor SB216763 and siRNA blocked ATO-induced Mcl-1 reduction as well as attenuated ATO-induced apoptosis in NB4 cells.	Arsenic Trioxide	85-88	glycogen synthase kinase 3 beta	Homo sapiens	5-35
22751450-5	2013	Both glycogen synthase kinase-3beta (GSK-3beta) inhibitor SB216763 and siRNA blocked ATO-induced Mcl-1 reduction as well as attenuated ATO-induced apoptosis in NB4 cells.	Arsenic Trioxide	85-88	glycogen synthase kinase 3 beta	Homo sapiens	37-46
23218026-4	2013	In this study, using the K562 CML cell line we showed that inhibition of Bcr-Abl signalling, by either Imatinib or Nilotinib, led to a significant reduction in ROS levels which was concurrent with the GSK-3beta dependent, post-translational down-regulation of the small membrane-bound protein p22phox, an essential component of the Nox complex.	Imatinib Mesylate	103-111	glycogen synthase kinase 3 beta	Homo sapiens	201-210
22751450-8	2013	Sorafenib, an Raf inhibitor, activated GSK-3beta by inhibiting its phosphorylation, decreased Mcl-1 levels and decreased intracellular glutathione levels in HL-60 cells.	Sorafenib	0-9	glycogen synthase kinase 3 beta	Homo sapiens	39-48
23218026-4	2013	In this study, using the K562 CML cell line we showed that inhibition of Bcr-Abl signalling, by either Imatinib or Nilotinib, led to a significant reduction in ROS levels which was concurrent with the GSK-3beta dependent, post-translational down-regulation of the small membrane-bound protein p22phox, an essential component of the Nox complex.	nilotinib	115-124	glycogen synthase kinase 3 beta	Homo sapiens	201-210
22751450-8	2013	Sorafenib, an Raf inhibitor, activated GSK-3beta by inhibiting its phosphorylation, decreased Mcl-1 levels and decreased intracellular glutathione levels in HL-60 cells.	Glutathione	135-146	glycogen synthase kinase 3 beta	Homo sapiens	39-48
22751450-10	2013	These results indicate that ATO induces Mcl-1 degradation through activation of GSK-3beta in APL cells and provide a rationale for utilizing ATO in combination with sorafenib for the treatment of non-APL AML patients.	Arsenic Trioxide	28-31	glycogen synthase kinase 3 beta	Homo sapiens	80-89
23178381-0	2013	Aspidin PB, a phloroglucinol derivative, induces apoptosis in human hepatocarcinoma HepG2 cells by modulating PI3K/Akt/GSK3beta pathway.	aspidin PB	0-10	glycogen synthase kinase 3 beta	Homo sapiens	119-127
23178381-7	2013	Western blot analysis revealed that aspidin PB inhibited PI3K expression, phosphorylation of Ser473 Akt and Ser9 GSK3beta followed by up-regulation of nonsteroidal anti-inflammatory drugs activated gene-1 (NAG-1) expression.	aspidin PB	36-46	glycogen synthase kinase 3 beta	Homo sapiens	113-121
23211630-8	2013	Furthermore, bFGF inactivated GSK-3beta through increasing the phosphorylation of Ser(9) on GSK-3beta, which is reversed by Y27632 through increased phosphorylation of Tyr(216) on GSK-3beta.	Y 27632	124-130	glycogen synthase kinase 3 beta	Homo sapiens	30-39
23211630-8	2013	Furthermore, bFGF inactivated GSK-3beta through increasing the phosphorylation of Ser(9) on GSK-3beta, which is reversed by Y27632 through increased phosphorylation of Tyr(216) on GSK-3beta.	Y 27632	124-130	glycogen synthase kinase 3 beta	Homo sapiens	92-101
23211630-8	2013	Furthermore, bFGF inactivated GSK-3beta through increasing the phosphorylation of Ser(9) on GSK-3beta, which is reversed by Y27632 through increased phosphorylation of Tyr(216) on GSK-3beta.	Y 27632	124-130	glycogen synthase kinase 3 beta	Homo sapiens	92-101
23211630-8	2013	Furthermore, bFGF inactivated GSK-3beta through increasing the phosphorylation of Ser(9) on GSK-3beta, which is reversed by Y27632 through increased phosphorylation of Tyr(216) on GSK-3beta.	Tyrosine	168-171	glycogen synthase kinase 3 beta	Homo sapiens	30-39
23211630-8	2013	Furthermore, bFGF inactivated GSK-3beta through increasing the phosphorylation of Ser(9) on GSK-3beta, which is reversed by Y27632 through increased phosphorylation of Tyr(216) on GSK-3beta.	Tyrosine	168-171	glycogen synthase kinase 3 beta	Homo sapiens	92-101
23149922-3	2013	COX-2/PGE2 activated EP4 to enhance Akt and GSK-3beta phosphorylation and beta-catenin/T-cell factor/lymphoid enhancer factor signaling leading to MIG-7 upregulation.	Dinoprostone	6-10	glycogen synthase kinase 3 beta	Homo sapiens	44-53
23211630-8	2013	Furthermore, bFGF inactivated GSK-3beta through increasing the phosphorylation of Ser(9) on GSK-3beta, which is reversed by Y27632 through increased phosphorylation of Tyr(216) on GSK-3beta.	Tyrosine	168-171	glycogen synthase kinase 3 beta	Homo sapiens	92-101
23223575-5	2013	In the presence of quercetin, reactivation of beta-catenin using the glycogen synthase kinase-3beta (GSK-3beta) inhibitor LiCl restores calcium accumulation, confirming that quercetin mechanism of action hinges on inhibition of the beta-catenin pathway.	Lithium Chloride	122-126	glycogen synthase kinase 3 beta	Homo sapiens	69-99
23223575-5	2013	In the presence of quercetin, reactivation of beta-catenin using the glycogen synthase kinase-3beta (GSK-3beta) inhibitor LiCl restores calcium accumulation, confirming that quercetin mechanism of action hinges on inhibition of the beta-catenin pathway.	Lithium Chloride	122-126	glycogen synthase kinase 3 beta	Homo sapiens	101-110
23223575-5	2013	In the presence of quercetin, reactivation of beta-catenin using the glycogen synthase kinase-3beta (GSK-3beta) inhibitor LiCl restores calcium accumulation, confirming that quercetin mechanism of action hinges on inhibition of the beta-catenin pathway.	Calcium	136-143	glycogen synthase kinase 3 beta	Homo sapiens	101-110
23223575-5	2013	In the presence of quercetin, reactivation of beta-catenin using the glycogen synthase kinase-3beta (GSK-3beta) inhibitor LiCl restores calcium accumulation, confirming that quercetin mechanism of action hinges on inhibition of the beta-catenin pathway.	Quercetin	174-183	glycogen synthase kinase 3 beta	Homo sapiens	69-99
23223575-5	2013	In the presence of quercetin, reactivation of beta-catenin using the glycogen synthase kinase-3beta (GSK-3beta) inhibitor LiCl restores calcium accumulation, confirming that quercetin mechanism of action hinges on inhibition of the beta-catenin pathway.	Quercetin	174-183	glycogen synthase kinase 3 beta	Homo sapiens	101-110
23332125-0	2013	ARTD10 substrate identification on protein microarrays: regulation of GSK3beta by mono-ADP-ribosylation.	mono-adp	82-90	glycogen synthase kinase 3 beta	Homo sapiens	70-78
22897592-0	2013	Pkb/Akt1 mediates Wnt/GSK3beta/beta-catenin signaling-induced apoptosis in human cord blood stem cells exposed to organophosphate pesticide monocrotophos.	Organophosphates	114-129	glycogen synthase kinase 3 beta	Homo sapiens	22-30
24117074-8	2013	Furthermore, 20(S)-PPD also triggered down-regulation of phosphorylated Akt (Ser473/Thr308) and glycogen synthase kinase 3beta (GSK 3beta).	protopanaxadiol	15-22	glycogen synthase kinase 3 beta	Homo sapiens	96-126
24117074-8	2013	Furthermore, 20(S)-PPD also triggered down-regulation of phosphorylated Akt (Ser473/Thr308) and glycogen synthase kinase 3beta (GSK 3beta).	protopanaxadiol	15-22	glycogen synthase kinase 3 beta	Homo sapiens	128-137
24117074-9	2013	Knockdown of GSK 3beta with siRNA promoted the apoptotic effects of 20(S)-PPD.	protopanaxadiol	70-77	glycogen synthase kinase 3 beta	Homo sapiens	13-22
23735868-0	2013	Hydrogen sulfide inhibits abnormal proliferation of lymphocytes via AKT/GSK3beta signal pathway in systemic lupus erythematosus patients.	Hydrogen Sulfide	0-16	glycogen synthase kinase 3 beta	Homo sapiens	72-80
23735868-13	2013	Pretreatment with NaHS decreased PHA-induced expression of CDK2, phosphorylation levels of AKT (ser473) and GSK3beta (ser9) and increased the expression of p27(Kip1) and p21(WAF1/CIP1).	sodium bisulfide	18-22	glycogen synthase kinase 3 beta	Homo sapiens	108-116
23735868-14	2013	Moreover, pretreatment with NaHS blunted the stimulation of SLE lymphocyte proliferation by GSK3beta inhibitor lithium chloride.	sodium bisulfide	28-32	glycogen synthase kinase 3 beta	Homo sapiens	92-100
23735868-14	2013	Moreover, pretreatment with NaHS blunted the stimulation of SLE lymphocyte proliferation by GSK3beta inhibitor lithium chloride.	Lithium Chloride	111-127	glycogen synthase kinase 3 beta	Homo sapiens	92-100
23735868-15	2013	CONCLUSION: These results demonstrate that H2S inhibits the abnormal activation of lymphocytes from SLE patients throuqh the AKT/GSK3beta signal pathway.	Hydrogen Sulfide	43-46	glycogen synthase kinase 3 beta	Homo sapiens	129-137
23178381-8	2013	Similarly, the effects of aspidin PB on PI3K, Akt, GSK3beta, NAG-1 expression were abolished by treatment with the PI3K inhibitor, wortmannin.	aspidin PB	26-36	glycogen synthase kinase 3 beta	Homo sapiens	51-59
23178381-8	2013	Similarly, the effects of aspidin PB on PI3K, Akt, GSK3beta, NAG-1 expression were abolished by treatment with the PI3K inhibitor, wortmannin.	Wortmannin	131-141	glycogen synthase kinase 3 beta	Homo sapiens	51-59
23178381-9	2013	Taken together, our data suggested that the PI3K/Akt/GSK3beta signal pathway may represent one of the major mechanisms of the effects of aspidin PB on human hepatocarcinoma cells.	aspidin PB	137-147	glycogen synthase kinase 3 beta	Homo sapiens	53-61
23211630-6	2013	Lithium (Li), an inhibitor of GSK-3beta, recovered Y27632-decreased proliferation and quercetin (Que), an inhibitor of beta-catenin pathway, reversed the recovery effect of Li.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	30-39
23211630-8	2013	Furthermore, bFGF inactivated GSK-3beta through increasing the phosphorylation of Ser(9) on GSK-3beta, which is reversed by Y27632 through increased phosphorylation of Tyr(216) on GSK-3beta.	Serine	82-85	glycogen synthase kinase 3 beta	Homo sapiens	30-39
23211630-8	2013	Furthermore, bFGF inactivated GSK-3beta through increasing the phosphorylation of Ser(9) on GSK-3beta, which is reversed by Y27632 through increased phosphorylation of Tyr(216) on GSK-3beta.	Serine	82-85	glycogen synthase kinase 3 beta	Homo sapiens	92-101
23211630-8	2013	Furthermore, bFGF inactivated GSK-3beta through increasing the phosphorylation of Ser(9) on GSK-3beta, which is reversed by Y27632 through increased phosphorylation of Tyr(216) on GSK-3beta.	Serine	82-85	glycogen synthase kinase 3 beta	Homo sapiens	92-101
23332125-9	2013	Further analysis of the novel ARTD10 substrate GSK3beta revealed mono-ADP-ribosylation as a regulatory mechanism of kinase activity by non-competitive inhibition in vitro.	mono-adp	65-73	glycogen synthase kinase 3 beta	Homo sapiens	47-55
23332125-14	2013	By studying one of the ARTD10 substrates more closely, the kinase GSK3beta, we identified mono-ADP-ribosylation as a negative regulator of kinase activity.	mono-adp	90-98	glycogen synthase kinase 3 beta	Homo sapiens	66-74
24900653-2	2013	X-ray cocrystallization using a surrogate protein, GSK3beta, and modeling studies confirmed the azaindole motif as the hinge binder.	benzimidazole	96-105	glycogen synthase kinase 3 beta	Homo sapiens	51-59
23710442-3	2013	In contrast, DEX restores CD2AP-PI3K-Akt-GSK3 beta signaling, which promotes the activity of antiapoptotic proteins and inhibits the activity of proapoptotic proteins.	Dexamethasone	13-16	glycogen synthase kinase 3 beta	Homo sapiens	41-50
23710442-7	2013	DEX treatment induced a concentration-dependent reversal of PAN-induced p-Akt and p-GSK3 beta downregulation.	Dexamethasone	0-3	glycogen synthase kinase 3 beta	Homo sapiens	84-93
23710442-8	2013	The PI3K inhibitor LY294002 blocked p-Akt and p-GSK3 beta expressions in podocytes.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	19-27	glycogen synthase kinase 3 beta	Homo sapiens	48-57
23710442-12	2013	These results strongly suggest that DEX protects podocytes by stabilizing the expression and subcellular distribution of CD2AP and by maintaining the expression of phosphor-activated Akt and GSK3beta .	Dexamethasone	36-39	glycogen synthase kinase 3 beta	Homo sapiens	191-199
24317053-5	2013	Apicidin-resistant (AR) HA22T cells showed higher beta-catenin nuclear accumulation and significantly decreased GSK-3-beta protein level, in relation to parental cells.	apicidin	0-8	glycogen synthase kinase 3 beta	Homo sapiens	112-122
23992308-8	2013	Finally, the activation of the PI3K/AKT/GSK-3beta signaling pathway was demonstrated to be involved in indometacin reversing HG-induced cell proliferation and invasion in PC cells.	Indomethacin	103-114	glycogen synthase kinase 3 beta	Homo sapiens	40-49
23956765-0	2013	Panax Quinquefolius Saponin of Stem and Leaf Attenuates Intermittent High Glucose-Induced Oxidative Stress Injury in Cultured Human Umbilical Vein Endothelial Cells via PI3K/Akt/GSK-3 beta Pathway.	Saponins	20-27	glycogen synthase kinase 3 beta	Homo sapiens	178-188
23956765-5	2013	Moreover, high glucose significantly reduced the phosphorylation of Akt and GSK-3 beta .	Glucose	15-22	glycogen synthase kinase 3 beta	Homo sapiens	76-86
23956765-7	2013	PQS treatment significantly attenuated intermittent high glucose-induced oxidative damage on HUVECs and meanwhile increased cell viability and phosphorylation of Akt and GSK-3 beta of HUVECs.	Primaquine	0-3	glycogen synthase kinase 3 beta	Homo sapiens	170-180
23956765-9	2013	These findings suggest that PQS attenuates intermittent-high-glucose-induced oxidative stress injury in HUVECs by PI3K/Akt/GSK-3 beta pathway.	Primaquine	28-31	glycogen synthase kinase 3 beta	Homo sapiens	123-133
23956765-9	2013	These findings suggest that PQS attenuates intermittent-high-glucose-induced oxidative stress injury in HUVECs by PI3K/Akt/GSK-3 beta pathway.	Glucose	61-68	glycogen synthase kinase 3 beta	Homo sapiens	123-133
24222885-8	2013	The scaffold of 3-aminopyrrolidine (inhibitor 6) exhibits high preferential affinity with GSK3beta.	3-Aminopyrrolidine	16-34	glycogen synthase kinase 3 beta	Homo sapiens	90-98
23948896-7	2013	Interestingly, total GSK3beta and GSK3beta phosphorylation on Ser-9 are not altered during nocodazole treatment.	Serine	62-65	glycogen synthase kinase 3 beta	Homo sapiens	21-29
23440594-7	2013	Mechanistically, IndOH-LNC induced inhibition of cell growth and cell-cycle arrest to be correlated with the inactivation of AKT and beta-catenin and the activation of GSK-3beta.	indoh-lnc	17-26	glycogen synthase kinase 3 beta	Homo sapiens	168-177
23948896-7	2013	Interestingly, total GSK3beta and GSK3beta phosphorylation on Ser-9 are not altered during nocodazole treatment.	Serine	62-65	glycogen synthase kinase 3 beta	Homo sapiens	34-42
23357875-5	2013	Pretreatment with the proteasome inhibitor MG132 or glycogen synthase kinase-3beta (GSK-3beta) inhibitors (LiCl and SB216763) attenuated the effect of DIF-1, suggesting that DIF-1 induced c-Myc protein degradation through GSK-3beta activation.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	43-48	glycogen synthase kinase 3 beta	Homo sapiens	222-231
23106494-6	2013	Moreover, we demonstrated that Hc-TeTx treatment initiate autophagy which is ERK1/2- and GSK3beta-dependent.	hc-tetx	31-38	glycogen synthase kinase 3 beta	Homo sapiens	89-97
23357875-5	2013	Pretreatment with the proteasome inhibitor MG132 or glycogen synthase kinase-3beta (GSK-3beta) inhibitors (LiCl and SB216763) attenuated the effect of DIF-1, suggesting that DIF-1 induced c-Myc protein degradation through GSK-3beta activation.	SB 216763	116-124	glycogen synthase kinase 3 beta	Homo sapiens	84-93
23357875-5	2013	Pretreatment with the proteasome inhibitor MG132 or glycogen synthase kinase-3beta (GSK-3beta) inhibitors (LiCl and SB216763) attenuated the effect of DIF-1, suggesting that DIF-1 induced c-Myc protein degradation through GSK-3beta activation.	SB 216763	116-124	glycogen synthase kinase 3 beta	Homo sapiens	222-231
23357875-5	2013	Pretreatment with the proteasome inhibitor MG132 or glycogen synthase kinase-3beta (GSK-3beta) inhibitors (LiCl and SB216763) attenuated the effect of DIF-1, suggesting that DIF-1 induced c-Myc protein degradation through GSK-3beta activation.	Lithium Chloride	107-111	glycogen synthase kinase 3 beta	Homo sapiens	52-82
23357875-5	2013	Pretreatment with the proteasome inhibitor MG132 or glycogen synthase kinase-3beta (GSK-3beta) inhibitors (LiCl and SB216763) attenuated the effect of DIF-1, suggesting that DIF-1 induced c-Myc protein degradation through GSK-3beta activation.	Lithium Chloride	107-111	glycogen synthase kinase 3 beta	Homo sapiens	84-93
23357875-5	2013	Pretreatment with the proteasome inhibitor MG132 or glycogen synthase kinase-3beta (GSK-3beta) inhibitors (LiCl and SB216763) attenuated the effect of DIF-1, suggesting that DIF-1 induced c-Myc protein degradation through GSK-3beta activation.	Lithium Chloride	107-111	glycogen synthase kinase 3 beta	Homo sapiens	222-231
23357875-5	2013	Pretreatment with the proteasome inhibitor MG132 or glycogen synthase kinase-3beta (GSK-3beta) inhibitors (LiCl and SB216763) attenuated the effect of DIF-1, suggesting that DIF-1 induced c-Myc protein degradation through GSK-3beta activation.	SB 216763	116-124	glycogen synthase kinase 3 beta	Homo sapiens	52-82
22990942-1	2013	Lithium is the mainstay for the treatment of bipolar disorder (BD) and inhibits glycogen synthase kinase 3-beta (GSK3-beta).	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	80-111
23572150-6	2013	Further studies revealed that KCNN4 channels increased intracellular calcium levels and activated components of cell signaling downstream of calcium, including CaM-kinase II and glycogen synthase kinase-3 beta (GSK-3 beta), which increased Snail expression.	Calcium	69-76	glycogen synthase kinase 3 beta	Homo sapiens	178-209
23572150-6	2013	Further studies revealed that KCNN4 channels increased intracellular calcium levels and activated components of cell signaling downstream of calcium, including CaM-kinase II and glycogen synthase kinase-3 beta (GSK-3 beta), which increased Snail expression.	Calcium	69-76	glycogen synthase kinase 3 beta	Homo sapiens	211-221
22926267-0	2013	A flexible-protein molecular docking study of the binding of ruthenium complex compounds to PIM1, GSK-3beta, and CDK2/Cyclin A protein kinases.	Ruthenium complex	61-78	glycogen synthase kinase 3 beta	Homo sapiens	98-107
22926267-1	2013	We employ ensemble docking simulations to characterize the interactions of two enantiomeric forms of a Ru-complex compound (1-R and 1-S) with three protein kinases, namely PIM1, GSK-3beta, and CDK2/cyclin A.	Ruthenium	103-105	glycogen synthase kinase 3 beta	Homo sapiens	178-187
22926267-1	2013	We employ ensemble docking simulations to characterize the interactions of two enantiomeric forms of a Ru-complex compound (1-R and 1-S) with three protein kinases, namely PIM1, GSK-3beta, and CDK2/cyclin A.	1-r	124-127	glycogen synthase kinase 3 beta	Homo sapiens	178-187
22926267-1	2013	We employ ensemble docking simulations to characterize the interactions of two enantiomeric forms of a Ru-complex compound (1-R and 1-S) with three protein kinases, namely PIM1, GSK-3beta, and CDK2/cyclin A.	1-s	132-135	glycogen synthase kinase 3 beta	Homo sapiens	178-187
24165455-3	2013	We find that GSK3beta in somatodendritic compartments of hippocampal neurons becomes highly phosphorylated at serine-9 upon synaptogenesis.	Serine	110-116	glycogen synthase kinase 3 beta	Homo sapiens	13-21
23596350-3	2013	Evidence from preclinical studies suggests that neuroprotection induced by lithium is mainly related to its potent inhibition of the enzyme glycogen synthase kinase-3beta (GSK-3beta) and its downstream effects, ie, reduction of both tau protein phosphorylation and amyloid-beta42 production.	Lithium	75-82	glycogen synthase kinase 3 beta	Homo sapiens	140-170
23596350-3	2013	Evidence from preclinical studies suggests that neuroprotection induced by lithium is mainly related to its potent inhibition of the enzyme glycogen synthase kinase-3beta (GSK-3beta) and its downstream effects, ie, reduction of both tau protein phosphorylation and amyloid-beta42 production.	Lithium	75-82	glycogen synthase kinase 3 beta	Homo sapiens	172-181
22990942-1	2013	Lithium is the mainstay for the treatment of bipolar disorder (BD) and inhibits glycogen synthase kinase 3-beta (GSK3-beta).	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	113-122
23198830-0	2012	In silico deconstruction of ATP-competitive inhibitors of glycogen synthase kinase-3beta.	Adenosine Triphosphate	28-31	glycogen synthase kinase 3 beta	Homo sapiens	58-88
24399733-9	2013	Furthermore, the GSK3beta inhibitor SB216763 or Wnt3a-conditioned medium (Wnt3a-CM) reversed the cleavages of caspase-3 and PARP induced by ursolic acid in PC-3 cells.	ursolic acid	140-152	glycogen synthase kinase 3 beta	Homo sapiens	17-25
23408967-8	2013	Inhibition of GSK3beta significantly reduced the proliferation and survival of cancer cells, sensitized them to gemcitabine and ionizing radiation, and attenuated their migration and invasion.	gemcitabine	112-123	glycogen synthase kinase 3 beta	Homo sapiens	14-22
23117412-6	2013	In addition, d-limonene decreased the levels of p-Akt (Ser473), p-Akt (Thr308)             and p-GSK-3beta (Ser9), suggesting that d-limonene induced apoptosis via the mitochondrial             death pathway and the suppression of the PI3K/Akt pathway.	Limonene	13-23	glycogen synthase kinase 3 beta	Homo sapiens	97-106
23117412-6	2013	In addition, d-limonene decreased the levels of p-Akt (Ser473), p-Akt (Thr308)             and p-GSK-3beta (Ser9), suggesting that d-limonene induced apoptosis via the mitochondrial             death pathway and the suppression of the PI3K/Akt pathway.	Limonene	131-141	glycogen synthase kinase 3 beta	Homo sapiens	97-106
24399733-8	2013	Interestingly, ursolic acid suppressed the expression of Wnt5alpha/beta and beta-catenin, and enhanced the phosphorylation of glycogen synthase kinase 3 beta (GSK3beta).	ursolic acid	15-27	glycogen synthase kinase 3 beta	Homo sapiens	126-157
24399733-8	2013	Interestingly, ursolic acid suppressed the expression of Wnt5alpha/beta and beta-catenin, and enhanced the phosphorylation of glycogen synthase kinase 3 beta (GSK3beta).	ursolic acid	15-27	glycogen synthase kinase 3 beta	Homo sapiens	159-167
24399733-9	2013	Furthermore, the GSK3beta inhibitor SB216763 or Wnt3a-conditioned medium (Wnt3a-CM) reversed the cleavages of caspase-3 and PARP induced by ursolic acid in PC-3 cells.	SB 216763	36-44	glycogen synthase kinase 3 beta	Homo sapiens	17-25
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	efavirenz	14-17	glycogen synthase kinase 3 beta	Homo sapiens	40-71
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	efavirenz	14-17	glycogen synthase kinase 3 beta	Homo sapiens	73-81
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	efavirenz	14-17	glycogen synthase kinase 3 beta	Homo sapiens	147-155
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	Valproic Acid	118-131	glycogen synthase kinase 3 beta	Homo sapiens	40-71
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	Valproic Acid	118-131	glycogen synthase kinase 3 beta	Homo sapiens	73-81
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	Valproic Acid	118-131	glycogen synthase kinase 3 beta	Homo sapiens	147-155
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	Valproic Acid	133-136	glycogen synthase kinase 3 beta	Homo sapiens	40-71
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	Valproic Acid	133-136	glycogen synthase kinase 3 beta	Homo sapiens	73-81
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	Valproic Acid	133-136	glycogen synthase kinase 3 beta	Homo sapiens	147-155
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	scd40l	204-210	glycogen synthase kinase 3 beta	Homo sapiens	73-81
23555843-4	2013	Additionally, EFV was found to activate glycogen synthase kinase 3 beta (GSK3beta) in platelets, and we now show that valproic acid (VPA), a known GSK3beta inhibitor, was able to attenuate the release of sCD40L in HIV infected individuals receiving EFV, and in isolated human platelets.	efavirenz	249-252	glycogen synthase kinase 3 beta	Homo sapiens	73-81
23349801-6	2013	GFX inhibited FGF-2-induced phosphorylation of glycogen synthase kinase-3beta (GSK-3beta), suggesting that FGF-2 induced PKC and then PKC inhibited the activity of GSK-3beta.	bisindolylmaleimide I	0-3	glycogen synthase kinase 3 beta	Homo sapiens	47-77
23349801-6	2013	GFX inhibited FGF-2-induced phosphorylation of glycogen synthase kinase-3beta (GSK-3beta), suggesting that FGF-2 induced PKC and then PKC inhibited the activity of GSK-3beta.	bisindolylmaleimide I	0-3	glycogen synthase kinase 3 beta	Homo sapiens	79-88
23349801-6	2013	GFX inhibited FGF-2-induced phosphorylation of glycogen synthase kinase-3beta (GSK-3beta), suggesting that FGF-2 induced PKC and then PKC inhibited the activity of GSK-3beta.	bisindolylmaleimide I	0-3	glycogen synthase kinase 3 beta	Homo sapiens	164-173
23194191-3	2012	This work was aimed to evaluate whether histamine improves radiosensitivity of PANC-1 cells in relation to phosphorylation/inhibition of glycogen synthase kinase-3beta (GSK-3beta).	Histamine	40-49	glycogen synthase kinase 3 beta	Homo sapiens	137-167
23225414-5	2012	Inhibition of DUOX by diphenylene iodium (DPI), intracellular calcium chelation and small-interfering RNA (siRNA) resulted in lower ROS levels, lower AKT and glycogen synthase kinase 3beta (GSK3beta) phosphorylation, as well as reduced cell viability and increased susceptibility to apoptosis stimulating fragment (FAS) induced apoptosis.	Calcium	62-69	glycogen synthase kinase 3 beta	Homo sapiens	158-188
23194191-3	2012	This work was aimed to evaluate whether histamine improves radiosensitivity of PANC-1 cells in relation to phosphorylation/inhibition of glycogen synthase kinase-3beta (GSK-3beta).	Histamine	40-49	glycogen synthase kinase 3 beta	Homo sapiens	169-178
23194191-7	2012	An increment in reactive oxygen species levels produced an augmentation in GSK-3beta phosphorylation and suppressed cell proliferation.	Reactive Oxygen Species	16-39	glycogen synthase kinase 3 beta	Homo sapiens	75-84
23194191-8	2012	In both control and histamine-treated irradiated cells, the rise in catalase activity lowered reactive oxygen species levels and only a small increase in phosphorylated GSK-3beta was detected.	Histamine	20-29	glycogen synthase kinase 3 beta	Homo sapiens	169-178
23194191-9	2012	Alternatively, 3-aminotriazole, an irreversible inhibitor of catalase, reduced the survival fraction in irradiated control cells along with an increment in phosphorylated GSK-3beta.	Amitrole	15-30	glycogen synthase kinase 3 beta	Homo sapiens	171-180
23073384-6	2012	Elevated IRS1 (pan-tyr) and GSK3beta (ser-9) phosphorylation were observed in two novel IGF1R variants with receptor L domain mutations.	Serine	38-41	glycogen synthase kinase 3 beta	Homo sapiens	28-36
23054864-7	2012	The results showed breast cancer cells respond in a diverse manner to LiCl, i.e., at lower concentrations (1, 5, and 10 mM), LiCl induces cell survival by inhibiting apoptosis through regulation of GSK-3beta, caspase-2, Bax, and cleaved caspase-7 and by activating anti-apoptotic proteins (Akt, beta-catenin, Bcl-2, and cyclin D1).	Lithium Chloride	70-74	glycogen synthase kinase 3 beta	Homo sapiens	198-207
23054864-7	2012	The results showed breast cancer cells respond in a diverse manner to LiCl, i.e., at lower concentrations (1, 5, and 10 mM), LiCl induces cell survival by inhibiting apoptosis through regulation of GSK-3beta, caspase-2, Bax, and cleaved caspase-7 and by activating anti-apoptotic proteins (Akt, beta-catenin, Bcl-2, and cyclin D1).	Lithium Chloride	125-129	glycogen synthase kinase 3 beta	Homo sapiens	198-207
23054864-2	2012	Lithium chloride (LiCl) is a selective inhibitor of glycogen synthase kinase-3beta (GSK-3beta), a serine/threonine kinase that regulates many cellular processes, in addition to its role in the regulation of glycogen synthase.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	84-93
23054864-2	2012	Lithium chloride (LiCl) is a selective inhibitor of glycogen synthase kinase-3beta (GSK-3beta), a serine/threonine kinase that regulates many cellular processes, in addition to its role in the regulation of glycogen synthase.	Lithium Chloride	18-22	glycogen synthase kinase 3 beta	Homo sapiens	84-93
23099099-0	2012	Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening.	benzothiazepinones	36-54	glycogen synthase kinase 3 beta	Homo sapiens	78-108
23099099-0	2012	Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening.	Adenosine Triphosphate	62-65	glycogen synthase kinase 3 beta	Homo sapiens	78-108
23099099-2	2012	Up to date, most of known inhibitors are bound to the ATP-binding pocket of GSK-3beta, which might lead widespread effects due to the high homology between kinases.	Adenosine Triphosphate	54-57	glycogen synthase kinase 3 beta	Homo sapiens	76-85
23099099-6	2012	Here, we successfully discovered a novel scaffold of benzothiazepinones (BTZs) as selective non-ATP competitive GSK-3beta inhibitors through virtual screening approach.	benzothiazepinones	53-71	glycogen synthase kinase 3 beta	Homo sapiens	112-121
23099099-6	2012	Here, we successfully discovered a novel scaffold of benzothiazepinones (BTZs) as selective non-ATP competitive GSK-3beta inhibitors through virtual screening approach.	btzs	73-77	glycogen synthase kinase 3 beta	Homo sapiens	112-121
23099099-6	2012	Here, we successfully discovered a novel scaffold of benzothiazepinones (BTZs) as selective non-ATP competitive GSK-3beta inhibitors through virtual screening approach.	Adenosine Triphosphate	96-99	glycogen synthase kinase 3 beta	Homo sapiens	112-121
23099099-9	2012	Among them, the representative compound 4j showed activity to GSK-3beta (IC(50): 25 muM) in non-ATP competitive mechanism, and nearly no inhibitory effect on other 10 related protein kinases.	Adenosine Triphosphate	96-99	glycogen synthase kinase 3 beta	Homo sapiens	62-71
23099099-10	2012	Overall, the results point out that BTZ compounds might be useful in treatment of Alzheimer"s disease and diabetes mellitus as novel GSK-3beta inhibitors.	btz	36-39	glycogen synthase kinase 3 beta	Homo sapiens	133-142
22576020-10	2012	Taking also previous studies into account we conclude that activating mutations of the regulatory GSK-3beta phosphorylation sites serine 33 and 37, encoded by CTNNB1 exon 3, rarely occur in parathyroid adenomas from patients with pHPT.	Serine	130-136	glycogen synthase kinase 3 beta	Homo sapiens	98-107
23026078-12	2012	Simvastatin activated Akt and mTOR, inactivated GSK-3beta and dephosphorylated APC in the injured PCNs.	Simvastatin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	48-57
23026078-14	2012	The beneficial effects of simvastatin on neurite outgrowth may be mediated through manipulation of the PI-3K/Akt/mTOR and PI-3K/GSK-3beta/APC pathways.	Simvastatin	26-37	glycogen synthase kinase 3 beta	Homo sapiens	128-137
23176969-2	2012	We have previously shown that cotinine exposure induces convergence and amplification of the GSK3beta-dependent PI3 kinase and cholinergic anti-inflammatory systems.	Cotinine	30-38	glycogen synthase kinase 3 beta	Homo sapiens	93-101
23176396-12	2012	Contrary to expectations, salinomycin induced the expression of EMT markers Snail, vimentin, and Zeb-1, decreased expression of E-cadherin, and also induced phosphorylation of Akt and its downstream targets GSK3-beta and mTOR.	salinomycin	26-37	glycogen synthase kinase 3 beta	Homo sapiens	207-216
23088521-2	2012	This study describes novel azaindolyl-maleimides with significant inhibition of PKs, such as VEGFR, FLT-3, and GSK-3beta which are related to carcinogenesis.	azaindolyl-maleimides	27-48	glycogen synthase kinase 3 beta	Homo sapiens	111-120
22935447-7	2012	Further studies indicated that resveratrol functions downstream of GSK3beta.	Resveratrol	31-42	glycogen synthase kinase 3 beta	Homo sapiens	67-75
22489897-0	2012	Discovery of novel potent and highly selective glycogen synthase kinase-3beta (GSK3beta) inhibitors for Alzheimer"s disease: design, synthesis, and characterization of pyrazines.	Pyrazines	168-177	glycogen synthase kinase 3 beta	Homo sapiens	47-77
22489897-1	2012	Glycogen synthase kinase-3beta, also called tau phosphorylating kinase, is a proline-directed serine/threonine kinase which was originally identified due to its role in glycogen metabolism.	Proline	77-84	glycogen synthase kinase 3 beta	Homo sapiens	0-30
22489897-1	2012	Glycogen synthase kinase-3beta, also called tau phosphorylating kinase, is a proline-directed serine/threonine kinase which was originally identified due to its role in glycogen metabolism.	Serine	94-100	glycogen synthase kinase 3 beta	Homo sapiens	0-30
22489897-1	2012	Glycogen synthase kinase-3beta, also called tau phosphorylating kinase, is a proline-directed serine/threonine kinase which was originally identified due to its role in glycogen metabolism.	Glycogen	169-177	glycogen synthase kinase 3 beta	Homo sapiens	0-30
22775567-6	2012	We also show that the treatment of neurally induced USSCs with BIO (6-bromoindirubin-3"-oxime), a specific GSK-3beta inhibitor and Wnt activator, for 5 and 10 days results in increased expression of a general neuronal marker (beta-tubulin III).	6-bromoindirubin-3'-oxime	68-93	glycogen synthase kinase 3 beta	Homo sapiens	107-116
23098063-4	2012	Initial screening to explorer association of IC(50) values of CDDP obtained by MTT assay and gene expression levels measured with oligonucleotide microarray and real-time RT-PCR provided 6 candidate genes, namely, NUBPL, C9orf30, ZNF12, TMEM158, GSK3B, and FBLP1 using 9 lung cancer cells consisting of 3 small and 6 NSCLC cells.	cddp	62-66	glycogen synthase kinase 3 beta	Homo sapiens	246-251
22992618-4	2012	Moreover, the kinases GSK3beta and mTOR, modulated by PI-3K/Akt, can inhibit NFAT activity, suggesting a cross-talk between the calcium and growth factor signaling pathways.	Calcium	128-135	glycogen synthase kinase 3 beta	Homo sapiens	22-30
22791347-5	2012	As regards the genes that influence the drug"s pharmacodynamics, polymorphisms of SLC6A4, HTR1A and MAO-A seem to be involved in the response to fluoxetine, while the genes COMT, CRHR1, PDEA1, PDEA11 GSK3B and serpin-1 also seem to play a role.	Fluoxetine	145-155	glycogen synthase kinase 3 beta	Homo sapiens	200-205
23098063-4	2012	Initial screening to explorer association of IC(50) values of CDDP obtained by MTT assay and gene expression levels measured with oligonucleotide microarray and real-time RT-PCR provided 6 candidate genes, namely, NUBPL, C9orf30, ZNF12, TMEM158, GSK3B, and FBLP1 using 9 lung cancer cells consisting of 3 small and 6 NSCLC cells.	monooxyethylene trimethylolpropane tristearate	79-82	glycogen synthase kinase 3 beta	Homo sapiens	246-251
23098063-4	2012	Initial screening to explorer association of IC(50) values of CDDP obtained by MTT assay and gene expression levels measured with oligonucleotide microarray and real-time RT-PCR provided 6 candidate genes, namely, NUBPL, C9orf30, ZNF12, TMEM158, GSK3B, and FBLP1 using 9 lung cancer cells consisting of 3 small and 6 NSCLC cells.	Oligonucleotides	130-145	glycogen synthase kinase 3 beta	Homo sapiens	246-251
22964853-6	2012	17AAG inhibited TGF-beta1-mediated phosphorylation of Smad2, Akt, glycogen synthase kinase-3beta, and extracellular signal-regulated kinase in HK2 cells.	tanespimycin	0-5	glycogen synthase kinase 3 beta	Homo sapiens	66-96
23248400-2	2012	This study sought to determine the usefulness of lithium chloride (LiCl) as a highly selective inhibitor of GSK-3beta to increase the sensitivity of LNCap cells to doxorubicin (Dox), etoposide (Eto), and vinblastine (Vin) drugs.	Lithium Chloride	49-65	glycogen synthase kinase 3 beta	Homo sapiens	108-117
23248400-2	2012	This study sought to determine the usefulness of lithium chloride (LiCl) as a highly selective inhibitor of GSK-3beta to increase the sensitivity of LNCap cells to doxorubicin (Dox), etoposide (Eto), and vinblastine (Vin) drugs.	Lithium Chloride	67-71	glycogen synthase kinase 3 beta	Homo sapiens	108-117
23248400-2	2012	This study sought to determine the usefulness of lithium chloride (LiCl) as a highly selective inhibitor of GSK-3beta to increase the sensitivity of LNCap cells to doxorubicin (Dox), etoposide (Eto), and vinblastine (Vin) drugs.	Doxorubicin	164-175	glycogen synthase kinase 3 beta	Homo sapiens	108-117
23248400-2	2012	This study sought to determine the usefulness of lithium chloride (LiCl) as a highly selective inhibitor of GSK-3beta to increase the sensitivity of LNCap cells to doxorubicin (Dox), etoposide (Eto), and vinblastine (Vin) drugs.	Doxorubicin	177-180	glycogen synthase kinase 3 beta	Homo sapiens	108-117
23248400-2	2012	This study sought to determine the usefulness of lithium chloride (LiCl) as a highly selective inhibitor of GSK-3beta to increase the sensitivity of LNCap cells to doxorubicin (Dox), etoposide (Eto), and vinblastine (Vin) drugs.	Etoposide	194-197	glycogen synthase kinase 3 beta	Homo sapiens	108-117
23248400-2	2012	This study sought to determine the usefulness of lithium chloride (LiCl) as a highly selective inhibitor of GSK-3beta to increase the sensitivity of LNCap cells to doxorubicin (Dox), etoposide (Eto), and vinblastine (Vin) drugs.	Vinblastine	204-215	glycogen synthase kinase 3 beta	Homo sapiens	108-117
22740511-11	2012	Moreover, LiCl and SB216763, inhibitors of GSK-3beta augmented cell migration as well as fascin-1 mRNA expression.	Lithium Chloride	10-14	glycogen synthase kinase 3 beta	Homo sapiens	43-52
22740511-11	2012	Moreover, LiCl and SB216763, inhibitors of GSK-3beta augmented cell migration as well as fascin-1 mRNA expression.	SB 216763	19-27	glycogen synthase kinase 3 beta	Homo sapiens	43-52
22678744-4	2012	In addition, caudatin treatment resulted in a decrease of beta-catenin and increase of phosphorylation of beta-catenin, and inhibited phosphorylation levels of GSK3beta (Ser 9) in A549 cells.	Serine	170-173	glycogen synthase kinase 3 beta	Homo sapiens	160-168
22999562-6	2012	LiCl treatment significantly affected cell morphology of U87MG and U87MG.Delta2-7 cells, while also increasing levels of phospho-GSK-3beta in a dose-dependent manner.	Lithium Chloride	0-4	glycogen synthase kinase 3 beta	Homo sapiens	129-138
22999562-9	2012	We have shown in this study that GSK-3beta regulation by phosphorylation is important for cell morphology and growth, and that LiCl enhances growth of U87MG and U87MG.Delta2-7 cells by inhibiting GSK-3beta through its phosphorylation, whereas AktX reduces growth via activation of GSK-3beta by inhibiting Akt"s kinase activity.	Lithium Chloride	127-131	glycogen synthase kinase 3 beta	Homo sapiens	196-205
22999562-9	2012	We have shown in this study that GSK-3beta regulation by phosphorylation is important for cell morphology and growth, and that LiCl enhances growth of U87MG and U87MG.Delta2-7 cells by inhibiting GSK-3beta through its phosphorylation, whereas AktX reduces growth via activation of GSK-3beta by inhibiting Akt"s kinase activity.	Lithium Chloride	127-131	glycogen synthase kinase 3 beta	Homo sapiens	196-205
23002080-0	2012	Circadian gating of epithelial-to-mesenchymal transition in breast cancer cells via melatonin-regulation of GSK3beta.	Melatonin	84-93	glycogen synthase kinase 3 beta	Homo sapiens	108-116
23002080-4	2012	Melatonin activates GSK3beta by inhibiting the serine-threonine kinase Akt phosphorylation, inducing beta-catenin degradation and inhibiting epithelial-to-mesenchymal transition, a fundamental process underlying cancer metastasis.	Melatonin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	20-28
22964364-2	2012	Lithium chloride (LiCl) has been considered to be a potent inhibitor of glycogen synthase kinase-3beta (GSK-3beta), a serine/threonine kinase that is involved in the control of cell proliferation, differentiation, and apoptosis.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	72-102
22872488-3	2012	Glycogen synthase kinase 3beta (GSK-3beta) inhibitors, SB216763 and lithium chloride (LiCl), were used to activate WNT/beta-catenin-signaling pathway.	SB 216763	55-63	glycogen synthase kinase 3 beta	Homo sapiens	0-30
22872488-3	2012	Glycogen synthase kinase 3beta (GSK-3beta) inhibitors, SB216763 and lithium chloride (LiCl), were used to activate WNT/beta-catenin-signaling pathway.	SB 216763	55-63	glycogen synthase kinase 3 beta	Homo sapiens	32-41
22872488-3	2012	Glycogen synthase kinase 3beta (GSK-3beta) inhibitors, SB216763 and lithium chloride (LiCl), were used to activate WNT/beta-catenin-signaling pathway.	Lithium Chloride	68-84	glycogen synthase kinase 3 beta	Homo sapiens	0-30
22872488-3	2012	Glycogen synthase kinase 3beta (GSK-3beta) inhibitors, SB216763 and lithium chloride (LiCl), were used to activate WNT/beta-catenin-signaling pathway.	Lithium Chloride	68-84	glycogen synthase kinase 3 beta	Homo sapiens	32-41
22872488-3	2012	Glycogen synthase kinase 3beta (GSK-3beta) inhibitors, SB216763 and lithium chloride (LiCl), were used to activate WNT/beta-catenin-signaling pathway.	Lithium Chloride	86-90	glycogen synthase kinase 3 beta	Homo sapiens	0-30
22872488-3	2012	Glycogen synthase kinase 3beta (GSK-3beta) inhibitors, SB216763 and lithium chloride (LiCl), were used to activate WNT/beta-catenin-signaling pathway.	Lithium Chloride	86-90	glycogen synthase kinase 3 beta	Homo sapiens	32-41
22964364-2	2012	Lithium chloride (LiCl) has been considered to be a potent inhibitor of glycogen synthase kinase-3beta (GSK-3beta), a serine/threonine kinase that is involved in the control of cell proliferation, differentiation, and apoptosis.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	104-113
22964364-2	2012	Lithium chloride (LiCl) has been considered to be a potent inhibitor of glycogen synthase kinase-3beta (GSK-3beta), a serine/threonine kinase that is involved in the control of cell proliferation, differentiation, and apoptosis.	Lithium Chloride	18-22	glycogen synthase kinase 3 beta	Homo sapiens	72-102
22964364-2	2012	Lithium chloride (LiCl) has been considered to be a potent inhibitor of glycogen synthase kinase-3beta (GSK-3beta), a serine/threonine kinase that is involved in the control of cell proliferation, differentiation, and apoptosis.	Lithium Chloride	18-22	glycogen synthase kinase 3 beta	Homo sapiens	104-113
22972931-0	2012	Regulation of inflammatory response by 3-methyladenine involves the coordinative actions on Akt and glycogen synthase kinase 3beta rather than autophagy.	3-methyladenine	39-54	glycogen synthase kinase 3 beta	Homo sapiens	100-130
22972931-7	2012	As glycogen synthase kinase 3beta (GSK3beta) is an important Akt substrate, we further explored its involvement in the actions of 3-MA.	3-methyladenine	130-134	glycogen synthase kinase 3 beta	Homo sapiens	3-33
22972931-7	2012	As glycogen synthase kinase 3beta (GSK3beta) is an important Akt substrate, we further explored its involvement in the actions of 3-MA.	3-methyladenine	130-134	glycogen synthase kinase 3 beta	Homo sapiens	35-43
22972931-8	2012	3-MA was found to enhance LPS-induced NF-kappaB activation, iNOS, and pro-IL-1beta expression, and these actions were reversed by either GSK3beta inhibitors or small interfering GSK3beta.	3-methyladenine	0-4	glycogen synthase kinase 3 beta	Homo sapiens	137-145
22972931-8	2012	3-MA was found to enhance LPS-induced NF-kappaB activation, iNOS, and pro-IL-1beta expression, and these actions were reversed by either GSK3beta inhibitors or small interfering GSK3beta.	3-methyladenine	0-4	glycogen synthase kinase 3 beta	Homo sapiens	178-186
23104438-7	2012	Furthermore, in transient transfection assays, the Kap beta2 binding site mutant induced a substantial reduction in the in vivo serine/threonine phosphorylation of GSK-3beta, where- as the GSK-3beta wild type did not.	Serine	128-134	glycogen synthase kinase 3 beta	Homo sapiens	164-173
22863953-2	2012	We demonstrated previously that GSK3beta inhibition in human brain microvascular endothelial cells (BMVECs) reduced monocyte adhesion/migration across BMVEC monolayers.	bmvec	100-105	glycogen synthase kinase 3 beta	Homo sapiens	32-40
22766766-5	2012	In addition, angelicin dose-dependently downregulated the expression of anti-apoptotic proteins including Bcl-2, Bcl-xL, and Mcl-1 suggesting the involvement of the intrinsic mitochondria-mediated apoptotic pathway which did not participate in Fas/FasL-induced caspase-8-mediated extrinsic, MAP kinases, and PI3K/AKT/GSK-3beta pathway.	angelicin	13-22	glycogen synthase kinase 3 beta	Homo sapiens	317-326
22884995-0	2012	Cadmium induces carcinogenesis in BEAS-2B cells through ROS-dependent activation of PI3K/AKT/GSK-3beta/beta-catenin signaling.	Cadmium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	93-102
22884995-0	2012	Cadmium induces carcinogenesis in BEAS-2B cells through ROS-dependent activation of PI3K/AKT/GSK-3beta/beta-catenin signaling.	Reactive Oxygen Species	56-59	glycogen synthase kinase 3 beta	Homo sapiens	93-102
22884995-8	2012	In particular, chronic cadmium exposure led to activation of signaling cascades involving PI3K, AKT, GSK-3beta, and beta-catenin and transfection with each of the above antioxidant enzymes markedly inhibited cadmium-mediated activation of these signaling proteins.	Cadmium	23-30	glycogen synthase kinase 3 beta	Homo sapiens	101-110
22266849-8	2012	Our mechanistic investigations reveal that DNAJB6 binds HSPA8 (heat-shock cognate protein, HSC70) and causes dephosphorylation of glycogen synthase kinase 3beta (GSK3beta) at Ser 9 by recruiting protein phosphatase, PP2A.	Serine	175-178	glycogen synthase kinase 3 beta	Homo sapiens	130-160
22266849-8	2012	Our mechanistic investigations reveal that DNAJB6 binds HSPA8 (heat-shock cognate protein, HSC70) and causes dephosphorylation of glycogen synthase kinase 3beta (GSK3beta) at Ser 9 by recruiting protein phosphatase, PP2A.	Serine	175-178	glycogen synthase kinase 3 beta	Homo sapiens	162-170
22736200-12	2012	Stabilization of glycogen synthase kinase 3beta phosphorylated at Ser(9) , beta-catenin, T cell factor 4, and ERK signaling attenuated Dkk-1 up-regulation of angiogenic factor and proteinase expression in synovial fibroblasts.	Serine	66-69	glycogen synthase kinase 3 beta	Homo sapiens	17-47
23104438-7	2012	Furthermore, in transient transfection assays, the Kap beta2 binding site mutant induced a substantial reduction in the in vivo serine/threonine phosphorylation of GSK-3beta, where- as the GSK-3beta wild type did not.	Threonine	135-144	glycogen synthase kinase 3 beta	Homo sapiens	164-173
22658982-2	2012	Recent studies have suggested the involvement of GSK-3beta in the pathogenesis and treatment target of DA-associated neuropsychiatric disorders, which has led to consider GSK-beta as one of the candidate genes for those disorders.	-beta	174-179	glycogen synthase kinase 3 beta	Homo sapiens	49-58
22410463-0	2012	Gambogenic acid induces G1 arrest via GSK3beta-dependent cyclin D1 degradation and triggers autophagy in lung cancer cells.	neo-gambogic acid	0-15	glycogen synthase kinase 3 beta	Homo sapiens	38-46
22922102-0	2012	Glycogen synthase kinase-3beta activation mediates rotenone-induced cytotoxicity with the involvement of microtubule destabilization.	Rotenone	51-59	glycogen synthase kinase 3 beta	Homo sapiens	0-30
22820424-9	2012	When cells were pre-treated with LiCl, the inhibitor of GSK-3beta, the decrease of cyclin D1 was blocked and the reduction of pRb was recovered.	Lithium Chloride	33-37	glycogen synthase kinase 3 beta	Homo sapiens	56-65
22922102-3	2012	In this study, we investigated glycogen synthase kinase-3beta (GSK3beta) involvement in rotenone-induced microtubule destabilization.	Rotenone	88-96	glycogen synthase kinase 3 beta	Homo sapiens	31-61
22922102-3	2012	In this study, we investigated glycogen synthase kinase-3beta (GSK3beta) involvement in rotenone-induced microtubule destabilization.	Rotenone	88-96	glycogen synthase kinase 3 beta	Homo sapiens	63-71
22922102-4	2012	Rotenone-induced cytotoxicity in SH-SY5Y cells was attenuated by the GSK3beta inhibitor SB216763.	Rotenone	0-8	glycogen synthase kinase 3 beta	Homo sapiens	69-77
22922102-4	2012	Rotenone-induced cytotoxicity in SH-SY5Y cells was attenuated by the GSK3beta inhibitor SB216763.	SB 216763	88-96	glycogen synthase kinase 3 beta	Homo sapiens	69-77
22922102-12	2012	Taken together, these results suggest that rotenone-induced cytotoxicity is mediated by microtubule destabilization via GSK3beta activation, and that microtubule destabilization is caused by reduction in the binding capacity of tau to microtubules, which is a result of tau phosphorylation via GSK3beta activation.	Rotenone	43-51	glycogen synthase kinase 3 beta	Homo sapiens	120-128
22922102-12	2012	Taken together, these results suggest that rotenone-induced cytotoxicity is mediated by microtubule destabilization via GSK3beta activation, and that microtubule destabilization is caused by reduction in the binding capacity of tau to microtubules, which is a result of tau phosphorylation via GSK3beta activation.	Rotenone	43-51	glycogen synthase kinase 3 beta	Homo sapiens	294-302
22771471-9	2012	Moreover, oxidative stress facilitated Fyn phosphorylation with repression of AMPKalpha and GSK3beta phosphorylation, which was abolished by kazinol E treatment.	Kazinol E	141-150	glycogen synthase kinase 3 beta	Homo sapiens	92-100
22773696-8	2012	Furthermore, transduction of MSCs with DeltaN-catenin, a truncation mutant that cannot be phosphorylated on the NH(2) terminus by GSK-3beta and is not degraded, was sufficient for myofibroblastic differentiation.	deltan-catenin	39-53	glycogen synthase kinase 3 beta	Homo sapiens	130-139
22814751-0	2012	ADP-stimulated activation of Akt during integrin outside-in signaling promotes platelet spreading by inhibiting glycogen synthase kinase-3beta.	Adenosine Diphosphate	0-3	glycogen synthase kinase 3 beta	Homo sapiens	112-142
22778223-8	2012	After 7 d of differentiation induced by 6-bromoindirubin-3"-oxime (a glycogen synthase kinase-3beta inhibitor), the human ES/iPS cells had differentiated into fetal liver kinase-1- and platelet derived growth factor receptor-alpha-expressing mesodermal lineage cells.	6-bromoindirubin-3'-oxime	40-65	glycogen synthase kinase 3 beta	Homo sapiens	69-99
22707636-5	2012	In addition, TNF-alpha treatment inhibited glycogen synthase kinase 3beta (GSK-3beta) activity through serine-9 phosphorylation mediated by the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway in RCC cells.	Serine	103-109	glycogen synthase kinase 3 beta	Homo sapiens	43-73
22771494-6	2012	Knockdown of GSK3beta but not GSK3alpha reduced endogenous GILZ induction in response to dexamethasone and GR-dependent reporter gene activity.	Dexamethasone	89-102	glycogen synthase kinase 3 beta	Homo sapiens	13-21
22800848-5	2012	An intrahippocampal injection of the GSK-3beta inhibitor, SB 216763, before the retention session blocked memory retrieval (but not reconsolidation) without affecting locomotor activity.	SB 216763	58-67	glycogen synthase kinase 3 beta	Homo sapiens	37-46
22710837-10	2012	Our results indicate             that AD-PTEN sensitization of breast cancer to LY294002 is achieved by increased             GSK-3beta activity, thus resulting in inhibition of the beta-catenin signaling pathway.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	80-88	glycogen synthase kinase 3 beta	Homo sapiens	126-135
22683934-0	2012	Inhibition of GSK-3beta reverses the pro-apoptotic effect of proadifen (SKF-525A) in HT-29 colon adenocarcinoma cells.	Proadifen	61-70	glycogen synthase kinase 3 beta	Homo sapiens	14-23
22683934-0	2012	Inhibition of GSK-3beta reverses the pro-apoptotic effect of proadifen (SKF-525A) in HT-29 colon adenocarcinoma cells.	Proadifen	72-80	glycogen synthase kinase 3 beta	Homo sapiens	14-23
22683934-8	2012	In contrast, we found that AR-A014418, the specific inhibitor of glycogen synthase kinase-3 beta (GSK-3beta), significantly decreased proadifen-induced apoptosis.	N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea	27-37	glycogen synthase kinase 3 beta	Homo sapiens	98-107
22683934-8	2012	In contrast, we found that AR-A014418, the specific inhibitor of glycogen synthase kinase-3 beta (GSK-3beta), significantly decreased proadifen-induced apoptosis.	Proadifen	134-143	glycogen synthase kinase 3 beta	Homo sapiens	98-107
22683934-9	2012	Inactivation of GSK-3beta (phosphorylation at serine 9) resulted in changes in phosphatidylserine externalization and caspase-3 activation.	Serine	46-52	glycogen synthase kinase 3 beta	Homo sapiens	16-25
22683934-10	2012	These data suggest that GSK-3beta is an important factor in the induction of apoptosis in HT-29 colon cancer cells treated with proadifen.	Proadifen	128-137	glycogen synthase kinase 3 beta	Homo sapiens	24-33
22685298-4	2012	Ser-1248 phosphorylation is mediated by GSK-3beta in a mechanism that involves a priming phosphorylation on Ser-1252.	Serine	0-3	glycogen synthase kinase 3 beta	Homo sapiens	40-49
22685298-4	2012	Ser-1248 phosphorylation is mediated by GSK-3beta in a mechanism that involves a priming phosphorylation on Ser-1252.	Serine	108-111	glycogen synthase kinase 3 beta	Homo sapiens	40-49
22179823-6	2012	Using a selective inhibitor of ALK, we demonstrated that the tyrosine kinase activity of ALK regulates the serine-9 phosphorylation of GSK3beta.	Serine	107-113	glycogen synthase kinase 3 beta	Homo sapiens	135-143
22622071-3	2012	The aim of the present study was to investigate the effect of short-and long-term sertraline treatment on the expression and phosphorylation of GSK3B in platelets of patients with late-life major depression.	Sertraline	82-92	glycogen synthase kinase 3 beta	Homo sapiens	144-149
22622071-6	2012	The expression of total and Ser-9 phosphorylated GSK3B (pGSK3B) was determined by Enzyme Immunometric Assay (EIA) in platelets of patients and controls at baseline, and after 3 and 12 months of sertraline treatments for patients only.	Serine	28-31	glycogen synthase kinase 3 beta	Homo sapiens	49-54
22622071-8	2012	GSK3B activity was indirectly estimated by calculating the proportion of inactive (phosphorylated) forms (pGSK3B) in relation to the total expression of the enzyme (i.e., GSK3B ratio).	pgsk3b	106-112	glycogen synthase kinase 3 beta	Homo sapiens	0-5
22622071-12	2012	CONCLUSIONS: Our findings indicate that GSK3B expression was upregulated by the continuous treatment with sertraline, along with an increment in the proportion of active forms of the enzyme.	Sertraline	106-116	glycogen synthase kinase 3 beta	Homo sapiens	40-45
22622071-13	2012	This is compatible with an increase in overall GSK3B activity, which may have been induced by the long-term treatment of late-life depression with sertraline.	Sertraline	147-157	glycogen synthase kinase 3 beta	Homo sapiens	47-52
22553359-6	2012	Of more importance, DC120 partially attenuated the phosphorylation levels of forkhead transcription factor (FKHR), FKHRL1, glycogen synthase kinase 3beta, and mammalian target of rapamycin in a dose-dependent and time-dependent fashion and led to an increase in the nuclear accumulation of exogenous FKHR in cancer cells.	N-(1-amino-3-(2,4-dichlorophenyl)propan-2-yl)-2-(2-(methylamino)pyrimidin-4-yl)thiazole-5-carboxamide	20-25	glycogen synthase kinase 3 beta	Homo sapiens	123-153
22700489-9	2012	Prominent rescue was also observed by inhibitors of GSK-3beta (e.g. GSK-3beta Inhibitor II and Kenpaullone).	kenpaullone	95-106	glycogen synthase kinase 3 beta	Homo sapiens	52-61
22847216-4	2012	Immunoblot experiments with P19 cells revealed that the mitogen activated protein kinases, including p-ERK, p38, pAKT, glycogen synthase kinase 3beta, and CREB were phosphorylated by treatment with 10 muM LPA.	lysophosphatidic acid	205-208	glycogen synthase kinase 3 beta	Homo sapiens	119-149
22372491-10	2012	Furthermore, prodigiosin induced PKB dephosphorylation, leading to PKB inhibition as revealed by decreased serine 9 phosphorylation of GSK-3beta.	Prodigiosin	13-24	glycogen synthase kinase 3 beta	Homo sapiens	135-144
22372491-14	2012	Mechanistically, prodigiosin induces PKB inhibition to down-regulate SKP2 in a GSK-3beta- and E2F1-independent manner.	Prodigiosin	17-28	glycogen synthase kinase 3 beta	Homo sapiens	79-98
22532441-10	2012	Treatment of FIH-1-transduced HCEKs with either a myristolated Akt or a GSK-3beta inhibitor restored glycogen stores, confirming the direct involvement of Akt/GSK-3beta signaling.	Glycogen	101-109	glycogen synthase kinase 3 beta	Homo sapiens	72-81
22707636-5	2012	In addition, TNF-alpha treatment inhibited glycogen synthase kinase 3beta (GSK-3beta) activity through serine-9 phosphorylation mediated by the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway in RCC cells.	Serine	103-109	glycogen synthase kinase 3 beta	Homo sapiens	75-84
22507665-3	2012	Lithium inhibits glycogen synthase kinase-3beta (GSK-3beta), which is involved in the regulation of synaptic plasticity.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	17-47
22507665-3	2012	Lithium inhibits glycogen synthase kinase-3beta (GSK-3beta), which is involved in the regulation of synaptic plasticity.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	49-58
22507665-4	2012	In animal preparations, inhibition of GSK-3beta by lithium up-regulated long-term potentiation (LTP) of excitatory synapses but down-regulated long-term depression (LTD).	Lithium	51-58	glycogen synthase kinase 3 beta	Homo sapiens	38-47
22634399-5	2012	Our results showed that ebselen decreased iron influx, reduced iron-induced ROS production, inhibited the activities of cyclin-dependent kinase 5 and glycogen synthase kinase 3beta, and ultimately attenuated the levels of tau phosphorylation at the sites of Thr205, Ser396 and Thr231.	ebselen	24-31	glycogen synthase kinase 3 beta	Homo sapiens	150-180
22707636-6	2012	Inhibition of PI3K/AKT by LY294002 reactivated GSK-3beta and suppressed the TNF-alpha-induced EMT of RCC cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	26-34	glycogen synthase kinase 3 beta	Homo sapiens	47-56
22683349-8	2012	Guanosine increased Akt and p-Ser-9-GSK-3beta phosphorylation confirming this pathway plays a key role in guanosine"s neuroprotective effect.	Guanosine	0-9	glycogen synthase kinase 3 beta	Homo sapiens	36-45
22683349-0	2012	Guanosine protects human neuroblastoma SH-SY5Y cells against mitochondrial oxidative stress by inducing heme oxigenase-1 via PI3K/Akt/GSK-3beta pathway.	Guanosine	0-9	glycogen synthase kinase 3 beta	Homo sapiens	134-143
22507665-13	2012	The switch from LTD- to LTP-like plasticity is best explained by the inhibitory action of lithium on GSK-3beta.	Lithium	90-97	glycogen synthase kinase 3 beta	Homo sapiens	101-110
22683349-8	2012	Guanosine increased Akt and p-Ser-9-GSK-3beta phosphorylation confirming this pathway plays a key role in guanosine"s neuroprotective effect.	Guanosine	106-115	glycogen synthase kinase 3 beta	Homo sapiens	36-45
22683349-12	2012	In conclusion, our results show that guanosine can afford protection against mitochondrial oxidative stress by a signaling pathway that implicates PI3K/Akt/GSK-3beta proteins and induction of the antioxidant enzyme HO-1.	Guanosine	37-46	glycogen synthase kinase 3 beta	Homo sapiens	156-165
23248963-13	2012	Cells in SB415286 (glycogen synthase kinase-3beta inhibitor) group were cultured with nutrient solution containing 10 micromol/L SB415286 (the same concentration for following experiments).	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	9-17	glycogen synthase kinase 3 beta	Homo sapiens	19-49
22941694-8	2012	Different concentrations of GSK-3beta inhibitor lithion chloride were used to treat the cell lines and Snail expression was significantly up-regulated in a dose-dependent manner (P&lt;0.01).	lithion chloride	48-64	glycogen synthase kinase 3 beta	Homo sapiens	28-37
22676038-6	2012	GSK-3beta inhibitors completely blocked high-dose (20 muM) DA-induced depressive effects on IPSCs but exhibited limited effects on the facilitating regulation of IPSC in low-dose DA (200 nM).	Dopamine	59-61	glycogen synthase kinase 3 beta	Homo sapiens	0-9
22732552-0	2012	Glycogen synthase kinase-3beta regulates leucine-309 demethylation of protein phosphatase-2A via PPMT1 and PME-1.	Leucine	41-48	glycogen synthase kinase 3 beta	Homo sapiens	0-30
22705730-0	2012	Atorvastatin enhances neurite outgrowth in cortical neurons in vitro via up-regulating the Akt/mTOR and Akt/GSK-3beta signaling pathways.	Atorvastatin	0-12	glycogen synthase kinase 3 beta	Homo sapiens	108-117
22705730-12	2012	In addition, atorvastatin (10 mumol/L) significantly increased the phosphorylated GSK-3beta level in the cortical neurons, which was prevented by both LY294002 and tricribine.	Atorvastatin	13-25	glycogen synthase kinase 3 beta	Homo sapiens	82-91
22705730-12	2012	In addition, atorvastatin (10 mumol/L) significantly increased the phosphorylated GSK-3beta level in the cortical neurons, which was prevented by both LY294002 and tricribine.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	151-159	glycogen synthase kinase 3 beta	Homo sapiens	82-91
22705730-12	2012	In addition, atorvastatin (10 mumol/L) significantly increased the phosphorylated GSK-3beta level in the cortical neurons, which was prevented by both LY294002 and tricribine.	tricribine	164-174	glycogen synthase kinase 3 beta	Homo sapiens	82-91
22705730-13	2012	CONCLUSION: These results suggest that activation of both the PI3K/Akt/mTOR and Akt/GSK-3beta signaling pathways is responsible for the atorvastatin-induced neurite outgrowth in cultured cortical neurons.	Atorvastatin	136-148	glycogen synthase kinase 3 beta	Homo sapiens	84-93
21912861-3	2012	Herein, molecular dynamics simulation, molecular mechanics generalized Born/surface area (MM_GBSA) calculation, and normal mode analysis are performed to explore the structural influence of the double mutations K214/A-E215/Q of FRATide on the GSK3beta-FRATide complex.	Fratide	228-235	glycogen synthase kinase 3 beta	Homo sapiens	243-251
21912861-4	2012	The results reveal that the priming phosphate-binding site, the primed substrate-binding site, the alignment of the critical active site residues in the ATP-binding site, as well as the periodic open-closed conformational change of the ATP-binding site, which are critical for the catalytic activity of GSK3beta, are negligibly influenced in the mutated system compared with the wild-type (WT) system.	Phosphates	36-45	glycogen synthase kinase 3 beta	Homo sapiens	303-311
21912861-4	2012	The results reveal that the priming phosphate-binding site, the primed substrate-binding site, the alignment of the critical active site residues in the ATP-binding site, as well as the periodic open-closed conformational change of the ATP-binding site, which are critical for the catalytic activity of GSK3beta, are negligibly influenced in the mutated system compared with the wild-type (WT) system.	Adenosine Triphosphate	153-156	glycogen synthase kinase 3 beta	Homo sapiens	303-311
21912861-4	2012	The results reveal that the priming phosphate-binding site, the primed substrate-binding site, the alignment of the critical active site residues in the ATP-binding site, as well as the periodic open-closed conformational change of the ATP-binding site, which are critical for the catalytic activity of GSK3beta, are negligibly influenced in the mutated system compared with the wild-type (WT) system.	Adenosine Triphosphate	236-239	glycogen synthase kinase 3 beta	Homo sapiens	303-311
22530628-6	2012	In AD, cotinine"s positive effect on memory is associated with the inhibition of Abeta aggregation, the stimulation of pro-survival factors such as Akt, and the inhibition of pro-apoptotic factors such as glycogen synthase kinase 3 beta (GSK3beta).	Cotinine	7-15	glycogen synthase kinase 3 beta	Homo sapiens	205-236
22676038-11	2012	The GSK-3beta signaling pathway is involved in DA-induced decrease in BIG2-dependent insertion and an increase in the dynamin-dependent internalization of GABAA receptors, which results in suppression of inhibitory synaptic transmission.	Dopamine	47-49	glycogen synthase kinase 3 beta	Homo sapiens	4-13
22547681-6	2012	The other subset of miR-519 target mRNAs encoded proteins that control intracellular calcium levels (notably, ATP2C1 and ORAI1); their downregulation by miR-519 aberrantly elevated levels of cytosolic [Ca(2+)] storage in HeLa cells, similarly increasing p21 levels in a manner dependent on the Ca(2+)-activated kinases CaMKII and GSK3beta.	Calcium	85-92	glycogen synthase kinase 3 beta	Homo sapiens	330-338
22514281-6	2012	Inhibition of GSK3beta by inhibitor SB216763 or down-regulation of GSK3beta by RNAi reduced the antiviral activity of ZAP.	SB 216763	36-44	glycogen synthase kinase 3 beta	Homo sapiens	14-22
22586270-4	2012	This process is further regulated by phosphorylation of additional adjacent serine residues by glycogen synthase kinase 3beta (GSK3beta), which maximizes ERbeta sumoylation in response to hormone.	Serine	76-82	glycogen synthase kinase 3 beta	Homo sapiens	95-125
22586270-4	2012	This process is further regulated by phosphorylation of additional adjacent serine residues by glycogen synthase kinase 3beta (GSK3beta), which maximizes ERbeta sumoylation in response to hormone.	Serine	76-82	glycogen synthase kinase 3 beta	Homo sapiens	127-135
22447231-10	2012	The resulting activation of AKT (phosphoSer473) also plays             a role as a central enhancer in glycogen synthesis through suppression of GSK3beta             via phosphorylation at Ser9.	phosphoser473	33-46	glycogen synthase kinase 3 beta	Homo sapiens	145-153
22496446-1	2012	Glycogen synthase kinase-3beta (GSK-3beta), a key regulator of neuronal apoptosis, is inhibited by the phosphorylation of Ser-9/Ser-389 and was recently shown to be cleaved by calpain at the N terminus, leading to its subsequent activation.	Serine	122-125	glycogen synthase kinase 3 beta	Homo sapiens	0-30
22496446-1	2012	Glycogen synthase kinase-3beta (GSK-3beta), a key regulator of neuronal apoptosis, is inhibited by the phosphorylation of Ser-9/Ser-389 and was recently shown to be cleaved by calpain at the N terminus, leading to its subsequent activation.	Serine	122-125	glycogen synthase kinase 3 beta	Homo sapiens	32-41
22496446-1	2012	Glycogen synthase kinase-3beta (GSK-3beta), a key regulator of neuronal apoptosis, is inhibited by the phosphorylation of Ser-9/Ser-389 and was recently shown to be cleaved by calpain at the N terminus, leading to its subsequent activation.	Serine	128-131	glycogen synthase kinase 3 beta	Homo sapiens	0-30
22496446-1	2012	Glycogen synthase kinase-3beta (GSK-3beta), a key regulator of neuronal apoptosis, is inhibited by the phosphorylation of Ser-9/Ser-389 and was recently shown to be cleaved by calpain at the N terminus, leading to its subsequent activation.	Serine	128-131	glycogen synthase kinase 3 beta	Homo sapiens	32-41
22496446-2	2012	In this study calpain was found to cleave GSK-3beta not only at the N terminus but also at the C terminus, and cleavage sites were identified at residues Thr-38-Thr-39 and Ile-384-Gln-385.	Threonine	154-157	glycogen synthase kinase 3 beta	Homo sapiens	42-51
22496446-2	2012	In this study calpain was found to cleave GSK-3beta not only at the N terminus but also at the C terminus, and cleavage sites were identified at residues Thr-38-Thr-39 and Ile-384-Gln-385.	Threonine	161-164	glycogen synthase kinase 3 beta	Homo sapiens	42-51
22496446-2	2012	In this study calpain was found to cleave GSK-3beta not only at the N terminus but also at the C terminus, and cleavage sites were identified at residues Thr-38-Thr-39 and Ile-384-Gln-385.	Isoleucine	172-175	glycogen synthase kinase 3 beta	Homo sapiens	42-51
22496446-2	2012	In this study calpain was found to cleave GSK-3beta not only at the N terminus but also at the C terminus, and cleavage sites were identified at residues Thr-38-Thr-39 and Ile-384-Gln-385.	Glutamine	180-183	glycogen synthase kinase 3 beta	Homo sapiens	42-51
22496446-3	2012	Furthermore, the cleavage of GSK-3beta occurred in tandem with Ser-9 dephosphorylation during cerebellar granule neuron apoptosis.	Serine	63-66	glycogen synthase kinase 3 beta	Homo sapiens	29-38
22496446-4	2012	Increasing Ser-9 phosphorylation of GSK-3beta by inhibiting phosphatase 1/2A or pretreating with purified active Akt inhibited calpain-mediated cleavage of GSK-3beta at both N and C termini, whereas non-phosphorylatable mutant GSK-3beta S9A facilitated its cleavage.	Serine	11-14	glycogen synthase kinase 3 beta	Homo sapiens	36-45
22496446-4	2012	Increasing Ser-9 phosphorylation of GSK-3beta by inhibiting phosphatase 1/2A or pretreating with purified active Akt inhibited calpain-mediated cleavage of GSK-3beta at both N and C termini, whereas non-phosphorylatable mutant GSK-3beta S9A facilitated its cleavage.	Serine	11-14	glycogen synthase kinase 3 beta	Homo sapiens	156-165
22496446-4	2012	Increasing Ser-9 phosphorylation of GSK-3beta by inhibiting phosphatase 1/2A or pretreating with purified active Akt inhibited calpain-mediated cleavage of GSK-3beta at both N and C termini, whereas non-phosphorylatable mutant GSK-3beta S9A facilitated its cleavage.	Serine	11-14	glycogen synthase kinase 3 beta	Homo sapiens	156-165
22496446-5	2012	In contrast, Ser-389 phosphorylation selectively inhibited the cleavage of GSK-3beta at the C terminus but not the N terminus.	Serine	13-16	glycogen synthase kinase 3 beta	Homo sapiens	75-84
22496446-9	2012	Taken together, these findings demonstrate that calpain-mediated cleavage activates GSK-3beta by removing its N- and C-terminal autoinhibitory domains and that Ser-9 phosphorylation inhibits the cleavage of GSK-3beta at both termini.	Serine	160-163	glycogen synthase kinase 3 beta	Homo sapiens	207-216
23359767-1	2012	OBJECTIVE: To explore the effects and mechanism of glycogen synthase kinase 3beta (GSK-3beta) inhibitor (2"Z,3"E)-6-bromo-indirubin-3"-oxime (BIO) on drug resistance in colon cancer cells.	2"z,3"e)-6-bromo-indirubin-3"-oxime	105-140	glycogen synthase kinase 3 beta	Homo sapiens	83-92
22640743-8	2012	It was reported that inhibition of GSK-3beta or Siah-1 stabilizes beta-catenin in colon cancer cells, but suppression of GSK-3beta or Siah-1 using siRNA in the presence of resveratrol instead diminished beta-catenin protein levels in Panc-PAUF cells.	Resveratrol	172-183	glycogen synthase kinase 3 beta	Homo sapiens	121-130
22724081-3	2012	In addition, whether lithium treatment alters Akt activity as measured by the kinase activity assay has not been reported, although it is known to inhibit GSK3beta activity.	Lithium	21-28	glycogen synthase kinase 3 beta	Homo sapiens	155-163
23359767-1	2012	OBJECTIVE: To explore the effects and mechanism of glycogen synthase kinase 3beta (GSK-3beta) inhibitor (2"Z,3"E)-6-bromo-indirubin-3"-oxime (BIO) on drug resistance in colon cancer cells.	2"z,3"e)-6-bromo-indirubin-3"-oxime	105-140	glycogen synthase kinase 3 beta	Homo sapiens	51-81
22447231-10	2012	The resulting activation of AKT (phosphoSer473) also plays             a role as a central enhancer in glycogen synthesis through suppression of GSK3beta             via phosphorylation at Ser9.	Glycogen	103-111	glycogen synthase kinase 3 beta	Homo sapiens	145-153
21898401-0	2012	Glycogen synthase kinase-3beta is critical for interferon-alpha-induced serotonin uptake in human Jurkat T cells.	Serotonin	72-81	glycogen synthase kinase 3 beta	Homo sapiens	0-30
21898401-9	2012	In addition to inhibiting ERK, a selective 5-HTT inhibitor fluoxetine blocked IFN-alpha-induced activations of Src, CaMKII-regulated Pyk2/GSK-3beta cascade, as well as STAT1 activation and translocation.	Fluoxetine	59-69	glycogen synthase kinase 3 beta	Homo sapiens	138-147
21898401-12	2012	Fluoxetine interfered with the Pyk2/GSK-3beta cascade, thereby inhibiting IFN-alpha-induced 5-HT uptake.	Fluoxetine	0-10	glycogen synthase kinase 3 beta	Homo sapiens	36-45
22234988-6	2012	Phosphorylated GSK-3beta (pGSK-3beta) levels decreased gradually during the normally regenerating spinal cord ranging from L13 to the 6th caudal vertebra.	pgsk-3beta	26-36	glycogen synthase kinase 3 beta	Homo sapiens	15-24
21996745-5	2012	LMTK2 signals via protein phosphatase-1C (PP1C) to increase inhibitory phosphorylation of GSK3beta on serine-9 that reduces KLC2 phosphorylation and promotes binding of the known KLC2 cargo Smad2.	Serine	102-108	glycogen synthase kinase 3 beta	Homo sapiens	90-98
22234988-10	2012	Bromodeoxyuridine (BrdU) staining demonstrated that inactivation of GSK-3beta decreased the proliferation of blastemal cells.	Bromodeoxyuridine	0-17	glycogen synthase kinase 3 beta	Homo sapiens	68-77
22234988-10	2012	Bromodeoxyuridine (BrdU) staining demonstrated that inactivation of GSK-3beta decreased the proliferation of blastemal cells.	Bromodeoxyuridine	19-23	glycogen synthase kinase 3 beta	Homo sapiens	68-77
22834106-0	2012	[Association between lithium sensitivity and GSK3beta gene polymorphisms in bipolar disorder].	Lithium	21-28	glycogen synthase kinase 3 beta	Homo sapiens	45-53
22834106-1	2012	GSK-3beta codes for an enzyme which is a target for the action of mood stabilizers, lithium and possibly of valproic acid.	Lithium	84-91	glycogen synthase kinase 3 beta	Homo sapiens	0-9
22834106-1	2012	GSK-3beta codes for an enzyme which is a target for the action of mood stabilizers, lithium and possibly of valproic acid.	Valproic Acid	108-121	glycogen synthase kinase 3 beta	Homo sapiens	0-9
22834106-2	2012	The relationship between the polymorphisms (SNPs) of GSK-3beta-50T/C and -1727A/T and the effect of lithium was studied among 29 Japanese bipolar patients.	Lithium	100-107	glycogen synthase kinase 3 beta	Homo sapiens	53-62
22834106-3	2012	It was shown that GSK-3beta-50T/C may be linked with the effect of lithium treatment.	Lithium	67-74	glycogen synthase kinase 3 beta	Homo sapiens	18-27
22443192-2	2012	PS1 is phosphorylated by glycogen synthase kinase 3 beta at the serine 353 and 357 residues.	Serine	64-70	glycogen synthase kinase 3 beta	Homo sapiens	25-56
22493441-5	2012	When GSK3beta is inactivated in these cells, beta-catenin gets stabilized, phosphorylated at Ser-552 by protein kinase A, accumulates in the nucleus, and regulates the expression of its target genes that include EGFR.	Serine	93-96	glycogen synthase kinase 3 beta	Homo sapiens	5-13
22364277-3	2012	RESULTS: As a potential glycogen synthase kinase-3beta (GSK-3beta) inhibitor, CBM-1078 primarily activated beta-catenin and Oct4 expression after inhibition of GSK-3beta.	cbm-1078	78-86	glycogen synthase kinase 3 beta	Homo sapiens	24-54
22364277-3	2012	RESULTS: As a potential glycogen synthase kinase-3beta (GSK-3beta) inhibitor, CBM-1078 primarily activated beta-catenin and Oct4 expression after inhibition of GSK-3beta.	cbm-1078	78-86	glycogen synthase kinase 3 beta	Homo sapiens	56-65
22364277-3	2012	RESULTS: As a potential glycogen synthase kinase-3beta (GSK-3beta) inhibitor, CBM-1078 primarily activated beta-catenin and Oct4 expression after inhibition of GSK-3beta.	cbm-1078	78-86	glycogen synthase kinase 3 beta	Homo sapiens	160-169
22150777-11	2012	When compared to controls, EtOH, at both 20 and 100 mM concentrations, suppressed the expression of Wnt3a and Wnt5a, receptor complex proteins p-LRP6, LRP6 and DVL2, and cytoplasmic proteins Ser-p-GSK3beta and beta-catenin.	Ethanol	27-31	glycogen synthase kinase 3 beta	Homo sapiens	197-205
22150777-12	2012	Expression of NKD-2 and DVL3 remained unchanged and the expression of active Tyr-p-GSK3beta increased significantly.	Tyrosine	77-80	glycogen synthase kinase 3 beta	Homo sapiens	83-91
22227283-7	2012	Furthermore, isoflavones directly stimulate Wnt signaling via estrogen receptors-dependent pathway, which inactivates glycogen synthase kinase-3 beta (GSK-3beta), transactivate T-cell factor/lymphoid-enhancer factor (TCF/LEF), the effector of Wnt signaling, degrade adipogenic peroxisome proliferator-activated receptor gamma (PPARgamma), augment p300/CBP, the transcriptional co-activators of TCF/LEF.	Isoflavones	13-24	glycogen synthase kinase 3 beta	Homo sapiens	118-149
22500970-5	2012	Recent studies addressing the inhibition of glycogen synthase kinase-3 beta (GSK3B) by lithium have further suggested the modification of biological cascades that pertain to the pathophysiology of Alzheimer"s disease (AD).	Lithium	87-94	glycogen synthase kinase 3 beta	Homo sapiens	44-75
22500970-5	2012	Recent studies addressing the inhibition of glycogen synthase kinase-3 beta (GSK3B) by lithium have further suggested the modification of biological cascades that pertain to the pathophysiology of Alzheimer"s disease (AD).	Lithium	87-94	glycogen synthase kinase 3 beta	Homo sapiens	77-82
22500970-7	2012	Therefore, lithium treatment may yield disease-modifying effects in AD, both by the specific modification of its pathophysiology via inhibition of overactive GSK3B, and by the unspecific provision of neurotrophic and neuroprotective support.	Lithium	11-18	glycogen synthase kinase 3 beta	Homo sapiens	158-163
22227283-7	2012	Furthermore, isoflavones directly stimulate Wnt signaling via estrogen receptors-dependent pathway, which inactivates glycogen synthase kinase-3 beta (GSK-3beta), transactivate T-cell factor/lymphoid-enhancer factor (TCF/LEF), the effector of Wnt signaling, degrade adipogenic peroxisome proliferator-activated receptor gamma (PPARgamma), augment p300/CBP, the transcriptional co-activators of TCF/LEF.	Isoflavones	13-24	glycogen synthase kinase 3 beta	Homo sapiens	151-160
22306656-0	2012	5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3beta (GSK-3beta) and phosphodiesterase 7 (PDE7) inhibitors: determination of blood-brain barrier penetration and binding to human serum albumin.	5-imino-1,2-4-thiadiazoles	0-26	glycogen synthase kinase 3 beta	Homo sapiens	59-89
22306656-0	2012	5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3beta (GSK-3beta) and phosphodiesterase 7 (PDE7) inhibitors: determination of blood-brain barrier penetration and binding to human serum albumin.	5-imino-1,2-4-thiadiazoles	0-26	glycogen synthase kinase 3 beta	Homo sapiens	91-100
22306656-0	2012	5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3beta (GSK-3beta) and phosphodiesterase 7 (PDE7) inhibitors: determination of blood-brain barrier penetration and binding to human serum albumin.	Quinazolines	31-43	glycogen synthase kinase 3 beta	Homo sapiens	59-89
22306656-0	2012	5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3beta (GSK-3beta) and phosphodiesterase 7 (PDE7) inhibitors: determination of blood-brain barrier penetration and binding to human serum albumin.	Quinazolines	31-43	glycogen synthase kinase 3 beta	Homo sapiens	91-100
22306656-1	2012	5-Imino-1,2,4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3beta (GSK-3beta) and phosphodiesterase 7 (PDE7) inhibitors were characterized for their ability to pass the blood-brain barrier (BBB) together with their human serum albumin (HSA) binding using high-performance liquid affinity chromatography (HPLAC) and circular dichroism (CD).	5-imino-1,2,4-thiadiazoles	0-26	glycogen synthase kinase 3 beta	Homo sapiens	59-89
22306656-1	2012	5-Imino-1,2,4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3beta (GSK-3beta) and phosphodiesterase 7 (PDE7) inhibitors were characterized for their ability to pass the blood-brain barrier (BBB) together with their human serum albumin (HSA) binding using high-performance liquid affinity chromatography (HPLAC) and circular dichroism (CD).	5-imino-1,2,4-thiadiazoles	0-26	glycogen synthase kinase 3 beta	Homo sapiens	91-100
22306656-1	2012	5-Imino-1,2,4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3beta (GSK-3beta) and phosphodiesterase 7 (PDE7) inhibitors were characterized for their ability to pass the blood-brain barrier (BBB) together with their human serum albumin (HSA) binding using high-performance liquid affinity chromatography (HPLAC) and circular dichroism (CD).	Quinazolines	31-43	glycogen synthase kinase 3 beta	Homo sapiens	59-89
22306656-1	2012	5-Imino-1,2,4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3beta (GSK-3beta) and phosphodiesterase 7 (PDE7) inhibitors were characterized for their ability to pass the blood-brain barrier (BBB) together with their human serum albumin (HSA) binding using high-performance liquid affinity chromatography (HPLAC) and circular dichroism (CD).	Quinazolines	31-43	glycogen synthase kinase 3 beta	Homo sapiens	91-100
22150072-6	2012	However, while ERK1/2 and Akt were activated, GSK3beta was inactivated during (3R,6R)-bassiatin(1)-induced apoptosis, suggesting that this compound is indeed an anti-oestrogen agent that can also activate the survival signalling pathway.	(3r,6r)-bassiatin	78-95	glycogen synthase kinase 3 beta	Homo sapiens	46-54
22334036-3	2012	The authors therefore hypothesize that propofol overdose induces macrophage apoptosis through GSK-3beta.	Propofol	39-47	glycogen synthase kinase 3 beta	Homo sapiens	94-103
22334036-11	2012	Propofol-activated GSK-3beta and inhibiting GSK-3beta prevented Mcl-1 destabilization, MTP loss, and lysosomal/mitochondrial apoptosis.	Propofol	0-8	glycogen synthase kinase 3 beta	Homo sapiens	19-28
22334036-11	2012	Propofol-activated GSK-3beta and inhibiting GSK-3beta prevented Mcl-1 destabilization, MTP loss, and lysosomal/mitochondrial apoptosis.	Propofol	0-8	glycogen synthase kinase 3 beta	Homo sapiens	44-53
22334036-13	2012	Decreased Akt was important for GSK-3beta activation caused by propofol.	Propofol	63-71	glycogen synthase kinase 3 beta	Homo sapiens	32-41
22334036-14	2012	CONCLUSIONS: These results suggest an essential role of GSK-3beta in propofol-induced lysosomal/mitochondrial apoptosis.	Propofol	69-77	glycogen synthase kinase 3 beta	Homo sapiens	56-65
23408470-1	2012	Hormone-independent prostate cancer cell lines are resistant to antineoplastic drugs, this study sought to determine the usefulness of lithium chloride as an inhibitor of glycogen synthase kinase-3beta to increase the cytotoxic effect of doxorubicin, etoposide or vinblastine antineoplastic drugs on DU145 cells.	Lithium Chloride	135-151	glycogen synthase kinase 3 beta	Homo sapiens	171-201
23408470-1	2012	Hormone-independent prostate cancer cell lines are resistant to antineoplastic drugs, this study sought to determine the usefulness of lithium chloride as an inhibitor of glycogen synthase kinase-3beta to increase the cytotoxic effect of doxorubicin, etoposide or vinblastine antineoplastic drugs on DU145 cells.	Doxorubicin	238-249	glycogen synthase kinase 3 beta	Homo sapiens	171-201
22168279-0	2012	3D-QSAR and molecular docking studies on 3-anilino-4-arylmaleimide derivatives as glycogen synthase kinase-3beta inhibitors.	3-anilino-4-arylmaleimide	41-66	glycogen synthase kinase 3 beta	Homo sapiens	82-112
22435049-6	2012	This study reported convergent evidence for a decrease in AKT1 protein levels and levels of phosphorylation of GSK-3beta in the peripheral lymphocytes and brains of individuals with schizophrenia; a significant association between schizophrenia and an AKT1 haplotype; and a greater sensitivity to the sensorimotor gating-disruptive effect of amphetamine, conferred by AKT1 deficiency.	Amphetamine	342-353	glycogen synthase kinase 3 beta	Homo sapiens	111-120
22514792-3	2012	In dementia models, Cerebrolysin decreases beta-amyloid deposition and microtubule-associated protein tau phosphorylation by regulating glycogen synthase kinase-3beta and cyclin-dependent kinase 5 activity, increases synaptic density and restores neuronal cytoarchitecture.	cerebrolysin	20-32	glycogen synthase kinase 3 beta	Homo sapiens	136-196
22234583-5	2012	Our findings demonstrate that resveratrol down-regulates the protein cyclin D1 and, in a concentration dependent manner, the phosphorylation levels of protein kinase B (Akt) and glycogen synthase kinase-3beta (GSK-3beta).	Resveratrol	30-41	glycogen synthase kinase 3 beta	Homo sapiens	178-208
22234583-5	2012	Our findings demonstrate that resveratrol down-regulates the protein cyclin D1 and, in a concentration dependent manner, the phosphorylation levels of protein kinase B (Akt) and glycogen synthase kinase-3beta (GSK-3beta).	Resveratrol	30-41	glycogen synthase kinase 3 beta	Homo sapiens	210-219
22369944-5	2012	Both ex vivo and in vitro experiments showed that phosphorylation by MAPK/Cyclin A/cdk2 and GSK3beta protected C/EBPbeta from mu-calpain-mediated proteolysis, while phosphorylation on Thr(188) by MAPK/Cyclin A/cdk2 contributed more to the stabilization of C/EBPbeta, Further studies indicated that phosphorylation mimic C/EBPbeta was insensitive to both calpain accelerator and calpain inhibitor.	Threonine	184-187	glycogen synthase kinase 3 beta	Homo sapiens	92-100
22343623-9	2012	CONCLUSION: The present results showed that stimulation of KOR reduces the growth of gefitinib-resistant NSCLC cells through the activation of GSK3beta.	Gefitinib	85-94	glycogen synthase kinase 3 beta	Homo sapiens	143-151
22266466-2	2012	Cyclin D1 level changes are partially controlled by GSK-3beta-dependent phosphorylation at threonine-286 (Thr286), which targets cyclin D1 for ubiquitination and proteolytic degradation.	Threonine	91-100	glycogen synthase kinase 3 beta	Homo sapiens	52-61
22568037-0	2012	Identification of curcumin targets in neuroinflammatory pathways: molecular docking scores with GSK-3beta, p38 MAPK, COX, ICE and TACE enzymes.	Curcumin	18-26	glycogen synthase kinase 3 beta	Homo sapiens	96-105
22568037-2	2012	The anti-inflammatory pathway of curcumin was identified through docking with of curcumin with various inflammation inducing enzymes like glycogen synthase kinase (GSK-3beta), p38 mitogen activated protein kinase (MAPK), COX, interleukin-1beta converting enzyme (ICE) and tumor necrosis factor-alpha converting enzyme (TACE).	Curcumin	33-41	glycogen synthase kinase 3 beta	Homo sapiens	164-173
22568037-2	2012	The anti-inflammatory pathway of curcumin was identified through docking with of curcumin with various inflammation inducing enzymes like glycogen synthase kinase (GSK-3beta), p38 mitogen activated protein kinase (MAPK), COX, interleukin-1beta converting enzyme (ICE) and tumor necrosis factor-alpha converting enzyme (TACE).	Curcumin	81-89	glycogen synthase kinase 3 beta	Homo sapiens	164-173
22568037-5	2012	The binding target GSK-3beta (-6.44) was found to be more selective for curcumin binding when compared with MAPK (-4.08), COX (-7.35), ICE (-4.02), TACE (-6.38) and their respective native ligand.	Curcumin	72-80	glycogen synthase kinase 3 beta	Homo sapiens	19-28
22568037-7	2012	The key amino acids involved were Vall35, Gln185 and Lys85 in GSK-3beta.	vall35	34-40	glycogen synthase kinase 3 beta	Homo sapiens	62-71
22568037-9	2012	These findings enabled us to identify the keto form of curcumin as a best choice of lead compound to target GSK-3beta.	Curcumin	55-63	glycogen synthase kinase 3 beta	Homo sapiens	108-117
22325951-0	2012	Structure-activity relationship of the 7-hydroxy benzimidazole analogs as glycogen synthase kinase 3beta inhibitor.	7-hydroxy benzimidazole	39-62	glycogen synthase kinase 3 beta	Homo sapiens	74-104
22325951-1	2012	Design, synthesis and the GSK3beta inhibitory activities of the 7-hydroxy benzimidazole analogs are described.	7-hydroxy benzimidazole	64-87	glycogen synthase kinase 3 beta	Homo sapiens	26-34
22315058-0	2012	Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3beta/snail signalling pathway.	Gefitinib	36-45	glycogen synthase kinase 3 beta	Homo sapiens	127-136
22315058-7	2012	LY294002, but not U0126, suppressed foetal bovine serum or heregulin-beta1-induced phosphorylation of Akt/GSK-3beta and snail expression together with the inhibition of 81B-Fb cell motility.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	glycogen synthase kinase 3 beta	Homo sapiens	106-115
22315058-9	2012	CONCLUSION: These results suggest that EMT in the gefitinib-resistant cells is mediated by the downregulation of EGFR and compensatory activation of Akt/GSK-3beta/snail pathway.	Gefitinib	50-59	glycogen synthase kinase 3 beta	Homo sapiens	153-162
22262776-0	2012	Targeting of GSK3beta promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.	Imatinib Mesylate	31-39	glycogen synthase kinase 3 beta	Homo sapiens	13-21
22262776-5	2012	Specifically, GSK3beta activity and nuclear import were increased by imatinib mesylate (IM), a selective ABL inhibitor, but prevented by dasatinib that targets both BCR-ABL- and cytokine-dependent MAPK/p60-SRC activity.	Imatinib Mesylate	69-86	glycogen synthase kinase 3 beta	Homo sapiens	14-22
22262776-5	2012	Specifically, GSK3beta activity and nuclear import were increased by imatinib mesylate (IM), a selective ABL inhibitor, but prevented by dasatinib that targets both BCR-ABL- and cytokine-dependent MAPK/p60-SRC activity.	Dasatinib	137-146	glycogen synthase kinase 3 beta	Homo sapiens	14-22
22266466-9	2012	Our results indicate a hitherto unreported role of NQO2 in the control of AKT/GSK-3beta/cyclin D1 and highlight the involvement of NQO2 in degradation of cyclin D1, as part of mechanism of chemoprevention by resveratrol.	Resveratrol	208-219	glycogen synthase kinase 3 beta	Homo sapiens	78-87
21571466-5	2012	And transfected GSK-3beta was found to be able to enhance PMS2 production, and increase cell apoptosis in CNE-2 cells in combination with cisplatin administration in vitro.	Cisplatin	138-147	glycogen synthase kinase 3 beta	Homo sapiens	16-25
22041920-0	2012	Glycogen synthase kinase 3beta inhibition sensitizes pancreatic cancer cells to gemcitabine.	gemcitabine	80-91	glycogen synthase kinase 3 beta	Homo sapiens	0-30
22041920-3	2012	Here, we investigated the effect of GSK3beta inhibition on pancreatic cancer cell sensitivity to gemcitabine and the underlying molecular mechanism.	gemcitabine	97-108	glycogen synthase kinase 3 beta	Homo sapiens	36-44
22041920-10	2012	DNA microarray analysis detected GSK3beta inhibition-associated changes in gene expression in gemcitabine-treated PANC-1 cells.	gemcitabine	94-105	glycogen synthase kinase 3 beta	Homo sapiens	33-41
22041920-11	2012	Among these changes, RT-PCR and Western blotting showed that expression of tumor protein 53-induced nuclear protein 1, a gene regulating cell death and DNA repair, was increased by gemcitabine treatment and substantially decreased by GSK3beta inhibition.	gemcitabine	181-192	glycogen synthase kinase 3 beta	Homo sapiens	234-242
22041920-12	2012	CONCLUSIONS: The results indicate that GSK3beta inhibition sensitizes pancreatic cancer cells to gemcitabine with altered expression of genes involved in DNA repair.	gemcitabine	97-108	glycogen synthase kinase 3 beta	Homo sapiens	39-47
27350769-0	2012	LY294002 induces differentiation and inhibits invasion of glioblastoma cells by targeting GSK-3beta and MMP.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	glycogen synthase kinase 3 beta	Homo sapiens	90-99
27350769-6	2012	Taken together, these findings suggest differentiation-inducing and invasion-inhibitory effectiveness of LY294002 in glioblastomas, most likely involving inhibition of GSK-3beta and MMP respectively.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	105-113	glycogen synthase kinase 3 beta	Homo sapiens	168-177
22310719-4	2012	MG132 caused the phosphorylation of GSK3beta at Ser(9) and, to a lesser extent, Thr(390), the dephosphorylation of p70S6K at Thr(389), and the phosphorylation of p70S6K at Thr(421) and Ser(424).	Serine	48-51	glycogen synthase kinase 3 beta	Homo sapiens	36-44
22310719-5	2012	The specific p38 inhibitor SB203080 reduced the p-GSK3beta(Ser9) and autophagy through the phosphorylation of p70S6K(Thr389); however, it augmented the levels of p-ERK, p-GSK3beta(Thr390), and p-70S6K(Thr421/Ser424) induced by MG132, and increased apoptotic cell death.	sb203080	27-35	glycogen synthase kinase 3 beta	Homo sapiens	50-58
22310719-5	2012	The specific p38 inhibitor SB203080 reduced the p-GSK3beta(Ser9) and autophagy through the phosphorylation of p70S6K(Thr389); however, it augmented the levels of p-ERK, p-GSK3beta(Thr390), and p-70S6K(Thr421/Ser424) induced by MG132, and increased apoptotic cell death.	sb203080	27-35	glycogen synthase kinase 3 beta	Homo sapiens	171-179
22310719-4	2012	MG132 caused the phosphorylation of GSK3beta at Ser(9) and, to a lesser extent, Thr(390), the dephosphorylation of p70S6K at Thr(389), and the phosphorylation of p70S6K at Thr(421) and Ser(424).	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	0-5	glycogen synthase kinase 3 beta	Homo sapiens	36-44
22363263-3	2012	Among several targets, lithium has been shown to directly inhibit glycogen synthase kinase 3 alpha and beta (GSK3alpha and GSK3beta).	Lithium	23-30	glycogen synthase kinase 3 beta	Homo sapiens	123-131
21725365-2	2012	Here, we report that when adherent onto fibronectin or osteoblast components, CD34(+)38(-)123(+) progenitors survive through an integrin-dependent activation of glycogen synthase kinase 3beta (GSK3beta) by serine 9-dephosphorylation.	Serine	206-212	glycogen synthase kinase 3 beta	Homo sapiens	161-191
21725365-2	2012	Here, we report that when adherent onto fibronectin or osteoblast components, CD34(+)38(-)123(+) progenitors survive through an integrin-dependent activation of glycogen synthase kinase 3beta (GSK3beta) by serine 9-dephosphorylation.	Serine	206-212	glycogen synthase kinase 3 beta	Homo sapiens	193-201
21725365-4	2012	GSK3beta inhibition restored sensitivity to etoposide, and impaired the clonogenic capacities of adherent leukemic progenitors from female patients.	Etoposide	44-53	glycogen synthase kinase 3 beta	Homo sapiens	0-8
22262180-0	2012	GSK3beta regulates Bcl2L12 and Bcl2L12A anti-apoptosis signaling in glioblastoma and is inhibited by LiCl.	Lithium Chloride	101-105	glycogen synthase kinase 3 beta	Homo sapiens	0-8
22262180-5	2012	We found that a BCL2L12(153-191) fragment located outside of the C-terminal BH2 motif is responsible for GSK3b binding.	bh2	76-79	glycogen synthase kinase 3 beta	Homo sapiens	105-110
21410737-0	2012	Thiazolidenediones induce tumour-cell apoptosis through the Akt-GSK3beta pathway.	thiazolidenediones	0-18	glycogen synthase kinase 3 beta	Homo sapiens	64-72
22119086-1	2012	BACKGROUND: Glycogen synthase kinase 3-beta (GSK3-beta) is involved in the control of cell behavior and in the mechanism of action of lithium and serotonergic antidepressants, and in humans a promoter variant (rs334558*C) was associated with reduced activity and better antidepressant response.	Lithium	134-141	glycogen synthase kinase 3 beta	Homo sapiens	12-43
22119086-1	2012	BACKGROUND: Glycogen synthase kinase 3-beta (GSK3-beta) is involved in the control of cell behavior and in the mechanism of action of lithium and serotonergic antidepressants, and in humans a promoter variant (rs334558*C) was associated with reduced activity and better antidepressant response.	Lithium	134-141	glycogen synthase kinase 3 beta	Homo sapiens	45-54
21448924-5	2012	Both protein and mRNA levels for GSK3beta but only the protein expression for beta-catenin, were increased in response to high glucose.	Glucose	127-134	glycogen synthase kinase 3 beta	Homo sapiens	33-41
21448924-8	2012	We show that high levels of glucose regulate mRNA and protein expression of GSK3beta, and consequently higher levels of activated beta-catenin protein, which locates to the nucleus and is associated with increased levels of cyclin D1 expression.	Glucose	28-35	glycogen synthase kinase 3 beta	Homo sapiens	76-84
21410737-8	2012	Furthermore, TZDs induce inactivation of GSK3beta, a multifunctional kinase that mediates essential events promoting prostate cancer development and acquisition of androgen independence.	tzds	13-17	glycogen synthase kinase 3 beta	Homo sapiens	41-49
21448924-9	2012	This event coincides with increased level of N-terminal Ser 9 phosphorylation of GSK3beta protein.	Serine	56-59	glycogen synthase kinase 3 beta	Homo sapiens	81-89
21448924-10	2012	The inhibition of both the hexosamine pathway and N-linked glycosylation along with Wnt signaling pathway by sFRP1 and DKK1 is associated with significant decrease of the protein levels of GSK3beta, beta-catenin, and TXNIP RNA.	Hexosamines	27-37	glycogen synthase kinase 3 beta	Homo sapiens	189-197
21410737-9	2012	In addition, the GSK3beta inhibitor lithium chloride sensitizes prostate cancer cells to TZDs cytotoxicity.	Lithium Chloride	36-52	glycogen synthase kinase 3 beta	Homo sapiens	17-25
21448924-10	2012	The inhibition of both the hexosamine pathway and N-linked glycosylation along with Wnt signaling pathway by sFRP1 and DKK1 is associated with significant decrease of the protein levels of GSK3beta, beta-catenin, and TXNIP RNA.	Nitrogen	50-51	glycogen synthase kinase 3 beta	Homo sapiens	189-197
21410737-9	2012	In addition, the GSK3beta inhibitor lithium chloride sensitizes prostate cancer cells to TZDs cytotoxicity.	tzds	89-93	glycogen synthase kinase 3 beta	Homo sapiens	17-25
22202172-0	2012	6-Position optimization of tricyclic 4-quinolone-based inhibitors of glycogen synthase kinase-3beta: discovery of nitrile derivatives with picomolar potency.	tricyclic 4-quinolone	27-48	glycogen synthase kinase 3 beta	Homo sapiens	69-99
21559963-0	2012	Binding of BIS like and other ligands with the GSK-3beta kinase: a combined docking and MM-PBSA study.	poly(tetramethylene succinate-co-tetramethylene adipate)	91-95	glycogen synthase kinase 3 beta	Homo sapiens	47-56
21559963-1	2012	Binding of several bisindolylmaleimide (BIS) like (BIS-3, BIS-8 and UCN1) and other ligands (H89, SB203580 and Y27632) with the glycogen synthase kinase-3 (GSK-3beta) has been studied using combined docking, molecular dynamics and Poisson-Boltzmann surface area analysis approaches.	bisindolylmaleimide	19-38	glycogen synthase kinase 3 beta	Homo sapiens	156-165
21559963-1	2012	Binding of several bisindolylmaleimide (BIS) like (BIS-3, BIS-8 and UCN1) and other ligands (H89, SB203580 and Y27632) with the glycogen synthase kinase-3 (GSK-3beta) has been studied using combined docking, molecular dynamics and Poisson-Boltzmann surface area analysis approaches.	bisindolylmaleimide	40-43	glycogen synthase kinase 3 beta	Homo sapiens	156-165
21559963-5	2012	It is also found that binding modes of BIS-3, BIS-8 and UCN1 with GSK-3beta and PDK1 kinases are similar.	bis-3	39-44	glycogen synthase kinase 3 beta	Homo sapiens	66-75
21559963-5	2012	It is also found that binding modes of BIS-3, BIS-8 and UCN1 with GSK-3beta and PDK1 kinases are similar.	bis-8	46-51	glycogen synthase kinase 3 beta	Homo sapiens	66-75
22221106-0	2012	NO-1886 ameliorates glycogen metabolism in insulin-resistant HepG2 cells by GSK-3beta signalling.	Glycogen	20-28	glycogen synthase kinase 3 beta	Homo sapiens	76-85
22416219-2	2012	Recently, we have reported that ghrelin protects motoneurons against chronic glutamate excitotoxicity through the activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol-3-kinase/Akt/glycogen synthase kinase-3beta pathways.	Ghrelin	32-39	glycogen synthase kinase 3 beta	Homo sapiens	208-238
22174377-0	2012	A SNP in steroid receptor coactivator-1 disrupts a GSK3beta phosphorylation site and is associated with altered tamoxifen response in bone.	Tamoxifen	112-121	glycogen synthase kinase 3 beta	Homo sapiens	51-59
22174377-13	2012	In summary, we have identified a functional genetic variant of SRC-1 with decreased activity, resulting, at least in part, from the loss of a GSK3beta phosphorylation site, which was also associated with decreased bone mineral density in tamoxifen-treated women.	Tamoxifen	238-247	glycogen synthase kinase 3 beta	Homo sapiens	142-150
21584871-7	2012	In addition, PI3K/Akt/ GSK 3beta, ERK and p38 MAPK were activated by curcumin, while inhibitors of these signals attenuated the inhibitory effects of curcumin on melanogenesis.	Curcumin	69-77	glycogen synthase kinase 3 beta	Homo sapiens	23-32
21584871-8	2012	These results suggest that curcumin inhibits melanogenesis in human melanocytes through activation of Akt/GSK 3beta, ERK or p38 MAPK signaling pathways.	Curcumin	27-35	glycogen synthase kinase 3 beta	Homo sapiens	106-115
21256630-5	2012	In ic-STZ animals, an alteration in integrin-linked kinase (ILK)-glycogen synthase kinase 3 beta (GSK-3-beta) signaling was identified (p < 0.05).	Streptozocin	6-9	glycogen synthase kinase 3 beta	Homo sapiens	65-96
22142471-12	2012	Importantly, NDGA caused inhibitory phosphorylation of GSK-3beta at Ser9 and at Thr390, and this was associated with a substantial reduction in Neh6 phosphorylation.	Masoprocol	13-17	glycogen synthase kinase 3 beta	Homo sapiens	55-64
22142472-7	2012	GSK-3beta overexpression inhibited the H(2)O(2)-stimulated STK38 activity.	Hydrogen Peroxide	39-47	glycogen synthase kinase 3 beta	Homo sapiens	0-9
22202172-0	2012	6-Position optimization of tricyclic 4-quinolone-based inhibitors of glycogen synthase kinase-3beta: discovery of nitrile derivatives with picomolar potency.	Nitriles	114-121	glycogen synthase kinase 3 beta	Homo sapiens	69-99
22202172-1	2012	We previously disclosed tricylic, 6-carboxylic acid-bearing 4-quinolones as GSK-3beta inhibitors.	6-carboxylic	34-46	glycogen synthase kinase 3 beta	Homo sapiens	76-85
22202172-1	2012	We previously disclosed tricylic, 6-carboxylic acid-bearing 4-quinolones as GSK-3beta inhibitors.	4-Quinolones	60-72	glycogen synthase kinase 3 beta	Homo sapiens	76-85
21983033-8	2012	The persistence of 7beta-hydroxycholesterol-induced stress led after 24 h to P38 activation, loss of GSK3beta activation and to cell death.	cholest-5-en-3 beta,7 alpha-diol	19-43	glycogen synthase kinase 3 beta	Homo sapiens	101-109
22062806-0	2012	Ginsenoside Rg2 induces orphan nuclear receptor SHP gene expression and inactivates GSK3beta via AMP-activated protein kinase to inhibit hepatic glucose production in HepG2 cells.	Ginsenosides	0-11	glycogen synthase kinase 3 beta	Homo sapiens	84-92
21837368-9	2012	Both the PPARgamma ligands, RGZ and GW9662, appear to reciprocally regulate the mRNA and protein expressions of GSK-3beta, which promotes apoptosis, and of beta-catenin, which blocks apoptosis.	2-chloro-5-nitrobenzanilide	36-42	glycogen synthase kinase 3 beta	Homo sapiens	112-121
22104147-5	2012	The screening of this triazole-based KFEF library allowed the rapid identification of potent lead candidates for FLT3 and GSK3beta kinase.	Triazoles	22-30	glycogen synthase kinase 3 beta	Homo sapiens	122-130
22791147-0	2012	Ursolic acid from Oldenlandia diffusa induces apoptosis via activation of caspases and phosphorylation of glycogen synthase kinase 3 beta in SK-OV-3 ovarian cancer cells.	ursolic acid	0-12	glycogen synthase kinase 3 beta	Homo sapiens	106-137
22791147-8	2012	Interestingly, ursolic acid suppressed beta-catenin degradation as well as enhanced phosphorylation of glycogen synthase kinase 3 beta (GSK 3beta).	ursolic acid	15-27	glycogen synthase kinase 3 beta	Homo sapiens	103-134
22791147-8	2012	Interestingly, ursolic acid suppressed beta-catenin degradation as well as enhanced phosphorylation of glycogen synthase kinase 3 beta (GSK 3beta).	ursolic acid	15-27	glycogen synthase kinase 3 beta	Homo sapiens	136-145
22791147-9	2012	Furthermore, GSK 3beta inhibitor SB216763 blocked the cleavages of caspase-3 and PARP induced by ursolic acid and proteosomal inhibitor MG132 disturbed down-regulation of beta-catenin, activation of caspase-3 and decreased mitochondrial membrane potential (MMP) induced by ursolic acid in SK-OV-3 cells.	SB 216763	33-41	glycogen synthase kinase 3 beta	Homo sapiens	13-22
22791147-9	2012	Furthermore, GSK 3beta inhibitor SB216763 blocked the cleavages of caspase-3 and PARP induced by ursolic acid and proteosomal inhibitor MG132 disturbed down-regulation of beta-catenin, activation of caspase-3 and decreased mitochondrial membrane potential (MMP) induced by ursolic acid in SK-OV-3 cells.	ursolic acid	97-109	glycogen synthase kinase 3 beta	Homo sapiens	13-22
22791147-9	2012	Furthermore, GSK 3beta inhibitor SB216763 blocked the cleavages of caspase-3 and PARP induced by ursolic acid and proteosomal inhibitor MG132 disturbed down-regulation of beta-catenin, activation of caspase-3 and decreased mitochondrial membrane potential (MMP) induced by ursolic acid in SK-OV-3 cells.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	136-141	glycogen synthase kinase 3 beta	Homo sapiens	13-22
22791147-9	2012	Furthermore, GSK 3beta inhibitor SB216763 blocked the cleavages of caspase-3 and PARP induced by ursolic acid and proteosomal inhibitor MG132 disturbed down-regulation of beta-catenin, activation of caspase-3 and decreased mitochondrial membrane potential (MMP) induced by ursolic acid in SK-OV-3 cells.	ursolic acid	273-285	glycogen synthase kinase 3 beta	Homo sapiens	13-22
22791147-10	2012	Overall, our findings suggest that ursolic acid induces apoptosis via activation of caspase and phosphorylation of GSK 3beta in SK-OV-3 cancer cells as a potent anti-cancer agent for ovarian cancer therapy.	ursolic acid	35-47	glycogen synthase kinase 3 beta	Homo sapiens	115-124
21837368-5	2012	In combination with Frizzled, Wnt suppresses GSK-3beta and causes degradation of beta-catenin and activation of many tumor proliferation factors.	frizzled	20-28	glycogen synthase kinase 3 beta	Homo sapiens	45-54
22811749-0	2012	Gallic Acid Attenuates Platelet Activation and Platelet-Leukocyte Aggregation: Involving Pathways of Akt and GSK3beta.	Gallic Acid	0-11	glycogen synthase kinase 3 beta	Homo sapiens	109-117
22811749-7	2012	Gallic acid prevented the elevation of intracellular calcium and attenuated phosphorylation of PKCalpha/p38 MAPK and Akt/GSK3beta on platelets stimulated by the stimulants ADP or U46619.	Gallic Acid	0-11	glycogen synthase kinase 3 beta	Homo sapiens	121-129
22675363-1	2012	Although glycogen synthase kinase-3 beta (GSK-3beta) was originally named for its ability to phosphorylate glycogen synthase and regulate glucose metabolism, this multifunctional kinase is presently known to be a key regulator of a wide range of cellular functions.	Glucose	138-145	glycogen synthase kinase 3 beta	Homo sapiens	42-51
22893788-3	2012	Previous studies have shown that phosphorylation of threonine 58 by glycogen synthase kinase 3beta (GSK3beta) within the conserved Myc Box I sequence results in binding by the ubiquitin ligase Fbw7-SCF complex, followed by ubiquitination and proteasome-mediated degradation of Myc.	Threonine	52-61	glycogen synthase kinase 3 beta	Homo sapiens	68-98
22893788-3	2012	Previous studies have shown that phosphorylation of threonine 58 by glycogen synthase kinase 3beta (GSK3beta) within the conserved Myc Box I sequence results in binding by the ubiquitin ligase Fbw7-SCF complex, followed by ubiquitination and proteasome-mediated degradation of Myc.	Threonine	52-61	glycogen synthase kinase 3 beta	Homo sapiens	100-108
22893788-4	2012	Here, we show that induction of Myc in several cell types correlates with loss of the inhibitory serine 9 phosphorylation of GSK3beta and its increased kinase activity.	Serine	97-103	glycogen synthase kinase 3 beta	Homo sapiens	125-133
22893788-7	2012	Furthermore, we find that B56delta associates with both GSK3beta and Myc, resulting in phosphorylation of Myc threonine 58, the well-established signal for ubiquitination and degradation.	b56delta	26-34	glycogen synthase kinase 3 beta	Homo sapiens	56-64
22893788-7	2012	Furthermore, we find that B56delta associates with both GSK3beta and Myc, resulting in phosphorylation of Myc threonine 58, the well-established signal for ubiquitination and degradation.	Threonine	110-119	glycogen synthase kinase 3 beta	Homo sapiens	56-64
22886017-0	2012	Curcumin-mediated neuroprotection against amyloid-beta-induced mitochondrial dysfunction involves the inhibition of GSK-3beta.	Curcumin	0-8	glycogen synthase kinase 3 beta	Homo sapiens	116-125
22886017-10	2012	Both total GSK-3beta expression and phospho-Ser9 GSK-3beta (pSer9-GSK-3beta) are down-regulated in the cells pre-treated with curcumin.	Curcumin	126-134	glycogen synthase kinase 3 beta	Homo sapiens	11-20
22886017-10	2012	Both total GSK-3beta expression and phospho-Ser9 GSK-3beta (pSer9-GSK-3beta) are down-regulated in the cells pre-treated with curcumin.	Curcumin	126-134	glycogen synthase kinase 3 beta	Homo sapiens	49-58
22886017-10	2012	Both total GSK-3beta expression and phospho-Ser9 GSK-3beta (pSer9-GSK-3beta) are down-regulated in the cells pre-treated with curcumin.	Curcumin	126-134	glycogen synthase kinase 3 beta	Homo sapiens	49-58
22886017-12	2012	Inhibition of GSK-3beta is involved in the protection of curcumin against Abeta-induced mitochondrial dysfunction.	Curcumin	57-65	glycogen synthase kinase 3 beta	Homo sapiens	14-23
22522861-7	2012	Lithium is a powerful inhibitor of the enzyme glycogen synthase kinase 3beta and this is associated with a lower activity of adenylate cyclase with a reduction in the cAMP levels inside of the cells.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	46-76
22522861-7	2012	Lithium is a powerful inhibitor of the enzyme glycogen synthase kinase 3beta and this is associated with a lower activity of adenylate cyclase with a reduction in the cAMP levels inside of the cells.	Cyclic AMP	167-171	glycogen synthase kinase 3 beta	Homo sapiens	46-76
21993922-6	2012	ZSTK474 also inhibited the phosphorylation             of Akt, GSK3beta and BAD.	ZSTK474	0-7	glycogen synthase kinase 3 beta	Homo sapiens	63-71
22098108-6	2012	In IGF-1-treated cells, genistein effectively inhibited the phosphorylation of IGF-1R and the phosphorylation of its downstream targets, such as Src, Akt, and glycogen synthase kinase-3beta (GSk-3beta).	Genistein	24-33	glycogen synthase kinase 3 beta	Homo sapiens	159-189
22098108-6	2012	In IGF-1-treated cells, genistein effectively inhibited the phosphorylation of IGF-1R and the phosphorylation of its downstream targets, such as Src, Akt, and glycogen synthase kinase-3beta (GSk-3beta).	Genistein	24-33	glycogen synthase kinase 3 beta	Homo sapiens	191-200
21875668-2	2012	Our results demonstrate that both CDK inhibitors prevented apoptosis induced by LY294002 (LY), as also occurs with SB415286 (SB4), a selective GSK3beta inhibitor.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	115-123	glycogen synthase kinase 3 beta	Homo sapiens	143-151
21875668-2	2012	Our results demonstrate that both CDK inhibitors prevented apoptosis induced by LY294002 (LY), as also occurs with SB415286 (SB4), a selective GSK3beta inhibitor.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	115-118	glycogen synthase kinase 3 beta	Homo sapiens	143-151
21875668-4	2012	Thus, the increased activity of GSK3beta induced by LY294002 and detected by dephosphorylation at Ser9 was prevented by both compounds.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	52-60	glycogen synthase kinase 3 beta	Homo sapiens	32-40
21875668-5	2012	Likewise, GSK3beta activity was measured by a radioactivity assay, revealing that CDK inhibitors and SB415286 prevented the increase in GSK3beta activity induced by PI3K inhibition.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	101-109	glycogen synthase kinase 3 beta	Homo sapiens	10-18
21875668-5	2012	Likewise, GSK3beta activity was measured by a radioactivity assay, revealing that CDK inhibitors and SB415286 prevented the increase in GSK3beta activity induced by PI3K inhibition.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	101-109	glycogen synthase kinase 3 beta	Homo sapiens	136-144
23272157-5	2012	Rosiglitazone-activated PPARgamma2 induced rapid proteolytic degradation of beta-catenin, which was prevented by either inhibiting glycogen synthase kinase 3 beta (GSK3beta) activity, or blocking pro-adipocytic activity of PPARgamma2 using selective antagonist GW9662 or mutation within PPARgamma2 protein.	Rosiglitazone	0-13	glycogen synthase kinase 3 beta	Homo sapiens	131-162
23251571-13	2012	Finally, inhibition of GSK3beta blocked ROS production, Bax activation and the down regulation of ROS scavenging genes.	Reactive Oxygen Species	40-43	glycogen synthase kinase 3 beta	Homo sapiens	23-31
23251571-13	2012	Finally, inhibition of GSK3beta blocked ROS production, Bax activation and the down regulation of ROS scavenging genes.	Reactive Oxygen Species	98-101	glycogen synthase kinase 3 beta	Homo sapiens	23-31
23272157-5	2012	Rosiglitazone-activated PPARgamma2 induced rapid proteolytic degradation of beta-catenin, which was prevented by either inhibiting glycogen synthase kinase 3 beta (GSK3beta) activity, or blocking pro-adipocytic activity of PPARgamma2 using selective antagonist GW9662 or mutation within PPARgamma2 protein.	Rosiglitazone	0-13	glycogen synthase kinase 3 beta	Homo sapiens	164-172
23077641-7	2012	Furthermore we also demonstrated PDGF-CC-mediated inactivation of the downstream mediator--glycogen synthase kinase 3beta (GSK3beta) evidenced by its phosphorylation at Ser-9.	Serine	169-172	glycogen synthase kinase 3 beta	Homo sapiens	123-131
23166798-8	2012	Additionally, the level of cellular glycogen synthase kinase 3beta (GSK3beta) is downregulated by SSS exposure and treatment with a specific GSK3beta inhibitor recapitulates the effects of SSS exposure on CAR expression and viral infection.	sss	98-101	glycogen synthase kinase 3 beta	Homo sapiens	36-66
23166798-8	2012	Additionally, the level of cellular glycogen synthase kinase 3beta (GSK3beta) is downregulated by SSS exposure and treatment with a specific GSK3beta inhibitor recapitulates the effects of SSS exposure on CAR expression and viral infection.	sss	98-101	glycogen synthase kinase 3 beta	Homo sapiens	68-76
23166798-8	2012	Additionally, the level of cellular glycogen synthase kinase 3beta (GSK3beta) is downregulated by SSS exposure and treatment with a specific GSK3beta inhibitor recapitulates the effects of SSS exposure on CAR expression and viral infection.	sss	98-101	glycogen synthase kinase 3 beta	Homo sapiens	141-149
23166798-8	2012	Additionally, the level of cellular glycogen synthase kinase 3beta (GSK3beta) is downregulated by SSS exposure and treatment with a specific GSK3beta inhibitor recapitulates the effects of SSS exposure on CAR expression and viral infection.	sss	189-192	glycogen synthase kinase 3 beta	Homo sapiens	36-66
23166798-8	2012	Additionally, the level of cellular glycogen synthase kinase 3beta (GSK3beta) is downregulated by SSS exposure and treatment with a specific GSK3beta inhibitor recapitulates the effects of SSS exposure on CAR expression and viral infection.	sss	189-192	glycogen synthase kinase 3 beta	Homo sapiens	68-76
23166798-8	2012	Additionally, the level of cellular glycogen synthase kinase 3beta (GSK3beta) is downregulated by SSS exposure and treatment with a specific GSK3beta inhibitor recapitulates the effects of SSS exposure on CAR expression and viral infection.	sss	189-192	glycogen synthase kinase 3 beta	Homo sapiens	141-149
23189201-6	2012	Second, we observed that LAN-A inhibits the translocation of Akt kinase to the membrane and thus Akt activation, as examined by the phosphorylation of various downstream targets of Akt such as GSK3beta, mTOR and BAD.	lancemaside A	25-30	glycogen synthase kinase 3 beta	Homo sapiens	193-201
23185275-12	2012	Treatment of cells with lithium, a potent GSK-3beta inhibitor, or with two specific GSK-3beta inhibitors (the L803-mts peptide inhibitor and CHIR99021) resulted in cilium elongation and decreased basal body levels of pCRMP-2 as well as increased levels of total CRMP-2 at the primary cilium.	Lithium	24-31	glycogen synthase kinase 3 beta	Homo sapiens	42-51
23077590-6	2012	Using GSK3 inhibitors and siRNA knock-down, we demonstrate that the mechanism of riluzole-induced Smad phosphorylation involved GSK3beta.	Riluzole	81-89	glycogen synthase kinase 3 beta	Homo sapiens	128-136
22536363-10	2012	These results suggest that acute high-dose thiamet-G injection can not only directly antagonize tau phosphorylation, but also stimulate GSK-3beta activity, with the downstream consequence being site-specific, bi-directional regulation of tau phosphorylation in the mammalian brain.	thiamet	43-50	glycogen synthase kinase 3 beta	Homo sapiens	136-145
22859966-4	2012	Here, we evaluated if T(SCM) can be obtained from human mature CD8(+) T cells following TCR and Wnt/ss-catenin activation through treatment with the chemical agent 4,6-disubstituted pyrrolopyrimidine (TWS119), which inhibits the glycogen synthase kinase-3beta (GSK-3beta), key inhibitor of the Wnt pathway.	disubstituted pyrrolopyrimidine	168-199	glycogen synthase kinase 3 beta	Homo sapiens	229-259
22859966-4	2012	Here, we evaluated if T(SCM) can be obtained from human mature CD8(+) T cells following TCR and Wnt/ss-catenin activation through treatment with the chemical agent 4,6-disubstituted pyrrolopyrimidine (TWS119), which inhibits the glycogen synthase kinase-3beta (GSK-3beta), key inhibitor of the Wnt pathway.	disubstituted pyrrolopyrimidine	168-199	glycogen synthase kinase 3 beta	Homo sapiens	261-270
22615875-7	2012	In addition, lithium chloride-mediated inhibition of GSK3beta also resulted in increase in MENA mRNA levels.	Lithium Chloride	13-29	glycogen synthase kinase 3 beta	Homo sapiens	53-61
22529978-5	2012	Epirubicin-treated GRP78 knockdown cells resulted in more inactivated Akt pathway members, such as phosphorylated Akt and GSK-3beta, as well as downstream targets of beta-catenin expression.	Epirubicin	0-10	glycogen synthase kinase 3 beta	Homo sapiens	122-131
22506014-6	2012	VPA analogs and other GSK3beta inhibitors that activate the Wnt/beta-catenin pathway such as 4-phenyl butyric acid, LiCl, and BeCl(2) also exhibited hair growth-promoting activities in vivo.	4-phenylbutyric acid	93-114	glycogen synthase kinase 3 beta	Homo sapiens	22-30
22506014-3	2012	We have identified a new function for valproic acid (VPA), a GSK3beta inhibitor that activates the Wnt/beta-catenin pathway, to promote hair re-growth in vitro and in vivo.	Valproic Acid	38-51	glycogen synthase kinase 3 beta	Homo sapiens	61-69
22506014-3	2012	We have identified a new function for valproic acid (VPA), a GSK3beta inhibitor that activates the Wnt/beta-catenin pathway, to promote hair re-growth in vitro and in vivo.	Valproic Acid	53-56	glycogen synthase kinase 3 beta	Homo sapiens	61-69
22506014-6	2012	VPA analogs and other GSK3beta inhibitors that activate the Wnt/beta-catenin pathway such as 4-phenyl butyric acid, LiCl, and BeCl(2) also exhibited hair growth-promoting activities in vivo.	Lithium Chloride	116-120	glycogen synthase kinase 3 beta	Homo sapiens	22-30
22506014-6	2012	VPA analogs and other GSK3beta inhibitors that activate the Wnt/beta-catenin pathway such as 4-phenyl butyric acid, LiCl, and BeCl(2) also exhibited hair growth-promoting activities in vivo.	beryllium chloride	126-133	glycogen synthase kinase 3 beta	Homo sapiens	22-30
22359572-0	2012	Dehydrocostuslactone suppresses angiogenesis in vitro and in vivo through inhibition of Akt/GSK-3beta and mTOR signaling pathways.	dehydrocostus lactone	0-20	glycogen synthase kinase 3 beta	Homo sapiens	92-101
22359572-4	2012	In this study, we demonstrated, for the first time, the anti-angiogenic mechanism of action of DHC to be via the induction of cell cycle progression at the G0/G1 phase due to abrogation of the Akt/glycogen synthase kinase-3beta (GSK-3beta)/cyclin D1 and mTOR signaling pathway.	dehydrocostus lactone	95-98	glycogen synthase kinase 3 beta	Homo sapiens	229-238
22359572-7	2012	With respect to the molecular mechanisms underlying the DHC-induced cyclin D1 down-regulation, this study demonstrated that DHC significantly inhibits Akt expression, resulting in the suppression of GSK-3beta phosphorylation and mTOR expression.	dehydrocostus lactone	56-59	glycogen synthase kinase 3 beta	Homo sapiens	199-208
22359572-7	2012	With respect to the molecular mechanisms underlying the DHC-induced cyclin D1 down-regulation, this study demonstrated that DHC significantly inhibits Akt expression, resulting in the suppression of GSK-3beta phosphorylation and mTOR expression.	dehydrocostus lactone	124-127	glycogen synthase kinase 3 beta	Homo sapiens	199-208
21717457-5	2011	Both OSU03012 and PI103 downregulated phosphorylation of Akt and inhibited the downstream targets glycogen synthase kinase-3beta (GSK3beta) and p70 S6 kinase-1 (S6K1), as well as downregulated the expression of cyclin D1 and Mycn protein.	OSU 03012	5-13	glycogen synthase kinase 3 beta	Homo sapiens	98-128
22363707-3	2012	Here, we report that GSK3beta can phosphorylate LCRMP-1 at Thr-628 in consensus sequences and this phosphorylation is crucial for function of LCRMP-1 to promote filopodia formation, migration and invasion in cancer cells.	Threonine	59-62	glycogen synthase kinase 3 beta	Homo sapiens	21-29
22363707-5	2012	Furthermore, we also found that patients with low-level Ser-9-phosphorylated GSK3beta expression and high-level LCRMP-1 expression have worse overall survival than those with high-level inactive GSK3beta expressions and low-level LCRMP-1 expressions (P&lt;0.0001).	Serine	56-59	glycogen synthase kinase 3 beta	Homo sapiens	77-85
22039048-7	2011	Moreover, adiponectin induces phosphorylation of Ser-389, a key inhibitory site of glycogen synthase kinase 3beta (GSK-3beta), and this effect can be blocked by inhibition of p38MAPK with SB203580.	Serine	49-52	glycogen synthase kinase 3 beta	Homo sapiens	83-113
22039048-7	2011	Moreover, adiponectin induces phosphorylation of Ser-389, a key inhibitory site of glycogen synthase kinase 3beta (GSK-3beta), and this effect can be blocked by inhibition of p38MAPK with SB203580.	Serine	49-52	glycogen synthase kinase 3 beta	Homo sapiens	115-124
22039048-7	2011	Moreover, adiponectin induces phosphorylation of Ser-389, a key inhibitory site of glycogen synthase kinase 3beta (GSK-3beta), and this effect can be blocked by inhibition of p38MAPK with SB203580.	SB 203580	188-196	glycogen synthase kinase 3 beta	Homo sapiens	83-113
22039048-7	2011	Moreover, adiponectin induces phosphorylation of Ser-389, a key inhibitory site of glycogen synthase kinase 3beta (GSK-3beta), and this effect can be blocked by inhibition of p38MAPK with SB203580.	SB 203580	188-196	glycogen synthase kinase 3 beta	Homo sapiens	115-124
21903578-13	2011	Moreover, induction of ASMCs(Des-/-) hypertrophy by the Erk-1/2/Egr-1/miR-26a/GSK-3beta pathway is consistent in human recombinant ASMCs, which stably suppresses 90% endogenous desmin expression.	asmcs	23-28	glycogen synthase kinase 3 beta	Homo sapiens	78-87
21903578-13	2011	Moreover, induction of ASMCs(Des-/-) hypertrophy by the Erk-1/2/Egr-1/miR-26a/GSK-3beta pathway is consistent in human recombinant ASMCs, which stably suppresses 90% endogenous desmin expression.	asmcs	131-136	glycogen synthase kinase 3 beta	Homo sapiens	78-87
21717457-5	2011	Both OSU03012 and PI103 downregulated phosphorylation of Akt and inhibited the downstream targets glycogen synthase kinase-3beta (GSK3beta) and p70 S6 kinase-1 (S6K1), as well as downregulated the expression of cyclin D1 and Mycn protein.	OSU 03012	5-13	glycogen synthase kinase 3 beta	Homo sapiens	130-138
22001093-0	2011	Synthesis of GSK3beta mimetic inhibitors of Akt featuring a novel extended dipeptide surrogate.	Dipeptides	75-84	glycogen synthase kinase 3 beta	Homo sapiens	13-21
22001093-3	2011	Here, we present the design and synthesis of conformationally constrained GSK3beta mimics featuring a novel extended dipeptide surrogate core.	Dipeptides	117-126	glycogen synthase kinase 3 beta	Homo sapiens	74-82
22039301-4	2011	Lentiviral-transduced short hairpin RNA knockdown of GSK3beta in both the HMC1.2 cells and HuMCs resulted in a significant reduction in cell survival as determined with the MTT assay.	monooxyethylene trimethylolpropane tristearate	173-176	glycogen synthase kinase 3 beta	Homo sapiens	53-61
21952585-9	2011	BCAA also inhibited phosphorylation of GSK-3beta, increased cellular levels of p21(CIP1), caused cell-cycle arrest in G(0)/G(1) phase, and induced apoptosis in HCC cells in the presence of visfatin.	Amino Acids, Branched-Chain	0-4	glycogen synthase kinase 3 beta	Homo sapiens	39-48
21988238-6	2011	Similarly, treatment with AB or AC reduced the declines in p85aPI3K, phosphorylated Akt, phosphorylated GSK-3beta, heat-shock transcription factor-1, and Bcl-2 induced by H(2) O(2) , as well as the increases in cyclooxygenase-2, cytosolic cytochrome c, cleaved caspase 9, and cleaved caspase 3.	Amlodipine	26-28	glycogen synthase kinase 3 beta	Homo sapiens	104-148
21988238-6	2011	Similarly, treatment with AB or AC reduced the declines in p85aPI3K, phosphorylated Akt, phosphorylated GSK-3beta, heat-shock transcription factor-1, and Bcl-2 induced by H(2) O(2) , as well as the increases in cyclooxygenase-2, cytosolic cytochrome c, cleaved caspase 9, and cleaved caspase 3.	Charcoal	32-34	glycogen synthase kinase 3 beta	Homo sapiens	104-148
21832246-6	2011	Genetic ablation of GSK-3beta using small interfering RNA resulted in specific sparing of MyHC-f, MyLC-1, and MyLC-3 protein levels after Dex treatment or impaired IGF-I/Akt signaling.	Dexamethasone	138-141	glycogen synthase kinase 3 beta	Homo sapiens	20-29
21893111-9	2011	These results suggest that olanzapine and aripiprazole may exert beneficial effects by upregulating BDNF, phosphorylated GSK-3beta, and beta-catenin in patients with schizophrenia.	Olanzapine	27-37	glycogen synthase kinase 3 beta	Homo sapiens	121-130
21893111-9	2011	These results suggest that olanzapine and aripiprazole may exert beneficial effects by upregulating BDNF, phosphorylated GSK-3beta, and beta-catenin in patients with schizophrenia.	Aripiprazole	42-54	glycogen synthase kinase 3 beta	Homo sapiens	121-130
21956113-0	2011	Mechanical regulation of glycogen synthase kinase 3beta (GSK3beta) in mesenchymal stem cells is dependent on Akt protein serine 473 phosphorylation via mTORC2 protein.	Serine	121-127	glycogen synthase kinase 3 beta	Homo sapiens	57-65
21956113-4	2011	Mechanical strain (2% magnitude, 0.17 Hz) induced phosphorylation of Akt at Ser-473 and Thr-308 in parallel with phosphorylation of GSK3beta at Ser-9.	Serine	144-147	glycogen synthase kinase 3 beta	Homo sapiens	132-140
21956113-5	2011	Inhibiting Akt (Akt1/2 kinase inhibitor treatment or Akt knockdown) prevented strain-induced phosphorylation of GSK3beta at Ser-9.	Serine	124-127	glycogen synthase kinase 3 beta	Homo sapiens	112-120
21956113-6	2011	Inhibition of PI3K prevented Thr-308 phosphorylation, but strain-induced Ser-473 phosphorylation was measurable and induced phosphorylation of GSK3beta, suggesting that Ser-473 phosphorylation is sufficient for the downstream mechanoresponse.	Serine	169-172	glycogen synthase kinase 3 beta	Homo sapiens	143-151
21956113-10	2011	In sum, mechanical input initiates a signaling cascade that is uniquely dependent on mTORC2 activation and phosphorylation of Akt at Ser-473, an effect sufficient to cause inactivation of GSK3beta.	Serine	133-136	glycogen synthase kinase 3 beta	Homo sapiens	188-196
21956113-11	2011	Thus, mechanical regulation of GSK3beta downstream of Akt is dependent on phosphorylation of Akt at Ser-473 in a manner distinct from that of growth factors.	Serine	100-103	glycogen synthase kinase 3 beta	Homo sapiens	31-39
21956113-0	2011	Mechanical regulation of glycogen synthase kinase 3beta (GSK3beta) in mesenchymal stem cells is dependent on Akt protein serine 473 phosphorylation via mTORC2 protein.	Serine	121-127	glycogen synthase kinase 3 beta	Homo sapiens	25-55
21832246-7	2011	Interestingly, loss of endogenous GSK-3beta suppressed both basal and atrophy stimulus-induced atrogin-1 and MuRF1 expression, whereas pharmacological GSK-3beta inhibition, using CHIR99021 or LiCl, only reduced atrogin-1 mRNA levels in response to LY294002 or Dex.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	248-256	glycogen synthase kinase 3 beta	Homo sapiens	34-43
21832246-7	2011	Interestingly, loss of endogenous GSK-3beta suppressed both basal and atrophy stimulus-induced atrogin-1 and MuRF1 expression, whereas pharmacological GSK-3beta inhibition, using CHIR99021 or LiCl, only reduced atrogin-1 mRNA levels in response to LY294002 or Dex.	Dexamethasone	260-263	glycogen synthase kinase 3 beta	Homo sapiens	34-43
21461888-9	2011	Furanodienone interfered with EGFR/HER2 signaling in treated cells as shown by decreases in phosphorylated EGFR, HER2, Akt, Gsk3beta and an increase in p27(kip1) protein.	furanodienone	0-13	glycogen synthase kinase 3 beta	Homo sapiens	124-132
21878813-4	2011	Novel maleimide-based GSK3beta inhibitors (GSK3betai) were synthesized, selected, and tested in vitro using SKOV3 and OVCA432 serous ovarian cancer cell lines.	maleimide	6-15	glycogen synthase kinase 3 beta	Homo sapiens	22-30
21878813-8	2011	GSK3betai upregulated phosphorylation of the inhibitory serine residue of GSK3beta in OVCA432 and SKOV3 cell lines and also inhibited phosphorylation of the downstream target glycogen synthase.	Serine	56-62	glycogen synthase kinase 3 beta	Homo sapiens	0-8
21461888-10	2011	Accordingly, furanodienone inhibited EGF-induced phosphorylation of EGFR, HER2, Akt, and Gsk3beta.	furanodienone	13-26	glycogen synthase kinase 3 beta	Homo sapiens	89-97
21781277-5	2011	Previous studies have shown that lithium regulates Rev-Erbalpha protein stability by inhibiting glycogen synthase kinase 3beta (GSK3beta).	Lithium	33-40	glycogen synthase kinase 3 beta	Homo sapiens	96-126
21781277-5	2011	Previous studies have shown that lithium regulates Rev-Erbalpha protein stability by inhibiting glycogen synthase kinase 3beta (GSK3beta).	Lithium	33-40	glycogen synthase kinase 3 beta	Homo sapiens	128-136
21781277-6	2011	We found that GSK3beta genotype was also suggestive of a lithium response association, but not statistically significant.	Lithium	57-64	glycogen synthase kinase 3 beta	Homo sapiens	14-22
21781277-7	2011	However, when GSK3beta and NR1D1 genotypes were considered together, they predicted lithium response robustly and additively in proportion to the number of response-associated alleles.	Lithium	84-91	glycogen synthase kinase 3 beta	Homo sapiens	14-22
21928294-6	2011	At the molecular levels, the results from Western blot analysis showed that THC significantly down-regulated phosphatidylinositol 3-kinase/protein kinase B and mitogen-activated protein kinase signalings including decreasing the phosphorylation of mammalian target of rapamycin, glycogen synthase kinase 3beta and p70 ribosomal protein S6 kinase.	tetrahydrocurcumin	76-79	glycogen synthase kinase 3 beta	Homo sapiens	279-309
21837363-0	2011	Activation of Akt/GSK3beta and Akt/Bcl-2 signaling pathways in nickel-transformed BEAS-2B cells.	Nickel	63-69	glycogen synthase kinase 3 beta	Homo sapiens	18-26
21837363-7	2011	Activation of Akt led to inhibition of GSK3beta by phosphorylation at Ser9 in nickel-transformed cells.	Nickel	78-84	glycogen synthase kinase 3 beta	Homo sapiens	39-47
21867737-5	2011	Pre-treatment of the PI3K inhibitor LY294002, 20min prior to Post C, significantly attenuated Post C-induced elevation of p-Akt and p-GSK3beta, as well as prevented Post C enhancement of mitochondrial integrity and Post C neuroprotection.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	36-44	glycogen synthase kinase 3 beta	Homo sapiens	134-142
21735136-7	2011	Signaling pathway analysis indicated that ABPP-E4 treatment stimulated the activation of Akt/Gsk3beta signaling in cultured SH-SY5Y cells, and anti-apoptotic effects of ABPP-E4 could be blocked by chemical inhibition of PI3K.	abpp-e4	42-49	glycogen synthase kinase 3 beta	Homo sapiens	93-101
21878650-10	2011	Moreover, ethanol induced changes in miRNAs, and their target genes were substantially prevented by pre-exposure to GSK-3B inhibitors.	Ethanol	10-17	glycogen synthase kinase 3 beta	Homo sapiens	116-122
21735136-8	2011	Taken together, all the results suggest that ABPP-E4 might exert protective effects against serum deprivation-induced neuronal apoptosis through modulation of PI3K/Akt/Gsk3beta pathways.	abpp-e4	45-52	glycogen synthase kinase 3 beta	Homo sapiens	168-176
21442609-0	2011	Mechanism of kinase inactivation and nonbinding of FRATide to GSK3beta due to K85M mutation: molecular dynamics simulation and normal mode analysis.	Fratide	51-58	glycogen synthase kinase 3 beta	Homo sapiens	62-70
21952626-7	2011	Pharmacological inhibition of GSK3beta by lithium chloride treatment mimicked effects of Cdc42 in promotion of PARP cleavage and/or apoptosis.	Lithium Chloride	42-58	glycogen synthase kinase 3 beta	Homo sapiens	30-38
21561378-1	2011	Glycogen synthase kinase-3beta (GSK-3beta), a serine/threonine kinase also known as tau protein kinase I, has been implicated in the pathogenic conditions of Alzheimer"s disease.	Serine	46-52	glycogen synthase kinase 3 beta	Homo sapiens	0-30
21923160-9	2011	Lycopene could effectively inhibit the phosphorylation of Akt, glycogen synthase kinase-3beta (GSK-3beta) and ERK 1/2 proteins.	Lycopene	0-8	glycogen synthase kinase 3 beta	Homo sapiens	63-93
21923160-9	2011	Lycopene could effectively inhibit the phosphorylation of Akt, glycogen synthase kinase-3beta (GSK-3beta) and ERK 1/2 proteins.	Lycopene	0-8	glycogen synthase kinase 3 beta	Homo sapiens	95-104
21442609-3	2011	To elucidate the mechanisms concerning kinase inactivation and nonbinding of FRATide to GSK3beta, molecular dynamics (MD) simulation, molecular mechanics generalized Born/surface area (MM_GBSA) calculation, and normal mode analysis (NMA) were performed on both the wild-type (WT) and the K85M mutation of the GSK3beta-FRATide complex.	Fratide	77-84	glycogen synthase kinase 3 beta	Homo sapiens	88-96
21442609-6	2011	Specifically, the correct folding pattern of GSK3beta was disrupted in the K85M mutant, resulting in the loss of two key hydrogen bonds between K214 of FRATide and E290 and K292 of GSK3beta, respectively.	Hydrogen	121-129	glycogen synthase kinase 3 beta	Homo sapiens	45-53
21873061-0	2011	Synthesis and structure-activity relationship of 4-quinolone-3-carboxylic acid based inhibitors of glycogen synthase kinase-3beta.	4-quinolone-3-carboxylic acid	49-78	glycogen synthase kinase 3 beta	Homo sapiens	99-129
21442609-6	2011	Specifically, the correct folding pattern of GSK3beta was disrupted in the K85M mutant, resulting in the loss of two key hydrogen bonds between K214 of FRATide and E290 and K292 of GSK3beta, respectively.	Fratide	152-159	glycogen synthase kinase 3 beta	Homo sapiens	45-53
21442609-8	2011	In addition, NMA demonstrated that the "rocking" of the N- and C-terminal domains of GSK3beta, which coordinates the mutual movement of both lobes, inducing the opening and closing of the active site of GSK3beta, which may assist the entry of ATP into the ATP binding site and the release of the ADP product.	Adenosine Triphosphate	243-246	glycogen synthase kinase 3 beta	Homo sapiens	85-93
21442609-8	2011	In addition, NMA demonstrated that the "rocking" of the N- and C-terminal domains of GSK3beta, which coordinates the mutual movement of both lobes, inducing the opening and closing of the active site of GSK3beta, which may assist the entry of ATP into the ATP binding site and the release of the ADP product.	Adenosine Triphosphate	243-246	glycogen synthase kinase 3 beta	Homo sapiens	203-211
21442609-8	2011	In addition, NMA demonstrated that the "rocking" of the N- and C-terminal domains of GSK3beta, which coordinates the mutual movement of both lobes, inducing the opening and closing of the active site of GSK3beta, which may assist the entry of ATP into the ATP binding site and the release of the ADP product.	Adenosine Triphosphate	256-259	glycogen synthase kinase 3 beta	Homo sapiens	85-93
21442609-8	2011	In addition, NMA demonstrated that the "rocking" of the N- and C-terminal domains of GSK3beta, which coordinates the mutual movement of both lobes, inducing the opening and closing of the active site of GSK3beta, which may assist the entry of ATP into the ATP binding site and the release of the ADP product.	Adenosine Triphosphate	256-259	glycogen synthase kinase 3 beta	Homo sapiens	203-211
21442609-8	2011	In addition, NMA demonstrated that the "rocking" of the N- and C-terminal domains of GSK3beta, which coordinates the mutual movement of both lobes, inducing the opening and closing of the active site of GSK3beta, which may assist the entry of ATP into the ATP binding site and the release of the ADP product.	Adenosine Diphosphate	296-299	glycogen synthase kinase 3 beta	Homo sapiens	85-93
21442609-8	2011	In addition, NMA demonstrated that the "rocking" of the N- and C-terminal domains of GSK3beta, which coordinates the mutual movement of both lobes, inducing the opening and closing of the active site of GSK3beta, which may assist the entry of ATP into the ATP binding site and the release of the ADP product.	Adenosine Diphosphate	296-299	glycogen synthase kinase 3 beta	Homo sapiens	203-211
21660051-5	2011	Silencing of GSK-3beta or p53 expression was cardioprotective, indicating that activation of the ERK-GSK-3beta-p53 signaling pathway is involved in Zn(2+)-sensitive myocyte death.	Zinc	148-150	glycogen synthase kinase 3 beta	Homo sapiens	13-22
21207227-0	2011	Wogonin induced apoptosis in human nasopharyngeal carcinoma cells by targeting GSK-3beta and DeltaNp63.	wogonin	0-7	glycogen synthase kinase 3 beta	Homo sapiens	79-88
21207227-8	2011	Dysregulation of GSK-3beta caused cell apoptosis was confirmed by pharmacological inhibitors (lithium chloroid, LiCl, and 6-bro-moindirubin-3-oxime, BIO).	lithium chloroid	94-110	glycogen synthase kinase 3 beta	Homo sapiens	17-26
21207227-8	2011	Dysregulation of GSK-3beta caused cell apoptosis was confirmed by pharmacological inhibitors (lithium chloroid, LiCl, and 6-bro-moindirubin-3-oxime, BIO).	Lithium Chloride	112-116	glycogen synthase kinase 3 beta	Homo sapiens	17-26
21207227-8	2011	Dysregulation of GSK-3beta caused cell apoptosis was confirmed by pharmacological inhibitors (lithium chloroid, LiCl, and 6-bro-moindirubin-3-oxime, BIO).	6-bromoindirubin-3'-oxime	122-147	glycogen synthase kinase 3 beta	Homo sapiens	17-26
21207227-9	2011	Administration of okadaic acid (OA, a protein phosphatase inhibitor) that significantly inactivated GSK-3beta also induced DeltaNp63 downregulation and apoptosis.	Okadaic Acid	18-30	glycogen synthase kinase 3 beta	Homo sapiens	100-109
21207227-9	2011	Administration of okadaic acid (OA, a protein phosphatase inhibitor) that significantly inactivated GSK-3beta also induced DeltaNp63 downregulation and apoptosis.	Okadaic Acid	32-34	glycogen synthase kinase 3 beta	Homo sapiens	100-109
21207227-11	2011	Furthermore, GSK-3beta or PP2A inhibitors enhanced wogonin-induced apoptosis via activation of caspase 3/7.	wogonin	51-58	glycogen synthase kinase 3 beta	Homo sapiens	13-22
21862498-11	2011	Desflurane increased the level of phosphorylation of Akt and GSK-3beta (P&lt;0.0001).	Desflurane	0-10	glycogen synthase kinase 3 beta	Homo sapiens	61-70
21862498-12	2011	CONCLUSIONS: Desflurane-induced post-conditioning in human myocardium from patients with type 2 diabetes was mediated by the activation of PKC, the opening of the mitoK(ATP) channels, and the phosphorylation of Akt and GSK-3beta.	Desflurane	13-23	glycogen synthase kinase 3 beta	Homo sapiens	219-228
21660051-5	2011	Silencing of GSK-3beta or p53 expression was cardioprotective, indicating that activation of the ERK-GSK-3beta-p53 signaling pathway is involved in Zn(2+)-sensitive myocyte death.	Zinc	148-150	glycogen synthase kinase 3 beta	Homo sapiens	101-110
21756288-0	2011	Binding studies and quantitative structure-activity relationship of 3-amino-1H-indazoles as inhibitors of GSK3beta.	3-amino-1h-indazoles	68-88	glycogen synthase kinase 3 beta	Homo sapiens	106-114
21756288-1	2011	Docking of 3-amino-1H-indazoles complexed with glycogen synthase kinase 3 beta (GSK3beta) was performed to gain insight into the structural requirements and preferred conformations of these inhibitors.	3-amino-1h-indazoles	11-31	glycogen synthase kinase 3 beta	Homo sapiens	47-78
21757005-7	2011	Inhibitors of GSK3beta (lithium) and p38 MAPK (SB203580) signaling pathways restored the depressed histone acetylation and Nrf2-related transcription whereas an inhibitor of Akt (Ly294002) caused a further decrease in Nrf2-related transcription.	Lithium	24-31	glycogen synthase kinase 3 beta	Homo sapiens	14-22
21756288-1	2011	Docking of 3-amino-1H-indazoles complexed with glycogen synthase kinase 3 beta (GSK3beta) was performed to gain insight into the structural requirements and preferred conformations of these inhibitors.	3-amino-1h-indazoles	11-31	glycogen synthase kinase 3 beta	Homo sapiens	80-88
21756288-3	2011	We found that the most active compounds established three hydrogen bonds with the residues of the hinge region of GSK3beta, but some of the less active compounds have other binding modes.	Hydrogen	58-66	glycogen synthase kinase 3 beta	Homo sapiens	114-122
21678465-0	2011	Effects of a glycogen synthase kinase-3beta inhibitor (LiCl) on c-myc protein in intervertebral disc cells.	Lithium Chloride	55-59	glycogen synthase kinase 3 beta	Homo sapiens	13-43
21929745-0	2011	Differential modulatory effects of GSK-3beta and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.	Sorafenib	57-66	glycogen synthase kinase 3 beta	Homo sapiens	35-44
21723896-4	2011	With the purpose of further investigating a possible mechanism of action, we analyzed the effect of GM1 treatment (1, 6, 12 and 24h) upon the Abeta-induced alterations on GSK3beta dephosphorylation/activation state.	G(M1) Ganglioside	100-103	glycogen synthase kinase 3 beta	Homo sapiens	171-179
21723896-5	2011	Results demonstrated an important effect after 24-h incubation, with GM1 preventing the Abeta-induced dephosphorylation (activation) of GSK3beta, a signaling pathway involved in apoptosis triggering and neuronal death in models of Alzheimer"s disease.	G(M1) Ganglioside	69-72	glycogen synthase kinase 3 beta	Homo sapiens	136-144
21929745-4	2011	We previously showed that the multikinase inhibitor sorafenib activated GSK-3beta and that this activation attenuated the cytotoxic effects of the drug in various BRAF-mutant melanoma cell lines.	Sorafenib	52-61	glycogen synthase kinase 3 beta	Homo sapiens	72-81
21929745-5	2011	In this report, we describe the results of studies exploring the effects of GSK-3beta on the cytotoxicity and antitumor activity of sorafenib combined with the HDM2 antagonist MI-319.	Sorafenib	132-141	glycogen synthase kinase 3 beta	Homo sapiens	76-85
21929745-10	2011	These modulatory effects of GSK-3beta on the activities of the sorafenib/MI-319 combination were the exact reverse of its effects on the activities of sorafenib alone, which induced the down modulation of Bcl-2 and Bcl-xL and the nuclear translocation of AIF only in cells in which GSK-3beta activity was either down modulated or constitutively low.	Sorafenib	63-72	glycogen synthase kinase 3 beta	Homo sapiens	28-37
21929745-10	2011	These modulatory effects of GSK-3beta on the activities of the sorafenib/MI-319 combination were the exact reverse of its effects on the activities of sorafenib alone, which induced the down modulation of Bcl-2 and Bcl-xL and the nuclear translocation of AIF only in cells in which GSK-3beta activity was either down modulated or constitutively low.	Sorafenib	63-72	glycogen synthase kinase 3 beta	Homo sapiens	282-291
21929745-10	2011	These modulatory effects of GSK-3beta on the activities of the sorafenib/MI-319 combination were the exact reverse of its effects on the activities of sorafenib alone, which induced the down modulation of Bcl-2 and Bcl-xL and the nuclear translocation of AIF only in cells in which GSK-3beta activity was either down modulated or constitutively low.	2-methyl-4-isothiazolin-3-one	73-75	glycogen synthase kinase 3 beta	Homo sapiens	28-37
21929745-10	2011	These modulatory effects of GSK-3beta on the activities of the sorafenib/MI-319 combination were the exact reverse of its effects on the activities of sorafenib alone, which induced the down modulation of Bcl-2 and Bcl-xL and the nuclear translocation of AIF only in cells in which GSK-3beta activity was either down modulated or constitutively low.	2-methyl-4-isothiazolin-3-one	73-75	glycogen synthase kinase 3 beta	Homo sapiens	282-291
21929745-10	2011	These modulatory effects of GSK-3beta on the activities of the sorafenib/MI-319 combination were the exact reverse of its effects on the activities of sorafenib alone, which induced the down modulation of Bcl-2 and Bcl-xL and the nuclear translocation of AIF only in cells in which GSK-3beta activity was either down modulated or constitutively low.	Sorafenib	151-160	glycogen synthase kinase 3 beta	Homo sapiens	28-37
21929745-13	2011	The data suggest that the ability of sorafenib to activate GSK-3beta and alter the intracellular distribution of p53 may be exploitable as an adjunct to agents that prevent the HDM2-dependent degradation of p53 in the treatment of melanoma.	Sorafenib	37-46	glycogen synthase kinase 3 beta	Homo sapiens	59-68
21557011-2	2011	Modulation of GSK-3beta in vSMC following ectopic expression of constitutively active GSK-3beta, siRNA knockdown and pharmacological inhibition with SB-216763 demonstrated that GSK-3beta positively regulates Notch intracellular domain expression, CBF-1/RBP-Jkappa transactivation and downstream target gene mRNA levels, while concomitantly promoting vSMC proliferation and inhibiting apoptosis.	vsmc	27-31	glycogen synthase kinase 3 beta	Homo sapiens	14-23
21557011-5	2011	Exposure of vSMC to changes in medial strain microenvironments in vivo following carotid artery ligation revealed that enhanced GSK-3beta activity was predominantly localized to medial and neointimal vSMC concomitant with increased Notch signaling, proliferating nuclear antigen and decreased Bax expression, respectively, as vascular remodeling progressed.	vsmc	12-16	glycogen synthase kinase 3 beta	Homo sapiens	128-137
21732538-4	2011	We designed a series of second generation benzofuran-3-yl-(indol-3-yl)maleimides containing a piperidine ring that possess IC50 values in the range of 4 to 680 nM against human GSK-3beta.	benzofuran-3-yl-(indol-3-yl)maleimides	42-80	glycogen synthase kinase 3 beta	Homo sapiens	177-186
21732538-4	2011	We designed a series of second generation benzofuran-3-yl-(indol-3-yl)maleimides containing a piperidine ring that possess IC50 values in the range of 4 to 680 nM against human GSK-3beta.	piperidine	94-104	glycogen synthase kinase 3 beta	Homo sapiens	177-186
21557011-2	2011	Modulation of GSK-3beta in vSMC following ectopic expression of constitutively active GSK-3beta, siRNA knockdown and pharmacological inhibition with SB-216763 demonstrated that GSK-3beta positively regulates Notch intracellular domain expression, CBF-1/RBP-Jkappa transactivation and downstream target gene mRNA levels, while concomitantly promoting vSMC proliferation and inhibiting apoptosis.	vsmc	27-31	glycogen synthase kinase 3 beta	Homo sapiens	86-95
21557011-2	2011	Modulation of GSK-3beta in vSMC following ectopic expression of constitutively active GSK-3beta, siRNA knockdown and pharmacological inhibition with SB-216763 demonstrated that GSK-3beta positively regulates Notch intracellular domain expression, CBF-1/RBP-Jkappa transactivation and downstream target gene mRNA levels, while concomitantly promoting vSMC proliferation and inhibiting apoptosis.	vsmc	27-31	glycogen synthase kinase 3 beta	Homo sapiens	86-95
21557011-4	2011	Exposure of vSMC to cyclic strain environments in vitro using both a Flexercell  Tension system and a novel Sylgard  phantom vessel following bare metal stent implantation revealed that cyclic strain inhibits GSK-3beta activity independent of p42/p44 MAPK and p38 activation concomitant with reduced Notch signaling and decreased vSMC proliferation and survival.	vsmc	12-16	glycogen synthase kinase 3 beta	Homo sapiens	209-218
21480364-4	2011	In addition, that forskolin down-regulated the cyclin D1 by proteolytic (post-transcriptional) mechanisms was dependent on GSK-3beta activation at Ser9.	Colforsin	18-27	glycogen synthase kinase 3 beta	Homo sapiens	123-132
21441955-0	2011	Mutant K-Ras increases GSK-3beta gene expression via an ETS-p300 transcriptional complex in pancreatic cancer.	ets	56-59	glycogen synthase kinase 3 beta	Homo sapiens	23-32
21663752-3	2011	In the present study, we compared the effects of amisulpride and haloperidol on the beta-arrestin 2-mediated Akt/GSK-3beta pathway in SH-SY5Y cells.	Amisulpride	49-60	glycogen synthase kinase 3 beta	Homo sapiens	113-122
21663752-8	2011	Furthermore, amisulpride increased the levels of Akt and GSK-3beta phosphorylation, while haloperidol had no effect.	Amisulpride	13-24	glycogen synthase kinase 3 beta	Homo sapiens	57-66
21613824-7	2011	Troglitazone inhibited the constitutive expression of GSK-3beta and activation of NFkappaB.	Troglitazone	0-12	glycogen synthase kinase 3 beta	Homo sapiens	54-63
21628454-2	2011	Here, we demonstrate the existence of a nuclear GSK-3beta-NFATc2 stabilization pathway that promotes breast and pancreatic cancer growth in vitro and in vivo and serves as a bona fide target of zoledronic acid.	Zoledronic Acid	194-209	glycogen synthase kinase 3 beta	Homo sapiens	48-57
21628454-3	2011	Specifically, the serine/threonine kinase GSK-3beta stabilizes nuclear NFATc2 through phosphorylation of the serine-rich SP2 domain, thus protecting the transcription factor from E3-ubiquitin ligase HDM2-mediated proteolysis.	Serine	18-24	glycogen synthase kinase 3 beta	Homo sapiens	42-51
21628454-4	2011	Zoledronic acid disrupts this NFATc2 stabilization pathway through two mechanisms, namely GSK-3beta inhibition and induction of HDM2 activity.	Zoledronic Acid	0-15	glycogen synthase kinase 3 beta	Homo sapiens	90-99
21628454-7	2011	In conclusion, this study demonstrates a critical role of the GSK-3beta-HDM2 signaling loop in the regulation of NFATc2 protein stability and growth promotion and suggests that double targeting of this pathway is responsible, at least to a significant part, for the potent and reliable anti-tumoral effects of zoledronic acid.	Zoledronic Acid	310-325	glycogen synthase kinase 3 beta	Homo sapiens	62-71
21613824-0	2011	Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFkappaB via suppression of GSK-3beta expression.	Troglitazone	0-12	glycogen synthase kinase 3 beta	Homo sapiens	125-134
21613824-8	2011	Co-treatment of troglitazone with a GSK-3beta inhibitor (AR-a014418) or GSK-3beta siRNA significantly augmented the inhibitory effect of troglitazone on the NFkappaB activity and on prostate cancer cell growth inhibition and apoptotic cell death.	Troglitazone	16-28	glycogen synthase kinase 3 beta	Homo sapiens	36-45
21613824-8	2011	Co-treatment of troglitazone with a GSK-3beta inhibitor (AR-a014418) or GSK-3beta siRNA significantly augmented the inhibitory effect of troglitazone on the NFkappaB activity and on prostate cancer cell growth inhibition and apoptotic cell death.	Troglitazone	137-149	glycogen synthase kinase 3 beta	Homo sapiens	36-45
21613824-8	2011	Co-treatment of troglitazone with a GSK-3beta inhibitor (AR-a014418) or GSK-3beta siRNA significantly augmented the inhibitory effect of troglitazone on the NFkappaB activity and on prostate cancer cell growth inhibition and apoptotic cell death.	Troglitazone	137-149	glycogen synthase kinase 3 beta	Homo sapiens	72-81
21613824-9	2011	However, overexpression of GSK-3beta hindered troglitazone-induced cell growth inhibition and NFkappaB inactivation.	Troglitazone	46-58	glycogen synthase kinase 3 beta	Homo sapiens	27-36
21613824-10	2011	These results suggest that PPARgamma agonist, troglitazone, inhibits prostate cancer cell growth through inactivation of NFkappaB via suppression of GSK-3beta expression.	Troglitazone	46-58	glycogen synthase kinase 3 beta	Homo sapiens	149-158
21683105-11	2011	Although previous reports suggest that apoptosis induced in CGNs by LY294002 and S/K deprivation causes PI3K inhibition and increases GSK3beta activity and c-Jun phosphorylation activation, our results demonstrate substantial differences between them and point to a key role of GSK3beta in the apoptosis induced in CGNs in the two models tested.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	68-76	glycogen synthase kinase 3 beta	Homo sapiens	134-142
21764580-0	2011	Identification of 2-(4-pyridyl)thienopyridinones as GSK-3beta inhibitors.	2-(4-pyridyl)thienopyridinones	18-48	glycogen synthase kinase 3 beta	Homo sapiens	52-61
21764580-1	2011	The discovery of a novel series of 2-(4-pyridyl)thienopyridinone GSK-3beta inhibitors is reported.	2-(4-pyridyl)thienopyridinone	35-64	glycogen synthase kinase 3 beta	Homo sapiens	65-74
21392092-5	2011	Furthermore, melatonin suppressed AKT/glycogen synthase kinase-3beta (GSK-3beta) signaling pathway, which stabilizes HIF-1alpha via inhibition of von Hippel-Lindau tumor suppressor protein.	Melatonin	13-22	glycogen synthase kinase 3 beta	Homo sapiens	70-79
21864408-11	2011	Treatment of cells with the GSK-3beta inhibitor SB-216763 increased p21 levels, while exogenous expression of GSK-3beta caused a decrease in p21, indicating that GSK-3beta actively reduces p21 levels.	SB 216763	48-57	glycogen synthase kinase 3 beta	Homo sapiens	28-37
21864408-12	2011	We found that a combined treatment of LY294002 and SB-216763 improved the cytotoxic effect against UMUC-3 and UMUC-14 carcinoma cells over LY294002 alone, suggesting potential therapeutic uses for GSK-3beta inhibitors.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	38-46	glycogen synthase kinase 3 beta	Homo sapiens	197-206
21864408-12	2011	We found that a combined treatment of LY294002 and SB-216763 improved the cytotoxic effect against UMUC-3 and UMUC-14 carcinoma cells over LY294002 alone, suggesting potential therapeutic uses for GSK-3beta inhibitors.	SB 216763	51-60	glycogen synthase kinase 3 beta	Homo sapiens	197-206
21672577-6	2011	Our results show that the inhibitors of GSK3beta, lithium and 6-BIO (6-bromoindirubin-3"-oxime), prevented OKA-induced tau phosphorylation and neuronal apoptosis.	6-bromoindirubin-3'-oxime	69-94	glycogen synthase kinase 3 beta	Homo sapiens	40-48
21672577-6	2011	Our results show that the inhibitors of GSK3beta, lithium and 6-BIO (6-bromoindirubin-3"-oxime), prevented OKA-induced tau phosphorylation and neuronal apoptosis.	Okadaic Acid	107-110	glycogen synthase kinase 3 beta	Homo sapiens	40-48
21672577-7	2011	The implication of GSK3beta in these OKA-induced effects was confirmed by its silencing by hairpin siRNA.	Okadaic Acid	37-40	glycogen synthase kinase 3 beta	Homo sapiens	19-27
21672577-9	2011	These results indicate that OKA-induced effects, especially neuronal apoptosis, are preferentially mediated by GSK3beta.	Okadaic Acid	28-31	glycogen synthase kinase 3 beta	Homo sapiens	111-119
21683105-11	2011	Although previous reports suggest that apoptosis induced in CGNs by LY294002 and S/K deprivation causes PI3K inhibition and increases GSK3beta activity and c-Jun phosphorylation activation, our results demonstrate substantial differences between them and point to a key role of GSK3beta in the apoptosis induced in CGNs in the two models tested.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	68-76	glycogen synthase kinase 3 beta	Homo sapiens	278-286
21554241-7	2011	GSK-3beta phosphorylates PTP1B at serine residues, and activation of GSK-3beta reduces the mRNA level of PTP1B.	Serine	34-40	glycogen synthase kinase 3 beta	Homo sapiens	0-9
21328310-8	2011	However, GSK3beta Y288F completely abolishes the FRATide binding without affecting GSKIPtide or AxinGID binding.	Fratide	49-56	glycogen synthase kinase 3 beta	Homo sapiens	9-17
21576240-7	2011	During hypoxic conditions, treatment of HT29 cells with the AR inhibitor fidarestat significantly decreased the expression of vascular endothelial growth factor, a down target of HIF-1alpha, at both mRNA and protein levels and also prevented the activation of PI3K/AKT, GSK3beta, Snail, and lysyl oxidase.	fidarestat	73-83	glycogen synthase kinase 3 beta	Homo sapiens	270-278
21690373-7	2011	This GSK-3beta-dependent Snail degradation occurred as a result of cytokine, growth factor, and bile acid signals that are known to drive liver regeneration.	Bile Acids and Salts	96-105	glycogen synthase kinase 3 beta	Homo sapiens	5-14
21469159-0	2011	Role of bridging water molecules in GSK3beta-inhibitor complexes: insights from QM/MM, MD, and molecular docking studies.	Water	17-22	glycogen synthase kinase 3 beta	Homo sapiens	36-44
21469159-2	2011	In this study, we employ the two-layer ONIOM-based quantum mechanics/molecular mechanics (QM/MM) calculations, molecular dynamics (MD) simulations, and molecular docking studies to investigate the effect of bridging water molecules at the GSK3beta-inhibitors interfaces.	Water	216-221	glycogen synthase kinase 3 beta	Homo sapiens	239-247
21469159-3	2011	The results obtained from the ONIOM geometry optimization and AIM analysis corroborated the presence of bridging water molecules that form hydrogen bonds with protein side chain of Thr138 and/or backbone of Gln185, and mediate interactions with inhibitors in the 10 selected GSK3beta-inhibitor complexes.	Water	113-118	glycogen synthase kinase 3 beta	Homo sapiens	275-283
21469159-3	2011	The results obtained from the ONIOM geometry optimization and AIM analysis corroborated the presence of bridging water molecules that form hydrogen bonds with protein side chain of Thr138 and/or backbone of Gln185, and mediate interactions with inhibitors in the 10 selected GSK3beta-inhibitor complexes.	Hydrogen	139-147	glycogen synthase kinase 3 beta	Homo sapiens	275-283
21469159-4	2011	Subsequently, MD simulations carried out on a representative system of 1R0E demonstrated that the bridging water molecule is stable at the GSK3beta-inhibitor interface and appears to contribute to the stability of the protein-inhibitor interactions.	Water	107-112	glycogen synthase kinase 3 beta	Homo sapiens	139-147
21469159-5	2011	Furthermore, molecular docking studies of GSK3beta-inhibitor complexes indicated that the inhibitors can increase binding affinities and the better docked conformation of inhibitors can be obtained by inclusion of the bridging water molecules, especially for the flexible inhibitors, in docking experiments into individual protein conformations.	Water	227-232	glycogen synthase kinase 3 beta	Homo sapiens	42-50
21469159-6	2011	Our results elucidate the importance of bridging water molecules at the GSK3beta-inhibitor interfaces and suggest that they might prove useful in rational drug design.	Water	49-54	glycogen synthase kinase 3 beta	Homo sapiens	72-80
21328310-6	2011	The single-point mutations of V267G and Y288F in GSK3beta differentiate the binding modes between GSK3 and GSKIPtide, AxinGID, and FRATide.	Fratide	131-138	glycogen synthase kinase 3 beta	Homo sapiens	49-57
21328310-9	2011	An analysis of the GSK3beta-GSKIPtide complex structure and the X-ray crystal structures of GSK3beta-FRATide and GSK3beta-AxinGID complexes suggests that the hydroxyl group of Y288 is crucial to maintaining a hydrogen bond network in GSK3beta-FRATide.	y288	176-180	glycogen synthase kinase 3 beta	Homo sapiens	19-27
21328310-7	2011	The V2677G mutation of GSK3beta reduces the GSKIPtide binding affinity by 70% and abolishes the binding affinity with AxinGID, but has no effect on FRATide.	axingid	118-125	glycogen synthase kinase 3 beta	Homo sapiens	23-31
21328310-9	2011	An analysis of the GSK3beta-GSKIPtide complex structure and the X-ray crystal structures of GSK3beta-FRATide and GSK3beta-AxinGID complexes suggests that the hydroxyl group of Y288 is crucial to maintaining a hydrogen bond network in GSK3beta-FRATide.	y288	176-180	glycogen synthase kinase 3 beta	Homo sapiens	92-100
21328310-9	2011	An analysis of the GSK3beta-GSKIPtide complex structure and the X-ray crystal structures of GSK3beta-FRATide and GSK3beta-AxinGID complexes suggests that the hydroxyl group of Y288 is crucial to maintaining a hydrogen bond network in GSK3beta-FRATide.	y288	176-180	glycogen synthase kinase 3 beta	Homo sapiens	92-100
21328310-9	2011	An analysis of the GSK3beta-GSKIPtide complex structure and the X-ray crystal structures of GSK3beta-FRATide and GSK3beta-AxinGID complexes suggests that the hydroxyl group of Y288 is crucial to maintaining a hydrogen bond network in GSK3beta-FRATide.	y288	176-180	glycogen synthase kinase 3 beta	Homo sapiens	92-100
21515255-3	2011	In Chinese hamster ovary cells transfected with the human delta-opioid receptor (CHO/DOR), NDMC induced a time- and concentration-dependent phosphorylation of Akt at Thr308 and glycogen synthase kinase-3beta (GSK-3beta) at Ser9 and these effects were fully blocked by the delta-opioid receptor antagonist naltrindole.	norclozapine	91-95	glycogen synthase kinase 3 beta	Homo sapiens	177-207
21244366-0	2011	Grape seed procyanidin B2 inhibits advanced glycation end product-induced endothelial cell apoptosis through regulating GSK3beta phosphorylation.	procyanidin B2	11-25	glycogen synthase kinase 3 beta	Homo sapiens	120-128
21606156-10	2011	In conclusion, Enzastaurin reduces cell proliferation by inducing apoptosis, with a mechanism likely involving GSK3beta signaling, and inhibits secretory activity in PNN in vitro models, suggesting that Enzastaurin might represent a possible medical treatment of human PNN.	enzastaurin	15-26	glycogen synthase kinase 3 beta	Homo sapiens	111-119
21358715-0	2011	Co-ordinated action of DISC1, PDE4B and GSK3beta in modulation of cAMP signalling.	Cyclic AMP	66-70	glycogen synthase kinase 3 beta	Homo sapiens	40-48
21615159-0	2011	A new protocol for predicting novel GSK-3beta ATP competitive inhibitors.	Adenosine Triphosphate	46-49	glycogen synthase kinase 3 beta	Homo sapiens	36-45
21615159-2	2011	This paper proposes a new lead identification protocol that predicts new GSK-3beta ATP competitive inhibitors with topologically diverse scaffolds.	Adenosine Triphosphate	83-86	glycogen synthase kinase 3 beta	Homo sapiens	73-82
21530509-0	2011	Ghrelin protects spinal cord motoneurons against chronic glutamate-induced excitotoxicity via ERK1/2 and phosphatidylinositol-3-kinase/Akt/glycogen synthase kinase-3beta pathways.	Ghrelin	0-7	glycogen synthase kinase 3 beta	Homo sapiens	139-169
21530509-0	2011	Ghrelin protects spinal cord motoneurons against chronic glutamate-induced excitotoxicity via ERK1/2 and phosphatidylinositol-3-kinase/Akt/glycogen synthase kinase-3beta pathways.	Glutamic Acid	57-66	glycogen synthase kinase 3 beta	Homo sapiens	139-169
21530509-8	2011	Treatment of spinal cord cultures with ghrelin caused rapid phosphorylation of extracellular signal-regulated kinase 1/2, Akt, and glycogen synthase kinase-3beta (GSK-3beta).	Ghrelin	39-46	glycogen synthase kinase 3 beta	Homo sapiens	131-161
21530509-8	2011	Treatment of spinal cord cultures with ghrelin caused rapid phosphorylation of extracellular signal-regulated kinase 1/2, Akt, and glycogen synthase kinase-3beta (GSK-3beta).	Ghrelin	39-46	glycogen synthase kinase 3 beta	Homo sapiens	163-172
21530509-11	2011	Our data also suggest that PI3K/Akt-mediated inactivation of GSK-3beta in motoneurons contributes to the protective effect of ghrelin.	Ghrelin	126-133	glycogen synthase kinase 3 beta	Homo sapiens	61-70
22152249-3	2011	Experiment groups included sham control group, liver IRI model group and glycogen synthase kinase-3 beta inhibitor-treated group (SB216763 in DMSO, 25 g/kg, i.p, 2 hour prior to the onset of liver ischemia).	SB 216763	130-138	glycogen synthase kinase 3 beta	Homo sapiens	73-104
22152249-9	2011	Glycogen synthase kinase-3 beta inhibitor SB216763-pretreatment ameliorated the liver damages significantly as compared to the controls (sALT: 2046+/-513 U/L vs 5809+/-1689 U/L, P = 0.0153), and suppressed the gene expressions of IL-12, TNFa, IL-1b and IL-6.	SB 216763	42-50	glycogen synthase kinase 3 beta	Homo sapiens	0-31
22152249-9	2011	Glycogen synthase kinase-3 beta inhibitor SB216763-pretreatment ameliorated the liver damages significantly as compared to the controls (sALT: 2046+/-513 U/L vs 5809+/-1689 U/L, P = 0.0153), and suppressed the gene expressions of IL-12, TNFa, IL-1b and IL-6.	Salts	137-141	glycogen synthase kinase 3 beta	Homo sapiens	0-31
21515255-3	2011	In Chinese hamster ovary cells transfected with the human delta-opioid receptor (CHO/DOR), NDMC induced a time- and concentration-dependent phosphorylation of Akt at Thr308 and glycogen synthase kinase-3beta (GSK-3beta) at Ser9 and these effects were fully blocked by the delta-opioid receptor antagonist naltrindole.	norclozapine	91-95	glycogen synthase kinase 3 beta	Homo sapiens	209-218
21524996-3	2011	ILK contains a highly degraded kinase active site but it has been argued that ILK may be an unusual manganese (Mn)-dependent serine-threonine kinase that targets specific substrates such as glycogen synthase kinase-3beta (GSK-3beta).	Manganese	100-109	glycogen synthase kinase 3 beta	Homo sapiens	190-220
21524996-3	2011	ILK contains a highly degraded kinase active site but it has been argued that ILK may be an unusual manganese (Mn)-dependent serine-threonine kinase that targets specific substrates such as glycogen synthase kinase-3beta (GSK-3beta).	Manganese	100-109	glycogen synthase kinase 3 beta	Homo sapiens	222-231
21315693-5	2011	Increased activation of extracellular signal-regulated kinase (ERK) and decreased activation of glycogen synthase kinase (GSK) 3beta were observed after H2O2 exposure, and B12H reversed the altered activation of GSK3beta, but not that of ERK.	Hydrogen Peroxide	153-157	glycogen synthase kinase 3 beta	Homo sapiens	212-220
21315693-7	2011	These findings strongly suggest that B12H prevents H2O2-induced neuronal apoptosis independent of inhibiting AChE, but through regulating VEGFR-2/Akt/GSK3beta signaling pathway.	Hydrogen Peroxide	51-55	glycogen synthase kinase 3 beta	Homo sapiens	150-158
21479670-8	2011	We also showed that gefitinib- and/or AG1024-induced cytostatic effects could be mediated by glycogen synthase kinase-3beta (GSK-3beta) activation.	Gefitinib	20-29	glycogen synthase kinase 3 beta	Homo sapiens	93-123
21440083-6	2011	We provide solid evidence supporting the role of the protein kinase GSK3beta as phosphorylating Pax3 at serine 201.	Serine	104-110	glycogen synthase kinase 3 beta	Homo sapiens	68-76
21524889-16	2011	Immunoblot further showed that minoxidil treatment increases the phosphorylation of GSK3beta, PKA and PKB.	Minoxidil	31-40	glycogen synthase kinase 3 beta	Homo sapiens	84-92
21479670-8	2011	We also showed that gefitinib- and/or AG1024-induced cytostatic effects could be mediated by glycogen synthase kinase-3beta (GSK-3beta) activation.	Gefitinib	20-29	glycogen synthase kinase 3 beta	Homo sapiens	125-134
21479670-8	2011	We also showed that gefitinib- and/or AG1024-induced cytostatic effects could be mediated by glycogen synthase kinase-3beta (GSK-3beta) activation.	tyrphostin AG 1024	38-44	glycogen synthase kinase 3 beta	Homo sapiens	93-123
21479670-8	2011	We also showed that gefitinib- and/or AG1024-induced cytostatic effects could be mediated by glycogen synthase kinase-3beta (GSK-3beta) activation.	tyrphostin AG 1024	38-44	glycogen synthase kinase 3 beta	Homo sapiens	125-134
21495724-0	2011	Molecular modeling and molecular dynamics simulation studies of the GSK3beta/ATP/substrate complex: understanding the unique P+4 primed phosphorylation specificity for GSK3beta substrates.	Adenosine Triphosphate	77-80	glycogen synthase kinase 3 beta	Homo sapiens	68-76
21385891-7	2011	Ganitumab inhibited rapamycin-induced IGF1R, Akt, and glycogen synthase kinase-3beta hyperphosphorylation in each sarcoma model.	Sirolimus	20-29	glycogen synthase kinase 3 beta	Homo sapiens	54-84
21471285-0	2011	The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3beta-dependent pathway.	N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea	53-62	glycogen synthase kinase 3 beta	Homo sapiens	110-140
21471285-0	2011	The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3beta-dependent pathway.	N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea	64-71	glycogen synthase kinase 3 beta	Homo sapiens	110-140
21471285-7	2011	We show that treatment with linifanib reduces phosphorylation of Akt and glycogen synthase kinase 3beta (GSK3beta).	N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea	28-37	glycogen synthase kinase 3 beta	Homo sapiens	73-103
21471285-7	2011	We show that treatment with linifanib reduces phosphorylation of Akt and glycogen synthase kinase 3beta (GSK3beta).	N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea	28-37	glycogen synthase kinase 3 beta	Homo sapiens	105-113
21471285-8	2011	In addition, we show that inhibition of GSK3beta decreases linifanib-induced apoptosis.	N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea	59-68	glycogen synthase kinase 3 beta	Homo sapiens	40-48
21455580-14	2011	NVP-ADW742 inhibited the activation of PI3K, Akt, P38 and GSK-3beta caused by temozolomide.	Temozolomide	78-90	glycogen synthase kinase 3 beta	Homo sapiens	58-67
21435383-6	2011	In an okadaic acid-induced tau hyperphosphorylation SH-SY5Y cell model, the anti-tau-phosphorylation effect of VPA was further confirmed, accompanied by a marked decrease in the activities of CDK5 and GSK3beta.	Okadaic Acid	6-18	glycogen synthase kinase 3 beta	Homo sapiens	201-209
21217772-5	2011	In Jurkat leukaemic T cells as well as in primary human T cells, tetradecanoylphorbolacetate/ionomycin- and CD3/CD28-induced RelB degradation were impaired by a GSK-3beta-specific pharmacological inhibitor, an ectopically expressed dominant-negative GSK-3beta mutant and by small-interfering RNA-mediated silencing of GSK-3beta expression.	Tetradecanoylphorbol Acetate	65-92	glycogen synthase kinase 3 beta	Homo sapiens	161-170
21217772-5	2011	In Jurkat leukaemic T cells as well as in primary human T cells, tetradecanoylphorbolacetate/ionomycin- and CD3/CD28-induced RelB degradation were impaired by a GSK-3beta-specific pharmacological inhibitor, an ectopically expressed dominant-negative GSK-3beta mutant and by small-interfering RNA-mediated silencing of GSK-3beta expression.	Tetradecanoylphorbol Acetate	65-92	glycogen synthase kinase 3 beta	Homo sapiens	250-259
21217772-5	2011	In Jurkat leukaemic T cells as well as in primary human T cells, tetradecanoylphorbolacetate/ionomycin- and CD3/CD28-induced RelB degradation were impaired by a GSK-3beta-specific pharmacological inhibitor, an ectopically expressed dominant-negative GSK-3beta mutant and by small-interfering RNA-mediated silencing of GSK-3beta expression.	Tetradecanoylphorbol Acetate	65-92	glycogen synthase kinase 3 beta	Homo sapiens	250-259
21217772-5	2011	In Jurkat leukaemic T cells as well as in primary human T cells, tetradecanoylphorbolacetate/ionomycin- and CD3/CD28-induced RelB degradation were impaired by a GSK-3beta-specific pharmacological inhibitor, an ectopically expressed dominant-negative GSK-3beta mutant and by small-interfering RNA-mediated silencing of GSK-3beta expression.	Ionomycin	93-102	glycogen synthase kinase 3 beta	Homo sapiens	161-170
21217772-5	2011	In Jurkat leukaemic T cells as well as in primary human T cells, tetradecanoylphorbolacetate/ionomycin- and CD3/CD28-induced RelB degradation were impaired by a GSK-3beta-specific pharmacological inhibitor, an ectopically expressed dominant-negative GSK-3beta mutant and by small-interfering RNA-mediated silencing of GSK-3beta expression.	Ionomycin	93-102	glycogen synthase kinase 3 beta	Homo sapiens	250-259
21217772-5	2011	In Jurkat leukaemic T cells as well as in primary human T cells, tetradecanoylphorbolacetate/ionomycin- and CD3/CD28-induced RelB degradation were impaired by a GSK-3beta-specific pharmacological inhibitor, an ectopically expressed dominant-negative GSK-3beta mutant and by small-interfering RNA-mediated silencing of GSK-3beta expression.	Ionomycin	93-102	glycogen synthase kinase 3 beta	Homo sapiens	250-259
21217772-8	2011	The serine residue 552 is a target of GSK-3beta-mediated phosphorylation in vitro and in vivo.	Serine	4-10	glycogen synthase kinase 3 beta	Homo sapiens	38-47
21430642-3	2011	We exposed renal epithelial cells to metabolic stress causing ATP depletion in the absence of glucose and found that this activated glycogen synthase kinase 3beta (GSK3beta) and Bax caused mitochondrial membrane injury and apoptosis.	Adenosine Triphosphate	62-65	glycogen synthase kinase 3 beta	Homo sapiens	132-162
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	Serine	328-334	glycogen synthase kinase 3 beta	Homo sapiens	211-219
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	Serine	328-334	glycogen synthase kinase 3 beta	Homo sapiens	211-219
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	atp gamma-phosphate	400-419	glycogen synthase kinase 3 beta	Homo sapiens	93-101
21495724-0	2011	Molecular modeling and molecular dynamics simulation studies of the GSK3beta/ATP/substrate complex: understanding the unique P+4 primed phosphorylation specificity for GSK3beta substrates.	Adenosine Triphosphate	77-80	glycogen synthase kinase 3 beta	Homo sapiens	168-176
21495724-2	2011	Glycogen synthase kinase 3beta (GSK3beta) has a unique substrate specificity that prefers phosphorylation of its substrates at the P+4 serine before it can further phosphorylate the substrate at the P0 serine in the canonical motif SXXXS(p), where S(p) is the primed phosphorylation site.	Serine	135-141	glycogen synthase kinase 3 beta	Homo sapiens	0-30
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	atp gamma-phosphate	400-419	glycogen synthase kinase 3 beta	Homo sapiens	211-219
21495724-2	2011	Glycogen synthase kinase 3beta (GSK3beta) has a unique substrate specificity that prefers phosphorylation of its substrates at the P+4 serine before it can further phosphorylate the substrate at the P0 serine in the canonical motif SXXXS(p), where S(p) is the primed phosphorylation site.	Serine	135-141	glycogen synthase kinase 3 beta	Homo sapiens	32-40
21495724-2	2011	Glycogen synthase kinase 3beta (GSK3beta) has a unique substrate specificity that prefers phosphorylation of its substrates at the P+4 serine before it can further phosphorylate the substrate at the P0 serine in the canonical motif SXXXS(p), where S(p) is the primed phosphorylation site.	Serine	202-208	glycogen synthase kinase 3 beta	Homo sapiens	0-30
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	atp gamma-phosphate	400-419	glycogen synthase kinase 3 beta	Homo sapiens	211-219
21495724-2	2011	Glycogen synthase kinase 3beta (GSK3beta) has a unique substrate specificity that prefers phosphorylation of its substrates at the P+4 serine before it can further phosphorylate the substrate at the P0 serine in the canonical motif SXXXS(p), where S(p) is the primed phosphorylation site.	Serine	202-208	glycogen synthase kinase 3 beta	Homo sapiens	32-40
21495724-4	2011	In this study, a three-dimensional (3D) model of the ternary complex of GSK3beta, ATP, and the phosphorylated glycogen synthase (pGS), termed GSK3beta/ATP/pGS, is constructed using a hierarchical approach and by integrating molecular modeling and molecular dynamics (MD) simulations.	Adenosine Triphosphate	82-85	glycogen synthase kinase 3 beta	Homo sapiens	142-150
21495724-4	2011	In this study, a three-dimensional (3D) model of the ternary complex of GSK3beta, ATP, and the phosphorylated glycogen synthase (pGS), termed GSK3beta/ATP/pGS, is constructed using a hierarchical approach and by integrating molecular modeling and molecular dynamics (MD) simulations.	Adenosine Triphosphate	151-154	glycogen synthase kinase 3 beta	Homo sapiens	72-80
21495724-5	2011	Based on the 3D model, the substrate primed phosphorylation mechanism is investigated via two 12 ns comparative MD simulations of the GSK3beta/ATP/pGS and GSK3beta/ATP/GS systems, which differ in the phosphate group bound to the P+4 serine of GS.	Adenosine Triphosphate	143-146	glycogen synthase kinase 3 beta	Homo sapiens	134-142
21495724-5	2011	Based on the 3D model, the substrate primed phosphorylation mechanism is investigated via two 12 ns comparative MD simulations of the GSK3beta/ATP/pGS and GSK3beta/ATP/GS systems, which differ in the phosphate group bound to the P+4 serine of GS.	2,3-di-O-phytanyl-sn-glycero-1-phospho-(3'-sn-glycerol-1'-sulfate)	147-150	glycogen synthase kinase 3 beta	Homo sapiens	134-142
21495724-5	2011	Based on the 3D model, the substrate primed phosphorylation mechanism is investigated via two 12 ns comparative MD simulations of the GSK3beta/ATP/pGS and GSK3beta/ATP/GS systems, which differ in the phosphate group bound to the P+4 serine of GS.	Adenosine Triphosphate	164-167	glycogen synthase kinase 3 beta	Homo sapiens	155-163
21495724-5	2011	Based on the 3D model, the substrate primed phosphorylation mechanism is investigated via two 12 ns comparative MD simulations of the GSK3beta/ATP/pGS and GSK3beta/ATP/GS systems, which differ in the phosphate group bound to the P+4 serine of GS.	Phosphates	200-209	glycogen synthase kinase 3 beta	Homo sapiens	134-142
21495724-5	2011	Based on the 3D model, the substrate primed phosphorylation mechanism is investigated via two 12 ns comparative MD simulations of the GSK3beta/ATP/pGS and GSK3beta/ATP/GS systems, which differ in the phosphate group bound to the P+4 serine of GS.	Phosphates	200-209	glycogen synthase kinase 3 beta	Homo sapiens	155-163
21495724-5	2011	Based on the 3D model, the substrate primed phosphorylation mechanism is investigated via two 12 ns comparative MD simulations of the GSK3beta/ATP/pGS and GSK3beta/ATP/GS systems, which differ in the phosphate group bound to the P+4 serine of GS.	Serine	233-239	glycogen synthase kinase 3 beta	Homo sapiens	134-142
21495724-5	2011	Based on the 3D model, the substrate primed phosphorylation mechanism is investigated via two 12 ns comparative MD simulations of the GSK3beta/ATP/pGS and GSK3beta/ATP/GS systems, which differ in the phosphate group bound to the P+4 serine of GS.	Serine	233-239	glycogen synthase kinase 3 beta	Homo sapiens	155-163
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	Adenosine Triphosphate	102-105	glycogen synthase kinase 3 beta	Homo sapiens	93-101
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	Adenosine Triphosphate	102-105	glycogen synthase kinase 3 beta	Homo sapiens	211-219
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	Adenosine Triphosphate	102-105	glycogen synthase kinase 3 beta	Homo sapiens	211-219
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	Phosphates	194-203	glycogen synthase kinase 3 beta	Homo sapiens	93-101
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	Phosphates	194-203	glycogen synthase kinase 3 beta	Homo sapiens	211-219
21310903-11	2011	Also observed was the interaction between GSK-3beta and Smad3, which was enhanced by lithium.	Lithium	85-92	glycogen synthase kinase 3 beta	Homo sapiens	42-51
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	Phosphates	194-203	glycogen synthase kinase 3 beta	Homo sapiens	211-219
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	Adenosine Triphosphate	220-223	glycogen synthase kinase 3 beta	Homo sapiens	93-101
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	Adenosine Triphosphate	220-223	glycogen synthase kinase 3 beta	Homo sapiens	211-219
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	Adenosine Triphosphate	220-223	glycogen synthase kinase 3 beta	Homo sapiens	211-219
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	2,3-di-O-phytanyl-sn-glycero-1-phospho-(3'-sn-glycerol-1'-sulfate)	182-185	glycogen synthase kinase 3 beta	Homo sapiens	93-101
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	2,3-di-O-phytanyl-sn-glycero-1-phospho-(3'-sn-glycerol-1'-sulfate)	182-185	glycogen synthase kinase 3 beta	Homo sapiens	211-219
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	2,3-di-O-phytanyl-sn-glycero-1-phospho-(3'-sn-glycerol-1'-sulfate)	182-185	glycogen synthase kinase 3 beta	Homo sapiens	211-219
21495724-7	2011	More importantly, comparison with the system simulated without primed phosphorylation in the GSK3beta/ATP/GS complex shows that for an optimal phosphorylation reaction to occur, the pGS priming phosphate in the GSK3beta/ATP/pGS system optimizes the proper orientation of the GSK3beta N- and C-terminal domains and clamps the P0 serine of pGS in the appropriate configuration for interaction with the ATP gamma-phosphate within the catalytic groove.	Serine	328-334	glycogen synthase kinase 3 beta	Homo sapiens	93-101
21253820-7	2011	Further, upon treatment with nanomolar concentrations of a GSK-3beta inhibitor (SB412682), C57 NSC and BEC behaviors could be brought to CD1 levels, consistent with the concept of GSK-3beta functioning as a multifunctional signaling pathway node, modulating several behaviors in these cells.	sb412682	80-88	glycogen synthase kinase 3 beta	Homo sapiens	59-68
21228102-2	2011	We found that prolonged rapamycin treatment in podocytes leads to an increase in glycogen synthase kinase 3beta (GSK3beta) phosphorylation, resulting in inactivation of total GSK3beta kinase activity.	Sirolimus	24-33	glycogen synthase kinase 3 beta	Homo sapiens	81-111
21228102-2	2011	We found that prolonged rapamycin treatment in podocytes leads to an increase in glycogen synthase kinase 3beta (GSK3beta) phosphorylation, resulting in inactivation of total GSK3beta kinase activity.	Sirolimus	24-33	glycogen synthase kinase 3 beta	Homo sapiens	113-121
21228102-2	2011	We found that prolonged rapamycin treatment in podocytes leads to an increase in glycogen synthase kinase 3beta (GSK3beta) phosphorylation, resulting in inactivation of total GSK3beta kinase activity.	Sirolimus	24-33	glycogen synthase kinase 3 beta	Homo sapiens	175-183
21573217-6	2011	Similar data were obtained with Akt-Ser(473), ERK1/2-Thr(202)/Tyr(204) and GSK3-beta Ser(9) in HepG2 and L6.	Serine	85-88	glycogen synthase kinase 3 beta	Homo sapiens	75-84
21711903-0	2011	Lithium promotes neural precursor cell proliferation: evidence for the involvement of the non-canonical GSK-3beta-NF-AT signaling.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	104-113
21711903-6	2011	One important function of lithium appeared to increase inhibitory phosphorylation of GSK-3beta, leading to GSK-3beta suppression and subsequent NF-AT activation.	Lithium	26-33	glycogen synthase kinase 3 beta	Homo sapiens	85-94
21711903-6	2011	One important function of lithium appeared to increase inhibitory phosphorylation of GSK-3beta, leading to GSK-3beta suppression and subsequent NF-AT activation.	Lithium	26-33	glycogen synthase kinase 3 beta	Homo sapiens	107-116
21711903-8	2011	These findings not only provide mechanistic insights into the clinical effects of lithium, but also suggest an alternative therapeutic strategy for bipolar disorder and other neural diseases by targeting the non-canonical GSK-3beta-NF-AT signaling.	Lithium	82-89	glycogen synthase kinase 3 beta	Homo sapiens	222-231
21335476-7	2011	Cell survival signaling was upregulated after H-R with PEG, as demonstrated by increased phosphorylation of Akt, GSK-3beta, and ERK1/2.	Polyethylene Glycols	55-58	glycogen synthase kinase 3 beta	Homo sapiens	113-122
21253820-7	2011	Further, upon treatment with nanomolar concentrations of a GSK-3beta inhibitor (SB412682), C57 NSC and BEC behaviors could be brought to CD1 levels, consistent with the concept of GSK-3beta functioning as a multifunctional signaling pathway node, modulating several behaviors in these cells.	sb412682	80-88	glycogen synthase kinase 3 beta	Homo sapiens	180-189
21409189-0	2011	Dissection of the difference between the group I metal ions in inhibiting GSK3beta: a computational study.	Metals	49-54	glycogen synthase kinase 3 beta	Homo sapiens	74-82
21443457-8	2011	Through this inhibition of GSK-3beta, EPO maintains beta-catenin activity, allows the translocation of beta-catenin from the EC cytoplasm to the nucleus through a Wnt1 pathway, and requires beta-catenin for protection against elevated D-glucose since gene silencing of beta-catenin eliminates the ability of EPO as well as Wnt1 to increase EC survival.	Glucose	235-244	glycogen synthase kinase 3 beta	Homo sapiens	27-36
21354561-8	2011	In part of the leiomyoma cells, ATRA induced a relative increase of Bax (proapoptotic) as well as a relative decrease of phosphorylated glycogen synthase kinase 3beta (proapoptotic).	Tretinoin	32-36	glycogen synthase kinase 3 beta	Homo sapiens	136-166
21360572-0	2011	Lithium chloride and staurosporine potentiate the accumulation of phosphorylated glycogen synthase kinase 3beta/Tyr216, resulting in glycogen synthase kinase 3beta activation in SH-SY5Y human neuroblastoma cell lines.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	81-111
21360572-0	2011	Lithium chloride and staurosporine potentiate the accumulation of phosphorylated glycogen synthase kinase 3beta/Tyr216, resulting in glycogen synthase kinase 3beta activation in SH-SY5Y human neuroblastoma cell lines.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	133-163
21360572-0	2011	Lithium chloride and staurosporine potentiate the accumulation of phosphorylated glycogen synthase kinase 3beta/Tyr216, resulting in glycogen synthase kinase 3beta activation in SH-SY5Y human neuroblastoma cell lines.	Staurosporine	21-34	glycogen synthase kinase 3 beta	Homo sapiens	81-111
21360572-0	2011	Lithium chloride and staurosporine potentiate the accumulation of phosphorylated glycogen synthase kinase 3beta/Tyr216, resulting in glycogen synthase kinase 3beta activation in SH-SY5Y human neuroblastoma cell lines.	Staurosporine	21-34	glycogen synthase kinase 3 beta	Homo sapiens	133-163
21360572-2	2011	Serine 9 phosphorylation of GSK3beta (pGSK3betaSer9), usually promoted by activation of the PI3K/Akt survival pathway, triggers GSK3beta inhibition.	Serine	0-6	glycogen synthase kinase 3 beta	Homo sapiens	28-36
21360572-2	2011	Serine 9 phosphorylation of GSK3beta (pGSK3betaSer9), usually promoted by activation of the PI3K/Akt survival pathway, triggers GSK3beta inhibition.	Serine	0-6	glycogen synthase kinase 3 beta	Homo sapiens	39-47
21360572-3	2011	By contrast, tyrosine 216 phosphorylation of GSK3beta (pGSK3betaTyr216) increases under apoptotic conditions, leading to GSK3beta activation.	Tyrosine	13-21	glycogen synthase kinase 3 beta	Homo sapiens	45-53
21360572-3	2011	By contrast, tyrosine 216 phosphorylation of GSK3beta (pGSK3betaTyr216) increases under apoptotic conditions, leading to GSK3beta activation.	Tyrosine	13-21	glycogen synthase kinase 3 beta	Homo sapiens	56-64
21360572-3	2011	By contrast, tyrosine 216 phosphorylation of GSK3beta (pGSK3betaTyr216) increases under apoptotic conditions, leading to GSK3beta activation.	pgsk3betatyr216	55-70	glycogen synthase kinase 3 beta	Homo sapiens	45-53
21360572-4	2011	Lithium chloride (LiCl) is usually described to increase pGSK3betaSer9 through the PI3K/Akt pathway, resulting in GSK3beta inhibition.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	58-66
21360572-4	2011	Lithium chloride (LiCl) is usually described to increase pGSK3betaSer9 through the PI3K/Akt pathway, resulting in GSK3beta inhibition.	Lithium Chloride	18-22	glycogen synthase kinase 3 beta	Homo sapiens	58-66
21360572-5	2011	The purpose of this study is to demonstrate that in some cases LiCl is also able to increase pGSK3betaTyr216, resulting in GSK3beta activation.	Lithium Chloride	63-67	glycogen synthase kinase 3 beta	Homo sapiens	94-102
21331449-7	2011	GA mediated the G0/G1 phase arrest in U2OS cells; this arrest was associated with a decrease in phospho-GSK3-beta (Ser9) and the expression of cyclin D1.	gambogic acid	0-2	glycogen synthase kinase 3 beta	Homo sapiens	104-113
21565140-16	2011	CONCLUSION: Deguelin can inhibit the phosphorylation of GSK-3beta (Ser9) via inhibition of the phosphorylation of PTEN (Ser380) and PDK1 (Ser241) pathway, thus inducing apoptosis and inhibiting proliferation of MCF-7 cells.	deguelin	12-20	glycogen synthase kinase 3 beta	Homo sapiens	56-65
21296133-0	2011	Akt/GSK3beta signaling is involved in fipronil-induced apoptotic cell death of human neuroblastoma SH-SY5Y cells.	fipronil	38-46	glycogen synthase kinase 3 beta	Homo sapiens	4-12
21329734-8	2011	Visfatin inactivated glycogen synthase kinase 3beta (GSK3beta) by phosphorylating it at Ser-9, leading to the nuclear translocation of beta-catenin.	Serine	88-91	glycogen synthase kinase 3 beta	Homo sapiens	21-51
21329734-8	2011	Visfatin inactivated glycogen synthase kinase 3beta (GSK3beta) by phosphorylating it at Ser-9, leading to the nuclear translocation of beta-catenin.	Serine	88-91	glycogen synthase kinase 3 beta	Homo sapiens	53-61
21329734-9	2011	Both rapamycin co-treatment and p70S6K knockdown inhibited visfatin-induced GSK3beta phosphorylation at Ser-9 and nuclear translocation of beta-catenin.	Sirolimus	5-14	glycogen synthase kinase 3 beta	Homo sapiens	76-84
21329734-9	2011	Both rapamycin co-treatment and p70S6K knockdown inhibited visfatin-induced GSK3beta phosphorylation at Ser-9 and nuclear translocation of beta-catenin.	Serine	104-107	glycogen synthase kinase 3 beta	Homo sapiens	76-84
21369697-1	2011	Lithium is a specific inhibitor of GSK3-beta, and hence, an activator of the Wnt/beta-catenin pathway, whereas the epidermal growth factor (EGF) has been linked to malignant transformation in epithelial cancer cells.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	35-44
21369697-8	2011	However, lithium, but not EGF, inhibited GSK3-beta, indicating that these agents modulate this enzyme in a differential fashion.	Lithium	9-16	glycogen synthase kinase 3 beta	Homo sapiens	41-50
21278055-0	2011	Involvement of glycogen synthase kinase-3beta in arsenic trioxide-induced p21 expression.	Arsenic Trioxide	49-65	glycogen synthase kinase 3 beta	Homo sapiens	15-45
21278055-5	2011	Therefore, we hypothesized that ATO-induced p21 expression might be through the inhibition of GSK-3beta.	Arsenic Trioxide	32-35	glycogen synthase kinase 3 beta	Homo sapiens	94-103
21278055-7	2011	ATO, as well as LiCl (GSK-3beta inhibitor), could induce GSK-3beta(Ser9) phosphorylation and p21 expression in a time- and dose-dependent manner.	Arsenic Trioxide	0-3	glycogen synthase kinase 3 beta	Homo sapiens	57-66
21278055-7	2011	ATO, as well as LiCl (GSK-3beta inhibitor), could induce GSK-3beta(Ser9) phosphorylation and p21 expression in a time- and dose-dependent manner.	Lithium Chloride	16-20	glycogen synthase kinase 3 beta	Homo sapiens	22-31
21278055-7	2011	ATO, as well as LiCl (GSK-3beta inhibitor), could induce GSK-3beta(Ser9) phosphorylation and p21 expression in a time- and dose-dependent manner.	Lithium Chloride	16-20	glycogen synthase kinase 3 beta	Homo sapiens	57-66
21278055-10	2011	Furthermore, ATO-induced GSK-3beta(Ser9) phosphorylation was through the ERK pathway, but not the PI3K/Akt pathway.	Arsenic Trioxide	13-16	glycogen synthase kinase 3 beta	Homo sapiens	25-34
21278055-11	2011	We suggest that, taken together, ATO-induced ERK phosphorylation could inhibit GSK-3beta activity to dephosphorylate the C-terminus (Ser243) of c-Jun to increase p21 expression and resultant cell death.	Arsenic Trioxide	33-36	glycogen synthase kinase 3 beta	Homo sapiens	79-88
21352912-0	2011	Curcumin activates Wnt/beta-catenin signaling pathway through inhibiting the activity of GSK-3beta in APPswe transfected SY5Y cells.	Curcumin	0-8	glycogen synthase kinase 3 beta	Homo sapiens	89-98
21352912-2	2011	The study aims to investigate the effect of Curcumin on the expression of GSK-3beta, beta-catenin and CyclinD1 in vitro, which are tightly correlated with Wnt/beta-catenin signaling pathway, and also to explore the mechanisms, which will provide a novel therapeutic intervention for treatment of Alzheimer"s disease.	Curcumin	44-52	glycogen synthase kinase 3 beta	Homo sapiens	74-83
21317289-2	2011	Here, we report that Sufu is phosphorylated at Ser-342 and Ser-346 by GSK3beta and cAMP-dependent protein kinase A (PKA), respectively, and phosphorylation at this dual site stabilizes Sufu against Shh signaling-induced degradation.	Serine	47-50	glycogen synthase kinase 3 beta	Homo sapiens	70-78
21352912-5	2011	Cell lysates were collected for RT-PCR, Western blot assay and immunofluorescent staining were carried out for detecting the effect of Curcumin on the expression of GSK-3beta, beta-catenin and CyclinD1.	Curcumin	135-143	glycogen synthase kinase 3 beta	Homo sapiens	165-174
21352912-6	2011	RT-PCR and Western blot results showed that the expression of GSK-3beta mRNA and protein significantly decreased in the transfected cells treated with Curcumin, and that the changes were in a dose and time-dependent manner (P&lt;0.05); however, the protein expression of GSK-3beta-Ser9 was increased (P&lt;0.05).	Curcumin	151-159	glycogen synthase kinase 3 beta	Homo sapiens	62-71
21352912-6	2011	RT-PCR and Western blot results showed that the expression of GSK-3beta mRNA and protein significantly decreased in the transfected cells treated with Curcumin, and that the changes were in a dose and time-dependent manner (P&lt;0.05); however, the protein expression of GSK-3beta-Ser9 was increased (P&lt;0.05).	Curcumin	151-159	glycogen synthase kinase 3 beta	Homo sapiens	271-280
21352912-10	2011	Curcumin could activate the Wnt/beta-catenin signaling pathway through inhibiting the expression of GSK-3beta and inducing the expression of beta-catenin and CyclinD1, which will provide a new theory for treatment of neurodegenerative diseases by Curcumin.	Curcumin	0-8	glycogen synthase kinase 3 beta	Homo sapiens	100-109
21317289-2	2011	Here, we report that Sufu is phosphorylated at Ser-342 and Ser-346 by GSK3beta and cAMP-dependent protein kinase A (PKA), respectively, and phosphorylation at this dual site stabilizes Sufu against Shh signaling-induced degradation.	Serine	59-62	glycogen synthase kinase 3 beta	Homo sapiens	70-78
21435461-1	2011	The serine/threonine kinase GSK-3beta was initially described as a key enzyme involved in glucose metabolism, but it is now known to regulate a wide range of biological processes, including proliferation and apoptosis.	Glucose	90-97	glycogen synthase kinase 3 beta	Homo sapiens	28-37
21483640-7	2011	The TWS119 (a distinct GSK-3beta inhibitor)-induced total GST activity was significantly higher in HepG2 cells with beta-catenin accumulation than in those without beta-catenin accumulation in nuclei of HCC cells.	TWS 119	4-10	glycogen synthase kinase 3 beta	Homo sapiens	23-32
21277352-11	2011	Isoflurane post-treatment also significantly increased the phosphorylation of GSK3beta at Ser9 at 1 h after the OGD.	Isoflurane	0-10	glycogen synthase kinase 3 beta	Homo sapiens	78-86
21435461-4	2011	We found that glucose depletion caused a marked inhibition of GSK-3beta through posttranslational mechanisms and that this inhibition was much less pronounced in normal cells.	Glucose	14-21	glycogen synthase kinase 3 beta	Homo sapiens	62-71
21435461-5	2011	Further inhibition of GSK-3beta with lithium chloride, combined with glucose shortage, caused specific activation of AMP-activated protein kinase and significant suppression of proliferation in transformed but not normal cells.	Lithium Chloride	37-53	glycogen synthase kinase 3 beta	Homo sapiens	22-31
21296414-3	2011	We designed a chimeric protein, GFP-FRATtide, wherein GFP acts as a biomarker for fluorescence detection, and FRATtide binds to and blocks the active site of glycogen synthase kinase-3beta (GSK-3beta) - a protein kinase involved in Wnt signaling.	frattide	36-44	glycogen synthase kinase 3 beta	Homo sapiens	158-188
21296414-3	2011	We designed a chimeric protein, GFP-FRATtide, wherein GFP acts as a biomarker for fluorescence detection, and FRATtide binds to and blocks the active site of glycogen synthase kinase-3beta (GSK-3beta) - a protein kinase involved in Wnt signaling.	frattide	36-44	glycogen synthase kinase 3 beta	Homo sapiens	190-199
21296414-3	2011	We designed a chimeric protein, GFP-FRATtide, wherein GFP acts as a biomarker for fluorescence detection, and FRATtide binds to and blocks the active site of glycogen synthase kinase-3beta (GSK-3beta) - a protein kinase involved in Wnt signaling.	frattide	110-118	glycogen synthase kinase 3 beta	Homo sapiens	158-188
21296414-3	2011	We designed a chimeric protein, GFP-FRATtide, wherein GFP acts as a biomarker for fluorescence detection, and FRATtide binds to and blocks the active site of glycogen synthase kinase-3beta (GSK-3beta) - a protein kinase involved in Wnt signaling.	frattide	110-118	glycogen synthase kinase 3 beta	Homo sapiens	190-199
21308747-7	2011	Moreover, SPH-induced dephosphorylation of Akt at Ser(473) subsequently leads to the activation of GSK-3beta, caspase 3, PARP cleavage, and ultimately apoptosis.	Sphingosine	10-13	glycogen synthase kinase 3 beta	Homo sapiens	99-108
21308747-7	2011	Moreover, SPH-induced dephosphorylation of Akt at Ser(473) subsequently leads to the activation of GSK-3beta, caspase 3, PARP cleavage, and ultimately apoptosis.	Serine	50-53	glycogen synthase kinase 3 beta	Homo sapiens	99-108
21147505-9	2011	GSK-3 pharmacological inhibitors and shRNA-targeted knockdown of GSK-3alpha or GSK-3beta also suppressed JNK activation by palmitate.	Palmitates	123-132	glycogen synthase kinase 3 beta	Homo sapiens	79-88
21443429-0	2011	Citrus flavonoids luteolin, apigenin, and quercetin inhibit glycogen synthase kinase-3beta enzymatic activity by lowering the interaction energy within the binding cavity.	Flavonoids	7-17	glycogen synthase kinase 3 beta	Homo sapiens	60-90
21307779-5	2011	We found gradational increase (P &lt; 0.01) in phosphorylation of Akt(S473) and glycogen synthase kinase (GSK3beta(S9)) in hyperglycemia (10 and 20 mM) when compared with 5 mM glucose.	Glucose	176-183	glycogen synthase kinase 3 beta	Homo sapiens	106-114
21443429-0	2011	Citrus flavonoids luteolin, apigenin, and quercetin inhibit glycogen synthase kinase-3beta enzymatic activity by lowering the interaction energy within the binding cavity.	Luteolin	18-26	glycogen synthase kinase 3 beta	Homo sapiens	60-90
21443429-0	2011	Citrus flavonoids luteolin, apigenin, and quercetin inhibit glycogen synthase kinase-3beta enzymatic activity by lowering the interaction energy within the binding cavity.	Apigenin	28-36	glycogen synthase kinase 3 beta	Homo sapiens	60-90
21443429-0	2011	Citrus flavonoids luteolin, apigenin, and quercetin inhibit glycogen synthase kinase-3beta enzymatic activity by lowering the interaction energy within the binding cavity.	Quercetin	42-51	glycogen synthase kinase 3 beta	Homo sapiens	60-90
21443429-2	2011	In this investigation, various citrus compounds, including flavonoids, phenolic acids, and limonoids, were individually investigated for their inhibitory effects on GSK-3beta by using a luminescence assay.	Limonins	91-100	glycogen synthase kinase 3 beta	Homo sapiens	165-174
21443429-3	2011	Of the 22 citrus compounds tested, the flavonoids luteolin, apigenin, and quercetin had the highest inhibitory effects on GSK-3beta, with 50% inhibitory values of 1.5, 1.9, and 2.0 muM, respectively.	Flavonoids	39-49	glycogen synthase kinase 3 beta	Homo sapiens	122-131
21443429-3	2011	Of the 22 citrus compounds tested, the flavonoids luteolin, apigenin, and quercetin had the highest inhibitory effects on GSK-3beta, with 50% inhibitory values of 1.5, 1.9, and 2.0 muM, respectively.	Luteolin	50-58	glycogen synthase kinase 3 beta	Homo sapiens	122-131
21443429-3	2011	Of the 22 citrus compounds tested, the flavonoids luteolin, apigenin, and quercetin had the highest inhibitory effects on GSK-3beta, with 50% inhibitory values of 1.5, 1.9, and 2.0 muM, respectively.	Apigenin	60-68	glycogen synthase kinase 3 beta	Homo sapiens	122-131
21443429-3	2011	Of the 22 citrus compounds tested, the flavonoids luteolin, apigenin, and quercetin had the highest inhibitory effects on GSK-3beta, with 50% inhibitory values of 1.5, 1.9, and 2.0 muM, respectively.	Quercetin	74-83	glycogen synthase kinase 3 beta	Homo sapiens	122-131
21443429-4	2011	Molecular dockings were then performed to determine the potential interactions of each citrus flavonoid with GSK-3beta.	Flavonoids	94-103	glycogen synthase kinase 3 beta	Homo sapiens	109-118
21443429-5	2011	Luteolin, apigenin, and quercetin were predicted to fit within the binding pocket of GSK-3beta with low interaction energies (-76.4, -76.1, and -84.6 kcal mol(-1), respectively) and low complex energies (-718.1, -688.1, and -719.7 kcal mol(-1), respectively).	Apigenin	10-18	glycogen synthase kinase 3 beta	Homo sapiens	85-94
21443429-5	2011	Luteolin, apigenin, and quercetin were predicted to fit within the binding pocket of GSK-3beta with low interaction energies (-76.4, -76.1, and -84.6 kcal mol(-1), respectively) and low complex energies (-718.1, -688.1, and -719.7 kcal mol(-1), respectively).	Quercetin	24-33	glycogen synthase kinase 3 beta	Homo sapiens	85-94
21443429-6	2011	Our results indicate that several citrus flavonoids inhibit GSK-3beta activity and suggest that these have potential to suppress the growth of pancreatic tumors.	Flavonoids	41-51	glycogen synthase kinase 3 beta	Homo sapiens	60-69
21518487-6	2011	Compared with results of Western blot before treatment, expression of inactivated GSK-3beta, beta-catenin and Cyclin-D1 down-regulated in a dose-dependent manner after treatment with sorafenib, this same changes were observed after up-regulation of inactivated GSK-3beta by LiCl (p &lt; 0.05).	Sorafenib	183-192	glycogen synthase kinase 3 beta	Homo sapiens	82-91
21314327-7	2011	GSK3B activity was indirectly inferred by the GSK3B ratio (i.e. pGSK3B/tGSK3B).	pgsk3b	64-70	glycogen synthase kinase 3 beta	Homo sapiens	0-5
21314327-7	2011	GSK3B activity was indirectly inferred by the GSK3B ratio (i.e. pGSK3B/tGSK3B).	pgsk3b	64-70	glycogen synthase kinase 3 beta	Homo sapiens	46-51
21660151-9	2011	Active GSK3beta in the presence of 3-MA resulted in significantly increased formation of insoluble tau aggregates.	3-methyladenine	35-39	glycogen synthase kinase 3 beta	Homo sapiens	7-15
21518487-6	2011	Compared with results of Western blot before treatment, expression of inactivated GSK-3beta, beta-catenin and Cyclin-D1 down-regulated in a dose-dependent manner after treatment with sorafenib, this same changes were observed after up-regulation of inactivated GSK-3beta by LiCl (p &lt; 0.05).	Sorafenib	183-192	glycogen synthase kinase 3 beta	Homo sapiens	261-270
21518487-6	2011	Compared with results of Western blot before treatment, expression of inactivated GSK-3beta, beta-catenin and Cyclin-D1 down-regulated in a dose-dependent manner after treatment with sorafenib, this same changes were observed after up-regulation of inactivated GSK-3beta by LiCl (p &lt; 0.05).	Lithium Chloride	274-278	glycogen synthase kinase 3 beta	Homo sapiens	82-91
21518487-7	2011	It is concluded that sorafenib inhibits the proliferation of U937 cells and induces cell apoptosis through reducing negative regulation of WNT signal pathway on inactivated GSK-3beta and down-regulating beta-catenin and cyclin-D1 level, which result in U937 cell cycle G(1)/G(0) arrest.	Sorafenib	21-30	glycogen synthase kinase 3 beta	Homo sapiens	173-182
21212269-9	2011	In addition, Dll4 expression by the GSK3beta inhibitor was only observed in confluent cells, and was impeded by DAPT, a gamma-secretase inhibitor, implying requirement of the Notch signal in beta-catenin-dependent Dll4 expression.	dapt	112-116	glycogen synthase kinase 3 beta	Homo sapiens	36-44
21439087-0	2011	P27(Kip1), regulated by glycogen synthase kinase-3beta, results in HMBA-induced differentiation of human gastric cancer cells.	hexamethylene bisacetamide	67-71	glycogen synthase kinase 3 beta	Homo sapiens	24-54
21439087-6	2011	To investigate the effects of HMBA on protein localization and the activities of GSK-3beta, CDK2 and CDK4, kinase assays, immunoprecipitation and western blotting were performed.	hexamethylene bisacetamide	30-34	glycogen synthase kinase 3 beta	Homo sapiens	81-90
21238544-1	2011	Presenilin 1 (PS1), a causative molecule of familial Alzheimer"s disease (AD), is known to be an unprimed substrate of glycogen synthase kinase 3 beta (GSK3beta) [Twomey and McCarthy (2006) FEBS Lett 580:4015-4020] and is phosphorylated at serine 353, 357 residues in its cytoplasmic loop region [Kirschenbaum et al.	Serine	240-246	glycogen synthase kinase 3 beta	Homo sapiens	119-150
21244636-0	2011	Structural features underlying selective inhibition of GSK3beta by dibromocantharelline: implications for rational drug design.	dibromocantharelline	67-87	glycogen synthase kinase 3 beta	Homo sapiens	55-63
20518705-8	2011	Phosphatidylinositol 3-kinase activation results in phosphorylation of Akt promoting activation of nitric oxide synthase and nitric oxide production, which inhibits glycogen synthase kinase-3beta, perhaps the final cytosolic signaling step before inhibition of MPTP formation.	Nitric Oxide	99-111	glycogen synthase kinase 3 beta	Homo sapiens	165-195
21189258-7	2011	We found that TGF-beta1 induced glycogen synthase kinase-3beta (GSK-3beta) phosphorylation on Ser-9 in HKC-8 cells, leading to its inactivation.	Serine	94-97	glycogen synthase kinase 3 beta	Homo sapiens	32-62
21189258-7	2011	We found that TGF-beta1 induced glycogen synthase kinase-3beta (GSK-3beta) phosphorylation on Ser-9 in HKC-8 cells, leading to its inactivation.	Serine	94-97	glycogen synthase kinase 3 beta	Homo sapiens	64-73
21244636-2	2011	Hymenialdisine potently inhibits glycogen synthase kinase 3beta, cyclin-dependent kinase 2, and cyclin-dependent kinase 5, whereas dibromocantharelline only displays a significant inhibitory effect toward glycogen synthase kinase 3beta (IC(50)  = 3 mumol).	hymenialdisine	0-14	glycogen synthase kinase 3 beta	Homo sapiens	33-90
21244636-2	2011	Hymenialdisine potently inhibits glycogen synthase kinase 3beta, cyclin-dependent kinase 2, and cyclin-dependent kinase 5, whereas dibromocantharelline only displays a significant inhibitory effect toward glycogen synthase kinase 3beta (IC(50)  = 3 mumol).	hymenialdisine	0-14	glycogen synthase kinase 3 beta	Homo sapiens	33-63
21244636-4	2011	The similar binding modes of hymenialdisine in complex with cyclin-dependent kinase 5 and glycogen synthase kinase 3beta are consistent with the poor selectivity of hymenialdisine toward the two kinases.	hymenialdisine	29-43	glycogen synthase kinase 3 beta	Homo sapiens	90-120
21244636-4	2011	The similar binding modes of hymenialdisine in complex with cyclin-dependent kinase 5 and glycogen synthase kinase 3beta are consistent with the poor selectivity of hymenialdisine toward the two kinases.	hymenialdisine	165-179	glycogen synthase kinase 3 beta	Homo sapiens	90-120
20683916-5	2011	We found that GSK3beta activation could promote HF-LPLI-induced apoptosis, which could be prevented by lithium chloride (a selective inhibitor of GSK3beta) exposure or by GSK3beta-KD (a dominant-negative GSK3beta) overexpression.	Lithium Chloride	103-119	glycogen synthase kinase 3 beta	Homo sapiens	14-22
21239435-7	2011	In addition, lithium chloride, which increases GSK3beta phosphorylation and the nuclear translocation of beta-catenin, increased MT1-MMP levels in these ovarian cancer cells.	Lithium Chloride	13-29	glycogen synthase kinase 3 beta	Homo sapiens	47-55
21281991-0	2011	An application of two MIFs-based tools (Volsurf+ and Pentacle) to binary QSAR: the case of a palinurin-related data set of non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors.	palinurin	93-102	glycogen synthase kinase 3 beta	Homo sapiens	143-173
20683916-5	2011	We found that GSK3beta activation could promote HF-LPLI-induced apoptosis, which could be prevented by lithium chloride (a selective inhibitor of GSK3beta) exposure or by GSK3beta-KD (a dominant-negative GSK3beta) overexpression.	Lithium Chloride	103-119	glycogen synthase kinase 3 beta	Homo sapiens	146-154
20683916-5	2011	We found that GSK3beta activation could promote HF-LPLI-induced apoptosis, which could be prevented by lithium chloride (a selective inhibitor of GSK3beta) exposure or by GSK3beta-KD (a dominant-negative GSK3beta) overexpression.	Lithium Chloride	103-119	glycogen synthase kinase 3 beta	Homo sapiens	146-154
20683916-8	2011	Furthermore, vitamin c, a ROS scavenger, completely prevented the inactivation of Akt/GSK3beta pathway, indicating ROS generation was crucial for the inactivation.	Ascorbic Acid	13-22	glycogen synthase kinase 3 beta	Homo sapiens	86-94
20683916-8	2011	Furthermore, vitamin c, a ROS scavenger, completely prevented the inactivation of Akt/GSK3beta pathway, indicating ROS generation was crucial for the inactivation.	Reactive Oxygen Species	26-29	glycogen synthase kinase 3 beta	Homo sapiens	86-94
20683916-8	2011	Furthermore, vitamin c, a ROS scavenger, completely prevented the inactivation of Akt/GSK3beta pathway, indicating ROS generation was crucial for the inactivation.	Reactive Oxygen Species	115-118	glycogen synthase kinase 3 beta	Homo sapiens	86-94
21343617-3	2011	Akt-mediated phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) inhibits its enzymatic activity, thereby stimulating glycogen synthesis.	Glycogen	32-40	glycogen synthase kinase 3 beta	Homo sapiens	64-73
21229324-0	2011	Caffeine inhibits cell proliferation and regulates PKA/GSK3beta pathways in U87MG human glioma cells.	Caffeine	0-8	glycogen synthase kinase 3 beta	Homo sapiens	55-63
21229324-5	2011	Caffeine also phosphorylated serine 9 of glycogen synthase kinase 3 beta (GSK3beta).	Caffeine	0-8	glycogen synthase kinase 3 beta	Homo sapiens	41-72
21229324-5	2011	Caffeine also phosphorylated serine 9 of glycogen synthase kinase 3 beta (GSK3beta).	Caffeine	0-8	glycogen synthase kinase 3 beta	Homo sapiens	74-82
21229324-5	2011	Caffeine also phosphorylated serine 9 of glycogen synthase kinase 3 beta (GSK3beta).	Serine	29-35	glycogen synthase kinase 3 beta	Homo sapiens	41-72
21229324-5	2011	Caffeine also phosphorylated serine 9 of glycogen synthase kinase 3 beta (GSK3beta).	Serine	29-35	glycogen synthase kinase 3 beta	Homo sapiens	74-82
21229324-6	2011	Pretreatment with H89, a pharmacological inhibitor of protein kinase A (PKA), was able to antagonize caffeine-induced GSK3beta(ser9) phosphorylation, suggesting that the mechanism might involve a cAMP-dependent PKA-dependent pathway.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	18-21	glycogen synthase kinase 3 beta	Homo sapiens	118-126
21229324-6	2011	Pretreatment with H89, a pharmacological inhibitor of protein kinase A (PKA), was able to antagonize caffeine-induced GSK3beta(ser9) phosphorylation, suggesting that the mechanism might involve a cAMP-dependent PKA-dependent pathway.	Caffeine	101-109	glycogen synthase kinase 3 beta	Homo sapiens	118-126
21229324-6	2011	Pretreatment with H89, a pharmacological inhibitor of protein kinase A (PKA), was able to antagonize caffeine-induced GSK3beta(ser9) phosphorylation, suggesting that the mechanism might involve a cAMP-dependent PKA-dependent pathway.	Cyclic AMP	196-200	glycogen synthase kinase 3 beta	Homo sapiens	118-126
20926980-5	2011	Incubation of septic muscle with LiCl completely reversed the increased GSK-3[beta] activity and decreased proteolysis to basal nonseptic values, but only partially reduced proteosome activity and did not diminish atrogene expression.	Lithium Chloride	33-37	glycogen synthase kinase 3 beta	Homo sapiens	72-82
20926980-9	2011	These data suggest that in vitro lithium treatment, which inhibited GSK-3[beta] activity, (a) effectively reversed the sepsis-induced increase in proteolysis, but only in part by a reduction in the ubiquitin-proteosome pathway and not by a reduction in autophagy; and (b) was ineffective at reversing the sepsis-induced decrease in muscle protein synthesis.	Lithium	33-40	glycogen synthase kinase 3 beta	Homo sapiens	68-78
20956948-12	2011	These results together support Akt can upregulate the expression of Mre11 through GSK3beta/ beta-catenin/LEF pathway to elevate DSB-repair capacity in cancer cells.	1,2-di-(4-sulfamidophenyl)-4-butylpyrazolidine-3,5-dione	128-131	glycogen synthase kinase 3 beta	Homo sapiens	82-90
21343617-6	2011	The inhibitory effect of GSK-3beta on mTORC2-Akt signaling and cell proliferation was eliminated by blocking phosphorylation of rictor at serine-1235.	Serine	138-144	glycogen synthase kinase 3 beta	Homo sapiens	25-34
21343617-5	2011	We found that during cellular stress, GSK-3beta phosphorylated the mTORC2 component rictor at serine-1235, a modification that interfered with the binding of Akt to mTORC2.	Serine	94-100	glycogen synthase kinase 3 beta	Homo sapiens	38-47
20940044-5	2011	We found that Li(+) activated the mammalian target of rapamycin (mTOR) pathway via GSK-3beta in these cells, and the effect of Li(+) to induce c-Ret was amenable to the inhibitory effect of the mTOR inhibitor, rapamycin.	Sirolimus	54-63	glycogen synthase kinase 3 beta	Homo sapiens	83-92
21173986-0	2011	Copper(II) complexes of hybrid hydroxyquinoline-thiosemicarbazone ligands: GSK3beta inhibition due to intracellular delivery of copper.	cupric ion	0-10	glycogen synthase kinase 3 beta	Homo sapiens	75-83
21173986-0	2011	Copper(II) complexes of hybrid hydroxyquinoline-thiosemicarbazone ligands: GSK3beta inhibition due to intracellular delivery of copper.	hydroxyquinoline-thiosemicarbazone	31-65	glycogen synthase kinase 3 beta	Homo sapiens	75-83
21173986-0	2011	Copper(II) complexes of hybrid hydroxyquinoline-thiosemicarbazone ligands: GSK3beta inhibition due to intracellular delivery of copper.	Copper	128-134	glycogen synthase kinase 3 beta	Homo sapiens	75-83
21173986-3	2011	Increasing intracellular copper concentrations has been found to trigger pathways that result in inhibition of GSK3beta.	Copper	25-31	glycogen synthase kinase 3 beta	Homo sapiens	111-119
21173986-8	2011	The increased intracellular copper results in a dose-dependent inhibition (phosphorylation) of GSK3beta.	Copper	28-34	glycogen synthase kinase 3 beta	Homo sapiens	95-103
20672290-9	2011	The enhanced CD86 expression by LiCl involves the PI3K/AKT and GSK-3beta pathway.	Lithium Chloride	32-36	glycogen synthase kinase 3 beta	Homo sapiens	63-72
20863277-7	2011	Lithium-mediated neurotroprotective and neurotrophic effects involve mechanisms highly relevant to the post-stroke population including the increased expression of brain-derived neurotrophic factor (BDNF) and Bcl-2, and inhibition of GSK-3beta.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	234-243
20863277-8	2011	Lithium-induced increases in human gray matter have been reported and occur within a time frame consistent with the known effects of lithium through increased expression of BDNF, Bcl-2 and GSK-3beta inhibition.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	189-198
20863277-8	2011	Lithium-induced increases in human gray matter have been reported and occur within a time frame consistent with the known effects of lithium through increased expression of BDNF, Bcl-2 and GSK-3beta inhibition.	Lithium	133-140	glycogen synthase kinase 3 beta	Homo sapiens	189-198
21111724-10	2011	Kenpaullone (1, 3 muM) decreased the active- and increased the inactive form of cytoplasmic GSK-3beta, and increased nuclear AR and beta-catenin accumulation.	kenpaullone	0-11	glycogen synthase kinase 3 beta	Homo sapiens	92-101
20672290-11	2011	The effect of LiCl on IL-6/IL-8/IL-10 secretion in iDC is mediated through inhibition of GSK-3beta.	Lithium Chloride	14-18	glycogen synthase kinase 3 beta	Homo sapiens	89-98
20672290-12	2011	We have also demonstrated that PPARgamma is downstream of GSK-3beta and is responsible for the LiCl-mediated modulation of CD86/83 and CD1 expression, but not IL-6/8/10 secretion.	Lithium Chloride	95-99	glycogen synthase kinase 3 beta	Homo sapiens	58-67
21068446-3	2011	LPCAT1 was identified as a phosphoenzyme as Ser(178) within a phosphodegron was identified as a putative molecular recognition site for glycogen synthase kinase-3beta (GSK-3beta) phosphorylation that recruits beta-TrCP docking within the enzyme.	Serine	44-47	glycogen synthase kinase 3 beta	Homo sapiens	136-166
20576277-6	2011	The expression of platelet GSK3B (total- and Ser-9 phosphorylated GSK3B) was determined by Western blot.	Serine	45-48	glycogen synthase kinase 3 beta	Homo sapiens	27-32
20576277-8	2011	Ser-9 phosphorylated GSK3B was significantly reduced in patients with MCI and AD as compared to controls (p=0.04).	Serine	0-3	glycogen synthase kinase 3 beta	Homo sapiens	21-26
21068446-3	2011	LPCAT1 was identified as a phosphoenzyme as Ser(178) within a phosphodegron was identified as a putative molecular recognition site for glycogen synthase kinase-3beta (GSK-3beta) phosphorylation that recruits beta-TrCP docking within the enzyme.	Serine	44-47	glycogen synthase kinase 3 beta	Homo sapiens	168-177
21261990-2	2011	Both enzymes are similarly inactivated by serine phosphorylation (GSK-3alpha at Ser21 and GSK-3beta at Ser9) and activated by tyrosine phosphorylation (GSK-3alpha at Tyr279 and GSK-3beta at Tyr216).	Serine	42-48	glycogen synthase kinase 3 beta	Homo sapiens	90-99
21261990-2	2011	Both enzymes are similarly inactivated by serine phosphorylation (GSK-3alpha at Ser21 and GSK-3beta at Ser9) and activated by tyrosine phosphorylation (GSK-3alpha at Tyr279 and GSK-3beta at Tyr216).	Tyrosine	126-134	glycogen synthase kinase 3 beta	Homo sapiens	90-99
21261990-2	2011	Both enzymes are similarly inactivated by serine phosphorylation (GSK-3alpha at Ser21 and GSK-3beta at Ser9) and activated by tyrosine phosphorylation (GSK-3alpha at Tyr279 and GSK-3beta at Tyr216).	Serine	42-48	glycogen synthase kinase 3 beta	Homo sapiens	177-186
21261990-2	2011	Both enzymes are similarly inactivated by serine phosphorylation (GSK-3alpha at Ser21 and GSK-3beta at Ser9) and activated by tyrosine phosphorylation (GSK-3alpha at Tyr279 and GSK-3beta at Tyr216).	Tyrosine	126-134	glycogen synthase kinase 3 beta	Homo sapiens	177-186
24212624-6	2011	GSK3beta has also emerged as a mediator of pathological states, including glucose intolerance, inflammation, and various cancers (e.g., pancreatic cancer).	Glucose	74-81	glycogen synthase kinase 3 beta	Homo sapiens	0-8
21187413-1	2011	The D2/AKT1/GSK-3beta signaling pathway has been involved in the downstream intracellular effects of dopamine, in the pathophysiology of cognitive deficits and related brain activity in schizophrenia, as well as in response to treatment with antipsychotics.	Dopamine	101-109	glycogen synthase kinase 3 beta	Homo sapiens	12-21
20934407-0	2011	The anti-tumoral drug enzastaurin inhibits natural killer cell cytotoxicity via activation of glycogen synthase kinase-3beta.	enzastaurin	22-33	glycogen synthase kinase 3 beta	Homo sapiens	94-124
20934407-1	2011	Enzastaurin is a selective protein kinase Cbeta inhibitor which is shown to have direct antitumor effect as well as suppress glycogen synthase kinase-3beta (GSK-3beta) phosphorylation (resulting in its activation) in both tumor tissues and peripheral blood mononuclear cells (PBMC).	enzastaurin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	125-155
20934407-1	2011	Enzastaurin is a selective protein kinase Cbeta inhibitor which is shown to have direct antitumor effect as well as suppress glycogen synthase kinase-3beta (GSK-3beta) phosphorylation (resulting in its activation) in both tumor tissues and peripheral blood mononuclear cells (PBMC).	enzastaurin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	157-166
20934407-6	2011	Analysis of signal transduction revealed that enzastaurin activated GSK-3beta by inhibition of GSK-3beta phosphorylation.	enzastaurin	46-57	glycogen synthase kinase 3 beta	Homo sapiens	68-77
20934407-6	2011	Analysis of signal transduction revealed that enzastaurin activated GSK-3beta by inhibition of GSK-3beta phosphorylation.	enzastaurin	46-57	glycogen synthase kinase 3 beta	Homo sapiens	95-104
20934407-7	2011	Treatment of NK cells with GSK-3beta-specific inhibitor TDZD-8 prevented enzastaurin-induced inhibition of NK cell cytotoxicity.	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	56-62	glycogen synthase kinase 3 beta	Homo sapiens	27-36
20934407-7	2011	Treatment of NK cells with GSK-3beta-specific inhibitor TDZD-8 prevented enzastaurin-induced inhibition of NK cell cytotoxicity.	enzastaurin	73-84	glycogen synthase kinase 3 beta	Homo sapiens	27-36
21044952-6	2011	Pathway and motif activity analyses using transcriptome data additionally suggested that deregulated activation of GSK3beta (glycogen-synthase kinase 3beta) and MAPK1/3 signaling might be associated with altered activation of cAMP-responsive element-binding protein and AP-1 transcription factors in tamoxifen-resistant cells, and this hypothesis was validated by reporter assays.	Cyclic AMP	226-230	glycogen synthase kinase 3 beta	Homo sapiens	115-123
21044952-6	2011	Pathway and motif activity analyses using transcriptome data additionally suggested that deregulated activation of GSK3beta (glycogen-synthase kinase 3beta) and MAPK1/3 signaling might be associated with altered activation of cAMP-responsive element-binding protein and AP-1 transcription factors in tamoxifen-resistant cells, and this hypothesis was validated by reporter assays.	Cyclic AMP	226-230	glycogen synthase kinase 3 beta	Homo sapiens	125-155
21118993-5	2011	Serine 298 lies within a glycogen synthase kinase 3beta consensus sequence, and removal of growth factors fails to trigger HDAC4 degradation in cells deficient in this kinase.	Serine	0-6	glycogen synthase kinase 3 beta	Homo sapiens	25-55
21044952-7	2011	An examination of clinical samples revealed that inhibitory phosphorylation of GSK3beta at serine 9 was significantly lower in tamoxifen-treated breast cancer patients that eventually had relapses, implying that activation of GSK3beta may be associated with the tamoxifen-resistant phenotype.	Tamoxifen	127-136	glycogen synthase kinase 3 beta	Homo sapiens	79-87
21044952-7	2011	An examination of clinical samples revealed that inhibitory phosphorylation of GSK3beta at serine 9 was significantly lower in tamoxifen-treated breast cancer patients that eventually had relapses, implying that activation of GSK3beta may be associated with the tamoxifen-resistant phenotype.	Tamoxifen	127-136	glycogen synthase kinase 3 beta	Homo sapiens	226-234
21044952-6	2011	Pathway and motif activity analyses using transcriptome data additionally suggested that deregulated activation of GSK3beta (glycogen-synthase kinase 3beta) and MAPK1/3 signaling might be associated with altered activation of cAMP-responsive element-binding protein and AP-1 transcription factors in tamoxifen-resistant cells, and this hypothesis was validated by reporter assays.	Tamoxifen	300-309	glycogen synthase kinase 3 beta	Homo sapiens	115-123
21044952-7	2011	An examination of clinical samples revealed that inhibitory phosphorylation of GSK3beta at serine 9 was significantly lower in tamoxifen-treated breast cancer patients that eventually had relapses, implying that activation of GSK3beta may be associated with the tamoxifen-resistant phenotype.	Tamoxifen	262-271	glycogen synthase kinase 3 beta	Homo sapiens	79-87
21044952-7	2011	An examination of clinical samples revealed that inhibitory phosphorylation of GSK3beta at serine 9 was significantly lower in tamoxifen-treated breast cancer patients that eventually had relapses, implying that activation of GSK3beta may be associated with the tamoxifen-resistant phenotype.	Tamoxifen	262-271	glycogen synthase kinase 3 beta	Homo sapiens	226-234
21118993-6	2011	GSK3beta can phosphorylate HDAC4 in vitro, and phosphorylation of serine 302 seems to play the role of priming phosphate.	Phosphates	111-120	glycogen synthase kinase 3 beta	Homo sapiens	0-8
21044952-6	2011	Pathway and motif activity analyses using transcriptome data additionally suggested that deregulated activation of GSK3beta (glycogen-synthase kinase 3beta) and MAPK1/3 signaling might be associated with altered activation of cAMP-responsive element-binding protein and AP-1 transcription factors in tamoxifen-resistant cells, and this hypothesis was validated by reporter assays.	Tamoxifen	300-309	glycogen synthase kinase 3 beta	Homo sapiens	125-155
21044952-7	2011	An examination of clinical samples revealed that inhibitory phosphorylation of GSK3beta at serine 9 was significantly lower in tamoxifen-treated breast cancer patients that eventually had relapses, implying that activation of GSK3beta may be associated with the tamoxifen-resistant phenotype.	Serine	91-97	glycogen synthase kinase 3 beta	Homo sapiens	79-87
21044952-7	2011	An examination of clinical samples revealed that inhibitory phosphorylation of GSK3beta at serine 9 was significantly lower in tamoxifen-treated breast cancer patients that eventually had relapses, implying that activation of GSK3beta may be associated with the tamoxifen-resistant phenotype.	Serine	91-97	glycogen synthase kinase 3 beta	Homo sapiens	226-234
21173228-8	2011	Lithium is a GSK3beta inhibitor used therapeutically as mood-stabilizing drug, which underscores the relevance of this posttranslational modification for synaptic plasticity.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	13-21
21172821-3	2011	In particular, we found that the nuclear export of GSK3beta, which switches on the facilitative role of RCAN1 in the calcineurin-NFAT signaling pathway, is promoted by PI3K signaling.	nfat	129-133	glycogen synthase kinase 3 beta	Homo sapiens	51-59
20920551-2	2011	In the present study, we investigated the potential role of GSK3beta in 6-hydroxydopamine (6-OHDA)-induced toxicity in human neuroblastoma cell line SH-SY5Y.	Oxidopamine	91-97	glycogen synthase kinase 3 beta	Homo sapiens	60-68
20920551-4	2011	Furthermore, we downregulated the expression of GSK3beta by short hairpin RNA (shRNA) interference and compared the cell viability and expression of apoptotic proteins in knockdown group with those in control group under the treatment of 6-OHDA.	Oxidopamine	238-244	glycogen synthase kinase 3 beta	Homo sapiens	48-56
20920551-6	2011	Additionally, 6-OHDA decreased the ratio of pGSK3beta (Ser9)/GSK3beta and increased the ratio of pGSK3beta (Tyr216)/GSK3beta.	Oxidopamine	14-20	glycogen synthase kinase 3 beta	Homo sapiens	45-53
20920551-6	2011	Additionally, 6-OHDA decreased the ratio of pGSK3beta (Ser9)/GSK3beta and increased the ratio of pGSK3beta (Tyr216)/GSK3beta.	Oxidopamine	14-20	glycogen synthase kinase 3 beta	Homo sapiens	61-69
20920551-7	2011	Moreover, 6-OHDA induced less cell viability loss and lower expression of caspase-9 and caspase-3 in GSK3beta knockdown group compared with control.	Oxidopamine	10-16	glycogen synthase kinase 3 beta	Homo sapiens	101-109
20920551-8	2011	The present data indicate that 6-OHDA may induce apoptosis in SH-SY5Y via the intrinsic death pathway and GSK3beta knockdown can partly attenuate 6-OHDA-induced neuronal death and apoptosis, suggesting that GSK3beta may have the potential to serve as a therapeutic target for PD.	Oxidopamine	146-152	glycogen synthase kinase 3 beta	Homo sapiens	106-114
20920551-8	2011	The present data indicate that 6-OHDA may induce apoptosis in SH-SY5Y via the intrinsic death pathway and GSK3beta knockdown can partly attenuate 6-OHDA-induced neuronal death and apoptosis, suggesting that GSK3beta may have the potential to serve as a therapeutic target for PD.	Oxidopamine	146-152	glycogen synthase kinase 3 beta	Homo sapiens	207-215
21205744-9	2011	This reduction in NF-kappaB transcriptional activity may be due to increased phosphorylation of GSK-3beta following S-ibuprofen treatment.	Ibuprofen	116-127	glycogen synthase kinase 3 beta	Homo sapiens	96-105
21629716-7	2011	We also examine the potential of inducing GSK-3beta by small-molecule activators, dithiocarbamates, which potentially exert their beneficial therapeutic effects via the activation of the Nrf2 pathway.	dithiocarbamates	82-98	glycogen synthase kinase 3 beta	Homo sapiens	42-51
21677377-4	2011	In addition, in cells expressing 3PO-tau, both the percentage of cells with aggregates, as well as the size of aggregates, was increased following overexpression of cdk5 or GSK3beta, decreased following treatment with pharmacological agents (roscovitine and lithium) active against these kinases, and increased following treatment with the phosphatase inhibitor okadaic acid.	Roscovitine	242-253	glycogen synthase kinase 3 beta	Homo sapiens	173-181
21677377-4	2011	In addition, in cells expressing 3PO-tau, both the percentage of cells with aggregates, as well as the size of aggregates, was increased following overexpression of cdk5 or GSK3beta, decreased following treatment with pharmacological agents (roscovitine and lithium) active against these kinases, and increased following treatment with the phosphatase inhibitor okadaic acid.	Lithium	258-265	glycogen synthase kinase 3 beta	Homo sapiens	173-181
21677377-4	2011	In addition, in cells expressing 3PO-tau, both the percentage of cells with aggregates, as well as the size of aggregates, was increased following overexpression of cdk5 or GSK3beta, decreased following treatment with pharmacological agents (roscovitine and lithium) active against these kinases, and increased following treatment with the phosphatase inhibitor okadaic acid.	Okadaic Acid	362-374	glycogen synthase kinase 3 beta	Homo sapiens	173-181
20920551-0	2011	Knockdown of glycogen synthase kinase 3 beta attenuates 6-hydroxydopamine-induced apoptosis in SH-SY5Y cells.	Oxidopamine	56-73	glycogen synthase kinase 3 beta	Homo sapiens	13-44
20920551-2	2011	In the present study, we investigated the potential role of GSK3beta in 6-hydroxydopamine (6-OHDA)-induced toxicity in human neuroblastoma cell line SH-SY5Y.	Oxidopamine	72-89	glycogen synthase kinase 3 beta	Homo sapiens	60-68
21297267-5	2011	Berberine also restored protein phosphates 2A activity and reversed glycogen synthase kinase-3beta (GSK-3beta) activation, as determined by phosphatase activity assay and GSK-3beta phosphorylation at Tyr216 and Ser9, respectively.	Berberine	0-9	glycogen synthase kinase 3 beta	Homo sapiens	68-98
21297267-5	2011	Berberine also restored protein phosphates 2A activity and reversed glycogen synthase kinase-3beta (GSK-3beta) activation, as determined by phosphatase activity assay and GSK-3beta phosphorylation at Tyr216 and Ser9, respectively.	Berberine	0-9	glycogen synthase kinase 3 beta	Homo sapiens	100-109
21297267-5	2011	Berberine also restored protein phosphates 2A activity and reversed glycogen synthase kinase-3beta (GSK-3beta) activation, as determined by phosphatase activity assay and GSK-3beta phosphorylation at Tyr216 and Ser9, respectively.	Berberine	0-9	glycogen synthase kinase 3 beta	Homo sapiens	171-180
20821241-0	2011	Structure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase 3beta.	Ruthenium	24-33	glycogen synthase kinase 3 beta	Homo sapiens	65-95
20821241-1	2011	The 3.15-A-resolution crystal structure of the R enantiomer of the highly bioactive and antiproliferative half-sandwich ruthenium complex DW12 bound to the ATP binding site of glycogen synthase kinase 3beta (GSK-3beta) is reported and the binding is compared with the GSK-3beta binding of staurosporine and other organic inhibitors.	ruthenium complex dw12	120-142	glycogen synthase kinase 3 beta	Homo sapiens	176-206
20821241-1	2011	The 3.15-A-resolution crystal structure of the R enantiomer of the highly bioactive and antiproliferative half-sandwich ruthenium complex DW12 bound to the ATP binding site of glycogen synthase kinase 3beta (GSK-3beta) is reported and the binding is compared with the GSK-3beta binding of staurosporine and other organic inhibitors.	ruthenium complex dw12	120-142	glycogen synthase kinase 3 beta	Homo sapiens	208-217
20821241-1	2011	The 3.15-A-resolution crystal structure of the R enantiomer of the highly bioactive and antiproliferative half-sandwich ruthenium complex DW12 bound to the ATP binding site of glycogen synthase kinase 3beta (GSK-3beta) is reported and the binding is compared with the GSK-3beta binding of staurosporine and other organic inhibitors.	ruthenium complex dw12	120-142	glycogen synthase kinase 3 beta	Homo sapiens	268-277
20821241-1	2011	The 3.15-A-resolution crystal structure of the R enantiomer of the highly bioactive and antiproliferative half-sandwich ruthenium complex DW12 bound to the ATP binding site of glycogen synthase kinase 3beta (GSK-3beta) is reported and the binding is compared with the GSK-3beta binding of staurosporine and other organic inhibitors.	Adenosine Triphosphate	156-159	glycogen synthase kinase 3 beta	Homo sapiens	176-206
20821241-1	2011	The 3.15-A-resolution crystal structure of the R enantiomer of the highly bioactive and antiproliferative half-sandwich ruthenium complex DW12 bound to the ATP binding site of glycogen synthase kinase 3beta (GSK-3beta) is reported and the binding is compared with the GSK-3beta binding of staurosporine and other organic inhibitors.	Staurosporine	289-302	glycogen synthase kinase 3 beta	Homo sapiens	176-206
20821241-2	2011	The structure reveals a close packing of the organometallic inhibitor in the ATP binding site of GSK-3beta via an induced-fit mechanism.	Adenosine Triphosphate	77-80	glycogen synthase kinase 3 beta	Homo sapiens	97-106
20821241-3	2011	The molecular structure of (R)-DW12 with the CO ligand oriented perpendicular to the pyridocarbazole heterocycle allows the complex to stretch the whole distance sandwiched between the faces of the N- and C-terminal lobes and to interact tightly with the flexible glycine-rich loop, which is uncommon for the interaction of GSK-3beta with organic inhibitors.	(r)-dw12	27-35	glycogen synthase kinase 3 beta	Homo sapiens	324-333
20821241-3	2011	The molecular structure of (R)-DW12 with the CO ligand oriented perpendicular to the pyridocarbazole heterocycle allows the complex to stretch the whole distance sandwiched between the faces of the N- and C-terminal lobes and to interact tightly with the flexible glycine-rich loop, which is uncommon for the interaction of GSK-3beta with organic inhibitors.	pyridocarbazole	85-100	glycogen synthase kinase 3 beta	Homo sapiens	324-333
20821241-3	2011	The molecular structure of (R)-DW12 with the CO ligand oriented perpendicular to the pyridocarbazole heterocycle allows the complex to stretch the whole distance sandwiched between the faces of the N- and C-terminal lobes and to interact tightly with the flexible glycine-rich loop, which is uncommon for the interaction of GSK-3beta with organic inhibitors.	Glycine	264-271	glycogen synthase kinase 3 beta	Homo sapiens	324-333
20727368-3	2011	However, emerging evidence indicates that under hyperdopaminergic conditions, the protein kinase B (Akt)-glycogen synthase kinase 3beta (GSK-3beta) signaling cascade may mediate dopamine actions via D(2)-like receptors.	Dopamine	53-61	glycogen synthase kinase 3 beta	Homo sapiens	105-135
20952497-1	2011	Although dopamine (DA) regulates the serine/threonine kinase Akt and its downstream substrate glycogen synthase kinase-3beta (GSK-3beta), the direct influence of dopaminergic receptors remains poorly characterized.	Dopamine	19-21	glycogen synthase kinase 3 beta	Homo sapiens	126-135
20952497-4	2011	Akt and GSK-3beta phosphorylation mediated via CHO-expressed hD(2L) and hD3 receptors was prevented by pertussis toxin and by inhibitors of insulin-like growth factor-1 receptors as well as phosphatidylinositol 3-kinase and Src.	cho	47-50	glycogen synthase kinase 3 beta	Homo sapiens	8-17
20952497-5	2011	Likewise, chelation of intracellular Ca2+ and interference with an "atypical" phorbol ester-insensitive protein kinase C (PKC) abolished recruitment of Akt and GSK-3beta.	Phorbol Esters	78-91	glycogen synthase kinase 3 beta	Homo sapiens	160-169
20952497-1	2011	Although dopamine (DA) regulates the serine/threonine kinase Akt and its downstream substrate glycogen synthase kinase-3beta (GSK-3beta), the direct influence of dopaminergic receptors remains poorly characterized.	Dopamine	9-17	glycogen synthase kinase 3 beta	Homo sapiens	94-124
20952497-1	2011	Although dopamine (DA) regulates the serine/threonine kinase Akt and its downstream substrate glycogen synthase kinase-3beta (GSK-3beta), the direct influence of dopaminergic receptors remains poorly characterized.	Dopamine	9-17	glycogen synthase kinase 3 beta	Homo sapiens	126-135
20952497-1	2011	Although dopamine (DA) regulates the serine/threonine kinase Akt and its downstream substrate glycogen synthase kinase-3beta (GSK-3beta), the direct influence of dopaminergic receptors remains poorly characterized.	Dopamine	19-21	glycogen synthase kinase 3 beta	Homo sapiens	94-124
20727368-3	2011	However, emerging evidence indicates that under hyperdopaminergic conditions, the protein kinase B (Akt)-glycogen synthase kinase 3beta (GSK-3beta) signaling cascade may mediate dopamine actions via D(2)-like receptors.	Dopamine	53-61	glycogen synthase kinase 3 beta	Homo sapiens	137-146
20727368-6	2011	We discuss the relevance of the Akt/GSK-3beta signaling cascade for the expression of dopamine-dependent behaviors and the drug actions associated with dopaminergic systems.	Dopamine	86-94	glycogen synthase kinase 3 beta	Homo sapiens	36-45
22096483-8	2011	Versican G3 promoted cell apoptosis induced by C2-ceramide or Docetaxel by enhancing expression of pSAPK/JNK and decreasing expression of GSK-3beta (S9P), an observation blocked by AG 1478 or SP 6000125.	N-acetylsphingosine	47-58	glycogen synthase kinase 3 beta	Homo sapiens	138-147
21660227-5	2011	Elevated labeling for inhibited phospho-CDC2 (pTyr15CDC) correlates with elevated levels of phosphorylated glycogen synthase kinase 3beta (GSK3beta).	ptyr15cdc	46-55	glycogen synthase kinase 3 beta	Homo sapiens	107-137
21660227-5	2011	Elevated labeling for inhibited phospho-CDC2 (pTyr15CDC) correlates with elevated levels of phosphorylated glycogen synthase kinase 3beta (GSK3beta).	ptyr15cdc	46-55	glycogen synthase kinase 3 beta	Homo sapiens	139-147
22096483-7	2011	Both AG 1478 and PD 98059 enhanced expression of pSAPK/JNK, while selective JNK inhibitor SP 600125 enhanced expression of GSK-3beta (S9P).	pyrazolanthrone	90-99	glycogen synthase kinase 3 beta	Homo sapiens	123-132
22213040-7	2011	DHA also reduced beta-catenin expression, T cell factor/lymphoid-enhancing factor reporter activity and induced beta-catenin/Axin/GSK-3beta complex formation, a known precursor to beta-catenin degradation.	Docosahexaenoic Acids	0-3	glycogen synthase kinase 3 beta	Homo sapiens	130-139
21231855-13	2011	To identify the target(s) of GSK-3beta inhibition during differentiation into MK lineage cells, we performed a differential gene expression study and subsequent pathway analysis of the large (MK)-sized CD41 (+)/propidium iodide (-) cells cultured in TWS119 (+/-) for 3 days.	Propidium	211-227	glycogen synthase kinase 3 beta	Homo sapiens	29-38
22069492-9	2011	The inhibition of Akt by SH6 and GSK3beta by lithium chloride (LiCl) could respectively induce and inhibit the STS-mediated e-lam formation, cell migration and STC1 gene expression.	Lithium Chloride	45-61	glycogen synthase kinase 3 beta	Homo sapiens	33-41
22046442-0	2011	Sensitization of glioma cells to tamoxifen-induced apoptosis by Pl3-kinase inhibitor through the GSK-3beta/beta-catenin signaling pathway.	Tamoxifen	33-42	glycogen synthase kinase 3 beta	Homo sapiens	97-106
22046442-6	2011	By Western blotting, we found that combination treatment showed lower levels of phosphorylated Akt(Ser473) and GSK-3beta(Ser9) than a single treatment of LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	154-162	glycogen synthase kinase 3 beta	Homo sapiens	111-125
22046442-9	2011	Our results indicated that the synergistic cytotoxic effect of LY294002 and tamoxifen is achieved by the inhibition of GSK-3beta/beta-catenin signaling pathway.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	63-71	glycogen synthase kinase 3 beta	Homo sapiens	119-128
22046442-9	2011	Our results indicated that the synergistic cytotoxic effect of LY294002 and tamoxifen is achieved by the inhibition of GSK-3beta/beta-catenin signaling pathway.	Tamoxifen	76-85	glycogen synthase kinase 3 beta	Homo sapiens	119-128
22069492-9	2011	The inhibition of Akt by SH6 and GSK3beta by lithium chloride (LiCl) could respectively induce and inhibit the STS-mediated e-lam formation, cell migration and STC1 gene expression.	Lithium Chloride	63-67	glycogen synthase kinase 3 beta	Homo sapiens	33-41
21980429-5	2011	Exposure of these cells to the maleimide SB216763, a potent GSK-3beta inhibitor, resulted in a rapid nuclear export of the AR even under androgen-deprived conditions.	maleimide	31-40	glycogen synthase kinase 3 beta	Homo sapiens	60-69
21980429-5	2011	Exposure of these cells to the maleimide SB216763, a potent GSK-3beta inhibitor, resulted in a rapid nuclear export of the AR even under androgen-deprived conditions.	SB 216763	41-49	glycogen synthase kinase 3 beta	Homo sapiens	60-69
21829575-4	2011	Silymarin enhanced: (i) the levels of casein kinase 1alpha, glycogen synthase kinase-3beta and phosphorylated-beta-catenin on critical residues Ser(45), Ser(33/37) and Thr(41), and (ii) the binding of beta-transducin repeat-containing proteins (beta-TrCP) with phospho forms of beta-catenin in melanoma cells.	Serine	153-156	glycogen synthase kinase 3 beta	Homo sapiens	38-90
21931595-2	2011	Lithium stimulates neurogenesis by inhibiting GSK3b (glycogen synthetase kinase 3-beta) and increasing WNT/beta catenin.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	46-51
21931595-7	2011	GSK3beta inhibition either by a specific GSK3beta inhibitor SB216763 or overexpression of GID5-6 (GSK3beta Interaction Domain aa380 to 404) did not suppress astrogliogenesis and GRP proliferation.	SB 216763	60-68	glycogen synthase kinase 3 beta	Homo sapiens	0-8
21931595-9	2011	Together, these results indicate that lithium inhibits astrogliogenesis through non-GSK3beta-mediated inhibition of STAT.	Lithium	38-45	glycogen synthase kinase 3 beta	Homo sapiens	84-92
21829575-4	2011	Silymarin enhanced: (i) the levels of casein kinase 1alpha, glycogen synthase kinase-3beta and phosphorylated-beta-catenin on critical residues Ser(45), Ser(33/37) and Thr(41), and (ii) the binding of beta-transducin repeat-containing proteins (beta-TrCP) with phospho forms of beta-catenin in melanoma cells.	Silymarin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	38-90
21829575-4	2011	Silymarin enhanced: (i) the levels of casein kinase 1alpha, glycogen synthase kinase-3beta and phosphorylated-beta-catenin on critical residues Ser(45), Ser(33/37) and Thr(41), and (ii) the binding of beta-transducin repeat-containing proteins (beta-TrCP) with phospho forms of beta-catenin in melanoma cells.	Serine	144-147	glycogen synthase kinase 3 beta	Homo sapiens	38-90
21829575-4	2011	Silymarin enhanced: (i) the levels of casein kinase 1alpha, glycogen synthase kinase-3beta and phosphorylated-beta-catenin on critical residues Ser(45), Ser(33/37) and Thr(41), and (ii) the binding of beta-transducin repeat-containing proteins (beta-TrCP) with phospho forms of beta-catenin in melanoma cells.	Threonine	168-171	glycogen synthase kinase 3 beta	Homo sapiens	38-90
21829575-7	2011	Treatment of Mel 1241 cells with silymarin or FH535, an inhibitor of Wnt/beta-catenin pathway, significantly inhibited cell migration of Mel 1241 cells, which was associated with the elevated levels of casein kinase 1alpha and glycogen synthase kinase-3beta, and decreased accumulation of nuclear beta-catenin and inhibition of MMP-2 and MMP-9 levels.	Silymarin	33-42	glycogen synthase kinase 3 beta	Homo sapiens	227-257
21829575-7	2011	Treatment of Mel 1241 cells with silymarin or FH535, an inhibitor of Wnt/beta-catenin pathway, significantly inhibited cell migration of Mel 1241 cells, which was associated with the elevated levels of casein kinase 1alpha and glycogen synthase kinase-3beta, and decreased accumulation of nuclear beta-catenin and inhibition of MMP-2 and MMP-9 levels.	FH535	46-51	glycogen synthase kinase 3 beta	Homo sapiens	227-257
20960517-2	2011	Here, we report that treatment with an inhibitor of GSK-3beta, 6-bromoindirubin 3"-oxime (BIO) delayed cell cycle progression by increasing cell cycle time.	6-bromoindirubin-3'-oxime	63-88	glycogen synthase kinase 3 beta	Homo sapiens	52-61
20926391-0	2010	O-linked beta-N-acetylglucosamine (O-GlcNAc) regulates stress-induced heat shock protein expression in a GSK-3beta-dependent manner.	o-linked beta-n-acetylglucosamine	0-33	glycogen synthase kinase 3 beta	Homo sapiens	105-114
20506302-6	2011	Using selective pharmacological tools, we showed that enhanced intracellular calcium lead to cyclin-dependent kinase 5 (cdk5) activation, by calpain proteolysis of p35 to p25, as well as glycogen synthase kinase 3beta (GSK3beta) activation, by its phosphorylation at tyrosine 216.	Calcium	77-84	glycogen synthase kinase 3 beta	Homo sapiens	187-217
20506302-6	2011	Using selective pharmacological tools, we showed that enhanced intracellular calcium lead to cyclin-dependent kinase 5 (cdk5) activation, by calpain proteolysis of p35 to p25, as well as glycogen synthase kinase 3beta (GSK3beta) activation, by its phosphorylation at tyrosine 216.	Calcium	77-84	glycogen synthase kinase 3 beta	Homo sapiens	219-227
20841359-2	2010	The two mammalian isoforms of the kinase, GSK-3alpha and GSK-3beta, are inhibited by phosphorylation at Ser-21 and Ser-9, respectively.	Serine	104-107	glycogen synthase kinase 3 beta	Homo sapiens	57-66
20841359-2	2010	The two mammalian isoforms of the kinase, GSK-3alpha and GSK-3beta, are inhibited by phosphorylation at Ser-21 and Ser-9, respectively.	Serine	115-118	glycogen synthase kinase 3 beta	Homo sapiens	57-66
20841359-6	2010	Nonphosphorylatable GSK-3alpha/beta mutants (S21A/S9A) promoted apoptosis, whereas a peptide encompassing Ser-9 of GSK-3beta protected neurons in a phosphorylation-dependent manner; these results indicate a critical role for Ser-21/9 phosphorylation on depolarization-dependent neuron survival.	Serine	106-109	glycogen synthase kinase 3 beta	Homo sapiens	115-124
20841359-6	2010	Nonphosphorylatable GSK-3alpha/beta mutants (S21A/S9A) promoted apoptosis, whereas a peptide encompassing Ser-9 of GSK-3beta protected neurons in a phosphorylation-dependent manner; these results indicate a critical role for Ser-21/9 phosphorylation on depolarization-dependent neuron survival.	Serine	225-228	glycogen synthase kinase 3 beta	Homo sapiens	115-124
20926391-4	2010	GSK-3beta promotes apoptosis through numerous pathways, including phosphorylation of heat shock factor 1 (HSF1) at Ser(303) (Ser(P)(303) HSF1), which inactivates HSF1 and inhibits HSP expression.	Serine	125-128	glycogen synthase kinase 3 beta	Homo sapiens	0-9
20926391-6	2010	These data, combined with those showing that inhibition of GSK-3beta in OGT null cells recovers HSP72 expression, suggests that O-GlcNAc regulates the activity of GSK-3beta.	o-glcnac	128-136	glycogen synthase kinase 3 beta	Homo sapiens	59-68
20926391-6	2010	These data, combined with those showing that inhibition of GSK-3beta in OGT null cells recovers HSP72 expression, suggests that O-GlcNAc regulates the activity of GSK-3beta.	o-glcnac	128-136	glycogen synthase kinase 3 beta	Homo sapiens	163-172
21105670-4	2010	We found that GSK-3beta autophosphorylation at residue Tyr(216) results in widening of the catalytic groove, thereby facilitating substrate access.	Tyrosine	55-58	glycogen synthase kinase 3 beta	Homo sapiens	14-23
20926391-0	2010	O-linked beta-N-acetylglucosamine (O-GlcNAc) regulates stress-induced heat shock protein expression in a GSK-3beta-dependent manner.	o-glcnac	35-43	glycogen synthase kinase 3 beta	Homo sapiens	105-114
20926391-7	2010	In OGT null cells, stress-induced inactivation of GSK-3beta by phosphorylation at Ser(9) was ablated providing a molecular basis for these findings.	Serine	82-85	glycogen synthase kinase 3 beta	Homo sapiens	50-59
20926391-4	2010	GSK-3beta promotes apoptosis through numerous pathways, including phosphorylation of heat shock factor 1 (HSF1) at Ser(303) (Ser(P)(303) HSF1), which inactivates HSF1 and inhibits HSP expression.	Serine	115-118	glycogen synthase kinase 3 beta	Homo sapiens	0-9
20852051-11	2010	SB216763, a blocker of glycogen synthase kinase-3beta (GSK-3beta), decreased infarct size, and its infarct-sparing effect was not affected by l-NAME, suggesting GSK-3beta acted downstream or independently of NO.	SB 216763	0-8	glycogen synthase kinase 3 beta	Homo sapiens	23-53
20655656-7	2010	Activated GSK-3beta then targeted cyclin D1, causing phosphorylation of cyclin D1 at Thr(286) and subsequent proteasomal degradation.	Threonine	85-88	glycogen synthase kinase 3 beta	Homo sapiens	10-19
20858757-5	2010	Unexpectedly, the loss of phosphate and tensin homolog deleted on chromosome 10 (PTEN) expression in Pten(tm1Hwu/tm1Hwu);Amhr2(tm3(cre)Bhr/+) decidual cells was not accompanied by a detectable increase in AKT phosphorylation or altered expression or activation of PI3K/AKT downstream effectors such as mammalian target of rapamycin or glycogen synthase kinase-3beta.	Phosphates	26-35	glycogen synthase kinase 3 beta	Homo sapiens	335-365
20852051-11	2010	SB216763, a blocker of glycogen synthase kinase-3beta (GSK-3beta), decreased infarct size, and its infarct-sparing effect was not affected by l-NAME, suggesting GSK-3beta acted downstream or independently of NO.	SB 216763	0-8	glycogen synthase kinase 3 beta	Homo sapiens	55-64
20852051-11	2010	SB216763, a blocker of glycogen synthase kinase-3beta (GSK-3beta), decreased infarct size, and its infarct-sparing effect was not affected by l-NAME, suggesting GSK-3beta acted downstream or independently of NO.	SB 216763	0-8	glycogen synthase kinase 3 beta	Homo sapiens	161-170
19756375-8	2010	Since DH9 decreased the levels of beta-catenin in cells via a GSK3beta mediated degradation pathway, this acts as a mechanism for growth inhibition by DH9.	UNII-LL6562DY22	6-9	glycogen synthase kinase 3 beta	Homo sapiens	62-70
19756375-8	2010	Since DH9 decreased the levels of beta-catenin in cells via a GSK3beta mediated degradation pathway, this acts as a mechanism for growth inhibition by DH9.	UNII-LL6562DY22	151-154	glycogen synthase kinase 3 beta	Homo sapiens	62-70
20696143-0	2010	Resveratrol modulates angiogenesis through the GSK3beta/beta-catenin/TCF-dependent pathway in human endothelial cells.	Resveratrol	0-11	glycogen synthase kinase 3 beta	Homo sapiens	47-55
20615089-3	2010	One way investigators have investigated the molecular basis of BD and the therapeutic action of lithium is by microarray expression studies, since both GSK3beta- and PI-mediated signal transduction pathways are coupled to transcriptional activation and inhibition.	Lithium	96-103	glycogen synthase kinase 3 beta	Homo sapiens	152-160
20696185-7	2010	In conclusion, C(2)-ceramide initiates a series of events including an early inactivation of PI3K/AKT and ERK pathways followed by activation of JNK and activation of GSK3beta and neuronal death, changes that are counteracted by IGF-1.	N-acetylsphingosine	15-28	glycogen synthase kinase 3 beta	Homo sapiens	167-175
20959806-2	2010	O-phosphorylation of serine by glycogen synthase kinase-3beta on Snail1, a transcriptional repressor of E-cadherin and a key regulator of the epithelial-mesenchymal transition (EMT) programme, results in its proteasomal degradation.	Serine	21-27	glycogen synthase kinase 3 beta	Homo sapiens	31-61
20615089-1	2010	Therapeutic concentrations of lithium salts inhibit glycogen synthase kinase 3 beta (GSK3beta) and phosphoinositide (PI) signaling suggesting that abnormal activation of these pathways could be a factor in the pathophysiology of bipolar disorder (BD).	lithium salts	30-43	glycogen synthase kinase 3 beta	Homo sapiens	52-83
20615089-1	2010	Therapeutic concentrations of lithium salts inhibit glycogen synthase kinase 3 beta (GSK3beta) and phosphoinositide (PI) signaling suggesting that abnormal activation of these pathways could be a factor in the pathophysiology of bipolar disorder (BD).	lithium salts	30-43	glycogen synthase kinase 3 beta	Homo sapiens	85-93
20696185-0	2010	Differential regulation of AKT, MAPK and GSK3beta during C2-ceramide-induced neuronal death.	N-acetylsphingosine	57-68	glycogen synthase kinase 3 beta	Homo sapiens	41-49
20696185-3	2010	In the present paper we have analysed the contribution of PI3K/AKT-GSK3beta and MAPK (ERK and JNK) pathways to cell death in a catecholaminergic cell line following exposure to C(2)-ceramide.	N-acetylsphingosine	177-190	glycogen synthase kinase 3 beta	Homo sapiens	67-75
20696185-5	2010	We demonstrated that C(2)-ceramide-induced cell death is associated to an early decrease in phosphorylation (inhibition) of PI3K/AKT and ERK, followed by phosphorylation (activation) of JNK and de-phosphorylation (activation) of glycogen synthase kinase-3 beta (GSK3beta).	N-acetylsphingosine	21-34	glycogen synthase kinase 3 beta	Homo sapiens	229-260
20696185-5	2010	We demonstrated that C(2)-ceramide-induced cell death is associated to an early decrease in phosphorylation (inhibition) of PI3K/AKT and ERK, followed by phosphorylation (activation) of JNK and de-phosphorylation (activation) of glycogen synthase kinase-3 beta (GSK3beta).	N-acetylsphingosine	21-34	glycogen synthase kinase 3 beta	Homo sapiens	262-270
20617408-9	2010	DMH also activated PI3-kinase, Akt, Wnt, and beta-catenin expressions but reduced the glycogen synthase kinase-3beta (GSK-3beta) levels.	1,2-Dimethylhydrazine	0-3	glycogen synthase kinase 3 beta	Homo sapiens	86-116
20617408-9	2010	DMH also activated PI3-kinase, Akt, Wnt, and beta-catenin expressions but reduced the glycogen synthase kinase-3beta (GSK-3beta) levels.	1,2-Dimethylhydrazine	0-3	glycogen synthase kinase 3 beta	Homo sapiens	118-127
20617408-10	2010	Co-administration of diclofenac with DMH increased the mRNA expression of GSK-3beta while inactivating PI3-kinase, Akt, Wnt, and beta-catenin.	Diclofenac	21-31	glycogen synthase kinase 3 beta	Homo sapiens	74-83
20617408-10	2010	Co-administration of diclofenac with DMH increased the mRNA expression of GSK-3beta while inactivating PI3-kinase, Akt, Wnt, and beta-catenin.	1,2-Dimethylhydrazine	37-40	glycogen synthase kinase 3 beta	Homo sapiens	74-83
20696143-8	2010	Correspondingly, GSK3beta, a negative regulator of beta-catenin, turned into a less active state (phosphorylated at Ser9) in cells exposed to 5muM of resveratrol, but became more active at 20muM.	Resveratrol	150-161	glycogen synthase kinase 3 beta	Homo sapiens	17-25
20696143-9	2010	We demonstrated that both Akt and ERK signaling pathways, which are known to be critical for angiogenesis, became activated in response to 5muM of resveratrol and functioned to inactivate GSK3beta.	Resveratrol	147-158	glycogen synthase kinase 3 beta	Homo sapiens	188-196
20888430-7	2010	In addition, inhibition of GSK-3beta by TDZD-8, SB216763, and LiCl, as well as adenoviral transduction with a catalytically inactive GSK-3beta, reduced palmitate-induced VCAM-1 expression through inhibition of JNK activity and degradation of Ikappa-Balpha in human umbilical vein endothelial cells (HUVECs).	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	40-46	glycogen synthase kinase 3 beta	Homo sapiens	27-36
20821057-7	2010	As the downstream of this signal pathway, urocortin promoted phosphorylation of both glycogen synthase kinase 3beta and extracellular signal-regulated kinases, which are known to promote cell survival.	Urocortins	42-51	glycogen synthase kinase 3 beta	Homo sapiens	85-115
20888430-7	2010	In addition, inhibition of GSK-3beta by TDZD-8, SB216763, and LiCl, as well as adenoviral transduction with a catalytically inactive GSK-3beta, reduced palmitate-induced VCAM-1 expression through inhibition of JNK activity and degradation of Ikappa-Balpha in human umbilical vein endothelial cells (HUVECs).	SB 216763	48-56	glycogen synthase kinase 3 beta	Homo sapiens	27-36
20700048-4	2010	Nonetheless, when trying to dissect the various mechanisms of action of lithium, two primary targets emerge: glycogen synthase kinase 3beta and phosphatidylinositol phosphatase.	Lithium	72-79	glycogen synthase kinase 3 beta	Homo sapiens	109-139
20835687-5	2010	The luciferase activity in the stable clone was enhanced by the recombinant Wnt-3A (rWnt-3A; 100-400 ng/mL) and GSK3beta inhibitor (2"Z,3"E)-6-bromoindirubin-3"-oxime (BIO; 5 microM) but was inhibited by aspirin (5 mM).	2"z,3"e)-6-bromoindirubin-3"-oxime	132-166	glycogen synthase kinase 3 beta	Homo sapiens	112-120
20835687-5	2010	The luciferase activity in the stable clone was enhanced by the recombinant Wnt-3A (rWnt-3A; 100-400 ng/mL) and GSK3beta inhibitor (2"Z,3"E)-6-bromoindirubin-3"-oxime (BIO; 5 microM) but was inhibited by aspirin (5 mM).	Aspirin	204-211	glycogen synthase kinase 3 beta	Homo sapiens	112-120
20613717-6	2010	Treatment of MSCs with lithium (2.5 mM for 1 day) selectively elevated the transcript and protein levels of matrix metalloproteinase-9 (MMP-9) and its enzymatic activity; these effects were mimicked by inhibition or gene silencing of glycogen synthase kinase-3beta (GSK-3beta).	Lithium	23-30	glycogen synthase kinase 3 beta	Homo sapiens	234-264
20613717-6	2010	Treatment of MSCs with lithium (2.5 mM for 1 day) selectively elevated the transcript and protein levels of matrix metalloproteinase-9 (MMP-9) and its enzymatic activity; these effects were mimicked by inhibition or gene silencing of glycogen synthase kinase-3beta (GSK-3beta).	Lithium	23-30	glycogen synthase kinase 3 beta	Homo sapiens	266-275
20613717-9	2010	Overall, VPA and lithium stimulated MSC migration through distinct targets and mediators: HDAC-CXCR4 and GSK-3beta-MMP-9, respectively.	VALPROIC ACID	9-12	glycogen synthase kinase 3 beta	Homo sapiens	105-114
20613717-9	2010	Overall, VPA and lithium stimulated MSC migration through distinct targets and mediators: HDAC-CXCR4 and GSK-3beta-MMP-9, respectively.	Lithium	17-24	glycogen synthase kinase 3 beta	Homo sapiens	105-114
20708937-0	2010	Novel indolylmaleimide acts as GSK-3beta inhibitor in human neural progenitor cells.	indolylmaleimide	6-22	glycogen synthase kinase 3 beta	Homo sapiens	31-40
20708937-3	2010	In this study, non-symmetrically substituted indolylmaleimides have been synthesized and their ability to function as GSK-3beta inhibitors has been investigated in a human neural progenitor cell line.	indolylmaleimides	45-62	glycogen synthase kinase 3 beta	Homo sapiens	118-127
20708937-4	2010	Among the newly synthesized compounds, the substance IM-12 showed a significant activity in several biological tests which was comparable or even outplayed the effects of the known GSK-3beta inhibitor SB-216763.	substance im-12	43-58	glycogen synthase kinase 3 beta	Homo sapiens	181-190
20708937-4	2010	Among the newly synthesized compounds, the substance IM-12 showed a significant activity in several biological tests which was comparable or even outplayed the effects of the known GSK-3beta inhibitor SB-216763.	SB 216763	201-210	glycogen synthase kinase 3 beta	Homo sapiens	181-190
20708937-6	2010	Therefore we conclude that indolylmaleimides act via the canonical Wnt signalling pathway by inhibition of the key enzyme GSK-3beta.	indolylmaleimides	27-44	glycogen synthase kinase 3 beta	Homo sapiens	122-131
20561505-4	2010	Treatment of SW620 cells stably expressing the reporter with inhibitors of GSK3beta (SB415286 and LiCl) or CK1alpha (CKI-7) resulted in dose- and time-dependent increases in BGCR activity that were validated using Western blotting.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	85-93	glycogen synthase kinase 3 beta	Homo sapiens	75-83
20561505-6	2010	Imaging of mice tumor xenograft generated with BGCR-expressing SW620 cells following treatment with LiCl showed unique oscillations in GSK3beta activity that were corroborated by phosphorylated GSK3beta immunoblotting.	Lithium Chloride	100-104	glycogen synthase kinase 3 beta	Homo sapiens	135-143
20561505-6	2010	Imaging of mice tumor xenograft generated with BGCR-expressing SW620 cells following treatment with LiCl showed unique oscillations in GSK3beta activity that were corroborated by phosphorylated GSK3beta immunoblotting.	Lithium Chloride	100-104	glycogen synthase kinase 3 beta	Homo sapiens	194-202
20540935-0	2010	Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone.	Troglitazone	110-122	glycogen synthase kinase 3 beta	Homo sapiens	29-38
20540935-4	2010	To investigate the mechanisms of PPARgamma agonist-induced apoptosis of colon cancer cells, we examined the effect of troglitazone (0-16muM) on the activation of GSK-3beta and NF-kappaB.	Troglitazone	118-130	glycogen synthase kinase 3 beta	Homo sapiens	162-171
20540935-5	2010	Our study showed that the inhibitory effect of troglitazone on colon cancer cell growth was associated with inhibition of NF-kappaB activity and GSK-3beta expression in a dose-dependent manner.	Troglitazone	47-59	glycogen synthase kinase 3 beta	Homo sapiens	145-154
20540935-7	2010	Transient transfection of GSK-3beta recovered troglitazone-induced cell growth inhibition and NF-kappaB inactivation.	Troglitazone	46-58	glycogen synthase kinase 3 beta	Homo sapiens	26-35
20540935-8	2010	In contrast, co-treatment of troglitazone with a GSK-3beta inhibitor (AR-a014418) or siRNA against GSK-3beta, significantly augmented the inhibitory effect of troglitazone on the NF-kappaB activity, the cancer cell growth and on the expression of G(0)/G(1) phase regulatory proteins and pro-apoptosis regulatory proteins.	Troglitazone	29-41	glycogen synthase kinase 3 beta	Homo sapiens	49-58
20540935-8	2010	In contrast, co-treatment of troglitazone with a GSK-3beta inhibitor (AR-a014418) or siRNA against GSK-3beta, significantly augmented the inhibitory effect of troglitazone on the NF-kappaB activity, the cancer cell growth and on the expression of G(0)/G(1) phase regulatory proteins and pro-apoptosis regulatory proteins.	Troglitazone	29-41	glycogen synthase kinase 3 beta	Homo sapiens	99-108
20540935-8	2010	In contrast, co-treatment of troglitazone with a GSK-3beta inhibitor (AR-a014418) or siRNA against GSK-3beta, significantly augmented the inhibitory effect of troglitazone on the NF-kappaB activity, the cancer cell growth and on the expression of G(0)/G(1) phase regulatory proteins and pro-apoptosis regulatory proteins.	N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea	70-80	glycogen synthase kinase 3 beta	Homo sapiens	49-58
20540935-8	2010	In contrast, co-treatment of troglitazone with a GSK-3beta inhibitor (AR-a014418) or siRNA against GSK-3beta, significantly augmented the inhibitory effect of troglitazone on the NF-kappaB activity, the cancer cell growth and on the expression of G(0)/G(1) phase regulatory proteins and pro-apoptosis regulatory proteins.	Troglitazone	159-171	glycogen synthase kinase 3 beta	Homo sapiens	49-58
20540935-8	2010	In contrast, co-treatment of troglitazone with a GSK-3beta inhibitor (AR-a014418) or siRNA against GSK-3beta, significantly augmented the inhibitory effect of troglitazone on the NF-kappaB activity, the cancer cell growth and on the expression of G(0)/G(1) phase regulatory proteins and pro-apoptosis regulatory proteins.	Troglitazone	159-171	glycogen synthase kinase 3 beta	Homo sapiens	99-108
20540935-9	2010	These results suggest that the PPARgamma agonist, troglitazone, inhibits colon cancer cell growth via inactivation of NF-kappaB by suppressing GSK-3beta activity.	Troglitazone	50-62	glycogen synthase kinase 3 beta	Homo sapiens	143-152
20628792-7	2010	Further, silibinin reduced the expression of beta-catenin and phospho-GSK3beta in xenograft tissues.	Silybin	9-18	glycogen synthase kinase 3 beta	Homo sapiens	70-78
20861372-8	2010	Together with evidence in mammalian systems, our findings implicate proline-directed kinases in clock mechanisms and suggest that PER proteins are key downstream targets of lithium therapy, a potent inhibitor of GSK-3beta used to treat manic depression, a disorder associated with clock malfunction in humans.	Proline	68-75	glycogen synthase kinase 3 beta	Homo sapiens	212-221
20861372-8	2010	Together with evidence in mammalian systems, our findings implicate proline-directed kinases in clock mechanisms and suggest that PER proteins are key downstream targets of lithium therapy, a potent inhibitor of GSK-3beta used to treat manic depression, a disorder associated with clock malfunction in humans.	Lithium	173-180	glycogen synthase kinase 3 beta	Homo sapiens	212-221
20633632-8	2010	Compounds 1, 4, 5-12, and 14 displayed considerable effects on hepatic glucose production, AMPK activation, and phosphorylation of GSK-3beta in HepG2 cells under high glucose conditions.	Glucose	167-174	glycogen synthase kinase 3 beta	Homo sapiens	131-140
20571779-9	2010	In conclusion, we suggested that Ras overexpression leads to cell proliferation through activating Ras/PI3K/GSK3beta/EP(4) PGE(2) receptor signals and caused a feedback regulation of Ras by EP4 in colorectal tumor progression.	Prostaglandins E	123-126	glycogen synthase kinase 3 beta	Homo sapiens	108-116
20447678-3	2010	Here, the expression of phosphorylated glycogen synthase kinase 3beta at ser(9) was examined in gastric carcinoma and adjacent non-neoplastic mucosa by immunohistochemistry and Western blot, and compared with the clinicopathological parameters of carcinomas, including the expression of vascular endothelial growth factor, extracellular matrix metalloproteinase inducer and beta-catenin, and microvessel density labeled by CD34, as well as survival data.	Serine	73-76	glycogen synthase kinase 3 beta	Homo sapiens	39-69
20823611-0	2010	Enantioselective synthesis of the novel chiral sulfoxide derivative as a glycogen synthase kinase 3beta inhibitor.	sulfoxide	47-56	glycogen synthase kinase 3 beta	Homo sapiens	73-103
20960255-0	2010	The choice of atomic charges calculation scheme in 3D-QSAR modelling of GSK-3beta inhibition by paullones.	paullone	96-105	glycogen synthase kinase 3 beta	Homo sapiens	72-81
20447678-12	2010	Our study indicated that up-regulated expression of phosphorylated glycogen synthase kinase 3beta at ser(9) was closely linked to gastric carcinogenesis and subsequent progression, and could be employed as a good indicator of aggressive behaviors and prognosis of gastric carcinoma.	Serine	101-104	glycogen synthase kinase 3 beta	Homo sapiens	67-97
20654575-0	2010	The balance of TCF7L2 variants with differential activities in Wnt-signaling is regulated by lithium in a GSK3beta-independent manner.	Lithium	93-100	glycogen synthase kinase 3 beta	Homo sapiens	106-114
20664944-3	2010	Lithium targets a variety of enzymes among which there is GSK-3beta and a number of cell responses elicited by lithium are mediated by the Wnt pathway that is involved in medulloblastoma (MB) pathogenesis.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	58-67
20664944-5	2010	High doses of lithium inhibited GSK3-beta, decreased cell proliferation and induced non-apoptotic cell death in both cell lines independently by intracellular levels of beta-catenin that is consistently high only in D283MED.	Lithium	14-21	glycogen synthase kinase 3 beta	Homo sapiens	32-41
20654575-6	2010	While GSK3beta down-regulation increases TCF7L2 expression, there is no concomitant change in TCF7L2 mRNA isoforms, which demonstrate the dual effects of lithium on TCF7L2 expression via a GSK3beta-dependent up-regulation and a GSK3beta-independent modulation of RNA splicing.	Lithium	154-161	glycogen synthase kinase 3 beta	Homo sapiens	189-197
20654575-6	2010	While GSK3beta down-regulation increases TCF7L2 expression, there is no concomitant change in TCF7L2 mRNA isoforms, which demonstrate the dual effects of lithium on TCF7L2 expression via a GSK3beta-dependent up-regulation and a GSK3beta-independent modulation of RNA splicing.	Lithium	154-161	glycogen synthase kinase 3 beta	Homo sapiens	189-197
20704706-4	2010	In addition, gastric cancer cells were cultured and treated with a GSK-3beta inhibitor lithium chloride (LiCl) for immunoblot analysis.	Lithium Chloride	87-103	glycogen synthase kinase 3 beta	Homo sapiens	67-76
20546816-8	2010	In line with these results, a Western blot study showed that olanzapine (100 microM) increased phosphorylated levels of GSK-3beta and CREB, which are notable downstream effectors of the PKA, PI3K, PKC, and CaMKII signaling pathways.	Olanzapine	61-71	glycogen synthase kinase 3 beta	Homo sapiens	120-129
20704706-4	2010	In addition, gastric cancer cells were cultured and treated with a GSK-3beta inhibitor lithium chloride (LiCl) for immunoblot analysis.	Lithium Chloride	105-109	glycogen synthase kinase 3 beta	Homo sapiens	67-76
20432447-2	2010	This study shows that restriction of tyrosine and phenylalanine (Tyr/Phe), glutamine (Gln), or methionine (Met) differentially modulates glucose metabolism, glycogen synthase kinase 3beta (GSK3beta), p53, and pyruvate dehydrogenase (PDH) in these two cell lines.	Tyrosine	37-45	glycogen synthase kinase 3 beta	Homo sapiens	157-187
20681651-0	2010	Glycyrrhizic acid and 18beta-glycyrrhetinic acid inhibit inflammation via PI3K/Akt/GSK3beta signaling and glucocorticoid receptor activation.	Glycyrrhizic Acid	0-17	glycogen synthase kinase 3 beta	Homo sapiens	83-91
20681651-0	2010	Glycyrrhizic acid and 18beta-glycyrrhetinic acid inhibit inflammation via PI3K/Akt/GSK3beta signaling and glucocorticoid receptor activation.	18alpha-glycyrrhetinic acid	22-48	glycogen synthase kinase 3 beta	Homo sapiens	83-91
20725137-5	2010	The inhibitory effects of ZD4054 (zibotentan), a specific ETAR antagonist, in ET-1-dependent phosphorylation of ILK, Akt, and glycogen synthase kinase (GSK-3beta) demonstrated the involvement of the ETAR in these effects.	ZD4054	26-32	glycogen synthase kinase 3 beta	Homo sapiens	152-161
20725137-5	2010	The inhibitory effects of ZD4054 (zibotentan), a specific ETAR antagonist, in ET-1-dependent phosphorylation of ILK, Akt, and glycogen synthase kinase (GSK-3beta) demonstrated the involvement of the ETAR in these effects.	ZD4054	34-44	glycogen synthase kinase 3 beta	Homo sapiens	152-161
20204436-7	2010	Furthermore, the treatment of cells with isoflavones significantly reduced the microtubule-associated protein tau hyperphosphorylation by inactivating glycogen synthase kinase-3beta and activating serine/threonine-protein phosphatase 2A.	Isoflavones	41-52	glycogen synthase kinase 3 beta	Homo sapiens	151-181
20432447-2	2010	This study shows that restriction of tyrosine and phenylalanine (Tyr/Phe), glutamine (Gln), or methionine (Met) differentially modulates glucose metabolism, glycogen synthase kinase 3beta (GSK3beta), p53, and pyruvate dehydrogenase (PDH) in these two cell lines.	Methionine	95-105	glycogen synthase kinase 3 beta	Homo sapiens	157-187
20432447-2	2010	This study shows that restriction of tyrosine and phenylalanine (Tyr/Phe), glutamine (Gln), or methionine (Met) differentially modulates glucose metabolism, glycogen synthase kinase 3beta (GSK3beta), p53, and pyruvate dehydrogenase (PDH) in these two cell lines.	Methionine	95-105	glycogen synthase kinase 3 beta	Homo sapiens	189-197
20432447-2	2010	This study shows that restriction of tyrosine and phenylalanine (Tyr/Phe), glutamine (Gln), or methionine (Met) differentially modulates glucose metabolism, glycogen synthase kinase 3beta (GSK3beta), p53, and pyruvate dehydrogenase (PDH) in these two cell lines.	Tyrosine	37-45	glycogen synthase kinase 3 beta	Homo sapiens	189-197
20432447-6	2010	Tyr/Phe, Gln and Met restriction increase phosphorylation of GSK3beta-Ser(9), phosphorylation of p53-Ser(15) and reduce the mitochondrial localization of PDH.	Tyrosine	0-3	glycogen synthase kinase 3 beta	Homo sapiens	61-69
20432447-6	2010	Tyr/Phe, Gln and Met restriction increase phosphorylation of GSK3beta-Ser(9), phosphorylation of p53-Ser(15) and reduce the mitochondrial localization of PDH.	Phenylalanine	4-7	glycogen synthase kinase 3 beta	Homo sapiens	61-69
20432447-2	2010	This study shows that restriction of tyrosine and phenylalanine (Tyr/Phe), glutamine (Gln), or methionine (Met) differentially modulates glucose metabolism, glycogen synthase kinase 3beta (GSK3beta), p53, and pyruvate dehydrogenase (PDH) in these two cell lines.	Phenylalanine	50-63	glycogen synthase kinase 3 beta	Homo sapiens	157-187
20432447-6	2010	Tyr/Phe, Gln and Met restriction increase phosphorylation of GSK3beta-Ser(9), phosphorylation of p53-Ser(15) and reduce the mitochondrial localization of PDH.	Glutamine	9-12	glycogen synthase kinase 3 beta	Homo sapiens	61-69
20432447-2	2010	This study shows that restriction of tyrosine and phenylalanine (Tyr/Phe), glutamine (Gln), or methionine (Met) differentially modulates glucose metabolism, glycogen synthase kinase 3beta (GSK3beta), p53, and pyruvate dehydrogenase (PDH) in these two cell lines.	Phenylalanine	50-63	glycogen synthase kinase 3 beta	Homo sapiens	189-197
20432447-6	2010	Tyr/Phe, Gln and Met restriction increase phosphorylation of GSK3beta-Ser(9), phosphorylation of p53-Ser(15) and reduce the mitochondrial localization of PDH.	Serine	70-73	glycogen synthase kinase 3 beta	Homo sapiens	61-69
20432447-2	2010	This study shows that restriction of tyrosine and phenylalanine (Tyr/Phe), glutamine (Gln), or methionine (Met) differentially modulates glucose metabolism, glycogen synthase kinase 3beta (GSK3beta), p53, and pyruvate dehydrogenase (PDH) in these two cell lines.	Tyrosine	65-68	glycogen synthase kinase 3 beta	Homo sapiens	157-187
20432447-8	2010	In p53-null PC3 cells, Tyr/Phe, Gln and Met restriction decreases glucose consumption, reduces phosphorylation of Akt-Ser(473), and increases phosphorylation of GSK3beta-Ser(9).	Tyrosine	23-26	glycogen synthase kinase 3 beta	Homo sapiens	161-169
20432447-8	2010	In p53-null PC3 cells, Tyr/Phe, Gln and Met restriction decreases glucose consumption, reduces phosphorylation of Akt-Ser(473), and increases phosphorylation of GSK3beta-Ser(9).	Phenylalanine	27-30	glycogen synthase kinase 3 beta	Homo sapiens	161-169
20432447-2	2010	This study shows that restriction of tyrosine and phenylalanine (Tyr/Phe), glutamine (Gln), or methionine (Met) differentially modulates glucose metabolism, glycogen synthase kinase 3beta (GSK3beta), p53, and pyruvate dehydrogenase (PDH) in these two cell lines.	Tyrosine	65-68	glycogen synthase kinase 3 beta	Homo sapiens	189-197
20432447-8	2010	In p53-null PC3 cells, Tyr/Phe, Gln and Met restriction decreases glucose consumption, reduces phosphorylation of Akt-Ser(473), and increases phosphorylation of GSK3beta-Ser(9).	Glutamine	32-35	glycogen synthase kinase 3 beta	Homo sapiens	161-169
20432447-2	2010	This study shows that restriction of tyrosine and phenylalanine (Tyr/Phe), glutamine (Gln), or methionine (Met) differentially modulates glucose metabolism, glycogen synthase kinase 3beta (GSK3beta), p53, and pyruvate dehydrogenase (PDH) in these two cell lines.	Phenylalanine	69-72	glycogen synthase kinase 3 beta	Homo sapiens	157-187
20432447-8	2010	In p53-null PC3 cells, Tyr/Phe, Gln and Met restriction decreases glucose consumption, reduces phosphorylation of Akt-Ser(473), and increases phosphorylation of GSK3beta-Ser(9).	Serine	170-173	glycogen synthase kinase 3 beta	Homo sapiens	161-169
20432447-2	2010	This study shows that restriction of tyrosine and phenylalanine (Tyr/Phe), glutamine (Gln), or methionine (Met) differentially modulates glucose metabolism, glycogen synthase kinase 3beta (GSK3beta), p53, and pyruvate dehydrogenase (PDH) in these two cell lines.	Glutamine	75-84	glycogen synthase kinase 3 beta	Homo sapiens	157-187
20432447-10	2010	Addition of glucose increases phosphorylation of Akt-Ser(473) in amino acid-restricted cells reduces phosphorylation of GSK3beta-Ser(9) in Tyr/Phe and Gln restricted cells and increases phosphorylation of GSK3beta-Ser(9) in Met restricted cells.	Glucose	12-19	glycogen synthase kinase 3 beta	Homo sapiens	120-128
20432447-10	2010	Addition of glucose increases phosphorylation of Akt-Ser(473) in amino acid-restricted cells reduces phosphorylation of GSK3beta-Ser(9) in Tyr/Phe and Gln restricted cells and increases phosphorylation of GSK3beta-Ser(9) in Met restricted cells.	Glucose	12-19	glycogen synthase kinase 3 beta	Homo sapiens	205-213
20432447-2	2010	This study shows that restriction of tyrosine and phenylalanine (Tyr/Phe), glutamine (Gln), or methionine (Met) differentially modulates glucose metabolism, glycogen synthase kinase 3beta (GSK3beta), p53, and pyruvate dehydrogenase (PDH) in these two cell lines.	Glutamine	75-84	glycogen synthase kinase 3 beta	Homo sapiens	189-197
20432447-10	2010	Addition of glucose increases phosphorylation of Akt-Ser(473) in amino acid-restricted cells reduces phosphorylation of GSK3beta-Ser(9) in Tyr/Phe and Gln restricted cells and increases phosphorylation of GSK3beta-Ser(9) in Met restricted cells.	Serine	53-56	glycogen synthase kinase 3 beta	Homo sapiens	120-128
20432447-10	2010	Addition of glucose increases phosphorylation of Akt-Ser(473) in amino acid-restricted cells reduces phosphorylation of GSK3beta-Ser(9) in Tyr/Phe and Gln restricted cells and increases phosphorylation of GSK3beta-Ser(9) in Met restricted cells.	Serine	53-56	glycogen synthase kinase 3 beta	Homo sapiens	205-213
20432447-10	2010	Addition of glucose increases phosphorylation of Akt-Ser(473) in amino acid-restricted cells reduces phosphorylation of GSK3beta-Ser(9) in Tyr/Phe and Gln restricted cells and increases phosphorylation of GSK3beta-Ser(9) in Met restricted cells.	Phenylalanine	143-146	glycogen synthase kinase 3 beta	Homo sapiens	120-128
20432447-10	2010	Addition of glucose increases phosphorylation of Akt-Ser(473) in amino acid-restricted cells reduces phosphorylation of GSK3beta-Ser(9) in Tyr/Phe and Gln restricted cells and increases phosphorylation of GSK3beta-Ser(9) in Met restricted cells.	Glutamine	151-154	glycogen synthase kinase 3 beta	Homo sapiens	120-128
20432447-2	2010	This study shows that restriction of tyrosine and phenylalanine (Tyr/Phe), glutamine (Gln), or methionine (Met) differentially modulates glucose metabolism, glycogen synthase kinase 3beta (GSK3beta), p53, and pyruvate dehydrogenase (PDH) in these two cell lines.	Glutamine	86-89	glycogen synthase kinase 3 beta	Homo sapiens	157-187
20432447-11	2010	Addition of pyruvate reduces phosphorylation of GSK3beta-Ser(9) in all amino acid-restricted cells.	Pyruvic Acid	12-20	glycogen synthase kinase 3 beta	Homo sapiens	48-56
20432447-11	2010	Addition of pyruvate reduces phosphorylation of GSK3beta-Ser(9) in all amino acid-restricted cells.	Serine	57-60	glycogen synthase kinase 3 beta	Homo sapiens	48-56
20427117-6	2010	Furthermore, inhibition of GSK3beta activity blocked the ability of RA to direct cell differentiation along the neural lineage, suggesting a role for appropriately regulated WNT signalling.	Tretinoin	68-70	glycogen synthase kinase 3 beta	Homo sapiens	27-35
20357815-0	2010	Cyclic AMP suppresses matrix metalloproteinase-1 expression through inhibition of MAPK and GSK-3beta.	Cyclic AMP	0-10	glycogen synthase kinase 3 beta	Homo sapiens	91-100
20357815-7	2010	Further studies revealed that glycogen synthase kinase (GSK)-3beta can be inactivated by cAMP/PKA pathway and has important roles in MMP-1 expression, and showed that inactivation of GSK-3beta is critical for suppression of MMP-1 expression by cAMP elevation after TNF-alpha treatment.	Cyclic AMP	89-93	glycogen synthase kinase 3 beta	Homo sapiens	30-66
20357815-7	2010	Further studies revealed that glycogen synthase kinase (GSK)-3beta can be inactivated by cAMP/PKA pathway and has important roles in MMP-1 expression, and showed that inactivation of GSK-3beta is critical for suppression of MMP-1 expression by cAMP elevation after TNF-alpha treatment.	Cyclic AMP	89-93	glycogen synthase kinase 3 beta	Homo sapiens	183-192
20357815-7	2010	Further studies revealed that glycogen synthase kinase (GSK)-3beta can be inactivated by cAMP/PKA pathway and has important roles in MMP-1 expression, and showed that inactivation of GSK-3beta is critical for suppression of MMP-1 expression by cAMP elevation after TNF-alpha treatment.	Cyclic AMP	244-248	glycogen synthase kinase 3 beta	Homo sapiens	30-66
20357815-7	2010	Further studies revealed that glycogen synthase kinase (GSK)-3beta can be inactivated by cAMP/PKA pathway and has important roles in MMP-1 expression, and showed that inactivation of GSK-3beta is critical for suppression of MMP-1 expression by cAMP elevation after TNF-alpha treatment.	Cyclic AMP	244-248	glycogen synthase kinase 3 beta	Homo sapiens	183-192
20357815-8	2010	Taken together, our results suggest that cAMP/PKA pathway can suppress MMP-1 expression through inhibition of multiple signaling pathways, including MAPK and GSK-3beta.	Cyclic AMP	41-45	glycogen synthase kinase 3 beta	Homo sapiens	158-167
21364661-10	2010	Lithium reduced the ischemia-induced dephosphorylation of glycogen synthase kinase-3beta and extracellular signal-regulated kinase, the activation of calpain and caspase-3, the mitochondrial release of cytochrome c and apoptosis-inducing factor, as well as autophagy.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	58-88
20634980-7	2010	Interestingly, inhibition of GSK-3beta by SB 216763 or by RNA interference, augmented HBD-2 induction.	Antimony	42-44	glycogen synthase kinase 3 beta	Homo sapiens	29-38
19945766-9	2010	In cholesterol-depleted cells, EGF-induced phosphorylation of Src, Akt, and p44/42 in the detergent-insoluble fraction were inhibited whereas phosphorylation of GSK-3beta was unaffected.	Cholesterol	3-14	glycogen synthase kinase 3 beta	Homo sapiens	161-170
20663861-5	2010	In contrast, a selective inducible nitric oxide synthase inhibitor, 1400W, upregulated the expression of IRS-1 protein and the phosphorylation of IRS-1, Akt/PKB, and glycogen synthase kinase-3beta, along with enhanced proliferation and invasion of Panc-1 cells expressing inducible nitric oxide synthase protein.	N-((3-(aminomethyl)phenyl)methyl)ethanimidamide	68-73	glycogen synthase kinase 3 beta	Homo sapiens	166-196
20663927-3	2010	Previously, we had shown that NaBT increases nuclear GSK-3beta expression and kinase activity; GSK-3beta functions as a negative regulator of extracellular signal-regulated kinase (ERK) signaling.	NABT	30-34	glycogen synthase kinase 3 beta	Homo sapiens	53-62
19778547-4	2010	By activating this pathway through estrogen receptors, estradiol increases the levels of inactive GSK3beta (phosphorylated in serine 9).	Estradiol	55-64	glycogen synthase kinase 3 beta	Homo sapiens	98-106
19778547-4	2010	By activating this pathway through estrogen receptors, estradiol increases the levels of inactive GSK3beta (phosphorylated in serine 9).	Serine	126-132	glycogen synthase kinase 3 beta	Homo sapiens	98-106
20541550-5	2010	AEG was found to enhance glycogen synthesis through the inhibition of glycogen synthase kinase 3beta.	N-(2-aminoethyl)glycine	0-3	glycogen synthase kinase 3 beta	Homo sapiens	70-100
20541550-5	2010	AEG was found to enhance glycogen synthesis through the inhibition of glycogen synthase kinase 3beta.	Glycogen	25-33	glycogen synthase kinase 3 beta	Homo sapiens	70-100
20206143-9	2010	Further studies demonstrated that DHA accelerated the degradation of c-MYC protein and this process was blocked by pretreatment with the proteasome inhibitor MG-132 or GSK 3beta inhibitor LiCl in HCT116 cells.	artenimol	34-37	glycogen synthase kinase 3 beta	Homo sapiens	168-177
20926002-8	2010	Celecoxib inhibited MG-63 cell viability, possibly by activating GSK-3beta and inhibiting beta-catenin-dependent gene transcription, suggesting a role for celecoxib in osteosarcoma treatment.	Celecoxib	0-9	glycogen synthase kinase 3 beta	Homo sapiens	65-74
20333643-3	2010	In this study, based on real-time single-cell analysis, we demonstrated for the first time that LPLI inhibits staurosporine (STS)-induced cell apoptosis by inactivating the GSK-3beta/Bax pathway.	Staurosporine	110-123	glycogen synthase kinase 3 beta	Homo sapiens	173-182
20333643-3	2010	In this study, based on real-time single-cell analysis, we demonstrated for the first time that LPLI inhibits staurosporine (STS)-induced cell apoptosis by inactivating the GSK-3beta/Bax pathway.	Staurosporine	125-128	glycogen synthase kinase 3 beta	Homo sapiens	173-182
20333643-10	2010	Taken together, we conclude that LPLI protects against STS-induced apoptosis upstream of Bax translocation via the PI3K/Akt/GSK-3beta pathway.	Staurosporine	55-58	glycogen synthase kinase 3 beta	Homo sapiens	124-133
20077420-6	2010	Puerarin stimulated AMP-activated protein kinase (AMPK), acetyl-CoA carboxylase and glycogen synthase kinase-3beta phosphorylation, but puerarin decreased cAMP-responsive element-binding protein phosphorylation.	puerarin	0-8	glycogen synthase kinase 3 beta	Homo sapiens	84-114
19757160-5	2010	Results showed that the expression of beta-catenin protein in primary human thyrocytes was increased after GSK-3beta-targeting RNAi adenovirus infection, the proliferation of primary human thyrocytes was significantly stimulated using Bromodeoxyuridine (BrdU) assay, while cell apoptosis was slightly affected which was observed through flow cytometry.	Bromodeoxyuridine	235-252	glycogen synthase kinase 3 beta	Homo sapiens	107-116
19757160-5	2010	Results showed that the expression of beta-catenin protein in primary human thyrocytes was increased after GSK-3beta-targeting RNAi adenovirus infection, the proliferation of primary human thyrocytes was significantly stimulated using Bromodeoxyuridine (BrdU) assay, while cell apoptosis was slightly affected which was observed through flow cytometry.	Bromodeoxyuridine	254-258	glycogen synthase kinase 3 beta	Homo sapiens	107-116
20537156-0	2010	The chemopreventive retinoid 4HPR impairs prostate cancer cell migration and invasion by interfering with FAK/AKT/GSK3beta pathway and beta-catenin stability.	retinoid 4hpr	20-33	glycogen synthase kinase 3 beta	Homo sapiens	114-122
20190034-6	2010	GSK-3beta inhibition by lithium or SB-216763 increased cell size, protein synthesis, and contractile protein expression.	Lithium	24-31	glycogen synthase kinase 3 beta	Homo sapiens	0-9
20211702-4	2010	The microtubule-associated tau proteins were more phosphorylated in GSK-3beta and p25 transfected neurons, but ultrastructural observation showed that these cells still contained microtubules and nocodazole treatment further reduced residual mitochondria movements in GSK-3beta or p25 transfected neurons, indicating that microtubule disruption was not the primary cause of increased mitochondrial stationary behaviour in GSK-3beta or p25 transfected neurons.	Nocodazole	196-206	glycogen synthase kinase 3 beta	Homo sapiens	68-77
20211702-4	2010	The microtubule-associated tau proteins were more phosphorylated in GSK-3beta and p25 transfected neurons, but ultrastructural observation showed that these cells still contained microtubules and nocodazole treatment further reduced residual mitochondria movements in GSK-3beta or p25 transfected neurons, indicating that microtubule disruption was not the primary cause of increased mitochondrial stationary behaviour in GSK-3beta or p25 transfected neurons.	Nocodazole	196-206	glycogen synthase kinase 3 beta	Homo sapiens	268-277
20211702-4	2010	The microtubule-associated tau proteins were more phosphorylated in GSK-3beta and p25 transfected neurons, but ultrastructural observation showed that these cells still contained microtubules and nocodazole treatment further reduced residual mitochondria movements in GSK-3beta or p25 transfected neurons, indicating that microtubule disruption was not the primary cause of increased mitochondrial stationary behaviour in GSK-3beta or p25 transfected neurons.	Nocodazole	196-206	glycogen synthase kinase 3 beta	Homo sapiens	268-277
20190034-6	2010	GSK-3beta inhibition by lithium or SB-216763 increased cell size, protein synthesis, and contractile protein expression.	SB 216763	35-44	glycogen synthase kinase 3 beta	Homo sapiens	0-9
20490903-7	2010	Phosphorylated GSK-3beta inhibits mPTP opening presumably by multiple mechanisms, including preservation of hexokinase II in mPTP complex, prevention of interaction of cyclophilin-D with adenine nucleotide translocase, inhibition of p53 activation and attenuation of ATP hydrolysis during ischemia.	Adenosine Triphosphate	267-270	glycogen synthase kinase 3 beta	Homo sapiens	15-24
20460998-7	2010	GSK-3beta inhibitor VII was administered during the first few minutes of reoxygenation alone or in the presence of desflurane 6%, rapamycin, NG-nitro-L-arginine methyl ester, and atractyloside.	Atractyloside	179-192	glycogen synthase kinase 3 beta	Homo sapiens	0-9
20460998-12	2010	GSK-3beta inhibitor-induced postconditioning (84 +/- 5%, P &lt; 0.0001 vs. control) was not modified by desflurane (78 +/- 6%), rapamycin (81 +/- 6%), and NG-nitro-L-arginine methyl ester (82 +/- 10%), but it was abolished by atractyloside (49 +/- 6%).	NG-Nitroarginine Methyl Ester	155-187	glycogen synthase kinase 3 beta	Homo sapiens	0-9
20460998-12	2010	GSK-3beta inhibitor-induced postconditioning (84 +/- 5%, P &lt; 0.0001 vs. control) was not modified by desflurane (78 +/- 6%), rapamycin (81 +/- 6%), and NG-nitro-L-arginine methyl ester (82 +/- 10%), but it was abolished by atractyloside (49 +/- 6%).	Atractyloside	226-239	glycogen synthase kinase 3 beta	Homo sapiens	0-9
20460998-13	2010	Desflurane increased the phosphorylation of GSK-3beta (3.30 +/- 0.57-fold increase in desflurane vs. control; P &lt; 0.0001).	Desflurane	0-10	glycogen synthase kinase 3 beta	Homo sapiens	44-53
20460998-13	2010	Desflurane increased the phosphorylation of GSK-3beta (3.30 +/- 0.57-fold increase in desflurane vs. control; P &lt; 0.0001).	Desflurane	86-96	glycogen synthase kinase 3 beta	Homo sapiens	44-53
20460998-14	2010	CONCLUSIONS: In vitro, desflurane-induced postconditioning protects human myocardium through the activation of 70-kDa ribosomal protein S6 kinase, nitric oxide synthase, inhibition, and phosphorylation of GSK-3beta, and preventing mitochondrial permeability transition pore opening.	Desflurane	23-33	glycogen synthase kinase 3 beta	Homo sapiens	205-214
20490903-7	2010	Phosphorylated GSK-3beta inhibits mPTP opening presumably by multiple mechanisms, including preservation of hexokinase II in mPTP complex, prevention of interaction of cyclophilin-D with adenine nucleotide translocase, inhibition of p53 activation and attenuation of ATP hydrolysis during ischemia.	Adenine Nucleotides	187-205	glycogen synthase kinase 3 beta	Homo sapiens	15-24
20031160-0	2010	ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines.	N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide	0-8	glycogen synthase kinase 3 beta	Homo sapiens	62-71
20351317-13	2010	Furthermore, LH-directed changes in AMPK and GSK3B phosphorylation appear to exert a greater impact on progesterone synthesis in the corpus luteum than rapamycin-sensitive MTOR-mediated events.	Luteinizing Hormone	13-15	glycogen synthase kinase 3 beta	Homo sapiens	45-50
20351317-13	2010	Furthermore, LH-directed changes in AMPK and GSK3B phosphorylation appear to exert a greater impact on progesterone synthesis in the corpus luteum than rapamycin-sensitive MTOR-mediated events.	Progesterone	103-115	glycogen synthase kinase 3 beta	Homo sapiens	45-50
19228266-0	2010	4-Aminoethylamino-emodin--a novel potent inhibitor of GSK-3beta--acts as an insulin-sensitizer avoiding downstream effects of activated beta-catenin.	4-aminoethylamino-emodin	0-24	glycogen synthase kinase 3 beta	Homo sapiens	54-63
19228266-2	2010	Using comparative protein kinase assays and molecular docking studies we characterize the emodin-derivative 4-[N-2-(aminoethyl)-amino]-emodin (L4) as a sensitive and potent inhibitor of GSK-3beta with peculiar features.	4-aminoethylamino-emodin	108-141	glycogen synthase kinase 3 beta	Homo sapiens	186-195
20345749-6	2010	AmB was found to activate Akt and thereby suppress the activity of glycogen synthase kinase 3 beta.	Amphotericin B	0-3	glycogen synthase kinase 3 beta	Homo sapiens	67-98
20031160-2	2010	It has been shown to inhibit glycogen synthase kinase-3beta (GSK-3beta) through phosphorylation of GSK-3beta at Ser 9.	Serine	112-115	glycogen synthase kinase 3 beta	Homo sapiens	29-59
20031160-2	2010	It has been shown to inhibit glycogen synthase kinase-3beta (GSK-3beta) through phosphorylation of GSK-3beta at Ser 9.	Serine	112-115	glycogen synthase kinase 3 beta	Homo sapiens	61-70
20031160-2	2010	It has been shown to inhibit glycogen synthase kinase-3beta (GSK-3beta) through phosphorylation of GSK-3beta at Ser 9.	Serine	112-115	glycogen synthase kinase 3 beta	Homo sapiens	99-108
20031160-4	2010	Here we determine the effects of ZM336372 on GSK-3beta phosphorylation, apoptosis, and growth in pancreatic adenocarcinoma cell lines.	N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide	33-41	glycogen synthase kinase 3 beta	Homo sapiens	45-54
20031160-9	2010	RESULTS: A dose-dependent increase in phosphorylation of GSK-3beta was observed after treatment with both ZM336372 and LiCl.	N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide	106-114	glycogen synthase kinase 3 beta	Homo sapiens	57-66
20031160-9	2010	RESULTS: A dose-dependent increase in phosphorylation of GSK-3beta was observed after treatment with both ZM336372 and LiCl.	Lithium Chloride	119-123	glycogen synthase kinase 3 beta	Homo sapiens	57-66
20031160-12	2010	CONCLUSION: This is the first description of growth inhibition and apoptosis in pancreatic cancer cells related to GSK-3beta inhibition through treatment with ZM336372.	N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide	159-167	glycogen synthase kinase 3 beta	Homo sapiens	115-124
20520769-4	2010	We have shown previously that the neuromodulator serotonin increases mitochondrial movement in hippocampal neurons via the Akt-GSK3beta signaling pathway.	Serotonin	49-58	glycogen synthase kinase 3 beta	Homo sapiens	127-135
20043192-2	2010	Recent X-ray diffraction studies illuminated the relative binding residues on AxinGID and FRATtide for GSK3beta docking and appeared that GSK3beta Val267Gly (V267G) and Tyr288Phe (Y288F) could distinguish the direct interaction between AxinGID and FRATtide.	axingid	78-85	glycogen synthase kinase 3 beta	Homo sapiens	103-111
20043192-2	2010	Recent X-ray diffraction studies illuminated the relative binding residues on AxinGID and FRATtide for GSK3beta docking and appeared that GSK3beta Val267Gly (V267G) and Tyr288Phe (Y288F) could distinguish the direct interaction between AxinGID and FRATtide.	frattide	90-98	glycogen synthase kinase 3 beta	Homo sapiens	103-111
20043192-2	2010	Recent X-ray diffraction studies illuminated the relative binding residues on AxinGID and FRATtide for GSK3beta docking and appeared that GSK3beta Val267Gly (V267G) and Tyr288Phe (Y288F) could distinguish the direct interaction between AxinGID and FRATtide.	axingid	236-243	glycogen synthase kinase 3 beta	Homo sapiens	103-111
20043192-2	2010	Recent X-ray diffraction studies illuminated the relative binding residues on AxinGID and FRATtide for GSK3beta docking and appeared that GSK3beta Val267Gly (V267G) and Tyr288Phe (Y288F) could distinguish the direct interaction between AxinGID and FRATtide.	axingid	236-243	glycogen synthase kinase 3 beta	Homo sapiens	138-146
20043192-2	2010	Recent X-ray diffraction studies illuminated the relative binding residues on AxinGID and FRATtide for GSK3beta docking and appeared that GSK3beta Val267Gly (V267G) and Tyr288Phe (Y288F) could distinguish the direct interaction between AxinGID and FRATtide.	frattide	248-256	glycogen synthase kinase 3 beta	Homo sapiens	103-111
20043192-2	2010	Recent X-ray diffraction studies illuminated the relative binding residues on AxinGID and FRATtide for GSK3beta docking and appeared that GSK3beta Val267Gly (V267G) and Tyr288Phe (Y288F) could distinguish the direct interaction between AxinGID and FRATtide.	frattide	248-256	glycogen synthase kinase 3 beta	Homo sapiens	138-146
20043192-3	2010	In order to explore the mode that involved the binding of GSKIP to GSK3beta and compare it with that of AxinGID and FRATtide, we pinpointed the binding sites of GSKIP to GSK3beta through the single-point mutation of four corresponding sites within GSK3beta (residues 260-300) as scaffold-binding region I (designated SBR-I(260-300)).	axingid	104-111	glycogen synthase kinase 3 beta	Homo sapiens	170-178
20043192-3	2010	In order to explore the mode that involved the binding of GSKIP to GSK3beta and compare it with that of AxinGID and FRATtide, we pinpointed the binding sites of GSKIP to GSK3beta through the single-point mutation of four corresponding sites within GSK3beta (residues 260-300) as scaffold-binding region I (designated SBR-I(260-300)).	axingid	104-111	glycogen synthase kinase 3 beta	Homo sapiens	170-178
20043192-3	2010	In order to explore the mode that involved the binding of GSKIP to GSK3beta and compare it with that of AxinGID and FRATtide, we pinpointed the binding sites of GSKIP to GSK3beta through the single-point mutation of four corresponding sites within GSK3beta (residues 260-300) as scaffold-binding region I (designated SBR-I(260-300)).	frattide	116-124	glycogen synthase kinase 3 beta	Homo sapiens	170-178
20043192-3	2010	In order to explore the mode that involved the binding of GSKIP to GSK3beta and compare it with that of AxinGID and FRATtide, we pinpointed the binding sites of GSKIP to GSK3beta through the single-point mutation of four corresponding sites within GSK3beta (residues 260-300) as scaffold-binding region I (designated SBR-I(260-300)).	frattide	116-124	glycogen synthase kinase 3 beta	Homo sapiens	170-178
20043192-7	2010	Interestingly, many C-terminal helix region point-mutants of GSK3beta L359P, F362A, E366K, and L367P were able to eliminate the binding with FRATtide, but not AxinGID or GSKIP.	frattide	141-149	glycogen synthase kinase 3 beta	Homo sapiens	61-69
20043192-7	2010	Interestingly, many C-terminal helix region point-mutants of GSK3beta L359P, F362A, E366K, and L367P were able to eliminate the binding with FRATtide, but not AxinGID or GSKIP.	axingid	159-166	glycogen synthase kinase 3 beta	Homo sapiens	61-69
20144629-4	2010	IGF-I increased inhibitory Ser(9)-phosphorylation of GSK-3beta and stimulatory Ser(2448)-phosphorylation of mTOR.	Serine	27-30	glycogen synthase kinase 3 beta	Homo sapiens	53-62
20520769-10	2010	GSK3beta was found to co-localize with HDAC6 in hippocampal neurons, and inhibition of GSK3beta resulted in decreased binding of antibody to phosphoserine-22, a potential GSK3beta phosphorylation site in HDAC6.	Phosphoserine	141-154	glycogen synthase kinase 3 beta	Homo sapiens	87-95
20520769-10	2010	GSK3beta was found to co-localize with HDAC6 in hippocampal neurons, and inhibition of GSK3beta resulted in decreased binding of antibody to phosphoserine-22, a potential GSK3beta phosphorylation site in HDAC6.	Phosphoserine	141-154	glycogen synthase kinase 3 beta	Homo sapiens	87-95
20231273-5	2010	PDGF-DD induced glycogen synthase kinase-3beta (GSK3beta) Ser(9) phosphorylation and Tyr(216) dephosphorylation in vitro and in vivo, leading to increased cell survival.	Serine	58-61	glycogen synthase kinase 3 beta	Homo sapiens	16-46
20235153-6	2010	CTGF increased the mRNA levels of Protein kinase cyclic guanosine monophosphate (cGMP) dependent type II (Prkg2), the gene encoding for cGMP dependent protein kinase II (cGKII) which phosphorylates GSK3beta.	Cyclic GMP	49-79	glycogen synthase kinase 3 beta	Homo sapiens	198-206
20235153-6	2010	CTGF increased the mRNA levels of Protein kinase cyclic guanosine monophosphate (cGMP) dependent type II (Prkg2), the gene encoding for cGMP dependent protein kinase II (cGKII) which phosphorylates GSK3beta.	Cyclic GMP	81-85	glycogen synthase kinase 3 beta	Homo sapiens	198-206
20015942-0	2010	Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3beta, Snail1, and beta-catenin in renal proximal tubule cells.	Troglitazone	0-12	glycogen synthase kinase 3 beta	Homo sapiens	93-102
20231273-5	2010	PDGF-DD induced glycogen synthase kinase-3beta (GSK3beta) Ser(9) phosphorylation and Tyr(216) dephosphorylation in vitro and in vivo, leading to increased cell survival.	Serine	58-61	glycogen synthase kinase 3 beta	Homo sapiens	48-56
20399743-0	2010	Regulation of GSK-3beta and beta-Catenin by Galphaq in HEK293T cells.	galphaq	44-51	glycogen synthase kinase 3 beta	Homo sapiens	14-23
20399743-8	2010	Also, expression of GalphaqQL led to a significant reduction in GSK-3beta kinase activity, supporting the idea that the positive role of Galphaq signaling in inducing cellular accumulation of beta-Catenin is mediated through inhibition of GSK-3beta.	galphaqql	20-29	glycogen synthase kinase 3 beta	Homo sapiens	64-73
20399743-8	2010	Also, expression of GalphaqQL led to a significant reduction in GSK-3beta kinase activity, supporting the idea that the positive role of Galphaq signaling in inducing cellular accumulation of beta-Catenin is mediated through inhibition of GSK-3beta.	galphaqql	20-29	glycogen synthase kinase 3 beta	Homo sapiens	239-248
20399743-8	2010	Also, expression of GalphaqQL led to a significant reduction in GSK-3beta kinase activity, supporting the idea that the positive role of Galphaq signaling in inducing cellular accumulation of beta-Catenin is mediated through inhibition of GSK-3beta.	galphaq	20-27	glycogen synthase kinase 3 beta	Homo sapiens	64-73
20399743-8	2010	Also, expression of GalphaqQL led to a significant reduction in GSK-3beta kinase activity, supporting the idea that the positive role of Galphaq signaling in inducing cellular accumulation of beta-Catenin is mediated through inhibition of GSK-3beta.	galphaq	20-27	glycogen synthase kinase 3 beta	Homo sapiens	239-248
20015942-9	2010	HG and lithium chloride (GSK-3beta inhibitor) blocked Snail1 and beta-catenin activation.	Lithium Chloride	7-23	glycogen synthase kinase 3 beta	Homo sapiens	25-34
20513428-6	2010	However, if Akt is inactive, GSK3beta phosphorylates p52 at Ser 222.	Serine	60-63	glycogen synthase kinase 3 beta	Homo sapiens	29-37
20015942-0	2010	Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3beta, Snail1, and beta-catenin in renal proximal tubule cells.	Glucose	30-37	glycogen synthase kinase 3 beta	Homo sapiens	93-102
20015942-11	2010	Importantly, HG decreased PPARgamma activation and troglitazone reversed HG-induced expression of PI3K/Akt, GSK-3beta, Snail1, and beta-catenin as well as EMT proteins.	Troglitazone	51-63	glycogen synthase kinase 3 beta	Homo sapiens	108-117
20026081-0	2010	AMPK-mediated GSK3beta inhibition by isoliquiritigenin contributes to protecting mitochondria against iron-catalyzed oxidative stress.	isoliquiritigenin	37-54	glycogen synthase kinase 3 beta	Homo sapiens	14-22
20384568-4	2010	Ang II caused significant (p &lt; 0.05) inhibition of insulin-stimulated glucose transport (39%) and decreased phosphorylation of Akt Ser(473) (37%) and glycogen synthase kinase-3beta Ser(9) (42%) without affecting phosphorylation of IRS-1 Ser(307) or p38 MAPK.	Serine	184-187	glycogen synthase kinase 3 beta	Homo sapiens	153-183
20384568-4	2010	Ang II caused significant (p &lt; 0.05) inhibition of insulin-stimulated glucose transport (39%) and decreased phosphorylation of Akt Ser(473) (37%) and glycogen synthase kinase-3beta Ser(9) (42%) without affecting phosphorylation of IRS-1 Ser(307) or p38 MAPK.	Serine	184-187	glycogen synthase kinase 3 beta	Homo sapiens	153-183
20154265-8	2010	In conclusion, the H(2)S donor prevents cardiomyocyte apoptosis by inducing phosphorylation of GSK-3beta (Ser9) and subsequent inhibition of mPTP opening.	Hydrogen Sulfide	19-24	glycogen synthase kinase 3 beta	Homo sapiens	95-104
20026081-0	2010	AMPK-mediated GSK3beta inhibition by isoliquiritigenin contributes to protecting mitochondria against iron-catalyzed oxidative stress.	Iron	102-106	glycogen synthase kinase 3 beta	Homo sapiens	14-22
20026081-8	2010	ILQ treatment enhanced inhibitory phosphorylation of glycogen synthase kinase-3beta (GSK3beta), and prevented a decrease in the GSK3beta phosphorylation elicited by AA+iron, which contributed to protecting cells and mitochondria.	Iron	168-172	glycogen synthase kinase 3 beta	Homo sapiens	128-136
20026081-10	2010	These results demonstrate that ILQ has the ability to protect cells from AA+iron-induced H2O2 production and mitochondrial dysfunction, which is mediated with GSK3beta phosphorylation downstream of AMPK.	Iron	76-80	glycogen synthase kinase 3 beta	Homo sapiens	159-167
20454507-2	2010	Irradiation inhibits glycogen synthase kinase 3beta (GSK3beta) by phosphorylation at serine 9.	Serine	85-91	glycogen synthase kinase 3 beta	Homo sapiens	21-51
20331603-1	2010	Glycogen synthase kinase-3 beta (GSK3beta) is a multifunctional serine/threonine kinase which was originally identified as a regulator of glycogen metabolism.	Glycogen	138-146	glycogen synthase kinase 3 beta	Homo sapiens	0-31
20331603-1	2010	Glycogen synthase kinase-3 beta (GSK3beta) is a multifunctional serine/threonine kinase which was originally identified as a regulator of glycogen metabolism.	Glycogen	138-146	glycogen synthase kinase 3 beta	Homo sapiens	33-41
20331603-9	2010	The chemo space for small molecule modulators extracted from public and proprietary Kinase Chembiobase for GSK3beta are discussed.	chembiobase	91-102	glycogen synthase kinase 3 beta	Homo sapiens	107-115
20423992-3	2010	This ATP-competitive small molecule potently inhibits both AKT and p70S6K activity at the cellular level, as measured by inhibition of GSK3beta and S6 ribosomal protein phosphorylation, and also causes growth inhibition in a range of human cancer cell lines as a single agent.	Adenosine Triphosphate	5-8	glycogen synthase kinase 3 beta	Homo sapiens	135-143
20454507-2	2010	Irradiation inhibits glycogen synthase kinase 3beta (GSK3beta) by phosphorylation at serine 9.	Serine	85-91	glycogen synthase kinase 3 beta	Homo sapiens	53-61
20101221-6	2010	In addition, AT7519 inhibited glycogen synthase kinase 3beta (GSK-3beta) phosphorylation; conversely pretreatment with a selective GSK-3 inhibitor and shRNA GSK-3beta knockdown restored MM survival, suggesting the involvement of GSK-3beta in AT7519-induced apoptosis.	4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide	13-19	glycogen synthase kinase 3 beta	Homo sapiens	30-60
20101221-6	2010	In addition, AT7519 inhibited glycogen synthase kinase 3beta (GSK-3beta) phosphorylation; conversely pretreatment with a selective GSK-3 inhibitor and shRNA GSK-3beta knockdown restored MM survival, suggesting the involvement of GSK-3beta in AT7519-induced apoptosis.	4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide	13-19	glycogen synthase kinase 3 beta	Homo sapiens	62-71
20101221-6	2010	In addition, AT7519 inhibited glycogen synthase kinase 3beta (GSK-3beta) phosphorylation; conversely pretreatment with a selective GSK-3 inhibitor and shRNA GSK-3beta knockdown restored MM survival, suggesting the involvement of GSK-3beta in AT7519-induced apoptosis.	4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide	13-19	glycogen synthase kinase 3 beta	Homo sapiens	157-166
20101221-6	2010	In addition, AT7519 inhibited glycogen synthase kinase 3beta (GSK-3beta) phosphorylation; conversely pretreatment with a selective GSK-3 inhibitor and shRNA GSK-3beta knockdown restored MM survival, suggesting the involvement of GSK-3beta in AT7519-induced apoptosis.	4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide	13-19	glycogen synthase kinase 3 beta	Homo sapiens	157-166
20101221-7	2010	GSK-3beta activation was independent of RNA pol II dephosphorylation confirmed by alpha-amanitin, a specific RNA pol II inihibitor, showing potent inhibition of RNA pol II phosphorylation without corresponding effects on GSK-3beta phosphorylation.	Alpha-Amanitin	82-96	glycogen synthase kinase 3 beta	Homo sapiens	0-9
20404113-4	2010	Notch and GSK3beta-mediated beta-catenin signaling were activated downstream of cAMP through phosphatidylinositol-3 kinase.	Cyclic AMP	80-84	glycogen synthase kinase 3 beta	Homo sapiens	10-18
20219996-4	2010	Using calcium imaging, whole-cell patch-clamp, as well as specific Ca(2+) channel inhibitors, we demonstrate that GSK-3beta phosphorylates the intracellular loop-connecting domains II and III (L(II-III)) of P/Q-type Ca(2+) channels, which leads to a decrease of intracellular Ca(2+) rise through the P/Q-type voltage-dependent calcium channel.	Calcium	6-13	glycogen synthase kinase 3 beta	Homo sapiens	114-123
20026151-9	2010	In conclusion, our results showed that in MPTP monkeys, loss of striatal dopamine decreased Akt/GSK3 signaling and that increased phosphorylation of Akt and GSK3beta was associated with L-Dopa-induced dyskinesias.	Levodopa	186-192	glycogen synthase kinase 3 beta	Homo sapiens	157-165
20127713-6	2010	Furthermore, inhibition of GSK-3beta activity by pharmacological inhibitors like the maleimide SB216761, the chloromethyl-thienyl-ketone GSK-3 inhibitor VI or the aminopyrazol GSK-3 inhibitor XIII in cells grown in the presence of DHT triggered a rapid nuclear export of endogenous AR as well as of green fluorescent AR-EosFP.	maleimide	85-94	glycogen synthase kinase 3 beta	Homo sapiens	27-36
20127713-6	2010	Furthermore, inhibition of GSK-3beta activity by pharmacological inhibitors like the maleimide SB216761, the chloromethyl-thienyl-ketone GSK-3 inhibitor VI or the aminopyrazol GSK-3 inhibitor XIII in cells grown in the presence of DHT triggered a rapid nuclear export of endogenous AR as well as of green fluorescent AR-EosFP.	sb216761	95-103	glycogen synthase kinase 3 beta	Homo sapiens	27-36
20127713-6	2010	Furthermore, inhibition of GSK-3beta activity by pharmacological inhibitors like the maleimide SB216761, the chloromethyl-thienyl-ketone GSK-3 inhibitor VI or the aminopyrazol GSK-3 inhibitor XIII in cells grown in the presence of DHT triggered a rapid nuclear export of endogenous AR as well as of green fluorescent AR-EosFP.	chloromethyl-thienyl-ketone	109-136	glycogen synthase kinase 3 beta	Homo sapiens	27-36
20127713-6	2010	Furthermore, inhibition of GSK-3beta activity by pharmacological inhibitors like the maleimide SB216761, the chloromethyl-thienyl-ketone GSK-3 inhibitor VI or the aminopyrazol GSK-3 inhibitor XIII in cells grown in the presence of DHT triggered a rapid nuclear export of endogenous AR as well as of green fluorescent AR-EosFP.	Dihydrotestosterone	231-234	glycogen synthase kinase 3 beta	Homo sapiens	27-36
20127713-7	2010	The nuclear export of AR following GSK-3beta inhibition could be blocked by leptomycin B suggesting a CRM1-dependent export mechanism.	leptomycin B	76-88	glycogen synthase kinase 3 beta	Homo sapiens	35-44
20448354-3	2010	The expression of p-GSK-3beta and total GSK-3beta in HMPC was detected by Western blot after incubation with different concentrations (0, 5, 10, 20, and 40 mmol/L)of LiCl at different time points (0, 1, 3, 6, and 12 h).	Lithium Chloride	166-170	glycogen synthase kinase 3 beta	Homo sapiens	20-29
20448354-3	2010	The expression of p-GSK-3beta and total GSK-3beta in HMPC was detected by Western blot after incubation with different concentrations (0, 5, 10, 20, and 40 mmol/L)of LiCl at different time points (0, 1, 3, 6, and 12 h).	Lithium Chloride	166-170	glycogen synthase kinase 3 beta	Homo sapiens	40-49
20448354-6	2010	RESULTS: LiCl stimulated phosphorylation of GSK-3beta and the effect was time-dependent and concentration-dependent to limited extent (P&lt;0.05).	Lithium Chloride	9-13	glycogen synthase kinase 3 beta	Homo sapiens	44-53
20026151-5	2010	Dopamine depletion reduced phosphorylated GSK3beta(Ser9) levels, mainly in posterior putamen whereas pGSK3beta(Tyr216) and pGSK3alpha(Ser21) were unchanged.	Dopamine	0-8	glycogen synthase kinase 3 beta	Homo sapiens	42-50
20026151-8	2010	Extent of phosphorylation of Akt and GSK3beta in putamen correlated positively with dyskinesias scores of MPTP monkeys; these correlations were higher with dopaminergic drugs (L-Dopa, cabergoline) suggesting implication of additional mechanisms and/or signaling molecules in the NMDA antagonist antidyskinetic effect.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	106-110	glycogen synthase kinase 3 beta	Homo sapiens	37-45
20138829-6	2010	At apoptotic inducing concentration, curcumin induces a dramatic Akt phosphorylation, accompanied by an increased phosphorylation of glycogen synthase kinase 3beta (GSK3beta), which has been considered to be a pro-growth signaling molecule.	Curcumin	37-45	glycogen synthase kinase 3 beta	Homo sapiens	133-163
20138829-6	2010	At apoptotic inducing concentration, curcumin induces a dramatic Akt phosphorylation, accompanied by an increased phosphorylation of glycogen synthase kinase 3beta (GSK3beta), which has been considered to be a pro-growth signaling molecule.	Curcumin	37-45	glycogen synthase kinase 3 beta	Homo sapiens	165-173
20138829-8	2010	The inhibitor LY290042 was capable of attenuating curcumin-induced Akt phosphorylation and activation of GSK3beta.	LY 290042	14-22	glycogen synthase kinase 3 beta	Homo sapiens	105-113
20138829-8	2010	The inhibitor LY290042 was capable of attenuating curcumin-induced Akt phosphorylation and activation of GSK3beta.	Curcumin	50-58	glycogen synthase kinase 3 beta	Homo sapiens	105-113
20189807-1	2010	From potent and selective inhibitors of GSK3beta displaying CYP1A2 inhibition and poor PK properties, mostly linked to metabolic instability and in vivo hydrolysis of the amide bond, we were able to obtain safe and orally available inhibitors with good half lives.	Amides	171-176	glycogen synthase kinase 3 beta	Homo sapiens	40-48
20110283-0	2010	NSAID-activated gene-1 as a molecular target for capsaicin-induced apoptosis through a novel molecular mechanism involving GSK3beta, C/EBPbeta and ATF3.	Capsaicin	49-58	glycogen synthase kinase 3 beta	Homo sapiens	123-131
20110283-7	2010	Capsaicin treatment resulted in an increase of phosphorylated serine/threonine residues on C/EBPbeta, and the immunoprecipitation study showed that capsaicin enhanced binding of C/EBPbeta with glycogen synthase kinase 3beta (GSK3beta) and activating transcription factor 3 (ATF3).	Capsaicin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	193-223
20110283-7	2010	Capsaicin treatment resulted in an increase of phosphorylated serine/threonine residues on C/EBPbeta, and the immunoprecipitation study showed that capsaicin enhanced binding of C/EBPbeta with glycogen synthase kinase 3beta (GSK3beta) and activating transcription factor 3 (ATF3).	Capsaicin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	225-233
20110283-7	2010	Capsaicin treatment resulted in an increase of phosphorylated serine/threonine residues on C/EBPbeta, and the immunoprecipitation study showed that capsaicin enhanced binding of C/EBPbeta with glycogen synthase kinase 3beta (GSK3beta) and activating transcription factor 3 (ATF3).	Capsaicin	148-157	glycogen synthase kinase 3 beta	Homo sapiens	193-223
20110283-7	2010	Capsaicin treatment resulted in an increase of phosphorylated serine/threonine residues on C/EBPbeta, and the immunoprecipitation study showed that capsaicin enhanced binding of C/EBPbeta with glycogen synthase kinase 3beta (GSK3beta) and activating transcription factor 3 (ATF3).	Capsaicin	148-157	glycogen synthase kinase 3 beta	Homo sapiens	225-233
20110283-9	2010	Knockdown of C/EBPbeta, GSK3beta or ATF3 ameliorates NAG-1 expression induced by capsaicin treatment.	Capsaicin	81-90	glycogen synthase kinase 3 beta	Homo sapiens	24-32
20110283-10	2010	These data indicate that C/EBPbeta phosphorylation through GSK3beta may mediate capsaicin-induced expression of NAG-1 and apoptosis through cooperation with ATF3 in human colorectal cancer cells.	Capsaicin	80-89	glycogen synthase kinase 3 beta	Homo sapiens	59-67
19538984-7	2010	A delayed response of oxidative/electrophilic stress activates GSK-3beta that phosphorylates Fyn at unknown threonine residue(s).	Threonine	108-117	glycogen synthase kinase 3 beta	Homo sapiens	63-72
20352103-6	2010	PP2A and its regulatory subunit B" regulated the Ser-9 phosphorylation of GSK3beta.	Serine	49-52	glycogen synthase kinase 3 beta	Homo sapiens	74-82
20093106-6	2010	The inhibitory effect of LRP10 was consistently conserved in HEK293 cells even when GSK3beta phosphorylation was inhibited by incubation with lithium chloride and co-transfection with constitutively active S33Y-mutated beta-catenin.	Lithium Chloride	142-158	glycogen synthase kinase 3 beta	Homo sapiens	84-92
20150512-6	2010	With osteogenic supplements, the GSK3beta inhibitor 6-bromo-indirubin-3"-oxime (BIO) and the PPARgamma inhibitor GW9662 (GW) enhanced early osteogenic markers, alkaline phosphatase (ALP), and osteoprotegerin (OPG) by hMSCs and transcriptome analysis demonstrated up-regulation of genes encoding bone-related structural proteins.	6-bromoindirubin-3'-oxime	52-78	glycogen synthase kinase 3 beta	Homo sapiens	33-41
20138514-0	2010	3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3beta.	3-aryl-4-(arylhydrazono)-1h-pyrazol-5-ones	0-42	glycogen synthase kinase 3 beta	Homo sapiens	93-101
20138514-1	2010	A series of 3-aryl-4-(arylhydrazono)-1H-pyrazol-5-one inhibitors of GSK3beta was developed from a low molecular weight, highly ligand efficient screening hit 1.	3-aryl-4-(arylhydrazono)-1h-pyrazol-5-one	12-53	glycogen synthase kinase 3 beta	Homo sapiens	68-76
20165807-0	2010	A new facile synthesis of 3-amidoindole derivatives and their evaluation as potential GSK-3beta inhibitors.	3-amidoindole	26-39	glycogen synthase kinase 3 beta	Homo sapiens	86-95
19842009-14	2010	Postconditioning with levosimendan significantly increased the phosphorylation of protein kinase B (Akt) and glycogen synthase kinase-3beta (GSK-3beta) at 5 min of reperfusion, an effect which could be blocked completely by the additional administration of wortmannin.	Simendan	22-34	glycogen synthase kinase 3 beta	Homo sapiens	109-139
19842009-14	2010	Postconditioning with levosimendan significantly increased the phosphorylation of protein kinase B (Akt) and glycogen synthase kinase-3beta (GSK-3beta) at 5 min of reperfusion, an effect which could be blocked completely by the additional administration of wortmannin.	Simendan	22-34	glycogen synthase kinase 3 beta	Homo sapiens	141-150
19842009-14	2010	Postconditioning with levosimendan significantly increased the phosphorylation of protein kinase B (Akt) and glycogen synthase kinase-3beta (GSK-3beta) at 5 min of reperfusion, an effect which could be blocked completely by the additional administration of wortmannin.	Wortmannin	257-267	glycogen synthase kinase 3 beta	Homo sapiens	141-150
20126978-7	2010	Interestingly, EGF-induced phosphorylation of both Akt and glycogen synthase kinase-3beta (GSK-3beta), but not p44/p42 mitogen-activated protein (MAP) kinase, were dose-dependently enhanced when the cells were pretreated with Y27632 or fasudil, another Rho-kinase inhibitor.	Y 27632	226-232	glycogen synthase kinase 3 beta	Homo sapiens	59-89
20126978-7	2010	Interestingly, EGF-induced phosphorylation of both Akt and glycogen synthase kinase-3beta (GSK-3beta), but not p44/p42 mitogen-activated protein (MAP) kinase, were dose-dependently enhanced when the cells were pretreated with Y27632 or fasudil, another Rho-kinase inhibitor.	Y 27632	226-232	glycogen synthase kinase 3 beta	Homo sapiens	91-100
20126978-7	2010	Interestingly, EGF-induced phosphorylation of both Akt and glycogen synthase kinase-3beta (GSK-3beta), but not p44/p42 mitogen-activated protein (MAP) kinase, were dose-dependently enhanced when the cells were pretreated with Y27632 or fasudil, another Rho-kinase inhibitor.	fasudil	236-243	glycogen synthase kinase 3 beta	Homo sapiens	59-89
20126978-7	2010	Interestingly, EGF-induced phosphorylation of both Akt and glycogen synthase kinase-3beta (GSK-3beta), but not p44/p42 mitogen-activated protein (MAP) kinase, were dose-dependently enhanced when the cells were pretreated with Y27632 or fasudil, another Rho-kinase inhibitor.	fasudil	236-243	glycogen synthase kinase 3 beta	Homo sapiens	91-100
19505532-4	2010	Insulin responsiveness of GSFV was doubled by GSK-3beta knockdown (p&lt;0.05).	gsfv	26-30	glycogen synthase kinase 3 beta	Homo sapiens	46-55
20025854-3	2010	This study was designed to investigate whether (-)-epigallocatechin-3-gallate (EGCG) plays a neuroprotective role by inhibiting nitric oxide (NO) production and activating cellular signaling mechanisms including MAP kinase, PI3K, and GSK-3beta and acting on the antiapoptotic and the proapoptotic genes in N18D3 neural cells.	epigallocatechin gallate	47-77	glycogen synthase kinase 3 beta	Homo sapiens	234-243
20025854-3	2010	This study was designed to investigate whether (-)-epigallocatechin-3-gallate (EGCG) plays a neuroprotective role by inhibiting nitric oxide (NO) production and activating cellular signaling mechanisms including MAP kinase, PI3K, and GSK-3beta and acting on the antiapoptotic and the proapoptotic genes in N18D3 neural cells.	epigallocatechin gallate	79-83	glycogen synthase kinase 3 beta	Homo sapiens	234-243
19966058-0	2010	Morphine prevents the mitochondrial permeability transition pore opening through NO/cGMP/PKG/Zn2+/GSK-3beta signal pathway in cardiomyocytes.	Morphine	0-8	glycogen synthase kinase 3 beta	Homo sapiens	98-107
19966058-1	2010	The aim of this study was to test whether morphine prevents the mitochondrial permeability transition pore (mPTP) opening through Zn(2+) and glycogen synthase kinase 3beta (GSK-3beta).	Morphine	42-50	glycogen synthase kinase 3 beta	Homo sapiens	141-171
20069457-7	2010	14-3-3 association required basal phosphorylation by the serine/threonine kinase, glycogen synthase kinase 3beta (GSK-3beta), on serine 175, 178, and 179.	Serine	57-63	glycogen synthase kinase 3 beta	Homo sapiens	82-112
19966058-1	2010	The aim of this study was to test whether morphine prevents the mitochondrial permeability transition pore (mPTP) opening through Zn(2+) and glycogen synthase kinase 3beta (GSK-3beta).	Morphine	42-50	glycogen synthase kinase 3 beta	Homo sapiens	173-182
19966058-10	2010	The action of morphine on the mPTP was lost in cells transfected with the constitutively active GSK-3beta mutant, suggesting that morphine may prevent the mPTP opening by inactivating GSK-3beta.	Morphine	14-22	glycogen synthase kinase 3 beta	Homo sapiens	96-105
19966058-10	2010	The action of morphine on the mPTP was lost in cells transfected with the constitutively active GSK-3beta mutant, suggesting that morphine may prevent the mPTP opening by inactivating GSK-3beta.	Morphine	14-22	glycogen synthase kinase 3 beta	Homo sapiens	184-193
19966058-10	2010	The action of morphine on the mPTP was lost in cells transfected with the constitutively active GSK-3beta mutant, suggesting that morphine may prevent the mPTP opening by inactivating GSK-3beta.	Morphine	130-138	glycogen synthase kinase 3 beta	Homo sapiens	96-105
19966058-10	2010	The action of morphine on the mPTP was lost in cells transfected with the constitutively active GSK-3beta mutant, suggesting that morphine may prevent the mPTP opening by inactivating GSK-3beta.	Morphine	130-138	glycogen synthase kinase 3 beta	Homo sapiens	184-193
19966058-11	2010	In support, morphine significantly enhanced phosphorylation of GSK-3beta at Ser(9), and this was blocked by TPEN.	Morphine	12-20	glycogen synthase kinase 3 beta	Homo sapiens	63-72
19966058-11	2010	In support, morphine significantly enhanced phosphorylation of GSK-3beta at Ser(9), and this was blocked by TPEN.	Serine	76-79	glycogen synthase kinase 3 beta	Homo sapiens	63-72
19966058-11	2010	In support, morphine significantly enhanced phosphorylation of GSK-3beta at Ser(9), and this was blocked by TPEN.	N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine	108-112	glycogen synthase kinase 3 beta	Homo sapiens	63-72
19966058-13	2010	In conclusion, morphine mobilizes intracellular Zn(2+) through the NO/cGMP/PKG signaling pathway and prevents the mPTP opening by inactivating GSK-3beta through Zn(2+).	Morphine	15-23	glycogen synthase kinase 3 beta	Homo sapiens	143-152
19966058-13	2010	In conclusion, morphine mobilizes intracellular Zn(2+) through the NO/cGMP/PKG signaling pathway and prevents the mPTP opening by inactivating GSK-3beta through Zn(2+).	Zinc	161-163	glycogen synthase kinase 3 beta	Homo sapiens	143-152
20069457-7	2010	14-3-3 association required basal phosphorylation by the serine/threonine kinase, glycogen synthase kinase 3beta (GSK-3beta), on serine 175, 178, and 179.	Serine	57-63	glycogen synthase kinase 3 beta	Homo sapiens	114-123
20090934-4	2010	Inactivation of Akt pathway by Resveratrol subsequently blocked serine9 phosphorylation of Gsk3beta.	Resveratrol	31-42	glycogen synthase kinase 3 beta	Homo sapiens	91-99
19717166-2	2010	That GSK-3beta may be involved in the pathophysiology of bipolar (BP) illness is based on the observation that lithium, a mood-stabilizing drug, inhibits GSK-3beta both in vitro and in vivo.	Lithium	111-118	glycogen synthase kinase 3 beta	Homo sapiens	5-14
19717166-2	2010	That GSK-3beta may be involved in the pathophysiology of bipolar (BP) illness is based on the observation that lithium, a mood-stabilizing drug, inhibits GSK-3beta both in vitro and in vivo.	Lithium	111-118	glycogen synthase kinase 3 beta	Homo sapiens	154-163
20224723-2	2010	We recently reported that mantle cell lymphoma (MCL) frequently shows evidence of GSK-3beta inactivation, since GSK-3beta is phoshorylated at its functionally critical serine 9 residue in all MCL cell lines and the majority of MCL tumors examined.	Serine	168-174	glycogen synthase kinase 3 beta	Homo sapiens	82-91
20224723-2	2010	We recently reported that mantle cell lymphoma (MCL) frequently shows evidence of GSK-3beta inactivation, since GSK-3beta is phoshorylated at its functionally critical serine 9 residue in all MCL cell lines and the majority of MCL tumors examined.	Serine	168-174	glycogen synthase kinase 3 beta	Homo sapiens	112-121
20224723-3	2010	To further assess the clinical and biological significance of GSK-3beta inactivation in MCL, we employed immunohistochemistry to assess the expression of the phosphorylated/inactive form of GSK-3beta (pGSK-3beta) in 83 paraffin-embedded tumors, and correlated its expression with various biological and clinical parameters.	pgsk-3beta	201-211	glycogen synthase kinase 3 beta	Homo sapiens	62-71
20224723-3	2010	To further assess the clinical and biological significance of GSK-3beta inactivation in MCL, we employed immunohistochemistry to assess the expression of the phosphorylated/inactive form of GSK-3beta (pGSK-3beta) in 83 paraffin-embedded tumors, and correlated its expression with various biological and clinical parameters.	pgsk-3beta	201-211	glycogen synthase kinase 3 beta	Homo sapiens	190-199
20224723-3	2010	To further assess the clinical and biological significance of GSK-3beta inactivation in MCL, we employed immunohistochemistry to assess the expression of the phosphorylated/inactive form of GSK-3beta (pGSK-3beta) in 83 paraffin-embedded tumors, and correlated its expression with various biological and clinical parameters.	Paraffin	219-227	glycogen synthase kinase 3 beta	Homo sapiens	190-199
20090934-4	2010	Inactivation of Akt pathway by Resveratrol subsequently blocked serine9 phosphorylation of Gsk3beta.	serine9	64-71	glycogen synthase kinase 3 beta	Homo sapiens	91-99
20090934-7	2010	Inactivation of Gsk3beta activity by inhibitors SB261763 or LiCl upregulated Hsp70.	sb261763	48-56	glycogen synthase kinase 3 beta	Homo sapiens	16-24
20090934-7	2010	Inactivation of Gsk3beta activity by inhibitors SB261763 or LiCl upregulated Hsp70.	Lithium Chloride	60-64	glycogen synthase kinase 3 beta	Homo sapiens	16-24
21139228-0	2010	Biochemical characterization of epigallocatechin-3-gallate as an effective stimulator for the phosphorylation of its binding proteins by glycogen synthase kinase-3beta in vitro.	epigallocatechin gallate	32-58	glycogen synthase kinase 3 beta	Homo sapiens	137-167
27713242-0	2010	Role of Glycogen Synthase Kinase-3beta in APP Hyperphosphorylation Induced by NMDA Stimulation in Cortical Neurons.	N-Methylaspartate	78-82	glycogen synthase kinase 3 beta	Homo sapiens	8-38
27713242-5	2010	During NMDA stimulation APP hyperphosphorylation has to be assigned to GSK-3beta activity, since addition of L803-mts, a substrate competitive inhibitor of GSK-3beta reduced APP phosphorylation induced by NMDA.	N-Methylaspartate	7-11	glycogen synthase kinase 3 beta	Homo sapiens	71-80
27713242-5	2010	During NMDA stimulation APP hyperphosphorylation has to be assigned to GSK-3beta activity, since addition of L803-mts, a substrate competitive inhibitor of GSK-3beta reduced APP phosphorylation induced by NMDA.	N-Methylaspartate	7-11	glycogen synthase kinase 3 beta	Homo sapiens	156-165
27713242-5	2010	During NMDA stimulation APP hyperphosphorylation has to be assigned to GSK-3beta activity, since addition of L803-mts, a substrate competitive inhibitor of GSK-3beta reduced APP phosphorylation induced by NMDA.	N-Methylaspartate	205-209	glycogen synthase kinase 3 beta	Homo sapiens	71-80
27713242-5	2010	During NMDA stimulation APP hyperphosphorylation has to be assigned to GSK-3beta activity, since addition of L803-mts, a substrate competitive inhibitor of GSK-3beta reduced APP phosphorylation induced by NMDA.	N-Methylaspartate	205-209	glycogen synthase kinase 3 beta	Homo sapiens	156-165
19802005-6	2010	Importantly, Frat mutants deficient for binding to Gsk3b retain oncogenic activity in vivo, suggesting that Wnt/beta-catenin-independent events contribute to Frat-induced malignant transformation.	frat	13-17	glycogen synthase kinase 3 beta	Homo sapiens	51-56
19966835-10	2010	Aspirin inhibits GSK-3beta activation and suppresses the expression of its downstream gene products (cyclin D1 and Bcl-2), which are implicated in proliferation, survival and chemoresistance of pancreatic cancer.	Aspirin	0-7	glycogen synthase kinase 3 beta	Homo sapiens	17-26
19966835-12	2010	CONCLUSION: Our results suggest that aspirin inhibits the proliferation of gemcitabine-resistant pancreatic cancer cells and augments the antisurvival effect of gemcitabine, probably by suppressing the activity of GSK-3beta and its downstream gene products.	Aspirin	37-44	glycogen synthase kinase 3 beta	Homo sapiens	214-223
19966835-12	2010	CONCLUSION: Our results suggest that aspirin inhibits the proliferation of gemcitabine-resistant pancreatic cancer cells and augments the antisurvival effect of gemcitabine, probably by suppressing the activity of GSK-3beta and its downstream gene products.	gemcitabine	161-172	glycogen synthase kinase 3 beta	Homo sapiens	214-223
21139228-3	2010	In addition, the binding of EGCG to these two basic proteins induced to highly stimulate their phosphorylation, including novel potent sites for GSK-3beta, and to significantly reduce the K(m) value and increase the V(max) value of these two substrate proteins for the kinase in vitro.	epigallocatechin gallate	28-32	glycogen synthase kinase 3 beta	Homo sapiens	145-154
21139228-4	2010	These results provided here suggest that EGCG acts as an effective stimulator for the GSK-3beta-mediated phosphorylation of its binding proteins containing EGCG-inducible phosphorylation sites for the kinase in vitro.	epigallocatechin gallate	41-45	glycogen synthase kinase 3 beta	Homo sapiens	86-95
21139228-4	2010	These results provided here suggest that EGCG acts as an effective stimulator for the GSK-3beta-mediated phosphorylation of its binding proteins containing EGCG-inducible phosphorylation sites for the kinase in vitro.	epigallocatechin gallate	156-160	glycogen synthase kinase 3 beta	Homo sapiens	86-95
19839931-6	2010	Enzastaurin-pemetrexed combination was synergistic in preclinical models, including NSCLC cells, where enzastaurin reduced phosphoCdc25C, resulting in G2/M-checkpoint abrogation, and Akt and GSK3beta; phosphorylation, favoring apoptosis induction in pemetrexed-damaged cells.	enzastaurin-pemetrexed	0-22	glycogen synthase kinase 3 beta	Homo sapiens	191-199
19839931-6	2010	Enzastaurin-pemetrexed combination was synergistic in preclinical models, including NSCLC cells, where enzastaurin reduced phosphoCdc25C, resulting in G2/M-checkpoint abrogation, and Akt and GSK3beta; phosphorylation, favoring apoptosis induction in pemetrexed-damaged cells.	enzastaurin	103-114	glycogen synthase kinase 3 beta	Homo sapiens	191-199
20858169-1	2010	Glycogen Synthase Kinase 3 beta (GSK3beta) is a serine-threonine kinase originally identified for its role in the conversion of glucose to glycogen.	Glucose	128-135	glycogen synthase kinase 3 beta	Homo sapiens	0-31
19839931-6	2010	Enzastaurin-pemetrexed combination was synergistic in preclinical models, including NSCLC cells, where enzastaurin reduced phosphoCdc25C, resulting in G2/M-checkpoint abrogation, and Akt and GSK3beta; phosphorylation, favoring apoptosis induction in pemetrexed-damaged cells.	Pemetrexed	12-22	glycogen synthase kinase 3 beta	Homo sapiens	191-199
20858169-1	2010	Glycogen Synthase Kinase 3 beta (GSK3beta) is a serine-threonine kinase originally identified for its role in the conversion of glucose to glycogen.	Glucose	128-135	glycogen synthase kinase 3 beta	Homo sapiens	33-41
19839931-8	2010	Similarly, the accumulation of deoxyuridine (a marker of TS inhibition) and the reduction of GSK3beta phosphorylation were detectable in clinical samples from a phase-Ib trial of pemetrexed-enzastaurin combination.	Pemetrexed	179-189	glycogen synthase kinase 3 beta	Homo sapiens	93-101
20858169-1	2010	Glycogen Synthase Kinase 3 beta (GSK3beta) is a serine-threonine kinase originally identified for its role in the conversion of glucose to glycogen.	Glycogen	139-147	glycogen synthase kinase 3 beta	Homo sapiens	0-31
20858169-1	2010	Glycogen Synthase Kinase 3 beta (GSK3beta) is a serine-threonine kinase originally identified for its role in the conversion of glucose to glycogen.	Glycogen	139-147	glycogen synthase kinase 3 beta	Homo sapiens	33-41
19839931-8	2010	Similarly, the accumulation of deoxyuridine (a marker of TS inhibition) and the reduction of GSK3beta phosphorylation were detectable in clinical samples from a phase-Ib trial of pemetrexed-enzastaurin combination.	enzastaurin	190-201	glycogen synthase kinase 3 beta	Homo sapiens	93-101
19765735-3	2010	In this study, we investigate the ability of MG-132, a proteasome inhibitor, to inhibit carcinoid growth, the neuroendocrine phenotype, and its association with GSK-3beta.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	45-51	glycogen synthase kinase 3 beta	Homo sapiens	161-170
21504119-0	2010	LiCl attenuates thapsigargin-induced tau hyperphosphorylation by inhibiting GSK-3beta in vivo and in vitro.	Lithium Chloride	0-4	glycogen synthase kinase 3 beta	Homo sapiens	76-85
21504119-0	2010	LiCl attenuates thapsigargin-induced tau hyperphosphorylation by inhibiting GSK-3beta in vivo and in vitro.	Thapsigargin	16-28	glycogen synthase kinase 3 beta	Homo sapiens	76-85
21504119-6	2010	Concurrently, activation of GSK-3beta as evidenced by an increased phospho-GSK-3beta at Tyr-216 and decreased phospho-GSK-3beta at Ser-9 both in vitro and in vivo was detected.	Tyrosine	88-91	glycogen synthase kinase 3 beta	Homo sapiens	28-37
21504119-6	2010	Concurrently, activation of GSK-3beta as evidenced by an increased phospho-GSK-3beta at Tyr-216 and decreased phospho-GSK-3beta at Ser-9 both in vitro and in vivo was detected.	Tyrosine	88-91	glycogen synthase kinase 3 beta	Homo sapiens	75-84
21504119-6	2010	Concurrently, activation of GSK-3beta as evidenced by an increased phospho-GSK-3beta at Tyr-216 and decreased phospho-GSK-3beta at Ser-9 both in vitro and in vivo was detected.	Tyrosine	88-91	glycogen synthase kinase 3 beta	Homo sapiens	75-84
21504119-6	2010	Concurrently, activation of GSK-3beta as evidenced by an increased phospho-GSK-3beta at Tyr-216 and decreased phospho-GSK-3beta at Ser-9 both in vitro and in vivo was detected.	Serine	131-134	glycogen synthase kinase 3 beta	Homo sapiens	28-37
19878439-0	2010	In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis.	Lithium	162-169	glycogen synthase kinase 3 beta	Homo sapiens	120-128
19878439-5	2010	Lithium, an inhibitor of GSK3beta, was reported to reduce levels of both the total AbetaPP and p-AbetaPP in AD animal models.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	25-33
20734923-10	2010	Inhibition of EGFR signaling by AG1478 increased GSC senescence and apoptosis, likely via inhibition of AKT and activation of GSK3beta.	RTKI cpd	32-38	glycogen synthase kinase 3 beta	Homo sapiens	126-134
20595783-0	2010	Noradrenaline induces clock gene Per1 mRNA expression in C6 glioma cells through beta(2)-adrenergic receptor coupled with protein kinase A - cAMP response element binding protein (PKA-CREB) and Src-tyrosine kinase - glycogen synthase kinase-3beta (Src-GSK-3beta).	Norepinephrine	0-13	glycogen synthase kinase 3 beta	Homo sapiens	216-246
20595783-0	2010	Noradrenaline induces clock gene Per1 mRNA expression in C6 glioma cells through beta(2)-adrenergic receptor coupled with protein kinase A - cAMP response element binding protein (PKA-CREB) and Src-tyrosine kinase - glycogen synthase kinase-3beta (Src-GSK-3beta).	Norepinephrine	0-13	glycogen synthase kinase 3 beta	Homo sapiens	252-261
20595783-5	2010	We found that pretreatment with genistein or PP2 (general or Src tyrosine kinase inhibitors, respectively) or LiCl [inhibitor of glycogen synthase kinase-3beta (GSK-3beta)] significantly inhibited NA-induced Per1 mRNA expression.	Genistein	32-41	glycogen synthase kinase 3 beta	Homo sapiens	129-159
20595783-5	2010	We found that pretreatment with genistein or PP2 (general or Src tyrosine kinase inhibitors, respectively) or LiCl [inhibitor of glycogen synthase kinase-3beta (GSK-3beta)] significantly inhibited NA-induced Per1 mRNA expression.	Genistein	32-41	glycogen synthase kinase 3 beta	Homo sapiens	161-170
20595783-5	2010	We found that pretreatment with genistein or PP2 (general or Src tyrosine kinase inhibitors, respectively) or LiCl [inhibitor of glycogen synthase kinase-3beta (GSK-3beta)] significantly inhibited NA-induced Per1 mRNA expression.	Lithium Chloride	110-114	glycogen synthase kinase 3 beta	Homo sapiens	129-159
20595783-5	2010	We found that pretreatment with genistein or PP2 (general or Src tyrosine kinase inhibitors, respectively) or LiCl [inhibitor of glycogen synthase kinase-3beta (GSK-3beta)] significantly inhibited NA-induced Per1 mRNA expression.	Lithium Chloride	110-114	glycogen synthase kinase 3 beta	Homo sapiens	161-170
20595783-7	2010	NA markedly induced tyrosine phosphorylation of Src and GSK-3beta via activation of beta(2) adrenoceptors.	Tyrosine	20-28	glycogen synthase kinase 3 beta	Homo sapiens	56-65
20595783-8	2010	Phosphorylation of GSK-3beta by NA was completely eliminated by genistein or PP2.	Genistein	64-73	glycogen synthase kinase 3 beta	Homo sapiens	19-28
20053726-9	2010	Loss of phosphorylated AKT after sunitinib treatment was accompanied by decreased phosphorylation of downstream proteins glycogen synthase kinase-3beta and mammalian target of rapamycin.	Sunitinib	33-42	glycogen synthase kinase 3 beta	Homo sapiens	121-151
19800318-4	2009	In addition, cardamonin promoted the degradation of intracellular beta-catenin that was accumulated by Wnt3a-conditioned medium (Wnt3a CM) or bromoindirubin-3"-oxime (BIO), a glycogen synthase kinase-3beta (GSK-3beta) inhibitor, in HEK293 reporter cells and human normal melanocytes.	cardamonin	13-23	glycogen synthase kinase 3 beta	Homo sapiens	175-205
20049328-5	2010	PRINCIPAL FINDINGS: GSK3beta phosphorylates BMAL1 specifically on Ser 17 and Thr 21 and primes it for ubiquitylation.	Serine	66-69	glycogen synthase kinase 3 beta	Homo sapiens	20-28
20049328-5	2010	PRINCIPAL FINDINGS: GSK3beta phosphorylates BMAL1 specifically on Ser 17 and Thr 21 and primes it for ubiquitylation.	Threonine	77-80	glycogen synthase kinase 3 beta	Homo sapiens	20-28
20453533-9	2010	Preliminary studies to assess genetic influences on response probability to lithium augmentation have suggested a predictive role of the -50T/C single nucleotide polymorphism of the GSK3beta gene.	Lithium	76-83	glycogen synthase kinase 3 beta	Homo sapiens	182-190
19800318-4	2009	In addition, cardamonin promoted the degradation of intracellular beta-catenin that was accumulated by Wnt3a-conditioned medium (Wnt3a CM) or bromoindirubin-3"-oxime (BIO), a glycogen synthase kinase-3beta (GSK-3beta) inhibitor, in HEK293 reporter cells and human normal melanocytes.	cardamonin	13-23	glycogen synthase kinase 3 beta	Homo sapiens	207-216
19903849-6	2009	Moreover, phospho-Akt and its downstream substrates, e.g., NF-kappaB, phospho-GSK-3beta, and phospho-BAD, were downregulated upon tangeretin-cisplatin treatment.	tangeretin	130-140	glycogen synthase kinase 3 beta	Homo sapiens	78-87
19903849-6	2009	Moreover, phospho-Akt and its downstream substrates, e.g., NF-kappaB, phospho-GSK-3beta, and phospho-BAD, were downregulated upon tangeretin-cisplatin treatment.	Cisplatin	141-150	glycogen synthase kinase 3 beta	Homo sapiens	78-87
19764998-7	2009	Moreover, depletion of endogenous pescadillo resulted in decreased expression of cell cycle protein cyclin D1 and up-regulation of cyclin-dependent kinase inhibitor p27(Kip1), as well as attenuated protein kinase B (Akt)/glycogen synthase kinase 3 beta (GSK-3beta) signaling.	pescadillo	34-44	glycogen synthase kinase 3 beta	Homo sapiens	221-252
19764998-7	2009	Moreover, depletion of endogenous pescadillo resulted in decreased expression of cell cycle protein cyclin D1 and up-regulation of cyclin-dependent kinase inhibitor p27(Kip1), as well as attenuated protein kinase B (Akt)/glycogen synthase kinase 3 beta (GSK-3beta) signaling.	pescadillo	34-44	glycogen synthase kinase 3 beta	Homo sapiens	254-263
19903849-7	2009	The tangeretin-cisplatin-induced apoptosis in A2780/CP70 cells was increased by phosphoinositide-3 kinase (PI3K) inhibition and siRNA-mediated Akt silencing, but reduced by overexpression of constitutively activated Akt and GSK-3beta inhibition.	tangeretin	4-14	glycogen synthase kinase 3 beta	Homo sapiens	224-233
19903849-7	2009	The tangeretin-cisplatin-induced apoptosis in A2780/CP70 cells was increased by phosphoinositide-3 kinase (PI3K) inhibition and siRNA-mediated Akt silencing, but reduced by overexpression of constitutively activated Akt and GSK-3beta inhibition.	Cisplatin	15-24	glycogen synthase kinase 3 beta	Homo sapiens	224-233
19741007-4	2009	In receptor-expressing cells and brain slices, activation of both 5-HT1AR and 5-HT1BR reduced forskolin-stimulated cAMP production, but only the effect of 5-HT1BR was abolished by selective GSK3 inhibitors, deletion of GSK3beta by RNAi, or overexpression of impaired GSK3beta mutants (R96A and K85,86A).	Colforsin	94-103	glycogen synthase kinase 3 beta	Homo sapiens	219-227
19706045-8	2009	Stimulating the Wnt/beta-catenin pathway by both Wnt 3a and GSK-3beta inhibitors (LiCl and SB 216763), blocked aspirin-induced apoptosis and protected mitochondrial function, as demonstrated by decreased cytochrome c release and caspase-3 activity.	Lithium Chloride	82-86	glycogen synthase kinase 3 beta	Homo sapiens	60-69
19706045-8	2009	Stimulating the Wnt/beta-catenin pathway by both Wnt 3a and GSK-3beta inhibitors (LiCl and SB 216763), blocked aspirin-induced apoptosis and protected mitochondrial function, as demonstrated by decreased cytochrome c release and caspase-3 activity.	SB 216763	91-100	glycogen synthase kinase 3 beta	Homo sapiens	60-69
19706045-8	2009	Stimulating the Wnt/beta-catenin pathway by both Wnt 3a and GSK-3beta inhibitors (LiCl and SB 216763), blocked aspirin-induced apoptosis and protected mitochondrial function, as demonstrated by decreased cytochrome c release and caspase-3 activity.	Aspirin	111-118	glycogen synthase kinase 3 beta	Homo sapiens	60-69
19624598-8	2009	Fibronectin antagonized MMC-induced G0/G1-phase arrest by inactivating GSK-3beta to stabilize cyclin D1 expression in T24 cells.	Mitomycin	24-27	glycogen synthase kinase 3 beta	Homo sapiens	71-80
19440740-0	2009	Use of molecular modeling, docking, and 3D-QSAR studies for the determination of the binding mode of benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3beta inhibitors.	benzofuran-3-yl-(indol-3-yl)maleimides	101-139	glycogen synthase kinase 3 beta	Homo sapiens	143-152
19440740-2	2009	The approaches of comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) are used for the 3D-QSAR of 51 substituted benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3beta inhibitors.	benzofuran-3-yl-(indol-3-yl)maleimides	167-205	glycogen synthase kinase 3 beta	Homo sapiens	209-218
19741007-4	2009	In receptor-expressing cells and brain slices, activation of both 5-HT1AR and 5-HT1BR reduced forskolin-stimulated cAMP production, but only the effect of 5-HT1BR was abolished by selective GSK3 inhibitors, deletion of GSK3beta by RNAi, or overexpression of impaired GSK3beta mutants (R96A and K85,86A).	Colforsin	94-103	glycogen synthase kinase 3 beta	Homo sapiens	267-275
19903789-1	2009	PURPOSE: Glycogen synthase kinase-3beta (GSK3beta) regulates multiple cell signaling pathways and has been implicated in glucose intolerance, neurodegenerative disorders, and inflammation.	Glucose	121-128	glycogen synthase kinase 3 beta	Homo sapiens	9-39
19903789-1	2009	PURPOSE: Glycogen synthase kinase-3beta (GSK3beta) regulates multiple cell signaling pathways and has been implicated in glucose intolerance, neurodegenerative disorders, and inflammation.	Glucose	121-128	glycogen synthase kinase 3 beta	Homo sapiens	41-49
19814765-7	2009	Moreover, increases in the phosphorylation of glycogen synthase kinase 3beta, accumulation/activation of beta-catenin, and collagen synthesis induced by alpha-defensin-1 and alpha-defensin-2 were prevented by p38 mitogen-activated protein kinase inhibitor SB203580 and phosphoinositide 3-kinase inhibitor LY294002.	SB 203580	256-264	glycogen synthase kinase 3 beta	Homo sapiens	46-76
19588183-6	2009	The cardiomyocytes treated with T3 demonstrated a rapid activation of Akt/GSK-3beta/mTOR signaling pathway, which was completely inhibited by the use of PI3K inhibitors (LY294002, 10 microM and Wortmannin, 200 nM).	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	170-178	glycogen synthase kinase 3 beta	Homo sapiens	74-83
19588183-6	2009	The cardiomyocytes treated with T3 demonstrated a rapid activation of Akt/GSK-3beta/mTOR signaling pathway, which was completely inhibited by the use of PI3K inhibitors (LY294002, 10 microM and Wortmannin, 200 nM).	Wortmannin	194-204	glycogen synthase kinase 3 beta	Homo sapiens	74-83
19667122-4	2009	Specifically, we provide evidence that JNK binds to E-cadherin/beta-catenin complex and phosphorylates beta-catenin at serine 37 and threonine 41, the sites also phosphorylated by GSK-3beta.	Threonine	133-142	glycogen synthase kinase 3 beta	Homo sapiens	180-189
19666107-10	2009	GSK3beta phosphorylates Fyn at an unknown threonine residue(s), leading to the nuclear localization of Fyn.	Threonine	42-51	glycogen synthase kinase 3 beta	Homo sapiens	0-8
19814765-7	2009	Moreover, increases in the phosphorylation of glycogen synthase kinase 3beta, accumulation/activation of beta-catenin, and collagen synthesis induced by alpha-defensin-1 and alpha-defensin-2 were prevented by p38 mitogen-activated protein kinase inhibitor SB203580 and phosphoinositide 3-kinase inhibitor LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	305-313	glycogen synthase kinase 3 beta	Homo sapiens	46-76
19887546-6	2009	DHA and EPA treatment caused dephosphorylation and thus activation of GSK-3beta, leading to beta-catenin degradation in Hep3B cells.	Docosahexaenoic Acids	0-3	glycogen synthase kinase 3 beta	Homo sapiens	70-79
19819952-0	2009	Convergence of 3",5"-cyclic adenosine 5"-monophosphate/protein kinase A and glycogen synthase kinase-3beta/beta-catenin signaling in corpus luteum progesterone synthesis.	Progesterone	147-159	glycogen synthase kinase 3 beta	Homo sapiens	55-106
19819952-5	2009	We observed that LH via a cAMP/PKA-dependent mechanism stimulated the phosphorylation of GSK3beta at N-terminal Ser9 causing its inactivation and resulted in the accumulation of beta-catenin.	Luteinizing Hormone	17-19	glycogen synthase kinase 3 beta	Homo sapiens	89-97
19819952-5	2009	We observed that LH via a cAMP/PKA-dependent mechanism stimulated the phosphorylation of GSK3beta at N-terminal Ser9 causing its inactivation and resulted in the accumulation of beta-catenin.	Cyclic AMP	26-30	glycogen synthase kinase 3 beta	Homo sapiens	89-97
19819952-7	2009	In contrast, overexpression of a constitutively active mutant of GSK3beta (GSK-S9A) reduced beta-catenin levels and inhibited LH-stimulated steroidogenesis.	Luteinizing Hormone	126-128	glycogen synthase kinase 3 beta	Homo sapiens	65-73
19819952-9	2009	Collectively these data suggest that cAMP/PKA regulation of GSK3beta/beta-catenin signaling may contribute to the acute increase in progesterone production in response to LH.	Cyclic AMP	37-41	glycogen synthase kinase 3 beta	Homo sapiens	60-68
19819952-9	2009	Collectively these data suggest that cAMP/PKA regulation of GSK3beta/beta-catenin signaling may contribute to the acute increase in progesterone production in response to LH.	Progesterone	132-144	glycogen synthase kinase 3 beta	Homo sapiens	60-68
19819952-9	2009	Collectively these data suggest that cAMP/PKA regulation of GSK3beta/beta-catenin signaling may contribute to the acute increase in progesterone production in response to LH.	Luteinizing Hormone	171-173	glycogen synthase kinase 3 beta	Homo sapiens	60-68
19472218-3	2009	Furthermore, inhibition of phosphatidylinositol-3 kinase (PI3K) reversed the PLTP-induced increase in levels of GSK3 beta phosphorylated at serine 9 (pGSK3 beta(Ser9)) and partially reversed the PLTP-induced reduction in tau phosphorylation.	Serine	140-146	glycogen synthase kinase 3 beta	Homo sapiens	112-121
19472218-3	2009	Furthermore, inhibition of phosphatidylinositol-3 kinase (PI3K) reversed the PLTP-induced increase in levels of GSK3 beta phosphorylated at serine 9 (pGSK3 beta(Ser9)) and partially reversed the PLTP-induced reduction in tau phosphorylation.	pgsk3 beta	150-160	glycogen synthase kinase 3 beta	Homo sapiens	112-121
19817973-0	2009	Melatonin ameliorates high fat diet-induced diabetes and stimulates glycogen synthesis via a PKCzeta-Akt-GSK3beta pathway in hepatic cells.	Melatonin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	105-113
19817973-0	2009	Melatonin ameliorates high fat diet-induced diabetes and stimulates glycogen synthesis via a PKCzeta-Akt-GSK3beta pathway in hepatic cells.	Glycogen	68-76	glycogen synthase kinase 3 beta	Homo sapiens	105-113
19817973-7	2009	In addition, melatonin increased the phosphorylation of subcellular signals at the level of protein kinase C zeta (PKCzeta), Akt, and glycogen synthase kinase 3beta (GSK3beta) while the increase in glycogen synthesis induced by melatonin was inhibited by PKCzeta pseudo-peptide.	Melatonin	13-22	glycogen synthase kinase 3 beta	Homo sapiens	134-164
19817973-7	2009	In addition, melatonin increased the phosphorylation of subcellular signals at the level of protein kinase C zeta (PKCzeta), Akt, and glycogen synthase kinase 3beta (GSK3beta) while the increase in glycogen synthesis induced by melatonin was inhibited by PKCzeta pseudo-peptide.	Melatonin	13-22	glycogen synthase kinase 3 beta	Homo sapiens	166-174
19887546-8	2009	Additionally, DHA induced the formation of beta-catenin/Axin/GSK-3beta binding complex, which serves as a parallel mechanism for beta-catenin degradation.	Docosahexaenoic Acids	14-17	glycogen synthase kinase 3 beta	Homo sapiens	61-70
19887546-6	2009	DHA and EPA treatment caused dephosphorylation and thus activation of GSK-3beta, leading to beta-catenin degradation in Hep3B cells.	Eicosapentaenoic Acid	8-11	glycogen synthase kinase 3 beta	Homo sapiens	70-79
19887546-7	2009	The GSK-3beta inhibitor, LiCl, partially prevented DHA-induced beta-catenin protein degradation and apoptosis.	Lithium Chloride	25-29	glycogen synthase kinase 3 beta	Homo sapiens	4-13
19887546-7	2009	The GSK-3beta inhibitor, LiCl, partially prevented DHA-induced beta-catenin protein degradation and apoptosis.	Docosahexaenoic Acids	51-54	glycogen synthase kinase 3 beta	Homo sapiens	4-13
19823589-9	2009	Interference with GSK3beta activity by siRNA, the specific inhibitor SB216763, or lithium chloride (LiCl) induced tumor cell differentiation.	SB 216763	69-77	glycogen synthase kinase 3 beta	Homo sapiens	18-26
19799425-4	2009	We also found that 6-shogaol inhibited survival signaling through the AKT/mTOR signaling pathway by blocking the activation of AKT and downstream targets, including the mammalian target of rapamycin (mTOR), forkhead transcription factors (FKHR) and glycogen synthase kinase-3beta (GSK-3beta).	shogaol	19-28	glycogen synthase kinase 3 beta	Homo sapiens	249-279
19799425-4	2009	We also found that 6-shogaol inhibited survival signaling through the AKT/mTOR signaling pathway by blocking the activation of AKT and downstream targets, including the mammalian target of rapamycin (mTOR), forkhead transcription factors (FKHR) and glycogen synthase kinase-3beta (GSK-3beta).	shogaol	19-28	glycogen synthase kinase 3 beta	Homo sapiens	281-290
19682597-6	2009	Treatment with the nitric oxide donor, propylamine propylamine NONOate (PAPA-NO; 1 microM for 1 h) increased Akt and GSK-3beta phosphorylation, and induced NFATc1 nuclear translocation in WT and eNOS(-/-) myotubes, and eliminated differences from WT in the NOS knockout cultures.	Nitric Oxide	19-31	glycogen synthase kinase 3 beta	Homo sapiens	117-126
19682597-6	2009	Treatment with the nitric oxide donor, propylamine propylamine NONOate (PAPA-NO; 1 microM for 1 h) increased Akt and GSK-3beta phosphorylation, and induced NFATc1 nuclear translocation in WT and eNOS(-/-) myotubes, and eliminated differences from WT in the NOS knockout cultures.	propylamine propylamine nonoate	39-70	glycogen synthase kinase 3 beta	Homo sapiens	117-126
19682597-6	2009	Treatment with the nitric oxide donor, propylamine propylamine NONOate (PAPA-NO; 1 microM for 1 h) increased Akt and GSK-3beta phosphorylation, and induced NFATc1 nuclear translocation in WT and eNOS(-/-) myotubes, and eliminated differences from WT in the NOS knockout cultures.	PAPA-NO	72-79	glycogen synthase kinase 3 beta	Homo sapiens	117-126
19665018-8	2009	Furthermore, we showed that the level of glycogen synthase kinase 3beta (GSK-3beta), which phosphorylates and destabilizes beta-catenin, was reduced in response to resveratrol treatment.	Resveratrol	164-175	glycogen synthase kinase 3 beta	Homo sapiens	41-71
19665018-8	2009	Furthermore, we showed that the level of glycogen synthase kinase 3beta (GSK-3beta), which phosphorylates and destabilizes beta-catenin, was reduced in response to resveratrol treatment.	Resveratrol	164-175	glycogen synthase kinase 3 beta	Homo sapiens	73-82
19823589-9	2009	Interference with GSK3beta activity by siRNA, the specific inhibitor SB216763, or lithium chloride (LiCl) induced tumor cell differentiation.	Lithium Chloride	100-104	glycogen synthase kinase 3 beta	Homo sapiens	18-26
19573523-9	2009	The expression levels of two integral proteins of Wnt signaling, GSK3beta and E-cadherin were also altered by curcumin treatment.	Curcumin	110-118	glycogen synthase kinase 3 beta	Homo sapiens	65-73
19445946-10	2009	Molecular docking of 5-Me-6-BIO in CRK3 and 6-BIO in human GSK-3beta and LdGSK-3s active sites predict the existence of functional/structural differences that are sufficient to explain the observed difference in their affinity.	5-me-6-bio	21-31	glycogen synthase kinase 3 beta	Homo sapiens	59-68
19644051-11	2009	Inhibition of Akt phosphorylation with LY294002 abolished hypoxia-induced GSK-3beta inactivation, beta-catenin activation, and MMP-7 expression.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	39-47	glycogen synthase kinase 3 beta	Homo sapiens	74-83
19682504-7	2009	We also observed that GA inhibited the phosphorylation of NDRG1 by targeting its regulating kinases, serum- and glucocorticoid-induced kinase 1 (SGK1) and glycogen synthase kinase 3 beta (GSK3beta).	geldanamycin	22-24	glycogen synthase kinase 3 beta	Homo sapiens	155-186
19682504-7	2009	We also observed that GA inhibited the phosphorylation of NDRG1 by targeting its regulating kinases, serum- and glucocorticoid-induced kinase 1 (SGK1) and glycogen synthase kinase 3 beta (GSK3beta).	geldanamycin	22-24	glycogen synthase kinase 3 beta	Homo sapiens	188-196
19747834-1	2009	Thienylhalomethylketones, whose chemical, biological, and pharmaceutical data are here reported, are the first irreversible inhibitors of GSK-3beta described to date.	thienylhalomethylketones	0-24	glycogen synthase kinase 3 beta	Homo sapiens	138-147
19747834-4	2009	Overall, the results presented here support the potential use of halomethylketones as pharmacological tools for the study of GSK-3beta functions and suggest a new mechanism for GSK-3beta inhibition that may be considered for further drug design.	halomethylketones	65-82	glycogen synthase kinase 3 beta	Homo sapiens	125-134
19659461-2	2009	Treatment with calcineurin inhibitors increased phosphorylation of GSK-3beta at Ser-9 in SH-SY5Y human neuroblastoma cells.	Serine	80-83	glycogen synthase kinase 3 beta	Homo sapiens	67-76
19461118-9	2009	In SK-N-SH cells, simvastatin significantly increased cyclin-dependent kinase 5 and glycogen synthase kinase 3beta expression, while pravastatin increased amyloid precursor protein expression.	Simvastatin	18-29	glycogen synthase kinase 3 beta	Homo sapiens	84-114
19659461-6	2009	We conclude that in vitro, calcineurin can dephosphorylate GSK-3beta at Ser-9 and form a stable complex with GSK-3beta, suggesting the possibility that calcineurin regulates the dephosphorylation and activation of GSK-3betain vivo.	Serine	72-75	glycogen synthase kinase 3 beta	Homo sapiens	59-68
19620254-0	2009	Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3beta inhibition downstream of poly(ADP-ribose)polymerase-LKB1 pathway.	Resveratrol	0-11	glycogen synthase kinase 3 beta	Homo sapiens	105-135
19507062-0	2009	GSK3beta in ethanol neurotoxicity.	Ethanol	12-19	glycogen synthase kinase 3 beta	Homo sapiens	0-8
19620254-8	2009	Resveratrol increased inhibitory phosphorylation of glycogen synthase kinase-3beta (GSK3beta) downstream of AMPK, which contributed to mitochondrial protection and cell survival.	Resveratrol	0-11	glycogen synthase kinase 3 beta	Homo sapiens	52-82
19507062-11	2009	Available evidence indicates that the activity of GSK3beta in the CNS is affected by ethanol.	Ethanol	85-92	glycogen synthase kinase 3 beta	Homo sapiens	50-58
19620254-8	2009	Resveratrol increased inhibitory phosphorylation of glycogen synthase kinase-3beta (GSK3beta) downstream of AMPK, which contributed to mitochondrial protection and cell survival.	Resveratrol	0-11	glycogen synthase kinase 3 beta	Homo sapiens	84-92
19507062-12	2009	GSK3beta inhibition provides protection against ethanol neurotoxicity, whereas high GSK3beta activity/expression sensitizes neuronal cells to ethanol-induced damages.	Ethanol	48-55	glycogen synthase kinase 3 beta	Homo sapiens	0-8
19507062-12	2009	GSK3beta inhibition provides protection against ethanol neurotoxicity, whereas high GSK3beta activity/expression sensitizes neuronal cells to ethanol-induced damages.	Ethanol	142-149	glycogen synthase kinase 3 beta	Homo sapiens	84-92
19620254-12	2009	Thus, resveratrol protects cells from AA + iron-induced ROS production and mitochondrial dysfunction through AMPK-mediated inhibitory phosphorylation of GSK3beta downstream of poly(ADP-ribose)polymerase-LKB1 pathway.	Resveratrol	6-17	glycogen synthase kinase 3 beta	Homo sapiens	153-161
19507062-13	2009	It appears that GSK3beta is a converging signaling point that mediates some of ethanol"s neurotoxic effects.	Ethanol	79-86	glycogen synthase kinase 3 beta	Homo sapiens	16-24
19620254-12	2009	Thus, resveratrol protects cells from AA + iron-induced ROS production and mitochondrial dysfunction through AMPK-mediated inhibitory phosphorylation of GSK3beta downstream of poly(ADP-ribose)polymerase-LKB1 pathway.	Iron	43-47	glycogen synthase kinase 3 beta	Homo sapiens	153-161
19752325-0	2009	Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis.	Dehydroepiandrosterone	0-22	glycogen synthase kinase 3 beta	Homo sapiens	95-105
19752325-8	2009	These functional changes were accompanied by sustained molecular effects toward the same direction; by decreasing [Ca(2+)](i) and inhibiting GSK-3beta, DHEA inhibited the nuclear factor of activated T cells transcription factor, thus increasing expression of Kv channels (Kv1.5) and contributing to sustained mitochondrial depolarization.	Dehydroepiandrosterone	152-156	glycogen synthase kinase 3 beta	Homo sapiens	141-150
19369384-2	2009	Here, we investigated the kinase involved and show that the Tau-specific kinase, glycogen synthase kinase 3beta (GSK-3beta), is robustly activated in various MPP(+)/MPTP models of Parkinsonism (SH-SY5Y cotransfected cells, mesencephalic neurons, transgenic mice overexpressing alpha-Syn, and postmortem striatum of PD patients).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	165-169	glycogen synthase kinase 3 beta	Homo sapiens	81-111
19652548-5	2009	Moreover, inhibition of GSK3beta with lithium chloride or SB216763 induced T cell proliferation, and the most significant effects were observed in RSLE lymphocytes.	Lithium Chloride	38-54	glycogen synthase kinase 3 beta	Homo sapiens	24-32
19688630-2	2009	In this study, we investigated the specificity of two GSK3beta-specific inhibitors, AR-A014418 (A) and B6B30 (B) to prevent direct neurotoxicity in primary human neurons exposed to HIV (BaL).	N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea	84-94	glycogen synthase kinase 3 beta	Homo sapiens	54-62
19382207-0	2009	Overexpression of glycogen synthase kinase 3beta sensitizes neuronal cells to ethanol toxicity.	Ethanol	78-85	glycogen synthase kinase 3 beta	Homo sapiens	18-48
19382207-4	2009	We demonstrated that glycogen synthase kinase 3beta (GSK3beta), a multifunctional serine/threonine kinase, was involved in ethanol neurotoxicity.	Ethanol	123-130	glycogen synthase kinase 3 beta	Homo sapiens	21-51
19382207-4	2009	We demonstrated that glycogen synthase kinase 3beta (GSK3beta), a multifunctional serine/threonine kinase, was involved in ethanol neurotoxicity.	Ethanol	123-130	glycogen synthase kinase 3 beta	Homo sapiens	53-61
19382207-5	2009	The activity of GSK3beta is negatively regulated by its phosphorylation at serine 9 (Ser9).	Serine	75-81	glycogen synthase kinase 3 beta	Homo sapiens	16-24
19382207-7	2009	These ethanol-induced alterations were ameliorated by the pretreatment of a GSK3beta inhibitor, lithium.	Ethanol	6-13	glycogen synthase kinase 3 beta	Homo sapiens	76-84
19382207-7	2009	These ethanol-induced alterations were ameliorated by the pretreatment of a GSK3beta inhibitor, lithium.	Lithium	96-103	glycogen synthase kinase 3 beta	Homo sapiens	76-84
19382207-9	2009	Ethanol only modestly reduced the viability of parental SK-N-MC cells but drastically induced caspase-3 activation and apoptosis in cells overexpressing WT or S9A GSK3beta, indicating that the high levels of GSK3beta or the active form of GSK3beta increased cellular sensitivity to ethanol.	Ethanol	0-7	glycogen synthase kinase 3 beta	Homo sapiens	163-171
19382207-9	2009	Ethanol only modestly reduced the viability of parental SK-N-MC cells but drastically induced caspase-3 activation and apoptosis in cells overexpressing WT or S9A GSK3beta, indicating that the high levels of GSK3beta or the active form of GSK3beta increased cellular sensitivity to ethanol.	Ethanol	0-7	glycogen synthase kinase 3 beta	Homo sapiens	208-216
19382207-9	2009	Ethanol only modestly reduced the viability of parental SK-N-MC cells but drastically induced caspase-3 activation and apoptosis in cells overexpressing WT or S9A GSK3beta, indicating that the high levels of GSK3beta or the active form of GSK3beta increased cellular sensitivity to ethanol.	Ethanol	0-7	glycogen synthase kinase 3 beta	Homo sapiens	208-216
19382207-9	2009	Ethanol only modestly reduced the viability of parental SK-N-MC cells but drastically induced caspase-3 activation and apoptosis in cells overexpressing WT or S9A GSK3beta, indicating that the high levels of GSK3beta or the active form of GSK3beta increased cellular sensitivity to ethanol.	sk-n-mc	56-63	glycogen synthase kinase 3 beta	Homo sapiens	208-216
19382207-9	2009	Ethanol only modestly reduced the viability of parental SK-N-MC cells but drastically induced caspase-3 activation and apoptosis in cells overexpressing WT or S9A GSK3beta, indicating that the high levels of GSK3beta or the active form of GSK3beta increased cellular sensitivity to ethanol.	sk-n-mc	56-63	glycogen synthase kinase 3 beta	Homo sapiens	208-216
19382207-10	2009	Contrarily, overexpression of DN GSK3beta conferred resistance to ethanol toxicity.	Ethanol	66-73	glycogen synthase kinase 3 beta	Homo sapiens	33-41
19382207-11	2009	Lithium and other specific GSK3beta inhibitors abolished the hypersensitivity to ethanol caused by WT or S9A overexpression.	Ethanol	81-88	glycogen synthase kinase 3 beta	Homo sapiens	27-35
19382207-13	2009	Cells overexpressing WT or S9A GSK3beta were much more sensitive to ethanol-induced Bax activation than parental SK-N-MC cells.	Ethanol	68-75	glycogen synthase kinase 3 beta	Homo sapiens	31-39
19382207-13	2009	Cells overexpressing WT or S9A GSK3beta were much more sensitive to ethanol-induced Bax activation than parental SK-N-MC cells.	sk-n-mc	113-120	glycogen synthase kinase 3 beta	Homo sapiens	31-39
19382207-14	2009	Our results indicate that GSK3beta may be a mediator of ethanol neurotoxicity, and its expression status in a cell may determine ethanol vulnerability.	Ethanol	56-63	glycogen synthase kinase 3 beta	Homo sapiens	26-34
19591849-5	2009	We demonstrate, using pharmacological tools, that PKA activation causes increase of calcium levels, leading to cyclin-dependent kinase 5 activation by calpain proteolysis of p35 to p25 and glycogen synthase kinase 3beta activation by its phosphorylation at tyrosine 216.	Calcium	84-91	glycogen synthase kinase 3 beta	Homo sapiens	189-219
19616957-0	2009	The marine natural-derived inhibitors of glycogen synthase kinase-3beta phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling.	phenylmethylene hydantoins	72-98	glycogen synthase kinase 3 beta	Homo sapiens	41-71
19693275-5	2009	Inhibition of the pro-apoptotic signaling enzyme glycogen synthase kinase-3beta (GSK-3beta) blocked curcumin-induced apoptosis.	Curcumin	100-108	glycogen synthase kinase 3 beta	Homo sapiens	49-79
19693275-5	2009	Inhibition of the pro-apoptotic signaling enzyme glycogen synthase kinase-3beta (GSK-3beta) blocked curcumin-induced apoptosis.	Curcumin	100-108	glycogen synthase kinase 3 beta	Homo sapiens	81-90
19701501-5	2009	In these novel chemoresistant subclones, the expression of the enzastaurin targets PKCbetaII and glycogen synthase kinase 3beta (GSK3beta) was analyzed.	enzastaurin	63-74	glycogen synthase kinase 3 beta	Homo sapiens	83-127
19701501-5	2009	In these novel chemoresistant subclones, the expression of the enzastaurin targets PKCbetaII and glycogen synthase kinase 3beta (GSK3beta) was analyzed.	enzastaurin	63-74	glycogen synthase kinase 3 beta	Homo sapiens	129-137
19701501-6	2009	Exposition to enzastaurin showed various inhibitory effects on phosphorylated forms of GSK3beta and the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2.	enzastaurin	14-25	glycogen synthase kinase 3 beta	Homo sapiens	87-95
19433130-5	2009	GA treatment downregulated the expression of SRC-3 and then inhibited the activity of Akt kinase and its downstream targets p70 S6 kinase 1 (S6K1) and glycogen synthase kinase 3beta (GSK3beta) without changes in total protein levels of these three proteins, which thus influenced the expression of the apoptosis related gene Bcl-2 in K562 cells.	gambogic acid	0-2	glycogen synthase kinase 3 beta	Homo sapiens	151-181
19675674-4	2009	However, JNK2-mediated downregulation of beta-catenin was blocked by the proteasome inhibitor MG132 and GSK3beta inhibitor lithium chloride.	Lithium Chloride	123-139	glycogen synthase kinase 3 beta	Homo sapiens	104-112
19433130-5	2009	GA treatment downregulated the expression of SRC-3 and then inhibited the activity of Akt kinase and its downstream targets p70 S6 kinase 1 (S6K1) and glycogen synthase kinase 3beta (GSK3beta) without changes in total protein levels of these three proteins, which thus influenced the expression of the apoptosis related gene Bcl-2 in K562 cells.	gambogic acid	0-2	glycogen synthase kinase 3 beta	Homo sapiens	183-191
19571678-0	2009	Secalonic acid D induced leukemia cell apoptosis and cell cycle arrest of G(1) with involvement of GSK-3beta/beta-catenin/c-Myc pathway.	secalonic acid	0-14	glycogen synthase kinase 3 beta	Homo sapiens	99-108
19508320-6	2009	Phosphorylation state of the kinases Akt, GSK-3beta, mTOR and ERK1/ERK2 of H(2)O(2)-treated HK-2 cells was slightly altered in the presence of erythropoietin at concentration of 100 U/ml, but was significantly less in the presence of erythropoietin at a concentration of 400 U/ml.	Hydrogen Peroxide	75-83	glycogen synthase kinase 3 beta	Homo sapiens	42-51
19403565-2	2009	We developed a functional model of xenografted human endometrium to test whether similar mechanisms are operative in the human by using Lithium chloride (LiCl), an inhibitor of GSK3beta.	Lithium Chloride	136-152	glycogen synthase kinase 3 beta	Homo sapiens	177-185
19403565-2	2009	We developed a functional model of xenografted human endometrium to test whether similar mechanisms are operative in the human by using Lithium chloride (LiCl), an inhibitor of GSK3beta.	Lithium Chloride	154-158	glycogen synthase kinase 3 beta	Homo sapiens	177-185
19295548-3	2009	Elevated ROS in Bcr-Abl-expressing cells were found to activate PI3k/Akt pathway members such as Akt and GSK3beta as well as downstream targets beta-catenin and Mcl-1.	Reactive Oxygen Species	9-12	glycogen synthase kinase 3 beta	Homo sapiens	105-113
19602045-12	2009	Interestingly, MG-AGE-induced cardiomyocyte dysfunction was associated with mitochondrial membrane potential (MMP) depolarization and reduced GSK-3beta inactivation in control cardiomyocytes, similar to those from in vivo diabetes.	Magnesium	15-17	glycogen synthase kinase 3 beta	Homo sapiens	142-151
19537828-8	2009	The GSK3-beta inhibitor Bisindolylmaleimide-III was coupled to a peptide containing the fluorescein-tagged TAT epitope.	Fluorescein	88-99	glycogen synthase kinase 3 beta	Homo sapiens	4-13
19537828-10	2009	Using this approach, we captured the known Bisindolylmaleimide-III target GSK3-beta and previously unidentified targets from live cells.	bisindolylmaleimide	43-62	glycogen synthase kinase 3 beta	Homo sapiens	74-83
19478079-3	2009	Phosphorylation on Thr(188) by MAPK or cyclin A/cdk2 primes the phosphorylations on Ser(184)/Thr(179) by GSK3beta, and these phosphorylations are required for the acquisition of DNA binding activity of C/EBPbeta.	Threonine	19-22	glycogen synthase kinase 3 beta	Homo sapiens	105-113
19703066-7	2009	CAY10404 treatment inhibited the phosphorylation of Akt, glycogen synthase kinase-3beta and extracellular signal-regulated kinases 1/2 in H460 and H358 cells.	3-(4-methylsulfonylphenyl)-4-phenyl-5-trifluoromethylisoxazole	0-8	glycogen synthase kinase 3 beta	Homo sapiens	57-87
19478079-3	2009	Phosphorylation on Thr(188) by MAPK or cyclin A/cdk2 primes the phosphorylations on Ser(184)/Thr(179) by GSK3beta, and these phosphorylations are required for the acquisition of DNA binding activity of C/EBPbeta.	Serine	84-87	glycogen synthase kinase 3 beta	Homo sapiens	105-113
19478079-3	2009	Phosphorylation on Thr(188) by MAPK or cyclin A/cdk2 primes the phosphorylations on Ser(184)/Thr(179) by GSK3beta, and these phosphorylations are required for the acquisition of DNA binding activity of C/EBPbeta.	Threonine	93-96	glycogen synthase kinase 3 beta	Homo sapiens	105-113
19549690-6	2009	These experiments identified dual-specificity tyrosine-phosphorylation-regulated kinase (DYRK1A) as the kinase that primes sites of GSK3 beta phosphorylation in MAP1B, and we confirmed this by knocking down DYRK1A in cultured embryonic cortical neurons by using shRNA.	Tyrosine	46-54	glycogen synthase kinase 3 beta	Homo sapiens	132-141
19440698-13	2009	CONCLUSION: Valproate and atypical antipsychotics (Olanzapine and Clozapine) regulate SH-SY5Y cell proliferation and survival, activate the Akt/GSK-3beta axis, and stimulate gene expression of Akt-1 mRNA and protein, as does Lithium.	Valproic Acid	12-21	glycogen synthase kinase 3 beta	Homo sapiens	144-153
19440698-13	2009	CONCLUSION: Valproate and atypical antipsychotics (Olanzapine and Clozapine) regulate SH-SY5Y cell proliferation and survival, activate the Akt/GSK-3beta axis, and stimulate gene expression of Akt-1 mRNA and protein, as does Lithium.	Olanzapine	51-61	glycogen synthase kinase 3 beta	Homo sapiens	144-153
19440698-13	2009	CONCLUSION: Valproate and atypical antipsychotics (Olanzapine and Clozapine) regulate SH-SY5Y cell proliferation and survival, activate the Akt/GSK-3beta axis, and stimulate gene expression of Akt-1 mRNA and protein, as does Lithium.	Clozapine	66-75	glycogen synthase kinase 3 beta	Homo sapiens	144-153
19542364-3	2009	IFN-gamma treatment rapidly activated GSK-3beta via neutral sphingomyelinase- and okadaic acid-sensitive phosphatase-regulated dephosphorylation at Ser(9), and proline-rich tyrosine kinase 2 (Pyk2)-regulated phosphorylation at Tyr(216).	Serine	148-151	glycogen synthase kinase 3 beta	Homo sapiens	38-47
19542364-3	2009	IFN-gamma treatment rapidly activated GSK-3beta via neutral sphingomyelinase- and okadaic acid-sensitive phosphatase-regulated dephosphorylation at Ser(9), and proline-rich tyrosine kinase 2 (Pyk2)-regulated phosphorylation at Tyr(216).	Tyrosine	227-230	glycogen synthase kinase 3 beta	Homo sapiens	38-47
19477653-0	2009	Synthetic resveratrol aliphatic acid inhibits TLR2-mediated apoptosis and an involvement of Akt/GSK3beta pathway.	Resveratrol	10-21	glycogen synthase kinase 3 beta	Homo sapiens	96-104
19564345-9	2009	Altogether, our data show that zymosan induces il10 transcription by a CRE-dependent mechanism that involves autocrine secretion of PGE(2) and a network of interactions of PKA, MAP/ERK, glycogen-synthase kinase-3beta, and calcineurin, which regulate CREB transcriptional activity by binding the coactivators CBP and TORC2 and inhibiting CBP interaction with other transcription factors.	Zymosan	31-38	glycogen synthase kinase 3 beta	Homo sapiens	186-233
19477653-0	2009	Synthetic resveratrol aliphatic acid inhibits TLR2-mediated apoptosis and an involvement of Akt/GSK3beta pathway.	Fatty Acids	22-36	glycogen synthase kinase 3 beta	Homo sapiens	96-104
19477653-7	2009	Our study thus demonstrates that the resveratrol aliphatic acid inhibits cell apoptosis through TLR2 by the involvement of Akt/GSK3beta pathway.	Resveratrol	37-48	glycogen synthase kinase 3 beta	Homo sapiens	127-135
19477653-7	2009	Our study thus demonstrates that the resveratrol aliphatic acid inhibits cell apoptosis through TLR2 by the involvement of Akt/GSK3beta pathway.	Fatty Acids	49-63	glycogen synthase kinase 3 beta	Homo sapiens	127-135
19481464-0	2009	Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.	4-azaindolyl-indolyl-maleimides	45-76	glycogen synthase kinase 3 beta	Homo sapiens	80-110
19481464-0	2009	Synthesis and biological evaluation of novel 4-azaindolyl-indolyl-maleimides as glycogen synthase kinase-3beta (GSK-3beta) inhibitors.	4-azaindolyl-indolyl-maleimides	45-76	glycogen synthase kinase 3 beta	Homo sapiens	112-121
19481464-1	2009	A series of novel 4-azaindolyl-indolyl-maleimides were synthesized and evaluated for their GSK-3beta inhibitory activity.	4-azaindolyl-indolyl-maleimides	18-49	glycogen synthase kinase 3 beta	Homo sapiens	91-100
19481464-4	2009	Preliminary structure-activity relationships were discussed based on the experimental data obtained and showed that different substituents on the indole ring and side chains at 1-position of indole had varying degrees of influence on the GSK-3beta inhibitory potency.	indole	146-152	glycogen synthase kinase 3 beta	Homo sapiens	238-247
19481464-4	2009	Preliminary structure-activity relationships were discussed based on the experimental data obtained and showed that different substituents on the indole ring and side chains at 1-position of indole had varying degrees of influence on the GSK-3beta inhibitory potency.	indole	191-197	glycogen synthase kinase 3 beta	Homo sapiens	238-247
19440036-8	2009	Inhibition of glycogen synthase kinase-3beta by lithium chloride, a highly selective inhibitor, leading to phosphorylation of glycogen synthase kinase-3beta increased Snail expression.	Lithium Chloride	48-64	glycogen synthase kinase 3 beta	Homo sapiens	126-156
19440036-8	2009	Inhibition of glycogen synthase kinase-3beta by lithium chloride, a highly selective inhibitor, leading to phosphorylation of glycogen synthase kinase-3beta increased Snail expression.	Lithium Chloride	48-64	glycogen synthase kinase 3 beta	Homo sapiens	14-44
18830594-3	2009	METHOD: We investigated the effect of a DNA methyltransferase (DNMT) inhibitor, zebularine (Zeb), on the chemosensitivity of 5-FU and cisplatin (CDDP) by MTT and TUNEL methods, and compared the molecular mechanism of action with those of a GSK3beta inhibitor, LiCl, and an Hsp90 inhibitor, 17-AAG.	pyrimidin-2-one beta-ribofuranoside	80-90	glycogen synthase kinase 3 beta	Homo sapiens	240-248
19498210-7	2009	Bcl-2 family proteins and mPTP-regulatory elements, such as adenine nucleotide translocator and cyclophilin D (possibly voltage-dependent anion channel), may be the functional downstream target(s) of GSK-3beta.	Adenine Nucleotides	60-78	glycogen synthase kinase 3 beta	Homo sapiens	200-209
19416964-6	2009	We show that hypoxia triggers GCM1 degradation by suppressing the phosphatidylinositol 3-kinase-Akt signaling pathway, leading to GSK-3beta activation.	Phosphatidylinositols	66-86	glycogen synthase kinase 3 beta	Homo sapiens	130-139
19416964-8	2009	Importantly, the GSK-3beta inhibitor LiCl prevented hypoxia-induced GCM1 degradation.	Lithium Chloride	37-41	glycogen synthase kinase 3 beta	Homo sapiens	17-26
19429264-0	2009	Bleomycin-induced nuclear factor-kappaB activation in human bronchial epithelial cells involves the phosphorylation of glycogen synthase kinase 3beta.	Bleomycin	0-9	glycogen synthase kinase 3 beta	Homo sapiens	119-149
19429264-4	2009	GSK3beta is known to be a key downstream target of Akt, and LY294002, the PI3K (phosphatidylinositol 3-kinase)/Akt inhibitor, which promoted the dephosphorylation of GSK3beta, significantly attenuated BLM-induced NF-kappaB activation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	60-68	glycogen synthase kinase 3 beta	Homo sapiens	166-174
19111579-8	2009	High zinc concentrations also increased glycogen synthase kinase-3beta (GSK-3beta) phosphorylation on tyrosine 216, a phosphorylation associated with increased activity of this tau kinase.	Tyrosine	102-110	glycogen synthase kinase 3 beta	Homo sapiens	40-70
19475596-5	2009	GSK-3 possesses a very flexible ATP-binding site, a fact reflected in the variety of X-ray structures of the human GSK-3beta which are deposited in the protein data base and are crystallized with different ligands.	Adenosine Triphosphate	32-35	glycogen synthase kinase 3 beta	Homo sapiens	115-124
19111579-8	2009	High zinc concentrations also increased glycogen synthase kinase-3beta (GSK-3beta) phosphorylation on tyrosine 216, a phosphorylation associated with increased activity of this tau kinase.	Tyrosine	102-110	glycogen synthase kinase 3 beta	Homo sapiens	72-81
19196496-9	2009	Moreover, cells treated with aripirazole effectively increased the levels of GSK-3beta phosphorylation and Bcl-2 at doses of five and 10 microM (30% and 58% and 31% and 80%, respectively, p&lt;0.05 or p&lt;0.01).	aripirazole	29-40	glycogen synthase kinase 3 beta	Homo sapiens	77-86
19442631-5	2009	Exposure of cells to LiCl, which promotes canonical Wnt signaling by inhibiting GSK-3beta, increased beta-catenin nuclear translocation and up-regulated the transcriptional activity of a canonical Wnt-responsive promoters, suggesting that an endogenous canonical Wnt pathway functions in cementoblasts.	Lithium Chloride	21-25	glycogen synthase kinase 3 beta	Homo sapiens	80-89
18929433-7	2009	The H-bond with ARG141 appears to be unique to GSK-3beta and explains the high GSK-3beta selectivity observed for 1H-Quinazolin-4-ones and Benzo[e][1,3]oxazin-4-ones.	1h-quinazolin-4-ones	114-134	glycogen synthase kinase 3 beta	Homo sapiens	47-56
18929433-7	2009	The H-bond with ARG141 appears to be unique to GSK-3beta and explains the high GSK-3beta selectivity observed for 1H-Quinazolin-4-ones and Benzo[e][1,3]oxazin-4-ones.	1h-quinazolin-4-ones	114-134	glycogen synthase kinase 3 beta	Homo sapiens	79-88
18929433-7	2009	The H-bond with ARG141 appears to be unique to GSK-3beta and explains the high GSK-3beta selectivity observed for 1H-Quinazolin-4-ones and Benzo[e][1,3]oxazin-4-ones.	[1,3]oxazin-4-ones	147-165	glycogen synthase kinase 3 beta	Homo sapiens	47-56
18929433-7	2009	The H-bond with ARG141 appears to be unique to GSK-3beta and explains the high GSK-3beta selectivity observed for 1H-Quinazolin-4-ones and Benzo[e][1,3]oxazin-4-ones.	[1,3]oxazin-4-ones	147-165	glycogen synthase kinase 3 beta	Homo sapiens	79-88
19461126-4	2009	Analysis of signal transduction showed that LPA induces common signaling pathways of chemotaxins such as G(i) protein-dependent actin re-organization, activation of the mitogen-activated protein kinase p38 as well as phosphatidylinositol-3-kinase-dependent signal molecules [protein kinase B/Akt and glycogen synthase kinase-3beta (GSK-3beta)].	lysophosphatidic acid	44-47	glycogen synthase kinase 3 beta	Homo sapiens	300-330
19461126-4	2009	Analysis of signal transduction showed that LPA induces common signaling pathways of chemotaxins such as G(i) protein-dependent actin re-organization, activation of the mitogen-activated protein kinase p38 as well as phosphatidylinositol-3-kinase-dependent signal molecules [protein kinase B/Akt and glycogen synthase kinase-3beta (GSK-3beta)].	lysophosphatidic acid	44-47	glycogen synthase kinase 3 beta	Homo sapiens	332-341
19627200-8	2009	TM activated glycogen synthase kinase 3beta (GSK3beta), a kinase involved in tau phosphorylation; in contrast, isoflavones inactivated GSK3beta and decreased tau hyperphosphorylation.	Isoflavones	111-122	glycogen synthase kinase 3 beta	Homo sapiens	135-143
19171421-4	2009	Both Sorafenib and Sunitinib with Enzastaurin at concentrations feasible in vivo showed a synergistic reduction of viable RCC cells by inhibiting cell growth through inhibition of phospho-S6-kinase and GSK3-beta.	Sorafenib	5-14	glycogen synthase kinase 3 beta	Homo sapiens	202-211
19171421-4	2009	Both Sorafenib and Sunitinib with Enzastaurin at concentrations feasible in vivo showed a synergistic reduction of viable RCC cells by inhibiting cell growth through inhibition of phospho-S6-kinase and GSK3-beta.	Sunitinib	19-28	glycogen synthase kinase 3 beta	Homo sapiens	202-211
19171421-4	2009	Both Sorafenib and Sunitinib with Enzastaurin at concentrations feasible in vivo showed a synergistic reduction of viable RCC cells by inhibiting cell growth through inhibition of phospho-S6-kinase and GSK3-beta.	enzastaurin	34-45	glycogen synthase kinase 3 beta	Homo sapiens	202-211
19003984-2	2009	Presently, the similarity of activation loop between two crystal complexes, i.e. glycogen synthase kinase 3beta (GSK3beta)-AMPNP and GSK3beta-sulfate ion complex, indicates that the activation segment of GSK3beta is preformed requiring neither a phosphorylation event nor conformational changes.	Sulfates	142-149	glycogen synthase kinase 3 beta	Homo sapiens	81-111
19003984-2	2009	Presently, the similarity of activation loop between two crystal complexes, i.e. glycogen synthase kinase 3beta (GSK3beta)-AMPNP and GSK3beta-sulfate ion complex, indicates that the activation segment of GSK3beta is preformed requiring neither a phosphorylation event nor conformational changes.	Sulfates	142-149	glycogen synthase kinase 3 beta	Homo sapiens	133-141
19003984-2	2009	Presently, the similarity of activation loop between two crystal complexes, i.e. glycogen synthase kinase 3beta (GSK3beta)-AMPNP and GSK3beta-sulfate ion complex, indicates that the activation segment of GSK3beta is preformed requiring neither a phosphorylation event nor conformational changes.	Sulfates	142-149	glycogen synthase kinase 3 beta	Homo sapiens	133-141
19003984-3	2009	GSK3beta, when participated in glycogen synthesis and Wnt signaling pathways, possesses a unique feature with the preference of such substrate with a priming phosphate.	Glycogen	31-39	glycogen synthase kinase 3 beta	Homo sapiens	0-8
19003984-3	2009	GSK3beta, when participated in glycogen synthesis and Wnt signaling pathways, possesses a unique feature with the preference of such substrate with a priming phosphate.	Phosphates	158-167	glycogen synthase kinase 3 beta	Homo sapiens	0-8
19003984-5	2009	Based on two solved crystal structures, wild type (WT) and two mutants (R96K and R96A) GSK3beta-ATP-phospho-Serine (pSer) complexes were modeled.	atp-phospho-serine	96-114	glycogen synthase kinase 3 beta	Homo sapiens	87-95
19003984-5	2009	Based on two solved crystal structures, wild type (WT) and two mutants (R96K and R96A) GSK3beta-ATP-phospho-Serine (pSer) complexes were modeled.	pser	116-120	glycogen synthase kinase 3 beta	Homo sapiens	87-95
19003984-7	2009	The results indicate that the introduction of pSer to WT GSK3beta generates a slight lobe closure on GSK3beta without any remarkable changes, which may illuminate the experimental conclusion, whereas the conformations of GSK3beta and ATP undergo significant changes in two mutants.	Adenosine Triphosphate	234-237	glycogen synthase kinase 3 beta	Homo sapiens	57-65
19003984-8	2009	As to GSK3beta, the affected positions distribute over activation loop, alpha-helix, and glycine-rich loop.	Glycine	89-96	glycogen synthase kinase 3 beta	Homo sapiens	6-14
19333000-3	2009	In the ROS-GSK-3beta autophagy pathway, cadmium induces ROS most likely from the mitochondria, and the ROS consequently activate GSK-3beta leading to autophagic cell death.	ros	7-10	glycogen synthase kinase 3 beta	Homo sapiens	11-20
19333000-3	2009	In the ROS-GSK-3beta autophagy pathway, cadmium induces ROS most likely from the mitochondria, and the ROS consequently activate GSK-3beta leading to autophagic cell death.	ros	7-10	glycogen synthase kinase 3 beta	Homo sapiens	129-138
19333000-3	2009	In the ROS-GSK-3beta autophagy pathway, cadmium induces ROS most likely from the mitochondria, and the ROS consequently activate GSK-3beta leading to autophagic cell death.	Cadmium	40-47	glycogen synthase kinase 3 beta	Homo sapiens	11-20
19333000-3	2009	In the ROS-GSK-3beta autophagy pathway, cadmium induces ROS most likely from the mitochondria, and the ROS consequently activate GSK-3beta leading to autophagic cell death.	Cadmium	40-47	glycogen synthase kinase 3 beta	Homo sapiens	129-138
19333000-3	2009	In the ROS-GSK-3beta autophagy pathway, cadmium induces ROS most likely from the mitochondria, and the ROS consequently activate GSK-3beta leading to autophagic cell death.	ros	56-59	glycogen synthase kinase 3 beta	Homo sapiens	11-20
19333000-3	2009	In the ROS-GSK-3beta autophagy pathway, cadmium induces ROS most likely from the mitochondria, and the ROS consequently activate GSK-3beta leading to autophagic cell death.	ros	56-59	glycogen synthase kinase 3 beta	Homo sapiens	129-138
19333000-3	2009	In the ROS-GSK-3beta autophagy pathway, cadmium induces ROS most likely from the mitochondria, and the ROS consequently activate GSK-3beta leading to autophagic cell death.	ros	56-59	glycogen synthase kinase 3 beta	Homo sapiens	11-20
19333000-3	2009	In the ROS-GSK-3beta autophagy pathway, cadmium induces ROS most likely from the mitochondria, and the ROS consequently activate GSK-3beta leading to autophagic cell death.	ros	56-59	glycogen synthase kinase 3 beta	Homo sapiens	129-138
19188482-9	2009	Activating GSK-3beta caused K562 cells to be susceptible to tunicamycin-induced apoptosis.	Tunicamycin	60-71	glycogen synthase kinase 3 beta	Homo sapiens	11-20
19423950-0	2009	Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	63-93
19423950-4	2009	During the last five years, multiple lines of evidence have shown that the mood stabilization and neurogenesis by lithium are due to the lithium-induced inhibition of glycogen synthase kinase-3beta (GSK-3beta), allowing accumulation of beta-catenin and beta-catenin-dependent gene transcriptional events.	Lithium	114-121	glycogen synthase kinase 3 beta	Homo sapiens	167-197
19423950-4	2009	During the last five years, multiple lines of evidence have shown that the mood stabilization and neurogenesis by lithium are due to the lithium-induced inhibition of glycogen synthase kinase-3beta (GSK-3beta), allowing accumulation of beta-catenin and beta-catenin-dependent gene transcriptional events.	Lithium	114-121	glycogen synthase kinase 3 beta	Homo sapiens	199-208
19423950-4	2009	During the last five years, multiple lines of evidence have shown that the mood stabilization and neurogenesis by lithium are due to the lithium-induced inhibition of glycogen synthase kinase-3beta (GSK-3beta), allowing accumulation of beta-catenin and beta-catenin-dependent gene transcriptional events.	Lithium	137-144	glycogen synthase kinase 3 beta	Homo sapiens	167-197
19423950-4	2009	During the last five years, multiple lines of evidence have shown that the mood stabilization and neurogenesis by lithium are due to the lithium-induced inhibition of glycogen synthase kinase-3beta (GSK-3beta), allowing accumulation of beta-catenin and beta-catenin-dependent gene transcriptional events.	Lithium	137-144	glycogen synthase kinase 3 beta	Homo sapiens	199-208
19211828-5	2009	Inhibition of AKT by enterolactone resulted in decreased phosphorylation of its downstream targets, including p70S6K1 and glycogen synthase kinase-3 beta.	2,3-bis(3'-hydroxybenzyl)butyrolactone	21-34	glycogen synthase kinase 3 beta	Homo sapiens	122-153
19338355-0	2009	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.	benzofuran-3-yl-(indol-3-yl)maleimides	74-112	glycogen synthase kinase 3 beta	Homo sapiens	116-146
19338355-2	2009	Here, we report the design, synthesis, and biological evaluation of benzofuran-3-yl-(indol-3-yl)maleimides, potent GSK-3beta inhibitors.	benzofuran-3-yl-(indol-3-yl)maleimides	68-106	glycogen synthase kinase 3 beta	Homo sapiens	115-124
19371592-7	2009	Furthermore, MEK1/2 inhibition with U0126 blocked the higher phosphorylation of RSK-1 on Thr359/Ser363 and of GSK-3beta on Ser9 as well as the increased expression of RSK-1, beta-catenin and PIMT upon treatment with valproic acid.	U 0126	36-41	glycogen synthase kinase 3 beta	Homo sapiens	110-119
19371592-8	2009	RSK-1 knockdown by interfering RNA abrogated the increased expression of RSK-1, beta-catenin and PIMT as well as the induced phosphorylation of RSK-1 and GSK-3beta due to valproic acid.	Valproic Acid	171-184	glycogen synthase kinase 3 beta	Homo sapiens	154-163
19287192-5	2009	BMP4 is a transcriptional target of Wnt/beta-catenin signaling, and both the mRNA and protein levels of BMP4 were increased by treatment of valproic acid (VPA), a chemical inhibitor of glycogen synthase kinase 3beta (GSK3beta) activating the Wnt/beta-catenin pathway.	Valproic Acid	140-153	glycogen synthase kinase 3 beta	Homo sapiens	185-215
19141611-7	2009	The Ser and Thr residues in the motif appear to be also phosphorylated by glycogen synthase kinase 3beta (GSK3beta) and the CKI family kinases, as GSK3beta and CKIepsilon could enhance the interaction of Zbed3 with Axin.	Serine	4-7	glycogen synthase kinase 3 beta	Homo sapiens	74-104
19141611-7	2009	The Ser and Thr residues in the motif appear to be also phosphorylated by glycogen synthase kinase 3beta (GSK3beta) and the CKI family kinases, as GSK3beta and CKIepsilon could enhance the interaction of Zbed3 with Axin.	Serine	4-7	glycogen synthase kinase 3 beta	Homo sapiens	106-114
19141611-7	2009	The Ser and Thr residues in the motif appear to be also phosphorylated by glycogen synthase kinase 3beta (GSK3beta) and the CKI family kinases, as GSK3beta and CKIepsilon could enhance the interaction of Zbed3 with Axin.	Serine	4-7	glycogen synthase kinase 3 beta	Homo sapiens	147-155
19141611-7	2009	The Ser and Thr residues in the motif appear to be also phosphorylated by glycogen synthase kinase 3beta (GSK3beta) and the CKI family kinases, as GSK3beta and CKIepsilon could enhance the interaction of Zbed3 with Axin.	Threonine	12-15	glycogen synthase kinase 3 beta	Homo sapiens	74-104
19141611-7	2009	The Ser and Thr residues in the motif appear to be also phosphorylated by glycogen synthase kinase 3beta (GSK3beta) and the CKI family kinases, as GSK3beta and CKIepsilon could enhance the interaction of Zbed3 with Axin.	Threonine	12-15	glycogen synthase kinase 3 beta	Homo sapiens	106-114
19141611-7	2009	The Ser and Thr residues in the motif appear to be also phosphorylated by glycogen synthase kinase 3beta (GSK3beta) and the CKI family kinases, as GSK3beta and CKIepsilon could enhance the interaction of Zbed3 with Axin.	Threonine	12-15	glycogen synthase kinase 3 beta	Homo sapiens	147-155
19399237-7	2009	Interestingly, modulation of the GSK3beta signaling pathway by FGF1 or GSK3beta inhibitors (lithium, valproic acid) is protective against HIV neurotoxicity, and several pilot clinical trials have demonstrated cognitive improvements in HIV patients treated with GSK3beta inhibitors.	Lithium	92-99	glycogen synthase kinase 3 beta	Homo sapiens	33-41
19399237-7	2009	Interestingly, modulation of the GSK3beta signaling pathway by FGF1 or GSK3beta inhibitors (lithium, valproic acid) is protective against HIV neurotoxicity, and several pilot clinical trials have demonstrated cognitive improvements in HIV patients treated with GSK3beta inhibitors.	Lithium	92-99	glycogen synthase kinase 3 beta	Homo sapiens	71-79
19399237-7	2009	Interestingly, modulation of the GSK3beta signaling pathway by FGF1 or GSK3beta inhibitors (lithium, valproic acid) is protective against HIV neurotoxicity, and several pilot clinical trials have demonstrated cognitive improvements in HIV patients treated with GSK3beta inhibitors.	Lithium	92-99	glycogen synthase kinase 3 beta	Homo sapiens	71-79
19399237-7	2009	Interestingly, modulation of the GSK3beta signaling pathway by FGF1 or GSK3beta inhibitors (lithium, valproic acid) is protective against HIV neurotoxicity, and several pilot clinical trials have demonstrated cognitive improvements in HIV patients treated with GSK3beta inhibitors.	Valproic Acid	101-114	glycogen synthase kinase 3 beta	Homo sapiens	33-41
19399237-7	2009	Interestingly, modulation of the GSK3beta signaling pathway by FGF1 or GSK3beta inhibitors (lithium, valproic acid) is protective against HIV neurotoxicity, and several pilot clinical trials have demonstrated cognitive improvements in HIV patients treated with GSK3beta inhibitors.	Valproic Acid	101-114	glycogen synthase kinase 3 beta	Homo sapiens	71-79
19399237-7	2009	Interestingly, modulation of the GSK3beta signaling pathway by FGF1 or GSK3beta inhibitors (lithium, valproic acid) is protective against HIV neurotoxicity, and several pilot clinical trials have demonstrated cognitive improvements in HIV patients treated with GSK3beta inhibitors.	Valproic Acid	101-114	glycogen synthase kinase 3 beta	Homo sapiens	71-79
19287192-5	2009	BMP4 is a transcriptional target of Wnt/beta-catenin signaling, and both the mRNA and protein levels of BMP4 were increased by treatment of valproic acid (VPA), a chemical inhibitor of glycogen synthase kinase 3beta (GSK3beta) activating the Wnt/beta-catenin pathway.	Valproic Acid	155-158	glycogen synthase kinase 3 beta	Homo sapiens	185-215
19287192-5	2009	BMP4 is a transcriptional target of Wnt/beta-catenin signaling, and both the mRNA and protein levels of BMP4 were increased by treatment of valproic acid (VPA), a chemical inhibitor of glycogen synthase kinase 3beta (GSK3beta) activating the Wnt/beta-catenin pathway.	Valproic Acid	155-158	glycogen synthase kinase 3 beta	Homo sapiens	217-225
19200745-0	2009	Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.	1,3,4-oxadiazole	58-74	glycogen synthase kinase 3 beta	Homo sapiens	110-140
19200745-2	2009	Here we report design, synthesis and structure-activity relationships of a novel series of oxadiazole derivatives as GSK-3beta inhibitors.	Oxadiazoles	91-101	glycogen synthase kinase 3 beta	Homo sapiens	117-126
18823436-11	2009	CONCLUSION: The anti-cancer effects of celecoxib on gastric cancer cells might be partly mediated by downregulation of Akt, GSK3beta, FKHR, and upregulation of caspase-9, in the mitochondrial apoptotic pathway.	Celecoxib	39-48	glycogen synthase kinase 3 beta	Homo sapiens	124-132
19250614-6	2009	Our results suggest that SKIP plays a negative regulatory role in Akt/ GSK-3beta/GS (glycogen synthase) pathway leading to glycogen synthesis in myocytes.	Glycogen	85-93	glycogen synthase kinase 3 beta	Homo sapiens	71-80
19287192-5	2009	BMP4 is a transcriptional target of Wnt/beta-catenin signaling, and both the mRNA and protein levels of BMP4 were increased by treatment of valproic acid (VPA), a chemical inhibitor of glycogen synthase kinase 3beta (GSK3beta) activating the Wnt/beta-catenin pathway.	Valproic Acid	140-153	glycogen synthase kinase 3 beta	Homo sapiens	217-225
19196980-4	2009	Paradoxically, the GSK3beta inhibitors lithium chloride and SB216763 selectively decreased the proliferation of human breast and colorectal cancer cell lines with oncogenic PIK3CA mutations and led to a decrease in the GSK3beta target gene CYCLIN D1.	Lithium Chloride	39-55	glycogen synthase kinase 3 beta	Homo sapiens	19-27
19196980-4	2009	Paradoxically, the GSK3beta inhibitors lithium chloride and SB216763 selectively decreased the proliferation of human breast and colorectal cancer cell lines with oncogenic PIK3CA mutations and led to a decrease in the GSK3beta target gene CYCLIN D1.	Lithium Chloride	39-55	glycogen synthase kinase 3 beta	Homo sapiens	219-227
19196980-4	2009	Paradoxically, the GSK3beta inhibitors lithium chloride and SB216763 selectively decreased the proliferation of human breast and colorectal cancer cell lines with oncogenic PIK3CA mutations and led to a decrease in the GSK3beta target gene CYCLIN D1.	SB 216763	60-68	glycogen synthase kinase 3 beta	Homo sapiens	19-27
19196980-4	2009	Paradoxically, the GSK3beta inhibitors lithium chloride and SB216763 selectively decreased the proliferation of human breast and colorectal cancer cell lines with oncogenic PIK3CA mutations and led to a decrease in the GSK3beta target gene CYCLIN D1.	SB 216763	60-68	glycogen synthase kinase 3 beta	Homo sapiens	219-227
19190323-10	2009	Ly294002, an inhibitor of phosphatidylinositol 3-kinase, and dominant-negative AKT, suppressed TCF4 transcriptional activity induced by galectin-3 whereas LiCl, a GSK-3beta inhibitor, increased TCF4 activity, mimicking the effects of galectin-3.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	glycogen synthase kinase 3 beta	Homo sapiens	163-172
19060929-3	2009	Our results demonstrate a significant increase in the phosphorylation of GSK-3beta at Ser 9 following the overexpression of AURKA in AGS cells.	Serine	86-89	glycogen synthase kinase 3 beta	Homo sapiens	73-82
19060929-5	2009	The recombinant human AURKA protein phosphorylated the GSK-3beta protein at Ser 9 in a concentration-dependent manner, in vitro.	Serine	76-79	glycogen synthase kinase 3 beta	Homo sapiens	55-64
19004823-3	2009	Previously, we showed that GSK-3beta phosphorylated two stretches of serine residues within the nuclear export signal and the destruction box of Snail, provoking its cytoplasmic export for ubiquitin-mediated proteasome degradation.	Serine	69-75	glycogen synthase kinase 3 beta	Homo sapiens	27-36
19030935-8	2009	The HDAC inhibitors increased the amount of active Notch1 protein, whereas treatment with lithium was associated with inhibition of GSK-3beta.	Lithium	90-97	glycogen synthase kinase 3 beta	Homo sapiens	132-141
19030935-10	2009	Treatment of carcinoid cells with either VPA or SBHA and lithium chloride suppresses the neuroendocrine marker CgA while upregulating Notch1 and inhibiting GSK-3beta.	Valproic Acid	41-44	glycogen synthase kinase 3 beta	Homo sapiens	156-165
19030935-10	2009	Treatment of carcinoid cells with either VPA or SBHA and lithium chloride suppresses the neuroendocrine marker CgA while upregulating Notch1 and inhibiting GSK-3beta.	suberoyl bis-hydroxamic acid	48-52	glycogen synthase kinase 3 beta	Homo sapiens	156-165
19030935-10	2009	Treatment of carcinoid cells with either VPA or SBHA and lithium chloride suppresses the neuroendocrine marker CgA while upregulating Notch1 and inhibiting GSK-3beta.	Lithium Chloride	57-73	glycogen synthase kinase 3 beta	Homo sapiens	156-165
19188159-3	2009	EXPERIMENTAL DESIGN: The active fraction of GSK3beta that is phosphorylated at the tyrosine 216 residue (pGSK3betaY216) was identified in glioblastoma cell lines.	Tyrosine	83-91	glycogen synthase kinase 3 beta	Homo sapiens	44-52
19188159-3	2009	EXPERIMENTAL DESIGN: The active fraction of GSK3beta that is phosphorylated at the tyrosine 216 residue (pGSK3betaY216) was identified in glioblastoma cell lines.	pgsk3betay216	105-118	glycogen synthase kinase 3 beta	Homo sapiens	44-52
19188159-7	2009	Inhibition of GSK3beta was associated with increased expression of p53 and p21 in glioblastoma cells with wild-type p53 and with decreased Rb phosphorylation and expression of cyclin-dependent kinase 6 in all glioblastoma cell lines.	Rubidium	139-141	glycogen synthase kinase 3 beta	Homo sapiens	14-22
19374252-5	2009	Cyclin D1 destabilization involved its phosphorylation by GSK-3beta at threonine-286, since overexpression of the kinase-dead mutant of GSK-3beta or cyclin D1T(286A) Inutant conferred stability to cyclin D1.	Threonine	71-80	glycogen synthase kinase 3 beta	Homo sapiens	58-67
19374252-5	2009	Cyclin D1 destabilization involved its phosphorylation by GSK-3beta at threonine-286, since overexpression of the kinase-dead mutant of GSK-3beta or cyclin D1T(286A) Inutant conferred stability to cyclin D1.	Threonine	71-80	glycogen synthase kinase 3 beta	Homo sapiens	136-145
18606491-1	2009	Glycogen synthase kinase 3beta (GSK3beta), a multifunctional serine/threonine kinase found in all eukaryotes, had been initially identified as a key regulator of insulin-dependent glycogen synthesis.	Glycogen	180-188	glycogen synthase kinase 3 beta	Homo sapiens	0-30
18606491-1	2009	Glycogen synthase kinase 3beta (GSK3beta), a multifunctional serine/threonine kinase found in all eukaryotes, had been initially identified as a key regulator of insulin-dependent glycogen synthesis.	Glycogen	180-188	glycogen synthase kinase 3 beta	Homo sapiens	32-40
19116273-4	2009	APC also induced phosphorylation of Ser-9 in glycogen synthase kinase 3beta (GSK3beta), which was blocked by the PI3K inhibitor LY294002.	Serine	36-39	glycogen synthase kinase 3 beta	Homo sapiens	45-75
19116273-4	2009	APC also induced phosphorylation of Ser-9 in glycogen synthase kinase 3beta (GSK3beta), which was blocked by the PI3K inhibitor LY294002.	Serine	36-39	glycogen synthase kinase 3 beta	Homo sapiens	77-85
19116273-4	2009	APC also induced phosphorylation of Ser-9 in glycogen synthase kinase 3beta (GSK3beta), which was blocked by the PI3K inhibitor LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	128-136	glycogen synthase kinase 3 beta	Homo sapiens	45-75
19116273-4	2009	APC also induced phosphorylation of Ser-9 in glycogen synthase kinase 3beta (GSK3beta), which was blocked by the PI3K inhibitor LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	128-136	glycogen synthase kinase 3 beta	Homo sapiens	77-85
19030935-1	2009	In carcinoid cell lines, the histone deacetylase (HDAC) inhibitors valproic acid (VPA) and suberoyl bis-hydroxamic acid (SBHA) activate the Notch1 pathway, whereas lithium inhibits glycogen synthase kinase-3beta (GSK-3beta).	Valproic Acid	67-80	glycogen synthase kinase 3 beta	Homo sapiens	181-211
19030935-1	2009	In carcinoid cell lines, the histone deacetylase (HDAC) inhibitors valproic acid (VPA) and suberoyl bis-hydroxamic acid (SBHA) activate the Notch1 pathway, whereas lithium inhibits glycogen synthase kinase-3beta (GSK-3beta).	Valproic Acid	67-80	glycogen synthase kinase 3 beta	Homo sapiens	213-222
19030935-1	2009	In carcinoid cell lines, the histone deacetylase (HDAC) inhibitors valproic acid (VPA) and suberoyl bis-hydroxamic acid (SBHA) activate the Notch1 pathway, whereas lithium inhibits glycogen synthase kinase-3beta (GSK-3beta).	Valproic Acid	82-85	glycogen synthase kinase 3 beta	Homo sapiens	181-211
19030935-1	2009	In carcinoid cell lines, the histone deacetylase (HDAC) inhibitors valproic acid (VPA) and suberoyl bis-hydroxamic acid (SBHA) activate the Notch1 pathway, whereas lithium inhibits glycogen synthase kinase-3beta (GSK-3beta).	Valproic Acid	82-85	glycogen synthase kinase 3 beta	Homo sapiens	213-222
19030935-1	2009	In carcinoid cell lines, the histone deacetylase (HDAC) inhibitors valproic acid (VPA) and suberoyl bis-hydroxamic acid (SBHA) activate the Notch1 pathway, whereas lithium inhibits glycogen synthase kinase-3beta (GSK-3beta).	suberoyl bis-hydroxamic acid	91-119	glycogen synthase kinase 3 beta	Homo sapiens	181-211
19030935-1	2009	In carcinoid cell lines, the histone deacetylase (HDAC) inhibitors valproic acid (VPA) and suberoyl bis-hydroxamic acid (SBHA) activate the Notch1 pathway, whereas lithium inhibits glycogen synthase kinase-3beta (GSK-3beta).	suberoyl bis-hydroxamic acid	91-119	glycogen synthase kinase 3 beta	Homo sapiens	213-222
19030935-1	2009	In carcinoid cell lines, the histone deacetylase (HDAC) inhibitors valproic acid (VPA) and suberoyl bis-hydroxamic acid (SBHA) activate the Notch1 pathway, whereas lithium inhibits glycogen synthase kinase-3beta (GSK-3beta).	suberoyl bis-hydroxamic acid	121-125	glycogen synthase kinase 3 beta	Homo sapiens	181-211
19030935-1	2009	In carcinoid cell lines, the histone deacetylase (HDAC) inhibitors valproic acid (VPA) and suberoyl bis-hydroxamic acid (SBHA) activate the Notch1 pathway, whereas lithium inhibits glycogen synthase kinase-3beta (GSK-3beta).	suberoyl bis-hydroxamic acid	121-125	glycogen synthase kinase 3 beta	Homo sapiens	213-222
18839067-3	2009	Comparison of the active site residues of GSK-3alpha and GSK-3beta isoforms shows that all the key amino acids involved in polar interactions with the maleimides for the beta isoform are the same in the alpha isoform, except that Asp133 in the beta isoform is replaced by Glu196 in the alpha isoform.	Maleimides	151-161	glycogen synthase kinase 3 beta	Homo sapiens	57-66
19071090-6	2009	Interestingly, after mutation of threonine residue 286 of cyclin D1, which is reported to be the GSK-3beta phosphorylation site, the mutant protein showed resistance to irradiation-induced proteolysis although inhibitors of GSK-3beta failed to prevent cyclin D1 degradation.	Threonine	33-42	glycogen synthase kinase 3 beta	Homo sapiens	97-106
19071090-6	2009	Interestingly, after mutation of threonine residue 286 of cyclin D1, which is reported to be the GSK-3beta phosphorylation site, the mutant protein showed resistance to irradiation-induced proteolysis although inhibitors of GSK-3beta failed to prevent cyclin D1 degradation.	Threonine	33-42	glycogen synthase kinase 3 beta	Homo sapiens	224-233
19081248-1	2009	Glycogen synthase kinase-3beta (GSK-3beta) is involved in glycogen metabolism, neuronal cell development, osteoblast differentiation.	Glycogen	58-66	glycogen synthase kinase 3 beta	Homo sapiens	0-30
19081248-1	2009	Glycogen synthase kinase-3beta (GSK-3beta) is involved in glycogen metabolism, neuronal cell development, osteoblast differentiation.	Glycogen	58-66	glycogen synthase kinase 3 beta	Homo sapiens	32-41
19081248-3	2009	To identify GSK-3beta inhibitors with novel scaffold from chemical library, we primarily screened out putative inhibitors through computer modeling and subsequently evaluated the inhibitory activity of selected compounds against GSK-3beta by in vitro Z"-LYTEtrade mark assay.	z"-lytetrade	251-263	glycogen synthase kinase 3 beta	Homo sapiens	12-21
19081248-3	2009	To identify GSK-3beta inhibitors with novel scaffold from chemical library, we primarily screened out putative inhibitors through computer modeling and subsequently evaluated the inhibitory activity of selected compounds against GSK-3beta by in vitro Z"-LYTEtrade mark assay.	z"-lytetrade	251-263	glycogen synthase kinase 3 beta	Homo sapiens	229-238
19081248-5	2009	Also, we demonstrated that KRM-189 and KRM-191 competed with ATP for GSK-3beta, leading to decreased Vmax and constant Km with increasing concentrations of ATP as determined from Lineweaver-Berk equation.	Adenosine Triphosphate	61-64	glycogen synthase kinase 3 beta	Homo sapiens	69-78
19081248-5	2009	Also, we demonstrated that KRM-189 and KRM-191 competed with ATP for GSK-3beta, leading to decreased Vmax and constant Km with increasing concentrations of ATP as determined from Lineweaver-Berk equation.	Adenosine Triphosphate	156-159	glycogen synthase kinase 3 beta	Homo sapiens	69-78
19134195-5	2009	We also showed Akt/GSK-3beta signaling pathways are involved in iron nanoparticle-induced cell permeability.	Iron	64-68	glycogen synthase kinase 3 beta	Homo sapiens	19-28
19134195-6	2009	The inhibition of ROS demonstrate ROS play a major role in regulating Akt/GSK-3beta - mediated cell permeability upon iron nanoparticle exposure.	Reactive Oxygen Species	18-21	glycogen synthase kinase 3 beta	Homo sapiens	74-83
19134195-6	2009	The inhibition of ROS demonstrate ROS play a major role in regulating Akt/GSK-3beta - mediated cell permeability upon iron nanoparticle exposure.	Reactive Oxygen Species	34-37	glycogen synthase kinase 3 beta	Homo sapiens	74-83
19134195-6	2009	The inhibition of ROS demonstrate ROS play a major role in regulating Akt/GSK-3beta - mediated cell permeability upon iron nanoparticle exposure.	Iron	118-122	glycogen synthase kinase 3 beta	Homo sapiens	74-83
18801732-11	2008	In summary, phosphorylation (Ser-9) of GSK3beta is very likely to be critical for AMPK-mediated PEPCK-C gene suppression.	Serine	29-32	glycogen synthase kinase 3 beta	Homo sapiens	39-47
18957842-0	2009	Lithium chloride preconditioning optimizes skeletal myoblast functions for cellular cardiomyoplasty in vitro via glycogen synthase kinase-3beta/beta-catenin signaling.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	113-143
18957842-6	2009	These effects of LiCl were mediated by inactivating glycogen synthase kinase-3beta (GSK-3beta), stabilizing the effector protein beta-catenin and translocating it into the nucleus of SkMs, confirming that LiCl mimics canonical Wnt signaling.	Lithium Chloride	17-21	glycogen synthase kinase 3 beta	Homo sapiens	52-82
18957842-6	2009	These effects of LiCl were mediated by inactivating glycogen synthase kinase-3beta (GSK-3beta), stabilizing the effector protein beta-catenin and translocating it into the nucleus of SkMs, confirming that LiCl mimics canonical Wnt signaling.	Lithium Chloride	17-21	glycogen synthase kinase 3 beta	Homo sapiens	84-93
18957842-6	2009	These effects of LiCl were mediated by inactivating glycogen synthase kinase-3beta (GSK-3beta), stabilizing the effector protein beta-catenin and translocating it into the nucleus of SkMs, confirming that LiCl mimics canonical Wnt signaling.	Lithium Chloride	205-209	glycogen synthase kinase 3 beta	Homo sapiens	52-82
17590240-0	2009	Epigallocatechin gallate (EGCG) suppresses beta-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3 beta activation.	epigallocatechin gallate	0-24	glycogen synthase kinase 3 beta	Homo sapiens	134-143
17590240-0	2009	Epigallocatechin gallate (EGCG) suppresses beta-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3 beta activation.	epigallocatechin gallate	26-30	glycogen synthase kinase 3 beta	Homo sapiens	134-143
17590240-6	2009	Furthermore, EGCG also decreased nuclear translocation of c-Abl and blocked APP-C99-dependent GSK3 beta activation, and these inhibitory effects occurred through the interruption of c-Abl/Fe65 interaction.	epigallocatechin gallate	13-17	glycogen synthase kinase 3 beta	Homo sapiens	94-103
19251035-6	2009	Inhibition of c-Abl tyrosine kinase by STI571 attenuates the effect of insulin on Akt/GSK-3beta phosphorylation and glycogen synthesis, and at the same time, it enhances the effect of insulin on ERK activation, cell proliferation and migration.	Imatinib Mesylate	39-45	glycogen synthase kinase 3 beta	Homo sapiens	86-95
18803287-7	2008	In parallel, gefitinib downregulated constitutively phosphorylated HER2 and HER3, and activated GSK3beta with a concomitant degradation of cyclin D1.	Gefitinib	13-22	glycogen synthase kinase 3 beta	Homo sapiens	96-104
18801732-0	2008	AMP-activated protein kinase activation increases phosphorylation of glycogen synthase kinase 3beta and thereby reduces cAMP-responsive element transcriptional activity and phosphoenolpyruvate carboxykinase C gene expression in the liver.	Cyclic AMP	120-124	glycogen synthase kinase 3 beta	Homo sapiens	69-99
18801732-4	2008	Stimulation with AICAR or the GSK3beta inhibitor SB-415286 strongly inhibited CRE-containing promoter activity in HepG2 cells.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	49-58	glycogen synthase kinase 3 beta	Homo sapiens	30-38
19655410-3	2009	Western blots showed increased immunoreactivity for phospho-Akt and phospho-GSK3beta in EGCG-treated cells.	epigallocatechin gallate	88-92	glycogen synthase kinase 3 beta	Homo sapiens	76-84
19523343-5	2009	Lithium acts through multiple pathways to inhibit glycogen synthetase kinase-3beta (GSK3 beta).	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	84-93
19442155-0	2009	Lithium pharmacodynamics and pharmacogenetics: focus on inositol mono phosphatase (IMPase), inositol poliphosphatase (IPPase) and glycogen sinthase kinase 3 beta (GSK-3 beta).	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	163-173
19442155-3	2009	In the present paper, we focused on the most direct biochemical lithium targets at therapeutic concentration, for which some pharmacogenetic finding is present (i.e. inositol mono phosphatase (IMPase), inositol polyphosphate-1-phosphatase (IPPase) and glycogen sinthase kinase 3 beta (GSK-3 beta)).	Lithium	64-71	glycogen synthase kinase 3 beta	Homo sapiens	285-295
19442155-4	2009	They are all inhibited by lithium at therapeutic concentrations and are representative of the inositol depletion and of the GSK-3 beta based theories of lithium action.	Lithium	26-33	glycogen synthase kinase 3 beta	Homo sapiens	124-134
19442155-4	2009	They are all inhibited by lithium at therapeutic concentrations and are representative of the inositol depletion and of the GSK-3 beta based theories of lithium action.	Lithium	153-160	glycogen synthase kinase 3 beta	Homo sapiens	124-134
19442155-7	2009	IMPase2, IPPase and GSK-3 beta gene appear to be good candidates for the analysis of lithium prophylactic efficacy and bipolar disorder phenotypes but the genetic association analysis conducted so far reported negative or not unequivocal finding.	Lithium	85-92	glycogen synthase kinase 3 beta	Homo sapiens	20-30
19274078-4	2009	Inactivation of GSK3beta with lithium chloride or the GSK3 inhibitor BIO and GSK3beta knockdown with siRNA repressed cadherin-11 mRNA and protein levels.	Lithium Chloride	30-46	glycogen synthase kinase 3 beta	Homo sapiens	16-24
19430525-5	2009	In both cell models, MPTP/MPP(+) treatment caused cell death associated with time- and concentration-dependent activation of GSK-3beta, evidenced by the increased level of the active form of the kinase, i.e. GSK-3beta phosphorylated at tyrosine 216 residue.	Tyrosine	236-244	glycogen synthase kinase 3 beta	Homo sapiens	125-134
19430525-9	2009	Inhibition of GSK-3beta activity using well-characterized inhibitors, LiCl and kenpaullone, and RNA interference, prevented MPP(+)-induced cell death by blocking mitochondrial membrane potential changes and subsequent caspase-9 and -3 activation.	Lithium Chloride	70-74	glycogen synthase kinase 3 beta	Homo sapiens	14-23
19430525-9	2009	Inhibition of GSK-3beta activity using well-characterized inhibitors, LiCl and kenpaullone, and RNA interference, prevented MPP(+)-induced cell death by blocking mitochondrial membrane potential changes and subsequent caspase-9 and -3 activation.	kenpaullone	79-90	glycogen synthase kinase 3 beta	Homo sapiens	14-23
18701211-4	2008	Activation of GSK3beta induced translocation of survivin from the cytoplasm to the nucleus, resulting in G1 cell-cycle arrest and apoptosis, as well as sensitization to the chemotherapeutic drug doxorubicin.	Doxorubicin	195-206	glycogen synthase kinase 3 beta	Homo sapiens	14-22
18701211-5	2008	In contrast, inactivation of GSK3beta, either by transfection of a dominant-negative mutant inhibitor DN-GSK3beta or with selective inhibitor LiCl, increased cytoplasmic survivin expression, leading to cell-cycle progression and resistance to apoptosis.	Lithium Chloride	142-146	glycogen synthase kinase 3 beta	Homo sapiens	29-37
18801732-12	2008	Reduced CREB phosphorylation (Ser-129) associated with inactivation of GSK3beta by Ser-9 phosphorylation may be the major mechanism underlying PEPCK-C gene suppression by AMPK-activating agents such as biguanide.	Serine	30-33	glycogen synthase kinase 3 beta	Homo sapiens	71-79
18801732-12	2008	Reduced CREB phosphorylation (Ser-129) associated with inactivation of GSK3beta by Ser-9 phosphorylation may be the major mechanism underlying PEPCK-C gene suppression by AMPK-activating agents such as biguanide.	Serine	83-86	glycogen synthase kinase 3 beta	Homo sapiens	71-79
18801732-12	2008	Reduced CREB phosphorylation (Ser-129) associated with inactivation of GSK3beta by Ser-9 phosphorylation may be the major mechanism underlying PEPCK-C gene suppression by AMPK-activating agents such as biguanide.	Biguanides	202-211	glycogen synthase kinase 3 beta	Homo sapiens	71-79
18687779-4	2008	Inhibition of glycogen synthase kinase-3beta by lithium chloride or SB415286 also prevented adipogenesis, suggesting that preservation of beta-catenin levels was important to strain inhibition of adipogenesis.	Lithium Chloride	48-64	glycogen synthase kinase 3 beta	Homo sapiens	14-44
19026161-7	2008	The inhibition of the PI3K/Akt pathway using the LY294002 inhibitor prevented hypoxia-inhibited apoptosis in EPC and altered the phosphorylation state of glycogen synthase kinase-3beta, an effector protein involved in regulation of EPC apoptosis.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	49-57	glycogen synthase kinase 3 beta	Homo sapiens	154-184
18791199-7	2008	Experimental manipulation, including silencing of hypoxia-inducible factor (HIF)-1alpha and the specific inhibition of mitochondrial generation of reactive oxygen species (ROS), revealed that early EMT-related events induced by hypoxia (GSK-3beta inhibition and SNAIL translocation) were dependent on transient intracellular increased generation of ROS whereas late migration and invasiveness were sustained by HIF-1alpha- and vascular endothelial growth factor (VEGF)-dependent mechanisms.	Reactive Oxygen Species	147-170	glycogen synthase kinase 3 beta	Homo sapiens	237-246
18791199-7	2008	Experimental manipulation, including silencing of hypoxia-inducible factor (HIF)-1alpha and the specific inhibition of mitochondrial generation of reactive oxygen species (ROS), revealed that early EMT-related events induced by hypoxia (GSK-3beta inhibition and SNAIL translocation) were dependent on transient intracellular increased generation of ROS whereas late migration and invasiveness were sustained by HIF-1alpha- and vascular endothelial growth factor (VEGF)-dependent mechanisms.	Reactive Oxygen Species	172-175	glycogen synthase kinase 3 beta	Homo sapiens	237-246
18791199-7	2008	Experimental manipulation, including silencing of hypoxia-inducible factor (HIF)-1alpha and the specific inhibition of mitochondrial generation of reactive oxygen species (ROS), revealed that early EMT-related events induced by hypoxia (GSK-3beta inhibition and SNAIL translocation) were dependent on transient intracellular increased generation of ROS whereas late migration and invasiveness were sustained by HIF-1alpha- and vascular endothelial growth factor (VEGF)-dependent mechanisms.	Reactive Oxygen Species	349-352	glycogen synthase kinase 3 beta	Homo sapiens	237-246
19047162-5	2008	In the present study, we found that the inhibition of ODC by DFMO promotes cell survival by inducing the phosphorylation of Akt/PKB at residue Ser473 and glycogen synthase kinase-3beta at Ser9.	Eflornithine	61-65	glycogen synthase kinase 3 beta	Homo sapiens	154-184
18178198-9	2008	Tyrosine phosphorylation of GSK3beta also was higher in women with PCOS, compared with in control women.	Tyrosine	0-8	glycogen synthase kinase 3 beta	Homo sapiens	28-36
19129071-6	2008	The downstream genes and proteins of GSK-3beta(ser(9)) expression level decrease.	Serine	47-50	glycogen synthase kinase 3 beta	Homo sapiens	37-46
19129071-8	2008	The mechanism of meisoindigo activity against HT-29 cells may be related to its inhibition of glycogen synthase kinase-3beta, GSK-3beta(ser(9)) phosphorylation in Wnt signaling pathway.	Serine	136-139	glycogen synthase kinase 3 beta	Homo sapiens	126-135
18793648-1	2008	It has been suggested that phosphorylation at serine 9 near the N-terminus of glycogen synthase kinase-3beta (GSK-3beta) mimics the prephosphorylation of its substrate and, therefore, the N-terminus functions as a pseudosubstrate.	Serine	46-52	glycogen synthase kinase 3 beta	Homo sapiens	78-108
19073440-0	2008	Unregulated mitochondrial GSK3beta activity results in NADH: ubiquinone oxidoreductase deficiency.	NAD	55-59	glycogen synthase kinase 3 beta	Homo sapiens	26-34
19073440-3	2008	Here we selectively expressed constitutively active GSK3beta within the mitochondria and found that this enhanced the apoptosis signaling activated by the PD-mimetic NADH:ubiquinone oxidoreductase (complex I) inhibitors 1-methyl-4-phenylpyridinium ion (MPP+) and rotenone.	NAD	166-170	glycogen synthase kinase 3 beta	Homo sapiens	52-60
19073440-3	2008	Here we selectively expressed constitutively active GSK3beta within the mitochondria and found that this enhanced the apoptosis signaling activated by the PD-mimetic NADH:ubiquinone oxidoreductase (complex I) inhibitors 1-methyl-4-phenylpyridinium ion (MPP+) and rotenone.	1-Methyl-4-phenylpyridinium	220-251	glycogen synthase kinase 3 beta	Homo sapiens	52-60
19073440-3	2008	Here we selectively expressed constitutively active GSK3beta within the mitochondria and found that this enhanced the apoptosis signaling activated by the PD-mimetic NADH:ubiquinone oxidoreductase (complex I) inhibitors 1-methyl-4-phenylpyridinium ion (MPP+) and rotenone.	mangion-purified polysaccharide (Candida albicans)	253-257	glycogen synthase kinase 3 beta	Homo sapiens	52-60
19073440-3	2008	Here we selectively expressed constitutively active GSK3beta within the mitochondria and found that this enhanced the apoptosis signaling activated by the PD-mimetic NADH:ubiquinone oxidoreductase (complex I) inhibitors 1-methyl-4-phenylpyridinium ion (MPP+) and rotenone.	Rotenone	263-271	glycogen synthase kinase 3 beta	Homo sapiens	52-60
19073440-4	2008	Additionally, expression of GSK3beta in the mitochondria itself caused a significant decrease in complex I activity and ATP production.	Adenosine Triphosphate	120-123	glycogen synthase kinase 3 beta	Homo sapiens	28-36
19073440-5	2008	Increased mitochondrial a GSK3beta activity also increased reactive oxygen species production and perturbed the mitochondrial morphology.	Reactive Oxygen Species	59-82	glycogen synthase kinase 3 beta	Homo sapiens	26-34
19073440-6	2008	Conversely, chemical inhibitors of GSK3beta inhibited MPP+- and rotenone-induced apoptosis, and attenuated the mitochondrial GSK3beta-mediated impairment in complex I.	mangion-purified polysaccharide (Candida albicans)	54-58	glycogen synthase kinase 3 beta	Homo sapiens	35-43
19073440-6	2008	Conversely, chemical inhibitors of GSK3beta inhibited MPP+- and rotenone-induced apoptosis, and attenuated the mitochondrial GSK3beta-mediated impairment in complex I.	Rotenone	64-72	glycogen synthase kinase 3 beta	Homo sapiens	35-43
19043530-8	2008	Enz prevented radiation-induced GSK3beta phosphorylation of serine 9 while having no direct effect on VEGFR phosphorylation.	Serine	60-66	glycogen synthase kinase 3 beta	Homo sapiens	32-40
18838540-0	2008	Glycogen synthase kinase 3beta-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles.	Serine	40-46	glycogen synthase kinase 3 beta	Homo sapiens	0-30
18838540-5	2008	Specifically, we found hormone-dependent GR phosphorylation on serine 404 by GSK-3beta.	Serine	63-69	glycogen synthase kinase 3 beta	Homo sapiens	77-86
18793648-1	2008	It has been suggested that phosphorylation at serine 9 near the N-terminus of glycogen synthase kinase-3beta (GSK-3beta) mimics the prephosphorylation of its substrate and, therefore, the N-terminus functions as a pseudosubstrate.	Serine	46-52	glycogen synthase kinase 3 beta	Homo sapiens	110-119
18786602-3	2008	So far, we have demonstrated that activation of Wnt signaling protects neurons against neurotoxic injuries, including both amyloid-beta (Abeta) fibrils and Abeta oligomers by using either lithium, an inhibitor of the glycogen-synthase-kinase-3beta (GSK-3beta), or different Wnt ligands.	Lithium	188-195	glycogen synthase kinase 3 beta	Homo sapiens	217-247
19009649-12	2008	Abrogation of EGF-R signalling in IHH-Fos by treatment with AG1478, a specific EGF-R tyrosine kinase inhibitor, prevented the phosphorylation of GSK-3beta induced by serum stimulation and decreased Cyclin D1 stability in the nucleus.	RTKI cpd	60-66	glycogen synthase kinase 3 beta	Homo sapiens	145-154
18805899-7	2008	Mitochondrial translocation of Bcl-2-associated X protein (BAX) after exposure to H2O2 was inhibited by EPO pretreatment and by GSK-3beta knockdown.	Hydrogen Peroxide	82-86	glycogen synthase kinase 3 beta	Homo sapiens	128-137
18989859-9	2008	The fact that gemifloxacin was recently reported to potently inhibit the prodiabetic target glycogen synthase kinase 3beta (GSK-3beta) suggests that gemifloxacin is an excellent lead for the development of novel dual antidiabetic inhibitors against DPP IV and GSK-3beta.	Gemifloxacin	14-26	glycogen synthase kinase 3 beta	Homo sapiens	92-122
18989859-9	2008	The fact that gemifloxacin was recently reported to potently inhibit the prodiabetic target glycogen synthase kinase 3beta (GSK-3beta) suggests that gemifloxacin is an excellent lead for the development of novel dual antidiabetic inhibitors against DPP IV and GSK-3beta.	Gemifloxacin	14-26	glycogen synthase kinase 3 beta	Homo sapiens	124-133
18989859-9	2008	The fact that gemifloxacin was recently reported to potently inhibit the prodiabetic target glycogen synthase kinase 3beta (GSK-3beta) suggests that gemifloxacin is an excellent lead for the development of novel dual antidiabetic inhibitors against DPP IV and GSK-3beta.	Gemifloxacin	14-26	glycogen synthase kinase 3 beta	Homo sapiens	260-269
18989859-9	2008	The fact that gemifloxacin was recently reported to potently inhibit the prodiabetic target glycogen synthase kinase 3beta (GSK-3beta) suggests that gemifloxacin is an excellent lead for the development of novel dual antidiabetic inhibitors against DPP IV and GSK-3beta.	Gemifloxacin	149-161	glycogen synthase kinase 3 beta	Homo sapiens	92-122
18989859-9	2008	The fact that gemifloxacin was recently reported to potently inhibit the prodiabetic target glycogen synthase kinase 3beta (GSK-3beta) suggests that gemifloxacin is an excellent lead for the development of novel dual antidiabetic inhibitors against DPP IV and GSK-3beta.	Gemifloxacin	149-161	glycogen synthase kinase 3 beta	Homo sapiens	124-133
18989859-9	2008	The fact that gemifloxacin was recently reported to potently inhibit the prodiabetic target glycogen synthase kinase 3beta (GSK-3beta) suggests that gemifloxacin is an excellent lead for the development of novel dual antidiabetic inhibitors against DPP IV and GSK-3beta.	Gemifloxacin	149-161	glycogen synthase kinase 3 beta	Homo sapiens	260-269
18835709-2	2008	Modification of the hinge-binding amine or the C(2)- and C(6)-substitutions on the pyrazolopyridazine core provided potent inhibitors of CDK4 and demonstrated enzyme selectivity against VEGFR-2 and GSK3beta.	pyrazolopyridazine	83-101	glycogen synthase kinase 3 beta	Homo sapiens	198-206
18765729-3	2008	Using a panel of small-molecule inhibitors of mammalian kinases, we found that inhibitors of glycogen synthase kinase 3 beta (GSK-3beta) protected cells from ET-induced changes in the cell cycle.	et	158-160	glycogen synthase kinase 3 beta	Homo sapiens	93-124
18765729-3	2008	Using a panel of small-molecule inhibitors of mammalian kinases, we found that inhibitors of glycogen synthase kinase 3 beta (GSK-3beta) protected cells from ET-induced changes in the cell cycle.	et	158-160	glycogen synthase kinase 3 beta	Homo sapiens	126-135
18765729-6	2008	To investigate the outcome of this event, we examined the cellular location and activation state of beta-catenin, a critical substrate of GSK-3beta, and found that the protein was inactivated within the nucleus following intoxication with ET.	et	239-241	glycogen synthase kinase 3 beta	Homo sapiens	138-147
18602000-5	2008	Exposure of the murine melanoma cell line B16 and normal human melanocytes to GSK3beta specific inhibitors (SB216763, SB415286, BIO, and LiCl) resulted in a dose-dependent accumulation of beta-catenin.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	118-126	glycogen synthase kinase 3 beta	Homo sapiens	78-86
18655171-12	2008	Inhibiting protein tyrosine kinase Pyk2, an upstream regulator of GSK-3beta, caused inhibition on IFN-gamma/LPS-induced GSK-3beta phosphorylation at tyrosine 216 and iNOS/NO biosynthesis.	Tyrosine	19-27	glycogen synthase kinase 3 beta	Homo sapiens	66-75
18655171-12	2008	Inhibiting protein tyrosine kinase Pyk2, an upstream regulator of GSK-3beta, caused inhibition on IFN-gamma/LPS-induced GSK-3beta phosphorylation at tyrosine 216 and iNOS/NO biosynthesis.	Tyrosine	19-27	glycogen synthase kinase 3 beta	Homo sapiens	120-129
18687691-0	2008	Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells.	Isoflavones	59-69	glycogen synthase kinase 3 beta	Homo sapiens	25-34
18687691-6	2008	We found that isoflavone inhibited the phosphorylation of Akt and FOXO3a, regulated the phosphorylation of Src, and increased the expression of GSK-3beta, leading to the down-regulation of AR and its target gene PSA.	Isoflavones	14-24	glycogen synthase kinase 3 beta	Homo sapiens	144-153
18687691-9	2008	These results suggest that isoflavone-induced inhibition of cell proliferation and induction of apoptosis are partly mediated through the regulation of the Akt/FOXO3a/GSK-3beta/AR signaling network.	Isoflavones	27-37	glycogen synthase kinase 3 beta	Homo sapiens	167-176
19087546-8	2008	Western blot assay showed the changes in expression levels of phosphorylated AKT and GSK-3beta, which were decreased significantly after paclitaxel and bortezomib combination treatment [(3.2 +/- 0.8)%, (19.3 +/- 0.4)%; P &lt; 0.05].	Paclitaxel	137-147	glycogen synthase kinase 3 beta	Homo sapiens	85-94
18818515-6	2008	Cyclin D1 proteolysis requires phosphorylation by GSK3beta at Thr-286; additional work recently established that p286-D1 is a substrate for the SCF(Fbx4/alphaB-crystallin) E3 ligase.	Threonine	62-65	glycogen synthase kinase 3 beta	Homo sapiens	50-58
18615589-2	2008	In the present study, we show that inhibition of glycogen synthase kinase-3beta (GSK-3beta) by lithium chloride (LiCl) elicited a stimulatory effect on DeltaNp63 promoter activity in HEK 293T cells.	Lithium Chloride	95-111	glycogen synthase kinase 3 beta	Homo sapiens	49-79
18615589-2	2008	In the present study, we show that inhibition of glycogen synthase kinase-3beta (GSK-3beta) by lithium chloride (LiCl) elicited a stimulatory effect on DeltaNp63 promoter activity in HEK 293T cells.	Lithium Chloride	95-111	glycogen synthase kinase 3 beta	Homo sapiens	81-90
18615589-2	2008	In the present study, we show that inhibition of glycogen synthase kinase-3beta (GSK-3beta) by lithium chloride (LiCl) elicited a stimulatory effect on DeltaNp63 promoter activity in HEK 293T cells.	Lithium Chloride	113-117	glycogen synthase kinase 3 beta	Homo sapiens	49-79
18615589-2	2008	In the present study, we show that inhibition of glycogen synthase kinase-3beta (GSK-3beta) by lithium chloride (LiCl) elicited a stimulatory effect on DeltaNp63 promoter activity in HEK 293T cells.	Lithium Chloride	113-117	glycogen synthase kinase 3 beta	Homo sapiens	81-90
18615589-4	2008	The effect of GSK-3beta on DeltaNp63 expression was further confirmed by the use of two highly specific GSK-3beta inhibitors, SB216763 and SB415286.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	139-147	glycogen synthase kinase 3 beta	Homo sapiens	14-23
18582478-11	2008	Valproic acid, an antiepileptic drug with mood-stabilizing properties, up-regulated phospho-GSK-3beta (Ser9), beta-catenin and PIMT levels similarly to lithium.	Valproic Acid	0-13	glycogen synthase kinase 3 beta	Homo sapiens	92-101
18500637-4	2008	OBJECTIVE: To analyze GSK3beta genetic variants for association with schizophrenia and clozapine response.	Clozapine	87-96	glycogen synthase kinase 3 beta	Homo sapiens	22-30
18500637-5	2008	MATERIALS AND METHODS: We examined GSK3beta markers in 185 matched case-control subjects, 85 small nuclear families, and 150 schizophrenia patients treated with clozapine for 6 months.	Clozapine	161-170	glycogen synthase kinase 3 beta	Homo sapiens	35-43
19087546-8	2008	Western blot assay showed the changes in expression levels of phosphorylated AKT and GSK-3beta, which were decreased significantly after paclitaxel and bortezomib combination treatment [(3.2 +/- 0.8)%, (19.3 +/- 0.4)%; P &lt; 0.05].	Bortezomib	152-162	glycogen synthase kinase 3 beta	Homo sapiens	85-94
18769147-7	2008	Notably, rapamycin downregulated GSK-3beta Ser9 phosphorylation with concurrent nuclear export of cyclin D1 only in MCL cells in which GSK-3beta is under the control of mTOR.	Sirolimus	9-18	glycogen synthase kinase 3 beta	Homo sapiens	33-42
18769147-7	2008	Notably, rapamycin downregulated GSK-3beta Ser9 phosphorylation with concurrent nuclear export of cyclin D1 only in MCL cells in which GSK-3beta is under the control of mTOR.	Sirolimus	9-18	glycogen synthase kinase 3 beta	Homo sapiens	135-144
18478238-3	2008	Since ethanol inhibits PI3 Kinase-Akt and increases GSK-3beta activity in brain, we examined the effects of ethanol and GSK-3beta on AAH expression and directional motility in neuronal cells.	Ethanol	6-13	glycogen synthase kinase 3 beta	Homo sapiens	52-61
18462865-4	2008	Although enzastaurin independently produced a dose-dependent inhibition of cellular proliferation and decreased cell viability in each of the glioma cell lines examined, and partially down-regulated Akt and GSK3beta phosphorylation, median effective concentrations were at the upper limits of, or above, the clinically achievable range in all cell lines tested.	enzastaurin	9-20	glycogen synthase kinase 3 beta	Homo sapiens	207-215
18728666-6	2008	Enzastaurin reduced both phosphoCdc25C, resulting in G2/M checkpoint abrogation and apoptosis induction in pemetrexed-damaged cells, and GSK3 beta and Akt phosphorylation, which was additionally reduced by drug combination (-58% in A549).	enzastaurin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	137-146
18478238-7	2008	Further analysis revealed that: (1) AAH protein could be phosphorylated by GSK-3beta; (2) high levels of GSK-3beta activity decreased AAH protein; (3) inhibition of GSK-3beta and/or global Caspases increased AAH protein; (4) AAH protein was relatively more phosphorylated in ethanol-treated compared with control cells; and (5) chemical inhibition of GSK-3beta and/or global Caspases partially rescued ethanol-impaired AAH protein expression and motility.	Ethanol	275-282	glycogen synthase kinase 3 beta	Homo sapiens	105-114
18764945-2	2008	Following the G1/S transition, cyclin D1 activation is antagonized by GSK3beta-dependent threonine-286 (Thr-286) phosphorylation, triggering nuclear export and subsequent cytoplasmic degradation mediated by the SCFFbx4-alphaBcrystallin E3 ubiquitin ligase.	Threonine	89-98	glycogen synthase kinase 3 beta	Homo sapiens	70-78
18764945-2	2008	Following the G1/S transition, cyclin D1 activation is antagonized by GSK3beta-dependent threonine-286 (Thr-286) phosphorylation, triggering nuclear export and subsequent cytoplasmic degradation mediated by the SCFFbx4-alphaBcrystallin E3 ubiquitin ligase.	Threonine	104-107	glycogen synthase kinase 3 beta	Homo sapiens	70-78
18650261-5	2008	Conversely, expression of a constitutively active form of GSK-3beta resulted in at least a twofold decrease in GLUT1 expression and glucose uptake.	Glucose	132-139	glycogen synthase kinase 3 beta	Homo sapiens	58-67
18478238-7	2008	Further analysis revealed that: (1) AAH protein could be phosphorylated by GSK-3beta; (2) high levels of GSK-3beta activity decreased AAH protein; (3) inhibition of GSK-3beta and/or global Caspases increased AAH protein; (4) AAH protein was relatively more phosphorylated in ethanol-treated compared with control cells; and (5) chemical inhibition of GSK-3beta and/or global Caspases partially rescued ethanol-impaired AAH protein expression and motility.	Ethanol	275-282	glycogen synthase kinase 3 beta	Homo sapiens	105-114
18478238-7	2008	Further analysis revealed that: (1) AAH protein could be phosphorylated by GSK-3beta; (2) high levels of GSK-3beta activity decreased AAH protein; (3) inhibition of GSK-3beta and/or global Caspases increased AAH protein; (4) AAH protein was relatively more phosphorylated in ethanol-treated compared with control cells; and (5) chemical inhibition of GSK-3beta and/or global Caspases partially rescued ethanol-impaired AAH protein expression and motility.	Ethanol	275-282	glycogen synthase kinase 3 beta	Homo sapiens	105-114
18478238-7	2008	Further analysis revealed that: (1) AAH protein could be phosphorylated by GSK-3beta; (2) high levels of GSK-3beta activity decreased AAH protein; (3) inhibition of GSK-3beta and/or global Caspases increased AAH protein; (4) AAH protein was relatively more phosphorylated in ethanol-treated compared with control cells; and (5) chemical inhibition of GSK-3beta and/or global Caspases partially rescued ethanol-impaired AAH protein expression and motility.	Ethanol	402-409	glycogen synthase kinase 3 beta	Homo sapiens	105-114
18478238-7	2008	Further analysis revealed that: (1) AAH protein could be phosphorylated by GSK-3beta; (2) high levels of GSK-3beta activity decreased AAH protein; (3) inhibition of GSK-3beta and/or global Caspases increased AAH protein; (4) AAH protein was relatively more phosphorylated in ethanol-treated compared with control cells; and (5) chemical inhibition of GSK-3beta and/or global Caspases partially rescued ethanol-impaired AAH protein expression and motility.	Ethanol	402-409	glycogen synthase kinase 3 beta	Homo sapiens	105-114
18478238-7	2008	Further analysis revealed that: (1) AAH protein could be phosphorylated by GSK-3beta; (2) high levels of GSK-3beta activity decreased AAH protein; (3) inhibition of GSK-3beta and/or global Caspases increased AAH protein; (4) AAH protein was relatively more phosphorylated in ethanol-treated compared with control cells; and (5) chemical inhibition of GSK-3beta and/or global Caspases partially rescued ethanol-impaired AAH protein expression and motility.	Ethanol	402-409	glycogen synthase kinase 3 beta	Homo sapiens	105-114
18478238-10	2008	Therapeutic strategies to rectify CNS developmental abnormalities in FASD should target factors underlying the ethanol-associated increases in GSK-3beta and Caspase activation, e.g. IGF resistance and increased oxidative stress.	Ethanol	111-118	glycogen synthase kinase 3 beta	Homo sapiens	143-152
18577697-4	2008	The phosphorylation of PKB Ser(473) and p70(S6k) Thr(389) increased concomitantly with insulin, but whereas raising insulin to 30 mU/l increased the phosphorylation of mTOR Ser(2448), 4E-BP1 Thr(37/46), or GSK3beta Ser(9) and decreased that of eEF2 Thr(56), higher insulin doses to 72 and 167 mU/l did not augment these latter responses.	Serine	27-30	glycogen synthase kinase 3 beta	Homo sapiens	206-214
18786229-4	2008	Net GSK3beta activity is regulated by inhibitory phosphorylation of its serine 9 residue, and this occurred in CRAD.	Serine	72-78	glycogen synthase kinase 3 beta	Homo sapiens	4-12
18660440-3	2008	The effect of zinc on GSK-3beta activity was blocked by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY-294002 but not by the mammalian target of rapamycin (mTOR) inhibitor rapamycin or the PKC inhibitor chelerythrine, implying that PI3K but not mTOR or PKC accounts for the action of zinc.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	107-116	glycogen synthase kinase 3 beta	Homo sapiens	22-31
18660440-3	2008	The effect of zinc on GSK-3beta activity was blocked by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY-294002 but not by the mammalian target of rapamycin (mTOR) inhibitor rapamycin or the PKC inhibitor chelerythrine, implying that PI3K but not mTOR or PKC accounts for the action of zinc.	chelerythrine	210-223	glycogen synthase kinase 3 beta	Homo sapiens	22-31
18395973-9	2008	Perifosine-triggered GSK-3beta activation in PC-3 and LNCaP cells resulted in the expression of GSK-3beta-related differentiation markers.	perifosine	0-10	glycogen synthase kinase 3 beta	Homo sapiens	21-30
18972237-7	2008	The authors showed that LiCl mimicked the active canonical Wnt/beta-catenin signaling by glycogen synthase kinase-3beta (GSK-3beta) inactivation and accumulation of the effector protein beta-catenin into the nucleus.	Lithium Chloride	24-28	glycogen synthase kinase 3 beta	Homo sapiens	89-119
18972237-7	2008	The authors showed that LiCl mimicked the active canonical Wnt/beta-catenin signaling by glycogen synthase kinase-3beta (GSK-3beta) inactivation and accumulation of the effector protein beta-catenin into the nucleus.	Lithium Chloride	24-28	glycogen synthase kinase 3 beta	Homo sapiens	121-130
18546270-6	2008	Preincubation of BsB8 cells with fenofibrate attenuated IGF-I-induced IRS-1, Akt, ERKs and GSK3beta phosphorylation, and inhibited clonogenic growth.	Fenofibrate	33-44	glycogen synthase kinase 3 beta	Homo sapiens	91-99
18602896-8	2008	In addition, the expression levels of glycogen synthase kinase-3 beta (GSK-3beta), beta-catenin, and poly(ADP-ribose)polymerase (PARP), known to control the level and activity of NF-kappaB, were down-regulated upon treatment with CF502.	CF 502	230-235	glycogen synthase kinase 3 beta	Homo sapiens	38-69
18602896-8	2008	In addition, the expression levels of glycogen synthase kinase-3 beta (GSK-3beta), beta-catenin, and poly(ADP-ribose)polymerase (PARP), known to control the level and activity of NF-kappaB, were down-regulated upon treatment with CF502.	CF 502	230-235	glycogen synthase kinase 3 beta	Homo sapiens	71-80
18757413-0	2008	Glycogen synthase kinase 3beta regulates cell death induced by synthetic triterpenoids.	triterpenoids	73-86	glycogen synthase kinase 3 beta	Homo sapiens	0-30
18757413-5	2008	Interestingly, CDDO-Me induced inactivating phosphorylation at Ser(9) of glycogen synthase kinase 3beta (GSK3beta), a multifunctional kinase that mediates essential events promoting prostate cancer development and acquisition of androgen independence.	bardoxolone methyl	15-22	glycogen synthase kinase 3 beta	Homo sapiens	73-103
18757413-5	2008	Interestingly, CDDO-Me induced inactivating phosphorylation at Ser(9) of glycogen synthase kinase 3beta (GSK3beta), a multifunctional kinase that mediates essential events promoting prostate cancer development and acquisition of androgen independence.	bardoxolone methyl	15-22	glycogen synthase kinase 3 beta	Homo sapiens	105-113
18757413-5	2008	Interestingly, CDDO-Me induced inactivating phosphorylation at Ser(9) of glycogen synthase kinase 3beta (GSK3beta), a multifunctional kinase that mediates essential events promoting prostate cancer development and acquisition of androgen independence.	Serine	63-66	glycogen synthase kinase 3 beta	Homo sapiens	73-103
18757413-5	2008	Interestingly, CDDO-Me induced inactivating phosphorylation at Ser(9) of glycogen synthase kinase 3beta (GSK3beta), a multifunctional kinase that mediates essential events promoting prostate cancer development and acquisition of androgen independence.	Serine	63-66	glycogen synthase kinase 3 beta	Homo sapiens	105-113
18757413-7	2008	These data suggest that modulation of GSK3beta activation is involved in the cell death pathway engaged by CDDO-Me in prostate cancer cells.	bardoxolone methyl	107-114	glycogen synthase kinase 3 beta	Homo sapiens	38-46
18395973-9	2008	Perifosine-triggered GSK-3beta activation in PC-3 and LNCaP cells resulted in the expression of GSK-3beta-related differentiation markers.	perifosine	0-10	glycogen synthase kinase 3 beta	Homo sapiens	96-105
18395973-11	2008	The use of the GSK-3beta inhibitor lithium chloride indicated that GSK-3beta partially protects prostate cancer cells from the cytotoxic effects of perifosine.	Lithium Chloride	35-51	glycogen synthase kinase 3 beta	Homo sapiens	15-24
18395973-11	2008	The use of the GSK-3beta inhibitor lithium chloride indicated that GSK-3beta partially protects prostate cancer cells from the cytotoxic effects of perifosine.	Lithium Chloride	35-51	glycogen synthase kinase 3 beta	Homo sapiens	67-76
18395973-11	2008	The use of the GSK-3beta inhibitor lithium chloride indicated that GSK-3beta partially protects prostate cancer cells from the cytotoxic effects of perifosine.	perifosine	148-158	glycogen synthase kinase 3 beta	Homo sapiens	15-24
18395973-11	2008	The use of the GSK-3beta inhibitor lithium chloride indicated that GSK-3beta partially protects prostate cancer cells from the cytotoxic effects of perifosine.	perifosine	148-158	glycogen synthase kinase 3 beta	Homo sapiens	67-76
18395973-12	2008	Together, these findings indicate that perifosine induces GSK-3beta-related differentiation and caspase-independent cell death in prostate cancer PC-3 cells.	perifosine	39-49	glycogen synthase kinase 3 beta	Homo sapiens	58-67
18183482-6	2008	Several apoptosis-associated signaling factors, GSK-3beta, ERK1/2, and Rho GTPases, were observed to be activated in response to potassium deprivation and the activation/dephosphorylation of GSK-3beta was suppressed by LINGO-1-Fc pretreatment compared with control group.	Potassium	129-138	glycogen synthase kinase 3 beta	Homo sapiens	48-57
18183482-6	2008	Several apoptosis-associated signaling factors, GSK-3beta, ERK1/2, and Rho GTPases, were observed to be activated in response to potassium deprivation and the activation/dephosphorylation of GSK-3beta was suppressed by LINGO-1-Fc pretreatment compared with control group.	Potassium	129-138	glycogen synthase kinase 3 beta	Homo sapiens	191-200
18348280-6	2008	Glycogen synthase kinase-3beta (GSK-3beta) phosphorylates Ser/Thr residues located at the fourth position ahead of the pre-phosphorylated Ser/Thr residues, and inhibitors of GSK-3beta reduce the phosphorylation at Thr182.	Serine	58-61	glycogen synthase kinase 3 beta	Homo sapiens	0-30
18348280-6	2008	Glycogen synthase kinase-3beta (GSK-3beta) phosphorylates Ser/Thr residues located at the fourth position ahead of the pre-phosphorylated Ser/Thr residues, and inhibitors of GSK-3beta reduce the phosphorylation at Thr182.	Serine	58-61	glycogen synthase kinase 3 beta	Homo sapiens	32-41
18348280-6	2008	Glycogen synthase kinase-3beta (GSK-3beta) phosphorylates Ser/Thr residues located at the fourth position ahead of the pre-phosphorylated Ser/Thr residues, and inhibitors of GSK-3beta reduce the phosphorylation at Thr182.	Threonine	62-65	glycogen synthase kinase 3 beta	Homo sapiens	0-30
18348280-6	2008	Glycogen synthase kinase-3beta (GSK-3beta) phosphorylates Ser/Thr residues located at the fourth position ahead of the pre-phosphorylated Ser/Thr residues, and inhibitors of GSK-3beta reduce the phosphorylation at Thr182.	Threonine	62-65	glycogen synthase kinase 3 beta	Homo sapiens	32-41
18348280-6	2008	Glycogen synthase kinase-3beta (GSK-3beta) phosphorylates Ser/Thr residues located at the fourth position ahead of the pre-phosphorylated Ser/Thr residues, and inhibitors of GSK-3beta reduce the phosphorylation at Thr182.	Threonine	62-65	glycogen synthase kinase 3 beta	Homo sapiens	174-183
18348280-6	2008	Glycogen synthase kinase-3beta (GSK-3beta) phosphorylates Ser/Thr residues located at the fourth position ahead of the pre-phosphorylated Ser/Thr residues, and inhibitors of GSK-3beta reduce the phosphorylation at Thr182.	Serine	138-141	glycogen synthase kinase 3 beta	Homo sapiens	0-30
18348280-6	2008	Glycogen synthase kinase-3beta (GSK-3beta) phosphorylates Ser/Thr residues located at the fourth position ahead of the pre-phosphorylated Ser/Thr residues, and inhibitors of GSK-3beta reduce the phosphorylation at Thr182.	Serine	138-141	glycogen synthase kinase 3 beta	Homo sapiens	32-41
18348280-6	2008	Glycogen synthase kinase-3beta (GSK-3beta) phosphorylates Ser/Thr residues located at the fourth position ahead of the pre-phosphorylated Ser/Thr residues, and inhibitors of GSK-3beta reduce the phosphorylation at Thr182.	Threonine	142-145	glycogen synthase kinase 3 beta	Homo sapiens	0-30
18348280-6	2008	Glycogen synthase kinase-3beta (GSK-3beta) phosphorylates Ser/Thr residues located at the fourth position ahead of the pre-phosphorylated Ser/Thr residues, and inhibitors of GSK-3beta reduce the phosphorylation at Thr182.	Threonine	142-145	glycogen synthase kinase 3 beta	Homo sapiens	32-41
18547980-5	2008	Thus, our observations indicate that GSK 3beta binds to Fe65 through its (371)PPLA(374) motif and that this interaction regulates apoptosis and phosphorylation of Tyr 216 of GSK 3beta.	Tyrosine	163-166	glycogen synthase kinase 3 beta	Homo sapiens	174-183
18547980-2	2008	Here, we present evidence that human GSK 3beta is associated with Fe65, which has the characteristics of an adaptor protein, possessing a WW domain, and two phosphotyrosine interaction domains, PID1 and PID2.	Phosphotyrosine	157-172	glycogen synthase kinase 3 beta	Homo sapiens	37-46
18547980-4	2008	In addition, we detected co-localization of GSK 3beta and Fe65 by confocal microscopy, and this co-localization was disrupted by mutation of the putative WW domain binding motif of GSK 3beta.Finally, in transient transfection assays interaction of GSK 3 beta (wt) with Fe65 induced substantial cell apoptosis, whereas interaction with the GSK 3beta AALA mutant ((371)AALA(374)) did not, and we noted that phosphorylation of the Tyr 216 residue of the GSK 3beta AALA mutant was significantly reduced compared to that of GSK 3beta wild type.	Tyrosine	428-431	glycogen synthase kinase 3 beta	Homo sapiens	181-190
18547980-4	2008	In addition, we detected co-localization of GSK 3beta and Fe65 by confocal microscopy, and this co-localization was disrupted by mutation of the putative WW domain binding motif of GSK 3beta.Finally, in transient transfection assays interaction of GSK 3 beta (wt) with Fe65 induced substantial cell apoptosis, whereas interaction with the GSK 3beta AALA mutant ((371)AALA(374)) did not, and we noted that phosphorylation of the Tyr 216 residue of the GSK 3beta AALA mutant was significantly reduced compared to that of GSK 3beta wild type.	Tyrosine	428-431	glycogen synthase kinase 3 beta	Homo sapiens	181-190
18547980-4	2008	In addition, we detected co-localization of GSK 3beta and Fe65 by confocal microscopy, and this co-localization was disrupted by mutation of the putative WW domain binding motif of GSK 3beta.Finally, in transient transfection assays interaction of GSK 3 beta (wt) with Fe65 induced substantial cell apoptosis, whereas interaction with the GSK 3beta AALA mutant ((371)AALA(374)) did not, and we noted that phosphorylation of the Tyr 216 residue of the GSK 3beta AALA mutant was significantly reduced compared to that of GSK 3beta wild type.	Tyrosine	428-431	glycogen synthase kinase 3 beta	Homo sapiens	181-190
18391982-0	2008	Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3beta with p53.	Cisplatin	31-40	glycogen synthase kinase 3 beta	Homo sapiens	116-146
18547980-4	2008	In addition, we detected co-localization of GSK 3beta and Fe65 by confocal microscopy, and this co-localization was disrupted by mutation of the putative WW domain binding motif of GSK 3beta.Finally, in transient transfection assays interaction of GSK 3 beta (wt) with Fe65 induced substantial cell apoptosis, whereas interaction with the GSK 3beta AALA mutant ((371)AALA(374)) did not, and we noted that phosphorylation of the Tyr 216 residue of the GSK 3beta AALA mutant was significantly reduced compared to that of GSK 3beta wild type.	Tyrosine	428-431	glycogen synthase kinase 3 beta	Homo sapiens	181-190
18547980-5	2008	Thus, our observations indicate that GSK 3beta binds to Fe65 through its (371)PPLA(374) motif and that this interaction regulates apoptosis and phosphorylation of Tyr 216 of GSK 3beta.	Tyrosine	163-166	glycogen synthase kinase 3 beta	Homo sapiens	37-46
18391982-0	2008	Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3beta with p53.	triptolide	67-77	glycogen synthase kinase 3 beta	Homo sapiens	116-146
18391982-5	2008	We further demonstrated that the functional regulation of p53 by triptolide was mediated by an intranuclear association of p53 with glycogen synthase kinase-3beta (GSK3beta), which was inactivated by protein kinase C (PKC).	triptolide	65-75	glycogen synthase kinase 3 beta	Homo sapiens	132-162
18391982-5	2008	We further demonstrated that the functional regulation of p53 by triptolide was mediated by an intranuclear association of p53 with glycogen synthase kinase-3beta (GSK3beta), which was inactivated by protein kinase C (PKC).	triptolide	65-75	glycogen synthase kinase 3 beta	Homo sapiens	164-172
18632640-5	2008	Inhibition of GSK-3beta either by small molecules (SB216763 or SB415286) or by ectopic expression of kinase-inactive GSK-3beta before irradiation significantly attenuated radiation-induced apoptosis in hippocampal neurons.	SB 216763	51-59	glycogen synthase kinase 3 beta	Homo sapiens	14-23
18595720-2	2008	In this study, mono- and di-methylated quaternary carbolinium cations of manzamine A were synthesized and evaluated for their in vitro antimalarial and antimicrobial activity, cytotoxicity, and also their potential for glycogen synthase kinase (GSK-3beta) inhibition using molecular docking studies.	manzamine A	73-84	glycogen synthase kinase 3 beta	Homo sapiens	245-254
18665222-2	2008	In an earlier study, we found that serotonin (5-HT), acting through the 5-HT1A receptor subtype, promotes axonal transport of mitochondria in cultured hippocampal neurons by increasing Akt activity, and consequently decreasing glycogen synthase kinase (GSK3beta) activity.	Serotonin	35-44	glycogen synthase kinase 3 beta	Homo sapiens	253-261
18665222-5	2008	METHODOLOGY/PRINCIPAL FINDINGS: Here, we show that dopamine, like 5-HT, regulates mitochondrial motility in cultured hippocampal neurons through the Akt-GSK3beta signaling cascade.	Dopamine	51-59	glycogen synthase kinase 3 beta	Homo sapiens	153-161
18632640-5	2008	Inhibition of GSK-3beta either by small molecules (SB216763 or SB415286) or by ectopic expression of kinase-inactive GSK-3beta before irradiation significantly attenuated radiation-induced apoptosis in hippocampal neurons.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	63-71	glycogen synthase kinase 3 beta	Homo sapiens	14-23
18502415-2	2008	GSK-3 beta inhibitors inhibit apoptosis mediated by serum and potassium withdrawal (S/K withdrawal) and GSK-3 beta activation, as measured by beta-catenin degradation.	Potassium	62-71	glycogen synthase kinase 3 beta	Homo sapiens	0-10
18502415-4	2008	While the most specific GSK-3 beta inhibitor, SB-415286, demonstrated antioxidant effects, Li+ 10 mM did not.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	46-55	glycogen synthase kinase 3 beta	Homo sapiens	24-34
18502415-5	2008	These results indicate that lithium 10 mM and SB-415286 20 microM exert anti-apoptotic effects in cases of S/K withdrawal mediated by GSK-3 beta inhibition.	Lithium	28-35	glycogen synthase kinase 3 beta	Homo sapiens	134-144
18502415-5	2008	These results indicate that lithium 10 mM and SB-415286 20 microM exert anti-apoptotic effects in cases of S/K withdrawal mediated by GSK-3 beta inhibition.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	46-55	glycogen synthase kinase 3 beta	Homo sapiens	134-144
18437054-0	2008	Involvement of PI3K/AKT/GSK3beta pathway in tetrandrine-induced G1 arrest and apoptosis.	tetrandrine	44-55	glycogen synthase kinase 3 beta	Homo sapiens	24-32
18609681-2	2008	METHODS: Eca-109 cells were treated with lithium chloride, a highly selective inhibitor of glycogen synthase kinase 3beta (GSK-3beta), at different concentrations (2-30 mmol/L) and time points (0, 2, 4, 6 and 24 h).	Lithium Chloride	41-57	glycogen synthase kinase 3 beta	Homo sapiens	91-121
18609681-2	2008	METHODS: Eca-109 cells were treated with lithium chloride, a highly selective inhibitor of glycogen synthase kinase 3beta (GSK-3beta), at different concentrations (2-30 mmol/L) and time points (0, 2, 4, 6 and 24 h).	Lithium Chloride	41-57	glycogen synthase kinase 3 beta	Homo sapiens	123-132
18609681-8	2008	Western blotting showed that lithium inhibited GSK-3beta by Ser-9 phosphorylation and stabilized free beta-catenin in the cytoplasm.	Lithium	29-36	glycogen synthase kinase 3 beta	Homo sapiens	47-56
18609681-8	2008	Western blotting showed that lithium inhibited GSK-3beta by Ser-9 phosphorylation and stabilized free beta-catenin in the cytoplasm.	Serine	60-63	glycogen synthase kinase 3 beta	Homo sapiens	47-56
18495085-4	2008	In addition, the insulin stimulated phosphorylations in insulin receptor, Akt and GSK3beta were remarkably increased in the TSA-treated cells.	trichostatin A	124-127	glycogen synthase kinase 3 beta	Homo sapiens	82-90
18609681-11	2008	CONCLUSION: Lithium can inhibit the proliferation of human esophageal cancer cell line Eca-109 by inducing a G(2)/M cell cycle arrest, which is mainly mediated through the inhibition of lithium-sensitive molecule, GSK-3beta, and reduction of cyclin B1 expression.	Lithium	12-19	glycogen synthase kinase 3 beta	Homo sapiens	214-223
18318434-9	2008	Suppression of GSK-3beta activity using either a specific inhibitor or lithium chloride significantly reduced tau phosphorylation and partially rescued motor impairment.	Lithium Chloride	71-87	glycogen synthase kinase 3 beta	Homo sapiens	15-24
18508033-0	2008	GSK3beta and endoplasmic reticulum stress mediate rotenone-induced death of SK-N-MC neuroblastoma cells.	Rotenone	50-58	glycogen synthase kinase 3 beta	Homo sapiens	0-8
18508033-5	2008	We showed that rotenone activated GSK3beta by enhancing its phosphorylation at tyrosine 216 while inhibiting phosphorylation at serine 9.	Rotenone	15-23	glycogen synthase kinase 3 beta	Homo sapiens	34-42
18508033-5	2008	We showed that rotenone activated GSK3beta by enhancing its phosphorylation at tyrosine 216 while inhibiting phosphorylation at serine 9.	Tyrosine	79-87	glycogen synthase kinase 3 beta	Homo sapiens	34-42
18508033-5	2008	We showed that rotenone activated GSK3beta by enhancing its phosphorylation at tyrosine 216 while inhibiting phosphorylation at serine 9.	Serine	128-134	glycogen synthase kinase 3 beta	Homo sapiens	34-42
18508033-6	2008	Inhibitors of GSK3beta and dominant negative (kinase deficient) GSK3beta partially protected SK-N-MC cells against rotenone cytotoxicity.	Rotenone	115-123	glycogen synthase kinase 3 beta	Homo sapiens	14-22
18508033-6	2008	Inhibitors of GSK3beta and dominant negative (kinase deficient) GSK3beta partially protected SK-N-MC cells against rotenone cytotoxicity.	Rotenone	115-123	glycogen synthase kinase 3 beta	Homo sapiens	64-72
18508033-13	2008	Taken together, the results suggest that GSK3beta activation and ER stress contribute separately to rotenone cytotoxicity.	Rotenone	100-108	glycogen synthase kinase 3 beta	Homo sapiens	41-49
18437054-7	2008	These findings suggest that tetrandrine induces G(1) arrest and apoptosis through PI3K/AKT/GSK3beta pathway and identify GSK3beta as an important mediator in the processes.	tetrandrine	28-39	glycogen synthase kinase 3 beta	Homo sapiens	121-129
18437054-2	2008	In the present study, we investigated the role of PI3K/AKT/GSK3beta pathway in tetrandrine- induced G(1) arrest and apoptosis.	tetrandrine	79-90	glycogen synthase kinase 3 beta	Homo sapiens	59-67
18437054-3	2008	In HT-29 cells, tetrandrine induced dephosphorylation of AKT, activation and nuclear translocation of GSK3beta as well as upregulation of p27(kip1).	tetrandrine	16-27	glycogen synthase kinase 3 beta	Homo sapiens	102-110
18437054-4	2008	Activation of GSK3beta via AKT inhibitoion induced by tetrandrine resulted in enhanced phosphorylation and proteolysis of cyclin D(1), activation of caspase 3 and subsequent cleavage of PARP.	tetrandrine	54-65	glycogen synthase kinase 3 beta	Homo sapiens	14-22
18437054-5	2008	Selective GSK3beta inhibitiors and GSK3beta siRNA attenuated tetrandrine-induced G(1) arrest and apoptosis.	tetrandrine	61-72	glycogen synthase kinase 3 beta	Homo sapiens	35-43
18698164-0	2008	GSK-3beta is a critical mediator of tetrandrine induced cell cycle arrest and cytotoxicity.	tetrandrine	36-47	glycogen synthase kinase 3 beta	Homo sapiens	0-9
18437054-6	2008	Similar to tetrandrine, transfection of wild-type GSK3beta led to G(1) arrest and apoptosis via downregulation of cyclin D(1) and cleavage of PARP.	tetrandrine	11-22	glycogen synthase kinase 3 beta	Homo sapiens	50-58
18437054-7	2008	These findings suggest that tetrandrine induces G(1) arrest and apoptosis through PI3K/AKT/GSK3beta pathway and identify GSK3beta as an important mediator in the processes.	tetrandrine	28-39	glycogen synthase kinase 3 beta	Homo sapiens	91-99
18502121-1	2008	Synthesis, biological evaluation, and SAR dependencies for a series of novel aryl and heteroaryl substituted N-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamide inhibitors of GSK-3beta kinase are described.	n-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,4-oxadiazole-5-carboxamide	109-176	glycogen synthase kinase 3 beta	Homo sapiens	191-200
18407462-7	2008	Based on another finding indicating that Wnt5a upregulated PKA-mediated phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) at serine 9 that caused inactivation of GSK-3beta and subsequently resulted in activation of the beta-catenin pathway, we have speculated that the Wnt5a anti-apoptotic activity may be partially mediated by PKA-mediated phosphorylation of GSK-3beta and subsequent activation of the beta-catenin pathway.	Serine	137-143	glycogen synthase kinase 3 beta	Homo sapiens	91-121
18407462-7	2008	Based on another finding indicating that Wnt5a upregulated PKA-mediated phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) at serine 9 that caused inactivation of GSK-3beta and subsequently resulted in activation of the beta-catenin pathway, we have speculated that the Wnt5a anti-apoptotic activity may be partially mediated by PKA-mediated phosphorylation of GSK-3beta and subsequent activation of the beta-catenin pathway.	Serine	137-143	glycogen synthase kinase 3 beta	Homo sapiens	123-132
18407462-7	2008	Based on another finding indicating that Wnt5a upregulated PKA-mediated phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) at serine 9 that caused inactivation of GSK-3beta and subsequently resulted in activation of the beta-catenin pathway, we have speculated that the Wnt5a anti-apoptotic activity may be partially mediated by PKA-mediated phosphorylation of GSK-3beta and subsequent activation of the beta-catenin pathway.	Serine	137-143	glycogen synthase kinase 3 beta	Homo sapiens	174-183
18407462-7	2008	Based on another finding indicating that Wnt5a upregulated PKA-mediated phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) at serine 9 that caused inactivation of GSK-3beta and subsequently resulted in activation of the beta-catenin pathway, we have speculated that the Wnt5a anti-apoptotic activity may be partially mediated by PKA-mediated phosphorylation of GSK-3beta and subsequent activation of the beta-catenin pathway.	Serine	137-143	glycogen synthase kinase 3 beta	Homo sapiens	174-183
18553961-3	2008	Here we apply two different versions of the ASP methodology to three proteins, cytochrome P450cam, PcrA helicase, and glycogen synthase kinase 3beta (GSK3beta), and show that the method is capable of inducing significant conformational changes when compared to the X-ray crystal structures.	Aspartic Acid	44-47	glycogen synthase kinase 3 beta	Homo sapiens	118-148
18553961-3	2008	Here we apply two different versions of the ASP methodology to three proteins, cytochrome P450cam, PcrA helicase, and glycogen synthase kinase 3beta (GSK3beta), and show that the method is capable of inducing significant conformational changes when compared to the X-ray crystal structures.	Aspartic Acid	44-47	glycogen synthase kinase 3 beta	Homo sapiens	150-158
18375202-5	2008	These effects of desferrioxamine were accompanied by promoted phosphorylation of glycogen synthase kinase 3beta (GSK-3beta) and increased beta-catenin protein content, a direct GSK-3beta substrate.	Deferoxamine	17-32	glycogen synthase kinase 3 beta	Homo sapiens	81-111
20046351-6	2008	RESULTS: KCl-induced neuronal depolarization resulted in the transient dephosphorylation of AKT (Ser473) and GSK3beta (Ser9), followed by increased phosphorylation of the enzymes in SH-SY5Y cells.	Potassium Chloride	9-12	glycogen synthase kinase 3 beta	Homo sapiens	109-117
18000644-11	2008	CONCLUSIONS: mRNA expression levels of IL-8 and GSK-3beta correlate with antitumor activity of enzastaurin.	enzastaurin	95-106	glycogen synthase kinase 3 beta	Homo sapiens	48-57
18266928-6	2008	As a counterproof of the interaction of TRAIL with the Wnt pathway, the addition of the specific glycogen synthase kinase 3 beta inhibitor SB216763 resulted in rescue of a significant percent of cells from TRAIL-induced apoptosis.	SB 216763	139-147	glycogen synthase kinase 3 beta	Homo sapiens	97-128
18375202-5	2008	These effects of desferrioxamine were accompanied by promoted phosphorylation of glycogen synthase kinase 3beta (GSK-3beta) and increased beta-catenin protein content, a direct GSK-3beta substrate.	Deferoxamine	17-32	glycogen synthase kinase 3 beta	Homo sapiens	113-122
18375202-5	2008	These effects of desferrioxamine were accompanied by promoted phosphorylation of glycogen synthase kinase 3beta (GSK-3beta) and increased beta-catenin protein content, a direct GSK-3beta substrate.	Deferoxamine	17-32	glycogen synthase kinase 3 beta	Homo sapiens	177-186
18348127-1	2008	Glycogen synthase kinase-3beta (GSK-3beta) is involved in the hyperphosphorylation of previously phosphorylated (primed) substrates, and is currently assayed using an approach based on the incorporation of gamma-(32)P-radiolabelled isotopes into substrate peptides.	gamma-(32)p	206-217	glycogen synthase kinase 3 beta	Homo sapiens	0-30
18348127-1	2008	Glycogen synthase kinase-3beta (GSK-3beta) is involved in the hyperphosphorylation of previously phosphorylated (primed) substrates, and is currently assayed using an approach based on the incorporation of gamma-(32)P-radiolabelled isotopes into substrate peptides.	gamma-(32)p	206-217	glycogen synthase kinase 3 beta	Homo sapiens	32-41
18348127-4	2008	Optimum reaction conditions (level of Mg(2+), buffer type, ionic strength, pH, enzyme concentration, and reaction time) were established to both maintain the activity of GSK-3beta and allow for substrate and product quantification through ESI/MS/MS.	Magnesium	38-40	glycogen synthase kinase 3 beta	Homo sapiens	170-179
18262389-8	2008	Inhibiting Akt activity with the phosphoinositide-3-kinase inhibitor LY294002 or Akt inhibitor X suppressed HGF-induced phosphorylation of GSK-3beta, increased MAP2 phosphorylation, and blocked the ability of HGF to enhance dendritic length.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	69-77	glycogen synthase kinase 3 beta	Homo sapiens	139-148
18324764-0	2008	Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.	Cimetidine	174-184	glycogen synthase kinase 3 beta	Homo sapiens	117-147
18408738-4	2008	Moreover, treatment with NaBT increased the nuclear, but not the cytosolic, expression and activity of GSK-3beta.	NABT	25-29	glycogen synthase kinase 3 beta	Homo sapiens	103-112
18395713-4	2008	We here demonstrate that one of the main control molecules in the Wnt pathway, GSK-3 beta, is phosphorylated at the negative regulatory site ser-9 after treating the cells with PGE2.	Serine	141-144	glycogen synthase kinase 3 beta	Homo sapiens	79-89
18395713-4	2008	We here demonstrate that one of the main control molecules in the Wnt pathway, GSK-3 beta, is phosphorylated at the negative regulatory site ser-9 after treating the cells with PGE2.	Dinoprostone	177-181	glycogen synthase kinase 3 beta	Homo sapiens	79-89
17638069-5	2008	The decrease in cyclin D1 protein expression accompanies a dramatic decline in nuclear but not membranous beta-catenin expression and activation of glycogen synthase kinase-3-beta (GSK3beta) caused by inhibition of its serine-9 phosphorylation.	Serine	219-225	glycogen synthase kinase 3 beta	Homo sapiens	181-189
17990294-8	2008	Western blotting demonstrated that GSK-3beta was rapidly phosphorylated at Ser(9) on treatment with PTH or forskolin, leading to its inactivation.	Serine	75-78	glycogen synthase kinase 3 beta	Homo sapiens	35-44
17990294-8	2008	Western blotting demonstrated that GSK-3beta was rapidly phosphorylated at Ser(9) on treatment with PTH or forskolin, leading to its inactivation.	Colforsin	107-116	glycogen synthase kinase 3 beta	Homo sapiens	35-44
17990294-9	2008	Moreover, overexpression of a constitutively active mutant of GSK-3beta abolished the TCF-dependent transactivation induced by forskolin.	Colforsin	127-136	glycogen synthase kinase 3 beta	Homo sapiens	62-71
18252807-7	2008	Transfection of constitutive active mutant S6K1 eliminated the protective effect of oltipraz on GSK3beta phosphorylation, indicating that oltipraz restores insulin signaling by inhibiting S6K1 activation.	oltipraz	84-92	glycogen synthase kinase 3 beta	Homo sapiens	96-104
18252807-7	2008	Transfection of constitutive active mutant S6K1 eliminated the protective effect of oltipraz on GSK3beta phosphorylation, indicating that oltipraz restores insulin signaling by inhibiting S6K1 activation.	oltipraz	138-146	glycogen synthase kinase 3 beta	Homo sapiens	96-104
18252708-7	2008	Infection of human bronchial smooth muscle cells with pMSCV GSK-3beta-A9, a retroviral vector encoding a constitutively active, nonphosphorylatable GSK-3beta, blocked protein synthesis and alpha-actin expression induced by LiCl, SB216763, and CT-1 but not TGF-beta.	Lithium Chloride	223-227	glycogen synthase kinase 3 beta	Homo sapiens	60-69
18324764-0	2008	Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.	Hydroxychloroquine	186-204	glycogen synthase kinase 3 beta	Homo sapiens	117-147
18324764-0	2008	Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.	Gemifloxacin	210-222	glycogen synthase kinase 3 beta	Homo sapiens	117-147
18324764-4	2008	The validity of the QSAR equation and the associated pharmacophores was established by the identification of three nanomolar GSK-3beta inhibitors retrieved from our in-house-built structural database of established drugs, namely, hydroxychloroquine, cimetidine, and gemifloxacin.	Cimetidine	250-260	glycogen synthase kinase 3 beta	Homo sapiens	125-134
18324764-4	2008	The validity of the QSAR equation and the associated pharmacophores was established by the identification of three nanomolar GSK-3beta inhibitors retrieved from our in-house-built structural database of established drugs, namely, hydroxychloroquine, cimetidine, and gemifloxacin.	Gemifloxacin	266-278	glycogen synthase kinase 3 beta	Homo sapiens	125-134
18263590-4	2008	Using a human peripheral primitive neuroectodermal tumor cell line, SK-N-MC, we demonstrated FGF2 stimulated phosphorylation of ERK1 and ERK2 (pERK1/2) and GSK3beta (pGSK3beta(Tyr-216)), all of which were primarily retained in the cytoplasm.	sk-n-mc	68-75	glycogen synthase kinase 3 beta	Homo sapiens	156-164
18263590-4	2008	Using a human peripheral primitive neuroectodermal tumor cell line, SK-N-MC, we demonstrated FGF2 stimulated phosphorylation of ERK1 and ERK2 (pERK1/2) and GSK3beta (pGSK3beta(Tyr-216)), all of which were primarily retained in the cytoplasm.	pgsk3beta	166-175	glycogen synthase kinase 3 beta	Homo sapiens	156-164
18263590-8	2008	Similarly, expression of a kinase-deficient (K85R) GSK3beta or GSK3beta-small interfering RNA inhibited FGF2-regulated ERK/pGSK3beta(Tyr-216) association and translocated pERK to the nucleus.	pgsk3beta	123-132	glycogen synthase kinase 3 beta	Homo sapiens	51-59
18263590-8	2008	Similarly, expression of a kinase-deficient (K85R) GSK3beta or GSK3beta-small interfering RNA inhibited FGF2-regulated ERK/pGSK3beta(Tyr-216) association and translocated pERK to the nucleus.	pgsk3beta	123-132	glycogen synthase kinase 3 beta	Homo sapiens	63-71
18263590-7	2008	On the other hand, inhibitors of GSK3beta, but not PD98059 decreased ERK/pGSK3beta(Tyr-216) association and caused a nuclear translocation of pERK1/2.	pgsk3beta	73-82	glycogen synthase kinase 3 beta	Homo sapiens	33-41
18263590-8	2008	Similarly, expression of a kinase-deficient (K85R) GSK3beta or GSK3beta-small interfering RNA inhibited FGF2-regulated ERK/pGSK3beta(Tyr-216) association and translocated pERK to the nucleus.	Tyrosine	133-136	glycogen synthase kinase 3 beta	Homo sapiens	51-59
18263590-7	2008	On the other hand, inhibitors of GSK3beta, but not PD98059 decreased ERK/pGSK3beta(Tyr-216) association and caused a nuclear translocation of pERK1/2.	Tyrosine	83-86	glycogen synthase kinase 3 beta	Homo sapiens	33-41
18263590-8	2008	Similarly, expression of a kinase-deficient (K85R) GSK3beta or GSK3beta-small interfering RNA inhibited FGF2-regulated ERK/pGSK3beta(Tyr-216) association and translocated pERK to the nucleus.	Tyrosine	133-136	glycogen synthase kinase 3 beta	Homo sapiens	63-71
18243662-4	2008	Similarly, lithium chloride (LiCl) was found to increase the phosphorylation of GSK-3beta independently of ATM.	Lithium Chloride	11-27	glycogen synthase kinase 3 beta	Homo sapiens	80-89
18272817-7	2008	Similarly, A23187 (0.4 microM for 4 h) caused nuclear accumulation of NFAT and increased phosphorylation (i.e., inactivation) of GSK-3beta, whereas cotreatment with L-NAME or ODQ inhibited these responses.	Calcimycin	11-17	glycogen synthase kinase 3 beta	Homo sapiens	129-138
18272817-8	2008	Finally, the NO donor 3-(2-hydroxy-2-nitroso-1-propylhydrazino)-1-propanamine (PAPA-NO; 1 microM for 1 h) increased phosphorylation of GSK-3beta in a manner dependent on guanylate cyclase activity.	PAPA NONOate	22-77	glycogen synthase kinase 3 beta	Homo sapiens	135-144
18272817-8	2008	Finally, the NO donor 3-(2-hydroxy-2-nitroso-1-propylhydrazino)-1-propanamine (PAPA-NO; 1 microM for 1 h) increased phosphorylation of GSK-3beta in a manner dependent on guanylate cyclase activity.	PAPA-NO	79-86	glycogen synthase kinase 3 beta	Homo sapiens	135-144
18272817-9	2008	We conclude that NOS activity mediates calcium-induced phosphorylation of GSK-3beta and activation of NFAT-dependent transcription in myotubes.	Calcium	39-46	glycogen synthase kinase 3 beta	Homo sapiens	74-83
18283040-11	2008	In this study, lycopene, in dietary concentrations, reversed DHT effects of 6S cells on NPE cell death, decreased 6S cell IGF-I production by reducing AR and beta-catenin nuclear localization and inhibited IGF-I-stimulated NPE and PREC growth, perhaps by attenuating IGF-I"s effects on serine phosphorylation of Akt and GSK3beta and tyrosine phosphorylation of GSK3.	Lycopene	15-23	glycogen synthase kinase 3 beta	Homo sapiens	320-328
18243662-4	2008	Similarly, lithium chloride (LiCl) was found to increase the phosphorylation of GSK-3beta independently of ATM.	Lithium Chloride	29-33	glycogen synthase kinase 3 beta	Homo sapiens	80-89
18005231-10	2008	Moreover, GSK-3beta (Delta9) sensitized N2A neuroblasts to H2O2-induced oxidative stress and cell death.	Hydrogen Peroxide	59-63	glycogen synthase kinase 3 beta	Homo sapiens	10-19
18381444-7	2008	administration of GSK690693 inhibited GSK3 beta phosphorylation in a dose- and time-dependent manner.	GSK690693	18-27	glycogen synthase kinase 3 beta	Homo sapiens	38-47
18381444-8	2008	After a single dose of GSK690693, &gt;3 micromol/L drug concentration in BT474 tumor xenografts correlated with a sustained decrease in GSK3 beta phosphorylation.	GSK690693	23-32	glycogen synthase kinase 3 beta	Homo sapiens	136-145
18261724-6	2008	This response to ATP-depletion is independent of GSK3beta-dependent phosphorylation of pVHL30.	Adenosine Triphosphate	17-20	glycogen synthase kinase 3 beta	Homo sapiens	49-57
18005231-4	2008	In N2A neuroblasts, serum and H2O2 exhibited different kinetics of regulation for the Ser/Thr kinases Akt and glycogen synthase kinase 3beta (GSK-3beta) and for the transcription factor Nrf2, which governs redox homeostasis.	Hydrogen Peroxide	30-34	glycogen synthase kinase 3 beta	Homo sapiens	110-140
18005231-4	2008	In N2A neuroblasts, serum and H2O2 exhibited different kinetics of regulation for the Ser/Thr kinases Akt and glycogen synthase kinase 3beta (GSK-3beta) and for the transcription factor Nrf2, which governs redox homeostasis.	Hydrogen Peroxide	30-34	glycogen synthase kinase 3 beta	Homo sapiens	142-151
18005231-5	2008	Thus, H2O2 rapidly activated Akt, inhibited GSK-3beta, and directed the transcription factor Nrf2 to the nucleus, but after 4 h Akt was inactive, GSK-3beta was active and Nrf2 was more cytosolic than nuclear.	Hydrogen Peroxide	6-10	glycogen synthase kinase 3 beta	Homo sapiens	44-53
18041091-0	2008	alpha-Amino-3-hydroxy-5-methyl-4-isoxazole propionate attenuates glutamate-induced caspase-3 cleavage via regulation of glycogen synthase kinase 3beta.	alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate	0-53	glycogen synthase kinase 3 beta	Homo sapiens	120-150
18041091-0	2008	alpha-Amino-3-hydroxy-5-methyl-4-isoxazole propionate attenuates glutamate-induced caspase-3 cleavage via regulation of glycogen synthase kinase 3beta.	Glutamic Acid	65-74	glycogen synthase kinase 3 beta	Homo sapiens	120-150
18055082-9	2008	Western blot analysis showed that olanzapine, but not haloperidol, prevented the serum withdrawal-induced decrease in levels of neuroprotective proteins such as p-GSK-3beta, beta-catenin, and Bcl-2 (p&lt;0.01), whereas haloperidol robustly reduced the levels of these proteins at a 10 muM dose in serum-starved cells (p&lt;0.05).	Olanzapine	34-44	glycogen synthase kinase 3 beta	Homo sapiens	163-172
18041091-8	2008	Ser9-phosphorylated GSK3beta or inactivated form would be a key molecule for neuroprotection, insofar as lithium chloride (100 microM) and SB216763 (10 microM), inhibitors of GSK3beta, also induced phosphorylation of GSK3beta at Ser9 and exerted neuroprotection, respectively.	Lithium Chloride	105-121	glycogen synthase kinase 3 beta	Homo sapiens	20-28
18041091-8	2008	Ser9-phosphorylated GSK3beta or inactivated form would be a key molecule for neuroprotection, insofar as lithium chloride (100 microM) and SB216763 (10 microM), inhibitors of GSK3beta, also induced phosphorylation of GSK3beta at Ser9 and exerted neuroprotection, respectively.	SB 216763	139-147	glycogen synthase kinase 3 beta	Homo sapiens	20-28
18041091-8	2008	Ser9-phosphorylated GSK3beta or inactivated form would be a key molecule for neuroprotection, insofar as lithium chloride (100 microM) and SB216763 (10 microM), inhibitors of GSK3beta, also induced phosphorylation of GSK3beta at Ser9 and exerted neuroprotection, respectively.	SB 216763	139-147	glycogen synthase kinase 3 beta	Homo sapiens	175-183
18041091-8	2008	Ser9-phosphorylated GSK3beta or inactivated form would be a key molecule for neuroprotection, insofar as lithium chloride (100 microM) and SB216763 (10 microM), inhibitors of GSK3beta, also induced phosphorylation of GSK3beta at Ser9 and exerted neuroprotection, respectively.	SB 216763	139-147	glycogen synthase kinase 3 beta	Homo sapiens	175-183
18041091-11	2008	These findings suggest that AMPA activates PI3K-Akt and subsequently inhibits GSK3beta and that inactivated GSK3beta attenuates glutamate-induced caspase-3 cleavage and neurotoxicity.	Glutamic Acid	128-137	glycogen synthase kinase 3 beta	Homo sapiens	108-116
18413794-5	2008	The 2-DG-mediated Akt phosphorylation also led to the phosphorylation of Akt downstream targets, such as Foxo3a, GSK3beta, and Chk1.	Deoxyglucose	4-8	glycogen synthase kinase 3 beta	Homo sapiens	113-121
18346908-6	2008	TGF-beta1 also increased the expression of the Ser-9-phosphorylated inactive form of glycogen synthase kinase-3beta (GSK-3beta), an effect that was largely attenuated by PD98059.	Serine	47-50	glycogen synthase kinase 3 beta	Homo sapiens	85-115
18346908-6	2008	TGF-beta1 also increased the expression of the Ser-9-phosphorylated inactive form of glycogen synthase kinase-3beta (GSK-3beta), an effect that was largely attenuated by PD98059.	Serine	47-50	glycogen synthase kinase 3 beta	Homo sapiens	117-126
18346908-6	2008	TGF-beta1 also increased the expression of the Ser-9-phosphorylated inactive form of glycogen synthase kinase-3beta (GSK-3beta), an effect that was largely attenuated by PD98059.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	170-177	glycogen synthase kinase 3 beta	Homo sapiens	85-115
18346908-6	2008	TGF-beta1 also increased the expression of the Ser-9-phosphorylated inactive form of glycogen synthase kinase-3beta (GSK-3beta), an effect that was largely attenuated by PD98059.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	170-177	glycogen synthase kinase 3 beta	Homo sapiens	117-126
18346908-9	2008	Similarly to TGF-beta1, the GSK-3beta inhibitor lithium chloride (10mM), increased the total levels of beta-catenin and promoted alpha-SMA expression and collagen production.	Lithium Chloride	48-64	glycogen synthase kinase 3 beta	Homo sapiens	28-37
18055082-10	2008	Moreover, olanzapine alone significantly increased phosphorylation of GSK-3beta under normal conditions (p&lt;0.05).	Olanzapine	10-20	glycogen synthase kinase 3 beta	Homo sapiens	70-79
18055082-12	2008	The actions of signaling systems associated with GSK-3beta may be key targets for olanzapine and haloperidol, but their effects are distinct.	Olanzapine	82-92	glycogen synthase kinase 3 beta	Homo sapiens	49-58
18055082-12	2008	The actions of signaling systems associated with GSK-3beta may be key targets for olanzapine and haloperidol, but their effects are distinct.	Haloperidol	97-108	glycogen synthase kinase 3 beta	Homo sapiens	49-58
18242949-2	2008	To further examine the mechanism of arsenic-induced neurotoxicity with various arsenate metabolites (iAsV, MMAV and DMAV) and arsenite metabolites (iAsIII, MMAIII and DMAIII), we investigated the role of the proteolytic enzyme calpain and its involvement in the cleavage of p35 protein to p25, and also mRNA expression levels of calpain, cyclin-dependent kinase 5 (cdk5) and glycogen synthase kinase 3 beta (gsk3ss).	Arsenic	36-43	glycogen synthase kinase 3 beta	Homo sapiens	375-406
18289787-5	2008	Since lithium directly inhibits glycogen synthase kinase-3beta (GSK3beta), a key enzyme involved in tau phosphorylation, it was suggested that the therapeutic use of lithium could be expanded from mood disorders to neurodegenerative conditions.	Lithium	6-13	glycogen synthase kinase 3 beta	Homo sapiens	32-62
18201972-3	2008	Here we report that HGF through inactivation of GSK3beta suppresses NFkappaB p65 phosphorylation specifically at position Ser-468.	Serine	122-125	glycogen synthase kinase 3 beta	Homo sapiens	48-56
18201972-4	2008	The Ser-468 of RelA/p65 situates in a GSK3beta consensus motif and could be directly phosphorylated by GSK3beta both in vivo and in vitro, signifying Ser-468 of RelA/p65 as a putative substrate for GSK3beta.	Serine	4-7	glycogen synthase kinase 3 beta	Homo sapiens	38-46
18201972-4	2008	The Ser-468 of RelA/p65 situates in a GSK3beta consensus motif and could be directly phosphorylated by GSK3beta both in vivo and in vitro, signifying Ser-468 of RelA/p65 as a putative substrate for GSK3beta.	Serine	4-7	glycogen synthase kinase 3 beta	Homo sapiens	103-111
18201972-4	2008	The Ser-468 of RelA/p65 situates in a GSK3beta consensus motif and could be directly phosphorylated by GSK3beta both in vivo and in vitro, signifying Ser-468 of RelA/p65 as a putative substrate for GSK3beta.	Serine	150-153	glycogen synthase kinase 3 beta	Homo sapiens	38-46
18201972-4	2008	The Ser-468 of RelA/p65 situates in a GSK3beta consensus motif and could be directly phosphorylated by GSK3beta both in vivo and in vitro, signifying Ser-468 of RelA/p65 as a putative substrate for GSK3beta.	Serine	150-153	glycogen synthase kinase 3 beta	Homo sapiens	103-111
18201972-6	2008	Moreover, this domain was required for efficient phosphorylation of Ser-468 and was indispensable for the physical interaction between RelA/p65 and GSK3beta.	Serine	68-71	glycogen synthase kinase 3 beta	Homo sapiens	148-156
18289787-5	2008	Since lithium directly inhibits glycogen synthase kinase-3beta (GSK3beta), a key enzyme involved in tau phosphorylation, it was suggested that the therapeutic use of lithium could be expanded from mood disorders to neurodegenerative conditions.	Lithium	166-173	glycogen synthase kinase 3 beta	Homo sapiens	32-62
18347185-10	2008	CONCLUSIONS: We identified for the first time that OSU03013 inhibits cAMP-dependent protein kinase activity and causes dephosphorylation of glycogen synthase kinase 3-beta leading to beta-catenin degradation, which is often overexpressed in lung cancer.	OSU03013	51-59	glycogen synthase kinase 3 beta	Homo sapiens	140-171
18339873-8	2008	Glycogen synthase kinase 3beta phosphorylation, a reliable pharmacodynamic marker of enzastaurin activity, and Akt phosphorylation were both decreased after treatment with enzastaurin.	enzastaurin	85-96	glycogen synthase kinase 3 beta	Homo sapiens	0-30
18339873-8	2008	Glycogen synthase kinase 3beta phosphorylation, a reliable pharmacodynamic marker of enzastaurin activity, and Akt phosphorylation were both decreased after treatment with enzastaurin.	enzastaurin	172-183	glycogen synthase kinase 3 beta	Homo sapiens	0-30
18280153-1	2008	4-Amino-5,6-diaryl-furo[2,3-d]pyrimidines have been identified as inhibitors of glycogen synthase kinase-3beta (GSK-3beta).	4-amino-5,6-diaryl-furo[2,3-d]pyrimidines	0-41	glycogen synthase kinase 3 beta	Homo sapiens	80-110
18280153-1	2008	4-Amino-5,6-diaryl-furo[2,3-d]pyrimidines have been identified as inhibitors of glycogen synthase kinase-3beta (GSK-3beta).	4-amino-5,6-diaryl-furo[2,3-d]pyrimidines	0-41	glycogen synthase kinase 3 beta	Homo sapiens	112-121
18280153-2	2008	One representative derivative, 4-amino-3-(4-(benzenesulfonylamino)-phenyl)-2-(3-pyridyl)-furo[2,3-d]pyrimidine (12) exhibited potent GSK-3beta inhibitory activity in low nanomolar level of IC(50).	4-amino-3-(4-(benzenesulfonylamino)-phenyl)-2-(3-pyridyl)-furo[2,3-d]pyrimidine	31-110	glycogen synthase kinase 3 beta	Homo sapiens	133-142
18322101-7	2008	Transfection with GSK-3alpha small interfering RNA (siRNA) and/or GSK-3beta siRNA mimicked the ability of lithium to induce synergistic protection with VPA.	Lithium	106-113	glycogen synthase kinase 3 beta	Homo sapiens	66-75
17976739-3	2008	The -50T/C polymorphism, falling within the promoter region of the gene coding for GSK-3beta, was previously reported to be associated with age at onset, therapeutic response to lithium salts and total sleep deprivation in bipolar patients.	lithium salts	178-191	glycogen synthase kinase 3 beta	Homo sapiens	83-92
18322101-7	2008	Transfection with GSK-3alpha small interfering RNA (siRNA) and/or GSK-3beta siRNA mimicked the ability of lithium to induce synergistic protection with VPA.	Valproic Acid	152-155	glycogen synthase kinase 3 beta	Homo sapiens	66-75
17681085-2	2008	Dopamine D2 receptor (DRD2) activation induces a signalling complex of AKT1, PP2A and beta-arrestin2 which dephosphorylates/inactivates AKT1 thereby activating GSK-3beta, transducing dopamine-dependent behaviour.	Dopamine	183-191	glycogen synthase kinase 3 beta	Homo sapiens	160-169
18204489-2	2008	Glycogen synthase kinase 3 (GSK3, of which there are two isoforms, GSK3alpha and GSK3beta) was originally characterized in the context of regulation of glycogen metabolism, though it is now known to regulate many other cellular processes.	Glycogen	152-160	glycogen synthase kinase 3 beta	Homo sapiens	81-89
18316598-3	2008	Here, we show that constitutive oncogenic signaling downstream of ErbB2 and Ras stabilizes PRLr via inhibitory phosphorylation of glycogen synthase kinase-3beta (GSK3 beta) on Ser(9).	Serine	176-179	glycogen synthase kinase 3 beta	Homo sapiens	130-160
18316598-3	2008	Here, we show that constitutive oncogenic signaling downstream of ErbB2 and Ras stabilizes PRLr via inhibitory phosphorylation of glycogen synthase kinase-3beta (GSK3 beta) on Ser(9).	Serine	176-179	glycogen synthase kinase 3 beta	Homo sapiens	162-171
18316598-5	2008	Additional studies using pharmacologic, biochemical, and genetic approaches reveal that GSK3 beta is a bona fide PRLr kinase that phosphorylates PRLr on Ser(349) and is required for the recognition of PRLr by beta Trcp, as well as for PRLr ubiquitination and degradation.	Serine	153-156	glycogen synthase kinase 3 beta	Homo sapiens	88-97
18039685-0	2008	Biochemical characterization of phospholipids, sulfatide and heparin as potent stimulators for autophosphorylation of GSK-3beta and the GSK-3beta-mediated phosphorylation of myelin basic protein in vitro.	Phospholipids	32-45	glycogen synthase kinase 3 beta	Homo sapiens	118-127
18039685-0	2008	Biochemical characterization of phospholipids, sulfatide and heparin as potent stimulators for autophosphorylation of GSK-3beta and the GSK-3beta-mediated phosphorylation of myelin basic protein in vitro.	Phospholipids	32-45	glycogen synthase kinase 3 beta	Homo sapiens	136-145
18234058-5	2008	When compared to PBT, LPT show an increased activation of the phosphoinositide 3/protein kinase B/glycogen synthase kinase 3beta (PI3-kinase/AKT/GSK-3beta) pathway in response to CD2 stimulation.	CIS-(AMMINE)(CYCLOHEXYLAMINE)PLATINUM(II) COMPLEX	22-25	glycogen synthase kinase 3 beta	Homo sapiens	145-154
18039685-0	2008	Biochemical characterization of phospholipids, sulfatide and heparin as potent stimulators for autophosphorylation of GSK-3beta and the GSK-3beta-mediated phosphorylation of myelin basic protein in vitro.	Sulfoglycosphingolipids	47-56	glycogen synthase kinase 3 beta	Homo sapiens	118-127
18039685-0	2008	Biochemical characterization of phospholipids, sulfatide and heparin as potent stimulators for autophosphorylation of GSK-3beta and the GSK-3beta-mediated phosphorylation of myelin basic protein in vitro.	Sulfoglycosphingolipids	47-56	glycogen synthase kinase 3 beta	Homo sapiens	136-145
18039685-0	2008	Biochemical characterization of phospholipids, sulfatide and heparin as potent stimulators for autophosphorylation of GSK-3beta and the GSK-3beta-mediated phosphorylation of myelin basic protein in vitro.	Heparin	61-68	glycogen synthase kinase 3 beta	Homo sapiens	118-127
18039685-0	2008	Biochemical characterization of phospholipids, sulfatide and heparin as potent stimulators for autophosphorylation of GSK-3beta and the GSK-3beta-mediated phosphorylation of myelin basic protein in vitro.	Heparin	61-68	glycogen synthase kinase 3 beta	Homo sapiens	136-145
18039685-1	2008	The stimulatory effects of SH (sulfatide and heparin) and two phospholipids (PI and PS) on autophosphorylation of GSK-3beta and the GSK-3beta-mediated phosphorylation of myelin basic protein (MBP) and two synthetic MBP peptides (M86 and M156) were comparatively examined in vitro.	Sulfoglycosphingolipids	31-40	glycogen synthase kinase 3 beta	Homo sapiens	114-123
18039685-1	2008	The stimulatory effects of SH (sulfatide and heparin) and two phospholipids (PI and PS) on autophosphorylation of GSK-3beta and the GSK-3beta-mediated phosphorylation of myelin basic protein (MBP) and two synthetic MBP peptides (M86 and M156) were comparatively examined in vitro.	Sulfoglycosphingolipids	31-40	glycogen synthase kinase 3 beta	Homo sapiens	132-141
18039685-1	2008	The stimulatory effects of SH (sulfatide and heparin) and two phospholipids (PI and PS) on autophosphorylation of GSK-3beta and the GSK-3beta-mediated phosphorylation of myelin basic protein (MBP) and two synthetic MBP peptides (M86 and M156) were comparatively examined in vitro.	Heparin	45-52	glycogen synthase kinase 3 beta	Homo sapiens	114-123
18039685-1	2008	The stimulatory effects of SH (sulfatide and heparin) and two phospholipids (PI and PS) on autophosphorylation of GSK-3beta and the GSK-3beta-mediated phosphorylation of myelin basic protein (MBP) and two synthetic MBP peptides (M86 and M156) were comparatively examined in vitro.	Heparin	45-52	glycogen synthase kinase 3 beta	Homo sapiens	132-141
18039685-1	2008	The stimulatory effects of SH (sulfatide and heparin) and two phospholipids (PI and PS) on autophosphorylation of GSK-3beta and the GSK-3beta-mediated phosphorylation of myelin basic protein (MBP) and two synthetic MBP peptides (M86 and M156) were comparatively examined in vitro.	Phospholipids	62-75	glycogen synthase kinase 3 beta	Homo sapiens	114-123
18039685-1	2008	The stimulatory effects of SH (sulfatide and heparin) and two phospholipids (PI and PS) on autophosphorylation of GSK-3beta and the GSK-3beta-mediated phosphorylation of myelin basic protein (MBP) and two synthetic MBP peptides (M86 and M156) were comparatively examined in vitro.	Phospholipids	62-75	glycogen synthase kinase 3 beta	Homo sapiens	132-141
18039685-1	2008	The stimulatory effects of SH (sulfatide and heparin) and two phospholipids (PI and PS) on autophosphorylation of GSK-3beta and the GSK-3beta-mediated phosphorylation of myelin basic protein (MBP) and two synthetic MBP peptides (M86 and M156) were comparatively examined in vitro.	Phosphorus	84-86	glycogen synthase kinase 3 beta	Homo sapiens	114-123
18039685-1	2008	The stimulatory effects of SH (sulfatide and heparin) and two phospholipids (PI and PS) on autophosphorylation of GSK-3beta and the GSK-3beta-mediated phosphorylation of myelin basic protein (MBP) and two synthetic MBP peptides (M86 and M156) were comparatively examined in vitro.	Phosphorus	84-86	glycogen synthase kinase 3 beta	Homo sapiens	132-141
18039685-2	2008	It was found that (i) both PI and SH highly stimulated the GSK-3beta-mediated phosphorylation of MBP, but not glycogen synthase, and two MBP peptides through their direct binding to these substrates and (ii) both PI and heparin, as compared with sulfatide, highly stimulated autophosphorylation of GSK-3beta.	Heparin	220-227	glycogen synthase kinase 3 beta	Homo sapiens	59-68
18039685-2	2008	It was found that (i) both PI and SH highly stimulated the GSK-3beta-mediated phosphorylation of MBP, but not glycogen synthase, and two MBP peptides through their direct binding to these substrates and (ii) both PI and heparin, as compared with sulfatide, highly stimulated autophosphorylation of GSK-3beta.	Sulfoglycosphingolipids	246-255	glycogen synthase kinase 3 beta	Homo sapiens	59-68
18039685-4	2008	Under our experimental condition, similar stimulatory effects of PI and heparin were observed with the GSK-3beta-mediated phosphorylation of tau protein (TP) in vitro.	Heparin	72-79	glycogen synthase kinase 3 beta	Homo sapiens	103-112
18039685-5	2008	These results presented here suggest that these two phospholipids and SH may function as effective stimulators for autophosphorylation of GSK-3beta and for the GSK-3beta-mediated high phosphorylation of SH-binding proteins, including MBP and TP, in the highly accumulated levels of these acidic and sulfated modulators in the brain.	Phospholipids	52-65	glycogen synthase kinase 3 beta	Homo sapiens	138-147
18039685-5	2008	These results presented here suggest that these two phospholipids and SH may function as effective stimulators for autophosphorylation of GSK-3beta and for the GSK-3beta-mediated high phosphorylation of SH-binding proteins, including MBP and TP, in the highly accumulated levels of these acidic and sulfated modulators in the brain.	Phospholipids	52-65	glycogen synthase kinase 3 beta	Homo sapiens	160-169
18240065-7	2008	Valproic acid (VPA) and lithium are potentially beneficial GSK-3b inhibitors.	Valproic Acid	0-13	glycogen synthase kinase 3 beta	Homo sapiens	59-65
18058799-11	2008	Multiple mechanisms appear to be involved in 6-gingerol action, including protein degradation as well as beta-catenin, PKCepsilon, and GSK-3beta pathways.	gingerol	45-55	glycogen synthase kinase 3 beta	Homo sapiens	135-144
18208385-4	2008	The present study deals with the dynamic nature of GSK3beta and highlights the importance of studying protein plasticity in structure-based drug design, exemplified by our method called ASP (active-site pressurization).	Aspartic Acid	186-189	glycogen synthase kinase 3 beta	Homo sapiens	51-59
17968353-5	2008	Both downregulation of glycogen synthase kinase-3beta, a lithium-sensitive component of the canonical Wnt signaling pathway, and elevated beta-catenin, a downstream component of the same pathway produce effects similar to lithium.	Lithium	57-64	glycogen synthase kinase 3 beta	Homo sapiens	23-53
18201727-3	2008	Inhibition of GSK3beta activity by LiCl or siRNA technique mimicked insulin action to stimulate ET-1 gene expression.	Lithium Chloride	35-39	glycogen synthase kinase 3 beta	Homo sapiens	14-22
18240065-7	2008	Valproic acid (VPA) and lithium are potentially beneficial GSK-3b inhibitors.	Valproic Acid	15-18	glycogen synthase kinase 3 beta	Homo sapiens	59-65
18240065-7	2008	Valproic acid (VPA) and lithium are potentially beneficial GSK-3b inhibitors.	Lithium	24-31	glycogen synthase kinase 3 beta	Homo sapiens	59-65
18160324-3	2008	Fluprostenol-induced hypertrophy was associated with increased ROS, mTOR translocation from the nucleus to the cytoplasm, along with Akt, mTOR, GSK-3beta, PTEN and ERK1/2 but not JNK phosphorylation.	fluprostenol	0-12	glycogen synthase kinase 3 beta	Homo sapiens	144-153
18635421-3	2008	The review presents bisindolylmaleimide-mediated PKC-dependent and PKC-independent biological effects, such as reversal of MDR and modulation of Wnt signaling through GSK-3b and b-catenin.	bisindolylmaleimide	20-39	glycogen synthase kinase 3 beta	Homo sapiens	167-173
18054489-1	2008	Novel heterocyclic ring-substituted pyrimidines have been designed as inhibitors of glycogen synthase kinase-3beta (GSK-3beta) from the modification of known inhibitors.	Pyrimidines	36-47	glycogen synthase kinase 3 beta	Homo sapiens	84-114
18054489-1	2008	Novel heterocyclic ring-substituted pyrimidines have been designed as inhibitors of glycogen synthase kinase-3beta (GSK-3beta) from the modification of known inhibitors.	Pyrimidines	36-47	glycogen synthase kinase 3 beta	Homo sapiens	116-125
17991738-0	2008	GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines.	Sorafenib	30-39	glycogen synthase kinase 3 beta	Homo sapiens	0-9
17991738-3	2008	In this report, we show that sorafenib activates GSK-3beta in multiple subcellular compartments and that this activation undermines the lethality of the drug.	Sorafenib	29-38	glycogen synthase kinase 3 beta	Homo sapiens	49-58
17991738-7	2008	Sorafenib down-modulates the pro-apoptotic Bcl-2 family member Noxa in cells with high constitutive GSK-3beta activity.	Sorafenib	0-9	glycogen synthase kinase 3 beta	Homo sapiens	100-109
17991738-8	2008	Pharmacologic inhibition of GSK-3beta prevents the disappearance of Noxa induced by sorafenib and enhances the down-modulation of Mcl-1.	Sorafenib	84-93	glycogen synthase kinase 3 beta	Homo sapiens	28-37
17653089-7	2008	Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, using LY294002, prevented both H2-relaxin-mediated phosphorylation of Akt and GSK-3beta and translocation of beta-catenin/AR into the nucleus.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	74-82	glycogen synthase kinase 3 beta	Homo sapiens	146-155
17921520-4	2008	Here we show that glycogen synthase kinase-3beta (GSK-3beta), another enzyme inhibited by lithium, has opposite effects.	Lithium	90-97	glycogen synthase kinase 3 beta	Homo sapiens	18-48
18199552-6	2008	DHA and EPA treatment caused dephosphorylation (and hence, the activation) of glycogen synthase kinase-3beta (GSK-3beta) with a decline of beta-catenin protein.	Docosahexaenoic Acids	0-3	glycogen synthase kinase 3 beta	Homo sapiens	78-108
18199552-6	2008	DHA and EPA treatment caused dephosphorylation (and hence, the activation) of glycogen synthase kinase-3beta (GSK-3beta) with a decline of beta-catenin protein.	Docosahexaenoic Acids	0-3	glycogen synthase kinase 3 beta	Homo sapiens	110-119
18199552-6	2008	DHA and EPA treatment caused dephosphorylation (and hence, the activation) of glycogen synthase kinase-3beta (GSK-3beta) with a decline of beta-catenin protein.	Eicosapentaenoic Acid	8-11	glycogen synthase kinase 3 beta	Homo sapiens	78-108
18199552-6	2008	DHA and EPA treatment caused dephosphorylation (and hence, the activation) of glycogen synthase kinase-3beta (GSK-3beta) with a decline of beta-catenin protein.	Eicosapentaenoic Acid	8-11	glycogen synthase kinase 3 beta	Homo sapiens	110-119
18199552-8	2008	The GSK-3beta inhibitor, SB216763, partially prevented DHA-induced reduction of beta-catenin protein and TCF/LEF reporter activity, and restored cell growth, suggesting the involvement of GSK-3beta dephosphorylation in omega 3-PUFA-induced beta-catenin degradation.	SB 216763	25-33	glycogen synthase kinase 3 beta	Homo sapiens	4-13
18199552-8	2008	The GSK-3beta inhibitor, SB216763, partially prevented DHA-induced reduction of beta-catenin protein and TCF/LEF reporter activity, and restored cell growth, suggesting the involvement of GSK-3beta dephosphorylation in omega 3-PUFA-induced beta-catenin degradation.	SB 216763	25-33	glycogen synthase kinase 3 beta	Homo sapiens	188-197
18199552-8	2008	The GSK-3beta inhibitor, SB216763, partially prevented DHA-induced reduction of beta-catenin protein and TCF/LEF reporter activity, and restored cell growth, suggesting the involvement of GSK-3beta dephosphorylation in omega 3-PUFA-induced beta-catenin degradation.	Docosahexaenoic Acids	55-58	glycogen synthase kinase 3 beta	Homo sapiens	4-13
18199552-8	2008	The GSK-3beta inhibitor, SB216763, partially prevented DHA-induced reduction of beta-catenin protein and TCF/LEF reporter activity, and restored cell growth, suggesting the involvement of GSK-3beta dephosphorylation in omega 3-PUFA-induced beta-catenin degradation.	Docosahexaenoic Acids	55-58	glycogen synthase kinase 3 beta	Homo sapiens	188-197
18199552-9	2008	In parallel, DHA treatment also induced the formation of the beta-catenin/Axin/GSK-3beta binding complex, further leading to beta-catenin degradation.	Docosahexaenoic Acids	13-16	glycogen synthase kinase 3 beta	Homo sapiens	79-88
18537625-1	2008	Glycogen synthase kinase 3 beta (GSK-3beta) was one of the first kinases identified and studied, initially for its role in the regulation of glycogen synthesis.	Glycogen	141-149	glycogen synthase kinase 3 beta	Homo sapiens	0-31
17993264-1	2008	Inhibition of glycogen synthase kinase 3beta (GSK3beta) as a consequence of its phosphorylation by protein kinase B/Akt (PKB/Akt) has been implicated in cardiac myocyte hypertrophy in response to endothelin-1 or phenylephrine.	Phenylephrine	212-225	glycogen synthase kinase 3 beta	Homo sapiens	14-44
17993264-1	2008	Inhibition of glycogen synthase kinase 3beta (GSK3beta) as a consequence of its phosphorylation by protein kinase B/Akt (PKB/Akt) has been implicated in cardiac myocyte hypertrophy in response to endothelin-1 or phenylephrine.	Phenylephrine	212-225	glycogen synthase kinase 3 beta	Homo sapiens	46-54
17919914-0	2008	Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives.	Adenosine Triphosphate	4-7	glycogen synthase kinase 3 beta	Homo sapiens	20-50
17919914-0	2008	Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives.	Adenosine Triphosphate	4-7	glycogen synthase kinase 3 beta	Homo sapiens	52-61
17919914-0	2008	Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives.	Thiadiazolidinone	112-129	glycogen synthase kinase 3 beta	Homo sapiens	20-50
17919914-0	2008	Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives.	Thiadiazolidinone	112-129	glycogen synthase kinase 3 beta	Homo sapiens	52-61
17919914-1	2008	The 2,4-disubstituted thiadiazolidinones (TDZD) were described as the first non-ATP competitive GSK-3beta inhibitors.	2,4-disubstituted thiadiazolidinones	4-40	glycogen synthase kinase 3 beta	Homo sapiens	96-105
17919914-1	2008	The 2,4-disubstituted thiadiazolidinones (TDZD) were described as the first non-ATP competitive GSK-3beta inhibitors.	tdzd	42-46	glycogen synthase kinase 3 beta	Homo sapiens	96-105
17919914-1	2008	The 2,4-disubstituted thiadiazolidinones (TDZD) were described as the first non-ATP competitive GSK-3beta inhibitors.	Adenosine Triphosphate	80-83	glycogen synthase kinase 3 beta	Homo sapiens	96-105
17919914-4	2008	The GSK-3beta activity of the new thiadiazole derivatives here synthesized showed IC(50) values for some of the compounds in the micromolar range.	Thiadiazoles	34-45	glycogen synthase kinase 3 beta	Homo sapiens	4-13
18537625-1	2008	Glycogen synthase kinase 3 beta (GSK-3beta) was one of the first kinases identified and studied, initially for its role in the regulation of glycogen synthesis.	Glycogen	141-149	glycogen synthase kinase 3 beta	Homo sapiens	33-42
18054269-6	2008	These indicated that ginkgolides could mimic hypoxic preconditioning by increasing expression of HIF-1alpha as well as its target protein EPO and that the ginkgolides and hypoxic preconditioning role might be partly mediated by the activation of the p42/p44-mitogen-activated protein kinase and phosphatidylinositol 3"-kinase/AKT/glycogen synthase kinase 3beta pathways.	Ginkgolides	21-32	glycogen synthase kinase 3 beta	Homo sapiens	330-360
18054269-6	2008	These indicated that ginkgolides could mimic hypoxic preconditioning by increasing expression of HIF-1alpha as well as its target protein EPO and that the ginkgolides and hypoxic preconditioning role might be partly mediated by the activation of the p42/p44-mitogen-activated protein kinase and phosphatidylinositol 3"-kinase/AKT/glycogen synthase kinase 3beta pathways.	Ginkgolides	155-166	glycogen synthase kinase 3 beta	Homo sapiens	330-360
18311715-7	2008	In T. pyriformis, the frequency of developmental switch to OR morphogenesis increases in the presence of wortmannin, an inhibitor of the CDC42-GSK3beta-MARK pathway.	Wortmannin	105-115	glycogen synthase kinase 3 beta	Homo sapiens	143-151
18949077-5	2008	In this report, we showed that the SUMOylation of GSK 3beta occurs on its K(292) residue, and this modification promotes its nuclear localization in COS-1.	carbonyl sulfide	149-152	glycogen synthase kinase 3 beta	Homo sapiens	50-59
18978948-4	2008	Moreover, ligands inhibited Abeta-induced activation of molecules involved in AD pathology including calpain/cdk5, GSK3beta and c-Jun, and tau phosphorylation, and prevented Abeta-induced inactivation of AKT and CREB.	UNII-042A8N37WH	28-33	glycogen synthase kinase 3 beta	Homo sapiens	115-123
18978948-4	2008	Moreover, ligands inhibited Abeta-induced activation of molecules involved in AD pathology including calpain/cdk5, GSK3beta and c-Jun, and tau phosphorylation, and prevented Abeta-induced inactivation of AKT and CREB.	UNII-042A8N37WH	174-179	glycogen synthase kinase 3 beta	Homo sapiens	115-123
17951252-6	2007	Inhibitory Ser-9 phosphorylation of glycogen synthase kinase 3beta (GSK3beta) by Akt prevented proteasome-mediated cyclin D1 degradation and induced cell cycle progress in LeTx-intoxicated THP-1 cells.	Serine	11-14	glycogen synthase kinase 3 beta	Homo sapiens	36-66
18214825-0	2008	[A potential neuroprotective and synaptic plasticity mechanism induced by estradiol through PI3K/GSK3beta in cerebral ischaemia].	Estradiol	74-83	glycogen synthase kinase 3 beta	Homo sapiens	97-105
18214825-5	2008	CONCLUSIONS: Further work needs to be carried out to study the mechanisms of action of neuroactive steroids, especially the non-conventional ones, which involve proteins such as GSK-3beta and beta-catenin.	Steroids	99-107	glycogen synthase kinase 3 beta	Homo sapiens	178-187
17951252-6	2007	Inhibitory Ser-9 phosphorylation of glycogen synthase kinase 3beta (GSK3beta) by Akt prevented proteasome-mediated cyclin D1 degradation and induced cell cycle progress in LeTx-intoxicated THP-1 cells.	Serine	11-14	glycogen synthase kinase 3 beta	Homo sapiens	68-76
17982039-3	2007	For PI3K signaling, increases of cellular PIP(3) and phosphorylation of downstream molecules, such as Akt and glycogen synthase kinase-3beta (GSK3beta) (S9), were detected.	piperidine	42-45	glycogen synthase kinase 3 beta	Homo sapiens	110-140
17628506-0	2007	Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism.	Lithium	12-19	glycogen synthase kinase 3 beta	Homo sapiens	70-101
17628506-1	2007	BACKGROUND: Glycogen synthase kinase 3-beta (GSK3B) is a serine/threonine kinase which is directly inhibited by lithium.	Lithium	112-119	glycogen synthase kinase 3 beta	Homo sapiens	12-43
17628506-1	2007	BACKGROUND: Glycogen synthase kinase 3-beta (GSK3B) is a serine/threonine kinase which is directly inhibited by lithium.	Lithium	112-119	glycogen synthase kinase 3 beta	Homo sapiens	45-50
17628506-2	2007	A -50T/C single nucleotide polymorphism (SNP) localized within the promoter region of the GSK3B gene has previously been shown to be associated with response to lithium prophylaxis in bipolar disorder.	Lithium	161-168	glycogen synthase kinase 3 beta	Homo sapiens	90-95
17628506-3	2007	This study investigates the association of the GSK3B -50T/C SNP and response to lithium augmentation in acutely depressed antidepressant nonresponders.	Lithium	80-87	glycogen synthase kinase 3 beta	Homo sapiens	47-52
18027876-8	2007	The association of PTEN with the PI3K p85alpha subunit was substantially increased and led to the inhibition of downstream insulin-mediated survival signals through Akt, GSK3beta, and BAD; the ethanol effect was reversed by PTEN knockdown with small interfering RNA.	Ethanol	193-200	glycogen synthase kinase 3 beta	Homo sapiens	170-178
18089706-10	2007	During this period, etoposide treatment was associated with the dephosphorylation and activation of GSK-3beta in the mitochondria that was blocked by BDNF activation of TrkB.	Etoposide	20-29	glycogen synthase kinase 3 beta	Homo sapiens	100-109
17982039-3	2007	For PI3K signaling, increases of cellular PIP(3) and phosphorylation of downstream molecules, such as Akt and glycogen synthase kinase-3beta (GSK3beta) (S9), were detected.	piperidine	42-45	glycogen synthase kinase 3 beta	Homo sapiens	142-150
17692821-5	2007	TGF-beta1 increased the phosphorylated form of GSK-3beta in HKC-8 cells, and inhibition of GSK-3beta by the selective inhibitors lithium and TDZD-8 caused Snail1 protein to accumulate.	Lithium	129-136	glycogen synthase kinase 3 beta	Homo sapiens	47-56
18006785-5	2007	We determined the effect of radiation and enzastaurin on glycogen synthase kinase 3beta, a mediator of cell death in culture and in vivo.	enzastaurin	42-53	glycogen synthase kinase 3 beta	Homo sapiens	57-87
18006785-11	2007	Enzastaurin inhibited radiation-induced phosphorylation of glycogen synthase kinase 3beta at Ser(9) in pancreatic cancer cells in culture and in tumor xenografts, suggesting a possible mechanism for the observed radiosensitization.	enzastaurin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	59-89
18006785-11	2007	Enzastaurin inhibited radiation-induced phosphorylation of glycogen synthase kinase 3beta at Ser(9) in pancreatic cancer cells in culture and in tumor xenografts, suggesting a possible mechanism for the observed radiosensitization.	Serine	93-96	glycogen synthase kinase 3 beta	Homo sapiens	59-89
17764934-0	2007	Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.	7-hydroxy-1h-benzoimidazole	24-51	glycogen synthase kinase 3 beta	Homo sapiens	87-117
17764934-2	2007	Several derivatives of 7-hydroxyl-1H-benzoimidazole were designed as inhibitors of glycogen synthase kinase-3beta with the help of ab initio calculations and a docking study.	7-hydroxyl-1h-benzoimidazole	23-51	glycogen synthase kinase 3 beta	Homo sapiens	83-113
17961557-4	2007	More importantly, we demonstrate that TGFbeta significantly abolished Akt-mediated serine-9 phosphorylation of glycogen synthase kinase 3beta (GSK3beta), thus prevented its inactivation.	Serine	83-89	glycogen synthase kinase 3 beta	Homo sapiens	111-141
17961557-4	2007	More importantly, we demonstrate that TGFbeta significantly abolished Akt-mediated serine-9 phosphorylation of glycogen synthase kinase 3beta (GSK3beta), thus prevented its inactivation.	Serine	83-89	glycogen synthase kinase 3 beta	Homo sapiens	143-151
17692821-5	2007	TGF-beta1 increased the phosphorylated form of GSK-3beta in HKC-8 cells, and inhibition of GSK-3beta by the selective inhibitors lithium and TDZD-8 caused Snail1 protein to accumulate.	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	141-147	glycogen synthase kinase 3 beta	Homo sapiens	47-56
17692821-5	2007	TGF-beta1 increased the phosphorylated form of GSK-3beta in HKC-8 cells, and inhibition of GSK-3beta by the selective inhibitors lithium and TDZD-8 caused Snail1 protein to accumulate.	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	141-147	glycogen synthase kinase 3 beta	Homo sapiens	91-100
17692821-5	2007	TGF-beta1 increased the phosphorylated form of GSK-3beta in HKC-8 cells, and inhibition of GSK-3beta by the selective inhibitors lithium and TDZD-8 caused Snail1 protein to accumulate.	Lithium	129-136	glycogen synthase kinase 3 beta	Homo sapiens	91-100
17609434-8	2007	Furthermore, in vitro kinase assay depicted that GSK-3beta phosphorylates ERalpha at Ser-118.	Serine	85-88	glycogen synthase kinase 3 beta	Homo sapiens	49-58
17804190-8	2007	On the other hand, cesium inactivated GSK3beta by phosphorylation of serine-9 and GSK3beta-specific inhibitor SB415286 prevented neuronal apoptosis.	Cesium	19-25	glycogen synthase kinase 3 beta	Homo sapiens	38-46
17804190-8	2007	On the other hand, cesium inactivated GSK3beta by phosphorylation of serine-9 and GSK3beta-specific inhibitor SB415286 prevented neuronal apoptosis.	Cesium	19-25	glycogen synthase kinase 3 beta	Homo sapiens	82-90
17804190-8	2007	On the other hand, cesium inactivated GSK3beta by phosphorylation of serine-9 and GSK3beta-specific inhibitor SB415286 prevented neuronal apoptosis.	Serine	69-75	glycogen synthase kinase 3 beta	Homo sapiens	38-46
17804190-8	2007	On the other hand, cesium inactivated GSK3beta by phosphorylation of serine-9 and GSK3beta-specific inhibitor SB415286 prevented neuronal apoptosis.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	110-118	glycogen synthase kinase 3 beta	Homo sapiens	38-46
17804190-8	2007	On the other hand, cesium inactivated GSK3beta by phosphorylation of serine-9 and GSK3beta-specific inhibitor SB415286 prevented neuronal apoptosis.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	110-118	glycogen synthase kinase 3 beta	Homo sapiens	82-90
17623045-3	2007	Herein we show that, in transfected SK-N-MC cells, the H(3)R modulates the activity of the Akt/Glycogen synthase kinase 3beta (GSK-3beta) axis both in a constitutive and agonist-dependent fashion.	sk-n-mc	36-43	glycogen synthase kinase 3 beta	Homo sapiens	95-125
17623045-3	2007	Herein we show that, in transfected SK-N-MC cells, the H(3)R modulates the activity of the Akt/Glycogen synthase kinase 3beta (GSK-3beta) axis both in a constitutive and agonist-dependent fashion.	sk-n-mc	36-43	glycogen synthase kinase 3 beta	Homo sapiens	127-136
17595317-4	2007	In transfected cells, deletion of the N-terminal nine amino acids or mutation of the serine-9 phosphorylation site on GSK3-beta prevented its glucocorticoid-induced degradation.	Serine	85-91	glycogen synthase kinase 3 beta	Homo sapiens	118-127
17671694-7	2007	Lithium chloride, which is a GSK-3beta inhibitor and stimulates pGSK-3beta-ser-9, significantly increased the IC50 of cisplatin and counteracted cisplatin-induced apoptosis of A2780 and CP70 cells.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	29-38
17709384-4	2007	We show that cyclin D3 displays rapid turnover in proliferating myoblasts, which is positively regulated through glycogen synthase kinase 3beta (GSK-3beta)-mediated phosphorylation of cyclin D3 on Thr-283.	Threonine	197-200	glycogen synthase kinase 3 beta	Homo sapiens	113-143
17709384-4	2007	We show that cyclin D3 displays rapid turnover in proliferating myoblasts, which is positively regulated through glycogen synthase kinase 3beta (GSK-3beta)-mediated phosphorylation of cyclin D3 on Thr-283.	Threonine	197-200	glycogen synthase kinase 3 beta	Homo sapiens	145-154
17709384-5	2007	We describe a novel interaction between pRb and cyclin D3 that maps to the C terminus of pRb and to a region of cyclin D3 proximal to the Thr-283 residue and provide evidence that the pRb-cyclin D3 complex formation in terminally differentiated myotubes hinders the access of GSK-3beta to cyclin D3, thus inhibiting Thr-283 phosphorylation.	Threonine	138-141	glycogen synthase kinase 3 beta	Homo sapiens	276-285
17651692-1	2007	NFAT involvement in adipocyte physiological processes was examined by treatment with CsA and/or GSK3beta inhibitors (Li(+) or TZDZ-8), which prevent or increase NFAT nuclear translocation, respectively.	tzdz-8	126-132	glycogen synthase kinase 3 beta	Homo sapiens	96-104
17671694-0	2007	Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells.	Serine	54-60	glycogen synthase kinase 3 beta	Homo sapiens	19-50
17620332-4	2007	Inhibition of c-Abl tyrosine kinase by STI571 attenuates the effect of insulin on Akt/GSK-3beta phosphorylation and glycogen synthesis, and at the same time, it enhances the effect of insulin on ERK activation, cell proliferation, and migration.	Imatinib Mesylate	39-45	glycogen synthase kinase 3 beta	Homo sapiens	86-95
17671694-8	2007	In contrast, overexpression of a constitutively active S9A GSK-3beta mutant increased the sensitivity of CP70 cells to cisplatin and significantly enhanced cisplatin-mediated apoptosis.	Cisplatin	119-128	glycogen synthase kinase 3 beta	Homo sapiens	59-68
17671694-0	2007	Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells.	Cisplatin	71-80	glycogen synthase kinase 3 beta	Homo sapiens	19-50
17671694-5	2007	We compared the expression/phosphorylation of GSK-3beta between the cisplatin-sensitive ovarian carcinoma cell line A2780 and its cisplatin-resistant derivative CP70.	Cisplatin	68-77	glycogen synthase kinase 3 beta	Homo sapiens	46-55
17671694-5	2007	We compared the expression/phosphorylation of GSK-3beta between the cisplatin-sensitive ovarian carcinoma cell line A2780 and its cisplatin-resistant derivative CP70.	Cisplatin	130-139	glycogen synthase kinase 3 beta	Homo sapiens	46-55
17671694-8	2007	In contrast, overexpression of a constitutively active S9A GSK-3beta mutant increased the sensitivity of CP70 cells to cisplatin and significantly enhanced cisplatin-mediated apoptosis.	Cisplatin	156-165	glycogen synthase kinase 3 beta	Homo sapiens	59-68
17671694-12	2007	Our study establishes a potential role of GSK-3beta in the development of cisplatin resistance in initially sensitive tumors.	Cisplatin	74-83	glycogen synthase kinase 3 beta	Homo sapiens	42-51
17876055-6	2007	Mechanistic studies suggested roles for Akt, GSK-3beta, MDM2, and p53 in enterolactone-dependent apoptosis.	2,3-bis(3'-hydroxybenzyl)butyrolactone	73-86	glycogen synthase kinase 3 beta	Homo sapiens	45-54
17512084-5	2007	Phosphorylation of the key cell survival kinase, Akt, was significantly increased, resulting in increased serine phosphorylation of the downstream target, GSK3-beta.	Serine	106-112	glycogen synthase kinase 3 beta	Homo sapiens	155-164
17691973-8	2007	Interestingly, inhibition of GSK-3beta activity during elevated glucose leads to enhanced EC survival, but does not synergistically improve protection by EPO or Wnt1, suggesting that EPO and Wnt1 are closely tied to the blockade of GSK-3beta activity.	Glucose	64-71	glycogen synthase kinase 3 beta	Homo sapiens	29-38
17569795-5	2007	Furthermore, glycogen synthase kinase-3beta represented a key regulator in the effect of these thiazolidinedione derivatives on beta-catenin proteolysis even though these agents increased its phosphorylation level.	2,4-thiazolidinedione	95-112	glycogen synthase kinase 3 beta	Homo sapiens	13-43
17567589-7	2007	In NHK, arsenic triggers a sustained activation of the PI3K/PKB/glycogen synthase kinase-3 beta pathway, driving the cell into a cell-differentiated stage in which the proliferation signals are turned down.	Arsenic	8-15	glycogen synthase kinase 3 beta	Homo sapiens	64-95
17699780-11	2007	Overexpression of wild-type (WT) and S9A mutant GSK3beta in JB6 P+ cells suppressed EGF and TPA-mediated anchorage-independent growth in soft agar and tumorigenicity in nude mice.	Tetradecanoylphorbol Acetate	92-95	glycogen synthase kinase 3 beta	Homo sapiens	48-56
17666435-8	2007	These results indicate a role for GSK-3beta in ceramide-induced apoptosis, in which GSK-3beta acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 and caspase-8.	Ceramides	47-55	glycogen synthase kinase 3 beta	Homo sapiens	34-43
17666435-8	2007	These results indicate a role for GSK-3beta in ceramide-induced apoptosis, in which GSK-3beta acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 and caspase-8.	Ceramides	47-55	glycogen synthase kinase 3 beta	Homo sapiens	84-93
17565981-9	2007	There was no significant difference in FRET efficiency between T4 and T4C3, although only T4C3 in the presence of active GSK3beta leads to the formation of Sarkosyl-insoluble inclusions.	sarkosyl	156-164	glycogen synthase kinase 3 beta	Homo sapiens	121-129
17609201-0	2007	Phosphorylation of TIMAP by glycogen synthase kinase-3beta activates its associated protein phosphatase 1.	timap	19-24	glycogen synthase kinase 3 beta	Homo sapiens	28-58
17609201-4	2007	In cell-free assays, immunopurified TIMAP was phosphorylated by PKA and, after PKA priming, by GSK-3beta.	timap	36-41	glycogen synthase kinase 3 beta	Homo sapiens	95-104
17609201-5	2007	Site-specific Ser to Ala substitution identified amino acid residues Ser333/Ser337 as the likely PKA/GSK-3beta phosphorylation site.	Serine	14-17	glycogen synthase kinase 3 beta	Homo sapiens	101-110
17609201-5	2007	Site-specific Ser to Ala substitution identified amino acid residues Ser333/Ser337 as the likely PKA/GSK-3beta phosphorylation site.	Alanine	21-24	glycogen synthase kinase 3 beta	Homo sapiens	101-110
17609201-13	2007	We conclude that TIMAP is a target for PKA-primed GSK-3beta-mediated phosphorylation.	timap	17-22	glycogen synthase kinase 3 beta	Homo sapiens	50-59
17699852-5	2007	As a known PDK-1 inhibitor, OSU-03012 inhibited the PI3K/Akt pathway with downstream effects on BAD, GSK-3beta, FoxO1a, p70S6K, and MDM-2.	OSU 03012	28-37	glycogen synthase kinase 3 beta	Homo sapiens	101-110
17666435-0	2007	GSK-3beta acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramide-induced mitochondrial apoptosis.	Ceramides	96-104	glycogen synthase kinase 3 beta	Homo sapiens	0-9
17666435-3	2007	Here, we show the involvement of GSK-3beta in ceramide-induced mitochondrial apoptosis.	Ceramides	46-54	glycogen synthase kinase 3 beta	Homo sapiens	33-42
17666435-4	2007	Ceramide induced GSK-3beta activation via protein dephosphorylation at serine 9.	Ceramides	0-8	glycogen synthase kinase 3 beta	Homo sapiens	17-26
17666435-4	2007	Ceramide induced GSK-3beta activation via protein dephosphorylation at serine 9.	Serine	71-77	glycogen synthase kinase 3 beta	Homo sapiens	17-26
17666435-6	2007	In this study, we found that caspase-2 activation and the subsequent apoptotic events were abolished by the GSK-3beta inhibitors lithium chloride and SB216763, and by GSK-3beta knockdown using short interfering RNA.	Lithium Chloride	129-145	glycogen synthase kinase 3 beta	Homo sapiens	108-117
17666435-6	2007	In this study, we found that caspase-2 activation and the subsequent apoptotic events were abolished by the GSK-3beta inhibitors lithium chloride and SB216763, and by GSK-3beta knockdown using short interfering RNA.	SB 216763	150-158	glycogen synthase kinase 3 beta	Homo sapiens	108-117
17562708-7	2007	A combination of casein kinase 1delta and glycogen synthase kinase-3beta activities could account for over three-quarters of the serine/threonine phosphorylation sites identified in PHF-tau, indicating that casein kinase 1delta may have a role, together with glycogen synthase kinase-3beta, in the pathogenesis of Alzheimer disease.	Serine	129-135	glycogen synthase kinase 3 beta	Homo sapiens	42-72
17562708-7	2007	A combination of casein kinase 1delta and glycogen synthase kinase-3beta activities could account for over three-quarters of the serine/threonine phosphorylation sites identified in PHF-tau, indicating that casein kinase 1delta may have a role, together with glycogen synthase kinase-3beta, in the pathogenesis of Alzheimer disease.	Threonine	136-145	glycogen synthase kinase 3 beta	Homo sapiens	42-72
17601993-9	2007	Insulin increased phosphorylation of Akt Thr(308) and glycogen synthase kinase-3beta Ser(9), decreased phosphorylation of glycogen synthase (GS) site 3a + b, and increased GS activity (percent I-form) in skeletal muscle (P &lt; 0.01).	Serine	85-88	glycogen synthase kinase 3 beta	Homo sapiens	54-84
17580928-1	2007	We present molecular docking studies on the inhibitors of GSK-3beta kinase in the enzyme binding sites of the X-ray complexes (1H8F, 1PYX, 1O9U, 1Q4L, 1Q5K, and 1UV5) using the Schrodinger docking tool Glide.	1h8f	127-131	glycogen synthase kinase 3 beta	Homo sapiens	58-67
17552518-5	2007	Based upon continued efforts to understand the molecular target for lithium, it now appears that specific inhibitors of the enzyme glycogen synthase kinase-3beta (GSK-3beta) may mimic the therapeutic action of mood stabilizers and might therefore allow for the design of improved drugs for treating patients with bipolar disorder as well as certain neurodegenerative disorders.	Lithium	68-75	glycogen synthase kinase 3 beta	Homo sapiens	131-161
17552518-5	2007	Based upon continued efforts to understand the molecular target for lithium, it now appears that specific inhibitors of the enzyme glycogen synthase kinase-3beta (GSK-3beta) may mimic the therapeutic action of mood stabilizers and might therefore allow for the design of improved drugs for treating patients with bipolar disorder as well as certain neurodegenerative disorders.	Lithium	68-75	glycogen synthase kinase 3 beta	Homo sapiens	163-172
17310999-7	2007	The turnover of c-Myc protein is stringently regulated by post-transcriptional modifications, including phosphorylation of c-Myc threonine 58 (T58) by glycogen synthase kinase-3beta (GSK-3beta).	Threonine	129-138	glycogen synthase kinase 3 beta	Homo sapiens	151-181
17310999-7	2007	The turnover of c-Myc protein is stringently regulated by post-transcriptional modifications, including phosphorylation of c-Myc threonine 58 (T58) by glycogen synthase kinase-3beta (GSK-3beta).	Threonine	129-138	glycogen synthase kinase 3 beta	Homo sapiens	183-192
17522055-0	2007	Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3"-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells.	3,3'-diindolylmethane	57-78	glycogen synthase kinase 3 beta	Homo sapiens	34-43
17597616-3	2007	In the present study, we found that application of fenofibrate and overexpression of PPAR-alpha inhibited endothelin-1 (ET-1)-induced phosphorylation of protein kinase B (Akt) at Ser473 and glycogen synthase kinase3beta (GSK3beta) at Ser9, and prevented ET-1-induced nuclear translocation of NFATc4 in cardiomyocytes.	Fenofibrate	51-62	glycogen synthase kinase 3 beta	Homo sapiens	190-219
17597616-3	2007	In the present study, we found that application of fenofibrate and overexpression of PPAR-alpha inhibited endothelin-1 (ET-1)-induced phosphorylation of protein kinase B (Akt) at Ser473 and glycogen synthase kinase3beta (GSK3beta) at Ser9, and prevented ET-1-induced nuclear translocation of NFATc4 in cardiomyocytes.	Fenofibrate	51-62	glycogen synthase kinase 3 beta	Homo sapiens	221-229
17499232-9	2007	Both gAd and fAd elicited phosphorylation of AMP kinase, insulin receptor substrate-1, Akt and glycogen synthase kinase-3beta.	Flavin-Adenine Dinucleotide	13-16	glycogen synthase kinase 3 beta	Homo sapiens	95-125
17485418-10	2007	SB216763 and SB415286, inhibitors of glycogen synthase kinase-3beta, which is implicated in regulating reactive oxygen species-induced mPT in cardiac mitochondria, did not increase Ca2+ capacity of brain mitochondria.	SB 216763	0-8	glycogen synthase kinase 3 beta	Homo sapiens	37-67
17257745-0	2007	Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3beta/NAG-1 pathway.	Celecoxib	0-9	glycogen synthase kinase 3 beta	Homo sapiens	86-94
17257745-3	2007	Celecoxib inhibited Ser473 Akt and Ser9 GSK3beta phosphorylation and induced upregulation of nonsteroidal anti-inflammatory drugs-activated gene-1 (NAG-1) expression.	Celecoxib	0-9	glycogen synthase kinase 3 beta	Homo sapiens	40-48
17257745-4	2007	The effects of celecoxib on NAG-1 expression were abolished by pretreatment with GSK3beta inhibitor, SB216763.	Celecoxib	15-24	glycogen synthase kinase 3 beta	Homo sapiens	81-89
17257745-4	2007	The effects of celecoxib on NAG-1 expression were abolished by pretreatment with GSK3beta inhibitor, SB216763.	SB 216763	101-109	glycogen synthase kinase 3 beta	Homo sapiens	81-89
17257745-5	2007	Furthermore, GSK3beta gene silencing by siRNA inhibited the celecoxib-induced NAG-1 expression.	Celecoxib	60-69	glycogen synthase kinase 3 beta	Homo sapiens	13-21
17257745-6	2007	Our study demonstrated that Akt/GSK3beta/NAG-1 signal pathway may represent as the major mechanism of the COX-2-independent effects of celecoxib on gastric cancer cells.	Celecoxib	135-144	glycogen synthase kinase 3 beta	Homo sapiens	32-40
17485418-10	2007	SB216763 and SB415286, inhibitors of glycogen synthase kinase-3beta, which is implicated in regulating reactive oxygen species-induced mPT in cardiac mitochondria, did not increase Ca2+ capacity of brain mitochondria.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	13-21	glycogen synthase kinase 3 beta	Homo sapiens	37-67
17485418-10	2007	SB216763 and SB415286, inhibitors of glycogen synthase kinase-3beta, which is implicated in regulating reactive oxygen species-induced mPT in cardiac mitochondria, did not increase Ca2+ capacity of brain mitochondria.	Reactive Oxygen Species	103-126	glycogen synthase kinase 3 beta	Homo sapiens	37-67
17403689-10	2007	We further demonstrate that hydrogen peroxide phosphorylates tyrosine 216 of GSK-3beta.	Hydrogen Peroxide	28-45	glycogen synthase kinase 3 beta	Homo sapiens	77-86
17575141-7	2007	Dihydrotestosterone addition to preosteoblasts promoted Wnt-dependent transcriptional reporter activity associated with GSK3beta(S-9) phosphorylation and accumulation of nuclear beta-catenin as well as elevated Runx2 expression.	Dihydrotestosterone	0-19	glycogen synthase kinase 3 beta	Homo sapiens	120-128
17440966-12	2007	A novel GSK-3-specific inhibitor TDZD-8 and GSK-3beta siRNA also suppressed the expression of these E2F target genes, indicating that LiCl-induced anti-cancer effect was associated with GSK-3beta inhibition.	Lithium Chloride	134-138	glycogen synthase kinase 3 beta	Homo sapiens	44-53
17440966-12	2007	A novel GSK-3-specific inhibitor TDZD-8 and GSK-3beta siRNA also suppressed the expression of these E2F target genes, indicating that LiCl-induced anti-cancer effect was associated with GSK-3beta inhibition.	Lithium Chloride	134-138	glycogen synthase kinase 3 beta	Homo sapiens	186-195
17434145-0	2007	Phosphorylation of ataxin-3 by glycogen synthase kinase 3beta at serine 256 regulates the aggregation of ataxin-3.	Serine	65-71	glycogen synthase kinase 3 beta	Homo sapiens	31-61
17434145-4	2007	Here we show that S256 site in ataxin-3 is phosphorylated by GSK 3beta.	Coumaphos	18-22	glycogen synthase kinase 3 beta	Homo sapiens	61-70
17434145-7	2007	Our results imply that phosphorylation of serine 256 in ataxin-3 by GSK 3beta regulates ataxin-3 aggregation.	Serine	42-48	glycogen synthase kinase 3 beta	Homo sapiens	68-77
17401440-8	2007	In addition, NMDA caused a rapid deactivation of Akt kinase and this preceded the detrimental activation of the downstream kinase, GSK-3beta.	N-Methylaspartate	13-17	glycogen synthase kinase 3 beta	Homo sapiens	131-140
17401440-10	2007	In addition to preventing ROS accumulation and activation of calpain, BEO (0.01%) counteracted the deactivation of Akt and the consequent activation of GSK-3beta, induced by NMDA.	beo	70-73	glycogen synthase kinase 3 beta	Homo sapiens	152-161
17401440-10	2007	In addition to preventing ROS accumulation and activation of calpain, BEO (0.01%) counteracted the deactivation of Akt and the consequent activation of GSK-3beta, induced by NMDA.	N-Methylaspartate	174-178	glycogen synthase kinase 3 beta	Homo sapiens	152-161
17403689-10	2007	We further demonstrate that hydrogen peroxide phosphorylates tyrosine 216 of GSK-3beta.	Tyrosine	61-69	glycogen synthase kinase 3 beta	Homo sapiens	77-86
17403689-12	2007	The activated GSK-3beta phosphorylates Fyn at threonine residue(s).	Threonine	46-55	glycogen synthase kinase 3 beta	Homo sapiens	14-23
17495324-3	2007	Here, we report that expression of Mcl-1 was correlated with phosphorylated GSK-3beta (p-GSK-3beta) at Ser(9) (an inactivated form of GSK-3beta) in multiple cancer cell lines and primary human cancer samples.	Serine	103-106	glycogen synthase kinase 3 beta	Homo sapiens	76-85
17517424-0	2007	Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	80-84	glycogen synthase kinase 3 beta	Homo sapiens	14-44
17517424-4	2007	MPTP caused a rapid activation of GSK-3beta, evidenced by the decrease in level of phospho-Ser9 of GSK-3beta and the increase in level of phospho-Ser396 of tau, a known GSK-3beta substrate.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	glycogen synthase kinase 3 beta	Homo sapiens	34-43
17517424-4	2007	MPTP caused a rapid activation of GSK-3beta, evidenced by the decrease in level of phospho-Ser9 of GSK-3beta and the increase in level of phospho-Ser396 of tau, a known GSK-3beta substrate.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	glycogen synthase kinase 3 beta	Homo sapiens	99-108
17517424-4	2007	MPTP caused a rapid activation of GSK-3beta, evidenced by the decrease in level of phospho-Ser9 of GSK-3beta and the increase in level of phospho-Ser396 of tau, a known GSK-3beta substrate.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	glycogen synthase kinase 3 beta	Homo sapiens	99-108
17517424-5	2007	Blockage of GSK-3beta activity by its two specific inhibitors, indirubin-3"-oxime and AR-A014418, prevented dopaminergic neurons from MPTP-induced apoptosis.	indirubin-3'-monoxime	63-81	glycogen synthase kinase 3 beta	Homo sapiens	12-21
17517424-5	2007	Blockage of GSK-3beta activity by its two specific inhibitors, indirubin-3"-oxime and AR-A014418, prevented dopaminergic neurons from MPTP-induced apoptosis.	N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea	86-96	glycogen synthase kinase 3 beta	Homo sapiens	12-21
17517424-5	2007	Blockage of GSK-3beta activity by its two specific inhibitors, indirubin-3"-oxime and AR-A014418, prevented dopaminergic neurons from MPTP-induced apoptosis.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	134-138	glycogen synthase kinase 3 beta	Homo sapiens	12-21
17517424-6	2007	Additionally, inhibition of GSK-3beta activity restored the depletion of striatal dopamine and ameliorated behavioral impairments caused by MPTP.	Dopamine	82-90	glycogen synthase kinase 3 beta	Homo sapiens	28-37
17517424-6	2007	Additionally, inhibition of GSK-3beta activity restored the depletion of striatal dopamine and ameliorated behavioral impairments caused by MPTP.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	140-144	glycogen synthase kinase 3 beta	Homo sapiens	28-37
17350261-3	2007	An X-ray structure of a co-crystal of GSK-3beta and 3 (IC(50)=3nM) depicts the hydrogen bonding and hydrophobic interactions in the ATP-binding pocket of this serine/threonine protein kinase.	Hydrogen	79-87	glycogen synthase kinase 3 beta	Homo sapiens	38-53
17350261-3	2007	An X-ray structure of a co-crystal of GSK-3beta and 3 (IC(50)=3nM) depicts the hydrogen bonding and hydrophobic interactions in the ATP-binding pocket of this serine/threonine protein kinase.	Adenosine Triphosphate	132-135	glycogen synthase kinase 3 beta	Homo sapiens	38-53
17495324-3	2007	Here, we report that expression of Mcl-1 was correlated with phosphorylated GSK-3beta (p-GSK-3beta) at Ser(9) (an inactivated form of GSK-3beta) in multiple cancer cell lines and primary human cancer samples.	Serine	103-106	glycogen synthase kinase 3 beta	Homo sapiens	89-98
17495324-3	2007	Here, we report that expression of Mcl-1 was correlated with phosphorylated GSK-3beta (p-GSK-3beta) at Ser(9) (an inactivated form of GSK-3beta) in multiple cancer cell lines and primary human cancer samples.	Serine	103-106	glycogen synthase kinase 3 beta	Homo sapiens	89-98
17275129-4	2007	RESULTS: Celecoxib at high doses affected beta-catenin protein by inducing its degradation via GSK3beta and APC along with diminished tumor cell proliferation and survival.	Celecoxib	9-18	glycogen synthase kinase 3 beta	Homo sapiens	95-103
17360711-3	2007	We demonstrate that phosphorylation of serines 353 and 357 by glycogen synthase kinase-3beta (GSK3beta) induces a structural change of the hydrophilic loop of PS1 that can also be mimicked by substitution of the phosphorylation sites by negatively charged amino acids in vitro and in cultured cells.	Serine	39-46	glycogen synthase kinase 3 beta	Homo sapiens	62-92
17360711-3	2007	We demonstrate that phosphorylation of serines 353 and 357 by glycogen synthase kinase-3beta (GSK3beta) induces a structural change of the hydrophilic loop of PS1 that can also be mimicked by substitution of the phosphorylation sites by negatively charged amino acids in vitro and in cultured cells.	Serine	39-46	glycogen synthase kinase 3 beta	Homo sapiens	94-102
17283219-6	2007	Thalidomide-induced cell death was dramatically reduced in HEFs and in embryonic limb buds by the use of inhibitors against Bmps, Dkk1, and Gsk3beta, a beta-catenin antagonist acting downstream of Dkk1 in the Wnt pathway.	Thalidomide	0-11	glycogen synthase kinase 3 beta	Homo sapiens	140-148
17283219-7	2007	Most interestingly, blocking of Dkk1 or Gsk3beta dramatically counteracts thalidomide-induced limb truncations and microphthalmia.	Thalidomide	74-85	glycogen synthase kinase 3 beta	Homo sapiens	40-48
17275129-5	2007	R-Etodolac at physiological doses caused decrease in total and activated beta-catenin protein secondary to decrease in its gene expression and post-translationally through GSK3beta activation.	Etodolac	0-10	glycogen synthase kinase 3 beta	Homo sapiens	172-180
17050006-3	2007	In this work we show that GSK3beta phosphorylates human E2F1 in vitro at serine 403 and threonine 433, both residues localized at its transactivation domain.	Serine	73-79	glycogen synthase kinase 3 beta	Homo sapiens	26-34
17289399-4	2007	mTBI resulted in increased phosphorylation of inhibitory site serine(9) of GSK-3beta, which coincided with increased serine(473) phosphorylation of its upstream kinase PKB and accumulation of its downstream target beta-catenin in the hippocampus.	Serine	62-68	glycogen synthase kinase 3 beta	Homo sapiens	75-84
17289399-4	2007	mTBI resulted in increased phosphorylation of inhibitory site serine(9) of GSK-3beta, which coincided with increased serine(473) phosphorylation of its upstream kinase PKB and accumulation of its downstream target beta-catenin in the hippocampus.	Serine	117-123	glycogen synthase kinase 3 beta	Homo sapiens	75-84
17196174-7	2007	The promotion of NFAT nuclear location by PI3K activation may be mediated by negative regulation of glycogen synthase kinase-3beta (GSK3beta), since the PGD2-stimulated increase in phospho-GSK3beta was down-regulated by LY294002, and inhibition of GSK3beta by SB216763 enhanced PGD2-induced Th2 cytokine production and reversed the inhibitory effect of LY294002.	Prostaglandin D2	153-157	glycogen synthase kinase 3 beta	Homo sapiens	100-130
17196174-7	2007	The promotion of NFAT nuclear location by PI3K activation may be mediated by negative regulation of glycogen synthase kinase-3beta (GSK3beta), since the PGD2-stimulated increase in phospho-GSK3beta was down-regulated by LY294002, and inhibition of GSK3beta by SB216763 enhanced PGD2-induced Th2 cytokine production and reversed the inhibitory effect of LY294002.	Prostaglandin D2	153-157	glycogen synthase kinase 3 beta	Homo sapiens	132-140
17196174-7	2007	The promotion of NFAT nuclear location by PI3K activation may be mediated by negative regulation of glycogen synthase kinase-3beta (GSK3beta), since the PGD2-stimulated increase in phospho-GSK3beta was down-regulated by LY294002, and inhibition of GSK3beta by SB216763 enhanced PGD2-induced Th2 cytokine production and reversed the inhibitory effect of LY294002.	Prostaglandin D2	153-157	glycogen synthase kinase 3 beta	Homo sapiens	189-197
17196174-7	2007	The promotion of NFAT nuclear location by PI3K activation may be mediated by negative regulation of glycogen synthase kinase-3beta (GSK3beta), since the PGD2-stimulated increase in phospho-GSK3beta was down-regulated by LY294002, and inhibition of GSK3beta by SB216763 enhanced PGD2-induced Th2 cytokine production and reversed the inhibitory effect of LY294002.	Prostaglandin D2	153-157	glycogen synthase kinase 3 beta	Homo sapiens	189-197
17196174-7	2007	The promotion of NFAT nuclear location by PI3K activation may be mediated by negative regulation of glycogen synthase kinase-3beta (GSK3beta), since the PGD2-stimulated increase in phospho-GSK3beta was down-regulated by LY294002, and inhibition of GSK3beta by SB216763 enhanced PGD2-induced Th2 cytokine production and reversed the inhibitory effect of LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	220-228	glycogen synthase kinase 3 beta	Homo sapiens	100-130
17196174-7	2007	The promotion of NFAT nuclear location by PI3K activation may be mediated by negative regulation of glycogen synthase kinase-3beta (GSK3beta), since the PGD2-stimulated increase in phospho-GSK3beta was down-regulated by LY294002, and inhibition of GSK3beta by SB216763 enhanced PGD2-induced Th2 cytokine production and reversed the inhibitory effect of LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	220-228	glycogen synthase kinase 3 beta	Homo sapiens	132-140
17196174-7	2007	The promotion of NFAT nuclear location by PI3K activation may be mediated by negative regulation of glycogen synthase kinase-3beta (GSK3beta), since the PGD2-stimulated increase in phospho-GSK3beta was down-regulated by LY294002, and inhibition of GSK3beta by SB216763 enhanced PGD2-induced Th2 cytokine production and reversed the inhibitory effect of LY294002.	SB 216763	260-268	glycogen synthase kinase 3 beta	Homo sapiens	100-130
17196174-7	2007	The promotion of NFAT nuclear location by PI3K activation may be mediated by negative regulation of glycogen synthase kinase-3beta (GSK3beta), since the PGD2-stimulated increase in phospho-GSK3beta was down-regulated by LY294002, and inhibition of GSK3beta by SB216763 enhanced PGD2-induced Th2 cytokine production and reversed the inhibitory effect of LY294002.	SB 216763	260-268	glycogen synthase kinase 3 beta	Homo sapiens	132-140
17196174-7	2007	The promotion of NFAT nuclear location by PI3K activation may be mediated by negative regulation of glycogen synthase kinase-3beta (GSK3beta), since the PGD2-stimulated increase in phospho-GSK3beta was down-regulated by LY294002, and inhibition of GSK3beta by SB216763 enhanced PGD2-induced Th2 cytokine production and reversed the inhibitory effect of LY294002.	Prostaglandin D2	278-282	glycogen synthase kinase 3 beta	Homo sapiens	100-130
17196174-7	2007	The promotion of NFAT nuclear location by PI3K activation may be mediated by negative regulation of glycogen synthase kinase-3beta (GSK3beta), since the PGD2-stimulated increase in phospho-GSK3beta was down-regulated by LY294002, and inhibition of GSK3beta by SB216763 enhanced PGD2-induced Th2 cytokine production and reversed the inhibitory effect of LY294002.	Prostaglandin D2	278-282	glycogen synthase kinase 3 beta	Homo sapiens	132-140
17196174-7	2007	The promotion of NFAT nuclear location by PI3K activation may be mediated by negative regulation of glycogen synthase kinase-3beta (GSK3beta), since the PGD2-stimulated increase in phospho-GSK3beta was down-regulated by LY294002, and inhibition of GSK3beta by SB216763 enhanced PGD2-induced Th2 cytokine production and reversed the inhibitory effect of LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	353-361	glycogen synthase kinase 3 beta	Homo sapiens	100-130
17196174-7	2007	The promotion of NFAT nuclear location by PI3K activation may be mediated by negative regulation of glycogen synthase kinase-3beta (GSK3beta), since the PGD2-stimulated increase in phospho-GSK3beta was down-regulated by LY294002, and inhibition of GSK3beta by SB216763 enhanced PGD2-induced Th2 cytokine production and reversed the inhibitory effect of LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	353-361	glycogen synthase kinase 3 beta	Homo sapiens	132-140
17016438-6	2007	BsB8 cells were partially rescued from NVP-AEW541 by GSK3beta inhibitor, lithium chloride and were sensitized by GSK3beta activator, sodium nitroprusside (SNP).	Nitroprusside	133-153	glycogen synthase kinase 3 beta	Homo sapiens	113-121
17283049-2	2007	Here, we show that ser-114 phosphorylation of p21 protein by glycogen synthase kinase 3beta (GSK-3beta) is required for its degradation in response to UV irradiation and that GSK-3beta activation is a downstream event in the ATR signaling pathway triggered by UV.	Serine	19-22	glycogen synthase kinase 3 beta	Homo sapiens	61-91
17283049-2	2007	Here, we show that ser-114 phosphorylation of p21 protein by glycogen synthase kinase 3beta (GSK-3beta) is required for its degradation in response to UV irradiation and that GSK-3beta activation is a downstream event in the ATR signaling pathway triggered by UV.	Serine	19-22	glycogen synthase kinase 3 beta	Homo sapiens	93-102
17283049-2	2007	Here, we show that ser-114 phosphorylation of p21 protein by glycogen synthase kinase 3beta (GSK-3beta) is required for its degradation in response to UV irradiation and that GSK-3beta activation is a downstream event in the ATR signaling pathway triggered by UV.	Serine	19-22	glycogen synthase kinase 3 beta	Homo sapiens	175-184
17283049-3	2007	UV transiently increased GSK-3beta activity, and this increase could be blocked by caffeine or by ATR small interfering RNA, indicating ATR-dependent activation of GSK-3beta.	Caffeine	83-91	glycogen synthase kinase 3 beta	Homo sapiens	25-34
17283049-4	2007	ser-114, located within the putative GSK-3beta target sequence, was phosphorylated by GSK-3beta upon UV exposure.	Serine	0-3	glycogen synthase kinase 3 beta	Homo sapiens	37-46
17283049-4	2007	ser-114, located within the putative GSK-3beta target sequence, was phosphorylated by GSK-3beta upon UV exposure.	Serine	0-3	glycogen synthase kinase 3 beta	Homo sapiens	86-95
17283049-8	2007	These data show that GSK-3beta is activated by UV irradiation through the ATR signaling pathway and phosphorylates p21 at ser-114 for its degradation by the proteasome.	Serine	122-125	glycogen synthase kinase 3 beta	Homo sapiens	21-30
16733521-11	2007	The kinase glycogen synthase kinase 3 beta (GSK3beta) is considered as an interesting target of lithium, the classical drug used in BD.	Lithium	96-103	glycogen synthase kinase 3 beta	Homo sapiens	11-42
16733521-11	2007	The kinase glycogen synthase kinase 3 beta (GSK3beta) is considered as an interesting target of lithium, the classical drug used in BD.	Lithium	96-103	glycogen synthase kinase 3 beta	Homo sapiens	44-52
17318191-6	2007	Imatinib, a Bcr-Abl antagonist, impairs the beta-catenin/TCF-related transcription causing a rapid cytosolic retention of Y-unphosphorylated beta-catenin, which presents an increased binding affinity for the Axin/GSK3beta complex.	Imatinib Mesylate	0-8	glycogen synthase kinase 3 beta	Homo sapiens	213-221
17050006-3	2007	In this work we show that GSK3beta phosphorylates human E2F1 in vitro at serine 403 and threonine 433, both residues localized at its transactivation domain.	Threonine	88-97	glycogen synthase kinase 3 beta	Homo sapiens	26-34
17158207-8	2007	Effects of TNFalpha and C6 on insulin-stimulated phosphorylation of glycogen synthase kinase 3beta were prevented by myriocin and tautomycin, a PP1 inhibitor, further implicating a de novo ceramide-PP1 pathway.	thermozymocidin	117-125	glycogen synthase kinase 3 beta	Homo sapiens	68-98
17158207-8	2007	Effects of TNFalpha and C6 on insulin-stimulated phosphorylation of glycogen synthase kinase 3beta were prevented by myriocin and tautomycin, a PP1 inhibitor, further implicating a de novo ceramide-PP1 pathway.	Ceramides	189-197	glycogen synthase kinase 3 beta	Homo sapiens	68-98
17158207-8	2007	Effects of TNFalpha and C6 on insulin-stimulated phosphorylation of glycogen synthase kinase 3beta were prevented by myriocin and tautomycin, a PP1 inhibitor, further implicating a de novo ceramide-PP1 pathway.	tautomycin	130-140	glycogen synthase kinase 3 beta	Homo sapiens	68-98
17018257-0	2007	3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.	1H-pyrazolo[4,3-d]pyrimidine	41-59	glycogen synthase kinase 3 beta	Homo sapiens	75-105
18040831-5	2007	In a series of studies initiated using in vitro, then in vivo models of HIV-1-associated dementia (HAD), we have demonstrated the ability of the mood stabilizing and anticonvulsant drug, sodium valproate (VPA), that inhibits GSK-3beta activity and other downstream mediators, to reverse HIV-1-induced damage to synaptic pathways in the CNS.	Valproic Acid	205-208	glycogen synthase kinase 3 beta	Homo sapiens	225-234
17339365-9	2007	Increased Akt phosphorylation following treatment with doxorubicin was accompanied by increased phosphorylation of glycogen synthase kinase 3beta (GSK3beta) and FOXO3A, which are substrates of Akt (both GSK3beta and FOXO3A lose their proapoptotic activities when they are phosphorylated).	Doxorubicin	55-66	glycogen synthase kinase 3 beta	Homo sapiens	115-145
17339365-9	2007	Increased Akt phosphorylation following treatment with doxorubicin was accompanied by increased phosphorylation of glycogen synthase kinase 3beta (GSK3beta) and FOXO3A, which are substrates of Akt (both GSK3beta and FOXO3A lose their proapoptotic activities when they are phosphorylated).	Doxorubicin	55-66	glycogen synthase kinase 3 beta	Homo sapiens	147-155
17339365-9	2007	Increased Akt phosphorylation following treatment with doxorubicin was accompanied by increased phosphorylation of glycogen synthase kinase 3beta (GSK3beta) and FOXO3A, which are substrates of Akt (both GSK3beta and FOXO3A lose their proapoptotic activities when they are phosphorylated).	Doxorubicin	55-66	glycogen synthase kinase 3 beta	Homo sapiens	203-211
17339365-10	2007	Selenium reduced the abundance of phospho-GSK3beta induced by doxorubicin, whereas chemical inhibition of GSK3beta activity muted the apoptotic response to the selenium/doxorubicin combination.	Selenium	0-8	glycogen synthase kinase 3 beta	Homo sapiens	42-50
17339365-10	2007	Selenium reduced the abundance of phospho-GSK3beta induced by doxorubicin, whereas chemical inhibition of GSK3beta activity muted the apoptotic response to the selenium/doxorubicin combination.	Doxorubicin	62-73	glycogen synthase kinase 3 beta	Homo sapiens	42-50
17339365-10	2007	Selenium reduced the abundance of phospho-GSK3beta induced by doxorubicin, whereas chemical inhibition of GSK3beta activity muted the apoptotic response to the selenium/doxorubicin combination.	Selenium	160-168	glycogen synthase kinase 3 beta	Homo sapiens	106-114
17339365-10	2007	Selenium reduced the abundance of phospho-GSK3beta induced by doxorubicin, whereas chemical inhibition of GSK3beta activity muted the apoptotic response to the selenium/doxorubicin combination.	Doxorubicin	169-180	glycogen synthase kinase 3 beta	Homo sapiens	106-114
17363508-4	2007	Inactivation of GSK-3beta in TT cells with well-known GSK-3beta inhibitors such as lithium chloride (LiCl) and SB216763 is associated with both growth suppression and a significant decrease in neuroendocrine markers such as human achaete-scute complex-like 1 and chromogranin A.	Lithium Chloride	83-99	glycogen synthase kinase 3 beta	Homo sapiens	16-25
17363508-4	2007	Inactivation of GSK-3beta in TT cells with well-known GSK-3beta inhibitors such as lithium chloride (LiCl) and SB216763 is associated with both growth suppression and a significant decrease in neuroendocrine markers such as human achaete-scute complex-like 1 and chromogranin A.	Lithium Chloride	83-99	glycogen synthase kinase 3 beta	Homo sapiens	54-63
17363508-4	2007	Inactivation of GSK-3beta in TT cells with well-known GSK-3beta inhibitors such as lithium chloride (LiCl) and SB216763 is associated with both growth suppression and a significant decrease in neuroendocrine markers such as human achaete-scute complex-like 1 and chromogranin A.	Lithium Chloride	101-105	glycogen synthase kinase 3 beta	Homo sapiens	16-25
17363508-4	2007	Inactivation of GSK-3beta in TT cells with well-known GSK-3beta inhibitors such as lithium chloride (LiCl) and SB216763 is associated with both growth suppression and a significant decrease in neuroendocrine markers such as human achaete-scute complex-like 1 and chromogranin A.	Lithium Chloride	101-105	glycogen synthase kinase 3 beta	Homo sapiens	54-63
17363508-4	2007	Inactivation of GSK-3beta in TT cells with well-known GSK-3beta inhibitors such as lithium chloride (LiCl) and SB216763 is associated with both growth suppression and a significant decrease in neuroendocrine markers such as human achaete-scute complex-like 1 and chromogranin A.	SB 216763	111-119	glycogen synthase kinase 3 beta	Homo sapiens	16-25
17363508-4	2007	Inactivation of GSK-3beta in TT cells with well-known GSK-3beta inhibitors such as lithium chloride (LiCl) and SB216763 is associated with both growth suppression and a significant decrease in neuroendocrine markers such as human achaete-scute complex-like 1 and chromogranin A.	SB 216763	111-119	glycogen synthase kinase 3 beta	Homo sapiens	54-63
17234346-7	2007	We propose that the neuroprotective effect of lovastatin may be due to inactivation of GSK-3beta activity, resulting in induction of Wnt signaling.	Lovastatin	46-56	glycogen synthase kinase 3 beta	Homo sapiens	87-96
17148450-8	2007	GSK-3alpha silencing resulted in reduced tyrosine phosphorylation of GSK-3beta, suggesting that tyrosine phosphorylation is also a critical autoregulatory event.	Tyrosine	41-49	glycogen synthase kinase 3 beta	Homo sapiens	69-78
17148450-8	2007	GSK-3alpha silencing resulted in reduced tyrosine phosphorylation of GSK-3beta, suggesting that tyrosine phosphorylation is also a critical autoregulatory event.	Tyrosine	96-104	glycogen synthase kinase 3 beta	Homo sapiens	69-78
17234346-12	2007	Our results suggest that lovastatin protects neuronal cells from Abeta-induced apoptosis and causes reduction in GSK-3beta activity, resulting in activation of Wnt signaling.	Lovastatin	25-35	glycogen synthase kinase 3 beta	Homo sapiens	113-122
16806104-0	2007	Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	18-48
16806104-3	2007	We tested whether lithium modified GSK3beta in vivo or in vitro in peripheral blood mononuclear cells (PBMCs) from healthy control and bipolar disorder subjects.	Lithium	18-25	glycogen synthase kinase 3 beta	Homo sapiens	35-43
16806104-5	2007	Immunoblot analyses were used to measure the inhibited, serine9-phosphorylated GSK3beta.	serine9	56-63	glycogen synthase kinase 3 beta	Homo sapiens	79-87
16806104-6	2007	RESULTS: The level of phospho-Ser9-GSK3beta in PBMCs was regulated by agents that modified kinases and phosphatases acting on GSK3beta and was increased by in vitro lithium treatment.	Lithium	165-172	glycogen synthase kinase 3 beta	Homo sapiens	35-43
16806104-7	2007	More important, phospho-Ser9-GSK3beta levels were eightfold higher in PBMCs from lithium-treated bipolar than healthy control subjects.	Lithium	81-88	glycogen synthase kinase 3 beta	Homo sapiens	29-37
16806104-8	2007	CONCLUSIONS: Signaling pathways regulating serine9-phosphorylation of GSK3beta can be studied in human PBMCs.	serine9	43-50	glycogen synthase kinase 3 beta	Homo sapiens	70-78
16806104-9	2007	Both in vitro and in vivo therapeutic lithium treatment is associated with a large increase in phospho-Ser9-GSK3beta in PBMCs.	Lithium	38-45	glycogen synthase kinase 3 beta	Homo sapiens	108-116
16806104-10	2007	Therefore, the inhibitory serine9-phosphorylation of GSK3beta in human PBMCs may provide a biochemical marker to evaluate the association between GSK3beta inhibition and therapeutic responses to lithium treatment.	serine9	26-33	glycogen synthase kinase 3 beta	Homo sapiens	53-61
16806104-10	2007	Therefore, the inhibitory serine9-phosphorylation of GSK3beta in human PBMCs may provide a biochemical marker to evaluate the association between GSK3beta inhibition and therapeutic responses to lithium treatment.	serine9	26-33	glycogen synthase kinase 3 beta	Homo sapiens	146-154
16806104-10	2007	Therefore, the inhibitory serine9-phosphorylation of GSK3beta in human PBMCs may provide a biochemical marker to evaluate the association between GSK3beta inhibition and therapeutic responses to lithium treatment.	Lithium	195-202	glycogen synthase kinase 3 beta	Homo sapiens	53-61
16806104-10	2007	Therefore, the inhibitory serine9-phosphorylation of GSK3beta in human PBMCs may provide a biochemical marker to evaluate the association between GSK3beta inhibition and therapeutic responses to lithium treatment.	Lithium	195-202	glycogen synthase kinase 3 beta	Homo sapiens	146-154
17234779-4	2007	Blockade of PI3K or ILK signaling with pharmacologic inhibitors LY294002 or QLT0267 specifically inhibited stroma-induced phosphorylation of Akt and glycogen synthase kinase 3beta, suppressed STAT3 and ERK1/2 activation, and decreased Notch1 and Hes1 expression in leukemic cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	64-72	glycogen synthase kinase 3 beta	Homo sapiens	149-179
17040210-4	2007	BI-D1870 is cell permeant and prevents the RSK-mediated phorbol ester- and EGF (epidermal growth factor)-induced phosphoryl-ation of glycogen synthase kinase-3beta and LKB1 in human embry-onic kidney 293 cells and Rat-2 cells.	Phorbol Esters	56-69	glycogen synthase kinase 3 beta	Homo sapiens	133-163
17234779-4	2007	Blockade of PI3K or ILK signaling with pharmacologic inhibitors LY294002 or QLT0267 specifically inhibited stroma-induced phosphorylation of Akt and glycogen synthase kinase 3beta, suppressed STAT3 and ERK1/2 activation, and decreased Notch1 and Hes1 expression in leukemic cells.	QLT 0267	76-83	glycogen synthase kinase 3 beta	Homo sapiens	149-179
17046823-8	2006	Further, we found that not only GSK-3beta but also DYRK1B modulates cyclin D1 subcellular localization by the phosphorylation of Thr(288).	Threonine	129-132	glycogen synthase kinase 3 beta	Homo sapiens	32-41
17483602-0	2007	Involvement of glycogen synthase kinase-3beta in palmitate-induced human umbilical vein endothelial cell apoptosis.	Palmitates	49-58	glycogen synthase kinase 3 beta	Homo sapiens	15-45
17483602-6	2007	GSK-3beta was dephosphorylated and its enzymatic activity increased in palmitate-treated HUVECs.	Palmitates	71-80	glycogen synthase kinase 3 beta	Homo sapiens	0-9
17483602-7	2007	In addition, pretreatment with other GSK-3beta inhibitors, e.g. SB216763 or TDZD-8, as well as adenoviral transduction with a catalytically inactive GSK-3beta had significant protective effects against palmitate-induced HUVEC apoptosis.	SB 216763	64-72	glycogen synthase kinase 3 beta	Homo sapiens	37-46
17483602-7	2007	In addition, pretreatment with other GSK-3beta inhibitors, e.g. SB216763 or TDZD-8, as well as adenoviral transduction with a catalytically inactive GSK-3beta had significant protective effects against palmitate-induced HUVEC apoptosis.	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	76-82	glycogen synthase kinase 3 beta	Homo sapiens	37-46
17483602-7	2007	In addition, pretreatment with other GSK-3beta inhibitors, e.g. SB216763 or TDZD-8, as well as adenoviral transduction with a catalytically inactive GSK-3beta had significant protective effects against palmitate-induced HUVEC apoptosis.	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	76-82	glycogen synthase kinase 3 beta	Homo sapiens	149-158
17483602-7	2007	In addition, pretreatment with other GSK-3beta inhibitors, e.g. SB216763 or TDZD-8, as well as adenoviral transduction with a catalytically inactive GSK-3beta had significant protective effects against palmitate-induced HUVEC apoptosis.	Palmitates	202-211	glycogen synthase kinase 3 beta	Homo sapiens	37-46
17483602-7	2007	In addition, pretreatment with other GSK-3beta inhibitors, e.g. SB216763 or TDZD-8, as well as adenoviral transduction with a catalytically inactive GSK-3beta had significant protective effects against palmitate-induced HUVEC apoptosis.	Palmitates	202-211	glycogen synthase kinase 3 beta	Homo sapiens	149-158
17483602-8	2007	CONCLUSION: These results demonstrate that the GSK-3beta signalling pathway is involved in palmitate-induced HUVEC apoptosis.	Palmitates	91-100	glycogen synthase kinase 3 beta	Homo sapiens	47-56
17237295-0	2007	Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3beta activity in human breast cancer cells.	Prodigiosin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	52-82
17237295-8	2007	Prodigiosin-induced apoptosis was recovered by inhibiting GSK-3beta, which might be due, at least in part, to the blockade of the GSK-3beta-dependent up-regulation of death receptors 4 and 5 expression.	Prodigiosin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	58-67
17237295-8	2007	Prodigiosin-induced apoptosis was recovered by inhibiting GSK-3beta, which might be due, at least in part, to the blockade of the GSK-3beta-dependent up-regulation of death receptors 4 and 5 expression.	Prodigiosin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	130-139
17046823-9	2006	These results suggest that DIF-3 induces degradation of cyclin D1 through the GSK-3beta- and DYRK1B-mediated threonine phosphorylation in HeLa cells.	Threonine	109-118	glycogen synthase kinase 3 beta	Homo sapiens	78-87
17030602-7	2006	Overexpression of beta-catenin (SA), which cannot be phosphorylated by GSK-3beta and targeted for ubiquitination, significantly increased migration in fully confluent cells.	2-chloro-10-(4'(N-beta-hydroxyethyl)piperazinyl-1')acetylphenothiazine	32-34	glycogen synthase kinase 3 beta	Homo sapiens	71-80
16799642-8	2006	Upon treatment of L cells with Wnt3a-CM, glycogen synthase kinase-3 (GSK-3beta) becomes highly phosphorylated on Ser 9, which is completely abolished upon inhibition of ILK activity.	Serine	113-116	glycogen synthase kinase 3 beta	Homo sapiens	69-78
17145894-7	2006	Adiponectin-mediated suppression of cyclin D1 expression and attenuation of cell proliferation was abrogated by the GSK-3beta inhibitor lithium chloride.	Lithium Chloride	136-152	glycogen synthase kinase 3 beta	Homo sapiens	116-125
16821070-8	2006	LiCl, a molecule that can inhibit the GSK-3beta activity and down-regulate beta-catenin degradation, could inversely stimulate expression of alpha5 and beta1 integrin.	Lithium Chloride	0-4	glycogen synthase kinase 3 beta	Homo sapiens	38-47
16987962-5	2006	Overexpression of GSK3beta in starved fibroblasts inhibited LPA-induced stable MTs without inhibiting MTOC reorientation.	lysophosphatidic acid	60-63	glycogen synthase kinase 3 beta	Homo sapiens	18-26
16987962-4	2006	In the absence of other treatments, the GSK3beta inhibitors, LiCl or SB216763, induced the formation of stable MTs, but not MTOC reorientation, in starved fibroblasts.	Lithium Chloride	61-65	glycogen synthase kinase 3 beta	Homo sapiens	40-48
16987962-4	2006	In the absence of other treatments, the GSK3beta inhibitors, LiCl or SB216763, induced the formation of stable MTs, but not MTOC reorientation, in starved fibroblasts.	SB 216763	69-77	glycogen synthase kinase 3 beta	Homo sapiens	40-48
17188038-2	2006	Kinase activity is thought to be increased by intramolecular phosphorylation of a tyrosine in the activation loop (Y216 in GSK3beta), whose timing and mechanism is undefined.	Tyrosine	82-90	glycogen synthase kinase 3 beta	Homo sapiens	123-131
17188038-3	2006	We show that GSK3beta autophosphorylates Y216 as a chaperone-dependent transitional intermediate possessing intramolecular tyrosine kinase activity and displaying different sensitivity to small-molecule inhibitors compared to mature GSK3beta.	y216	41-45	glycogen synthase kinase 3 beta	Homo sapiens	13-21
17016648-7	2006	Furthermore, phosphorylated Akt protein (Ser473), which is catalyzed by DNA-PKcs, as well as phosphorylated GSK3beta (a substrate of activated Akt), markedly decreased in bromovanin-treated Jurkat cells, suggesting that bromovanin leads to inactivation of Akt pathway via cleaving DNA-PKcs.	bromovanin	171-181	glycogen synthase kinase 3 beta	Homo sapiens	108-116
16968709-6	2006	Furthermore, glycogen synthase kinase 3beta (GSK3beta) contributes to pai-1 repression by phosphorylating and stabilizing Rev-erb alpha protein, which can be blocked by lithium.	Lithium	169-176	glycogen synthase kinase 3 beta	Homo sapiens	13-43
16968709-6	2006	Furthermore, glycogen synthase kinase 3beta (GSK3beta) contributes to pai-1 repression by phosphorylating and stabilizing Rev-erb alpha protein, which can be blocked by lithium.	Lithium	169-176	glycogen synthase kinase 3 beta	Homo sapiens	45-53
16542821-8	2006	These results suggest that the antipsychotic drug CZP modulates the PI3K/Akt/GSK-3beta pathway by counteracting Ca(2+)/CaM in PTEN-negative U-87MG glioblastoma cells.	Clozapine	50-53	glycogen synthase kinase 3 beta	Homo sapiens	77-86
16542821-2	2006	This study investigated the effect of CZP on the modulation of the PI3K/Akt/GSK-3beta pathway in PTEN-negative U-87MG glioblastoma cells.	Clozapine	38-41	glycogen synthase kinase 3 beta	Homo sapiens	76-85
16542821-5	2006	A voltage-sensitive Ca(2+) channel blocker and calmodulin (CaM) antagonists inhibited Akt phosphorylation, whereas elevation of the intracellular Ca(2+) concentration prevented CZP-induced dephosphorylation of Akt and GSK-3beta, suggesting that Ca(2+)/CaM participates in the inhibition of Akt by CZP in U-87MG cells.	Clozapine	177-180	glycogen synthase kinase 3 beta	Homo sapiens	218-227
16542821-7	2006	The reduction in the cyclin D1 level induced by CZP was abrogated by the inhibition of GSK-3beta, the inhibition of proteasome-dependent proteolysis, or an increase in the intracellular Ca(2+) concentration.	Clozapine	48-51	glycogen synthase kinase 3 beta	Homo sapiens	87-96
16987514-4	2006	Overexpression of the selective protein phosphatase-1 inhibitor protein, inhibitor-2, increased basal GSK3 phosphorylation at Ser21/9 and significantly blocked the KCl-induced dephosphorylation of GSK3beta, but not GSK3alpha.	Potassium Chloride	164-167	glycogen synthase kinase 3 beta	Homo sapiens	197-205
17200689-8	2006	Suppression of GSK-3beta by SB216763 (100 nM) increases CREB phosphorylation, cyclin D1 and fibronectin levels.	SB 216763	28-36	glycogen synthase kinase 3 beta	Homo sapiens	15-24
17200689-9	2006	Two dimensional gel electrophoresis followed by MALDI-TOF mass spectrometric analysis of mesangial proteins reveals that IGF-1 treatment or an inhibition of GSK-3beta increases the expression of the phosphorylated Ser/Thr binding signal adapter protein 14-3-3zeta.	Serine	214-217	glycogen synthase kinase 3 beta	Homo sapiens	157-166
17200689-9	2006	Two dimensional gel electrophoresis followed by MALDI-TOF mass spectrometric analysis of mesangial proteins reveals that IGF-1 treatment or an inhibition of GSK-3beta increases the expression of the phosphorylated Ser/Thr binding signal adapter protein 14-3-3zeta.	Threonine	218-221	glycogen synthase kinase 3 beta	Homo sapiens	157-166
17018141-0	2006	Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells.	trichostatin A	123-137	glycogen synthase kinase 3 beta	Homo sapiens	8-39
16893889-5	2006	Protein-protein docking of GSK-3beta and the phosphorylated cAMP responsive element binding protein (pCREB) (using the available experimentally determined structures), identified Phe67, Gln89, and Asn95 of GSK-3beta as putative binding sites interacting with the CREB phosphorylation motif.	Cyclic AMP	60-64	glycogen synthase kinase 3 beta	Homo sapiens	206-215
16893889-6	2006	Mutations of these residues to alanine impaired GSK-3beta phosphorylation of several substrates, without abrogating its autocatalytic activity.	Alanine	31-38	glycogen synthase kinase 3 beta	Homo sapiens	48-57
17018141-0	2006	Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells.	trichostatin A	123-137	glycogen synthase kinase 3 beta	Homo sapiens	41-49
17018141-0	2006	Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells.	trichostatin A	139-142	glycogen synthase kinase 3 beta	Homo sapiens	8-39
17018141-0	2006	Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells.	trichostatin A	139-142	glycogen synthase kinase 3 beta	Homo sapiens	41-49
17018141-7	2006	In the present study, we investigated the role of GSK3beta in mediating the cytotoxic effects in MCF-7 breast cancer cells treated with trichostatin A (TSA), a prototype HDACI.	trichostatin A	136-150	glycogen synthase kinase 3 beta	Homo sapiens	50-58
17018141-7	2006	In the present study, we investigated the role of GSK3beta in mediating the cytotoxic effects in MCF-7 breast cancer cells treated with trichostatin A (TSA), a prototype HDACI.	trichostatin A	152-155	glycogen synthase kinase 3 beta	Homo sapiens	50-58
17018141-8	2006	We show that TSA induces Akt dephosphorylation in a PP1-dependent manner, resulting in activation of GSK3beta in MCF-7 cells.	trichostatin A	13-16	glycogen synthase kinase 3 beta	Homo sapiens	101-109
17018141-10	2006	Selective inhibition of GSK3beta attenuated TSA induced cytotoxicity and resulted in enhanced proliferation following drug removal.	trichostatin A	44-47	glycogen synthase kinase 3 beta	Homo sapiens	24-32
17018141-11	2006	Our findings identify GSK3beta as an important mediator of TSA-induced cytotoxicity in MCF-7 breast cancer cells.	trichostatin A	59-62	glycogen synthase kinase 3 beta	Homo sapiens	22-30
16968061-5	2006	A polyphenol-rich apple juice extract (AE02) was found to effectively inhibit the kinase activity of GSK3beta, immunoprecipitated from HT29 cells.	Polyphenols	2-12	glycogen synthase kinase 3 beta	Homo sapiens	101-109
17018636-8	2006	Furthermore, combinations of celecoxib and 4HPR suppressed the phosphorylation levels of serine/threonine kinase Akt and its substrate glycogen synthase kinase-3beta more effectively than the single agents did.	Celecoxib	29-38	glycogen synthase kinase 3 beta	Homo sapiens	135-165
17018636-8	2006	Furthermore, combinations of celecoxib and 4HPR suppressed the phosphorylation levels of serine/threonine kinase Akt and its substrate glycogen synthase kinase-3beta more effectively than the single agents did.	Fenretinide	43-47	glycogen synthase kinase 3 beta	Homo sapiens	135-165
16860989-7	2006	Immunoblotting revealed that resveratrol 50 microM induced the phosphorylation/activation of Akt and extracellular signal-regulated kinase-1 and -2 (ERK1/2) and the phosphorylation/inactivation of glycogen synthase kinase-3beta (GSK-3beta).	Resveratrol	29-40	glycogen synthase kinase 3 beta	Homo sapiens	197-227
16860989-7	2006	Immunoblotting revealed that resveratrol 50 microM induced the phosphorylation/activation of Akt and extracellular signal-regulated kinase-1 and -2 (ERK1/2) and the phosphorylation/inactivation of glycogen synthase kinase-3beta (GSK-3beta).	Resveratrol	29-40	glycogen synthase kinase 3 beta	Homo sapiens	229-238
17003457-9	2006	RESULTS: H2O2 induced Akt phosphorylation in a dose-dependent manner and also induced the phosphorylation of downstream effectors FKHR and GSK-3beta.	Hydrogen Peroxide	9-13	glycogen synthase kinase 3 beta	Homo sapiens	139-148
16767496-3	2006	We previously showed that NaCl also regulates MAPK in different tumor cell lines and we now show that when hypertonic conditions induced with NaCl and other osmolytes were used to stimulate several tumor cell lines, Glycogen Synthase Kinase 3beta (GSK3beta) was rapidly dephosphorylated at serine 9 and its kinase activity was increased.	Sodium Chloride	26-30	glycogen synthase kinase 3 beta	Homo sapiens	216-246
16767496-3	2006	We previously showed that NaCl also regulates MAPK in different tumor cell lines and we now show that when hypertonic conditions induced with NaCl and other osmolytes were used to stimulate several tumor cell lines, Glycogen Synthase Kinase 3beta (GSK3beta) was rapidly dephosphorylated at serine 9 and its kinase activity was increased.	Sodium Chloride	26-30	glycogen synthase kinase 3 beta	Homo sapiens	248-256
16767496-3	2006	We previously showed that NaCl also regulates MAPK in different tumor cell lines and we now show that when hypertonic conditions induced with NaCl and other osmolytes were used to stimulate several tumor cell lines, Glycogen Synthase Kinase 3beta (GSK3beta) was rapidly dephosphorylated at serine 9 and its kinase activity was increased.	Sodium Chloride	142-146	glycogen synthase kinase 3 beta	Homo sapiens	216-246
16767496-3	2006	We previously showed that NaCl also regulates MAPK in different tumor cell lines and we now show that when hypertonic conditions induced with NaCl and other osmolytes were used to stimulate several tumor cell lines, Glycogen Synthase Kinase 3beta (GSK3beta) was rapidly dephosphorylated at serine 9 and its kinase activity was increased.	Sodium Chloride	142-146	glycogen synthase kinase 3 beta	Homo sapiens	248-256
16767496-3	2006	We previously showed that NaCl also regulates MAPK in different tumor cell lines and we now show that when hypertonic conditions induced with NaCl and other osmolytes were used to stimulate several tumor cell lines, Glycogen Synthase Kinase 3beta (GSK3beta) was rapidly dephosphorylated at serine 9 and its kinase activity was increased.	Serine	290-296	glycogen synthase kinase 3 beta	Homo sapiens	216-246
16968061-9	2006	The free aglycon phloretin as well as the flavonol quercetin effectively inhibited isolated GSK3beta, but did not affect the respective kinase activity within HT29 cells.	aglycon phloretin	9-26	glycogen synthase kinase 3 beta	Homo sapiens	92-100
16968061-9	2006	The free aglycon phloretin as well as the flavonol quercetin effectively inhibited isolated GSK3beta, but did not affect the respective kinase activity within HT29 cells.	3-hydroxyflavone	42-50	glycogen synthase kinase 3 beta	Homo sapiens	92-100
16968061-9	2006	The free aglycon phloretin as well as the flavonol quercetin effectively inhibited isolated GSK3beta, but did not affect the respective kinase activity within HT29 cells.	Quercetin	51-60	glycogen synthase kinase 3 beta	Homo sapiens	92-100
16940750-3	2006	FGF signals are transduced through FGF receptor to the FRS2-GRB2-GAB1-PI3K-AKT signaling cascade to downregulate GSK3beta activity depending on Ser 9 phosphorylation.	Serine	144-147	glycogen synthase kinase 3 beta	Homo sapiens	113-121
16954730-13	2006	Based on published in vitro data, lithium may exert this effect by inhibiting neuronal glycogen synthase kinase-3beta.	Lithium	34-41	glycogen synthase kinase 3 beta	Homo sapiens	87-117
16855632-7	2006	Moreover, stabilized c-Myc from the ALL cell lines showed decreased affinity for glycogen synthase kinase3beta, the kinase that phosphorylates c-Myc at Threonine 58 and facilitates its degradation.	Threonine	152-161	glycogen synthase kinase 3 beta	Homo sapiens	81-110
16914735-7	2006	Reduction of GCKR expression inhibits Wnt3a-induced phosphorylation of GSK3beta at serine 9 and decreases the accumulation of cytosolic beta-catenin.	Serine	83-89	glycogen synthase kinase 3 beta	Homo sapiens	71-79
16984735-5	2006	Pretreatment with Go6976 (which inhibits PKCalpha and PKCbeta1) or downregulation of endogenous PKCalpha or PKCbeta1 blocked NT-mediated GSK-3beta (but not GSK-3alpha) phosphorylation.	Go 6976	18-24	glycogen synthase kinase 3 beta	Homo sapiens	137-146
16984735-6	2006	Moreover, a selective PKCbeta inhibitor, LY379196, reduced NT-mediated GSK-3beta (but not GSK-3alpha) phosphorylation, suggesting a role for PKCbeta1 in the NT-mediated phosphorylation of GSK-3beta and an undefined kinase in the NT-mediated phosphorylation of GSK-3alpha.	5,21 - 12,17-dimetheneo-18H-dibenzo(i,o)pyrrolo(3,4-1)(1,8)diazacyclohexandecine-18,10(19H)dione,8((dimethylamino)methyl)-6,7,8,9,10,11-hexahydro,monomethanesulfonate	41-49	glycogen synthase kinase 3 beta	Homo sapiens	71-80
16882987-0	2006	Expression of endometrial glycogen synthase kinase-3beta protein throughout the menstrual cycle and its regulation by progesterone.	Progesterone	118-130	glycogen synthase kinase 3 beta	Homo sapiens	26-56
16882987-1	2006	Glycogen synthase kinase-3beta (GSK-3beta) is a serine/threonine kinase that plays a role in glycogen synthesis by inhibiting glycogen synthase (GS) through phosphorylation.	Glycogen	93-101	glycogen synthase kinase 3 beta	Homo sapiens	0-30
16882987-1	2006	Glycogen synthase kinase-3beta (GSK-3beta) is a serine/threonine kinase that plays a role in glycogen synthesis by inhibiting glycogen synthase (GS) through phosphorylation.	Glycogen	93-101	glycogen synthase kinase 3 beta	Homo sapiens	32-41
16882987-2	2006	We hypothesized that GSK-3beta by virtue of its role in glycogen synthesis through the inhibition of GS will play a role in the preparation of the endometrium for blastocyst implantation.	Glycogen	56-64	glycogen synthase kinase 3 beta	Homo sapiens	21-30
16882987-4	2006	WBA showed more than 5-fold higher endometrial expression of the phosphorylated GSK-3beta (pGSK-3beta) isoform (inactive) in the secretory phase as compared with the proliferative phase (P &lt; 0.001), whereas no differences in total GSK-3beta expression were detected.	pgsk-3beta	91-101	glycogen synthase kinase 3 beta	Homo sapiens	80-89
16984735-6	2006	Moreover, a selective PKCbeta inhibitor, LY379196, reduced NT-mediated GSK-3beta (but not GSK-3alpha) phosphorylation, suggesting a role for PKCbeta1 in the NT-mediated phosphorylation of GSK-3beta and an undefined kinase in the NT-mediated phosphorylation of GSK-3alpha.	5,21 - 12,17-dimetheneo-18H-dibenzo(i,o)pyrrolo(3,4-1)(1,8)diazacyclohexandecine-18,10(19H)dione,8((dimethylamino)methyl)-6,7,8,9,10,11-hexahydro,monomethanesulfonate	41-49	glycogen synthase kinase 3 beta	Homo sapiens	188-197
16849547-10	2006	Lithium chloride (LiCl), an inhibitor of glycogen synthase kinase-3beta, increased cytosolic and nuclear beta-catenin level, NOS2 expression, and NO.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	41-71
16951581-4	2006	Estradiol treatment decreased hippocampal injury, inhibited glycogen synthase kinase-3beta and decreased the hyperphosphorylation of Tau and the interaction of Tau with glycogen synthase kinase-3beta and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor.	Estradiol	0-9	glycogen synthase kinase 3 beta	Homo sapiens	60-90
16951581-4	2006	Estradiol treatment decreased hippocampal injury, inhibited glycogen synthase kinase-3beta and decreased the hyperphosphorylation of Tau and the interaction of Tau with glycogen synthase kinase-3beta and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor.	Estradiol	0-9	glycogen synthase kinase 3 beta	Homo sapiens	169-199
16951581-5	2006	These findings suggest that ischemia produces a strong association between Tau and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor, and estradiol can exert at least part of its neuroprotective activity through inhibition of glycogen synthase kinase-3beta.	Estradiol	154-163	glycogen synthase kinase 3 beta	Homo sapiens	242-272
16787414-8	2006	Thus, we believe that the thiazolidinedione regulates tau phosphorylation through a PPARgamma-dependent/independent mechanism involving an Akt/glycogen synthase kinase-3(GSK-3beta)-independent signalling cascade: PDK1/p70S6K/mTor.	2,4-thiazolidinedione	26-43	glycogen synthase kinase 3 beta	Homo sapiens	143-179
16723502-4	2006	Inactivation of GSK-3beta may be due to the NGF/TrkA-mediated activation of phosphatidylinositol-3 kinase (PI-3 kinase), which increases the levels of phosphatydilinositol 3-phosphate [PI3P].	phosphatydilinositol 3-phosphate	151-183	glycogen synthase kinase 3 beta	Homo sapiens	16-25
16849547-10	2006	Lithium chloride (LiCl), an inhibitor of glycogen synthase kinase-3beta, increased cytosolic and nuclear beta-catenin level, NOS2 expression, and NO.	Lithium Chloride	18-22	glycogen synthase kinase 3 beta	Homo sapiens	41-71
16735023-3	2006	Here, we report that the induction of apoptosis by withdrawal of serum and potassium triggers dephosphorylation of GSK-3beta at serine 9 and subsequent translocation of these molecules into neuronal lipid raft microdomains.	Potassium	75-84	glycogen synthase kinase 3 beta	Homo sapiens	115-124
16735023-3	2006	Here, we report that the induction of apoptosis by withdrawal of serum and potassium triggers dephosphorylation of GSK-3beta at serine 9 and subsequent translocation of these molecules into neuronal lipid raft microdomains.	Serine	128-134	glycogen synthase kinase 3 beta	Homo sapiens	115-124
15993040-0	2006	Involvement of glycogen synthase kinase-3beta in hydrogen peroxide-induced suppression of Tcf/Lef-dependent transcriptional activity.	Hydrogen Peroxide	49-66	glycogen synthase kinase 3 beta	Homo sapiens	15-45
16891464-9	2006	GSK3beta phosphorylation, a reliable pharmacodynamic marker for enzastaurin activity, and AKT phosphorylation were both decreased with enzastaurin treatment.	enzastaurin	64-75	glycogen synthase kinase 3 beta	Homo sapiens	0-8
16891464-9	2006	GSK3beta phosphorylation, a reliable pharmacodynamic marker for enzastaurin activity, and AKT phosphorylation were both decreased with enzastaurin treatment.	enzastaurin	135-146	glycogen synthase kinase 3 beta	Homo sapiens	0-8
16583435-1	2006	AKT-glycogen synthase kinase 3beta (GSK3beta) signaling is a target of lithium and has been implicated in the pathogenesis of mood disorders and schizophrenia.	Lithium	71-78	glycogen synthase kinase 3 beta	Homo sapiens	36-44
16678015-4	2006	PDTC reduced the HI-induced dephosphorylation of Akt and glycogen synthase kinase-3beta (GSK-3beta), expression of cleaved caspase-3, and nuclear translocation of NF-kappaB in the neonatal brain.	hi	17-19	glycogen synthase kinase 3 beta	Homo sapiens	57-87
16678015-4	2006	PDTC reduced the HI-induced dephosphorylation of Akt and glycogen synthase kinase-3beta (GSK-3beta), expression of cleaved caspase-3, and nuclear translocation of NF-kappaB in the neonatal brain.	hi	17-19	glycogen synthase kinase 3 beta	Homo sapiens	89-98
15993040-5	2006	Overexpression of Akt/PKB attenuates H(2)O(2)-induced dephosphorylation of GSK-3beta.	Hydrogen Peroxide	37-45	glycogen synthase kinase 3 beta	Homo sapiens	75-84
15993040-8	2006	These findings suggest that GSK-3beta is involved in H(2)O(2)-mediated inhibition of Tcf/Lef-dependent transcriptional activity.	Hydrogen Peroxide	53-61	glycogen synthase kinase 3 beta	Homo sapiens	28-37
16645590-5	2006	Furthermore, enzastaurin downregulated AKT activity and its downstream effectors GSK3beta and ribosomal protein S6.	enzastaurin	13-24	glycogen synthase kinase 3 beta	Homo sapiens	81-89
15993040-3	2006	In the present study, we show that GSK-3beta is rapidly dephosphorylated and activated in response to H(2)O(2) treatment.	Hydrogen Peroxide	102-110	glycogen synthase kinase 3 beta	Homo sapiens	35-44
16817865-7	2006	Activation of GSK-3beta, in turn, results in modification of the NF-kappaB subunit RelA at serine 468, thereby regulating the physical interaction of RelA with histone deacetylase-3 corepressor molecules.	Serine	91-97	glycogen synthase kinase 3 beta	Homo sapiens	14-23
16641230-5	2006	Key mediators of synaptic NMDA receptor-dependent neuroprotection, phosphatidylinositol 3 kinase-Akt (PI3 kinase-Akt) signaling to Forkhead box subgroup O (FOXO) export and glycogen synthase kinase 3beta (GSK3beta) inhibition and cAMP response element-binding protein-dependent (CREB-dependent) activation of brain-derived neurotrophic factor (BDNF), can be induced only by low doses of NMDA via this action potential-dependent route.	N-Methylaspartate	26-30	glycogen synthase kinase 3 beta	Homo sapiens	205-213
16331257-3	2006	We have previously shown that both basal and cAMP-induced degradation of cyclin D3 in Reh cells is dependent on Thr-283 phosphorylation by glycogen synthase kinase-3beta (GSK-3beta).	Threonine	112-115	glycogen synthase kinase 3 beta	Homo sapiens	139-169
16331257-3	2006	We have previously shown that both basal and cAMP-induced degradation of cyclin D3 in Reh cells is dependent on Thr-283 phosphorylation by glycogen synthase kinase-3beta (GSK-3beta).	Threonine	112-115	glycogen synthase kinase 3 beta	Homo sapiens	171-180
16622124-13	2006	ZSTK474 inhibited phosphorylation of signaling components downstream from PI3K, such as Akt and glycogen synthase kinase 3beta, and mediated a decrease in cyclin D1 levels.	ZSTK474	0-7	glycogen synthase kinase 3 beta	Homo sapiens	96-126
16331257-3	2006	We have previously shown that both basal and cAMP-induced degradation of cyclin D3 in Reh cells is dependent on Thr-283 phosphorylation by glycogen synthase kinase-3beta (GSK-3beta).	Cyclic AMP	45-49	glycogen synthase kinase 3 beta	Homo sapiens	139-169
16331257-3	2006	We have previously shown that both basal and cAMP-induced degradation of cyclin D3 in Reh cells is dependent on Thr-283 phosphorylation by glycogen synthase kinase-3beta (GSK-3beta).	Cyclic AMP	45-49	glycogen synthase kinase 3 beta	Homo sapiens	171-180
16452634-5	2006	LPA concomitantly activates the Ca(2+)-dependent tyrosine kinase Pyk2, which is detected in a complex with GSK-3beta.	lysophosphatidic acid	0-3	glycogen synthase kinase 3 beta	Homo sapiens	107-116
16630125-8	2006	Curcumin reduced the expression of cell cycle regulators, cyclin D1 and c-Myc proteins, which are both degraded by activated GSK-3beta.	Curcumin	0-8	glycogen synthase kinase 3 beta	Homo sapiens	125-134
16371352-4	2006	Furthermore, inhibition of glycogen synthase kinase-3beta (GSK-3beta) by SB415286 induced expression of COX-2 mRNA and protein as well as the enzyme activity in the gastric cancer cells.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	73-81	glycogen synthase kinase 3 beta	Homo sapiens	27-57
16648553-10	2006	In ovarian carcinoma xenografts, ABT-627, a specific ET(A)R antagonist, suppresses ILK expression, Akt and glycogen synthase kinase-3beta phosphorylation, and tumor growth.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	33-36	glycogen synthase kinase 3 beta	Homo sapiens	107-137
16570353-13	2006	Western blot analysis showed that phospho- GSK-3beta (ser9) was induced by the gemcitabine treatment.	gemcitabine	79-90	glycogen synthase kinase 3 beta	Homo sapiens	43-52
16494969-6	2006	Docking of 2-[[-5-bromo-2-oxoindolin-3-ylidene]amino]-3-(1H-imidazol2-yl)propanoic acid 14 to CDK5/p25 indicates that this compound can interact with the enzyme through four hydrogen bonds; for GSK/3beta, the ligand poses itself in another orientation, also four hydrogen bonds can be formed between the ligand and the receptor, otherwise hydrophobic interactions seem to predominate.	2-[[-5-bromo-2-oxoindolin-3-ylidene]amino]-3-(1h-imidazol2-yl)propanoic acid	11-87	glycogen synthase kinase 3 beta	Homo sapiens	194-203
16494969-6	2006	Docking of 2-[[-5-bromo-2-oxoindolin-3-ylidene]amino]-3-(1H-imidazol2-yl)propanoic acid 14 to CDK5/p25 indicates that this compound can interact with the enzyme through four hydrogen bonds; for GSK/3beta, the ligand poses itself in another orientation, also four hydrogen bonds can be formed between the ligand and the receptor, otherwise hydrophobic interactions seem to predominate.	Hydrogen	174-182	glycogen synthase kinase 3 beta	Homo sapiens	194-203
16494969-6	2006	Docking of 2-[[-5-bromo-2-oxoindolin-3-ylidene]amino]-3-(1H-imidazol2-yl)propanoic acid 14 to CDK5/p25 indicates that this compound can interact with the enzyme through four hydrogen bonds; for GSK/3beta, the ligand poses itself in another orientation, also four hydrogen bonds can be formed between the ligand and the receptor, otherwise hydrophobic interactions seem to predominate.	Hydrogen	263-271	glycogen synthase kinase 3 beta	Homo sapiens	194-203
16371352-4	2006	Furthermore, inhibition of glycogen synthase kinase-3beta (GSK-3beta) by SB415286 induced expression of COX-2 mRNA and protein as well as the enzyme activity in the gastric cancer cells.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	73-81	glycogen synthase kinase 3 beta	Homo sapiens	59-68
16371352-5	2006	The effect of SB415286 was confirmed by the use of two additional GSK-3beta inhibitors, lithium chloride and SB216763.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	14-22	glycogen synthase kinase 3 beta	Homo sapiens	66-75
16504004-2	2006	GSK3beta phosphorylates cyclin D1 on Thr-286, resulting in enhanced ubiquitylation, nuclear export and degradation of the cyclin in the cytoplasm.	Threonine	37-40	glycogen synthase kinase 3 beta	Homo sapiens	0-8
16289783-1	2006	Glycogen synthase kinase-3beta (GSK3beta) is a target of lithium as well as sodium valproate, both of which are effective mood stabilizing prophylatics/treatments for bipolar disorder, a highly heritable psychiatric disorder.	Lithium	57-64	glycogen synthase kinase 3 beta	Homo sapiens	0-30
16289783-1	2006	Glycogen synthase kinase-3beta (GSK3beta) is a target of lithium as well as sodium valproate, both of which are effective mood stabilizing prophylatics/treatments for bipolar disorder, a highly heritable psychiatric disorder.	Lithium	57-64	glycogen synthase kinase 3 beta	Homo sapiens	32-40
16289783-1	2006	Glycogen synthase kinase-3beta (GSK3beta) is a target of lithium as well as sodium valproate, both of which are effective mood stabilizing prophylatics/treatments for bipolar disorder, a highly heritable psychiatric disorder.	Valproic Acid	76-92	glycogen synthase kinase 3 beta	Homo sapiens	0-30
16289783-1	2006	Glycogen synthase kinase-3beta (GSK3beta) is a target of lithium as well as sodium valproate, both of which are effective mood stabilizing prophylatics/treatments for bipolar disorder, a highly heritable psychiatric disorder.	Valproic Acid	76-92	glycogen synthase kinase 3 beta	Homo sapiens	32-40
16504004-6	2006	RESULTS: Here we provide further evidence for TSA-induced ubiquitin-dependent degradation of cyclin D1 and demonstrate that GSK3beta-mediated nuclear export facilitates this activity.	trichostatin A	46-49	glycogen synthase kinase 3 beta	Homo sapiens	124-132
16504004-7	2006	Our observations suggest that TSA treatment results in enhanced cyclin D1 degradation via the GSK3beta/CRM1-dependent nuclear export/26S proteasomal degradation pathway in MCF-7 cells.	trichostatin A	30-33	glycogen synthase kinase 3 beta	Homo sapiens	94-102
16504004-8	2006	CONCLUSION: We have demonstrated that rapid TSA-induced cyclin D1 degradation in MCF-7 cells requires GSK3beta-mediated Thr-286 phosphorylation and the ubiquitin-dependent 26S proteasome pathway.	trichostatin A	44-47	glycogen synthase kinase 3 beta	Homo sapiens	102-110
16504004-8	2006	CONCLUSION: We have demonstrated that rapid TSA-induced cyclin D1 degradation in MCF-7 cells requires GSK3beta-mediated Thr-286 phosphorylation and the ubiquitin-dependent 26S proteasome pathway.	Threonine	120-123	glycogen synthase kinase 3 beta	Homo sapiens	102-110
16337154-7	2006	Blocking PI3-kinase by wortmannin or LY294002 reduced the PARP inhibitor-elicited robust Akt and GSK-3beta phosphorylation upon ischemia-reperfusion, and significantly diminished the recovery of ATP and creatine phosphate showing the importance of Akt activation in the recovery of energy metabolism.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	37-45	glycogen synthase kinase 3 beta	Homo sapiens	97-106
16452215-7	2006	Octreotide treatment decreased the tyrosine phosphorylation levels of the PI3K regulatory subunit p85, induced dephosphorylation of phosphoinositide-dependent kinase 1 (PDK1) and Akt, and activated glycogen synthase kinase 3beta (GSKbeta).	Octreotide	0-10	glycogen synthase kinase 3 beta	Homo sapiens	198-228
16337154-7	2006	Blocking PI3-kinase by wortmannin or LY294002 reduced the PARP inhibitor-elicited robust Akt and GSK-3beta phosphorylation upon ischemia-reperfusion, and significantly diminished the recovery of ATP and creatine phosphate showing the importance of Akt activation in the recovery of energy metabolism.	Wortmannin	23-33	glycogen synthase kinase 3 beta	Homo sapiens	97-106
16162663-5	2006	We assessed whether pharmacological inhibition of GSK-3beta with lithium chloride (LiCl) was sufficient to stimulate myogenesis.	Lithium Chloride	83-87	glycogen synthase kinase 3 beta	Homo sapiens	50-59
16265667-6	2006	Furthermore, our studies on the intracellular signaling pathways reveal that poly(I:C) stimulation activates IkappaB kinase (IKK), extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK) in CRT-MG. Pharmacological inhibitors of nuclear factor-kappaB (NF-kappaB), JNK, ERK, glycogen synthase kinase-3beta (GSK-3beta), and dsRNA-activated protein kinase (PKR) inhibit the expression of IL-8 and IP-10 in astrocytes, indicating that the activation of these signaling molecules is required for the TLR3-mediated chemokine gene induction.	Poly I-C	77-86	glycogen synthase kinase 3 beta	Homo sapiens	296-326
15982448-1	2006	Recent evidence suggests that the AKT1-GSK3beta signalling cascade partially mediates dopamine-dependent behaviours.	Dopamine	86-94	glycogen synthase kinase 3 beta	Homo sapiens	39-47
16397900-1	2006	Tungstate treatment increases the phosphorylation of glycogen synthase kinase-3beta (GSK3beta) at serine 9, which triggers its inactivation both in cultured neural cells and in vivo.	tungstate	0-9	glycogen synthase kinase 3 beta	Homo sapiens	53-83
16397900-1	2006	Tungstate treatment increases the phosphorylation of glycogen synthase kinase-3beta (GSK3beta) at serine 9, which triggers its inactivation both in cultured neural cells and in vivo.	tungstate	0-9	glycogen synthase kinase 3 beta	Homo sapiens	85-93
16397900-1	2006	Tungstate treatment increases the phosphorylation of glycogen synthase kinase-3beta (GSK3beta) at serine 9, which triggers its inactivation both in cultured neural cells and in vivo.	Serine	98-104	glycogen synthase kinase 3 beta	Homo sapiens	53-83
16397900-1	2006	Tungstate treatment increases the phosphorylation of glycogen synthase kinase-3beta (GSK3beta) at serine 9, which triggers its inactivation both in cultured neural cells and in vivo.	Serine	98-104	glycogen synthase kinase 3 beta	Homo sapiens	85-93
16397900-4	2006	Tungstate reduces tau phosphorylation only in primed sequences, namely, those prephosphorylated by other kinases before GSK3beta modification, which are serines 198, 199, or 202 and threonine 231.	tungstate	0-9	glycogen synthase kinase 3 beta	Homo sapiens	120-128
16265667-6	2006	Furthermore, our studies on the intracellular signaling pathways reveal that poly(I:C) stimulation activates IkappaB kinase (IKK), extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK) in CRT-MG. Pharmacological inhibitors of nuclear factor-kappaB (NF-kappaB), JNK, ERK, glycogen synthase kinase-3beta (GSK-3beta), and dsRNA-activated protein kinase (PKR) inhibit the expression of IL-8 and IP-10 in astrocytes, indicating that the activation of these signaling molecules is required for the TLR3-mediated chemokine gene induction.	Poly I-C	77-86	glycogen synthase kinase 3 beta	Homo sapiens	328-337
16611133-9	2006	More recent findings have shown that the effects of lithium on invertebrates may be mediated through inhibition of GSK-3beta in the Wnt-GSK-3 pathway.	Lithium	52-59	glycogen synthase kinase 3 beta	Homo sapiens	115-124
17652946-5	2006	Inhibition of cancer cell-derived GSK3beta activity by GSK3beta inhibitors (SB-216763, AR-A014418) was detected by the NRIKA.	SB 216763	76-85	glycogen synthase kinase 3 beta	Homo sapiens	34-42
17652946-5	2006	Inhibition of cancer cell-derived GSK3beta activity by GSK3beta inhibitors (SB-216763, AR-A014418) was detected by the NRIKA.	SB 216763	76-85	glycogen synthase kinase 3 beta	Homo sapiens	55-63
17652946-5	2006	Inhibition of cancer cell-derived GSK3beta activity by GSK3beta inhibitors (SB-216763, AR-A014418) was detected by the NRIKA.	N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea	87-97	glycogen synthase kinase 3 beta	Homo sapiens	34-42
17652946-5	2006	Inhibition of cancer cell-derived GSK3beta activity by GSK3beta inhibitors (SB-216763, AR-A014418) was detected by the NRIKA.	N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea	87-97	glycogen synthase kinase 3 beta	Homo sapiens	55-63
16861141-0	2006	Association study of the glycogen synthase kinase-3beta gene polymorphism with prophylactic lithium response in bipolar patients.	Lithium	92-99	glycogen synthase kinase 3 beta	Homo sapiens	25-55
16861141-1	2006	A relationship between response to lithium prophylaxis and T-50C polymorphism of glycogen synthase kinase-3beta (GSK-3beta) gene was investigated in 89 bipolar patients (41 male and 48 female) who have been taking lithium for at least 5 years.	Lithium	35-42	glycogen synthase kinase 3 beta	Homo sapiens	81-111
16861141-1	2006	A relationship between response to lithium prophylaxis and T-50C polymorphism of glycogen synthase kinase-3beta (GSK-3beta) gene was investigated in 89 bipolar patients (41 male and 48 female) who have been taking lithium for at least 5 years.	Lithium	35-42	glycogen synthase kinase 3 beta	Homo sapiens	113-122
16861141-1	2006	A relationship between response to lithium prophylaxis and T-50C polymorphism of glycogen synthase kinase-3beta (GSK-3beta) gene was investigated in 89 bipolar patients (41 male and 48 female) who have been taking lithium for at least 5 years.	Lithium	214-221	glycogen synthase kinase 3 beta	Homo sapiens	81-111
16861141-1	2006	A relationship between response to lithium prophylaxis and T-50C polymorphism of glycogen synthase kinase-3beta (GSK-3beta) gene was investigated in 89 bipolar patients (41 male and 48 female) who have been taking lithium for at least 5 years.	Lithium	214-221	glycogen synthase kinase 3 beta	Homo sapiens	113-122
16322400-4	2005	In other cell types lithium activates canonical Wnt signalling by GSK-3beta inhibition, which in turn stabilizes cytosolic free beta-catenin.	Lithium	20-27	glycogen synthase kinase 3 beta	Homo sapiens	66-75
16213715-0	2005	Structural basis for the GSK-3beta binding affinity and selectivity against CDK-2 of 1-(4-aminofurazan-3yl)-5-dialkylaminomethyl-1H-[1,2,3] triazole-4-carboxylic acid derivatives.	1-(4-aminofurazan-3yl)-5-dialkylaminomethyl-1h-[1,2,3] triazole-4-carboxylic acid	85-166	glycogen synthase kinase 3 beta	Homo sapiens	25-34
16257959-4	2005	Our first finding that treatment of cells with LiCl, a selective inhibitor of another major tau kinase, glycogen synthase kinase-3beta (GSK-3beta), inhibits phosphorylation of Ser-262 of tau led us to investigate the possible involvement of GSK-3beta in MARK2 activation.	Lithium Chloride	47-51	glycogen synthase kinase 3 beta	Homo sapiens	104-134
16257959-4	2005	Our first finding that treatment of cells with LiCl, a selective inhibitor of another major tau kinase, glycogen synthase kinase-3beta (GSK-3beta), inhibits phosphorylation of Ser-262 of tau led us to investigate the possible involvement of GSK-3beta in MARK2 activation.	Serine	176-179	glycogen synthase kinase 3 beta	Homo sapiens	104-134
16322400-7	2005	RESULTS: LiCl dose-dependently inhibited GSK-3beta, stabilized free beta-catenin and inhibited beta-catenin degradation.	Lithium Chloride	9-13	glycogen synthase kinase 3 beta	Homo sapiens	41-50
16235045-6	2005	Treatment of 3T3-L1 adipocytes with 0.25 mM VO(acac)2 in the presence of 0.25 mM serum albumin synergistically increased glycogen accumulation stimulated by 0.1 and 1 nM insulin, and increased the phosphorylation of IRbeta, IRS1, protein kinase B, and glycogen synthase kinase-3beta.	bis(acetylacetonato)oxovanadium(IV)	44-53	glycogen synthase kinase 3 beta	Homo sapiens	252-282
16153639-5	2005	DIF-1 induced cyclin D1 degradation, but this effect was prevented by treatment with lithium chloride and SB216763, the inhibitors of glycogen synthase kinase-3beta (GSK-3beta).	Lithium Chloride	85-101	glycogen synthase kinase 3 beta	Homo sapiens	134-164
16273260-9	2005	ANKRD6, NKD1 and NKD2 induce class switch from the WNT/GSK3beta signaling pathway to the WNT/PCP signaling pathway.	pcp	93-96	glycogen synthase kinase 3 beta	Homo sapiens	55-63
16253246-0	2005	Nitric oxide induces tau hyperphosphorylation via glycogen synthase kinase-3beta activation.	Nitric Oxide	0-12	glycogen synthase kinase 3 beta	Homo sapiens	50-80
16253246-3	2005	Here we show that nitric oxide produced by sodium nitroprusside (SNP), a recognized donor of nitric oxide, induces tau hyperphosphorylation at Ser396/404 and Ser262 in HEK293/tau441 cells with a simultaneous activation of glycogen synthase kinase-3beta (GSK-3beta).	Nitric Oxide	18-30	glycogen synthase kinase 3 beta	Homo sapiens	222-252
16253246-3	2005	Here we show that nitric oxide produced by sodium nitroprusside (SNP), a recognized donor of nitric oxide, induces tau hyperphosphorylation at Ser396/404 and Ser262 in HEK293/tau441 cells with a simultaneous activation of glycogen synthase kinase-3beta (GSK-3beta).	Nitric Oxide	18-30	glycogen synthase kinase 3 beta	Homo sapiens	254-263
16253246-3	2005	Here we show that nitric oxide produced by sodium nitroprusside (SNP), a recognized donor of nitric oxide, induces tau hyperphosphorylation at Ser396/404 and Ser262 in HEK293/tau441 cells with a simultaneous activation of glycogen synthase kinase-3beta (GSK-3beta).	Nitroprusside	43-63	glycogen synthase kinase 3 beta	Homo sapiens	222-252
16253246-3	2005	Here we show that nitric oxide produced by sodium nitroprusside (SNP), a recognized donor of nitric oxide, induces tau hyperphosphorylation at Ser396/404 and Ser262 in HEK293/tau441 cells with a simultaneous activation of glycogen synthase kinase-3beta (GSK-3beta).	Nitroprusside	43-63	glycogen synthase kinase 3 beta	Homo sapiens	254-263
16253246-4	2005	Pretreatment of the cells with 10 mM lithium chloride (LiCl), an inhibitor of GSK-3, 1 h before SNP administration inhibits GSK-3beta activation and prevents tau from hyperphosphorylation.	Lithium Chloride	37-53	glycogen synthase kinase 3 beta	Homo sapiens	124-133
16253246-4	2005	Pretreatment of the cells with 10 mM lithium chloride (LiCl), an inhibitor of GSK-3, 1 h before SNP administration inhibits GSK-3beta activation and prevents tau from hyperphosphorylation.	Lithium Chloride	55-59	glycogen synthase kinase 3 beta	Homo sapiens	124-133
16253246-5	2005	This is the first direct evidence demonstrating that nitric oxide induces AD-like tau hyperphosphorylation in vitro, and GSK-3beta activation is partially responsible for the nitric oxide-induced tau hyperphosphorylation.	Nitric Oxide	175-187	glycogen synthase kinase 3 beta	Homo sapiens	121-130
16153639-5	2005	DIF-1 induced cyclin D1 degradation, but this effect was prevented by treatment with lithium chloride and SB216763, the inhibitors of glycogen synthase kinase-3beta (GSK-3beta).	Lithium Chloride	85-101	glycogen synthase kinase 3 beta	Homo sapiens	166-175
16153639-5	2005	DIF-1 induced cyclin D1 degradation, but this effect was prevented by treatment with lithium chloride and SB216763, the inhibitors of glycogen synthase kinase-3beta (GSK-3beta).	SB 216763	106-114	glycogen synthase kinase 3 beta	Homo sapiens	134-164
16153639-5	2005	DIF-1 induced cyclin D1 degradation, but this effect was prevented by treatment with lithium chloride and SB216763, the inhibitors of glycogen synthase kinase-3beta (GSK-3beta).	SB 216763	106-114	glycogen synthase kinase 3 beta	Homo sapiens	166-175
16204075-5	2005	We found that this effect is associated with the modulation of inhibitory Ser(9) phosphorylation of GSK-3beta but not with the activating tyrosine phosphorylation.	Serine	74-77	glycogen synthase kinase 3 beta	Homo sapiens	100-109
16107342-5	2005	Although CK2 mainly phosphorylated PTEN at Ser-370 and Ser-385, GSK3beta phosphorylated Ser-362 and Thr-366.	Threonine	100-103	glycogen synthase kinase 3 beta	Homo sapiens	64-72
16107342-6	2005	More importantly, prior phosphorylation of PTEN at Ser-370 by CK2 strongly increased its phosphorylation at Thr-366 by GSK3beta, suggesting that the two may synergize.	Serine	51-54	glycogen synthase kinase 3 beta	Homo sapiens	119-127
16107342-6	2005	More importantly, prior phosphorylation of PTEN at Ser-370 by CK2 strongly increased its phosphorylation at Thr-366 by GSK3beta, suggesting that the two may synergize.	Threonine	108-111	glycogen synthase kinase 3 beta	Homo sapiens	119-127
15946992-5	2005	Inhibition of the glycogen-synthase-kinase-3beta (GSK-3beta) by LiCl prevented this celecoxib-induced translocation, suggesting that phosphorylation of beta-catenin by the GSK-3beta kinase was essential for this release.	Lithium Chloride	64-68	glycogen synthase kinase 3 beta	Homo sapiens	18-48
15927518-9	2005	In addition, the GSK-3beta inhibitors LiCl and TDZD-8 reduced protein degradation in a similar fashion as IGF-I.	Lithium Chloride	38-42	glycogen synthase kinase 3 beta	Homo sapiens	17-26
15927518-9	2005	In addition, the GSK-3beta inhibitors LiCl and TDZD-8 reduced protein degradation in a similar fashion as IGF-I.	4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	47-53	glycogen synthase kinase 3 beta	Homo sapiens	17-26
15927518-10	2005	Our results suggest that PI3K/Akt-mediated inactivation of GSK-3beta and activation of mTOR contribute to the anabolic effects of IGF-I in dexamethasone-treated myotubes.	Dexamethasone	139-152	glycogen synthase kinase 3 beta	Homo sapiens	59-68
16103100-7	2005	As in cultured tumor cells, Enzastaurin treatment suppresses the phosphorylation of GSK3beta in these xenograft tumor tissues.	enzastaurin	28-39	glycogen synthase kinase 3 beta	Homo sapiens	84-92
16103100-9	2005	These data show that Enzastaurin has a direct antitumor effect and that Enzastaurin treatment suppresses GSK3beta phosphorylation in both tumor tissue and in PBMCs, suggesting that GSK3beta phosphorylation may serve as a reliable pharmacodynamic marker for Enzastaurin activity.	enzastaurin	72-83	glycogen synthase kinase 3 beta	Homo sapiens	105-113
16103100-9	2005	These data show that Enzastaurin has a direct antitumor effect and that Enzastaurin treatment suppresses GSK3beta phosphorylation in both tumor tissue and in PBMCs, suggesting that GSK3beta phosphorylation may serve as a reliable pharmacodynamic marker for Enzastaurin activity.	enzastaurin	72-83	glycogen synthase kinase 3 beta	Homo sapiens	181-189
16103100-9	2005	These data show that Enzastaurin has a direct antitumor effect and that Enzastaurin treatment suppresses GSK3beta phosphorylation in both tumor tissue and in PBMCs, suggesting that GSK3beta phosphorylation may serve as a reliable pharmacodynamic marker for Enzastaurin activity.	enzastaurin	72-83	glycogen synthase kinase 3 beta	Homo sapiens	105-113
16103100-9	2005	These data show that Enzastaurin has a direct antitumor effect and that Enzastaurin treatment suppresses GSK3beta phosphorylation in both tumor tissue and in PBMCs, suggesting that GSK3beta phosphorylation may serve as a reliable pharmacodynamic marker for Enzastaurin activity.	enzastaurin	72-83	glycogen synthase kinase 3 beta	Homo sapiens	181-189
15878526-5	2005	Lithium chloride treatment, which inhibits GSK3beta activity, reversed these serum starvation effects, which suggests an inverse relationship between Wnt signaling and giant cell formation.	Lithium Chloride	0-16	glycogen synthase kinase 3 beta	Homo sapiens	43-51
15927518-0	2005	Insulin-like growth factor-I inhibits dexamethasone-induced proteolysis in cultured L6 myotubes through PI3K/Akt/GSK-3beta and PI3K/Akt/mTOR-dependent mechanisms.	Dexamethasone	38-51	glycogen synthase kinase 3 beta	Homo sapiens	113-122
15927518-4	2005	Here we tested the hypothesis that PI3K/Akt-mediated inactivation of GSK-3beta and activation of mTOR contribute to the anabolic effects of IGF-I in dexamethasone-treated myotubes.	Dexamethasone	149-162	glycogen synthase kinase 3 beta	Homo sapiens	69-78
16141410-5	2005	In vitro and in vivo (HEK 293 cells) kinase assays with synthetic peptides and full-length myocardin demonstrated that myocardin was a "primed" GSK3beta substrate, with serines 455 to 467 and 624 to 636 being the major GSK3beta phosphorylation sites.	Serine	169-176	glycogen synthase kinase 3 beta	Homo sapiens	144-152
16141410-6	2005	Myocardin-induced ANF transcription and increase in total protein amount were enhanced by GSK3beta blockade (10 mmol/L LiCl), indicating that GSK3beta inhibits myocardin.	Lithium Chloride	119-123	glycogen synthase kinase 3 beta	Homo sapiens	90-98
16141410-6	2005	Myocardin-induced ANF transcription and increase in total protein amount were enhanced by GSK3beta blockade (10 mmol/L LiCl), indicating that GSK3beta inhibits myocardin.	Lithium Chloride	119-123	glycogen synthase kinase 3 beta	Homo sapiens	142-150
16055922-7	2005	In the present work, we show that cGMP/cGMP-dependent protein kinase (PKG) induced dephosphorylation and activation of C/EBPbeta by inhibiting glycogen synthase kinase-3beta (GSK-3beta).	Cyclic GMP	34-38	glycogen synthase kinase 3 beta	Homo sapiens	143-173
16055922-7	2005	In the present work, we show that cGMP/cGMP-dependent protein kinase (PKG) induced dephosphorylation and activation of C/EBPbeta by inhibiting glycogen synthase kinase-3beta (GSK-3beta).	Cyclic GMP	34-38	glycogen synthase kinase 3 beta	Homo sapiens	175-184
16055922-10	2005	We determined that GSK-3beta phosphorylated C/EBPbeta in vitro on Thr189, Ser185, Ser181, and Ser177; C/EBPbeta was phosphorylated on these same sites in intact, unstimulated osteoblasts, and phosphorylation was decreased in cGMP-treated cells.	Cyclic GMP	225-229	glycogen synthase kinase 3 beta	Homo sapiens	19-28
16055922-12	2005	cGMP regulation of C/EBPbeta was disrupted by a mutant GSK-3beta(Ala9) resistant to cGMP/PKG phosphorylation and inhibition.	Cyclic GMP	0-4	glycogen synthase kinase 3 beta	Homo sapiens	55-64
16055922-12	2005	cGMP regulation of C/EBPbeta was disrupted by a mutant GSK-3beta(Ala9) resistant to cGMP/PKG phosphorylation and inhibition.	Cyclic GMP	84-88	glycogen synthase kinase 3 beta	Homo sapiens	55-64
15975931-6	2005	Lu gp is phosphorylated by glycogen synthase kinase 3 beta, casein kinase II, and PKA at serines 596, 598, and 621, respectively.	Serine	89-96	glycogen synthase kinase 3 beta	Homo sapiens	27-58
15975931-7	2005	Alanine substitutions of serines 596 and 598 abolished phosphorylation by glycogen synthase kinase 3 beta and casein kinase II, respectively, but had no effect on adhesion of K562 cells to laminin under flow conditions.	Alanine	0-7	glycogen synthase kinase 3 beta	Homo sapiens	74-105
15975931-7	2005	Alanine substitutions of serines 596 and 598 abolished phosphorylation by glycogen synthase kinase 3 beta and casein kinase II, respectively, but had no effect on adhesion of K562 cells to laminin under flow conditions.	Serine	25-32	glycogen synthase kinase 3 beta	Homo sapiens	74-105
16104747-4	2005	This approach lead to the conclusion that several AGC group protein kinases (including PKCalpha, PKCbeta, MSK1, p70 S6K, PDK-1, and MAPKAP-K1alpha) may be best inhibited by bisindolylmaleimides which adopt a compressed approximately C2-symmetric anti conformation; in constrast, GSK3beta may be best inhibited by bisindolylmaleimides whose ground state is a distorted syn conformation.	bisindolylmaleimide	173-193	glycogen synthase kinase 3 beta	Homo sapiens	279-287
15946992-5	2005	Inhibition of the glycogen-synthase-kinase-3beta (GSK-3beta) by LiCl prevented this celecoxib-induced translocation, suggesting that phosphorylation of beta-catenin by the GSK-3beta kinase was essential for this release.	Lithium Chloride	64-68	glycogen synthase kinase 3 beta	Homo sapiens	50-59
15946992-5	2005	Inhibition of the glycogen-synthase-kinase-3beta (GSK-3beta) by LiCl prevented this celecoxib-induced translocation, suggesting that phosphorylation of beta-catenin by the GSK-3beta kinase was essential for this release.	Lithium Chloride	64-68	glycogen synthase kinase 3 beta	Homo sapiens	172-181
15946992-5	2005	Inhibition of the glycogen-synthase-kinase-3beta (GSK-3beta) by LiCl prevented this celecoxib-induced translocation, suggesting that phosphorylation of beta-catenin by the GSK-3beta kinase was essential for this release.	Celecoxib	84-93	glycogen synthase kinase 3 beta	Homo sapiens	18-48
15946992-5	2005	Inhibition of the glycogen-synthase-kinase-3beta (GSK-3beta) by LiCl prevented this celecoxib-induced translocation, suggesting that phosphorylation of beta-catenin by the GSK-3beta kinase was essential for this release.	Celecoxib	84-93	glycogen synthase kinase 3 beta	Homo sapiens	50-59
15946992-5	2005	Inhibition of the glycogen-synthase-kinase-3beta (GSK-3beta) by LiCl prevented this celecoxib-induced translocation, suggesting that phosphorylation of beta-catenin by the GSK-3beta kinase was essential for this release.	Celecoxib	84-93	glycogen synthase kinase 3 beta	Homo sapiens	172-181
16039586-4	2005	Erk, which is activated by HBX, associates with GSK-3beta through a docking motif ((291)FKFP) of GSK-3beta and phosphorylates GSK-3beta at the (43)Thr residue, which primes GSK-3beta for its subsequent phosphorylation at Ser9 by p90RSK, resulting in inactivation of GSK-3beta and upregulation of beta-catenin.	Threonine	147-150	glycogen synthase kinase 3 beta	Homo sapiens	48-57
15845746-0	2005	Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase--&gt;AKT--&gt;GSK-3beta--&gt;cyclin D1--&gt;pRB pathway to block uterine epithelial cell proliferation.	Progesterone	0-12	glycogen synthase kinase 3 beta	Homo sapiens	83-92
15845746-7	2005	Inhibition of the GSK-3beta activity in P4-treated uteri by the specific inhibitor, LiCl, reversed the nuclear accumulation of cyclin D1 and in doing so, caused pRB phosphorylation and the induction of downstream genes, proliferating cell nuclear antigen and Ki67.	Lithium Chloride	84-88	glycogen synthase kinase 3 beta	Homo sapiens	18-27
15845746-8	2005	Conversely, inhibition of phosphoinositide 3 kinase by LY294002 or Wortmanin reversed the E2-induced GSK-3beta Ser9 inhibitory phosphorylation and blocked nuclear accumulation of cyclin D1.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	55-63	glycogen synthase kinase 3 beta	Homo sapiens	101-110
15845746-8	2005	Conversely, inhibition of phosphoinositide 3 kinase by LY294002 or Wortmanin reversed the E2-induced GSK-3beta Ser9 inhibitory phosphorylation and blocked nuclear accumulation of cyclin D1.	Wortmannin	67-76	glycogen synthase kinase 3 beta	Homo sapiens	101-110
16190365-5	2005	Here, we showed that glycogen synthase kinase-3beta (GSK-3beta) phosphorylated CRMP-2 at Thr-514 and inactivated it.	Threonine	89-92	glycogen synthase kinase 3 beta	Homo sapiens	21-51
16190365-5	2005	Here, we showed that glycogen synthase kinase-3beta (GSK-3beta) phosphorylated CRMP-2 at Thr-514 and inactivated it.	Threonine	89-92	glycogen synthase kinase 3 beta	Homo sapiens	53-62
15723355-1	2005	We studied in vitro effects of glycogen synthase kinase 3beta (GSK3beta)-inhibitor lithium on the growth of hepatocellular carcinoma (HCC) cells.	Lithium	83-90	glycogen synthase kinase 3 beta	Homo sapiens	31-61
15723355-1	2005	We studied in vitro effects of glycogen synthase kinase 3beta (GSK3beta)-inhibitor lithium on the growth of hepatocellular carcinoma (HCC) cells.	Lithium	83-90	glycogen synthase kinase 3 beta	Homo sapiens	63-71
15723355-4	2005	Lithium induced the accumulation of N-terminally phosphorylated inactive form of GSK3beta with concomitant increase in beta-catenin and beta-catenin/TCF transcriptional activity in both cell lines.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	81-89
15723355-4	2005	Lithium induced the accumulation of N-terminally phosphorylated inactive form of GSK3beta with concomitant increase in beta-catenin and beta-catenin/TCF transcriptional activity in both cell lines.	Nitrogen	36-37	glycogen synthase kinase 3 beta	Homo sapiens	81-89
15996564-5	2005	The involvement of PI3-K/Akt pathway in the imipramine action was confirmed by Western blot study, which showed that this drug increased phospho-Ser-473 Akt level, but had no effect on total Akt and glycogen synthase kinase (GSK-3beta) levels.	Imipramine	44-54	glycogen synthase kinase 3 beta	Homo sapiens	225-234
16039586-4	2005	Erk, which is activated by HBX, associates with GSK-3beta through a docking motif ((291)FKFP) of GSK-3beta and phosphorylates GSK-3beta at the (43)Thr residue, which primes GSK-3beta for its subsequent phosphorylation at Ser9 by p90RSK, resulting in inactivation of GSK-3beta and upregulation of beta-catenin.	Threonine	147-150	glycogen synthase kinase 3 beta	Homo sapiens	97-106
16039586-4	2005	Erk, which is activated by HBX, associates with GSK-3beta through a docking motif ((291)FKFP) of GSK-3beta and phosphorylates GSK-3beta at the (43)Thr residue, which primes GSK-3beta for its subsequent phosphorylation at Ser9 by p90RSK, resulting in inactivation of GSK-3beta and upregulation of beta-catenin.	Threonine	147-150	glycogen synthase kinase 3 beta	Homo sapiens	97-106
16039586-4	2005	Erk, which is activated by HBX, associates with GSK-3beta through a docking motif ((291)FKFP) of GSK-3beta and phosphorylates GSK-3beta at the (43)Thr residue, which primes GSK-3beta for its subsequent phosphorylation at Ser9 by p90RSK, resulting in inactivation of GSK-3beta and upregulation of beta-catenin.	Threonine	147-150	glycogen synthase kinase 3 beta	Homo sapiens	97-106
16039586-4	2005	Erk, which is activated by HBX, associates with GSK-3beta through a docking motif ((291)FKFP) of GSK-3beta and phosphorylates GSK-3beta at the (43)Thr residue, which primes GSK-3beta for its subsequent phosphorylation at Ser9 by p90RSK, resulting in inactivation of GSK-3beta and upregulation of beta-catenin.	Threonine	147-150	glycogen synthase kinase 3 beta	Homo sapiens	97-106
15901738-3	2005	Ceramide and its analogs activated PKCzeta prior to binding to PAR-4, as determined by increased levels of phosphorylated PKCzeta and glycogen synthase kinase-3beta and emergence of a PAR-4-to-phosphorylated PKCzeta fluorescence resonance energy transfer signal that co-localizes with ceramide.	Ceramides	0-8	glycogen synthase kinase 3 beta	Homo sapiens	134-164
15985551-5	2005	Ex vivo and in vitro experiments with C/EBPbeta show that phosphorylation of Thr-188 by mitogen-activating protein kinase "primes" C/EBPbeta for subsequent phosphorylation on Ser-184 and Thr-179 by glycogen synthase kinase 3beta, acquisition of DNA-binding function, and transactivation of the C/EBPalpha and PPARgamma genes.	Threonine	77-80	glycogen synthase kinase 3 beta	Homo sapiens	198-228
15985551-5	2005	Ex vivo and in vitro experiments with C/EBPbeta show that phosphorylation of Thr-188 by mitogen-activating protein kinase "primes" C/EBPbeta for subsequent phosphorylation on Ser-184 and Thr-179 by glycogen synthase kinase 3beta, acquisition of DNA-binding function, and transactivation of the C/EBPalpha and PPARgamma genes.	Serine	175-178	glycogen synthase kinase 3 beta	Homo sapiens	198-228
15985551-5	2005	Ex vivo and in vitro experiments with C/EBPbeta show that phosphorylation of Thr-188 by mitogen-activating protein kinase "primes" C/EBPbeta for subsequent phosphorylation on Ser-184 and Thr-179 by glycogen synthase kinase 3beta, acquisition of DNA-binding function, and transactivation of the C/EBPalpha and PPARgamma genes.	Threonine	187-190	glycogen synthase kinase 3 beta	Homo sapiens	198-228
15960984-3	2005	Recent work has identified novel pathways, such as the Wnt pathway and the serine-threonine kinase Akt, as central modulators that oversee cellular apoptosis and the formation of neurofibrillary tangles through their downstream substrates that include glycogen synthase kinase-3beta, Bad, and Bcl-xL.	Serine	75-81	glycogen synthase kinase 3 beta	Homo sapiens	252-282
16014605-6	2005	LPA was shown to stimulate nuclear accumulation of beta-catenin in a manner that depended on activation of Galpha(q) by LPA(2,3"), activation of phospholipase Cbeta, activation of a conventional protein kinase C, and phosphorylation and inhibition of glycogen synthase kinase 3-beta.	lysophosphatidic acid	0-3	glycogen synthase kinase 3 beta	Homo sapiens	251-282
15878157-6	2005	Ethanol inhibited EGF-induced EGFR autophosphorylation, phosphorylation of ERK as well as Akt and its substrate GSK-3beta, and subsequently blocked EGF-stimulated AP-1 activation in B82L cells.	Ethanol	0-7	glycogen synthase kinase 3 beta	Homo sapiens	112-121
15942663-0	2005	GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	28-36	glycogen synthase kinase 3 beta	Homo sapiens	0-9
15942663-6	2005	In Hep3B cells, LY294002 led to the reactivation of glycogen synthase kinase-3beta (GSK-3beta) by promoting its dephosphorylation on the serine 9 residue independently from Akt inhibition.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	16-24	glycogen synthase kinase 3 beta	Homo sapiens	52-82
15942663-6	2005	In Hep3B cells, LY294002 led to the reactivation of glycogen synthase kinase-3beta (GSK-3beta) by promoting its dephosphorylation on the serine 9 residue independently from Akt inhibition.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	16-24	glycogen synthase kinase 3 beta	Homo sapiens	84-93
15942663-6	2005	In Hep3B cells, LY294002 led to the reactivation of glycogen synthase kinase-3beta (GSK-3beta) by promoting its dephosphorylation on the serine 9 residue independently from Akt inhibition.	Serine	137-143	glycogen synthase kinase 3 beta	Homo sapiens	52-82
15942663-6	2005	In Hep3B cells, LY294002 led to the reactivation of glycogen synthase kinase-3beta (GSK-3beta) by promoting its dephosphorylation on the serine 9 residue independently from Akt inhibition.	Serine	137-143	glycogen synthase kinase 3 beta	Homo sapiens	84-93
15942663-7	2005	The transient transfection of a constitutively active and non-phosphorylable S9AGSK-3beta mutant sensitized cells to etoposide cytotoxic effects while cell treatment with the small GSK-3beta inhibitor SB-415286 repressed the sensitizing effect of LY294002 on chemotherapy-induced apoptosis and caspase-8 activation.	Etoposide	117-126	glycogen synthase kinase 3 beta	Homo sapiens	80-89
15942663-7	2005	The transient transfection of a constitutively active and non-phosphorylable S9AGSK-3beta mutant sensitized cells to etoposide cytotoxic effects while cell treatment with the small GSK-3beta inhibitor SB-415286 repressed the sensitizing effect of LY294002 on chemotherapy-induced apoptosis and caspase-8 activation.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	201-210	glycogen synthase kinase 3 beta	Homo sapiens	80-89
15942663-7	2005	The transient transfection of a constitutively active and non-phosphorylable S9AGSK-3beta mutant sensitized cells to etoposide cytotoxic effects while cell treatment with the small GSK-3beta inhibitor SB-415286 repressed the sensitizing effect of LY294002 on chemotherapy-induced apoptosis and caspase-8 activation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	247-255	glycogen synthase kinase 3 beta	Homo sapiens	80-89
15930119-3	2005	Treatment of hydra with alsterpaullone, a specific inhibitor of glycogen synthase kinase-3beta, results in the body column acquiring characteristics of the head organizer, as measured by transplantation experiments, and by the expression of genes associated with the head organizer.	alsterpaullone	24-38	glycogen synthase kinase 3 beta	Homo sapiens	64-94
15799972-4	2005	The depolarization by treating with 100 mm KCl for 5 min resulted in the undulating phosphorylation of GSK-3beta at Ser-9 in SH-SY5Y human neuroblastoma cells, in H19 -7/IGF-IR rat embryonic hippocampal cells, and in PC12 rat pheochromocytoma cells, but not in A172 human glioblastoma cells.	Potassium Chloride	43-46	glycogen synthase kinase 3 beta	Homo sapiens	103-112
15799972-4	2005	The depolarization by treating with 100 mm KCl for 5 min resulted in the undulating phosphorylation of GSK-3beta at Ser-9 in SH-SY5Y human neuroblastoma cells, in H19 -7/IGF-IR rat embryonic hippocampal cells, and in PC12 rat pheochromocytoma cells, but not in A172 human glioblastoma cells.	Serine	116-119	glycogen synthase kinase 3 beta	Homo sapiens	103-112
15799972-5	2005	Cellular beta-catenin contents showed a temporal pattern similar to that of the Ser-9 phosphorylation of GSK-3beta.	Serine	80-83	glycogen synthase kinase 3 beta	Homo sapiens	105-114
15799972-6	2005	Treatment with wortmannin or calphostin C or the expression of dominant negative Akt inhibited phosphorylation of GSK-3beta at Ser-9 following the KCl-induced depolarization of SH-SY5Y cells.	Wortmannin	15-25	glycogen synthase kinase 3 beta	Homo sapiens	114-123
15799972-6	2005	Treatment with wortmannin or calphostin C or the expression of dominant negative Akt inhibited phosphorylation of GSK-3beta at Ser-9 following the KCl-induced depolarization of SH-SY5Y cells.	calphostin C	29-41	glycogen synthase kinase 3 beta	Homo sapiens	114-123
15799972-6	2005	Treatment with wortmannin or calphostin C or the expression of dominant negative Akt inhibited phosphorylation of GSK-3beta at Ser-9 following the KCl-induced depolarization of SH-SY5Y cells.	Serine	127-130	glycogen synthase kinase 3 beta	Homo sapiens	114-123
15799972-6	2005	Treatment with wortmannin or calphostin C or the expression of dominant negative Akt inhibited phosphorylation of GSK-3beta at Ser-9 following the KCl-induced depolarization of SH-SY5Y cells.	Potassium Chloride	147-150	glycogen synthase kinase 3 beta	Homo sapiens	114-123
15799972-7	2005	Moreover, pretreatment with okadaic acid or cyclosporin A blocked the dephosphorylation of GSK-3beta at Ser-9 at 0, 15, and 30 min after KCl-induced depolarization, and the activity of protein phosphatases (PP) 2A and 2B increased at these times.	Okadaic Acid	28-40	glycogen synthase kinase 3 beta	Homo sapiens	91-100
15799972-7	2005	Moreover, pretreatment with okadaic acid or cyclosporin A blocked the dephosphorylation of GSK-3beta at Ser-9 at 0, 15, and 30 min after KCl-induced depolarization, and the activity of protein phosphatases (PP) 2A and 2B increased at these times.	Cyclosporine	44-57	glycogen synthase kinase 3 beta	Homo sapiens	91-100
15799972-7	2005	Moreover, pretreatment with okadaic acid or cyclosporin A blocked the dephosphorylation of GSK-3beta at Ser-9 at 0, 15, and 30 min after KCl-induced depolarization, and the activity of protein phosphatases (PP) 2A and 2B increased at these times.	Serine	104-107	glycogen synthase kinase 3 beta	Homo sapiens	91-100
15799972-7	2005	Moreover, pretreatment with okadaic acid or cyclosporin A blocked the dephosphorylation of GSK-3beta at Ser-9 at 0, 15, and 30 min after KCl-induced depolarization, and the activity of protein phosphatases (PP) 2A and 2B increased at these times.	Potassium Chloride	137-140	glycogen synthase kinase 3 beta	Homo sapiens	91-100
15799972-8	2005	Treatment with nifedipine or calcium-free medium inhibited GSK-3beta dephosphorylation following membrane depolarization, and the amounts of co-immunoprecipitated GSK-3beta and PP2A changed in parallel with GSK-3beta dephosphorylation.	Nifedipine	15-25	glycogen synthase kinase 3 beta	Homo sapiens	59-68
15799972-8	2005	Treatment with nifedipine or calcium-free medium inhibited GSK-3beta dephosphorylation following membrane depolarization, and the amounts of co-immunoprecipitated GSK-3beta and PP2A changed in parallel with GSK-3beta dephosphorylation.	Nifedipine	15-25	glycogen synthase kinase 3 beta	Homo sapiens	163-172
15799972-8	2005	Treatment with nifedipine or calcium-free medium inhibited GSK-3beta dephosphorylation following membrane depolarization, and the amounts of co-immunoprecipitated GSK-3beta and PP2A changed in parallel with GSK-3beta dephosphorylation.	Nifedipine	15-25	glycogen synthase kinase 3 beta	Homo sapiens	163-172
15799972-8	2005	Treatment with nifedipine or calcium-free medium inhibited GSK-3beta dephosphorylation following membrane depolarization, and the amounts of co-immunoprecipitated GSK-3beta and PP2A changed in parallel with GSK-3beta dephosphorylation.	Calcium	29-36	glycogen synthase kinase 3 beta	Homo sapiens	59-68
15799972-8	2005	Treatment with nifedipine or calcium-free medium inhibited GSK-3beta dephosphorylation following membrane depolarization, and the amounts of co-immunoprecipitated GSK-3beta and PP2A changed in parallel with GSK-3beta dephosphorylation.	Calcium	29-36	glycogen synthase kinase 3 beta	Homo sapiens	163-172
15799972-8	2005	Treatment with nifedipine or calcium-free medium inhibited GSK-3beta dephosphorylation following membrane depolarization, and the amounts of co-immunoprecipitated GSK-3beta and PP2A changed in parallel with GSK-3beta dephosphorylation.	Calcium	29-36	glycogen synthase kinase 3 beta	Homo sapiens	163-172
15799972-9	2005	Our study demonstrated that KCl-induced depolarization caused undulating GSK-3beta phosphorylation/dephosphorylation, which was regulated for the most part by phosphatidylinositol 3-kinase and Akt (phosphorylation) and PP2A and PP2B (dephosphorylation), respectively.	Potassium Chloride	28-31	glycogen synthase kinase 3 beta	Homo sapiens	73-82
15800129-6	2005	Here it is reported that the AGA neomycin and gentamicin elicit acute, phosphatidylinositol-3 kinase-dependent phosphorylation of Akt, glycogen synthase kinase 3beta, and p38 mitogen-activated protein kinase.	aga neomycin	29-41	glycogen synthase kinase 3 beta	Homo sapiens	135-165
15800129-6	2005	Here it is reported that the AGA neomycin and gentamicin elicit acute, phosphatidylinositol-3 kinase-dependent phosphorylation of Akt, glycogen synthase kinase 3beta, and p38 mitogen-activated protein kinase.	Gentamicins	46-56	glycogen synthase kinase 3 beta	Homo sapiens	135-165
15921460-5	2005	These studies were the starting point to analyze a new GSK-3beta ligand, a thieno[2,3-b]pyrrolizinone derivative.	thieno[2,3-b]pyrrolizinone	75-101	glycogen synthase kinase 3 beta	Homo sapiens	55-64
15752768-0	2005	Characterization of two non-testis-specific CABYR variants that bind to GSK3beta with a proline-rich extensin-like domain.	Proline	88-95	glycogen synthase kinase 3 beta	Homo sapiens	72-80
15701629-8	2005	Because Wnts inhibit glycogen synthase kinase-3beta, we further determined whether the glycogen synthase kinase-3beta inhibitor LiCl also enhanced cardiac differentiation of CPCs.	Lithium Chloride	128-132	glycogen synthase kinase 3 beta	Homo sapiens	87-117
15837931-5	2005	Moreover, LPA activates the main signaling events in the beta-catenin pathway: phosphorylation of glycogen synthase kinase 3beta (GSK3beta), nuclear translocation of beta-catenin, transcriptional activation of T cell factor (Tcf)/lymphoid-enhancer factor (Lef), and expression of target genes.	lysophosphatidic acid	10-13	glycogen synthase kinase 3 beta	Homo sapiens	98-128
15837931-5	2005	Moreover, LPA activates the main signaling events in the beta-catenin pathway: phosphorylation of glycogen synthase kinase 3beta (GSK3beta), nuclear translocation of beta-catenin, transcriptional activation of T cell factor (Tcf)/lymphoid-enhancer factor (Lef), and expression of target genes.	lysophosphatidic acid	10-13	glycogen synthase kinase 3 beta	Homo sapiens	130-138
15921460-1	2005	Comparison with a thieno[2,3-b]pyrrolizinone derivative, a new potential lead for GSK-3beta ligands.	thieno[2,3-b]pyrrolizinone	18-44	glycogen synthase kinase 3 beta	Homo sapiens	82-91
15921460-2	2005	The three-dimensional structures of 3-anilino-4-arylmaleimides, selective GSK-3beta inhibitors, were correlated to their biological affinities by 3D-QSAR studies (CoMFA method).	3-anilino-4-arylmaleimides	36-62	glycogen synthase kinase 3 beta	Homo sapiens	74-83
15752768-3	2005	Molecular characterization showed that CABYR variants formed a dimer with a proline-rich extensin-like domain, which slightly overlapped with GSK3beta-binding site.	Proline	76-83	glycogen synthase kinase 3 beta	Homo sapiens	142-150
15721290-4	2005	LiCl, an inhibitor of glycogen synthase kinase-3beta, also enhanced the Tcf/Lef-dependent transcriptional activity, which was, however, not inhibited by dexamethasone.	Lithium Chloride	0-4	glycogen synthase kinase 3 beta	Homo sapiens	22-52
15659394-5	2005	4) Two key Wnt signaling components were affected by E2 and Trolox; in fact, the enzyme glycogen synthase kinase 3beta was inhibited by both E2 and Trolox, and both compounds were able to stabilize cytoplasmic beta-catenin.	Estradiol	53-55	glycogen synthase kinase 3 beta	Homo sapiens	88-118
15805245-7	2005	Furthermore, valproic acid inhibits GSK3beta by phosphorylation on Ser9 accompanied by an activation of the Wnt signaling pathway as well as by an up-regulation of HoxB4, a target gene of Wnt signaling.	Valproic Acid	13-26	glycogen synthase kinase 3 beta	Homo sapiens	36-44
15668231-6	2005	Inhibition of GSK-3beta activity by LiCl augmented accumulation of beta-catenin and caused induction of versican-Luc activity as well as versican mRNA levels.	Lithium Chloride	36-40	glycogen synthase kinase 3 beta	Homo sapiens	14-23
15659394-5	2005	4) Two key Wnt signaling components were affected by E2 and Trolox; in fact, the enzyme glycogen synthase kinase 3beta was inhibited by both E2 and Trolox, and both compounds were able to stabilize cytoplasmic beta-catenin.	6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid	60-66	glycogen synthase kinase 3 beta	Homo sapiens	88-118
15659394-5	2005	4) Two key Wnt signaling components were affected by E2 and Trolox; in fact, the enzyme glycogen synthase kinase 3beta was inhibited by both E2 and Trolox, and both compounds were able to stabilize cytoplasmic beta-catenin.	Estradiol	141-143	glycogen synthase kinase 3 beta	Homo sapiens	88-118
15659394-5	2005	4) Two key Wnt signaling components were affected by E2 and Trolox; in fact, the enzyme glycogen synthase kinase 3beta was inhibited by both E2 and Trolox, and both compounds were able to stabilize cytoplasmic beta-catenin.	6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid	148-154	glycogen synthase kinase 3 beta	Homo sapiens	88-118
15952593-5	2005	Pretreatment with ginsenoside Rbl or lithium chloride, a specific inhibitor of GSK-3beta, markedly reduced beta-AP(25-35)-induced tau hyperphosphorylation and the expression of GSK-3beta.	ginsenoside-rbl	18-33	glycogen synthase kinase 3 beta	Homo sapiens	79-88
15696597-4	2005	The novel 2-cyanoethylalsterpaullone (7) proved to be the most potent paullone described so far, exhibiting inhibitory concentrations for CDK1/ cyclin B and GSK-3beta in the picomolar range.	2-cyanoethylalsterpaullone	10-36	glycogen synthase kinase 3 beta	Homo sapiens	157-166
15696597-4	2005	The novel 2-cyanoethylalsterpaullone (7) proved to be the most potent paullone described so far, exhibiting inhibitory concentrations for CDK1/ cyclin B and GSK-3beta in the picomolar range.	paullone	28-36	glycogen synthase kinase 3 beta	Homo sapiens	157-166
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	Sirolimus	46-55	glycogen synthase kinase 3 beta	Homo sapiens	159-168
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	Wortmannin	57-67	glycogen synthase kinase 3 beta	Homo sapiens	159-168
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	69-77	glycogen synthase kinase 3 beta	Homo sapiens	159-168
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	U 0126	83-88	glycogen synthase kinase 3 beta	Homo sapiens	159-168
15715661-5	2005	Treatment with different inhibitors including rapamycin, wortmannin, LY294002, and U0126, and their combinations, indicated that phosphorylation of p70S6K and GSK-3beta is regulated by rapamycin-dependent, PI3K and MAPK pathways.	Sirolimus	185-194	glycogen synthase kinase 3 beta	Homo sapiens	159-168
15694273-0	2005	Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP.	Lithium	22-29	glycogen synthase kinase 3 beta	Homo sapiens	76-107
15694273-3	2005	GSK3-beta codes for an enzyme which is a target for the action of lithium and possibly of valproic acid.	Lithium	66-73	glycogen synthase kinase 3 beta	Homo sapiens	0-9
15694273-3	2005	GSK3-beta codes for an enzyme which is a target for the action of lithium and possibly of valproic acid.	Valproic Acid	90-103	glycogen synthase kinase 3 beta	Homo sapiens	0-9
15706224-0	2005	Inactivation of GSK-3beta in okadaic acid-induced neurodegeneration: relevance to Alzheimer"s disease.	Okadaic Acid	29-41	glycogen synthase kinase 3 beta	Homo sapiens	16-25
15706224-3	2005	Using Western blotting, we found that the amounts of activated PKB[pS-473] and inactivated GSK-3beta[pS-9] were increased in proportion to the progress of okadaic acid induced tau phosphorylation.	Okadaic Acid	155-167	glycogen synthase kinase 3 beta	Homo sapiens	91-100
15706224-4	2005	Immunocytochemistry showed that PKB[pS-473] and GSK-3beta[pS-9] immunoreactivity increased in dystrophic neurites and cell bodies in degenerating neurons after okadaic acid treatment.	Okadaic Acid	160-172	glycogen synthase kinase 3 beta	Homo sapiens	48-57
15706224-5	2005	Double staining with phosphospecific tau antibodies showed that PKB[pS-473] and GSK-3beta[pS-9] were colocalized with phosphospecific tau in response to okadaic acid.	Okadaic Acid	153-165	glycogen synthase kinase 3 beta	Homo sapiens	80-89
15952593-5	2005	Pretreatment with ginsenoside Rbl or lithium chloride, a specific inhibitor of GSK-3beta, markedly reduced beta-AP(25-35)-induced tau hyperphosphorylation and the expression of GSK-3beta.	ginsenoside-rbl	18-33	glycogen synthase kinase 3 beta	Homo sapiens	177-186
15952593-5	2005	Pretreatment with ginsenoside Rbl or lithium chloride, a specific inhibitor of GSK-3beta, markedly reduced beta-AP(25-35)-induced tau hyperphosphorylation and the expression of GSK-3beta.	Lithium Chloride	37-53	glycogen synthase kinase 3 beta	Homo sapiens	79-88
15952593-5	2005	Pretreatment with ginsenoside Rbl or lithium chloride, a specific inhibitor of GSK-3beta, markedly reduced beta-AP(25-35)-induced tau hyperphosphorylation and the expression of GSK-3beta.	Lithium Chloride	37-53	glycogen synthase kinase 3 beta	Homo sapiens	177-186
15542598-10	2005	When tau was phosphorylated by glycogen synthase kinase-3beta, most of these proteolytic processes were inhibited, except for the first cleavage at the Arg(155)-Gly(156) bond.	Arginine	152-155	glycogen synthase kinase 3 beta	Homo sapiens	31-61
15542598-10	2005	When tau was phosphorylated by glycogen synthase kinase-3beta, most of these proteolytic processes were inhibited, except for the first cleavage at the Arg(155)-Gly(156) bond.	Glycine	161-164	glycogen synthase kinase 3 beta	Homo sapiens	31-61
15652488-3	2005	Here, we showed that glycogen synthase kinase-3beta (GSK-3beta) phosphorylated CRMP-2 at Thr-514 and inactivated it.	Threonine	89-92	glycogen synthase kinase 3 beta	Homo sapiens	21-51
15537647-2	2005	In MC3T3-E1 osteoblast-like cultures, dexamethasone (DEX) activates glycogen synthase kinase-3beta (GSK3beta) and inhibits a differentiation-related cell cycle that occurs at a commitment stage immediately after confluence.	Dexamethasone	38-51	glycogen synthase kinase 3 beta	Homo sapiens	68-98
15537647-2	2005	In MC3T3-E1 osteoblast-like cultures, dexamethasone (DEX) activates glycogen synthase kinase-3beta (GSK3beta) and inhibits a differentiation-related cell cycle that occurs at a commitment stage immediately after confluence.	Dexamethasone	38-51	glycogen synthase kinase 3 beta	Homo sapiens	100-108
15537647-2	2005	In MC3T3-E1 osteoblast-like cultures, dexamethasone (DEX) activates glycogen synthase kinase-3beta (GSK3beta) and inhibits a differentiation-related cell cycle that occurs at a commitment stage immediately after confluence.	Dexamethasone	53-56	glycogen synthase kinase 3 beta	Homo sapiens	68-98
15537647-2	2005	In MC3T3-E1 osteoblast-like cultures, dexamethasone (DEX) activates glycogen synthase kinase-3beta (GSK3beta) and inhibits a differentiation-related cell cycle that occurs at a commitment stage immediately after confluence.	Dexamethasone	53-56	glycogen synthase kinase 3 beta	Homo sapiens	100-108
15537647-4	2005	These inhibitory activities are no longer observed in the presence of lithium, a GSK3beta inhibitor.	Lithium	70-77	glycogen synthase kinase 3 beta	Homo sapiens	81-89
15537647-13	2005	These results suggest that inhibition of a PI3K/Akt/GSK3beta/beta-catenin/LEF axis and stimulation of HDAC1 cooperate to mediate the inhibitory effect of DEX on Wnt signaling and the osteoblast differentiation-related cell cycle.	Dexamethasone	154-157	glycogen synthase kinase 3 beta	Homo sapiens	52-60
15642371-0	2005	Inhibition of GSK3beta by indirubins restores HIF-1alpha accumulation under prolonged periods of hypoxia/anoxia.	indirubin	26-36	glycogen synthase kinase 3 beta	Homo sapiens	14-22
15642371-6	2005	GSK3beta inhibition by indirubins circumvented the effect of hypoxia/anoxia or LY294002 on HIF-1alpha.	indirubin	23-33	glycogen synthase kinase 3 beta	Homo sapiens	0-8
15642371-6	2005	GSK3beta inhibition by indirubins circumvented the effect of hypoxia/anoxia or LY294002 on HIF-1alpha.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	79-87	glycogen synthase kinase 3 beta	Homo sapiens	0-8
15661493-0	2005	Application of graph theory: prediction of glycogen synthase kinase-3 beta inhibitory activity of thiadiazolidinones as potential drugs for the treatment of Alzheimer"s disease.	thiadiazolidinones	98-116	glycogen synthase kinase 3 beta	Homo sapiens	43-74
15652488-3	2005	Here, we showed that glycogen synthase kinase-3beta (GSK-3beta) phosphorylated CRMP-2 at Thr-514 and inactivated it.	Threonine	89-92	glycogen synthase kinase 3 beta	Homo sapiens	53-62
15837120-0	2005	Glycogen synthase kinase 3beta links neuroprotection by 17beta-estradiol to key Alzheimer processes.	Estradiol	56-72	glycogen synthase kinase 3 beta	Homo sapiens	0-30
15507471-5	2005	Upstream activation of Wnt signaling by the Wnt-2 and Wnt-3a ligands, stable overexpression of Wnt-2, as well as GSK-3beta inhibition by lithium, SB216763, and GSK-3beta dominant negative forms (K85R and R96E) conferred the invasive phenotype through several proinvasive pathways.	Lithium	137-144	glycogen synthase kinase 3 beta	Homo sapiens	113-122
15837120-3	2005	We have previously shown that MAPK and glycogen synthase kinase-3beta (GSK-3beta) are involved in the cell death/cell survival induced by kainic acid.	Kainic Acid	138-149	glycogen synthase kinase 3 beta	Homo sapiens	39-69
15837120-3	2005	We have previously shown that MAPK and glycogen synthase kinase-3beta (GSK-3beta) are involved in the cell death/cell survival induced by kainic acid.	Kainic Acid	138-149	glycogen synthase kinase 3 beta	Homo sapiens	71-80
15494420-9	2004	However, in the presence of GSK3 beta, Tau-D421, but not full-length tau, was present in the Sarkosyl-insoluble fraction and formed thioflavin-S-positive inclusions in the cell.	thioflavin T	132-144	glycogen synthase kinase 3 beta	Homo sapiens	28-37
15979805-5	2005	Here we report that colchicine induces dephosphorylation in Ser-9 and phosphorylation in Tyr-216, and thus activation, of glycogen synthase kinase-3beta in cerebellar granule neurons, and that this modification is inhibited by the presence of 5 mM lithium.	Colchicine	20-30	glycogen synthase kinase 3 beta	Homo sapiens	122-152
15979805-5	2005	Here we report that colchicine induces dephosphorylation in Ser-9 and phosphorylation in Tyr-216, and thus activation, of glycogen synthase kinase-3beta in cerebellar granule neurons, and that this modification is inhibited by the presence of 5 mM lithium.	Tyrosine	89-92	glycogen synthase kinase 3 beta	Homo sapiens	122-152
15979805-5	2005	Here we report that colchicine induces dephosphorylation in Ser-9 and phosphorylation in Tyr-216, and thus activation, of glycogen synthase kinase-3beta in cerebellar granule neurons, and that this modification is inhibited by the presence of 5 mM lithium.	Lithium	248-255	glycogen synthase kinase 3 beta	Homo sapiens	122-152
15513923-1	2004	GSK-3beta-dependent phosphorylation of cyclin D1 at a conserved C-terminal residue, Thr-286, promotes CRM1-dependent cyclin D1 nuclear export.	Threonine	84-87	glycogen synthase kinase 3 beta	Homo sapiens	0-9
15475565-9	2004	Prior tau dephosphorylation by a glycogen synthase kinase-3beta inhibitor, lithium, enhanced tau cleavage and sensitized neurons to staurosporine-induced apoptosis.	Lithium	75-82	glycogen synthase kinase 3 beta	Homo sapiens	33-63
15475565-9	2004	Prior tau dephosphorylation by a glycogen synthase kinase-3beta inhibitor, lithium, enhanced tau cleavage and sensitized neurons to staurosporine-induced apoptosis.	Staurosporine	132-145	glycogen synthase kinase 3 beta	Homo sapiens	33-63
15574783-7	2004	Furthermore, naltrindole treatment not only reduced the phosphorylation of the Akt/PKB upstream kinase phosphoinositide-dependent kinase-1, but also its downstream effectors glycogen synthase kinase-3beta and the Forkhead transcription factors AFX and FKHR.	naltrindole	13-24	glycogen synthase kinase 3 beta	Homo sapiens	174-204
15347600-9	2004	Inhibition of GSK3beta by lithium chloride treatment of HeLa cells converted the HIF-1alpha, p16 and p27 loss to levels unchanged by hypoxic exposure.	Lithium Chloride	26-42	glycogen synthase kinase 3 beta	Homo sapiens	14-22
15465828-0	2004	Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity.	Serine	19-25	glycogen synthase kinase 3 beta	Homo sapiens	33-42
15569265-7	2004	Furthermore, the neuroprotective effects of minocycline were blocked by phosphatidylinositol 3-kinase (PI3-K) inhibitors LY294002 and wortmannin, while pharmacologic inhibition of glycogen synthase kinase 3beta (GSK3beta) attenuated glutamate-induced apoptosis.	Minocycline	44-55	glycogen synthase kinase 3 beta	Homo sapiens	180-210
15569265-7	2004	Furthermore, the neuroprotective effects of minocycline were blocked by phosphatidylinositol 3-kinase (PI3-K) inhibitors LY294002 and wortmannin, while pharmacologic inhibition of glycogen synthase kinase 3beta (GSK3beta) attenuated glutamate-induced apoptosis.	Minocycline	44-55	glycogen synthase kinase 3 beta	Homo sapiens	212-220
15569265-8	2004	In addition, immunoblots revealed that minocycline reversed the suppression of phosphorylated Akt and GSK3beta caused by glutamate, as were abolished by PI3-K inhibitors.	Minocycline	39-50	glycogen synthase kinase 3 beta	Homo sapiens	102-110
15569265-8	2004	In addition, immunoblots revealed that minocycline reversed the suppression of phosphorylated Akt and GSK3beta caused by glutamate, as were abolished by PI3-K inhibitors.	Glutamic Acid	121-130	glycogen synthase kinase 3 beta	Homo sapiens	102-110
15377673-7	2004	Inhibition of GSK-3beta, which is negatively regulated by AKT, using AR-A014418 and lithium chloride completely abolished LY294002-induced NAG-1 expression as well as the NAG-1 promoter activity.	Lithium Chloride	84-100	glycogen synthase kinase 3 beta	Homo sapiens	14-23
15377673-7	2004	Inhibition of GSK-3beta, which is negatively regulated by AKT, using AR-A014418 and lithium chloride completely abolished LY294002-induced NAG-1 expression as well as the NAG-1 promoter activity.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	122-130	glycogen synthase kinase 3 beta	Homo sapiens	14-23
15465828-4	2004	Serine 468 lies within a GSK-3beta consensus site, and recombinant GSK-3beta specifically phosphorylates a GST-p65-(354-551) fusion protein at Ser(468) in vitro.	Serine	0-6	glycogen synthase kinase 3 beta	Homo sapiens	25-34
15465828-4	2004	Serine 468 lies within a GSK-3beta consensus site, and recombinant GSK-3beta specifically phosphorylates a GST-p65-(354-551) fusion protein at Ser(468) in vitro.	Serine	0-3	glycogen synthase kinase 3 beta	Homo sapiens	25-34
15465828-5	2004	In intact cells, phosphorylation of endogenous Ser(468) of p65 is induced by the PP1/PP2A phosphatase inhibitor calyculin A and this effect is inhibited by the GSK-3beta inhibitor LiCl.	Serine	47-50	glycogen synthase kinase 3 beta	Homo sapiens	160-169
15465828-5	2004	In intact cells, phosphorylation of endogenous Ser(468) of p65 is induced by the PP1/PP2A phosphatase inhibitor calyculin A and this effect is inhibited by the GSK-3beta inhibitor LiCl.	calyculin A	112-123	glycogen synthase kinase 3 beta	Homo sapiens	160-169
15465828-5	2004	In intact cells, phosphorylation of endogenous Ser(468) of p65 is induced by the PP1/PP2A phosphatase inhibitor calyculin A and this effect is inhibited by the GSK-3beta inhibitor LiCl.	Lithium Chloride	180-184	glycogen synthase kinase 3 beta	Homo sapiens	160-169
15465828-7	2004	Collectively our results suggest that a GSK-3beta-PP1-dependent mechanism regulates phosphorylation of p65 NF-kappaB at Ser(468) in unstimulated cells and thereby controls the basal activity of NF-kappaB.	Serine	120-123	glycogen synthase kinase 3 beta	Homo sapiens	40-49
15527765-2	2004	The effect of GSK-3beta inhibition was dose- and time-dependent and can be further augmented by its concomitant incubation with Clostridium difficile toxin B, an inhibitor of small Rho proteins, or H-1152, an inhibitor of Rho-associated kinase.	2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine	198-204	glycogen synthase kinase 3 beta	Homo sapiens	14-23
15527765-3	2004	Using AG-490 and caffeic acid phenethyl ester (CAPE), it is further demonstrated that the effect of GSK-3beta inhibition on sPLA2-IIA expression depends on Janus kinase-2 and NF-kappaB-signaling.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	6-12	glycogen synthase kinase 3 beta	Homo sapiens	100-109
15527765-3	2004	Using AG-490 and caffeic acid phenethyl ester (CAPE), it is further demonstrated that the effect of GSK-3beta inhibition on sPLA2-IIA expression depends on Janus kinase-2 and NF-kappaB-signaling.	caffeic acid phenethyl ester	17-45	glycogen synthase kinase 3 beta	Homo sapiens	100-109
15527765-3	2004	Using AG-490 and caffeic acid phenethyl ester (CAPE), it is further demonstrated that the effect of GSK-3beta inhibition on sPLA2-IIA expression depends on Janus kinase-2 and NF-kappaB-signaling.	caffeic acid phenethyl ester	47-51	glycogen synthase kinase 3 beta	Homo sapiens	100-109
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	121-130
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	Serine	149-155	glycogen synthase kinase 3 beta	Homo sapiens	38-47
15475000-0	2004	GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression.	Lithium	24-31	glycogen synthase kinase 3 beta	Homo sapiens	0-9
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	Serine	149-155	glycogen synthase kinase 3 beta	Homo sapiens	121-130
15475000-1	2004	Lithium exerts neuroprotective actions that involve the inhibition of glycogen synthase kinase-3beta (GSK-3beta).	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	70-100
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	Serine	149-155	glycogen synthase kinase 3 beta	Homo sapiens	121-130
15475000-1	2004	Lithium exerts neuroprotective actions that involve the inhibition of glycogen synthase kinase-3beta (GSK-3beta).	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	102-111
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	Serine	149-155	glycogen synthase kinase 3 beta	Homo sapiens	121-130
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	38-47
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	121-130
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	195-204	glycogen synthase kinase 3 beta	Homo sapiens	38-47
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	121-130
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	195-204	glycogen synthase kinase 3 beta	Homo sapiens	121-130
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	195-204	glycogen synthase kinase 3 beta	Homo sapiens	121-130
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione	195-204	glycogen synthase kinase 3 beta	Homo sapiens	121-130
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	Lithium	214-221	glycogen synthase kinase 3 beta	Homo sapiens	38-47
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	Lithium	214-221	glycogen synthase kinase 3 beta	Homo sapiens	121-130
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	Lithium	214-221	glycogen synthase kinase 3 beta	Homo sapiens	121-130
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	Lithium	214-221	glycogen synthase kinase 3 beta	Homo sapiens	121-130
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	Lithium	305-312	glycogen synthase kinase 3 beta	Homo sapiens	38-47
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	Lithium	305-312	glycogen synthase kinase 3 beta	Homo sapiens	121-130
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	Lithium	305-312	glycogen synthase kinase 3 beta	Homo sapiens	121-130
15475000-6	2004	Lithium acted through deregulation of GSK-3beta signaling since (1) it provoked a rapid and sustained phosphorylation of GSK-3beta on the inhibitory serine 9 residue; (2) the GSK-3beta inhibitor SB-415286 mimicked lithium effects by repressing drug-induced apoptosis and CD95 membrane expression; and (3) lithium promoted the disruption of nuclear GSK-3beta/p53 complexes.	Lithium	305-312	glycogen synthase kinase 3 beta	Homo sapiens	121-130
15475000-7	2004	Moreover, the overexpression of an inactivated GSK-3beta mutant counteracted the stimulatory effects of etoposide and camptothecin on a luciferase reporter plasmid driven by a p53-responsive sequence from the CD95 gene.	Etoposide	104-113	glycogen synthase kinase 3 beta	Homo sapiens	47-56
15475000-7	2004	Moreover, the overexpression of an inactivated GSK-3beta mutant counteracted the stimulatory effects of etoposide and camptothecin on a luciferase reporter plasmid driven by a p53-responsive sequence from the CD95 gene.	Camptothecin	118-130	glycogen synthase kinase 3 beta	Homo sapiens	47-56
15475000-8	2004	In conclusion, we provide the first evidence that lithium confers resistance to apoptosis in cancer cells through GSK-3beta inhibition and subsequent repression of CD95 gene expression.	Lithium	50-57	glycogen synthase kinase 3 beta	Homo sapiens	114-123
15351432-3	2004	GSK3-beta codes for an enzyme which is a target for the action of lithium and valproic acid, and the inhibition of which causes antidepressant-like behaviors in a preclinical model.	Lithium	66-73	glycogen synthase kinase 3 beta	Homo sapiens	0-9
15483118-6	2004	Cdk5 phosphorylates CRMP-2 at serine 522, possibly facilitating phosphorylation of serine 518 and threonine 514 by glycogen synthase kinase 3beta (GSK3beta), a kinase previously implicated in Sema 3A signaling.	Serine	83-89	glycogen synthase kinase 3 beta	Homo sapiens	115-145
15483118-6	2004	Cdk5 phosphorylates CRMP-2 at serine 522, possibly facilitating phosphorylation of serine 518 and threonine 514 by glycogen synthase kinase 3beta (GSK3beta), a kinase previously implicated in Sema 3A signaling.	Serine	83-89	glycogen synthase kinase 3 beta	Homo sapiens	147-155
15483118-6	2004	Cdk5 phosphorylates CRMP-2 at serine 522, possibly facilitating phosphorylation of serine 518 and threonine 514 by glycogen synthase kinase 3beta (GSK3beta), a kinase previously implicated in Sema 3A signaling.	Threonine	98-107	glycogen synthase kinase 3 beta	Homo sapiens	115-145
15483118-6	2004	Cdk5 phosphorylates CRMP-2 at serine 522, possibly facilitating phosphorylation of serine 518 and threonine 514 by glycogen synthase kinase 3beta (GSK3beta), a kinase previously implicated in Sema 3A signaling.	Threonine	98-107	glycogen synthase kinase 3 beta	Homo sapiens	147-155
15375789-0	2004	Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3beta on a muscle-specific promoter.	Glucose	15-22	glycogen synthase kinase 3 beta	Homo sapiens	80-110
15375508-5	2004	Both estradiol and LiCl enhanced the expression of eNOS mRNA with the phosphorylation of GSK-3beta, but not Akt.	Estradiol	5-14	glycogen synthase kinase 3 beta	Homo sapiens	89-98
15375508-5	2004	Both estradiol and LiCl enhanced the expression of eNOS mRNA with the phosphorylation of GSK-3beta, but not Akt.	Lithium Chloride	19-23	glycogen synthase kinase 3 beta	Homo sapiens	89-98
15375508-7	2004	We conclude that the estradiol-induced eNOS expression is modulated by PI3-kinase-dependent GSK-3beta pathway.	Estradiol	21-30	glycogen synthase kinase 3 beta	Homo sapiens	92-101
15488156-4	2004	In addition, lithium reduces pro-apoptotic function by directly and indirectly inhibiting glycogen synthase kinase-3beta activity and indirectly inhibiting N-methyl-D-aspartate (NMDA)-receptor-mediated calcium influx.	Lithium	13-20	glycogen synthase kinase 3 beta	Homo sapiens	90-120
15486189-6	2004	Of 13 additional protein kinases tested, isogranulatimide significantly inhibits only glycogen synthase kinase-3beta (IC(50), 0.5 micromol/L).	isogranulatimide	41-57	glycogen synthase kinase 3 beta	Homo sapiens	86-116
15351432-3	2004	GSK3-beta codes for an enzyme which is a target for the action of lithium and valproic acid, and the inhibition of which causes antidepressant-like behaviors in a preclinical model.	Valproic Acid	78-91	glycogen synthase kinase 3 beta	Homo sapiens	0-9
15364539-9	2004	Suspension-induced reporter activation was selectively enhanced by LiCl, which prevented GSK-3beta effects on the simultaneously released beta-catenin.	Lithium Chloride	67-71	glycogen synthase kinase 3 beta	Homo sapiens	89-98
15247282-8	2004	In addition, the pretreatment with nerve growth factor or lithium chloride, a glycogen synthase kinase-3beta inhibitor, suppressed the cyclin D1 down-regulation caused by MPP(+).	Lithium Chloride	58-74	glycogen synthase kinase 3 beta	Homo sapiens	78-108
15337265-2	2004	Here, we report that indirubin-3"-oxime, a known effective inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3-beta (GSK-3beta), has a significant inhibitory effect on JNK.	indirubin-3'-monoxime	21-39	glycogen synthase kinase 3 beta	Homo sapiens	108-139
15337265-2	2004	Here, we report that indirubin-3"-oxime, a known effective inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3-beta (GSK-3beta), has a significant inhibitory effect on JNK.	indirubin-3'-monoxime	21-39	glycogen synthase kinase 3 beta	Homo sapiens	141-150
15353303-5	2004	The capacity of nicotinamide to govern not only intrinsic cellular integrity, but also extrinsic cellular inflammation rests with the modulation of a host of cellular targets that involve protein kinase B, glycogen synthase kinase-3 beta (GSK-3 beta), Forkhead transcription factors, mitochondrial dysfunction, poly(ADP-ribose) polymerase, cysteine proteases, and microglial activation.	Niacinamide	16-28	glycogen synthase kinase 3 beta	Homo sapiens	206-237
15353303-5	2004	The capacity of nicotinamide to govern not only intrinsic cellular integrity, but also extrinsic cellular inflammation rests with the modulation of a host of cellular targets that involve protein kinase B, glycogen synthase kinase-3 beta (GSK-3 beta), Forkhead transcription factors, mitochondrial dysfunction, poly(ADP-ribose) polymerase, cysteine proteases, and microglial activation.	Niacinamide	16-28	glycogen synthase kinase 3 beta	Homo sapiens	239-249
15252116-0	2004	cAMP-induced degradation of cyclin D3 through association with GSK-3beta.	Cyclic AMP	0-4	glycogen synthase kinase 3 beta	Homo sapiens	63-72
15559249-5	2004	Seven of these have been co-crystallized with GSK-3beta and all localize within the ATP-binding pocket of the enzyme.	Adenosine Triphosphate	84-87	glycogen synthase kinase 3 beta	Homo sapiens	46-55
15252116-2	2004	We demonstrate that elevation of intracellular levels of cAMP promotes degradation of cyclin D3 in proteasomes, and that this occurs via glycogen synthase kinase-3beta (GSK-3beta)-mediated phosphorylation of cyclin D3 at Thr-283.	Cyclic AMP	57-61	glycogen synthase kinase 3 beta	Homo sapiens	137-167
15252116-2	2004	We demonstrate that elevation of intracellular levels of cAMP promotes degradation of cyclin D3 in proteasomes, and that this occurs via glycogen synthase kinase-3beta (GSK-3beta)-mediated phosphorylation of cyclin D3 at Thr-283.	Cyclic AMP	57-61	glycogen synthase kinase 3 beta	Homo sapiens	169-178
15252116-2	2004	We demonstrate that elevation of intracellular levels of cAMP promotes degradation of cyclin D3 in proteasomes, and that this occurs via glycogen synthase kinase-3beta (GSK-3beta)-mediated phosphorylation of cyclin D3 at Thr-283.	Threonine	221-224	glycogen synthase kinase 3 beta	Homo sapiens	137-167
15252116-2	2004	We demonstrate that elevation of intracellular levels of cAMP promotes degradation of cyclin D3 in proteasomes, and that this occurs via glycogen synthase kinase-3beta (GSK-3beta)-mediated phosphorylation of cyclin D3 at Thr-283.	Threonine	221-224	glycogen synthase kinase 3 beta	Homo sapiens	169-178
15252116-4	2004	However, cAMP promoted the interaction between cyclin D3 and GSK-3beta both in vitro and in vivo, indicating that GSK-3beta-mediated phosphorylation of cyclin D3 might require the association between the two proteins.	Cyclic AMP	9-13	glycogen synthase kinase 3 beta	Homo sapiens	61-70
15252116-4	2004	However, cAMP promoted the interaction between cyclin D3 and GSK-3beta both in vitro and in vivo, indicating that GSK-3beta-mediated phosphorylation of cyclin D3 might require the association between the two proteins.	Cyclic AMP	9-13	glycogen synthase kinase 3 beta	Homo sapiens	114-123
15132987-0	2004	Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death.	Oxidopamine	51-68	glycogen synthase kinase 3 beta	Homo sapiens	0-30
15370202-8	2004	GSK-3beta a kinase regulated via PI3-kinase dependent, down-stream kinases, was responsible for regulating cyclin D1 levels in CLL cells, but neither GSK-3beta nor calpain was responsible for induction of apoptosis, or activation of executioner caspase 3, following LY294002 treatment.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	266-274	glycogen synthase kinase 3 beta	Homo sapiens	0-9
15282298-9	2004	Ser-302 and Ser-306 are part of a consensus site for the mammalian homolog of Rim11, glycogen synthase kinase 3-beta.	Serine	0-3	glycogen synthase kinase 3 beta	Homo sapiens	85-116
15282298-9	2004	Ser-302 and Ser-306 are part of a consensus site for the mammalian homolog of Rim11, glycogen synthase kinase 3-beta.	Serine	12-15	glycogen synthase kinase 3 beta	Homo sapiens	85-116
15178691-5	2004	The suppression of AR transactivation by GSK3 beta was abolished by the GSK3 beta inhibitor lithium chloride.	Lithium Chloride	92-108	glycogen synthase kinase 3 beta	Homo sapiens	41-50
15178691-5	2004	The suppression of AR transactivation by GSK3 beta was abolished by the GSK3 beta inhibitor lithium chloride.	Lithium Chloride	92-108	glycogen synthase kinase 3 beta	Homo sapiens	72-81
15178691-7	2004	GSK3 beta interrupted the interaction between the NH(2) and COOH termini of AR, and overexpression of the constitutively active form of GSK3 beta, S9A-GSK3 beta, reduced the androgen-induced prostate cancer cell growth in stably transfected CWR22R cells.	Carbonic Acid	60-64	glycogen synthase kinase 3 beta	Homo sapiens	0-9
15282275-7	2004	Furthermore, lithium chloride, a modulator of glycogen synthase kinase-3beta (GSK-3beta) promoted Schwann cell differentiation, suggesting the involvement of GSK-3beta as a downstream molecule of PI3K-Akt pathways.	Lithium Chloride	13-29	glycogen synthase kinase 3 beta	Homo sapiens	46-76
15282275-7	2004	Furthermore, lithium chloride, a modulator of glycogen synthase kinase-3beta (GSK-3beta) promoted Schwann cell differentiation, suggesting the involvement of GSK-3beta as a downstream molecule of PI3K-Akt pathways.	Lithium Chloride	13-29	glycogen synthase kinase 3 beta	Homo sapiens	78-87
15282275-7	2004	Furthermore, lithium chloride, a modulator of glycogen synthase kinase-3beta (GSK-3beta) promoted Schwann cell differentiation, suggesting the involvement of GSK-3beta as a downstream molecule of PI3K-Akt pathways.	Lithium Chloride	13-29	glycogen synthase kinase 3 beta	Homo sapiens	158-167
15155564-13	2004	Inactivation of GSK3beta by hypoxia/reoxygenation, possibly integrating PI3-kinase and ERK pathways downstream of beta2-AR and ROS, is a prerequisite for CRE-dependent transcription.	Reactive Oxygen Species	127-130	glycogen synthase kinase 3 beta	Homo sapiens	16-24
15073173-1	2004	In mammalian brain, tau, glycogen synthase kinase 3beta (GSK3beta), and 14-3-3, a phosphoserine-binding protein, are parts of a multiprotein tau phosphorylation complex.	Phosphoserine	82-95	glycogen synthase kinase 3 beta	Homo sapiens	57-65
15073173-6	2004	In this study, we find that GSK3beta within the tau phosphorylation complex is phosphorylated on Ser(9).	Serine	97-100	glycogen synthase kinase 3 beta	Homo sapiens	28-36
15073173-9	2004	In vitro, 14-3-3 binds to GSK3beta only when the kinase is phosphorylated on Ser(9).	Serine	77-80	glycogen synthase kinase 3 beta	Homo sapiens	26-34
15073173-10	2004	In transfected HEK-293 cells, 14-3-3 binds to Ser(9)-phosphorylated GSK3beta and does not bind to GSK3beta (S9A).	Serine	46-49	glycogen synthase kinase 3 beta	Homo sapiens	68-76
15073173-12	2004	Moreover, 14-3-3 enhances the binding of tau with Ser(9)-phosphorylated GSK3beta by approximately 3-fold but not with GSK3beta (S9A).	Serine	50-53	glycogen synthase kinase 3 beta	Homo sapiens	72-80
15073173-13	2004	Similarly, 14-3-3 stimulates phosphorylation of tau by Ser(9)-phosphorylated GSK3beta but not by GSK3beta (S9A).	Serine	55-58	glycogen synthase kinase 3 beta	Homo sapiens	77-85
15073173-14	2004	In transfected HEK-293 cells, Ser(9) phosphorylation suppresses GSK3beta-catalyzed tau phosphorylation in the absence of 14-3-3.	Serine	30-33	glycogen synthase kinase 3 beta	Homo sapiens	64-72
15149684-1	2004	A novel series of acyclic 3-(7-azaindolyl)-4-(aryl/heteroaryl)maleimides was synthesized and evaluated for activity against GSK-3beta and selectivity versus PKC-betaII, as well as a broad panel of protein kinases.	3-(7-azaindolyl)-4-(aryl/heteroaryl)maleimides	26-72	glycogen synthase kinase 3 beta	Homo sapiens	124-133
15073173-15	2004	In the presence of 14-3-3, however, Ser(9)-phosphorylated GSK3beta remains active and phosphorylates tau.	Serine	36-39	glycogen synthase kinase 3 beta	Homo sapiens	58-66
15073173-16	2004	Our data indicate that within the tau phosphorylation complex, 14-3-3 connects Ser(9)-phosphorylated GSK3beta to tau and Ser(9)-phosphorylated GSK3beta phosphorylates tau.	Serine	79-82	glycogen synthase kinase 3 beta	Homo sapiens	101-109
15073173-16	2004	Our data indicate that within the tau phosphorylation complex, 14-3-3 connects Ser(9)-phosphorylated GSK3beta to tau and Ser(9)-phosphorylated GSK3beta phosphorylates tau.	Serine	121-124	glycogen synthase kinase 3 beta	Homo sapiens	101-109
15073173-16	2004	Our data indicate that within the tau phosphorylation complex, 14-3-3 connects Ser(9)-phosphorylated GSK3beta to tau and Ser(9)-phosphorylated GSK3beta phosphorylates tau.	Serine	121-124	glycogen synthase kinase 3 beta	Homo sapiens	143-151
15158785-0	2004	Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors.	7-azaindolyl-heteroaryl-maleimides	54-88	glycogen synthase kinase 3 beta	Homo sapiens	113-143
15064718-1	2004	Beta-Catenin, a member of the Wnt signaling pathway, is downregulated by glycogen synthase kinase-3beta (GSK-3beta)-dependent phosphorylation of Ser/Thr residues in the N-terminus of the protein, followed by ubiquitination and proteosomal degradation.	Serine	145-148	glycogen synthase kinase 3 beta	Homo sapiens	105-114
15064718-1	2004	Beta-Catenin, a member of the Wnt signaling pathway, is downregulated by glycogen synthase kinase-3beta (GSK-3beta)-dependent phosphorylation of Ser/Thr residues in the N-terminus of the protein, followed by ubiquitination and proteosomal degradation.	Threonine	149-152	glycogen synthase kinase 3 beta	Homo sapiens	73-103
15064718-1	2004	Beta-Catenin, a member of the Wnt signaling pathway, is downregulated by glycogen synthase kinase-3beta (GSK-3beta)-dependent phosphorylation of Ser/Thr residues in the N-terminus of the protein, followed by ubiquitination and proteosomal degradation.	Threonine	149-152	glycogen synthase kinase 3 beta	Homo sapiens	105-114
15064718-2	2004	In human and rodent cancers, mutations that substitute one of the critical Ser/Thr residues in the GSK-3beta region of beta-catenin stabilize the protein and activate beta-catenin/TCF/LEF target genes.	Serine	75-78	glycogen synthase kinase 3 beta	Homo sapiens	99-108
15064718-2	2004	In human and rodent cancers, mutations that substitute one of the critical Ser/Thr residues in the GSK-3beta region of beta-catenin stabilize the protein and activate beta-catenin/TCF/LEF target genes.	Threonine	79-82	glycogen synthase kinase 3 beta	Homo sapiens	99-108
15064718-1	2004	Beta-Catenin, a member of the Wnt signaling pathway, is downregulated by glycogen synthase kinase-3beta (GSK-3beta)-dependent phosphorylation of Ser/Thr residues in the N-terminus of the protein, followed by ubiquitination and proteosomal degradation.	Serine	145-148	glycogen synthase kinase 3 beta	Homo sapiens	73-103
15158785-0	2004	Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors.	7-azaindolyl-heteroaryl-maleimides	54-88	glycogen synthase kinase 3 beta	Homo sapiens	145-154
15147515-1	2004	The potential role of 4-hydroxynonenal (HNE), a major product of membrane lipid peroxidation, in regulating glycogen synthase kinase-3beta (GSK3beta) activity was examined in human neuroblastoma IMR-32 cells.	4-hydroxy-2-nonenal	22-38	glycogen synthase kinase 3 beta	Homo sapiens	108-138
14988390-1	2004	Despite the specificity inferred by its name, glycogen synthase kinase (GSK)-3beta is an important kinase with a plethora of significant cellular targets, including cytoskeletal proteins and transcription factors, and its activity is regulated by phosphorylation on tyrosine/serine residues.	Tyrosine	266-274	glycogen synthase kinase 3 beta	Homo sapiens	46-82
14988390-1	2004	Despite the specificity inferred by its name, glycogen synthase kinase (GSK)-3beta is an important kinase with a plethora of significant cellular targets, including cytoskeletal proteins and transcription factors, and its activity is regulated by phosphorylation on tyrosine/serine residues.	Serine	275-281	glycogen synthase kinase 3 beta	Homo sapiens	46-82
14988390-3	2004	Pretreatment of prostate cancer cells harboring wild-type or mutant androgen receptor with the GSK-3beta inhibitors, lithium chloride (LiCl), RO318220, or GF109203X, inhibited R1881-stimulated androgen-responsive reporter activity in a dose- and time-dependent manner.	Lithium Chloride	117-133	glycogen synthase kinase 3 beta	Homo sapiens	95-104
14988390-3	2004	Pretreatment of prostate cancer cells harboring wild-type or mutant androgen receptor with the GSK-3beta inhibitors, lithium chloride (LiCl), RO318220, or GF109203X, inhibited R1881-stimulated androgen-responsive reporter activity in a dose- and time-dependent manner.	Lithium Chloride	135-139	glycogen synthase kinase 3 beta	Homo sapiens	95-104
14988390-3	2004	Pretreatment of prostate cancer cells harboring wild-type or mutant androgen receptor with the GSK-3beta inhibitors, lithium chloride (LiCl), RO318220, or GF109203X, inhibited R1881-stimulated androgen-responsive reporter activity in a dose- and time-dependent manner.	bisindolylmaleimide I	155-164	glycogen synthase kinase 3 beta	Homo sapiens	95-104
14988390-6	2004	Moreover, R1881 treatment of the cells increased phosphorylation status of GSK-3beta on tyrosine residue Y(216) but not on serine residue S(9).	Tyrosine	88-96	glycogen synthase kinase 3 beta	Homo sapiens	75-84
14988390-7	2004	Pretreatment of the cells with phosphatidylinositol 3-kinase inhibitor LY294002 or wortmannin, which blocks androgen action in cells, abolished R1881-induced GSK-3beta Y(216) phosphorylation.	Phosphatidylinositols	31-51	glycogen synthase kinase 3 beta	Homo sapiens	158-167
14988390-7	2004	Pretreatment of the cells with phosphatidylinositol 3-kinase inhibitor LY294002 or wortmannin, which blocks androgen action in cells, abolished R1881-induced GSK-3beta Y(216) phosphorylation.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	71-79	glycogen synthase kinase 3 beta	Homo sapiens	158-167
14988390-7	2004	Pretreatment of the cells with phosphatidylinositol 3-kinase inhibitor LY294002 or wortmannin, which blocks androgen action in cells, abolished R1881-induced GSK-3beta Y(216) phosphorylation.	Wortmannin	83-93	glycogen synthase kinase 3 beta	Homo sapiens	158-167
15173880-4	2004	Cell protection that exhibits a memory (preconditioning) results from triggered mitochondrial swelling that causes enhanced substrate oxidation and ROS production, leading to redox activation of PKC, which inhibits glycogen synthase kinase-3beta (GSK-3beta).	Reactive Oxygen Species	148-151	glycogen synthase kinase 3 beta	Homo sapiens	215-245
15173880-4	2004	Cell protection that exhibits a memory (preconditioning) results from triggered mitochondrial swelling that causes enhanced substrate oxidation and ROS production, leading to redox activation of PKC, which inhibits glycogen synthase kinase-3beta (GSK-3beta).	Reactive Oxygen Species	148-151	glycogen synthase kinase 3 beta	Homo sapiens	247-256
15147515-1	2004	The potential role of 4-hydroxynonenal (HNE), a major product of membrane lipid peroxidation, in regulating glycogen synthase kinase-3beta (GSK3beta) activity was examined in human neuroblastoma IMR-32 cells.	4-hydroxy-2-nonenal	22-38	glycogen synthase kinase 3 beta	Homo sapiens	140-148
15147515-5	2004	Ser9-GSK3beta phosphorylation induced by HNE was abolished by treatment with LY294002 or U0126, two inhibitors of PI3K/AKT and ERK pathways, respectively.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	77-85	glycogen synthase kinase 3 beta	Homo sapiens	5-13
15147515-5	2004	Ser9-GSK3beta phosphorylation induced by HNE was abolished by treatment with LY294002 or U0126, two inhibitors of PI3K/AKT and ERK pathways, respectively.	U 0126	89-94	glycogen synthase kinase 3 beta	Homo sapiens	5-13
15126379-10	2004	In addition, caffeine did not affect p16INK4 or p27Kip1 protein levels, but inhibited the phosphorylation of protein kinase B (Akt) and glycogen synthase kinase 3beta.	Caffeine	13-21	glycogen synthase kinase 3 beta	Homo sapiens	136-166
15020584-0	2004	Glycogen synthase kinase-3beta regulates growth, calcium homeostasis, and diastolic function in the heart.	Calcium	49-56	glycogen synthase kinase 3 beta	Homo sapiens	0-30
15020584-6	2004	The alterations in calcium handling are due at least in part to direct down-regulation of the sarcoplasmic reticulum calcium ATPase (SERCA2a) by GSK-3beta, acting at the level of the SERCA2 promoter.	Calcium	19-26	glycogen synthase kinase 3 beta	Homo sapiens	145-154
15176713-4	2004	This study shows that 3 of 67 medulloblastomas harbor beta-catenin mutations, each of which converts a GSK-3beta phosphorylation site from serine to cysteine.	Serine	139-145	glycogen synthase kinase 3 beta	Homo sapiens	103-112
15176713-4	2004	This study shows that 3 of 67 medulloblastomas harbor beta-catenin mutations, each of which converts a GSK-3beta phosphorylation site from serine to cysteine.	Cysteine	149-157	glycogen synthase kinase 3 beta	Homo sapiens	103-112
15073527-6	2004	We conclude that GSK-3beta regulates cAMP-induced CCK transcription by reducing CREB binding to the CRE(-80) element in the CCK promoter.	Cyclic AMP	37-41	glycogen synthase kinase 3 beta	Homo sapiens	17-26
15107622-5	2004	This process requires the phosphorylation of p53 at serine 315 and serine 376, which is mediated by the activation of glycogen synthase kinase-3beta (GSK-3beta).	Serine	52-58	glycogen synthase kinase 3 beta	Homo sapiens	118-148
15107622-5	2004	This process requires the phosphorylation of p53 at serine 315 and serine 376, which is mediated by the activation of glycogen synthase kinase-3beta (GSK-3beta).	Serine	52-58	glycogen synthase kinase 3 beta	Homo sapiens	150-159
15107622-5	2004	This process requires the phosphorylation of p53 at serine 315 and serine 376, which is mediated by the activation of glycogen synthase kinase-3beta (GSK-3beta).	Serine	67-73	glycogen synthase kinase 3 beta	Homo sapiens	118-148
15107622-5	2004	This process requires the phosphorylation of p53 at serine 315 and serine 376, which is mediated by the activation of glycogen synthase kinase-3beta (GSK-3beta).	Serine	67-73	glycogen synthase kinase 3 beta	Homo sapiens	150-159
14985354-3	2004	Conversely, the glycogen synthase kinase-3 beta inhibitor lithium chloride suppressed the glycogen synthase kinase-3 beta-mediated phosphorylation of the androgen receptor, thereby enabling androgen receptor-driven transcription to occur.	Lithium Chloride	58-74	glycogen synthase kinase 3 beta	Homo sapiens	16-47
14985354-3	2004	Conversely, the glycogen synthase kinase-3 beta inhibitor lithium chloride suppressed the glycogen synthase kinase-3 beta-mediated phosphorylation of the androgen receptor, thereby enabling androgen receptor-driven transcription to occur.	Lithium Chloride	58-74	glycogen synthase kinase 3 beta	Homo sapiens	90-121
14985354-5	2004	Furthermore, androgen receptor phosphorylation was augmented by LY294002, an indirect inhibitor of protein kinase B/Akt that inhibits glycogen synthase kinase-3 beta.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	64-72	glycogen synthase kinase 3 beta	Homo sapiens	134-165
21214996-3	2004	The activity of GSK-3beta among those three cell lines was detected by immunoprecipitation and analysed by a radioactive isotope scintillation counter before and after treating with 20 mmol/L LiCl.	Lithium Chloride	192-196	glycogen synthase kinase 3 beta	Homo sapiens	16-25
21214996-8	2004	(3) After treatment with 20 mmol/L LiCl, the expressive indensity of GSK-3beta of cytoplasm and nucleus was (4 718+-549) and (3 823+-350) IOD in L9981-nm23-H1, (2 030+-155) and (217+-15) IOD in L9981-pLXSN, and (2 164+-151) and (224+-19) IOD in L9981, respectively.	Lithium Chloride	35-39	glycogen synthase kinase 3 beta	Homo sapiens	69-78
21214996-11	2004	(4) After treatment with 20 mmol/L LiCl, the GSK-3beta activity in cytoplasm and nucleus was (11 099+-1 112) and (3 748+-215) CPM in L9981-nm23-H1, (4 447+-430) and (1067+-159) CPM in L9981, and (4 435+-427) and (909+-156) CPM in L9981-pLXSN, respectively.	Lithium Chloride	35-39	glycogen synthase kinase 3 beta	Homo sapiens	45-54
21214996-12	2004	The GSK-3beta activity both in cytoplasm and nucleus after treatment with LiCl was remarkably lower than that before treatment in L9981-nm23-H1, L9981-pLXSN and L9981 (P &lt; 0.01 or P &lt; 0.05).	Lithium Chloride	74-78	glycogen synthase kinase 3 beta	Homo sapiens	4-13
15073527-0	2004	GSK-3beta reduces cAMP-induced cholecystokinin gene expression by inhibiting CREB binding.	Cyclic AMP	18-22	glycogen synthase kinase 3 beta	Homo sapiens	0-9
15073527-2	2004	In the present study we examined the function of glycogen synthase kinase-3beta (GSK-3beta) on cAMP-induced CCK gene transcription.	Cyclic AMP	95-99	glycogen synthase kinase 3 beta	Homo sapiens	49-79
15073527-2	2004	In the present study we examined the function of glycogen synthase kinase-3beta (GSK-3beta) on cAMP-induced CCK gene transcription.	Cyclic AMP	95-99	glycogen synthase kinase 3 beta	Homo sapiens	81-90
15073527-3	2004	Co-transfection of GSK-3beta reduced the cAMP-induced CCK promoter activity with approximately 80% and approximately 60% in SK-N-MC and PC12 cells, respectively.	Cyclic AMP	41-45	glycogen synthase kinase 3 beta	Homo sapiens	19-28
15094071-4	2004	IGF1 acts in an autocrine and/or paracrine manner to promote glucose utilization, using phosphatidylinositol 3 kinase (PI3K)/Akt, also known as protein kinase B (PKB)/glycogen synthase kinase 3beta (GSK3beta) pathways similar to insulin signaling in peripheral tissues.	Glucose	61-68	glycogen synthase kinase 3 beta	Homo sapiens	167-197
15094071-4	2004	IGF1 acts in an autocrine and/or paracrine manner to promote glucose utilization, using phosphatidylinositol 3 kinase (PI3K)/Akt, also known as protein kinase B (PKB)/glycogen synthase kinase 3beta (GSK3beta) pathways similar to insulin signaling in peripheral tissues.	Glucose	61-68	glycogen synthase kinase 3 beta	Homo sapiens	199-207
15073527-3	2004	Co-transfection of GSK-3beta reduced the cAMP-induced CCK promoter activity with approximately 80% and approximately 60% in SK-N-MC and PC12 cells, respectively.	sk-n-mc	124-131	glycogen synthase kinase 3 beta	Homo sapiens	19-28
15020233-0	2004	Glycogen synthase kinase-3beta is tyrosine-phosphorylated by MEK1 in human skin fibroblasts.	Tyrosine	34-42	glycogen synthase kinase 3 beta	Homo sapiens	0-30
15073527-5	2004	Finally, mutation of serine-129, which is a phosphorylation site for GSK-3beta, did not abolish cAMP-induced CREB-dependent transcription, and cAMP-mediated GAL4-CREB transcription was unaffected by co-transfection with GSK-3beta.	Serine	21-27	glycogen synthase kinase 3 beta	Homo sapiens	69-78
15020233-3	2004	U0126, a MEK1/2 inhibitor, inhibited tyrosine phosphorylation of GSK-3beta, suggesting that MEK1/2 was involved in the phosphorylation of Tyr(216) in GSK-3beta.	Tyrosine	37-45	glycogen synthase kinase 3 beta	Homo sapiens	150-159
15020233-3	2004	U0126, a MEK1/2 inhibitor, inhibited tyrosine phosphorylation of GSK-3beta, suggesting that MEK1/2 was involved in the phosphorylation of Tyr(216) in GSK-3beta.	U 0126	0-5	glycogen synthase kinase 3 beta	Homo sapiens	65-74
15020233-3	2004	U0126, a MEK1/2 inhibitor, inhibited tyrosine phosphorylation of GSK-3beta, suggesting that MEK1/2 was involved in the phosphorylation of Tyr(216) in GSK-3beta.	Tyrosine	138-141	glycogen synthase kinase 3 beta	Homo sapiens	65-74
15020233-3	2004	U0126, a MEK1/2 inhibitor, inhibited tyrosine phosphorylation of GSK-3beta, suggesting that MEK1/2 was involved in the phosphorylation of Tyr(216) in GSK-3beta.	Tyrosine	138-141	glycogen synthase kinase 3 beta	Homo sapiens	150-159
15020233-3	2004	U0126, a MEK1/2 inhibitor, inhibited tyrosine phosphorylation of GSK-3beta, suggesting that MEK1/2 was involved in the phosphorylation of Tyr(216) in GSK-3beta.	U 0126	0-5	glycogen synthase kinase 3 beta	Homo sapiens	150-159
15020233-4	2004	In vitro kinase assay was carried out using a recombinant human active MEK1 and we found that GSK-3beta was phosphorylated on Tyr(216) by this kinase in a dose- and time-dependent manner.	Tyrosine	126-129	glycogen synthase kinase 3 beta	Homo sapiens	94-103
15020233-3	2004	U0126, a MEK1/2 inhibitor, inhibited tyrosine phosphorylation of GSK-3beta, suggesting that MEK1/2 was involved in the phosphorylation of Tyr(216) in GSK-3beta.	Tyrosine	37-45	glycogen synthase kinase 3 beta	Homo sapiens	65-74
15020233-5	2004	Further, the pretreatment of fibroblasts with U0126 inhibited serum-induced nuclear translocation of GSK-3beta.	U 0126	46-51	glycogen synthase kinase 3 beta	Homo sapiens	101-110
15020233-6	2004	These results suggested that MEK1/2 induces tyrosine phosphorylation of GSK-3beta and this cellular event might induce nuclear translocation of GSK-3beta.	Tyrosine	44-52	glycogen synthase kinase 3 beta	Homo sapiens	72-81
14993667-2	2004	Here, binary complex structures of full-length TPK I/GSK3 beta with the ATP analogues ADP and AMPPNP solved by the X-ray diffraction method at 2.1 and 1.8 A resolution, respectively, are reported.	Adenosine Triphosphate	72-75	glycogen synthase kinase 3 beta	Homo sapiens	53-62
15020233-6	2004	These results suggested that MEK1/2 induces tyrosine phosphorylation of GSK-3beta and this cellular event might induce nuclear translocation of GSK-3beta.	Tyrosine	44-52	glycogen synthase kinase 3 beta	Homo sapiens	144-153
15005626-7	2004	We demonstrated that the inhibition of GSK3beta activity by treatment of cells with the inhibitor 5-iodo-indirubin-3"-monoxime, as well as with a dominant-negative GSK3beta mutant, induced the accumulation of alphaNAC in the nuclei of cells.	5-iodoindirubin-3'-monoxime	98-126	glycogen synthase kinase 3 beta	Homo sapiens	39-47
15121343-7	2004	Evidence shows that chronic administration of VPA or lithium can stimulate bcl-2 expression as well as inhibit GSK-3 beta activity, which renders a cell less susceptible to apoptosis.	Valproic Acid	46-49	glycogen synthase kinase 3 beta	Homo sapiens	111-121
15121343-7	2004	Evidence shows that chronic administration of VPA or lithium can stimulate bcl-2 expression as well as inhibit GSK-3 beta activity, which renders a cell less susceptible to apoptosis.	Lithium	53-60	glycogen synthase kinase 3 beta	Homo sapiens	111-121
14993667-2	2004	Here, binary complex structures of full-length TPK I/GSK3 beta with the ATP analogues ADP and AMPPNP solved by the X-ray diffraction method at 2.1 and 1.8 A resolution, respectively, are reported.	Adenosine Diphosphate	86-89	glycogen synthase kinase 3 beta	Homo sapiens	53-62
14993667-2	2004	Here, binary complex structures of full-length TPK I/GSK3 beta with the ATP analogues ADP and AMPPNP solved by the X-ray diffraction method at 2.1 and 1.8 A resolution, respectively, are reported.	Adenylyl Imidodiphosphate	94-100	glycogen synthase kinase 3 beta	Homo sapiens	53-62
14993667-6	2004	The overall structure and substrate-binding residues are similar to those observed in other Ser/Thr protein kinases, while Arg141 (which is not conserved among other Ser/Thr protein kinases) is one of the key residues for specific ATP/ADP recognition by TPK I/GSK3 beta.	Adenosine Triphosphate	231-234	glycogen synthase kinase 3 beta	Homo sapiens	260-269
14993667-6	2004	The overall structure and substrate-binding residues are similar to those observed in other Ser/Thr protein kinases, while Arg141 (which is not conserved among other Ser/Thr protein kinases) is one of the key residues for specific ATP/ADP recognition by TPK I/GSK3 beta.	Adenosine Diphosphate	235-238	glycogen synthase kinase 3 beta	Homo sapiens	260-269
14570592-3	2004	GSK3beta expressed in insect Sf 21 cells or E. coli was extensively phosphorylated at Tyr216, but the few molecules lacking phosphate at this position could autophosphorylate at Tyr216 in vitro after incubation with MgATP.	Phosphates	124-133	glycogen synthase kinase 3 beta	Homo sapiens	0-8
14988008-1	2004	We investigated the effect of 10 microM clozapine on the activity of glycogen synthase kinase-3beta (GSK-3beta) and its upstream and downstream molecules in SH-SY5Y human neuroblastoma cells.	Clozapine	40-49	glycogen synthase kinase 3 beta	Homo sapiens	69-99
14988008-1	2004	We investigated the effect of 10 microM clozapine on the activity of glycogen synthase kinase-3beta (GSK-3beta) and its upstream and downstream molecules in SH-SY5Y human neuroblastoma cells.	Clozapine	40-49	glycogen synthase kinase 3 beta	Homo sapiens	101-110
14988008-2	2004	Clozapine activates both Akt- and Dvl-mediated phosphorylation of GSK-3beta through phosphorylation at Ser9, and increased total cellular and intranuclear levels of beta-catenin.	Clozapine	0-9	glycogen synthase kinase 3 beta	Homo sapiens	66-75
14988008-3	2004	Pretreatment with the specific inhibitor of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway, LY294002 (20 microM), prevented the phosphorylation of Akt but did not affect the phosphorylation of GSK-3beta.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	98-106	glycogen synthase kinase 3 beta	Homo sapiens	199-208
14988008-4	2004	These results suggest that clozapine regulates the phosphorylation of GSK-3beta through Wnt signal pathways involving Dvl upstream but not through the PI3K-Akt pathway in SH-SY5Y cells.	Clozapine	27-36	glycogen synthase kinase 3 beta	Homo sapiens	70-79
14607840-7	2004	Importantly, enhanced RMIC survival produced by GSK 3beta inhibition was completely dependent on COX 2 because it was abolished by a COX 2-specific inhibitor, SC58236.	4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide	159-166	glycogen synthase kinase 3 beta	Homo sapiens	48-57
14980636-0	2004	Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-3 beta (GSK-3 beta) inhibitors.	bis-7-azaindolylmaleimides	57-83	glycogen synthase kinase 3 beta	Homo sapiens	115-146
14980636-0	2004	Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-3 beta (GSK-3 beta) inhibitors.	bis-7-azaindolylmaleimides	57-83	glycogen synthase kinase 3 beta	Homo sapiens	148-158
14980636-2	2004	Among the three series of macrocycles, the oxygen atom and thiophene containing linkers yielded molecules with higher inhibitory potency at GSK-3 beta (K(i)=0.011-0.079 microM) while the nitrogen atom containing linkers yielded molecules with lower potency (K(i)=0.150-&gt;1 microM).	Oxygen	43-49	glycogen synthase kinase 3 beta	Homo sapiens	140-150
14980636-2	2004	Among the three series of macrocycles, the oxygen atom and thiophene containing linkers yielded molecules with higher inhibitory potency at GSK-3 beta (K(i)=0.011-0.079 microM) while the nitrogen atom containing linkers yielded molecules with lower potency (K(i)=0.150-&gt;1 microM).	Thiophenes	59-68	glycogen synthase kinase 3 beta	Homo sapiens	140-150
14980636-2	2004	Among the three series of macrocycles, the oxygen atom and thiophene containing linkers yielded molecules with higher inhibitory potency at GSK-3 beta (K(i)=0.011-0.079 microM) while the nitrogen atom containing linkers yielded molecules with lower potency (K(i)=0.150-&gt;1 microM).	Nitrogen	187-195	glycogen synthase kinase 3 beta	Homo sapiens	140-150
14980636-6	2004	Molecular docking studies were conducted in an attempt to rationalize the GSK-3 beta selectivity of azaindolylmaleimides.	azaindolylmaleimides	100-120	glycogen synthase kinase 3 beta	Homo sapiens	74-84
14761195-3	2004	Using the cocrystal structures of various indirubins with GSK-3beta, CDK2 and CDK5/p25, we have modeled the binding of indirubins within the ATP-binding pocket of these kinases.	indirubin	42-52	glycogen synthase kinase 3 beta	Homo sapiens	58-67
14761195-3	2004	Using the cocrystal structures of various indirubins with GSK-3beta, CDK2 and CDK5/p25, we have modeled the binding of indirubins within the ATP-binding pocket of these kinases.	Adenosine Triphosphate	141-144	glycogen synthase kinase 3 beta	Homo sapiens	58-67
14744935-3	2004	The mechanism of inhibition involves the increased cytoplasmic localization of p53 due to phosphorylation at serine 315 and serine 376, which is mediated by glycogen synthase kinase-3 beta (GSK-3beta).	Serine	109-115	glycogen synthase kinase 3 beta	Homo sapiens	157-188
14744935-3	2004	The mechanism of inhibition involves the increased cytoplasmic localization of p53 due to phosphorylation at serine 315 and serine 376, which is mediated by glycogen synthase kinase-3 beta (GSK-3beta).	Serine	109-115	glycogen synthase kinase 3 beta	Homo sapiens	190-199
14744935-3	2004	The mechanism of inhibition involves the increased cytoplasmic localization of p53 due to phosphorylation at serine 315 and serine 376, which is mediated by glycogen synthase kinase-3 beta (GSK-3beta).	Serine	124-130	glycogen synthase kinase 3 beta	Homo sapiens	157-188
14744935-3	2004	The mechanism of inhibition involves the increased cytoplasmic localization of p53 due to phosphorylation at serine 315 and serine 376, which is mediated by glycogen synthase kinase-3 beta (GSK-3beta).	Serine	124-130	glycogen synthase kinase 3 beta	Homo sapiens	190-199
14751515-9	2004	The kinase activities of ILK, PKBalpha/Akt, and GSK-3beta were strongly induced by irradiation on polystyrene, but not on FN, which was a result of a FN-mediated increase of basal kinase activities.	Polystyrenes	98-109	glycogen synthase kinase 3 beta	Homo sapiens	48-57
14698171-2	2004	Among the novel structures, 1-azakenpaullone was found to act as a selective GSK-3beta versus CDK1 inhibitor.	kenpaullone	28-44	glycogen synthase kinase 3 beta	Homo sapiens	77-86
14698171-3	2004	The charge distribution within the 1-azakenpaullone molecule is discussed as a possible explanation for the enhanced GSK-3beta selectivity of 1-azakenpaullone compared to other paullone derivatives.	kenpaullone	35-51	glycogen synthase kinase 3 beta	Homo sapiens	117-126
14698171-3	2004	The charge distribution within the 1-azakenpaullone molecule is discussed as a possible explanation for the enhanced GSK-3beta selectivity of 1-azakenpaullone compared to other paullone derivatives.	kenpaullone	142-158	glycogen synthase kinase 3 beta	Homo sapiens	117-126
14698171-3	2004	The charge distribution within the 1-azakenpaullone molecule is discussed as a possible explanation for the enhanced GSK-3beta selectivity of 1-azakenpaullone compared to other paullone derivatives.	paullone	43-51	glycogen synthase kinase 3 beta	Homo sapiens	117-126
14570592-3	2004	GSK3beta expressed in insect Sf 21 cells or E. coli was extensively phosphorylated at Tyr216, but the few molecules lacking phosphate at this position could autophosphorylate at Tyr216 in vitro after incubation with MgATP.	Adenosine Triphosphate	216-221	glycogen synthase kinase 3 beta	Homo sapiens	0-8
15129823-8	2004	The lithium-treated flies also show reduced activity of one of the previously reported targets of lithium action, Glycogen Synthase Kinase 3beta (GSK 3beta).	Lithium	4-11	glycogen synthase kinase 3 beta	Homo sapiens	114-144
15129823-8	2004	The lithium-treated flies also show reduced activity of one of the previously reported targets of lithium action, Glycogen Synthase Kinase 3beta (GSK 3beta).	Lithium	4-11	glycogen synthase kinase 3 beta	Homo sapiens	146-155
15129823-0	2004	Glycogen synthase kinase 3beta as a likely target for the action of lithium on circadian clocks.	Lithium	68-75	glycogen synthase kinase 3 beta	Homo sapiens	0-30
15129823-8	2004	The lithium-treated flies also show reduced activity of one of the previously reported targets of lithium action, Glycogen Synthase Kinase 3beta (GSK 3beta).	Lithium	98-105	glycogen synthase kinase 3 beta	Homo sapiens	114-144
15129823-8	2004	The lithium-treated flies also show reduced activity of one of the previously reported targets of lithium action, Glycogen Synthase Kinase 3beta (GSK 3beta).	Lithium	98-105	glycogen synthase kinase 3 beta	Homo sapiens	146-155
15129823-10	2004	The tau elongation resembles the effect seen with lithium administration in a number of organisms including man, and taken together with the earlier observations our results suggest that lithium inhibits the activity of GSK 3beta to produce its effect on circadian clocks.	Lithium	50-57	glycogen synthase kinase 3 beta	Homo sapiens	220-229
15129823-10	2004	The tau elongation resembles the effect seen with lithium administration in a number of organisms including man, and taken together with the earlier observations our results suggest that lithium inhibits the activity of GSK 3beta to produce its effect on circadian clocks.	Lithium	187-194	glycogen synthase kinase 3 beta	Homo sapiens	220-229
15456937-1	2004	Lithium, a known mood-stabilizer frequently used in treatment of bipolar disorders, is an effective glycogen synthase kinase-3beta (GSK-3beta) inhibitor.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	100-130
15078145-5	2004	Recent crystal structures, including the active (phosphorylated Tyr-216) form of GSK3beta, provide a wealth of structural information and greater understanding of GSK3"s unique regulation and substrate specificity.	Tyrosine	64-67	glycogen synthase kinase 3 beta	Homo sapiens	81-89
15456937-0	2004	Lithium-mediated phosphorylation of glycogen synthase kinase-3beta involves PI3 kinase-dependent activation of protein kinase C-alpha.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	36-66
15456937-1	2004	Lithium, a known mood-stabilizer frequently used in treatment of bipolar disorders, is an effective glycogen synthase kinase-3beta (GSK-3beta) inhibitor.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	132-141
15456937-2	2004	This led to the idea that GSK-3beta is an in vivo target directly inhibited by lithium.	Lithium	79-86	glycogen synthase kinase 3 beta	Homo sapiens	26-35
15456937-3	2004	As lithium is a weak in vitro inhibitor of GSK-3beta (IC50=2 mM), however, we speculated that it inhibits GSK-3beta via an indirect, yet unknown, mechanism.	Lithium	3-10	glycogen synthase kinase 3 beta	Homo sapiens	43-52
15456937-3	2004	As lithium is a weak in vitro inhibitor of GSK-3beta (IC50=2 mM), however, we speculated that it inhibits GSK-3beta via an indirect, yet unknown, mechanism.	Lithium	3-10	glycogen synthase kinase 3 beta	Homo sapiens	106-115
15456937-4	2004	The present studies show that lithium increased the phosphorylation of a key inhibitory site of GSK-3beta, serine-9 (Ser-9), in HEK293 cells and in PC12 cells.	Lithium	30-37	glycogen synthase kinase 3 beta	Homo sapiens	96-105
15456937-4	2004	The present studies show that lithium increased the phosphorylation of a key inhibitory site of GSK-3beta, serine-9 (Ser-9), in HEK293 cells and in PC12 cells.	Serine	107-113	glycogen synthase kinase 3 beta	Homo sapiens	96-105
15456937-4	2004	The present studies show that lithium increased the phosphorylation of a key inhibitory site of GSK-3beta, serine-9 (Ser-9), in HEK293 cells and in PC12 cells.	Serine	117-120	glycogen synthase kinase 3 beta	Homo sapiens	96-105
15456937-7	2004	Because PI3 kinase is a potential upstream regulator of cPKC, its inhibition by wortmannin or LY294002 also abolished the lithium-induced serine phosphorylation of GSK-3beta in HEK293 and PC12 cells.	Wortmannin	80-90	glycogen synthase kinase 3 beta	Homo sapiens	164-173
15456937-7	2004	Because PI3 kinase is a potential upstream regulator of cPKC, its inhibition by wortmannin or LY294002 also abolished the lithium-induced serine phosphorylation of GSK-3beta in HEK293 and PC12 cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	94-102	glycogen synthase kinase 3 beta	Homo sapiens	164-173
15456937-7	2004	Because PI3 kinase is a potential upstream regulator of cPKC, its inhibition by wortmannin or LY294002 also abolished the lithium-induced serine phosphorylation of GSK-3beta in HEK293 and PC12 cells.	Lithium	122-129	glycogen synthase kinase 3 beta	Homo sapiens	164-173
15456937-7	2004	Because PI3 kinase is a potential upstream regulator of cPKC, its inhibition by wortmannin or LY294002 also abolished the lithium-induced serine phosphorylation of GSK-3beta in HEK293 and PC12 cells.	Serine	138-144	glycogen synthase kinase 3 beta	Homo sapiens	164-173
15456937-9	2004	Finally, intracerebroventricular injection of lithium increased GSK-3beta Ser-9 phosphorylation and enhanced PKC-alpha activity 1.8-fold in mouse hippocampus, confirming this lithium response in vivo.	Lithium	46-53	glycogen synthase kinase 3 beta	Homo sapiens	64-73
15456937-9	2004	Finally, intracerebroventricular injection of lithium increased GSK-3beta Ser-9 phosphorylation and enhanced PKC-alpha activity 1.8-fold in mouse hippocampus, confirming this lithium response in vivo.	Serine	74-77	glycogen synthase kinase 3 beta	Homo sapiens	64-73
15456937-10	2004	Our studies propose a new mechanism by which lithium indirectly inhibits GSK-3beta via phosphatidylinositol 3 kinase- dependent activation of PKC-alpha.	Lithium	45-52	glycogen synthase kinase 3 beta	Homo sapiens	73-82
15714002-5	2004	RESULTS: ATP or adenosine (100 microM) induced extracellular signal-regulated protein kinase (ERK), Akt and GSK3beta phosphorylation.	Adenosine Triphosphate	9-12	glycogen synthase kinase 3 beta	Homo sapiens	108-116
15283964-10	2004	In comparison, okadaic acid treatment severely depleted the content of GSK3beta and downregulated the remaining GSK3beta activity by Akt-dependent inhibition, consistent with minimal changes in phospho-T212.	Okadaic Acid	15-27	glycogen synthase kinase 3 beta	Homo sapiens	71-79
15283964-10	2004	In comparison, okadaic acid treatment severely depleted the content of GSK3beta and downregulated the remaining GSK3beta activity by Akt-dependent inhibition, consistent with minimal changes in phospho-T212.	Okadaic Acid	15-27	glycogen synthase kinase 3 beta	Homo sapiens	112-120
15714002-5	2004	RESULTS: ATP or adenosine (100 microM) induced extracellular signal-regulated protein kinase (ERK), Akt and GSK3beta phosphorylation.	Adenosine	16-25	glycogen synthase kinase 3 beta	Homo sapiens	108-116
14563838-3	2003	On the protein level, histamine treatment increases phosphorylation of glycogen synthase kinase 3-beta in HeLa cells, murine macrophages, and DLD-1, HT-29, and SW-480 colon cell lines.	Histamine	22-31	glycogen synthase kinase 3 beta	Homo sapiens	71-102
14563837-5	2003	Conversely, overexpression of GSK-3 alpha or GSK-3 beta enhances Thr-58 phosphorylation and ubiquitination of c-Myc.	Threonine	65-68	glycogen synthase kinase 3 beta	Homo sapiens	45-55
14617795-4	2003	In the presence of lithium chloride (LiCl) or SB216763, the GSK-3beta inhibitors, TRAIL-induced cell death was dramatically enhanced, and the enhanced cell death was an augmented apoptotic response evidenced by increased Annexin V labeling and caspase-3 activation.	Lithium Chloride	19-35	glycogen synthase kinase 3 beta	Homo sapiens	60-69
14663202-4	2003	Stimulation of apoptotic signaling by treatment with camptothecin or thapsigargin activated GSK3 beta in the nucleus and mitochondria, but not the cytosol, whereas inhibition of GSK3 beta by lithium treatment affected all three pools of GSK3 beta.	Camptothecin	53-65	glycogen synthase kinase 3 beta	Homo sapiens	92-101
14663202-4	2003	Stimulation of apoptotic signaling by treatment with camptothecin or thapsigargin activated GSK3 beta in the nucleus and mitochondria, but not the cytosol, whereas inhibition of GSK3 beta by lithium treatment affected all three pools of GSK3 beta.	Camptothecin	53-65	glycogen synthase kinase 3 beta	Homo sapiens	178-187
14663202-4	2003	Stimulation of apoptotic signaling by treatment with camptothecin or thapsigargin activated GSK3 beta in the nucleus and mitochondria, but not the cytosol, whereas inhibition of GSK3 beta by lithium treatment affected all three pools of GSK3 beta.	Camptothecin	53-65	glycogen synthase kinase 3 beta	Homo sapiens	178-187
14663202-4	2003	Stimulation of apoptotic signaling by treatment with camptothecin or thapsigargin activated GSK3 beta in the nucleus and mitochondria, but not the cytosol, whereas inhibition of GSK3 beta by lithium treatment affected all three pools of GSK3 beta.	Thapsigargin	69-81	glycogen synthase kinase 3 beta	Homo sapiens	92-101
14663202-4	2003	Stimulation of apoptotic signaling by treatment with camptothecin or thapsigargin activated GSK3 beta in the nucleus and mitochondria, but not the cytosol, whereas inhibition of GSK3 beta by lithium treatment affected all three pools of GSK3 beta.	Lithium	191-198	glycogen synthase kinase 3 beta	Homo sapiens	178-187
14663202-4	2003	Stimulation of apoptotic signaling by treatment with camptothecin or thapsigargin activated GSK3 beta in the nucleus and mitochondria, but not the cytosol, whereas inhibition of GSK3 beta by lithium treatment affected all three pools of GSK3 beta.	Lithium	191-198	glycogen synthase kinase 3 beta	Homo sapiens	178-187
12928438-4	2003	We report the co-crystallization of AR-A014418 with the GSK3beta protein and provide a description of the interactions within the ATP pocket, as well as an understanding of the structural basis for the selectivity of AR-A014418.	Adenosine Triphosphate	130-133	glycogen synthase kinase 3 beta	Homo sapiens	56-64
14738154-0	2003	Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways.	Imatinib Mesylate	81-87	glycogen synthase kinase 3 beta	Homo sapiens	135-144
14738154-7	2003	We found that serine phosphorylation of both MAPK and glycogen synthase kinase-3beta were suppressed by aminopeptidase inhibitors in parent K562 and STI571-resistant K562 cells.	Serine	14-20	glycogen synthase kinase 3 beta	Homo sapiens	54-84
14644163-9	2003	Treatment of HUVEC with LiCl, which inhibits the activity of GSK-3beta and mimicked Wnt-1 signaling, also inhibited the BrdU incorporation in endothelial cells.	Lithium Chloride	24-28	glycogen synthase kinase 3 beta	Homo sapiens	61-70
14685691-4	2003	In addition, NTP protein was more stable and it progressively accumulated in cells that were stimulated with insulin for 24 or 48 h. Metabolic labeling and phospho-amino acid analysis demonstrated phosphorylation of NTP on Serine residues, 30-60 min after insulin or IGF-1 stimulation, when glycogen synthase kinase 3beta (GSK-3beta) activity would no longer have been suppressed.	Serine	223-229	glycogen synthase kinase 3 beta	Homo sapiens	291-321
14685691-4	2003	In addition, NTP protein was more stable and it progressively accumulated in cells that were stimulated with insulin for 24 or 48 h. Metabolic labeling and phospho-amino acid analysis demonstrated phosphorylation of NTP on Serine residues, 30-60 min after insulin or IGF-1 stimulation, when glycogen synthase kinase 3beta (GSK-3beta) activity would no longer have been suppressed.	Serine	223-229	glycogen synthase kinase 3 beta	Homo sapiens	323-332
14757934-8	2003	Sarkosyl-insoluble fractions of the hippocampus were enriched in p38-P and GSK-3 beta-P in Alzheimer"s disease (AD) cases, processed in parallel for comparative purposes, but not in the P310L mutation.	sarkosyl	0-8	glycogen synthase kinase 3 beta	Homo sapiens	65-85
14612495-1	2003	Glycogen synthase kinase-3beta-dependent phosphorylation of cyclin D1 at a conserved COOH-terminal residue, Thr-286, promotes CRM1-dependent cyclin D1 nuclear export at the G(1)-S boundary.	Carbonic Acid	85-89	glycogen synthase kinase 3 beta	Homo sapiens	0-30
14612495-1	2003	Glycogen synthase kinase-3beta-dependent phosphorylation of cyclin D1 at a conserved COOH-terminal residue, Thr-286, promotes CRM1-dependent cyclin D1 nuclear export at the G(1)-S boundary.	Threonine	108-111	glycogen synthase kinase 3 beta	Homo sapiens	0-30
14617795-4	2003	In the presence of lithium chloride (LiCl) or SB216763, the GSK-3beta inhibitors, TRAIL-induced cell death was dramatically enhanced, and the enhanced cell death was an augmented apoptotic response evidenced by increased Annexin V labeling and caspase-3 activation.	Lithium Chloride	37-41	glycogen synthase kinase 3 beta	Homo sapiens	60-69
14617795-4	2003	In the presence of lithium chloride (LiCl) or SB216763, the GSK-3beta inhibitors, TRAIL-induced cell death was dramatically enhanced, and the enhanced cell death was an augmented apoptotic response evidenced by increased Annexin V labeling and caspase-3 activation.	SB 216763	46-54	glycogen synthase kinase 3 beta	Homo sapiens	60-69
14617795-6	2003	Importantly, TRAIL stimulation increased GSK-3beta tyrosine phosphorylation at Y216, suggesting that GSK-3beta is activated by TRAIL.	Tyrosine	51-59	glycogen synthase kinase 3 beta	Homo sapiens	41-50
14617795-6	2003	Importantly, TRAIL stimulation increased GSK-3beta tyrosine phosphorylation at Y216, suggesting that GSK-3beta is activated by TRAIL.	Tyrosine	51-59	glycogen synthase kinase 3 beta	Homo sapiens	101-110
14550274-7	2003	Inhibition of GSK3beta by LiCl blocks L6 myogenesis, indicating that ILK-mediated inhibition of GSK3beta is not sufficient for differentiation.	Lithium Chloride	26-30	glycogen synthase kinase 3 beta	Homo sapiens	14-22
14529625-0	2003	Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors.	Adenosine Triphosphate	91-94	glycogen synthase kinase 3 beta	Homo sapiens	35-44
14572648-1	2003	Recently, LiCl has been shown to inhibit amyloid beta peptide secretion in association with diminished glycogen synthase kinase beta (GSK3beta) activity.	Lithium Chloride	10-14	glycogen synthase kinase 3 beta	Homo sapiens	134-142
14572648-2	2003	However, it remains unclear if direct inhibition of GSK3beta activity will result in decreased Abeta production.	UNII-042A8N37WH	95-100	glycogen synthase kinase 3 beta	Homo sapiens	52-60
14561081-0	2003	Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching.	thienyl and phenyl alpha-halomethyl ketones	0-43	glycogen synthase kinase 3 beta	Homo sapiens	89-98
14561081-3	2003	In this initial letter, some thienyl and phenyl alpha-halomethyl ketones are described as new non-ATP competitive inhibitors of GSK-3beta.	thienyl and phenyl alpha-halomethyl ketones	29-72	glycogen synthase kinase 3 beta	Homo sapiens	128-137
14561081-3	2003	In this initial letter, some thienyl and phenyl alpha-halomethyl ketones are described as new non-ATP competitive inhibitors of GSK-3beta.	Adenosine Triphosphate	98-101	glycogen synthase kinase 3 beta	Homo sapiens	128-137
12900420-0	2003	Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei.	Cyclic AMP	101-105	glycogen synthase kinase 3 beta	Homo sapiens	31-61
12900420-1	2003	Glycogen synthase kinase-3beta (GSK-3beta) activity is suppressed when it becomes phosphorylated on serine 9 by protein kinase B (Akt).	Serine	100-106	glycogen synthase kinase 3 beta	Homo sapiens	0-30
12900420-1	2003	Glycogen synthase kinase-3beta (GSK-3beta) activity is suppressed when it becomes phosphorylated on serine 9 by protein kinase B (Akt).	Serine	100-106	glycogen synthase kinase 3 beta	Homo sapiens	32-41
12900420-3	2003	In some experiments, LY294002, a specific inhibitor of phosphatidylinositol 3-kinase (a kinase involved in activating Akt) and tumor necrosis factor-alpha (TNF-alpha) were used to activate GSK-3beta.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	21-29	glycogen synthase kinase 3 beta	Homo sapiens	189-198
12900420-7	2003	When transcription factors activator protein-1 and cyclic AMP-response element (CRE)-binding protein were analyzed as targets of GSK-3beta activity, overexpression of wild-type GSK-3beta suppressed AP1-mediated transcription and activated CRE-mediated transcription.	Cyclic AMP	51-61	glycogen synthase kinase 3 beta	Homo sapiens	129-138
12900420-7	2003	When transcription factors activator protein-1 and cyclic AMP-response element (CRE)-binding protein were analyzed as targets of GSK-3beta activity, overexpression of wild-type GSK-3beta suppressed AP1-mediated transcription and activated CRE-mediated transcription.	Cyclic AMP	51-61	glycogen synthase kinase 3 beta	Homo sapiens	177-186
14529625-3	2003	In order to characterize the active site of GSK-3beta, we determined crystal structures of unphosphorylated GSK-3beta in complex with selective and non-selective ATP-mimetic inhibitors.	Adenosine Triphosphate	162-165	glycogen synthase kinase 3 beta	Homo sapiens	44-53
14529625-3	2003	In order to characterize the active site of GSK-3beta, we determined crystal structures of unphosphorylated GSK-3beta in complex with selective and non-selective ATP-mimetic inhibitors.	Adenosine Triphosphate	162-165	glycogen synthase kinase 3 beta	Homo sapiens	108-117
12871932-3	2003	GSK-3 beta forms an in vivo complex with and specifically phosphorylates NF-kappa B1/p105 at Ser-903 and Ser-907 in vitro.	Serine	93-96	glycogen synthase kinase 3 beta	Homo sapiens	0-10
12871932-3	2003	GSK-3 beta forms an in vivo complex with and specifically phosphorylates NF-kappa B1/p105 at Ser-903 and Ser-907 in vitro.	Serine	105-108	glycogen synthase kinase 3 beta	Homo sapiens	0-10
12871932-7	2003	Moreover, p105 degradation in response to TNF-alpha is prevented in GSK-3 beta-/- fibroblasts and by a Ser to Ala point mutation on p105 at positions 903 or 907.	Alanine	110-113	glycogen synthase kinase 3 beta	Homo sapiens	68-78
12943659-3	2003	The catalytic activity was moderately decreased following the inhibition of GSK3beta with LiCl.	Lithium Chloride	90-94	glycogen synthase kinase 3 beta	Homo sapiens	76-84
14550568-1	2003	In this study we show that both glycogen synthase kinase 3 (GSK3) isoforms, GSK3alpha and GSK3beta, are present in human platelets and are phosphorylated on Ser(21) and Ser(9), respectively, in platelets stimulated with collagen, convulxin and thrombin.	Serine	157-160	glycogen synthase kinase 3 beta	Homo sapiens	90-98
14550568-1	2003	In this study we show that both glycogen synthase kinase 3 (GSK3) isoforms, GSK3alpha and GSK3beta, are present in human platelets and are phosphorylated on Ser(21) and Ser(9), respectively, in platelets stimulated with collagen, convulxin and thrombin.	Serine	169-172	glycogen synthase kinase 3 beta	Homo sapiens	90-98
12896906-5	2003	Serum treatment increased the pErbB3/p85 complexes and also stimulated phosphorylation of Akt and GSK3beta, increase in cyclin D1 and cell cycle progression, and these events were blocked by the Akt activation inhibitor LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	220-228	glycogen synthase kinase 3 beta	Homo sapiens	98-106
12794074-8	2003	Consistent with this, GSK-3 beta inhibits the transcriptional activation of Notch target genes both in vitro and in vivo, whereas lithium chloride treatment or Wnt-1 overexpression that results in GSK-3 beta inhibition leads to the up-regulation of the Hes-1 promoter.	Lithium Chloride	130-146	glycogen synthase kinase 3 beta	Homo sapiens	197-207
12954055-0	2003	Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.	bis-7-azaindolylmaleimides	54-80	glycogen synthase kinase 3 beta	Homo sapiens	130-160
12954055-1	2003	Attempts to design the macrocyclic maleimides as selective protein kinase C gamma inhibitors led to the unexpected discovery of a novel series of potent and highly selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors.	macrocyclic maleimides	23-45	glycogen synthase kinase 3 beta	Homo sapiens	174-204
12954055-1	2003	Attempts to design the macrocyclic maleimides as selective protein kinase C gamma inhibitors led to the unexpected discovery of a novel series of potent and highly selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors.	macrocyclic maleimides	23-45	glycogen synthase kinase 3 beta	Homo sapiens	206-215
12954055-3	2003	All three macrocyclic series (bisindolyl-, mixed 7-azaindoleindolyl-, and bis-7-azaindolylmaleimides) were found to have submicromolar inhibitory potency at GSK-3beta with various degrees of selectivity toward other protein kinases.	bisindolyl-, mixed 7-azaindoleindolyl-, and bis-7-azaindolylmaleimides	30-100	glycogen synthase kinase 3 beta	Homo sapiens	157-166
12954055-5	2003	To achieve the selectivity at GSK-3beta, the additional nitrogen atoms in the indole rings may contribute to a significant degree.	Nitrogen	56-64	glycogen synthase kinase 3 beta	Homo sapiens	30-39
12954055-9	2003	Molecular docking studies were conducted in an attempt to rationalize the GSK-3beta selectivity of azaindolylmaleimides.	azaindolylmaleimides	99-119	glycogen synthase kinase 3 beta	Homo sapiens	74-83
12794074-4	2003	We identify three specific phosphorylation sites in the Notch2 serine/threonine-rich domain that are dependent on GSK-3 beta activity.	Serine	63-69	glycogen synthase kinase 3 beta	Homo sapiens	114-124
12794074-4	2003	We identify three specific phosphorylation sites in the Notch2 serine/threonine-rich domain that are dependent on GSK-3 beta activity.	Threonine	70-79	glycogen synthase kinase 3 beta	Homo sapiens	114-124
12540292-9	2003	Wortmannin blocked heat-shock-induced Akt/GSK-3 beta phosphorylation, prevented 2-deoxyglucose uptake and abolished the heat-shock-induced glycogen synthesis.	Wortmannin	0-10	glycogen synthase kinase 3 beta	Homo sapiens	42-52
12764143-10	2003	At that time, Akt was no longer present or active, which resulted in a decrease in the inhibiting phosphorylation of GSK3beta on Ser-9 and hence in an increased GSK3beta activity.	Serine	129-132	glycogen synthase kinase 3 beta	Homo sapiens	117-125
12889910-0	2003	Enantiospecific formal total synthesis of the tumor and GSK-3 beta inhibiting alkaloid, (-)-agelastatin A.	Alkaloids	78-86	glycogen synthase kinase 3 beta	Homo sapiens	56-66
12889910-0	2003	Enantiospecific formal total synthesis of the tumor and GSK-3 beta inhibiting alkaloid, (-)-agelastatin A.	agelastatin A	88-105	glycogen synthase kinase 3 beta	Homo sapiens	56-66
12787068-10	2003	Lithium also attenuated MEF2D hyperphosphorylation and apoptosis induced by calcineurin inhibition under depolarizing conditions, a GSK-3 beta-independent model of neuronal death.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	132-142
12813129-9	2003	Inhibition of this process by LiCl pointed to participation of GSK-3beta.	Lithium Chloride	30-34	glycogen synthase kinase 3 beta	Homo sapiens	63-72
12813129-10	2003	Unexpectedly, GSK-3beta was also phosphorylated upon aspirin treatment in six colorectal cancer cell lines.	Aspirin	53-60	glycogen synthase kinase 3 beta	Homo sapiens	14-23
12917374-8	2003	However, Abeta toxicity is inhibited by caspase inhibitors and the glycogen synthase kinase 3beta inhibitor lithium.	Lithium	108-115	glycogen synthase kinase 3 beta	Homo sapiens	67-97
12869192-6	2003	Three other kinases [cyclin-dependent protein kinase 2 (CDK2), phosphorylase kinase and glycogen synthase kinase 3beta] exhibit approximately 10-fold weaker affinity for TBB than CK2.	4,5,6,7-tetrabromobenzotriazole	170-173	glycogen synthase kinase 3 beta	Homo sapiens	88-118
12866584-2	2003	Mutational analysis of exon 3 in ctnnb-1, which encodes the serine/threonine residues for GSK3beta phosphorylation sites, was performed for 21 gallbladder carcinomas affected with/without the pancreaticobiliary malunion, PBM, and 6 non-cancerous tissues affected with PBM.	Serine	60-66	glycogen synthase kinase 3 beta	Homo sapiens	90-98
12866584-2	2003	Mutational analysis of exon 3 in ctnnb-1, which encodes the serine/threonine residues for GSK3beta phosphorylation sites, was performed for 21 gallbladder carcinomas affected with/without the pancreaticobiliary malunion, PBM, and 6 non-cancerous tissues affected with PBM.	Threonine	67-76	glycogen synthase kinase 3 beta	Homo sapiens	90-98
12551948-4	2003	In this study, we find that when purified brain microtubules are subjected to Superose 12 gel filtration column chromatography, the dimeric scaffold protein 14-3-3 zeta co-elutes with the tau phosphorylation complex components tau and GSK3 beta.	Superose 12	78-89	glycogen synthase kinase 3 beta	Homo sapiens	235-244
12584189-6	2003	Exposure of cells to insulin inhibited the activation of MEKK1 by GSK3 beta, and this inhibitory effect of insulin was abolished by the phosphatidylinositol 3-kinase inhibitor wortmannin.	Wortmannin	176-186	glycogen synthase kinase 3 beta	Homo sapiens	66-75
12522140-6	2003	DIF-3-induced degradation of cyclin D1 was also prevented by treatment with lithium chloride, an inhibitor of glycogen synthase kinase-3beta (GSK-3beta), suggesting that DIF-3 induced cyclin D1 proteolysis through the activation of GSK-3beta.	Lithium Chloride	76-92	glycogen synthase kinase 3 beta	Homo sapiens	110-140
12522140-6	2003	DIF-3-induced degradation of cyclin D1 was also prevented by treatment with lithium chloride, an inhibitor of glycogen synthase kinase-3beta (GSK-3beta), suggesting that DIF-3 induced cyclin D1 proteolysis through the activation of GSK-3beta.	Lithium Chloride	76-92	glycogen synthase kinase 3 beta	Homo sapiens	142-151
12522140-6	2003	DIF-3-induced degradation of cyclin D1 was also prevented by treatment with lithium chloride, an inhibitor of glycogen synthase kinase-3beta (GSK-3beta), suggesting that DIF-3 induced cyclin D1 proteolysis through the activation of GSK-3beta.	Lithium Chloride	76-92	glycogen synthase kinase 3 beta	Homo sapiens	232-241
12522140-7	2003	Indeed, DIF-3 dephosphorylated Ser(9) and phosphorylated tyrosine on GSK-3beta, and it stimulated GSK-3beta activity in an in vitro kinase assay.	Tyrosine	57-65	glycogen synthase kinase 3 beta	Homo sapiens	69-78
12614848-2	2003	Here, we found that sodium arsenite (NaAsO(2)) also triggers the signal for activation of Akt and downstream glycogen synthase 3beta (GSK3beta).	sodium arsenite	20-35	glycogen synthase kinase 3 beta	Homo sapiens	134-142
12614848-2	2003	Here, we found that sodium arsenite (NaAsO(2)) also triggers the signal for activation of Akt and downstream glycogen synthase 3beta (GSK3beta).	naaso	37-42	glycogen synthase kinase 3 beta	Homo sapiens	134-142
12614848-3	2003	Such Akt/GSK3beta activation was abrogated completely by wortmannin, an inhibitor of PI-3 kinase, and greatly by pertussis toxin, a G-protein inhibitor.	Wortmannin	57-67	glycogen synthase kinase 3 beta	Homo sapiens	9-17
12614848-5	2003	Reducing reagents/reactive oxygen species (ROS) scavengers reduced arsenite-induced Akt phosphorylation and beta cyclodextrin reduced arsenite-mediated ROS production, suggesting that arsenite-induced G-protein/Akt/GSK3beta pathway is membrane raft dependent and redox linked.	arsenite	67-75	glycogen synthase kinase 3 beta	Homo sapiens	215-223
12614848-5	2003	Reducing reagents/reactive oxygen species (ROS) scavengers reduced arsenite-induced Akt phosphorylation and beta cyclodextrin reduced arsenite-mediated ROS production, suggesting that arsenite-induced G-protein/Akt/GSK3beta pathway is membrane raft dependent and redox linked.	betadex	108-125	glycogen synthase kinase 3 beta	Homo sapiens	215-223
12691738-0	2003	Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3beta, and induction of the mitochondrial-dependent intrinsic caspase pathway.	Ceramides	0-8	glycogen synthase kinase 3 beta	Homo sapiens	92-101
12691738-4	2003	We show that ceramide treatment initiates a cascade of biochemical alterations associated with cell death: earliest signal transduction changes involve Akt dephosphorylation and inactivation followed by dephosphorylation of proapoptotic regulators such as BAD (proapoptotic Bcl-2 family member), Forkhead family transcription factors, glycogen synthase kinase 3-beta, mitochondrial depolarization and permeabilization, release of cytochrome c into the cytosol, and caspase-3 activation.	Ceramides	13-21	glycogen synthase kinase 3 beta	Homo sapiens	335-366
12598741-5	2003	We also found that lithium induces phosphorylation of the serine 9 residue of glycogen synthase kinase-3beta together with inhibition of tau phosphorylation on PHF-1 epitope in all the three cell lines.	Lithium	19-26	glycogen synthase kinase 3 beta	Homo sapiens	78-108
12598741-5	2003	We also found that lithium induces phosphorylation of the serine 9 residue of glycogen synthase kinase-3beta together with inhibition of tau phosphorylation on PHF-1 epitope in all the three cell lines.	Serine	58-64	glycogen synthase kinase 3 beta	Homo sapiens	78-108
12598741-6	2003	This suggests a novel mechanism whereby lithium-mediated inhibition of GSK-3beta activity influences tau phosphorylation.	Lithium	40-47	glycogen synthase kinase 3 beta	Homo sapiens	71-80
12403723-4	2002	Accumulation of beta-catenin by the inhibition of glycogen synthase kinase-3beta with LiCl inhibited chondrogenesis by stabilizing cell-cell adhesion.	Lithium Chloride	86-90	glycogen synthase kinase 3 beta	Homo sapiens	50-80
12364325-6	2002	Nuclear accumulation of cyclin D1 and cell cycle progression were also observed when LiCl, a known inhibitor of GSK3beta, was added to E(2)-stimulated cells.	Lithium Chloride	85-89	glycogen synthase kinase 3 beta	Homo sapiens	112-120
12393899-5	2002	Furthermore, cortical neuron apoptosis induced by LY294002-mediated activation of endogenous GSK3beta was blocked by expression of constitutively active MKK1 or by BDNF via stimulation of the endogenous ERK1/2 pathway.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	50-58	glycogen synthase kinase 3 beta	Homo sapiens	93-101
12393899-7	2002	Interestingly, PI3K (but not ERK1/2) induced the inhibitory phosphorylation of GSK3beta at Ser-9.	Serine	91-94	glycogen synthase kinase 3 beta	Homo sapiens	79-87
12393899-10	2002	Furthermore, ERK1/2 inhibits GSK3beta activity via a novel mechanism that is independent of Ser-9 phosphorylation and likely does not involve Tyr-216 phosphorylation.	Serine	92-95	glycogen synthase kinase 3 beta	Homo sapiens	29-37
12228224-2	2002	Thapsigargin, which causes ER stress by inhibiting the ER Ca(2+)-ATPase, was found to not only activate the apoptosis effector caspase-3 but also to cause a large and prolonged increase in the activity of glycogen synthase kinase-3beta (GSK3beta).	Thapsigargin	0-12	glycogen synthase kinase 3 beta	Homo sapiens	205-235
12228224-4	2002	Thapsigargin treatment activated GSK3beta by inducing dephosphorylation of phospho-Ser-9 of GSK3beta, a phosphorylation that normally maintains GSK3beta inactivated.	Serine	83-86	glycogen synthase kinase 3 beta	Homo sapiens	33-41
12228224-4	2002	Thapsigargin treatment activated GSK3beta by inducing dephosphorylation of phospho-Ser-9 of GSK3beta, a phosphorylation that normally maintains GSK3beta inactivated.	Serine	83-86	glycogen synthase kinase 3 beta	Homo sapiens	92-100
12447879-6	2002	By using LY294002 and ML-9, which act as phosphatidylinositol 3-kinase (PI3-K) and Akt inhibitors, respectively, we showed that GSK-3beta phosphorylation required PI3-K activation in both cell lines whereas downstream Akt activation was required only in Mahlavu cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	9-17	glycogen synthase kinase 3 beta	Homo sapiens	128-137
12447879-8	2002	The blockage of GSK-3beta phosphorylation markedly inhibited glycogen synthesis and decreased beta-catenin expression.	Glycogen	61-69	glycogen synthase kinase 3 beta	Homo sapiens	16-25
12447879-12	2002	Persistent phosphorylation of GSK-3beta could be critical for regulation of glycogen metabolism and cell growth in hepatoma cells.	Glycogen	76-84	glycogen synthase kinase 3 beta	Homo sapiens	30-39
12504922-0	2002	Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium.	Valproic Acid	73-89	glycogen synthase kinase 3 beta	Homo sapiens	22-53
12504922-0	2002	Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium.	Lithium	94-101	glycogen synthase kinase 3 beta	Homo sapiens	22-53
12504922-1	2002	This study tested if sodium valproate or lithium, two agents used to treat bipolar mood disorder, altered the regulatory phosphorylations of Akt or glycogen synthase kinase-3beta (GSK3beta) in human neuroblastoma SH-SY5Y cells.	Valproic Acid	21-37	glycogen synthase kinase 3 beta	Homo sapiens	148-178
12504922-1	2002	This study tested if sodium valproate or lithium, two agents used to treat bipolar mood disorder, altered the regulatory phosphorylations of Akt or glycogen synthase kinase-3beta (GSK3beta) in human neuroblastoma SH-SY5Y cells.	Valproic Acid	21-37	glycogen synthase kinase 3 beta	Homo sapiens	180-188
12504922-1	2002	This study tested if sodium valproate or lithium, two agents used to treat bipolar mood disorder, altered the regulatory phosphorylations of Akt or glycogen synthase kinase-3beta (GSK3beta) in human neuroblastoma SH-SY5Y cells.	Lithium	41-48	glycogen synthase kinase 3 beta	Homo sapiens	148-178
12504922-1	2002	This study tested if sodium valproate or lithium, two agents used to treat bipolar mood disorder, altered the regulatory phosphorylations of Akt or glycogen synthase kinase-3beta (GSK3beta) in human neuroblastoma SH-SY5Y cells.	Lithium	41-48	glycogen synthase kinase 3 beta	Homo sapiens	180-188
12504922-2	2002	Treatment with sodium valproate caused a gradual but relatively large increase in the activation-associated phosphorylation of Akt on Ser-473, and a similarly gradual but more modest increase in the inhibition-associated phosphorylation of GSK3beta on Ser-9.	Valproic Acid	15-31	glycogen synthase kinase 3 beta	Homo sapiens	240-248
12504922-2	2002	Treatment with sodium valproate caused a gradual but relatively large increase in the activation-associated phosphorylation of Akt on Ser-473, and a similarly gradual but more modest increase in the inhibition-associated phosphorylation of GSK3beta on Ser-9.	Serine	252-255	glycogen synthase kinase 3 beta	Homo sapiens	240-248
12504922-3	2002	Two other inhibitors of histone deacetylase, a recently identified target of sodium valproate, also caused gradual increases in the phosphorylation of Akt and GSK3beta.	Valproic Acid	77-93	glycogen synthase kinase 3 beta	Homo sapiens	159-167
12504922-5	2002	These results identify novel effects of sodium valproate on the Akt/GSK3beta signaling pathway, indicating that histone deacetylase inhibition is linked to activation of Akt, and show that two anti-bipolar agents have a common action, the increased inhibitory phosphorylation of Ser-9-GSK3beta.	Valproic Acid	40-56	glycogen synthase kinase 3 beta	Homo sapiens	68-76
12504922-5	2002	These results identify novel effects of sodium valproate on the Akt/GSK3beta signaling pathway, indicating that histone deacetylase inhibition is linked to activation of Akt, and show that two anti-bipolar agents have a common action, the increased inhibitory phosphorylation of Ser-9-GSK3beta.	Valproic Acid	40-56	glycogen synthase kinase 3 beta	Homo sapiens	285-293
12504922-5	2002	These results identify novel effects of sodium valproate on the Akt/GSK3beta signaling pathway, indicating that histone deacetylase inhibition is linked to activation of Akt, and show that two anti-bipolar agents have a common action, the increased inhibitory phosphorylation of Ser-9-GSK3beta.	Serine	279-282	glycogen synthase kinase 3 beta	Homo sapiens	68-76
12504922-6	2002	The latter finding, along with previous reports that lithium directly inhibits GSK3beta, reveals the possibly unique situation where a single target, GSK3beta, is inhibited by two independent mechanisms, directly and by phosphorylation following lithium administration, and further, that two mood stabilizers have inhibitory effects on GSK3beta.	Lithium	53-60	glycogen synthase kinase 3 beta	Homo sapiens	79-87
12504922-6	2002	The latter finding, along with previous reports that lithium directly inhibits GSK3beta, reveals the possibly unique situation where a single target, GSK3beta, is inhibited by two independent mechanisms, directly and by phosphorylation following lithium administration, and further, that two mood stabilizers have inhibitory effects on GSK3beta.	Lithium	53-60	glycogen synthase kinase 3 beta	Homo sapiens	150-158
12504922-6	2002	The latter finding, along with previous reports that lithium directly inhibits GSK3beta, reveals the possibly unique situation where a single target, GSK3beta, is inhibited by two independent mechanisms, directly and by phosphorylation following lithium administration, and further, that two mood stabilizers have inhibitory effects on GSK3beta.	Lithium	53-60	glycogen synthase kinase 3 beta	Homo sapiens	150-158
12504922-6	2002	The latter finding, along with previous reports that lithium directly inhibits GSK3beta, reveals the possibly unique situation where a single target, GSK3beta, is inhibited by two independent mechanisms, directly and by phosphorylation following lithium administration, and further, that two mood stabilizers have inhibitory effects on GSK3beta.	Lithium	246-253	glycogen synthase kinase 3 beta	Homo sapiens	150-158
12504922-6	2002	The latter finding, along with previous reports that lithium directly inhibits GSK3beta, reveals the possibly unique situation where a single target, GSK3beta, is inhibited by two independent mechanisms, directly and by phosphorylation following lithium administration, and further, that two mood stabilizers have inhibitory effects on GSK3beta.	Lithium	246-253	glycogen synthase kinase 3 beta	Homo sapiens	150-158
12228224-4	2002	Thapsigargin treatment activated GSK3beta by inducing dephosphorylation of phospho-Ser-9 of GSK3beta, a phosphorylation that normally maintains GSK3beta inactivated.	Serine	83-86	glycogen synthase kinase 3 beta	Homo sapiens	92-100
12228224-5	2002	Caspase-3 activation induced by thapsigargin was blocked by increasing the phosphorylation of Ser-9-GSK3beta with insulin-like growth factor-1 or with the phosphatase inhibitors okadaic acid and calyculin A, but the calcineurin inhibitors FK506 and cyclosporin A were ineffective.	Thapsigargin	32-44	glycogen synthase kinase 3 beta	Homo sapiens	100-108
12228224-5	2002	Caspase-3 activation induced by thapsigargin was blocked by increasing the phosphorylation of Ser-9-GSK3beta with insulin-like growth factor-1 or with the phosphatase inhibitors okadaic acid and calyculin A, but the calcineurin inhibitors FK506 and cyclosporin A were ineffective.	ser-9	94-99	glycogen synthase kinase 3 beta	Homo sapiens	100-108
12228224-5	2002	Caspase-3 activation induced by thapsigargin was blocked by increasing the phosphorylation of Ser-9-GSK3beta with insulin-like growth factor-1 or with the phosphatase inhibitors okadaic acid and calyculin A, but the calcineurin inhibitors FK506 and cyclosporin A were ineffective.	calyculin A	195-206	glycogen synthase kinase 3 beta	Homo sapiens	100-108
12228224-5	2002	Caspase-3 activation induced by thapsigargin was blocked by increasing the phosphorylation of Ser-9-GSK3beta with insulin-like growth factor-1 or with the phosphatase inhibitors okadaic acid and calyculin A, but the calcineurin inhibitors FK506 and cyclosporin A were ineffective.	Tacrolimus	239-244	glycogen synthase kinase 3 beta	Homo sapiens	100-108
12228224-5	2002	Caspase-3 activation induced by thapsigargin was blocked by increasing the phosphorylation of Ser-9-GSK3beta with insulin-like growth factor-1 or with the phosphatase inhibitors okadaic acid and calyculin A, but the calcineurin inhibitors FK506 and cyclosporin A were ineffective.	Cyclosporine	249-262	glycogen synthase kinase 3 beta	Homo sapiens	100-108
12228224-7	2002	Thus, ER stress activates GSK3beta through dephosphorylation of phospho-Ser-9, a prerequisite for caspase-3 activation, and this process is amenable to pharmacological intervention.	Serine	72-75	glycogen synthase kinase 3 beta	Homo sapiens	26-34
12228224-2	2002	Thapsigargin, which causes ER stress by inhibiting the ER Ca(2+)-ATPase, was found to not only activate the apoptosis effector caspase-3 but also to cause a large and prolonged increase in the activity of glycogen synthase kinase-3beta (GSK3beta).	Thapsigargin	0-12	glycogen synthase kinase 3 beta	Homo sapiens	237-245
12228224-3	2002	Activation of GSK3beta was obligatory for thapsigargin-induced activation of caspase-3, because inhibition of GSK3beta by expression of dominant-negative GSK3beta or by the GSK3beta inhibitor lithium blocked caspase-3 activation.	Thapsigargin	42-54	glycogen synthase kinase 3 beta	Homo sapiens	14-22
12228224-3	2002	Activation of GSK3beta was obligatory for thapsigargin-induced activation of caspase-3, because inhibition of GSK3beta by expression of dominant-negative GSK3beta or by the GSK3beta inhibitor lithium blocked caspase-3 activation.	Thapsigargin	42-54	glycogen synthase kinase 3 beta	Homo sapiens	110-118
12228224-3	2002	Activation of GSK3beta was obligatory for thapsigargin-induced activation of caspase-3, because inhibition of GSK3beta by expression of dominant-negative GSK3beta or by the GSK3beta inhibitor lithium blocked caspase-3 activation.	Thapsigargin	42-54	glycogen synthase kinase 3 beta	Homo sapiens	110-118
12228224-3	2002	Activation of GSK3beta was obligatory for thapsigargin-induced activation of caspase-3, because inhibition of GSK3beta by expression of dominant-negative GSK3beta or by the GSK3beta inhibitor lithium blocked caspase-3 activation.	Thapsigargin	42-54	glycogen synthase kinase 3 beta	Homo sapiens	110-118
12228224-3	2002	Activation of GSK3beta was obligatory for thapsigargin-induced activation of caspase-3, because inhibition of GSK3beta by expression of dominant-negative GSK3beta or by the GSK3beta inhibitor lithium blocked caspase-3 activation.	Lithium	192-199	glycogen synthase kinase 3 beta	Homo sapiens	14-22
12228224-4	2002	Thapsigargin treatment activated GSK3beta by inducing dephosphorylation of phospho-Ser-9 of GSK3beta, a phosphorylation that normally maintains GSK3beta inactivated.	Thapsigargin	0-12	glycogen synthase kinase 3 beta	Homo sapiens	33-41
12228224-4	2002	Thapsigargin treatment activated GSK3beta by inducing dephosphorylation of phospho-Ser-9 of GSK3beta, a phosphorylation that normally maintains GSK3beta inactivated.	Thapsigargin	0-12	glycogen synthase kinase 3 beta	Homo sapiens	92-100
12228224-4	2002	Thapsigargin treatment activated GSK3beta by inducing dephosphorylation of phospho-Ser-9 of GSK3beta, a phosphorylation that normally maintains GSK3beta inactivated.	Thapsigargin	0-12	glycogen synthase kinase 3 beta	Homo sapiens	92-100
12375019-5	2002	All of the mutations occurred at the serine/threonine phosphorylation sites of glycogen synthase kinase-3beta (GSK-3beta) or their neighboring residues.	Serine	37-43	glycogen synthase kinase 3 beta	Homo sapiens	79-109
12375019-5	2002	All of the mutations occurred at the serine/threonine phosphorylation sites of glycogen synthase kinase-3beta (GSK-3beta) or their neighboring residues.	Serine	37-43	glycogen synthase kinase 3 beta	Homo sapiens	111-120
12375019-5	2002	All of the mutations occurred at the serine/threonine phosphorylation sites of glycogen synthase kinase-3beta (GSK-3beta) or their neighboring residues.	Threonine	44-53	glycogen synthase kinase 3 beta	Homo sapiens	79-109
12375019-5	2002	All of the mutations occurred at the serine/threonine phosphorylation sites of glycogen synthase kinase-3beta (GSK-3beta) or their neighboring residues.	Threonine	44-53	glycogen synthase kinase 3 beta	Homo sapiens	111-120
12147701-6	2002	When COS cells were treated with dibutyryl cyclic AMP to activate PKA, the activity of GSK-3beta bound to AKAP220 decreased more markedly than the total GSK-3beta activity.	Bucladesine	33-53	glycogen synthase kinase 3 beta	Homo sapiens	87-96
12147701-6	2002	When COS cells were treated with dibutyryl cyclic AMP to activate PKA, the activity of GSK-3beta bound to AKAP220 decreased more markedly than the total GSK-3beta activity.	Bucladesine	33-53	glycogen synthase kinase 3 beta	Homo sapiens	153-162
12147701-7	2002	Calyculin A, a protein phosphatase inhibitor, also inhibited the activity of GSK-3beta bound to AKAP220 more strongly than the total GSK-3beta activity.	calyculin A	0-11	glycogen synthase kinase 3 beta	Homo sapiens	77-86
12147701-7	2002	Calyculin A, a protein phosphatase inhibitor, also inhibited the activity of GSK-3beta bound to AKAP220 more strongly than the total GSK-3beta activity.	calyculin A	0-11	glycogen synthase kinase 3 beta	Homo sapiens	133-142
12093801-0	2002	Glycogen synthase kinase 3beta is activated by cAMP and plays an active role in the regulation of melanogenesis.	Cyclic AMP	47-51	glycogen synthase kinase 3 beta	Homo sapiens	0-30
12408804-6	2002	We have also identified essential phosphotyrosines in GSK3, confirmed their role in activated/deactivated regulation and cell fate decisions, and relate them to the predicted 3D structure of GSK3beta.	Phosphotyrosine	34-50	glycogen synthase kinase 3 beta	Homo sapiens	191-199
12244165-4	2002	We find that in the presence but not the absence of EC, NFAT1 can be detected in the nuclei of CsA-treated T cells within 8 h of triggering, reaching a maximal level of 60% of control by 24 h. Glycogen synthase kinase-3beta (GSK-3beta), which rephosphorylates NFAT and promotes nuclear export, is inhibited by EC costimulation.	Cyclosporine	95-98	glycogen synthase kinase 3 beta	Homo sapiens	193-223
12244165-4	2002	We find that in the presence but not the absence of EC, NFAT1 can be detected in the nuclei of CsA-treated T cells within 8 h of triggering, reaching a maximal level of 60% of control by 24 h. Glycogen synthase kinase-3beta (GSK-3beta), which rephosphorylates NFAT and promotes nuclear export, is inhibited by EC costimulation.	Cyclosporine	95-98	glycogen synthase kinase 3 beta	Homo sapiens	225-234
12097329-0	2002	Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington"s disease mutation.	polyglutamine	59-72	glycogen synthase kinase 3 beta	Homo sapiens	0-30
12130654-6	2002	GSK3beta was shown to phosphorylate at Ser-493 in vitro by phosphopeptide mapping and site-directed mutagenesis, and in vivo in HEK293 cells using the phospho-Ser-493 antibody, but did not phosphorylate Ser-501.	Serine	39-42	glycogen synthase kinase 3 beta	Homo sapiens	0-8
12130654-6	2002	GSK3beta was shown to phosphorylate at Ser-493 in vitro by phosphopeptide mapping and site-directed mutagenesis, and in vivo in HEK293 cells using the phospho-Ser-493 antibody, but did not phosphorylate Ser-501.	Serine	159-162	glycogen synthase kinase 3 beta	Homo sapiens	0-8
12130654-6	2002	GSK3beta was shown to phosphorylate at Ser-493 in vitro by phosphopeptide mapping and site-directed mutagenesis, and in vivo in HEK293 cells using the phospho-Ser-493 antibody, but did not phosphorylate Ser-501.	Serine	159-162	glycogen synthase kinase 3 beta	Homo sapiens	0-8
12093801-6	2002	Consistent with the role of AKT in the regulation of glycogen synthase kinase 3beta (GSK3beta), cAMP decreased the phosphorylation of GSK3beta and stimulated its activity.	Cyclic AMP	96-100	glycogen synthase kinase 3 beta	Homo sapiens	53-83
12093801-6	2002	Consistent with the role of AKT in the regulation of glycogen synthase kinase 3beta (GSK3beta), cAMP decreased the phosphorylation of GSK3beta and stimulated its activity.	Cyclic AMP	96-100	glycogen synthase kinase 3 beta	Homo sapiens	85-93
12093801-6	2002	Consistent with the role of AKT in the regulation of glycogen synthase kinase 3beta (GSK3beta), cAMP decreased the phosphorylation of GSK3beta and stimulated its activity.	Cyclic AMP	96-100	glycogen synthase kinase 3 beta	Homo sapiens	134-142
12093801-9	2002	Additionally, lithium, a GSK3beta inhibitor, impaired the response of the tyrosinase promoter to cAMP, and cAMP increased the binding of MITF to the M-box.	Lithium	14-21	glycogen synthase kinase 3 beta	Homo sapiens	25-33
12093801-9	2002	Additionally, lithium, a GSK3beta inhibitor, impaired the response of the tyrosinase promoter to cAMP, and cAMP increased the binding of MITF to the M-box.	Cyclic AMP	97-101	glycogen synthase kinase 3 beta	Homo sapiens	25-33
12093801-10	2002	Taking into account that GSK3beta phosphorylates MITF and increases the ability of MITF to bind its target sequence, our results indicate that activation of GSK3beta by cAMP facilitates MITF binding to the tyrosinase promoter, thereby leading to stimulation of melanogenesis.	Cyclic AMP	169-173	glycogen synthase kinase 3 beta	Homo sapiens	25-33
12093801-10	2002	Taking into account that GSK3beta phosphorylates MITF and increases the ability of MITF to bind its target sequence, our results indicate that activation of GSK3beta by cAMP facilitates MITF binding to the tyrosinase promoter, thereby leading to stimulation of melanogenesis.	Cyclic AMP	169-173	glycogen synthase kinase 3 beta	Homo sapiens	157-165
12077367-5	2002	Inhibition of both GSK-3beta and the proteasome resulted in a rapid (t1/2=10 minutes) and reversible reduction in pbeta-catenin levels, suggesting that the protein can undergo dephosphorylation in live cells, at a rate comparable to its phosphorylation by GSK-3beta.	pbeta-catenin	114-127	glycogen synthase kinase 3 beta	Homo sapiens	19-28
12063252-6	2002	Moreover, we show that the repression of AR activity by LY294002 is mediated through phosphorylation and inactivation of GSK3beta, a downstream substrate of PI3K/Akt, which results in the nuclear accumulation of beta-catenin.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	56-64	glycogen synthase kinase 3 beta	Homo sapiens	121-129
12107064-3	2002	Application of IGF-I (250 ng/ml) or LiCl (10 mM) alone (i.e., both inhibit GSK-3beta activity) increased the area of C(2)C(12) myotubes by 80 and 85%, respectively.	Lithium Chloride	36-40	glycogen synthase kinase 3 beta	Homo sapiens	75-84
12107064-5	2002	LY-294002 (100 microM) and wortmannin (150 microM), specific inhibitors of phosphatidylinositol 3"-kinase, attenuated IGF-I-induced GSK-3beta phosphorylation by 67 and 92%, respectively.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-9	glycogen synthase kinase 3 beta	Homo sapiens	132-141
12107064-5	2002	LY-294002 (100 microM) and wortmannin (150 microM), specific inhibitors of phosphatidylinositol 3"-kinase, attenuated IGF-I-induced GSK-3beta phosphorylation by 67 and 92%, respectively.	Wortmannin	27-37	glycogen synthase kinase 3 beta	Homo sapiens	132-141
12107064-9	2002	LiCl, which inhibits GSK-3beta, removed the block by cGSK-3beta on IGF-I-inducible NFAT-responsive reporter gene activity.	Lithium Chloride	0-4	glycogen synthase kinase 3 beta	Homo sapiens	21-30
12077367-5	2002	Inhibition of both GSK-3beta and the proteasome resulted in a rapid (t1/2=10 minutes) and reversible reduction in pbeta-catenin levels, suggesting that the protein can undergo dephosphorylation in live cells, at a rate comparable to its phosphorylation by GSK-3beta.	pbeta-catenin	114-127	glycogen synthase kinase 3 beta	Homo sapiens	256-265
12091467-4	2002	BDNF also increased serine(9) -phosphorylation of GSK3beta, which inhibits GSK3beta activity.	Serine	20-26	glycogen synthase kinase 3 beta	Homo sapiens	50-58
12091467-4	2002	BDNF also increased serine(9) -phosphorylation of GSK3beta, which inhibits GSK3beta activity.	Serine	20-26	glycogen synthase kinase 3 beta	Homo sapiens	75-83
12091467-6	2002	This inhibition of BDNF-induced CREB phosphorylation in GSK3beta-overexpressing SH-SY5Y cells was blocked by treatment with lithium.	Lithium	124-131	glycogen synthase kinase 3 beta	Homo sapiens	56-64
12048243-3	2002	DNA damage induced by camptothecin, which activates the tumor suppressor p53, was found to activate GSK3beta.	Camptothecin	22-34	glycogen synthase kinase 3 beta	Homo sapiens	100-108
11967263-8	2002	Furthermore, if Ser(45) in beta-catenin is mutated to Ala, beta-catenin is markedly stabilized, and phosphorylation of Ser(33), Ser(37), and Thr(41) in beta-catenin by wild type GSK-3beta is prevented in intact cells.	Serine	16-19	glycogen synthase kinase 3 beta	Homo sapiens	178-187
11967263-11	2002	In conclusion, we have found that the Arg(96) mutant has a dominant-negative effect on GSK-3beta-dependent phosphorylation of beta-catenin and that targeting of beta-catenin for degradation requires prior priming through phosphorylation of Ser(45).	Arginine	38-41	glycogen synthase kinase 3 beta	Homo sapiens	87-96
11967263-11	2002	In conclusion, we have found that the Arg(96) mutant has a dominant-negative effect on GSK-3beta-dependent phosphorylation of beta-catenin and that targeting of beta-catenin for degradation requires prior priming through phosphorylation of Ser(45).	Serine	240-243	glycogen synthase kinase 3 beta	Homo sapiens	87-96
12027456-4	2002	Thus far three serines (S33, 37, 45) and one threonine (T41) are considered to be the substrates for GSK-3beta phosphorylation.	Serine	15-22	glycogen synthase kinase 3 beta	Homo sapiens	101-110
12027456-4	2002	Thus far three serines (S33, 37, 45) and one threonine (T41) are considered to be the substrates for GSK-3beta phosphorylation.	Threonine	45-54	glycogen synthase kinase 3 beta	Homo sapiens	101-110
12054501-0	2002	Human serum and glucocorticoid-inducible kinase-like kinase (SGKL) phosphorylates glycogen syntheses kinase 3 beta (GSK-3beta) at serine-9 through direct interaction.	Serine	130-136	glycogen synthase kinase 3 beta	Homo sapiens	116-125
12033942-3	2002	As expected, hyperphosphorylation of F-IRS-1 and F-IRS-2 by GSK3beta decreased their subsequent phosphorylation on tyrosine residues by the insulin receptor.	Tyrosine	115-123	glycogen synthase kinase 3 beta	Homo sapiens	60-68
12093158-3	2002	Recent studies suggest that lithium and VPA inhibit GSK-3beta, a serine/threonine kinase involved in the insulin and WNT signaling pathways.	Lithium	28-35	glycogen synthase kinase 3 beta	Homo sapiens	52-61
12093158-3	2002	Recent studies suggest that lithium and VPA inhibit GSK-3beta, a serine/threonine kinase involved in the insulin and WNT signaling pathways.	Valproic Acid	40-43	glycogen synthase kinase 3 beta	Homo sapiens	52-61
12093158-4	2002	Inhibition of GSK-3beta by high concentrations of lithium has been shown to mimic WNT-7a signaling by inducing axonal remodeling and clustering of synapsin I in developing neurons.	Lithium	50-57	glycogen synthase kinase 3 beta	Homo sapiens	14-23
12093158-9	2002	In vitro kinase assays show that therapeutic concentrations of VPA do not inhibit GSK-3beta but that therapeutic concentrations of lithium partially inhibit GSK-3beta activity.	Lithium	131-138	glycogen synthase kinase 3 beta	Homo sapiens	157-166
12093158-11	2002	Lithium directly inhibits GSK-3beta in contrast to VPA, which inhibits GSK-3beta indirectly by an as-yet-unknown pathway.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	26-35
12093158-11	2002	Lithium directly inhibits GSK-3beta in contrast to VPA, which inhibits GSK-3beta indirectly by an as-yet-unknown pathway.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	71-80
12037688-5	2002	This observation suggests that the treatment of cells with IB-MECA augments the activity of GSK-3beta in the cells.	N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine	59-66	glycogen synthase kinase 3 beta	Homo sapiens	92-101
12037688-8	2002	These observations which link cAMP to the Wnt signaling pathway provide mechanistic evidence for the involvement of Wnt pathway via its key elements GSK-3beta and beta-catenin in the anti-tumor activity of A3AR agonists.	Cyclic AMP	30-34	glycogen synthase kinase 3 beta	Homo sapiens	149-158
11809746-6	2002	Moreover, the ability of insulin to inactivate GS kinase-3beta (GSK-3beta), the regulatory enzyme immediately upstream of GS, by serine phosphorylation (308 +/- 16, 321 +/- 41, and 458 +/- 34 optical densitometric units (odu) in NON, CMV2, and WT, respectively, p &lt; 0.02 for WT versus CMV2) was attenuated in the presence of either FAT (205 +/- 14, p &lt; 0.01) or KR (189 +/- 4, p &lt; 0.005) mutants.	Serine	129-135	glycogen synthase kinase 3 beta	Homo sapiens	64-73
12054501-7	2002	The present results provide strong evidences that SGKL could utilize GSK-3beta as a direct downstream target by phosphorylating GSK-3beta at serine-9.	Serine	141-147	glycogen synthase kinase 3 beta	Homo sapiens	69-78
11809746-9	2002	We conclude that FAK regulates the activity of Akt/protein kinase B and GSK-3beta and the association of GSK-3beta with FAK to influence insulin-stimulated glycogen synthesis in hepatocytes.	Glycogen	156-164	glycogen synthase kinase 3 beta	Homo sapiens	105-114
11877389-7	2002	This was accompanied by GC-mediated attenuation of GSK3beta Ser(9) inhibitory phosphorylation and increased GSK3beta kinase activity.	Serine	60-63	glycogen synthase kinase 3 beta	Homo sapiens	51-59
12054501-7	2002	The present results provide strong evidences that SGKL could utilize GSK-3beta as a direct downstream target by phosphorylating GSK-3beta at serine-9.	Serine	141-147	glycogen synthase kinase 3 beta	Homo sapiens	128-137
12086851-5	2002	The inhibitory effect of DeltaNp63 on GSK3beta mediates a decrease in phosphorylation levels of beta-catenin, which induces intranuclear accumulation of beta-catenin and activates beta-catenin-dependent transcription.	deltanp63	25-34	glycogen synthase kinase 3 beta	Homo sapiens	38-46
11992561-9	2002	Furthermore, lithium has been shown to regulate circadian cycles in diverse species, including humans, possibly through inhibition of glycogen synthase kinase 3-beta (GSK-3beta), a known target of lithium.	Lithium	13-20	glycogen synthase kinase 3 beta	Homo sapiens	134-165
11992561-9	2002	Furthermore, lithium has been shown to regulate circadian cycles in diverse species, including humans, possibly through inhibition of glycogen synthase kinase 3-beta (GSK-3beta), a known target of lithium.	Lithium	13-20	glycogen synthase kinase 3 beta	Homo sapiens	167-176
11877389-10	2002	The attenuated cell cycle and the reduced c-Myc level were returned to control levels by specific inhibition of GSK3beta using lithium chloride.	Lithium Chloride	127-143	glycogen synthase kinase 3 beta	Homo sapiens	112-120
11965545-6	2002	In addition, when GSK-3beta activity was inhibited by lithium chloride, both c-fos promoter activity and protein levels increased.	Lithium Chloride	54-70	glycogen synthase kinase 3 beta	Homo sapiens	18-27
12065646-7	2002	Furthermore, the activity of glycogen synthase kinase-3beta (GSK-3beta) increased transiently, as demonstrated by the kinase activity assay and by immunoblottings of serine-9 and tyrosine-216 phosphorylated of GSK-3beta.	Serine	166-172	glycogen synthase kinase 3 beta	Homo sapiens	29-59
12065646-7	2002	Furthermore, the activity of glycogen synthase kinase-3beta (GSK-3beta) increased transiently, as demonstrated by the kinase activity assay and by immunoblottings of serine-9 and tyrosine-216 phosphorylated of GSK-3beta.	Serine	166-172	glycogen synthase kinase 3 beta	Homo sapiens	61-70
12065646-7	2002	Furthermore, the activity of glycogen synthase kinase-3beta (GSK-3beta) increased transiently, as demonstrated by the kinase activity assay and by immunoblottings of serine-9 and tyrosine-216 phosphorylated of GSK-3beta.	Tyrosine	179-187	glycogen synthase kinase 3 beta	Homo sapiens	29-59
12065646-7	2002	Furthermore, the activity of glycogen synthase kinase-3beta (GSK-3beta) increased transiently, as demonstrated by the kinase activity assay and by immunoblottings of serine-9 and tyrosine-216 phosphorylated of GSK-3beta.	Tyrosine	179-187	glycogen synthase kinase 3 beta	Homo sapiens	61-70
12065646-9	2002	The increase in tau phosphorylation was inhibited by the GSK-3beta inhibitor, lithium.	Lithium	78-85	glycogen synthase kinase 3 beta	Homo sapiens	57-66
11903055-7	2002	In kinase assays PKA phosphorylated Ser-87 of hnRNP D, whereas glycogen synthase kinase-3 beta (GSK-3 beta) phosphorylated Ser-83, but only if Ser-87 had been pre-phosphorylated by PKA.	Serine	123-126	glycogen synthase kinase 3 beta	Homo sapiens	63-94
11903055-7	2002	In kinase assays PKA phosphorylated Ser-87 of hnRNP D, whereas glycogen synthase kinase-3 beta (GSK-3 beta) phosphorylated Ser-83, but only if Ser-87 had been pre-phosphorylated by PKA.	Serine	123-126	glycogen synthase kinase 3 beta	Homo sapiens	96-106
11903055-7	2002	In kinase assays PKA phosphorylated Ser-87 of hnRNP D, whereas glycogen synthase kinase-3 beta (GSK-3 beta) phosphorylated Ser-83, but only if Ser-87 had been pre-phosphorylated by PKA.	Serine	123-126	glycogen synthase kinase 3 beta	Homo sapiens	63-94
11903055-7	2002	In kinase assays PKA phosphorylated Ser-87 of hnRNP D, whereas glycogen synthase kinase-3 beta (GSK-3 beta) phosphorylated Ser-83, but only if Ser-87 had been pre-phosphorylated by PKA.	Serine	123-126	glycogen synthase kinase 3 beta	Homo sapiens	96-106
11956818-8	2002	All of the missense mutations were confined to the former two serine residues of the GSK-3 beta phosphorylation sites and their flanking residues (codons 32, 33, 34, 37).	Serine	62-68	glycogen synthase kinase 3 beta	Homo sapiens	85-95
12071511-5	2002	Recently, lithium has been identified as a selective and direct inhibitor of GSK-3beta.	Lithium	10-17	glycogen synthase kinase 3 beta	Homo sapiens	77-86
12071511-6	2002	Based on these findings, we have proposed that part of the neuroprotectant properties of lithium is due to its ability to inhibit GSK-3beta, and thus block the facilitation of apoptosis produced by GSK-3beta.	Lithium	89-96	glycogen synthase kinase 3 beta	Homo sapiens	130-139
12071511-6	2002	Based on these findings, we have proposed that part of the neuroprotectant properties of lithium is due to its ability to inhibit GSK-3beta, and thus block the facilitation of apoptosis produced by GSK-3beta.	Lithium	89-96	glycogen synthase kinase 3 beta	Homo sapiens	198-207
12071511-8	2002	In addition to lithium, both valproic acid and lamotrigine, but not carbamazepine, provided protection from GSK-3beta-facilitated apoptosis in human neuroblastoma SH-SY5Y cells.	Valproic Acid	29-42	glycogen synthase kinase 3 beta	Homo sapiens	108-117
12071511-8	2002	In addition to lithium, both valproic acid and lamotrigine, but not carbamazepine, provided protection from GSK-3beta-facilitated apoptosis in human neuroblastoma SH-SY5Y cells.	Lamotrigine	47-58	glycogen synthase kinase 3 beta	Homo sapiens	108-117
11779850-7	2002	Upon serum stimulation of EC, GSK-3beta was phosphorylated at Ser-9.	Serine	62-65	glycogen synthase kinase 3 beta	Homo sapiens	30-39
12071524-2	2002	Mutational analysis of exon3 in CTNNB-1, which encodes the serine/threonine residues for GSK-3beta phosphorylation sites, was performed on 21 cases of carcinoma of the ampulla of Vater, by means of polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) followed by nucleotide sequencing.	Serine	59-65	glycogen synthase kinase 3 beta	Homo sapiens	89-98
12071524-2	2002	Mutational analysis of exon3 in CTNNB-1, which encodes the serine/threonine residues for GSK-3beta phosphorylation sites, was performed on 21 cases of carcinoma of the ampulla of Vater, by means of polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) followed by nucleotide sequencing.	Threonine	66-75	glycogen synthase kinase 3 beta	Homo sapiens	89-98
11579131-3	2001	Inhibition of GSK3 beta by another paradigm, treatment with the selective inhibitor lithium, also increased CREB DNA binding activity.	Lithium	84-91	glycogen synthase kinase 3 beta	Homo sapiens	14-23
11986994-1	2002	Glycogen synthase kinase-3beta (GSK3beta) is a central figure in many intracellular signaling systems and is directly regulated by lithium.	Lithium	131-138	glycogen synthase kinase 3 beta	Homo sapiens	0-30
11986994-1	2002	Glycogen synthase kinase-3beta (GSK3beta) is a central figure in many intracellular signaling systems and is directly regulated by lithium.	Lithium	131-138	glycogen synthase kinase 3 beta	Homo sapiens	32-40
11986994-2	2002	Substantial evidence now indicates that an important property of the mood stabilizer, lithium, is to influence GSK3beta-linked signaling pathways.	Lithium	86-93	glycogen synthase kinase 3 beta	Homo sapiens	111-119
11986994-4	2002	Downstream targets of GSK3beta, and thus potential targets of mood stabilizers, are several key transcription factors, including beta-catenin, AP-1, cyclic AMP-response element binding protein, NFkappaB, Myc, heat shock factor-1, nuclear factor of activated T-cells and CCAAT/enhancer-binding proteins.	Cyclic AMP	149-159	glycogen synthase kinase 3 beta	Homo sapiens	22-30
11738041-0	2001	The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation.	frattide	68-76	glycogen synthase kinase 3 beta	Homo sapiens	32-41
11738041-4	2001	RESULTS: Structures of uncomplexed Tyr216 phosphorylated GSK-3beta and of its complex with a peptide and a sulfate ion both show the activation loop adopting a conformation similar to that in the phosphorylated and active forms of the related kinases CDK2 and ERK2.	Sulfates	107-114	glycogen synthase kinase 3 beta	Homo sapiens	57-66
11689167-5	2001	To test if glycogen synthase kinase-3beta (GSK3beta), a pro-apoptotic kinase that is inhibited by Akt, is involved in regulating MPP-induced apoptosis, overexpression of GSK3beta and lithium, a selective inhibitor of GSK3beta, were used to directly alter GSK3beta activity.	Lithium	183-190	glycogen synthase kinase 3 beta	Homo sapiens	11-41
11689167-5	2001	To test if glycogen synthase kinase-3beta (GSK3beta), a pro-apoptotic kinase that is inhibited by Akt, is involved in regulating MPP-induced apoptosis, overexpression of GSK3beta and lithium, a selective inhibitor of GSK3beta, were used to directly alter GSK3beta activity.	Lithium	183-190	glycogen synthase kinase 3 beta	Homo sapiens	43-51
11689167-7	2001	Conversely, the GSK3beta inhibitor lithium attenuated MPP-induced caspase-3 activation.	Lithium	35-42	glycogen synthase kinase 3 beta	Homo sapiens	16-24
11689167-9	2001	Rotenone-induced activation of caspase-3 was enhanced by inhibition of PI3K or increased GSK3beta activity, and was attenuated by inhibiting GSK3beta with lithium.	Rotenone	0-8	glycogen synthase kinase 3 beta	Homo sapiens	89-97
11689167-9	2001	Rotenone-induced activation of caspase-3 was enhanced by inhibition of PI3K or increased GSK3beta activity, and was attenuated by inhibiting GSK3beta with lithium.	Rotenone	0-8	glycogen synthase kinase 3 beta	Homo sapiens	141-149
11689167-9	2001	Rotenone-induced activation of caspase-3 was enhanced by inhibition of PI3K or increased GSK3beta activity, and was attenuated by inhibiting GSK3beta with lithium.	Lithium	155-162	glycogen synthase kinase 3 beta	Homo sapiens	141-149
11689167-10	2001	Overall, these results indicate that inhibition of GSK3beta provides protection against the toxic effects of agents, such as MPP and rotenone, that impair mitochondrial function.	1-Methyl-4-phenylpyridinium	125-128	glycogen synthase kinase 3 beta	Homo sapiens	51-59
11689167-10	2001	Overall, these results indicate that inhibition of GSK3beta provides protection against the toxic effects of agents, such as MPP and rotenone, that impair mitochondrial function.	Rotenone	133-141	glycogen synthase kinase 3 beta	Homo sapiens	51-59
11495916-3	2001	The nuclear level of GSK-3 beta was rapidly increased after exposure of cells to serum-free media, heat shock, or staurosporine.	Staurosporine	114-127	glycogen synthase kinase 3 beta	Homo sapiens	21-31
11495916-4	2001	Although each of these conditions caused changes in the serine 9 and/or tyrosine phosphorylation of GSK-3 beta, neither of these modifications was correlated with nuclear accumulation of GSK-3 beta.	Tyrosine	72-80	glycogen synthase kinase 3 beta	Homo sapiens	100-110
11495916-5	2001	Heat shock and staurosporine treatments increased nuclear GSK-3 beta prior to activation of caspase-9 and caspase-3, and this nuclear accumulation of GSK-3 beta was unaltered by pretreatment with a general caspase inhibitor.	Staurosporine	15-28	glycogen synthase kinase 3 beta	Homo sapiens	58-68
11495916-5	2001	Heat shock and staurosporine treatments increased nuclear GSK-3 beta prior to activation of caspase-9 and caspase-3, and this nuclear accumulation of GSK-3 beta was unaltered by pretreatment with a general caspase inhibitor.	Staurosporine	15-28	glycogen synthase kinase 3 beta	Homo sapiens	150-160
11495916-6	2001	The GSK-3 beta inhibitor lithium did not alter heat shock-induced nuclear accumulation of GSK-3 beta but increased the nuclear level of cyclin D1, indicating that cyclin D1 is a substrate of nuclear GSK-3 beta.	Lithium	25-32	glycogen synthase kinase 3 beta	Homo sapiens	4-14
11593435-7	2001	These include inhibition of, both the biochemical activation of ILK, inhibition of serine 9 GSK3beta phosphorylation and the enhancement of TCF-4 transcriptional activity.	Serine	83-89	glycogen synthase kinase 3 beta	Homo sapiens	92-100
11805297-0	2002	Testosterone prevents the heat shock-induced overactivation of glycogen synthase kinase-3 beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau: implications for Alzheimer"s disease.	Testosterone	0-12	glycogen synthase kinase 3 beta	Homo sapiens	63-94
11579131-5	2001	These results demonstrate that inhibition of GSK3 beta by serine-9 phosphorylation or directly by lithium increases CREB activation.	Serine	58-64	glycogen synthase kinase 3 beta	Homo sapiens	45-54
11579131-5	2001	These results demonstrate that inhibition of GSK3 beta by serine-9 phosphorylation or directly by lithium increases CREB activation.	Lithium	98-105	glycogen synthase kinase 3 beta	Homo sapiens	45-54
11579131-6	2001	Conversely, overexpression of active GSK3 beta to 3.5-fold the normal levels completely blocked increases in CREB DNA binding activity induced by epidermal growth factor, insulin-like growth factor-1, forskolin, and cyclic AMP.	Colforsin	201-210	glycogen synthase kinase 3 beta	Homo sapiens	37-46
11579131-6	2001	Conversely, overexpression of active GSK3 beta to 3.5-fold the normal levels completely blocked increases in CREB DNA binding activity induced by epidermal growth factor, insulin-like growth factor-1, forskolin, and cyclic AMP.	Cyclic AMP	216-226	glycogen synthase kinase 3 beta	Homo sapiens	37-46
11579131-7	2001	The inhibitory effects due to overexpressed GSK3 beta were reversed by treatment with lithium and with another GSK 3beta inhibitor, sodium valproate.	Lithium	86-93	glycogen synthase kinase 3 beta	Homo sapiens	44-53
11579131-7	2001	The inhibitory effects due to overexpressed GSK3 beta were reversed by treatment with lithium and with another GSK 3beta inhibitor, sodium valproate.	Valproic Acid	132-148	glycogen synthase kinase 3 beta	Homo sapiens	44-53
11579131-7	2001	The inhibitory effects due to overexpressed GSK3 beta were reversed by treatment with lithium and with another GSK 3beta inhibitor, sodium valproate.	Valproic Acid	132-148	glycogen synthase kinase 3 beta	Homo sapiens	111-120
11520307-12	2001	Glycogen synthesis in the normal and insulin-resistant adipocytes was stimulated by lithium, an inhibitor of glycogen synthase kinase 3 beta, suggesting the involvement of phosphorylation events in dexamethasone-induced insulin resistance.	Glycogen	0-8	glycogen synthase kinase 3 beta	Homo sapiens	109-140
11402035-6	2001	Similar increases in only CTF levels were seen when cells expressing wild type PS1 were treated with lithium chloride, an inhibitor of GSK-3beta.	Lithium Chloride	101-117	glycogen synthase kinase 3 beta	Homo sapiens	135-144
11402035-9	2001	These data demonstrate that PS1 NTF.CTF endoproteolytic fragments are generated in excess, that phosphorylation at Ser(397) by GSK-3beta regulates the discard of excess CTF, and that the disposal of surplus NTF is mediated by an independent mechanism.	Serine	115-118	glycogen synthase kinase 3 beta	Homo sapiens	127-136
11520307-12	2001	Glycogen synthesis in the normal and insulin-resistant adipocytes was stimulated by lithium, an inhibitor of glycogen synthase kinase 3 beta, suggesting the involvement of phosphorylation events in dexamethasone-induced insulin resistance.	Lithium	84-91	glycogen synthase kinase 3 beta	Homo sapiens	109-140
11334423-7	2001	Provocatively, the enhanced glucose metabolism in GLUT1 overexpressing VSMC as well as neointimal tissue correlated with the inactivation of the proapoptotic kinase, glycogen synthase kinase 3beta (GSK3beta).	Glucose	28-35	glycogen synthase kinase 3 beta	Homo sapiens	166-196
11382772-8	2001	Leptomycin B, an inhibitor for Crm1, increased basal nuclear GATA4 and suppressed GSK3beta-induced decreases in nuclear GATA4.	leptomycin B	0-12	glycogen synthase kinase 3 beta	Homo sapiens	82-90
11408933-3	2001	Of approximately 1200 genes in the array, those associated with integrin-linked kinase (ILK), fibronectin precursor and glycogen synthase kinase-3beta (GSK-3beta) were markedly stimulated after exposure of Hep3B cells to low oxygen (1%) for 6 h. Epo, HIF-1, and von Hippel-Lindau cDNAs were measured in parallel as markers of low oxygen responses in Hep3B cells.	Oxygen	225-231	glycogen synthase kinase 3 beta	Homo sapiens	120-150
11408933-3	2001	Of approximately 1200 genes in the array, those associated with integrin-linked kinase (ILK), fibronectin precursor and glycogen synthase kinase-3beta (GSK-3beta) were markedly stimulated after exposure of Hep3B cells to low oxygen (1%) for 6 h. Epo, HIF-1, and von Hippel-Lindau cDNAs were measured in parallel as markers of low oxygen responses in Hep3B cells.	Oxygen	225-231	glycogen synthase kinase 3 beta	Homo sapiens	152-161
11408933-3	2001	Of approximately 1200 genes in the array, those associated with integrin-linked kinase (ILK), fibronectin precursor and glycogen synthase kinase-3beta (GSK-3beta) were markedly stimulated after exposure of Hep3B cells to low oxygen (1%) for 6 h. Epo, HIF-1, and von Hippel-Lindau cDNAs were measured in parallel as markers of low oxygen responses in Hep3B cells.	Oxygen	330-336	glycogen synthase kinase 3 beta	Homo sapiens	120-150
11408933-3	2001	Of approximately 1200 genes in the array, those associated with integrin-linked kinase (ILK), fibronectin precursor and glycogen synthase kinase-3beta (GSK-3beta) were markedly stimulated after exposure of Hep3B cells to low oxygen (1%) for 6 h. Epo, HIF-1, and von Hippel-Lindau cDNAs were measured in parallel as markers of low oxygen responses in Hep3B cells.	Oxygen	330-336	glycogen synthase kinase 3 beta	Homo sapiens	152-161
11440715-0	2001	Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition.	Phosphates	75-84	glycogen synthase kinase 3 beta	Homo sapiens	21-52
11440715-2	2001	The crystal structure of human GSK3 beta shows a catalytically active conformation in the absence of activation-segment phosphorylation, with the sulphonate of a buffer molecule bridging the activation-segment and N-terminal domain in the same way as the phosphate group of the activation-segment phospho-Ser/Thr in other kinases.	Phosphates	255-264	glycogen synthase kinase 3 beta	Homo sapiens	31-40
11440715-2	2001	The crystal structure of human GSK3 beta shows a catalytically active conformation in the absence of activation-segment phosphorylation, with the sulphonate of a buffer molecule bridging the activation-segment and N-terminal domain in the same way as the phosphate group of the activation-segment phospho-Ser/Thr in other kinases.	Serine	305-308	glycogen synthase kinase 3 beta	Homo sapiens	31-40
11440715-2	2001	The crystal structure of human GSK3 beta shows a catalytically active conformation in the absence of activation-segment phosphorylation, with the sulphonate of a buffer molecule bridging the activation-segment and N-terminal domain in the same way as the phosphate group of the activation-segment phospho-Ser/Thr in other kinases.	Threonine	309-312	glycogen synthase kinase 3 beta	Homo sapiens	31-40
11440715-3	2001	The location of this oxyanion binding site in the substrate binding cleft indicates direct coupling of P+4 phosphate-primed substrate binding and catalytic activation, explains the ability of GSK3 beta to processively hyperphosphorylate substrates with Ser/Thr pentad-repeats, and suggests a mechanism for autoinhibition in which the phosphorylated N terminus binds as a competitive pseudosubstrate with phospho-Ser 9 occupying the P+4 site.	Phosphates	107-116	glycogen synthase kinase 3 beta	Homo sapiens	192-201
11440715-3	2001	The location of this oxyanion binding site in the substrate binding cleft indicates direct coupling of P+4 phosphate-primed substrate binding and catalytic activation, explains the ability of GSK3 beta to processively hyperphosphorylate substrates with Ser/Thr pentad-repeats, and suggests a mechanism for autoinhibition in which the phosphorylated N terminus binds as a competitive pseudosubstrate with phospho-Ser 9 occupying the P+4 site.	Serine	253-256	glycogen synthase kinase 3 beta	Homo sapiens	192-201
11440715-3	2001	The location of this oxyanion binding site in the substrate binding cleft indicates direct coupling of P+4 phosphate-primed substrate binding and catalytic activation, explains the ability of GSK3 beta to processively hyperphosphorylate substrates with Ser/Thr pentad-repeats, and suggests a mechanism for autoinhibition in which the phosphorylated N terminus binds as a competitive pseudosubstrate with phospho-Ser 9 occupying the P+4 site.	Threonine	257-260	glycogen synthase kinase 3 beta	Homo sapiens	192-201
11440715-3	2001	The location of this oxyanion binding site in the substrate binding cleft indicates direct coupling of P+4 phosphate-primed substrate binding and catalytic activation, explains the ability of GSK3 beta to processively hyperphosphorylate substrates with Ser/Thr pentad-repeats, and suggests a mechanism for autoinhibition in which the phosphorylated N terminus binds as a competitive pseudosubstrate with phospho-Ser 9 occupying the P+4 site.	Serine	412-415	glycogen synthase kinase 3 beta	Homo sapiens	192-201
11385321-13	2001	The mutations affected one of the serine/threonine residues targeted for phosphorylation by glycogen synthase kinase-3beta or adjacent residues.	Serine	34-40	glycogen synthase kinase 3 beta	Homo sapiens	92-122
11385321-13	2001	The mutations affected one of the serine/threonine residues targeted for phosphorylation by glycogen synthase kinase-3beta or adjacent residues.	Threonine	41-50	glycogen synthase kinase 3 beta	Homo sapiens	92-122
11405549-3	2001	Signal transduction systems known to be perturbed by lithium involve phosphoinositide (PI) turnover, activation of the Wnt pathway via inhibition of glycogen synthase kinase-3beta (GSK-3beta), and a growth factor-induced, Akt-mediated signalling that promotes cell survival.	Lithium	53-60	glycogen synthase kinase 3 beta	Homo sapiens	149-179
11405549-3	2001	Signal transduction systems known to be perturbed by lithium involve phosphoinositide (PI) turnover, activation of the Wnt pathway via inhibition of glycogen synthase kinase-3beta (GSK-3beta), and a growth factor-induced, Akt-mediated signalling that promotes cell survival.	Lithium	53-60	glycogen synthase kinase 3 beta	Homo sapiens	181-190
11334423-10	2001	Taken together, upregulation of glucose metabolism during intimal lesion formation promotes an antiapoptotic signaling pathway that is linked to the inactivation of GSK3beta.	Glucose	32-39	glycogen synthase kinase 3 beta	Homo sapiens	165-173
11427888-7	2001	The structure explains the unique primed phosphorylation mechanism of GSK3beta and how GSK3beta relies on a phosphoserine in the substrate for the alignment of the beta- and alpha-helical domains.	Phosphoserine	108-121	glycogen synthase kinase 3 beta	Homo sapiens	70-78
11427888-7	2001	The structure explains the unique primed phosphorylation mechanism of GSK3beta and how GSK3beta relies on a phosphoserine in the substrate for the alignment of the beta- and alpha-helical domains.	Phosphoserine	108-121	glycogen synthase kinase 3 beta	Homo sapiens	87-95
11351304-2	2001	The level of beta-catenin is regulated through GSK-3beta phosphorylation of specific serine and threonine residues, all of which are encoded for in exon 3 of the beta-catenin gene (CTNNB1).	Serine	85-91	glycogen synthase kinase 3 beta	Homo sapiens	47-56
11351304-2	2001	The level of beta-catenin is regulated through GSK-3beta phosphorylation of specific serine and threonine residues, all of which are encoded for in exon 3 of the beta-catenin gene (CTNNB1).	Threonine	96-105	glycogen synthase kinase 3 beta	Homo sapiens	47-56
11389054-5	2001	Similarly, UVB caused phosphorylation of GSK-3beta (Ser-9) and presumably inactivation of GSK-3beta.	Serine	52-55	glycogen synthase kinase 3 beta	Homo sapiens	41-50
11389054-6	2001	Inhibition of GSK-3beta by lithium induced endogenous COX-2 protein expression and COX-2 promoter activity.	Lithium	27-34	glycogen synthase kinase 3 beta	Homo sapiens	14-23
11334423-7	2001	Provocatively, the enhanced glucose metabolism in GLUT1 overexpressing VSMC as well as neointimal tissue correlated with the inactivation of the proapoptotic kinase, glycogen synthase kinase 3beta (GSK3beta).	Glucose	28-35	glycogen synthase kinase 3 beta	Homo sapiens	198-206
11334423-9	2001	GSK3beta-induced apoptosis was significantly attenuated by GLUT1 overexpression (GSK3beta 29 +/- 3% vs. GLUT1 + GSK3beta 6 +/- 1%, n = 12, P &lt; 0.001), suggesting that the antiapoptotic effect of enhanced glucose metabolism is linked to the inactivation of GSK3beta.	Glucose	207-214	glycogen synthase kinase 3 beta	Homo sapiens	0-8
11170292-3	2001	Missense mutations causing substitutions of Ser/Thr residues critical for regulation by GSK-3beta were detected in one (2%) of the cell lines, A427, and two (4%) of the surgical specimens.	Serine	44-47	glycogen synthase kinase 3 beta	Homo sapiens	88-97
11104755-5	2001	Site-directed mutagenesis, together with in vitro and in vivo phosphorylation assays, indicates that PS1 residues Ser(353) and Ser(357) are glycogen synthase kinase-3beta targets.	Serine	114-117	glycogen synthase kinase 3 beta	Homo sapiens	140-170
11267862-7	2001	LiCl, a potent inhibitor of Glycogen Synthase Kinase 3beta (GSK3beta) activity, abrogated the IL-6-induced inhibition of wild-type beta-catenin.	Lithium Chloride	0-4	glycogen synthase kinase 3 beta	Homo sapiens	28-58
11267862-7	2001	LiCl, a potent inhibitor of Glycogen Synthase Kinase 3beta (GSK3beta) activity, abrogated the IL-6-induced inhibition of wild-type beta-catenin.	Lithium Chloride	0-4	glycogen synthase kinase 3 beta	Homo sapiens	60-68
11403684-8	2001	PAF-mediated inhibition of neuronal migration in reaggregated CGNs or induction of apoptosis in CGNs that have ceased to migrate can be reversed by either PAF receptor antagonists, or the GSK-3beta inhibitors lithium or valproic acid, in a dose-dependent manner.	Lithium	209-216	glycogen synthase kinase 3 beta	Homo sapiens	188-197
11403684-8	2001	PAF-mediated inhibition of neuronal migration in reaggregated CGNs or induction of apoptosis in CGNs that have ceased to migrate can be reversed by either PAF receptor antagonists, or the GSK-3beta inhibitors lithium or valproic acid, in a dose-dependent manner.	Valproic Acid	220-233	glycogen synthase kinase 3 beta	Homo sapiens	188-197
11278002-1	2001	In vitro phosphorylation of recombinant wild-type 2N4R tau and FTDP-17 exonic mutant forms P301L, V337M and R406W by glycogen synthase kinase 3beta (GSK3beta) was examined by two dimensional phosphopeptide mapping analysis on thin layer cellulose plates.	Cellulose	237-246	glycogen synthase kinase 3 beta	Homo sapiens	117-147
11278002-1	2001	In vitro phosphorylation of recombinant wild-type 2N4R tau and FTDP-17 exonic mutant forms P301L, V337M and R406W by glycogen synthase kinase 3beta (GSK3beta) was examined by two dimensional phosphopeptide mapping analysis on thin layer cellulose plates.	Cellulose	237-246	glycogen synthase kinase 3 beta	Homo sapiens	149-157
11289110-7	2001	Activation of Akt by hypoxia resulted in the phosphorylation of GSK-3alpha and GSK-3beta at Ser-9 and Ser-21, two well-documented Akt phosphorylation sites, respectively, that are inactivating modifications of each GSK-3 isoform.	Serine	92-95	glycogen synthase kinase 3 beta	Homo sapiens	79-88
11289110-7	2001	Activation of Akt by hypoxia resulted in the phosphorylation of GSK-3alpha and GSK-3beta at Ser-9 and Ser-21, two well-documented Akt phosphorylation sites, respectively, that are inactivating modifications of each GSK-3 isoform.	Serine	102-105	glycogen synthase kinase 3 beta	Homo sapiens	79-88
11104755-5	2001	Site-directed mutagenesis, together with in vitro and in vivo phosphorylation assays, indicates that PS1 residues Ser(353) and Ser(357) are glycogen synthase kinase-3beta targets.	Serine	127-130	glycogen synthase kinase 3 beta	Homo sapiens	140-170
11170292-3	2001	Missense mutations causing substitutions of Ser/Thr residues critical for regulation by GSK-3beta were detected in one (2%) of the cell lines, A427, and two (4%) of the surgical specimens.	Threonine	48-51	glycogen synthase kinase 3 beta	Homo sapiens	88-97
11483158-0	2001	Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53"s transcriptional activity.	Serine	46-52	glycogen synthase kinase 3 beta	Homo sapiens	0-30
11013232-5	2001	We report here that indirubins are also powerful inhibitors (IC(50): 5-50 nm) of an evolutionarily related kinase, glycogen synthase kinase-3beta (GSK-3 beta).	indirubin	20-30	glycogen synthase kinase 3 beta	Homo sapiens	115-145
11483158-4	2001	RESULTS: The 2 isoforms of GSK3, GSK3alpha and GSK3beta, phosphorylate the sequence Ser-X-X-X-Ser(P) when the C-terminal serine residue is already phosphorylated.	Serine	84-87	glycogen synthase kinase 3 beta	Homo sapiens	47-55
11483158-4	2001	RESULTS: The 2 isoforms of GSK3, GSK3alpha and GSK3beta, phosphorylate the sequence Ser-X-X-X-Ser(P) when the C-terminal serine residue is already phosphorylated.	Serine	94-97	glycogen synthase kinase 3 beta	Homo sapiens	47-55
11483158-4	2001	RESULTS: The 2 isoforms of GSK3, GSK3alpha and GSK3beta, phosphorylate the sequence Ser-X-X-X-Ser(P) when the C-terminal serine residue is already phosphorylated.	Serine	121-127	glycogen synthase kinase 3 beta	Homo sapiens	47-55
11483158-6	2001	Our results demonstrate that phosphorylation of serine 37 of p53 by DNA-PK creates a site for GSK3beta phosphorylation at serine 33 in vitro.	Serine	48-54	glycogen synthase kinase 3 beta	Homo sapiens	94-102
11483158-6	2001	Our results demonstrate that phosphorylation of serine 37 of p53 by DNA-PK creates a site for GSK3beta phosphorylation at serine 33 in vitro.	Serine	122-128	glycogen synthase kinase 3 beta	Homo sapiens	94-102
11483158-9	2001	Mutation of either serine 33 or serine 37 of p53 to alanine blocked the ability of GSK3beta to regulate p53 transcriptional activity.	Serine	19-25	glycogen synthase kinase 3 beta	Homo sapiens	83-91
11483158-9	2001	Mutation of either serine 33 or serine 37 of p53 to alanine blocked the ability of GSK3beta to regulate p53 transcriptional activity.	Serine	32-38	glycogen synthase kinase 3 beta	Homo sapiens	83-91
11483158-9	2001	Mutation of either serine 33 or serine 37 of p53 to alanine blocked the ability of GSK3beta to regulate p53 transcriptional activity.	Alanine	52-59	glycogen synthase kinase 3 beta	Homo sapiens	83-91
11483158-13	2001	CONCLUSIONS: GSK3beta can regulate p53"s transcriptional activity by phosphorylating serine 33.	Serine	85-91	glycogen synthase kinase 3 beta	Homo sapiens	13-21
11035789-9	2000	IGF-1 did, however, enhance transcriptional activity in combination with lithium chloride, an inhibitor of glycogen synthase kinase 3 beta, which also stabilizes beta-catenin.	Lithium Chloride	73-89	glycogen synthase kinase 3 beta	Homo sapiens	107-138
10944533-5	2000	Axam inhibited the complex formation of Dvl with Axin and the activity of Dvl to suppress GSK-3beta-dependent phosphorylation of Axin.	axam	0-4	glycogen synthase kinase 3 beta	Homo sapiens	90-99
11018058-4	2000	Herein, we report that glycogen synthase kinase-3beta (GSK-3beta), a protein kinase previously implicated in processes as diverse as development and tumorigenesis, is inactivated by hypertrophic stimuli via a phosphoinositide 3-kinase-dependent protein kinase that phosphorylates GSK-3beta on ser 9.	Serine	293-296	glycogen synthase kinase 3 beta	Homo sapiens	23-53
11035810-1	2000	GSK-3 activity is inhibited through phosphorylation of serine 21 in GSK-3 alpha and serine 9 in GSK-3 beta.	Serine	84-90	glycogen synthase kinase 3 beta	Homo sapiens	96-106
11035810-3	2000	Here, we show that serine 21 in GSK-3 alpha and serine 9 in GSK-3 beta are also physiological substrates of cAMP-dependent protein kinase A.	Serine	19-25	glycogen synthase kinase 3 beta	Homo sapiens	60-70
11035810-3	2000	Here, we show that serine 21 in GSK-3 alpha and serine 9 in GSK-3 beta are also physiological substrates of cAMP-dependent protein kinase A.	Serine	48-54	glycogen synthase kinase 3 beta	Homo sapiens	60-70
11035810-3	2000	Here, we show that serine 21 in GSK-3 alpha and serine 9 in GSK-3 beta are also physiological substrates of cAMP-dependent protein kinase A.	Cyclic AMP	108-112	glycogen synthase kinase 3 beta	Homo sapiens	60-70
11018058-4	2000	Herein, we report that glycogen synthase kinase-3beta (GSK-3beta), a protein kinase previously implicated in processes as diverse as development and tumorigenesis, is inactivated by hypertrophic stimuli via a phosphoinositide 3-kinase-dependent protein kinase that phosphorylates GSK-3beta on ser 9.	Serine	293-296	glycogen synthase kinase 3 beta	Homo sapiens	55-64
11018058-4	2000	Herein, we report that glycogen synthase kinase-3beta (GSK-3beta), a protein kinase previously implicated in processes as diverse as development and tumorigenesis, is inactivated by hypertrophic stimuli via a phosphoinositide 3-kinase-dependent protein kinase that phosphorylates GSK-3beta on ser 9.	Serine	293-296	glycogen synthase kinase 3 beta	Homo sapiens	280-289
11018058-5	2000	Using adenovirus-mediated gene transfer of GSK-3beta containing a ser 9 to alanine mutation, which prevents inactivation by hypertrophic stimuli, we demonstrate that inactivation of GSK-3beta is required for cardiomyocytes to undergo hypertrophy.	Serine	66-69	glycogen synthase kinase 3 beta	Homo sapiens	43-52
11018058-5	2000	Using adenovirus-mediated gene transfer of GSK-3beta containing a ser 9 to alanine mutation, which prevents inactivation by hypertrophic stimuli, we demonstrate that inactivation of GSK-3beta is required for cardiomyocytes to undergo hypertrophy.	Serine	66-69	glycogen synthase kinase 3 beta	Homo sapiens	182-191
11018058-5	2000	Using adenovirus-mediated gene transfer of GSK-3beta containing a ser 9 to alanine mutation, which prevents inactivation by hypertrophic stimuli, we demonstrate that inactivation of GSK-3beta is required for cardiomyocytes to undergo hypertrophy.	Alanine	75-82	glycogen synthase kinase 3 beta	Homo sapiens	43-52
11018058-5	2000	Using adenovirus-mediated gene transfer of GSK-3beta containing a ser 9 to alanine mutation, which prevents inactivation by hypertrophic stimuli, we demonstrate that inactivation of GSK-3beta is required for cardiomyocytes to undergo hypertrophy.	Alanine	75-82	glycogen synthase kinase 3 beta	Homo sapiens	182-191
10998059-3	2000	We here report that paullones also act as very potent inhibitors of glycogen synthase kinase-3beta (GSK-3beta) (IC50: 4-80 nM) and the neuronal CDK5/p25 (IC50: 20-200 nM).	paullone	20-29	glycogen synthase kinase 3 beta	Homo sapiens	68-98
10995469-4	2000	Nerve growth factor withdrawal from differentiated PC12 cells and staurosporine treatment of SH-SY5Y cells led to increased phosphorylation at Y(216), GSK3beta activity, and cell death.	Staurosporine	66-79	glycogen synthase kinase 3 beta	Homo sapiens	151-159
10998059-0	2000	Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.	paullone	0-9	glycogen synthase kinase 3 beta	Homo sapiens	35-65
10766840-4	2000	Previous studies have demonstrated that cyclin D1 ubiquitination is dependent on its phosphorylation by glycogen synthase kinase 3beta (GSK-3beta) on threonine 286 and that this phosphorylation event is greatly enhanced by binding to CDK4 (Diehl, J.	Threonine	150-159	glycogen synthase kinase 3 beta	Homo sapiens	104-134
10980116-3	2000	Of the whole series, 57 (13.1%) of 434 tumors examined had beta-catenin mutations, 34 occurred at the serine/threonine residues of the GSK-3beta region of beta-catenin.	Serine	102-108	glycogen synthase kinase 3 beta	Homo sapiens	135-144
10980116-3	2000	Of the whole series, 57 (13.1%) of 434 tumors examined had beta-catenin mutations, 34 occurred at the serine/threonine residues of the GSK-3beta region of beta-catenin.	Threonine	109-118	glycogen synthase kinase 3 beta	Homo sapiens	135-144
10873564-8	2000	This induction-dependent increase of GSK-3beta is markedly reduced in response to inhibitors of alanyl-aminopeptidase, actinonin, leuhistin, and RB3014.	rb3014	145-151	glycogen synthase kinase 3 beta	Homo sapiens	37-46
11055555-11	2000	The inactivation of GSK-3beta and activation of PKB by insulin were associated with their phosphorylation and this was also reversed by wortmannin.	Wortmannin	136-146	glycogen synthase kinase 3 beta	Homo sapiens	20-29
10749878-3	2000	Previous studies on both Xenopus and mammalian cells indicate that lithium mimics Wnt signaling by inactivating GSK-3beta.	Lithium	67-74	glycogen synthase kinase 3 beta	Homo sapiens	112-121
10766840-4	2000	Previous studies have demonstrated that cyclin D1 ubiquitination is dependent on its phosphorylation by glycogen synthase kinase 3beta (GSK-3beta) on threonine 286 and that this phosphorylation event is greatly enhanced by binding to CDK4 (Diehl, J.	Threonine	150-159	glycogen synthase kinase 3 beta	Homo sapiens	136-145
10713065-0	2000	Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis.	Staurosporine	43-56	glycogen synthase kinase 3 beta	Homo sapiens	0-30
10713065-4	2000	Overexpression of glycogen synthase kinase-3beta to levels 3.5 times that in control cells did not alter basal indices of apoptosis but potentiated staurosporine-induced activation of caspase-3, caspase-9, proteolysis of poly(ADP-ribose) polymerase, and morphological changes indicative of apoptosis.	Staurosporine	148-161	glycogen synthase kinase 3 beta	Homo sapiens	18-48
10713065-5	2000	Inhibition of glycogen synthase kinase-3beta by lithium attenuated the enhanced staurosporine-induced activation of caspase-3 in cells overexpressing glycogen synthase kinase-3beta.	Lithium	48-55	glycogen synthase kinase 3 beta	Homo sapiens	14-44
10713065-5	2000	Inhibition of glycogen synthase kinase-3beta by lithium attenuated the enhanced staurosporine-induced activation of caspase-3 in cells overexpressing glycogen synthase kinase-3beta.	Lithium	48-55	glycogen synthase kinase 3 beta	Homo sapiens	150-180
10713065-5	2000	Inhibition of glycogen synthase kinase-3beta by lithium attenuated the enhanced staurosporine-induced activation of caspase-3 in cells overexpressing glycogen synthase kinase-3beta.	Staurosporine	80-93	glycogen synthase kinase 3 beta	Homo sapiens	14-44
10713065-5	2000	Inhibition of glycogen synthase kinase-3beta by lithium attenuated the enhanced staurosporine-induced activation of caspase-3 in cells overexpressing glycogen synthase kinase-3beta.	Staurosporine	80-93	glycogen synthase kinase 3 beta	Homo sapiens	150-180
10713065-6	2000	In cells subjected to heat shock, caspase-3 activity was more than three times greater in glycogen synthase kinase-3beta-transfected than control cells, and this potentiated response was inhibited by lithium treatment.	Lithium	200-207	glycogen synthase kinase 3 beta	Homo sapiens	90-120
10713065-8	2000	These findings indicate that glycogen synthase kinase-3beta may contribute to pro-apoptotic-signaling activity, that inhibition of glycogen synthase kinase-3beta can contribute to anti-apoptotic-signaling mechanisms, and that the neuroprotective actions of lithium may be due in part to its inhibitory modulation of glycogen synthase kinase-3beta.	Lithium	257-264	glycogen synthase kinase 3 beta	Homo sapiens	131-161
10713065-8	2000	These findings indicate that glycogen synthase kinase-3beta may contribute to pro-apoptotic-signaling activity, that inhibition of glycogen synthase kinase-3beta can contribute to anti-apoptotic-signaling mechanisms, and that the neuroprotective actions of lithium may be due in part to its inhibitory modulation of glycogen synthase kinase-3beta.	Lithium	257-264	glycogen synthase kinase 3 beta	Homo sapiens	131-161
10826655-3	2000	Recent molecular studies have revealed the action of lithium on signal transduction mechanisms, such as phosphoinositide hydrolysis, adenylyl cyclase, G protein, glycogen synthase kinase-3beta, protein kinase C, and its substrate myristoylated alanine-rich C kinase substrate.	Lithium	53-60	glycogen synthase kinase 3 beta	Homo sapiens	133-192
10664610-2	2000	Among the proposed mechanisms, two lithium-sensitive signal transduction pathways are active in the brain; these are mediated by glycogen synthase kinase 3beta (GSK-3beta) and inositol (1,4,5)-trisphosphate [Ins(1,4,5)P3] signalling.	Lithium	35-42	glycogen synthase kinase 3 beta	Homo sapiens	129-159
10664610-2	2000	Among the proposed mechanisms, two lithium-sensitive signal transduction pathways are active in the brain; these are mediated by glycogen synthase kinase 3beta (GSK-3beta) and inositol (1,4,5)-trisphosphate [Ins(1,4,5)P3] signalling.	Lithium	35-42	glycogen synthase kinase 3 beta	Homo sapiens	161-170
10664610-2	2000	Among the proposed mechanisms, two lithium-sensitive signal transduction pathways are active in the brain; these are mediated by glycogen synthase kinase 3beta (GSK-3beta) and inositol (1,4,5)-trisphosphate [Ins(1,4,5)P3] signalling.	Inositol 1,4,5-Trisphosphate	208-220	glycogen synthase kinase 3 beta	Homo sapiens	161-170
10826655-5	2000	Through its effects on glycogen synthase kinase-3beta and protein kinase C, lithium may alter the level of phosphorylation of cytoskeletal proteins, which leads to neuroplastic changes associated with mood stabilization.	Lithium	76-83	glycogen synthase kinase 3 beta	Homo sapiens	23-53
10826666-6	2000	Lithium has also been demonstrated to inhibit glycogen synthase kinase 3beta (GSK-3beta), an enzyme known to regulate the levels of phosphorylated tau and beta-catenin (both of which may play a role in the neurodegeneration observed in certain forms of Alzheimer"s disease).	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	46-76
10826666-6	2000	Lithium has also been demonstrated to inhibit glycogen synthase kinase 3beta (GSK-3beta), an enzyme known to regulate the levels of phosphorylated tau and beta-catenin (both of which may play a role in the neurodegeneration observed in certain forms of Alzheimer"s disease).	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	78-87
10826666-7	2000	Consistent with the increases in bc1-2 levels and inhibition of GSK-3beta, lithium has been demonstrated to exert robust protective effects against diverse insults both in vitro and in vivo.	Lithium	75-82	glycogen synthase kinase 3 beta	Homo sapiens	64-73
10493495-0	1999	Cripto-1 induces phosphatidylinositol 3"-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3beta in human cervical carcinoma cells.	cripto-1	0-8	glycogen synthase kinase 3 beta	Homo sapiens	85-115
11252664-5	1999	Recent findings demonstrate that lithium directly inhibits, in a non-competitive fashion, the activity of glycogen synthase kinase (GSK)-3beta, a serine/threonine kinase highly expressed in the central nervous system.	Lithium	33-40	glycogen synthase kinase 3 beta	Homo sapiens	106-142
10518159-4	1999	RESULTS: Lithium"s acute effects are mediated through inhibition of specific enzymes involved in two distinct but interacting signaling pathways--the protein kinase C and glycogen synthase kinase 3 beta signaling cascades--that converge at the level of gene transcriptional regulation.	Lithium	9-16	glycogen synthase kinase 3 beta	Homo sapiens	171-202
10504342-2	1999	Mapping studies identified a region of MAP1B high in serine-proline motifs that is phosphorylated by GSK3beta.	Serine	53-59	glycogen synthase kinase 3 beta	Homo sapiens	101-109
10504342-2	1999	Mapping studies identified a region of MAP1B high in serine-proline motifs that is phosphorylated by GSK3beta.	Proline	60-67	glycogen synthase kinase 3 beta	Homo sapiens	101-109
10504342-10	1999	To test this prediction, we reduced the levels of MAP1B-P in neuronal growth cones of dorsal root ganglion cells in culture by inhibiting GSK3beta with lithium.	Lithium	152-159	glycogen synthase kinase 3 beta	Homo sapiens	138-146
11341469-0	2000	Sodium butyrate-induced differentiation of human LIM2537 colon cancer cells decreases GSK-3beta activity and increases levels of both membrane-bound and Apc/axin/GSK-3beta complex-associated pools of beta-catenin.	Butyric Acid	0-15	glycogen synthase kinase 3 beta	Homo sapiens	86-95
11341469-0	2000	Sodium butyrate-induced differentiation of human LIM2537 colon cancer cells decreases GSK-3beta activity and increases levels of both membrane-bound and Apc/axin/GSK-3beta complex-associated pools of beta-catenin.	Butyric Acid	0-15	glycogen synthase kinase 3 beta	Homo sapiens	162-171
11341469-2	2000	Treatment of LIM2537 cells, a poorly differentiated colon cancer cell line, with the potent differentiating agent sodium butyrate resulted in 34% reduction in GSK-3beta activity in the treated cells (P &lt; 0.028, n = 3).	Butyric Acid	114-129	glycogen synthase kinase 3 beta	Homo sapiens	159-168
10622182-4	1999	More recently, studies have demonstrated robust effects of lithium on another kinase system, GSK-3beta, and on neuroprotective/neurotrophic proteins in the brain.	Lithium	59-66	glycogen synthase kinase 3 beta	Homo sapiens	93-102
10509176-5	1999	Lithium has also been demonstrated to inhibit glycogen synthase kinase 3 beta (GSK-3 beta), an enzyme known to regulate the levels of phosphorylated tau and beta-catenin (both of which may play a role in the neurodegeneration observed in Alzheimer"s disease).	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	46-77
10509176-5	1999	Lithium has also been demonstrated to inhibit glycogen synthase kinase 3 beta (GSK-3 beta), an enzyme known to regulate the levels of phosphorylated tau and beta-catenin (both of which may play a role in the neurodegeneration observed in Alzheimer"s disease).	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	79-89
10509176-6	1999	Consistent with the increases in bcl-2 levels and inhibition of GSK-3 beta, lithium has been demonstrated to exert robust protective effects against diverse insults both in vitro and in vivo.	Lithium	76-83	glycogen synthase kinase 3 beta	Homo sapiens	64-74
10493495-5	1999	Phosphorylation of AKT and GSK-3beta by CR-1 can be blocked by LY294002, a specific inhibitor of PI3K, thus leading to apoptosis.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	63-71	glycogen synthase kinase 3 beta	Homo sapiens	27-36
10417756-6	1999	All mutations were missense changes within the GSK3beta consensus site, affecting serine residues at codons 33 and 37 and glycine at codon 34.	Serine	82-88	glycogen synthase kinase 3 beta	Homo sapiens	47-55
10417756-6	1999	All mutations were missense changes within the GSK3beta consensus site, affecting serine residues at codons 33 and 37 and glycine at codon 34.	Glycine	122-129	glycogen synthase kinase 3 beta	Homo sapiens	47-55
10449722-4	1999	TMAO is also found to promote tubulin assembly of glycogen synthase kinase-3beta-phosphorylated tau (1.6 mol phosphates/mol).	trimethyloxamine	0-4	glycogen synthase kinase 3 beta	Homo sapiens	50-80
10449722-4	1999	TMAO is also found to promote tubulin assembly of glycogen synthase kinase-3beta-phosphorylated tau (1.6 mol phosphates/mol).	Phosphates	109-119	glycogen synthase kinase 3 beta	Homo sapiens	50-80
10428053-7	1999	Application of PAF to neuronal cultures activated GSK-3beta, and coincubation with lithium ameliorated PAF-induced neuronal apoptosis.	Platelet Activating Factor	15-18	glycogen synthase kinase 3 beta	Homo sapiens	50-59
10409701-0	1999	Transient increases in intracellular calcium result in prolonged site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3beta-dependent pathway.	Calcium	37-44	glycogen synthase kinase 3 beta	Homo sapiens	123-153
10409701-7	1999	However, the calcium-induced increase in tau phosphorylation was inhibited by lithium, a noncompetitive inhibitor of glycogen synthase kinase-3beta (GSK-3beta), and by the tyrosine kinase inhibitor, genistein.	Calcium	13-20	glycogen synthase kinase 3 beta	Homo sapiens	117-147
10409701-7	1999	However, the calcium-induced increase in tau phosphorylation was inhibited by lithium, a noncompetitive inhibitor of glycogen synthase kinase-3beta (GSK-3beta), and by the tyrosine kinase inhibitor, genistein.	Calcium	13-20	glycogen synthase kinase 3 beta	Homo sapiens	149-158
10409701-7	1999	However, the calcium-induced increase in tau phosphorylation was inhibited by lithium, a noncompetitive inhibitor of glycogen synthase kinase-3beta (GSK-3beta), and by the tyrosine kinase inhibitor, genistein.	Lithium	78-85	glycogen synthase kinase 3 beta	Homo sapiens	117-147
10409701-7	1999	However, the calcium-induced increase in tau phosphorylation was inhibited by lithium, a noncompetitive inhibitor of glycogen synthase kinase-3beta (GSK-3beta), and by the tyrosine kinase inhibitor, genistein.	Lithium	78-85	glycogen synthase kinase 3 beta	Homo sapiens	149-158
10409701-8	1999	Furthermore, transient increases in calcium resulted in a prolonged increase in GSK-3beta tyrosine phosphorylation concomitant with the increase in tau phosphorylation.	Calcium	36-43	glycogen synthase kinase 3 beta	Homo sapiens	80-89
10409701-8	1999	Furthermore, transient increases in calcium resulted in a prolonged increase in GSK-3beta tyrosine phosphorylation concomitant with the increase in tau phosphorylation.	Tyrosine	90-98	glycogen synthase kinase 3 beta	Homo sapiens	80-89
10409701-9	1999	Therefore, this study is the first to indicate that transient increases in intracellular calcium result in increased tyrosine phosphorylation and activation of GSK-3beta which subsequently results in a sustained increase in the phosphorylation state of tau.	Calcium	89-96	glycogen synthase kinase 3 beta	Homo sapiens	160-169
10413115-0	1999	Phosphorylation of tau protein by recombinant GSK-3beta: pronounced phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser262 in the repeat domain.	Serine	94-97	glycogen synthase kinase 3 beta	Homo sapiens	46-55
10413115-0	1999	Phosphorylation of tau protein by recombinant GSK-3beta: pronounced phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser262 in the repeat domain.	Threonine	98-101	glycogen synthase kinase 3 beta	Homo sapiens	46-55
10413115-2	1999	However, it has been claimed that GSK-3beta can also phosphorylate the non-proline-directed KXGS motifs in the presence of heparin, including Ser262 in the repeat domain of tau, which could induce the detachment of tau from microtubules.	Proline	75-82	glycogen synthase kinase 3 beta	Homo sapiens	34-43
10413115-2	1999	However, it has been claimed that GSK-3beta can also phosphorylate the non-proline-directed KXGS motifs in the presence of heparin, including Ser262 in the repeat domain of tau, which could induce the detachment of tau from microtubules.	Heparin	123-130	glycogen synthase kinase 3 beta	Homo sapiens	34-43
10413115-5	1999	We also show that the non-proline-directed activity at KXGS motifs is not due to GSK-3beta itself, but to kinase contaminations in common GSK-3beta preparations from tissues which are activated upon addition of heparin.	Proline	26-33	glycogen synthase kinase 3 beta	Homo sapiens	81-90
10413115-5	1999	We also show that the non-proline-directed activity at KXGS motifs is not due to GSK-3beta itself, but to kinase contaminations in common GSK-3beta preparations from tissues which are activated upon addition of heparin.	Proline	26-33	glycogen synthase kinase 3 beta	Homo sapiens	138-147
10413115-5	1999	We also show that the non-proline-directed activity at KXGS motifs is not due to GSK-3beta itself, but to kinase contaminations in common GSK-3beta preparations from tissues which are activated upon addition of heparin.	Heparin	211-218	glycogen synthase kinase 3 beta	Homo sapiens	138-147
10196136-3	1999	Treatment of COS cells with LiCl, a GSK-3beta inhibitor, and okadaic acid, a protein phosphatase inhibitor, decreased and increased, respectively, the cellular protein level of Axin.	Lithium Chloride	28-32	glycogen synthase kinase 3 beta	Homo sapiens	36-45
10381572-7	1999	Further, lithium which inhibits the cytoplasmic kinase GSK3beta and hence influences beta-catenin levels did cause differentiation of NTERA2 cells.	Lithium	9-16	glycogen synthase kinase 3 beta	Homo sapiens	55-63
10364240-0	1999	The role of glycogen synthase kinase 3beta in insulin-stimulated glucose metabolism.	Glucose	65-72	glycogen synthase kinase 3 beta	Homo sapiens	12-42
10364240-5	1999	To further evaluate the role of GSK3beta in insulin signaling, the GSK3beta inhibitor lithium was used to mimic the consequences of insulin-stimulated GSK3beta inactivation.	Lithium	86-93	glycogen synthase kinase 3 beta	Homo sapiens	67-75
10364240-5	1999	To further evaluate the role of GSK3beta in insulin signaling, the GSK3beta inhibitor lithium was used to mimic the consequences of insulin-stimulated GSK3beta inactivation.	Lithium	86-93	glycogen synthase kinase 3 beta	Homo sapiens	67-75
10364240-7	1999	Lithium stimulation of glycogen synthesis was insensitive to wortmannin, which is consistent with its acting directly on GSK3beta downstream of phosphatidylinositol 3-kinase.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	121-129
10364240-8	1999	These data support the hypothesis that GSK3beta contributes to insulin regulation of glycogen synthesis, but is not responsible for the increase in glucose transport.	Glycogen	85-93	glycogen synthase kinase 3 beta	Homo sapiens	39-47
10391090-4	1999	All of these mutations altered at the serine/threonine residues that are potential sites of GSK3-beta phosphorylation.	Serine	38-44	glycogen synthase kinase 3 beta	Homo sapiens	92-101
10391090-4	1999	All of these mutations altered at the serine/threonine residues that are potential sites of GSK3-beta phosphorylation.	Threonine	45-54	glycogen synthase kinase 3 beta	Homo sapiens	92-101
10208444-4	1999	(ii) Lithium modulates signals impacting on the cytoskeleton, a dynamic system contributing to neural plasticity, at multiple levels, including glycogen synthase kinase-3beta, cyclic AMP-dependent kinase, and protein kinase C, which may be critical for the neural plasticity involved in mood recovery and stabilization.	Lithium	5-12	glycogen synthase kinase 3 beta	Homo sapiens	144-174
10217415-4	1999	Glycogen synthase kinase-3beta phosphorylated peptides with Ser(P) and Thr(P) in the priming position, but peptides with Tyr(P), Thr, Glu or Asp were not phosphorylated.	Serine	60-63	glycogen synthase kinase 3 beta	Homo sapiens	0-30
10217415-4	1999	Glycogen synthase kinase-3beta phosphorylated peptides with Ser(P) and Thr(P) in the priming position, but peptides with Tyr(P), Thr, Glu or Asp were not phosphorylated.	Threonine	71-74	glycogen synthase kinase 3 beta	Homo sapiens	0-30
10037507-4	1999	These results suggest that lithium may increase AP-1 DNA binding activity by inhibiting GSK-3beta.	Lithium	27-34	glycogen synthase kinase 3 beta	Homo sapiens	88-97
10037507-7	1999	Incubation of intact human neuroblastoma SH-SY5Y cells with VPA results in an increase in the subsequent in vitro recombinant GSK-3beta-mediated 32P incorporation into two putative GSK-3 substrates (approximately 85 and 200 kDa), compatible with inhibition of endogenous GSK-3beta by VPA.	Valproic Acid	60-63	glycogen synthase kinase 3 beta	Homo sapiens	126-135
10037507-7	1999	Incubation of intact human neuroblastoma SH-SY5Y cells with VPA results in an increase in the subsequent in vitro recombinant GSK-3beta-mediated 32P incorporation into two putative GSK-3 substrates (approximately 85 and 200 kDa), compatible with inhibition of endogenous GSK-3beta by VPA.	Valproic Acid	60-63	glycogen synthase kinase 3 beta	Homo sapiens	271-280
10037507-7	1999	Incubation of intact human neuroblastoma SH-SY5Y cells with VPA results in an increase in the subsequent in vitro recombinant GSK-3beta-mediated 32P incorporation into two putative GSK-3 substrates (approximately 85 and 200 kDa), compatible with inhibition of endogenous GSK-3beta by VPA.	Phosphorus-32	145-148	glycogen synthase kinase 3 beta	Homo sapiens	126-135
10037507-7	1999	Incubation of intact human neuroblastoma SH-SY5Y cells with VPA results in an increase in the subsequent in vitro recombinant GSK-3beta-mediated 32P incorporation into two putative GSK-3 substrates (approximately 85 and 200 kDa), compatible with inhibition of endogenous GSK-3beta by VPA.	Phosphorus-32	145-148	glycogen synthase kinase 3 beta	Homo sapiens	271-280
10037507-8	1999	Consistent with GSK-3beta inhibition, incubation of SH-SY5Y cells with VPA results in a significant time-dependent increase in both cytosolic and nuclear beta-catenin levels.	Valproic Acid	71-74	glycogen synthase kinase 3 beta	Homo sapiens	16-25
10037507-9	1999	GSK-3beta plays a critical role in the CNS by regulating various cytoskeletal processes as well as long-term nuclear events and is a common target for both lithium and VPA; inhibition of GSK-3beta in the CNS may thus underlie some of the long-term therapeutic effects of mood-stabilizing agents.	Lithium	156-163	glycogen synthase kinase 3 beta	Homo sapiens	0-9
10037507-9	1999	GSK-3beta plays a critical role in the CNS by regulating various cytoskeletal processes as well as long-term nuclear events and is a common target for both lithium and VPA; inhibition of GSK-3beta in the CNS may thus underlie some of the long-term therapeutic effects of mood-stabilizing agents.	Lithium	156-163	glycogen synthase kinase 3 beta	Homo sapiens	187-196
10037507-9	1999	GSK-3beta plays a critical role in the CNS by regulating various cytoskeletal processes as well as long-term nuclear events and is a common target for both lithium and VPA; inhibition of GSK-3beta in the CNS may thus underlie some of the long-term therapeutic effects of mood-stabilizing agents.	Valproic Acid	168-171	glycogen synthase kinase 3 beta	Homo sapiens	0-9
10037507-9	1999	GSK-3beta plays a critical role in the CNS by regulating various cytoskeletal processes as well as long-term nuclear events and is a common target for both lithium and VPA; inhibition of GSK-3beta in the CNS may thus underlie some of the long-term therapeutic effects of mood-stabilizing agents.	Valproic Acid	168-171	glycogen synthase kinase 3 beta	Homo sapiens	187-196
9930729-4	1999	The increase in GSK-3beta tyrosine phosphorylation corresponded directly to an increase in the association of Fyn tyrosine kinase with GSK-3beta, and Fyn immunoprecipitated from cells treated with insulin for 1 min phosphorylated GSK-3beta to a significantly greater extent than Fyn immunoprecipitated from control cells.	Tyrosine	26-34	glycogen synthase kinase 3 beta	Homo sapiens	135-144
9930729-3	1999	The insulin-induced increase in tau phosphorylation and concurrent activation of GSK-3beta was rapid (&lt;2 min) and transient, and was associated with increased tyrosine phosphorylation of GSK-3beta.	Tyrosine	162-170	glycogen synthase kinase 3 beta	Homo sapiens	81-90
9930729-4	1999	The increase in GSK-3beta tyrosine phosphorylation corresponded directly to an increase in the association of Fyn tyrosine kinase with GSK-3beta, and Fyn immunoprecipitated from cells treated with insulin for 1 min phosphorylated GSK-3beta to a significantly greater extent than Fyn immunoprecipitated from control cells.	Tyrosine	26-34	glycogen synthase kinase 3 beta	Homo sapiens	135-144
9930729-3	1999	The insulin-induced increase in tau phosphorylation and concurrent activation of GSK-3beta was rapid (&lt;2 min) and transient, and was associated with increased tyrosine phosphorylation of GSK-3beta.	Tyrosine	162-170	glycogen synthase kinase 3 beta	Homo sapiens	190-199
9930729-4	1999	The increase in GSK-3beta tyrosine phosphorylation corresponded directly to an increase in the association of Fyn tyrosine kinase with GSK-3beta, and Fyn immunoprecipitated from cells treated with insulin for 1 min phosphorylated GSK-3beta to a significantly greater extent than Fyn immunoprecipitated from control cells.	Tyrosine	26-34	glycogen synthase kinase 3 beta	Homo sapiens	16-25
10076565-2	1999	Mutational analysis of exon 3 of the beta-catenin gene, encoding the serine/threonine residues for GSK-3 beta phosphorylation, was performed for 35 tumors.	Serine	69-75	glycogen synthase kinase 3 beta	Homo sapiens	99-109
10651115-1	1999	Therapeutic concentrations of the anti-bipolar drug lithium inhibit the activity of glycogen synthase kinase-3beta, which raises the possibility that this enzyme and its substrates may be altered in the brain of subjects with bipolar disorder.	Lithium	52-59	glycogen synthase kinase 3 beta	Homo sapiens	84-114
10076565-2	1999	Mutational analysis of exon 3 of the beta-catenin gene, encoding the serine/threonine residues for GSK-3 beta phosphorylation, was performed for 35 tumors.	Threonine	76-85	glycogen synthase kinase 3 beta	Homo sapiens	99-109
10076565-4	1999	Each of the mutations resulted in the substitution of serine/threonine residues that have been implicated in the down-regulation of beta-catenin through phosphorylation by GSK-3 beta kinase.	Serine	54-60	glycogen synthase kinase 3 beta	Homo sapiens	172-182
10076565-4	1999	Each of the mutations resulted in the substitution of serine/threonine residues that have been implicated in the down-regulation of beta-catenin through phosphorylation by GSK-3 beta kinase.	Threonine	61-70	glycogen synthase kinase 3 beta	Homo sapiens	172-182
10076565-10	1999	Our results suggested that mutations at serine/threonine residues involved in phosphorylation by GSK-3 beta affected the stability of beta-catenin.	Serine	40-46	glycogen synthase kinase 3 beta	Homo sapiens	97-107
10076565-10	1999	Our results suggested that mutations at serine/threonine residues involved in phosphorylation by GSK-3 beta affected the stability of beta-catenin.	Threonine	47-56	glycogen synthase kinase 3 beta	Homo sapiens	97-107
9809590-5	1998	Treatment with TPK I/GSK-3beta antisense oligonucleotide inhibited the enhancement of tau phosphorylation induced by Abeta(25-35) exposure.	Oligonucleotides	41-56	glycogen synthase kinase 3 beta	Homo sapiens	21-30
9838099-3	1998	In cultured granule cells, IGF-I inhibits GSK-3 activity and leads to phosphorylation of serine9 an inhibitory site on GSK-3beta.	serine9	89-96	glycogen synthase kinase 3 beta	Homo sapiens	119-128
9819408-4	1998	GSK3beta binds directly to an STDRSPYE site in MUC1 and phosphorylates the serine adjacent to proline.	Serine	75-81	glycogen synthase kinase 3 beta	Homo sapiens	0-8
9819408-4	1998	GSK3beta binds directly to an STDRSPYE site in MUC1 and phosphorylates the serine adjacent to proline.	Proline	94-101	glycogen synthase kinase 3 beta	Homo sapiens	0-8
9721853-5	1998	All mutations identified were single-base missense mutations on serine/threonine residues (codons 33, 37, 41, and 45), altering the glycogen synthase kinase-3beta phosphorylation consensus motif, which participates in the degradation of beta-catenin.	Serine	64-70	glycogen synthase kinase 3 beta	Homo sapiens	132-162
9721853-5	1998	All mutations identified were single-base missense mutations on serine/threonine residues (codons 33, 37, 41, and 45), altering the glycogen synthase kinase-3beta phosphorylation consensus motif, which participates in the degradation of beta-catenin.	Threonine	71-80	glycogen synthase kinase 3 beta	Homo sapiens	132-162
9500446-4	1998	Here we show that 3 of 67 medulloblastomas harbor beta-catenin mutations, each of which converts a GSK-3beta phosphorylation site from serine to cysteine.	Serine	135-141	glycogen synthase kinase 3 beta	Homo sapiens	99-108
9570753-3	1998	Lithium, an inhibitor of GSK-3beta, mimics WNT-7a in granule cells.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	25-34
9570753-11	1998	Our data suggest that WNT-7a and lithium induce changes in microtubule dynamics by inhibiting GSK-3beta which in turn lead to changes in the phosphorylation of MAP-1B.	Lithium	33-40	glycogen synthase kinase 3 beta	Homo sapiens	94-103
9500446-4	1998	Here we show that 3 of 67 medulloblastomas harbor beta-catenin mutations, each of which converts a GSK-3beta phosphorylation site from serine to cysteine.	Cysteine	145-153	glycogen synthase kinase 3 beta	Homo sapiens	99-108
9373175-0	1997	Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216.	Serine	131-134	glycogen synthase kinase 3 beta	Homo sapiens	40-70
9373175-5	1997	Coexpression of WT-GSK3beta in 293 cells with either PKB alpha (also known as AKT) or PDK1 (the "upstream" activator of PKB) mimicked the IGF-1- or insulin-induced phosphorylation of Ser-9 and inactivation of GSK3beta.	Serine	183-186	glycogen synthase kinase 3 beta	Homo sapiens	19-27
10367940-4	1998	In this study we screened the beta-catenin gene in 13 sporadic desmoid tumors for alterations in exon 3, which encodes several serine/threonine residues that are targets for phosphorylation by GSK-3beta.	Serine	127-133	glycogen synthase kinase 3 beta	Homo sapiens	193-202
10367940-4	1998	In this study we screened the beta-catenin gene in 13 sporadic desmoid tumors for alterations in exon 3, which encodes several serine/threonine residues that are targets for phosphorylation by GSK-3beta.	Threonine	134-143	glycogen synthase kinase 3 beta	Homo sapiens	193-202
9405095-6	1997	Lithium mimics WNT-7a in granule cells by inhibiting GSK-3beta, a component of the WNT signaling pathway.	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	53-62
9233789-5	1997	Mutagenesis experiments demonstrate that substitution of the serine residues in the glycogen synthase kinase 3beta (GSK3beta) phosphorylation consensus motif of beta-catenin inhibits ubiquitination and results in stabilization of the protein.	Serine	61-67	glycogen synthase kinase 3 beta	Homo sapiens	84-114
9233789-5	1997	Mutagenesis experiments demonstrate that substitution of the serine residues in the glycogen synthase kinase 3beta (GSK3beta) phosphorylation consensus motif of beta-catenin inhibits ubiquitination and results in stabilization of the protein.	Serine	61-67	glycogen synthase kinase 3 beta	Homo sapiens	116-124
33813310-2	2021	A series of benzofuran-based compounds was synthesised and evaluated as inhibitors of recombinantly expressed and purified PfGSK-3 and human glycogen synthase kinase-3 beta (HsGSK-3beta).	benzofuran	12-22	glycogen synthase kinase 3 beta	Homo sapiens	141-172
8764598-5	1996	The sole site of phosphorylation in APPcyt by GSK-3beta was determined by phosphoamino acid analysis and phosphorylation of APPcyt mutant peptides to be Thr743 (numbering as for APP770).	Phosphoamino Acids	74-91	glycogen synthase kinase 3 beta	Homo sapiens	46-55
7980435-0	1994	Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation.	Serine	76-82	glycogen synthase kinase 3 beta	Homo sapiens	24-55
7980435-2	1994	GSK-3 beta is phosphorylated in vitro at serine 9 by p70 S6 kinase and p90rsk-1, resulting in its inhibition [Sutherland, Leighton, and Cohen (1993) Biochem.	Serine	41-47	glycogen synthase kinase 3 beta	Homo sapiens	0-10
7980435-5	1994	Using HeLa cells expressing GSK-3 beta or a mutant containing alanine at residue 9, we demonstrate that serine 9 is modified in intact cells and is targeted specifically by p90rsk-1, and that phosphorylation leads to loss of activity.	Serine	104-110	glycogen synthase kinase 3 beta	Homo sapiens	28-38
8050597-0	1994	PHF-tau from Alzheimer"s brain comprises four species on SDS-PAGE which can be mimicked by in vitro phosphorylation of human brain tau by glycogen synthase kinase-3 beta.	Sodium Dodecyl Sulfate	57-60	glycogen synthase kinase 3 beta	Homo sapiens	138-169
33769184-0	2021	Xanthone glucoside 2-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one binds to the ATP-binding pocket of glycogen synthase kinase 3beta and inhibits its activity: implications in prostate cancer and associated cardiovascular disease risk.	xanthone glucoside	0-18	glycogen synthase kinase 3 beta	Homo sapiens	116-146
33769184-0	2021	Xanthone glucoside 2-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one binds to the ATP-binding pocket of glycogen synthase kinase 3beta and inhibits its activity: implications in prostate cancer and associated cardiovascular disease risk.	mangiferin	19-80	glycogen synthase kinase 3 beta	Homo sapiens	116-146
33769184-0	2021	Xanthone glucoside 2-beta-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one binds to the ATP-binding pocket of glycogen synthase kinase 3beta and inhibits its activity: implications in prostate cancer and associated cardiovascular disease risk.	Adenosine Triphosphate	94-97	glycogen synthase kinase 3 beta	Homo sapiens	116-146
8524294-3	1996	Like GSK-3 beta, skp1 is phosphorylated on a conserved tyrosine residue, and this phosphorylation is required for efficient activity.	Tyrosine	55-63	glycogen synthase kinase 3 beta	Homo sapiens	5-15
7695638-2	1995	Phosphorylation of p90rsk by both GSK-3 alpha and GSK-3 beta isoforms was predominantly on threonine residues.	Threonine	91-100	glycogen synthase kinase 3 beta	Homo sapiens	50-60
33820886-7	2021	Furthermore, the study revealed that 50microM of EPS concentration reduced the glycogen synthase kinase-3 beta (GSK3-beta) expression and total tau protein level in H2O2 (100microM) treated cells.	epalrestat	49-52	glycogen synthase kinase 3 beta	Homo sapiens	79-110
33820886-7	2021	Furthermore, the study revealed that 50microM of EPS concentration reduced the glycogen synthase kinase-3 beta (GSK3-beta) expression and total tau protein level in H2O2 (100microM) treated cells.	Hydrogen Peroxide	165-169	glycogen synthase kinase 3 beta	Homo sapiens	79-110
25676548-2	2015	Signalling pathways appear to converge on glycogen regulatory enzymes via insulin (glycogen synthase kinase 3beta, protein phosphatase 1, allosteric action of glucose-6-phosphate), beta-adrenergic (phosphorylase kinase protein phosphatase 1 inhibitor), and 5" adenosine monophosphate-activated protein kinase (allosteric action of glucose-6-phosphate, direct glycogen binding, insulin receptor).	Glycogen	42-50	glycogen synthase kinase 3 beta	Homo sapiens	83-136
26628990-10	2015	EGCG significantly promoted the phosphorylation of Akt and GSK-3beta and down-regulated PTEN, thus activating PI3/Akt signalling.	epigallocatechin gallate	0-4	glycogen synthase kinase 3 beta	Homo sapiens	59-68
34902644-0	2022	Structure-Based design of Marine-derived Meridianin C derivatives as glycogen synthase kinase 3beta inhibitors with improved oral bioavailability: From aminopyrimidyl-indoles to the sulfonyl analogues.	aminopyrimidyl-indoles	152-174	glycogen synthase kinase 3 beta	Homo sapiens	69-99
19454287-6	2009	The GSK3beta inhibitor 6-bromoindirubin-3"-oxime (BIO) was used for beta-catenin stabilization.	6-bromoindirubin-3'-oxime	23-48	glycogen synthase kinase 3 beta	Homo sapiens	4-12
34975828-2	2021	Glycogen synthase kinase 3beta (GSK3beta) is a serine/threonine kinase and regulates numerous cell/tissue-specific functions, including cell survival, metabolism, and differentiation.	Serine	47-53	glycogen synthase kinase 3 beta	Homo sapiens	0-30
34213342-0	2022	Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3beta Inhibitors.	Water	33-38	glycogen synthase kinase 3 beta	Homo sapiens	99-129
34213342-0	2022	Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3beta Inhibitors.	pyrimidoindole	78-92	glycogen synthase kinase 3 beta	Homo sapiens	99-129
34213342-2	2022	Here, by addressing a high-energy water, we improved the IC50 value of our co-crystallized glycogen synthase kinase-3beta (GSK-3beta) inhibitor by nearly two orders of magnitude.	Water	34-39	glycogen synthase kinase 3 beta	Homo sapiens	91-121
34751792-2	2022	Lithium is a potent inhibitor of glycogen synthase kinase-3beta (GSK3beta), the most important tau kinase in neurons, and may also affect tau phosphorylation by modifying the expression and/or activity of other kinases, such as protein kinase A (PKA), Akt (PKB), and calcium calmodulin kinase-II (CaMKII).	Lithium	0-7	glycogen synthase kinase 3 beta	Homo sapiens	33-63
34800627-6	2022	Activation of mitochondrial ATP-sensitive potassium channels (mitoKATP) channels, uncoupling proteins, and inhibition of glycogen synthase kinase-3beta (GSK3beta) phosphorylation have been identified to delay mitochondrial permeability transition pore opening and reduce reactive oxygen species formation, thereby decreasing infarct size.	Oxygen	280-286	glycogen synthase kinase 3 beta	Homo sapiens	121-151
34404214-3	2021	Among the targets of lithium, glycogen synthase kinase 3beta (GSK-3beta) may be responsible for its therapeutic effects.	Lithium	21-28	glycogen synthase kinase 3 beta	Homo sapiens	30-60
34881239-0	2021	Immobilization of Glycogen Synthase Kinase-3beta Inhibitor on 316L Stainless Steel via Polydopamine to Accelerate Endothelialization.	Stainless Steel	67-82	glycogen synthase kinase 3 beta	Homo sapiens	18-48
34881239-0	2021	Immobilization of Glycogen Synthase Kinase-3beta Inhibitor on 316L Stainless Steel via Polydopamine to Accelerate Endothelialization.	polydopamine	87-99	glycogen synthase kinase 3 beta	Homo sapiens	18-48
34533953-0	2021	Effect of Lithium Drug on Binding Affinities of Glycogen Synthase Kinase-3 beta to Its Network Partners: A New Computational Approach.	Lithium	10-17	glycogen synthase kinase 3 beta	Homo sapiens	48-79
34098017-11	2021	Moreover, PUE-GLY could influence the Wnt signaling pathway by upregulating GSK3B and downregulating CTNNB1 synergistically.	pue-gly	10-17	glycogen synthase kinase 3 beta	Homo sapiens	76-81
34196102-5	2021	As expected, PREP deletion and inhibition blocked the lithium-induced phosphorylation on GSK3b and Akt in both cell lines.	Lithium	54-61	glycogen synthase kinase 3 beta	Homo sapiens	89-94
34196102-7	2021	Therefore, we conclude that PREP deletion or inhibition blocks the intracellular effects of lithium on GSK3b and Akt via PP2A activation.	Lithium	92-99	glycogen synthase kinase 3 beta	Homo sapiens	103-108
34503515-2	2021	Obese women have elevated free fatty acids (FFAs) levels in their follicular fluids and decreased FSHR expression in GCs, which is related to an altered protein kinase B/glycogen synthase kinase 3beta (Akt/GSK3beta) signaling pathway.	Fatty Acids, Nonesterified	26-42	glycogen synthase kinase 3 beta	Homo sapiens	170-200
34461526-4	2021	Glycogen synthase kinase 3 beta (GSK3beta) is a conserved serine/threonine kinase, which regulates key cellular processes including cell proliferation, DNA repair, cell cycle progression, signaling and metabolic pathways.	Serine	58-64	glycogen synthase kinase 3 beta	Homo sapiens	0-31
34432352-4	2021	The results showed that metformin effectively prevented tau hyperphosphorylation at Ser202 caused by MC-LR through PP2A and GSK-3b activity.	Metformin	24-33	glycogen synthase kinase 3 beta	Homo sapiens	124-130
34432352-4	2021	The results showed that metformin effectively prevented tau hyperphosphorylation at Ser202 caused by MC-LR through PP2A and GSK-3b activity.	mc-lr	101-106	glycogen synthase kinase 3 beta	Homo sapiens	124-130
34488124-1	2021	Isoorientin is a C-glycosyl flavone with a wide range of health beneficial effects and inhibits glycogen synthase kinase 3beta (GSK-3beta) potentially against Alzheimer"s disease.	homoorientin	0-11	glycogen synthase kinase 3 beta	Homo sapiens	96-126
34486216-4	2021	Interestingly the biological evaluation results revealed that Compounds IV & V , with bromo/chloro functionalities in the aromatic core were advantaged of  being highly selective towards the target GSK3b over others.	Hydrochloric Acid	92-98	glycogen synthase kinase 3 beta	Homo sapiens	198-203
34486216-6	2021	Surprisingly, our investigation underpined that for both the compounds IV/V, a primary H-bonding existed between the designed molecules ( IV/V) and Val 135 residue in the receptor GSK3b, inline with the reference ligand.	Valine	148-151	glycogen synthase kinase 3 beta	Homo sapiens	180-185
34464676-3	2021	Our recent studies suggest that a single subanesthetic dose of NMDAR antagonists ketamine or nitrous oxide (N2O) gradually evoke 1-4 Hz electrophysiological activity (delta-rhythm) of cerebral cortex that is accompanied by molecular signaling associated with synaptic plasticity (e.g. activation of tropomyosin receptor kinase B (TrkB) and inhibition of glycogen synthase kinase 3beta (GSK3beta)).	Ketamine	81-89	glycogen synthase kinase 3 beta	Homo sapiens	354-384
34464676-3	2021	Our recent studies suggest that a single subanesthetic dose of NMDAR antagonists ketamine or nitrous oxide (N2O) gradually evoke 1-4 Hz electrophysiological activity (delta-rhythm) of cerebral cortex that is accompanied by molecular signaling associated with synaptic plasticity (e.g. activation of tropomyosin receptor kinase B (TrkB) and inhibition of glycogen synthase kinase 3beta (GSK3beta)).	Nitrous Oxide	93-106	glycogen synthase kinase 3 beta	Homo sapiens	354-384
34464676-3	2021	Our recent studies suggest that a single subanesthetic dose of NMDAR antagonists ketamine or nitrous oxide (N2O) gradually evoke 1-4 Hz electrophysiological activity (delta-rhythm) of cerebral cortex that is accompanied by molecular signaling associated with synaptic plasticity (e.g. activation of tropomyosin receptor kinase B (TrkB) and inhibition of glycogen synthase kinase 3beta (GSK3beta)).	Nitrous Oxide	108-111	glycogen synthase kinase 3 beta	Homo sapiens	354-384
34499814-3	2021	Here, it is shown that the integration of the glycogen synthase kinase-3beta inhibitor CHIR99021 in collagen I hydrogels promotes proliferation of human-induced pluripotent stem cell-derived (hiPSC) cardiomyocytes post-fabrication improving contractility of and calcium flow in engineered 3D cardiac microtissues.	Calcium	262-269	glycogen synthase kinase 3 beta	Homo sapiens	46-76
34196102-0	2021	Deletion or inhibition of prolyl oligopeptidase blocks lithium-induced phosphorylation of GSK3b and Akt by activation of protein phosphatase 2A.	Lithium	55-62	glycogen synthase kinase 3 beta	Homo sapiens	90-95
33642370-0	2021	Corrigendum: Glycogen synthase kinase-3beta inhibitor SB216763 promotes DNA repair in ischemic retinal neurons.	SB 216763	54-62	glycogen synthase kinase 3 beta	Homo sapiens	13-43
34540977-8	2021	Aspirin has been reported to suppress the Wnt pathway by inducing beta-catenin phosphorylation through the activation of glycogen synthase kinase 3 beta via cyclooxygenase-2 pathway inhibition.	Aspirin	0-7	glycogen synthase kinase 3 beta	Homo sapiens	121-152
34070360-0	2021	Adenosine and Cordycepin Accelerate Tissue Remodeling Process through Adenosine Receptor Mediated Wnt/beta-Catenin Pathway Stimulation by Regulating GSK3b Activity.	Adenosine	0-9	glycogen synthase kinase 3 beta	Homo sapiens	149-154
34440091-0	2021	Pharmacologically Inhibiting Glycogen Synthase Kinase-3beta Ameliorates Renal Inflammation and Nephrotoxicity in an Animal Model of Cisplatin-Induced Acute Kidney Injury.	Cisplatin	132-141	glycogen synthase kinase 3 beta	Homo sapiens	29-59
34445773-13	2021	The phosphorylation of glycogen synthase kinase-3beta was decreased, whereas the beta-catenin expression was increased in human endothelial cells treated with ellipticine.	ellipticine	159-170	glycogen synthase kinase 3 beta	Homo sapiens	23-53
34298987-4	2021	Finally, the administration of tideglusib and VP0.7, ATP non-competitive inhibitors of glycogen synthase kinase 3beta (GSK-3beta), restore the expression and phosphorylation of these proteins in LGMDR1 cells, opening the possibility of their use as therapeutic options.	Adenosine Triphosphate	53-56	glycogen synthase kinase 3 beta	Homo sapiens	87-117
34070360-0	2021	Adenosine and Cordycepin Accelerate Tissue Remodeling Process through Adenosine Receptor Mediated Wnt/beta-Catenin Pathway Stimulation by Regulating GSK3b Activity.	cordycepin	14-24	glycogen synthase kinase 3 beta	Homo sapiens	149-154
34070360-0	2021	Adenosine and Cordycepin Accelerate Tissue Remodeling Process through Adenosine Receptor Mediated Wnt/beta-Catenin Pathway Stimulation by Regulating GSK3b Activity.	Adenosine	70-79	glycogen synthase kinase 3 beta	Homo sapiens	149-154
34589270-9	2021	Downregulated FOXO3 was identified in OC, whereas miR-29a-3p targeted FOXO3 to suppress glycogen synthase kinase 3beta (GSK3beta) activity via the serine/threonine protein kinase (AKT)/GSK3beta pathway.	Serine	147-153	glycogen synthase kinase 3 beta	Homo sapiens	88-118
35625744-3	2022	The greatest differences in the carbohydrate metabolism compared to adjacent noncancerous tissues were identified in the tumor tissue: reduction in the levels of lactate and glycogen synthase kinase-3beta.	Carbohydrates	32-44	glycogen synthase kinase 3 beta	Homo sapiens	174-204
35609318-10	2022	Additionally, miR-582-3p upregulation also reduced the expression levels of Wnt, beta-catenin, and C-myc, but enhanced the expression levels of glycogen synthase kinase-3beta, both in vitro and in vivo.	mir-582-3p	14-24	glycogen synthase kinase 3 beta	Homo sapiens	144-174
34162557-0	2021	Downregulation of GSK3B by miR-132-3p Enhances Etoposide-Induced Breast Cancer Cell Apoptosis.	Etoposide	47-56	glycogen synthase kinase 3 beta	Homo sapiens	18-23
35390715-1	2022	Glycogen synthase kinase-3beta (GSK-3beta) is a conserved serine/threonine kinase that participates in the transmission of multiple signaling pathways and plays an important role in the occurrence and development of human diseases, such as metabolic diseases, neurological diseases and cancer, making it to be a potential and promising drug target.	Serine	58-64	glycogen synthase kinase 3 beta	Homo sapiens	0-30
35543239-0	2022	Prediction of binding affinity of 1,2-diphenyline ketone analogues at adenosine triphosphate binding site of glycogen synthase kinase-3beta: a molecular docking and dynamic simulation study.	1,2-diphenyline ketone	34-56	glycogen synthase kinase 3 beta	Homo sapiens	109-139
35543239-0	2022	Prediction of binding affinity of 1,2-diphenyline ketone analogues at adenosine triphosphate binding site of glycogen synthase kinase-3beta: a molecular docking and dynamic simulation study.	Adenosine	70-79	glycogen synthase kinase 3 beta	Homo sapiens	109-139
35563887-11	2022	Phosphorylating the motif by GSK3b at serine residues led to its nuclear translocation to promote motility.	Serine	38-44	glycogen synthase kinase 3 beta	Homo sapiens	29-34
35410376-6	2022	At the protein level, AKAP-11 interacts with GSK3B, the hypothesized target of lithium, a primary treatment for BD.	Lithium	79-86	glycogen synthase kinase 3 beta	Homo sapiens	45-50
35625744-6	2022	Bioinformatic analysis of the interactions of immunohistochemical markers of gliomas and carbohydrate metabolism enzymes using the databases of STRING, BioGrid, and Signor revealed the presence of biologically significant interactions with glycogen synthase kinase 3beta, hexokinase, glucose-6-phosphate dehydrogenase, and transketolase.	Carbohydrates	89-101	glycogen synthase kinase 3 beta	Homo sapiens	240-270
35443844-5	2022	Then glycogen synthase kinase-3 beta (GSK3beta) contributes to the hyperphosphorylation of Tau protein, the main component of neurofibrillary tangles, one of the hallmarks of AD as one of the mechanisms behind Al neurotoxicity will be covered.	Aluminum	210-212	glycogen synthase kinase 3 beta	Homo sapiens	5-36
35468223-7	2022	While inhibition of the PAM pathway causes MYC phosphorylation at threonine 58 via glycogen synthase kinase 3 beta and subsequent degradation, ATRA reduces its expression.	Threonine	66-75	glycogen synthase kinase 3 beta	Homo sapiens	83-114
35465844-3	2022	Herein, we explore the molecular docking and the molecular dynamics simulations of alpha-mangostin on glycogen synthase kinase 3beta (GSK3beta; PDB ID: 4ACC).	mangostin	83-98	glycogen synthase kinase 3 beta	Homo sapiens	102-132
35409221-1	2022	Glycogen synthase kinase 3 beta (GSK-3beta) is an evolutionarily conserved serine-threonine kinase dysregulated in numerous pathologies, such as Alzheimer"s disease and cancer.	Serine	75-81	glycogen synthase kinase 3 beta	Homo sapiens	0-31
35457230-1	2022	Glycogen synthase kinase 3beta (GSK3) is a multifaceted serine/threonine (S/T) kinase expressed in all eukaryotic cells.	Serine	56-62	glycogen synthase kinase 3 beta	Homo sapiens	0-30
35347072-10	2022	Mechanistically, eEF2K directly bound to and inactivated glycogen synthase kinase 3 beta (GSK3beta) by phosphorylating it at serine 9 (S9), leading to PD-L1 protein stabilization and upregulation, and subsequently tumor immune evasion.	Serine	125-131	glycogen synthase kinase 3 beta	Homo sapiens	57-88
35364429-7	2022	These vitamins can also modulate genes induced by DAB (IL1B, IL6, IL10, iNOS, COX2, NFkappaB, GSK3B, TNF, and APP) in SH-SY5Y cells.	3,3'-Diaminobenzidine	50-53	glycogen synthase kinase 3 beta	Homo sapiens	94-99
35164239-3	2022	PDA-66, a structural analogue of the inhibitor of serine-threonine kinase glycogen synthase kinase 3beta SB216763, has shown preclinical antitumour effects in various cell lines, with the key pathways of its anticancer activity being cell cycle modulation, DNA replication and p53 signalling.	PDA-66	0-6	glycogen synthase kinase 3 beta	Homo sapiens	74-104
35012639-9	2022	In vitro experiments showed that pioglitazone downregulated glycogen synthase kinase 3 beta (GSK3beta) and cyclin-dependent kinase (CDK5) in human microglia cells, supporting a possible mechanism-of-action for its beneficial effect in AD.	Pioglitazone	33-45	glycogen synthase kinase 3 beta	Homo sapiens	60-91
35163593-0	2022	Propolin G-Suppressed Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer Cells via Glycogen Synthase Kinase 3beta-Mediated Snail and HDAC6-Regulated Vimentin Degradation.	propolin G	0-10	glycogen synthase kinase 3 beta	Homo sapiens	102-132
35163593-12	2022	The activation of glycogen synthase kinase 3beta (GSK-3beta) by propolin G resulted in increasing GSK-3beta interaction with Snail.	propolin G	64-74	glycogen synthase kinase 3 beta	Homo sapiens	18-48
35308128-6	2022	This synaptic protection was prevented by both the activation of NMDA receptor leading to intracellular signaling and the regulatory pathway of lithium including inositol depletion and glycogen synthase kinase-3beta (GSK-3beta).	Lithium	144-151	glycogen synthase kinase 3 beta	Homo sapiens	185-215